Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna

ABSTRACT

This invention relates to compounds, compositions, and methods useful for reducing β-catenin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent applicationSer. No. 14/925,952, filed Oct. 28, 2015, pending, which is acontinuation of U.S. patent application Ser. No. 14/300,754, filed Jun.10, 2014, granted, which is a divisional of U.S. patent application Ser.No. 13/718,525, filed Dec. 18, 2012, granted, which is a continuation ofPCT international application Ser. No. PCT/US2011/042820, filed Jul. 1,2011, designating the United States, which claims benefit under 35U.S.C. §119(e) of U.S. provisional patent application No. 61/361,776,filed Jul. 6, 2010. The entire contents of the aforementioned patentapplications are incorporated herein by this reference.

FIELD OF THE INVENTION

The present invention relates to compounds, compositions, and methodsfor the study, diagnosis, and treatment of traits, diseases andconditions that respond to the modulation of CTNNB1 (β-catenin) geneexpression and/or activity.

BACKGROUND OF THE INVENTION

Wnt pathway signaling mediates development, regeneration, cellularproliferation and stem cell formation (Fuerer et al. EMBO Rep 9: 134-8).Abnormal Wnt pathway signaling has been associated with a wide range ofdiseases, including cancer (Moon et al. Nat Rev Genet. 5: 691-701).Mutations in β-catenin (encoded by the CTNNB1 gene in humans)—anoncogene that is the key mediator of Wnt signaling—have beenspecifically associated with colorectal, desmoid, endometrial, gastric,hepatocellular, hepatoblastoma, kidney (Wilms' tumor), medulloblastoma,melanoma, ovarian (endometrioid), pancreatic, pilomatricoma, prostate,thyroid (anaplastic) and uterine (endometrium) cancers (Polakis P. GenesDev. 14: 1837-51; Samowitz et al. Cancer Res. 59: 1442-4; Iwao et al.Cancer Res. 58: 1021-6; Mirabelli-Primdahl et al. Cancer Res. 59:3346-51; Shitoh et al. J Clin Path. 52: 695-6; Tejpar et al. Oncogene18: 6615-20; Kitaeva et al. Cancer Res. 57: 4478-81; Sparks et al.Cancer Res. 58: 1130-4; Miyaki et al. Cancer Res. 59: 4506-9; Park etal. Cancer Res. 59: 4257-60; Huang et al. Am J Pathol. 155: 1795-801;Nhieu et al. Am J Pathol. 155: 703-10; Legoix et al. Oncogene 18:4044-6; Jeng et al. Cancer Lett. 152: 45-51; Koch et al. Cancer Res. 59:269-73; Wei et al. Oncogene 19: 498-504; Koesters et al. Cancer Res. 59:3880-2; Maiti et al. Cancer Res. 60: 6288-92; Zurawel et al. Cancer Res.58: 896-9; Gamallo et al. Am J Pathol. 155: 527-36; Palacios and GamalloCancer Res. 58: 1344-7; Wright et al. Int J Cancer 82: 625-9; Gerdes etal. Digestion 60: 544-8; Chan et al. Nat Genet. 21: 410-3; Voeller etal. Cancer Res. 58: 2520-3; Garcia-Rostan et al. Cancer Res. 59: 1811-5;Fukuchi et al. Cancer Res. 58: 3526-8). Many such mutations in β-cateninare believed to impart increased stability to the β-catenin protein,making β-catenin an attractive target for development of therapeuticsthat inhibit and/or reduce levels of the β-catenin protein. Given therole of β-catenin in the development of cancer and other diseases and/ordisorders (e.g., proper β-catenin activity is important for hairfollicle/epithelial stem cell function, meaning that certain inhibitorsof β-catenin possess depilatory properties), there remains an unmet needfor therapeutically effective inhibitors of β-catenin.

Double-stranded RNA (dsRNA) agents possessing strand lengths of 25 to 35nucleotides have been described as effective inhibitors of target geneexpression in mammalian cells (Rossi et al., U.S. Patent ApplicationNos. 2005/0244858 and US 2005/0277610). dsRNA agents of such length arebelieved to be processed by the Dicer enzyme of the RNA interference(RNAi) pathway, leading such agents to be termed “Dicer substrate siRNA”(“DsiRNA”) agents. Additional modified structures of DsiRNA agents werepreviously described (Rossi et al., U.S. Patent Application No.2007/0265220).

BRIEF SUMMARY OF THE INVENTION

The present invention is directed to compositions that contain doublestranded RNA (“dsRNA”), and methods for preparing them. The dsRNAs ofthe invention are capable of reducing the expression of a target CTNNB1gene (encoding β-catenin) in a cell, either in vitro or in a mammaliansubject. More particularly, the invention is directed to Dicer substratesiRNAs (“DsiRNAs”) with structures and modification patterns which actas effective and highly potent β-catenin inhibitory agents, and also maypossess extended duration of inhibitory effect. A number of such DsiRNAspossess target-specific inhibitory potencies and efficacies that aresignificantly enhanced relative to 21 nucleotide siRNAs directed againstthe same target RNA.

In one aspect, the invention provides an isolated double strandedribonucleic acid (dsRNA) comprising first and second nucleic acidstrands and a duplex region of at least 25 base pairs, wherein the firststrand is 25-34 nucleotides in length and the second strand is 26-35nucleotides in length and comprises 1-5 single-stranded nucleotides atits 3′ terminus, where the second oligonucleotide strand is sufficientlycomplementary to a target β-catenin cDNA sequence of SEQ ID NOs:2226-3334 along at least 15 nucleotides of the second oligonucleotidestrand length to reduce β-catenin target gene expression when the doublestranded nucleic acid is introduced into a mammalian cell. Optionally,the second oligonucleotide strand is complementary to a target β-catenincDNA sequence of SEQ ID NOs: 1-3 and 5-6 along at most 27 nucleotides ofits length.

In one embodiment, starting from the first nucleotide (position 1) atthe 3′ terminus of the first oligonucleotide strand, position 1, 2and/or 3 is substituted with a modified nucleotide. In certainembodiments, the modified nucleotide residue of the 3′ terminus of thefirst strand is a deoxyribonucleotide, an acyclonucleotide or afluorescent molecule. In a related embodiment, position 1 of the 3′terminus of the first oligonucleotide strand is a deoxyribonucleotide.

In an additional embodiment, the 3′ terminus of the first strand and the5′ terminus of the second strand form a blunt end.

In another embodiment, the first strand is 25 nucleotides in length andthe second strand is 27 nucleotides in length.

In one embodiment, the second strand includes a sequence of SEQ ID NOs:1117-2225.

In another embodiment, the first strand includes a sequence of SEQ IDNOs: 8-1116, 3335-3822 and 3823-4443.

In an additional embodiment, the dsRNA includes a pair of firststrand/second strand sequences as shown for a DsiRNA agent of Tables2-4, 6, 9 or 11.

In one embodiment, each of the first and the second strands has a lengthwhich is at least 26 nucleotides.

In another embodiment, the nucleotides of the 3′ overhang include amodified nucleotide. Optionally, the modified nucleotide of the 3′overhang is a 2′-O-methyl ribonucleotide. In a related embodiment, allnucleotides of the 3′ overhang are modified nucleotides.

In an additional embodiment, one or both of the first and secondoligonucleotide strands includes a 5′ phosphate.

In another embodiment, the modified nucleotide residues of the dsRNA are2′-O-methyl, 2′-methoxyethoxy, 2′-fluoro, 2′-allyl,2′-O-[2-(methylamino)-2-oxoethyl], 4′-thio, 4′-CH2-O-2′-bridge,4′-(CH2)2-O-2′-bridge, 2′-LNA, 2′-amino or 2′-O—(N-methlycarbamate).

In one embodiment, the 3′ overhang of the dsRNA is 1-3 nucleotides inlength. Optionally, the 3′ overhang is 1-2 nucleotides in length. In arelated embodiment, the 3′ overhang is two nucleotides in length and themodified nucleotide of the 3′ overhang is a 2′-O-methyl modifiedribonucleotide.

In a further embodiment, the second oligonucleotide strand, startingfrom the nucleotide residue of the second strand that is complementaryto the 5′ terminal nucleotide residue of the first oligonucleotidestrand, includes alternating modified and unmodified nucleotideresidues. In another embodiment, the second oligonucleotide strand,starting from the nucleotide residue of the second strand that iscomplementary to the 5′ terminal nucleotide residue of the firstoligonucleotide strand, includes unmodified nucleotide residues at allpositions from position 18 to the 5′ terminus of the secondoligonucleotide strand.

In another embodiment, each of the first and the second strands has alength which is at least 26 and at most 30 nucleotides.

In one embodiment, the dsRNA is cleaved endogenously in the cell byDicer.

In an additional embodiment, the amount of the isolated double strandednucleic acid sufficient to reduce expression of the target gene is 1nanomolar or less, 200 picomolar or less, 100 picomolar or less, 50picomolar or less, 20 picomolar or less, 10 picomolar or less, 5picomolar or less, 2 picomolar or less or 1 picomolar or less in theenvironment of the cell.

In a further embodiment, the isolated dsRNA possesses greater potencythan isolated 21mer siRNAs directed to the identical at least 15nucleotides of the target β-catenin cDNA in reducing target β-cateningene expression when assayed in vitro in a mammalian cell at aneffective concentration in the environment of a cell of 1 nanomolar orless, 200 picomolar or less, 100 picomolar or less, 50 picomolar orless, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2picomolar or less or 1 picomolar or less.

In another embodiment, the isolated dsRNA is sufficiently complementaryto the target β-catenin cDNA sequence to reduce β-catenin target geneexpression by at least 10%, at least 50%, at least 80-90%, at least 95%,at least 98%, or at least 99% when the double stranded nucleic acid isintroduced into a mammalian cell.

In a further embodiment, the first and second strands are joined by achemical linker. In a related embodiment, the 3′ terminus of the firststrand and the 5′ terminus of the second strand are joined by a chemicallinker.

In one embodiment, a nucleotide of the second or first strand issubstituted with a modified nucleotide that directs the orientation ofDicer cleavage.

In another embodiment, the dsRNA has a modified nucleotide that is adeoxyribonucleotide, a dideoxyribonucleotide, an acyclonucleotide, a3′-deoxyadenosine (cordycepin), a 3′-azido-3′-deoxythymidine (AZT), a2′,3′-dideoxyinosine (ddI), a 2′,3′-dideoxy-3′-thiacytidine (3TC), a2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a monophosphate nucleotideof 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxy-3′-thiacytidine(3TC) and a monophosphate nucleotide of2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a 4-thiouracil, a5-bromouracil, a 5-iodouracil, a 5-(3-aminoallyl)-uracil, a 2′-O-alkylribonucleotide, a 2′-O-methyl ribonucleotide, a 2′-amino ribonucleotide,a 2′-fluoro ribonucleotide, or a locked nucleic acid.

In an additional embodiment, the dsRNA has a phosphonate, aphosphorothioate or a phosphotriesterphosphate backbone modification.

In one embodiment, the invention provides a method for reducingexpression of a target β-catenin gene in a mammalian cell havingcontacting a mammalian cell in vitro with an isolated dsRNA as describedin an amount sufficient to reduce expression of a target β-catenin genein the cell.

In one embodiment, target β-catenin gene expression is reduced by atleast 10%, at least 50%, or at least 80-90%. In another embodiment,target β-catenin mRNA levels are reduced at least 90% at least 8 daysafter the cell is contacted with the dsRNA. In a further embodiment,β-catenin mRNA levels are reduced by at least 70% at least 10 days afterthe cell is contacted with the dsRNA.

In a further embodiment, the invention provides a method for reducingexpression of a target β-catenin gene in a mammal by administering anisolated dsRNA as described to a mammal in an amount sufficient toreduce expression of a target β-catenin gene in the mammal.

In one embodiment, the isolated dsRNA is administered at a dosage of 1microgram to 5 milligrams per kilogram of the mammal per day, 100micrograms to 0.5 milligrams per kilogram, 0.001 to 0.25 milligrams perkilogram, 0.01 to 20 micrograms per kilogram, 0.01 to 10 micrograms perkilogram, 0.10 to 5 micrograms per kilogram, or 0.1 to 2.5 microgramsper kilogram.

In another embodiment, the isolated dsRNA possesses greater potency thanisolated 21mer siRNAs directed to the identical at least 15 nucleotidesof the target β-catenin cDNA in reducing target β-catenin geneexpression when assayed in vitro in a mammalian cell at an effectiveconcentration in the environment of a cell of 1 nanomolar or less.

In an additional embodiment, the administering step includes intravenousinjection, intramuscular injection, intraperitoneal injection, infusion,subcutaneous injection, transdermal, aerosol, rectal, vaginal, topical,oral or inhaled delivery.

In a further embodiment, the invention provides a method for selectivelyinhibiting the growth of a cell by contacting a cell with an amount ofan isolated dsRNA as described, in an amount sufficient to inhibit thegrowth of the cell.

In one embodiment, the cell is a tumor cell of a subject. Optionally,the cell is a tumor cell in vitro. In a related embodiment, the cell isa human cell.

In an additional embodiment, the invention provides a formulation whichincludes an isolated dsRNA as described, where the dsRNA is present inan amount effective to reduce target β-catenin RNA levels when the dsRNAis introduced into a mammalian cell in vitro by at least 10%, at least50% or at least 80-90%, and where the dsRNA possesses greater potencythan isolated 21mer siRNAs directed to the identical at least 15nucleotides of the target β-catenin cDNA in reducing target β-cateninRNA levels when assayed in vitro in a mammalian cell at an effectiveconcentration in the environment of a cell of 1 nanomolar or less.

In one embodiment, the effective amount is 1 nanomolar or less, 200picomolar or less, 100 picomolar or less, 50 picomolar or less, 20picomolar or less, 10 picomolar or less, 5 picomolar or less, 2picomolar or less or 1 picomolar or less in the environment of the cell.

In another embodiment, the invention provides a formulation whichincludes an isolated dsRNA as described, where the dsRNA is present inan amount effective to reduce target RNA levels when the dsRNA isintroduced into a cell of a mammalian subject by at least 10%, at least50% or at least 80-90%, and where the dsRNA possesses greater potencythan isolated 21mer siRNAs directed to the identical at least 15nucleotides of the target β-catenin cDNA in reducing target β-cateninRNA levels when assayed in vitro in a mammalian cell at an effectiveconcentration in the environment of a cell of 1 nanomolar or less.

In one embodiment, the effective amount is a dosage of 1 microgram to 5milligrams per kilogram of the subject per day, 100 micrograms to 0.5milligrams per kilogram, 0.001 to 0.25 milligrams per kilogram, 0.01 to20 micrograms per kilogram, 0.01 to 10 micrograms per kilogram, 0.10 to5 micrograms per kilogram, or 0.1 to 2.5 micrograms per kilogram.

In an additional embodiment, the invention provides a mammalian cellcontaining an isolated dsRNA as described.

Another embodiment of the invention provides a pharmaceuticalcomposition which includes an isolated dsRNA as described and apharmaceutically acceptable carrier. A further embodiment of theinvention provides a kit having an isolated dsRNA as described andinstructions for its use.

In an additional aspect, the invention provides a composition possessingβ-catenin inhibitory activity consisting essentially of an isolateddouble stranded ribonucleic acid (dsRNA) comprising first and secondnucleic acid strands and a duplex region of at least 25 base pairs,where the first strand is 25-34 nucleotides in length and the secondstrand is 26-35 nucleotides in length and comprises 1-5 single-strandednucleotides at its 3′ terminus, where the second oligonucleotide strandis sufficiently complementary to a target β-catenin cDNA sequence of SEQID NOs: 2226-3334 along at least 15 nucleotides of the secondoligonucleotide strand length to reduce β-catenin target gene expressionwhen the double stranded nucleic acid is introduced into a mammaliancell.

In another embodiment, the invention provides a method for treating orpreventing a β-catenin-associated disease or disorder in a subject byadministering a dsRNA and/or dsRNA-containing composition of theinvention and a pharmaceutically acceptable carrier to a subject in anamount sufficient to treat or prevent a β-catenin-associated disease ordisorder in the subject. In a related embodiment, theβ-catenin-associated disease or disorder is colorectal or hepatocellularcancer. Optionally, the β-catenin-associated disease or disorder ismelanoma.

In another aspect, the invention provides an isolated double strandedribonucleic acid (dsRNA) comprising first and second nucleic acidstrands and a duplex region of at least 25 base pairs, wherein the dsRNAcomprises blunt ends, where each of the first and second oligonucleotidestrands consists of the same number of nucleotide residues and is atmost 35 nucleotides in length, wherein the second oligonucleotide strandis sufficiently complementary to a target β-catenin cDNA sequence of SEQID NOs: 2226-3334 along at least 15 nucleotides of the secondoligonucleotide strand length to reduce β-catenin target gene expressionwhen the double stranded nucleic acid is introduced into a mammaliancell.

In one embodiment, the dsRNA is capable of reducing target geneexpression at a concentration of less than 1 nanomolar in theenvironment of a cell. In another embodiment, each of the first and thesecond strands has a length which is at least 26 nucleotides. In arelated embodiment, each of the first and the second strands has alength which is 26-30 nucleotides. Optionally, each of the first and thesecond strands has a length which is 27 nucleotides.

In certain embodiments, the second strand of the dsRNA includes asequence selected from SEQ ID NOs: 1117-2225. (Optionally, the secondstrand is a sequence selected from SEQ ID NOs: 1117-2225.) In relatedembodiments, the first strand of the dsRNA includes a sequence selectedfrom SEQ ID NOs: 5553-7770. (Optionally, the first strand is a sequenceselected from SEQ ID NOs: 5553-7770.) In a further embodiment, the dsRNAincludes a pair of first strand and corresponding second strandsequences selected from Tables 7-8 or 12-13.

Another aspect of the invention provides an isolated double strandedribonucleic acid (dsRNA) comprising first and second nucleic acidstrands and a duplex region of at least 25 base pairs, where the dsRNAcomprises a blunt end, where each of the first and secondoligonucleotide strands consists of the same number of nucleotideresidues and is at most 35 nucleotides in length, where the ultimate andpenultimate residues of the 3′ terminus of the first strand and theultimate and penultimate residues of said 5′ terminus of the secondstrand form one or two mismatched based pairs. where the secondoligonucleotide strand is sufficiently complementary to a targetβ-catenin cDNA sequence of SEQ ID NOs: 2226-3334 along at least 15nucleotides of the second oligonucleotide strand length to reduceβ-catenin target gene expression when the double stranded nucleic acidis introduced into a mammalian cell.

In one embodiment, the first strand includes a sequence of SEQ ID NOs:5553-6661.

In an additional aspect, the invention provides a composition possessingβ-catenin inhibitory activity consisting essentially of an isolateddouble stranded ribonucleic acid (dsRNA) comprising first and secondnucleic acid strands and a duplex region of at least 25 base pairs,where the dsRNA comprises blunt ends, where each of the first and secondoligonucleotide strands consists of the same number of nucleotideresidues and is at most 35 nucleotides in length, where the secondoligonucleotide strand is sufficiently complementary to a targetβ-catenin cDNA sequence of SEQ ID NOs: 2226-3334 along at least 15nucleotides of the second oligonucleotide strand length to reduceβ-catenin target gene expression when the double stranded nucleic acidis introduced into a mammalian cell and the second oligonucleotidestrand is complementary to a target β-catenin cDNA sequence of SEQ IDNOs: 1-3 and 5-6 along at most 35 nucleotides of its length.

In another aspect, the invention provides an isolated dsRNA moleculeconsisting of a sense region and an antisense region, where the senseregion and the antisense region together form a duplex region consistingof 19-35 base pairs and the antisense region includes a sequence that isthe complement of a sequence of SEQ ID NOs 4444-5552, and the isolateddsRNA further includes from zero to two 3′ overhang regions where eachoverhang region is six or fewer nucleotides in length. Optionally, theduplex region consists of 25-35 base pairs.

In a further aspect, the invention provides a siRNA molecule consistingof a sense region and an antisense region, where the sense region andthe antisense region together form a duplex region consisting of 19-23base pairs and the antisense region includes a sequence that is thecomplement of a sequence of SEQ ID NOs 4444-5552, and the isolated dsRNAfurther includes from zero to four overhang regions, where each overhangregion is six or fewer nucleotides in length.

In a further aspect, the invention provides an isolated double strandedribonucleic acid (dsRNA) comprising first and second nucleic acidstrands, wherein the first strand is 15-35 nucleotides in length and thesecond strand is 19-35 nucleotides in length, wherein the secondoligonucleotide strand is sufficiently complementary to a targetβ-catenin cDNA sequence of Table 18 along at least 19 nucleotides of thesecond oligonucleotide strand length to reduce β-catenin target geneexpression when the double stranded nucleic acid is introduced into amammalian cell. In certain embodiments, the isolated dsRNA possesses aduplex region of at least 25 base pairs. In one embodiment, the secondstrand of the isolated dsRNA includes a one to five nucleotide singlestranded overhang of the first strand at the 3′ terminus of the secondstrand. In another embodiment, the first strand is 25-35 nucleotides inlength. In an additional embodiment, the second strand is 25-35nucleotides in length. Optionally, the second oligonucleotide strand iscomplementary to a target β-catenin cDNA sequence of GenBank AccessionNos. NM_001904.3, NM_001098209.1 or NM_001098210.1 along at most 27nucleotides of the second oligonucleotide strand length.

In one embodiment, starting from the first nucleotide (position 1) atthe 3′ terminus of the first oligonucleotide strand, position 1, 2and/or 3 is substituted with a modified nucleotide. In certainembodiments, the modified nucleotide residue of the 3′ terminus of thefirst strand is a deoxyribonucleotide, an acyclonucleotide or afluorescent molecule. In a related embodiment, position 1 of the 3′terminus of the first oligonucleotide strand is a deoxyribonucleotide.

In an additional embodiment, the 3′ terminus of the first strand and the5′ terminus of the second strand form a blunt end.

In another embodiment, the first strand is 25 nucleotides in length andthe second strand is 27 nucleotides in length.

In one embodiment, the second strand includes a sequence of SEQ ID NOs:1122, 1126, 1216, 1239, 1282, 1368, 1165, 1509, 1536 and 1552.

In another embodiment, the first strand includes a sequence of SEQ IDNOs: 13, 17, 107, 130, 173, 259, 56, 400, 427 and 443.

In an additional embodiment, the dsRNA includes a pair of firststrand/second strand sequences as shown for a DsiRNA agent of Tables2-3, 6-9 and 11-13.

In one embodiment, each of the first and the second strands has a lengthwhich is at least 26 nucleotides.

In another embodiment, the nucleotides of the 3′ overhang include amodified nucleotide. Optionally, the modified nucleotide of the 3′overhang is a 2′-O-methyl ribonucleotide. In a related embodiment, allnucleotides of the 3′ overhang are modified nucleotides.

In an additional embodiment, one or both of the first and secondoligonucleotide strands includes a 5′ phosphate.

In another embodiment, the modified nucleotide residues of the dsRNA are2′-O-methyl, 2′-methoxyethoxy, 2′-fluoro, 2′-allyl,2′-O-[2-(methylamino)-2-oxoethyl], 4′-thio, 4′-CH2-O-2′-bridge,4′-(CH2)2-O-2′-bridge, 2′-LNA, 2′-amino or 2′-O—(N-methlycarbamate).

In one embodiment, the 3′ overhang of the dsRNA is 1-3 nucleotides inlength. Optionally, the 3′ overhang is 1-2 nucleotides in length. In arelated embodiment, the 3′ overhang is two nucleotides in length and themodified nucleotide of the 3′ overhang is a 2′-O-methyl modifiedribonucleotide.

In a further embodiment, the second oligonucleotide strand, startingfrom the nucleotide residue of the second strand that is complementaryto the 5′ terminal nucleotide residue of the first oligonucleotidestrand, includes alternating modified and unmodified nucleotideresidues. In another embodiment, the second oligonucleotide strand,starting from the nucleotide residue of the second strand that iscomplementary to the 5′ terminal nucleotide residue of the firstoligonucleotide strand, includes unmodified nucleotide residues at allpositions from position 18 to the 5′ terminus of the secondoligonucleotide strand.

In another embodiment, each of the first and the second strands has alength which is at least 26 and at most 30 nucleotides.

In one embodiment, the dsRNA is cleaved endogenously in the cell byDicer.

In an additional embodiment, the amount of the isolated double strandednucleic acid sufficient to reduce expression of the target gene is 1nanomolar or less, 200 picomolar or less, 100 picomolar or less, 50picomolar or less, 20 picomolar or less, 10 picomolar or less, 5picomolar or less, 2 picomolar or less or 1 picomolar or less in theenvironment of the cell.

In a further embodiment, the isolated dsRNA possesses greater potencythan isolated 21mer siRNAs directed to the identical at least 19nucleotides of the target β-catenin cDNA in reducing target β-cateningene expression when assayed in vitro in a mammalian cell at aneffective concentration in the environment of a cell of 1 nanomolar orless, 200 picomolar or less, 100 picomolar or less, 50 picomolar orless, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2picomolar or less or 1 picomolar or less.

In another embodiment, the isolated dsRNA is sufficiently complementaryto the target β-catenin cDNA sequence to reduce β-catenin target geneexpression by at least 10%, at least 50%, at least 80-90%, at least 95%,at least 98%, or at least 99% when the double stranded nucleic acid isintroduced into a mammalian cell.

In a further embodiment, the first and second strands are joined by achemical linker. In a related embodiment, the 3′ terminus of the firststrand and the 5′ terminus of the second strand are joined by a chemicallinker.

In one embodiment, a nucleotide of the second or first strand issubstituted with a modified nucleotide that directs the orientation ofDicer cleavage.

In another embodiment, the dsRNA has a modified nucleotide that is adeoxyribonucleotide, a dideoxyribonucleotide, an acyclonucleotide, a3′-deoxyadenosine (cordycepin), a 3′-azido-3′-deoxythymidine (AZT), a2′,3′-dideoxyinosine (ddI), a 2′,3′-dideoxy-3′-thiacytidine (3TC), a2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a monophosphate nucleotideof 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxy-3′-thiacytidine(3TC) and a monophosphate nucleotide of2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a 4-thiouracil, a5-bromouracil, a 5-iodouracil, a 5-(3-aminoallyl)-uracil, a 2′-O-alkylribonucleotide, a 2′-O-methyl ribonucleotide, a 2′-amino ribonucleotide,a 2′-fluoro ribonucleotide, or a locked nucleic acid.

In an additional embodiment, the dsRNA has a phosphonate, aphosphorothioate or a phosphotriesterphosphate backbone modification.

In a further embodiment, the dsRNA contains a morpholino nucleic acid oroligonucleotide, or a peptide nucleic acid (PNA).

In one embodiment, the invention provides a method for reducingexpression of a target β-catenin gene in a mammalian cell havingcontacting a mammalian cell in vitro with an isolated dsRNA as describedin an amount sufficient to reduce expression of a target β-catenin genein the cell.

In one embodiment, target β-catenin gene expression is reduced by atleast 10%, at least 50%, or at least 80-90%. In another embodiment,target β-catenin mRNA levels are reduced at least 90% at least 8 daysafter the cell is contacted with the dsRNA. In a further embodiment,β-catenin mRNA levels are reduced by at least 70% at least 10 days afterthe cell is contacted with the dsRNA.

In a further embodiment, the invention provides a method for reducingexpression of a target β-catenin gene in a mammal by administering anisolated dsRNA as described to a mammal in an amount sufficient toreduce expression of a target β-catenin gene in the mammal.

In one embodiment, the isolated dsRNA is administered at a dosage of 1microgram to 5 milligrams per kilogram of the mammal per day, 100micrograms to 0.5 milligrams per kilogram, 0.001 to 0.25 milligrams perkilogram, 0.01 to 20 micrograms per kilogram, 0.01 to 10 micrograms perkilogram, 0.10 to 5 micrograms per kilogram, or 0.1 to 2.5 microgramsper kilogram.

In another embodiment, the isolated dsRNA possesses greater potency thanisolated 21mer siRNAs directed to the identical at least 19 nucleotidesof the target β-catenin cDNA in reducing target β-catenin geneexpression when assayed in vitro in a mammalian cell at an effectiveconcentration in the environment of a cell of 1 nanomolar or less.

In an additional embodiment, the administering step includes intravenousinjection, intramuscular injection, intraperitoneal injection, infusion,subcutaneous injection, transdermal, aerosol, rectal, vaginal, topical,oral or inhaled delivery.

In a further embodiment, the invention provides a method for selectivelyinhibiting the growth of a cell by contacting a cell with an amount ofan isolated dsRNA as described, in an amount sufficient to inhibit thegrowth of the cell.

In one embodiment, the cell is a tumor cell of a subject. Optionally,the cell is a tumor cell in vitro, e.g., a hepatocellular (e.g., HepG2or HuH7) or colorectal (e.g., HCT116) cancer cell, or a HeLa or othercancer cell. In certain embodiments, the cell is a mammalian liver cell.In a related embodiment, the cell is a human cell.

In an additional embodiment, the invention provides a formulation whichincludes an isolated dsRNA as described, where the dsRNA is present inan amount effective to reduce target β-catenin RNA levels when the dsRNAis introduced into a mammalian cell in vitro by at least 10%, at least50% or at least 80-90%, and where the dsRNA possesses greater potencythan isolated 21mer siRNAs directed to the identical at least 19nucleotides of the target β-catenin cDNA in reducing target β-cateninRNA levels when assayed in vitro in a mammalian cell at an effectiveconcentration in the environment of a cell of 1 nanomolar or less.

In one embodiment, the effective amount is 1 nanomolar or less, 200picomolar or less, 100 picomolar or less, 50 picomolar or less, 20picomolar or less, 10 picomolar or less, 5 picomolar or less, 2picomolar or less or 1 picomolar or less in the environment of the cell.

In another embodiment, the invention provides a formulation whichincludes an isolated dsRNA as described, where the dsRNA is present inan amount effective to reduce target RNA levels when the dsRNA isintroduced into a cell of a mammalian subject by at least 10%, at least50% or at least 80-90%, and where the dsRNA possesses greater potencythan isolated 21mer siRNAs directed to the identical at least 19nucleotides of the target β-catenin cDNA in reducing target β-cateninRNA levels when assayed in vitro in a mammalian cell at an effectiveconcentration in the environment of a cell of 1 nanomolar or less.

In one embodiment, the effective amount is a dosage of 1 microgram to 5milligrams per kilogram of the subject per day, 100 micrograms to 0.5milligrams per kilogram, 0.001 to 0.25 milligrams per kilogram, 0.01 to20 micrograms per kilogram, 0.01 to 10 micrograms per kilogram, 0.10 to5 micrograms per kilogram, or 0.1 to 2.5 micrograms per kilogram.

In an additional embodiment, the invention provides a mammalian cellcontaining an isolated dsRNA as described.

Another embodiment of the invention provides a pharmaceuticalcomposition which includes an isolated dsRNA as described and apharmaceutically acceptable carrier. A further embodiment of theinvention provides a kit having an isolated dsRNA as described andinstructions for its use.

In an additional aspect, the invention provides a composition possessingβ-catenin inhibitory activity consisting essentially of an isolateddouble stranded ribonucleic acid (dsRNA) comprising first and secondnucleic acid strands, wherein the first strand is 15-35 nucleotides inlength and the second strand is 19-35 nucleotides in length, wherein thesecond oligonucleotide strand is sufficiently complementary to a targetβ-catenin cDNA sequence of Table 18 along at least 19 nucleotides of thesecond oligonucleotide strand length to reduce β-catenin target geneexpression when the double stranded nucleic acid is introduced into amammalian cell.

In another embodiment, the invention provides a method for treating orpreventing a β-catenin-associated disease or disorder in a subject byadministering a dsRNA and/or dsRNA-containing composition of theinvention and a pharmaceutically acceptable carrier to a subject in anamount sufficient to treat or prevent a β-catenin-associated disease ordisorder in the subject. In a related embodiment, theβ-catenin-associated disease or disorder is hepatocellular or colorectalcancer, or, optionally, renal, breast, lung, ovarian, cervical,esophageal, oropharyngeal or pancreatic cancer.

In another aspect, the invention provides an isolated double strandedribonucleic acid (dsRNA) comprising first and second nucleic acidstrands, wherein the dsRNA comprises blunt ends, wherein each of thefirst and second oligonucleotide strands consists of the same number ofnucleotide residues and is at most 35 nucleotides in length, wherein thesecond oligonucleotide strand is sufficiently complementary to a targetβ-catenin cDNA sequence of Table 18 along at least 19 nucleotides of thesecond oligonucleotide strand length to reduce β-catenin target geneexpression when the double stranded nucleic acid is introduced into amammalian cell.

In one embodiment, the dsRNA is capable of reducing target geneexpression at a concentration of less than 1 nanomolar in theenvironment of a cell. In another embodiment, each of the first and thesecond strands has a length which is at least 26 nucleotides. In arelated embodiment, each of the first and the second strands has alength which is 26-30 nucleotides. Optionally, each of the first and thesecond strands has a length which is 27 nucleotides.

In certain embodiments, the second strand of the dsRNA includes asequence selected from SEQ ID NOs: 1122, 1126, 1216, 1239, 1282, 1368,1165, 1509, 1536 and 1552. In related embodiments, the first strand ofthe dsRNA includes a sequence selected from SEQ ID NOs: 6667, 6671,6761, 6784, 6827, 6913, 6710, 7054, 7081 and 7097. In a furtherembodiment, the dsRNA includes a pair of first strand and correspondingsecond strand sequences selected from Tables 2-3, 6-9 and 11-13.

Another aspect of the invention provides an isolated double strandedribonucleic acid (dsRNA) comprising first and second nucleic acidstrands, wherein the dsRNA comprises a blunt end, wherein each of thefirst and second oligonucleotide strands consists of the same number ofnucleotide residues and is at most 35 nucleotides in length, wherein theultimate and penultimate residues of the 3′ terminus of the first strandand the ultimate and penultimate residues of said 5′ terminus of thesecond strand form one or two mismatched based pairs, wherein the secondoligonucleotide strand is sufficiently complementary to a targetβ-catenin cDNA sequence of Table 18 along at least 19 nucleotides of thesecond oligonucleotide strand length to reduce β-catenin target geneexpression when the double stranded nucleic acid is introduced into amammalian cell.

In one embodiment, the first strand includes a sequence of SEQ ID NOs:5558, 5562, 5652, 5675, 5718, 5804, 5601, 5945, 5972 and 5988.

In an additional aspect, the invention provides a composition possessingβ-catenin inhibitory activity consisting essentially of an isolateddouble stranded ribonucleic acid (dsRNA) comprising first and secondnucleic acid strands, wherein the dsRNA comprises blunt ends, whereineach of the first and second oligonucleotide strands consists of thesame number of nucleotide residues and is at most 35 nucleotides inlength, wherein the second oligonucleotide strand is sufficientlycomplementary to a target β-catenin cDNA sequence of Table 18 along atleast 19 nucleotides of the second oligonucleotide strand length toreduce β-catenin target gene expression when the double stranded nucleicacid is introduced into a mammalian cell.

In another aspect, the invention provides an isolated dsRNA moleculeconsisting of a sense region and an antisense region, where the senseregion and the antisense region together form a duplex region consistingof 15-35 base pairs and the antisense region includes a sequence that isthe complement of a sequence of Table 18, and the isolated dsRNA furtherincludes from zero to two 3′ overhang regions where each overhang regionis six or fewer nucleotides in length. Optionally, the duplex regionconsists of 19-35 base pairs. In certain embodiments, the duplex regionconsists of 25-35 base pairs. In additional embodiments, the duplexregion consists of 25-30 base pairs.

In a further aspect, the invention provides a siRNA molecule consistingof a sense region and an antisense region, where the sense region andthe antisense region together form a duplex region consisting of 19-23base pairs and the antisense region includes a sequence that is thecomplement of a sequence of Table 18, and the isolated dsRNA furtherincludes from zero to four overhang regions, where each overhang regionis six or fewer nucleotides in length.

In certain aspects, the invention is directed to Dicer substrate siRNAs(“DsiRNAs”) with structures and modification patterns that act aseffective and highly potent β-catenin inhibitory agents, optionallypossessing extended duration of inhibitory effect. A number of suchDsiRNAs possess target-specific inhibitory potencies and efficacies thatare significantly enhanced relative to 19-23 base pair double strandednucleic acids (e.g., 21 nucleotide siRNAs) directed against the sametarget RNA. In certain such embodiments, such a DsiRNA is more potent atreducing β-catenin target gene expression in a mammalian cell than a 19,20, 21, 22 or 23 base pair sequence that is contained within it, whensuitably formulated at a concentration of 1 nM or less.

The present invention is also directed to compounds, compositions, andmethods relating to traits, diseases and conditions that respond to themodulation of expression and/or activity of genes involved in CTNNB1gene expression pathways or other cellular processes that mediate themaintenance or development of such traits, diseases and conditions.Specifically, the invention relates to small nucleic acid molecules thatare capable of being processed by the Dicer enzyme, such as Dicersubstrate siRNAs (DsiRNAs) capable of mediating RNA interference (RNAi)against CTNNB1 (β-catenin) gene expression. Such anti-β-catenin DsiRNAsare useful, for example, in providing compositions for treatment oftraits, diseases and conditions that can respond to modulation ofβ-catenin in a subject, such as cancer and/or other proliferativediseases, disorders, or conditions. Efficacy, potency, toxicity andother effects of an anti-β-catenin DsiRNA can be examined in one or moreanimal models of proliferative disease (exemplary suitable animal modelsof proliferative disease are recited below).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the structures of exemplary DsiRNA agents targeting a sitein the β-catenin RNA referred to herein as the “βc-1569” target site.UPPER case=unmodified RNA, lower case=DNA, Bold=mismatch base pairnucleotides; arrowheads indicate projected Dicer enzyme cleavage sites;dashed line indicates sense strand (top strand) sequences correspondingto the projected Argonaute 2 (Ago2) cleavage site within the targetedβ-catenin sequence.

FIGS. 2 and 3 show plots of human β-catenin inhibitory efficaciesobserved at 1 nM in the environment of HeLa cells for DsiRNAs targetingsites progressing from 5′ to 3′ across the human β-catenin transcript.Human β-catenin levels were normalized to HPRT and SFRS9 levels.

FIGS. 4 and 5 show plots of mouse β-catenin inhibitory efficaciesobserved at 1 nM in the environment of Hepa 1-6 cells for DsiRNAstargeting sites progressing from 5′ to 3′ across the mouse β-catenintranscript. Mouse β-catenin levels were normalized to HPRT and Rpl23levels.

FIG. 6 shows that human β-catenin targeting DsiRNAs effectively reducedβ-catenin RNA levels by 90% or more in human HCT116 colon carcinomacells. HCT116 cells were transfected in vitro with indicated DsiRNAs at3 nM or 10 nM, and cells were assayed for β-catenin RNA levels at a 24hour timepoint.

FIG. 7 shows that human β-catenin targeting DsiRNAs significantlyinhibited growth of human HepG2 hepatocarcinoma cells. HepG2 cells weretransfected in vitro with indicated DsiRNAs at 3 nM, and HepG2 celllines were assayed for growth at a three day timepoint.

FIGS. 8-11 show histograms of human β-catenin inhibitory efficaciesobserved for indicated DsiRNAs. “P1” indicates phase 1, while “P2”indicates phase 2. In phase 1, DsiRNAs were tested at 1 nM in theenvironment of HeLa cells. In phase 2, DsiRNAs were tested at 1 nM, at0.3 nM and at 0.1 nM in the environment of HeLa cells. Individual barsrepresent average human β-catenin levels observed in triplicate, withstandard errors shown. Human β-catenin levels were normalized to HPRTand SFRS9 levels. Expression levels were assayed with probe ampliconspositioned at both positions 1297-1397 and 3506-3659 in Hs CTNNB1. (Itis noted that the histograms of FIG. 8 reflect phase 2 values obtainedfor a subpar transfection.)

FIGS. 12-15 show histograms of mouse β-catenin inhibitory efficaciesobserved for indicated DsiRNAs. “P1” indicates phase 1, while “P2”indicates phase 2. In phase 1, DsiRNAs were tested at 1 nM in theenvironment of mouse Hepa 1-6 cells. In phase 2, DsiRNAs were tested at1 nM, at 0.3 nM and at 0.1 nM in the environment of mouse Hepa 1-6cells. Individual bars represent average human β-catenin levels observedin triplicate, with standard errors shown. Human β-catenin levels werenormalized to HPRT and RPL23 levels. Expression levels were assayed withprobe amplicons positioned at both positions 1232-1394 and 2848-2930 inMm CTNNB1. (It is noted that the histograms of FIG. 13 reflect phase 2values obtained for a subpar transfection.)

FIG. 16 shows antisense (guide) strand 2′-O-methyl modification patternsemployed in phase 3 assays.

FIGS. 17-24 present histograms showing phase 3 efficacy data for sixdifferent guide strand modification patterns each across 32β-catenin-targeting DsiRNAs in human HeLa cells at 0.1 nM (parallelassays) and 1 nM. Expression levels were assayed with probe ampliconspositioned at both positions 1297-1397 and 3506-3659 in Hs CTNNB1, withhuman β-catenin levels normalized to HPRT and SFRS9 levels.

FIG. 25 shows that assayed DsiRNAs targeting human β-catenin(βcat-h1569, βcat-h1683, βcat-h2612 and βcat-h3393) effectivelyinhibited expression of Axin-2, a downstream target of β-catenin, inboth HCT116 (colon carcinoma) and HepG2 (hepatocellular carcinoma) celllines. Cells were assayed at two days post-transfection at indicatedconcentrations (3 nM and 10 nM) with designated DsiRNAs.

FIG. 26 shows that transfection of human colorectal cancer cell lineHCT116 cells with certain DsiRNAs targeting human β-catenin (βc-h1683,βc-h2612 and βc-h3393) inhibited the growth of such cells at five dayspost-transfection, as compared to cells administered a control DsiRNA.Cell growth inhibition was assayed using a CellTiter-Blue® CellViability Assay (Promega) at five days post-transfection.

FIG. 27 shows that transfection of human hepatocellular carcinoma cellline HuH7 cells with a DsiRNA targeting human β-catenin inhibited thegrowth of such cells at five days post-transfection, as compared tocells administered a control DsiRNA. Cell growth inhibition was assayedusing a CellTiter-Blue® Cell Viability Assay (Promega) at five dayspost-transfection.

FIG. 28 shows that transfection of human hepatocellular carcinoma cellline HuH7 cells with a DsiRNA targeting human β-catenin (specifically, aβc-h3393 25/27mer possessing an “M11” modified antisense (guide) strandconsisting of 2′-O-methyl modifications at the following positionsstarting from the 5′-terminus (position 1) of the antisense strand: 1,2, 3, 4, 11, 13, 25 and 27) produced knockdown of β-catenin levels ofapproximately 80% at two days post-transfection, when administered witha control DsiRNA, as compared to cells administered only the controlDsiRNA.

FIG. 29 shows fractionated human β-catenin protein levels found in HeLa(cervical cancer), HepG2 (hepatocellular liver carcinoma) and HCT116(colorectal carcinoma) cell lines. Nuclear and cytoplasmic levels ofβ-catenin were identified for each cell line via Western blot, withβ-actin levels assayed as an internal control. Cell extracts wereobtained from confluent six well plates, using a NE-PER Nuclear andCytoplasmic Extraction Reagents Kit (Thermo Fisher Scientific Inc). 75ug of protein was loaded from each cell line. A known truncation mutantform of β-catenin protein was observed in HepG2 cells.

FIG. 30 demonstrates that DsiRNAs targeting human β-catenin were activein vivo in normal mouse liver, inhibiting both β-catenin mRNA (toppanel) and protein (bottom panel) levels significantly (e.g., in manyinstances, approximately 70-90% knockdown was observed) whenadministered as a single dose intravenously to normal mice (n=5 mice pergroup) at 10 mg/kg and formulated in Invivofectamine® 2.0 (Invitrogen™,Carlsbad, Calif.). Liver tissue was harvested at 72 hourspost-administration. All DsiRNAs targeting human β-catenin possessed“M11” modified antisense (guide) strands.

FIG. 31 shows that DsiRNAs targeting human β-catenin were active in vivoin normal mouse liver, inhibiting both β-catenin mRNA (top panel) andAxin-2 mRNA (bottom panel) levels significantly (e.g., in manyinstances, approximately 70-90% knockdown was observed) whenadministered as a single dose intravenously to normal mice (n=5 mice pergroup) at 10 mg/kg and formulated in Invivofectamine® 2.0 (Invitrogen™,Carlsbad, Calif.). Liver tissue was harvested at 72 hourspost-administration. DsiRNAs targeting human β-catenin possessed varyingmodification patterns as indicated, with, e.g., an “M0/M11” patterncorresponding to a 25/27mer DsiRNA possessing an unmodified sense(passenger) strand and a modified antisense (guide) strand having the“M11” pattern of 2′-O-methlyation. It is noted that the “M14”modification pattern of the sense strand corresponds to modification ofthe sense strand at the following positions, starting from the5′-terminus (position 1) of the sense strand: 2, 4, 6, 8, 12, 14, 16 and18.

FIG. 32 demonstrates that DsiRNAs targeting human β-catenin were alsoactive at a 48 hour timepoint in vivo in normal mouse liver, inhibitingboth β-catenin mRNA (top panel) and Axin-2 mRNA (bottom panel) levelssignificantly (e.g., in many instances, approximately 70-90% knockdownwas observed) when administered as a single dose intravenously to normalmice (n=5 mice per group) at 10 mg/kg and formulated in Invivofectamine®2.0 (Invitrogen™, Carlsbad, Calif.). Liver tissue was harvested at 48hours post-administration. DsiRNAs targeting human β-catenin possessedvarying modification patterns as indicated and as described above.Control DsiRNAs possessed similar patterns of modification of sense andantisense strands.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compositions that contain doublestranded RNA (“dsRNA”), and methods for preparing them, that are capableof reducing the level and/or expression of the β-catenin gene in vivo orin vitro. One of the strands of the dsRNA contains a region ofnucleotide sequence that has a length that ranges from 19 to 35nucleotides that can direct the destruction and/or translationalinhibition of the targeted β-catenin transcript.

DEFINITIONS

Unless defined otherwise, all technical and scientific terms used hereinhave the meaning commonly understood by a person skilled in the art towhich this invention belongs. The following references provide one ofskill with a general definition of many of the terms used in thisinvention: Singleton et al., Dictionary of Microbiology and MolecularBiology (2nd ed. 1994); The Cambridge Dictionary of Science andTechnology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R.Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, TheHarper Collins Dictionary of Biology (1991). As used herein, thefollowing terms have the meanings ascribed to them below, unlessspecified otherwise.

The present invention features one or more DsiRNA molecules that canmodulate (e.g., inhibit) β-catenin expression. The DsiRNAs of theinvention optionally can be used in combination with modulators of othergenes and/or gene products associated with the maintenance ordevelopment of diseases or disorders associated with β-cateninmisregulation (e.g., tumor formation and/or growth, etc.). The DsiRNAagents of the invention modulate β-catenin RNAs such as thosecorresponding to the cDNA sequences referred to by GenBank AccessionNos. NM_001904.3 (human β-catenin, transcript variant 1), NM_001098209.1(human β-catenin, transcript variant 2), NM_001098210.1 (humanβ-catenin, transcript variant 3) and NM_007614.2 & NM_007614.3 (mouseβ-catenin), which are recited below and referred to herein generally as“β-catenin.”

The below description of the various aspects and embodiments of theinvention is provided with reference to exemplary β-catenin RNAs,generally referred to herein as β-catenin. However, such reference ismeant to be exemplary only and the various aspects and embodiments ofthe invention are also directed to alternate β-catenin RNAs, such asmutant β-catenin RNAs or additional β-catenin splice variants. Certainaspects and embodiments are also directed to other genes involved inβ-catenin pathways, including genes whose misregulation acts inassociation with that of β-catenin (or is affected or affects β-cateninregulation) to produce phenotypic effects that may be targeted fortreatment (e.g., tumor formation and/or growth, etc.). Such additionalgenes can be targeted using DsiRNA and the methods described herein foruse of β-catenin targeting DsiRNAs. Thus, the inhibition and the effectsof such inhibition of the other genes can be performed as describedherein.

The terms “β-catenin” and “CTNNB1” refer to nucleic acid sequencesencoding a β-catenin protein, peptide, or polypeptide (e.g., β-catenintranscripts, such as the sequences of β-catenin Genbank Accession Nos.NM_001904.3, NM_001098209.1, NM_001098210.1, NM_007614.2 andNM_007614.3). In certain embodiments, the term “β-catenin” is also meantto include other β-catenin encoding sequence, such as other β-cateninisoforms, mutant β-catenin genes, splice variants of β-catenin genes,and β-catenin gene polymorphisms. The term “β-catenin” is used to referto the polypeptide gene product of a β-catenin gene/transript, e.g., aβ-catenin protein, peptide, or polypeptide, such as those encoded byβ-catenin Genbank Accession Nos. NM_001904.3, NM_001098209.1,NM_001098210.1, NM_007614.2 and NM_007614.3.

As used herein, a “β-catenin-associated disease or disorder” refers to adisease or disorder known in the art to be associated with alteredβ-catenin expression, level and/or activity. Notably, a“β-catenin-associated disease or disorder” includes cancer and/orproliferative diseases, conditions, or disorders. Two exemplary“β-catenin-associated diseases or disorders” are colorectal cancer andmelanoma.

By “proliferative disease” or “cancer” as used herein is meant, adisease, condition, trait, genotype or phenotype characterized byunregulated cell growth or replication as is known in the art; includingleukemias, for example, acute myelogenous leukemia (AML), chronicmyelogenous leukemia (CML), acute lymphocytic leukemia (ALL), andchronic lymphocytic leukemia, AIDS related cancers such as Kaposi'ssarcoma; breast cancers; bone cancers such as Osteosarcoma,Chondrosarcomas, Ewing's sarcoma, Fibrosarcomas, Giant cell tumors,Adamantinomas, and Chordomas; Brain cancers such as Meningiomas,Glioblastomas, Lower-Grade Astrocytomas, Oligodendrocytomas, PituitaryTumors, Schwannomas, and Metastatic brain cancers; cancers of the headand neck including various lymphomas such as mantle cell lymphoma,non-Hodgkins lymphoma, adenoma, squamous cell carcinoma, laryngealcarcinoma, gallbladder and bile duct cancers, cancers of the retina suchas retinoblastoma, cancers of the esophagus, gastric cancers, multiplemyeloma, ovarian cancer, uterine cancer, thyroid cancer, testicularcancer, endometrial cancer, melanoma, colorectal cancer, lung cancer,bladder cancer, prostate cancer, lung cancer (including non-small celllung carcinoma), pancreatic cancer, sarcomas, Wilms' tumor, cervicalcancer, head and neck cancer, skin cancers, nasopharyngeal carcinoma,liposarcoma, epithelial carcinoma, renal cell carcinoma, gallbladderadeno carcinoma, parotid adenocarcinoma, endometrial sarcoma, multidrugresistant cancers; and proliferative diseases and conditions, such asneovascularization associated with tumor angiogenesis, maculardegeneration (e.g., wet/dry AMD), corneal neovascularization, diabeticretinopathy, neovascular glaucoma, myopic degeneration and otherproliferative diseases and conditions such as restenosis and polycystickidney disease, and other cancer or proliferative disease, condition,trait, genotype or phenotype that can respond to the modulation ofdisease related gene expression in a cell or tissue, alone or incombination with other therapies.

In certain embodiments, dsRNA-mediated inhibition of a β-catenin targetsequence is assessed. In such embodiments, β-catenin RNA levels can beassessed by art-recognized methods (e.g., RT-PCR, Northern blot,expression array, etc.), optionally via comparison of β-catenin levelsin the presence of an anti-β-catenin dsRNA of the invention relative tothe absence of such an anti-β-catenin dsRNA. In certain embodiments,β-catenin levels in the presence of an anti-β-catenin dsRNA are comparedto those observed in the presence of vehicle alone, in the presence of adsRNA directed against an unrelated target RNA, or in the absence of anytreatment.

It is also recognized that levels of β-catenin protein can be assessedas indicative of β-catenin RNA levels, but only to the extent that it isknown, under a given set of cellular and/or tissue conditions, whetherthe level of β-catenin protein is directly or indirectly related toβ-catenin RNA levels and/or the extent to which a dsRNA inhibitsβ-catenin expression, thus art-recognized methods of assessing β-cateninprotein levels (e.g., Western blot, immunoprecipitation, otherantibody-based methods, etc.) can also be employed to examine theinhibitory effect of a dsRNA of the invention.

An anti-β-catenin dsRNA of the invention is deemed to possess “β-catenininhibitory activity” if a statistically significant reduction inβ-catenin RNA level is seen when an anti-β-catenin dsRNA of theinvention is administered to a system (e.g., cell-free in vitro system),cell, tissue or organism, as compared to a selected control. Thedistribution of experimental values and the number of replicate assaysperformed will tend to dictate the parameters of what levels ofreduction in β-catenin RNA (either as a % or in absolute terms) isdeemed statistically significant (as assessed by standard methods ofdetermining statistical significance known in the art). However, incertain embodiments, “β-catenin inhibitory activity” is defined basedupon a % or absolute level of reduction in the level of β-catenin mRNAin a system, cell, tissue or organism. For example, in certainembodiments, a DsiRNA of the invention is deemed to possess β-catenininhibitory activity if at least a 5% reduction or at least a 10%reduction in β-catenin RNA is observed in the presence of a DsiRNA ofthe invention relative to β-catenin mRNA levels seen for a suitablecontrol. (For example, in vivo β-catenin levels in a tissue and/orsubject can, in certain embodiments, be deemed to be inhibited by aDsiRNA agent of the invention if, e.g., a 5% or 10% reduction inβ-catenin levels is observed relative to a control.) In certain otherembodiments, a DsiRNA of the invention is deemed to possess β-catenininhibitory activity if β-catenin RNA levels are observed to be reducedby at least 15% relative to a selected control, by at least 20% relativeto a selected control, by at least 25% relative to a selected control,by at least 30% relative to a selected control, by at least 35% relativeto a selected control, by at least 40% relative to a selected control,by at least 45% relative to a selected control, by at least 50% relativeto a selected control, by at least 55% relative to a selected control,by at least 60% relative to a selected control, by at least 65% relativeto a selected control, by at least 70% relative to a selected control,by at least 75% relative to a selected control, by at least 80% relativeto a selected control, by at least 85% relative to a selected control,by at least 90% relative to a selected control, by at least 95% relativeto a selected control, by at least 96% relative to a selected control,by at least 97% relative to a selected control, by at least 98% relativeto a selected control or by at least 99% relative to a selected control.In some embodiments, complete inhibition of β-catenin is required for aDsiRNA to be deemed to possess β-catenin inhibitory activity. In certainmodels (e.g., cell culture), a DsiRNA is deemed to possess β-catenininhibitory activity if at least a 50% reduction in β-catenin levels isobserved relative to a suitable control. In certain other embodiments, aDsiRNA is deemed to possess β-catenin inhibitory activity if at least an80% reduction in β-catenin levels is observed relative to a suitablecontrol.

By way of specific example, in the Examples below, a series of DsiRNAstargeting β-catenin were tested for the ability to reduce β-catenin mRNAlevels in human HeLa or mouse Hepa 1-6 cells in vitro, at 1 nMconcentrations in the environment of such cells and in the presence of atransfection agent (Lipofectamine™ RNAiMAX, Invitrogen). Within thebelow Examples, β-catenin inhibitory activity was initially ascribed tothose DsiRNAs that were observed to effect at least a 70% reduction ofβ-catenin mRNA levels under the assayed conditions. It is contemplatedthat β-catenin inhibitory activity could also be attributed to a dsRNAunder either more or less stringent conditions than those employed forthe Examples below, even when the same or a similar assay and conditionsare employed. For example, in certain embodiments, a tested dsRNA of theinvention is deemed to possess β-catenin inhibitory activity if at leasta 10% reduction, at least a 20% reduction, at least a 30% reduction, atleast a 40% reduction, at least a 50% reduction, at least a 60%reduction, at least a 75% reduction, at least an 80% reduction, at leastan 85% reduction, at least a 90% reduction, or at least a 95% reductionin β-catenin mRNA levels is observed in a mammalian cell line in vitroat 1 nM dsRNA concentration or lower in the environment of a cell,relative to a suitable control.

Use of other endpoints for determination of whether a double strandedRNA of the invention possesses β-catenin inhibitory activity is alsocontemplated. Specifically, in one embodiment, in addition to or as analternative to assessing β-catenin mRNA levels, the ability of a testeddsRNA to reduce β-catenin protein levels (e.g., at 48 hours aftercontacting a mammalian cell in vitro or in vivo) is assessed, and atested dsRNA is deemed to possess β-catenin inhibitory activity if atleast a 10% reduction, at least a 20% reduction, at least a 30%reduction, at least a 40% reduction, at least a 50% reduction, at leasta 60% reduction, at least a 70% reduction, at least a 75% reduction, atleast an 80% reduction, at least an 85% reduction, at least a 90%reduction, or at least a 95% reduction in β-catenin protein levels isobserved in a mammalian cell contacted with the assayed double strandedRNA in vitro or in vivo, relative to a suitable control. Additionalendpoints contemplated include, e.g., assessment of a phenotypeassociated with reduction of β-catenin levels—e.g., reduction of growthof a contacted mammalian cell line in vitro and/or reduction of growthof a tumor in vivo, including, e.g., halting or reducing the growth oftumor or cancer cell levels as described in greater detail elsewhereherein.

β-catenin inhibitory activity can also be evaluated over time (duration)and over concentration ranges (potency), with assessment of whatconstitutes a dsRNA possessing β-catenin inhibitory activity adjusted inaccordance with concentrations administered and duration of timefollowing administration. Thus, in certain embodiments, a DsiRNA of theinvention is deemed to possess β-catenin inhibitory activity if at leasta 50% reduction in β-catenin activity is observed at a duration of timeof 2 hours, 5 hours, 10 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6days, 7 days, 8 days, 9 days, 10 days or more after administration isobserved/persists. In additional embodiments, a DsiRNA of the inventionis deemed to be a potent β-catenin inhibitory agent if β-catenininhibitory activity (e.g., in certain embodiments, at least 50%inhibition of β-catenin) is observed at a concentration of 1 nM or less,500 pM or less, 200 pM or less, 100 pM or less, 50 pM or less, 20 pM orless, 10 pM or less, 5 pM or less, 2 pM or less or even 1 pM or less inthe environment of a cell, for example, within an in vitro assay forβ-catenin inhibitory activity as described herein. In certainembodiments, a potent β-catenin inhibitory dsRNA of the invention isdefined as one that is capable of β-catenin inhibitory activity (e.g.,in certain embodiments, at least 20% reduction of β-catenin levels) at aformulated concentration of 10 mg/kg or less when administered to asubject in an effective delivery vehicle (e.g., an effective lipidnanoparticle formulation). Preferably, a potent β-catenin inhibitorydsRNA of the invention is defined as one that is capable of β-catenininhibitory activity (e.g., in certain embodiments, at least 50%reduction of β-catenin levels) at a formulated concentration of 5 mg/kgor less when administered to a subject in an effective delivery vehicle.More preferably, a potent β-catenin inhibitory dsRNA of the invention isdefined as one that is capable of β-catenin inhibitory activity (e.g.,in certain embodiments, at least 50% reduction of β-catenin levels) at aformulated concentration of 5 mg/kg or less when administered to asubject in an effective delivery vehicle. Optionally, a potent β-catenininhibitory dsRNA of the invention is defined as one that is capable ofβ-catenin inhibitory activity (e.g., in certain embodiments, at least50% reduction of β-catenin levels) at a formulated concentration of 2mg/kg or less, or even 1 mg/kg or less, when administered to a subjectin an effective delivery vehicle.

In certain embodiments, potency of a dsRNA of the invention isdetermined in reference to the number of copies of a dsRNA present inthe cytoplasm of a target cell that are required to achieve a certainlevel of target gene knockdown. For example, in certain embodiments, apotent dsRNA is one capable of causing 50% or greater knockdown of atarget mRNA when present in the cytoplasm of a target cell at a copynumber of 1000 or fewer RISC-loaded antisense strands per cell. Morepreferably, a potent dsRNA is one capable of producing 50% or greaterknockdown of a target mRNA when present in the cytoplasm of a targetcell at a copy number of 500 or fewer RISC-loaded antisense strands percell. Optionally, a potent dsRNA is one capable of producing 50% orgreater knockdown of a target mRNA when present in the cytoplasm of atarget cell at a copy number of 300 or fewer RISC-loaded antisensestrands per cell.

In further embodiments, the potency of a DsiRNA of the invention can bedefined in reference to a 19 to 23mer dsRNA directed to the same targetsequence within the same target gene. For example, a DsiRNA of theinvention that possesses enhanced potency relative to a corresponding 19to 23mer dsRNA can be a DsiRNA that reduces a target gene by anadditional 5% or more, an additional 10% or more, an additional 20% ormore, an additional 30% or more, an additional 40% or more, or anadditional 50% or more as compared to a corresponding 19 to 23mer dsRNA,when assayed in an in vitro assay as described herein at a sufficientlylow concentration to allow for detection of a potency difference (e.g.,transfection concentrations at or below 1 nM in the environment of acell, at or below 100 pM in the environment of a cell, at or below 10 pMin the environment of a cell, at or below 1 nM in the environment of acell, in an in vitro assay as described herein; notably, it isrecognized that potency differences can be best detected via performanceof such assays across a range of concentrations—e.g., 0.1 pM to 10nM—for purpose of generating a dose-response curve and identifying anIC50 value associated with a DsiRNA/dsRNA).

β-catenin inhibitory levels and/or β-catenin levels may also be assessedindirectly, e.g., measurement of a reduction in a β-catenin-associateddisease marker protein or target gene, such as MYC, Cyclin D1, or Axin2,or reduction of the size or number of polyps or tumors (e.g., colontumors) in a subject may be used to assess β-catenin levels and/orβ-catenin inhibitory efficacy of a double-stranded nucleic acid of theinstant invention.

In certain embodiments, the phrase “consists essentially of” is used inreference to the anti-β-catenin dsRNAs of the invention. In some suchembodiments, “consists essentially of” refers to a composition thatcomprises a dsRNA of the invention which possesse at least a certainlevel of β-catenin inhibitory activity (e.g., at least 50% β-catenininhibitory activity) and that also comprises one or more additionalcomponents and/or modifications that do not significantly impact theβ-catenin inhibitory activity of the dsRNA. For example, in certainembodiments, a composition “consists essentially of” a dsRNA of theinvention where modifications of the dsRNA of the invention and/ordsRNA-associated components of the composition do not alter theβ-catenin inhibitory activity (optionally including potency or durationof β-catenin inhibitory activity) by greater than 3%, greater than 5%,greater than 10%, greater than 15%, greater than 20%, greater than 25%,greater than 30%, greater than 35%, greater than 40%, greater than 45%,or greater than 50% relative to the dsRNA of the invention in isolation.In certain embodiments, a composition is deemed to consist essentiallyof a dsRNA of the invention even if more dramatic reduction of β-catenininhibitory activity (e.g., 80% reduction, 90% reduction, etc. inefficacy, duration and/or potency) occurs in the presence of additionalcomponents or modifications, yet where β-catenin inhibitory activity isnot significantly elevated (e.g., observed levels of β-catenininhibitory activity are within 10% of those observed for the isolateddsRNA of the invention) in the presence of additional components and/ormodifications.

As used herein, the phrase “dsRNA reduces β-catenin mRNA levels by atleast X % when assayed in vitro in a mammalian cell at an effectiveconcentration in the environment of said cell of 1 nanomolar or less”refers to a requirement for the dsRNA to reduce the native β-cateninmRNA levels of a HeLa cell population by at least X %, when assayed at atransfection concentration of 1 nanomolar or less in the presence ofLipofectamine™ RNAiMAX (Invitrogen) and following manufacturer'sinstructions. Such HeLa cells are obtained from ATCC and maintained inDMEM (HyClone) supplemented with 10% fetal bovine serum (HyClone) at 37°C. under 5% CO₂. β-catenin mRNA levels are then assayed at 24 h or 48 hpost-transfection to assess % inhibition, with respect to an appropriatecontrol as described elsewhere herein. In certain embodiments, the HeLacells of such assays are replaced with HepG2, HCT116, HuH7 or other cellline.

As used herein, the term “nucleic acid” refers to deoxyribonucleotides,ribonucleotides, or modified nucleotides, and polymers thereof insingle- or double-stranded form. The term encompasses nucleic acidscontaining known nucleotide analogs or modified backbone residues orlinkages, which are synthetic, naturally occurring, and non-naturallyoccurring, which have similar binding properties as the referencenucleic acid, and which are metabolized in a manner similar to thereference nucleotides. Examples of such analogs include, withoutlimitation, phosphorothioates, phosphoramidates, methyl phosphonates,chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleicacids (PNAs).

As used herein, “nucleotide” is used as recognized in the art to includethose with natural bases (standard), and modified bases well known inthe art. Such bases are generally located at the 1′ position of anucleotide sugar moiety. Nucleotides generally comprise a base, sugarand a phosphate group. The nucleotides can be unmodified or modified atthe sugar, phosphate and/or base moiety, (also referred tointerchangeably as nucleotide analogs, modified nucleotides, non-naturalnucleotides, non-standard nucleotides and other; see, e.g., Usman andMcSwiggen US 2009/0137500; Eckstein et al., International PCTPublication No. WO 92/07065; Usman et al., International PCT PublicationNo. WO 93/15187; Uhlman & Peyman U.S. Pat. No. 6,326,487, all are herebyincorporated by reference herein). There are several examples ofmodified nucleic acid bases known in the art as summarized by Limbach etal., Nucleic Acids Res. 22:2183, 1994. Some of the non-limiting examplesof base modifications that can be introduced into nucleic acid moleculesinclude, hypoxanthine, purine, pyridin-4-one, pyridin-2-one, phenyl,pseudouracil, 2,4,6-trimethoxy benzene, 3-methyl uracil, dihydrouridine,naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine),5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g.,5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g.6-methyluridine), propyne, and others (Burgin, et al., Biochemistry35:14090, 1996; Uhlman & Peyman, supra). By “modified bases” in thisaspect is meant nucleotide bases other than adenine, guanine, cytosineand uracil at 1′ position or their equivalents.

As used herein, “modified nucleotide” refers to a nucleotide that hasone or more modifications to the nucleoside, the nucleobase, pentosering, or phosphate group. For example, modified nucleotides excluderibonucleotides containing adenosine monophosphate, guanosinemonophosphate, uridine monophosphate, and cytidine monophosphate anddeoxyribonucleotides containing deoxyadenosine monophosphate,deoxyguanosine monophosphate, deoxythymidine monophosphate, anddeoxycytidine monophosphate. Modifications include those naturallyoccurring that result from modification by enzymes that modifynucleotides, such as methyltransferases. Modified nucleotides alsoinclude synthetic or non-naturally occurring nucleotides. Synthetic ornon-naturally occurring modifications in nucleotides include those with2′ modifications, e.g., 2′-methoxyethoxy, 2′-fluoro, 2′-allyl,2′-O-[2-(methylamino)-2-oxoethyl], 4′-thio, 4′-O—CH₂—O-2′-bridge,4′-(CH₂)₂—O-2′-bridge, 2′-LNA, and 2′-O—(N-methylcarbamate) or thosecomprising base analogs. In connection with 2′-modified nucleotides asdescribed for the present disclosure, by “amino” is meant 2′-NH₂ or2′-O—NH₂, which can be modified or unmodified. Such modified groups aredescribed, e.g., in Eckstein et al., U.S. Pat. No. 5,672,695 andMatulic-Adamic et al., U.S. Pat. No. 6,248,878.

In reference to the nucleic acid molecules of the present disclosure,modifications may exist upon these agents in patterns on one or bothstrands of the double stranded ribonucleic acid (dsRNA). As used herein,“alternating positions” refers to a pattern where every other nucleotideis a modified nucleotide or there is an unmodified nucleotide (e.g., anunmodified ribonucleotide) between every modified nucleotide over adefined length of a strand of the dsRNA (e.g., 5′-MNMNMN-3′;3′-MNMNMN-5′; where M is a modified nucleotide and N is an unmodifiednucleotide). The modification pattern starts from the first nucleotideposition at either the 5′ or 3′ terminus according to a positionnumbering convention, e.g., as described herein (in certain embodiments,position 1 is designated in reference to the terminal residue of astrand following a projected Dicer cleavage event of a DsiRNA agent ofthe invention; thus, position 1 does not always constitute a 3′ terminalor 5′ terminal residue of a pre-processed agent of the invention). Thepattern of modified nucleotides at alternating positions may run thefull length of the strand, but in certain embodiments includes at least4, 6, 8, 10, 12, 14 nucleotides containing at least 2, 3, 4, 5, 6 or 7modified nucleotides, respectively. As used herein, “alternating pairsof positions” refers to a pattern where two consecutive modifiednucleotides are separated by two consecutive unmodified nucleotides overa defined length of a strand of the dsRNA (e.g., 5′-MMNNMMNNMMNN-3′;3′-MMNNMMNNMMNN-5′; where M is a modified nucleotide and N is anunmodified nucleotide). The modification pattern starts from the firstnucleotide position at either the 5′ or 3′ terminus according to aposition numbering convention such as those described herein. Thepattern of modified nucleotides at alternating positions may run thefull length of the strand, but preferably includes at least 8, 12, 16,20, 24, 28 nucleotides containing at least 4, 6, 8, 10, 12 or 14modified nucleotides, respectively. It is emphasized that the abovemodification patterns are exemplary and are not intended as limitationson the scope of the invention.

As used herein, “base analog” refers to a heterocyclic moiety which islocated at the 1′ position of a nucleotide sugar moiety in a modifiednucleotide that can be incorporated into a nucleic acid duplex (or theequivalent position in a nucleotide sugar moiety substitution that canbe incorporated into a nucleic acid duplex). In the dsRNAs of theinvention, a base analog is generally either a purine or pyrimidine baseexcluding the common bases guanine (G), cytosine (C), adenine (A),thymine (T), and uracil (U). Base analogs can duplex with other bases orbase analogs in dsRNAs. Base analogs include those useful in thecompounds and methods of the invention, e.g., those disclosed in U.S.Pat. Nos. 5,432,272 and 6,001,983 to Benner and US Patent PublicationNo. 20080213891 to Manoharan, which are herein incorporated byreference. Non-limiting examples of bases include hypoxanthine (I),xanthine (X), 3β-D-ribofuranosyl-(2,6-diaminopyrimidine) (K),3-β-D-ribofuranosyl-(1-methyl-pyrazolo[4,3-d]pyrimidine-5,7(4H,6H)-dione)(P), iso-cytosine (iso-C), iso-guanine (iso-G),1-β-D-ribofuranosyl-(5-nitroindole),1-β-D-ribofuranosyl-(3-nitropyrrole), 5-bromouracil, 2-aminopurine,4-thio-dT, 7-(2-thienyl)-imidazo[4,5-b]pyridine (Ds) andpyrrole-2-carbaldehyde (Pa), 2-amino-6-(2-thienyl)purine (S),2-oxopyridine (Y), difluorotolyl, 4-fluoro-6-methylbenzimidazole,4-methylbenzimidazole, 3-methyl isocarbostyrilyl, 5-methylisocarbostyrilyl, and 3-methyl-7-propynyl isocarbostyrilyl,7-azaindolyl, 6-methyl-7-azaindolyl, imidizopyridinyl,9-methyl-imidizopyridinyl, pyrrolopyrizinyl, isocarbostyrilyl,7-propynyl isocarbostyrilyl, propynyl-7-azaindolyl,2,4,5-trimethylphenyl, 4-methylindolyl, 4,6-dimethylindolyl, phenyl,napthalenyl, anthracenyl, phenanthracenyl, pyrenyl, stilbenzyl,tetracenyl, pentacenyl, and structural derivates thereof (Schweitzer etal., J. Org. Chem., 59:7238-7242 (1994); Berger et al., Nucleic AcidsResearch, 28(15):2911-2914 (2000); Moran et al., J. Am. Chem. Soc.,119:2056-2057 (1997); Morales et al., J. Am. Chem. Soc., 121:2323-2324(1999); Guckian et al., J. Am. Chem. Soc., 118:8182-8183 (1996); Moraleset al., J. Am. Chem. Soc., 122(6):1001-1007 (2000); McMinn et al., J.Am. Chem. Soc., 121:11585-11586 (1999); Guckian et al., J. Org. Chem.,63:9652-9656 (1998); Moran et al., Proc. Natl. Acad. Sci.,94:10506-10511 (1997); Das et al., J. Chem. Soc., Perkin Trans.,1:197-206 (2002); Shibata et al., J. Chem. Soc., Perkin Trans., 1:1605-1611 (2001); Wu et al., J. Am. Chem. Soc., 122(32):7621-7632(2000); O'Neill et al., J. Org. Chem., 67:5869-5875 (2002); Chaudhuri etal., J. Am. Chem. Soc., 117:10434-10442 (1995); and U.S. Pat. No.6,218,108). Base analogs may also be a universal base.

As used herein, “universal base” refers to a heterocyclic moiety locatedat the 1′ position of a nucleotide sugar moiety in a modifiednucleotide, or the equivalent position in a nucleotide sugar moietysubstitution, that, when present in a nucleic acid duplex, can bepositioned opposite more than one type of base without altering thedouble helical structure (e.g., the structure of the phosphatebackbone). Additionally, the universal base does not destroy the abilityof the single stranded nucleic acid in which it resides to duplex to atarget nucleic acid. The ability of a single stranded nucleic acidcontaining a universal base to duplex a target nucleic can be assayed bymethods apparent to one in the art (e.g., UV absorbance, circulardichroism, gel shift, single stranded nuclease sensitivity, etc.).Additionally, conditions under which duplex formation is observed may bevaried to determine duplex stability or formation, e.g., temperature, asmelting temperature (Tm) correlates with the stability of nucleic acidduplexes. Compared to a reference single stranded nucleic acid that isexactly complementary to a target nucleic acid, the single strandednucleic acid containing a universal base forms a duplex with the targetnucleic acid that has a lower Tm than a duplex formed with thecomplementary nucleic acid. However, compared to a reference singlestranded nucleic acid in which the universal base has been replaced witha base to generate a single mismatch, the single stranded nucleic acidcontaining the universal base forms a duplex with the target nucleicacid that has a higher Tm than a duplex formed with the nucleic acidhaving the mismatched base.

Some universal bases are capable of base pairing by forming hydrogenbonds between the universal base and all of the bases guanine (G),cytosine (C), adenine (A), thymine (T), and uracil (U) under base pairforming conditions. A universal base is not a base that forms a basepair with only one single complementary base. In a duplex, a universalbase may form no hydrogen bonds, one hydrogen bond, or more than onehydrogen bond with each of G, C, A, T, and U opposite to it on theopposite strand of a duplex. Preferably, the universal base does notinteract with the base opposite to it on the opposite strand of aduplex. In a duplex, base pairing involving a universal base occurswithout altering the double helical structure of the phosphate backbone.A universal base may also interact with bases in adjacent nucleotides onthe same nucleic acid strand by stacking interactions. Such stackinginteractions stabilize the duplex, especially in situations where theuniversal base does not form any hydrogen bonds with the base positionedopposite to it on the opposite strand of the duplex. Non-limitingexamples of universal-binding nucleotides include inosine,1-β-D-ribofuranosyl-5-nitroindole, and/or1-β-D-ribofuranosyl-3-nitropyrrole (US Pat. Appl. Publ. No. 20070254362to Quay et al.; Van Aerschot et al., An acyclic 5-nitroindazolenucleoside analogue as ambiguous nucleoside. Nucleic Acids Res. 1995Nov. 11; 23(21):4363-70; Loakes et al., 3-Nitropyrrole and 5-nitroindoleas universal bases in primers for DNA sequencing and PCR. Nucleic AcidsRes. 1995 Jul. 11; 23(13):2361-6; Loakes and Brown, 5-Nitroindole as anuniversal base analogue. Nucleic Acids Res. 1994 Oct. 11;22(20):4039-43).

As used herein, “loop” refers to a structure formed by a single strandof a nucleic acid, in which complementary regions that flank aparticular single stranded nucleotide region hybridize in a way that thesingle stranded nucleotide region between the complementary regions isexcluded from duplex formation or Watson-Crick base pairing. A loop is asingle stranded nucleotide region of any length. Examples of loopsinclude the unpaired nucleotides present in such structures as hairpins,stem loops, or extended loops.

As used herein, “extended loop” in the context of a dsRNA refers to asingle stranded loop and in addition 1, 2, 3, 4, 5, 6 or up to 20 basepairs or duplexes flanking the loop. In an extended loop, nucleotidesthat flank the loop on the 5′ side form a duplex with nucleotides thatflank the loop on the 3′ side. An extended loop may form a hairpin orstem loop.

As used herein, “tetraloop” in the context of a dsRNA refers to a loop(a single stranded region) consisting of four nucleotides that forms astable secondary structure that contributes to the stability of anadjacent Watson-Crick hybridized nucleotides. Without being limited totheory, a tetraloop may stabilize an adjacent Watson-Crick base pair bystacking interactions. In addition, interactions among the fournucleotides in a tetraloop include but are not limited tonon-Watson-Crick base pairing, stacking interactions, hydrogen bonding,and contact interactions (Cheong et al., Nature 1990 Aug. 16;346(6285):680-2; Heus and Pardi, Science 1991 Jul. 12; 253(5016):191-4).A tetraloop confers an increase in the melting temperature (Tm) of anadjacent duplex that is higher than expected from a simple model loopsequence consisting of four random bases. For example, a tetraloop canconfer a melting temperature of at least 55° C. in 10 mM NaHPO₄ to ahairpin comprising a duplex of at least 2 base pairs in length. Atetraloop may contain ribonucleotides, deoxyribonucleotides, modifiednucleotides, and combinations thereof. Examples of RNA tetraloopsinclude the UNCG family of tetraloops (e.g., UUCG), the GNRA family oftetraloops (e.g., GAAA), and the CUUG tetraloop. (Woese et al., ProcNatl Acad Sci USA. 1990 November; 87(21):8467-71; Antao et al., NucleicAcids Res. 1991 Nov. 11; 19(21):5901-5). Examples of DNA tetraloopsinclude the d(GNNA) family of tetraloops (e.g., d(GTTA), the d(GNRA))family of tetraloops, the d(GNAB) family of tetraloops, the d(CNNG)family of tetraloops, the d(TNCG) family of tetraloops (e.g., d(TTCG)).(Nakano et al. Biochemistry, 41 (48), 14281-14292, 2002; SHINJI et al.Nippon Kagakkai Koen Yokoshu VOL. 78th; NO. 2; PAGE. 731 (2000).)

As used herein, the term “siRNA” refers to a double stranded nucleicacid in which each strand comprises RNA, RNA analog(s) or RNA and DNA.The siRNA comprises between 19 and 23 nucleotides or comprises 21nucleotides. The siRNA typically has 2 bp overhangs on the 3′ ends ofeach strand such that the duplex region in the siRNA comprises 17-21nucleotides, or 19 nucleotides. Typically, the antisense strand of thesiRNA is sufficiently complementary with the target sequence of theβ-catenin gene/RNA.

An anti-β-catenin DsiRNA of the instant invention possesses strandlengths of at least 25 nucleotides. Accordingly, in certain embodiments,an anti-β-catenin DsiRNA contains one oligonucleotide sequence, a firstsequence, that is at least 25 nucleotides in length and no longer than35 or up to 50 or more nucleotides. This sequence of RNA can be between26 and 35, 26 and 34, 26 and 33, 26 and 32, 26 and 31, 26 and 30, and 26and 29 nucleotides in length. This sequence can be 27 or 28 nucleotidesin length or 27 nucleotides in length. The second sequence of the DsiRNAagent can be a sequence that anneals to the first sequence underbiological conditions, such as within the cytoplasm of a eukaryoticcell. Generally, the second oligonucleotide sequence will have at least19 complementary base pairs with the first oligonucleotide sequence,more typically the second oligonucleotide sequence will have 21 or morecomplementary base pairs, or 25 or more complementary base pairs withthe first oligonucleotide sequence. In one embodiment, the secondsequence is the same length as the first sequence, and the DsiRNA agentis blunt ended. In another embodiment, the ends of the DsiRNA agent haveone or more overhangs.

In certain embodiments, the first and second oligonucleotide sequencesof the DsiRNA agent exist on separate oligonucleotide strands that canbe and typically are chemically synthesized. In some embodiments, bothstrands are between 26 and 35 nucleotides in length. In otherembodiments, both strands are between 25 and 30 or 26 and 30 nucleotidesin length. In one embodiment, both strands are 27 nucleotides in length,are completely complementary and have blunt ends. In certain embodimentsof the instant invention, the first and second sequences of ananti-β-catenin DsiRNA exist on separate RNA oligonucleotides (strands).In one embodiment, one or both oligonucleotide strands are capable ofserving as a substrate for Dicer. In other embodiments, at least onemodification is present that promotes Dicer to bind to thedouble-stranded RNA structure in an orientation that maximizes thedouble-stranded RNA structure's effectiveness in inhibiting geneexpression. In certain embodiments of the instant invention, theanti-β-catenin DsiRNA agent is comprised of two oligonucleotide strandsof differing lengths, with the anti-β-catenin DsiRNA possessing a bluntend at the 3′ terminus of a first strand (sense strand) and a 3′overhang at the 3′ terminus of a second strand (antisense strand). TheDsiRNA can also contain one or more deoxyribonucleic acid (DNA) basesubstitutions.

Suitable DsiRNA compositions that contain two separate oligonucleotidescan be chemically linked outside their annealing region by chemicallinking groups. Many suitable chemical linking groups are known in theart and can be used. Suitable groups will not block Dicer activity onthe DsiRNA and will not interfere with the directed destruction of theRNA transcribed from the target gene. Alternatively, the two separateoligonucleotides can be linked by a third oligonucleotide such that ahairpin structure is produced upon annealing of the two oligonucleotidesmaking up the DsiRNA composition. The hairpin structure will not blockDicer activity on the DsiRNA and will not interfere with the directeddestruction of the target RNA.

As used herein, a dsRNA, e.g., DsiRNA or siRNA, having a sequence“sufficiently complementary” to a target RNA or cDNA sequence (e.g.,β-catenin mRNA) means that the dsRNA has a sequence sufficient totrigger the destruction of the target RNA (where a cDNA sequence isrecited, the RNA sequence corresponding to the recited cDNA sequence) bythe RNAi machinery (e.g., the RISC complex) or process. For example, adsRNA that is “sufficiently complementary” to a target RNA or cDNAsequence to trigger the destruction of the target RNA by the RNAimachinery or process can be identified as a dsRNA that causes adetectable reduction in the level of the target RNA in an appropriateassay of dsRNA activity (e.g., an in vitro assay as described in Example2 below), or, in further examples, a dsRNA that is sufficientlycomplementary to a target RNA or cDNA sequence to trigger thedestruction of the target RNA by the RNAi machinery or process can beidentified as a dsRNA that produces at least a 5%, at least a 10%, atleast a 15%, at least a 20%, at least a 25%, at least a 30%, at least a35%, at least a 40%, at least a 45%, at least a 50%, at least a 55%, atleast a 60%, at least a 65%, at least a 70%, at least a 75%, at least a80%, at least a 85%, at least a 90%, at least a 95%, at least a 98% orat least a 99% reduction in the level of the target RNA in anappropriate assay of dsRNA activity. In additional examples, a dsRNAthat is sufficiently complementary to a target RNA or cDNA sequence totrigger the destruction of the target RNA by the RNAi machinery orprocess can be identified based upon assessment of the duration of acertain level of inhibitory activity with respect to the target RNA orprotein levels in a cell or organism. For example, a dsRNA that issufficiently complementary to a target RNA or cDNA sequence to triggerthe destruction of the target RNA by the RNAi machinery or process canbe identified as a dsRNA capable of reducing target mRNA levels by atleast 20% at least 48 hours post-administration of said dsRNA to a cellor organism. Preferably, a dsRNA that is sufficiently complementary to atarget RNA or cDNA sequence to trigger the destruction of the target RNAby the RNAi machinery or process is identified as a dsRNA capable ofreducing target mRNA levels by at least 40% at least 72 hourspost-administration of said dsRNA to a cell or organism, by at least 40%at least four, five or seven days post-administration of said dsRNA to acell or organism, by at least 50% at least 48 hours post-administrationof said dsRNA to a cell or organism, by at least 50% at least 72 hourspost-administration of said dsRNA to a cell or organism, by at least 50%at least four, five or seven days post-administration of said dsRNA to acell or organism, by at least 80% at least 48 hours post-administrationof said dsRNA to a cell or organism, by at least 80% at least 72 hourspost-administration of said dsRNA to a cell or organism, or by at least80% at least four, five or seven days post-administration of said dsRNAto a cell or organism.

The dsRNA molecule can be designed such that every residue of theantisense strand is complementary to a residue in the target molecule.Alternatively, substitutions can be made within the molecule to increasestability and/or enhance processing activity of said molecule.Substitutions can be made within the strand or can be made to residuesat the ends of the strand. In certain embodiments, substitutions and/ormodifications are made at specific residues within a DsiRNA agent. Suchsubstitutions and/or modifications can include, e.g.,deoxy-modifications at one or more residues of positions 1, 2 and 3 whennumbering from the 3′ terminal position of the sense strand of a DsiRNAagent; and introduction of 2′-O-alkyl (e.g., 2′-O-methyl) modificationsat the 3′ terminal residue of the antisense strand of DsiRNA agents,with such modifications also being performed at overhang positions ofthe 3′ portion of the antisense strand and at alternating residues ofthe antisense strand of the DsiRNA that are included within the regionof a DsiRNA agent that is processed to form an active siRNA agent. Thepreceding modifications are offered as exemplary, and are not intendedto be limiting in any manner. Further consideration of the structure ofpreferred DsiRNA agents, including further description of themodifications and substitutions that can be performed upon theanti-β-catenin DsiRNA agents of the instant invention, can be foundbelow.

Where a first sequence is referred to as “substantially complementary”with respect to a second sequence herein, the two sequences can be fullycomplementary, or they may form one or more, but generally not more than4, 3 or 2 mismatched base pairs upon hybridization, while retaining theability to hybridize under the conditions most relevant to theirultimate application. However, where two oligonucleotides are designedto form, upon hybridization, one or more single stranded overhangs, suchoverhangs shall not be regarded as mismatches with regard to thedetermination of complementarity. For example, a dsRNA comprising oneoligonucleotide 21 nucleotides in length and another oligonucleotide 23nucleotides in length, wherein the longer oligonucleotide comprises asequence of 21 nucleotides that is fully complementary to the shorteroligonucleotide, may yet be referred to as “fully complementary” for thepurposes of the invention.

The term “double-stranded RNA” or “dsRNA”, as used herein, refers to acomplex of ribonucleic acid molecules, having a duplex structurecomprising two anti-parallel and substantially complementary, as definedabove, nucleic acid strands. The two strands forming the duplexstructure may be different portions of one larger RNA molecule, or theymay be separate RNA molecules. Where separate RNA molecules, such dsRNAare often referred to as siRNA (“short interfering RNA”) or DsiRNA(“Dicer substrate siRNAs”). Where the two strands are part of one largermolecule, and therefore are connected by an uninterrupted chain ofnucleotides between the 3′-end of one strand and the 5′ end of therespective other strand forming the duplex structure, the connecting RNAchain is referred to as a “hairpin loop”, “short hairpin RNA” or“shRNA”. Where the two strands are connected covalently by means otherthan an uninterrupted chain of nucleotides between the 3′-end of onestrand and the 5′end of the respective other strand forming the duplexstructure, the connecting structure is referred to as a “linker”. TheRNA strands may have the same or a different number of nucleotides. Themaximum number of base pairs is the number of nucleotides in theshortest strand of the dsRNA minus any overhangs that are present in theduplex. In addition to the duplex structure, a dsRNA may comprise one ormore nucleotide overhangs. In addition, as used herein, “dsRNA” mayinclude chemical modifications to ribonucleotides, internucleosidelinkages, end-groups, caps, and conjugated moieties, includingsubstantial modifications at multiple nucleotides and including alltypes of modifications disclosed herein or known in the art. Any suchmodifications, as used in an siRNA- or DsiRNA-type molecule, areencompassed by “dsRNA” for the purposes of this specification andclaims.

The phrase “duplex region” refers to the region in two complementary orsubstantially complementary oligonucleotides that form base pairs withone another, either by Watson-Crick base pairing or other manner thatallows for a duplex between oligonucleotide strands that arecomplementary or substantially complementary. For example, anoligonucleotide strand having 21 nucleotide units can base pair withanother oligonucleotide of 21 nucleotide units, yet only 19 bases oneach strand are complementary or substantially complementary, such thatthe “duplex region” consists of 19 base pairs. The remaining base pairsmay, for example, exist as 5′ and 3′ overhangs. Further, within theduplex region, 100% complementarity is not required; substantialcomplementarity is allowable within a duplex region. Substantialcomplementarity refers to complementarity between the strands such thatthey are capable of annealing under biological conditions. Techniques toempirically determine if two strands are capable of annealing underbiological conditions are well know in the art. Alternatively, twostrands can be synthesized and added together under biologicalconditions to determine if they anneal to one another.

Single-stranded nucleic acids that base pair over a number of bases aresaid to “hybridize.” Hybridization is typically determined underphysiological or biologically relevant conditions (e.g., intracellular:pH 7.2, 140 mM potassium ion; extracellular pH 7.4, 145 mM sodium ion).Hybridization conditions generally contain a monovalent cation andbiologically acceptable buffer and may or may not contain a divalentcation, complex anions, e.g. gluconate from potassium gluconate,uncharged species such as sucrose, and inert polymers to reduce theactivity of water in the sample, e.g. PEG. Such conditions includeconditions under which base pairs can form.

Hybridization is measured by the temperature required to dissociatesingle stranded nucleic acids forming a duplex, i.e., (the meltingtemperature; Tm). Hybridization conditions are also conditions underwhich base pairs can form. Various conditions of stringency can be usedto determine hybridization (see, e.g., Wahl, G. M. and S. L. Berger(1987) Methods Enzymol. 152:399; Kimmel, A. R. (1987) Methods Enzymol.152:507). Stringent temperature conditions will ordinarily includetemperatures of at least about 30° C., more preferably of at least about37° C., and most preferably of at least about 42° C. The hybridizationtemperature for hybrids anticipated to be less than 50 base pairs inlength should be 5-10° C. less than the melting temperature (Tm) of thehybrid, where Tm is determined according to the following equations. Forhybrids less than 18 base pairs in length, Tm(° C.)=2(# of A+Tbases)+4(# of G+C bases). For hybrids between 18 and 49 base pairs inlength, Tm(° C.)=81.5+16.6(log 10[Na+])+0.41 (% G+C)−(600/N), where N isthe number of bases in the hybrid, and [Na+] is the concentration ofsodium ions in the hybridization buffer ([Na+] for 1×SSC=0.165 M). Forexample, a hybridization determination buffer is shown in Table 1.

TABLE 1 To make 50 mL final conc. Vender Cat# Lot# m.w./Stock solutionNaCl 100 mM Sigma S-5150 41K8934  5M 1 mL KCl 80 mM Sigma P-9541 70K0002 74.55 0.298 g MgCl₂ 8 mM Sigma M-1028 120K8933  1M 0.4 mL sucrose 2%w/v Fisher BP220- 907105 342.3 1 g 212 Tris-HCl 16 mM Fisher BP1757- 12419  1M 0.8 mL 500 NaH₂PO₄ 1 mM Sigma S-3193 52H- 120.0 0.006 g029515 EDTA 0.02 mM Sigma E-7889 110K89271  0.5M 2 μL H₂O Sigma W-450251K2359 to 50 mL pH = 7.0 adjust with at 20° C. HCl

Useful variations on hybridization conditions will be readily apparentto those skilled in the art. Hybridization techniques are well known tothose skilled in the art and are described, for example, in Benton andDavis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad.Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in MolecularBiology, Wiley Interscience, New York, 2001); Berger and Kimmel(Antisense to Molecular Cloning Techniques, 1987, Academic Press, NewYork); and Sambrook et al., Molecular Cloning: A Laboratory Manual, ColdSpring Harbor Laboratory Press, New York.

As used herein, “oligonucleotide strand” is a single stranded nucleicacid molecule. An oligonucleotide may comprise ribonucleotides,deoxyribonucleotides, modified nucleotides (e.g., nucleotides with 2′modifications, synthetic base analogs, etc.) or combinations thereof.Such modified oligonucleotides can be preferred over native formsbecause of properties such as, for example, enhanced cellular uptake andincreased stability in the presence of nucleases.

As used herein, the term “ribonucleotide” encompasses natural andsynthetic, unmodified and modified ribonucleotides. Modificationsinclude changes to the sugar moiety, to the base moiety and/or to thelinkages between ribonucleotides in the oligonucleotide. As used herein,the term “ribonucleotide” specifically excludes a deoxyribonucleotide,which is a nucleotide possessing a single proton group at the 2′ ribosering position.

As used herein, the term “deoxyribonucleotide” encompasses natural andsynthetic, unmodified and modified deoxyribonucleotides. Modificationsinclude changes to the sugar moiety, to the base moiety and/or to thelinkages between deoxyribonucleotide in the oligonucleotide. As usedherein, the term “deoxyribonucleotide” also includes a modifiedribonucleotide that does not permit Dicer cleavage of a dsRNA agent,e.g., a 2′-O-methyl ribonucleotide, a phosphorothioate-modifiedribonucleotide residue, etc., that does not permit Dicer cleavage tooccur at a bond of such a residue.

As used herein, the term “PS-NA” refers to a phosphorothioate-modifiednucleotide residue. The term “PS-NA” therefore encompasses bothphosphorothioate-modified ribonucleotides (“PS-RNAs”) andphosphorothioate-modified deoxyribonucleotides (“PS-DNAs”).

As used herein, “Dicer” refers to an endoribonuclease in the RNase IIIfamily that cleaves a dsRNA or dsRNA-containing molecule, e.g.,double-stranded RNA (dsRNA) or pre-microRNA (miRNA), intodouble-stranded nucleic acid fragments 19-25 nucleotides long, usuallywith a two-base overhang on the 3′ end. With respect to the dsRNAs ofthe invention, the duplex formed by a dsRNA region of an agent of theinvention is recognized by Dicer and is a Dicer substrate on at leastone strand of the duplex. Dicer catalyzes the first step in the RNAinterference pathway, which consequently results in the degradation of atarget RNA. The protein sequence of human Dicer is provided at the NCBIdatabase under accession number NP_085124, hereby incorporated byreference.

Dicer “cleavage” is determined as follows (e.g., see Collingwood et al.,Oligonucleotides 18:187-200 (2008)). In a Dicer cleavage assay, RNAduplexes (100 pmol) are incubated in 20 μL of 20 mM Tris pH 8.0, 200 mMNaCl, 2.5 mM MgCl2 with or without 1 unit of recombinant human Dicer(Stratagene, La Jolla, Calif.) at 37° C. for 18-24 hours. Samples aredesalted using a Performa SR 96-well plate (Edge Biosystems,Gaithersburg, Md.). Electrospray-ionization liquid chromatography massspectroscopy (ESI-LCMS) of duplex RNAs pre- and post-treatment withDicer is done using an Oligo HTCS system (Novatia, Princeton, N.J.; Hailet al., 2004), which consists of a ThermoFinnigan TSQ7000, Xcalibur datasystem, ProMass data processing software and Paradigm MS4 HPLC (MichromBioResources, Auburn, Calif.). In this assay, Dicer cleavage occurswhere at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, oreven 100% of the Dicer substrate dsRNA, (i.e., 25-30 bp, dsRNA,preferably 26-30 bp dsRNA) is cleaved to a shorter dsRNA (e.g., 19-23 bpdsRNA, preferably, 21-23 bp dsRNA).

As used herein, “Dicer cleavage site” refers to the sites at which Dicercleaves a dsRNA (e.g., the dsRNA region of a DsiRNA agent of theinvention). Dicer contains two RNase III domains which typically cleaveboth the sense and antisense strands of a dsRNA. The average distancebetween the RNase III domains and the PAZ domain determines the lengthof the short double-stranded nucleic acid fragments it produces and thisdistance can vary (Macrae et al. (2006) Science 311: 195-8). As shown inFIG. 1, Dicer is projected to cleave certain double-stranded ribonucleicacids of the instant invention that possess an antisense strand having a2 nucleotide 3′ overhang at a site between the 21^(st) and 22^(nd)nucleotides removed from the 3′ terminus of the antisense strand, and ata corresponding site between the 21^(st) and 22^(nd) nucleotides removedfrom the 5′ terminus of the sense strand. The projected and/or prevalentDicer cleavage site(s) for dsRNA molecules distinct from those depictedin FIG. 1 may be similarly identified via art-recognized methods,including those described in Macrae et al. While the Dicer cleavageevents depicted in FIG. 1 generate 21 nucleotide siRNAs, it is notedthat Dicer cleavage of a dsRNA (e.g., DsiRNA) can result in generationof Dicer-processed siRNA lengths of 19 to 23 nucleotides in length.Indeed, in certain embodiments, a double-stranded DNA region may beincluded within a dsRNA for purpose of directing prevalent Dicerexcision of a typically non-preferred 19mer or 20mer siRNA, rather thana 21mer.

As used herein, “overhang” refers to unpaired nucleotides, in thecontext of a duplex having one or more free ends at the 5′ terminus or3′ terminus of a dsRNA. In certain embodiments, the overhang is a 3′ or5′ overhang on the antisense strand or sense strand. In someembodiments, the overhang is a 3′ overhang having a length of betweenone and six nucleotides, optionally one to five, one to four, one tothree, one to two, two to six, two to five, two to four, two to three,three to six, three to five, three to four, four to six, four to five,five to six nucleotides, or one, two, three, four, five or sixnucleotides.

A dsRNA of the invention comprises two RNA strands that are sufficientlycomplementary to hybridize to form a duplex structure. One strand of thedsRNA (the antisense strand) comprises a region of complementarity thatis substantially complementary, and generally fully complementary, to atarget sequence, derived from the sequence of an mRNA formed during theexpression of the β-catenin target gene, the other strand (the sensestrand) comprises a region which is complementary to the antisensestrand, such that the two strands hybridize and form a duplex structurewhen combined under suitable conditions. Generally, the duplex structureis between 15 and 35, optionally between 25 and 30, between 26 and 30,between 18 and 25, between 19 and 24, or between 19 and 21 base pairs inlength. Similarly, the region of complementarity to the target sequenceis between 15 and 35, optionally between 18 and 30, between 25 and 30,between 19 and 24, or between 19 and 21 nucleotides in length. The dsRNAof the invention may further comprise one or more single-strandednucleotide overhang(s). It has been identified that dsRNAs comprisingduplex structures of between 15 and 35 base pairs in length can beeffective in inducing RNA interference, including DsiRNAs (generally ofat least 25 base pairs in length) and siRNAs (in certain embodiments,duplex structures of siRNAs are between 20 and 23, and optionally,specifically 21 base pairs (Elbashir et al., EMBO 20: 6877-6888)). Ithas also been identified that dsRNAs possessing duplexes shorter than 20base pairs can be effective as well (e.g., 15, 16, 17, 18 or 19 basepair duplexes). In certain embodiments, the dsRNAs of the invention cancomprise at least one strand of a length of 19 nucleotides or more. Incertain embodiments, it can be reasonably expected that shorter dsRNAscomprising a sequence complementary to one of the sequences of Table 10below, minus only a few nucleotides on one or both ends may be similarlyeffective as compared to the dsRNAs described above and in Tables 2-5and 7-10. Hence, dsRNAs comprising a partial sequence of at least 15,16, 17, 18, 19, 20, or more contiguous nucleotides sufficientlycomplementary to one of the sequences of Table 10, and differing intheir ability to inhibit the expression of the β-catenin target gene inan assay as described herein by not more than 5, 10, 15, 20, 25, or 30%inhibition from a dsRNA comprising the full sequence, are contemplatedby the invention. In one embodiment, at least one end of the dsRNA has asingle-stranded nucleotide overhang of 1 to 5, optionally 1 to 4, incertain embodiments, 1 or 2 nucleotides. Certain dsRNA structures havingat least one nucleotide overhang possess superior inhibitory propertiesas compared to counterparts possessing base-paired blunt ends at bothends of the dsRNA molecule.

As used herein, the term “RNA processing” refers to processingactivities performed by components of the siRNA, miRNA or RNase Hpathways (e.g., Drosha, Dicer, Argonaute2 or other RISCendoribonucleases, and RNaseH), which are described in greater detailbelow (see “RNA Processing” section below). The term is explicitlydistinguished from the post-transcriptional processes of 5′ capping ofRNA and degradation of RNA via non-RISC- or non-RNase H-mediatedprocesses. Such “degradation” of an RNA can take several forms, e.g.deadenylation (removal of a 3′ poly(A) tail), and/or nuclease digestionof part or all of the body of the RNA by one or more of several endo- orexo-nucleases (e.g., RNase III, RNase P, RNase T1, RNase A (1, 2, 3,4/5), oligonucleotidase, etc.).

By “homologous sequence” is meant, a nucleotide sequence that is sharedby one or more polynucleotide sequences, such as genes, gene transcriptsand/or non-coding polynucleotides. For example, a homologous sequencecan be a nucleotide sequence that is shared by two or more genesencoding related but different proteins, such as different members of agene family, different protein epitopes, different protein isoforms orcompletely divergent genes, such as a cytokine and its correspondingreceptors. A homologous sequence can be a nucleotide sequence that isshared by two or more non-coding polynucleotides, such as noncoding DNAor RNA, regulatory sequences, introns, and sites of transcriptionalcontrol or regulation. Homologous sequences can also include conservedsequence regions shared by more than one polynucleotide sequence.Homology does not need to be perfect homology (e.g., 100%), as partiallyhomologous sequences are also contemplated by the instant invention(e.g., 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%,86%, 85%, 84%, 83%, 82%, 81%, 80% etc.). Indeed, design and use of theDsiRNA agents of the instant invention contemplates the possibility ofusing such DsiRNA agents not only against target RNAs of β-cateninpossessing perfect complementarity with the presently described DsiRNAagents, but also against target β-catenin RNAs possessing sequences thatare, e.g., only 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%,88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80% etc. complementary to saidDsiRNA agents. Similarly, it is contemplated that the presentlydescribed DsiRNA agents of the instant invention might be readilyaltered by the skilled artisan to enhance the extent of complementaritybetween said DsiRNA agents and a target β-catenin RNA, e.g., of aspecific allelic variant of β-catenin (e.g., an allele of enhancedtherapeutic interest). Indeed, DsiRNA agent sequences with insertions,deletions, and single point mutations relative to the target β-cateninsequence can also be effective for inhibition. Alternatively, DsiRNAagent sequences with nucleotide analog substitutions or insertions canbe effective for inhibition.

Sequence identity may be determined by sequence comparison and alignmentalgorithms known in the art. To determine the percent identity of twonucleic acid sequences (or of two amino acid sequences), the sequencesare aligned for comparison purposes (e.g., gaps can be introduced in thefirst sequence or second sequence for optimal alignment). Thenucleotides (or amino acid residues) at corresponding nucleotide (oramino acid) positions are then compared. When a position in the firstsequence is occupied by the same residue as the corresponding positionin the second sequence, then the molecules are identical at thatposition. The percent identity between the two sequences is a functionof the number of identical positions shared by the sequences (i.e., %homology=# of identical positions/total # of positions.times. 100),optionally penalizing the score for the number of gaps introduced and/orlength of gaps introduced.

The comparison of sequences and determination of percent identitybetween two sequences can be accomplished using a mathematicalalgorithm. In one embodiment, the alignment generated over a certainportion of the sequence aligned having sufficient identity but not overportions having low degree of identity (i.e., a local alignment). Apreferred, non-limiting example of a local alignment algorithm utilizedfor the comparison of sequences is the algorithm of Karlin and Altschul(1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as in Karlin andAltschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77. Such an algorithmis incorporated into the BLAST programs (version 2.0) of Altschul, etal. (1990) J. Mol. Biol. 215:403-10.

In another embodiment, a gapped alignment is formed by introducing gaps,and percent identity is determined over the length of the alignedsequences. To obtain gapped alignments for comparison purposes, GappedBLAST can be utilized as described in Altschul et al., (1997) NucleicAcids Res. 25(17):3389-3402. In another embodiment, a global alignmentis formed by introducing gaps, and percent identity is determined overthe entire length of the sequences aligned. A preferred, non-limitingexample of a mathematical algorithm utilized for the global comparisonof sequences is the algorithm of Myers and Miller, CABIOS (1989). Suchan algorithm is incorporated into the ALIGN program (version 2.0) whichis part of the GCG sequence alignment software package. When utilizingthe ALIGN program for comparing amino acid sequences, a PAM120 weightresidue table, a gap length penalty of 12, and a gap penalty of 4 can beused.

Greater than 80% sequence identity, e.g., 80%, 81%, 82%, 83%, 84%, 85%,86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% oreven 100% sequence identity, between the DsiRNA antisense strand and theportion of the β-catenin RNA sequence is preferred. Alternatively, theDsiRNA may be defined functionally as a nucleotide sequence (oroligonucleotide sequence) that is capable of hybridizing with a portionof the β-catenin RNA (e.g., 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA,50° C. or 70° C. hybridization for 12-16 hours; followed by washing).Additional preferred hybridization conditions include hybridization at70° C. in 1×SSC or 50° C. in 1×SSC, 50% formamide followed by washing at70° C. in 0.3×SSC or hybridization at 70° C. in 4×SSC or 50° C. in4×SSC, 50% formamide followed by washing at 67° C. in 1×SSC. Thehybridization temperature for hybrids anticipated to be less than 50base pairs in length should be 5-10° C. less than the meltingtemperature (Tm) of the hybrid, where Tm is determined according to thefollowing equations. For hybrids less than 18 base pairs in length, Tm(°C.)=2(# of A+T bases)+4(# of G+C bases). For hybrids between 18 and 49base pairs in length, Tm(° C.)=81.5+16.6(log 10[Na+])+0.41 (%G+C)−(600/N), where N is the number of bases in the hybrid, and [Na+] isthe concentration of sodium ions in the hybridization buffer ([Na+] for1×SSC=0.165 M). Additional examples of stringency conditions forpolynucleotide hybridization are provided in Sambrook, J., E. F.Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual,Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters9 and 11, and Current Protocols in Molecular Biology, 1995, F. M.Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and6.3-6.4. The length of the identical nucleotide sequences may be atleast 10, 12, 15, 17, 20, 22, 25, 27 or 30 bases.

By “conserved sequence region” is meant, a nucleotide sequence of one ormore regions in a polynucleotide does not vary significantly betweengenerations or from one biological system, subject, or organism toanother biological system, subject, or organism. The polynucleotide caninclude both coding and non-coding DNA and RNA.

By “sense region” is meant a nucleotide sequence of a DsiRNA moleculehaving complementarity to an antisense region of the DsiRNA molecule. Inaddition, the sense region of a DsiRNA molecule can comprise a nucleicacid sequence having homology with a target nucleic acid sequence.

By “antisense region” is meant a nucleotide sequence of a DsiRNAmolecule having complementarity to a target nucleic acid sequence. Inaddition, the antisense region of a DsiRNA molecule comprises a nucleicacid sequence having complementarity to a sense region of the DsiRNAmolecule.

As used herein, “antisense strand” refers to a single stranded nucleicacid molecule which has a sequence complementary to that of a targetRNA. When the antisense strand contains modified nucleotides with baseanalogs, it is not necessarily complementary over its entire length, butmust at least hybridize with a target RNA.

As used herein, “sense strand” refers to a single stranded nucleic acidmolecule which has a sequence complementary to that of an antisensestrand. When the antisense strand contains modified nucleotides withbase analogs, the sense strand need not be complementary over the entirelength of the antisense strand, but must at least duplex with theantisense strand.

As used herein, “guide strand” refers to a single stranded nucleic acidmolecule of a dsRNA or dsRNA-containing molecule, which has a sequencesufficiently complementary to that of a target RNA to result in RNAinterference.

After cleavage of the dsRNA or dsRNA-containing molecule by Dicer, afragment of the guide strand remains associated with RISC, binds atarget RNA as a component of the RISC complex, and promotes cleavage ofa target RNA by RISC. As used herein, the guide strand does notnecessarily refer to a continuous single stranded nucleic acid and maycomprise a discontinuity, preferably at a site that is cleaved by Dicer.A guide strand is an antisense strand.

As used herein, “passenger strand” refers to an oligonucleotide strandof a dsRNA or dsRNA-containing molecule, which has a sequence that iscomplementary to that of the guide strand. As used herein, the passengerstrand does not necessarily refer to a continuous single strandednucleic acid and may comprise a discontinuity, preferably at a site thatis cleaved by Dicer. A passenger strand is a sense strand.

By “target nucleic acid” is meant a nucleic acid sequence whoseexpression, level or activity is to be modulated. The target nucleicacid can be DNA or RNA. For agents that target AR, in certainembodiments target nucleic acid is β-catenin RNA. β-catenin RNA targetsites can also interchangeably be referenced by corresponding cDNAsequences. Levels of β-catenin may also be targeted via targeting ofupstream effectors of β-catenin, or the effects of modulated ormisregulated β-catenin may also be modulated by targeting of moleculesdownstream of β-catenin in the β-catenin signalling pathway.

By “complementarity” is meant that a nucleic acid can form hydrogenbond(s) with another nucleic acid sequence by either traditionalWatson-Crick or other non-traditional types. In reference to the nucleicmolecules of the present invention, the binding free energy for anucleic acid molecule with its complementary sequence is sufficient toallow the relevant function of the nucleic acid to proceed, e.g., RNAiactivity. Determination of binding free energies for nucleic acidmolecules is well known in the art (see, e.g., Turner et al., 1987, CSHSymp. Quant. Biol. LII pp. 123-133; Frier et al., 1986, Proc. Nat. Acad.Sci. USA 83:9373-9377; Turner et al., 1987, J. Am. Chem. Soc.109:3783-3785). A percent complementarity indicates the percentage ofcontiguous residues in a nucleic acid molecule that can form hydrogenbonds (e.g., Watson-Crick base pairing) with a second nucleic acidsequence (e.g., 5, 6, 7, 8, 9, or 10 nucleotides out of a total of 10nucleotides in the first oligonucleotide being based paired to a secondnucleic acid sequence having 10 nucleotides represents 50%, 60%, 70%,80%, 90%, and 100% complementary respectively). “Perfectlycomplementary” means that all the contiguous residues of a nucleic acidsequence will hydrogen bond with the same number of contiguous residuesin a second nucleic acid sequence. In one embodiment, a DsiRNA moleculeof the invention comprises 19 to 30 (e.g., 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, or 30 or more) nucleotides that are complementary to oneor more target nucleic acid molecules or a portion thereof.

In one embodiment, DsiRNA molecules of the invention that down regulateor reduce β-catenin gene expression are used for treating, preventing orreducing β-catenin-related diseases or disorders (e.g., cancer) in asubject or organism.

In one embodiment of the present invention, each sequence of a DsiRNAmolecule of the invention is independently 25 to 35 nucleotides inlength, in specific embodiments 25, 26, 27, 28, 29, 30, 31, 32, 33, 34or 35 nucleotides in length. In another embodiment, the DsiRNA duplexesof the invention independently comprise 25 to 30 base pairs (e.g., 25,26, 27, 28, 29, or 30). In another embodiment, one or more strands ofthe DsiRNA molecule of the invention independently comprises 19 to 35nucleotides (e.g., 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34 or 35) that are complementary to a target (AR) nucleic acidmolecule. In certain embodiments, a DsiRNA molecule of the inventionpossesses a length of duplexed nucleotides between 25 and 34 nucleotidesin length (e.g., 25, 26, 27, 28, 29, 30, 31, 32, 33 or 34 nucleotides inlength; optionally, all such nucleotides base pair with cognatenucleotides of the opposite strand). (Exemplary DsiRNA molecules of theinvention are shown in FIG. 1, and below.

As used herein “cell” is used in its usual biological sense, and doesnot refer to an entire multicellular organism, e.g., specifically doesnot refer to a human. The cell can be present in an organism, e.g.,birds, plants and mammals such as humans, cows, sheep, apes, monkeys,swine, dogs, and cats. The cell can be prokaryotic (e.g., bacterialcell) or eukaryotic (e.g., mammalian or plant cell). The cell can be ofsomatic or germ line origin, totipotent or pluripotent, dividing ornon-dividing. The cell can also be derived from or can comprise a gameteor embryo, a stem cell, or a fully differentiated cell. Within certainaspects, the term “cell” refers specifically to mammalian cells, such ashuman cells, that contain one or more isolated dsRNA molecules of thepresent disclosure. In particular aspects, a cell processes dsRNAs ordsRNA-containing molecules resulting in RNA intereference of targetnucleic acids, and contains proteins and protein complexes required forRNAi, e.g., Dicer and RISC.

In certain embodiments, dsRNAs of the invention are Dicer substratesiRNAs (“DsiRNAs”). DsiRNAs can possess certain advantages as comparedto inhibitory nucleic acids that are not dicer substrates(“non-DsiRNAs”). Such advantages include, but are not limited to,enhanced duration of effect of a DsiRNA relative to a non-DsiRNA, aswell as enhanced inhibitory activity of a DsiRNA as compared to anon-DsiRNA (e.g., a 19-23mer siRNA) when each inhibitory nucleic acid issuitably formulated and assessed for inhibitory activity in a mammaliancell at the same concentration (in this latter scenario, the DsiRNAwould be identified as more potent than the non-DsiRNA). Detection ofthe enhanced potency of a DsiRNA relative to a non-DsiRNA is often mostreadily achieved at a formulated concentration (e.g., transfectionconcentration of the dsRNA) that results in the DsiRNA elicitingapproximately 30-70% knockdown activity upon a target RNA (e.g., amRNA). For active DsiRNAs, such levels of knockdown activity are mostoften achieved at in vitro mammalian cell DsiRNA transfectionconcentrations of 1 nM or less of as suitably formulated, and in certaininstances are observed at DsiRNA transfection concentrations of 200 pMor less, 100 pM or less, 50 pM or less, 20 pM or less, 10 pM or less, 5pM or less, or even 1 pM or less. Indeed, due to the variability amongDsiRNAs of the precise concentration at which 30-70% knockdown of atarget RNA is observed, construction of an IC50 curve via assessment ofthe inhibitory activity of DsiRNAs and non-DsiRNAs across a range ofeffective concentrations is a preferred method for detecting theenhanced potency of a DsiRNA relative to a non-DsiRNA inhibitory agent.

In certain embodiments, a DsiRNA (in a state as initially formed, priorto dicer cleavage) is more potent at reducing β-catenin target geneexpression in a mammalian cell than a 19, 20, 21, 22 or 23 base pairsequence that is contained within it. In certain such embodiments, aDsiRNA prior to dicer cleavage is more potent than a 19-21mer containedwithin it. Optionally, a DsiRNA prior to dicer cleavage is more potentthan a 19 base pair duplex contained within it that is synthesized withsymmetric dTdT overhangs (thereby forming a siRNA possessing 21nucleotide strand lengths having dTdT overhangs). In certainembodiments, the DsiRNA is more potent than a 19-23mer siRNA (e.g., a 19base pair duplex with dTdT overhangs) that targets at least 15nucleotides of the 21 nucleotide target sequence that is recited for aDsiRNA of the invention (without wishing to be bound by theory, theidentity of a such a target site for a DsiRNA is identified viaidentification of the Ago2 cleavage site for the DsiRNA; once the Ago2cleavage site of a DsiRNA is determined for a DsiRNA, identification ofthe Ago2 cleavage site for any other inhibitory dsRNA can be performedand these Ago2 cleavage sites can be aligned, thereby determining thealignment of projected target nucleotide sequences for multiple dsRNAs).In certain related embodiments, the DsiRNA is more potent than a19-23mer siRNA that targets at least 20 nucleotides of the 21 nucleotidetarget sequence that is recited for a DsiRNA of the invention.Optionally, the DsiRNA is more potent than a 19-23mer siRNA that targetsthe same 21 nucleotide target sequence that is recited for a DsiRNA ofthe invention. In certain embodiments, the DsiRNA is more potent thanany 21mer siRNA that targets the same 21 nucleotide target sequence thatis recited for a DsiRNA of the invention. Optionally, the DsiRNA is morepotent than any 21 or 22mer siRNA that targets the same 21 nucleotidetarget sequence that is recited for a DsiRNA of the invention. Incertain embodiments, the DsiRNA is more potent than any 21, 22 or 23mersiRNA that targets the same 21 nucleotide target sequence that isrecited for a DsiRNA of the invention. As noted above, such potencyassessments are most effectively performed upon dsRNAs that are suitablyformulated (e.g., formulated with an appropriate transfection reagent)at a concentration of 1 nM or less. Optionally, an IC50 assessment isperformed to evaluate activity across a range of effective inhibitoryconcentrations, thereby allowing for robust comparison of the relativepotencies of dsRNAs so assayed.

The dsRNA molecules of the invention are added directly, or can becomplexed with lipids (e.g., cationic lipids), packaged withinliposomes, or otherwise delivered to target cells or tissues. Thenucleic acid or nucleic acid complexes can be locally administered torelevant tissues ex vivo, or in vivo through direct dermal application,transdermal application, or injection, with or without theirincorporation in biopolymers. In particular embodiments, the nucleicacid molecules of the invention comprise sequences shown in FIG. 1, andthe below exemplary structures. Examples of such nucleic acid moleculesconsist essentially of sequences defined in these figures and exemplarystructures. Furthermore, where such agents are modified in accordancewith the below description of modification patterning of DsiRNA agents,chemically modified forms of constructs described in FIG. 1, and thebelow exemplary structures can be used in all uses described for theDsiRNA agents of FIG. 1, and the below exemplary structures.

In another aspect, the invention provides mammalian cells containing oneor more DsiRNA molecules of this invention. The one or more DsiRNAmolecules can independently be targeted to the same or different sites.

By “RNA” is meant a molecule comprising at least one, and preferably atleast 4, 8 and 12 ribonucleotide residues. The at least 4, 8 or 12 RNAresidues may be contiguous. By “ribonucleotide” is meant a nucleotidewith a hydroxyl group at the 2′ position of a β-D-ribofuranose moiety.The terms include double-stranded RNA, single-stranded RNA, isolated RNAsuch as partially purified RNA, essentially pure RNA, synthetic RNA,recombinantly produced RNA, as well as altered RNA that differs fromnaturally occurring RNA by the addition, deletion, substitution and/oralteration of one or more nucleotides. Such alterations can includeaddition of non-nucleotide material, such as to the end(s) of the DsiRNAor internally, for example at one or more nucleotides of the RNA.Nucleotides in the RNA molecules of the instant invention can alsocomprise non-standard nucleotides, such as non-naturally occurringnucleotides or chemically synthesized nucleotides or deoxynucleotides.These altered RNAs can be referred to as analogs or analogs ofnaturally-occurring RNA.

By “subject” is meant an organism, which is a donor or recipient ofexplanted cells or the cells themselves. “Subject” also refers to anorganism to which the DsiRNA agents of the invention can beadministered. A subject can be a mammal or mammalian cells, including ahuman or human cells.

The phrase “pharmaceutically acceptable carrier” refers to a carrier forthe administration of a therapeutic agent. Exemplary carriers includesaline, buffered saline, dextrose, water, glycerol, ethanol, andcombinations thereof. For drugs administered orally, pharmaceuticallyacceptable carriers include, but are not limited to pharmaceuticallyacceptable excipients such as inert diluents, disintegrating agents,binding agents, lubricating agents, sweetening agents, flavoring agents,coloring agents and preservatives. Suitable inert diluents includesodium and calcium carbonate, sodium and calcium phosphate, and lactose,while corn starch and alginic acid are suitable disintegrating agents.Binding agents may include starch and gelatin, while the lubricatingagent, if present, will generally be magnesium stearate, stearic acid ortalc. If desired, the tablets may be coated with a material such asglyceryl monostearate or glyceryl distearate, to delay absorption in thegastrointestinal tract. The pharmaceutically acceptable carrier of thedisclosed dsRNA compositions may be micellar structures, such as aliposomes, capsids, capsoids, polymeric nanocapsules, or polymericmicrocapsules.

Polymeric nanocapsules or microcapsules facilitate transport and releaseof the encapsulated or bound dsRNA into the cell. They include polymericand monomeric materials, especially including polybutylcyanoacrylate. Asummary of materials and fabrication methods has been published (seeKreuter, 1991). The polymeric materials which are formed from monomericand/or oligomeric precursors in the polymerization/nanoparticlegeneration step, are per se known from the prior art, as are themolecular weights and molecular weight distribution of the polymericmaterial which a person skilled in the field of manufacturingnanoparticles may suitably select in accordance with the usual skill.

Various methodologies of the instant invention include step thatinvolves comparing a value, level, feature, characteristic, property,etc. to a “suitable control”, referred to interchangeably herein as an“appropriate control”. A “suitable control” or “appropriate control” isa control or standard familiar to one of ordinary skill in the artuseful for comparison purposes. In one embodiment, a “suitable control”or “appropriate control” is a value, level, feature, characteristic,property, etc. determined prior to performing an RNAi methodology, asdescribed herein. For example, a transcription rate, mRNA level,translation rate, protein level, biological activity, cellularcharacteristic or property, genotype, phenotype, etc. can be determinedprior to introducing an RNA silencing agent (e.g., DsiRNA) of theinvention into a cell or organism. In another embodiment, a “suitablecontrol” or “appropriate control” is a value, level, feature,characteristic, property, etc. determined in a cell or organism, e.g., acontrol or normal cell or organism, exhibiting, for example, normaltraits. In yet another embodiment, a “suitable control” or “appropriatecontrol” is a predefined value, level, feature, characteristic,property, etc.

The term “in vitro” has its art recognized meaning, e.g., involvingpurified reagents or extracts, e.g., cell extracts. The term “in vivo”also has its art recognized meaning, e.g., involving living cells, e.g.,immortalized cells, primary cells, cell lines, and/or cells in anorganism.

“Treatment”, or “treating” as used herein, is defined as the applicationor administration of a therapeutic agent (e.g., a DsiRNA agent or avector or transgene encoding same) to a patient, or application oradministration of a therapeutic agent to an isolated tissue or cell linefrom a patient, who has a disorder with the purpose to cure, heal,alleviate, relieve, alter, remedy, ameliorate, improve or affect thedisease or disorder, or symptoms of the disease or disorder. The term“treatment” or “treating” is also used herein in the context ofadministering agents prophylactically.

The term “effective dose” or “effective dosage” is defined as an amountsufficient to achieve or at least partially achieve the desired effect.The term “therapeutically effective dose” is defined as an amountsufficient to cure or at least partially arrest the disease and itscomplications in a patient already suffering from the disease. The term“patient” includes human and other mammalian subjects that receiveeither prophylactic or therapeutic treatment.

Structures of Anti-β-Catenin DsiRNA Agents

In certain embodiments, the anti-β-catenin DsiRNA agents of theinvention have the following structures:

In one such embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “Y” is an overhang domain comprised of 1-4 RNAmonomers that are optionally 2′-O-methyl RNA monomers. In a relatedembodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “Y” is an overhang domain comprised of 1-4 RNA monomersthat are optionally 2′-O-methyl RNA monomers, and “D”=DNA. In oneembodiment, the top strand is the sense strand, and the bottom strand isthe antisense strand. Alternatively, the bottom strand is the sensestrand and the top strand is the antisense strand.

DsiRNAs of the invention can carry a broad range of modificationpatterns (e.g., 2′-O-methyl RNA patterns, e.g., within extended DsiRNAagents). Certain modification patterns of the second strand of DsiRNAsof the invention are presented below.

In one embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. In arelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers, and“D”=DNA. The top strand is the sense strand, and the bottom strand isthe antisense strand.

In another such embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. In arelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand.

In another such embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. In arelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand.

In further embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. In arelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. In a further relatedembodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. In arelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. The top strand is the sense strand, and the bottomstrand is the antisense strand. In another related embodiment, theDsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In other embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In a related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In anotherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In a related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In a related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In other embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In a related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In a related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In other embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In a related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In other embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In a related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In further embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

In additional embodiments, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers and underlined residues are 2′-O-methyl RNA monomers. The topstrand is the sense strand, and the bottom strand is the antisensestrand. In one related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-YXXXXXXXXXXXXXXXXXXXXXXXXX-5′

wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an overhang domaincomprised of 1-4 RNA monomers that are optionally 2′-O-methyl RNAmonomers, underlined residues are 2′-O-methyl RNA monomers, and “D”=DNA.The top strand is the sense strand, and the bottom strand is theantisense strand. In another related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXXX-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA and “X”=2′-O-methyl RNA. The top strand is the sensestrand, and the bottom strand is the antisense strand. In a furtherrelated embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ 3′-XXXXXXXXXXXXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, and “D”=DNA. The top strand is thesense strand, and the bottom strand is the antisense strand.

The above modification patterns can also be incorporated into, e.g., theextended DsiRNA structures and mismatch and/or frayed DsiRNA structuresdescribed below.

In another embodiment, the DsiRNA comprises strands having equal lengthspossessing 1-3 mismatched residues that serve to orient Dicer cleavage(specifically, one or more of positions 1, 2 or 3 on the first strand ofthe DsiRNA, when numbering from the 3′-terminal residue, are mismatchedwith corresponding residues of the 5′-terminal region on the secondstrand when first and second strands are annealed to one another). Anexemplary 27mer DsiRNA agent with two terminal mismatched residues isshown:

wherein “X”=RNA, “M”=Nucleic acid residues (RNA, DNA or non-natural ormodified nucleic acids) that do not base pair (hydrogen bond) withcorresponding “M” residues of otherwise complementary strand whenstrands are annealed. Any of the residues of such agents can optionallybe 2′-O-methyl RNA monomers—alternating positioning of 2′-O-methyl RNAmonomers that commences from the 3′-terminal residue of the bottom(second) strand, as shown for above asymmetric agents, can also be usedin the above “blunt/fray” DsiRNA agent. In one embodiment, the topstrand is the sense strand, and the bottom strand is the antisensestrand. Alternatively, the bottom strand is the sense strand and the topstrand is the antisense strand.

In certain additional embodiments, the present invention providescompositions for RNA interference (RNAi) that possess one or more basepaired deoxyribonucleotides within a region of a double strandedribonucleic acid (dsRNA) that is positioned 3′ of a projected sensestrand Dicer cleavage site and correspondingly 5′ of a projectedantisense strand Dicer cleavage site. The compositions of the inventioncomprise a dsRNA which is a precursor molecule, i.e., the dsRNA of thepresent invention is processed in vivo to produce an active smallinterfering nucleic acid (siRNA). The dsRNA is processed by Dicer to anactive siRNA which is incorporated into RISC.

In certain embodiments, the DsiRNA agents of the invention can have thefollowing exemplary structures (noting that any of the followingexemplary structures can be combined, e.g., with the bottom strandmodification patterns of the above-described structures—in one specificexample, the bottom strand modification pattern shown in any of theabove structures is applied to the 27 most 3′ residues of the bottomstrand of any of the following structures; in another specific example,the bottom strand modification pattern shown in any of the abovestructures upon the 23 most 3′ residues of the bottom strand is appliedto the 23 most 3′ residues of the bottom strand of any of the followingstructures):

In one such embodiment, the DsiRNA comprises the following (an exemplary“right-extended”, “DNA extended” DsiRNA):

5′-XXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)DD-3′3′-YXXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)XX-5′wherein “X”=RNA, “Y” is an optional overhang domain comprised of 0-10RNA monomers that are optionally 2′-O-methyl RNA monomers—in certainembodiments, “Y” is an overhang domain comprised of 1-4 RNA monomersthat are optionally 2′-O-methyl RNA monomers, “D”=DNA, and “N”=1 to 50or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but isoptionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand isthe sense strand, and the bottom strand is the antisense strand.Alternatively, the bottom strand is the sense strand and the top strandis the antisense strand.

In a related embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)DD-3′3′-YXXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)DD-5′wherein “X”=RNA, “Y” is an optional overhang domain comprised of 0-10RNA monomers that are optionally 2′-O-methyl RNA monomers—in certainembodiments, “Y” is an overhang domain comprised of 1-4 RNA monomersthat are optionally 2′-O-methyl RNA monomers, “D”=DNA, and “N”=1 to 50or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but isoptionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand isthe sense strand, and the bottom strand is the antisense strand.Alternatively, the bottom strand is the sense strand and the top strandis the antisense strand.

In an additional embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)DD-3′3′-YXXXXXXXXXXXXXXXXXXXXXXXX_(N*)D_(N)ZZ-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an optional overhang domaincomprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNAmonomers—in certain embodiments, “Y” is an overhang domain comprised of1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, “D”=DNA,“Z”=DNA or RNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10.“N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In oneembodiment, the top strand is the sense strand, and the bottom strand isthe antisense strand. Alternatively, the bottom strand is the sensestrand and the top strand is the antisense strand, with 2′-O-methyl RNAmonomers located at alternating residues along the top strand, ratherthan the bottom strand presently depicted in the above schematic.

In another such embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXX_(N)*D_(N)DD-3′3′-YXXXXXXXXXXXXXXXXXXXXXXXX_(N)*D_(N)ZZ-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an optional overhang domaincomprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNAmonomers—in certain embodiments, “Y” is an overhang domain comprised of1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, “D”=DNA,“Z”=DNA or RNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10.“N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In oneembodiment, the top strand is the sense strand, and the bottom strand isthe antisense strand. Alternatively, the bottom strand is the sensestrand and the top strand is the antisense strand, with 2′-O-methyl RNAmonomers located at alternating residues along the top strand, ratherthan the bottom strand presently depicted in the above schematic.

In another such embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXX_(N)*D_(N)DD-3′3′-YXXXXXXXXXXXXXXXXXXXXXXXX_(N)*D_(N)ZZ-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “Y” is an optional overhang domaincomprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNAmonomers—in certain embodiments, “Y” is an overhang domain comprised of1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers, “D”=DNA,“Z”=DNA or RNA, and “N”=1 to 50 or more, but is optionally 1-8 or 1-10.“N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In oneembodiment, the top strand is the sense strand, and the bottom strand isthe antisense strand. Alternatively, the bottom strand is the sensestrand and the top strand is the antisense strand, with 2′-O-methyl RNAmonomers located at alternating residues along the top strand, ratherthan the bottom strand presently depicted in the above schematic.

In another embodiment, the DsiRNA comprises:

5′-XXXXXXXXXXXXXXXXXXXXXXXX_(N)*[X1/D1]_(N)DD-3′3′-YXXXXXXXXXXXXXXXXXXXXXXXX_(N)*[X2/D2]_(N)ZZ-5′wherein “X”=RNA, “Y” is an optional overhang domain comprised of 0-10RNA monomers that are optionally 2′-O-methyl RNA monomers—in certainembodiments, “Y” is an overhang domain comprised of 1-4 RNA monomersthat are optionally 2′-O-methyl RNA monomers, “D”=DNA, “Z”=DNA or RNA,and “N”=1 to 50 or more, but is optionally 1-8 or 1-10, where at leastone D1_(N) is present in the top strand and is base paired with acorresponding D2_(N) in the bottom strand. Optionally, D1_(N) andD1_(N+1) are base paired with corresponding D2_(N) and D2_(N+1); D1_(N),D1_(N+1) and D1_(N+2) are base paired with corresponding D2_(N),D1_(N+1) and D1_(N+2), etc. “N*”=0 to 15 or more, but is optionally 0,1, 2, 3, 4, 5 or 6. In one embodiment, the top strand is the sensestrand, and the bottom strand is the antisense strand. Alternatively,the bottom strand is the sense strand and the top strand is theantisense strand, with 2′-O-methyl RNA monomers located at alternatingresidues along the top strand, rather than the bottom strand presentlydepicted in the above schematic.

In the structures depicted herein, the 5′ end of either the sense strandor antisense strand can optionally comprise a phosphate group.

In another embodiment, a DNA:DNA-extended DsiRNA comprises strandshaving equal lengths possessing 1-3 mismatched residues that serve toorient Dicer cleavage (specifically, one or more of positions 1, 2 or 3on the first strand of the DsiRNA, when numbering from the 3′-terminalresidue, are mismatched with corresponding residues of the 5′-terminalregion on the second strand when first and second strands are annealedto one another). An exemplary DNA:DNA-extended DsiRNA agent with twoterminal mismatched residues is shown:

wherein “X”=RNA, “M”=Nucleic acid residues (RNA, DNA or non-natural ormodified nucleic acids) that do not base pair (hydrogen bond) withcorresponding “M” residues of otherwise complementary strand whenstrands are annealed, “D”=DNA and “N”=1 to 50 or more, but is optionally1-15 or, optionally, 1-8. “N*”=0 to 15 or more, but is optionally 0, 1,2, 3, 4, 5 or 6. Any of the residues of such agents can optionally be2′-O-methyl RNA monomers—alternating positioning of 2′-O-methyl RNAmonomers that commences from the 3′-terminal residue of the bottom(second) strand, as shown for above asymmetric agents, can also be usedin the above “blunt/fray” DsiRNA agent. In one embodiment, the topstrand (first strand) is the sense strand, and the bottom strand (secondstrand) is the antisense strand. Alternatively, the bottom strand is thesense strand and the top strand is the antisense strand. Modificationand DNA:DNA extension patterns paralleling those shown above forasymmetric/overhang agents can also be incorporated into such“blunt/frayed” agents.

In one embodiment, a length-extended DsiRNA agent is provided thatcomprises deoxyribonucleotides positioned at sites modeled to functionvia specific direction of Dicer cleavage, yet which does not require thepresence of a base-paired deoxyribonucleotide in the dsRNA structure. Anexemplary structure for such a molecule is shown:

5′-XXXXXXXXXXXXXXXXXXXDDXX-3′ 3′-YXXXXXXXXXXXXXXXXXDDXXXX-5′wherein “X”=RNA, “Y” is an optional overhang domain comprised of 0-10RNA monomers that are optionally 2′-O-methyl RNA monomers—in certainembodiments, “Y” is an overhang domain comprised of 1-4 RNA monomersthat are optionally 2′-O-methyl RNA monomers, and “D”=DNA. In oneembodiment, the top strand is the sense strand, and the bottom strand isthe antisense strand. Alternatively, the bottom strand is the sensestrand and the top strand is the antisense strand. The above structureis modeled to force Dicer to cleave a minimum of a 21mer duplex as itsprimary post-processing form. In embodiments where the bottom strand ofthe above structure is the antisense strand, the positioning of twodeoxyribonucleotide residues at the ultimate and penultimate residues ofthe 5′ end of the antisense strand may reduce off-target effects for agiven compound.

In one embodiment, the DsiRNA comprises the following (an exemplary“left-extended”, “DNA extended” DsiRNA):

5′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N)*Y-3′3′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N)*-5′wherein “X”=RNA, “Y” is an optional overhang domain comprised of 0-10RNA monomers that are optionally 2′-O-methyl RNA monomers—in certainembodiments, “Y” is an overhang domain comprised of 1-4 RNA monomersthat are optionally 2′-O-methyl RNA monomers, “D”=DNA, and “N”=1 to 50or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but isoptionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand isthe sense strand, and the bottom strand is the antisense strand.Alternatively, the bottom strand is the sense strand and the top strandis the antisense strand.

In a related embodiment, the DsiRNA comprises:

5′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N)*DD-3′3′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N)*XX-5′wherein “X”=RNA, optionally a 2′-O-methyl RNA monomers “D”=DNA, “N”=1 to50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but isoptionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strand isthe sense strand, and the bottom strand is the antisense strand.Alternatively, the bottom strand is the sense strand and the top strandis the antisense strand.

In an additional embodiment, the DsiRNA comprises:

5′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N)*DD-3′ 3′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N)*ZZ-5′wherein “X”=RNA, optionally a 2′-O-methyl RNA monomers “D”=DNA, “N”=1 to50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but isoptionally 0, 1, 2, 3, 4, 5 or 6. “Z”=DNA or RNA. In one embodiment, thetop strand is the sense strand, and the bottom strand is the antisensestrand. Alternatively, the bottom strand is the sense strand and the topstrand is the antisense strand, with 2′-O-methyl RNA monomers located atalternating residues along the top strand, rather than the bottom strandpresently depicted in the above schematic.

In another such embodiment, the DsiRNA comprises:

5′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N)*DD-3′ 3′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N)*ZZ-5′wherein “X”=RNA, optionally a 2′-O-methyl RNA monomers “D”=DNA, “N”=1 to50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, but isoptionally 0, 1, 2, 3, 4, 5 or 6. “Z”=DNA or RNA. In one embodiment, thetop strand is the sense strand, and the bottom strand is the antisensestrand. Alternatively, the bottom strand is the sense strand and the topstrand is the antisense strand, with 2′-O-methyl RNA monomers located atalternating residues along the top strand, rather than the bottom strandpresently depicted in the above schematic.

In another such embodiment, the DsiRNA comprises:

5′-D_(N)ZZXXXXXXXXXXXXXXXXXXXXXXXX_(N)*DD-3′ 3′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXXXX_(N)*ZZ-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “D”=DNA, “Z”=DNA or RNA, and “N”=1to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, butis optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, the top strandis the sense strand, and the bottom strand is the antisense strand.Alternatively, the bottom strand is the sense strand and the top strandis the antisense strand, with 2′-O-methyl RNA monomers located atalternating residues along the top strand, rather than the bottom strandpresently depicted in the above schematic.

In another such embodiment, the DsiRNA comprises:

5′-D_(N)ZZXXXXXXXXXXXXXXXXXXXXXXXX_(N)*Y-3′ 3′-D_(N)XXXXXXXXXXXXXXXXXXXXXXXXXX_(N)*-5′wherein “X”=RNA, “X”=2′-O-methyl RNA, “D”=DNA, “Z”=DNA or RNA, and “N”=1to 50 or more, but is optionally 1-8 or 1-10. “N*”=0 to 15 or more, butis optionally 0, 1, 2, 3, 4, 5 or 6. “Y” is an optional overhang domaincomprised of 0-10 RNA monomers that are optionally 2′-O-methyl RNAmonomers—in certain embodiments, “Y” is an overhang domain comprised of1-4 RNA monomers that are optionally 2′-O-methyl RNA monomers. In oneembodiment, the top strand is the sense strand, and the bottom strand isthe antisense strand. Alternatively, the bottom strand is the sensestrand and the top strand is the antisense strand, with 2′-O-methyl RNAmonomers located at alternating residues along the top strand, ratherthan the bottom strand presently depicted in the above schematic.

In another embodiment, the DsiRNA comprises:

5′-[X1/D1]_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N)*DD-3′3′-[X2/D2]_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N)*ZZ-5′wherein “X”=RNA, “D”=DNA, “Z”=DNA or RNA, and “N”=1 to 50 or more, butis optionally 1-8 or 1-10, where at least one D1_(N) is present in thetop strand and is base paired with a corresponding D2_(N) in the bottomstrand. Optionally, D1_(N) and D1_(N+1) are base paired withcorresponding D2_(N) and D2_(N+1); D1_(N), D1_(N+1) and D1_(N+2) arebase paired with corresponding D2_(N), D1_(N+1) and D1_(N+2), etc.“N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In oneembodiment, the top strand is the sense strand, and the bottom strand isthe antisense strand. Alternatively, the bottom strand is the sensestrand and the top strand is the antisense strand, with 2′-O-methyl RNAmonomers located at alternating residues along the top strand, ratherthan the bottom strand presently depicted in the above schematic.

In a related embodiment, the DsiRNA comprises:

5′-[X1/D1]_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N)*Y-3′3′-[X2/D2]_(N)XXXXXXXXXXXXXXXXXXXXXXXX_(N)*-5′wherein “X”=RNA, “D”=DNA, “Y” is an optional overhang domain comprisedof 0-10 RNA monomers that are optionally 2′-O-methyl RNA monomers—incertain embodiments, “Y” is an overhang domain comprised of 1-4 RNAmonomers that are optionally 2′-O-methyl RNA monomers, and “N”=1 to 50or more, but is optionally 1-8 or 1-10, where at least one D1_(N) ispresent in the top strand and is base paired with a corresponding D2_(N)in the bottom strand. Optionally, D1_(N) and D1_(N+1) are base pairedwith corresponding D2_(N) and D2_(N+1); D1_(N), D1_(N+1) and D1_(N+2)are base paired with corresponding D2_(N), D1_(N+1) and D1_(N+2), etc.“N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In oneembodiment, the top strand is the sense strand, and the bottom strand isthe antisense strand. Alternatively, the bottom strand is the sensestrand and the top strand is the antisense strand, with 2′-O-methyl RNAmonomers located at alternating residues along the top strand, ratherthan the bottom strand presently depicted in the above schematic.

In another embodiment, the DNA:DNA-extended DsiRNA comprises strandshaving equal lengths possessing 1-3 mismatched residues that serve toorient Dicer cleavage (specifically, one or more of positions 1, 2 or 3on the first strand of the DsiRNA, when numbering from the 3′-terminalresidue, are mismatched with corresponding residues of the 5′-terminalregion on the second strand when first and second strands are annealedto one another). An exemplary DNA:DNA-extended DsiRNA agent with twoterminal mismatched residues is shown:

wherein “X”=RNA, “M”=Nucleic acid residues (RNA, DNA or non-natural ormodified nucleic acids) that do not base pair (hydrogen bond) withcorresponding “M” residues of otherwise complementary strand whenstrands are annealed, “D”=DNA and “N”=1 to 50 or more, but is optionally1-8 or 1-10. “N*”=0 to 15 or more, but is optionally 0, 1, 2, 3, 4, 5 or6. Any of the residues of such agents can optionally be 2′-O-methyl RNAmonomers—alternating positioning of 2′-O-methyl RNA monomers thatcommences from the 3′-terminal residue of the bottom (second) strand, asshown for above asymmetric agents, can also be used in the above“blunt/fray” DsiRNA agent. In one embodiment, the top strand (firststrand) is the sense strand, and the bottom strand (second strand) isthe antisense strand. Alternatively, the bottom strand is the sensestrand and the top strand is the antisense strand. Modification andDNA:DNA extension patterns paralleling those shown above forasymmetric/overhang agents can also be incorporated into such“blunt/frayed” agents.

In another embodiment, a length-extended DsiRNA agent is provided thatcomprises deoxyribonucleotides positioned at sites modeled to functionvia specific direction of Dicer cleavage, yet which does not require thepresence of a base-paired deoxyribonucleotide in the dsRNA structure.Exemplary structures for such a molecule are shown:

5′-XXDDXXXXXXXXXXXXXXXXXXXX_(N)*Y-3′ 3′-DDXXXXXXXXXXXXXXXXXXXXXX_(N)*-5′or 5′-XDXDXXXXXXXXXXXXXXXXXXXX_(N)*Y-3′3′-DXDXXXXXXXXXXXXXXXXXXXXX_(N)*-5′wherein “X”=RNA, “Y” is an optional overhang domain comprised of 0-10RNA monomers that are optionally 2′-O-methyl RNA monomers—in certainembodiments, “Y” is an overhang domain comprised of 1-4 RNA monomersthat are optionally 2′-O-methyl RNA monomers, and “D”=DNA. “N*”=0 to 15or more, but is optionally 0, 1, 2, 3, 4, 5 or 6. In one embodiment, thetop strand is the sense strand, and the bottom strand is the antisensestrand. Alternatively, the bottom strand is the sense strand and the topstrand is the antisense strand.

In any of the above embodiments where the bottom strand of the abovestructure is the antisense strand, the positioning of twodeoxyribonucleotide residues at the ultimate and penultimate residues ofthe 5′ end of the antisense strand may reduce off-target effects.

In certain embodiments, the “D” residues of the above structures includeat least one PS-DNA or PS-RNA. Optionally, the “D” residues of the abovestructures include at least one modified nucleotide that inhibits Dicercleavage.

While the above-described “DNA-extended” DsiRNA agents can becategorized as either “left extended” or “right extended”, DsiRNA agentscomprising both left- and right-extended DNA-containing sequences withina single agent (e.g., both flanks surrounding a core dsRNA structure aredsDNA extensions) can also be generated and used in similar manner tothose described herein for “right-extended” and “left-extended” agents.

In some embodiments, the DsiRNA of the instant invention furthercomprises a linking moiety or domain that joins the sense and antisensestrands of a DNA:DNA-extended DsiRNA agent. Optionally, such a linkingmoiety domain joins the 3′ end of the sense strand and the 5′ end of theantisense strand. The linking moiety may be a chemical (non-nucleotide)linker, such as an oligomethylenediol linker, oligoethylene glycollinker, or other art-recognized linker moiety. Alternatively, the linkercan be a nucleotide linker, optionally including an extended loop and/ortetraloop.

In one embodiment, the DsiRNA agent has an asymmetric structure, withthe sense strand having a 25-base pair length, and the antisense strandhaving a 27-base pair length with a 1-4 base 3′-overhang (e.g., a onebase 3′-overhang, a two base 3′-overhang, a three base 3′-overhang or afour base 3′-overhang). In another embodiment, this DsiRNA agent has anasymmetric structure further containing 2 deoxynucleotides at the 3′ endof the sense strand.

In another embodiment, the DsiRNA agent has an asymmetric structure,with the antisense strand having a 25-base pair length, and the sensestrand having a 27-base pair length with a 1-4 base 3′-overhang (e.g., aone base 3′-overhang, a two base 3′-overhang, a three base 3′-overhangor a four base 3′-overhang). In another embodiment, this DsiRNA agenthas an asymmetric structure further containing 2 deoxyribonucleotides atthe 3′ end of the antisense strand.

Exemplary β-catenin targeting DsiRNA agents of the invention include thefollowing:

TABLE 2 Selected Anti-β-catenin DsiRNAs, Homo sapiens Unique Duplexes5′-CUGAGGGUAUUUGAAGUAUACCAta-3′ (SEQ ID NO: 8)3′-GGGACUCCCAUAAACUUCAUAUGGUAU-5′ (SEQ ID NO: 1117) βc-240 Target:5′-CCCTGAGGGTATTTGAAGTATACCATA-3′ (SEQ ID NO: 2226)5′-GGGUAUUUGAAGUAUACCAUACAac-3′ (SEQ ID NO: 9)3′-CUCCCAUAAACUUCAUAUGGUAUGUUG-5′ (SEQ ID NO: 1118) βc-244 Target:5′-GAGGGTATTTGAAGTATACCATACAAC-3′ (SEQ ID NO: 2227)5′-AAGUAUACCAUACAACUGUUUUGaa-3′ (SEQ ID NO: 10)3′-ACUUCAUAUGGUAUGUUGACAAAACUU-5′ (SEQ ID NO: 1119) βc-253 Target:5′-TGAAGTATACCATACAACTGTTTTGAA-3′ (SEQ ID NO: 2228)5′-ACCAUACAACUGUUUUGAAAAUCca-3′ (SEQ ID NO: 11)3′-UAUGGUAUGUUGACAAAACUUUUAGGU-5′ (SEQ ID NO: 1120) βc-259 Target:5′-ATACCATACAACTGTTTTGAAAATCCA-3′ (SEQ ID NO: 2229)5′-ACAACUGUUUUGAAAAUCCAGCGtg-3′ (SEQ ID NO: 12)3′-UAUGUUGACAAAACUUUUAGGUCGCAC-5′ (SEQ ID NO: 1121) βc-264 Target:5′-ATACAACTGTTTTGAAAATCCAGCGTG-3′ (SEQ ID NO: 2230)5′-GGGAUUUUCUCAGUCCUUCACUCaa-3′ (SEQ ID NO: 13)3′-GUCCCUAAAAGAGUCAGGAAGUGAGUU-5′ (SEQ ID NO: 1122) βc-496 Target:5′-CAGGGATTTTCTCAGTCCTTCACTCAA-3′ (SEQ ID NO: 2231)5′-CUCAAGAACAAGUAGCUGAUAUUga-3′ (SEQ ID NO: 14)3′-GUGAGUUCUUGUUCAUCGACUAUAACU-5′ (SEQ ID NO: 1123) βc-516 Target:5′-CACTCAAGAACAAGTAGCTGATATTGA-3′ (SEQ ID NO: 2232)5′-AACAAGUAGCUGAUAUUGAUGGAca-3′ (SEQ ID NO: 15)3′-UCUUGUUCAUCGACUAUAACUACCUGU-5′ (SEQ ID NO: 1124) βc-522 Target:5′-AGAACAAGTAGCTGATATTGATGGACA-3′ (SEQ ID NO: 2233)5′-CAAGUAGCUGAUAUUGAUGGACAgt-3′ (SEQ ID NO: 16)3′-UUGUUCAUCGACUAUAACUACCUGUCA-5′ (SEQ ID NO: 1125) βc-524 Target:5′-AACAAGTAGCTGATATTGATGGACAGT-3′ (SEQ ID NO: 2234)5′-AUGGACAGUAUGCAAUGACUCGAgc-3′ (SEQ ID NO: 17)3′-ACUACCUGUCAUACGUUACUGAGCUCG-5′ (SEQ ID NO: 1126) βc-540 Target:5′-TGATGGACAGTATGCAATGACTCGAGC-3′ (SEQ ID NO: 2235)5′-CUAUGUUCCCUGAGACAUUAGAUga-3′ (SEQ ID NO: 18)3′-ACGAUACAAGGGACUCUGUAAUCUACU-5′ (SEQ ID NO: 1127) βc-582 Target:5′-TGCTATGTTCCCTGAGACATTAGATGA-3′ (SEQ ID NO: 2236)5′-CUGAAACAUGCAGUUGUAAACUUga-3′ (SEQ ID NO: 19)3′-ACGACUUUGUACGUCAACAUUUGAACU-5′ (SEQ ID NO: 1128) βc-686 Target:5′-TGCTGAAACATGCAGTTGTAAACTTGA-3′ (SEQ ID NO: 2237)5′-CAUGCAGUUGUAAACUUGAUUAAct-3′ (SEQ ID NO: 20)3′-UUGUACGUCAACAUUUGAACUAAUUGA-5′ (SEQ ID NO: 1129) βc-692 Target:5′-AACATGCAGTTGTAAACTTGATTAACT-3′ (SEQ ID NO: 2238)5′-AGUUGUAAACUUGAUUAACUAUCaa-3′ (SEQ ID NO: 21)3′-CGUCAACAUUUGAACUAAUUGAUAGUU-5′ (SEQ ID NO: 1130) βc-697 Target:5′-GCAGTTGTAAACTTGATTAACTATCAA-3′ (SEQ ID NO: 2239)5′-UUGAUUAACUAUCAAGAUGAUGCag-3′ (SEQ ID NO: 22)3′-UGAACUAAUUGAUAGUUCUACUACGUC-5′ (SEQ ID NO: 1131) βc-707 Target:5′-ACTTGATTAACTATCAAGATGATGCAG-3′ (SEQ ID NO: 2240)5′-CUGAACUGACAAAACUGCUAAAUga-3′ (SEQ ID NO: 23)3′-GGGACUUGACUGUUUUGACGAUUUACU-5′ (SEQ ID NO: 1132) βc-753 Target:5′-CCCTGAACTGACAAAACTGCTAAATGA-3′ (SEQ ID NO: 2241)5′-AGAUGGUGUCUGCUAUUGUACGUac-3′ (SEQ ID NO: 24)3′-AGUCUACCACAGACGAUAACAUGCAUG-5′ (SEQ ID NO: 1133) βc-870 Target:5′-TCAGATGGTGTCTGCTATTGTACGTAC-3′ (SEQ ID NO: 2242)5′-ACGUACCAUGCAGAAUACAAAUGat-3′ (SEQ ID NO: 25)3′-CAUGCAUGGUACGUCUUAUGUUUACUA-5′ (SEQ ID NO: 1134) βc-889 Target:5′-GTACGTACCATGCAGAATACAAATGAT-3′ (SEQ ID NO: 2243)5′-UACAACUCUCCACAACCUUUUAUta-3′ (SEQ ID NO: 26)3′-UAAUGUUGAGAGGUGUUGGAAAAUAAU-5′ (SEQ ID NO: 1135) βc-1060 Target:5′-ATTACAACTCTCCACAACCTTTTATTA-3′ (SEQ ID NO: 2244)5′-CUCUCCACAACCUUUUAUUACAUca-3′ (SEQ ID NO: 27)3′-UUGAGAGGUGUUGGAAAAUAAUGUAGU-5′ (SEQ ID NO: 1136) βc-1065 Target:5′-AACTCTCCACAACCTTTTATTACATCA-3′ (SEQ ID NO: 2245)5′-CACAACCUUUUAUUACAUCAAGAag-3′ (SEQ ID NO: 28)3′-AGGUGUUGGAAAAUAAUGUAGUUCUUC-5′ (SEQ ID NO: 1137) βc-1070 Target:5′-TCCACAACCTTTTATTACATCAAGAAG-3′ (SEQ ID NO: 2246)5′-CUUUUAUUACAUCAAGAAGGAGCta-3′ (SEQ ID NO: 29)3′-UGGAAAAUAAUGUAGUUCUUCCUCGAU-5′ (SEQ ID NO: 1138) βc-1076 Target:5′-ACCTTTTATTACATCAAGAAGGAGCTA-3′ (SEQ ID NO: 2247)5′-AAAACAAAUGUUAAAUUCUUGGCta-3′ (SEQ ID NO: 30)3′-UGUUUUGUUUACAAUUUAAGAACCGAU-5′ (SEQ ID NO: 1139) βc-1154 Target:5′-ACAAAACAAATGTTAAATTCTTGGCTA-3′ (SEQ ID NO: 2248)5′-UACGACAGACUGCCUUCAAAUUUta-3′ (SEQ ID NO: 31)3′-UAAUGCUGUCUGACGGAAGUUUAAAAU-5′ (SEQ ID NO: 1140) βc-1180 Target:5′-ATTACGACAGACTGCCTTCAAATTTTA-3′ (SEQ ID NO: 2249)5′-CAGACUGCCUUCAAAUUUUAGCUta-3′ (SEQ ID NO: 32)3′-CUGUCUGACGGAAGUUUAAAAUCGAAU-5′ (SEQ ID NO: 1141) βc-1185 Target:5′-GACAGACTGCCTTCAAATTTTAGCTTA-3′ (SEQ ID NO: 2250)5′-CUUUAGUAAAUAUAAUGAGGACCta-3′ (SEQ ID NO: 33)3′-UCGAAAUCAUUUAUAUUACUCCUGGAU-5′ (SEQ ID NO: 1142) βc-1260 Target:5′-AGCTTTAGTAAATATAATGAGGACCTA-3′ (SEQ ID NO: 2251)5′-AAAACUACUGUGGACCACAAGCAga-3′ (SEQ ID NO: 34)3′-CUUUUUGAUGACACCUGGUGUUCGUCU-5′ (SEQ ID NO: 1143) βc-1294 Target:5′-GAAAAACTACTGTGGACCACAAGCAGA-3′ (SEQ ID NO: 2252)5′-AGUCAACGUCUUGUUCAGAACUGtc-3′ (SEQ ID NO: 35)3′-GUUCAGUUGCAGAACAAGUCUUGACAG-5′ (SEQ ID NO: 1144) βc-1412 Target:5′-CAAGTCAACGTCTTGTTCAGAACTGTC-3′ (SEQ ID NO: 2253)5′-CGUCUUGUUCAGAACUGUCUUUGga-3′ (SEQ ID NO: 36)3′-UUGCAGAACAAGUCUUGACAGAAACCU-5′ (SEQ ID NO: 1145) βc-1418 Target:5′-AACGTCTTGTTCAGAACTGTCTTTGGA-3′ (SEQ ID NO: 2254)5′-UGUUCAGAACUGUCUUUGGACUCtc-3′ (SEQ ID NO: 37)3′-GAACAAGUCUUGACAGAAACCUGAGAG-5′ (SEQ ID NO: 1146) βc-1423 Target:5′-CTTGTTCAGAACTGTCTTTGGACTCTC-3′ (SEQ ID NO: 2255)5′-GGUUCAGAUGAUAUAAAUGUGGUca-3′ (SEQ ID NO: 38)3′-ACCCAAGUCUACUAUAUUUACACCAGU-5′ (SEQ ID NO: 1147) βc-1520 Target:5′-TGGGTTCAGATGATATAAATGTGGTCA-3′ (SEQ ID NO: 2256)5′-UCUUUCUAACCUCACUUGCAAUAat-3′ (SEQ ID NO: 39)3′-UAAGAAAGAUUGGAGUGAACGUUAUUA-5′ (SEQ ID NO: 1148) βc-1561 Target:5′-ATTCTTTCTAACCTCACTTGCAATAAT-3′ (SEQ ID NO: 2257)5′-CUCACUUGCAAUAAUUAUAAGAAca-3′ (SEQ ID NO: 40)3′-UGGAGUGAACGUUAUUAAUAUUCUUGU-5′ (SEQ ID NO: 1149) βc-1571 Target:5′-ACCTCACTTGCAATAATTATAAGAACA-3′ (SEQ ID NO: 2258)5′-CAAUAAUUAUAAGAACAAGAUGAtg-3′ (SEQ ID NO: 41)3′-ACGUUAUUAAUAUUCUUGUUCUACUAC-5′ (SEQ ID NO: 1150) βc-1579 Target:5′-TGCAATAATTATAAGAACAAGATGATG-3′ (SEQ ID NO: 2259)5′-GUAUAGAGGCUCUUGUGCGUACUgt-3′ (SEQ ID NO: 42)3′-ACCAUAUCUCCGAGAACACGCAUGACA-5′ (SEQ ID NO: 1151) βc-1620 Target:5′-TGGTATAGAGGCTCTTGTGCGTACTGT-3′ (SEQ ID NO: 2260)5′-GGCUACUGUUGGAUUGAUUCGAAat-3′ (SEQ ID NO: 43)3′-UUCCGAUGACAACCUAACUAAGCUUUA-5′ (SEQ ID NO: 1152) βc-1816 Target:5′-AAGGCTACTGTTGGATTGATTCGAAAT-3′ (SEQ ID NO: 2261)5′-CAUGGAAGAAAUAGUUGAAGGUUgt-3′ (SEQ ID NO: 44)3′-GCGUACCUUCUUUAUCAACUUCCAACA-5′ (SEQ ID NO: 1153) βc-1987 Target:5′-CGCATGGAAGAAATAGTTGAAGGTTGT-3′ (SEQ ID NO: 2262)5′-UGGAAGAAAUAGUUGAAGGUUGUac-3′ (SEQ ID NO: 45)3′-GUACCUUCUUUAUCAACUUCCAACAUG-5′ (SEQ ID NO: 1154) βc-1989 Target:5′-CATGGAAGAAATAGTTGAAGGTTGTAC-3′ (SEQ ID NO: 2263)5′-AUUGAAAACAUCCAAAGAGUAGCtg-3′ (SEQ ID NO: 46)3′-GGUAACUUUUGUAGGUUUCUCAUCGAC-5′ (SEQ ID NO: 1155) βc-2111 Target:5′-CCATTGAAAACATCCAAAGAGTAGCTG-3′ (SEQ ID NO: 2264)5′-GAGGACAAGCCACAAGAUUACAAga-3′ (SEQ ID NO: 47)3′-GACUCCUGUUCGGUGUUCUAAUGUUCU-5′ (SEQ ID NO: 1156) βc-2282 Target:5′-CTGAGGACAAGCCACAAGATTACAAGA-3′ (SEQ ID NO: 2265)5′-GAUACUGACCUGUAAAUCAUCCUtt-3′ (SEQ ID NO: 48)3′-AACUAUGACUGGACAUUUAGUAGGAAA-5′ (SEQ ID NO: 1157) βc-2624 Target:5′-TTGATACTGACCTGTAAATCATCCTTT-3′ (SEQ ID NO: 2266)5′-UUAGGUAAGAAGUUUUAAAAAGCca-3′ (SEQ ID NO: 49)3′-GAAAUCCAUUCUUCAAAAUUUUUCGGU-5′ (SEQ ID NO: 1158) βc-2647 Target:5′-CTTTAGGTAAGAAGTTTTAAAAAGCCA-3′ (SEQ ID NO: 2267)5′-CAGGUAUAUACUUUGAAAGGAGAtg-3′ (SEQ ID NO: 50)3′-UUGUCCAUAUAUGAAACUUUCCUCUAC-5′ (SEQ ID NO: 1159) βc-2770 Target:5′-AACAGGTATATACTTTGAAAGGAGATG-3′ (SEQ ID NO: 2268)5′-GAAGUUAUUAACUUUAAUGUUUUtt-3′ (SEQ ID NO: 51)3′-ACCUUCAAUAAUUGAAAUUACAAAAAA-5′ (SEQ ID NO: 1160) βc-2848 Target:5′-TGGAAGTTATTAACTTTAATGTTTTTT-3′ (SEQ ID NO: 2269)5′-CCACAGCUUUUGCAACUUAAUACtc-3′ (SEQ ID NO: 52)3′-ACGGUGUCGAAAACGUUGAAUUAUGAG-5′ (SEQ ID NO: 1161) βc-2874 Target:5′-TGCCACAGCTTTTGCAACTTAATACTC-3′ (SEQ ID NO: 2270)5′-CAUUUGCUGUUUUAAACAUUAAUag-3′ (SEQ ID NO: 53)3′-UUGUAAACGACAAAAUUUGUAAUUAUC-5′ (SEQ ID NO: 1162) βc-2909 Target:5′-AACATTTGCTGTTTTAAACATTAATAG-3′ (SEQ ID NO: 2271)5′-CAAUUGAAGUAAACUUUUUGUUCtg-3′ (SEQ ID NO: 54)3′-UUGUUAACUUCAUUUGAAAAACAAGAC-5′ (SEQ ID NO: 1163) βc-3074 Target:5′-AACAATTGAAGTAAACTTTTTGTTCTG-3′ (SEQ ID NO: 2272)5′-ACCCUAGCCUUGCUUGUUAAAUUtt-3′ (SEQ ID NO: 55)3′-UUUGGGAUCGGAACGAACAAUUUAAAA-5′ (SEQ ID NO: 1164) βc-3197 Target:5′-AAACCCTAGCCTTGCTTGTTAAATTTT-3′ (SEQ ID NO: 2273)5′-GCCUUGCUUGUUAAAUUUUUUUUtt-3′ (SEQ ID NO: 56)3′-AUCGGAACGAACAAUUUAAAAAAAAAA-5′ (SEQ ID NO: 1165) βc-3203 Target:5′-TAGCCTTGCTTGTTAAATTTTTTTTTT-3′ (SEQ ID NO: 2274)5′-GAAGUAGCUCUUUUUUUUUUUUUtt-3′ (SEQ ID NO: 57)3′-AACUUCAUCGAGAAAAAAAAAAAAAAA-5′ (SEQ ID NO: 1166) βc-3273 Target:5′-TTGAAGTAGCTCTTTTTTTTTTTTTTT-3′ (SEQ ID NO: 2275)5′-GUAGUGUUAAGUUAUAGUGAAUAct-3′ (SEQ ID NO: 58)3′-AGCAUCACAAUUCAAUAUCACUUAUGA-5′ (SEQ ID NO: 1167) βc-3333 Target:5′-TCGTAGTGTTAAGTTATAGTGAATACT-3′ (SEQ ID NO: 2276)5′-GUGAAUACUGCUACAGCAAUUUCta-3′ (SEQ ID NO: 59)3′-AUCACUUAUGACGAUGUCGUUAAAGAU-5′ (SEQ ID NO: 1168) βc-3349 Target:5′-TAGTGAATACTGCTACAGCAATTTCTA-3′ (SEQ ID NO: 2277)5′-UACUGCUACAGCAAUUUCUAAUUtt-3′ (SEQ ID NO: 60)3′-UUAUGACGAUGUCGUUAAAGAUUAAAA-5′ (SEQ ID NO: 1169) βc-3354 Target:5′-AATACTGCTACAGCAATTTCTAATTTT-3′ (SEQ ID NO: 2278)5′-CUAAUUUUUAAGAAUUGAGUAAUgg-3′ (SEQ ID NO: 61)3′-AAGAUUAAAAAUUCUUAACUCAUUACC-5′ (SEQ ID NO: 1170) βc-3371 Target:5′-TTCTAATTTTTAAGAATTGAGTAATGG-3′ (SEQ ID NO: 2279)5′-UUUUAAGAAUUGAGUAAUGGUGUag-3′ (SEQ ID NO: 62)3′-UAAAAAUUCUUAACUCAUUACCACAUC-5′ (SEQ ID NO: 1171) βc-3376 Target:5′-ATTTTTAAGAATTGAGTAATGGTGTAG-3′ (SEQ ID NO: 2280)5′-CAUAAUCACUCUAAUUAAUUGUAat-3′ (SEQ ID NO: 63)3′-AAGUAUUAGUGAGAUUAAUUAACAUUA-5′ (SEQ ID NO: 1172) βc-3411 Target:5′-TTCATAATCACTCTAATTAATTGTAAT-3′ (SEQ ID NO: 2281)5′-UAAUUGUAAUCUGAAUAAAGUGUaa-3′ (SEQ ID NO: 64)3′-UAAUUAACAUUAGACUUAUUUCACAUU-5′ (SEQ ID NO: 1173) βc-3426 Target:5′-ATTAATTGTAATCTGAATAAAGTGTAA-3′ (SEQ ID NO: 2282)5′-GUAAUCUGAAUAAAGUGUAACAAtt-3′ (SEQ ID NO: 65)3′-AACAUUAGACUUAUUUCACAUUGUUAA-5′ (SEQ ID NO: 1174) βc-3431 Target:5′-TTGTAATCTGAATAAAGTGTAACAATT-3′ (SEQ ID NO: 2283)5′-UGAAUAAAGUGUAACAAUUGUGUag-3′ (SEQ ID NO: 66)3′-AGACUUAUUUCACAUUGUUAACACAUC-5′ (SEQ ID NO: 1175) βc-3437 Target:5′-TCTGAATAAAGTGTAACAATTGTGTAG-3′ (SEQ ID NO: 2284)5′-GUAGCCUUUUUGUAUAAAAUAGAca-3′ (SEQ ID NO: 67)3′-CACAUCGGAAAAACAUAUUUUAUCUGU-5′ (SEQ ID NO: 1176) βc-3458 Target:5′-GTGTAGCCTTTTTGTATAAAATAGACA-3′ (SEQ ID NO: 2285)5′-UGUAUAAAAUAGACAAAUAGAAAat-3′ (SEQ ID NO: 68)3′-AAACAUAUUUUAUCUGUUUAUCUUUUA-5′ (SEQ ID NO: 1177) βc-3468 Target:5′-TTTGTATAAAATAGACAAATAGAAAAT-3′ (SEQ ID NO: 2286)5′-AAAAUGGUCCAAUUAGUUUCCUUtt-3′ (SEQ ID NO: 69)3′-UCUUUUACCAGGUUAAUCAAAGGAAAA-5′ (SEQ ID NO: 1178) βc-3488 Target:5′-AGAAAATGGTCCAATTAGTTTCCTTTT-3′ (SEQ ID NO: 2287)5′-CCAAUUAGUUUCCUUUUUAAUAUgc-3′ (SEQ ID NO: 70)3′-CAGGUUAAUCAAAGGAAAAAUUAUACG-5′ (SEQ ID NO: 1179) βc-3496 Target:5′-GTCCAATTAGTTTCCTTTTTAATATGC-3′ (SEQ ID NO: 2288)5′-UUUGAUCAAAAACUAUUUGGGAUat-3′ (SEQ ID NO: 71)3′-AAAAACUAGUUUUUGAUAAACCCUAUA-5′ (SEQ ID NO: 1180) βc-3552 Target:5′-TTTTTGATCAAAAACTATTTGGGATAT-3′ (SEQ ID NO: 2289)5′-GAGGUGUUAUUUGGAACCUUGUUtt-3′ (SEQ ID NO: 72)3′-UUCUCCACAAUAAACCUUGGAACAAAA-5′ (SEQ ID NO: 1181) βc-3600 Target:5′-AAGAGGTGTTATTTGGAACCTTGTTTT-3′ (SEQ ID NO: 2290)5′-GUUAUUUGGAACCUUGUUUUGGAca-3′ (SEQ ID NO: 73)3′-CACAAUAAACCUUGGAACAAAACCUGU-5′ (SEQ ID NO: 1182) βc-3605 Target:5′-GTGTTATTTGGAACCTTGTTTTGGACA-3′ (SEQ ID NO: 2291)5′-ACCUUGUUUUGGACAGUUUACCAgt-3′ (SEQ ID NO: 74)3′-CUUGGAACAAAACCUGUCAAAUGGUCA-5′ (SEQ ID NO: 1183) βc-3615 Target:5′-GAACCTTGTTTTGGACAGTTTACCAGT-3′ (SEQ ID NO: 2292)5′-GAUACGAUGCUUCAAGAGAAAAUgc-3′ (SEQ ID NO: 75)3′-CACUAUGCUACGAAGUUCUCUUUUACG-5′ (SEQ ID NO: 1184) βc-3674 Target:5′-GTGATACGATGCTTCAAGAGAAAATGC-3′ (SEQ ID NO: 2293)5′-CAAGAGAAAAUGCGGUUAUAAAAaa-3′ (SEQ ID NO: 76)3′-AAGUUCUCUUUUACGCCAAUAUUUUUU-5′ (SEQ ID NO: 1185) βc-3686 Target:5′-TTCAAGAGAAAATGCGGTTATAAAAAA-3′ (SEQ ID NO: 2294)5′-GAAAAUGCGGUUAUAAAAAAUGGtt-3′ (SEQ ID NO: 77)3′-CUCUUUUACGCCAAUAUUUUUUACCAA-5′ (SEQ ID NO: 1186) βc-3691 Target:5′-GAGAAAATGCGGTTATAAAAAATGGTT-3′ (SEQ ID NO: 2295)5′-GUUAUAAAAAAUGGUUCAGAAUUaa-3′ (SEQ ID NO: 78)3′-GCCAAUAUUUUUUACCAAGUCUUAAUU-5′ (SEQ ID NO: 1187) βc-3700 Target:5′-CGGTTATAAAAAATGGTTCAGAATTAA-3′ (SEQ ID NO: 2296)5′-AAAAUGGUUCAGAAUUAAACUUUta-3′ (SEQ ID NO: 79)3′-UUUUUUACCAAGUCUUAAUUUGAAAAU-5′ (SEQ ID NO: 1188) βc-3707 Target:5′-AAAAAATGGTTCAGAATTAAACTTTTA-3′ (SEQ ID NO: 2297)

TABLE 3 Selected Anti-β-catenin DsiRNAs, Duplexes Targeting Both Humanand Mouse Sequences 5′-GCGUGGACAAUGGCUACUCAAGCtg-3′ (SEQ ID NO: 80)3′-GUCGCACCUGUUACCGAUGAGUUCGAC-5′ (SEQ ID NO: 1189) βc-284 Target:5′-CAGCGTGGACAATGGCTACTCAAGCTG-3′ (SEQ ID NO: 2298)5′-CGUGGACAAUGGCUACUCAAGCUga-3′ (SEQ ID NO: 81)3′-UCGCACCUGUUACCGAUGAGUUCGACU-5′ (SEQ ID NO: 1190) βc-285 Target:5′-AGCGTGGACAATGGCTACTCAAGCTGA-3′ (SEQ ID NO: 2299)5′-GUGGACAAUGGCUACUCAAGCUGat-3′ (SEQ ID NO: 82)3′-CGCACCUGUUACCGAUGAGUUCGACUA-5′ (SEQ ID NO: 1191) βc-286 Target:5′-GCGTGGACAATGGCTACTCAAGCTGAT-3′ (SEQ ID NO: 2300)5′-UGGACAAUGGCUACUCAAGCUGAtt-3′ (SEQ ID NO: 83)3′-GCACCUGUUACCGAUGAGUUCGACUAA-5′ (SEQ ID NO: 1192) βc-287 Target:5′-CGTGGACAATGGCTACTCAAGCTGATT-3′ (SEQ ID NO: 2301)5′-GGACAAUGGCUACUCAAGCUGAUtt-3′ (SEQ ID NO: 84)3′-CACCUGUUACCGAUGAGUUCGACUAAA-5′ (SEQ ID NO: 1193) βc-288 Target:5′-GTGGACAATGGCTACTCAAGCTGATTT-3′ (SEQ ID NO: 2302)5′-GACAAUGGCUACUCAAGCUGAUUtg-3′ (SEQ ID NO: 85)3′-ACCUGUUACCGAUGAGUUCGACUAAAC-5′ (SEQ ID NO: 1194) βc-289 Target:5′-TGGACAATGGCTACTCAAGCTGATTTG-3′ (SEQ ID NO: 2303)5′-ACAAUGGCUACUCAAGCUGAUUUga-3′ (SEQ ID NO: 86)3′-CCUGUUACCGAUGAGUUCGACUAAACU-5′ (SEQ ID NO: 1195) βc-290 Target:5′-GGACAATGGCTACTCAAGCTGATTTGA-3′ (SEQ ID NO: 2304)5′-CAAUGGCUACUCAAGCUGAUUUGat-3′ (SEQ ID NO: 87)3′-CUGUUACCGAUGAGUUCGACUAAACUA-5′ (SEQ ID NO: 1196) βc-291 Target:5′-GACAATGGCTACTCAAGCTGATTTGAT-3′ (SEQ ID NO: 2305)5′-UGAUGGAGUUGGACAUGGCCAUGga-3′ (SEQ ID NO: 88)3′-AAACUACCUCAACCUGUACCGGUACCU-5′ (SEQ ID NO: 1197) βc-312 Target:5′-TTTGATGGAGTTGGACATGGCCATGGA-3′ (SEQ ID NO: 2306)5′-GAUGGAGUUGGACAUGGCCAUGGaa-3′ (SEQ ID NO: 89)3′-AACUACCUCAACCUGUACCGGUACCUU-5′ (SEQ ID NO: 1198) βc-313 Target:5′-TTGATGGAGTTGGACATGGCCATGGAA-3′ (SEQ ID NO: 2307)5′-AUGGAGUUGGACAUGGCCAUGGAac-3′ (SEQ ID NO: 90)3′-ACUACCUCAACCUGUACCGGUACCUUG-5′ (SEQ ID NO: 1199) βc-314 Target:5′-TGATGGAGTTGGACATGGCCATGGAAC-3′ (SEQ ID NO: 2308)5′-UGGAGUUGGACAUGGCCAUGGAAcc-3′ (SEQ ID NO: 91)3′-CUACCUCAACCUGUACCGGUACCUUGG-5′ (SEQ ID NO: 1200) βc-315 Target:5′-GATGGAGTTGGACATGGCCATGGAACC-3′ (SEQ ID NO: 2309)5′-GGAGUUGGACAUGGCCAUGGAACca-3′ (SEQ ID NO: 92)3′-UACCUCAACCUGUACCGGUACCUUGGU-5′ (SEQ ID NO: 1201) βc-316 Target:5′-ATGGAGTTGGACATGGCCATGGAACCA-3′ (SEQ ID NO: 2310)5′-GAGUUGGACAUGGCCAUGGAACCag-3′ (SEQ ID NO: 93)3′-ACCUCAACCUGUACCGGUACCUUGGUC-5′ (SEQ ID NO: 1202) βc-317 Target:5′-TGGAGTTGGACATGGCCATGGAACCAG-3′ (SEQ ID NO: 2311)5′-AGUUGGACAUGGCCAUGGAACCAga-3′ (SEQ ID NO: 94)3′-CCUCAACCUGUACCGGUACCUUGGUCU-5′ (SEQ ID NO: 1203) βc-318 Target:5′-GGAGTTGGACATGGCCATGGAACCAGA-3′ (SEQ ID NO: 2312)5′-UCUGGAAUCCAUUCUGGUGCCACta-3′ (SEQ ID NO: 95)3′-UGAGACCUUAGGUAAGACCACGGUGAU-5′ (SEQ ID NO: 1204) βc-389 Target:5′-ACTCTGGAATCCATTCTGGTGCCACTA-3′ (SEQ ID NO: 2313)5′-CUGGAAUCCAUUCUGGUGCCACUac-3′ (SEQ ID NO: 96)3′-GAGACCUUAGGUAAGACCACGGUGAUG-5′ (SEQ ID NO: 1205) βc-390 Target:5′-CTCTGGAATCCATTCTGGTGCCACTAC-3′ (SEQ ID NO: 2314)5′-UGGAAUCCAUUCUGGUGCCACUAcc-3′ (SEQ ID NO: 97)3′-AGACCUUAGGUAAGACCACGGUGAUGG-5′ (SEQ ID NO: 1206) βc-391 Target:5′-TCTGGAATCCATTCTGGTGCCACTACC-3′ (SEQ ID NO: 2315)5′-GGAAUCCAUUCUGGUGCCACUACca-3′ (SEQ ID NO: 98)3′-GACCUUAGGUAAGACCACGGUGAUGGU-5′ (SEQ ID NO: 1207) βc-392 Target:5′-CTGGAATCCATTCTGGTGCCACTACCA-3′ (SEQ ID NO: 2316)5′-GAAUCCAUUCUGGUGCCACUACCac-3′ (SEQ ID NO: 99)3′-ACCUUAGGUAAGACCACGGUGAUGGUG-5′ (SEQ ID NO: 1208) βc-393 Target:5′-TGGAATCCATTCTGGTGCCACTACCAC-3′ (SEQ ID NO: 2317)5′-UAGAUGAGGGCAUGCAGAUCCCAtc-3′ (SEQ ID NO: 100)3′-UAAUCUACUCCCGUACGUCUAGGGUAG-5′ (SEQ ID NO: 1209) βc-600 Target:5′-ATTAGATGAGGGCATGCAGATCCCATC-3′ (SEQ ID NO: 2318)5′-AGAUGAGGGCAUGCAGAUCCCAUct-3′ (SEQ ID NO: 101)3′-AAUCUACUCCCGUACGUCUAGGGUAGA-5′ (SEQ ID NO: 1210) βc-601 Target:5′-TTAGATGAGGGCATGCAGATCCCATCT-3′ (SEQ ID NO: 2319)5′-GAUGAGGGCAUGCAGAUCCCAUCta-3′ (SEQ ID NO: 102)3′-AUCUACUCCCGUACGUCUAGGGUAGAU-5′ (SEQ ID NO: 1211) βc-602 Target:5′-TAGATGAGGGCATGCAGATCCCATCTA-3′ (SEQ ID NO: 2320)5′-AUGAGGGCAUGCAGAUCCCAUCUac-3′ (SEQ ID NO: 103)3′-UCUACUCCCGUACGUCUAGGGUAGAUG-5′ (SEQ ID NO: 1212) βc-603 Target:5′-AGATGAGGGCATGCAGATCCCATCTAC-3′ (SEQ ID NO: 2321)5′-UGAGGGCAUGCAGAUCCCAUCUAca-3′ (SEQ ID NO: 104)3′-CUACUCCCGUACGUCUAGGGUAGAUGU-5′ (SEQ ID NO: 1213) βc-604 Target:5′-GATGAGGGCATGCAGATCCCATCTACA-3′ (SEQ ID NO: 2322)5′-GAGGGCAUGCAGAUCCCAUCUACac-3′ (SEQ ID NO: 105)3′-UACUCCCGUACGUCUAGGGUAGAUGUG-5′ (SEQ ID NO: 1214) βc-605 Target:5′-ATGAGGGCATGCAGATCCCATCTACAC-3′ (SEQ ID NO: 2323)5′-GCUGCUCAUCCCACUAAUGUCCAgc-3′ (SEQ ID NO: 106)3′-UACGACGAGUAGGGUGAUUACAGGUCG-5′ (SEQ ID NO: 1215) βc-638 Target:5′-ATGCTGCTCATCCCACTAATGTCCAGC-3′ (SEQ ID NO: 2324)5′-CUGCUCAUCCCACUAAUGUCCAGcg-3′ (SEQ ID NO: 107)3′-ACGACGAGUAGGGUGAUUACAGGUCGC-5′ (SEQ ID NO: 1216) βc-639 Target:5′-TGCTGCTCATCCCACTAATGTCCAGCG-3′ (SEQ ID NO: 2325)5′-UGCUCAUCCCACUAAUGUCCAGCgt-3′ (SEQ ID NO: 108)3′-CGACGAGUAGGGUGAUUACAGGUCGCA-5′ (SEQ ID NO: 1217) βc-640 Target:5′-GCTGCTCATCCCACTAATGTCCAGCGT-3′ (SEQ ID NO: 2326)5′-GCUCAUCCCACUAAUGUCCAGCGtt-3′ (SEQ ID NO: 109)3′-GACGAGUAGGGUGAUUACAGGUCGCAA-5′ (SEQ ID NO: 1218) βc-641 Target:5′-CTGCTCATCCCACTAATGTCCAGCGTT-3′ (SEQ ID NO: 2327)5′-CUCAUCCCACUAAUGUCCAGCGUtt-3′ (SEQ ID NO: 110)3′-ACGAGUAGGGUGAUUACAGGUCGCAAA-5′ (SEQ ID NO: 1219) βc-642 Target:5′-TGCTCATCCCACTAATGTCCAGCGTTT-3′ (SEQ ID NO: 2328)5′-UCAUCCCACUAAUGUCCAGCGUUtg-3′ (SEQ ID NO: 111)3′-CGAGUAGGGUGAUUACAGGUCGCAAAC-5′ (SEQ ID NO: 1220) βc-643 Target:5′-GCTCATCCCACTAATGTCCAGCGTTTG-3′ (SEQ ID NO: 2329)5′-CAUCCCACUAAUGUCCAGCGUUUgg-3′ (SEQ ID NO: 112)3′-GAGUAGGGUGAUUACAGGUCGCAAACC-5′ (SEQ ID NO: 1221) βc-644 Target:5′-CTCATCCCACTAATGTCCAGCGTTTGG-3′ (SEQ ID NO: 2330)5′-AUCCCACUAAUGUCCAGCGUUUGgc-3′ (SEQ ID NO: 113)3′-AGUAGGGUGAUUACAGGUCGCAAACCG-5′ (SEQ ID NO: 1222) βc-645 Target:5′-TCATCCCACTAATGTCCAGCGTTTGGC-3′ (SEQ ID NO: 2331)5′-UUGGCUGAACCAUCACAGAUGCUga-3′ (SEQ ID NO: 114)3′-CAAACCGACUUGGUAGUGUCUACGACU-5′ (SEQ ID NO: 1223) βc-665 Target:5′-GTTTGGCTGAACCATCACAGATGCTGA-3′ (SEQ ID NO: 2332)5′-UGGCUGAACCAUCACAGAUGCUGaa-3′ (SEQ ID NO: 115)3′-AAACCGACUUGGUAGUGUCUACGACUU-5′ (SEQ ID NO: 1224) βc-666 Target:5′-TTTGGCTGAACCATCACAGATGCTGAA-3′ (SEQ ID NO: 2333)5′-GGCUGAACCAUCACAGAUGCUGAaa-3′ (SEQ ID NO: 116)3′-AACCGACUUGGUAGUGUCUACGACUUU-5′ (SEQ ID NO: 1225) βc-667 Target:5′-TTGGCTGAACCATCACAGATGCTGAAA-3′ (SEQ ID NO: 2334)5′-GAACUUGCCACACGUGCAAUCCCtg-3′ (SEQ ID NO: 117)3′-GUCUUGAACGGUGUGCACGUUAGGGAC-5′ (SEQ ID NO: 1226) βc-731 Target:5′-CAGAACTTGCCACACGTGCAATCCCTG-3′ (SEQ ID NO: 2335)5′-AACUUGCCACACGUGCAAUCCCUga-3′ (SEQ ID NO: 118)3′-UCUUGAACGGUGUGCACGUUAGGGACU-5′ (SEQ ID NO: 1227) βc-732 Target:5′-AGAACTTGCCACACGTGCAATCCCTGA-3′ (SEQ ID NO: 2336)5′-GUUAUGGUCCAUCAGCUUUCUAAaa-3′ (SEQ ID NO: 119)3′-GUCAAUACCAGGUAGUCGAAAGAUUUU-5′ (SEQ ID NO: 1228) βc-809 Target:5′-CAGTTATGGTCCATCAGCTTTCTAAAA-3′ (SEQ ID NO: 2337)5′-UUAUGGUCCAUCAGCUUUCUAAAaa-3′ (SEQ ID NO: 120)3′-UCAAUACCAGGUAGUCGAAAGAUUUUU-5′ (SEQ ID NO: 1229) βc-810 Target:5′-AGTTATGGTCCATCAGCTTTCTAAAAA-3′ (SEQ ID NO: 2338)5′-AAAAAGGAAGCUUCCAGACACGCta-3′ (SEQ ID NO: 121)3′-GAUUUUUCCUUCGAAGGUCUGUGCGAU-5′ (SEQ ID NO: 1230) βc-830 Target:5′-CTAAAAAGGAAGCTTCCAGACACGCTA-3′ (SEQ ID NO: 2339)5′-AAAAGGAAGCUUCCAGACACGCUat-3′ (SEQ ID NO: 122)3′-AUUUUUCCUUCGAAGGUCUGUGCGAUA-5′ (SEQ ID NO: 1231) βc-831 Target:5′-TAAAAAGGAAGCTTCCAGACACGCTAT-3′ (SEQ ID NO: 2340)5′-ACCAUGCAGAAUACAAAUGAUGUag-3′ (SEQ ID NO: 123)3′-CAUGGUACGUCUUAUGUUUACUACAUC-5′ (SEQ ID NO: 1232) βc-893 Target:5′-GTACCATGCAGAATACAAATGATGTAG-3′ (SEQ ID NO: 2341)5′-CCAUGCAGAAUACAAAUGAUGUAga-3′ (SEQ ID NO: 124)3′-AUGGUACGUCUUAUGUUUACUACAUCU-5′ (SEQ ID NO: 1233) βc-894 Target:5′-TACCATGCAGAATACAAATGATGTAGA-3′ (SEQ ID NO: 2342)5′-CAUGCAGAAUACAAAUGAUGUAGaa-3′ (SEQ ID NO: 125)3′-UGGUACGUCUUAUGUUUACUACAUCUU-5′ (SEQ ID NO: 1234) βc-895 Target:5′-ACCATGCAGAATACAAATGATGTAGAA-3′ (SEQ ID NO: 2343)5′-AUGCAGAAUACAAAUGAUGUAGAaa-3′ (SEQ ID NO: 126)3′-GGUACGUCUUAUGUUUACUACAUCUUU-5′ (SEQ ID NO: 1235) βc-896 Target:5′-CCATGCAGAATACAAATGATGTAGAAA-3′ (SEQ ID NO: 2344)5′-UGCAGAAUACAAAUGAUGUAGAAac-3′ (SEQ ID NO: 127)3′-GUACGUCUUAUGUUUACUACAUCUUUG-5′ (SEQ ID NO: 1236) βc-897 Target:5′-CATGCAGAATACAAATGATGTAGAAAC-3′ (SEQ ID NO: 2345)5′-GCAGAAUACAAAUGAUGUAGAAAca-3′ (SEQ ID NO: 128)3′-UACGUCUUAUGUUUACUACAUCUUUGU-5′ (SEQ ID NO: 1237) βc-898 Target:5′-ATGCAGAATACAAATGATGTAGAAACA-3′ (SEQ ID NO: 2346)5′-CAGAAUACAAAUGAUGUAGAAACag-3′ (SEQ ID NO: 129)3′-ACGUCUUAUGUUUACUACAUCUUUGUC-5′ (SEQ ID NO: 1238) βc-899 Target:5′-TGCAGAATACAAATGATGTAGAAACAG-3′ (SEQ ID NO: 2347)5′-AGAAUACAAAUGAUGUAGAAACAgc-3′ (SEQ ID NO: 130)3′-CGUCUUAUGUUUACUACAUCUUUGUCG-5′ (SEQ ID NO: 1239) βc-900 Target:5′-GCAGAATACAAATGATGTAGAAACAGC-3′ (SEQ ID NO: 2348)5′-CUGGCCAUCUUUAAGUCUGGAGGca-3′ (SEQ ID NO: 131)3′-AUGACCGGUAGAAAUUCAGACCUCCGU-5′ (SEQ ID NO: 1240) βc-977 Target:5′-TACTGGCCATCTTTAAGTCTGGAGGCA-3′ (SEQ ID NO: 2349)5′-UGGCCAUCUUUAAGUCUGGAGGCat-3′ (SEQ ID NO: 132)3′-UGACCGGUAGAAAUUCAGACCUCCGUA-5′ (SEQ ID NO: 1241) βc-978 Target:5′-ACTGGCCATCTTTAAGTCTGGAGGC-3′ (SEQ ID NO: 2350)5′-GAAGGAGCUAAAAUGGCAGUGCGtt-3′ (SEQ ID NO: 133)3′-UUCUUCCUCGAUUUUACCGUCACGCAA-5′ (SEQ ID NO: 1242) βc-1091 Target:5′-AAGAAGGAGCTAAAATGGCAGTGCGTT-3′ (SEQ ID NO: 2351)5′-AAGGAGCUAAAAUGGCAGUGCGUtt-3′ (SEQ ID NO: 134)3′-UCUUCCUCGAUUUUACCGUCACGCAAA-5′ (SEQ ID NO: 1243) βc-1092 Target:5′-AGAAGGAGCTAAAATGGCAGTGCGTTT-3′ (SEQ ID NO: 2352)5′-AGGAGCUAAAAUGGCAGUGCGUUta-3′ (SEQ ID NO: 135)3′-CUUCCUCGAUUUUACCGUCACGCAAAU-5′ (SEQ ID NO: 1244) βc-1093 Target:5′-GAAGGAGCTAAAATGGCAGTGCGTTTA-3′ (SEQ ID NO: 2353)5′-GGAGCUAAAAUGGCAGUGCGUUUag-3′ (SEQ ID NO: 136)3′-UUCCUCGAUUUUACCGUCACGCAAAUC-5′ (SEQ ID NO: 1245) βc-1094 Target:5′-AAGGAGCTAAAATGGCAGTGCGTTTAG-3′ (SEQ ID NO: 2354)5′-GAGCUAAAAUGGCAGUGCGUUUAgc-3′ (SEQ ID NO: 137)3′-UCCUCGAUUUUACCGUCACGCAAAUCG-5′ (SEQ ID NO: 1246) βc-1095 Target:5′-AGGAGCTAAAATGGCAGTGCGTTTAGC-3′ (SEQ ID NO: 2355)5′-CUGUGGACCACAAGCAGAGUGCUga-3′ (SEQ ID NO: 138)3′-AUGACACCUGGUGUUCGUCUCACGACU-5′ (SEQ ID NO: 1247) βc-1301 Target:5′-TACTGTGGACCACAAGCAGAGTGCTGA-3′ (SEQ ID NO: 2356)5′-UGUGGACCACAAGCAGAGUGCUGaa-3′ (SEQ ID NO: 139)3′-UGACACCUGGUGUUCGUCUCACGACUU-5′ (SEQ ID NO: 1248) βc-1302 Target:5′-ACTGTGGACCACAAGCAGAGTGCTGAA-3′ (SEQ ID NO: 2357)5′-GUGGACCACAAGCAGAGUGCUGAag-3′ (SEQ ID NO: 140)3′-GACACCUGGUGUUCGUCUCACGACUUC-5′ (SEQ ID NO: 1249) βc-1303 Target:5′-CTGTGGACCACAAGCAGAGTGCTGAAG-3′ (SEQ ID NO: 2358)5′-UGGACCACAAGCAGAGUGCUGAAgg-3′ (SEQ ID NO: 141)3′-ACACCUGGUGUUCGUCUCACGACUUCC-5′ (SEQ ID NO: 1250) βc-1304 Target:5′-TGTGGACCACAAGCAGAGTGCTGAAGG-3′ (SEQ ID NO: 2359)5′-GGACCACAAGCAGAGUGCUGAAGgt-3′ (SEQ ID NO: 142)3′-CACCUGGUGUUCGUCUCACGACUUCCA-5′ (SEQ ID NO: 1251) βc-1305 Target:5′-GTGGACCACAAGCAGAGTGCTGAAGGT-3′ (SEQ ID NO: 2360)5′-GACCACAAGCAGAGUGCUGAAGGtg-3′ (SEQ ID NO: 143)3′-ACCUGGUGUUCGUCUCACGACUUCCAC-5′ (SEQ ID NO: 1252) βc-1306 Target:5′-TGGACCACAAGCAGAGTGCTGAAGGTG-3′ (SEQ ID NO: 2361)5′-ACCACAAGCAGAGUGCUGAAGGUgc-3′ (SEQ ID NO: 144)3′-CCUGGUGUUCGUCUCACGACUUCCACG-5′ (SEQ ID NO: 1253) βc-1307 Target:5′-GGACCACAAGCAGAGTGCTGAAGGTGC-3′ (SEQ ID NO: 2362)5′-CCACAAGCAGAGUGCUGAAGGUGct-3′ (SEQ ID NO: 145)3′-CUGGUGUUCGUCUCACGACUUCCACGA-5′ (SEQ ID NO: 1254) βc-1308 Target:5′-GACCACAAGCAGAGTGCTGAAGGTGCT-3′ (SEQ ID NO: 2363)5′-CACAAGCAGAGUGCUGAAGGUGCta-3′ (SEQ ID NO: 146)3′-UGGUGUUCGUCUCACGACUUCCACGAU-5′ (SEQ ID NO: 1255) βc-1309 Target:5′-ACCACAAGCAGAGTGCTGAAGGTGCTA-3′ (SEQ ID NO: 2364)5′-ACAAGCAGAGUGCUGAAGGUGCUat-3′ (SEQ ID NO: 147)3′-GGUGUUCGUCUCACGACUUCCACGAUA-5′ (SEQ ID NO: 1256) βc-1310 Target:5′-CCACAAGCAGAGTGCTGAAGGTGCTAT-3′ (SEQ ID NO: 2365)5′-CAAGCAGAGUGCUGAAGGUGCUAtc-3′ (SEQ ID NO: 148)3′-GUGUUCGUCUCACGACUUCCACGAUAG-5′ (SEQ ID NO: 1257) βc-1311 Target:5′-CACAAGCAGAGTGCTGAAGGTGCTATC-3′ (SEQ ID NO: 2366)5′-AAGCAGAGUGCUGAAGGUGCUAUct-3′ (SEQ ID NO: 149)3′-UGUUCGUCUCACGACUUCCACGAUAGA-5′ (SEQ ID NO: 1258) βc-1312 Target:5′-ACAAGCAGAGTGCTGAAGGTGCTATCT-3′ (SEQ ID NO: 2367)5′-AGCAGAGUGCUGAAGGUGCUAUCtg-3′ (SEQ ID NO: 150)3′-GUUCGUCUCACGACUUCCACGAUAGAC-5′ (SEQ ID NO: 1259) βc-1313 Target:5′-CAAGCAGAGTGCTGAAGGTGCTATCTG-3′ (SEQ ID NO: 2368)5′-GCAGAGUGCUGAAGGUGCUAUCUgt-3′ (SEQ ID NO: 151)3′-UUCGUCUCACGACUUCCACGAUAGACA-5′ (SEQ ID NO: 1260) βc-1314 Target:5′-AAGCAGAGTGCTGAAGGTGCTATCTGT-3′ (SEQ ID NO: 2369)5′-AACUGUCUUUGGACUCUCAGGAAtc-3′ (SEQ ID NO: 152)3′-UCUUGACAGAAACCUGAGAGUCCUUAG-5′ (SEQ ID NO: 1261) βc-1430 Target:5′-AGAACTGTCTTTGGACTCTCAGGAATC-3′ (SEQ ID NO: 2370)5′-ACUGUCUUUGGACUCUCAGGAAUct-3′ (SEQ ID NO: 153)3′-CUUGACAGAAACCUGAGAGUCCUUAGA-5′ (SEQ ID NO: 1262) βc-1431 Target:5′-GAACTGTCTTTGGACTCTCAGGAATCT-3′ (SEQ ID NO: 2371)5′-GAUGAUAUAAAUGUGGUCACCUGtg-3′ (SEQ ID NO: 154)3′-GUCUACUAUAUUUACACCAGUGGACAC-5′ (SEQ ID NO: 1263) βc-1526 Target:5′-CAGATGATATAAATGTGGTCACCTGTG-3′ (SEQ ID NO: 2372)5′-AUGAUAUAAAUGUGGUCACCUGUgc-3′ (SEQ ID NO: 155)3′-UCUACUAUAUUUACACCAGUGGACACG-5′ (SEQ ID NO: 1264) βc-1527 Target:5′-AGATGATATAAATGTGGTCACCTGTGC-3′ (SEQ ID NO: 2373)5′-UGAUAUAAAUGUGGUCACCUGUGca-3′ (SEQ ID NO: 156)3′-CUACUAUAUUUACACCAGUGGACACGU-5′ (SEQ ID NO: 1265) βc-1528 Target:5′-GATGATATAAATGTGGTCACCTGTGCA-3′ (SEQ ID NO: 2374)5′-GAUAUAAAUGUGGUCACCUGUGCag-3′ (SEQ ID NO: 157)3′-UACUAUAUUUACACCAGUGGACACGUC-5′ (SEQ ID NO: 1266) βc-1529 Target:5′-ATGATATAAATGTGGTCACCTGTGCAG-3′ (SEQ ID NO: 2375)5′-AUAUAAAUGUGGUCACCUGUGCAgc-3′ (SEQ ID NO: 158)3′-ACUAUAUUUACACCAGUGGACACGUCG-5′ (SEQ ID NO: 1267) βc-1530 Target:5′-TGATATAAATGTGGTCACCTGTGCAGC-3′ (SEQ ID NO: 2376)5′-UAUAAAUGUGGUCACCUGUGCAGct-3′ (SEQ ID NO: 159)3′-CUAUAUUUACACCAGUGGACACGUCGA-5′ (SEQ ID NO: 1268) βc-1531 Target:5′-GATATAAATGTGGTCACCTGTGCAGCT-3′ (SEQ ID NO: 2377)5′-AUAAAUGUGGUCACCUGUGCAGCtg-3′ (SEQ ID NO: 160)3′-UAUAUUUACACCAGUGGACACGUCGAC-5′ (SEQ ID NO: 1269) βc-1532 Target:5′-ATATAAATGTGGTCACCTGTGCAGCTG-3′ (SEQ ID NO: 2378)5′-UAAAUGUGGUCACCUGUGCAGCUgg-3′ (SEQ ID NO: 161)3′-AUAUUUACACCAGUGGACACGUCGACC-5′ (SEQ ID NO: 1270) βc-1533 Target:5′-TATAAATGTGGTCACCTGTGCAGCTGG-3′ (SEQ ID NO: 2379)5′-AAAUGUGGUCACCUGUGCAGCUGga-3′ (SEQ ID NO: 162)3′-UAUUUACACCAGUGGACACGUCGACCU-5′ (SEQ ID NO: 1271) βc-1534 Target:5′-ATAAATGTGGTCACCTGTGCAGCTGGA-3′ (SEQ ID NO: 2380)5′-AAUGUGGUCACCUGUGCAGCUGGaa-3′ (SEQ ID NO: 163)3′-AUUUACACCAGUGGACACGUCGACCUU-5′ (SEQ ID NO: 1272) βc-1535 Target:5′-TAAATGTGGTCACCTGTGCAGCTGGAA-3′ (SEQ ID NO: 2381)5′-AUGUGGUCACCUGUGCAGCUGGAat-3′ (SEQ ID NO: 164)3′-UUUACACCAGUGGACACGUCGACCUUA-5′ (SEQ ID NO: 1273) βc-1536 Target:5′-AAATGTGGTCACCTGTGCAGCTGGAAT-3′ (SEQ ID NO: 2382)5′-UGUGGUCACCUGUGCAGCUGGAAtt-3′ (SEQ ID NO: 165)3′-UUACACCAGUGGACACGUCGACCUUAA-5′ (SEQ ID NO: 1274) βc-1537 Target:5′-AATGTGGTCACCTGTGCAGCTGGAATT-3′ (SEQ ID NO: 2383)5′-GUGGUCACCUGUGCAGCUGGAAUtc-3′ (SEQ ID NO: 166)3′-UACACCAGUGGACACGUCGACCUUAAG-5′ (SEQ ID NO: 1275) βc-1538 Target:5′-ATGTGGTCACCTGTGCAGCTGGAATTC-3′ (SEQ ID NO: 2384)5′-UGGUCACCUGUGCAGCUGGAAUUct-3′ (SEQ ID NO: 167)3′-ACACCAGUGGACACGUCGACCUUAAGA-5′ (SEQ ID NO: 1276) βc-1539 Target:5′-TGTGGTCACCTGTGCAGCTGGAATTCT-3′ (SEQ ID NO: 2385)5′-GGUCACCUGUGCAGCUGGAAUUCtt-3′ (SEQ ID NO: 168)3′-CACCAGUGGACACGUCGACCUUAAGAA-5′ (SEQ ID NO: 1277) βc-1540 Target:5′-GTGGTCACCTGTGCAGCTGGAATTCTT-3′ (SEQ ID NO: 2386)5′-GUCACCUGUGCAGCUGGAAUUCUtt-3′ (SEQ ID NO: 169)3′-ACCAGUGGACACGUCGACCUUAAGAAA-5′ (SEQ ID NO: 1278) βc-1541 Target:5′-TGGTCACCTGTGCAGCTGGAATTCTTT-3′ (SEQ ID NO: 2387)5′-UCACCUGUGCAGCUGGAAUUCUUtc-3′ (SEQ ID NO: 170)3′-CCAGUGGACACGUCGACCUUAAGAAAG-5′ (SEQ ID NO: 1279) βc-1542 Target:5′-GGTCACCTGTGCAGCTGGAATTCTTTC-3′ (SEQ ID NO: 2388)5′-CACCUGUGCAGCUGGAAUUCUUUct-3′ (SEQ ID NO: 171)3′-CAGUGGACACGUCGACCUUAAGAAAGA-5′ (SEQ ID NO: 1280) βc-1543 Target:5′-GTCACCTGTGCAGCTGGAATTCTTTCT-3′ (SEQ ID NO: 2389)5′-ACCUGUGCAGCUGGAAUUCUUUCta-3′ (SEQ ID NO: 172)3′-AGUGGACACGUCGACCUUAAGAAAGAU-5′ (SEQ ID NO: 1281) βc-1544 Target:5′-TCACCTGTGCAGCTGGAATTCTTTCTA-3′ (SEQ ID NO: 2390)5′-CCUGUGCAGCUGGAAUUCUUUCUaa-3′ (SEQ ID NO: 173)3′-GUGGACACGUCGACCUUAAGAAAGAUU-5′ (SEQ ID NO: 1282) βc-1545 Target:5′-CACCTGTGCAGCTGGAATTCTTTCTAA-3′ (SEQ ID NO: 2391)5′-UCUAACCUCACUUGCAAUAAUUAta-3′ (SEQ ID NO: 174)3′-AAAGAUUGGAGUGAACGUUAUUAAUAU-5′ (SEQ ID NO: 1283) βc-1565 Target:5′-TTTCTAACCTCACTTGCAATAATTATA-3′ (SEQ ID NO: 2392)5′-CUAACCUCACUUGCAAUAAUUAUaa-3′ (SEQ ID NO: 175)3′-AAGAUUGGAGUGAACGUUAUUAAUAUU-5′ (SEQ ID NO: 1284) βc-1566 Target:5′-TTCTAACCTCACTTGCAATAATTATAA-3′ (SEQ ID NO: 2393)5′-UAACCUCACUUGCAAUAAUUAUAag-3′ (SEQ ID NO: 176)3′-AGAUUGGAGUGAACGUUAUUAAUAUUC-5′ (SEQ ID NO: 1285) βc-1567 Target:5′-TCTAACCTCACTTGCAATAATTATAAG-3′ (SEQ ID NO: 2394)5′-AACCUCACUUGCAAUAAUUAUAAga-3′ (SEQ ID NO: 177)3′-GAUUGGAGUGAACGUUAUUAAUAUUCU-5′ (SEQ ID NO: 1286) βc-1568 Target:5′-CTAACCTCACTTGCAATAATTATAAGA-3′ (SEQ ID NO: 2395)5′-ACCUCACUUGCAAUAAUUAUAAGaa-3′ (SEQ ID NO: 178)3′-AUUGGAGUGAACGUUAUUAAUAUUCUU-5′ (SEQ ID NO: 1287) βc-1569 Target:5′-TAACCTCACTTGCAATAATTATAAGAA-3′ (SEQ ID NO: 2396)5′-GCUGGUGACAGGGAAGACAUCACtg-3′ (SEQ ID NO: 179)3′-CCCGACCACUGUCCCUUCUGUAGUGAC-5′ (SEQ ID NO: 1288) βc-1652 Target:5′-GGGCTGGTGACAGGGAAGACATCACTG-3′ (SEQ ID NO: 2397)5′-CUGGUGACAGGGAAGACAUCACUga-3′ (SEQ ID NO: 180)3′-CCGACCACUGUCCCUUCUGUAGUGACU-5′ (SEQ ID NO: 1289) βc-1653 Target:5′-GGCTGGTGACAGGGAAGACATCACTGA-3′ (SEQ ID NO: 2398)5′-UGGUGACAGGGAAGACAUCACUGag-3′ (SEQ ID NO: 181)3′-CGACCACUGUCCCUUCUGUAGUGACUC-5′ (SEQ ID NO: 1290) βc-1654 Target:5′-GCTGGTGACAGGGAAGACATCACTGAG-3′ (SEQ ID NO: 2399)5′-GGUGACAGGGAAGACAUCACUGAgc-3′ (SEQ ID NO: 182)3′-GACCACUGUCCCUUCUGUAGUGACUCG-5′ (SEQ ID NO: 1291) βc-1655 Target:5′-CTGGTGACAGGGAAGACATCACTGAGC-3′ (SEQ ID NO: 2400)5′-GUGACAGGGAAGACAUCACUGAGcc-3′ (SEQ ID NO: 183)3′-ACCACUGUCCCUUCUGUAGUGACUCGG-5′ (SEQ ID NO: 1292) βc-1656 Target:5′-TGGTGACAGGGAAGACATCACTGAGCC-3′ (SEQ ID NO: 2401)5′-UGACAGGGAAGACAUCACUGAGCct-3′ (SEQ ID NO: 184)3′-CCACUGUCCCUUCUGUAGUGACUCGGA-5′ (SEQ ID NO: 1293) βc-1657 Target:5′-GGTGACAGGGAAGACATCACTGAGCCT-3′ (SEQ ID NO: 2402)5′-GACAGGGAAGACAUCACUGAGCCtg-3′ (SEQ ID NO: 185)3′-CACUGUCCCUUCUGUAGUGACUCGGAC-5′ (SEQ ID NO: 1294) βc-1658 Target:5′-GTGACAGGGAAGACATCACTGAGCCTG-3′ (SEQ ID NO: 2403)5′-ACAGGGAAGACAUCACUGAGCCUgc-3′ (SEQ ID NO: 186)3′-ACUGUCCCUUCUGUAGUGACUCGGACG-5′ (SEQ ID NO: 1295) βc-1659 Target:5′-TGACAGGGAAGACATCACTGAGCCTGC-3′ (SEQ ID NO: 2404)5′-CAGGGAAGACAUCACUGAGCCUGcc-3′ (SEQ ID NO: 187)3′-CUGUCCCUUCUGUAGUGACUCGGACGG-5′ (SEQ ID NO: 1296) βc-1660 Target:5′-GACAGGGAAGACATCACTGAGCCTGCC-3′ (SEQ ID NO: 2405)5′-AGGGAAGACAUCACUGAGCCUGCca-3′ (SEQ ID NO: 188)3′-UGUCCCUUCUGUAGUGACUCGGACGGU-5′ (SEQ ID NO: 1297) βc-1661 Target:5′-ACAGGGAAGACATCACTGAGCCTGCCA-3′ (SEQ ID NO: 2406)5′-GGGAAGACAUCACUGAGCCUGCCat-3′ (SEQ ID NO: 189)3′-GUCCCUUCUGUAGUGACUCGGACGGUA-5′ (SEQ ID NO: 1298) βc-1662 Target:5′-CAGGGAAGACATCACTGAGCCTGCC-3′ (SEQ ID NO: 2407)5′-GGAAGACAUCACUGAGCCUGCCAtc-3′ (SEQ ID NO: 190)3′-UCCCUUCUGUAGUGACUCGGACGGUAG-5′ (SEQ ID NO: 1299) βc-1663 Target:5′-AGGGAAGACATCACTGAGCCTGCCATC-3′ (SEQ ID NO: 2408)5′-GAAGACAUCACUGAGCCUGCCAUct-3′ (SEQ ID NO: 191)3′-CCCUUCUGUAGUGACUCGGACGGUAGA-5′ (SEQ ID NO: 1300) βc-1664 Target:5′-GGGAAGACATCACTGAGCCTGCCATCT-3′ (SEQ ID NO: 2409)5′-AAGACAUCACUGAGCCUGCCAUCtg-3′ (SEQ ID NO: 192)3′-CCUUCUGUAGUGACUCGGACGGUAGAC-5′ (SEQ ID NO: 1301) βc-1665 Target:5′-GGAAGACATCACTGAGCCTGCCATCTG-3′ (SEQ ID NO: 2410)5′-AGACAUCACUGAGCCUGCCAUCUgt-3′ (SEQ ID NO: 193)3′-CUUCUGUAGUGACUCGGACGGUAGACA-5′ (SEQ ID NO: 1302) βc-1666 Target:5′-GAAGACATCACTGAGCCTGCCATCTGT-3′ (SEQ ID NO: 2411)5′-GACAUCACUGAGCCUGCCAUCUGtg-3′ (SEQ ID NO: 194)3′-UUCUGUAGUGACUCGGACGGUAGACAC-5′ (SEQ ID NO: 1303) βc-1667 Target:5′-AAGACATCACTGAGCCTGCCATCTGTG-3′ (SEQ ID NO: 2412)5′-ACAUCACUGAGCCUGCCAUCUGUgc-3′ (SEQ ID NO: 195)3′-UCUGUAGUGACUCGGACGGUAGACACG-5′ (SEQ ID NO: 1304) βc-1668 Target:5′-AGACATCACTGAGCCTGCCATCTGTGC-3′ (SEQ ID NO: 2413)5′-CAUCACUGAGCCUGCCAUCUGUGct-3′ (SEQ ID NO: 196)3′-CUGUAGUGACUCGGACGGUAGACACGA-5′ (SEQ ID NO: 1305) βc-1669 Target:5′-GACATCACTGAGCCTGCCATCTGTGCT-3′ (SEQ ID NO: 2414)5′-AUCACUGAGCCUGCCAUCUGUGCtc-3′ (SEQ ID NO: 197)3′-UGUAGUGACUCGGACGGUAGACACGAG-5′ (SEQ ID NO: 1306) βc-1670 Target:5′-ACATCACTGAGCCTGCCATCTGTGCTC-3′ (SEQ ID NO: 2415)5′-UCACUGAGCCUGCCAUCUGUGCUct-3′ (SEQ ID NO: 198)3′-GUAGUGACUCGGACGGUAGACACGAGA-5′ (SEQ ID NO: 1307) βc-1671 Target:5′-CATCACTGAGCCTGCCATCTGTGCTCT-3′ (SEQ ID NO: 2416)5′-CACUGAGCCUGCCAUCUGUGCUCtt-3′ (SEQ ID NO: 199)3′-UAGUGACUCGGACGGUAGACACGAGAA-5′ (SEQ ID NO: 1308) βc-1672 Target:5′-ATCACTGAGCCTGCCATCTGTGCTCTT-3′ (SEQ ID NO: 2417)5′-ACUGAGCCUGCCAUCUGUGCUCUtc-3′ (SEQ ID NO: 200)3′-AGUGACUCGGACGGUAGACACGAGAAG-5′ (SEQ ID NO: 1309) βc-1673 Target:5′-TCACTGAGCCTGCCATCTGTGCTCTTC-3′ (SEQ ID NO: 2418)5′-CUGAGCCUGCCAUCUGUGCUCUUcg-3′ (SEQ ID NO: 201)3′-GUGACUCGGACGGUAGACACGAGAAGC-5′ (SEQ ID NO: 1310) βc-1674 Target:5′-CACTGAGCCTGCCATCTGTGCTCTTCG-3′ (SEQ ID NO: 2419)5′-UGAGCCUGCCAUCUGUGCUCUUCgt-3′ (SEQ ID NO: 202)3′-UGACUCGGACGGUAGACACGAGAAGCA-5′ (SEQ ID NO: 1311) βc-1675 Target:5′-ACTGAGCCTGCCATCTGTGCTCTTCGT-3′ (SEQ ID NO: 2420)5′-GAGCCUGCCAUCUGUGCUCUUCGtc-3′ (SEQ ID NO: 203)3′-GACUCGGACGGUAGACACGAGAAGCAG-5′ (SEQ ID NO: 1312) βc-1676 Target:5′-CTGAGCCTGCCATCTGTGCTCTTCGTC-3′ (SEQ ID NO: 2421)5′-AGCCUGCCAUCUGUGCUCUUCGUca-3′ (SEQ ID NO: 204)3′-ACUCGGACGGUAGACACGAGAAGCAGU-5′ (SEQ ID NO: 1313) βc-1677 Target:5′-TGAGCCTGCCATCTGTGCTCTTCGTCA-3′ (SEQ ID NO: 2422)5′-GCCUGCCAUCUGUGCUCUUCGUCat-3′ (SEQ ID NO: 205)3′-CUCGGACGGUAGACACGAGAAGCAGUA-5′ (SEQ ID NO: 1314) βc-1678 Target:5′-GAGCCTGCCATCTGTGCTCTTCGTC-3′ (SEQ ID NO: 2423)5′-CCUGCCAUCUGUGCUCUUCGUCAtc-3′ (SEQ ID NO: 206)3′-UCGGACGGUAGACACGAGAAGCAGUAG-5′ (SEQ ID NO: 1315) βc-1679 Target:5′-AGCCTGCCATCTGTGCTCTTCGTCATC-3′ (SEQ ID NO: 2424)5′-CUGCCAUCUGUGCUCUUCGUCAUct-3′ (SEQ ID NO: 207)3′-CGGACGGUAGACACGAGAAGCAGUAGA-5′ (SEQ ID NO: 1316) βc-1680 Target:5′-GCCTGCCATCTGTGCTCTTCGTCATCT-3′ (SEQ ID NO: 2425)5′-UGCCAUCUGUGCUCUUCGUCAUCtg-3′ (SEQ ID NO: 208)3′-GGACGGUAGACACGAGAAGCAGUAGAC-5′ (SEQ ID NO: 1317) βc-1681 Target:5′-CCTGCCATCTGTGCTCTTCGTCATCTG-3′ (SEQ ID NO: 2426)5′-GCCAUCUGUGCUCUUCGUCAUCUga-3′ (SEQ ID NO: 209)3′-GACGGUAGACACGAGAAGCAGUAGACU-5′ (SEQ ID NO: 1318) βc-1682 Target:5′-CTGCCATCTGTGCTCTTCGTCATCTGA-3′ (SEQ ID NO: 2427)5′-CCAUCUGUGCUCUUCGUCAUCUGac-3′ (SEQ ID NO: 210)3′-ACGGUAGACACGAGAAGCAGUAGACUG-5′ (SEQ ID NO: 1319) βc-1683 Target:5′-TGCCATCTGTGCTCTTCGTCATCTGAC-3′ (SEQ ID NO: 2428)5′-CAUCUGUGCUCUUCGUCAUCUGAcc-3′ (SEQ ID NO: 211)3′-CGGUAGACACGAGAAGCAGUAGACUGG-5′ (SEQ ID NO: 1320) βc-1684 Target:5′-GCCATCTGTGCTCTTCGTCATCTGACC-3′ (SEQ ID NO: 2429)5′-AUCUGUGCUCUUCGUCAUCUGACca-3′ (SEQ ID NO: 212)3′-GGUAGACACGAGAAGCAGUAGACUGGU-5′ (SEQ ID NO: 1321) βc-1685 Target:5′-CCATCTGTGCTCTTCGTCATCTGACCA-3′ (SEQ ID NO: 2430)5′-UCUGUGCUCUUCGUCAUCUGACCag-3′ (SEQ ID NO: 213)3′-GUAGACACGAGAAGCAGUAGACUGGUC-5′ (SEQ ID NO: 1322) βc-1686 Target:5′-CATCTGTGCTCTTCGTCATCTGACCAG-3′ (SEQ ID NO: 2431)5′-CUGUGCUCUUCGUCAUCUGACCAgc-3′ (SEQ ID NO: 214)3′-UAGACACGAGAAGCAGUAGACUGGUCG-5′ (SEQ ID NO: 1323) βc-1687 Target:5′-ATCTGTGCTCTTCGTCATCTGACCAGC-3′ (SEQ ID NO: 2432)5′-UGUGCUCUUCGUCAUCUGACCAGcc-3′ (SEQ ID NO: 215)3′-AGACACGAGAAGCAGUAGACUGGUCGG-5′ (SEQ ID NO: 1324) βc-1688 Target:5′-TCTGTGCTCTTCGTCATCTGACCAGCC-3′ (SEQ ID NO: 2433)5′-GUGCUCUUCGUCAUCUGACCAGCcg-3′ (SEQ ID NO: 216)3′-GACACGAGAAGCAGUAGACUGGUCGGC-5′ (SEQ ID NO: 1325) βc-1689 Target:5′-CTGTGCTCTTCGTCATCTGACCAGCCG-3′ (SEQ ID NO: 2434)5′-UGCUCUUCGUCAUCUGACCAGCCga-3′ (SEQ ID NO: 217)3′-ACACGAGAAGCAGUAGACUGGUCGGCU-5′ (SEQ ID NO: 1326) βc-1690 Target:5′-TGTGCTCTTCGTCATCTGACCAGCCGA-3′ (SEQ ID NO: 2435)5′-GCUCUUCGUCAUCUGACCAGCCGac-3′ (SEQ ID NO: 218)3′-CACGAGAAGCAGUAGACUGGUCGGCUG-5′ (SEQ ID NO: 1327) βc-1691 Target:5′-GTGCTCTTCGTCATCTGACCAGCCGAC-3′ (SEQ ID NO: 2436)5′-CUCUUCGUCAUCUGACCAGCCGAca-3′ (SEQ ID NO: 219)3′-ACGAGAAGCAGUAGACUGGUCGGCUGU-5′ (SEQ ID NO: 1328) βc-1692 Target:5′-TGCTCTTCGTCATCTGACCAGCCGACA-3′ (SEQ ID NO: 2437)5′-UCUUCGUCAUCUGACCAGCCGACac-3′ (SEQ ID NO: 220)3′-CGAGAAGCAGUAGACUGGUCGGCUGUG-5′ (SEQ ID NO: 1329) βc-1693 Target:5′-GCTCTTCGTCATCTGACCAGCCGACAC-3′ (SEQ ID NO: 2438)5′-CUUCGUCAUCUGACCAGCCGACAcc-3′ (SEQ ID NO: 221)3′-GAGAAGCAGUAGACUGGUCGGCUGUGG-5′ (SEQ ID NO: 1330) βc-1694 Target:5′-CTCTTCGTCATCTGACCAGCCGACACC-3′ (SEQ ID NO: 2439)5′-UUCGUCAUCUGACCAGCCGACACca-3′ (SEQ ID NO: 222)3′-AGAAGCAGUAGACUGGUCGGCUGUGGU-5′ (SEQ ID NO: 1331) βc-1695 Target:5′-TCTTCGTCATCTGACCAGCCGACACCA-3′ (SEQ ID NO: 2440)5′-CACCCACCAUCCCACUGGCCUCUga-3′ (SEQ ID NO: 223)3′-AUGUGGGUGGUAGGGUGACCGGAGACU-5′ (SEQ ID NO: 1332) βc-1787 Target:5′-TACACCCACCATCCCACTGGCCTCTGA-3′ (SEQ ID NO: 2441)5′-ACCCACCAUCCCACUGGCCUCUGat-3′ (SEQ ID NO: 224)3′-UGUGGGUGGUAGGGUGACCGGAGACUA-5′ (SEQ ID NO: 1333) βc-1788 Target:5′-ACACCCACCATCCCACTGGCCTCTGAT-3′ (SEQ ID NO: 2442)5′-CCCACCAUCCCACUGGCCUCUGAta-3′ (SEQ ID NO: 225)3′-GUGGGUGGUAGGGUGACCGGAGACUAU-5′ (SEQ ID NO: 1334) βc-1789 Target:5′-CACCCACCATCCCACTGGCCTCTGATA-3′ (SEQ ID NO: 2443)5′-CCACCAUCCCACUGGCCUCUGAUaa-3′ (SEQ ID NO: 226)3′-UGGGUGGUAGGGUGACCGGAGACUAUU-5′ (SEQ ID NO: 1335) βc-1790 Target:5′-ACCCACCATCCCACTGGCCTCTGATAA-3′ (SEQ ID NO: 2444)5′-CACCAUCCCACUGGCCUCUGAUAaa-3′ (SEQ ID NO: 227)3′-GGGUGGUAGGGUGACCGGAGACUAUUU-5′ (SEQ ID NO: 1336) βc-1791 Target:5′-CCCACCATCCCACTGGCCTCTGATAAA-3′ (SEQ ID NO: 2445)5′-ACCAUCCCACUGGCCUCUGAUAAag-3′ (SEQ ID NO: 228)3′-GGUGGUAGGGUGACCGGAGACUAUUUC-5′ (SEQ ID NO: 1337) βc-1792 Target:5′-CCACCATCCCACTGGCCTCTGATAAAG-3′ (SEQ ID NO: 2446)5′-CCAUCCCACUGGCCUCUGAUAAAgg-3′ (SEQ ID NO: 229)3′-GUGGUAGGGUGACCGGAGACUAUUUCC-5′ (SEQ ID NO: 1338) βc-1793 Target:5′-CACCATCCCACTGGCCTCTGATAAAGG-3′ (SEQ ID NO: 2447)5′-CAUCCCACUGGCCUCUGAUAAAGgc-3′ (SEQ ID NO: 230)3′-UGGUAGGGUGACCGGAGACUAUUUCCG-5′ (SEQ ID NO: 1339) βc-1794 Target:5′-ACCATCCCACTGGCCTCTGATAAAGGC-3′ (SEQ ID NO: 2448)5′-AUCCCACUGGCCUCUGAUAAAGGct-3′ (SEQ ID NO: 231)3′-GGUAGGGUGACCGGAGACUAUUUCCGA-5′ (SEQ ID NO: 1340) βc-1795 Target:5′-CCATCCCACTGGCCTCTGATAAAGGCT-3′ (SEQ ID NO: 2449)5′-UCCCACUGGCCUCUGAUAAAGGCta-3′ (SEQ ID NO: 232)3′-GUAGGGUGACCGGAGACUAUUUCCGAU-5′ (SEQ ID NO: 1341) βc-1796 Target:5′-CATCCCACTGGCCTCTGATAAAGGCTA-3′ (SEQ ID NO: 2450)5′-CCCACUGGCCUCUGAUAAAGGCUac-3′ (SEQ ID NO: 233)3′-UAGGGUGACCGGAGACUAUUUCCGAUG-5′ (SEQ ID NO: 1342) βc-1797 Target:5′-ATCCCACTGGCCTCTGATAAAGGCTAC-3′ (SEQ ID NO: 2451)5′-CCACUGGCCUCUGAUAAAGGCUAct-3′ (SEQ ID NO: 234)3′-AGGGUGACCGGAGACUAUUUCCGAUGA-5′ (SEQ ID NO: 1343) βc-1798 Target:5′-TCCCACTGGCCTCTGATAAAGGCTACT-3′ (SEQ ID NO: 2452)5′-CACUGGCCUCUGAUAAAGGCUACtg-3′ (SEQ ID NO: 235)3′-GGGUGACCGGAGACUAUUUCCGAUGAC-5′ (SEQ ID NO: 1344) βc-1799 Target:5′-CCCACTGGCCTCTGATAAAGGCTACTG-3′ (SEQ ID NO: 2453)5′-ACUGGCCUCUGAUAAAGGCUACUgt-3′ (SEQ ID NO: 236)3′-GGUGACCGGAGACUAUUUCCGAUGACA-5′ (SEQ ID NO: 1345) βc-1800 Target:5′-CCACTGGCCTCTGATAAAGGCTACTGT-3′ (SEQ ID NO: 2454)5′-ACUGUUGGAUUGAUUCGAAAUCUtg-3′ (SEQ ID NO: 237)3′-GAUGACAACCUAACUAAGCUUUAGAAC-5′ (SEQ ID NO: 1346) βc-1820 Target:5′-CTACTGTTGGATTGATTCGAAATCTTG-3′ (SEQ ID NO: 2455)5′-CUGUUGGAUUGAUUCGAAAUCUUgc-3′ (SEQ ID NO: 238)3′-AUGACAACCUAACUAAGCUUUAGAACG-5′ (SEQ ID NO: 1347) βc-1821 Target:5′-TACTGTTGGATTGATTCGAAATCTTGC-3′ (SEQ ID NO: 2456)5′-AAUACCAUUCCAUUGUUUGUGCAgc-3′ (SEQ ID NO: 239)3′-AUUUAUGGUAAGGUAACAAACACGUCG-5′ (SEQ ID NO: 1348) βc-2072 Target:5′-TAAATACCATTCCATTGTTTGTGCAGC-3′ (SEQ ID NO: 2457)5′-AUACCAUUCCAUUGUUUGUGCAGct-3′ (SEQ ID NO: 240)3′-UUUAUGGUAAGGUAACAAACACGUCGA-5′ (SEQ ID NO: 1349) βc-2073 Target:5′-AAATACCATTCCATTGTTTGTGCAGCT-3′ (SEQ ID NO: 2458)5′-UACCAUUCCAUUGUUUGUGCAGCtg-3′ (SEQ ID NO: 241)3′-UUAUGGUAAGGUAACAAACACGUCGAC-5′ (SEQ ID NO: 1350) βc-2074 Target:5′-AATACCATTCCATTGTTTGTGCAGCTG-3′ (SEQ ID NO: 2459)5′-ACCAUUCCAUUGUUUGUGCAGCUgc-3′ (SEQ ID NO: 242)3′-UAUGGUAAGGUAACAAACACGUCGACG-5′ (SEQ ID NO: 1351) βc-2075 Target:5′-ATACCATTCCATTGTTTGTGCAGCTGC-3′ (SEQ ID NO: 2460)5′-CCAUUCCAUUGUUUGUGCAGCUGct-3′ (SEQ ID NO: 243)3′-AUGGUAAGGUAACAAACACGUCGACGA-5′ (SEQ ID NO: 1352) βc-2076 Target:5′-TACCATTCCATTGTTTGTGCAGCTGCT-3′ (SEQ ID NO: 2461)5′-CAUUCCAUUGUUUGUGCAGCUGCtt-3′ (SEQ ID NO: 244)3′-UGGUAAGGUAACAAACACGUCGACGAA-5′ (SEQ ID NO: 1353) βc-2077 Target:5′-ACCATTCCATTGTTTGTGCAGCTGCTT-3′ (SEQ ID NO: 2462)5′-UGCUUUAUUCUCCCAUUGAAAACat-3′ (SEQ ID NO: 245)3′-CGACGAAAUAAGAGGGUAACUUUUGUA-5′ (SEQ ID NO: 1354) βc-2097 Target:5′-GCTGCTTTATTCTCCCATTGAAAAC-3′ (SEQ ID NO: 2463)5′-GCUUUAUUCUCCCAUUGAAAACAtc-3′ (SEQ ID NO: 246)3′-GACGAAAUAAGAGGGUAACUUUUGUAG-5′ (SEQ ID NO: 1355) βc-2098 Target:5′-CTGCTTTATTCTCCCATTGAAAACATC-3′ (SEQ ID NO: 2464)5′-CUUUAUUCUCCCAUUGAAAACAUcc-3′ (SEQ ID NO: 247)3′-ACGAAAUAAGAGGGUAACUUUUGUAGG-5′ (SEQ ID NO: 1356) βc-2099 Target:5′-TGCTTTATTCTCCCATTGAAAACATCC-3′ (SEQ ID NO: 2465)5′-UUUAUUCUCCCAUUGAAAACAUCca-3′ (SEQ ID NO: 248)3′-CGAAAUAAGAGGGUAACUUUUGUAGGU-5′ (SEQ ID NO: 1357) βc-2100 Target:5′-GCTTTATTCTCCCATTGAAAACATCCA-3′ (SEQ ID NO: 2466)5′-GUCCUCUGUGAACUUGCUCAGGAca-3′ (SEQ ID NO: 249)3′-CCCAGGAGACACUUGAACGAGUCCUGU-5′ (SEQ ID NO: 1358) βc-2141 Target:5′-GGGTCCTCTGTGAACTTGCTCAGGACA-3′ (SEQ ID NO: 2467)5′-UCCUCUGUGAACUUGCUCAGGACaa-3′ (SEQ ID NO: 250)3′-CCAGGAGACACUUGAACGAGUCCUGUU-5′ (SEQ ID NO: 1359) βc-2142 Target:5′-GGTCCTCTGTGAACTTGCTCAGGACAA-3′ (SEQ ID NO: 2468)5′-CCUCUGUGAACUUGCUCAGGACAag-3′ (SEQ ID NO: 251)3′-CAGGAGACACUUGAACGAGUCCUGUUC-5′ (SEQ ID NO: 1360) βc-2143 Target:5′-GTCCTCTGTGAACTTGCTCAGGACAAG-3′ (SEQ ID NO: 2469)5′-CUCUGUGAACUUGCUCAGGACAAgg-3′ (SEQ ID NO: 252)3′-AGGAGACACUUGAACGAGUCCUGUUCC-5′ (SEQ ID NO: 1361) βc-2144 Target:5′-TCCTCTGTGAACTTGCTCAGGACAAGG-3′ (SEQ ID NO: 2470)5′-UCUGUGAACUUGCUCAGGACAAGga-3′ (SEQ ID NO: 253)3′-GGAGACACUUGAACGAGUCCUGUUCCU-5′ (SEQ ID NO: 1362) βc-2145 Target:5′-CCTCTGTGAACTTGCTCAGGACAAGGA-3′ (SEQ ID NO: 2471)5′-CUGUGAACUUGCUCAGGACAAGGaa-3′ (SEQ ID NO: 254)3′-GAGACACUUGAACGAGUCCUGUUCCUU-5′ (SEQ ID NO: 1363) βc-2146 Target:5′-CTCTGTGAACTTGCTCAGGACAAGGAA-3′ (SEQ ID NO: 2472)5′-UGUGAACUUGCUCAGGACAAGGAag-3′ (SEQ ID NO: 255)3′-AGACACUUGAACGAGUCCUGUUCCUUC-5′ (SEQ ID NO: 1364) βc-2147 Target:5′-TCTGTGAACTTGCTCAGGACAAGGAAG-3′ (SEQ ID NO: 2473)5′-GUGAACUUGCUCAGGACAAGGAAgc-3′ (SEQ ID NO: 256)3′-GACACUUGAACGAGUCCUGUUCCUUCG-5′ (SEQ ID NO: 1365) βc-2148 Target:5′-CTGTGAACTTGCTCAGGACAAGGAAGC-3′ (SEQ ID NO: 2474)5′-UGAACUUGCUCAGGACAAGGAAGct-3′ (SEQ ID NO: 257)3′-ACACUUGAACGAGUCCUGUUCCUUCGA-5′ (SEQ ID NO: 1366) βc-2149 Target:5′-TGTGAACTTGCTCAGGACAAGGAAGCT-3′ (SEQ ID NO: 2475)5′-GAACUUGCUCAGGACAAGGAAGCtg-3′ (SEQ ID NO: 258)3′-CACUUGAACGAGUCCUGUUCCUUCGAC-5′ (SEQ ID NO: 1367) βc-2150 Target:5′-GTGAACTTGCTCAGGACAAGGAAGCTG-3′ (SEQ ID NO: 2476)5′-AACUUGCUCAGGACAAGGAAGCUgc-3′ (SEQ ID NO: 259)3′-ACUUGAACGAGUCCUGUUCCUUCGACG-5′ (SEQ ID NO: 1368) βc-2151 Target:5′-TGAACTTGCTCAGGACAAGGAAGCTGC-3′ (SEQ ID NO: 2477)5′-AUUGAAGCUGAGGGAGCCACAGCtc-3′ (SEQ ID NO: 260)3′-GAUAACUUCGACUCCCUCGGUGUCGAG-5′ (SEQ ID NO: 1369) βc-2183 Target:5′-CTATTGAAGCTGAGGGAGCCACAGCTC-3′ (SEQ ID NO: 2478)5′-UUGAAGCUGAGGGAGCCACAGCUcc-3′ (SEQ ID NO: 261)3′-AUAACUUCGACUCCCUCGGUGUCGAGG-5′ (SEQ ID NO: 1370) βc-2184 Target:5′-TATTGAAGCTGAGGGAGCCACAGCTCC-3′ (SEQ ID NO: 2479)5′-UGAAGCUGAGGGAGCCACAGCUCct-3′ (SEQ ID NO: 262)3′-UAACUUCGACUCCCUCGGUGUCGAGGA-5′ (SEQ ID NO: 1371) βc-2185 Target:5′-ATTGAAGCTGAGGGAGCCACAGCTCCT-3′ (SEQ ID NO: 2480)5′-UUCCGAAUGUCUGAGGACAAGCCac-3′ (SEQ ID NO: 263)3′-ACAAGGCUUACAGACUCCUGUUCGGUG-5′ (SEQ ID NO: 1372) βc-2270 Target:5′-TGTTCCGAATGTCTGAGGACAAGCCAC-3′ (SEQ ID NO: 2481)5′-UCCGAAUGUCUGAGGACAAGCCAca-3′ (SEQ ID NO: 264)3′-CAAGGCUUACAGACUCCUGUUCGGUGU-5′ (SEQ ID NO: 1373) βc-2271 Target:5′-GTTCCGAATGTCTGAGGACAAGCCACA-3′ (SEQ ID NO: 2482)5′-CCGAAUGUCUGAGGACAAGCCACaa-3′ (SEQ ID NO: 265)3′-AAGGCUUACAGACUCCUGUUCGGUGUU-5′ (SEQ ID NO: 1374) βc-2272 Target:5′-TTCCGAATGTCTGAGGACAAGCCACAA-3′ (SEQ ID NO: 2483)5′-CGAAUGUCUGAGGACAAGCCACAag-3′ (SEQ ID NO: 266)3′-AGGCUUACAGACUCCUGUUCGGUGUUC-5′ (SEQ ID NO: 1375) βc-2273 Target:5′-TCCGAATGTCTGAGGACAAGCCACAAG-3′ (SEQ ID NO: 2484)5′-GAAUGUCUGAGGACAAGCCACAAga-3′ (SEQ ID NO: 267)3′-GGCUUACAGACUCCUGUUCGGUGUUCU-5′ (SEQ ID NO: 1376) βc-2274 Target:5′-CCGAATGTCTGAGGACAAGCCACAAGA-3′ (SEQ ID NO: 2485)5′-AAUGUCUGAGGACAAGCCACAAGat-3′ (SEQ ID NO: 268)3′-GCUUACAGACUCCUGUUCGGUGUUCUA-5′ (SEQ ID NO: 1377) βc-2275 Target:5′-CGAATGTCTGAGGACAAGCCACAAGAT-3′ (SEQ ID NO: 2486)5′-AUGUCUGAGGACAAGCCACAAGAtt-3′ (SEQ ID NO: 269)3′-CUUACAGACUCCUGUUCGGUGUUCUAA-5′ (SEQ ID NO: 1378) βc-2276 Target:5′-GAATGTCTGAGGACAAGCCACAAGATT-3′ (SEQ ID NO: 2487)5′-UGUCUGAGGACAAGCCACAAGAUta-3′ (SEQ ID NO: 270)3′-UUACAGACUCCUGUUCGGUGUUCUAAU-5′ (SEQ ID NO: 1379) βc-2277 Target:5′-AATGTCTGAGGACAAGCCACAAGATTA-3′ (SEQ ID NO: 2488)5′-ACAGAGCCAAUGGCUUGGAAUGAga-3′ (SEQ ID NO: 271)3′-CUUGUCUCGGUUACCGAACCUUACUCU-5′ (SEQ ID NO: 1380) βc-2345 Target:5′-GAACAGAGCCAATGGCTTGGAATGAGA-3′ (SEQ ID NO: 2489)5′-CAGAGCCAAUGGCUUGGAAUGAGac-3′ (SEQ ID NO: 272)3′-UUGUCUCGGUUACCGAACCUUACUCUG-5′ (SEQ ID NO: 1381) βc-2346 Target:5′-AACAGAGCCAATGGCTTGGAATGAGAC-3′ (SEQ ID NO: 2490)5′-AGAGCCAAUGGCUUGGAAUGAGAct-3′ (SEQ ID NO: 273)3′-UGUCUCGGUUACCGAACCUUACUCUGA-5′ (SEQ ID NO: 1382) βc-2347 Target:5′-ACAGAGCCAATGGCTTGGAATGAGACT-3′ (SEQ ID NO: 2491)5′-GAGCCAAUGGCUUGGAAUGAGACtg-3′ (SEQ ID NO: 274)3′-GUCUCGGUUACCGAACCUUACUCUGAC-5′ (SEQ ID NO: 1383) βc-2348 Target:5′-CAGAGCCAATGGCTTGGAATGAGACTG-3′ (SEQ ID NO: 2492)5′-AGCCAAUGGCUUGGAAUGAGACUgc-3′ (SEQ ID NO: 275)3′-UCUCGGUUACCGAACCUUACUCUGACG-5′ (SEQ ID NO: 1384) βc-2349 Target:5′-AGAGCCAATGGCTTGGAATGAGACTGC-3′ (SEQ ID NO: 2493)5′-GCCAAUGGCUUGGAAUGAGACUGct-3′ (SEQ ID NO: 276)3′-CUCGGUUACCGAACCUUACUCUGACGA-5′ (SEQ ID NO: 1385) βc-2350 Target:5′-GAGCCAATGGCTTGGAATGAGACTGCT-3′ (SEQ ID NO: 2494)5′-CCAAUGGCUUGGAAUGAGACUGCtg-3′ (SEQ ID NO: 277)3′-UCGGUUACCGAACCUUACUCUGACGAC-5′ (SEQ ID NO: 1386) βc-2351 Target:5′-AGCCAATGGCTTGGAATGAGACTGCTG-3′ (SEQ ID NO: 2495)5′-CAAUGGCUUGGAAUGAGACUGCUga-3′ (SEQ ID NO: 278)3′-CGGUUACCGAACCUUACUCUGACGACU-5′ (SEQ ID NO: 1387) βc-2352 Target:5′-GCCAATGGCTTGGAATGAGACTGCTGA-3′ (SEQ ID NO: 2496)5′-AAUGGCUUGGAAUGAGACUGCUGat-3′ (SEQ ID NO: 279)3′-GGUUACCGAACCUUACUCUGACGACUA-5′ (SEQ ID NO: 1388) βc-2353 Target:5′-CCAATGGCTTGGAATGAGACTGCTGAT-3′ (SEQ ID NO: 2497)5′-AUGGCUUGGAAUGAGACUGCUGAtc-3′ (SEQ ID NO: 280)3′-GUUACCGAACCUUACUCUGACGACUAG-5′ (SEQ ID NO: 1389) βc-2354 Target:5′-CAATGGCTTGGAATGAGACTGCTGATC-3′ (SEQ ID NO: 2498)5′-UGGCUUGGAAUGAGACUGCUGAUct-3′ (SEQ ID NO: 281)3′-UUACCGAACCUUACUCUGACGACUAGA-5′ (SEQ ID NO: 1390) βc-2355 Target:5′-AATGGCTTGGAATGAGACTGCTGATCT-3′ (SEQ ID NO: 2499)5′-CUUGGAUAUCGCCAGGAUGAUCCta-3′ (SEQ ID NO: 282)3′-GGGAACCUAUAGCGGUCCUACUAGGAU-5′ (SEQ ID NO: 1391) βc-2411 Target:5′-CCCTTGGATATCGCCAGGATGATCCTA-3′ (SEQ ID NO: 2500)5′-UUGGAUAUCGCCAGGAUGAUCCUag-3′ (SEQ ID NO: 283)3′-GGAACCUAUAGCGGUCCUACUAGGAUC-5′ (SEQ ID NO: 1392) βc-2412 Target:5′-CCTTGGATATCGCCAGGATGATCCTAG-3′ (SEQ ID NO: 2501)5′-UGGAUAUCGCCAGGAUGAUCCUAgc-3′ (SEQ ID NO: 284)3′-GAACCUAUAGCGGUCCUACUAGGAUCG-5′ (SEQ ID NO: 1393) βc-2413 Target:5′-CTTGGATATCGCCAGGATGATCCTAGC-3′ (SEQ ID NO: 2502)5′-GGAUAUCGCCAGGAUGAUCCUAGct-3′ (SEQ ID NO: 285)3′-AACCUAUAGCGGUCCUACUAGGAUCGA-5′ (SEQ ID NO: 1394) βc-2414 Target:5′-TTGGATATCGCCAGGATGATCCTAGCT-3′ (SEQ ID NO: 2503)5′-GAUAUCGCCAGGAUGAUCCUAGCta-3′ (SEQ ID NO: 286)3′-ACCUAUAGCGGUCCUACUAGGAUCGAU-5′ (SEQ ID NO: 1395) βc-2415 Target:5′-TGGATATCGCCAGGATGATCCTAGCTA-3′ (SEQ ID NO: 2504)5′-CGUUCUUUUCACUCUGGUGGAUAtg-3′ (SEQ ID NO: 287)3′-UAGCAAGAAAAGUGAGACCACCUAUAC-5′ (SEQ ID NO: 1396) βc-2441 Target:5′-ATCGTTCTTTTCACTCTGGTGGATATG-3′ (SEQ ID NO: 2505)5′-GUUCUUUUCACUCUGGUGGAUAUgg-3′ (SEQ ID NO: 288)3′-AGCAAGAAAAGUGAGACCACCUAUACC-5′ (SEQ ID NO: 1397) βc-2442 Target:5′-TCGTTCTTTTCACTCTGGTGGATATGG-3′ (SEQ ID NO: 2506)5′-UUCUUUUCACUCUGGUGGAUAUGgc-3′ (SEQ ID NO: 289)3′-GCAAGAAAAGUGAGACCACCUAUACCG-5′ (SEQ ID NO: 1398) βc-2443 Target:5′-CGTTCTTTTCACTCTGGTGGATATGGC-3′ (SEQ ID NO: 2507)5′-UCUUUUCACUCUGGUGGAUAUGGcc-3′ (SEQ ID NO: 290)3′-CAAGAAAAGUGAGACCACCUAUACCGG-5′ (SEQ ID NO: 1399) βc-2444 Target:5′-GTTCTTTTCACTCTGGTGGATATGGCC-3′ (SEQ ID NO: 2508)5′-CUUUUCACUCUGGUGGAUAUGGCca-3′ (SEQ ID NO: 291)3′-AAGAAAAGUGAGACCACCUAUACCGGU-5′ (SEQ ID NO: 1400) βc-2445 Target:5′-TTCTTTTCACTCTGGTGGATATGGCCA-3′ (SEQ ID NO: 2509)5′-CAUGAGAUGGGUGGCCACCACCCtg-3′ (SEQ ID NO: 292)3′-UUGUACUCUACCCACCGGUGGUGGGAC-5′ (SEQ ID NO: 1401) βc-2501 Target:5′-AACATGAGATGGGTGGCCACCACCCTG-3′ (SEQ ID NO: 2510)5′-AUGAGAUGGGUGGCCACCACCCUgg-3′ (SEQ ID NO: 293)3′-UGUACUCUACCCACCGGUGGUGGGACC-5′ (SEQ ID NO: 1402) βc-2502 Target:5′-ACATGAGATGGGTGGCCACCACCCTGG-3′ (SEQ ID NO: 2511)5′-UGAGAUGGGUGGCCACCACCCUGgt-3′ (SEQ ID NO: 294)3′-GUACUCUACCCACCGGUGGUGGGACCA-5′ (SEQ ID NO: 1403) βc-2503 Target:5′-CATGAGATGGGTGGCCACCACCCTGGT-3′ (SEQ ID NO: 2512)5′-GAGAUGGGUGGCCACCACCCUGGtg-3′ (SEQ ID NO: 295)3′-UACUCUACCCACCGGUGGUGGGACCAC-5′ (SEQ ID NO: 1404) βc-2504 Target:5′-ATGAGATGGGTGGCCACCACCCTGGTG-3′ (SEQ ID NO: 2513)5′-AGAUGGGUGGCCACCACCCUGGUgc-3′ (SEQ ID NO: 296)3′-ACUCUACCCACCGGUGGUGGGACCACG-5′ (SEQ ID NO: 1405) βc-2505 Target:5′-TGAGATGGGTGGCCACCACCCTGGTGC-3′ (SEQ ID NO: 2514)5′-GAUGGGUGGCCACCACCCUGGUGct-3′ (SEQ ID NO: 297)3′-CUCUACCCACCGGUGGUGGGACCACGA-5′ (SEQ ID NO: 1406) βc-2506 Target:5′-GAGATGGGTGGCCACCACCCTGGTGCT-3′ (SEQ ID NO: 2515)5′-AUGGGUGGCCACCACCCUGGUGCtg-3′ (SEQ ID NO: 298)3′-UCUACCCACCGGUGGUGGGACCACGAC-5′ (SEQ ID NO: 1407) βc-2507 Target:5′-AGATGGGTGGCCACCACCCTGGTGCTG-3′ (SEQ ID NO: 2516)5′-UGGGUGGCCACCACCCUGGUGCUga-3′ (SEQ ID NO: 299)3′-CUACCCACCGGUGGUGGGACCACGACU-5′ (SEQ ID NO: 1408) βc-2508 Target:5′-GATGGGTGGCCACCACCCTGGTGCTGA-3′ (SEQ ID NO: 2517)5′-GGGUGGCCACCACCCUGGUGCUGac-3′ (SEQ ID NO: 300)3′-UACCCACCGGUGGUGGGACCACGACUG-5′ (SEQ ID NO: 1409) βc-2509 Target:5′-ATGGGTGGCCACCACCCTGGTGCTGAC-3′ (SEQ ID NO: 2518)5′-GGUGGCCACCACCCUGGUGCUGAct-3′ (SEQ ID NO: 301)3′-ACCCACCGGUGGUGGGACCACGACUGA-5′ (SEQ ID NO: 1410) βc-2510 Target:5′-TGGGTGGCCACCACCCTGGTGCTGACT-3′ (SEQ ID NO: 2519)5′-GUGGCCACCACCCUGGUGCUGACta-3′ (SEQ ID NO: 302)3′-CCCACCGGUGGUGGGACCACGACUGAU-5′ (SEQ ID NO: 1411) βc-2511 Target:5′-GGGTGGCCACCACCCTGGTGCTGACTA-3′ (SEQ ID NO: 2520)5′-UGGCCACCACCCUGGUGCUGACUat-3′ (SEQ ID NO: 303)3′-CCACCGGUGGUGGGACCACGACUGAUA-5′ (SEQ ID NO: 1412) βc-2512 Target:5′-GGTGGCCACCACCCTGGTGCTGACTAT-3′ (SEQ ID NO: 2521)5′-GGCCACCACCCUGGUGCUGACUAtc-3′ (SEQ ID NO: 304)3′-CACCGGUGGUGGGACCACGACUGAUAG-5′ (SEQ ID NO: 1413) βc-2513 Target:5′-GTGGCCACCACCCTGGTGCTGACTATC-3′ (SEQ ID NO: 2522)5′-GCCACCACCCUGGUGCUGACUAUcc-3′ (SEQ ID NO: 305)3′-ACCGGUGGUGGGACCACGACUGAUAGG-5′ (SEQ ID NO: 1414) βc-2514 Target:5′-TGGCCACCACCCTGGTGCTGACTATCC-3′ (SEQ ID NO: 2523)5′-CCACCACCCUGGUGCUGACUAUCca-3′ (SEQ ID NO: 306)3′-CCGGUGGUGGGACCACGACUGAUAGGU-5′ (SEQ ID NO: 1415) βc-2515 Target:5′-GGCCACCACCCTGGTGCTGACTATCCA-3′ (SEQ ID NO: 2524)5′-CACCACCCUGGUGCUGACUAUCCag-3′ (SEQ ID NO: 307)3′-CGGUGGUGGGACCACGACUGAUAGGUC-5′ (SEQ ID NO: 1416) βc-2516 Target:5′-GCCACCACCCTGGTGCTGACTATCCAG-3′ (SEQ ID NO: 2525)5′-ACCACCCUGGUGCUGACUAUCCAgt-3′ (SEQ ID NO: 308)3′-GGUGGUGGGACCACGACUGAUAGGUCA-5′ (SEQ ID NO: 1417) βc-2517 Target:5′-CCACCACCCTGGTGCTGACTATCCAGT-3′ (SEQ ID NO: 2526)5′-CCACCCUGGUGCUGACUAUCCAGtt-3′ (SEQ ID NO: 309)3′-GUGGUGGGACCACGACUGAUAGGUCAA-5′ (SEQ ID NO: 1418) βc-2518 Target:5′-CACCACCCTGGTGCTGACTATCCAGTT-3′ (SEQ ID NO: 2527)5′-CACCCUGGUGCUGACUAUCCAGUtg-3′ (SEQ ID NO: 310)3′-UGGUGGGACCACGACUGAUAGGUCAAC-5′ (SEQ ID NO: 1419) βc-2519 Target:5′-ACCACCCTGGTGCTGACTATCCAGTTG-3′ (SEQ ID NO: 2528)5′-ACCCUGGUGCUGACUAUCCAGUUga-3′ (SEQ ID NO: 311)3′-GGUGGGACCACGACUGAUAGGUCAACU-5′ (SEQ ID NO: 1420) βc-2520 Target:5′-CCACCCTGGTGCTGACTATCCAGTTGA-3′ (SEQ ID NO: 2529)5′-CCCUGGUGCUGACUAUCCAGUUGat-3′ (SEQ ID NO: 312)3′-GUGGGACCACGACUGAUAGGUCAACUA-5′ (SEQ ID NO: 1421) βc-2521 Target:5′-CACCCTGGTGCTGACTATCCAGTTGAT-3′ (SEQ ID NO: 2530)5′-CCUGGUGCUGACUAUCCAGUUGAtg-3′ (SEQ ID NO: 313)3′-UGGGACCACGACUGAUAGGUCAACUAC-5′ (SEQ ID NO: 1422) βc-2522 Target:5′-ACCCTGGTGCTGACTATCCAGTTGATG-3′ (SEQ ID NO: 2531)5′-CUGGUGCUGACUAUCCAGUUGAUgg-3′ (SEQ ID NO: 314)3′-GGGACCACGACUGAUAGGUCAACUACC-5′ (SEQ ID NO: 1423) βc-2523 Target:5′-CCCTGGTGCTGACTATCCAGTTGATGG-3′ (SEQ ID NO: 2532)5′-UGGUGCUGACUAUCCAGUUGAUGgg-3′ (SEQ ID NO: 315)3′-GGACCACGACUGAUAGGUCAACUACCC-5′ (SEQ ID NO: 1424) βc-2524 Target:5′-CCTGGTGCTGACTATCCAGTTGATGGG-3′ (SEQ ID NO: 2533)5′-GGUGCUGACUAUCCAGUUGAUGGgc-3′ (SEQ ID NO: 316)3′-GACCACGACUGAUAGGUCAACUACCCG-5′ (SEQ ID NO: 1425) βc-2525 Target:5′-CTGGTGCTGACTATCCAGTTGATGGGC-3′ (SEQ ID NO: 2534)5′-GUGCUGACUAUCCAGUUGAUGGGct-3′ (SEQ ID NO: 317)3′-ACCACGACUGAUAGGUCAACUACCCGA-5′ (SEQ ID NO: 1426) βc-2526 Target:5′-TGGTGCTGACTATCCAGTTGATGGGCT-3′ (SEQ ID NO: 2535)5′-UGCUGACUAUCCAGUUGAUGGGCtg-3′ (SEQ ID NO: 318)3′-CCACGACUGAUAGGUCAACUACCCGAC-5′ (SEQ ID NO: 1427) βc-2527 Target:5′-GGTGCTGACTATCCAGTTGATGGGCTG-3′ (SEQ ID NO: 2536)5′-GCUGACUAUCCAGUUGAUGGGCUgc-3′ (SEQ ID NO: 319)3′-CACGACUGAUAGGUCAACUACCCGACG-5′ (SEQ ID NO: 1428) βc-2528 Target:5′-GTGCTGACTATCCAGTTGATGGGCTGC-3′ (SEQ ID NO: 2537)5′-CUGACUAUCCAGUUGAUGGGCUGcc-3′ (SEQ ID NO: 320)3′-ACGACUGAUAGGUCAACUACCCGACGG-5′ (SEQ ID NO: 1429) βc-2529 Target:5′-TGCTGACTATCCAGTTGATGGGCTGCC-3′ (SEQ ID NO: 2538)5′-UGACUAUCCAGUUGAUGGGCUGCca-3′ (SEQ ID NO: 321)3′-CGACUGAUAGGUCAACUACCCGACGGU-5′ (SEQ ID NO: 1430) βc-2530 Target:5′-GCTGACTATCCAGTTGATGGGCTGCCA-3′ (SEQ ID NO: 2539)5′-GACUAUCCAGUUGAUGGGCUGCCag-3′ (SEQ ID NO: 322)3′-GACUGAUAGGUCAACUACCCGACGGUC-5′ (SEQ ID NO: 1431) βc-2531 Target:5′-CTGACTATCCAGTTGATGGGCTGCCAG-3′ (SEQ ID NO: 2540)5′-ACUAUCCAGUUGAUGGGCUGCCAga-3′ (SEQ ID NO: 323)3′-ACUGAUAGGUCAACUACCCGACGGUCU-5′ (SEQ ID NO: 1432) βc-2532 Target:5′-TGACTATCCAGTTGATGGGCTGCCAGA-3′ (SEQ ID NO: 2541)5′-CUAUCCAGUUGAUGGGCUGCCAGat-3′ (SEQ ID NO: 324)3′-CUGAUAGGUCAACUACCCGACGGUCUA-5′ (SEQ ID NO: 1433) βc-2533 Target:5′-GACTATCCAGTTGATGGGCTGCCAGAT-3′ (SEQ ID NO: 2542)5′-UAUCCAGUUGAUGGGCUGCCAGAtc-3′ (SEQ ID NO: 325)3′-UGAUAGGUCAACUACCCGACGGUCUAG-5′ (SEQ ID NO: 1434) βc-2534 Target:5′-ACTATCCAGTTGATGGGCTGCCAGATC-3′ (SEQ ID NO: 2543)5′-AUCCAGUUGAUGGGCUGCCAGAUct-3′ (SEQ ID NO: 326)3′-GAUAGGUCAACUACCCGACGGUCUAGA-5′ (SEQ ID NO: 1435) βc-2535 Target:5′-CTATCCAGTTGATGGGCTGCCAGATCT-3′ (SEQ ID NO: 2544)5′-GCCCAGGACCUCAUGGAUGGGCUgc-3′ (SEQ ID NO: 327)3′-UACGGGUCCUGGAGUACCUACCCGACG-5′ (SEQ ID NO: 1436) βc-2567 Target:5′-ATGCCCAGGACCTCATGGATGGGCTGC-3′ (SEQ ID NO: 2545)5′-CCCAGGACCUCAUGGAUGGGCUGcc-3′ (SEQ ID NO: 328)3′-ACGGGUCCUGGAGUACCUACCCGACGG-5′ (SEQ ID NO: 1437) βc-2568 Target:5′-TGCCCAGGACCTCATGGATGGGCTGCC-3′ (SEQ ID NO: 2546)5′-CCAGGACCUCAUGGAUGGGCUGCct-3′ (SEQ ID NO: 329)3′-CGGGUCCUGGAGUACCUACCCGACGGA-5′ (SEQ ID NO: 1438) βc-2569 Target:5′-GCCCAGGACCTCATGGATGGGCTGCCT-3′ (SEQ ID NO: 2547)5′-AGCAAUCAGCUGGCCUGGUUUGAta-3′ (SEQ ID NO: 330)3′-UGUCGUUAGUCGACCGGACCAAACUAU-5′ (SEQ ID NO: 1439) βc-2603 Target:5′-ACAGCAATCAGCTGGCCTGGTTTGATA-3′ (SEQ ID NO: 2548)5′-GCAAUCAGCUGGCCUGGUUUGAUac-3′ (SEQ ID NO: 331)3′-GUCGUUAGUCGACCGGACCAAACUAUG-5′ (SEQ ID NO: 1440) βc-2604 Target:5′-CAGCAATCAGCTGGCCTGGTTTGATAC-3′ (SEQ ID NO: 2549)5′-CAAUCAGCUGGCCUGGUUUGAUAct-3′ (SEQ ID NO: 332)3′-UCGUUAGUCGACCGGACCAAACUAUGA-5′ (SEQ ID NO: 1441) βc-2605 Target:5′-AGCAATCAGCTGGCCTGGTTTGATACT-3′ (SEQ ID NO: 2550)5′-AAUCAGCUGGCCUGGUUUGAUACtg-3′ (SEQ ID NO: 333)3′-CGUUAGUCGACCGGACCAAACUAUGAC-5′ (SEQ ID NO: 1442) βc-2606 Target:5′-GCAATCAGCTGGCCTGGTTTGATACTG-3′ (SEQ ID NO: 2551)5′-AUCAGCUGGCCUGGUUUGAUACUga-3′ (SEQ ID NO: 334)3′-GUUAGUCGACCGGACCAAACUAUGACU-5′ (SEQ ID NO: 1443) βc-2607 Target:5′-CAATCAGCTGGCCTGGTTTGATACTGA-3′ (SEQ ID NO: 2552)5′-UCAGCUGGCCUGGUUUGAUACUGac-3′ (SEQ ID NO: 335)3′-UUAGUCGACCGGACCAAACUAUGACUG-5′ (SEQ ID NO: 1444) βc-2608 Target:5′-AATCAGCTGGCCTGGTTTGATACTGAC-3′ (SEQ ID NO: 2553)5′-CAGCUGGCCUGGUUUGAUACUGAcc-3′ (SEQ ID NO: 336)3′-UAGUCGACCGGACCAAACUAUGACUGG-5′ (SEQ ID NO: 1445) βc-2609 Target:5′-ATCAGCTGGCCTGGTTTGATACTGACC-3′ (SEQ ID NO: 2554)5′-AGCUGGCCUGGUUUGAUACUGACct-3′ (SEQ ID NO: 337)3′-AGUCGACCGGACCAAACUAUGACUGGA-5′ (SEQ ID NO: 1446) βc-2610 Target:5′-TCAGCTGGCCTGGTTTGATACTGACCT-3′ (SEQ ID NO: 2555)5′-GCUGGCCUGGUUUGAUACUGACCtg-3′ (SEQ ID NO: 338)3′-GUCGACCGGACCAAACUAUGACUGGAC-5′ (SEQ ID NO: 1447) βc-2611 Target:5′-CAGCTGGCCTGGTTTGATACTGACCTG-3′ (SEQ ID NO: 2556)5′-CUGGCCUGGUUUGAUACUGACCUgt-3′ (SEQ ID NO: 339)3′-UCGACCGGACCAAACUAUGACUGGACA-5′ (SEQ ID NO: 1448) βc-2612 Target:5′-AGCTGGCCTGGTTTGATACTGACCTGT-3′ (SEQ ID NO: 2557)5′-UGGCCUGGUUUGAUACUGACCUGta-3′ (SEQ ID NO: 340)3′-CGACCGGACCAAACUAUGACUGGACAU-5′ (SEQ ID NO: 1449) βc-2613 Target:5′-GCTGGCCTGGTTTGATACTGACCTGTA-3′ (SEQ ID NO: 2558)5′-GGCCUGGUUUGAUACUGACCUGUaa-3′ (SEQ ID NO: 341)3′-GACCGGACCAAACUAUGACUGGACAUU-5′ (SEQ ID NO: 1450) βc-2614 Target:5′-CTGGCCTGGTTTGATACTGACCTGTAA-3′ (SEQ ID NO: 2559)5′-GCCUGGUUUGAUACUGACCUGUAaa-3′ (SEQ ID NO: 342)3′-ACCGGACCAAACUAUGACUGGACAUUU-5′ (SEQ ID NO: 1451) βc-2615 Target:5′-TGGCCTGGTTTGATACTGACCTGTAAA-3′ (SEQ ID NO: 2560)5′-CCUGGUUUGAUACUGACCUGUAAat-3′ (SEQ ID NO: 343)3′-CCGGACCAAACUAUGACUGGACAUUUA-5′ (SEQ ID NO: 1452) βc-2616 Target:5′-GGCCTGGTTTGATACTGACCTGTAAAT-3′ (SEQ ID NO: 2561)5′-CUGGUUUGAUACUGACCUGUAAAtc-3′ (SEQ ID NO: 344)3′-CGGACCAAACUAUGACUGGACAUUUAG-5′ (SEQ ID NO: 1453) βc-2617 Target:5′-GCCTGGTTTGATACTGACCTGTAAATC-3′ (SEQ ID NO: 2562)5′-UGGUUUGAUACUGACCUGUAAAUca-3′ (SEQ ID NO: 345)3′-GGACCAAACUAUGACUGGACAUUUAGU-5′ (SEQ ID NO: 1454) βc-2618 Target:5′-CCTGGTTTGATACTGACCTGTAAATCA-3′ (SEQ ID NO: 2563)5′-GGUUUGAUACUGACCUGUAAAUCat-3′ (SEQ ID NO: 346)3′-GACCAAACUAUGACUGGACAUUUAGUA-5′ (SEQ ID NO: 1455) βc-2619 Target:5′-CTGGTTTGATACTGACCTGTAAATC-3′ (SEQ ID NO: 2564)5′-GUUUGAUACUGACCUGUAAAUCAtc-3′ (SEQ ID NO: 347)3′-ACCAAACUAUGACUGGACAUUUAGUAG-5′ (SEQ ID NO: 1456) βc-2620 Target:5′-TGGTTTGATACTGACCTGTAAATCATC-3′ (SEQ ID NO: 2565)5′-UUUGAUACUGACCUGUAAAUCAUcc-3′ (SEQ ID NO: 348)3′-CCAAACUAUGACUGGACAUUUAGUAGG-5′ (SEQ ID NO: 1457) βc-2621 Target:5′-GGTTTGATACTGACCTGTAAATCATCC-3′ (SEQ ID NO: 2566)5′-UUGAUACUGACCUGUAAAUCAUCct-3′ (SEQ ID NO: 349)3′-CAAACUAUGACUGGACAUUUAGUAGGA-5′ (SEQ ID NO: 1458) βc-2622 Target:5′-GTTTGATACTGACCTGTAAATCATCCT-3′ (SEQ ID NO: 2567)5′-UGAUACUGACCUGUAAAUCAUCCtt-3′ (SEQ ID NO: 350)3′-AAACUAUGACUGGACAUUUAGUAGGAA-5′ (SEQ ID NO: 1459) βc-2623 Target:5′-TTTGATACTGACCTGTAAATCATCCTT-3′ (SEQ ID NO: 2568)5′-UUUUGCCACAGCUUUUGCAACUUaa-3′ (SEQ ID NO: 351)3′-AAAAAACGGUGUCGAAAACGUUGAAUU-5′ (SEQ ID NO: 1460) βc-2869 Target:5′-TTTTTTGCCACAGCTTTTGCAACTTAA-3′ (SEQ ID NO: 2569)5′-UGAGUAACAUUUGCUGUUUUAAAca-3′ (SEQ ID NO: 352)3′-UUACUCAUUGUAAACGACAAAAUUUGU-5′ (SEQ ID NO: 1461) βc-2902 Target:5′-AATGAGTAACATTTGCTGTTTTAAACA-3′ (SEQ ID NO: 2570)5′-AACAUUAAUAGCAGCCUUUCUCUct-3′ (SEQ ID NO: 353)3′-AUUUGUAAUUAUCGUCGGAAAGAGAGA-5′ (SEQ ID NO: 1462) βc-2923 Target:5′-TAAACATTAATAGCAGCCTTTCTCTCT-3′ (SEQ ID NO: 2571)5′-CAUUAAUAGCAGCCUUUCUCUCUtt-3′ (SEQ ID NO: 354)3′-UUGUAAUUAUCGUCGGAAAGAGAGAAA-5′ (SEQ ID NO: 1463) βc-2925 Target:5′-AACATTAATAGCAGCCTTTCTCTCTTT-3′ (SEQ ID NO: 2572)5′-UUAAUAGCAGCCUUUCUCUCUUUat-3′ (SEQ ID NO: 355)3′-GUAAUUAUCGUCGGAAAGAGAGAAAUA-5′ (SEQ ID NO: 1464) βc-2927 Target:5′-CATTAATAGCAGCCTTTCTCTCTTTAT-3′ (SEQ ID NO: 2573)5′-AAUAGCAGCCUUUCUCUCUUUAUac-3′ (SEQ ID NO: 356)3′-AAUUAUCGUCGGAAAGAGAGAAAUAUG-5′ (SEQ ID NO: 1465) βc-2929 Target:5′-TTAATAGCAGCCTTTCTCTCTTTATAC-3′ (SEQ ID NO: 2574)5′-GCAUUGUGAUUGGCCUGUAGAGUtg-3′ (SEQ ID NO: 357)3′-AACGUAACACUAACCGGACAUCUCAAC-5′ (SEQ ID NO: 1466) βc-2973 Target:5′-TTGCATTGTGATTGGCCTGTAGAGTTG-3′ (SEQ ID NO: 2575)5′-AUUGUGAUUGGCCUGUAGAGUUGct-3′ (SEQ ID NO: 358)3′-CGUAACACUAACCGGACAUCUCAACGA-5′ (SEQ ID NO: 1467) βc-2975 Target:5′-GCATTGTGATTGGCCTGTAGAGTTGCT-3′ (SEQ ID NO: 2576)5′-UGUGAUUGGCCUGUAGAGUUGCUga-3′ (SEQ ID NO: 359)3′-UAACACUAACCGGACAUCUCAACGACU-5′ (SEQ ID NO: 1468) βc-2977 Target:5′-ATTGTGATTGGCCTGTAGAGTTGCTGA-3′ (SEQ ID NO: 2577)5′-UGAUUGGCCUGUAGAGUUGCUGAga-3′ (SEQ ID NO: 360)3′-ACACUAACCGGACAUCUCAACGACUCU-5′ (SEQ ID NO: 1469) βc-2979 Target:5′-TGTGATTGGCCTGTAGAGTTGCTGAGA-3′ (SEQ ID NO: 2578)5′-AUUGGCCUGUAGAGUUGCUGAGAgg-3′ (SEQ ID NO: 361)3′-ACUAACCGGACAUCUCAACGACUCUCC-5′ (SEQ ID NO: 1470) βc-2981 Target:5′-TGATTGGCCTGTAGAGTTGCTGAGAGG-3′ (SEQ ID NO: 2579)5′-UGGCCUGUAGAGUUGCUGAGAGGgc-3′ (SEQ ID NO: 362)3′-UAACCGGACAUCUCAACGACUCUCCCG-5′ (SEQ ID NO: 1471) βc-2983 Target:5′-ATTGGCCTGTAGAGTTGCTGAGAGGGC-3′ (SEQ ID NO: 2580)5′-GCCUGUAGAGUUGCUGAGAGGGCtc-3′ (SEQ ID NO: 363)3′-ACCGGACAUCUCAACGACUCUCCCGAG-5′ (SEQ ID NO: 1472) βc-2985 Target:5′-TGGCCTGTAGAGTTGCTGAGAGGGCTC-3′ (SEQ ID NO: 2581)5′-CUGUAGAGUUGCUGAGAGGGCUCga-3′ (SEQ ID NO: 364)3′-CGGACAUCUCAACGACUCUCCCGAGCU-5′ (SEQ ID NO: 1473) βc-2987 Target:5′-GCCTGTAGAGTTGCTGAGAGGGCTCGA-3′ (SEQ ID NO: 2582)5′-GUAGAGUUGCUGAGAGGGCUCGAgg-3′ (SEQ ID NO: 365)3′-GACAUCUCAACGACUCUCCCGAGCUCC-5′ (SEQ ID NO: 1474) βc-2989 Target:5′-CTGTAGAGTTGCTGAGAGGGCTCGAGG-3′ (SEQ ID NO: 2583)5′-GUGGGCUGGUAUCUCAGAAAGUGcc-3′ (SEQ ID NO: 366)3′-CCCACCCGACCAUAGAGUCUUUCACGG-5′ (SEQ ID NO: 1475) βc-3015 Target:5′-GGGTGGGCTGGTATCTCAGAAAGTGCC-3′ (SEQ ID NO: 2584)5′-GGGCUGGUAUCUCAGAAAGUGCCtg-3′ (SEQ ID NO: 367)3′-CACCCGACCAUAGAGUCUUUCACGGAC-5′ (SEQ ID NO: 1476) βc-3017 Target:5′-GTGGGCTGGTATCTCAGAAAGTGCCTG-3′ (SEQ ID NO: 2585)5′-GCUGGUAUCUCAGAAAGUGCCUGac-3′ (SEQ ID NO: 368)3′-CCCGACCAUAGAGUCUUUCACGGACUG-5′ (SEQ ID NO: 1477) βc-3019 Target:5′-GGGCTGGTATCTCAGAAAGTGCCTGAC-3′ (SEQ ID NO: 2586)5′-UGGUAUCUCAGAAAGUGCCUGACac-3′ (SEQ ID NO: 369)3′-CGACCAUAGAGUCUUUCACGGACUGUG-5′ (SEQ ID NO: 1478) βc-3021 Target:5′-GCTGGTATCTCAGAAAGTGCCTGACAC-3′ (SEQ ID NO: 2587)5′-ACUAACCAAGCUGAGUUUCCUAUgg-3′ (SEQ ID NO: 370)3′-UGUGAUUGGUUCGACUCAAAGGAUACC-5′ (SEQ ID NO: 1479) βc-3046 Target:5′-ACACTAACCAAGCTGAGTTTCCTATGG-3′ (SEQ ID NO: 2588)5′-UAACCAAGCUGAGUUUCCUAUGGga-3′ (SEQ ID NO: 371)3′-UGAUUGGUUCGACUCAAAGGAUACCCU-5′ (SEQ ID NO: 1480) βc-3048 Target:5′-ACTAACCAAGCTGAGTTTCCTATGGGA-3′ (SEQ ID NO: 2589)5′-ACCAAGCUGAGUUUCCUAUGGGAac-3′ (SEQ ID NO: 372)3′-AUUGGUUCGACUCAAAGGAUACCCUUG-5′ (SEQ ID NO: 1481) βc-3050 Target:5′-TAACCAAGCTGAGTTTCCTATGGGAAC-3′ (SEQ ID NO: 2590)5′-CAAGCUGAGUUUCCUAUGGGAACaa-3′ (SEQ ID NO: 373)3′-UGGUUCGACUCAAAGGAUACCCUUGUU-5′ (SEQ ID NO: 1482) βc-3052 Target:5′-ACCAAGCTGAGTTTCCTATGGGAACAA-3′ (SEQ ID NO: 2591)5′-AGCUGAGUUUCCUAUGGGAACAAtt-3′ (SEQ ID NO: 374)3′-GUUCGACUCAAAGGAUACCCUUGUUAA-5′ (SEQ ID NO: 1483) βc-3054 Target:5′-CAAGCTGAGTTTCCTATGGGAACAATT-3′ (SEQ ID NO: 2592)5′-CUGAGUUUCCUAUGGGAACAAUUga-3′ (SEQ ID NO: 375)3′-UCGACUCAAAGGAUACCCUUGUUAACU-5′ (SEQ ID NO: 1484) βc-3056 Target:5′-AGCTGAGTTTCCTATGGGAACAATTGA-3′ (SEQ ID NO: 2593)5′-CUUUUUGUUCUGGUCCUUUUUGGtc-3′ (SEQ ID NO: 376)3′-UUGAAAAACAAGACCAGGAAAAACCAG-5′ (SEQ ID NO: 1485) βc-3087 Target:5′-AACTTTTTGTTCTGGTCCTTTTTGGTC-3′ (SEQ ID NO: 2594)5′-UUUUGUUCUGGUCCUUUUUGGUCga-3′ (SEQ ID NO: 377)3′-GAAAAACAAGACCAGGAAAAACCAGCU-5′ (SEQ ID NO: 1486) βc-3089 Target:5′-CTTTTTGTTCTGGTCCTTTTTGGTCGA-3′ (SEQ ID NO: 2595)5′-UUGUUCUGGUCCUUUUUGGUCGAgg-3′ (SEQ ID NO: 378)3′-AAAACAAGACCAGGAAAAACCAGCUCC-5′ (SEQ ID NO: 1487) βc-3091 Target:5′-TTTTGTTCTGGTCCTTTTTGGTCGAGG-3′ (SEQ ID NO: 2596)5′-GUUCUGGUCCUUUUUGGUCGAGGag-3′ (SEQ ID NO: 379)3′-AACAAGACCAGGAAAAACCAGCUCCUC-5′ (SEQ ID NO: 1488) βc-3093 Target:5′-TTGTTCTGGTCCTTTTTGGTCGAGGAG-3′ (SEQ ID NO: 2597)5′-UCUGGUCCUUUUUGGUCGAGGAGta-3′ (SEQ ID NO: 380)3′-CAAGACCAGGAAAAACCAGCUCCUCAU-5′ (SEQ ID NO: 1489) βc-3095 Target:5′-GTTCTGGTCCTTTTTGGTCGAGGAGTA-3′ (SEQ ID NO: 2598)5′-UGGUCCUUUUUGGUCGAGGAGUAac-3′ (SEQ ID NO: 381)3′-AGACCAGGAAAAACCAGCUCCUCAUUG-5′ (SEQ ID NO: 1490) βc-3097 Target:5′-TCTGGTCCTTTTTGGTCGAGGAGTAAC-3′ (SEQ ID NO: 2599)5′-GUCCUUUUUGGUCGAGGAGUAACaa-3′ (SEQ ID NO: 382)3′-ACCAGGAAAAACCAGCUCCUCAUUGUU-5′ (SEQ ID NO: 1491) βc-3099 Target:5′-TGGTCCTTTTTGGTCGAGGAGTAACAA-3′ (SEQ ID NO: 2600)5′-CCUUUUUGGUCGAGGAGUAACAAta-3′ (SEQ ID NO: 383)3′-CAGGAAAAACCAGCUCCUCAUUGUUAU-5′ (SEQ ID NO: 1492) βc-3101 Target:5′-GTCCTTTTTGGTCGAGGAGTAACAATA-3′ (SEQ ID NO: 2601)5′-UUUUUGGUCGAGGAGUAACAAUAca-3′ (SEQ ID NO: 384)3′-GGAAAAACCAGCUCCUCAUUGUUAUGU-5′ (SEQ ID NO: 1493) βc-3103 Target:5′-CCTTTTTGGTCGAGGAGTAACAATACA-3′ (SEQ ID NO: 2602)5′-UUUGGUCGAGGAGUAACAAUACAaa-3′ (SEQ ID NO: 385)3′-AAAAACCAGCUCCUCAUUGUUAUGUUU-5′ (SEQ ID NO: 1494) βc-3105 Target:5′-TTTTTGGTCGAGGAGTAACAATACAAA-3′ (SEQ ID NO: 2603)5′-UGGUCGAGGAGUAACAAUACAAAtg-3′ (SEQ ID NO: 386)3′-AAACCAGCUCCUCAUUGUUAUGUUUAC-5′ (SEQ ID NO: 1495) βc-3107 Target:5′-TTTGGTCGAGGAGTAACAATACAAATG-3′ (SEQ ID NO: 2604)5′-GUCGAGGAGUAACAAUACAAAUGga-3′ (SEQ ID NO: 387)3′-ACCAGCUCCUCAUUGUUAUGUUUACCU-5′ (SEQ ID NO: 1496) βc-3109 Target:5′-TGGTCGAGGAGTAACAATACAAATGGA-3′ (SEQ ID NO: 2605)5′-CGAGGAGUAACAAUACAAAUGGAtt-3′ (SEQ ID NO: 388)3′-CAGCUCCUCAUUGUUAUGUUUACCUAA-5′ (SEQ ID NO: 1497) βc-3111 Target:5′-GTCGAGGAGTAACAATACAAATGGATT-3′ (SEQ ID NO: 2606)5′-AGGAGUAACAAUACAAAUGGAUUtt-3′ (SEQ ID NO: 389)3′-GCUCCUCAUUGUUAUGUUUACCUAAAA-5′ (SEQ ID NO: 1498) βc-3113 Target:5′-CGAGGAGTAACAATACAAATGGATTTT-3′ (SEQ ID NO: 2607)5′-GAGUAACAAUACAAAUGGAUUUUgg-3′ (SEQ ID NO: 390)3′-UCCUCAUUGUUAUGUUUACCUAAAACC-5′ (SEQ ID NO: 1499) βc-3115 Target:5′-AGGAGTAACAATACAAATGGATTTTGG-3′ (SEQ ID NO: 2608)5′-UAUCAAACCCUAGCCUUGCUUGUta-3′ (SEQ ID NO: 391)3′-AAAUAGUUUGGGAUCGGAACGAACAAU-5′ (SEQ ID NO: 1500) βc-3191 Target:5′-TTTATCAAACCCTAGCCTTGCTTGTTA-3′ (SEQ ID NO: 2609)5′-UCAAACCCUAGCCUUGCUUGUUAaa-3′ (SEQ ID NO: 392)3′-AUAGUUUGGGAUCGGAACGAACAAUUU-5′ (SEQ ID NO: 1501) βc-3193 Target:5′-TATCAAACCCTAGCCTTGCTTGTTAAA-3′ (SEQ ID NO: 2610)5′-AAACCCUAGCCUUGCUUGUUAAAtt-3′ (SEQ ID NO: 393)3′-AGUUUGGGAUCGGAACGAACAAUUUAA-5′ (SEQ ID NO: 1502) βc-3195 Target:5′-TCAAACCCTAGCCTTGCTTGTTAAATT-3′ (SEQ ID NO: 2611)5′-GAGUAAUGGUGUAGAACACUAAUtc-3′ (SEQ ID NO: 394)3′-AACUCAUUACCACAUCUUGUGAUUAAG-5′ (SEQ ID NO: 1503) βc-3387 Target:5′-TTGAGTAATGGTGTAGAACACTAATTC-3′ (SEQ ID NO: 2612)5′-GUAAUGGUGUAGAACACUAAUUCat-3′ (SEQ ID NO: 395)3′-CUCAUUACCACAUCUUGUGAUUAAGUA-5′ (SEQ ID NO: 1504) βc-3389 Target:5′-GAGTAATGGTGTAGAACACTAATTC-3′ (SEQ ID NO: 2613)5′-AAUGGUGUAGAACACUAAUUCAUaa-3′ (SEQ ID NO: 396)3′-CAUUACCACAUCUUGUGAUUAAGUAUU-5′ (SEQ ID NO: 1505) βc-3391 Target:5′-GTAATGGTGTAGAACACTAATTCATAA-3′ (SEQ ID NO: 2614)5′-UGGUGUAGAACACUAAUUCAUAAtc-3′ (SEQ ID NO: 397)3′-UUACCACAUCUUGUGAUUAAGUAUUAG-5′ (SEQ ID NO: 1506) βc-3393 Target:5′-AATGGTGTAGAACACTAATTCATAATC-3′ (SEQ ID NO: 2615)5′-GUGUAGAACACUAAUUCAUAAUCac-3′ (SEQ ID NO: 398)3′-ACCACAUCUUGUGAUUAAGUAUUAGUG-5′ (SEQ ID NO: 1507) βc-3395 Target:5′-TGGTGTAGAACACTAATTCATAATCAC-3′ (SEQ ID NO: 2616)5′-GUAGAACACUAAUUCAUAAUCACtc-3′ (SEQ ID NO: 399)3′-CACAUCUUGUGAUUAAGUAUUAGUGAG-5′ (SEQ ID NO: 1508) βc-3397 Target:5′-GTGTAGAACACTAATTCATAATCACTC-3′ (SEQ ID NO: 2617)5′-AGAACACUAAUUCAUAAUCACUCta-3′ (SEQ ID NO: 400)3′-CAUCUUGUGAUUAAGUAUUAGUGAGAU-5′ (SEQ ID NO: 1509) βc-3399 Target:5′-GTAGAACACTAATTCATAATCACTCTA-3′ (SEQ ID NO: 2618)5′-AACACUAAUUCAUAAUCACUCUAat-3′ (SEQ ID NO: 401)3′-UCUUGUGAUUAAGUAUUAGUGAGAUUA-5′ (SEQ ID NO: 1510) βc-3401 Target:5′-AGAACACTAATTCATAATCACTCTAAT-3′ (SEQ ID NO: 2619)5′-UUAGUUUCCUUUUUAAUAUGCUUaa-3′ (SEQ ID NO: 402)3′-UUAAUCAAAGGAAAAAUUAUACGAAUU-5′ (SEQ ID NO: 1511) βc-3500 Target:5′-AATTAGTTTCCTTTTTAATATGCTTAA-3′ (SEQ ID NO: 2620)5′-AGUUUCCUUUUUAAUAUGCUUAAaa-3′ (SEQ ID NO: 403)3′-AAUCAAAGGAAAAAUUAUACGAAUUUU-5′ (SEQ ID NO: 1512) βc-3502 Target:5′-TTAGTTTCCTTTTTAATATGCTTAAAA-3′ (SEQ ID NO: 2621)5′-UUUCCUUUUUAAUAUGCUUAAAAta-3′ (SEQ ID NO: 404)3′-UCAAAGGAAAAAUUAUACGAAUUUUAU-5′ (SEQ ID NO: 1513) βc-3504 Target:5′-AGTTTCCTTTTTAATATGCTTAAAATA-3′ (SEQ ID NO: 2622)5′-UCCUUUUUAAUAUGCUUAAAAUAag-3′ (SEQ ID NO: 405)3′-AAAGGAAAAAUUAUACGAAUUUUAUUC-5′ (SEQ ID NO: 1514) βc-3506 Target:5′-TTTCCTTTTTAATATGCTTAAAATAAG-3′ (SEQ ID NO: 2623)5′-CUUUUUAAUAUGCUUAAAAUAAGca-3′ (SEQ ID NO: 406)3′-AGGAAAAAUUAUACGAAUUUUAUUCGU-5′ (SEQ ID NO: 1515) βc-3508 Target:5′-TCCTTTTTAATATGCTTAAAATAAGCA-3′ (SEQ ID NO: 2624)5′-UUUUUAAUAUGCUUAAAAUAAGCag-3′ (SEQ ID NO: 407)3′-GGAAAAAUUAUACGAAUUUUAUUCGUC-5′ (SEQ ID NO: 1516) βc-3509 Target:5′-CCTTTTTAATATGCTTAAAATAAGCAG-3′ (SEQ ID NO: 2625)5′-UUUUAAUAUGCUUAAAAUAAGCAgg-3′ (SEQ ID NO: 408)3′-GAAAAAUUAUACGAAUUUUAUUCGUCC-5′ (SEQ ID NO: 1517) βc-3510 Target:5′-CTTTTTAATATGCTTAAAATAAGCAGG-3′ (SEQ ID NO: 2626)5′-UUAAUAUGCUUAAAAUAAGCAGGtg-3′ (SEQ ID NO: 409)3′-AAAAUUAUACGAAUUUUAUUCGUCCAC-5′ (SEQ ID NO: 1518) βc-3512 Target:5′-TTTTAATATGCTTAAAATAAGCAGGTG-3′ (SEQ ID NO: 2627)5′-AAUAUGCUUAAAAUAAGCAGGUGga-3′ (SEQ ID NO: 410)3′-AAUUAUACGAAUUUUAUUCGUCCACCU-5′ (SEQ ID NO: 1519) βc-3514 Target:5′-TTAATATGCTTAAAATAAGCAGGTGGA-3′ (SEQ ID NO: 2628)5′-UAUGCUUAAAAUAAGCAGGUGGAtc-3′ (SEQ ID NO: 411)3′-UUAUACGAAUUUUAUUCGUCCACCUAG-5′ (SEQ ID NO: 1520) βc-3516 Target:5′-AATATGCTTAAAATAAGCAGGTGGATC-3′ (SEQ ID NO: 2629)5′-UGCUUAAAAUAAGCAGGUGGAUCta-3′ (SEQ ID NO: 412)3′-AUACGAAUUUUAUUCGUCCACCUAGAU-5′ (SEQ ID NO: 1521) βc-3518 Target:5′-TATGCTTAAAATAAGCAGGTGGATCTA-3′ (SEQ ID NO: 2630)5′-CUUAAAAUAAGCAGGUGGAUCUAtt-3′ (SEQ ID NO: 413)3′-ACGAAUUUUAUUCGUCCACCUAGAUAA-5′ (SEQ ID NO: 1522) βc-3520 Target:5′-TGCTTAAAATAAGCAGGTGGATCTATT-3′ (SEQ ID NO: 2631)5′-UAAAAUAAGCAGGUGGAUCUAUUtc-3′ (SEQ ID NO: 414)3′-GAAUUUUAUUCGUCCACCUAGAUAAAG-5′ (SEQ ID NO: 1523) βc-3522 Target:5′-CTTAAAATAAGCAGGTGGATCTATTTC-3′ (SEQ ID NO: 2632)5′-AAAUAAGCAGGUGGAUCUAUUUCat-3′ (SEQ ID NO: 415)3′-AUUUUAUUCGUCCACCUAGAUAAAGUA-5′ (SEQ ID NO: 1524) βc-3524 Target:5′-TAAAATAAGCAGGTGGATCTATTTC-3′ (SEQ ID NO: 2633)5′-AUAAGCAGGUGGAUCUAUUUCAUgt-3′ (SEQ ID NO: 416)3′-UUUAUUCGUCCACCUAGAUAAAGUACA-5′ (SEQ ID NO: 1525) βc-3526 Target:5′-AAATAAGCAGGTGGATCTATTTCATGT-3′ (SEQ ID NO: 2634)5′-AAGCAGGUGGAUCUAUUUCAUGUtt-3′ (SEQ ID NO: 417)3′-UAUUCGUCCACCUAGAUAAAGUACAAA-5′ (SEQ ID NO: 1526) βc-3528 Target:5′-ATAAGCAGGTGGATCTATTTCATGTTT-3′ (SEQ ID NO: 2635)5′-GCAGGUGGAUCUAUUUCAUGUUUtt-3′ (SEQ ID NO: 418)3′-UUCGUCCACCUAGAUAAAGUACAAAAA-5′ (SEQ ID NO: 1527) βc-3530 Target:5′-AAGCAGGTGGATCTATTTCATGTTTTT-3′ (SEQ ID NO: 2636)5′-AGGUGGAUCUAUUUCAUGUUUUUga-3′ (SEQ ID NO: 419)3′-CGUCCACCUAGAUAAAGUACAAAAACU-5′ (SEQ ID NO: 1528) βc-3532 Target:5′-GCAGGTGGATCTATTTCATGTTTTTGA-3′ (SEQ ID NO: 2637)5′-GUGGAUCUAUUUCAUGUUUUUGAtc-3′ (SEQ ID NO: 420)3′-UCCACCUAGAUAAAGUACAAAAACUAG-5′ (SEQ ID NO: 1529) βc-3534 Target:5′-AGGTGGATCTATTTCATGTTTTTGATC-3′ (SEQ ID NO: 2638)5′-GGAUCUAUUUCAUGUUUUUGAUCaa-3′ (SEQ ID NO: 421)3′-CACCUAGAUAAAGUACAAAAACUAGUU-5′ (SEQ ID NO: 1530) βc-3536 Target:5′-GTGGATCTATTTCATGTTTTTGATCAA-3′ (SEQ ID NO: 2639)5′-AUCUAUUUCAUGUUUUUGAUCAAaa-3′ (SEQ ID NO: 422)3′-CCUAGAUAAAGUACAAAAACUAGUUUU-5′ (SEQ ID NO: 1531) βc-3538 Target:5′-GGATCTATTTCATGTTTTTGATCAAAA-3′ (SEQ ID NO: 2640)5′-GUAGGGUAAAUCAGUAAGAGGUGtt-3′ (SEQ ID NO: 423)3′-CCCAUCCCAUUUAGUCAUUCUCCACAA-5′ (SEQ ID NO: 1532) βc-3583 Target:5′-GGGTAGGGTAAATCAGTAAGAGGTGTT-3′ (SEQ ID NO: 2641)5′-AGGGUAAAUCAGUAAGAGGUGUUat-3′ (SEQ ID NO: 424)3′-CAUCCCAUUUAGUCAUUCUCCACAAUA-5′ (SEQ ID NO: 1533) βc-3585 Target:5′-GTAGGGTAAATCAGTAAGAGGTGTTAT-3′ (SEQ ID NO: 2642)5′-GGUAAAUCAGUAAGAGGUGUUAUtt-3′ (SEQ ID NO: 425)3′-UCCCAUUUAGUCAUUCUCCACAAUAAA-5′ (SEQ ID NO: 1534) βc-3587 Target:5′-AGGGTAAATCAGTAAGAGGTGTTATTT-3′ (SEQ ID NO: 2643)5′-UAAAUCAGUAAGAGGUGUUAUUUgg-3′ (SEQ ID NO: 426)3′-CCAUUUAGUCAUUCUCCACAAUAAACC-5′ (SEQ ID NO: 1535) βc-3589 Target:5′-GGTAAATCAGTAAGAGGTGTTATTTGG-3′ (SEQ ID NO: 2644)5′-AAUCAGUAAGAGGUGUUAUUUGGaa-3′ (SEQ ID NO: 427)3′-AUUUAGUCAUUCUCCACAAUAAACCUU-5′ (SEQ ID NO: 1536) βc-3591 Target:5′-TAAATCAGTAAGAGGTGTTATTTGGAA-3′ (SEQ ID NO: 2645)5′-UCAGUAAGAGGUGUUAUUUGGAAcc-3′ (SEQ ID NO: 428)3′-UUAGUCAUUCUCCACAAUAAACCUUGG-5′ (SEQ ID NO: 1537) βc-3593 Target:5′-AATCAGTAAGAGGTGTTATTTGGAACC-3′ (SEQ ID NO: 2646)5′-UACCAGUUGCCUUUUAUCCCAAAgt-3′ (SEQ ID NO: 429)3′-AAAUGGUCAACGGAAAAUAGGGUUUCA-5′ (SEQ ID NO: 1538) βc-3633 Target:5′-TTTACCAGTTGCCTTTTATCCCAAAGT-3′ (SEQ ID NO: 2647)5′-CCAGUUGCCUUUUAUCCCAAAGUtg-3′ (SEQ ID NO: 430)3′-AUGGUCAACGGAAAAUAGGGUUUCAAC-5′ (SEQ ID NO: 1539) βc-3635 Target:5′-TACCAGTTGCCTTTTATCCCAAAGTTG-3′ (SEQ ID NO: 2648)5′-AGUUGCCUUUUAUCCCAAAGUUGtt-3′ (SEQ ID NO: 431)3′-GGUCAACGGAAAAUAGGGUUUCAACAA-5′ (SEQ ID NO: 1540) βc-3637 Target:5′-CCAGTTGCCTTTTATCCCAAAGTTGTT-3′ (SEQ ID NO: 2649)5′-UUGCCUUUUAUCCCAAAGUUGUUgt-3′ (SEQ ID NO: 432)3′-UCAACGGAAAAUAGGGUUUCAACAACA-5′ (SEQ ID NO: 1541) βc-3639 Target:5′-AGTTGCCTTTTATCCCAAAGTTGTTGT-3′ (SEQ ID NO: 2650)5′-GCCUUUUAUCCCAAAGUUGUUGUaa-3′ (SEQ ID NO: 433)3′-AACGGAAAAUAGGGUUUCAACAACAUU-5′ (SEQ ID NO: 1542) βc-3641 Target:5′-TTGCCTTTTATCCCAAAGTTGTTGTAA-3′ (SEQ ID NO: 2651)5′-CUUUUAUCCCAAAGUUGUUGUAAcc-3′ (SEQ ID NO: 434)3′-CGGAAAAUAGGGUUUCAACAACAUUGG-5′ (SEQ ID NO: 1543) βc-3643 Target:5′-GCCTTTTATCCCAAAGTTGTTGTAACC-3′ (SEQ ID NO: 2652)5′-UUUAUCCCAAAGUUGUUGUAACCtg-3′ (SEQ ID NO: 435)3′-GAAAAUAGGGUUUCAACAACAUUGGAC-5′ (SEQ ID NO: 1544) βc-3645 Target:5′-CTTTTATCCCAAAGTTGTTGTAACCTG-3′ (SEQ ID NO: 2653)5′-UAUCCCAAAGUUGUUGUAACCUGct-3′ (SEQ ID NO: 436)3′-AAAUAGGGUUUCAACAACAUUGGACGA-5′ (SEQ ID NO: 1545) βc-3647 Target:5′-TTTATCCCAAAGTTGTTGTAACCTGCT-3′ (SEQ ID NO: 2654)5′-UCCCAAAGUUGUUGUAACCUGCUgt-3′ (SEQ ID NO: 437)3′-AUAGGGUUUCAACAACAUUGGACGACA-5′ (SEQ ID NO: 1546) βc-3649 Target:5′-TATCCCAAAGTTGTTGTAACCTGCTGT-3′ (SEQ ID NO: 2655)5′-CCAAAGUUGUUGUAACCUGCUGUga-3′ (SEQ ID NO: 438)3′-AGGGUUUCAACAACAUUGGACGACACU-5′ (SEQ ID NO: 1547) βc-3651 Target:5′-TCCCAAAGTTGTTGTAACCTGCTGTGA-3′ (SEQ ID NO: 2656)5′-AAAGUUGUUGUAACCUGCUGUGAta-3′ (SEQ ID NO: 439)3′-GGUUUCAACAACAUUGGACGACACUAU-5′ (SEQ ID NO: 1548) βc-3653 Target:5′-CCAAAGTTGTTGTAACCTGCTGTGATA-3′ (SEQ ID NO: 2657)5′-AGUUGUUGUAACCUGCUGUGAUAcg-3′ (SEQ ID NO: 440)3′-UUUCAACAACAUUGGACGACACUAUGC-5′ (SEQ ID NO: 1549) βc-3655 Target:5′-AAAGTTGTTGTAACCTGCTGTGATACG-3′ (SEQ ID NO: 2658)5′-UUGUUGUAACCUGCUGUGAUACGat-3′ (SEQ ID NO: 441)3′-UCAACAACAUUGGACGACACUAUGCUA-5′ (SEQ ID NO: 1550) βc-3657 Target:5′-AGTTGTTGTAACCTGCTGTGATACGAT-3′ (SEQ ID NO: 2659)5′-GUUGUAACCUGCUGUGAUACGAUgc-3′ (SEQ ID NO: 442)3′-AACAACAUUGGACGACACUAUGCUACG-5′ (SEQ ID NO: 1551) βc-3659 Target:5′-TTGTTGTAACCTGCTGTGATACGATGC-3′ (SEQ ID NO: 2660)5′-AAAUGGUUCAGAAUUAAACUUUUaa-3′ (SEQ ID NO: 443)3′-UUUUUACCAAGUCUUAAUUUGAAAAUU-5′ (SEQ ID NO: 1552) βc-3708 Target:5′-AAAAATGGTTCAGAATTAAACTTTTAA-3′ (SEQ ID NO: 2661)5′-AUGGUUCAGAAUUAAACUUUUAAtt-3′ (SEQ ID NO: 444)3′-UUUACCAAGUCUUAAUUUGAAAAUUAA-5′ (SEQ ID NO: 1553) βc-3710 Target:5′-AAATGGTTCAGAATTAAACTTTTAATT-3′ (SEQ ID NO: 2662)5′-GGUUCAGAAUUAAACUUUUAAUUca-3′ (SEQ ID NO: 445)3′-UACCAAGUCUUAAUUUGAAAAUUAAGU-5′ (SEQ ID NO: 1554) βc-3712 Target:5′-ATGGTTCAGAATTAAACTTTTAATTCA-3′ (SEQ ID NO: 2663)5′-UUCAGAAUUAAACUUUUAAUUCAtt-3′ (SEQ ID NO: 446)3′-CCAAGUCUUAAUUUGAAAAUUAAGUAA-5′ (SEQ ID NO: 1555) βc-3714 Target:5′-GGTTCAGAATTAAACTTTTAATTCATT-3′ (SEQ ID NO: 2664)5′-CAGAAUUAAACUUUUAAUUCAUUcg-3′ (SEQ ID NO: 447)3′-AAGUCUUAAUUUGAAAAUUAAGUAAGC-5′ (SEQ ID NO: 1556) βc-3716 Target:5′-TTCAGAATTAAACTTTTAATTCATTCG-3′ (SEQ ID NO: 2665)

TABLE 4 Selected Anti-β-catenin DsiRNAs, Mus musculus Unique Duplexes5′-GCAGCAGUCUUACUUGGAUUCUGga-3′ (SEQ ID NO: 448)3′-GUCGUCGUCAGAAUGAACCUAAGACCU-5′ (SEQ ID NO: 1557) βc-m314 Target:5′-CAGCAGCAGTCTTACTTGGATTCTGGA-3′ (SEQ ID NO: 2666)5′-ACUUGGAUUCUGGAAUCCAUUCUgg-3′ (SEQ ID NO: 449)3′-AAUGAACCUAAGACCUUAGGUAAGACC-5′ (SEQ ID NO: 1558) βc-m325 Target:5′-TTACTTGGATTCTGGAATCCATTCTGG-3′ (SEQ ID NO: 2667)5′-GACACCUCCCAAGUCCUUUAUGAat-3′ (SEQ ID NO: 450)3′-AACUGUGGAGGGUUCAGGAAAUACUUA-5′ (SEQ ID NO: 1559) βc-m408 Target:5′-TTGACACCTCCCAAGTCCTTTATGAAT-3′ (SEQ ID NO: 2668)5′-CGCAAGAGCAAGUAGCUGAUAUUga-3′ (SEQ ID NO: 451)3′-GUGCGUUCUCGUUCAUCGACUAUAACU-5′ (SEQ ID NO: 1560) βc-m460 Target:5′-CACGCAAGAGCAAGTAGCTGATATTGA-3′ (SEQ ID NO: 2669)5′-CCAUGUUCCCUGAGACGCUAGAUga-3′ (SEQ ID NO: 452)3′-ACGGUACAAGGGACUCUGCGAUCUACU-5′ (SEQ ID NO: 1561) βc-m526 Target:5′-TGCCATGTTCCCTGAGACGCTAGATGA-3′ (SEQ ID NO: 2670)5′-UGAAACAUGCAGUUGUCAAUUUGat-3′ (SEQ ID NO: 453)3′-CAACUUUGUACGUCAACAGUUAAACUA-5′ (SEQ ID NO: 1562) βc-m631 Target:5′-GTTGAAACATGCAGTTGTCAATTTGAT-3′ (SEQ ID NO: 2671)5′-CAUGCAGUUGUCAAUUUGAUUAAct-3′ (SEQ ID NO: 454)3′-UUGUACGUCAACAGUUAAACUAAUUGA-5′ (SEQ ID NO: 1563) βc-m636 Target:5′-AACATGCAGTTGTCAATTTGATTAACT-3′ (SEQ ID NO: 2672)5′-GUUGUCAAUUUGAUUAACUAUCAgg-3′ (SEQ ID NO: 455)3′-GUCAACAGUUAAACUAAUUGAUAGUCC-5′ (SEQ ID NO: 1564) βc-m642 Target:5′-CAGTTGTCAATTTGATTAACTATCAGG-3′ (SEQ ID NO: 2673)5′-GAGGACCAGGUGGUAGUUAAUAAag-3′ (SEQ ID NO: 456)3′-UACUCCUGGUCCACCAUCAAUUAUUUC-5′ (SEQ ID NO: 1565) βc-m723 Target:5′-ATGAGGACCAGGTGGTAGTTAATAAAG-3′ (SEQ ID NO: 2674)5′-GGUCACCAGUGGAUUCUGUACUGtt-3′ (SEQ ID NO: 457)3′-ACCCAGUGGUCACCUAAGACAUGACAA-5′ (SEQ ID NO: 1566) βc-m970 Target:5′-TGGGTCACCAGTGGATTCTGTACTGTT-3′ (SEQ ID NO: 2675)5′-CAGUGGAUUCUGUACUGUUCUACgc-3′ (SEQ ID NO: 458)3′-UGGUCACCUAAGACAUGACAAGAUGCG-5′ (SEQ ID NO: 1567) βc-m976 Target:5′-ACCAGTGGATTCTGTACTGTTCTACGC-3′ (SEQ ID NO: 2676)5′-GAUUCUGUACUGUUCUACGCCAUca-3′ (SEQ ID NO: 459)3′-ACCUAAGACAUGACAAGAUGCGGUAGU-5′ (SEQ ID NO: 1568) βc-m981 Target:5′-TGGATTCTGTACTGTTCTACGCCATCA-3′ (SEQ ID NO: 2677)5′-GUGGACUGCAGAAAAUGGUUGCUtt-3′ (SEQ ID NO: 460)3′-ACCACCUGACGUCUUUUACCAACGAAA-5′ (SEQ ID NO: 1569) βc-m1066 Target:5′-TGGTGGACTGCAGAAAATGGTTGCTTT-3′ (SEQ ID NO: 2678)5′-CGUGAAAUUCUUGGCUAUUACAAca-3′ (SEQ ID NO: 461)3′-UUGCACUUUAAGAACCGAUAAUGUUGU-5′ (SEQ ID NO: 1570) βc-m1106 Target:5′-AACGTGAAATTCTTGGCTATTACAACA-3′ (SEQ ID NO: 2679)5′-CAAGUCAGCGACUUGUUCAAAACtg-3′ (SEQ ID NO: 462)3′-GGGUUCAGUCGCUGAACAAGUUUUGAC-5′ (SEQ ID NO: 1571) βc-m1354 Target:5′-CCCAAGTCAGCGACTTGTTCAAAACTG-3′ (SEQ ID NO: 2680)5′-GACUUGUUCAAAACUGUCUUUGGac-3′ (SEQ ID NO: 463)3′-CGCUGAACAAGUUUUGACAGAAACCUG-5′ (SEQ ID NO: 1572) βc-m1363 Target:5′-GCGACTTGTTCAAAACTGTCTTTGGAC-3′ (SEQ ID NO: 2681)5′-AAACUGUCUUUGGACUCUCAGAAac-3′ (SEQ ID NO: 464)3′-GUUUUGACAGAAACCUGAGAGUCUUUG-5′ (SEQ ID NO: 1573) βc-m1373 Target:5′-CAAAACTGTCTTTGGACTCTCAGAAAC-3′ (SEQ ID NO: 2682)5′-CUCUAACCUCACUUGCAAUAAUUac-3′ (SEQ ID NO: 465)3′-GAGAGAUUGGAGUGAACGUUAUUAAUG-5′ (SEQ ID NO: 1574) βc-m1508 Target:5′-CTCTCTAACCTCACTTGCAATAATTAC-3′ (SEQ ID NO: 2683)5′-CUCACUUGCAAUAAUUACAAAAAca-3′ (SEQ ID NO: 466)3′-UGGAGUGAACGUUAUUAAUGUUUUUGU-5′ (SEQ ID NO: 1575) βc-m1515 Target:5′-ACCTCACTTGCAATAATTACAAAAACA-3′ (SEQ ID NO: 2684)5′-GAAUGCCGUUCGCCUUCAUUAUGga-3′ (SEQ ID NO: 467)3′-GUCUUACGGCAAGCGGAAGUAAUACCU-5′ (SEQ ID NO: 1576) βc-m1682 Target:5′-CAGAATGCCGTTCGCCTTCATTATGGA-3′ (SEQ ID NO: 2685)5′-GCCUUCAUUAUGGACUGCCUGUUgt-3′ (SEQ ID NO: 468)3′-AGCGGAAGUAAUACCUGACGGACAACA-5′ (SEQ ID NO: 1577) βc-m1693 Target:5′-TCGCCTTCATTATGGACTGCCTGTTGT-3′ (SEQ ID NO: 2686)5′-CAUUAUGGACUGCCUGUUGUGGUta-3′ (SEQ ID NO: 469)3′-AAGUAAUACCUGACGGACAACACCAAU-5′ (SEQ ID NO: 1578) βc-m1698 Target:5′-TTCATTATGGACTGCCTGTTGTGGTTA-3′ (SEQ ID NO: 2687)5′-GACUGCCUGUUGUGGUUAAACUCct-3′ (SEQ ID NO: 470)3′-ACCUGACGGACAACACCAAUUUGAGGA-5′ (SEQ ID NO: 1579) βc-m1705 Target:5′-TGGACTGCCTGTTGTGGTTAAACTCCT-3′ (SEQ ID NO: 2688)5′-AACUGUUGGAUUGAUUCGAAACCtt-3′ (SEQ ID NO: 471)3′-CGUUGACAACCUAACUAAGCUUUGGAA-5′ (SEQ ID NO: 1580) βc-m1763 Target:5′-GCAACTGTTGGATTGATTCGAAACCTT-3′ (SEQ ID NO: 2689)5′-GAGGACUCAAUACCAUUCCAUUGtt-3′ (SEQ ID NO: 472)3′-GGCUCCUGAGUUAUGGUAAGGUAACAA-5′ (SEQ ID NO: 1581) βc-m2008 Target:5′-CCGAGGACTCAATACCATTCCATTGTT-3′ (SEQ ID NO: 2690)5′-GAGGACAAGCCACAGGAUUACAAga-3′ (SEQ ID NO: 473)3′-GACUCCUGUUCGGUGUCCUAAUGUUCU-5′ (SEQ ID NO: 1582) βc-m2226 Target:5′-CTGAGGACAAGCCACAGGATTACAAGA-3′ (SEQ ID NO: 2691)5′-AUGGACCCUAUGAUGGAGCAUGAga-3′ (SEQ ID NO: 474)3′-CCUACCUGGGAUACUACCUCGUACUCU-5′ (SEQ ID NO: 1583) βc-m2427 Target:5′-GGATGGACCCTATGATGGAGCATGAGA-3′ (SEQ ID NO: 2692)5′-GAUACUGACCUGUAAAUCGUCCUtt-3′ (SEQ ID NO: 475)3′-AACUAUGACUGGACAUUUAGCAGGAAA-5′ (SEQ ID NO: 1584) βc-m2568 Target:5′-TTGATACTGACCTGTAAATCGTCCTTT-3′ (SEQ ID NO: 2693)5′-CCAGUGUGGGUGAAUACUUUACUct-3′ (SEQ ID NO: 476)3′-UCGGUCACACCCACUUAUGAAAUGAGA-5′ (SEQ ID NO: 1585) βc-m2614 Target:5′-AGCCAGTGTGGGTGAATACTTTACTCT-3′ (SEQ ID NO: 2694)5′-CCACAGCUUUUGCAGCGUUAUACtc-3′ (SEQ ID NO: 477)3′-ACGGUGUCGAAAACGUCGCAAUAUGAG-5′ (SEQ ID NO: 1586) βc-m2770 Target:5′-TGCCACAGCTTTTGCAGCGTTATACTC-3′ (SEQ ID NO: 2695)5′-UUUUGCAGCGUUAUACUCAGAUGag-3′ (SEQ ID NO: 478)3′-CGAAAACGUCGCAAUAUGAGUCUACUC-5′ (SEQ ID NO: 1587) βc-m2777 Target:5′-GCTTTTGCAGCGTTATACTCAGATGAG-3′ (SEQ ID NO: 2696)5′-GCGUUAUACUCAGAUGAGUAACAtt-3′ (SEQ ID NO: 479)3′-GUCGCAAUAUGAGUCUACUCAUUGUAA-5′ (SEQ ID NO: 1588) βc-m2784 Target:5′-CAGCGTTATACTCAGATGAGTAACATT-3′ (SEQ ID NO: 2697)5′-AUUUGCUGUUUUCAACAUUAAUAgc-3′ (SEQ ID NO: 480)3′-UGUAAACGACAAAAGUUGUAAUUAUCG-5′ (SEQ ID NO: 1589) βc-m2806 Target:5′-ACATTTGCTGTTTTCAACATTAATAGC-3′ (SEQ ID NO: 2698)5′-CUGUAGUGUCUGAACGUGCAUUGtg-3′ (SEQ ID NO: 481)3′-UCGACAUCACAGACUUGCACGUAACAC-5′ (SEQ ID NO: 1590) βc-m2850 Target:5′-AGCTGTAGTGTCTGAACGTGCATTGTG-3′ (SEQ ID NO: 2699)5′-GAACAGUCGAAGUACGCUUUUUGtt-3′ (SEQ ID NO: 482)3′-CCCUUGUCAGCUUCAUGCGAAAAACAA-5′ (SEQ ID NO: 1591) βc-m2965 Target:5′-GGGAACAGTCGAAGTACGCTTTTTGTT-3′ (SEQ ID NO: 2700)5′-GUCGAAGUACGCUUUUUGUUCUGgt-3′ (SEQ ID NO: 483)3′-GUCAGCUUCAUGCGAAAAACAAGACCA-5′ (SEQ ID NO: 1592) βc-m2970 Target:5′-CAGTCGAAGTACGCTTTTTGTTCTGGT-3′ (SEQ ID NO: 2701)5′-GUACGCUUUUUGUUCUGGUCCUUtt-3′ (SEQ ID NO: 484)3′-UUCAUGCGAAAAACAAGACCAGGAAAA-5′ (SEQ ID NO: 1593) βc-m2976 Target:5′-AAGTACGCTTTTTGTTCTGGTCCTTTT-3′ (SEQ ID NO: 2702)5′-CCUAGCCUUGCUUGUUCUUUGUUtt-3′ (SEQ ID NO: 485)3′-UGGGAUCGGAACGAACAAGAAACAAAA-5′ (SEQ ID NO: 1594) βc-m3092 Target:5′-ACCCTAGCCTTGCTTGTTCTTTGTTTT-3′ (SEQ ID NO: 2703)5′-CCUUGCUUGUUCUUUGUUUUAAUat-3′ (SEQ ID NO: 486)3′-UCGGAACGAACAAGAAACAAAAUUAUA-5′ (SEQ ID NO: 1595) βc-m3097 Target:5′-AGCCTTGCTTGTTCTTTGTTTTAATAT-3′ (SEQ ID NO: 2704)5′-AACCUGCUACAGCAAUUUCUGAUtt-3′ (SEQ ID NO: 487)3′-ACUUGGACGAUGUCGUUAAAGACUAAA-5′ (SEQ ID NO: 1596) βc-m3198 Target:5′-TGAACCTGCTACAGCAATTTCTGATTT-3′ (SEQ ID NO: 2705)5′-CAGCAAUUUCUGAUUUCUAAGAAcc-3′ (SEQ ID NO: 488)3′-AUGUCGUUAAAGACUAAAGAUUCUUGG-5′ (SEQ ID NO: 1597) βc-m3207 Target:5′-TACAGCAATTTCTGATTTCTAAGAACC-3′ (SEQ ID NO: 2706)5′-GUAAGAGGUGUUAUUUGAGCCUUgt-3′ (SEQ ID NO: 489)3′-GUCAUUCUCCACAAUAAACUCGGAACA-5′ (SEQ ID NO: 1598) βc-m3433 Target:5′-CAGTAAGAGGTGTTATTTGAGCCTTGT-3′ (SEQ ID NO: 2707)5′-GGUGUUAUUUGAGCCUUGUUUUGga-3′ (SEQ ID NO: 490)3′-CUCCACAAUAAACUCGGAACAAAACCU-5′ (SEQ ID NO: 1599) βc-m3439 Target:5′-GAGGTGTTATTTGAGCCTTGTTTTGGA-3′ (SEQ ID NO: 2708)5′-UAUUUGAGCCUUGUUUUGGACAGta-3′ (SEQ ID NO: 491)3′-CAAUAAACUCGGAACAAAACCUGUCAU-5′ (SEQ ID NO: 1600) βc-m3444 Target:5′-GTTATTTGAGCCTTGTTTTGGACAGTA-3′ (SEQ ID NO: 2709)5′-GAGCCUUGUUUUGGACAGUAUACca-3′ (SEQ ID NO: 492)3′-AACUCGGAACAAAACCUGUCAUAUGGU-5′ (SEQ ID NO: 1601) βc-m3449 Target:5′-TTGAGCCTTGTTTTGGACAGTATACCA-3′ (SEQ ID NO: 2710)5′-CAACAGAUGCGGUUAUAGAAAUGgt-3′ (SEQ ID NO: 493)3′-AAGUUGUCUACGCCAAUAUCUUUACCA-5′ (SEQ ID NO: 1602) βc-m3522 Target:5′-TTCAACAGATGCGGTTATAGAAATGGT-3′ (SEQ ID NO: 2711)5′-GUUAUAGAAAUGGUUCAGAAUUAaa-3′ (SEQ ID NO: 494)3′-GCCAAUAUCUUUACCAAGUCUUAAUUU-5′ (SEQ ID NO: 1603) βc-m3533 Target:5′-CGGTTATAGAAATGGTTCAGAATTAAA-3′ (SEQ ID NO: 2712)5′-AGAAAUGGUUCAGAAUUAAACUUtt-3′ (SEQ ID NO: 495)3′-UAUCUUUACCAAGUCUUAAUUUGAAAA-5′ (SEQ ID NO: 1604) βc-m3538 Target:5′-ATAGAAATGGTTCAGAATTAAACTTTT-3′ (SEQ ID NO: 2713)

Projected 21 nucleotide target sequences for each DsiRNA of Tables 2-4above and of Tables 6-8 below are presented in Table 5.

TABLE 5 21 Nucleotide Target Sequences of Selected DsiRNAs βc-240 21 ntTarget: 5′-CCCTGAGGGTATTTGAAGTAT-3′ (SEQ ID NO: 4444) βc-244 21 ntTarget: 5′-GAGGGTATTTGAAGTATACCA-3′ (SEQ ID NO: 4445) βc-253 21 ntTarget: 5′-TGAAGTATACCATACAACTGT-3′ (SEQ ID NO: 4446) βc-259 21 ntTarget: 5′-ATACCATACAACTGTTTTGAA-3′ (SEQ ID NO: 4447) βc-264 21 ntTarget: 5′-ATACAACTGTTTTGAAAATCC-3′ (SEQ ID NO: 4448) βc-496 21 ntTarget: 5′-CAGGGATTTTCTCAGTCCTTC-3′ (SEQ ID NO: 4449) βc-516 21 ntTarget: 5′-CACTCAAGAACAAGTAGCTGA-3′ (SEQ ID NO: 4450) βc-522 21 ntTarget: 5′-AGAACAAGTAGCTGATATTGA-3′ (SEQ ID NO: 4451) βc-524 21 ntTarget: 5′-AACAAGTAGCTGATATTGATG-3′ (SEQ ID NO: 4452) βc-540 21 ntTarget: 5′-TGATGGACAGTATGCAATGAC-3′ (SEQ ID NO: 4453) βc-582 21 ntTarget: 5′-TGCTATGTTCCCTGAGACATT-3′ (SEQ ID NO: 4454) βc-686 21 ntTarget: 5′-TGCTGAAACATGCAGTTGTAA-3′ (SEQ ID NO: 4455) βc-692 21 ntTarget: 5′-AACATGCAGTTGTAAACTTGA-3′ (SEQ ID NO: 4456) βc-697 21 ntTarget: 5′-GCAGTTGTAAACTTGATTAAC-3′ (SEQ ID NO: 4457) βc-707 21 ntTarget: 5′-ACTTGATTAACTATCAAGATG-3′ (SEQ ID NO: 4458) βc-753 21 ntTarget: 5′-CCCTGAACTGACAAAACTGCT-3′ (SEQ ID NO: 4459) βc-870 21 ntTarget: 5′-TCAGATGGTGTCTGCTATTGT-3′ (SEQ ID NO: 4460) βc-889 21 ntTarget: 5′-GTACGTACCATGCAGAATACA-3′ (SEQ ID NO: 4461) βc-1060 21 ntTarget: 5′-ATTACAACTCTCCACAACCTT-3′ (SEQ ID NO: 4462) βc-1065 21 ntTarget: 5′-AACTCTCCACAACCTTTTATT-3′ (SEQ ID NO: 4463) βc-1070 21 ntTarget: 5′-TCCACAACCTTTTATTACATC-3′ (SEQ ID NO: 4464) βc-1076 21 ntTarget: 5′-ACCTTTTATTACATCAAGAAG-3′ (SEQ ID NO: 4465) βc-1154 21 ntTarget: 5′-ACAAAACAAATGTTAAATTCT-3′ (SEQ ID NO: 4466) βc-1180 21 ntTarget: 5′-ATTACGACAGACTGCCTTCAA-3′ (SEQ ID NO: 4467) βc-1185 21 ntTarget: 5′-GACAGACTGCCTTCAAATTTT-3′ (SEQ ID NO: 4468) βc-1260 21 ntTarget: 5′-AGCTTTAGTAAATATAATGAG-3′ (SEQ ID NO: 4469) βc-1294 21 ntTarget: 5′-GAAAAACTACTGTGGACCACA-3′ (SEQ ID NO: 4470) βc-1412 21 ntTarget: 5′-CAAGTCAACGTCTTGTTCAGA-3′ (SEQ ID NO: 4471) βc-1418 21 ntTarget: 5′-AACGTCTTGTTCAGAACTGTC-3′ (SEQ ID NO: 4472) βc-1423 21 ntTarget: 5′-CTTGTTCAGAACTGTCTTTGG-3′ (SEQ ID NO: 4473) βc-1520 21 ntTarget: 5′-TGGGTTCAGATGATATAAATG-3′ (SEQ ID NO: 4474) βc-1561 21 ntTarget: 5′-ATTCTTTCTAACCTCACTTGC-3′ (SEQ ID NO: 4475) βc-1571 21 ntTarget: 5′-ACCTCACTTGCAATAATTATA-3′ (SEQ ID NO: 4476) βc-1579 21 ntTarget: 5′-TGCAATAATTATAAGAACAAG-3′ (SEQ ID NO: 4477) βc-1620 21 ntTarget: 5′-TGGTATAGAGGCTCTTGTGCG-3′ (SEQ ID NO: 4478) βc-1816 21 ntTarget: 5′-AAGGCTACTGTTGGATTGATT-3′ (SEQ ID NO: 4479) βc-1987 21 ntTarget: 5′-CGCATGGAAGAAATAGTTGAA-3′ (SEQ ID NO: 4480) βc-1989 21 ntTarget: 5′-CATGGAAGAAATAGTTGAAGG-3′ (SEQ ID NO: 4481) βc-2111 21 ntTarget: 5′-CCATTGAAAACATCCAAAGAG-3′ (SEQ ID NO: 4482) βc-2282 21 ntTarget: 5′-CTGAGGACAAGCCACAAGATT-3′ (SEQ ID NO: 4483) βc-2624 21 ntTarget: 5′-TTGATACTGACCTGTAAATCA-3′ (SEQ ID NO: 4484) βc-2647 21 ntTarget: 5′-CTTTAGGTAAGAAGTTTTAAA-3′ (SEQ ID NO: 4485) βc-2770 21 ntTarget: 5′-AACAGGTATATACTTTGAAAG-3′ (SEQ ID NO: 4486) βc-2848 21 ntTarget: 5′-TGGAAGTTATTAACTTTAATG-3′ (SEQ ID NO: 4487) βc-2874 21 ntTarget: 5′-TGCCACAGCTTTTGCAACTTA-3′ (SEQ ID NO: 4488) βc-2909 21 ntTarget: 5′-AACATTTGCTGTTTTAAACAT-3′ (SEQ ID NO: 4489) βc-3074 21 ntTarget: 5′-AACAATTGAAGTAAACTTTTT-3′ (SEQ ID NO: 4490) βc-3197 21 ntTarget: 5′-AAACCCTAGCCTTGCTTGTTA-3′ (SEQ ID NO: 4491) βc-3203 21 ntTarget: 5′-TAGCCTTGCTTGTTAAATTTT-3′ (SEQ ID NO: 4492) βc-3273 21 ntTarget: 5′-TTGAAGTAGCTCTTTTTTTTT-3′ (SEQ ID NO: 4493) βc-3333 21 ntTarget: 5′-TCGTAGTGTTAAGTTATAGTG-3′ (SEQ ID NO: 4494) βc-3349 21 ntTarget: 5′-TAGTGAATACTGCTACAGCAA-3′ (SEQ ID NO: 4495) βc-3354 21 ntTarget: 5′-AATACTGCTACAGCAATTTCT-3′ (SEQ ID NO: 4496) βc-3371 21 ntTarget: 5′-TTCTAATTTTTAAGAATTGAG-3′ (SEQ ID NO: 4497) βc-3376 21 ntTarget: 5′-ATTTTTAAGAATTGAGTAATG-3′ (SEQ ID NO: 4498) βc-3411 21 ntTarget: 5′-TTCATAATCACTCTAATTAAT-3′ (SEQ ID NO: 4499) βc-3426 21 ntTarget: 5′-ATTAATTGTAATCTGAATAAA-3′ (SEQ ID NO: 4500) βc-3431 21 ntTarget: 5′-TTGTAATCTGAATAAAGTGTA-3′ (SEQ ID NO: 4501) βc-3437 21 ntTarget: 5′-TCTGAATAAAGTGTAACAATT-3′ (SEQ ID NO: 4502) βc-3458 21 ntTarget: 5′-GTGTAGCCTTTTTGTATAAAA-3′ (SEQ ID NO: 4503) βc-3468 21 ntTarget: 5′-TTTGTATAAAATAGACAAATA-3′ (SEQ ID NO: 4504) βc-3488 21 ntTarget: 5′-AGAAAATGGTCCAATTAGTTT-3′ (SEQ ID NO: 4505) βc-3496 21 ntTarget: 5′-GTCCAATTAGTTTCCTTTTTA-3′ (SEQ ID NO: 4506) βc-3552 21 ntTarget: 5′-TTTTTGATCAAAAACTATTTG-3′ (SEQ ID NO: 4507) βc-3600 21 ntTarget: 5′-AAGAGGTGTTATTTGGAACCT-3′ (SEQ ID NO: 4508) βc-3605 21 ntTarget: 5′-GTGTTATTTGGAACCTTGTTT-3′ (SEQ ID NO: 4509) βc-3615 21 ntTarget: 5′-GAACCTTGTTTTGGACAGTTT-3′ (SEQ ID NO: 4510) βc-3674 21 ntTarget: 5′-GTGATACGATGCTTCAAGAGA-3′ (SEQ ID NO: 4511) βc-3686 21 ntTarget: 5′-TTCAAGAGAAAATGCGGTTAT-3′ (SEQ ID NO: 4512) βc-3691 21 ntTarget: 5′-GAGAAAATGCGGTTATAAAAA-3′ (SEQ ID NO: 4513) βc-3700 21 ntTarget: 5′-CGGTTATAAAAAATGGTTCAG-3′ (SEQ ID NO: 4514) βc-3707 21 ntTarget: 5′-AAAAAATGGTTCAGAATTAAA-3′ (SEQ ID NO: 4515) βc-284 21 ntTarget: 5′-CAGCGTGGACAATGGCTACTC-3′ (SEQ ID NO: 4516) βc-285 21 ntTarget: 5′-AGCGTGGACAATGGCTACTCA-3′ (SEQ ID NO: 4517) βc-286 21 ntTarget: 5′-GCGTGGACAATGGCTACTCAA-3′ (SEQ ID NO: 4518) βc-287 21 ntTarget: 5′-CGTGGACAATGGCTACTCAAG-3′ (SEQ ID NO: 4519) βc-288 21 ntTarget: 5′-GTGGACAATGGCTACTCAAGC-3′ (SEQ ID NO: 4520) βc-289 21 ntTarget: 5′-TGGACAATGGCTACTCAAGCT-3′ (SEQ ID NO: 4521) βc-290 21 ntTarget: 5′-GGACAATGGCTACTCAAGCTG-3′ (SEQ ID NO: 4522) βc-291 21 ntTarget: 5′-GACAATGGCTACTCAAGCTGA-3′ (SEQ ID NO: 4523) βc-312 21 ntTarget: 5′-TTTGATGGAGTTGGACATGGC-3′ (SEQ ID NO: 4524) βc-313 21 ntTarget: 5′-TTGATGGAGTTGGACATGGCC-3′ (SEQ ID NO: 4525) βc-314 21 ntTarget: 5′-TGATGGAGTTGGACATGGCCA-3′ (SEQ ID NO: 4526) βc-315 21 ntTarget: 5′-GATGGAGTTGGACATGGCCAT-3′ (SEQ ID NO: 4527) βc-316 21 ntTarget: 5′-ATGGAGTTGGACATGGCCATG-3′ (SEQ ID NO: 4528) βc-317 21 ntTarget: 5′-TGGAGTTGGACATGGCCATGG-3′ (SEQ ID NO: 4529) βc-318 21 ntTarget: 5′-GGAGTTGGACATGGCCATGGA-3′ (SEQ ID NO: 4530) βc-389 21 ntTarget: 5′-ACTCTGGAATCCATTCTGGTG-3′ (SEQ ID NO: 4531) βc-390 21 ntTarget: 5′-CTCTGGAATCCATTCTGGTGC-3′ (SEQ ID NO: 4532) βc-391 21 ntTarget: 5′-TCTGGAATCCATTCTGGTGCC-3′ (SEQ ID NO: 4533) βc-392 21 ntTarget: 5′-CTGGAATCCATTCTGGTGCCA-3′ (SEQ ID NO: 4534) βc-393 21 ntTarget: 5′-TGGAATCCATTCTGGTGCCAC-3′ (SEQ ID NO: 4535) βc-600 21 ntTarget: 5′-ATTAGATGAGGGCATGCAGAT-3′ (SEQ ID NO: 4536) βc-601 21 ntTarget: 5′-TTAGATGAGGGCATGCAGATC-3′ (SEQ ID NO: 4537) βc-602 21 ntTarget: 5′-TAGATGAGGGCATGCAGATCC-3′ (SEQ ID NO: 4538) βc-603 21 ntTarget: 5′-AGATGAGGGCATGCAGATCCC-3′ (SEQ ID NO: 4539) βc-604 21 ntTarget: 5′-GATGAGGGCATGCAGATCCCA-3′ (SEQ ID NO: 4540) βc-605 21 ntTarget: 5′-ATGAGGGCATGCAGATCCCAT-3′ (SEQ ID NO: 4541) βc-638 21 ntTarget: 5′-ATGCTGCTCATCCCACTAATG-3′ (SEQ ID NO: 4542) βc-639 21 ntTarget: 5′-TGCTGCTCATCCCACTAATGT-3′ (SEQ ID NO: 4543) βc-640 21 ntTarget: 5′-GCTGCTCATCCCACTAATGTC-3′ (SEQ ID NO: 4544) βc-641 21 ntTarget: 5′-CTGCTCATCCCACTAATGTCC-3′ (SEQ ID NO: 4545) βc-642 21 ntTarget: 5′-TGCTCATCCCACTAATGTCCA-3′ (SEQ ID NO: 4546) βc-643 21 ntTarget: 5′-GCTCATCCCACTAATGTCCAG-3′ (SEQ ID NO: 4547) βc-644 21 ntTarget: 5′-CTCATCCCACTAATGTCCAGC-3′ (SEQ ID NO: 4548) βc-645 21 ntTarget: 5′-TCATCCCACTAATGTCCAGCG-3′ (SEQ ID NO: 4549) βc-665 21 ntTarget: 5′-GTTTGGCTGAACCATCACAGA-3′ (SEQ ID NO: 4550) βc-666 21 ntTarget: 5′-TTTGGCTGAACCATCACAGAT-3′ (SEQ ID NO: 4551) βc-667 21 ntTarget: 5′-TTGGCTGAACCATCACAGATG-3′ (SEQ ID NO: 4552) βc-731 21 ntTarget: 5′-CAGAACTTGCCACACGTGCAA-3′ (SEQ ID NO: 4553) βc-732 21 ntTarget: 5′-AGAACTTGCCACACGTGCAAT-3′ (SEQ ID NO: 4554) βc-809 21 ntTarget: 5′-CAGTTATGGTCCATCAGCTTT-3′ (SEQ ID NO: 4555) βc-810 21 ntTarget: 5′-AGTTATGGTCCATCAGCTTTC-3′ (SEQ ID NO: 4556) βc-830 21 ntTarget: 5′-CTAAAAAGGAAGCTTCCAGAC-3′ (SEQ ID NO: 4557) βc-831 21 ntTarget: 5′-TAAAAAGGAAGCTTCCAGACA-3′ (SEQ ID NO: 4558) βc-893 21 ntTarget: 5′-GTACCATGCAGAATACAAATG-3′ (SEQ ID NO: 4559) βc-894 21 ntTarget: 5′-TACCATGCAGAATACAAATGA-3′ (SEQ ID NO: 4560) βc-895 21 ntTarget: 5′-ACCATGCAGAATACAAATGAT-3′ (SEQ ID NO: 4561) βc-896 21 ntTarget: 5′-CCATGCAGAATACAAATGATG-3′ (SEQ ID NO: 4562) βc-897 21 ntTarget: 5′-CATGCAGAATACAAATGATGT-3′ (SEQ ID NO: 4563) βc-898 21 ntTarget: 5′-ATGCAGAATACAAATGATGTA-3′ (SEQ ID NO: 4564) βc-899 21 ntTarget: 5′-TGCAGAATACAAATGATGTAG-3′ (SEQ ID NO: 4565) βc-900 21 ntTarget: 5′-GCAGAATACAAATGATGTAGA-3′ (SEQ ID NO: 4566) βc-977 21 ntTarget: 5′-TACTGGCCATCTTTAAGTCTG-3′ (SEQ ID NO: 4567) βc-978 21 ntTarget: 5′-ACTGGCCATCTTTAAGTCTGG-3′ (SEQ ID NO: 4568) βc-1091 21 ntTarget: 5′-AAGAAGGAGCTAAAATGGCAG-3′ (SEQ ID NO: 4569) βc-1092 21 ntTarget: 5′-AGAAGGAGCTAAAATGGCAGT-3′ (SEQ ID NO: 4570) βc-1093 21 ntTarget: 5′-GAAGGAGCTAAAATGGCAGTG-3′ (SEQ ID NO: 4571) βc-1094 21 ntTarget: 5′-AAGGAGCTAAAATGGCAGTGC-3′ (SEQ ID NO: 4572) βc-1095 21 ntTarget: 5′-AGGAGCTAAAATGGCAGTGCG-3′ (SEQ ID NO: 4573) βc-1301 21 ntTarget: 5′-TACTGTGGACCACAAGCAGAG-3′ (SEQ ID NO: 4574) βc-1302 21 ntTarget: 5′-ACTGTGGACCACAAGCAGAGT-3′ (SEQ ID NO: 4575) βc-1303 21 ntTarget: 5′-CTGTGGACCACAAGCAGAGTG-3′ (SEQ ID NO: 4576) βc-1304 21 ntTarget: 5′-TGTGGACCACAAGCAGAGTGC-3′ (SEQ ID NO: 4577) βc-1305 21 ntTarget: 5′-GTGGACCACAAGCAGAGTGCT-3′ (SEQ ID NO: 4578) βc-1306 21 ntTarget: 5′-TGGACCACAAGCAGAGTGCTG-3′ (SEQ ID NO: 4579) βc-1307 21 ntTarget: 5′-GGACCACAAGCAGAGTGCTGA-3′ (SEQ ID NO: 4580) βc-1308 21 ntTarget: 5′-GACCACAAGCAGAGTGCTGAA-3′ (SEQ ID NO: 4581) βc-1309 21 ntTarget: 5′-ACCACAAGCAGAGTGCTGAAG-3′ (SEQ ID NO: 4582) βc-1310 21 ntTarget: 5′-CCACAAGCAGAGTGCTGAAGG-3′ (SEQ ID NO: 4583) βc-1311 21 ntTarget: 5′-CACAAGCAGAGTGCTGAAGGT-3′ (SEQ ID NO: 4584) βc-1312 21 ntTarget: 5′-ACAAGCAGAGTGCTGAAGGTG-3′ (SEQ ID NO: 4585) βc-1313 21 ntTarget: 5′-CAAGCAGAGTGCTGAAGGTGC-3′ (SEQ ID NO: 4586) βc-1314 21 ntTarget: 5′-AAGCAGAGTGCTGAAGGTGCT-3′ (SEQ ID NO: 4587) βc-1430 21 ntTarget: 5′-AGAACTGTCTTTGGACTCTCA-3′ (SEQ ID NO: 4588) βc-1431 21 ntTarget: 5′-GAACTGTCTTTGGACTCTCAG-3′ (SEQ ID NO: 4589) βc-1526 21 ntTarget: 5′-CAGATGATATAAATGTGGTCA-3′ (SEQ ID NO: 4590) βc-1527 21 ntTarget: 5′-AGATGATATAAATGTGGTCAC-3′ (SEQ ID NO: 4591) βc-1528 21 ntTarget: 5′-GATGATATAAATGTGGTCACC-3′ (SEQ ID NO: 4592) βc-1529 21 ntTarget: 5′-ATGATATAAATGTGGTCACCT-3′ (SEQ ID NO: 4593) βc-1530 21 ntTarget: 5′-TGATATAAATGTGGTCACCTG-3′ (SEQ ID NO: 4594) βc-1531 21 ntTarget: 5′-GATATAAATGTGGTCACCTGT-3′ (SEQ ID NO: 4595) βc-1532 21 ntTarget: 5′-ATATAAATGTGGTCACCTGTG-3′ (SEQ ID NO: 4596) βc-1533 21 ntTarget: 5′-TATAAATGTGGTCACCTGTGC-3′ (SEQ ID NO: 4597) βc-1534 21 ntTarget: 5′-ATAAATGTGGTCACCTGTGCA-3′ (SEQ ID NO: 4598) βc-1535 21 ntTarget: 5′-TAAATGTGGTCACCTGTGCAG-3′ (SEQ ID NO: 4599) βc-1536 21 ntTarget: 5′-AAATGTGGTCACCTGTGCAGC-3′ (SEQ ID NO: 4600) βc-1537 21 ntTarget: 5′-AATGTGGTCACCTGTGCAGCT-3′ (SEQ ID NO: 4601) βc-1538 21 ntTarget: 5′-ATGTGGTCACCTGTGCAGCTG-3′ (SEQ ID NO: 4602) βc-1539 21 ntTarget: 5′-TGTGGTCACCTGTGCAGCTGG-3′ (SEQ ID NO: 4603) βc-1540 21 ntTarget: 5′-GTGGTCACCTGTGCAGCTGGA-3′ (SEQ ID NO: 4604) βc-1541 21 ntTarget: 5′-TGGTCACCTGTGCAGCTGGAA-3′ (SEQ ID NO: 4605) βc-1542 21 ntTarget: 5′-GGTCACCTGTGCAGCTGGAAT-3′ (SEQ ID NO: 4606) βc-1543 21 ntTarget: 5′-GTCACCTGTGCAGCTGGAATT-3′ (SEQ ID NO: 4607) βc-1544 21 ntTarget: 5′-TCACCTGTGCAGCTGGAATTC-3′ (SEQ ID NO: 4608) βc-1545 21 ntTarget: 5′-CACCTGTGCAGCTGGAATTCT-3′ (SEQ ID NO: 4609) βc-1565 21 ntTarget: 5′-TTTCTAACCTCACTTGCAATA-3′ (SEQ ID NO: 4610) βc-1566 21 ntTarget: 5′-TTCTAACCTCACTTGCAATAA-3′ (SEQ ID NO: 4611) βc-1567 21 ntTarget: 5′-TCTAACCTCACTTGCAATAAT-3′ (SEQ ID NO: 4612) βc-1568 21 ntTarget: 5′-CTAACCTCACTTGCAATAATT-3′ (SEQ ID NO: 4613) βc-1569 21 ntTarget: 5′-TAACCTCACTTGCAATAATTA-3′ (SEQ ID NO: 4614) βc-1652 21 ntTarget: 5′-GGGCTGGTGACAGGGAAGACA-3′ (SEQ ID NO: 4615) βc-1653 21 ntTarget: 5′-GGCTGGTGACAGGGAAGACAT-3′ (SEQ ID NO: 4616) βc-1654 21 ntTarget: 5′-GCTGGTGACAGGGAAGACATC-3′ (SEQ ID NO: 4617) βc-1655 21 ntTarget: 5′-CTGGTGACAGGGAAGACATCA-3′ (SEQ ID NO: 4618) βc-1656 21 ntTarget: 5′-TGGTGACAGGGAAGACATCAC-3′ (SEQ ID NO: 4619) βc-1657 21 ntTarget: 5′-GGTGACAGGGAAGACATCACT-3′ (SEQ ID NO: 4620) βc-1658 21 ntTarget: 5′-GTGACAGGGAAGACATCACTG-3′ (SEQ ID NO: 4621) βc-1659 21 ntTarget: 5′-TGACAGGGAAGACATCACTGA-3′ (SEQ ID NO: 4622) βc-1660 21 ntTarget: 5′-GACAGGGAAGACATCACTGAG-3′ (SEQ ID NO: 4623) βc-1661 21 ntTarget: 5′-ACAGGGAAGACATCACTGAGC-3′ (SEQ ID NO: 4624) βc-1662 21 ntTarget: 5′-CAGGGAAGACATCACTGAGCC-3′ (SEQ ID NO: 4625) βc-1663 21 ntTarget: 5′-AGGGAAGACATCACTGAGCCT-3′ (SEQ ID NO: 4626) βc-1664 21 ntTarget: 5′-GGGAAGACATCACTGAGCCTG-3′ (SEQ ID NO: 4627) βc-1665 21 ntTarget: 5′-GGAAGACATCACTGAGCCTGC-3′ (SEQ ID NO: 4628) βc-1666 21 ntTarget: 5′-GAAGACATCACTGAGCCTGCC-3′ (SEQ ID NO: 4629) βc-1667 21 ntTarget: 5′-AAGACATCACTGAGCCTGCCA-3′ (SEQ ID NO: 4630) βc-1668 21 ntTarget: 5′-AGACATCACTGAGCCTGCCAT-3′ (SEQ ID NO: 4631) βc-1669 21 ntTarget: 5′-GACATCACTGAGCCTGCCATC-3′ (SEQ ID NO: 4632) βc-1670 21 ntTarget: 5′-ACATCACTGAGCCTGCCATCT-3′ (SEQ ID NO: 4633) βc-1671 21 ntTarget: 5′-CATCACTGAGCCTGCCATCTG-3′ (SEQ ID NO: 4634) βc-1672 21 ntTarget: 5′-ATCACTGAGCCTGCCATCTGT-3′ (SEQ ID NO: 4635) βc-1673 21 ntTarget: 5′-TCACTGAGCCTGCCATCTGTG-3′ (SEQ ID NO: 4636) βc-1674 21 ntTarget: 5′-CACTGAGCCTGCCATCTGTGC-3′ (SEQ ID NO: 4637) βc-1675 21 ntTarget: 5′-ACTGAGCCTGCCATCTGTGCT-3′ (SEQ ID NO: 4638) βc-1676 21 ntTarget: 5′-CTGAGCCTGCCATCTGTGCTC-3′ (SEQ ID NO: 4639) βc-1677 21 ntTarget: 5′-TGAGCCTGCCATCTGTGCTCT-3′ (SEQ ID NO: 4640) βc-1678 21 ntTarget: 5′-GAGCCTGCCATCTGTGCTCTT-3′ (SEQ ID NO: 4641) βc-1679 21 ntTarget: 5′-AGCCTGCCATCTGTGCTCTTC-3′ (SEQ ID NO: 4642) βc-1680 21 ntTarget: 5′-GCCTGCCATCTGTGCTCTTCG-3′ (SEQ ID NO: 4643) βc-1681 21 ntTarget: 5′-CCTGCCATCTGTGCTCTTCGT-3′ (SEQ ID NO: 4644) βc-1682 21 ntTarget: 5′-CTGCCATCTGTGCTCTTCGTC-3′ (SEQ ID NO: 4645) βc-1683 21 ntTarget: 5′-TGCCATCTGTGCTCTTCGTCA-3′ (SEQ ID NO: 4646) βc-1684 21 ntTarget: 5′-GCCATCTGTGCTCTTCGTCAT-3′ (SEQ ID NO: 4647) βc-1685 21 ntTarget: 5′-CCATCTGTGCTCTTCGTCATC-3′ (SEQ ID NO: 4648) βc-1686 21 ntTarget: 5′-CATCTGTGCTCTTCGTCATCT-3′ (SEQ ID NO: 4649) βc-1687 21 ntTarget: 5′-ATCTGTGCTCTTCGTCATCTG-3′ (SEQ ID NO: 4650) βc-1688 21 ntTarget: 5′-TCTGTGCTCTTCGTCATCTGA-3′ (SEQ ID NO: 4651) βc-1689 21 ntTarget: 5′-CTGTGCTCTTCGTCATCTGAC-3′ (SEQ ID NO: 4652) βc-1690 21 ntTarget: 5′-TGTGCTCTTCGTCATCTGACC-3′ (SEQ ID NO: 4653) βc-1691 21 ntTarget: 5′-GTGCTCTTCGTCATCTGACCA-3′ (SEQ ID NO: 4654) βc-1692 21 ntTarget: 5′-TGCTCTTCGTCATCTGACCAG-3′ (SEQ ID NO: 4655) βc-1693 21 ntTarget: 5′-GCTCTTCGTCATCTGACCAGC-3′ (SEQ ID NO: 4656) βc-1694 21 ntTarget: 5′-CTCTTCGTCATCTGACCAGCC-3′ (SEQ ID NO: 4657) βc-1695 21 ntTarget: 5′-TCTTCGTCATCTGACCAGCCG-3′ (SEQ ID NO: 4658) βc-1787 21 ntTarget: 5′-TACACCCACCATCCCACTGGC-3′ (SEQ ID NO: 4659) βc-1788 21 ntTarget: 5′-ACACCCACCATCCCACTGGCC-3′ (SEQ ID NO: 4660) βc-1789 21 ntTarget: 5′-CACCCACCATCCCACTGGCCT-3′ (SEQ ID NO: 4661) βc-1790 21 ntTarget: 5′-ACCCACCATCCCACTGGCCTC-3′ (SEQ ID NO: 4662) βc-1791 21 ntTarget: 5′-CCCACCATCCCACTGGCCTCT-3′ (SEQ ID NO: 4663) βc-1792 21 ntTarget: 5′-CCACCATCCCACTGGCCTCTG-3′ (SEQ ID NO: 4664) βc-1793 21 ntTarget: 5′-CACCATCCCACTGGCCTCTGA-3′ (SEQ ID NO: 4665) βc-1794 21 ntTarget: 5′-ACCATCCCACTGGCCTCTGAT-3′ (SEQ ID NO: 4666) βc-1795 21 ntTarget: 5′-CCATCCCACTGGCCTCTGATA-3′ (SEQ ID NO: 4667) βc-1796 21 ntTarget: 5′-CATCCCACTGGCCTCTGATAA-3′ (SEQ ID NO: 4668) βc-1797 21 ntTarget: 5′-ATCCCACTGGCCTCTGATAAA-3′ (SEQ ID NO: 4669) βc-1798 21 ntTarget: 5′-TCCCACTGGCCTCTGATAAAG-3′ (SEQ ID NO: 4670) βc-1799 21 ntTarget: 5′-CCCACTGGCCTCTGATAAAGG-3′ (SEQ ID NO: 4671) βc-1800 21 ntTarget: 5′-CCACTGGCCTCTGATAAAGGC-3′ (SEQ ID NO: 4672) βc-1820 21 ntTarget: 5′-CTACTGTTGGATTGATTCGAA-3′ (SEQ ID NO: 4673) βc-1821 21 ntTarget: 5′-TACTGTTGGATTGATTCGAAA-3′ (SEQ ID NO: 4674) βc-2072 21 ntTarget: 5′-TAAATACCATTCCATTGTTTG-3′ (SEQ ID NO: 4675) βc-2073 21 ntTarget: 5′-AAATACCATTCCATTGTTTGT-3′ (SEQ ID NO: 4676) βc-2074 21 ntTarget: 5′-AATACCATTCCATTGTTTGTG-3′ (SEQ ID NO: 4677) βc-2075 21 ntTarget: 5′-ATACCATTCCATTGTTTGTGC-3′ (SEQ ID NO: 4678) βc-2076 21 ntTarget: 5′-TACCATTCCATTGTTTGTGCA-3′ (SEQ ID NO: 4679) βc-2077 21 ntTarget: 5′-ACCATTCCATTGTTTGTGCAG-3′ (SEQ ID NO: 4680) βc-2097 21 ntTarget: 5′-GCTGCTTTATTCTCCCATTGA-3′ (SEQ ID NO: 4681) βc-2098 21 ntTarget: 5′-CTGCTTTATTCTCCCATTGAA-3′ (SEQ ID NO: 4682) βc-2099 21 ntTarget: 5′-TGCTTTATTCTCCCATTGAAA-3′ (SEQ ID NO: 4683) βc-2100 21 ntTarget: 5′-GCTTTATTCTCCCATTGAAAA-3′ (SEQ ID NO: 4684) βc-2141 21 ntTarget: 5′-GGGTCCTCTGTGAACTTGCTC-3′ (SEQ ID NO: 4685) βc-2142 21 ntTarget: 5′-GGTCCTCTGTGAACTTGCTCA-3′ (SEQ ID NO: 4686) βc-2143 21 ntTarget: 5′-GTCCTCTGTGAACTTGCTCAG-3′ (SEQ ID NO: 4687) βc-2144 21 ntTarget: 5′-TCCTCTGTGAACTTGCTCAGG-3′ (SEQ ID NO: 4688) βc-2145 21 ntTarget: 5′-CCTCTGTGAACTTGCTCAGGA-3′ (SEQ ID NO: 4689) βc-2146 21 ntTarget: 5′-CTCTGTGAACTTGCTCAGGAC-3′ (SEQ ID NO: 4690) βc-2147 21 ntTarget: 5′-TCTGTGAACTTGCTCAGGACA-3′ (SEQ ID NO: 4691) βc-2148 21 ntTarget: 5′-CTGTGAACTTGCTCAGGACAA-3′ (SEQ ID NO: 4692) βc-2149 21 ntTarget: 5′-TGTGAACTTGCTCAGGACAAG-3′ (SEQ ID NO: 4693) βc-2150 21 ntTarget: 5′-GTGAACTTGCTCAGGACAAGG-3′ (SEQ ID NO: 4694) βc-2151 21 ntTarget: 5′-TGAACTTGCTCAGGACAAGGA-3′ (SEQ ID NO: 4695) βc-2183 21 ntTarget: 5′-CTATTGAAGCTGAGGGAGCCA-3′ (SEQ ID NO: 4696) βc-2184 21 ntTarget: 5′-TATTGAAGCTGAGGGAGCCAC-3′ (SEQ ID NO: 4697) βc-2185 21 ntTarget: 5′-ATTGAAGCTGAGGGAGCCACA-3′ (SEQ ID NO: 4698) βc-2270 21 ntTarget: 5′-TGTTCCGAATGTCTGAGGACA-3′ (SEQ ID NO: 4699) βc-2271 21 ntTarget: 5′-GTTCCGAATGTCTGAGGACAA-3′ (SEQ ID NO: 4700) βc-2272 21 ntTarget: 5′-TTCCGAATGTCTGAGGACAAG-3′ (SEQ ID NO: 4701) βc-2273 21 ntTarget: 5′-TCCGAATGTCTGAGGACAAGC-3′ (SEQ ID NO: 4702) βc-2274 21 ntTarget: 5′-CCGAATGTCTGAGGACAAGCC-3′ (SEQ ID NO: 4703) βc-2275 21 ntTarget: 5′-CGAATGTCTGAGGACAAGCCA-3′ (SEQ ID NO: 4704) βc-2276 21 ntTarget: 5′-GAATGTCTGAGGACAAGCCAC-3′ (SEQ ID NO: 4705) βc-2277 21 ntTarget: 5′-AATGTCTGAGGACAAGCCACA-3′ (SEQ ID NO: 4706) βc-2345 21 ntTarget: 5′-GAACAGAGCCAATGGCTTGGA-3′ (SEQ ID NO: 4707) βc-2346 21 ntTarget: 5′-AACAGAGCCAATGGCTTGGAA-3′ (SEQ ID NO: 4708) βc-2347 21 ntTarget: 5′-ACAGAGCCAATGGCTTGGAAT-3′ (SEQ ID NO: 4709) βc-2348 21 ntTarget: 5′-CAGAGCCAATGGCTTGGAATG-3′ (SEQ ID NO: 4710) βc-2349 21 ntTarget: 5′-AGAGCCAATGGCTTGGAATGA-3′ (SEQ ID NO: 4711) βc-2350 21 ntTarget: 5′-GAGCCAATGGCTTGGAATGAG-3′ (SEQ ID NO: 4712) βc-2351 21 ntTarget: 5′-AGCCAATGGCTTGGAATGAGA-3′ (SEQ ID NO: 4713) βc-2352 21 ntTarget: 5′-GCCAATGGCTTGGAATGAGAC-3′ (SEQ ID NO: 4714) βc-2353 21 ntTarget: 5′-CCAATGGCTTGGAATGAGACT-3′ (SEQ ID NO: 4715) βc-2354 21 ntTarget: 5′-CAATGGCTTGGAATGAGACTG-3′ (SEQ ID NO: 4716) βc-2355 21 ntTarget: 5′-AATGGCTTGGAATGAGACTGC-3′ (SEQ ID NO: 4717) βc-2411 21 ntTarget: 5′-CCCTTGGATATCGCCAGGATG-3′ (SEQ ID NO: 4718) βc-2412 21 ntTarget: 5′-CCTTGGATATCGCCAGGATGA-3′ (SEQ ID NO: 4719) βc-2413 21 ntTarget: 5′-CTTGGATATCGCCAGGATGAT-3′ (SEQ ID NO: 4720) βc-2414 21 ntTarget: 5′-TTGGATATCGCCAGGATGATC-3′ (SEQ ID NO: 4721) βc-2415 21 ntTarget: 5′-TGGATATCGCCAGGATGATCC-3′ (SEQ ID NO: 4722) βc-2441 21 ntTarget: 5′-ATCGTTCTTTTCACTCTGGTG-3′ (SEQ ID NO: 4723) βc-2442 21 ntTarget: 5′-TCGTTCTTTTCACTCTGGTGG-3′ (SEQ ID NO: 4724) βc-2443 21 ntTarget: 5′-CGTTCTTTTCACTCTGGTGGA-3′ (SEQ ID NO: 4725) βc-2444 21 ntTarget: 5′-GTTCTTTTCACTCTGGTGGAT-3′ (SEQ ID NO: 4726) βc-2445 21 ntTarget: 5′-TTCTTTTCACTCTGGTGGATA-3′ (SEQ ID NO: 4727) βc-2501 21 ntTarget: 5′-AACATGAGATGGGTGGCCACC-3′ (SEQ ID NO: 4728) βc-2502 21 ntTarget: 5′-ACATGAGATGGGTGGCCACCA-3′ (SEQ ID NO: 4729) βc-2503 21 ntTarget: 5′-CATGAGATGGGTGGCCACCAC-3′ (SEQ ID NO: 4730) βc-2504 21 ntTarget: 5′-ATGAGATGGGTGGCCACCACC-3′ (SEQ ID NO: 4731) βc-2505 21 ntTarget: 5′-TGAGATGGGTGGCCACCACCC-3′ (SEQ ID NO: 4732) βc-2506 21 ntTarget: 5′-GAGATGGGTGGCCACCACCCT-3′ (SEQ ID NO: 4733) βc-2507 21 ntTarget: 5′-AGATGGGTGGCCACCACCCTG-3′ (SEQ ID NO: 4734) βc-2508 21 ntTarget: 5′-GATGGGTGGCCACCACCCTGG-3′ (SEQ ID NO: 4735) βc-2509 21 ntTarget: 5′-ATGGGTGGCCACCACCCTGGT-3′ (SEQ ID NO: 4736) βc-2510 21 ntTarget: 5′-TGGGTGGCCACCACCCTGGTG-3′ (SEQ ID NO: 4737) βc-2511 21 ntTarget: 5′-GGGTGGCCACCACCCTGGTGC-3′ (SEQ ID NO: 4738) βc-2512 21 ntTarget: 5′-GGTGGCCACCACCCTGGTGCT-3′ (SEQ ID NO: 4739) βc-2513 21 ntTarget: 5′-GTGGCCACCACCCTGGTGCTG-3′ (SEQ ID NO: 4740) βc-2514 21 ntTarget: 5′-TGGCCACCACCCTGGTGCTGA-3′ (SEQ ID NO: 4741) βc-2515 21 ntTarget: 5′-GGCCACCACCCTGGTGCTGAC-3′ (SEQ ID NO: 4742) βc-2516 21 ntTarget: 5′-GCCACCACCCTGGTGCTGACT-3′ (SEQ ID NO: 4743) βc-2517 21 ntTarget: 5′-CCACCACCCTGGTGCTGACTA-3′ (SEQ ID NO: 4744) βc-2518 21 ntTarget: 5′-CACCACCCTGGTGCTGACTAT-3′ (SEQ ID NO: 4745) βc-2519 21 ntTarget: 5′-ACCACCCTGGTGCTGACTATC-3′ (SEQ ID NO: 4746) βc-2520 21 ntTarget: 5′-CCACCCTGGTGCTGACTATCC-3′ (SEQ ID NO: 4747) βc-2521 21 ntTarget: 5′-CACCCTGGTGCTGACTATCCA-3′ (SEQ ID NO: 4748) βc-2522 21 ntTarget: 5′-ACCCTGGTGCTGACTATCCAG-3′ (SEQ ID NO: 4749) βc-2523 21 ntTarget: 5′-CCCTGGTGCTGACTATCCAGT-3′ (SEQ ID NO: 4750) βc-2524 21 ntTarget: 5′-CCTGGTGCTGACTATCCAGTT-3′ (SEQ ID NO: 4751) βc-2525 21 ntTarget: 5′-CTGGTGCTGACTATCCAGTTG-3′ (SEQ ID NO: 4752) βc-2526 21 ntTarget: 5′-TGGTGCTGACTATCCAGTTGA-3′ (SEQ ID NO: 4753) βc-2527 21 ntTarget: 5′-GGTGCTGACTATCCAGTTGAT-3′ (SEQ ID NO: 4754) βc-2528 21 ntTarget: 5′-GTGCTGACTATCCAGTTGATG-3′ (SEQ ID NO: 4755) βc-2529 21 ntTarget: 5′-TGCTGACTATCCAGTTGATGG-3′ (SEQ ID NO: 4756) βc-2530 21 ntTarget: 5′-GCTGACTATCCAGTTGATGGG-3′ (SEQ ID NO: 4757) βc-2531 21 ntTarget: 5′-CTGACTATCCAGTTGATGGGC-3′ (SEQ ID NO: 4758) βc-2532 21 ntTarget: 5′-TGACTATCCAGTTGATGGGCT-3′ (SEQ ID NO: 4759) βc-2533 21 ntTarget: 5′-GACTATCCAGTTGATGGGCTG-3′ (SEQ ID NO: 4760) βc-2534 21 ntTarget: 5′-ACTATCCAGTTGATGGGCTGC-3′ (SEQ ID NO: 4761) βc-2535 21 ntTarget: 5′-CTATCCAGTTGATGGGCTGCC-3′ (SEQ ID NO: 4762) βc-2567 21 ntTarget: 5′-ATGCCCAGGACCTCATGGATG-3′ (SEQ ID NO: 4763) βc-2568 21 ntTarget: 5′-TGCCCAGGACCTCATGGATGG-3′ (SEQ ID NO: 4764) βc-2569 21 ntTarget: 5′-GCCCAGGACCTCATGGATGGG-3′ (SEQ ID NO: 4765) βc-2603 21 ntTarget: 5′-ACAGCAATCAGCTGGCCTGGT-3′ (SEQ ID NO: 4766) βc-2604 21 ntTarget: 5′-CAGCAATCAGCTGGCCTGGTT-3′ (SEQ ID NO: 4767) βc-2605 21 ntTarget: 5′-AGCAATCAGCTGGCCTGGTTT-3′ (SEQ ID NO: 4768) βc-2606 21 ntTarget: 5′-GCAATCAGCTGGCCTGGTTTG-3′ (SEQ ID NO: 4769) βc-2607 21 ntTarget: 5′-CAATCAGCTGGCCTGGTTTGA-3′ (SEQ ID NO: 4770) βc-2608 21 ntTarget: 5′-AATCAGCTGGCCTGGTTTGAT-3′ (SEQ ID NO: 4771) βc-2609 21 ntTarget: 5′-ATCAGCTGGCCTGGTTTGATA-3′ (SEQ ID NO: 4772) βc-2610 21 ntTarget: 5′-TCAGCTGGCCTGGTTTGATAC-3′ (SEQ ID NO: 4773) βc-2611 21 ntTarget: 5′-CAGCTGGCCTGGTTTGATACT-3′ (SEQ ID NO: 4774) βc-2612 21 ntTarget: 5′-AGCTGGCCTGGTTTGATACTG-3′ (SEQ ID NO: 4775) βc-2613 21 ntTarget: 5′-GCTGGCCTGGTTTGATACTGA-3′ (SEQ ID NO: 4776) βc-2614 21 ntTarget: 5′-CTGGCCTGGTTTGATACTGAC-3′ (SEQ ID NO: 4777) βc-2615 21 ntTarget: 5′-TGGCCTGGTTTGATACTGACC-3′ (SEQ ID NO: 4778) βc-2616 21 ntTarget: 5′-GGCCTGGTTTGATACTGACCT-3′ (SEQ ID NO: 4779) βc-2617 21 ntTarget: 5′-GCCTGGTTTGATACTGACCTG-3′ (SEQ ID NO: 4780) βc-2618 21 ntTarget: 5′-CCTGGTTTGATACTGACCTGT-3′ (SEQ ID NO: 4781) βc-2619 21 ntTarget: 5′-CTGGTTTGATACTGACCTGTA-3′ (SEQ ID NO: 4782) βc-2620 21 ntTarget: 5′-TGGTTTGATACTGACCTGTAA-3′ (SEQ ID NO: 4783) βc-2621 21 ntTarget: 5′-GGTTTGATACTGACCTGTAAA-3′ (SEQ ID NO: 4784) βc-2622 21 ntTarget: 5′-GTTTGATACTGACCTGTAAAT-3′ (SEQ ID NO: 4785) βc-2623 21 ntTarget: 5′-TTTGATACTGACCTGTAAATC-3′ (SEQ ID NO: 4786) βc-2869 21 ntTarget: 5′-TTTTTTGCCACAGCTTTTGCA-3′ (SEQ ID NO: 4787) βc-2902 21 ntTarget: 5′-AATGAGTAACATTTGCTGTTT-3′ (SEQ ID NO: 4788) βc-2923 21 ntTarget: 5′-TAAACATTAATAGCAGCCTTT-3′ (SEQ ID NO: 4789) βc-2925 21 ntTarget: 5′-AACATTAATAGCAGCCTTTCT-3′ (SEQ ID NO: 4790) βc-2927 21 ntTarget: 5′-CATTAATAGCAGCCTTTCTCT-3′ (SEQ ID NO: 4791) βc-2929 21 ntTarget: 5′-TTAATAGCAGCCTTTCTCTCT-3′ (SEQ ID NO: 4792) βc-2973 21 ntTarget: 5′-TTGCATTGTGATTGGCCTGTA-3′ (SEQ ID NO: 4793) βc-2975 21 ntTarget: 5′-GCATTGTGATTGGCCTGTAGA-3′ (SEQ ID NO: 4794) βc-2977 21 ntTarget: 5′-ATTGTGATTGGCCTGTAGAGT-3′ (SEQ ID NO: 4795) βc-2979 21 ntTarget: 5′-TGTGATTGGCCTGTAGAGTTG-3′ (SEQ ID NO: 4796) βc-2981 21 ntTarget: 5′-TGATTGGCCTGTAGAGTTGCT-3′ (SEQ ID NO: 4797) βc-2983 21 ntTarget: 5′-ATTGGCCTGTAGAGTTGCTGA-3′ (SEQ ID NO: 4798) βc-2985 21 ntTarget: 5′-TGGCCTGTAGAGTTGCTGAGA-3′ (SEQ ID NO: 4799) βc-2987 21 ntTarget: 5′-GCCTGTAGAGTTGCTGAGAGG-3′ (SEQ ID NO: 4800) βc-2989 21 ntTarget: 5′-CTGTAGAGTTGCTGAGAGGGC-3′ (SEQ ID NO: 4801) βc-3015 21 ntTarget: 5′-GGGTGGGCTGGTATCTCAGAA-3′ (SEQ ID NO: 4802) βc-3017 21 ntTarget: 5′-GTGGGCTGGTATCTCAGAAAG-3′ (SEQ ID NO: 4803) βc-3019 21 ntTarget: 5′-GGGCTGGTATCTCAGAAAGTG-3′ (SEQ ID NO: 4804) βc-3021 21 ntTarget: 5′-GCTGGTATCTCAGAAAGTGCC-3′ (SEQ ID NO: 4805) βc-3046 21 ntTarget: 5′-ACACTAACCAAGCTGAGTTTC-3′ (SEQ ID NO: 4806) βc-3048 21 ntTarget: 5′-ACTAACCAAGCTGAGTTTCCT-3′ (SEQ ID NO: 4807) βc-3050 21 ntTarget: 5′-TAACCAAGCTGAGTTTCCTAT-3′ (SEQ ID NO: 4808) βc-3052 21 ntTarget: 5′-ACCAAGCTGAGTTTCCTATGG-3′ (SEQ ID NO: 4809) βc-3054 21 ntTarget: 5′-CAAGCTGAGTTTCCTATGGGA-3′ (SEQ ID NO: 4810) βc-3056 21 ntTarget: 5′-AGCTGAGTTTCCTATGGGAAC-3′ (SEQ ID NO: 4811) βc-3087 21 ntTarget: 5′-AACTTTTTGTTCTGGTCCTTT-3′ (SEQ ID NO: 4812) βc-3089 21 ntTarget: 5′-CTTTTTGTTCTGGTCCTTTTT-3′ (SEQ ID NO: 4813) βc-3091 21 ntTarget: 5′-TTTTGTTCTGGTCCTTTTTGG-3′ (SEQ ID NO: 4814) βc-3093 21 ntTarget: 5′-TTGTTCTGGTCCTTTTTGGTC-3′ (SEQ ID NO: 4815) βc-3095 21 ntTarget: 5′-GTTCTGGTCCTTTTTGGTCGA-3′ (SEQ ID NO: 4816) βc-3097 21 ntTarget: 5′-TCTGGTCCTTTTTGGTCGAGG-3′ (SEQ ID NO: 4817) βc-3099 21 ntTarget: 5′-TGGTCCTTTTTGGTCGAGGAG-3′ (SEQ ID NO: 4818) βc-3101 21 ntTarget: 5′-GTCCTTTTTGGTCGAGGAGTA-3′ (SEQ ID NO: 4819) βc-3103 21 ntTarget: 5′-CCTTTTTGGTCGAGGAGTAAC-3′ (SEQ ID NO: 4820) βc-3105 21 ntTarget: 5′-TTTTTGGTCGAGGAGTAACAA-3′ (SEQ ID NO: 4821) βc-3107 21 ntTarget: 5′-TTTGGTCGAGGAGTAACAATA-3′ (SEQ ID NO: 4822) βc-3109 21 ntTarget: 5′-TGGTCGAGGAGTAACAATACA-3′ (SEQ ID NO: 4823) βc-3111 21 ntTarget: 5′-GTCGAGGAGTAACAATACAAA-3′ (SEQ ID NO: 4824) βc-3113 21 ntTarget: 5′-CGAGGAGTAACAATACAAATG-3′ (SEQ ID NO: 4825) βc-3115 21 ntTarget: 5′-AGGAGTAACAATACAAATGGA-3′ (SEQ ID NO: 4826) βc-3191 21 ntTarget: 5′-TTTATCAAACCCTAGCCTTGC-3′ (SEQ ID NO: 4827) βc-3193 21 ntTarget: 5′-TATCAAACCCTAGCCTTGCTT-3′ (SEQ ID NO: 4828) βc-3195 21 ntTarget: 5′-TCAAACCCTAGCCTTGCTTGT-3′ (SEQ ID NO: 4829) βc-3387 21 ntTarget: 5′-TTGAGTAATGGTGTAGAACAC-3′ (SEQ ID NO: 4830) βc-3389 21 ntTarget: 5′-GAGTAATGGTGTAGAACACTA-3′ (SEQ ID NO: 4831) βc-3391 21 ntTarget: 5′-GTAATGGTGTAGAACACTAAT-3′ (SEQ ID NO: 4832) βc-3393 21 ntTarget: 5′-AATGGTGTAGAACACTAATTC-3′ (SEQ ID NO: 4833) βc-3395 21 ntTarget: 5′-TGGTGTAGAACACTAATTCAT-3′ (SEQ ID NO: 4834) βc-3397 21 ntTarget: 5′-GTGTAGAACACTAATTCATAA-3′ (SEQ ID NO: 4835) βc-3399 21 ntTarget: 5′-GTAGAACACTAATTCATAATC-3′ (SEQ ID NO: 4836) βc-3401 21 ntTarget: 5′-AGAACACTAATTCATAATCAC-3′ (SEQ ID NO: 4837) βc-3500 21 ntTarget: 5′-AATTAGTTTCCTTTTTAATAT-3′ (SEQ ID NO: 4838) βc-3502 21 ntTarget: 5′-TTAGTTTCCTTTTTAATATGC-3′ (SEQ ID NO: 4839) βc-3504 21 ntTarget: 5′-AGTTTCCTTTTTAATATGCTT-3′ (SEQ ID NO: 4840) βc-3506 21 ntTarget: 5′-TTTCCTTTTTAATATGCTTAA-3′ (SEQ ID NO: 4841) βc-3508 21 ntTarget: 5′-TCCTTTTTAATATGCTTAAAA-3′ (SEQ ID NO: 4842) βc-3509 21 ntTarget: 5′-CCTTTTTAATATGCTTAAAAT-3′ (SEQ ID NO: 4843) βc-3510 21 ntTarget: 5′-CTTTTTAATATGCTTAAAATA-3′ (SEQ ID NO: 4844) βc-3512 21 ntTarget: 5′-TTTTAATATGCTTAAAATAAG-3′ (SEQ ID NO: 4845) βc-3514 21 ntTarget: 5′-TTAATATGCTTAAAATAAGCA-3′ (SEQ ID NO: 4846) βc-3516 21 ntTarget: 5′-AATATGCTTAAAATAAGCAGG-3′ (SEQ ID NO: 4847) βc-3518 21 ntTarget: 5′-TATGCTTAAAATAAGCAGGTG-3′ (SEQ ID NO: 4848) βc-3520 21 ntTarget: 5′-TGCTTAAAATAAGCAGGTGGA-3′ (SEQ ID NO: 4849) βc-3522 21 ntTarget: 5′-CTTAAAATAAGCAGGTGGATC-3′ (SEQ ID NO: 4850) βc-3524 21 ntTarget: 5′-TAAAATAAGCAGGTGGATCTA-3′ (SEQ ID NO: 4851) βc-3526 21 ntTarget: 5′-AAATAAGCAGGTGGATCTATT-3′ (SEQ ID NO: 4852) βc-3528 21 ntTarget: 5′-ATAAGCAGGTGGATCTATTTC-3′ (SEQ ID NO: 4853) βc-3530 21 ntTarget: 5′-AAGCAGGTGGATCTATTTCAT-3′ (SEQ ID NO: 4854) βc-3532 21 ntTarget: 5′-GCAGGTGGATCTATTTCATGT-3′ (SEQ ID NO: 4855) βc-3534 21 ntTarget: 5′-AGGTGGATCTATTTCATGTTT-3′ (SEQ ID NO: 4856) βc-3536 21 ntTarget: 5′-GTGGATCTATTTCATGTTTTT-3′ (SEQ ID NO: 4857) βc-3538 21 ntTarget: 5′-GGATCTATTTCATGTTTTTGA-3′ (SEQ ID NO: 4858) βc-3583 21 ntTarget: 5′-GGGTAGGGTAAATCAGTAAGA-3′ (SEQ ID NO: 4859) βc-3585 21 ntTarget: 5′-GTAGGGTAAATCAGTAAGAGG-3′ (SEQ ID NO: 4860) βc-3587 21 ntTarget: 5′-AGGGTAAATCAGTAAGAGGTG-3′ (SEQ ID NO: 4861) βc-3589 21 ntTarget: 5′-GGTAAATCAGTAAGAGGTGTT-3′ (SEQ ID NO: 4862) βc-3591 21 ntTarget: 5′-TAAATCAGTAAGAGGTGTTAT-3′ (SEQ ID NO: 4863) βc-3593 21 ntTarget: 5′-AATCAGTAAGAGGTGTTATTT-3′ (SEQ ID NO: 4864) βc-3633 21 ntTarget: 5′-TTTACCAGTTGCCTTTTATCC-3′ (SEQ ID NO: 4865) βc-3635 21 ntTarget: 5′-TACCAGTTGCCTTTTATCCCA-3′ (SEQ ID NO: 4866) βc-3637 21 ntTarget: 5′-CCAGTTGCCTTTTATCCCAAA-3′ (SEQ ID NO: 4867) βc-3639 21 ntTarget: 5′-AGTTGCCTTTTATCCCAAAGT-3′ (SEQ ID NO: 4868) βc-3641 21 ntTarget: 5′-TTGCCTTTTATCCCAAAGTTG-3′ (SEQ ID NO: 4869) βc-3643 21 ntTarget: 5′-GCCTTTTATCCCAAAGTTGTT-3′ (SEQ ID NO: 4870) βc-3645 21 ntTarget: 5′-CTTTTATCCCAAAGTTGTTGT-3′ (SEQ ID NO: 4871) βc-3647 21 ntTarget: 5′-TTTATCCCAAAGTTGTTGTAA-3′ (SEQ ID NO: 4872) βc-3649 21 ntTarget: 5′-TATCCCAAAGTTGTTGTAACC-3′ (SEQ ID NO: 4873) βc-3651 21 ntTarget: 5′-TCCCAAAGTTGTTGTAACCTG-3′ (SEQ ID NO: 4874) βc-3653 21 ntTarget: 5′-CCAAAGTTGTTGTAACCTGCT-3′ (SEQ ID NO: 4875) βc-3655 21 ntTarget: 5′-AAAGTTGTTGTAACCTGCTGT-3′ (SEQ ID NO: 4876) βc-3657 21 ntTarget: 5′-AGTTGTTGTAACCTGCTGTGA-3′ (SEQ ID NO: 4877) βc-3659 21 ntTarget: 5′-TTGTTGTAACCTGCTGTGATA-3′ (SEQ ID NO: 4878) βc-3708 21 ntTarget: 5′-AAAAATGGTTCAGAATTAAAC-3′ (SEQ ID NO: 4879) βc-3710 21 ntTarget: 5′-AAATGGTTCAGAATTAAACTT-3′ (SEQ ID NO: 4880) βc-3712 21 ntTarget: 5′-ATGGTTCAGAATTAAACTTTT-3′ (SEQ ID NO: 4881) βc-3714 21 ntTarget: 5′-GGTTCAGAATTAAACTTTTAA-3′ (SEQ ID NO: 4882) βc-3716 21 ntTarget: 5′-TTCAGAATTAAACTTTTAATT-3′ (SEQ ID NO: 4883) βc-m314 21 ntTarget: 5′-CAGCAGCAGTCTTACTTGGAT-3′ (SEQ ID NO: 4884) βc-m325 21 ntTarget: 5′-TTACTTGGATTCTGGAATCCA-3′ (SEQ ID NO: 4885) βc-m408 21 ntTarget: 5′-TTGACACCTCCCAAGTCCTTT-3′ (SEQ ID NO: 4886) βc-m460 21 ntTarget: 5′-CACGCAAGAGCAAGTAGCTGA-3′ (SEQ ID NO: 4887) βc-m526 21 ntTarget: 5′-TGCCATGTTCCCTGAGACGCT-3′ (SEQ ID NO: 4888) βc-m631 21 ntTarget: 5′-GTTGAAACATGCAGTTGTCAA-3′ (SEQ ID NO: 4889) βc-m636 21 ntTarget: 5′-AACATGCAGTTGTCAATTTGA-3′ (SEQ ID NO: 4890) βc-m642 21 ntTarget: 5′-CAGTTGTCAATTTGATTAACT-3′ (SEQ ID NO: 4891) βc-m723 21 ntTarget: 5′-ATGAGGACCAGGTGGTAGTTA-3′ (SEQ ID NO: 4892) βc-m970 21 ntTarget: 5′-TGGGTCACCAGTGGATTCTGT-3′ (SEQ ID NO: 4893) βc-m976 21 ntTarget: 5′-ACCAGTGGATTCTGTACTGTT-3′ (SEQ ID NO: 4894) βc-m981 21 ntTarget: 5′-TGGATTCTGTACTGTTCTACG-3′ (SEQ ID NO: 4895) βc-m1066 21 ntTarget: 5′-TGGTGGACTGCAGAAAATGGT-3′ (SEQ ID NO: 4896) βc-m1106 21 ntTarget: 5′-AACGTGAAATTCTTGGCTATT-3′ (SEQ ID NO: 4897) βc-m1354 21 ntTarget: 5′-CCCAAGTCAGCGACTTGTTCA-3′ (SEQ ID NO: 4898) βc-m1363 21 ntTarget: 5′-GCGACTTGTTCAAAACTGTCT-3′ (SEQ ID NO: 4899) βc-m1373 21 ntTarget: 5′-CAAAACTGTCTTTGGACTCTC-3′ (SEQ ID NO: 4900) βc-m1508 21 ntTarget: 5′-CTCTCTAACCTCACTTGCAAT-3′ (SEQ ID NO: 4901) βc-m1515 21 ntTarget: 5′-ACCTCACTTGCAATAATTACA-3′ (SEQ ID NO: 4902) βc-m1682 21 ntTarget: 5′-CAGAATGCCGTTCGCCTTCAT-3′ (SEQ ID NO: 4903) βc-m1693 21 ntTarget: 5′-TCGCCTTCATTATGGACTGCC-3′ (SEQ ID NO: 4904) βc-m1698 21 ntTarget: 5′-TTCATTATGGACTGCCTGTTG-3′ (SEQ ID NO: 4905) βc-m1705 21 ntTarget: 5′-TGGACTGCCTGTTGTGGTTAA-3′ (SEQ ID NO: 4906) βc-m1763 21 ntTarget: 5′-GCAACTGTTGGATTGATTCGA-3′ (SEQ ID NO: 4907) βc-m2008 21 ntTarget: 5′-CCGAGGACTCAATACCATTCC-3′ (SEQ ID NO: 4908) βc-m2226 21 ntTarget: 5′-CTGAGGACAAGCCACAGGATT-3′ (SEQ ID NO: 4909) βc-m2427 21 ntTarget: 5′-GGATGGACCCTATGATGGAGC-3′ (SEQ ID NO: 4910) βc-m2568 21 ntTarget: 5′-TTGATACTGACCTGTAAATCG-3′ (SEQ ID NO: 4911) βc-m2614 21 ntTarget: 5′-AGCCAGTGTGGGTGAATACTT-3′ (SEQ ID NO: 4912) βc-m2770 21 ntTarget: 5′-TGCCACAGCTTTTGCAGCGTT-3′ (SEQ ID NO: 4913) βc-m2777 21 ntTarget: 5′-GCTTTTGCAGCGTTATACTCA-3′ (SEQ ID NO: 4914) βc-m2784 21 ntTarget: 5′-CAGCGTTATACTCAGATGAGT-3′ (SEQ ID NO: 4915) βc-m2806 21 ntTarget: 5′-ACATTTGCTGTTTTCAACATT-3′ (SEQ ID NO: 4916) βc-m2850 21 ntTarget: 5′-AGCTGTAGTGTCTGAACGTGC-3′ (SEQ ID NO: 4917) βc-m2965 21 ntTarget: 5′-GGGAACAGTCGAAGTACGCTT-3′ (SEQ ID NO: 4918) βc-m2970 21 ntTarget: 5′-CAGTCGAAGTACGCTTTTTGT-3′ (SEQ ID NO: 4919) βc-m2976 21 ntTarget: 5′-AAGTACGCTTTTTGTTCTGGT-3′ (SEQ ID NO: 4920) βc-m3092 21 ntTarget: 5′-ACCCTAGCCTTGCTTGTTCTT-3′ (SEQ ID NO: 4921) βc-m3097 21 ntTarget: 5′-AGCCTTGCTTGTTCTTTGTTT-3′ (SEQ ID NO: 4922) βc-m3198 21 ntTarget: 5′-TGAACCTGCTACAGCAATTTC-3′ (SEQ ID NO: 4923) βc-m3207 21 ntTarget: 5′-TACAGCAATTTCTGATTTCTA-3′ (SEQ ID NO: 4924) βc-m3433 21 ntTarget: 5′-CAGTAAGAGGTGTTATTTGAG-3′ (SEQ ID NO: 4925) βc-m3439 21 ntTarget: 5′-GAGGTGTTATTTGAGCCTTGT-3′ (SEQ ID NO: 4926) βc-m3444 21 ntTarget: 5′-GTTATTTGAGCCTTGTTTTGG-3′ (SEQ ID NO: 4927) βc-m3449 21 ntTarget: 5′-TTGAGCCTTGTTTTGGACAGT-3′ (SEQ ID NO: 4928) βc-m3522 21 ntTarget: 5′-TTCAACAGATGCGGTTATAGA-3′ (SEQ ID NO: 4929) βc-m3533 21 ntTarget: 5′-CGGTTATAGAAATGGTTCAGA-3′ (SEQ ID NO: 4930) βc-m3538 21 ntTarget: 5′-ATAGAAATGGTTCAGAATTAA-3′ (SEQ ID NO: 4931)

TABLE 6 Selected Anti-β-catenin DsiRNA Agents, Unmodified Duplexes5′-CUGAGGGUAUUUGAAGUAUACCAUA-3′ (SEQ ID NO: 3335)3′-GGGACUCCCAUAAACUUCAUAUGGUAU-5′ (SEQ ID NO: 1117) βc-240 Target:5′-CCCTGAGGGTATTTGAAGTATACCATA-3′ (SEQ ID NO: 2226)5′-GGGUAUUUGAAGUAUACCAUACAAC-3′ (SEQ ID NO: 3336)3′-CUCCCAUAAACUUCAUAUGGUAUGUUG-5′ (SEQ ID NO: 1118) βc-244 Target:5′-GAGGGTATTTGAAGTATACCATACAAC-3′ (SEQ ID NO: 2227)5′-AAGUAUACCAUACAACUGUUUUGAA-3′ (SEQ ID NO: 3337)3′-ACUUCAUAUGGUAUGUUGACAAAACUU-5′ (SEQ ID NO: 1119) βc-253 Target:5′-TGAAGTATACCATACAACTGTTTTGAA-3′ (SEQ ID NO: 2228)5′-ACCAUACAACUGUUUUGAAAAUCCA-3′ (SEQ ID NO: 3338)3′-UAUGGUAUGUUGACAAAACUUUUAGGU-5′ (SEQ ID NO: 1120) βc-259 Target:5′-ATACCATACAACTGTTTTGAAAATCCA-3′ (SEQ ID NO: 2229)5′-ACAACUGUUUUGAAAAUCCAGCGUG-3′ (SEQ ID NO: 3339)3′-UAUGUUGACAAAACUUUUAGGUCGCAC-5′ (SEQ ID NO: 1121) βc-264 Target:5′-ATACAACTGTTTTGAAAATCCAGCGTG-3′ (SEQ ID NO: 2230)5′-GGGAUUUUCUCAGUCCUUCACUCAA-3′ (SEQ ID NO: 3340)3′-GUCCCUAAAAGAGUCAGGAAGUGAGUU-5′ (SEQ ID NO: 1122) βc-496 Target:5′-CAGGGATTTTCTCAGTCCTTCACTCAA-3′ (SEQ ID NO: 2231)5′-CUCAAGAACAAGUAGCUGAUAUUGA-3′ (SEQ ID NO: 3341)3′-GUGAGUUCUUGUUCAUCGACUAUAACU-5′ (SEQ ID NO: 1123) βc-516 Target:5′-CACTCAAGAACAAGTAGCTGATATTGA-3′ (SEQ ID NO: 2232)5′-AACAAGUAGCUGAUAUUGAUGGACA-3′ (SEQ ID NO: 3342)3′-UCUUGUUCAUCGACUAUAACUACCUGU-5′ (SEQ ID NO: 1124) βc-522 Target:5′-AGAACAAGTAGCTGATATTGATGGACA-3′ (SEQ ID NO: 2233)5′-CAAGUAGCUGAUAUUGAUGGACAGU-3′ (SEQ ID NO: 3343)3′-UUGUUCAUCGACUAUAACUACCUGUCA-5′ (SEQ ID NO: 1125) βc-524 Target:5′-AACAAGTAGCTGATATTGATGGACAGT-3′ (SEQ ID NO: 2234)5′-AUGGACAGUAUGCAAUGACUCGAGC-3′ (SEQ ID NO: 3344)3′-ACUACCUGUCAUACGUUACUGAGCUCG-5′ (SEQ ID NO: 1126) βc-540 Target:5′-TGATGGACAGTATGCAATGACTCGAGC-3′ (SEQ ID NO: 2235)5′-CUAUGUUCCCUGAGACAUUAGAUGA-3′ (SEQ ID NO: 3345)3′-ACGAUACAAGGGACUCUGUAAUCUACU-5′ (SEQ ID NO: 1127) βc-582 Target:5′-TGCTATGTTCCCTGAGACATTAGATGA-3′ (SEQ ID NO: 2236)5′-CUGAAACAUGCAGUUGUAAACUUGA-3′ (SEQ ID NO: 3346)3′-ACGACUUUGUACGUCAACAUUUGAACU-5′ (SEQ ID NO: 1128) βc-686 Target:5′-TGCTGAAACATGCAGTTGTAAACTTGA-3′ (SEQ ID NO: 2237)5′-CAUGCAGUUGUAAACUUGAUUAACU-3′ (SEQ ID NO: 3347)3′-UUGUACGUCAACAUUUGAACUAAUUGA-5′ (SEQ ID NO: 1129) βc-692 Target:5′-AACATGCAGTTGTAAACTTGATTAACT-3′ (SEQ ID NO: 2238)5′-AGUUGUAAACUUGAUUAACUAUCAA-3′ (SEQ ID NO: 3348)3′-CGUCAACAUUUGAACUAAUUGAUAGUU-5′ (SEQ ID NO: 1130) βc-697 Target:5′-GCAGTTGTAAACTTGATTAACTATCAA-3′ (SEQ ID NO: 2239)5′-UUGAUUAACUAUCAAGAUGAUGCAG-3′ (SEQ ID NO: 3349)3′-UGAACUAAUUGAUAGUUCUACUACGUC-5′ (SEQ ID NO: 1131) βc-707 Target:5′-ACTTGATTAACTATCAAGATGATGCAG-3′ (SEQ ID NO: 2240)5′-CUGAACUGACAAAACUGCUAAAUGA-3′ (SEQ ID NO: 3350)3′-GGGACUUGACUGUUUUGACGAUUUACU-5′ (SEQ ID NO: 1132) βc-753 Target:5′-CCCTGAACTGACAAAACTGCTAAATGA-3′ (SEQ ID NO: 2241)5′-AGAUGGUGUCUGCUAUUGUACGUAC-3′ (SEQ ID NO: 3351)3′-AGUCUACCACAGACGAUAACAUGCAUG-5′ (SEQ ID NO: 1133) βc-870 Target:5′-TCAGATGGTGTCTGCTATTGTACGTAC-3′ (SEQ ID NO: 2242)5′-ACGUACCAUGCAGAAUACAAAUGAU-3′ (SEQ ID NO: 3352)3′-CAUGCAUGGUACGUCUUAUGUUUACUA-5′ (SEQ ID NO: 1134) βc-889 Target:5′-GTACGTACCATGCAGAATACAAATGAT-3′ (SEQ ID NO: 2243)5′-UACAACUCUCCACAACCUUUUAUUA-3′ (SEQ ID NO: 3353)3′-UAAUGUUGAGAGGUGUUGGAAAAUAAU-5′ (SEQ ID NO: 1135) βc-1060 Target:5′-ATTACAACTCTCCACAACCTTTTATTA-3′ (SEQ ID NO: 2244)5′-CUCUCCACAACCUUUUAUUACAUCA-3′ (SEQ ID NO: 3354)3′-UUGAGAGGUGUUGGAAAAUAAUGUAGU-5′ (SEQ ID NO: 1136) βc-1065 Target:5′-AACTCTCCACAACCTTTTATTACATCA-3′ (SEQ ID NO: 2245)5′-CACAACCUUUUAUUACAUCAAGAAG-3′ (SEQ ID NO: 3355)3′-AGGUGUUGGAAAAUAAUGUAGUUCUUC-5′ (SEQ ID NO: 1137) βc-1070 Target:5′-TCCACAACCTTTTATTACATCAAGAAG-3′ (SEQ ID NO: 2246)5′-CUUUUAUUACAUCAAGAAGGAGCUA-3′ (SEQ ID NO: 3356)3′-UGGAAAAUAAUGUAGUUCUUCCUCGAU-5′ (SEQ ID NO: 1138) βc-1076 Target:5′-ACCTTTTATTACATCAAGAAGGAGCTA-3′ (SEQ ID NO: 2247)5′-AAAACAAAUGUUAAAUUCUUGGCUA-3′ (SEQ ID NO: 3357)3′-UGUUUUGUUUACAAUUUAAGAACCGAU-5′ (SEQ ID NO: 1139) βc-1154 Target:5′-ACAAAACAAATGTTAAATTCTTGGCTA-3′ (SEQ ID NO: 2248)5′-UACGACAGACUGCCUUCAAAUUUUA-3′ (SEQ ID NO: 3358)3′-UAAUGCUGUCUGACGGAAGUUUAAAAU-5′ (SEQ ID NO: 1140) βc-1180 Target:5′-ATTACGACAGACTGCCTTCAAATTTTA-3′ (SEQ ID NO: 2249)5′-CAGACUGCCUUCAAAUUUUAGCUUA-3′ (SEQ ID NO: 3359)3′-CUGUCUGACGGAAGUUUAAAAUCGAAU-5′ (SEQ ID NO: 1141) βc-1185 Target:5′-GACAGACTGCCTTCAAATTTTAGCTTA-3′ (SEQ ID NO: 2250)5′-CUUUAGUAAAUAUAAUGAGGACCUA-3′ (SEQ ID NO: 3360)3′-UCGAAAUCAUUUAUAUUACUCCUGGAU-5′ (SEQ ID NO: 1142) βc-1260 Target:5′-AGCTTTAGTAAATATAATGAGGACCTA-3′ (SEQ ID NO: 2251)5′-AAAACUACUGUGGACCACAAGCAGA-3′ (SEQ ID NO: 3361)3′-CUUUUUGAUGACACCUGGUGUUCGUCU-5′ (SEQ ID NO: 1143) βc-1294 Target:5′-GAAAAACTACTGTGGACCACAAGCAGA-3′ (SEQ ID NO: 2252)5′-AGUCAACGUCUUGUUCAGAACUGUC-3′ (SEQ ID NO: 3362)3′-GUUCAGUUGCAGAACAAGUCUUGACAG-5′ (SEQ ID NO: 1144) βc-1412 Target:5′-CAAGTCAACGTCTTGTTCAGAACTGTC-3′ (SEQ ID NO: 2253)5′-CGUCUUGUUCAGAACUGUCUUUGGA-3′ (SEQ ID NO: 3363)3′-UUGCAGAACAAGUCUUGACAGAAACCU-5′ (SEQ ID NO: 1145) βc-1418 Target:5′-AACGTCTTGTTCAGAACTGTCTTTGGA-3′ (SEQ ID NO: 2254)5′-UGUUCAGAACUGUCUUUGGACUCUC-3′ (SEQ ID NO: 3364)3′-GAACAAGUCUUGACAGAAACCUGAGAG-5′ (SEQ ID NO: 1146) βc-1423 Target:5′-CTTGTTCAGAACTGTCTTTGGACTCTC-3′ (SEQ ID NO: 2255)5′-GGUUCAGAUGAUAUAAAUGUGGUCA-3′ (SEQ ID NO: 3365)3′-ACCCAAGUCUACUAUAUUUACACCAGU-5′ (SEQ ID NO: 1147) βc-1520 Target:5′-TGGGTTCAGATGATATAAATGTGGTCA-3′ (SEQ ID NO: 2256)5′-UCUUUCUAACCUCACUUGCAAUAAU-3′ (SEQ ID NO: 3366)3′-UAAGAAAGAUUGGAGUGAACGUUAUUA-5′ (SEQ ID NO: 1148) βc-1561 Target:5′-ATTCTTTCTAACCTCACTTGCAATAAT-3′ (SEQ ID NO: 2257)5′-CUCACUUGCAAUAAUUAUAAGAACA-3′ (SEQ ID NO: 3367)3′-UGGAGUGAACGUUAUUAAUAUUCUUGU-5′ (SEQ ID NO: 1149) βc-1571 Target:5′-ACCTCACTTGCAATAATTATAAGAACA-3′ (SEQ ID NO: 2258)5′-CAAUAAUUAUAAGAACAAGAUGAUG-3′ (SEQ ID NO: 3368)3′-ACGUUAUUAAUAUUCUUGUUCUACUAC-5′ (SEQ ID NO: 1150) βc-1579 Target:5′-TGCAATAATTATAAGAACAAGATGATG-3′ (SEQ ID NO: 2259)5′-GUAUAGAGGCUCUUGUGCGUACUGU-3′ (SEQ ID NO: 3369)3′-ACCAUAUCUCCGAGAACACGCAUGACA-5′ (SEQ ID NO: 1151) βc-1620 Target:5′-TGGTATAGAGGCTCTTGTGCGTACTGT-3′ (SEQ ID NO: 2260)5′-GGCUACUGUUGGAUUGAUUCGAAAU-3′ (SEQ ID NO: 3370)3′-UUCCGAUGACAACCUAACUAAGCUUUA-5′ (SEQ ID NO: 1152) βc-1816 Target:5′-AAGGCTACTGTTGGATTGATTCGAAAT-3′ (SEQ ID NO: 2261)5′-CAUGGAAGAAAUAGUUGAAGGUUGU-3′ (SEQ ID NO: 3371)3′-GCGUACCUUCUUUAUCAACUUCCAACA-5′ (SEQ ID NO: 1153) βc-1987 Target:5′-CGCATGGAAGAAATAGTTGAAGGTTGT-3′ (SEQ ID NO: 2262)5′-UGGAAGAAAUAGUUGAAGGUUGUAC-3′ (SEQ ID NO: 3372)3′-GUACCUUCUUUAUCAACUUCCAACAUG-5′ (SEQ ID NO: 1154) βc-1989 Target:5′-CATGGAAGAAATAGTTGAAGGTTGTAC-3′ (SEQ ID NO: 2263)5′-AUUGAAAACAUCCAAAGAGUAGCUG-3′ (SEQ ID NO: 3373)3′-GGUAACUUUUGUAGGUUUCUCAUCGAC-5′ (SEQ ID NO: 1155) βc-2111 Target:5′-CCATTGAAAACATCCAAAGAGTAGCTG-3′ (SEQ ID NO: 2264)5′-GAGGACAAGCCACAAGAUUACAAGA-3′ (SEQ ID NO: 3374)3′-GACUCCUGUUCGGUGUUCUAAUGUUCU-5′ (SEQ ID NO: 1156) βc-2282 Target:5′-CTGAGGACAAGCCACAAGATTACAAGA-3′ (SEQ ID NO: 2265)5′-GAUACUGACCUGUAAAUCAUCCUUU-3′ (SEQ ID NO: 3375)3′-AACUAUGACUGGACAUUUAGUAGGAAA-5′ (SEQ ID NO: 1157) βc-2624 Target:5′-TTGATACTGACCTGTAAATCATCCTTT-3′ (SEQ ID NO: 2266)5′-UUAGGUAAGAAGUUUUAAAAAGCCA-3′ (SEQ ID NO: 3376)3′-GAAAUCCAUUCUUCAAAAUUUUUCGGU-5′ (SEQ ID NO: 1158) βc-2647 Target:5′-CTTTAGGTAAGAAGTTTTAAAAAGCCA-3′ (SEQ ID NO: 2267)5′-CAGGUAUAUACUUUGAAAGGAGAUG-3′ (SEQ ID NO: 3377)3′-UUGUCCAUAUAUGAAACUUUCCUCUAC-5′ (SEQ ID NO: 1159) βc-2770 Target:5′-AACAGGTATATACTTTGAAAGGAGATG-3′ (SEQ ID NO: 2268)5′-GAAGUUAUUAACUUUAAUGUUUUUU-3′ (SEQ ID NO: 3378)3′-ACCUUCAAUAAUUGAAAUUACAAAAAA-5′ (SEQ ID NO: 1160) βc-2848 Target:5′-TGGAAGTTATTAACTTTAATGTTTTTT-3′ (SEQ ID NO: 2269)5′-CCACAGCUUUUGCAACUUAAUACUC-3′ (SEQ ID NO: 3379)3′-ACGGUGUCGAAAACGUUGAAUUAUGAG-5′ (SEQ ID NO: 1161) βc-2874 Target:5′-TGCCACAGCTTTTGCAACTTAATACTC-3′ (SEQ ID NO: 2270)5′-CAUUUGCUGUUUUAAACAUUAAUAG-3′ (SEQ ID NO: 3380)3′-UUGUAAACGACAAAAUUUGUAAUUAUC-5′ (SEQ ID NO: 1162) βc-2909 Target:5′-AACATTTGCTGTTTTAAACATTAATAG-3′ (SEQ ID NO: 2271)5′-CAAUUGAAGUAAACUUUUUGUUCUG-3′ (SEQ ID NO: 3381)3′-UUGUUAACUUCAUUUGAAAAACAAGAC-5′ (SEQ ID NO: 1163) βc-3074 Target:5′-AACAATTGAAGTAAACTTTTTGTTCTG-3′ (SEQ ID NO: 2272)5′-ACCCUAGCCUUGCUUGUUAAAUUUU-3′ (SEQ ID NO: 3382)3′-UUUGGGAUCGGAACGAACAAUUUAAAA-5′ (SEQ ID NO: 1164) βc-3197 Target:5′-AAACCCTAGCCTTGCTTGTTAAATTTT-3′ (SEQ ID NO: 2273)5′-GCCUUGCUUGUUAAAUUUUUUUUUU-3′ (SEQ ID NO: 3383)3′-AUCGGAACGAACAAUUUAAAAAAAAAA-5′ (SEQ ID NO: 1165) βc-3203 Target:5′-TAGCCTTGCTTGTTAAATTTTTTTTTT-3′ (SEQ ID NO: 2274)5′-GAAGUAGCUCUUUUUUUUUUUUUUU-3′ (SEQ ID NO: 3384)3′-AACUUCAUCGAGAAAAAAAAAAAAAAA-5′ (SEQ ID NO: 1166) βc-3273 Target:5′-TTGAAGTAGCTCTTTTTTTTTTTTTTT-3′ (SEQ ID NO: 2275)5′-GUAGUGUUAAGUUAUAGUGAAUACU-3′ (SEQ ID NO: 3385)3′-AGCAUCACAAUUCAAUAUCACUUAUGA-5′ (SEQ ID NO: 1167) βc-3333 Target:5′-TCGTAGTGTTAAGTTATAGTGAATACT-3′ (SEQ ID NO: 2276)5′-GUGAAUACUGCUACAGCAAUUUCUA-3′ (SEQ ID NO: 3386)3′-AUCACUUAUGACGAUGUCGUUAAAGAU-5′ (SEQ ID NO: 1168) βc-3349 Target:5′-TAGTGAATACTGCTACAGCAATTTCTA-3′ (SEQ ID NO: 2277)5′-UACUGCUACAGCAAUUUCUAAUUUU-3′ (SEQ ID NO: 3387)3′-UUAUGACGAUGUCGUUAAAGAUUAAAA-5′ (SEQ ID NO: 1169) βc-3354 Target:5′-AATACTGCTACAGCAATTTCTAATTTT-3′ (SEQ ID NO: 2278)5′-CUAAUUUUUAAGAAUUGAGUAAUGG-3′ (SEQ ID NO: 3388)3′-AAGAUUAAAAAUUCUUAACUCAUUACC-5′ (SEQ ID NO: 1170) βc-3371 Target:5′-TTCTAATTTTTAAGAATTGAGTAATGG-3′ (SEQ ID NO: 2279)5′-UUUUAAGAAUUGAGUAAUGGUGUAG-3′ (SEQ ID NO: 3389)3′-UAAAAAUUCUUAACUCAUUACCACAUC-5′ (SEQ ID NO: 1171) βc-3376 Target:5′-ATTTTTAAGAATTGAGTAATGGTGTAG-3′ (SEQ ID NO: 2280)5′-CAUAAUCACUCUAAUUAAUUGUAAU-3′ (SEQ ID NO: 3390)3′-AAGUAUUAGUGAGAUUAAUUAACAUUA-5′ (SEQ ID NO: 1172) βc-3411 Target:5′-TTCATAATCACTCTAATTAATTGTAAT-3′ (SEQ ID NO: 2281)5′-UAAUUGUAAUCUGAAUAAAGUGUAA-3′ (SEQ ID NO: 3391)3′-UAAUUAACAUUAGACUUAUUUCACAUU-5′ (SEQ ID NO: 1173) βc-3426 Target:5′-ATTAATTGTAATCTGAATAAAGTGTAA-3′ (SEQ ID NO: 2282)5′-GUAAUCUGAAUAAAGUGUAACAAUU-3′ (SEQ ID NO: 3392)3′-AACAUUAGACUUAUUUCACAUUGUUAA-5′ (SEQ ID NO: 1174) βc-3431 Target:5′-TTGTAATCTGAATAAAGTGTAACAATT-3′ (SEQ ID NO: 2283)5′-UGAAUAAAGUGUAACAAUUGUGUAG-3′ (SEQ ID NO: 3393)3′-AGACUUAUUUCACAUUGUUAACACAUC-5′ (SEQ ID NO: 1175) βc-3437 Target:5′-TCTGAATAAAGTGTAACAATTGTGTAG-3′ (SEQ ID NO: 2284)5′-GUAGCCUUUUUGUAUAAAAUAGACA-3′ (SEQ ID NO: 3394)3′-CACAUCGGAAAAACAUAUUUUAUCUGU-5′ (SEQ ID NO: 1176) βc-3458 Target:5′-GTGTAGCCTTTTTGTATAAAATAGACA-3′ (SEQ ID NO: 2285)5′-UGUAUAAAAUAGACAAAUAGAAAAU-3′ (SEQ ID NO: 3395)3′-AAACAUAUUUUAUCUGUUUAUCUUUUA-5′ (SEQ ID NO: 1177) βc-3468 Target:5′-TTTGTATAAAATAGACAAATAGAAAAT-3′ (SEQ ID NO: 2286)5′-AAAAUGGUCCAAUUAGUUUCCUUUU-3′ (SEQ ID NO: 3396)3′-UCUUUUACCAGGUUAAUCAAAGGAAAA-5′ (SEQ ID NO: 1178) βc-3488 Target:5′-AGAAAATGGTCCAATTAGTTTCCTTTT-3′ (SEQ ID NO: 2287)5′-CCAAUUAGUUUCCUUUUUAAUAUGC-3′ (SEQ ID NO: 3397)3′-CAGGUUAAUCAAAGGAAAAAUUAUACG-5′ (SEQ ID NO: 1179) βc-3496 Target:5′-GTCCAATTAGTTTCCTTTTTAATATGC-3′ (SEQ ID NO: 2288)5′-UUUGAUCAAAAACUAUUUGGGAUAU-3′ (SEQ ID NO: 3398)3′-AAAAACUAGUUUUUGAUAAACCCUAUA-5′ (SEQ ID NO: 1180) βc-3552 Target:5′-TTTTTGATCAAAAACTATTTGGGATAT-3′ (SEQ ID NO: 2289)5′-GAGGUGUUAUUUGGAACCUUGUUUU-3′ (SEQ ID NO: 3399)3′-UUCUCCACAAUAAACCUUGGAACAAAA-5′ (SEQ ID NO: 1181) βc-3600 Target:5′-AAGAGGTGTTATTTGGAACCTTGTTTT-3′ (SEQ ID NO: 2290)5′-GUUAUUUGGAACCUUGUUUUGGACA-3′ (SEQ ID NO: 3400)3′-CACAAUAAACCUUGGAACAAAACCUGU-5′ (SEQ ID NO: 1182) βc-3605 Target:5′-GTGTTATTTGGAACCTTGTTTTGGACA-3′ (SEQ ID NO: 2291)5′-ACCUUGUUUUGGACAGUUUACCAGU-3′ (SEQ ID NO: 3401)3′-CUUGGAACAAAACCUGUCAAAUGGUCA-5′ (SEQ ID NO: 1183) βc-3615 Target:5′-GAACCTTGTTTTGGACAGTTTACCAGT-3′ (SEQ ID NO: 2292)5′-GAUACGAUGCUUCAAGAGAAAAUGC-3′ (SEQ ID NO: 3402)3′-CACUAUGCUACGAAGUUCUCUUUUACG-5′ (SEQ ID NO: 1184) βc-3674 Target:5′-GTGATACGATGCTTCAAGAGAAAATGC-3′ (SEQ ID NO: 2293)5′-CAAGAGAAAAUGCGGUUAUAAAAAA-3′ (SEQ ID NO: 3403)3′-AAGUUCUCUUUUACGCCAAUAUUUUUU-5′ (SEQ ID NO: 1185) βc-3686 Target:5′-TTCAAGAGAAAATGCGGTTATAAAAAA-3′ (SEQ ID NO: 2294)5′-GAAAAUGCGGUUAUAAAAAAUGGUU-3′ (SEQ ID NO: 3404)3′-CUCUUUUACGCCAAUAUUUUUUACCAA-5′ (SEQ ID NO: 1186) βc-3691 Target:5′-GAGAAAATGCGGTTATAAAAAATGGTT-3′ (SEQ ID NO: 2295)5′-GUUAUAAAAAAUGGUUCAGAAUUAA-3′ (SEQ ID NO: 3405)3′-GCCAAUAUUUUUUACCAAGUCUUAAUU-5′ (SEQ ID NO: 1187) βc-3700 Target:5′-CGGTTATAAAAAATGGTTCAGAATTAA-3′ (SEQ ID NO: 2296)5′-AAAAUGGUUCAGAAUUAAACUUUUA-3′ (SEQ ID NO: 3406)3′-UUUUUUACCAAGUCUUAAUUUGAAAAU-5′ (SEQ ID NO: 1188) βc-3707 Target:5′-AAAAAATGGTTCAGAATTAAACTTTTA-3′ (SEQ ID NO: 2297)5′-GCGUGGACAAUGGCUACUCAAGCUG-3′ (SEQ ID NO: 3407)3′-GUCGCACCUGUUACCGAUGAGUUCGAC-5′ (SEQ ID NO: 1189) βc-284 Target:5′-CAGCGTGGACAATGGCTACTCAAGCTG-3′ (SEQ ID NO: 2298)5′-CGUGGACAAUGGCUACUCAAGCUGA-3′ (SEQ ID NO: 3408)3′-UCGCACCUGUUACCGAUGAGUUCGACU-5′ (SEQ ID NO: 1190) βc-285 Target:5′-AGCGTGGACAATGGCTACTCAAGCTGA-3′ (SEQ ID NO: 2299)5′-GUGGACAAUGGCUACUCAAGCUGAU-3′ (SEQ ID NO: 3409)3′-CGCACCUGUUACCGAUGAGUUCGACUA-5′ (SEQ ID NO: 1191) βc-286 Target:5′-GCGTGGACAATGGCTACTCAAGCTGAT-3′ (SEQ ID NO: 2300)5′-UGGACAAUGGCUACUCAAGCUGAUU-3′ (SEQ ID NO: 3410)3′-GCACCUGUUACCGAUGAGUUCGACUAA-5′ (SEQ ID NO: 1192) βc-287 Target:5′-CGTGGACAATGGCTACTCAAGCTGATT-3′ (SEQ ID NO: 2301)5′-GGACAAUGGCUACUCAAGCUGAUUU-3′ (SEQ ID NO: 3411)3′-CACCUGUUACCGAUGAGUUCGACUAAA-5′ (SEQ ID NO: 1193) βc-288 Target:5′-GTGGACAATGGCTACTCAAGCTGATTT-3′ (SEQ ID NO: 2302)5′-GACAAUGGCUACUCAAGCUGAUUUG-3′ (SEQ ID NO: 3412)3′-ACCUGUUACCGAUGAGUUCGACUAAAC-5′ (SEQ ID NO: 1194) βc-289 Target:5′-TGGACAATGGCTACTCAAGCTGATTTG-3′ (SEQ ID NO: 2303)5′-ACAAUGGCUACUCAAGCUGAUUUGA-3′ (SEQ ID NO: 3413)3′-CCUGUUACCGAUGAGUUCGACUAAACU-5′ (SEQ ID NO: 1195) βc-290 Target:5′-GGACAATGGCTACTCAAGCTGATTTGA-3′ (SEQ ID NO: 2304)5′-CAAUGGCUACUCAAGCUGAUUUGAU-3′ (SEQ ID NO: 3414)3′-CUGUUACCGAUGAGUUCGACUAAACUA-5′ (SEQ ID NO: 1196) βc-291 Target:5′-GACAATGGCTACTCAAGCTGATTTGAT-3′ (SEQ ID NO: 2305)5′-UGAUGGAGUUGGACAUGGCCAUGGA-3′ (SEQ ID NO: 3415)3′-AAACUACCUCAACCUGUACCGGUACCU-5′ (SEQ ID NO: 1197) βc-312 Target:5′-TTTGATGGAGTTGGACATGGCCATGGA-3′ (SEQ ID NO: 2306)5′-GAUGGAGUUGGACAUGGCCAUGGAA-3′ (SEQ ID NO: 3416)3′-AACUACCUCAACCUGUACCGGUACCUU-5′ (SEQ ID NO: 1198) βc-313 Target:5′-TTGATGGAGTTGGACATGGCCATGGAA-3′ (SEQ ID NO: 2307)5′-AUGGAGUUGGACAUGGCCAUGGAAC-3′ (SEQ ID NO: 3417)3′-ACUACCUCAACCUGUACCGGUACCUUG-5′ (SEQ ID NO: 1199) βc-314 Target:5′-TGATGGAGTTGGACATGGCCATGGAAC-3′ (SEQ ID NO: 2308)5′-UGGAGUUGGACAUGGCCAUGGAACC-3′ (SEQ ID NO: 3418)3′-CUACCUCAACCUGUACCGGUACCUUGG-5′ (SEQ ID NO: 1200) βc-315 Target:5′-GATGGAGTTGGACATGGCCATGGAACC-3′ (SEQ ID NO: 2309)5′-GGAGUUGGACAUGGCCAUGGAACCA-3′ (SEQ ID NO: 3419)3′-UACCUCAACCUGUACCGGUACCUUGGU-5′ (SEQ ID NO: 1201) βc-316 Target:5′-ATGGAGTTGGACATGGCCATGGAACCA-3′ (SEQ ID NO: 2310)5′-GAGUUGGACAUGGCCAUGGAACCAG-3′ (SEQ ID NO: 3420)3′-ACCUCAACCUGUACCGGUACCUUGGUC-5′ (SEQ ID NO: 1202) βc-317 Target:5′-TGGAGTTGGACATGGCCATGGAACCAG-3′ (SEQ ID NO: 2311)5′-AGUUGGACAUGGCCAUGGAACCAGA-3′ (SEQ ID NO: 3421)3′-CCUCAACCUGUACCGGUACCUUGGUCU-5′ (SEQ ID NO: 1203) βc-318 Target:5′-GGAGTTGGACATGGCCATGGAACCAGA-3′ (SEQ ID NO: 2312)5′-UCUGGAAUCCAUUCUGGUGCCACUA-3′ (SEQ ID NO: 3422)3′-UGAGACCUUAGGUAAGACCACGGUGAU-5′ (SEQ ID NO: 1204) βc-389 Target:5′-ACTCTGGAATCCATTCTGGTGCCACTA-3′ (SEQ ID NO: 2313)5′-CUGGAAUCCAUUCUGGUGCCACUAC-3′ (SEQ ID NO: 3423)3′-GAGACCUUAGGUAAGACCACGGUGAUG-5′ (SEQ ID NO: 1205) βc-390 Target:5′-CTCTGGAATCCATTCTGGTGCCACTAC-3′ (SEQ ID NO: 2314)5′-UGGAAUCCAUUCUGGUGCCACUACC-3′ (SEQ ID NO: 3424)3′-AGACCUUAGGUAAGACCACGGUGAUGG-5′ (SEQ ID NO: 1206) βc-391 Target:5′-TCTGGAATCCATTCTGGTGCCACTACC-3′ (SEQ ID NO: 2315)5′-GGAAUCCAUUCUGGUGCCACUACCA-3′ (SEQ ID NO: 3425)3′-GACCUUAGGUAAGACCACGGUGAUGGU-5′ (SEQ ID NO: 1207) βc-392 Target:5′-CTGGAATCCATTCTGGTGCCACTACCA-3′ (SEQ ID NO: 2316)5′-GAAUCCAUUCUGGUGCCACUACCAC-3′ (SEQ ID NO: 3426)3′-ACCUUAGGUAAGACCACGGUGAUGGUG-5′ (SEQ ID NO: 1208) βc-393 Target:5′-TGGAATCCATTCTGGTGCCACTACCAC-3′ (SEQ ID NO: 2317)5′-UAGAUGAGGGCAUGCAGAUCCCAUC-3′ (SEQ ID NO: 3427)3′-UAAUCUACUCCCGUACGUCUAGGGUAG-5′ (SEQ ID NO: 1209) βc-600 Target:5′-ATTAGATGAGGGCATGCAGATCCCATC-3′ (SEQ ID NO: 2318)5′-AGAUGAGGGCAUGCAGAUCCCAUCU-3′ (SEQ ID NO: 3428)3′-AAUCUACUCCCGUACGUCUAGGGUAGA-5′ (SEQ ID NO: 1210) βc-601 Target:5′-TTAGATGAGGGCATGCAGATCCCATCT-3′ (SEQ ID NO: 2319)5′-GAUGAGGGCAUGCAGAUCCCAUCUA-3′ (SEQ ID NO: 3429)3′-AUCUACUCCCGUACGUCUAGGGUAGAU-5′ (SEQ ID NO: 1211) βc-602 Target:5′-TAGATGAGGGCATGCAGATCCCATCTA-3′ (SEQ ID NO: 2320)5′-AUGAGGGCAUGCAGAUCCCAUCUAC-3′ (SEQ ID NO: 3430)3′-UCUACUCCCGUACGUCUAGGGUAGAUG-5′ (SEQ ID NO: 1212) βc-603 Target:5′-AGATGAGGGCATGCAGATCCCATCTAC-3′ (SEQ ID NO: 2321)5′-UGAGGGCAUGCAGAUCCCAUCUACA-3′ (SEQ ID NO: 3431)3′-CUACUCCCGUACGUCUAGGGUAGAUGU-5′ (SEQ ID NO: 1213) βc-604 Target:5′-GATGAGGGCATGCAGATCCCATCTACA-3′ (SEQ ID NO: 2322)5′-GAGGGCAUGCAGAUCCCAUCUACAC-3′ (SEQ ID NO: 3432)3′-UACUCCCGUACGUCUAGGGUAGAUGUG-5′ (SEQ ID NO: 1214) βc-605 Target:5′-ATGAGGGCATGCAGATCCCATCTACAC-3′ (SEQ ID NO: 2323)5′-GCUGCUCAUCCCACUAAUGUCCAGC-3′ (SEQ ID NO: 3433)3′-UACGACGAGUAGGGUGAUUACAGGUCG-5′ (SEQ ID NO: 1215) βc-638 Target:5′-ATGCTGCTCATCCCACTAATGTCCAGC-3′ (SEQ ID NO: 2324)5′-CUGCUCAUCCCACUAAUGUCCAGCG-3′ (SEQ ID NO: 3434)3′-ACGACGAGUAGGGUGAUUACAGGUCGC-5′ (SEQ ID NO: 1216) βc-639 Target:5′-TGCTGCTCATCCCACTAATGTCCAGCG-3′ (SEQ ID NO: 2325)5′-UGCUCAUCCCACUAAUGUCCAGCGU-3′ (SEQ ID NO: 3435)3′-CGACGAGUAGGGUGAUUACAGGUCGCA-5′ (SEQ ID NO: 1217) βc-640 Target:5′-GCTGCTCATCCCACTAATGTCCAGCGT-3′ (SEQ ID NO: 2326)5′-GCUCAUCCCACUAAUGUCCAGCGUU-3′ (SEQ ID NO: 3436)3′-GACGAGUAGGGUGAUUACAGGUCGCAA-5′ (SEQ ID NO: 1218) βc-641 Target:5′-CTGCTCATCCCACTAATGTCCAGCGTT-3′ (SEQ ID NO: 2327)5′-CUCAUCCCACUAAUGUCCAGCGUUU-3′ (SEQ ID NO: 3437)3′-ACGAGUAGGGUGAUUACAGGUCGCAAA-5′ (SEQ ID NO: 1219) βc-642 Target:5′-TGCTCATCCCACTAATGTCCAGCGTTT-3′ (SEQ ID NO: 2328)5′-UCAUCCCACUAAUGUCCAGCGUUUG-3′ (SEQ ID NO: 3438)3′-CGAGUAGGGUGAUUACAGGUCGCAAAC-5′ (SEQ ID NO: 1220) βc-643 Target:5′-GCTCATCCCACTAATGTCCAGCGTTTG-3′ (SEQ ID NO: 2329)5′-CAUCCCACUAAUGUCCAGCGUUUGG-3′ (SEQ ID NO: 3439)3′-GAGUAGGGUGAUUACAGGUCGCAAACC-5′ (SEQ ID NO: 1221) βc-644 Target:5′-CTCATCCCACTAATGTCCAGCGTTTGG-3′ (SEQ ID NO: 2330)5′-AUCCCACUAAUGUCCAGCGUUUGGC-3′ (SEQ ID NO: 3440)3′-AGUAGGGUGAUUACAGGUCGCAAACCG-5′ (SEQ ID NO: 1222) βc-645 Target:5′-TCATCCCACTAATGTCCAGCGTTTGGC-3′ (SEQ ID NO: 2331)5′-UUGGCUGAACCAUCACAGAUGCUGA-3′ (SEQ ID NO: 3441)3′-CAAACCGACUUGGUAGUGUCUACGACU-5′ (SEQ ID NO: 1223) βc-665 Target:5′-GTTTGGCTGAACCATCACAGATGCTGA-3′ (SEQ ID NO: 2332)5′-UGGCUGAACCAUCACAGAUGCUGAA-3′ (SEQ ID NO: 3442)3′-AAACCGACUUGGUAGUGUCUACGACUU-5′ (SEQ ID NO: 1224) βc-666 Target:5′-TTTGGCTGAACCATCACAGATGCTGAA-3′ (SEQ ID NO: 2333)5′-GGCUGAACCAUCACAGAUGCUGAAA-3′ (SEQ ID NO: 3443)3′-AACCGACUUGGUAGUGUCUACGACUUU-5′ (SEQ ID NO: 1225) βc-667 Target:5′-TTGGCTGAACCATCACAGATGCTGAAA-3′ (SEQ ID NO: 2334)5′-GAACUUGCCACACGUGCAAUCCCUG-3′ (SEQ ID NO: 3444)3′-GUCUUGAACGGUGUGCACGUUAGGGAC-5′ (SEQ ID NO: 1226) βc-731 Target:5′-CAGAACTTGCCACACGTGCAATCCCTG-3′ (SEQ ID NO: 2335)5′-AACUUGCCACACGUGCAAUCCCUGA-3′ (SEQ ID NO: 3445)3′-UCUUGAACGGUGUGCACGUUAGGGACU-5′ (SEQ ID NO: 1227) βc-732 Target:5′-AGAACTTGCCACACGTGCAATCCCTGA-3′ (SEQ ID NO: 2336)5′-GUUAUGGUCCAUCAGCUUUCUAAAA-3′ (SEQ ID NO: 3446)3′-GUCAAUACCAGGUAGUCGAAAGAUUUU-5′ (SEQ ID NO: 1228) βc-809 Target:5′-CAGTTATGGTCCATCAGCTTTCTAAAA-3′ (SEQ ID NO: 2337)5′-UUAUGGUCCAUCAGCUUUCUAAAAA-3′ (SEQ ID NO: 3447)3′-UCAAUACCAGGUAGUCGAAAGAUUUUU-5′ (SEQ ID NO: 1229) βc-810 Target:5′-AGTTATGGTCCATCAGCTTTCTAAAAA-3′ (SEQ ID NO: 2338)5′-AAAAAGGAAGCUUCCAGACACGCUA-3′ (SEQ ID NO: 3448)3′-GAUUUUUCCUUCGAAGGUCUGUGCGAU-5′ (SEQ ID NO: 1230) βc-830 Target:5′-CTAAAAAGGAAGCTTCCAGACACGCTA-3′ (SEQ ID NO: 2339)5′-AAAAGGAAGCUUCCAGACACGCUAU-3′ (SEQ ID NO: 3449)3′-AUUUUUCCUUCGAAGGUCUGUGCGAUA-5′ (SEQ ID NO: 1231) βc-831 Target:5′-TAAAAAGGAAGCTTCCAGACACGCTAT-3′ (SEQ ID NO: 2340)5′-ACCAUGCAGAAUACAAAUGAUGUAG-3′ (SEQ ID NO: 3450)3′-CAUGGUACGUCUUAUGUUUACUACAUC-5′ (SEQ ID NO: 1232) βc-893 Target:5′-GTACCATGCAGAATACAAATGATGTAG-3′ (SEQ ID NO: 2341)5′-CCAUGCAGAAUACAAAUGAUGUAGA-3′ (SEQ ID NO: 3451)3′-AUGGUACGUCUUAUGUUUACUACAUCU-5′ (SEQ ID NO: 1233) βc-894 Target:5′-TACCATGCAGAATACAAATGATGTAGA-3′ (SEQ ID NO: 2342)5′-CAUGCAGAAUACAAAUGAUGUAGAA-3′ (SEQ ID NO: 3452)3′-UGGUACGUCUUAUGUUUACUACAUCUU-5′ (SEQ ID NO: 1234) βc-895 Target:5′-ACCATGCAGAATACAAATGATGTAGAA-3′ (SEQ ID NO: 2343)5′-AUGCAGAAUACAAAUGAUGUAGAAA-3′ (SEQ ID NO: 3453)3′-GGUACGUCUUAUGUUUACUACAUCUUU-5′ (SEQ ID NO: 1235) βc-896 Target:5′-CCATGCAGAATACAAATGATGTAGAAA-3′ (SEQ ID NO: 2344)5′-UGCAGAAUACAAAUGAUGUAGAAAC-3′ (SEQ ID NO: 3454)3′-GUACGUCUUAUGUUUACUACAUCUUUG-5′ (SEQ ID NO: 1236) βc-897 Target:5′-CATGCAGAATACAAATGATGTAGAAAC-3′ (SEQ ID NO: 2345)5′-GCAGAAUACAAAUGAUGUAGAAACA-3′ (SEQ ID NO: 3455)3′-UACGUCUUAUGUUUACUACAUCUUUGU-5′ (SEQ ID NO: 1237) βc-898 Target:5′-ATGCAGAATACAAATGATGTAGAAACA-3′ (SEQ ID NO: 2346)5′-CAGAAUACAAAUGAUGUAGAAACAG-3′ (SEQ ID NO: 3456)3′-ACGUCUUAUGUUUACUACAUCUUUGUC-5′ (SEQ ID NO: 1238) βc-899 Target:5′-TGCAGAATACAAATGATGTAGAAACAG-3′ (SEQ ID NO: 2347)5′-AGAAUACAAAUGAUGUAGAAACAGC-3′ (SEQ ID NO: 3457)3′-CGUCUUAUGUUUACUACAUCUUUGUCG-5′ (SEQ ID NO: 1239) βc-900 Target:5′-GCAGAATACAAATGATGTAGAAACAGC-3′ (SEQ ID NO: 2348)5′-CUGGCCAUCUUUAAGUCUGGAGGCA-3′ (SEQ ID NO: 3458)3′-AUGACCGGUAGAAAUUCAGACCUCCGU-5′ (SEQ ID NO: 1240) βc-977 Target:5′-TACTGGCCATCTTTAAGTCTGGAGGCA-3′ (SEQ ID NO: 2349)5′-UGGCCAUCUUUAAGUCUGGAGGCAU-3′ (SEQ ID NO: 3459)3′-UGACCGGUAGAAAUUCAGACCUCCGUA-5′ (SEQ ID NO: 1241) βc-978 Target:5′-ACTGGCCATCTTTAAGTCTGGAGGC-3′ (SEQ ID NO: 2350)5′-GAAGGAGCUAAAAUGGCAGUGCGUU-3′ (SEQ ID NO: 3460)3′-UUCUUCCUCGAUUUUACCGUCACGCAA-5′ (SEQ ID NO: 1242) βc-1091 Target:5′-AAGAAGGAGCTAAAATGGCAGTGCGTT-3′ (SEQ ID NO: 2351)5′-AAGGAGCUAAAAUGGCAGUGCGUUU-3′ (SEQ ID NO: 3461)3′-UCUUCCUCGAUUUUACCGUCACGCAAA-5′ (SEQ ID NO: 1243) βc-1092 Target:5′-AGAAGGAGCTAAAATGGCAGTGCGTTT-3′ (SEQ ID NO: 2352)5′-AGGAGCUAAAAUGGCAGUGCGUUUA-3′ (SEQ ID NO: 3462)3′-CUUCCUCGAUUUUACCGUCACGCAAAU-5′ (SEQ ID NO: 1244) βc-1093 Target:5′-GAAGGAGCTAAAATGGCAGTGCGTTTA-3′ (SEQ ID NO: 2353)5′-GGAGCUAAAAUGGCAGUGCGUUUAG-3′ (SEQ ID NO: 3463)3′-UUCCUCGAUUUUACCGUCACGCAAAUC-5′ (SEQ ID NO: 1245) βc-1094 Target:5′-AAGGAGCTAAAATGGCAGTGCGTTTAG-3′ (SEQ ID NO: 2354)5′-GAGCUAAAAUGGCAGUGCGUUUAGC-3′ (SEQ ID NO: 3464)3′-UCCUCGAUUUUACCGUCACGCAAAUCG-5′ (SEQ ID NO: 1246) βc-1095 Target:5′-AGGAGCTAAAATGGCAGTGCGTTTAGC-3′ (SEQ ID NO: 2355)5′-CUGUGGACCACAAGCAGAGUGCUGA-3′ (SEQ ID NO: 3465)3′-AUGACACCUGGUGUUCGUCUCACGACU-5′ (SEQ ID NO: 1247) βc-1301 Target:5′-TACTGTGGACCACAAGCAGAGTGCTGA-3′ (SEQ ID NO: 2356)5′-UGUGGACCACAAGCAGAGUGCUGAA-3′ (SEQ ID NO: 3466)3′-UGACACCUGGUGUUCGUCUCACGACUU-5′ (SEQ ID NO: 1248) βc-1302 Target:5′-ACTGTGGACCACAAGCAGAGTGCTGAA-3′ (SEQ ID NO: 2357)5′-GUGGACCACAAGCAGAGUGCUGAAG-3′ (SEQ ID NO: 3467)3′-GACACCUGGUGUUCGUCUCACGACUUC-5′ (SEQ ID NO: 1249) βc-1303 Target:5′-CTGTGGACCACAAGCAGAGTGCTGAAG-3′ (SEQ ID NO: 2358)5′-UGGACCACAAGCAGAGUGCUGAAGG-3′ (SEQ ID NO: 3468)3′-ACACCUGGUGUUCGUCUCACGACUUCC-5′ (SEQ ID NO: 1250) βc-1304 Target:5′-TGTGGACCACAAGCAGAGTGCTGAAGG-3′ (SEQ ID NO: 2359)5′-GGACCACAAGCAGAGUGCUGAAGGU-3′ (SEQ ID NO: 3469)3′-CACCUGGUGUUCGUCUCACGACUUCCA-5′ (SEQ ID NO: 1251) βc-1305 Target:5′-GTGGACCACAAGCAGAGTGCTGAAGGT-3′ (SEQ ID NO: 2360)5′-GACCACAAGCAGAGUGCUGAAGGUG-3′ (SEQ ID NO: 3470)3′-ACCUGGUGUUCGUCUCACGACUUCCAC-5′ (SEQ ID NO: 1252) βc-1306 Target:5′-TGGACCACAAGCAGAGTGCTGAAGGTG-3′ (SEQ ID NO: 2361)5′-ACCACAAGCAGAGUGCUGAAGGUGC-3′ (SEQ ID NO: 3471)3′-CCUGGUGUUCGUCUCACGACUUCCACG-5′ (SEQ ID NO: 1253) βc-1307 Target:5′-GGACCACAAGCAGAGTGCTGAAGGTGC-3′ (SEQ ID NO: 2362)5′-CCACAAGCAGAGUGCUGAAGGUGCU-3′ (SEQ ID NO: 3472)3′-CUGGUGUUCGUCUCACGACUUCCACGA-5′ (SEQ ID NO: 1254) βc-1308 Target:5′-GACCACAAGCAGAGTGCTGAAGGTGCT-3′ (SEQ ID NO: 2363)5′-CACAAGCAGAGUGCUGAAGGUGCUA-3′ (SEQ ID NO: 3473)3′-UGGUGUUCGUCUCACGACUUCCACGAU-5′ (SEQ ID NO: 1255) βc-1309 Target:5′-ACCACAAGCAGAGTGCTGAAGGTGCTA-3′ (SEQ ID NO: 2364)5′-ACAAGCAGAGUGCUGAAGGUGCUAU-3′ (SEQ ID NO: 3474)3′-GGUGUUCGUCUCACGACUUCCACGAUA-5′ (SEQ ID NO: 1256) βc-1310 Target:5′-CCACAAGCAGAGTGCTGAAGGTGCTAT-3′ (SEQ ID NO: 2365)5′-CAAGCAGAGUGCUGAAGGUGCUAUC-3′ (SEQ ID NO: 3475)3′-GUGUUCGUCUCACGACUUCCACGAUAG-5′ (SEQ ID NO: 1257) βc-1311 Target:5′-CACAAGCAGAGTGCTGAAGGTGCTATC-3′ (SEQ ID NO: 2366)5′-AAGCAGAGUGCUGAAGGUGCUAUCU-3′ (SEQ ID NO: 3476)3′-UGUUCGUCUCACGACUUCCACGAUAGA-5′ (SEQ ID NO: 1258) βc-1312 Target:5′-ACAAGCAGAGTGCTGAAGGTGCTATCT-3′ (SEQ ID NO: 2367)5′-AGCAGAGUGCUGAAGGUGCUAUCUG-3′ (SEQ ID NO: 3477)3′-GUUCGUCUCACGACUUCCACGAUAGAC-5′ (SEQ ID NO: 1259) βc-1313 Target:5′-CAAGCAGAGTGCTGAAGGTGCTATCTG-3′ (SEQ ID NO: 2368)5′-GCAGAGUGCUGAAGGUGCUAUCUGU-3′ (SEQ ID NO: 3478)3′-UUCGUCUCACGACUUCCACGAUAGACA-5′ (SEQ ID NO: 1260) βc-1314 Target:5′-AAGCAGAGTGCTGAAGGTGCTATCTGT-3′ (SEQ ID NO: 2369)5′-AACUGUCUUUGGACUCUCAGGAAUC-3′ (SEQ ID NO: 3479)3′-UCUUGACAGAAACCUGAGAGUCCUUAG-5′ (SEQ ID NO: 1261) βc-1430 Target:5′-AGAACTGTCTTTGGACTCTCAGGAATC-3′ (SEQ ID NO: 2370)5′-ACUGUCUUUGGACUCUCAGGAAUCU-3′ (SEQ ID NO: 3480)3′-CUUGACAGAAACCUGAGAGUCCUUAGA-5′ (SEQ ID NO: 1262) βc-1431 Target:5′-GAACTGTCTTTGGACTCTCAGGAATCT-3′ (SEQ ID NO: 2371)5′-GAUGAUAUAAAUGUGGUCACCUGUG-3′ (SEQ ID NO: 3481)3′-GUCUACUAUAUUUACACCAGUGGACAC-5′ (SEQ ID NO: 1263) βc-1526 Target:5′-CAGATGATATAAATGTGGTCACCTGTG-3′ (SEQ ID NO: 2372)5′-AUGAUAUAAAUGUGGUCACCUGUGC-3′ (SEQ ID NO: 3482)3′-UCUACUAUAUUUACACCAGUGGACACG-5′ (SEQ ID NO: 1264) βc-1527 Target:5′-AGATGATATAAATGTGGTCACCTGTGC-3′ (SEQ ID NO: 2373)5′-UGAUAUAAAUGUGGUCACCUGUGCA-3′ (SEQ ID NO: 3483)3′-CUACUAUAUUUACACCAGUGGACACGU-5′ (SEQ ID NO: 1265) βc-1528 Target:5′-GATGATATAAATGTGGTCACCTGTGCA-3′ (SEQ ID NO: 2374)5′-GAUAUAAAUGUGGUCACCUGUGCAG-3′ (SEQ ID NO: 3484)3′-UACUAUAUUUACACCAGUGGACACGUC-5′ (SEQ ID NO: 1266) βc-1529 Target:5′-ATGATATAAATGTGGTCACCTGTGCAG-3′ (SEQ ID NO: 2375)5′-AUAUAAAUGUGGUCACCUGUGCAGC-3′ (SEQ ID NO: 3485)3′-ACUAUAUUUACACCAGUGGACACGUCG-5′ (SEQ ID NO: 1267) βc-1530 Target:5′-TGATATAAATGTGGTCACCTGTGCAGC-3′ (SEQ ID NO: 2376)5′-UAUAAAUGUGGUCACCUGUGCAGCU-3′ (SEQ ID NO: 3486)3′-CUAUAUUUACACCAGUGGACACGUCGA-5′ (SEQ ID NO: 1268) βc-1531 Target:5′-GATATAAATGTGGTCACCTGTGCAGCT-3′ (SEQ ID NO: 2377)5′-AUAAAUGUGGUCACCUGUGCAGCUG-3′ (SEQ ID NO: 3487)3′-UAUAUUUACACCAGUGGACACGUCGAC-5′ (SEQ ID NO: 1269) βc-1532 Target:5′-ATATAAATGTGGTCACCTGTGCAGCTG-3′ (SEQ ID NO: 2378)5′-UAAAUGUGGUCACCUGUGCAGCUGG-3′ (SEQ ID NO: 3488)3′-AUAUUUACACCAGUGGACACGUCGACC-5′ (SEQ ID NO: 1270) βc-1533 Target:5′-TATAAATGTGGTCACCTGTGCAGCTGG-3′ (SEQ ID NO: 2379)5′-AAAUGUGGUCACCUGUGCAGCUGGA-3′ (SEQ ID NO: 3489)3′-UAUUUACACCAGUGGACACGUCGACCU-5′ (SEQ ID NO: 1271) βc-1534 Target:5′-ATAAATGTGGTCACCTGTGCAGCTGGA-3′ (SEQ ID NO: 2380)5′-AAUGUGGUCACCUGUGCAGCUGGAA-3′ (SEQ ID NO: 3490)3′-AUUUACACCAGUGGACACGUCGACCUU-5′ (SEQ ID NO: 1272) βc-1535 Target:5′-TAAATGTGGTCACCTGTGCAGCTGGAA-3′ (SEQ ID NO: 2381)5′-AUGUGGUCACCUGUGCAGCUGGAAU-3′ (SEQ ID NO: 3491)3′-UUUACACCAGUGGACACGUCGACCUUA-5′ (SEQ ID NO: 1273) βc-1536 Target:5′-AAATGTGGTCACCTGTGCAGCTGGAAT-3′ (SEQ ID NO: 2382)5′-UGUGGUCACCUGUGCAGCUGGAAUU-3′ (SEQ ID NO: 3492)3′-UUACACCAGUGGACACGUCGACCUUAA-5′ (SEQ ID NO: 1274) βc-1537 Target:5′-AATGTGGTCACCTGTGCAGCTGGAATT-3′ (SEQ ID NO: 2383)5′-GUGGUCACCUGUGCAGCUGGAAUUC-3′ (SEQ ID NO: 3493)3′-UACACCAGUGGACACGUCGACCUUAAG-5′ (SEQ ID NO: 1275) βc-1538 Target:5′-ATGTGGTCACCTGTGCAGCTGGAATTC-3′ (SEQ ID NO: 2384)5′-UGGUCACCUGUGCAGCUGGAAUUCU-3′ (SEQ ID NO: 3494)3′-ACACCAGUGGACACGUCGACCUUAAGA-5′ (SEQ ID NO: 1276) βc-1539 Target:5′-TGTGGTCACCTGTGCAGCTGGAATTCT-3′ (SEQ ID NO: 2385)5′-GGUCACCUGUGCAGCUGGAAUUCUU-3′ (SEQ ID NO: 3495)3′-CACCAGUGGACACGUCGACCUUAAGAA-5′ (SEQ ID NO: 1277) βc-1540 Target:5′-GTGGTCACCTGTGCAGCTGGAATTCTT-3′ (SEQ ID NO: 2386)5′-GUCACCUGUGCAGCUGGAAUUCUUU-3′ (SEQ ID NO: 3496)3′-ACCAGUGGACACGUCGACCUUAAGAAA-5′ (SEQ ID NO: 1278) βc-1541 Target:5′-TGGTCACCTGTGCAGCTGGAATTCTTT-3′ (SEQ ID NO: 2387)5′-UCACCUGUGCAGCUGGAAUUCUUUC-3′ (SEQ ID NO: 3497)3′-CCAGUGGACACGUCGACCUUAAGAAAG-5′ (SEQ ID NO: 1279) βc-1542 Target:5′-GGTCACCTGTGCAGCTGGAATTCTTTC-3′ (SEQ ID NO: 2388)5′-CACCUGUGCAGCUGGAAUUCUUUCU-3′ (SEQ ID NO: 3498)3′-CAGUGGACACGUCGACCUUAAGAAAGA-5′ (SEQ ID NO: 1280) βc-1543 Target:5′-GTCACCTGTGCAGCTGGAATTCTTTCT-3′ (SEQ ID NO: 2389)5′-ACCUGUGCAGCUGGAAUUCUUUCUA-3′ (SEQ ID NO: 3499)3′-AGUGGACACGUCGACCUUAAGAAAGAU-5′ (SEQ ID NO: 1281) βc-1544 Target:5′-TCACCTGTGCAGCTGGAATTCTTTCTA-3′ (SEQ ID NO: 2390)5′-CCUGUGCAGCUGGAAUUCUUUCUAA-3′ (SEQ ID NO: 3500)3′-GUGGACACGUCGACCUUAAGAAAGAUU-5′ (SEQ ID NO: 1282) βc-1545 Target:5′-CACCTGTGCAGCTGGAATTCTTTCTAA-3′ (SEQ ID NO: 2391)5′-UCUAACCUCACUUGCAAUAAUUAUA-3′ (SEQ ID NO: 3501)3′-AAAGAUUGGAGUGAACGUUAUUAAUAU-5′ (SEQ ID NO: 1283) βc-1565 Target:5′-TTTCTAACCTCACTTGCAATAATTATA-3′ (SEQ ID NO: 2392)5′-CUAACCUCACUUGCAAUAAUUAUAA-3′ (SEQ ID NO: 3502)3′-AAGAUUGGAGUGAACGUUAUUAAUAUU-5′ (SEQ ID NO: 1284) βc-1566 Target:5′-TTCTAACCTCACTTGCAATAATTATAA-3′ (SEQ ID NO: 2393)5′-UAACCUCACUUGCAAUAAUUAUAAG-3′ (SEQ ID NO: 3503)3′-AGAUUGGAGUGAACGUUAUUAAUAUUC-5′ (SEQ ID NO: 1285) βc-1567 Target:5′-TCTAACCTCACTTGCAATAATTATAAG-3′ (SEQ ID NO: 2394)5′-AACCUCACUUGCAAUAAUUAUAAGA-3′ (SEQ ID NO: 3504)3′-GAUUGGAGUGAACGUUAUUAAUAUUCU-5′ (SEQ ID NO: 1286) βc-1568 Target:5′-CTAACCTCACTTGCAATAATTATAAGA-3′ (SEQ ID NO: 2395)5′-ACCUCACUUGCAAUAAUUAUAAGAA-3′ (SEQ ID NO: 3505)3′-AUUGGAGUGAACGUUAUUAAUAUUCUU-5′ (SEQ ID NO: 1287) βc-1569 Target:5′-TAACCTCACTTGCAATAATTATAAGAA-3′ (SEQ ID NO: 2396)5′-GCUGGUGACAGGGAAGACAUCACUG-3′ (SEQ ID NO: 3506)3′-CCCGACCACUGUCCCUUCUGUAGUGAC-5′ (SEQ ID NO: 1288) βc-1652 Target:5′-GGGCTGGTGACAGGGAAGACATCACTG-3′ (SEQ ID NO: 2397)5′-CUGGUGACAGGGAAGACAUCACUGA-3′ (SEQ ID NO: 3507)3′-CCGACCACUGUCCCUUCUGUAGUGACU-5′ (SEQ ID NO: 1289) βc-1653 Target:5′-GGCTGGTGACAGGGAAGACATCACTGA-3′ (SEQ ID NO: 2398)5′-UGGUGACAGGGAAGACAUCACUGAG-3′ (SEQ ID NO: 3508)3′-CGACCACUGUCCCUUCUGUAGUGACUC-5′ (SEQ ID NO: 1290) βc-1654 Target:5′-GCTGGTGACAGGGAAGACATCACTGAG-3′ (SEQ ID NO: 2399)5′-GGUGACAGGGAAGACAUCACUGAGC-3′ (SEQ ID NO: 3509)3′-GACCACUGUCCCUUCUGUAGUGACUCG-5′ (SEQ ID NO: 1291) βc-1655 Target:5′-CTGGTGACAGGGAAGACATCACTGAGC-3′ (SEQ ID NO: 2400)5′-GUGACAGGGAAGACAUCACUGAGCC-3′ (SEQ ID NO: 3510)3′-ACCACUGUCCCUUCUGUAGUGACUCGG-5′ (SEQ ID NO: 1292) βc-1656 Target:5′-TGGTGACAGGGAAGACATCACTGAGCC-3′ (SEQ ID NO: 2401)5′-UGACAGGGAAGACAUCACUGAGCCU-3′ (SEQ ID NO: 3511)3′-CCACUGUCCCUUCUGUAGUGACUCGGA-5′ (SEQ ID NO: 1293) βc-1657 Target:5′-GGTGACAGGGAAGACATCACTGAGCCT-3′ (SEQ ID NO: 2402)5′-GACAGGGAAGACAUCACUGAGCCUG-3′ (SEQ ID NO: 3512)3′-CACUGUCCCUUCUGUAGUGACUCGGAC-5′ (SEQ ID NO: 1294) βc-1658 Target:5′-GTGACAGGGAAGACATCACTGAGCCTG-3′ (SEQ ID NO: 2403)5′-ACAGGGAAGACAUCACUGAGCCUGC-3′ (SEQ ID NO: 3513)3′-ACUGUCCCUUCUGUAGUGACUCGGACG-5′ (SEQ ID NO: 1295) βc-1659 Target:5′-TGACAGGGAAGACATCACTGAGCCTGC-3′ (SEQ ID NO: 2404)5′-CAGGGAAGACAUCACUGAGCCUGCC-3′ (SEQ ID NO: 3514)3′-CUGUCCCUUCUGUAGUGACUCGGACGG-5′ (SEQ ID NO: 1296) βc-1660 Target:5′-GACAGGGAAGACATCACTGAGCCTGCC-3′ (SEQ ID NO: 2405)5′-AGGGAAGACAUCACUGAGCCUGCCA-3′ (SEQ ID NO: 3515)3′-UGUCCCUUCUGUAGUGACUCGGACGGU-5′ (SEQ ID NO: 1297) βc-1661 Target:5′-ACAGGGAAGACATCACTGAGCCTGCCA-3′ (SEQ ID NO: 2406)5′-GGGAAGACAUCACUGAGCCUGCCAU-3′ (SEQ ID NO: 3516)3′-GUCCCUUCUGUAGUGACUCGGACGGUA-5′ (SEQ ID NO: 1298) βc-1662 Target:5′-CAGGGAAGACATCACTGAGCCTGCC-3′ (SEQ ID NO: 2407)5′-GGAAGACAUCACUGAGCCUGCCAUC-3′ (SEQ ID NO: 3517)3′-UCCCUUCUGUAGUGACUCGGACGGUAG-5′ (SEQ ID NO: 1299) βc-1663 Target:5′-AGGGAAGACATCACTGAGCCTGCCATC-3′ (SEQ ID NO: 2408)5′-GAAGACAUCACUGAGCCUGCCAUCU-3′ (SEQ ID NO: 3518)3′-CCCUUCUGUAGUGACUCGGACGGUAGA-5′ (SEQ ID NO: 1300) βc-1664 Target:5′-GGGAAGACATCACTGAGCCTGCCATCT-3′ (SEQ ID NO: 2409)5′-AAGACAUCACUGAGCCUGCCAUCUG-3′ (SEQ ID NO: 3519)3′-CCUUCUGUAGUGACUCGGACGGUAGAC-5′ (SEQ ID NO: 1301) βc-1665 Target:5′-GGAAGACATCACTGAGCCTGCCATCTG-3′ (SEQ ID NO: 2410)5′-AGACAUCACUGAGCCUGCCAUCUGU-3′ (SEQ ID NO: 3520)3′-CUUCUGUAGUGACUCGGACGGUAGACA-5′ (SEQ ID NO: 1302) βc-1666 Target:5′-GAAGACATCACTGAGCCTGCCATCTGT-3′ (SEQ ID NO: 2411)5′-GACAUCACUGAGCCUGCCAUCUGUG-3′ (SEQ ID NO: 3521)3′-UUCUGUAGUGACUCGGACGGUAGACAC-5′ (SEQ ID NO: 1303) βc-1667 Target:5′-AAGACATCACTGAGCCTGCCATCTGTG-3′ (SEQ ID NO: 2412)5′-ACAUCACUGAGCCUGCCAUCUGUGC-3′ (SEQ ID NO: 3522)3′-UCUGUAGUGACUCGGACGGUAGACACG-5′ (SEQ ID NO: 1304) βc-1668 Target:5′-AGACATCACTGAGCCTGCCATCTGTGC-3′ (SEQ ID NO: 2413)5′-CAUCACUGAGCCUGCCAUCUGUGCU-3′ (SEQ ID NO: 3523)3′-CUGUAGUGACUCGGACGGUAGACACGA-5′ (SEQ ID NO: 1305) βc-1669 Target:5′-GACATCACTGAGCCTGCCATCTGTGCT-3′ (SEQ ID NO: 2414)5′-AUCACUGAGCCUGCCAUCUGUGCUC-3′ (SEQ ID NO: 3524)3′-UGUAGUGACUCGGACGGUAGACACGAG-5′ (SEQ ID NO: 1306) βc-1670 Target:5′-ACATCACTGAGCCTGCCATCTGTGCTC-3′ (SEQ ID NO: 2415)5′-UCACUGAGCCUGCCAUCUGUGCUCU-3′ (SEQ ID NO: 3525)3′-GUAGUGACUCGGACGGUAGACACGAGA-5′ (SEQ ID NO: 1307) βc-1671 Target:5′-CATCACTGAGCCTGCCATCTGTGCTCT-3′ (SEQ ID NO: 2416)5′-CACUGAGCCUGCCAUCUGUGCUCUU-3′ (SEQ ID NO: 3526)3′-UAGUGACUCGGACGGUAGACACGAGAA-5′ (SEQ ID NO: 1308) βc-1672 Target:5′-ATCACTGAGCCTGCCATCTGTGCTCTT-3′ (SEQ ID NO: 2417)5′-ACUGAGCCUGCCAUCUGUGCUCUUC-3′ (SEQ ID NO: 3527)3′-AGUGACUCGGACGGUAGACACGAGAAG-5′ (SEQ ID NO: 1309) βc-1673 Target:5′-TCACTGAGCCTGCCATCTGTGCTCTTC-3′ (SEQ ID NO: 2418)5′-CUGAGCCUGCCAUCUGUGCUCUUCG-3′ (SEQ ID NO: 3528)3′-GUGACUCGGACGGUAGACACGAGAAGC-5′ (SEQ ID NO: 1310) βc-1674 Target:5′-CACTGAGCCTGCCATCTGTGCTCTTCG-3′ (SEQ ID NO: 2419)5′-UGAGCCUGCCAUCUGUGCUCUUCGU-3′ (SEQ ID NO: 3529)3′-UGACUCGGACGGUAGACACGAGAAGCA-5′ (SEQ ID NO: 1311) βc-1675 Target:5′-ACTGAGCCTGCCATCTGTGCTCTTCGT-3′ (SEQ ID NO: 2420)5′-GAGCCUGCCAUCUGUGCUCUUCGUC-3′ (SEQ ID NO: 3530)3′-GACUCGGACGGUAGACACGAGAAGCAG-5′ (SEQ ID NO: 1312) βc-1676 Target:5′-CTGAGCCTGCCATCTGTGCTCTTCGTC-3′ (SEQ ID NO: 2421)5′-AGCCUGCCAUCUGUGCUCUUCGUCA-3′ (SEQ ID NO: 3531)3′-ACUCGGACGGUAGACACGAGAAGCAGU-5′ (SEQ ID NO: 1313) βc-1677 Target:5′-TGAGCCTGCCATCTGTGCTCTTCGTCA-3′ (SEQ ID NO: 2422)5′-GCCUGCCAUCUGUGCUCUUCGUCAU-3′ (SEQ ID NO: 3532)3′-CUCGGACGGUAGACACGAGAAGCAGUA-5′ (SEQ ID NO: 1314) βc-1678 Target:5′-GAGCCTGCCATCTGTGCTCTTCGTC-3′ (SEQ ID NO: 2423)5′-CCUGCCAUCUGUGCUCUUCGUCAUC-3′ (SEQ ID NO: 3533)3′-UCGGACGGUAGACACGAGAAGCAGUAG-5′ (SEQ ID NO: 1315) βc-1679 Target:5′-AGCCTGCCATCTGTGCTCTTCGTCATC-3′ (SEQ ID NO: 2424)5′-CUGCCAUCUGUGCUCUUCGUCAUCU-3′ (SEQ ID NO: 3534)3′-CGGACGGUAGACACGAGAAGCAGUAGA-5′ (SEQ ID NO: 1316) βc-1680 Target:5′-GCCTGCCATCTGTGCTCTTCGTCATCT-3′ (SEQ ID NO: 2425)5′-UGCCAUCUGUGCUCUUCGUCAUCUG-3′ (SEQ ID NO: 3535)3′-GGACGGUAGACACGAGAAGCAGUAGAC-5′ (SEQ ID NO: 1317) βc-1681 Target:5′-CCTGCCATCTGTGCTCTTCGTCATCTG-3′ (SEQ ID NO: 2426)5′-GCCAUCUGUGCUCUUCGUCAUCUGA-3′ (SEQ ID NO: 3536)3′-GACGGUAGACACGAGAAGCAGUAGACU-5′ (SEQ ID NO: 1318) βc-1682 Target:5′-CTGCCATCTGTGCTCTTCGTCATCTGA-3′ (SEQ ID NO: 2427)5′-CCAUCUGUGCUCUUCGUCAUCUGAC-3′ (SEQ ID NO: 3537)3′-ACGGUAGACACGAGAAGCAGUAGACUG-5′ (SEQ ID NO: 1319) βc-1683 Target:5′-TGCCATCTGTGCTCTTCGTCATCTGAC-3′ (SEQ ID NO: 2428)5′-CAUCUGUGCUCUUCGUCAUCUGACC-3′ (SEQ ID NO: 3538)3′-CGGUAGACACGAGAAGCAGUAGACUGG-5′ (SEQ ID NO: 1320) βc-1684 Target:5′-GCCATCTGTGCTCTTCGTCATCTGACC-3′ (SEQ ID NO: 2429)5′-AUCUGUGCUCUUCGUCAUCUGACCA-3′ (SEQ ID NO: 3539)3′-GGUAGACACGAGAAGCAGUAGACUGGU-5′ (SEQ ID NO: 1321) βc-1685 Target:5′-CCATCTGTGCTCTTCGTCATCTGACCA-3′ (SEQ ID NO: 2430)5′-UCUGUGCUCUUCGUCAUCUGACCAG-3′ (SEQ ID NO: 3540)3′-GUAGACACGAGAAGCAGUAGACUGGUC-5′ (SEQ ID NO: 1322) βc-1686 Target:5′-CATCTGTGCTCTTCGTCATCTGACCAG-3′ (SEQ ID NO: 2431)5′-CUGUGCUCUUCGUCAUCUGACCAGC-3′ (SEQ ID NO: 3541)3′-UAGACACGAGAAGCAGUAGACUGGUCG-5′ (SEQ ID NO: 1323) βc-1687 Target:5′-ATCTGTGCTCTTCGTCATCTGACCAGC-3′ (SEQ ID NO: 2432)5′-UGUGCUCUUCGUCAUCUGACCAGCC-3′ (SEQ ID NO: 3542)3′-AGACACGAGAAGCAGUAGACUGGUCGG-5′ (SEQ ID NO: 1324) βc-1688 Target:5′-TCTGTGCTCTTCGTCATCTGACCAGCC-3′ (SEQ ID NO: 2433)5′-GUGCUCUUCGUCAUCUGACCAGCCG-3′ (SEQ ID NO: 3543)3′-GACACGAGAAGCAGUAGACUGGUCGGC-5′ (SEQ ID NO: 1325) βc-1689 Target:5′-CTGTGCTCTTCGTCATCTGACCAGCCG-3′ (SEQ ID NO: 2434)5′-UGCUCUUCGUCAUCUGACCAGCCGA-3′ (SEQ ID NO: 3544)3′-ACACGAGAAGCAGUAGACUGGUCGGCU-5′ (SEQ ID NO: 1326) βc-1690 Target:5′-TGTGCTCTTCGTCATCTGACCAGCCGA-3′ (SEQ ID NO: 2435)5′-GCUCUUCGUCAUCUGACCAGCCGAC-3′ (SEQ ID NO: 3545)3′-CACGAGAAGCAGUAGACUGGUCGGCUG-5′ (SEQ ID NO: 1327) βc-1691 Target:5′-GTGCTCTTCGTCATCTGACCAGCCGAC-3′ (SEQ ID NO: 2436)5′-CUCUUCGUCAUCUGACCAGCCGACA-3′ (SEQ ID NO: 3546)3′-ACGAGAAGCAGUAGACUGGUCGGCUGU-5′ (SEQ ID NO: 1328) βc-1692 Target:5′-TGCTCTTCGTCATCTGACCAGCCGACA-3′ (SEQ ID NO: 2437)5′-UCUUCGUCAUCUGACCAGCCGACAC-3′ (SEQ ID NO: 3547)3′-CGAGAAGCAGUAGACUGGUCGGCUGUG-5′ (SEQ ID NO: 1329) βc-1693 Target:5′-GCTCTTCGTCATCTGACCAGCCGACAC-3′ (SEQ ID NO: 2438)5′-CUUCGUCAUCUGACCAGCCGACACC-3′ (SEQ ID NO: 3548)3′-GAGAAGCAGUAGACUGGUCGGCUGUGG-5′ (SEQ ID NO: 1330) βc-1694 Target:5′-CTCTTCGTCATCTGACCAGCCGACACC-3′ (SEQ ID NO: 2439)5′-UUCGUCAUCUGACCAGCCGACACCA-3′ (SEQ ID NO: 3549)3′-AGAAGCAGUAGACUGGUCGGCUGUGGU-5′ (SEQ ID NO: 1331) βc-1695 Target:5′-TCTTCGTCATCTGACCAGCCGACACCA-3′ (SEQ ID NO: 2440)5′-CACCCACCAUCCCACUGGCCUCUGA-3′ (SEQ ID NO: 3550)3′-AUGUGGGUGGUAGGGUGACCGGAGACU-5′ (SEQ ID NO: 1332) βc-1787 Target:5′-TACACCCACCATCCCACTGGCCTCTGA-3′ (SEQ ID NO: 2441)5′-ACCCACCAUCCCACUGGCCUCUGAU-3′ (SEQ ID NO: 3551)3′-UGUGGGUGGUAGGGUGACCGGAGACUA-5′ (SEQ ID NO: 1333) βc-1788 Target:5′-ACACCCACCATCCCACTGGCCTCTGAT-3′ (SEQ ID NO: 2442)5′-CCCACCAUCCCACUGGCCUCUGAUA-3′ (SEQ ID NO: 3552)3′-GUGGGUGGUAGGGUGACCGGAGACUAU-5′ (SEQ ID NO: 1334) βc-1789 Target:5′-CACCCACCATCCCACTGGCCTCTGATA-3′ (SEQ ID NO: 2443)5′-CCACCAUCCCACUGGCCUCUGAUAA-3′ (SEQ ID NO: 3553)3′-UGGGUGGUAGGGUGACCGGAGACUAUU-5′ (SEQ ID NO: 1335) βc-1790 Target:5′-ACCCACCATCCCACTGGCCTCTGATAA-3′ (SEQ ID NO: 2444)5′-CACCAUCCCACUGGCCUCUGAUAAA-3′ (SEQ ID NO: 3554)3′-GGGUGGUAGGGUGACCGGAGACUAUUU-5′ (SEQ ID NO: 1336) βc-1791 Target:5′-CCCACCATCCCACTGGCCTCTGATAAA-3′ (SEQ ID NO: 2445)5′-ACCAUCCCACUGGCCUCUGAUAAAG-3′ (SEQ ID NO: 3555)3′-GGUGGUAGGGUGACCGGAGACUAUUUC-5′ (SEQ ID NO: 1337) βc-1792 Target:5′-CCACCATCCCACTGGCCTCTGATAAAG-3′ (SEQ ID NO: 2446)5′-CCAUCCCACUGGCCUCUGAUAAAGG-3′ (SEQ ID NO: 3556)3′-GUGGUAGGGUGACCGGAGACUAUUUCC-5′ (SEQ ID NO: 1338) βc-1793 Target:5′-CACCATCCCACTGGCCTCTGATAAAGG-3′ (SEQ ID NO: 2447)5′-CAUCCCACUGGCCUCUGAUAAAGGC-3′ (SEQ ID NO: 3557)3′-UGGUAGGGUGACCGGAGACUAUUUCCG-5′ (SEQ ID NO: 1339) βc-1794 Target:5′-ACCATCCCACTGGCCTCTGATAAAGGC-3′ (SEQ ID NO: 2448)5′-AUCCCACUGGCCUCUGAUAAAGGCU-3′ (SEQ ID NO: 3558)3′-GGUAGGGUGACCGGAGACUAUUUCCGA-5′ (SEQ ID NO: 1340) βc-1795 Target:5′-CCATCCCACTGGCCTCTGATAAAGGCT-3′ (SEQ ID NO: 2449)5′-UCCCACUGGCCUCUGAUAAAGGCUA-3′ (SEQ ID NO: 3559)3′-GUAGGGUGACCGGAGACUAUUUCCGAU-5′ (SEQ ID NO: 1341) βc-1796 Target:5′-CATCCCACTGGCCTCTGATAAAGGCTA-3′ (SEQ ID NO: 2450)5′-CCCACUGGCCUCUGAUAAAGGCUAC-3′ (SEQ ID NO: 3560)3′-UAGGGUGACCGGAGACUAUUUCCGAUG-5′ (SEQ ID NO: 1342) βc-1797 Target:5′-ATCCCACTGGCCTCTGATAAAGGCTAC-3′ (SEQ ID NO: 2451)5′-CCACUGGCCUCUGAUAAAGGCUACU-3′ (SEQ ID NO: 3561)3′-AGGGUGACCGGAGACUAUUUCCGAUGA-5′ (SEQ ID NO: 1343) βc-1798 Target:5′-TCCCACTGGCCTCTGATAAAGGCTACT-3′ (SEQ ID NO: 2452)5′-CACUGGCCUCUGAUAAAGGCUACUG-3′ (SEQ ID NO: 3562)3′-GGGUGACCGGAGACUAUUUCCGAUGAC-5′ (SEQ ID NO: 1344) βc-1799 Target:5′-CCCACTGGCCTCTGATAAAGGCTACTG-3′ (SEQ ID NO: 2453)5′-ACUGGCCUCUGAUAAAGGCUACUGU-3′ (SEQ ID NO: 3563)3′-GGUGACCGGAGACUAUUUCCGAUGACA-5′ (SEQ ID NO: 1345) βc-1800 Target:5′-CCACTGGCCTCTGATAAAGGCTACTGT-3′ (SEQ ID NO: 2454)5′-ACUGUUGGAUUGAUUCGAAAUCUUG-3′ (SEQ ID NO: 3564)3′-GAUGACAACCUAACUAAGCUUUAGAAC-5′ (SEQ ID NO: 1346) βc-1820 Target:5′-CTACTGTTGGATTGATTCGAAATCTTG-3′ (SEQ ID NO: 2455)5′-CUGUUGGAUUGAUUCGAAAUCUUGC-3′ (SEQ ID NO: 3565)3′-AUGACAACCUAACUAAGCUUUAGAACG-5′ (SEQ ID NO: 1347) βc-1821 Target:5′-TACTGTTGGATTGATTCGAAATCTTGC-3′ (SEQ ID NO: 2456)5′-AAUACCAUUCCAUUGUUUGUGCAGC-3′ (SEQ ID NO: 3566)3′-AUUUAUGGUAAGGUAACAAACACGUCG-5′ (SEQ ID NO: 1348) βc-2072 Target:5′-TAAATACCATTCCATTGTTTGTGCAGC-3′ (SEQ ID NO: 2457)5′-AUACCAUUCCAUUGUUUGUGCAGCU-3′ (SEQ ID NO: 3567)3′-UUUAUGGUAAGGUAACAAACACGUCGA-5′ (SEQ ID NO: 1349) βc-2073 Target:5′-AAATACCATTCCATTGTTTGTGCAGCT-3′ (SEQ ID NO: 2458)5′-UACCAUUCCAUUGUUUGUGCAGCUG-3′ (SEQ ID NO: 3568)3′-UUAUGGUAAGGUAACAAACACGUCGAC-5′ (SEQ ID NO: 1350) βc-2074 Target:5′-AATACCATTCCATTGTTTGTGCAGCTG-3′ (SEQ ID NO: 2459)5′-ACCAUUCCAUUGUUUGUGCAGCUGC-3′ (SEQ ID NO: 3569)3′-UAUGGUAAGGUAACAAACACGUCGACG-5′ (SEQ ID NO: 1351) βc-2075 Target:5′-ATACCATTCCATTGTTTGTGCAGCTGC-3′ (SEQ ID NO: 2460)5′-CCAUUCCAUUGUUUGUGCAGCUGCU-3′ (SEQ ID NO: 3570)3′-AUGGUAAGGUAACAAACACGUCGACGA-5′ (SEQ ID NO: 1352) βc-2076 Target:5′-TACCATTCCATTGTTTGTGCAGCTGCT-3′ (SEQ ID NO: 2461)5′-CAUUCCAUUGUUUGUGCAGCUGCUU-3′ (SEQ ID NO: 3571)3′-UGGUAAGGUAACAAACACGUCGACGAA-5′ (SEQ ID NO: 1353) βc-2077 Target:5′-ACCATTCCATTGTTTGTGCAGCTGCTT-3′ (SEQ ID NO: 2462)5′-UGCUUUAUUCUCCCAUUGAAAACAU-3′ (SEQ ID NO: 3572)3′-CGACGAAAUAAGAGGGUAACUUUUGUA-5′ (SEQ ID NO: 1354) βc-2097 Target:5′-GCTGCTTTATTCTCCCATTGAAAAC-3′ (SEQ ID NO: 2463)5′-GCUUUAUUCUCCCAUUGAAAACAUC-3′ (SEQ ID NO: 3573)3′-GACGAAAUAAGAGGGUAACUUUUGUAG-5′ (SEQ ID NO: 1355) βc-2098 Target:5′-CTGCTTTATTCTCCCATTGAAAACATC-3′ (SEQ ID NO: 2464)5′-CUUUAUUCUCCCAUUGAAAACAUCC-3′ (SEQ ID NO: 3574)3′-ACGAAAUAAGAGGGUAACUUUUGUAGG-5′ (SEQ ID NO: 1356) βc-2099 Target:5′-TGCTTTATTCTCCCATTGAAAACATCC-3′ (SEQ ID NO: 2465)5′-UUUAUUCUCCCAUUGAAAACAUCCA-3′ (SEQ ID NO: 3575)3′-CGAAAUAAGAGGGUAACUUUUGUAGGU-5′ (SEQ ID NO: 1357) βc-2100 Target:5′-GCTTTATTCTCCCATTGAAAACATCCA-3′ (SEQ ID NO: 2466)5′-GUCCUCUGUGAACUUGCUCAGGACA-3′ (SEQ ID NO: 3576)3′-CCCAGGAGACACUUGAACGAGUCCUGU-5′ (SEQ ID NO: 1358) βc-2141 Target:5′-GGGTCCTCTGTGAACTTGCTCAGGACA-3′ (SEQ ID NO: 2467)5′-UCCUCUGUGAACUUGCUCAGGACAA-3′ (SEQ ID NO: 3577)3′-CCAGGAGACACUUGAACGAGUCCUGUU-5′ (SEQ ID NO: 1359) βc-2142 Target:5′-GGTCCTCTGTGAACTTGCTCAGGACAA-3′ (SEQ ID NO: 2468)5′-CCUCUGUGAACUUGCUCAGGACAAG-3′ (SEQ ID NO: 3578)3′-CAGGAGACACUUGAACGAGUCCUGUUC-5′ (SEQ ID NO: 1360) βc-2143 Target:5′-GTCCTCTGTGAACTTGCTCAGGACAAG-3′ (SEQ ID NO: 2469)5′-CUCUGUGAACUUGCUCAGGACAAGG-3′ (SEQ ID NO: 3579)3′-AGGAGACACUUGAACGAGUCCUGUUCC-5′ (SEQ ID NO: 1361) βc-2144 Target:5′-TCCTCTGTGAACTTGCTCAGGACAAGG-3′ (SEQ ID NO: 2470)5′-UCUGUGAACUUGCUCAGGACAAGGA-3′ (SEQ ID NO: 3580)3′-GGAGACACUUGAACGAGUCCUGUUCCU-5′ (SEQ ID NO: 1362) βc-2145 Target:5′-CCTCTGTGAACTTGCTCAGGACAAGGA-3′ (SEQ ID NO: 2471)5′-CUGUGAACUUGCUCAGGACAAGGAA-3′ (SEQ ID NO: 3581)3′-GAGACACUUGAACGAGUCCUGUUCCUU-5′ (SEQ ID NO: 1363) βc-2146 Target:5′-CTCTGTGAACTTGCTCAGGACAAGGAA-3′ (SEQ ID NO: 2472)5′-UGUGAACUUGCUCAGGACAAGGAAG-3′ (SEQ ID NO: 3582)3′-AGACACUUGAACGAGUCCUGUUCCUUC-5′ (SEQ ID NO: 1364) βc-2147 Target:5′-TCTGTGAACTTGCTCAGGACAAGGAAG-3′ (SEQ ID NO: 2473)5′-GUGAACUUGCUCAGGACAAGGAAGC-3′ (SEQ ID NO: 3583)3′-GACACUUGAACGAGUCCUGUUCCUUCG-5′ (SEQ ID NO: 1365) βc-2148 Target:5′-CTGTGAACTTGCTCAGGACAAGGAAGC-3′ (SEQ ID NO: 2474)5′-UGAACUUGCUCAGGACAAGGAAGCU-3′ (SEQ ID NO: 3584)3′-ACACUUGAACGAGUCCUGUUCCUUCGA-5′ (SEQ ID NO: 1366) βc-2149 Target:5′-TGTGAACTTGCTCAGGACAAGGAAGCT-3′ (SEQ ID NO: 2475)5′-GAACUUGCUCAGGACAAGGAAGCUG-3′ (SEQ ID NO: 3585)3′-CACUUGAACGAGUCCUGUUCCUUCGAC-5′ (SEQ ID NO: 1367) βc-2150 Target:5′-GTGAACTTGCTCAGGACAAGGAAGCTG-3′ (SEQ ID NO: 2476)5′-AACUUGCUCAGGACAAGGAAGCUGC-3′ (SEQ ID NO: 3586)3′-ACUUGAACGAGUCCUGUUCCUUCGACG-5′ (SEQ ID NO: 1368) βc-2151 Target:5′-TGAACTTGCTCAGGACAAGGAAGCTGC-3′ (SEQ ID NO: 2477)5′-AUUGAAGCUGAGGGAGCCACAGCUC-3′ (SEQ ID NO: 3587)3′-GAUAACUUCGACUCCCUCGGUGUCGAG-5′ (SEQ ID NO: 1369) βc-2183 Target:5′-CTATTGAAGCTGAGGGAGCCACAGCTC-3′ (SEQ ID NO: 2478)5′-UUGAAGCUGAGGGAGCCACAGCUCC-3′ (SEQ ID NO: 3588)3′-AUAACUUCGACUCCCUCGGUGUCGAGG-5′ (SEQ ID NO: 1370) βc-2184 Target:5′-TATTGAAGCTGAGGGAGCCACAGCTCC-3′ (SEQ ID NO: 2479)5′-UGAAGCUGAGGGAGCCACAGCUCCU-3′ (SEQ ID NO: 3589)3′-UAACUUCGACUCCCUCGGUGUCGAGGA-5′ (SEQ ID NO: 1371) βc-2185 Target:5′-ATTGAAGCTGAGGGAGCCACAGCTCCT-3′ (SEQ ID NO: 2480)5′-UUCCGAAUGUCUGAGGACAAGCCAC-3′ (SEQ ID NO: 3590)3′-ACAAGGCUUACAGACUCCUGUUCGGUG-5′ (SEQ ID NO: 1372) βc-2270 Target:5′-TGTTCCGAATGTCTGAGGACAAGCCAC-3′ (SEQ ID NO: 2481)5′-UCCGAAUGUCUGAGGACAAGCCACA-3′ (SEQ ID NO: 3591)3′-CAAGGCUUACAGACUCCUGUUCGGUGU-5′ (SEQ ID NO: 1373) βc-2271 Target:5′-GTTCCGAATGTCTGAGGACAAGCCACA-3′ (SEQ ID NO: 2482)5′-CCGAAUGUCUGAGGACAAGCCACAA-3′ (SEQ ID NO: 3592)3′-AAGGCUUACAGACUCCUGUUCGGUGUU-5′ (SEQ ID NO: 1374) βc-2272 Target:5′-TTCCGAATGTCTGAGGACAAGCCACAA-3′ (SEQ ID NO: 2483)5′-CGAAUGUCUGAGGACAAGCCACAAG-3′ (SEQ ID NO: 3593)3′-AGGCUUACAGACUCCUGUUCGGUGUUC-5′ (SEQ ID NO: 1375) βc-2273 Target:5′-TCCGAATGTCTGAGGACAAGCCACAAG-3′ (SEQ ID NO: 2484)5′-GAAUGUCUGAGGACAAGCCACAAGA-3′ (SEQ ID NO: 3594)3′-GGCUUACAGACUCCUGUUCGGUGUUCU-5′ (SEQ ID NO: 1376) βc-2274 Target:5′-CCGAATGTCTGAGGACAAGCCACAAGA-3′ (SEQ ID NO: 2485)5′-AAUGUCUGAGGACAAGCCACAAGAU-3′ (SEQ ID NO: 3595)3′-GCUUACAGACUCCUGUUCGGUGUUCUA-5′ (SEQ ID NO: 1377) βc-2275 Target:5′-CGAATGTCTGAGGACAAGCCACAAGAT-3′ (SEQ ID NO: 2486)5′-AUGUCUGAGGACAAGCCACAAGAUU-3′ (SEQ ID NO: 3596)3′-CUUACAGACUCCUGUUCGGUGUUCUAA-5′ (SEQ ID NO: 1378) βc-2276 Target:5′-GAATGTCTGAGGACAAGCCACAAGATT-3′ (SEQ ID NO: 2487)5′-UGUCUGAGGACAAGCCACAAGAUUA-3′ (SEQ ID NO: 3597)3′-UUACAGACUCCUGUUCGGUGUUCUAAU-5′ (SEQ ID NO: 1379) βc-2277 Target:5′-AATGTCTGAGGACAAGCCACAAGATTA-3′ (SEQ ID NO: 2488)5′-ACAGAGCCAAUGGCUUGGAAUGAGA-3′ (SEQ ID NO: 3598)3′-CUUGUCUCGGUUACCGAACCUUACUCU-5′ (SEQ ID NO: 1380) βc-2345 Target:5′-GAACAGAGCCAATGGCTTGGAATGAGA-3′ (SEQ ID NO: 2489)5′-CAGAGCCAAUGGCUUGGAAUGAGAC-3′ (SEQ ID NO: 3599)3′-UUGUCUCGGUUACCGAACCUUACUCUG-5′ (SEQ ID NO: 1381) βc-2346 Target:5′-AACAGAGCCAATGGCTTGGAATGAGAC-3′ (SEQ ID NO: 2490)5′-AGAGCCAAUGGCUUGGAAUGAGACU-3′ (SEQ ID NO: 3600)3′-UGUCUCGGUUACCGAACCUUACUCUGA-5′ (SEQ ID NO: 1382) βc-2347 Target:5′-ACAGAGCCAATGGCTTGGAATGAGACT-3′ (SEQ ID NO: 2491)5′-GAGCCAAUGGCUUGGAAUGAGACUG-3′ (SEQ ID NO: 3601)3′-GUCUCGGUUACCGAACCUUACUCUGAC-5′ (SEQ ID NO: 1383) βc-2348 Target:5′-CAGAGCCAATGGCTTGGAATGAGACTG-3′ (SEQ ID NO: 2492)5′-AGCCAAUGGCUUGGAAUGAGACUGC-3′ (SEQ ID NO: 3602)3′-UCUCGGUUACCGAACCUUACUCUGACG-5′ (SEQ ID NO: 1384) βc-2349 Target:5′-AGAGCCAATGGCTTGGAATGAGACTGC-3′ (SEQ ID NO: 2493)5′-GCCAAUGGCUUGGAAUGAGACUGCU-3′ (SEQ ID NO: 3603)3′-CUCGGUUACCGAACCUUACUCUGACGA-5′ (SEQ ID NO: 1385) βc-2350 Target:5′-GAGCCAATGGCTTGGAATGAGACTGCT-3′ (SEQ ID NO: 2494)5′-CCAAUGGCUUGGAAUGAGACUGCUG-3′ (SEQ ID NO: 3604)3′-UCGGUUACCGAACCUUACUCUGACGAC-5′ (SEQ ID NO: 1386) βc-2351 Target:5′-AGCCAATGGCTTGGAATGAGACTGCTG-3′ (SEQ ID NO: 2495)5′-CAAUGGCUUGGAAUGAGACUGCUGA-3′ (SEQ ID NO: 3605)3′-CGGUUACCGAACCUUACUCUGACGACU-5′ (SEQ ID NO: 1387) βc-2352 Target:5′-GCCAATGGCTTGGAATGAGACTGCTGA-3′ (SEQ ID NO: 2496)5′-AAUGGCUUGGAAUGAGACUGCUGAU-3′ (SEQ ID NO: 3606)3′-GGUUACCGAACCUUACUCUGACGACUA-5′ (SEQ ID NO: 1388) βc-2353 Target:5′-CCAATGGCTTGGAATGAGACTGCTGAT-3′ (SEQ ID NO: 2497)5′-AUGGCUUGGAAUGAGACUGCUGAUC-3′ (SEQ ID NO: 3607)3′-GUUACCGAACCUUACUCUGACGACUAG-5′ (SEQ ID NO: 1389) βc-2354 Target:5′-CAATGGCTTGGAATGAGACTGCTGATC-3′ (SEQ ID NO: 2498)5′-UGGCUUGGAAUGAGACUGCUGAUCU-3′ (SEQ ID NO: 3608)3′-UUACCGAACCUUACUCUGACGACUAGA-5′ (SEQ ID NO: 1390) βc-2355 Target:5′-AATGGCTTGGAATGAGACTGCTGATCT-3′ (SEQ ID NO: 2499)5′-CUUGGAUAUCGCCAGGAUGAUCCUA-3′ (SEQ ID NO: 3609)3′-GGGAACCUAUAGCGGUCCUACUAGGAU-5′ (SEQ ID NO: 1391) βc-2411 Target:5′-CCCTTGGATATCGCCAGGATGATCCTA-3′ (SEQ ID NO: 2500)5′-UUGGAUAUCGCCAGGAUGAUCCUAG-3′ (SEQ ID NO: 3610)3′-GGAACCUAUAGCGGUCCUACUAGGAUC-5′ (SEQ ID NO: 1392) βc-2412 Target:5′-CCTTGGATATCGCCAGGATGATCCTAG-3′ (SEQ ID NO: 2501)5′-UGGAUAUCGCCAGGAUGAUCCUAGC-3′ (SEQ ID NO: 3611)3′-GAACCUAUAGCGGUCCUACUAGGAUCG-5′ (SEQ ID NO: 1393) βc-2413 Target:5′-CTTGGATATCGCCAGGATGATCCTAGC-3′ (SEQ ID NO: 2502)5′-GGAUAUCGCCAGGAUGAUCCUAGCU-3′ (SEQ ID NO: 3612)3′-AACCUAUAGCGGUCCUACUAGGAUCGA-5′ (SEQ ID NO: 1394) βc-2414 Target:5′-TTGGATATCGCCAGGATGATCCTAGCT-3′ (SEQ ID NO: 2503)5′-GAUAUCGCCAGGAUGAUCCUAGCUA-3′ (SEQ ID NO: 3613)3′-ACCUAUAGCGGUCCUACUAGGAUCGAU-5′ (SEQ ID NO: 1395) βc-2415 Target:5′-TGGATATCGCCAGGATGATCCTAGCTA-3′ (SEQ ID NO: 2504)5′-CGUUCUUUUCACUCUGGUGGAUAUG-3′ (SEQ ID NO: 3614)3′-UAGCAAGAAAAGUGAGACCACCUAUAC-5′ (SEQ ID NO: 1396) βc-2441 Target:5′-ATCGTTCTTTTCACTCTGGTGGATATG-3′ (SEQ ID NO: 2505)5′-GUUCUUUUCACUCUGGUGGAUAUGG-3′ (SEQ ID NO: 3615)3′-AGCAAGAAAAGUGAGACCACCUAUACC-5′ (SEQ ID NO: 1397) βc-2442 Target:5′-TCGTTCTTTTCACTCTGGTGGATATGG-3′ (SEQ ID NO: 2506)5′-UUCUUUUCACUCUGGUGGAUAUGGC-3′ (SEQ ID NO: 3616)3′-GCAAGAAAAGUGAGACCACCUAUACCG-5′ (SEQ ID NO: 1398) βc-2443 Target:5′-CGTTCTTTTCACTCTGGTGGATATGGC-3′ (SEQ ID NO: 2507)5′-UCUUUUCACUCUGGUGGAUAUGGCC-3′ (SEQ ID NO: 3617)3′-CAAGAAAAGUGAGACCACCUAUACCGG-5′ (SEQ ID NO: 1399) βc-2444 Target:5′-GTTCTTTTCACTCTGGTGGATATGGCC-3′ (SEQ ID NO: 2508)5′-CUUUUCACUCUGGUGGAUAUGGCCA-3′ (SEQ ID NO: 3618)3′-AAGAAAAGUGAGACCACCUAUACCGGU-5′ (SEQ ID NO: 1400) βc-2445 Target:5′-TTCTTTTCACTCTGGTGGATATGGCCA-3′ (SEQ ID NO: 2509)5′-CAUGAGAUGGGUGGCCACCACCCUG-3′ (SEQ ID NO: 3619)3′-UUGUACUCUACCCACCGGUGGUGGGAC-5′ (SEQ ID NO: 1401) βc-2501 Target:5′-AACATGAGATGGGTGGCCACCACCCTG-3′ (SEQ ID NO: 2510)5′-AUGAGAUGGGUGGCCACCACCCUGG-3′ (SEQ ID NO: 3620)3′-UGUACUCUACCCACCGGUGGUGGGACC-5′ (SEQ ID NO: 1402) βc-2502 Target:5′-ACATGAGATGGGTGGCCACCACCCTGG-3′ (SEQ ID NO: 2511)5′-UGAGAUGGGUGGCCACCACCCUGGU-3′ (SEQ ID NO: 3621)3′-GUACUCUACCCACCGGUGGUGGGACCA-5′ (SEQ ID NO: 1403) βc-2503 Target:5′-CATGAGATGGGTGGCCACCACCCTGGT-3′ (SEQ ID NO: 2512)5′-GAGAUGGGUGGCCACCACCCUGGUG-3′ (SEQ ID NO: 3622)3′-UACUCUACCCACCGGUGGUGGGACCAC-5′ (SEQ ID NO: 1404) βc-2504 Target:5′-ATGAGATGGGTGGCCACCACCCTGGTG-3′ (SEQ ID NO: 2513)5′-AGAUGGGUGGCCACCACCCUGGUGC-3′ (SEQ ID NO: 3623)3′-ACUCUACCCACCGGUGGUGGGACCACG-5′ (SEQ ID NO: 1405) βc-2505 Target:5′-TGAGATGGGTGGCCACCACCCTGGTGC-3′ (SEQ ID NO: 2514)5′-GAUGGGUGGCCACCACCCUGGUGCU-3′ (SEQ ID NO: 3624)3′-CUCUACCCACCGGUGGUGGGACCACGA-5′ (SEQ ID NO: 1406) βc-2506 Target:5′-GAGATGGGTGGCCACCACCCTGGTGCT-3′ (SEQ ID NO: 2515)5′-AUGGGUGGCCACCACCCUGGUGCUG-3′ (SEQ ID NO: 3625)3′-UCUACCCACCGGUGGUGGGACCACGAC-5′ (SEQ ID NO: 1407) βc-2507 Target:5′-AGATGGGTGGCCACCACCCTGGTGCTG-3′ (SEQ ID NO: 2516)5′-UGGGUGGCCACCACCCUGGUGCUGA-3′ (SEQ ID NO: 3626)3′-CUACCCACCGGUGGUGGGACCACGACU-5′ (SEQ ID NO: 1408) βc-2508 Target:5′-GATGGGTGGCCACCACCCTGGTGCTGA-3′ (SEQ ID NO: 2517)5′-GGGUGGCCACCACCCUGGUGCUGAC-3′ (SEQ ID NO: 3627)3′-UACCCACCGGUGGUGGGACCACGACUG-5′ (SEQ ID NO: 1409) βc-2509 Target:5′-ATGGGTGGCCACCACCCTGGTGCTGAC-3′ (SEQ ID NO: 2518)5′-GGUGGCCACCACCCUGGUGCUGACU-3′ (SEQ ID NO: 3628)3′-ACCCACCGGUGGUGGGACCACGACUGA-5′ (SEQ ID NO: 1410) βc-2510 Target:5′-TGGGTGGCCACCACCCTGGTGCTGACT-3′ (SEQ ID NO: 2519)5′-GUGGCCACCACCCUGGUGCUGACUA-3′ (SEQ ID NO: 3629)3′-CCCACCGGUGGUGGGACCACGACUGAU-5′ (SEQ ID NO: 1411) βc-2511 Target:5′-GGGTGGCCACCACCCTGGTGCTGACTA-3′ (SEQ ID NO: 2520)5′-UGGCCACCACCCUGGUGCUGACUAU-3′ (SEQ ID NO: 3630)3′-CCACCGGUGGUGGGACCACGACUGAUA-5′ (SEQ ID NO: 1412) βc-2512 Target:5′-GGTGGCCACCACCCTGGTGCTGACTAT-3′ (SEQ ID NO: 2521)5′-GGCCACCACCCUGGUGCUGACUAUC-3′ (SEQ ID NO: 3631)3′-CACCGGUGGUGGGACCACGACUGAUAG-5′ (SEQ ID NO: 1413) βc-2513 Target:5′-GTGGCCACCACCCTGGTGCTGACTATC-3′ (SEQ ID NO: 2522)5′-GCCACCACCCUGGUGCUGACUAUCC-3′ (SEQ ID NO: 3632)3′-ACCGGUGGUGGGACCACGACUGAUAGG-5′ (SEQ ID NO: 1414) βc-2514 Target:5′-TGGCCACCACCCTGGTGCTGACTATCC-3′ (SEQ ID NO: 2523)5′-CCACCACCCUGGUGCUGACUAUCCA-3′ (SEQ ID NO: 3633)3′-CCGGUGGUGGGACCACGACUGAUAGGU-5′ (SEQ ID NO: 1415) βc-2515 Target:5′-GGCCACCACCCTGGTGCTGACTATCCA-3′ (SEQ ID NO: 2524)5′-CACCACCCUGGUGCUGACUAUCCAG-3′ (SEQ ID NO: 3634)3′-CGGUGGUGGGACCACGACUGAUAGGUC-5′ (SEQ ID NO: 1416) βc-2516 Target:5′-GCCACCACCCTGGTGCTGACTATCCAG-3′ (SEQ ID NO: 2525)5′-ACCACCCUGGUGCUGACUAUCCAGU-3′ (SEQ ID NO: 3635)3′-GGUGGUGGGACCACGACUGAUAGGUCA-5′ (SEQ ID NO: 1417) βc-2517 Target:5′-CCACCACCCTGGTGCTGACTATCCAGT-3′ (SEQ ID NO: 2526)5′-CCACCCUGGUGCUGACUAUCCAGUU-3′ (SEQ ID NO: 3636)3′-GUGGUGGGACCACGACUGAUAGGUCAA-5′ (SEQ ID NO: 1418) βc-2518 Target:5′-CACCACCCTGGTGCTGACTATCCAGTT-3′ (SEQ ID NO: 2527)5′-CACCCUGGUGCUGACUAUCCAGUUG-3′ (SEQ ID NO: 3637)3′-UGGUGGGACCACGACUGAUAGGUCAAC-5′ (SEQ ID NO: 1419) βc-2519 Target:5′-ACCACCCTGGTGCTGACTATCCAGTTG-3′ (SEQ ID NO: 2528)5′-ACCCUGGUGCUGACUAUCCAGUUGA-3′ (SEQ ID NO: 3638)3′-GGUGGGACCACGACUGAUAGGUCAACU-5′ (SEQ ID NO: 1420) βc-2520 Target:5′-CCACCCTGGTGCTGACTATCCAGTTGA-3′ (SEQ ID NO: 2529)5′-CCCUGGUGCUGACUAUCCAGUUGAU-3′ (SEQ ID NO: 3639)3′-GUGGGACCACGACUGAUAGGUCAACUA-5′ (SEQ ID NO: 1421) βc-2521 Target:5′-CACCCTGGTGCTGACTATCCAGTTGAT-3′ (SEQ ID NO: 2530)5′-CCUGGUGCUGACUAUCCAGUUGAUG-3′ (SEQ ID NO: 3640)3′-UGGGACCACGACUGAUAGGUCAACUAC-5′ (SEQ ID NO: 1422) βc-2522 Target:5′-ACCCTGGTGCTGACTATCCAGTTGATG-3′ (SEQ ID NO: 2531)5′-CUGGUGCUGACUAUCCAGUUGAUGG-3′ (SEQ ID NO: 3641)3′-GGGACCACGACUGAUAGGUCAACUACC-5′ (SEQ ID NO: 1423) βc-2523 Target:5′-CCCTGGTGCTGACTATCCAGTTGATGG-3′ (SEQ ID NO: 2532)5′-UGGUGCUGACUAUCCAGUUGAUGGG-3′ (SEQ ID NO: 3642)3′-GGACCACGACUGAUAGGUCAACUACCC-5′ (SEQ ID NO: 1424) βc-2524 Target:5′-CCTGGTGCTGACTATCCAGTTGATGGG-3′ (SEQ ID NO: 2533)5′-GGUGCUGACUAUCCAGUUGAUGGGC-3′ (SEQ ID NO: 3643)3′-GACCACGACUGAUAGGUCAACUACCCG-5′ (SEQ ID NO: 1425) βc-2525 Target:5′-CTGGTGCTGACTATCCAGTTGATGGGC-3′ (SEQ ID NO: 2534)5′-GUGCUGACUAUCCAGUUGAUGGGCU-3′ (SEQ ID NO: 3644)3′-ACCACGACUGAUAGGUCAACUACCCGA-5′ (SEQ ID NO: 1426) βc-2526 Target:5′-TGGTGCTGACTATCCAGTTGATGGGCT-3′ (SEQ ID NO: 2535)5′-UGCUGACUAUCCAGUUGAUGGGCUG-3′ (SEQ ID NO: 3645)3′-CCACGACUGAUAGGUCAACUACCCGAC-5′ (SEQ ID NO: 1427) βc-2527 Target:5′-GGTGCTGACTATCCAGTTGATGGGCTG-3′ (SEQ ID NO: 2536)5′-GCUGACUAUCCAGUUGAUGGGCUGC-3′ (SEQ ID NO: 3646)3′-CACGACUGAUAGGUCAACUACCCGACG-5′ (SEQ ID NO: 1428) βc-2528 Target:5′-GTGCTGACTATCCAGTTGATGGGCTGC-3′ (SEQ ID NO: 2537)5′-CUGACUAUCCAGUUGAUGGGCUGCC-3′ (SEQ ID NO: 3647)3′-ACGACUGAUAGGUCAACUACCCGACGG-5′ (SEQ ID NO: 1429) βc-2529 Target:5′-TGCTGACTATCCAGTTGATGGGCTGCC-3′ (SEQ ID NO: 2538)5′-UGACUAUCCAGUUGAUGGGCUGCCA-3′ (SEQ ID NO: 3648)3′-CGACUGAUAGGUCAACUACCCGACGGU-5′ (SEQ ID NO: 1430) βc-2530 Target:5′-GCTGACTATCCAGTTGATGGGCTGCCA-3′ (SEQ ID NO: 2539)5′-GACUAUCCAGUUGAUGGGCUGCCAG-3′ (SEQ ID NO: 3649)3′-GACUGAUAGGUCAACUACCCGACGGUC-5′ (SEQ ID NO: 1431) βc-2531 Target:5′-CTGACTATCCAGTTGATGGGCTGCCAG-3′ (SEQ ID NO: 2540)5′-ACUAUCCAGUUGAUGGGCUGCCAGA-3′ (SEQ ID NO: 3650)3′-ACUGAUAGGUCAACUACCCGACGGUCU-5′ (SEQ ID NO: 1432) βc-2532 Target:5′-TGACTATCCAGTTGATGGGCTGCCAGA-3′ (SEQ ID NO: 2541)5′-CUAUCCAGUUGAUGGGCUGCCAGAU-3′ (SEQ ID NO: 3651)3′-CUGAUAGGUCAACUACCCGACGGUCUA-5′ (SEQ ID NO: 1433) βc-2533 Target:5′-GACTATCCAGTTGATGGGCTGCCAGAT-3′ (SEQ ID NO: 2542)5′-UAUCCAGUUGAUGGGCUGCCAGAUC-3′ (SEQ ID NO: 3652)3′-UGAUAGGUCAACUACCCGACGGUCUAG-5′ (SEQ ID NO: 1434) βc-2534 Target:5′-ACTATCCAGTTGATGGGCTGCCAGATC-3′ (SEQ ID NO: 2543)5′-AUCCAGUUGAUGGGCUGCCAGAUCU-3′ (SEQ ID NO: 3653)3′-GAUAGGUCAACUACCCGACGGUCUAGA-5′ (SEQ ID NO: 1435) βc-2535 Target:5′-CTATCCAGTTGATGGGCTGCCAGATCT-3′ (SEQ ID NO: 2544)5′-GCCCAGGACCUCAUGGAUGGGCUGC-3′ (SEQ ID NO: 3654)3′-UACGGGUCCUGGAGUACCUACCCGACG-5′ (SEQ ID NO: 1436) βc-2567 Target:5′-ATGCCCAGGACCTCATGGATGGGCTGC-3′ (SEQ ID NO: 2545)5′-CCCAGGACCUCAUGGAUGGGCUGCC-3′ (SEQ ID NO: 3655)3′-ACGGGUCCUGGAGUACCUACCCGACGG-5′ (SEQ ID NO: 1437) βc-2568 Target:5′-TGCCCAGGACCTCATGGATGGGCTGCC-3′ (SEQ ID NO: 2546)5′-CCAGGACCUCAUGGAUGGGCUGCCU-3′ (SEQ ID NO: 3656)3′-CGGGUCCUGGAGUACCUACCCGACGGA-5′ (SEQ ID NO: 1438) βc-2569 Target:5′-GCCCAGGACCTCATGGATGGGCTGCCT-3′ (SEQ ID NO: 2547)5′-AGCAAUCAGCUGGCCUGGUUUGAUA-3′ (SEQ ID NO: 3657)3′-UGUCGUUAGUCGACCGGACCAAACUAU-5′ (SEQ ID NO: 1439) βc-2603 Target:5′-ACAGCAATCAGCTGGCCTGGTTTGATA-3′ (SEQ ID NO: 2548)5′-GCAAUCAGCUGGCCUGGUUUGAUAC-3′ (SEQ ID NO: 3658)3′-GUCGUUAGUCGACCGGACCAAACUAUG-5′ (SEQ ID NO: 1440) βc-2604 Target:5′-CAGCAATCAGCTGGCCTGGTTTGATAC-3′ (SEQ ID NO: 2549)5′-CAAUCAGCUGGCCUGGUUUGAUACU-3′ (SEQ ID NO: 3659)3′-UCGUUAGUCGACCGGACCAAACUAUGA-5′ (SEQ ID NO: 1441) βc-2605 Target:5′-AGCAATCAGCTGGCCTGGTTTGATACT-3′ (SEQ ID NO: 2550)5′-AAUCAGCUGGCCUGGUUUGAUACUG-3′ (SEQ ID NO: 3660)3′-CGUUAGUCGACCGGACCAAACUAUGAC-5′ (SEQ ID NO: 1442) βc-2606 Target:5′-GCAATCAGCTGGCCTGGTTTGATACTG-3′ (SEQ ID NO: 2551)5′-AUCAGCUGGCCUGGUUUGAUACUGA-3′ (SEQ ID NO: 3661)3′-GUUAGUCGACCGGACCAAACUAUGACU-5′ (SEQ ID NO: 1443) βc-2607 Target:5′-CAATCAGCTGGCCTGGTTTGATACTGA-3′ (SEQ ID NO: 2552)5′-UCAGCUGGCCUGGUUUGAUACUGAC-3′ (SEQ ID NO: 3662)3′-UUAGUCGACCGGACCAAACUAUGACUG-5′ (SEQ ID NO: 1444) βc-2608 Target:5′-AATCAGCTGGCCTGGTTTGATACTGAC-3′ (SEQ ID NO: 2553)5′-CAGCUGGCCUGGUUUGAUACUGACC-3′ (SEQ ID NO: 3663)3′-UAGUCGACCGGACCAAACUAUGACUGG-5′ (SEQ ID NO: 1445) βc-2609 Target:5′-ATCAGCTGGCCTGGTTTGATACTGACC-3′ (SEQ ID NO: 2554)5′-AGCUGGCCUGGUUUGAUACUGACCU-3′ (SEQ ID NO: 3664)3′-AGUCGACCGGACCAAACUAUGACUGGA-5′ (SEQ ID NO: 1446) βc-2610 Target:5′-TCAGCTGGCCTGGTTTGATACTGACCT-3′ (SEQ ID NO: 2555)5′-GCUGGCCUGGUUUGAUACUGACCUG-3′ (SEQ ID NO: 3665)3′-GUCGACCGGACCAAACUAUGACUGGAC-5′ (SEQ ID NO: 1447) βc-2611 Target:5′-CAGCTGGCCTGGTTTGATACTGACCTG-3′ (SEQ ID NO: 2556)5′-CUGGCCUGGUUUGAUACUGACCUGU-3′ (SEQ ID NO: 3666)3′-UCGACCGGACCAAACUAUGACUGGACA-5′ (SEQ ID NO: 1448) βc-2612 Target:5′-AGCTGGCCTGGTTTGATACTGACCTGT-3′ (SEQ ID NO: 2557)5′-UGGCCUGGUUUGAUACUGACCUGUA-3′ (SEQ ID NO: 3667)3′-CGACCGGACCAAACUAUGACUGGACAU-5′ (SEQ ID NO: 1449) βc-2613 Target:5′-GCTGGCCTGGTTTGATACTGACCTGTA-3′ (SEQ ID NO: 2558)5′-GGCCUGGUUUGAUACUGACCUGUAA-3′ (SEQ ID NO: 3668)3′-GACCGGACCAAACUAUGACUGGACAUU-5′ (SEQ ID NO: 1450) βc-2614 Target:5′-CTGGCCTGGTTTGATACTGACCTGTAA-3′ (SEQ ID NO: 2559)5′-GCCUGGUUUGAUACUGACCUGUAAA-3′ (SEQ ID NO: 3669)3′-ACCGGACCAAACUAUGACUGGACAUUU-5′ (SEQ ID NO: 1451) βc-2615 Target:5′-TGGCCTGGTTTGATACTGACCTGTAAA-3′ (SEQ ID NO: 2560)5′-CCUGGUUUGAUACUGACCUGUAAAU-3′ (SEQ ID NO: 3670)3′-CCGGACCAAACUAUGACUGGACAUUUA-5′ (SEQ ID NO: 1452) βc-2616 Target:5′-GGCCTGGTTTGATACTGACCTGTAAAT-3′ (SEQ ID NO: 2561)5′-CUGGUUUGAUACUGACCUGUAAAUC-3′ (SEQ ID NO: 3671)3′-CGGACCAAACUAUGACUGGACAUUUAG-5′ (SEQ ID NO: 1453) βc-2617 Target:5′-GCCTGGTTTGATACTGACCTGTAAATC-3′ (SEQ ID NO: 2562)5′-UGGUUUGAUACUGACCUGUAAAUCA-3′ (SEQ ID NO: 3672)3′-GGACCAAACUAUGACUGGACAUUUAGU-5′ (SEQ ID NO: 1454) βc-2618 Target:5′-CCTGGTTTGATACTGACCTGTAAATCA-3′ (SEQ ID NO: 2563)5′-GGUUUGAUACUGACCUGUAAAUCAU-3′ (SEQ ID NO: 3673)3′-GACCAAACUAUGACUGGACAUUUAGUA-5′ (SEQ ID NO: 1455) βc-2619 Target:5′-CTGGTTTGATACTGACCTGTAAATC-3′ (SEQ ID NO: 2564)5′-GUUUGAUACUGACCUGUAAAUCAUC-3′ (SEQ ID NO: 3674)3′-ACCAAACUAUGACUGGACAUUUAGUAG-5′ (SEQ ID NO: 1456) βc-2620 Target:5′-TGGTTTGATACTGACCTGTAAATCATC-3′ (SEQ ID NO: 2565)5′-UUUGAUACUGACCUGUAAAUCAUCC-3′ (SEQ ID NO: 3675)3′-CCAAACUAUGACUGGACAUUUAGUAGG-5′ (SEQ ID NO: 1457) βc-2621 Target:5′-GGTTTGATACTGACCTGTAAATCATCC-3′ (SEQ ID NO: 2566)5′-UUGAUACUGACCUGUAAAUCAUCCU-3′ (SEQ ID NO: 3676)3′-CAAACUAUGACUGGACAUUUAGUAGGA-5′ (SEQ ID NO: 1458) βc-2622 Target:5′-GTTTGATACTGACCTGTAAATCATCCT-3′ (SEQ ID NO: 2567)5′-UGAUACUGACCUGUAAAUCAUCCUU-3′ (SEQ ID NO: 3677)3′-AAACUAUGACUGGACAUUUAGUAGGAA-5′ (SEQ ID NO: 1459) βc-2623 Target:5′-TTTGATACTGACCTGTAAATCATCCTT-3′ (SEQ ID NO: 2568)5′-UUUUGCCACAGCUUUUGCAACUUAA-3′ (SEQ ID NO: 3678)3′-AAAAAACGGUGUCGAAAACGUUGAAUU-5′ (SEQ ID NO: 1460) βc-2869 Target:5′-TTTTTTGCCACAGCTTTTGCAACTTAA-3′ (SEQ ID NO: 2569)5′-UGAGUAACAUUUGCUGUUUUAAACA-3′ (SEQ ID NO: 3679)3′-UUACUCAUUGUAAACGACAAAAUUUGU-5′ (SEQ ID NO: 1461) βc-2902 Target:5′-AATGAGTAACATTTGCTGTTTTAAACA-3′ (SEQ ID NO: 2570)5′-AACAUUAAUAGCAGCCUUUCUCUCU-3′ (SEQ ID NO: 3680)3′-AUUUGUAAUUAUCGUCGGAAAGAGAGA-5′ (SEQ ID NO: 1462) βc-2923 Target:5′-TAAACATTAATAGCAGCCTTTCTCTCT-3′ (SEQ ID NO: 2571)5′-CAUUAAUAGCAGCCUUUCUCUCUUU-3′ (SEQ ID NO: 3681)3′-UUGUAAUUAUCGUCGGAAAGAGAGAAA-5′ (SEQ ID NO: 1463) βc-2925 Target:5′-AACATTAATAGCAGCCTTTCTCTCTTT-3′ (SEQ ID NO: 2572)5′-UUAAUAGCAGCCUUUCUCUCUUUAU-3′ (SEQ ID NO: 3682)3′-GUAAUUAUCGUCGGAAAGAGAGAAAUA-5′ (SEQ ID NO: 1464) βc-2927 Target:5′-CATTAATAGCAGCCTTTCTCTCTTTAT-3′ (SEQ ID NO: 2573)5′-AAUAGCAGCCUUUCUCUCUUUAUAC-3′ (SEQ ID NO: 3683)3′-AAUUAUCGUCGGAAAGAGAGAAAUAUG-5′ (SEQ ID NO: 1465) βc-2929 Target:5′-TTAATAGCAGCCTTTCTCTCTTTATAC-3′ (SEQ ID NO: 2574)5′-GCAUUGUGAUUGGCCUGUAGAGUUG-3′ (SEQ ID NO: 3684)3′-AACGUAACACUAACCGGACAUCUCAAC-5′ (SEQ ID NO: 1466) βc-2973 Target:5′-TTGCATTGTGATTGGCCTGTAGAGTTG-3′ (SEQ ID NO: 2575)5′-AUUGUGAUUGGCCUGUAGAGUUGCU-3′ (SEQ ID NO: 3685)3′-CGUAACACUAACCGGACAUCUCAACGA-5′ (SEQ ID NO: 1467) βc-2975 Target:5′-GCATTGTGATTGGCCTGTAGAGTTGCT-3′ (SEQ ID NO: 2576)5′-UGUGAUUGGCCUGUAGAGUUGCUGA-3′ (SEQ ID NO: 3686)3′-UAACACUAACCGGACAUCUCAACGACU-5′ (SEQ ID NO: 1468) βc-2977 Target:5′-ATTGTGATTGGCCTGTAGAGTTGCTGA-3′ (SEQ ID NO: 2577)5′-UGAUUGGCCUGUAGAGUUGCUGAGA-3′ (SEQ ID NO: 3687)3′-ACACUAACCGGACAUCUCAACGACUCU-5′ (SEQ ID NO: 1469) βc-2979 Target:5′-TGTGATTGGCCTGTAGAGTTGCTGAGA-3′ (SEQ ID NO: 2578)5′-AUUGGCCUGUAGAGUUGCUGAGAGG-3′ (SEQ ID NO: 3688)3′-ACUAACCGGACAUCUCAACGACUCUCC-5′ (SEQ ID NO: 1470) βc-2981 Target:5′-TGATTGGCCTGTAGAGTTGCTGAGAGG-3′ (SEQ ID NO: 2579)5′-UGGCCUGUAGAGUUGCUGAGAGGGC-3′ (SEQ ID NO: 3689)3′-UAACCGGACAUCUCAACGACUCUCCCG-5′ (SEQ ID NO: 1471) βc-2983 Target:5′-ATTGGCCTGTAGAGTTGCTGAGAGGGC-3′ (SEQ ID NO: 2580)5′-GCCUGUAGAGUUGCUGAGAGGGCUC-3′ (SEQ ID NO: 3690)3′-ACCGGACAUCUCAACGACUCUCCCGAG-5′ (SEQ ID NO: 1472) βc-2985 Target:5′-TGGCCTGTAGAGTTGCTGAGAGGGCTC-3′ (SEQ ID NO: 2581)5′-CUGUAGAGUUGCUGAGAGGGCUCGA-3′ (SEQ ID NO: 3691)3′-CGGACAUCUCAACGACUCUCCCGAGCU-5′ (SEQ ID NO: 1473) βc-2987 Target:5′-GCCTGTAGAGTTGCTGAGAGGGCTCGA-3′ (SEQ ID NO: 2582)5′-GUAGAGUUGCUGAGAGGGCUCGAGG-3′ (SEQ ID NO: 3692)3′-GACAUCUCAACGACUCUCCCGAGCUCC-5′ (SEQ ID NO: 1474) βc-2989 Target:5′-CTGTAGAGTTGCTGAGAGGGCTCGAGG-3′ (SEQ ID NO: 2583)5′-GUGGGCUGGUAUCUCAGAAAGUGCC-3′ (SEQ ID NO: 3693)3′-CCCACCCGACCAUAGAGUCUUUCACGG-5′ (SEQ ID NO: 1475) βc-3015 Target:5′-GGGTGGGCTGGTATCTCAGAAAGTGCC-3′ (SEQ ID NO: 2584)5′-GGGCUGGUAUCUCAGAAAGUGCCUG-3′ (SEQ ID NO: 3694)3′-CACCCGACCAUAGAGUCUUUCACGGAC-5′ (SEQ ID NO: 1476) βc-3017 Target:5′-GTGGGCTGGTATCTCAGAAAGTGCCTG-3′ (SEQ ID NO: 2585)5′-GCUGGUAUCUCAGAAAGUGCCUGAC-3′ (SEQ ID NO: 3695)3′-CCCGACCAUAGAGUCUUUCACGGACUG-5′ (SEQ ID NO: 1477) βc-3019 Target:5′-GGGCTGGTATCTCAGAAAGTGCCTGAC-3′ (SEQ ID NO: 2586)5′-UGGUAUCUCAGAAAGUGCCUGACAC-3′ (SEQ ID NO: 3696)3′-CGACCAUAGAGUCUUUCACGGACUGUG-5′ (SEQ ID NO: 1478) βc-3021 Target:5′-GCTGGTATCTCAGAAAGTGCCTGACAC-3′ (SEQ ID NO: 2587)5′-ACUAACCAAGCUGAGUUUCCUAUGG-3′ (SEQ ID NO: 3697)3′-UGUGAUUGGUUCGACUCAAAGGAUACC-5′ (SEQ ID NO: 1479) βc-3046 Target:5′-ACACTAACCAAGCTGAGTTTCCTATGG-3′ (SEQ ID NO: 2588)5′-UAACCAAGCUGAGUUUCCUAUGGGA-3′ (SEQ ID NO: 3698)3′-UGAUUGGUUCGACUCAAAGGAUACCCU-5′ (SEQ ID NO: 1480) βc-3048 Target:5′-ACTAACCAAGCTGAGTTTCCTATGGGA-3′ (SEQ ID NO: 2589)5′-ACCAAGCUGAGUUUCCUAUGGGAAC-3′ (SEQ ID NO: 3699)3′-AUUGGUUCGACUCAAAGGAUACCCUUG-5′ (SEQ ID NO: 1481) βc-3050 Target:5′-TAACCAAGCTGAGTTTCCTATGGGAAC-3′ (SEQ ID NO: 2590)5′-CAAGCUGAGUUUCCUAUGGGAACAA-3′ (SEQ ID NO: 3700)3′-UGGUUCGACUCAAAGGAUACCCUUGUU-5′ (SEQ ID NO: 1482) βc-3052 Target:5′-ACCAAGCTGAGTTTCCTATGGGAACAA-3′ (SEQ ID NO: 2591)5′-AGCUGAGUUUCCUAUGGGAACAAUU-3′ (SEQ ID NO: 3701)3′-GUUCGACUCAAAGGAUACCCUUGUUAA-5′ (SEQ ID NO: 1483) βc-3054 Target:5′-CAAGCTGAGTTTCCTATGGGAACAATT-3′ (SEQ ID NO: 2592)5′-CUGAGUUUCCUAUGGGAACAAUUGA-3′ (SEQ ID NO: 3702)3′-UCGACUCAAAGGAUACCCUUGUUAACU-5′ (SEQ ID NO: 1484) βc-3056 Target:5′-AGCTGAGTTTCCTATGGGAACAATTGA-3′ (SEQ ID NO: 2593)5′-CUUUUUGUUCUGGUCCUUUUUGGUC-3′ (SEQ ID NO: 3703)3′-UUGAAAAACAAGACCAGGAAAAACCAG-5′ (SEQ ID NO: 1485) βc-3087 Target:5′-AACTTTTTGTTCTGGTCCTTTTTGGTC-3′ (SEQ ID NO: 2594)5′-UUUUGUUCUGGUCCUUUUUGGUCGA-3′ (SEQ ID NO: 3704)3′-GAAAAACAAGACCAGGAAAAACCAGCU-5′ (SEQ ID NO: 1486) βc-3089 Target:5′-CTTTTTGTTCTGGTCCTTTTTGGTCGA-3′ (SEQ ID NO: 2595)5′-UUGUUCUGGUCCUUUUUGGUCGAGG-3′ (SEQ ID NO: 3705)3′-AAAACAAGACCAGGAAAAACCAGCUCC-5′ (SEQ ID NO: 1487) βc-3091 Target:5′-TTTTGTTCTGGTCCTTTTTGGTCGAGG-3′ (SEQ ID NO: 2596)5′-GUUCUGGUCCUUUUUGGUCGAGGAG-3′ (SEQ ID NO: 3706)3′-AACAAGACCAGGAAAAACCAGCUCCUC-5′ (SEQ ID NO: 1488) βc-3093 Target:5′-TTGTTCTGGTCCTTTTTGGTCGAGGAG-3′ (SEQ ID NO: 2597)5′-UCUGGUCCUUUUUGGUCGAGGAGUA-3′ (SEQ ID NO: 3707)3′-CAAGACCAGGAAAAACCAGCUCCUCAU-5′ (SEQ ID NO: 1489) βc-3095 Target:5′-GTTCTGGTCCTTTTTGGTCGAGGAGTA-3′ (SEQ ID NO: 2598)5′-UGGUCCUUUUUGGUCGAGGAGUAAC-3′ (SEQ ID NO: 3708)3′-AGACCAGGAAAAACCAGCUCCUCAUUG-5′ (SEQ ID NO: 1490) βc-3097 Target:5′-TCTGGTCCTTTTTGGTCGAGGAGTAAC-3′ (SEQ ID NO: 2599)5′-GUCCUUUUUGGUCGAGGAGUAACAA-3′ (SEQ ID NO: 3709)3′-ACCAGGAAAAACCAGCUCCUCAUUGUU-5′ (SEQ ID NO: 1491) βc-3099 Target:5′-TGGTCCTTTTTGGTCGAGGAGTAACAA-3′ (SEQ ID NO: 2600)5′-CCUUUUUGGUCGAGGAGUAACAAUA-3′ (SEQ ID NO: 3710)3′-CAGGAAAAACCAGCUCCUCAUUGUUAU-5′ (SEQ ID NO: 1492) βc-3101 Target:5′-GTCCTTTTTGGTCGAGGAGTAACAATA-3′ (SEQ ID NO: 2601)5′-UUUUUGGUCGAGGAGUAACAAUACA-3′ (SEQ ID NO: 3711)3′-GGAAAAACCAGCUCCUCAUUGUUAUGU-5′ (SEQ ID NO: 1493) βc-3103 Target:5′-CCTTTTTGGTCGAGGAGTAACAATACA-3′ (SEQ ID NO: 2602)5′-UUUGGUCGAGGAGUAACAAUACAAA-3′ (SEQ ID NO: 3712)3′-AAAAACCAGCUCCUCAUUGUUAUGUUU-5′ (SEQ ID NO: 1494) βc-3105 Target:5′-TTTTTGGTCGAGGAGTAACAATACAAA-3′ (SEQ ID NO: 2603)5′-UGGUCGAGGAGUAACAAUACAAAUG-3′ (SEQ ID NO: 3713)3′-AAACCAGCUCCUCAUUGUUAUGUUUAC-5′ (SEQ ID NO: 1495) βc-3107 Target:5′-TTTGGTCGAGGAGTAACAATACAAATG-3′ (SEQ ID NO: 2604)5′-GUCGAGGAGUAACAAUACAAAUGGA-3′ (SEQ ID NO: 3714)3′-ACCAGCUCCUCAUUGUUAUGUUUACCU-5′ (SEQ ID NO: 1496) βc-3109 Target:5′-TGGTCGAGGAGTAACAATACAAATGGA-3′ (SEQ ID NO: 2605)5′-CGAGGAGUAACAAUACAAAUGGAUU-3′ (SEQ ID NO: 3715)3′-CAGCUCCUCAUUGUUAUGUUUACCUAA-5′ (SEQ ID NO: 1497) βc-3111 Target:5′-GTCGAGGAGTAACAATACAAATGGATT-3′ (SEQ ID NO: 2606)5′-AGGAGUAACAAUACAAAUGGAUUUU-3′ (SEQ ID NO: 3716)3′-GCUCCUCAUUGUUAUGUUUACCUAAAA-5′ (SEQ ID NO: 1498) βc-3113 Target:5′-CGAGGAGTAACAATACAAATGGATTTT-3′ (SEQ ID NO: 2607)5′-GAGUAACAAUACAAAUGGAUUUUGG-3′ (SEQ ID NO: 3717)3′-UCCUCAUUGUUAUGUUUACCUAAAACC-5′ (SEQ ID NO: 1499) βc-3115 Target:5′-AGGAGTAACAATACAAATGGATTTTGG-3′ (SEQ ID NO: 2608)5′-UAUCAAACCCUAGCCUUGCUUGUUA-3′ (SEQ ID NO: 3718)3′-AAAUAGUUUGGGAUCGGAACGAACAAU-5′ (SEQ ID NO: 1500) βc-3191 Target:5′-TTTATCAAACCCTAGCCTTGCTTGTTA-3′ (SEQ ID NO: 2609)5′-UCAAACCCUAGCCUUGCUUGUUAAA-3′ (SEQ ID NO: 3719)3′-AUAGUUUGGGAUCGGAACGAACAAUUU-5′ (SEQ ID NO: 1501) βc-3193 Target:5′-TATCAAACCCTAGCCTTGCTTGTTAAA-3′ (SEQ ID NO: 2610)5′-AAACCCUAGCCUUGCUUGUUAAAUU-3′ (SEQ ID NO: 3720)3′-AGUUUGGGAUCGGAACGAACAAUUUAA-5′ (SEQ ID NO: 1502) βc-3195 Target:5′-TCAAACCCTAGCCTTGCTTGTTAAATT-3′ (SEQ ID NO: 2611)5′-GAGUAAUGGUGUAGAACACUAAUUC-3′ (SEQ ID NO: 3721)3′-AACUCAUUACCACAUCUUGUGAUUAAG-5′ (SEQ ID NO: 1503) βc-3387 Target:5′-TTGAGTAATGGTGTAGAACACTAATTC-3′ (SEQ ID NO: 2612)5′-GUAAUGGUGUAGAACACUAAUUCAU-3′ (SEQ ID NO: 3722)3′-CUCAUUACCACAUCUUGUGAUUAAGUA-5′ (SEQ ID NO: 1504) βc-3389 Target:5′-GAGTAATGGTGTAGAACACTAATTC-3′ (SEQ ID NO: 2613)5′-AAUGGUGUAGAACACUAAUUCAUAA-3′ (SEQ ID NO: 3723)3′-CAUUACCACAUCUUGUGAUUAAGUAUU-5′ (SEQ ID NO: 1505) βc-3391 Target:5′-GTAATGGTGTAGAACACTAATTCATAA-3′ (SEQ ID NO: 2614)5′-UGGUGUAGAACACUAAUUCAUAAUC-3′ (SEQ ID NO: 3724)3′-UUACCACAUCUUGUGAUUAAGUAUUAG-5′ (SEQ ID NO: 1506) βc-3393 Target:5′-AATGGTGTAGAACACTAATTCATAATC-3′ (SEQ ID NO: 2615)5′-GUGUAGAACACUAAUUCAUAAUCAC-3′ (SEQ ID NO: 3725)3′-ACCACAUCUUGUGAUUAAGUAUUAGUG-5′ (SEQ ID NO: 1507) βc-3395 Target:5′-TGGTGTAGAACACTAATTCATAATCAC-3′ (SEQ ID NO: 2616)5′-GUAGAACACUAAUUCAUAAUCACUC-3′ (SEQ ID NO: 3726)3′-CACAUCUUGUGAUUAAGUAUUAGUGAG-5′ (SEQ ID NO: 1508) βc-3397 Target:5′-GTGTAGAACACTAATTCATAATCACTC-3′ (SEQ ID NO: 2617)5′-AGAACACUAAUUCAUAAUCACUCUA-3′ (SEQ ID NO: 3727)3′-CAUCUUGUGAUUAAGUAUUAGUGAGAU-5′ (SEQ ID NO: 1509) βc-3399 Target:5′-GTAGAACACTAATTCATAATCACTCTA-3′ (SEQ ID NO: 2618)5′-AACACUAAUUCAUAAUCACUCUAAU-3′ (SEQ ID NO: 3728)3′-UCUUGUGAUUAAGUAUUAGUGAGAUUA-5′ (SEQ ID NO: 1510) βc-3401 Target:5′-AGAACACTAATTCATAATCACTCTAAT-3′ (SEQ ID NO: 2619)5′-UUAGUUUCCUUUUUAAUAUGCUUAA-3′ (SEQ ID NO: 3729)3′-UUAAUCAAAGGAAAAAUUAUACGAAUU-5′ (SEQ ID NO: 1511) βc-3500 Target:5′-AATTAGTTTCCTTTTTAATATGCTTAA-3′ (SEQ ID NO: 2620)5′-AGUUUCCUUUUUAAUAUGCUUAAAA-3′ (SEQ ID NO: 3730)3′-AAUCAAAGGAAAAAUUAUACGAAUUUU-5′ (SEQ ID NO: 1512) βc-3502 Target:5′-TTAGTTTCCTTTTTAATATGCTTAAAA-3′ (SEQ ID NO: 2621)5′-UUUCCUUUUUAAUAUGCUUAAAAUA-3′ (SEQ ID NO: 3731)3′-UCAAAGGAAAAAUUAUACGAAUUUUAU-5′ (SEQ ID NO: 1513) βc-3504 Target:5′-AGTTTCCTTTTTAATATGCTTAAAATA-3′ (SEQ ID NO: 2622)5′-UCCUUUUUAAUAUGCUUAAAAUAAG-3′ (SEQ ID NO: 3732)3′-AAAGGAAAAAUUAUACGAAUUUUAUUC-5′ (SEQ ID NO: 1514) βc-3506 Target:5′-TTTCCTTTTTAATATGCTTAAAATAAG-3′ (SEQ ID NO: 2623)5′-CUUUUUAAUAUGCUUAAAAUAAGCA-3′ (SEQ ID NO: 3733)3′-AGGAAAAAUUAUACGAAUUUUAUUCGU-5′ (SEQ ID NO: 1515) βc-3508 Target:5′-TCCTTTTTAATATGCTTAAAATAAGCA-3′ (SEQ ID NO: 2624)5′-UUUUUAAUAUGCUUAAAAUAAGCAG-3′ (SEQ ID NO: 3734)3′-GGAAAAAUUAUACGAAUUUUAUUCGUC-5′ (SEQ ID NO: 1516) βc-3509 Target:5′-CCTTTTTAATATGCTTAAAATAAGCAG-3′ (SEQ ID NO: 2625)5′-UUUUAAUAUGCUUAAAAUAAGCAGG-3′ (SEQ ID NO: 3735)3′-GAAAAAUUAUACGAAUUUUAUUCGUCC-5′ (SEQ ID NO: 1517) βc-3510 Target:5′-CTTTTTAATATGCTTAAAATAAGCAGG-3′ (SEQ ID NO: 2626)5′-UUAAUAUGCUUAAAAUAAGCAGGUG-3′ (SEQ ID NO: 3736)3′-AAAAUUAUACGAAUUUUAUUCGUCCAC-5′ (SEQ ID NO: 1518) βc-3512 Target:5′-TTTTAATATGCTTAAAATAAGCAGGTG-3′ (SEQ ID NO: 2627)5′-AAUAUGCUUAAAAUAAGCAGGUGGA-3′ (SEQ ID NO: 3737)3′-AAUUAUACGAAUUUUAUUCGUCCACCU-5′ (SEQ ID NO: 1519) βc-3514 Target:5′-TTAATATGCTTAAAATAAGCAGGTGGA-3′ (SEQ ID NO: 2628)5′-UAUGCUUAAAAUAAGCAGGUGGAUC-3′ (SEQ ID NO: 3738)3′-UUAUACGAAUUUUAUUCGUCCACCUAG-5′ (SEQ ID NO: 1520) βc-3516 Target:5′-AATATGCTTAAAATAAGCAGGTGGATC-3′ (SEQ ID NO: 2629)5′-UGCUUAAAAUAAGCAGGUGGAUCUA-3′ (SEQ ID NO: 3739)3′-AUACGAAUUUUAUUCGUCCACCUAGAU-5′ (SEQ ID NO: 1521) βc-3518 Target:5′-TATGCTTAAAATAAGCAGGTGGATCTA-3′ (SEQ ID NO: 2630)5′-CUUAAAAUAAGCAGGUGGAUCUAUU-3′ (SEQ ID NO: 3740)3′-ACGAAUUUUAUUCGUCCACCUAGAUAA-5′ (SEQ ID NO: 1522) βc-3520 Target:5′-TGCTTAAAATAAGCAGGTGGATCTATT-3′ (SEQ ID NO: 2631)5′-UAAAAUAAGCAGGUGGAUCUAUUUC-3′ (SEQ ID NO: 3741)3′-GAAUUUUAUUCGUCCACCUAGAUAAAG-5′ (SEQ ID NO: 1523) βc-3522 Target:5′-CTTAAAATAAGCAGGTGGATCTATTTC-3′ (SEQ ID NO: 2632)5′-AAAUAAGCAGGUGGAUCUAUUUCAU-3′ (SEQ ID NO: 3742)3′-AUUUUAUUCGUCCACCUAGAUAAAGUA-5′ (SEQ ID NO: 1524) βc-3524 Target:5′-TAAAATAAGCAGGTGGATCTATTTC-3′ (SEQ ID NO: 2633)5′-AUAAGCAGGUGGAUCUAUUUCAUGU-3′ (SEQ ID NO: 3743)3′-UUUAUUCGUCCACCUAGAUAAAGUACA-5′ (SEQ ID NO: 1525) βc-3526 Target:5′-AAATAAGCAGGTGGATCTATTTCATGT-3′ (SEQ ID NO: 2634)5′-AAGCAGGUGGAUCUAUUUCAUGUUU-3′ (SEQ ID NO: 3744)3′-UAUUCGUCCACCUAGAUAAAGUACAAA-5′ (SEQ ID NO: 1526) βc-3528 Target:5′-ATAAGCAGGTGGATCTATTTCATGTTT-3′ (SEQ ID NO: 2635)5′-GCAGGUGGAUCUAUUUCAUGUUUUU-3′ (SEQ ID NO: 3745)3′-UUCGUCCACCUAGAUAAAGUACAAAAA-5′ (SEQ ID NO: 1527) βc-3530 Target:5′-AAGCAGGTGGATCTATTTCATGTTTTT-3′ (SEQ ID NO: 2636)5′-AGGUGGAUCUAUUUCAUGUUUUUGA-3′ (SEQ ID NO: 3746)3′-CGUCCACCUAGAUAAAGUACAAAAACU-5′ (SEQ ID NO: 1528) βc-3532 Target:5′-GCAGGTGGATCTATTTCATGTTTTTGA-3′ (SEQ ID NO: 2637)5′-GUGGAUCUAUUUCAUGUUUUUGAUC-3′ (SEQ ID NO: 3747)3′-UCCACCUAGAUAAAGUACAAAAACUAG-5′ (SEQ ID NO: 1529) βc-3534 Target:5′-AGGTGGATCTATTTCATGTTTTTGATC-3′ (SEQ ID NO: 2638)5′-GGAUCUAUUUCAUGUUUUUGAUCAA-3′ (SEQ ID NO: 3748)3′-CACCUAGAUAAAGUACAAAAACUAGUU-5′ (SEQ ID NO: 1530) βc-3536 Target:5′-GTGGATCTATTTCATGTTTTTGATCAA-3′ (SEQ ID NO: 2639)5′-AUCUAUUUCAUGUUUUUGAUCAAAA-3′ (SEQ ID NO: 3749)3′-CCUAGAUAAAGUACAAAAACUAGUUUU-5′ (SEQ ID NO: 1531) βc-3538 Target:5′-GGATCTATTTCATGTTTTTGATCAAAA-3′ (SEQ ID NO: 2640)5′-GUAGGGUAAAUCAGUAAGAGGUGUU-3′ (SEQ ID NO: 3750)3′-CCCAUCCCAUUUAGUCAUUCUCCACAA-5′ (SEQ ID NO: 1532) βc-3583 Target:5′-GGGTAGGGTAAATCAGTAAGAGGTGTT-3′ (SEQ ID NO: 2641)5′-AGGGUAAAUCAGUAAGAGGUGUUAU-3′ (SEQ ID NO: 3751)3′-CAUCCCAUUUAGUCAUUCUCCACAAUA-5′ (SEQ ID NO: 1533) βc-3585 Target:5′-GTAGGGTAAATCAGTAAGAGGTGTTAT-3′ (SEQ ID NO: 2642)5′-GGUAAAUCAGUAAGAGGUGUUAUUU-3′ (SEQ ID NO: 3752)3′-UCCCAUUUAGUCAUUCUCCACAAUAAA-5′ (SEQ ID NO: 1534) βc-3587 Target:5′-AGGGTAAATCAGTAAGAGGTGTTATTT-3′ (SEQ ID NO: 2643)5′-UAAAUCAGUAAGAGGUGUUAUUUGG-3′ (SEQ ID NO: 3753)3′-CCAUUUAGUCAUUCUCCACAAUAAACC-5′ (SEQ ID NO: 1535) βc-3589 Target:5′-GGTAAATCAGTAAGAGGTGTTATTTGG-3′ (SEQ ID NO: 2644)5′-AAUCAGUAAGAGGUGUUAUUUGGAA-3′ (SEQ ID NO: 3754)3′-AUUUAGUCAUUCUCCACAAUAAACCUU-5′ (SEQ ID NO: 1536) βc-3591 Target:5′-TAAATCAGTAAGAGGTGTTATTTGGAA-3′ (SEQ ID NO: 2645)5′-UCAGUAAGAGGUGUUAUUUGGAACC-3′ (SEQ ID NO: 3755)3′-UUAGUCAUUCUCCACAAUAAACCUUGG-5′ (SEQ ID NO: 1537) βc-3593 Target:5′-AATCAGTAAGAGGTGTTATTTGGAACC-3′ (SEQ ID NO: 2646)5′-UACCAGUUGCCUUUUAUCCCAAAGU-3′ (SEQ ID NO: 3756)3′-AAAUGGUCAACGGAAAAUAGGGUUUCA-5′ (SEQ ID NO: 1538) βc-3633 Target:5′-TTTACCAGTTGCCTTTTATCCCAAAGT-3′ (SEQ ID NO: 2647)5′-CCAGUUGCCUUUUAUCCCAAAGUUG-3′ (SEQ ID NO: 3757)3′-AUGGUCAACGGAAAAUAGGGUUUCAAC-5′ (SEQ ID NO: 1539) βc-3635 Target:5′-TACCAGTTGCCTTTTATCCCAAAGTTG-3′ (SEQ ID NO: 2648)5′-AGUUGCCUUUUAUCCCAAAGUUGUU-3′ (SEQ ID NO: 3758)3′-GGUCAACGGAAAAUAGGGUUUCAACAA-5′ (SEQ ID NO: 1540) βc-3637 Target:5′-CCAGTTGCCTTTTATCCCAAAGTTGTT-3′ (SEQ ID NO: 2649)5′-UUGCCUUUUAUCCCAAAGUUGUUGU-3′ (SEQ ID NO: 3759)3′-UCAACGGAAAAUAGGGUUUCAACAACA-5′ (SEQ ID NO: 1541) βc-3639 Target:5′-AGTTGCCTTTTATCCCAAAGTTGTTGT-3′ (SEQ ID NO: 2650)5′-GCCUUUUAUCCCAAAGUUGUUGUAA-3′ (SEQ ID NO: 3760)3′-AACGGAAAAUAGGGUUUCAACAACAUU-5′ (SEQ ID NO: 1542) βc-3641 Target:5′-TTGCCTTTTATCCCAAAGTTGTTGTAA-3′ (SEQ ID NO: 2651)5′-CUUUUAUCCCAAAGUUGUUGUAACC-3′ (SEQ ID NO: 3761)3′-CGGAAAAUAGGGUUUCAACAACAUUGG-5′ (SEQ ID NO: 1543) βc-3643 Target:5′-GCCTTTTATCCCAAAGTTGTTGTAACC-3′ (SEQ ID NO: 2652)5′-UUUAUCCCAAAGUUGUUGUAACCUG-3′ (SEQ ID NO: 3762)3′-GAAAAUAGGGUUUCAACAACAUUGGAC-5′ (SEQ ID NO: 1544) βc-3645 Target:5′-CTTTTATCCCAAAGTTGTTGTAACCTG-3′ (SEQ ID NO: 2653)5′-UAUCCCAAAGUUGUUGUAACCUGCU-3′ (SEQ ID NO: 3763)3′-AAAUAGGGUUUCAACAACAUUGGACGA-5′ (SEQ ID NO: 1545) βc-3647 Target:5′-TTTATCCCAAAGTTGTTGTAACCTGCT-3′ (SEQ ID NO: 2654)5′-UCCCAAAGUUGUUGUAACCUGCUGU-3′ (SEQ ID NO: 3764)3′-AUAGGGUUUCAACAACAUUGGACGACA-5′ (SEQ ID NO: 1546) βc-3649 Target:5′-TATCCCAAAGTTGTTGTAACCTGCTGT-3′ (SEQ ID NO: 2655)5′-CCAAAGUUGUUGUAACCUGCUGUGA-3′ (SEQ ID NO: 3765)3′-AGGGUUUCAACAACAUUGGACGACACU-5′ (SEQ ID NO: 1547) βc-3651 Target:5′-TCCCAAAGTTGTTGTAACCTGCTGTGA-3′ (SEQ ID NO: 2656)5′-AAAGUUGUUGUAACCUGCUGUGAUA-3′ (SEQ ID NO: 3766)3′-GGUUUCAACAACAUUGGACGACACUAU-5′ (SEQ ID NO: 1548) βc-3653 Target:5′-CCAAAGTTGTTGTAACCTGCTGTGATA-3′ (SEQ ID NO: 2657)5′-AGUUGUUGUAACCUGCUGUGAUACG-3′ (SEQ ID NO: 3767)3′-UUUCAACAACAUUGGACGACACUAUGC-5′ (SEQ ID NO: 1549) βc-3655 Target:5′-AAAGTTGTTGTAACCTGCTGTGATACG-3′ (SEQ ID NO: 2658)5′-UUGUUGUAACCUGCUGUGAUACGAU-3′ (SEQ ID NO: 3768)3′-UCAACAACAUUGGACGACACUAUGCUA-5′ (SEQ ID NO: 1550) βc-3657 Target:5′-AGTTGTTGTAACCTGCTGTGATACGAT-3′ (SEQ ID NO: 2659)5′-GUUGUAACCUGCUGUGAUACGAUGC-3′ (SEQ ID NO: 3769)3′-AACAACAUUGGACGACACUAUGCUACG-5′ (SEQ ID NO: 1551) βc-3659 Target:5′-TTGTTGTAACCTGCTGTGATACGATGC-3′ (SEQ ID NO: 2660)5′-AAAUGGUUCAGAAUUAAACUUUUAA-3′ (SEQ ID NO: 3770)3′-UUUUUACCAAGUCUUAAUUUGAAAAUU-5′ (SEQ ID NO: 1552) βc-3708 Target:5′-AAAAATGGTTCAGAATTAAACTTTTAA-3′ (SEQ ID NO: 2661)5′-AUGGUUCAGAAUUAAACUUUUAAUU-3′ (SEQ ID NO: 3771)3′-UUUACCAAGUCUUAAUUUGAAAAUUAA-5′ (SEQ ID NO: 1553) βc-3710 Target:5′-AAATGGTTCAGAATTAAACTTTTAATT-3′ (SEQ ID NO: 2662)5′-GGUUCAGAAUUAAACUUUUAAUUCA-3′ (SEQ ID NO: 3772)3′-UACCAAGUCUUAAUUUGAAAAUUAAGU-5′ (SEQ ID NO: 1554) βc-3712 Target:5′-ATGGTTCAGAATTAAACTTTTAATTCA-3′ (SEQ ID NO: 2663)5′-UUCAGAAUUAAACUUUUAAUUCAUU-3′ (SEQ ID NO: 3773)3′-CCAAGUCUUAAUUUGAAAAUUAAGUAA-5′ (SEQ ID NO: 1555) βc-3714 Target:5′-GGTTCAGAATTAAACTTTTAATTCATT-3′ (SEQ ID NO: 2664)5′-CAGAAUUAAACUUUUAAUUCAUUCG-3′ (SEQ ID NO: 3774)3′-AAGUCUUAAUUUGAAAAUUAAGUAAGC-5′ (SEQ ID NO: 1556) βc-3716 Target:5′-TTCAGAATTAAACTTTTAATTCATTCG-3′ (SEQ ID NO: 2665)5′-GCAGCAGUCUUACUUGGAUUCUGGA-3′ (SEQ ID NO: 3775)3′-GUCGUCGUCAGAAUGAACCUAAGACCU-5′ (SEQ ID NO: 1557) βc-m314 Target:5′-CAGCAGCAGTCTTACTTGGATTCTGGA-3′ (SEQ ID NO: 2666)5′-ACUUGGAUUCUGGAAUCCAUUCUGG-3′ (SEQ ID NO: 3776)3′-AAUGAACCUAAGACCUUAGGUAAGACC-5′ (SEQ ID NO: 1558) βc-m325 Target:5′-TTACTTGGATTCTGGAATCCATTCTGG-3′ (SEQ ID NO: 2667)5′-GACACCUCCCAAGUCCUUUAUGAAU-3′ (SEQ ID NO: 3777)3′-AACUGUGGAGGGUUCAGGAAAUACUUA-5′ (SEQ ID NO: 1559) βc-m408 Target:5′-TTGACACCTCCCAAGTCCTTTATGAAT-3′ (SEQ ID NO: 2668)5′-CGCAAGAGCAAGUAGCUGAUAUUGA-3′ (SEQ ID NO: 3778)3′-GUGCGUUCUCGUUCAUCGACUAUAACU-5′ (SEQ ID NO: 1560) βc-m460 Target:5′-CACGCAAGAGCAAGTAGCTGATATTGA-3′ (SEQ ID NO: 2669)5′-CCAUGUUCCCUGAGACGCUAGAUGA-3′ (SEQ ID NO: 3779)3′-ACGGUACAAGGGACUCUGCGAUCUACU-5′ (SEQ ID NO: 1561) βc-m526 Target:5′-TGCCATGTTCCCTGAGACGCTAGATGA-3′ (SEQ ID NO: 2670)5′-UGAAACAUGCAGUUGUCAAUUUGAU-3′ (SEQ ID NO: 3780)3′-CAACUUUGUACGUCAACAGUUAAACUA-5′ (SEQ ID NO: 1562) βc-m631 Target:5′-GTTGAAACATGCAGTTGTCAATTTGAT-3′ (SEQ ID NO: 2671)5′-CAUGCAGUUGUCAAUUUGAUUAACU-3′ (SEQ ID NO: 3781)3′-UUGUACGUCAACAGUUAAACUAAUUGA-5′ (SEQ ID NO: 1563) βc-m636 Target:5′-AACATGCAGTTGTCAATTTGATTAACT-3′ (SEQ ID NO: 2672)5′-GUUGUCAAUUUGAUUAACUAUCAGG-3′ (SEQ ID NO: 3782)3′-GUCAACAGUUAAACUAAUUGAUAGUCC-5′ (SEQ ID NO: 1564) βc-m642 Target:5′-CAGTTGTCAATTTGATTAACTATCAGG-3′ (SEQ ID NO: 2673)5′-GAGGACCAGGUGGUAGUUAAUAAAG-3′ (SEQ ID NO: 3783)3′-UACUCCUGGUCCACCAUCAAUUAUUUC-5′ (SEQ ID NO: 1565) βc-m723 Target:5′-ATGAGGACCAGGTGGTAGTTAATAAAG-3′ (SEQ ID NO: 2674)5′-GGUCACCAGUGGAUUCUGUACUGUU-3′ (SEQ ID NO: 3784)3′-ACCCAGUGGUCACCUAAGACAUGACAA-5′ (SEQ ID NO: 1566) βc-m970 Target:5′-TGGGTCACCAGTGGATTCTGTACTGTT-3′ (SEQ ID NO: 2675)5′-CAGUGGAUUCUGUACUGUUCUACGC-3′ (SEQ ID NO: 3785)3′-UGGUCACCUAAGACAUGACAAGAUGCG-5′ (SEQ ID NO: 1567) βc-m976 Target:5′-ACCAGTGGATTCTGTACTGTTCTACGC-3′ (SEQ ID NO: 2676)5′-GAUUCUGUACUGUUCUACGCCAUCA-3′ (SEQ ID NO: 3786)3′-ACCUAAGACAUGACAAGAUGCGGUAGU-5′ (SEQ ID NO: 1568) βc-m981 Target:5′-TGGATTCTGTACTGTTCTACGCCATCA-3′ (SEQ ID NO: 2677)5′-GUGGACUGCAGAAAAUGGUUGCUUU-3′ (SEQ ID NO: 3787)3′-ACCACCUGACGUCUUUUACCAACGAAA-5′ (SEQ ID NO: 1569) βc-m1066 Target:5′-TGGTGGACTGCAGAAAATGGTTGCTTT-3′ (SEQ ID NO: 2678)5′-CGUGAAAUUCUUGGCUAUUACAACA-3′ (SEQ ID NO: 3788)3′-UUGCACUUUAAGAACCGAUAAUGUUGU-5′ (SEQ ID NO: 1570) βc-m1106 Target:5′-AACGTGAAATTCTTGGCTATTACAACA-3′ (SEQ ID NO: 2679)5′-CAAGUCAGCGACUUGUUCAAAACUG-3′ (SEQ ID NO: 3789)3′-GGGUUCAGUCGCUGAACAAGUUUUGAC-5′ (SEQ ID NO: 1571) βc-m1354 Target:5′-CCCAAGTCAGCGACTTGTTCAAAACTG-3′ (SEQ ID NO: 2680)5′-GACUUGUUCAAAACUGUCUUUGGAC-3′ (SEQ ID NO: 3790)3′-CGCUGAACAAGUUUUGACAGAAACCUG-5′ (SEQ ID NO: 1572) βc-m1363 Target:5′-GCGACTTGTTCAAAACTGTCTTTGGAC-3′ (SEQ ID NO: 2681)5′-AAACUGUCUUUGGACUCUCAGAAAC-3′ (SEQ ID NO: 3791)3′-GUUUUGACAGAAACCUGAGAGUCUUUG-5′ (SEQ ID NO: 1573) βc-m1373 Target:5′-CAAAACTGTCTTTGGACTCTCAGAAAC-3′ (SEQ ID NO: 2682)5′-CUCUAACCUCACUUGCAAUAAUUAC-3′ (SEQ ID NO: 3792)3′-GAGAGAUUGGAGUGAACGUUAUUAAUG-5′ (SEQ ID NO: 1574) βc-m1508 Target:5′-CTCTCTAACCTCACTTGCAATAATTAC-3′ (SEQ ID NO: 2683)5′-CUCACUUGCAAUAAUUACAAAAACA-3′ (SEQ ID NO: 3793)3′-UGGAGUGAACGUUAUUAAUGUUUUUGU-5′ (SEQ ID NO: 1575) βc-m1515 Target:5′-ACCTCACTTGCAATAATTACAAAAACA-3′ (SEQ ID NO: 2684)5′-GAAUGCCGUUCGCCUUCAUUAUGGA-3′ (SEQ ID NO: 3794)3′-GUCUUACGGCAAGCGGAAGUAAUACCU-5′ (SEQ ID NO: 1576) βc-m1682 Target:5′-CAGAATGCCGTTCGCCTTCATTATGGA-3′ (SEQ ID NO: 2685)5′-GCCUUCAUUAUGGACUGCCUGUUGU-3′ (SEQ ID NO: 3795)3′-AGCGGAAGUAAUACCUGACGGACAACA-5′ (SEQ ID NO: 1577) βc-m1693 Target:5′-TCGCCTTCATTATGGACTGCCTGTTGT-3′ (SEQ ID NO: 2686)5′-CAUUAUGGACUGCCUGUUGUGGUUA-3′ (SEQ ID NO: 3796)3′-AAGUAAUACCUGACGGACAACACCAAU-5′ (SEQ ID NO: 1578) βc-m1698 Target:5′-TTCATTATGGACTGCCTGTTGTGGTTA-3′ (SEQ ID NO: 2687)5′-GACUGCCUGUUGUGGUUAAACUCCU-3′ (SEQ ID NO: 3797)3′-ACCUGACGGACAACACCAAUUUGAGGA-5′ (SEQ ID NO: 1579) βc-m1705 Target:5′-TGGACTGCCTGTTGTGGTTAAACTCCT-3′ (SEQ ID NO: 2688)5′-AACUGUUGGAUUGAUUCGAAACCUU-3′ (SEQ ID NO: 3798)3′-CGUUGACAACCUAACUAAGCUUUGGAA-5′ (SEQ ID NO: 1580) βc-m1763 Target:5′-GCAACTGTTGGATTGATTCGAAACCTT-3′ (SEQ ID NO: 2689)5′-GAGGACUCAAUACCAUUCCAUUGUU-3′ (SEQ ID NO: 3799)3′-GGCUCCUGAGUUAUGGUAAGGUAACAA-5′ (SEQ ID NO: 1581) βc-m2008 Target:5′-CCGAGGACTCAATACCATTCCATTGTT-3′ (SEQ ID NO: 2690)5′-GAGGACAAGCCACAGGAUUACAAGA-3′ (SEQ ID NO: 3800)3′-GACUCCUGUUCGGUGUCCUAAUGUUCU-5′ (SEQ ID NO: 1582) βc-m2226 Target:5′-CTGAGGACAAGCCACAGGATTACAAGA-3′ (SEQ ID NO: 2691)5′-AUGGACCCUAUGAUGGAGCAUGAGA-3′ (SEQ ID NO: 3801)3′-CCUACCUGGGAUACUACCUCGUACUCU-5′ (SEQ ID NO: 1583) βc-m2427 Target:5′-GGATGGACCCTATGATGGAGCATGAGA-3′ (SEQ ID NO: 2692)5′-GAUACUGACCUGUAAAUCGUCCUUU-3′ (SEQ ID NO: 3802)3′-AACUAUGACUGGACAUUUAGCAGGAAA-5′ (SEQ ID NO: 1584) βc-m2568 Target:5′-TTGATACTGACCTGTAAATCGTCCTTT-3′ (SEQ ID NO: 2693)5′-CCAGUGUGGGUGAAUACUUUACUCU-3′ (SEQ ID NO: 3803)3′-UCGGUCACACCCACUUAUGAAAUGAGA-5′ (SEQ ID NO: 1585) βc-m2614 Target:5′-AGCCAGTGTGGGTGAATACTTTACTCT-3′ (SEQ ID NO: 2694)5′-CCACAGCUUUUGCAGCGUUAUACUC-3′ (SEQ ID NO: 3804)3′-ACGGUGUCGAAAACGUCGCAAUAUGAG-5′ (SEQ ID NO: 1586) βc-m2770 Target:5′-TGCCACAGCTTTTGCAGCGTTATACTC-3′ (SEQ ID NO: 2695)5′-UUUUGCAGCGUUAUACUCAGAUGAG-3′ (SEQ ID NO: 3805)3′-CGAAAACGUCGCAAUAUGAGUCUACUC-5′ (SEQ ID NO: 1587) βc-m2777 Target:5′-GCTTTTGCAGCGTTATACTCAGATGAG-3′ (SEQ ID NO: 2696)5′-GCGUUAUACUCAGAUGAGUAACAUU-3′ (SEQ ID NO: 3806)3′-GUCGCAAUAUGAGUCUACUCAUUGUAA-5′ (SEQ ID NO: 1588) βc-m2784 Target:5′-CAGCGTTATACTCAGATGAGTAACATT-3′ (SEQ ID NO: 2697)5′-AUUUGCUGUUUUCAACAUUAAUAGC-3′ (SEQ ID NO: 3807)3′-UGUAAACGACAAAAGUUGUAAUUAUCG-5′ (SEQ ID NO: 1589) βc-m2806 Target:5′-ACATTTGCTGTTTTCAACATTAATAGC-3′ (SEQ ID NO: 2698)5′-CUGUAGUGUCUGAACGUGCAUUGUG-3′ (SEQ ID NO: 3808)3′-UCGACAUCACAGACUUGCACGUAACAC-5′ (SEQ ID NO: 1590) βc-m2850 Target:5′-AGCTGTAGTGTCTGAACGTGCATTGTG-3′ (SEQ ID NO: 2699)5′-GAACAGUCGAAGUACGCUUUUUGUU-3′ (SEQ ID NO: 3809)3′-CCCUUGUCAGCUUCAUGCGAAAAACAA-5′ (SEQ ID NO: 1591) βc-m2965 Target:5′-GGGAACAGTCGAAGTACGCTTTTTGTT-3′ (SEQ ID NO: 2700)5′-GUCGAAGUACGCUUUUUGUUCUGGU-3′ (SEQ ID NO: 3810)3′-GUCAGCUUCAUGCGAAAAACAAGACCA-5′ (SEQ ID NO: 1592) βc-m2970 Target:5′-CAGTCGAAGTACGCTTTTTGTTCTGGT-3′ (SEQ ID NO: 2701)5′-GUACGCUUUUUGUUCUGGUCCUUUU-3′ (SEQ ID NO: 3811)3′-UUCAUGCGAAAAACAAGACCAGGAAAA-5′ (SEQ ID NO: 1593) βc-m2976 Target:5′-AAGTACGCTTTTTGTTCTGGTCCTTTT-3′ (SEQ ID NO: 2702)5′-CCUAGCCUUGCUUGUUCUUUGUUUU-3′ (SEQ ID NO: 3812)3′-UGGGAUCGGAACGAACAAGAAACAAAA-5′ (SEQ ID NO: 1594) βc-m3092 Target:5′-ACCCTAGCCTTGCTTGTTCTTTGTTTT-3′ (SEQ ID NO: 2703)5′-CCUUGCUUGUUCUUUGUUUUAAUAU-3′ (SEQ ID NO: 3813)3′-UCGGAACGAACAAGAAACAAAAUUAUA-5′ (SEQ ID NO: 1595) βc-m3097 Target:5′-AGCCTTGCTTGTTCTTTGTTTTAATAT-3′ (SEQ ID NO: 2704)5′-AACCUGCUACAGCAAUUUCUGAUUU-3′ (SEQ ID NO: 3814)3′-ACUUGGACGAUGUCGUUAAAGACUAAA-5′ (SEQ ID NO: 1596) βc-m3198 Target:5′-TGAACCTGCTACAGCAATTTCTGATTT-3′ (SEQ ID NO: 2705)5′-CAGCAAUUUCUGAUUUCUAAGAACC-3′ (SEQ ID NO: 3815)3′-AUGUCGUUAAAGACUAAAGAUUCUUGG-5′ (SEQ ID NO: 1597) βc-m3207 Target:5′-TACAGCAATTTCTGATTTCTAAGAACC-3′ (SEQ ID NO: 2706)5′-GUAAGAGGUGUUAUUUGAGCCUUGU-3′ (SEQ ID NO: 3816)3′-GUCAUUCUCCACAAUAAACUCGGAACA-5′ (SEQ ID NO: 1598) βc-m3433 Target:5′-CAGTAAGAGGTGTTATTTGAGCCTTGT-3′ (SEQ ID NO: 2707)5′-GGUGUUAUUUGAGCCUUGUUUUGGA-3′ (SEQ ID NO: 3817)3′-CUCCACAAUAAACUCGGAACAAAACCU-5′ (SEQ ID NO: 1599) βc-m3439 Target:5′-GAGGTGTTATTTGAGCCTTGTTTTGGA-3′ (SEQ ID NO: 2708)5′-UAUUUGAGCCUUGUUUUGGACAGUA-3′ (SEQ ID NO: 3818)3′-CAAUAAACUCGGAACAAAACCUGUCAU-5′ (SEQ ID NO: 1600) βc-m3444 Target:5′-GTTATTTGAGCCTTGTTTTGGACAGTA-3′ (SEQ ID NO: 2709)5′-GAGCCUUGUUUUGGACAGUAUACCA-3′ (SEQ ID NO: 3819)3′-AACUCGGAACAAAACCUGUCAUAUGGU-5′ (SEQ ID NO: 1601) βc-m3449 Target:5′-TTGAGCCTTGTTTTGGACAGTATACCA-3′ (SEQ ID NO: 2710)5′-CAACAGAUGCGGUUAUAGAAAUGGU-3′ (SEQ ID NO: 3820)3′-AAGUUGUCUACGCCAAUAUCUUUACCA-5′ (SEQ ID NO: 1602) βc-m3522 Target:5′-TTCAACAGATGCGGTTATAGAAATGGT-3′ (SEQ ID NO: 2711)5′-GUUAUAGAAAUGGUUCAGAAUUAAA-3′ (SEQ ID NO: 3821)3′-GCCAAUAUCUUUACCAAGUCUUAAUUU-5′ (SEQ ID NO: 1603) βc-m3533 Target:5′-CGGTTATAGAAATGGTTCAGAATTAAA-3′ (SEQ ID NO: 2712)5′-AGAAAUGGUUCAGAAUUAAACUUUU-3′ (SEQ ID NO: 3822)3′-UAUCUUUACCAAGUCUUAAUUUGAAAA-5′ (SEQ ID NO: 1604) βc-m3538 Target:5′-ATAGAAATGGTTCAGAATTAAACTTTT-3′ (SEQ ID NO: 2713)

TABLE 7 Selected Anti-β-catenin DsiRNA  Agents, Blunt/Frayed Duplexes

(SEQ ID NO: 5553)

(SEQ ID NO: 1117) βc-240 Target: 5′—CCCTGAGGGTATTTGAAGTATACCATA—3′(SEQ ID NO: 2226)

(SEQ ID NO: 5554)

(SEQ ID NO: 1118) βc-244 Target: 5′—GAGGGTATTTGAAGTATACCATACAAC—3′(SEQ ID NO: 2227)

(SEQ ID NO: 5555)

(SEQ ID NO: 1119) βc-253 Target: 5′—TGAAGTATACCATACAACTGTTTTGAA—3′(SEQ ID NO: 2228)

(SEQ ID NO: 5556)

(SEQ ID NO: 1120) βc-259 Target: 5′—ATACCATACAACTGTTTTGAAAATCCA—3′(SEQ ID NO: 2229)

(SEQ ID NO: 5557)

(SEQ ID NO: 1121) βc-264 Target: 5′—ATACAACTGTTTTGAAAATCCAGCGTG—3′(SEQ ID NO: 2230)

(SEQ ID NO: 5558)

(SEQ ID NO: 1122) βc-496 Target: 5′—CAGGGATTTTCTCAGTCCTTCACTCAA—3′(SEQ ID NO: 2231)

(SEQ ID NO: 5559)

(SEQ ID NO: 1123) βc-516 Target: 5′—CACTCAAGAACAAGTAGCTGATATTGA—3′(SEQ ID NO: 2232)

(SEQ ID NO: 5560)

(SEQ ID NO: 1124) βc-522 Target: 5′—AGAACAAGTAGCTGATATTGATGGACA—3′(SEQ ID NO: 2233)

(SEQ ID NO: 5561)

(SEQ ID NO: 1125) βc-524 Target: 5′—AACAAGTAGCTGATATTGATGGACAGT—3′(SEQ ID NO: 2234)

(SEQ ID NO: 5562)

(SEQ ID NO: 1126) βc-540 Target: 5′—TGATGGACAGTATGCAATGACTCGAGC—3′(SEQ ID NO: 2235)

(SEQ ID NO: 5563)

(SEQ ID NO: 1127) βc-582 Target: 5′—TGCTATGTTCCCTGAGACATTAGATGA—3′(SEQ ID NO: 2236)

(SEQ ID NO: 5564)

(SEQ ID NO: 1128) βc-686 Target: 5′—TGCTGAAACATGCAGTTGTAAACTTGA—3′(SEQ ID NO: 2237)

(SEQ ID NO: 5565)

(SEQ ID NO: 1129) βc-692 Target: 5′—AACATGCAGTTGTAAACTTGATTAACT—3′(SEQ ID NO: 2238)

(SEQ ID NO: 5566)

(SEQ ID NO: 1130) βc-697 Target: 5′—GCAGTTGTAAACTTGATTAACTATCAA—3′(SEQ ID NO: 2239)

(SEQ ID NO: 5567)

(SEQ ID NO: 1131) βc-707 Target: 5′—ACTTGATTAACTATCAAGATGATGCAG—3′(SEQ ID NO: 2240)

(SEQ ID NO: 5568)

(SEQ ID NO: 1132) βc-753 Target: 5′—CCCTGAACTGACAAAACTGCTAAATGA—3′(SEQ ID NO: 2241)

(SEQ ID NO: 5569)

(SEQ ID NO: 1133) βc-870 Target: 5′—TCAGATGGTGTCTGCTATTGTACGTAC—3′(SEQ ID NO: 2242)

(SEQ ID NO: 5570)

(SEQ ID NO: 1134) βc-889 Target: 5′—GTACGTACCATGCAGAATACAAATGAT—3′(SEQ ID NO: 2243)

(SEQ ID NO: 5571)

(SEQ ID NO: 1135) βc-1060 Target: 5′—ATTACAACTCTCCACAACCTTTTATTA—3′(SEQ ID NO: 2244)

(SEQ ID NO: 5572)

(SEQ ID NO: 1136) βc-1065 Target: 5′—AACTCTCCACAACCTTTTATTACATCA—3′(SEQ ID NO: 2245)

(SEQ ID NO: 5573)

(SEQ ID NO: 1137) βc-1070 Target: 5′—TCCACAACCTTTTATTACATCAAGAAG—3′(SEQ ID NO: 2246)

(SEQ ID NO: 5574)

(SEQ ID NO: 1138) βc-1076 Target: 5′—ACCTTTTATTACATCAAGAAGGAGCTA—3′(SEQ ID NO: 2247)

(SEQ ID NO: 5575)

(SEQ ID NO: 1139) βc-1154 Target: 5′—ACAAAACAAATGTTAAATTCTTGGCTA—3′(SEQ ID NO: 2248)

(SEQ ID NO: 5576)

(SEQ ID NO: 1140) βc-1180 Target: 5′—ATTACGACAGACTGCCTTCAAATTTTA—3′(SEQ ID NO: 2249)

(SEQ ID NO: 5577)

(SEQ ID NO: 1141) βc-1185 Target: 5′—GACAGACTGCCTTCAAATTTTAGCTTA—3′(SEQ ID NO: 2250)

(SEQ ID NO: 5578)

(SEQ ID NO: 1142) βc-1260 Target: 5′—AGCTTTAGTAAATATAATGAGGACCTA—3′(SEQ ID NO: 2251)

(SEQ ID NO: 5579)

(SEQ ID NO: 1143) βc-1294 Target: 5′—GAAAAACTACTGTGGACCACAAGCAGA—3′(SEQ ID NO: 2252)

(SEQ ID NO: 5580)

(SEQ ID NO: 1144) βc-1412 Target: 5′—CAAGTCAACGTCTTGTTCAGAACTGTC—3′(SEQ ID NO: 2253)

(SEQ ID NO: 5581)

(SEQ ID NO: 1145) βc-1418 Target: 5′—AACGTCTTGTTCAGAACTGTCTTTGGA—3′(SEQ ID NO: 2254)

(SEQ ID NO: 5582)

(SEQ ID NO: 1146) βc-1423 Target: 5′—CTTGTTCAGAACTGTCTTTGGACTCTC—3′(SEQ ID NO: 2255)

(SEQ ID NO: 5583)

(SEQ ID NO: 1147) βc-1520 Target: 5′—TGGGTTCAGATGATATAAATGTGGTCA—3′(SEQ ID NO: 2256)

(SEQ ID NO: 5584)

(SEQ ID NO: 1148) βc-1561 Target: 5′—ATTCTTTCTAACCTCACTTGCAATAAT—3′(SEQ ID NO: 2257)

(SEQ ID NO: 5585)

(SEQ ID NO: 1149) βc-1571 Target: 5′—ACCTCACTTGCAATAATTATAAGAACA—3′(SEQ ID NO: 2258)

(SEQ ID NO: 5586)

(SEQ ID NO: 1150) βc-1579 Target: 5′—TGCAATAATTATAAGAACAAGATGATG—3′(SEQ ID NO: 2259)

(SEQ ID NO: 5587)

(SEQ ID NO: 1151) βc-1620 Target: 5′—TGGTATAGAGGCTCTTGTGCGTACTGT—3′(SEQ ID NO: 2260)

(SEQ ID NO: 5588)

(SEQ ID NO: 1152) βc-1816 Target: 5′—AAGGCTACTGTTGGATTGATTCGAAAT—3′(SEQ ID NO: 2261)

(SEQ ID NO: 5589)

(SEQ ID NO: 1153) βc-1987 Target: 5′—CGCATGGAAGAAATAGTTGAAGGTTGT—3′(SEQ ID NO: 2262)

(SEQ ID NO: 5590)

(SEQ ID NO: 1154) βc-1989 Target: 5′—CATGGAAGAAATAGTTGAAGGTTGTAC—3′(SEQ ID NO: 2263)

(SEQ ID NO: 5591)

(SEQ ID NO: 1155) βc-2111 Target: 5′—CCATTGAAAACATCCAAAGAGTAGCTG—3′(SEQ ID NO: 2264)

(SEQ ID NO: 5592)

(SEQ ID NO: 1156) βc-2282 Target: 5′—CTGAGGACAAGCCACAAGATTACAAGA—3′(SEQ ID NO: 2265)

(SEQ ID NO: 5593)

(SEQ ID NO: 1157) βc-2624 Target: 5′—TTGATACTGACCTGTAAATCATCCTTT—3′(SEQ ID NO: 2266)

(SEQ ID NO: 5594)

(SEQ ID NO: 1158) βc-2647 Target: 5′—CTTTAGGTAAGAAGTTTTAAAAAGCCA—3′(SEQ ID NO: 2267)

(SEQ ID NO: 5595)

(SEQ ID NO: 1159) βc-2770 Target: 5′—AACAGGTATATACTTTGAAAGGAGATG—3′(SEQ ID NO: 2268)

(SEQ ID NO: 5596)

(SEQ ID NO: 1160) βc-2848 Target: 5′—TGGAAGTTATTAACTTTAATGTTTTTT—3′(SEQ ID NO: 2269)

(SEQ ID NO: 5597)

(SEQ ID NO: 1161) βc-2874 Target: 5′—TGCCACAGCTTTTGCAACTTAATACTC—3′(SEQ ID NO: 2270)

(SEQ ID NO: 5598)

(SEQ ID NO: 1162) βc-2909 Target: 5′—AACATTTGCTGTTTTAAACATTAATAG—3′(SEQ ID NO: 2271)

(SEQ ID NO: 5599)

(SEQ ID NO: 1163) βc-3074 Target: 5′—AACAATTGAAGTAAACTTTTTGTTCTG—3′(SEQ ID NO: 2272)

(SEQ ID NO: 5600)

(SEQ ID NO: 1164) βc-3197 Target: 5′—AAACCCTAGCCTTGCTTGTTAAATTTT—3′(SEQ ID NO: 2273)

(SEQ ID NO: 5601)

(SEQ ID NO: 1165) βc-3203 Target: 5′—TAGCCTTGCTTGTTAAATTTTTTTTTT—3′(SEQ ID NO: 2274)

(SEQ ID NO: 5602)

(SEQ ID NO: 1166) βc-3273 Target: 5′—TTGAAGTAGCTCTTTTTTTTTTTTTTT—3′(SEQ ID NO: 2275)

(SEQ ID NO: 5603)

(SEQ ID NO: 1167) βc-3333 Target: 5′—TCGTAGTGTTAAGTTATAGTGAATACT—3′(SEQ ID NO: 2276)

(SEQ ID NO: 5604)

(SEQ ID NO: 1168) βc-3349 Target: 5′—TAGTGAATACTGCTACAGCAATTTCTA—3′(SEQ ID NO: 2277)

(SEQ ID NO: 5605)

(SEQ ID NO: 1169) βc-3354 Target: 5′—AATACTGCTACAGCAATTTCTAATTTT—3′(SEQ ID NO: 2278)

(SEQ ID NO: 5606)

(SEQ ID NO: 1170) βc-3371 Target: 5′—TTCTAATTTTTAAGAATTGAGTAATGG—3′(SEQ ID NO: 2279)

(SEQ ID NO: 5607)

(SEQ ID NO: 1171) βc-3376 Target: 5′—ATTTTTAAGAATTGAGTAATGGTGTAG—3′(SEQ ID NO: 2280)

(SEQ ID NO: 5608)

(SEQ ID NO: 1172) βc-3411 Target: 5′—TTCATAATCACTCTAATTAATTGTAAT—3′(SEQ ID NO: 2281)

(SEQ ID NO: 5609)

(SEQ ID NO: 1173) βc-3426 Target: 5′—ATTAATTGTAATCTGAATAAAGTGTAA—3′(SEQ ID NO: 2282)

(SEQ ID NO: 5610)

(SEQ ID NO: 1174) βc-3431 Target: 5′—TTGTAATCTGAATAAAGTGTAACAATT—3′(SEQ ID NO: 2283)

(SEQ ID NO: 5611)

(SEQ ID NO: 1175) βc-3437 Target: 5′—TCTGAATAAAGTGTAACAATTGTGTAG—3′(SEQ ID NO: 2284)

(SEQ ID NO: 5612)

(SEQ ID NO: 1176) βc-3458 Target: 5′—GTGTAGCCTTTTTGTATAAAATAGACA—3′(SEQ ID NO: 2285)

(SEQ ID NO: 5613)

(SEQ ID NO: 1177) βc-3468 Target: 5′—TTTGTATAAAATAGACAAATAGAAAAT—3′(SEQ ID NO: 2286)

(SEQ ID NO: 5614)

(SEQ ID NO: 1178) βc-3488 Target: 5′—AGAAAATGGTCCAATTAGTTTCCTTTT—3′(SEQ ID NO: 2287)

(SEQ ID NO: 5615)

(SEQ ID NO: 1179) βc-3496 Target: 5′—GTCCAATTAGTTTCCTTTTTAATATGC—3′(SEQ ID NO: 2288)

(SEQ ID NO: 5616)

(SEQ ID NO: 1180) βc-3552 Target: 5′—TTTTTGATCAAAAACTATTTGGGATAT—3′(SEQ ID NO: 2289)

(SEQ ID NO: 5617)

(SEQ ID NO: 1181) βc-3600 Target: 5′—AAGAGGTGTTATTTGGAACCTTGTTTT—3′(SEQ ID NO: 2290)

(SEQ ID NO: 5618)

(SEQ ID NO: 1182) βc-3605 Target: 5′—GTGTTATTTGGAACCTTGTTTTGGACA—3′(SEQ ID NO: 2291)

(SEQ ID NO: 5619)

(SEQ ID NO: 1183) βc-3615 Target: 5′—GAACCTTGTTTTGGACAGTTTACCAGT—3′(SEQ ID NO: 2292)

(SEQ ID NO: 5620)

(SEQ ID NO: 1184) βc-3674 Target: 5′—GTGATACGATGCTTCAAGAGAAAATGC—3′(SEQ ID NO: 2293)

(SEQ ID NO: 5621)

(SEQ ID NO: 1185) βc-3686 Target: 5′—TTCAAGAGAAAATGCGGTTATAAAAAA—3′(SEQ ID NO: 2294)

(SEQ ID NO: 5622)

(SEQ ID NO: 1186) βc-3691 Target: 5′—GAGAAAATGCGGTTATAAAAAATGGTT—3′(SEQ ID NO: 2295)

(SEQ ID NO: 5623)

(SEQ ID NO: 1187) βc-3700 Target: 5′—CGGTTATAAAAAATGGTTCAGAATTAA—3′(SEQ ID NO: 2296)

(SEQ ID NO: 5624)

(SEQ ID NO: 1188) βc-3707 Target: 5′—AAAAAATGGTTCAGAATTAAACTTTTA—3′(SEQ ID NO: 2297)

(SEQ ID NO: 5625)

(SEQ ID NO: 1189) βc-284 Target: 5′—CAGCGTGGACAATGGCTACTCAAGCTG—3′(SEQ ID NO: 2298)

(SEQ ID NO: 5626)

(SEQ ID NO: 1190) βc-285 Target: 5′—AGCGTGGACAATGGCTACTCAAGCTGA—3′(SEQ ID NO: 2299)

(SEQ ID NO: 5627)

(SEQ ID NO: 1191) βc-286 Target: 5′—GCGTGGACAATGGCTACTCAAGCTGAT—3′(SEQ ID NO: 2300)

(SEQ ID NO: 5628)

(SEQ ID NO: 1192) βc-287 Target: 5′—CGTGGACAATGGCTACTCAAGCTGATT—3′(SEQ ID NO: 2301)

(SEQ ID NO: 5629)

(SEQ ID NO: 1193) βc-288 Target: 5′—GTGGACAATGGCTACTCAAGCTGATTT—3′(SEQ ID NO: 2302)

(SEQ ID NO: 5630)

(SEQ ID NO: 1194) βc-289 Target: 5′—TGGACAATGGCTACTCAAGCTGATTTG—3′(SEQ ID NO: 2303)

(SEQ ID NO: 5631)

(SEQ ID NO: 1195) βc-290 Target: 5′—GGACAATGGCTACTCAAGCTGATTTGA—3′(SEQ ID NO: 2304)

(SEQ ID NO: 5632)

(SEQ ID NO: 1196) βc-291 Target: 5′—GACAATGGCTACTCAAGCTGATTTGAT—3′(SEQ ID NO: 2305)

(SEQ ID NO: 5633)

(SEQ ID NO: 1197) βc-312 Target: 5′—TTTGATGGAGTTGGACATGGCCATGGA—3′(SEQ ID NO: 2306)

(SEQ ID NO: 5634)

(SEQ ID NO: 1198) βc-313 Target: 5′—TTGATGGAGTTGGACATGGCCATGGAA—3′(SEQ ID NO: 2307)

(SEQ ID NO: 5635)

(SEQ ID NO: 1199) βc-314 Target: 5′—TGATGGAGTTGGACATGGCCATGGAAC—3′(SEQ ID NO: 2308)

(SEQ ID NO: 5636)

(SEQ ID NO: 1200) βc-315 Target: 5′—GATGGAGTTGGACATGGCCATGGAACC—3′(SEQ ID NO: 2309)

(SEQ ID NO: 5637)

(SEQ ID NO: 1201) βc-316 Target: 5′—ATGGAGTTGGACATGGCCATGGAACCA—3′(SEQ ID NO: 2310)

(SEQ ID NO: 5638)

(SEQ ID NO: 1202) βc-317 Target: 5′—TGGAGTTGGACATGGCCATGGAACCAG—3′(SEQ ID NO: 2311)

(SEQ ID NO: 5639)

(SEQ ID NO: 1203) βc-318 Target: 5′—GGAGTTGGACATGGCCATGGAACCAGA—3′(SEQ ID NO: 2312)

(SEQ ID NO: 5640)

(SEQ ID NO: 1204) βc-389 Target: 5′—ACTCTGGAATCCATTCTGGTGCCACTA—3′(SEQ ID NO: 2313)

(SEQ ID NO: 5641)

(SEQ ID NO: 1205) βc-390 Target: 5′—CTCTGGAATCCATTCTGGTGCCACTAC—3′(SEQ ID NO: 2314)

(SEQ ID NO: 5642)

(SEQ ID NO: 1206) βc-391 Target: 5′—TCTGGAATCCATTCTGGTGCCACTACC—3′(SEQ ID NO: 2315)

(SEQ ID NO: 5643)

(SEQ ID NO: 1207) βc-392 Target: 5′—CTGGAATCCATTCTGGTGCCACTACCA—3′(SEQ ID NO: 2316)

(SEQ ID NO: 5644)

(SEQ ID NO: 1208) βc-393 Target: 5′—TGGAATCCATTCTGGTGCCACTACCAC—3′(SEQ ID NO: 2317)

(SEQ ID NO: 5645)

(SEQ ID NO: 1209) βc-600 Target: 5′—ATTAGATGAGGGCATGCAGATCCCATC—3′(SEQ ID NO: 2318)

(SEQ ID NO: 5646)

(SEQ ID NO: 1210) βc-601 Target: 5′—TTAGATGAGGGCATGCAGATCCCATCT—3′(SEQ ID NO: 2319)

(SEQ ID NO: 5647)

(SEQ ID NO: 1211) βc-602 Target: 5′—TAGATGAGGGCATGCAGATCCCATCTA—3′(SEQ ID NO: 2320)

(SEQ ID NO: 5648)

(SEQ ID NO: 1212) βc-603 Target: 5′—AGATGAGGGCATGCAGATCCCATCTAC—3′(SEQ ID NO: 2321)

(SEQ ID NO: 5649)

(SEQ ID NO: 1213) βc-604 Target: 5′—GATGAGGGCATGCAGATCCCATCTACA—3′(SEQ ID NO: 2322)

(SEQ ID NO: 5650)

(SEQ ID NO: 1214) βc-605 Target: 5′—ATGAGGGCATGCAGATCCCATCTACAC—3′(SEQ ID NO: 2323)

(SEQ ID NO: 5651)

(SEQ ID NO: 1215) βc-638 Target: 5′—ATGCTGCTCATCCCACTAATGTCCAGC—3′(SEQ ID NO: 2324)

(SEQ ID NO: 5652)

(SEQ ID NO: 1216) βc-639 Target: 5′—TGCTGCTCATCCCACTAATGTCCAGCG—3′(SEQ ID NO: 2325)

(SEQ ID NO: 5653)

(SEQ ID NO: 1217) βc-640 Target: 5′—GCTGCTCATCCCACTAATGTCCAGCGT—3′(SEQ ID NO: 2326)

(SEQ ID NO: 5654)

(SEQ ID NO: 1218) βc-641 Target: 5′—CTGCTCATCCCACTAATGTCCAGCGTT—3′(SEQ ID NO: 2327)

(SEQ ID NO: 5655)

(SEQ ID NO: 1219) βc-642 Target: 5′—TGCTCATCCCACTAATGTCCAGCGTTT—3′(SEQ ID NO: 2328)

(SEQ ID NO: 5656)

(SEQ ID NO: 1220) βc-643 Target: 5′—GCTCATCCCACTAATGTCCAGCGTTTG—3′(SEQ ID NO: 2329)

(SEQ ID NO: 5657)

(SEQ ID NO: 1221) βc-644 Target: 5′—CTCATCCCACTAATGTCCAGCGTTTGG—3′(SEQ ID NO: 2330)

(SEQ ID NO: 5658)

(SEQ ID NO: 1222) βc-645 Target: 5′—TCATCCCACTAATGTCCAGCGTTTGGC—3′(SEQ ID NO: 2331)

(SEQ ID NO: 5659)

(SEQ ID NO: 1223) βc-665 Target: 5′—GTTTGGCTGAACCATCACAGATGCTGA—3′(SEQ ID NO: 2332)

(SEQ ID NO: 5660)

(SEQ ID NO: 1224) βc-666 Target: 5′—TTTGGCTGAACCATCACAGATGCTGAA—3′(SEQ ID NO: 2333)

(SEQ ID NO: 5661)

(SEQ ID NO: 1225) βc-667 Target: 5′—TTGGCTGAACCATCACAGATGCTGAAA—3′(SEQ ID NO: 2334)

(SEQ ID NO: 5662)

(SEQ ID NO: 1226) βc-731 Target: 5′—CAGAACTTGCCACACGTGCAATCCCTG—3′(SEQ ID NO: 2335)

(SEQ ID NO: 5663)

(SEQ ID NO: 1227) βc-732 Target: 5′—AGAACTTGCCACACGTGCAATCCCTGA—3′(SEQ ID NO: 2336)

(SEQ ID NO: 5664)

(SEQ ID NO: 1228) βc-809 Target: 5′—CAGTTATGGTCCATCAGCTTTCTAAAA—3′(SEQ ID NO: 2337)

(SEQ ID NO: 5665)

(SEQ ID NO: 1229) βc-810 Target: 5′—AGTTATGGTCCATCAGCTTTCTAAAAA—3′(SEQ ID NO: 2338)

(SEQ ID NO: 5666)

(SEQ ID NO: 1230) βc-830 Target: 5′—CTAAAAAGGAAGCTTCCAGACACGCTA—3′(SEQ ID NO: 2339)

(SEQ ID NO: 5667)

(SEQ ID NO: 1231) βc-831 Target: 5′—TAAAAAGGAAGCTTCCAGACACGCTAT—3′(SEQ ID NO: 2340)

(SEQ ID NO: 5668)

(SEQ ID NO: 1232) βc-893 Target: 5′—GTACCATGCAGAATACAAATGATGTAG—3′(SEQ ID NO: 2341)

(SEQ ID NO: 5669)

(SEQ ID NO: 1233) βc-894 Target: 5′—TACCATGCAGAATACAAATGATGTAGA—3′(SEQ ID NO: 2342)

(SEQ ID NO: 5670)

(SEQ ID NO: 1234) βc-895 Target: 5′—ACCATGCAGAATACAAATGATGTAGAA—3′(SEQ ID NO: 2343)

(SEQ ID NO: 5671)

(SEQ ID NO: 1235) βc-896 Target: 5′ CCATGCAGAATACAAATGATGTAGAAA—3′(SEQ ID NO: 2344)

(SEQ ID NO: 5672)

(SEQ ID NO: 1236)βc-897 Target: 5′ CATGCAGAATACAAATGATGTAGAAAC—3′(SEQ ID NO: 2345)

(SEQ ID NO: 5673)

(SEQ ID NO: 1237) βc-898 Target: 5′ ATGCAGAATACAAATGATGTAGAAACA—3′(SEQ ID NO: 2346)

(SEQ ID NO: 5674)

(SEQ ID NO: 1238) βc-899 Target: 5′ TGCAGAATACAAATGATGTAGAAACAG—3′(SEQ ID NO: 2347)

(SEQ ID NO: 5675)

(SEQ ID NO: 1239) βc-900 Target: 5′—GCAGAATACAAATGATGTAGAAACAGC—3′(SEQ ID NO: 2348)

(SEQ ID NO: 5676)

(SEQ ID NO: 1240) βc-977 Target: 5′—TACTGGCCATCTTTAAGTCTGGAGGCA—3′(SEQ ID NO: 2349)

(SEQ ID NO: 5677)

(SEQ ID NO: 1241) βc-978 Target: 5′—ACTGGCCATCTTTAAGTCTGGAGGC—3′(SEQ ID NO: 2350)

(SEQ ID NO: 5678)

(SEQ ID NO: 1242) βc-1091 Target: 5′—AAGAAGGAGCTAAAATGGCAGTGCGTT—3′(SEQ ID NO: 2351)

(SEQ ID NO: 5679)

(SEQ ID NO: 1243) βc-1092 Target: 5′—AGAAGGAGCTAAAATGGCAGTGCGTTT—3′(SEQ ID NO: 2352)

(SEQ ID NO: 5680)

(SEQ ID NO: 1244) βc-1093 Target: 5′—GAAGGAGCTAAAATGGCAGTGCGTTTA—3′(SEQ ID NO: 2353)

(SEQ ID NO: 5681)

(SEQ ID NO: 1245) βc-1094 Target: 5′—AAGGAGCTAAAATGGCAGTGCGTTTAG—3′(SEQ ID NO: 2354)

(SEQ ID NO: 5682)

(SEQ ID NO: 1246) βc-1095 Target: 5′—AGGAGCTAAAATGGCAGTGCGTTTAGC—3′(SEQ ID NO: 2355)

(SEQ ID NO: 5683)

(SEQ ID NO: 1247) βc-1301 Target: 5′—TACTGTGGACCACAAGCAGAGTGCTGA—3′(SEQ ID NO: 2356)

(SEQ ID NO: 5684)

(SEQ ID NO: 1248) βc-1302 Target: 5′—ACTGTGGACCACAAGCAGAGTGCTGAA—3′(SEQ ID NO: 2357)

(SEQ ID NO: 5685)

(SEQ ID NO: 1249) βc-1303 Target: 5′—CTGTGGACCACAAGCAGAGTGCTGAAG—3′(SEQ ID NO: 2358)

(SEQ ID NO: 5686)

(SEQ ID NO: 1250) βc-1304 Target: 5′—TGTGGACCACAAGCAGAGTGCTGAAGG—3′(SEQ ID NO: 2359)

(SEQ ID NO: 5687)

(SEQ ID NO: 1251) βc-1305 Target: 5′—GTGGACCACAAGCAGAGTGCTGAAGGT—3′(SEQ ID NO: 2360)

(SEQ ID NO: 5688)

(SEQ ID NO: 1252) βc-1306 Target: 5′—TGGACCACAAGCAGAGTGCTGAAGGTG—3′(SEQ ID NO: 2361)

(SEQ ID NO: 5689)

(SEQ ID NO: 1253) βc-1307 Target: 5′—GGACCACAAGCAGAGTGCTGAAGGTGC—3′(SEQ ID NO: 2362)

(SEQ ID NO: 5690)

(SEQ ID NO: 1254) βc-1308 Target: 5′—GACCACAAGCAGAGTGCTGAAGGTGCT—3′(SEQ ID NO: 2363)

(SEQ ID NO: 5691)

(SEQ ID NO: 1255) βc-1309 Target: 5′—ACCACAAGCAGAGTGCTGAAGGTGCTA—3′(SEQ ID NO: 2364)

(SEQ ID NO: 5692)

(SEQ ID NO: 1256) βc-1310 Target: 5′—CCACAAGCAGAGTGCTGAAGGTGCTAT—3′(SEQ ID NO: 2365)

(SEQ ID NO: 5693)

(SEQ ID NO: 1257) βc-1311 Target: 5′—CACAAGCAGAGTGCTGAAGGTGCTATC—3′(SEQ ID NO: 2366)

(SEQ ID NO: 5694)

(SEQ ID NO: 1258) βc-1312 Target: 5′—ACAAGCAGAGTGCTGAAGGTGCTATCT—3′(SEQ ID NO: 2367)

(SEQ ID NO: 5695)

(SEQ ID NO: 1259) βc-1313 Target: 5′—CAAGCAGAGTGCTGAAGGTGCTATCTG—3′(SEQ ID NO: 2368)

(SEQ ID NO: 5696)

(SEQ ID NO: 1260) βc-1314 Target: 5′—AAGCAGAGTGCTGAAGGTGCTATCTGT—3′(SEQ ID NO: 2369)

(SEQ ID NO: 5697)

(SEQ ID NO: 1261) βc-1430 Target: 5′—AGAACTGTCTTTGGACTCTCAGGAATC—3′(SEQ ID NO: 2370)

(SEQ ID NO: 5698)

(SEQ ID NO: 1262) βc-1431 Target: 5′—GAACTGTCTTTGGACTCTCAGGAATCT—3′(SEQ ID NO: 2371)

(SEQ ID NO: 5699)

(SEQ ID NO: 1263) βc-1526 Target: 5′—CAGATGATATAAATGTGGTCACCTGTG—3′(SEQ ID NO: 2372)

(SEQ ID NO: 5700)

(SEQ ID NO: 1264) βc-1527 Target: 5′—AGATGATATAAATGTGGTCACCTGTGC—3′(SEQ ID NO: 2373)

(SEQ ID NO: 5701)

(SEQ ID NO: 1265) βc-1528 Target: 5′—GATGATATAAATGTGGTCACCTGTGCA—3′(SEQ ID NO: 2374)

(SEQ ID NO: 5702)

(SEQ ID NO: 1266) βc-1529 Target: 5′—ATGATATAAATGTGGTCACCTGTGCAG—3′(SEQ ID NO: 2375)

(SEQ ID NO: 5703)

(SEQ ID NO: 1267) βc-1530 Target: 5′—TGATATAAATGTGGTCACCTGTGCAGC—3′(SEQ ID NO: 2376)

(SEQ ID NO: 5704)

(SEQ ID NO: 1268) βc-1531 Target: 5′—GATATAAATGTGGTCACCTGTGCAGCT—3′(SEQ ID NO: 2377)

(SEQ ID NO: 5705)

(SEQ ID NO: 1269) βc-1532 Target: 5′—ATATAAATGTGGTCACCTGTGCAGCTG—3′(SEQ ID NO: 2378)

(SEQ ID NO: 5706)

(SEQ ID NO: 1270) βc-1533 Target: 5′—TATAAATGTGGTCACCTGTGCAGCTGG—3′(SEQ ID NO: 2379)

(SEQ ID NO: 5707)

(SEQ ID NO: 1271) βc-1534 Target: 5′—ATAAATGTGGTCACCTGTGCAGCTGGA—3′(SEQ ID NO: 2380)

(SEQ ID NO: 5708)

(SEQ ID NO: 1272) βc-1535 Target: 5′—TAAATGTGGTCACCTGTGCAGCTGGAA—3′(SEQ ID NO: 2381)

(SEQ ID NO: 5709)

(SEQ ID NO: 1273) βc-1536 Target: 5′—AAATGTGGTCACCTGTGCAGCTGGAAT—3′(SEQ ID NO: 2382)

(SEQ ID NO: 5710)

(SEQ ID NO: 1274) βc-1537 Target: 5′—AATGTGGTCACCTGTGCAGCTGGAATT—3′(SEQ ID NO: 2383)

(SEQ ID NO: 5711)

(SEQ ID NO: 1275) βc-1538 Target: 5′—ATGTGGTCACCTGTGCAGCTGGAATTC—3′(SEQ ID NO: 2384)

(SEQ ID NO: 5712)

(SEQ ID NO: 1276) βc-1539 Target: 5′—TGTGGTCACCTGTGCAGCTGGAATTCT—3′(SEQ ID NO: 2385)

(SEQ ID NO: 5713)

(SEQ ID NO: 1277) βc-1540 Target: 5′—GTGGTCACCTGTGCAGCTGGAATTCTT—3′(SEQ ID NO: 2386)

(SEQ ID NO: 5714)

(SEQ ID NO: 1278) βc-1541 Target: 5′—TGGTCACCTGTGCAGCTGGAATTCTTT—3′(SEQ ID NO: 2387)

(SEQ ID NO: 5715)

(SEQ ID NO: 1279) βc-1542 Target: 5′—GGTCACCTGTGCAGCTGGAATTCTTTC—3′(SEQ ID NO: 2388)

(SEQ ID NO: 5716)

(SEQ ID NO: 1280) βc-1543 Target: 5′—GTCACCTGTGCAGCTGGAATTCTTTCT—3′(SEQ ID NO: 2389)

(SEQ ID NO: 5717)

(SEQ ID NO: 1281) βc-1544 Target: 5′—TCACCTGTGCAGCTGGAATTCTTTCTA—3′(SEQ ID NO: 2390)

(SEQ ID NO: 5718)

(SEQ ID NO: 1282) βc-1545 Target: 5′—CACCTGTGCAGCTGGAATTCTTTCTAA—3′(SEQ ID NO: 2391)

(SEQ ID NO: 5719)

(SEQ ID NO: 1283) βc-1565 Target: 5′—TTTCTAACCTCACTTGCAATAATTATA—3′(SEQ ID NO: 2392)

(SEQ ID NO: 5720)

(SEQ ID NO: 1284) βc-1566 Target: 5′—TTCTAACCTCACTTGCAATAATTATAA—3′(SEQ ID NO: 2393)

(SEQ ID NO: 5721)

(SEQ ID NO: 1285) βc-1567 Target: 5′—TCTAACCTCACTTGCAATAATTATAAG—3′(SEQ ID NO: 2394)

(SEQ ID NO: 5722)

(SEQ ID NO: 1286) βc-1568 Target: 5′—CTAACCTCACTTGCAATAATTATAAGA—3′(SEQ ID NO: 2395)

(SEQ ID NO: 5723)

(SEQ ID NO: 1287) βc-1569 Target: 5′—TAACCTCACTTGCAATAATTATAAGAA—3′(SEQ ID NO: 2396)

(SEQ ID NO: 5724)

(SEQ ID NO: 1288) βc-1652 Target: 5′—GGGCTGGTGACAGGGAAGACATCACTG—3′(SEQ ID NO: 2397)

(SEQ ID NO: 5725)

(SEQ ID NO: 1289) βc-1653 Target: 5′—GGCTGGTGACAGGGAAGACATCACTGA—3′(SEQ ID NO: 2398)

(SEQ ID NO: 5726)

(SEQ ID NO: 1290) βc-1654 Target: 5′—GCTGGTGACAGGGAAGACATCACTGAG—3′(SEQ ID NO: 2399)

(SEQ ID NO: 5727)

(SEQ ID NO: 1291) βc-1655 Target: 5′—CTGGTGACAGGGAAGACATCACTGAGC—3′(SEQ ID NO: 2400)

(SEQ ID NO: 5728)

(SEQ ID NO: 1292) βc-1656 Target: 5′—TGGTGACAGGGAAGACATCACTGAGCC—3′(SEQ ID NO: 2401)

(SEQ ID NO: 5729)

(SEQ ID NO: 1293) βc-1657 Target: 5′—GGTGACAGGGAAGACATCACTGAGCCT—3′(SEQ ID NO: 2402)

(SEQ ID NO: 5730)

(SEQ ID NO: 1294) βc-1658 Target: 5′—GTGACAGGGAAGACATCACTGAGCCTG—3′(SEQ ID NO: 2403)

(SEQ ID NO: 5731)

(SEQ ID NO: 1295) βc-1659 Target: 5′—TGACAGGGAAGACATCACTGAGCCTGC—3′(SEQ ID NO: 2404)

(SEQ ID NO: 5732)

(SEQ ID NO: 1296) βc-1660 Target: 5′—GACAGGGAAGACATCACTGAGCCTGCC—3′(SEQ ID NO: 2405)

(SEQ ID NO: 5733)

(SEQ ID NO: 1297) βc-1661 Target: 5′—ACAGGGAAGACATCACTGAGCCTGCCA—3′(SEQ ID NO: 2406)

(SEQ ID NO: 5734)

(SEQ ID NO: 1298) βc-1662 Target: 5′—CAGGGAAGACATCACTGAGCCTGCC—3′(SEQ ID NO: 2407)

(SEQ ID NO: 5735)

(SEQ ID NO: 1299) βc-1663 Target: 5′—AGGGAAGACATCACTGAGCCTGCCATC—3′(SEQ ID NO: 2408)

(SEQ ID NO: 5736)

(SEQ ID NO: 1300) βc-1664 Target: 5′—GGGAAGACATCACTGAGCCTGCCATCT—3′(SEQ ID NO: 2409)

(SEQ ID NO: 5737)

(SEQ ID NO: 1301) βc-1665 Target: 5′—GGAAGACATCACTGAGCCTGCCATCTG—3′(SEQ ID NO: 2410)

(SEQ ID NO: 5738)

(SEQ ID NO: 1302) βc-1666 Target: 5′—GAAGACATCACTGAGCCTGCCATCTGT—3′(SEQ ID NO: 2411)

(SEQ ID NO: 5739)

(SEQ ID NO: 1303) βc-1667 Target: 5′—AAGACATCACTGAGCCTGCCATCTGTG—3′(SEQ ID NO: 2412)

(SEQ ID NO: 5740)

(SEQ ID NO: 1304) βc-1668 Target: 5′—AGACATCACTGAGCCTGCCATCTGTGC—3′(SEQ ID NO: 2413)

(SEQ ID NO: 5741)

(SEQ ID NO: 1305) βc-1669 Target: 5′—GACATCACTGAGCCTGCCATCTGTGCT—3′(SEQ ID NO: 2414)

(SEQ ID NO: 5742)

(SEQ ID NO: 1306) βc-1670 Target: 5′—ACATCACTGAGCCTGCCATCTGTGCTC—3′(SEQ ID NO: 2415)

(SEQ ID NO: 5743)

(SEQ ID NO: 1307) βc-1671 Target: 5′—CATCACTGAGCCTGCCATCTGTGCTCT—3′(SEQ ID NO: 2416)

(SEQ ID NO: 5744)

(SEQ ID NO: 1308) βc-1672 Target: 5′—ATCACTGAGCCTGCCATCTGTGCTCTT—3′(SEQ ID NO: 2417)

(SEQ ID NO: 5745)

(SEQ ID NO: 1309) βc-1673 Target: 5′—TCACTGAGCCTGCCATCTGTGCTCTTC—3′(SEQ ID NO: 2418)

(SEQ ID NO: 5746)

(SEQ ID NO: 1310) βc-1674 Target: 5′—CACTGAGCCTGCCATCTGTGCTCTTCG—3′(SEQ ID NO: 2419)

(SEQ ID NO: 5747)

(SEQ ID NO: 1311) βc-1675 Target: 5′—ACTGAGCCTGCCATCTGTGCTCTTCGT—3′(SEQ ID NO: 2420)

(SEQ ID NO: 5748)

(SEQ ID NO: 1312) βc-1676 Target: 5′—CTGAGCCTGCCATCTGTGCTCTTCGTC—3′(SEQ ID NO: 2421)

(SEQ ID NO: 5749)

(SEQ ID NO: 1313) βc-1677 Target: 5′—TGAGCCTGCCATCTGTGCTCTTCGTCA—3′(SEQ ID NO: 2422)

(SEQ ID NO: 5750)

(SEQ ID NO: 1314) βc-1678 Target: 5′—GAGCCTGCCATCTGTGCTCTTCGTC—3′(SEQ ID NO: 2423)

(SEQ ID NO: 5751)

(SEQ ID NO: 1315) βc-1679 Target: 5′—AGCCTGCCATCTGTGCTCTTCGTCATC—3′(SEQ ID NO: 2424)

(SEQ ID NO: 5752)

(SEQ ID NO: 1316) βc-1680 Target: 5′—GCCTGCCATCTGTGCTCTTCGTCATCT—3′(SEQ ID NO: 2425)

(SEQ ID NO: 5753)

(SEQ ID NO: 1317) βc-1681 Target: 5′—CCTGCCATCTGTGCTCTTCGTCATCTG—3′(SEQ ID NO: 2426)

(SEQ ID NO: 5754)

(SEQ ID NO: 1318) βc-1682 Target: 5′—CTGCCATCTGTGCTCTTCGTCATCTGA—3′(SEQ ID NO: 2427)

(SEQ ID NO: 5755)

(SEQ ID NO: 1319) βc-1683 Target: 5′—TGCCATCTGTGCTCTTCGTCATCTGAC—3′(SEQ ID NO: 2428)

(SEQ ID NO: 5756)

(SEQ ID NO: 1320) βc-1684 Target: 5′—GCCATCTGTGCTCTTCGTCATCTGACC—3′(SEQ ID NO: 2429)

(SEQ ID NO: 5757)

(SEQ ID NO: 1321) βc-1685 Target: 5′—CCATCTGTGCTCTTCGTCATCTGACCA—3′(SEQ ID NO: 2430)

(SEQ ID NO: 5758)

(SEQ ID NO: 1322) βc-1686 Target: 5′—CATCTGTGCTCTTCGTCATCTGACCAG—3′(SEQ ID NO: 2431)

(SEQ ID NO: 5759)

(SEQ ID NO: 1323) βc-1687 Target: 5′—ATCTGTGCTCTTCGTCATCTGACCAGC—3′(SEQ ID NO: 2432)

(SEQ ID NO: 5760)

(SEQ ID NO: 1324) βc-1688 Target: 5′—TCTGTGCTCTTCGTCATCTGACCAGCC—3′(SEQ ID NO: 2433)

(SEQ ID NO: 5761)

(SEQ ID NO: 1325) βc-1689 Target: 5′—CTGTGCTCTTCGTCATCTGACCAGCCG—3′(SEQ ID NO: 2434)

(SEQ ID NO: 5762)

(SEQ ID NO: 1326) βc-1690 Target: 5′—TGTGCTCTTCGTCATCTGACCAGCCGA—3′(SEQ ID NO: 2435)

(SEQ ID NO: 5763)

(SEQ ID NO: 1327) βc-1691 Target: 5′—GTGCTCTTCGTCATCTGACCAGCCGAC—3′(SEQ ID NO: 2436)

(SEQ ID NO: 5764)

(SEQ ID NO: 1328) βc-1692 Target: 5′—TGCTCTTCGTCATCTGACCAGCCGACA—3′(SEQ ID NO: 2437)

(SEQ ID NO: 5765)

(SEQ ID NO: 1329) βc-1693 Target: 5′—GCTCTTCGTCATCTGACCAGCCGACAC—3′(SEQ ID NO: 2438)

(SEQ ID NO: 5766)

(SEQ ID NO: 1330) βc-1694 Target: 5′—CTCTTCGTCATCTGACCAGCCGACACC—3′(SEQ ID NO: 2439)

(SEQ ID NO: 5767)

(SEQ ID NO: 1331) βc-1695 Target: 5′—TCTTCGTCATCTGACCAGCCGACACCA—3′(SEQ ID NO: 2440)

(SEQ ID NO: 5768)

(SEQ ID NO: 1332) βc-1787 Target: 5′—TACACCCACCATCCCACTGGCCTCTGA—3′(SEQ ID NO: 2441)

(SEQ ID NO: 5769)

(SEQ ID NO: 1333) βc-1788 Target: 5′—ACACCCACCATCCCACTGGCCTCTGAT—3′(SEQ ID NO: 2442)

(SEQ ID NO: 5770)

(SEQ ID NO: 1334) βc-1789 Target: 5′—CACCCACCATCCCACTGGCCTCTGATA—3′(SEQ ID NO: 2443)

(SEQ ID NO: 5771)

(SEQ ID NO: 1335) βc-1790 Target: 5′—ACCCACCATCCCACTGGCCTCTGATAA—3′(SEQ ID NO: 2444)

(SEQ ID NO: 5772)

(SEQ ID NO: 1336) βc-1791 Target: 5′—CCCACCATCCCACTGGCCTCTGATAAA—3′(SEQ ID NO: 2445)

(SEQ ID NO: 5773)

(SEQ ID NO: 1337) βc-1792 Target: 5′—CCACCATCCCACTGGCCTCTGATAAAG—3′(SEQ ID NO: 2446)

(SEQ ID NO: 5774)

(SEQ ID NO: 1338) βc-1793 Target: 5′—CACCATCCCACTGGCCTCTGATAAAGG—3′(SEQ ID NO: 2447)

(SEQ ID NO: 5775)

(SEQ ID NO: 1339) βc-1794 Target: 5′—ACCATCCCACTGGCCTCTGATAAAGGC—3′(SEQ ID NO: 2448)

(SEQ ID NO: 5776)

(SEQ ID NO: 1340) βc-1795 Target: 5′—CCATCCCACTGGCCTCTGATAAAGGCT—3′(SEQ ID NO: 2449)

(SEQ ID NO: 5777)

(SEQ ID NO: 1341) βc-1796 Target: 5′—CATCCCACTGGCCTCTGATAAAGGCTA—3′(SEQ ID NO: 2450)

(SEQ ID NO: 5778)

(SEQ ID NO: 1342) βc-1797 Target: 5′—ATCCCACTGGCCTCTGATAAAGGCTAC—3′(SEQ ID NO: 2451)

(SEQ ID NO: 5779)

(SEQ ID NO: 1343) βc-1798 Target: 5′—TCCCACTGGCCTCTGATAAAGGCTACT—3′(SEQ ID NO: 2452)

(SEQ ID NO: 5780)

(SEQ ID NO: 1344) βc-1799 Target: 5′—CCCACTGGCCTCTGATAAAGGCTACTG—3′(SEQ ID NO: 2453)

(SEQ ID NO: 5781)

(SEQ ID NO: 1345) βc-1800 Target: 5′—CCACTGGCCTCTGATAAAGGCTACTGT—3′(SEQ ID NO: 2454)

(SEQ ID NO: 5782)

(SEQ ID NO: 1346) βc-1820 Target: 5′—CTACTGTTGGATTGATTCGAAATCTTG—3′(SEQ ID NO: 2455)

(SEQ ID NO: 5783)

(SEQ ID NO: 1347) βc-1821 Target: 5′—TACTGTTGGATTGATTCGAAATCTTGC—3′(SEQ ID NO: 2456)

(SEQ ID NO: 5784)

(SEQ ID NO: 1348) βc-2072 Target: 5′—TAAATACCATTCCATTGTTTGTGCAGC—3′(SEQ ID NO: 2457)

(SEQ ID NO: 5785)

(SEQ ID NO: 1349) βc-2073 Target: 5′—AAATACCATTCCATTGTTTGTGCAGCT—3′(SEQ ID NO: 2458)

(SEQ ID NO: 5786)

(SEQ ID NO: 1350) βc-2074 Target: 5′—AATACCATTCCATTGTTTGTGCAGCTG—3′(SEQ ID NO: 2459)

(SEQ ID NO: 5787)

(SEQ ID NO: 1351) βc-2075 Target: 5′—ATACCATTCCATTGTTTGTGCAGCTGC—3′(SEQ ID NO: 2460)

(SEQ ID NO: 5788)

(SEQ ID NO: 1352) βc-2076 Target: 5′—TACCATTCCATTGTTTGTGCAGCTGCT—3′(SEQ ID NO: 2461)

(SEQ ID NO: 5789)

(SEQ ID NO: 1353) βc-2077 Target: 5′—ACCATTCCATTGTTTGTGCAGCTGCTT—3′(SEQ ID NO: 2462)

(SEQ ID NO: 5790)

(SEQ ID NO: 1354) βc-2097 Target: 5′—GCTGCTTTATTCTCCCATTGAAAAC—3′(SEQ ID NO: 2463)

(SEQ ID NO: 5791)

(SEQ ID NO: 1355) βc-2098 Target: 5′—CTGCTTTATTCTCCCATTGAAAACATC—3′(SEQ ID NO: 2464)

(SEQ ID NO: 5792)

(SEQ ID NO: 1356) βc-2099 Target: 5′—TGCTTTATTCTCCCATTGAAAACATCC—3′(SEQ ID NO: 2465)

(SEQ ID NO: 5793)

(SEQ ID NO: 1357) βc-2100 Target: 5′—GCTTTATTCTCCCATTGAAAACATCCA—3′(SEQ ID NO: 2466)

(SEQ ID NO: 5794)

(SEQ ID NO: 1358) βc-2141 Target: 5′—GGGTCCTCTGTGAACTTGCTCAGGACA—3′(SEQ ID NO: 2467)

(SEQ ID NO: 5795)

(SEQ ID NO: 1359) βc-2142 Target: 5′—GGTCCTCTGTGAACTTGCTCAGGACAA—3′(SEQ ID NO: 2468)

(SEQ ID NO: 5796)

(SEQ ID NO: 1360) βc-2143 Target: 5′—GTCCTCTGTGAACTTGCTCAGGACAAG—3′(SEQ ID NO: 2469)

(SEQ ID NO: 5797)

(SEQ ID NO: 1361) βc-2144 Target: 5′—TCCTCTGTGAACTTGCTCAGGACAAGG—3′(SEQ ID NO: 2470)

(SEQ ID NO: 5798)

(SEQ ID NO: 1362) βc-2145 Target: 5′—CCTCTGTGAACTTGCTCAGGACAAGGA—3′(SEQ ID NO: 2471)

(SEQ ID NO: 5799)

(SEQ ID NO: 1363) βc-2146 Target: 5′—CTCTGTGAACTTGCTCAGGACAAGGAA—3′(SEQ ID NO: 2472)

(SEQ ID NO: 5800)

(SEQ ID NO: 1364) βc-2147 Target: 5′—TCTGTGAACTTGCTCAGGACAAGGAAG—3′(SEQ ID NO: 2473)

(SEQ ID NO: 5801)

(SEQ ID NO: 1365) βc-2148 Target: 5′—CTGTGAACTTGCTCAGGACAAGGAAGC—3′(SEQ ID NO: 2474)

(SEQ ID NO: 5802)

(SEQ ID NO: 1366) βc-2149 Target: 5′—TGTGAACTTGCTCAGGACAAGGAAGCT—3′(SEQ ID NO: 2475)

(SEQ ID NO: 5803)

(SEQ ID NO: 1367) βc-2150 Target: 5′—GTGAACTTGCTCAGGACAAGGAAGCTG—3′(SEQ ID NO: 2476)

(SEQ ID NO: 5804)

(SEQ ID NO: 1368) βc-2151 Target: 5′—TGAACTTGCTCAGGACAAGGAAGCTGC—3′(SEQ ID NO: 2477)

(SEQ ID NO: 5805)

(SEQ ID NO: 1369) βc-2183 Target: 5′—CTATTGAAGCTGAGGGAGCCACAGCTC—3′(SEQ ID NO: 2478)

(SEQ ID NO: 5806)

(SEQ ID NO: 1370) βc-2184 Target: 5′—TATTGAAGCTGAGGGAGCCACAGCTCC—3′(SEQ ID NO: 2479)

(SEQ ID NO: 5807)

(SEQ ID NO: 1371) βc-2185 Target: 5′—ATTGAAGCTGAGGGAGCCACAGCTCCT—3′(SEQ ID NO: 2480)

(SEQ ID NO: 5808)

(SEQ ID NO: 1372) βc-2270 Target: 5′—TGTTCCGAATGTCTGAGGACAAGCCAC—3′(SEQ ID NO: 2481)

(SEQ ID NO: 5809)

(SEQ ID NO: 1373) βc-2271 Target: 5′—GTTCCGAATGTCTGAGGACAAGCCACA—3′(SEQ ID NO: 2482)

(SEQ ID NO: 5810)

(SEQ ID NO: 1374) βc-2272 Target: 5′—TTCCGAATGTCTGAGGACAAGCCACAA—3′(SEQ ID NO: 2483)

(SEQ ID NO: 5811)

(SEQ ID NO: 1375) βc-2273 Target: 5′—TCCGAATGTCTGAGGACAAGCCACAAG—3′(SEQ ID NO: 2484)

(SEQ ID NO: 5812)

(SEQ ID NO: 1376) βc-2274 Target: 5′—CCGAATGTCTGAGGACAAGCCACAAGA—3′(SEQ ID NO: 2485)

(SEQ ID NO: 5813)

(SEQ ID NO: 1377) βc-2275 Target: 5′—CGAATGTCTGAGGACAAGCCACAAGAT—3′(SEQ ID NO: 2486)

(SEQ ID NO: 5814)

(SEQ ID NO: 1378) βc-2276 Target: 5′—GAATGTCTGAGGACAAGCCACAAGATT—3′(SEQ ID NO: 2487)

(SEQ ID NO: 5815)

(SEQ ID NO: 1379) βc-2277 Target: 5′—AATGTCTGAGGACAAGCCACAAGATTA—3′(SEQ ID NO: 2488)

(SEQ ID NO: 5816)

(SEQ ID NO: 1380) βc-2345 Target: 5′—GAACAGAGCCAATGGCTTGGAATGAGA—3′(SEQ ID NO: 2489)

(SEQ ID NO: 5817)

(SEQ ID NO: 1381) βc-2346 Target: 5′—AACAGAGCCAATGGCTTGGAATGAGAC—3′(SEQ ID NO: 2490)

(SEQ ID NO: 5818)

(SEQ ID NO: 1382) βc-2347 Target: 5′—ACAGAGCCAATGGCTTGGAATGAGACT—3′(SEQ ID NO: 2491)

(SEQ ID NO: 5819)

(SEQ ID NO: 1383) βc-2348 Target: 5′—CAGAGCCAATGGCTTGGAATGAGACTG—3′(SEQ ID NO: 2492)

(SEQ ID NO: 5820)

(SEQ ID NO: 1384) βc-2349 Target: 5′—AGAGCCAATGGCTTGGAATGAGACTGC—3′(SEQ ID NO: 2493)

(SEQ ID NO: 5821)

(SEQ ID NO: 1385) βc-2350 Target: 5′—GAGCCAATGGCTTGGAATGAGACTGCT—3′(SEQ ID NO: 2494)

(SEQ ID NO: 5822)

(SEQ ID NO: 1386) βc-2351 Target: 5′—AGCCAATGGCTTGGAATGAGACTGCTG—3′(SEQ ID NO: 2495)

(SEQ ID NO: 5823)

(SEQ ID NO: 1387) βc-2352 Target: 5′—GCCAATGGCTTGGAATGAGACTGCTGA—3′(SEQ ID NO: 2496)

(SEQ ID NO: 5824)

(SEQ ID NO: 1388) βc-2353 Target: 5′—CCAATGGCTTGGAATGAGACTGCTGAT—3′(SEQ ID NO: 2497)

(SEQ ID NO: 5825)

(SEQ ID NO: 1389) βc-2354 Target: 5′—CAATGGCTTGGAATGAGACTGCTGATC—3′(SEQ ID NO: 2498)

(SEQ ID NO: 5826)

(SEQ ID NO: 1390) βc-2355 Target: 5′—AATGGCTTGGAATGAGACTGCTGATCT—3′(SEQ ID NO: 2499)

(SEQ ID NO: 5827)

(SEQ ID NO: 1391) βc-2411 Target: 5′—CCCTTGGATATCGCCAGGATGATCCTA—3′(SEQ ID NO: 2500)

(SEQ ID NO: 5828)

(SEQ ID NO: 1392) βc-2412 Target: 5′—CCTTGGATATCGCCAGGATGATCCTAG—3′(SEQ ID NO: 2501)

(SEQ ID NO: 5829)

(SEQ ID NO: 1393) βc-2413 Target: 5′—CTTGGATATCGCCAGGATGATCCTAGC—3′(SEQ ID NO: 2502)

(SEQ ID NO: 5830)

(SEQ ID NO: 1394) βc-2414 Target: 5′—TTGGATATCGCCAGGATGATCCTAGCT—3′(SEQ ID NO: 2503)

(SEQ ID NO: 5831)

(SEQ ID NO: 1395) βc-2415 Target: 5′—TGGATATCGCCAGGATGATCCTAGCTA—3′(SEQ ID NO: 2504)

(SEQ ID NO: 5832)

(SEQ ID NO: 1396) βc-2441 Target: 5′—ATCGTTCTTTTCACTCTGGTGGATATG—3′(SEQ ID NO: 2505)

(SEQ ID NO: 5833)

(SEQ ID NO: 1397) βc-2442 Target: 5′—TCGTTCTTTTCACTCTGGTGGATATGG—3′(SEQ ID NO: 2506)

(SEQ ID NO: 5834)

(SEQ ID NO: 1398) βc-2443 Target: 5′—CGTTCTTTTCACTCTGGTGGATATGGC—3′(SEQ ID NO: 2507)

(SEQ ID NO: 5835)

(SEQ ID NO: 1399) βc-2444 Target: 5′—GTTCTTTTCACTCTGGTGGATATGGCC—3′(SEQ ID NO: 2508)

(SEQ ID NO: 5836)

(SEQ ID NO: 1400) βc-2445 Target: 5′—TTCTTTTCACTCTGGTGGATATGGCCA—3′(SEQ ID NO: 2509)

(SEQ ID NO: 5837)

(SEQ ID NO: 1401) βc-2501 Target: 5′—AACATGAGATGGGTGGCCACCACCCTG—3′(SEQ ID NO: 2510)

(SEQ ID NO: 5838)

(SEQ ID NO: 1402) βc-2502 Target: 5′—ACATGAGATGGGTGGCCACCACCCTGG—3′(SEQ ID NO: 2511)

(SEQ ID NO: 5839)

(SEQ ID NO: 1403) βc-2503 Target: 5′—CATGAGATGGGTGGCCACCACCCTGGT—3′(SEQ ID NO: 2512)

(SEQ ID NO: 5840)

(SEQ ID NO: 1404) βc-2504 Target: 5′—ATGAGATGGGTGGCCACCACCCTGGTG—3′(SEQ ID NO: 2513)

(SEQ ID NO: 5841)

(SEQ ID NO: 1405) βc-2505 Target: 5′—TGAGATGGGTGGCCACCACCCTGGTGC—3′(SEQ ID NO: 2514)

(SEQ ID NO: 5842)

(SEQ ID NO: 1406) βc-2506 Target: 5′—GAGATGGGTGGCCACCACCCTGGTGCT—3′(SEQ ID NO: 2515)

(SEQ ID NO: 5843)

(SEQ ID NO: 1407) βc-2507 Target: 5′—AGATGGGTGGCCACCACCCTGGTGCTG—3′(SEQ ID NO: 2516)

(SEQ ID NO: 5844)

(SEQ ID NO: 1408) βc-2508 Target: 5′—GATGGGTGGCCACCACCCTGGTGCTGA—3′(SEQ ID NO: 2517)

(SEQ ID NO: 5845)

(SEQ ID NO: 1409) βc-2509 Target: 5′—ATGGGTGGCCACCACCCTGGTGCTGAC—3′(SEQ ID NO: 2518)

(SEQ ID NO: 5846)

(SEQ ID NO: 1410) βc-2510 Target: 5′—TGGGTGGCCACCACCCTGGTGCTGACT—3′(SEQ ID NO: 2519)

(SEQ ID NO: 5847)

(SEQ ID NO: 1411) βc-2511 Target: 5′—GGGTGGCCACCACCCTGGTGCTGACTA—3′(SEQ ID NO: 2520)

(SEQ ID NO: 5848)

(SEQ ID NO: 1412) βc-2512 Target: 5′—GGTGGCCACCACCCTGGTGCTGACTAT—3′(SEQ ID NO: 2521)

(SEQ ID NO: 5849)

(SEQ ID NO: 1413) βc-2513 Target: 5′—GTGGCCACCACCCTGGTGCTGACTATC—3′(SEQ ID NO: 2522)

(SEQ ID NO: 5850)

(SEQ ID NO: 1414) βc-2514 Target: 5′—TGGCCACCACCCTGGTGCTGACTATCC—3′(SEQ ID NO: 2523)

(SEQ ID NO: 5851)

(SEQ ID NO: 1415) βc-2515 Target: 5′—GGCCACCACCCTGGTGCTGACTATCCA—3′(SEQ ID NO: 2524)

(SEQ ID NO: 5852)

(SEQ ID NO: 1416) βc-2516 Target: 5′—GCCACCACCCTGGTGCTGACTATCCAG—3′(SEQ ID NO: 2525)

(SEQ ID NO: 5853)

(SEQ ID NO: 1417) βc-2517 Target: 5′—CCACCACCCTGGTGCTGACTATCCAGT—3′(SEQ ID NO: 2526)

(SEQ ID NO: 5854)

(SEQ ID NO: 1418) βc-2518 Target: 5′—CACCACCCTGGTGCTGACTATCCAGTT—3′(SEQ ID NO: 2527)

(SEQ ID NO: 5855)

(SEQ ID NO: 1419) βc-2519 Target: 5′—ACCACCCTGGTGCTGACTATCCAGTTG—3′(SEQ ID NO: 2528)

(SEQ ID NO: 5856)

(SEQ ID NO: 1420) βc-2520 Target: 5′—CCACCCTGGTGCTGACTATCCAGTTGA—3′(SEQ ID NO: 2529)

(SEQ ID NO: 5857)

(SEQ ID NO: 1421) βc-2521 Target: 5′—CACCCTGGTGCTGACTATCCAGTTGAT—3′(SEQ ID NO: 2530)

(SEQ ID NO: 5858)

(SEQ ID NO: 1422) βc-2522 Target: 5′—ACCCTGGTGCTGACTATCCAGTTGATG—3′(SEQ ID NO: 2531)

(SEQ ID NO: 5859)

(SEQ ID NO: 1423) βc-2523 Target: 5′—CCCTGGTGCTGACTATCCAGTTGATGG—3′(SEQ ID NO: 2532)

(SEQ ID NO: 5860)

(SEQ ID NO: 1424) βc-2524 Target: 5′—CCTGGTGCTGACTATCCAGTTGATGGG—3′(SEQ ID NO: 2533)

(SEQ ID NO: 5861)

(SEQ ID NO: 1425) βc-2525 Target: 5′—CTGGTGCTGACTATCCAGTTGATGGGC—3′(SEQ ID NO: 2534)

(SEQ ID NO: 5862)

(SEQ ID NO: 1426) βc-2526 Target: 5′—TGGTGCTGACTATCCAGTTGATGGGCT—3′(SEQ ID NO: 2535)

(SEQ ID NO: 5863)

(SEQ ID NO: 1427) βc-2527 Target: 5′—GGTGCTGACTATCCAGTTGATGGGCTG—3′(SEQ ID NO: 2536)

(SEQ ID NO: 5864)

(SEQ ID NO: 1428) βc-2528 Target: 5′—GTGCTGACTATCCAGTTGATGGGCTGC—3′(SEQ ID NO: 2537)

(SEQ ID NO: 5865)

(SEQ ID NO: 1429) βc-2529 Target: 5′—TGCTGACTATCCAGTTGATGGGCTGCC—3′(SEQ ID NO: 2538)

(SEQ ID NO: 5866)

(SEQ ID NO: 1430) βc-2530 Target: 5′—GCTGACTATCCAGTTGATGGGCTGCCA—3′(SEQ ID NO: 2539)

(SEQ ID NO: 5867)

(SEQ ID NO: 1431) βc-2531 Target: 5′—CTGACTATCCAGTTGATGGGCTGCCAG—3′(SEQ ID NO: 2540)

(SEQ ID NO: 5868)

(SEQ ID NO: 1432) βc-2532 Target: 5′—TGACTATCCAGTTGATGGGCTGCCAGA—3′(SEQ ID NO: 2541)

(SEQ ID NO: 5869)

(SEQ ID NO: 1433) βc-2533 Target: 5′—GACTATCCAGTTGATGGGCTGCCAGAT—3′(SEQ ID NO: 2542)

(SEQ ID NO: 5870)

(SEQ ID NO: 1434) βc-2534 Target: 5′—ACTATCCAGTTGATGGGCTGCCAGATC-3′(SEQ ID NO: 2543)

(SEQ ID NO: 5871)

(SEQ ID NO: 1435) βc-2535 Target: 5′—CTATCCAGTTGATGGGCTGCCAGATCT—3′(SEQ ID NO: 2544)

(SEQ ID NO: 5872)

(SEQ ID NO: 1436) βc-2567 Target: 5′—ATGCCCAGGACCTCATGGATGGGCTGC—3′(SEQ ID NO: 2545)

(SEQ ID NO: 5873)

(SEQ ID NO: 1437) βc-2568 Target: 5′—TGCCCAGGACCTCATGGATGGGCTGCC—3′(SEQ ID NO: 2546)

(SEQ ID NO: 5874)

(SEQ ID NO: 1438) βc-2569 Target: 5′—GCCCAGGACCTCATGGATGGGCTGCCT—3′(SEQ ID NO: 2547)

(SEQ ID NO: 5875)

(SEQ ID NO: 1439) βc-2603 Target: 5′—ACAGCAATCAGCTGGCCTGGTTTGATA—3′(SEQ ID NO: 2548)

(SEQ ID NO: 5876)

(SEQ ID NO: 1440) βc-2604 Target: 5′—CAGCAATCAGCTGGCCTGGTTTGATAC—3′(SEQ ID NO: 2549)

(SEQ ID NO: 5877)

(SEQ ID NO: 1441) βc-2605 Target: 5′—AGCAATCAGCTGGCCTGGTTTGATACT—3′(SEQ ID NO: 2550)

(SEQ ID NO: 5878)

(SEQ ID NO: 1442) βc-2606 Target: 5′—GCAATCAGCTGGCCTGGTTTGATACTG—3′(SEQ ID NO: 2551)

(SEQ ID NO: 5879)

(SEQ ID NO: 1443) βc-2607 Target: 5′—CAATCAGCTGGCCTGGTTTGATACTGA—3′(SEQ ID NO: 2552)

(SEQ ID NO: 5880)

(SEQ ID NO: 1444) βc-2608 Target: 5′—AATCAGCTGGCCTGGTTTGATACTGAC—3′(SEQ ID NO: 2553)

(SEQ ID NO: 5881)

(SEQ ID NO: 1445) βc-2609 Target: 5′—ATCAGCTGGCCTGGTTTGATACTGACC—3′(SEQ ID NO: 2554)

(SEQ ID NO: 5882)

(SEQ ID NO: 1446) βc-2610 Target: 5′—TCAGCTGGCCTGGTTTGATACTGACCT—3′(SEQ ID NO: 2555)

(SEQ ID NO: 5883)

(SEQ ID NO: 1447) βc-2611 Target: 5′—CAGCTGGCCTGGTTTGATACTGACCTG—3′(SEQ ID NO: 2556)

(SEQ ID NO: 5884)

(SEQ ID NO: 1448) βc-2612 Target: 5′—AGCTGGCCTGGTTTGATACTGACCTGT—3′(SEQ ID NO: 2557)

(SEQ ID NO: 5885)

(SEQ ID NO: 1449) βc-2613 Target: 5′—GCTGGCCTGGTTTGATACTGACCTGTA—3′(SEQ ID NO: 2558)

(SEQ ID NO: 5886)

(SEQ ID NO: 1450) βc-2614 Target: 5′—CTGGCCTGGTTTGATACTGACCTGTAA—3′(SEQ ID NO: 2559)

(SEQ ID NO: 5887)

(SEQ ID NO: 1451) βc-2615 Target: 5′—TGGCCTGGTTTGATACTGACCTGTAAA—3′(SEQ ID NO: 2560)

(SEQ ID NO: 5888)

(SEQ ID NO: 1452) βc-2616 Target: 5′—GGCCTGGTTTGATACTGACCTGTAAAT—3′(SEQ ID NO: 2561)

(SEQ ID NO: 5889)

(SEQ ID NO: 1453) βc-2617 Target: 5′—GCCTGGTTTGATACTGACCTGTAAATC—3′(SEQ ID NO: 2562)

(SEQ ID NO: 5890)

(SEQ ID NO: 1454) βc-2618 Target: 5′—CCTGGTTTGATACTGACCTGTAAATCA—3′(SEQ ID NO: 2563)

(SEQ ID NO: 5891)

(SEQ ID NO: 1455) βc-2619 Target: 5′—CTGGTTTGATACTGACCTGTAAATC—3′(SEQ ID NO: 2564)

(SEQ ID NO: 5892)

(SEQ ID NO: 1456) βc-2620 Target: 5′—TGGTTTGATACTGACCTGTAAATCATC—3′(SEQ ID NO: 2565)

(SEQ ID NO: 5893)

(SEQ ID NO: 1457) βc-2621 Target: 5′—GGTTTGATACTGACCTGTAAATCATCC—3′(SEQ ID NO: 2566)

(SEQ ID NO: 5894)

(SEQ ID NO: 1458) βc-2622 Target: 5′—GTTTGATACTGACCTGTAAATCATCCT—3′(SEQ ID NO: 2567)

(SEQ ID NO: 5895)

(SEQ ID NO: 1459) βc-2623 Target: 5′—TTTGATACTGACCTGTAAATCATCCTT—3′(SEQ ID NO: 2568)

(SEQ ID NO: 5896)

(SEQ ID NO: 1460) βc-2869 Target: 5′—TTTTTTGCCACAGCTTTTGCAACTTAA—3′(SEQ ID NO: 2569)

(SEQ ID NO: 5897)

(SEQ ID NO: 1461) βc-2902 Target: 5′—AATGAGTAACATTTGCTGTTTTAAACA—3′(SEQ ID NO: 2570)

(SEQ ID NO: 5898)

(SEQ ID NO: 1462) βc-2923 Target: 5′—TAAACATTAATAGCAGCCTTTCTCTCT—3′(SEQ ID NO: 2571)

(SEQ ID NO: 5899)

(SEQ ID NO: 1463) βc-2925 Target: 5′—AACATTAATAGCAGCCTTTCTCTCTTT—3′(SEQ ID NO: 2572)

(SEQ ID NO: 5900)

(SEQ ID NO: 1464) βc-2927 Target: 5′—CATTAATAGCAGCCTTTCTCTCTTTAT—3′(SEQ ID NO: 2573)

(SEQ ID NO: 5901)

(SEQ ID NO: 1465) βc-2929 Target: 5′—TTAATAGCAGCCTTTCTCTCTTTATAC—3′(SEQ ID NO: 2574)

(SEQ ID NO: 5902)

(SEQ ID NO: 1466) βc-2973 Target: 5′—TTGCATTGTGATTGGCCTGTAGAGTTG—3′(SEQ ID NO: 2575)

(SEQ ID NO: 5903)

(SEQ ID NO: 1467) βc-2975 Target: 5′—GCATTGTGATTGGCCTGTAGAGTTGCT—3′(SEQ ID NO: 2576)

(SEQ ID NO: 5904)

(SEQ ID NO: 1468) βc-2977 Target: 5′—ATTGTGATTGGCCTGTAGAGTTGCTGA—3′(SEQ ID NO: 2577)

(SEQ ID NO: 5905)

(SEQ ID NO: 1469) βc-2979 Target: 5′—TGTGATTGGCCTGTAGAGTTGCTGAGA—3′(SEQ ID NO: 2578)

(SEQ ID NO: 5906)

(SEQ ID NO: 1470) βc-2981 Target: 5′—TGATTGGCCTGTAGAGTTGCTGAGAGG—3′(SEQ ID NO: 2579)

(SEQ ID NO: 5907)

(SEQ ID NO: 1471) βc-2983 Target: 5′—ATTGGCCTGTAGAGTTGCTGAGAGGGC—3′(SEQ ID NO: 2580)

(SEQ ID NO: 5908)

(SEQ ID NO: 1472) βc-2985 Target: 5′—TGGCCTGTAGAGTTGCTGAGAGGGCTC—3′(SEQ ID NO: 2581)

(SEQ ID NO: 5909)

(SEQ ID NO: 1473) βc-2987 Target: 5′—GCCTGTAGAGTTGCTGAGAGGGCTCGA—3′(SEQ ID NO: 2582)

(SEQ ID NO: 5910)

(SEQ ID NO: 1474) βc-2989 Target: 5′—CTGTAGAGTTGCTGAGAGGGCTCGAGG—3′(SEQ ID NO: 2583)

(SEQ ID NO: 5911)

(SEQ ID NO: 1475) βc-3015 Target: 5′—GGGTGGGCTGGTATCTCAGAAAGTGCC—3′(SEQ ID NO: 2584)

(SEQ ID NO: 5912)

(SEQ ID NO: 1476) βc-3017 Target: 5′—GTGGGCTGGTATCTCAGAAAGTGCCTG—3′(SEQ ID NO: 2585)

(SEQ ID NO: 5913)

(SEQ ID NO: 1477) βc-3019 Target: 5′—GGGCTGGTATCTCAGAAAGTGCCTGAC—3′(SEQ ID NO: 2586)

(SEQ ID NO: 5914)

(SEQ ID NO: 1478) βc-3021 Target: 5′—GCTGGTATCTCAGAAAGTGCCTGACAC—3′(SEQ ID NO: 2587)

(SEQ ID NO: 5915)

(SEQ ID NO: 1479) βc-3046 Target: 5′—ACACTAACCAAGCTGAGTTTCCTATGG—3′(SEQ ID NO: 2588)

(SEQ ID NO: 5916)

(SEQ ID NO: 1480) βc-3048 Target: 5′—ACTAACCAAGCTGAGTTTCCTATGGGA—3′(SEQ ID NO: 2589)

(SEQ ID NO: 5917)

(SEQ ID NO: 1481) βc-3050 Target: 5′—TAACCAAGCTGAGTTTCCTATGGGAAC—3′(SEQ ID NO: 2590)

(SEQ ID NO: 5918)

(SEQ ID NO: 1482) βc-3052 Target: 5′—ACCAAGCTGAGTTTCCTATGGGAACAA—3′(SEQ ID NO: 2591)

(SEQ ID NO: 5919)

(SEQ ID NO: 1483) βc-3054 Target: 5′—CAAGCTGAGTTTCCTATGGGAACAATT—3′(SEQ ID NO: 2592)

(SEQ ID NO: 5920)

(SEQ ID NO: 1484) βc-3056 Target: 5′—AGCTGAGTTTCCTATGGGAACAATTGA—3′(SEQ ID NO: 2593)

(SEQ ID NO: 5921)

(SEQ ID NO: 1485) βc-3087 Target: 5′—AACTTTTTGTTCTGGTCCTTTTTGGTC—3′(SEQ ID NO: 2594)

(SEQ ID NO: 5922)

(SEQ ID NO: 1486) βc-3089 Target: 5′—CTTTTTGTTCTGGTCCTTTTTGGTCGA—3′(SEQ ID NO: 2595)

(SEQ ID NO: 5923)

(SEQ ID NO: 1487) βc-3091 Target: 5′—TTTTGTTCTGGTCCTTTTTGGTCGAGG—3′(SEQ ID NO: 2596)

(SEQ ID NO: 5924)

(SEQ ID NO: 1488) βc-3093 Target: 5′—TTGTTCTGGTCCTTTTTGGTCGAGGAG—3′(SEQ ID NO: 2597)

(SEQ ID NO: 5925)

(SEQ ID NO: 1489) βc-3095 Target: 5′—GTTCTGGTCCTTTTTGGTCGAGGAGTA—3′(SEQ ID NO: 2598)

(SEQ ID NO: 5926)

(SEQ ID NO: 1490) βc-3097 Target: 5′—TCTGGTCCTTTTTGGTCGAGGAGTAAC—3′(SEQ ID NO: 2599)

(SEQ ID NO: 5927)

(SEQ ID NO: 1491) βc-3099 Target: 5′—TGGTCCTTTTTGGTCGAGGAGTAACAA—3′(SEQ ID NO: 2600)

(SEQ ID NO: 5928)

(SEQ ID NO: 1492) βc-3101 Target: 5′—GTCCTTTTTGGTCGAGGAGTAACAATA—3′(SEQ ID NO: 2601)

(SEQ ID NO: 5929)

(SEQ ID NO: 1493) βc-3103 Target: 5′—CCTTTTTGGTCGAGGAGTAACAATACA—3′(SEQ ID NO: 2602)

(SEQ ID NO: 5930)

(SEQ ID NO: 1494) βc-3105 Target: 5′—TTTTTGGTCGAGGAGTAACAATACAAA—3′(SEQ ID NO: 2603)

(SEQ ID NO: 5931)

(SEQ ID NO: 1495) βc-3107 Target: 5′—TTTGGTCGAGGAGTAACAATACAAATG—3′(SEQ ID NO: 2604)

(SEQ ID NO: 5932)

(SEQ ID NO: 1496) βc-3109 Target: 5′—TGGTCGAGGAGTAACAATACAAATGGA—3′(SEQ ID NO: 2605)

(SEQ ID NO: 5933)

(SEQ ID NO: 1497) βc-3111 Target: 5′—GTCGAGGAGTAACAATACAAATGGATT—3′(SEQ ID NO: 2606)

(SEQ ID NO: 5934)

(SEQ ID NO: 1498) βc-3113 Target: 5′—CGAGGAGTAACAATACAAATGGATTTT—3′(SEQ ID NO: 2607)

(SEQ ID NO: 5935)

(SEQ ID NO: 1499) βc-3115 Target: 5′—AGGAGTAACAATACAAATGGATTTTGG—3′(SEQ ID NO: 2608)

(SEQ ID NO: 5936)

(SEQ ID NO: 1500) βc-3191 Target: 5′—TTTATCAAACCCTAGCCTTGCTTGTTA—3′(SEQ ID NO: 2609)

(SEQ ID NO: 5937)

(SEQ ID NO: 1501) βc-3193 Target: 5′—TATCAAACCCTAGCCTTGCTTGTTAAA—3′(SEQ ID NO: 2610)

(SEQ ID NO: 5938)

(SEQ ID NO: 1502) βc-3195 Target: 5′—TCAAACCCTAGCCTTGCTTGTTAAATT—3′(SEQ ID NO: 2611)

(SEQ ID NO: 5939)

(SEQ ID NO: 1503) βc-3387 Target: 5′—TTGAGTAATGGTGTAGAACACTAATTC—3′(SEQ ID NO: 2612)

(SEQ ID NO: 5940)

(SEQ ID NO: 1504) βc-3389 Target: 5′—GAGTAATGGTGTAGAACACTAATTC—3′ (SEQ ID NO: 2613)

(SEQ ID NO: 5941)

(SEQ ID NO: 1505) βc-3391 Target: 5′—GTAATGGTGTAGAACACTAATTCATAA—3′(SEQ ID NO: 2614)

(SEQ ID NO: 5942)

(SEQ ID NO: 1506) βc-3393 Target: 5′—AATGGTGTAGAACACTAATTCATAATC—3′(SEQ ID NO: 2615)

(SEQ ID NO: 5943)

(SEQ ID NO: 1507) βc-3395 Target: 5′—TGGTGTAGAACACTAATTCATAATCAC—3′(SEQ ID NO: 2616)

(SEQ ID NO: 5944)

(SEQ ID NO: 1508) βc-3397 Target: 5′—GTGTAGAACACTAATTCATAATCACTC—3′(SEQ ID NO: 2617)

(SEQ ID NO: 5945)

(SEQ ID NO: 1509) βc-3399 Target: 5′—GTAGAACACTAATTCATAATCACTCTA—3′(SEQ ID NO: 2618)

(SEQ ID NO: 5946)

(SEQ ID NO: 1510) βc-3401 Target: 5′—AGAACACTAATTCATAATCACTCTAAT—3′(SEQ ID NO: 2619)

(SEQ ID NO: 5947)

(SEQ ID NO: 1511) βc-3500 Target: 5′—AATTAGTTTCCTTTTTAATATGCTTAA—3′(SEQ ID NO: 2620)

(SEQ ID NO: 5948)

(SEQ ID NO: 1512) βc-3502 Target: 5′—TTAGTTTCCTTTTTAATATGCTTAAAA—3′(SEQ ID NO: 2621)

(SEQ ID NO: 5949)

(SEQ ID NO: 1513) βc-3504 Target: 5′—AGTTTCCTTTTTAATATGCTTAAAATA—3′(SEQ ID NO: 2622)

(SEQ ID NO: 5950)

(SEQ ID NO: 1514) βc-3506 Target: 5′—TTTCCTTTTTAATATGCTTAAAATAAG—3′(SEQ ID NO: 2623)

(SEQ ID NO: 5951)

(SEQ ID NO: 1515) βc-3508 Target: 5′—TCCTTTTTAATATGCTTAAAATAAGCA—3′(SEQ ID NO: 2624)

(SEQ ID NO: 5952)

(SEQ ID NO: 1516) βc-3509 Target: 5′—CCTTTTTAATATGCTTAAAATAAGCAG—3′(SEQ ID NO: 2625)

(SEQ ID NO: 5953)

(SEQ ID NO: 1517) βc-3510 Target: 5′—CTTTTTAATATGCTTAAAATAAGCAGG—3′(SEQ ID NO: 2626)

(SEQ ID NO: 5954)

(SEQ ID NO: 1518) βc-3512 Target: 5′—TTTTAATATGCTTAAAATAAGCAGGTG—3′(SEQ ID NO: 2627)

(SEQ ID NO: 5955)

(SEQ ID NO: 1519) βc-3514 Target: 5′—TTAATATGCTTAAAATAAGCAGGTGGA—3′(SEQ ID NO: 2628)

(SEQ ID NO: 5956)

(SEQ ID NO: 1520) βc-3516 Target: 5′—AATATGCTTAAAATAAGCAGGTGGATC—3′(SEQ ID NO: 2629)

(SEQ ID NO: 5957)

(SEQ ID NO: 1521) βc-3518 Target: 5′—TATGCTTAAAATAAGCAGGTGGATCTA—3′(SEQ ID NO: 2630)

(SEQ ID NO: 5958)

(SEQ ID NO: 1522) βc-3520 Target: 5′—TGCTTAAAATAAGCAGGTGGATCTATT—3′(SEQ ID NO: 2631)

(SEQ ID NO: 5959)

(SEQ ID NO: 1523) βc-3522 Target: 5′—CTTAAAATAAGCAGGTGGATCTATTTC—3′(SEQ ID NO: 2632)

(SEQ ID NO: 5960)

(SEQ ID NO: 1524) βc-3524 Target: 5′—TAAAATAAGCAGGTGGATCTATTTC—3′(SEQ ID NO: 2633)

(SEQ ID NO: 5961)

(SEQ ID NO: 1525) βc-3526 Target: 5′—AAATAAGCAGGTGGATCTATTTCATGT—3′(SEQ ID NO: 2634)

(SEQ ID NO: 5962)

(SEQ ID NO: 1526) βc-3528 Target: 5′—ATAAGCAGGTGGATCTATTTCATGTTT—3′(SEQ ID NO: 2635)

(SEQ ID NO: 5963)

(SEQ ID NO: 1527) βc-3530 Target: 5′—AAGCAGGTGGATCTATTTCATGTTTTT—3′(SEQ ID NO: 2636)

(SEQ ID NO: 5964)

(SEQ ID NO: 1528) βc-3532 Target: 5′—GCAGGTGGATCTATTTCATGTTTTTGA—3′(SEQ ID NO: 2637)

(SEQ ID NO: 5965)

(SEQ ID NO: 1529) βc-3534 Target: 5′—AGGTGGATCTATTTCATGTTTTTGATC—3′(SEQ ID NO: 2638)

(SEQ ID NO: 5966)

(SEQ ID NO: 1530) βc-3536 Target: 5′—GTGGATCTATTTCATGTTTTTGATCAA—3′(SEQ ID NO: 2639)

(SEQ ID NO: 5967)

(SEQ ID NO: 1531) βc-3538 Target: 5′—GGATCTATTTCATGTTTTTGATCAAAA—3′(SEQ ID NO: 2640)

(SEQ ID NO: 5968)

(SEQ ID NO: 1532) βc-3583 Target: 5′—GGGTAGGGTAAATCAGTAAGAGGTGTT—3′(SEQ ID NO: 2641)

(SEQ ID NO: 5969)

(SEQ ID NO: 1533) βc-3585 Target: 5′—GTAGGGTAAATCAGTAAGAGGTGTTAT—3′(SEQ ID NO: 2642)

(SEQ ID NO: 5970)

(SEQ ID NO: 1534) βc-3587 Target: 5′—AGGGTAAATCAGTAAGAGGTGTTATTT—3′(SEQ ID NO: 2643)

(SEQ ID NO: 5971)

(SEQ ID NO: 1535) βc-3589 Target: 5′—GGTAAATCAGTAAGAGGTGTTATTTGG—3′(SEQ ID NO: 2644)

(SEQ ID NO: 5972)

(SEQ ID NO: 1536) βc-3591 Target: 5′—TAAATCAGTAAGAGGTGTTATTTGGAA—3′(SEQ ID NO: 2645)

(SEQ ID NO: 5973)

(SEQ ID NO: 1537) βc-3593 Target: 5′—AATCAGTAAGAGGTGTTATTTGGAACC—3′(SEQ ID NO: 2646)

(SEQ ID NO: 5974)

(SEQ ID NO: 1538) βc-3633 Target: 5′—TTTACCAGTTGCCTTTTATCCCAAAGT—3′(SEQ ID NO: 2647)

(SEQ ID NO: 5975)

(SEQ ID NO: 1539) βc-3635 Target: 5′—TACCAGTTGCCTTTTATCCCAAAGTTG—3′(SEQ ID NO: 2648)

(SEQ ID NO: 5976)

(SEQ ID NO: 1540) βc-3637 Target: 5′—CCAGTTGCCTTTTATCCCAAAGTTGTT—3′(SEQ ID NO: 2649)

(SEQ ID NO: 5977)

(SEQ ID NO: 1541) βc-3639 Target: 5′—AGTTGCCTTTTATCCCAAAGTTGTTGT—3′(SEQ ID NO: 2650)

(SEQ ID NO: 5978)

(SEQ ID NO: 1542) βc-3641 Target: 5′—TTGCCTTTTATCCCAAAGTTGTTGTAA—3′(SEQ ID NO: 2651)

(SEQ ID NO: 5979)

(SEQ ID NO: 1543) βc-3643 Target: 5′—GCCTTTTATCCCAAAGTTGTTGTAACC—3′(SEQ ID NO: 2652)

(SEQ ID NO: 5980)

(SEQ ID NO: 1544) βc-3645 Target: 5′—CTTTTATCCCAAAGTTGTTGTAACCTG—3′(SEQ ID NO: 2653)

(SEQ ID NO: 5981)

(SEQ ID NO: 1545) βc-3647 Target: 5′—TTTATCCCAAAGTTGTTGTAACCTGCT—3′(SEQ ID NO: 2654)

(SEQ ID NO: 5982)

(SEQ ID NO: 1546) βc-3649 Target: 5′—TATCCCAAAGTTGTTGTAACCTGCTGT—3′(SEQ ID NO: 2655)

(SEQ ID NO: 5983)

(SEQ ID NO: 1547) βc-3651 Target: 5′—TCCCAAAGTTGTTGTAACCTGCTGTGA—3′(SEQ ID NO: 2656)

(SEQ ID NO: 5984)

(SEQ ID NO: 1548) βc-3653 Target: 5′—CCAAAGTTGTTGTAACCTGCTGTGATA—3′(SEQ ID NO: 2657)

(SEQ ID NO: 5985)

(SEQ ID NO: 1549) βc-3655 Target: 5′—AAAGTTGTTGTAACCTGCTGTGATACG—3′(SEQ ID NO: 2658)

(SEQ ID NO: 5986)

(SEQ ID NO: 1550) βc-3657 Target: 5′—AGTTGTTGTAACCTGCTGTGATACGAT—3′(SEQ ID NO: 2659)

(SEQ ID NO: 5987)

(SEQ ID NO: 1551) βc-3659 Target: 5′—TTGTTGTAACCTGCTGTGATACGATGC—3′(SEQ ID NO: 2660)

(SEQ ID NO: 5988)

(SEQ ID NO: 1552) βc-3708 Target: 5′—AAAAATGGTTCAGAATTAAACTTTTAA—3′(SEQ ID NO: 2661)

(SEQ ID NO: 5989)

(SEQ ID NO: 1553) βc-3710 Target: 5′—AAATGGTTCAGAATTAAACTTTTAATT—3′(SEQ ID NO: 2662)

(SEQ ID NO: 5990)

(SEQ ID NO: 1554) βc-3712 Target: 5′—ATGGTTCAGAATTAAACTTTTAATTCA—3′(SEQ ID NO: 2663)

(SEQ ID NO: 5991)

(SEQ ID NO: 1555) βc-3714 Target: 5′—GGTTCAGAATTAAACTTTTAATTCATT—3′(SEQ ID NO: 2664)

(SEQ ID NO: 5992)

(SEQ ID NO: 1556) βc-3716 Target: 5′—TTCAGAATTAAACTTTTAATTCATTCG—3′(SEQ ID NO: 2665)

(SEQ ID NO: 5993)

(SEQ ID NO: 1557) βc-m314 Target: 5′—CAGCAGCAGTCTTACTTGGATTCTGGA—3′(SEQ ID NO: 2666)

(SEQ ID NO: 5994)

(SEQ ID NO: 1558) βc-m325 Target: 5′—TTACTTGGATTCTGGAATCCATTCTGG—3′(SEQ ID NO: 2667)

(SEQ ID NO: 5995)

(SEQ ID NO: 1559) βc-m408 Target: 5′—TTGACACCTCCCAAGTCCTTTATGAAT—3′(SEQ ID NO: 2668)

(SEQ ID NO: 5996)

(SEQ ID NO: 1560) βc-m460 Target: 5′—CACGCAAGAGCAAGTAGCTGATATTGA—3′(SEQ ID NO: 2669)

(SEQ ID NO: 5997)

(SEQ ID NO: 1561) βc-m526 Target: 5′—TGCCATGTTCCCTGAGACGCTAGATGA—3′(SEQ ID NO: 2670)

(SEQ ID NO: 5998)

(SEQ ID NO: 1562) βc-m631 Target: 5′—GTTGAAACATGCAGTTGTCAATTTGAT—3′(SEQ ID NO: 2671)

(SEQ ID NO: 5999)

(SEQ ID NO: 1563) βc-m636 Target: 5′—AACATGCAGTTGTCAATTTGATTAACT—3′(SEQ ID NO: 2672)

(SEQ ID NO: 6000)

(SEQ ID NO: 1564) βc-m642 Target: 5′—CAGTTGTCAATTTGATTAACTATCAGG—3′(SEQ ID NO: 2673)

(SEQ ID NO: 6001)

(SEQ ID NO: 1565) βc-m723 Target: 5′—ATGAGGACCAGGTGGTAGTTAATAAAG—3′(SEQ ID NO: 2674)

(SEQ ID NO: 6002)

(SEQ ID NO: 1566) βc-m970 Target: 5′—TGGGTCACCAGTGGATTCTGTACTGTT—3′(SEQ ID NO: 2675)

(SEQ ID NO: 6003)

(SEQ ID NO: 1567) βc-m976 Target: 5′—ACCAGTGGATTCTGTACTGTTCTACGC—3′(SEQ ID NO: 2676)

(SEQ ID NO: 6004)

(SEQ ID NO: 1568) βc-m981 Target: 5′—TGGATTCTGTACTGTTCTACGCCATCA—3′(SEQ ID NO: 2677)

(SEQ ID NO: 6005)

(SEQ ID NO: 1569) βc-m1066 Target: 5′—TGGTGGACTGCAGAAAATGGTTGCTTT—3′(SEQ ID NO: 2678)

(SEQ ID NO: 6006)

(SEQ ID NO: 1570) βc-m1106 Target: 5′—AACGTGAAATTCTTGGCTATTACAACA—3′(SEQ ID NO: 2679)

(SEQ ID NO: 6007)

(SEQ ID NO: 1571) βc-m1354 Target: 5′—CCCAAGTCAGCGACTTGTTCAAAACTG—3′(SEQ ID NO: 2680)

(SEQ ID NO: 6008)

(SEQ ID NO: 1572) βc-m1363 Target: 5′—GCGACTTGTTCAAAACTGTCTTTGGAC—3′(SEQ ID NO: 2681)

(SEQ ID NO: 6009)

(SEQ ID NO: 1573) βc-m1373 Target: 5′—CAAAACTGTCTTTGGACTCTCAGAAAC—3′(SEQ ID NO: 2682)

(SEQ ID NO: 6010)

(SEQ ID NO: 1574) βc-m1508 Target: 5′—CTCTCTAACCTCACTTGCAATAATTAC—3′(SEQ ID NO: 2683)

(SEQ ID NO: 6011)

(SEQ ID NO: 1575) βc-m1515 Target: 5′—ACCTCACTTGCAATAATTACAAAAACA—3′(SEQ ID NO: 2684)

(SEQ ID NO: 6012)

(SEQ ID NO: 1576) βc-m1682 Target: 5′—CAGAATGCCGTTCGCCTTCATTATGGA—3′(SEQ ID NO: 2685)

(SEQ ID NO: 6013)

(SEQ ID NO: 1577) βc-m1693 Target: 5′—TCGCCTTCATTATGGACTGCCTGTTGT—3′(SEQ ID NO: 2686)

(SEQ ID NO: 6014)

(SEQ ID NO: 1578) βc-m1698 Target: 5′—TTCATTATGGACTGCCTGTTGTGGTTA—3′(SEQ ID NO: 2687)

(SEQ ID NO: 6015)

(SEQ ID NO: 1579) βc-m1705 Target: 5′—TGGACTGCCTGTTGTGGTTAAACTCCT—3′(SEQ ID NO: 2688)

(SEQ ID NO: 6016)

(SEQ ID NO: 1580) βc-m1763 Target: 5′—GCAACTGTTGGATTGATTCGAAACCTT—3′(SEQ ID NO: 2689)

(SEQ ID NO: 6017)

(SEQ ID NO: 1581) βc-m2008 Target: 5′—CCGAGGACTCAATACCATTCCATTGTT—3′(SEQ ID NO: 2690)

(SEQ ID NO: 6018)

(SEQ ID NO: 1582) βc-m2226 Target: 5′—CTGAGGACAAGCCACAGGATTACAAGA—3′(SEQ ID NO: 2691)

(SEQ ID NO: 6019)

(SEQ ID NO: 1583) βc-m2427 Target: 5′—GGATGGACCCTATGATGGAGCATGAGA—3′(SEQ ID NO: 2692)

(SEQ ID NO: 6020)

(SEQ ID NO: 1584) βc-m2568 Target: 5′—TTGATACTGACCTGTAAATCGTCCTTT—3′(SEQ ID NO: 2693)

(SEQ ID NO: 6021)

(SEQ ID NO: 1585) βc-m2614 Target: 5′—AGCCAGTGTGGGTGAATACTTTACTCT—3′(SEQ ID NO: 2694)

(SEQ ID NO: 6022)

(SEQ ID NO: 1586) βc-m2770 Target: 5′—TGCCACAGCTTTTGCAGCGTTATACTC—3′(SEQ ID NO: 2695)

(SEQ ID NO: 6023)

(SEQ ID NO: 1587) βc-m2777 Target: 5′—GCTTTTGCAGCGTTATACTCAGATGAG—3′(SEQ ID NO: 2696)

(SEQ ID NO: 6024)

(SEQ ID NO: 1588) βc-m2784 Target: 5′—CAGCGTTATACTCAGATGAGTAACATT—3′(SEQ ID NO: 2697)

(SEQ ID NO: 6025)

(SEQ ID NO: 1589) βc-m2806 Target: 5′—ACATTTGCTGTTTTCAACATTAATAGC—3′(SEQ ID NO: 2698)

(SEQ ID NO: 6026)

(SEQ ID NO: 1590) βc-m2850 Target: 5′—AGCTGTAGTGTCTGAACGTGCATTGTG—3′(SEQ ID NO: 2699)

(SEQ ID NO: 6027)

(SEQ ID NO: 1591) βc-m2965 Target: 5′—GGGAACAGTCGAAGTACGCTTTTTGTT—3′(SEQ ID NO: 2700)

(SEQ ID NO: 6028)

(SEQ ID NO: 1592) βc-m2970 Target: 5′—CAGTCGAAGTACGCTTTTTGTTCTGGT—3′(SEQ ID NO: 2701)

(SEQ ID NO: 6029)

(SEQ ID NO: 1593) βc-m2976 Target: 5′—AAGTACGCTTTTTGTTCTGGTCCTTTT—3′(SEQ ID NO: 2702)

(SEQ ID NO: 6030)

(SEQ ID NO: 1594) βc-m3092 Target: 5′—ACCCTAGCCTTGCTTGTTCTTTGTTTT—3′(SEQ ID NO: 2703)

(SEQ ID NO: 6031)

(SEQ ID NO: 1595) βc-m3097 Target: 5′—AGCCTTGCTTGTTCTTTGTTTTAATAT—3′(SEQ ID NO: 2704)

(SEQ ID NO: 6032)

(SEQ ID NO: 1596) βc-m3198 Target: 5′—TGAACCTGCTACAGCAATTTCTGATTT—3′(SEQ ID NO: 2705)

(SEQ ID NO: 6033)

(SEQ ID NO: 1597) βc-m3207 Target: 5′—TACAGCAATTTCTGATTTCTAAGAACC—3′(SEQ ID NO: 2706)

(SEQ ID NO: 6034)

(SEQ ID NO: 1598) βc-m3433 Target: 5′—CAGTAAGAGGTGTTATTTGAGCCTTGT—3′(SEQ ID NO: 2707)

(SEQ ID NO: 6035)

(SEQ ID NO: 1599) βc-m3439 Target: 5′—GAGGTGTTATTTGAGCCTTGTTTTGGA—3′(SEQ ID NO: 2708)

(SEQ ID NO: 6036)

(SEQ ID NO: 1600) βc-m3444 Target: 5′—GTTATTTGAGCCTTGTTTTGGACAGTA—3′(SEQ ID NO: 2709)

(SEQ ID NO: 6037)

(SEQ ID NO: 1601) βc-m3449 Target: 5′—TTGAGCCTTGTTTTGGACAGTATACCA—3′(SEQ ID NO: 2710)

(SEQ ID NO: 6038)

(SEQ ID NO: 1602) βc-m3522 Target: 5′—TTCAACAGATGCGGTTATAGAAATGGT—3′(SEQ ID NO: 2711)

(SEQ ID NO: 6039)

(SEQ ID NO: 1603) βc-m3533 Target: 5′—CGGTTATAGAAATGGTTCAGAATTAAA—3′(SEQ ID NO: 2712)

(SEQ ID NO: 6040)

(SEQ ID NO: 1604) βc-m3538 Target: 5′—ATAGAAATGGTTCAGAATTAAACTTTT—3′(SEQ ID NO: 2713)

TABLE 8 Selected Anti-β-catenin DsiRNA Agents, Blunt Duplexes5′-CCCUGAGGGUAUUUGAAGUAUACCAUA-3′ (SEQ ID NO: 6662)3′-GGGACUCCCAUAAACUUCAUAUGGUAU-5′ (SEQ ID NO: 1117) βc-240 Target:5′-CCCTGAGGGTATTTGAAGTATACCATA-3′ (SEQ ID NO: 2226)5′-GAGGGUAUUUGAAGUAUACCAUACAAC-3′ (SEQ ID NO: 6663)3′-CUCCCAUAAACUUCAUAUGGUAUGUUG-5′ (SEQ ID NO: 1118) βc-244 Target:5′-GAGGGTATTTGAAGTATACCATACAAC-3′ (SEQ ID NO: 2227)5′-UGAAGUAUACCAUACAACUGUUUUGAA-3′ (SEQ ID NO: 6664)3′-ACUUCAUAUGGUAUGUUGACAAAACUU-5′ (SEQ ID NO: 1119) βc-253 Target:5′-TGAAGTATACCATACAACTGTTTTGAA-3′ (SEQ ID NO: 2228)5′-AUACCAUACAACUGUUUUGAAAAUCCA-3′ (SEQ ID NO: 6665)3′-UAUGGUAUGUUGACAAAACUUUUAGGU-5′ (SEQ ID NO: 1120) βc-259 Target:5′-ATACCATACAACTGTTTTGAAAATCCA-3′ (SEQ ID NO: 2229)5′-AUACAACUGUUUUGAAAAUCCAGCGUG-3′ (SEQ ID NO: 6666)3′-UAUGUUGACAAAACUUUUAGGUCGCAC-5′ (SEQ ID NO: 1121) βc-264 Target:5′-ATACAACTGTTTTGAAAATCCAGCGTG-3′ (SEQ ID NO: 2230)5′-CAGGGAUUUUCUCAGUCCUUCACUCAA-3′ (SEQ ID NO: 6667)3′-GUCCCUAAAAGAGUCAGGAAGUGAGUU-5′ (SEQ ID NO: 1122) βc-496 Target:5′-CAGGGATTTTCTCAGTCCTTCACTCAA-3′ (SEQ ID NO: 2231)5′-CACUCAAGAACAAGUAGCUGAUAUUGA-3′ (SEQ ID NO: 6668)3′-GUGAGUUCUUGUUCAUCGACUAUAACU-5′ (SEQ ID NO: 1123) βc-516 Target:5′-CACTCAAGAACAAGTAGCTGATATTGA-3′ (SEQ ID NO: 2232)5′-AGAACAAGUAGCUGAUAUUGAUGGACA-3′ (SEQ ID NO: 6669)3′-UCUUGUUCAUCGACUAUAACUACCUGU-5′ (SEQ ID NO: 1124) βc-522 Target:5′-AGAACAAGTAGCTGATATTGATGGACA-3′ (SEQ ID NO: 2233)5′-AACAAGUAGCUGAUAUUGAUGGACAGU-3′ (SEQ ID NO: 6670)3′-UUGUUCAUCGACUAUAACUACCUGUCA-5′ (SEQ ID NO: 1125) βc-524 Target:5′-AACAAGTAGCTGATATTGATGGACAGT-3′ (SEQ ID NO: 2234)5′-UGAUGGACAGUAUGCAAUGACUCGAGC-3′ (SEQ ID NO: 6671)3′-ACUACCUGUCAUACGUUACUGAGCUCG-5′ (SEQ ID NO: 1126) βc-540 Target:5′-TGATGGACAGTATGCAATGACTCGAGC-3′ (SEQ ID NO: 2235)5′-UGCUAUGUUCCCUGAGACAUUAGAUGA-3′ (SEQ ID NO: 6672)3′-ACGAUACAAGGGACUCUGUAAUCUACU-5′ (SEQ ID NO: 1127) βc-582 Target:5′-TGCTATGTTCCCTGAGACATTAGATGA-3′ (SEQ ID NO: 2236)5′-UGCUGAAACAUGCAGUUGUAAACUUGA-3′ (SEQ ID NO: 6673)3′-ACGACUUUGUACGUCAACAUUUGAACU-5′ (SEQ ID NO: 1128) βc-686 Target:5′-TGCTGAAACATGCAGTTGTAAACTTGA-3′ (SEQ ID NO: 2237)5′-AACAUGCAGUUGUAAACUUGAUUAACU-3′ (SEQ ID NO: 6674)3′-UUGUACGUCAACAUUUGAACUAAUUGA-5′ (SEQ ID NO: 1129) βc-692 Target:5′-AACATGCAGTTGTAAACTTGATTAACT-3′ (SEQ ID NO: 2238)5′-GCAGUUGUAAACUUGAUUAACUAUCAA-3′ (SEQ ID NO: 6675)3′-CGUCAACAUUUGAACUAAUUGAUAGUU-5′ (SEQ ID NO: 1130) βc-697 Target:5′-GCAGTTGTAAACTTGATTAACTATCAA-3′ (SEQ ID NO: 2239)5′-ACUUGAUUAACUAUCAAGAUGAUGCAG-3′ (SEQ ID NO: 6676)3′-UGAACUAAUUGAUAGUUCUACUACGUC-5′ (SEQ ID NO: 1131) βc-707 Target:5′-ACTTGATTAACTATCAAGATGATGCAG-3′ (SEQ ID NO: 2240)5′-CCCUGAACUGACAAAACUGCUAAAUGA-3′ (SEQ ID NO: 6677)3′-GGGACUUGACUGUUUUGACGAUUUACU-5′ (SEQ ID NO: 1132) βc-753 Target:5′-CCCTGAACTGACAAAACTGCTAAATGA-3′ (SEQ ID NO: 2241)5′-UCAGAUGGUGUCUGCUAUUGUACGUAC-3′ (SEQ ID NO: 6678)3′-AGUCUACCACAGACGAUAACAUGCAUG-5′ (SEQ ID NO: 1133) βc-870 Target:5′-TCAGATGGTGTCTGCTATTGTACGTAC-3′ (SEQ ID NO: 2242)5′-GUACGUACCAUGCAGAAUACAAAUGAU-3′ (SEQ ID NO: 6679)3′-CAUGCAUGGUACGUCUUAUGUUUACUA-5′ (SEQ ID NO: 1134) βc-889 Target:5′-GTACGTACCATGCAGAATACAAATGAT-3′ (SEQ ID NO: 2243)5′-AUUACAACUCUCCACAACCUUUUAUUA-3′ (SEQ ID NO: 6680)3′-UAAUGUUGAGAGGUGUUGGAAAAUAAU-5′ (SEQ ID NO: 1135) βc-1060 Target:5′-ATTACAACTCTCCACAACCTTTTATTA-3′ (SEQ ID NO: 2244)5′-AACUCUCCACAACCUUUUAUUACAUCA-3′ (SEQ ID NO: 6681)3′-UUGAGAGGUGUUGGAAAAUAAUGUAGU-5′ (SEQ ID NO: 1136) βc-1065 Target:5′-AACTCTCCACAACCTTTTATTACATCA-3′ (SEQ ID NO: 2245)5′-UCCACAACCUUUUAUUACAUCAAGAAG-3′ (SEQ ID NO: 6682)3′-AGGUGUUGGAAAAUAAUGUAGUUCUUC-5′ (SEQ ID NO: 1137) βc-1070 Target:5′-TCCACAACCTTTTATTACATCAAGAAG-3′ (SEQ ID NO: 2246)5′-ACCUUUUAUUACAUCAAGAAGGAGCUA-3′ (SEQ ID NO: 6683)3′-UGGAAAAUAAUGUAGUUCUUCCUCGAU-5′ (SEQ ID NO: 1138) βc-1076 Target:5′-ACCTTTTATTACATCAAGAAGGAGCTA-3′ (SEQ ID NO: 2247)5′-ACAAAACAAAUGUUAAAUUCUUGGCUA-3′ (SEQ ID NO: 6684)3′-UGUUUUGUUUACAAUUUAAGAACCGAU-5′ (SEQ ID NO: 1139) βc-1154 Target:5′-ACAAAACAAATGTTAAATTCTTGGCTA-3′ (SEQ ID NO: 2248)5′-AUUACGACAGACUGCCUUCAAAUUUUA-3′ (SEQ ID NO: 6685)3′-UAAUGCUGUCUGACGGAAGUUUAAAAU-5′ (SEQ ID NO: 1140) βc-1180 Target:5′-ATTACGACAGACTGCCTTCAAATTTTA-3′ (SEQ ID NO: 2249)5′-GACAGACUGCCUUCAAAUUUUAGCUUA-3′ (SEQ ID NO: 6686)3′-CUGUCUGACGGAAGUUUAAAAUCGAAU-5′ (SEQ ID NO: 1141) βc-1185 Target:5′-GACAGACTGCCTTCAAATTTTAGCTTA-3′ (SEQ ID NO: 2250)5′-AGCUUUAGUAAAUAUAAUGAGGACCUA-3′ (SEQ ID NO: 6687)3′-UCGAAAUCAUUUAUAUUACUCCUGGAU-5′ (SEQ ID NO: 1142) βc-1260 Target:5′-AGCTTTAGTAAATATAATGAGGACCTA-3′ (SEQ ID NO: 2251)5′-GAAAAACUACUGUGGACCACAAGCAGA-3′ (SEQ ID NO: 6688)3′-CUUUUUGAUGACACCUGGUGUUCGUCU-5′ (SEQ ID NO: 1143) βc-1294 Target:5′-GAAAAACTACTGTGGACCACAAGCAGA-3′ (SEQ ID NO: 2252)5′-CAAGUCAACGUCUUGUUCAGAACUGUC-3′ (SEQ ID NO: 6689)3′-GUUCAGUUGCAGAACAAGUCUUGACAG-5′ (SEQ ID NO: 1144) βc-1412 Target:5′-CAAGTCAACGTCTTGTTCAGAACTGTC-3′ (SEQ ID NO: 2253)5′-AACGUCUUGUUCAGAACUGUCUUUGGA-3′ (SEQ ID NO: 6690)3′-UUGCAGAACAAGUCUUGACAGAAACCU-5′ (SEQ ID NO: 1145) βc-1418 Target:5′-AACGTCTTGTTCAGAACTGTCTTTGGA-3′ (SEQ ID NO: 2254)5′-CUUGUUCAGAACUGUCUUUGGACUCUC-3′ (SEQ ID NO: 6691)3′-GAACAAGUCUUGACAGAAACCUGAGAG-5′ (SEQ ID NO: 1146) βc-1423 Target:5′-CTTGTTCAGAACTGTCTTTGGACTCTC-3′ (SEQ ID NO: 2255)5′-UGGGUUCAGAUGAUAUAAAUGUGGUCA-3′ (SEQ ID NO: 6692)3′-ACCCAAGUCUACUAUAUUUACACCAGU-5′ (SEQ ID NO: 1147) βc-1520 Target:5′-TGGGTTCAGATGATATAAATGTGGTCA-3′ (SEQ ID NO: 2256)5′-AUUCUUUCUAACCUCACUUGCAAUAAU-3′ (SEQ ID NO: 6693)3′-UAAGAAAGAUUGGAGUGAACGUUAUUA-5′ (SEQ ID NO: 1148) βc-1561 Target:5′-ATTCTTTCTAACCTCACTTGCAATAAT-3′ (SEQ ID NO: 2257)5′-ACCUCACUUGCAAUAAUUAUAAGAACA-3′ (SEQ ID NO: 6694)3′-UGGAGUGAACGUUAUUAAUAUUCUUGU-5′ (SEQ ID NO: 1149) βc-1571 Target:5′-ACCTCACTTGCAATAATTATAAGAACA-3′ (SEQ ID NO: 2258)5′-UGCAAUAAUUAUAAGAACAAGAUGAUG-3′ (SEQ ID NO: 6695)3′-ACGUUAUUAAUAUUCUUGUUCUACUAC-5′ (SEQ ID NO: 1150) βc-1579 Target:5′-TGCAATAATTATAAGAACAAGATGATG-3′ (SEQ ID NO: 2259)5′-UGGUAUAGAGGCUCUUGUGCGUACUGU-3′ (SEQ ID NO: 6696)3′-ACCAUAUCUCCGAGAACACGCAUGACA-5′ (SEQ ID NO: 1151) βc-1620 Target:5′-TGGTATAGAGGCTCTTGTGCGTACTGT-3′ (SEQ ID NO: 2260)5′-AAGGCUACUGUUGGAUUGAUUCGAAAU-3′ (SEQ ID NO: 6697)3′-UUCCGAUGACAACCUAACUAAGCUUUA-5′ (SEQ ID NO: 1152) βc-1816 Target:5′-AAGGCTACTGTTGGATTGATTCGAAAT-3′ (SEQ ID NO: 2261)5′-CGCAUGGAAGAAAUAGUUGAAGGUUGU-3′ (SEQ ID NO: 6698)3′-GCGUACCUUCUUUAUCAACUUCCAACA-5′ (SEQ ID NO: 1153) βc-1987 Target:5′-CGCATGGAAGAAATAGTTGAAGGTTGT-3′ (SEQ ID NO: 2262)5′-CAUGGAAGAAAUAGUUGAAGGUUGUAC-3′ (SEQ ID NO: 6699)3′-GUACCUUCUUUAUCAACUUCCAACAUG-5′ (SEQ ID NO: 1154) βc-1989 Target:5′-CATGGAAGAAATAGTTGAAGGTTGTAC-3′ (SEQ ID NO: 2263)5′-CCAUUGAAAACAUCCAAAGAGUAGCUG-3′ (SEQ ID NO: 6700)3′-GGUAACUUUUGUAGGUUUCUCAUCGAC-5′ (SEQ ID NO: 1155) βc-2111 Target:5′-CCATTGAAAACATCCAAAGAGTAGCTG-3′ (SEQ ID NO: 2264)5′-CUGAGGACAAGCCACAAGAUUACAAGA-3′ (SEQ ID NO: 6701)3′-GACUCCUGUUCGGUGUUCUAAUGUUCU-5′ (SEQ ID NO: 1156) βc-2282 Target:5′-CTGAGGACAAGCCACAAGATTACAAGA-3′ (SEQ ID NO: 2265)5′-UUGAUACUGACCUGUAAAUCAUCCUUU-3′ (SEQ ID NO: 6702)3′-AACUAUGACUGGACAUUUAGUAGGAAA-5′ (SEQ ID NO: 1157) βc-2624 Target:5′-TTGATACTGACCTGTAAATCATCCTTT-3′ (SEQ ID NO: 2266)5′-CUUUAGGUAAGAAGUUUUAAAAAGCCA-3′ (SEQ ID NO: 6703)3′-GAAAUCCAUUCUUCAAAAUUUUUCGGU-5′ (SEQ ID NO: 1158) βc-2647 Target:5′-CTTTAGGTAAGAAGTTTTAAAAAGCCA-3′ (SEQ ID NO: 2267)5′-AACAGGUAUAUACUUUGAAAGGAGAUG-3′ (SEQ ID NO: 6704)3′-UUGUCCAUAUAUGAAACUUUCCUCUAC-5′ (SEQ ID NO: 1159) βc-2770 Target:5′-AACAGGTATATACTTTGAAAGGAGATG-3′ (SEQ ID NO: 2268)5′-UGGAAGUUAUUAACUUUAAUGUUUUUU-3′ (SEQ ID NO: 6705)3′-ACCUUCAAUAAUUGAAAUUACAAAAAA-5′ (SEQ ID NO: 1160) βc-2848 Target:5′-TGGAAGTTATTAACTTTAATGTTTTTT-3′ (SEQ ID NO: 2269)5′-UGCCACAGCUUUUGCAACUUAAUACUC-3′ (SEQ ID NO: 6706)3′-ACGGUGUCGAAAACGUUGAAUUAUGAG-5′ (SEQ ID NO: 1161) βc-2874 Target:5′-TGCCACAGCTTTTGCAACTTAATACTC-3′ (SEQ ID NO: 2270)5′-AACAUUUGCUGUUUUAAACAUUAAUAG-3′ (SEQ ID NO: 6707)3′-UUGUAAACGACAAAAUUUGUAAUUAUC-5′ (SEQ ID NO: 1162) βc-2909 Target:5′-AACATTTGCTGTTTTAAACATTAATAG-3′ (SEQ ID NO: 2271)5′-AACAAUUGAAGUAAACUUUUUGUUCUG-3′ (SEQ ID NO: 6708)3′-UUGUUAACUUCAUUUGAAAAACAAGAC-5′ (SEQ ID NO: 1163) βc-3074 Target:5′-AACAATTGAAGTAAACTTTTTGTTCTG-3′ (SEQ ID NO: 2272)5′-AAACCCUAGCCUUGCUUGUUAAAUUUU-3′ (SEQ ID NO: 6709)3′-UUUGGGAUCGGAACGAACAAUUUAAAA-5′ (SEQ ID NO: 1164) βc-3197 Target:5′-AAACCCTAGCCTTGCTTGTTAAATTTT-3′ (SEQ ID NO: 2273)5′-UAGCCUUGCUUGUUAAAUUUUUUUUUU-3′ (SEQ ID NO: 6710)3′-AUCGGAACGAACAAUUUAAAAAAAAAA-5′ (SEQ ID NO: 1165) βc-3203 Target:5′-TAGCCTTGCTTGTTAAATTTTTTTTTT-3′ (SEQ ID NO: 2274)5′-UUGAAGUAGCUCUUUUUUUUUUUUUUU-3′ (SEQ ID NO: 6711)3′-AACUUCAUCGAGAAAAAAAAAAAAAAA-5′ (SEQ ID NO: 1166) βc-3273 Target:5′-TTGAAGTAGCTCTTTTTTTTTTTTTTT-3′ (SEQ ID NO: 2275)5′-UCGUAGUGUUAAGUUAUAGUGAAUACU-3′ (SEQ ID NO: 6712)3′-AGCAUCACAAUUCAAUAUCACUUAUGA-5′ (SEQ ID NO: 1167) βc-3333 Target:5′-TCGTAGTGTTAAGTTATAGTGAATACT-3′ (SEQ ID NO: 2276)5′-UAGUGAAUACUGCUACAGCAAUUUCUA-3′ (SEQ ID NO: 6713)3′-AUCACUUAUGACGAUGUCGUUAAAGAU-5′ (SEQ ID NO: 1168) βc-3349 Target:5′-TAGTGAATACTGCTACAGCAATTTCTA-3′ (SEQ ID NO: 2277)5′-AAUACUGCUACAGCAAUUUCUAAUUUU-3′ (SEQ ID NO: 6714)3′-UUAUGACGAUGUCGUUAAAGAUUAAAA-5′ (SEQ ID NO: 1169) βc-3354 Target:5′-AATACTGCTACAGCAATTTCTAATTTT-3′ (SEQ ID NO: 2278)5′-UUCUAAUUUUUAAGAAUUGAGUAAUGG-3′ (SEQ ID NO: 6715)3′-AAGAUUAAAAAUUCUUAACUCAUUACC-5′ (SEQ ID NO: 1170) βc-3371 Target:5′-TTCTAATTTTTAAGAATTGAGTAATGG-3′ (SEQ ID NO: 2279)5′-AUUUUUAAGAAUUGAGUAAUGGUGUAG-3′ (SEQ ID NO: 6716)3′-UAAAAAUUCUUAACUCAUUACCACAUC-5′ (SEQ ID NO: 1171) βc-3376 Target:5′-ATTTTTAAGAATTGAGTAATGGTGTAG-3′ (SEQ ID NO: 2280)5′-UUCAUAAUCACUCUAAUUAAUUGUAAU-3′ (SEQ ID NO: 6717)3′-AAGUAUUAGUGAGAUUAAUUAACAUUA-5′ (SEQ ID NO: 1172) βc-3411 Target:5′-TTCATAATCACTCTAATTAATTGTAAT-3′ (SEQ ID NO: 2281)5′-AUUAAUUGUAAUCUGAAUAAAGUGUAA-3′ (SEQ ID NO: 6718)3′-UAAUUAACAUUAGACUUAUUUCACAUU-5′ (SEQ ID NO: 1173) βc-3426 Target:5′-ATTAATTGTAATCTGAATAAAGTGTAA-3′ (SEQ ID NO: 2282)5′-UUGUAAUCUGAAUAAAGUGUAACAAUU-3′ (SEQ ID NO: 6719)3′-AACAUUAGACUUAUUUCACAUUGUUAA-5′ (SEQ ID NO: 1174) βc-3431 Target:5′-TTGTAATCTGAATAAAGTGTAACAATT-3′ (SEQ ID NO: 2283)5′-UCUGAAUAAAGUGUAACAAUUGUGUAG-3′ (SEQ ID NO: 6720)3′-AGACUUAUUUCACAUUGUUAACACAUC-5′ (SEQ ID NO: 1175) βc-3437 Target:5′-TCTGAATAAAGTGTAACAATTGTGTAG-3′ (SEQ ID NO: 2284)5′-GUGUAGCCUUUUUGUAUAAAAUAGACA-3′ (SEQ ID NO: 6721)3′-CACAUCGGAAAAACAUAUUUUAUCUGU-5′ (SEQ ID NO: 1176) βc-3458 Target:5′-GTGTAGCCTTTTTGTATAAAATAGACA-3′ (SEQ ID NO: 2285)5′-UUUGUAUAAAAUAGACAAAUAGAAAAU-3′ (SEQ ID NO: 6722)3′-AAACAUAUUUUAUCUGUUUAUCUUUUA-5′ (SEQ ID NO: 1177) βc-3468 Target:5′-TTTGTATAAAATAGACAAATAGAAAAT-3′ (SEQ ID NO: 2286)5′-AGAAAAUGGUCCAAUUAGUUUCCUUUU-3′ (SEQ ID NO: 6723)3′-UCUUUUACCAGGUUAAUCAAAGGAAAA-5′ (SEQ ID NO: 1178) βc-3488 Target:5′-AGAAAATGGTCCAATTAGTTTCCTTTT-3′ (SEQ ID NO: 2287)5′-GUCCAAUUAGUUUCCUUUUUAAUAUGC-3′ (SEQ ID NO: 6724)3′-CAGGUUAAUCAAAGGAAAAAUUAUACG-5′ (SEQ ID NO: 1179) βc-3496 Target:5′-GTCCAATTAGTTTCCTTTTTAATATGC-3′ (SEQ ID NO: 2288)5′-UUUUUGAUCAAAAACUAUUUGGGAUAU-3′ (SEQ ID NO: 6725)3′-AAAAACUAGUUUUUGAUAAACCCUAUA-5′ (SEQ ID NO: 1180) βc-3552 Target:5′-TTTTTGATCAAAAACTATTTGGGATAT-3′ (SEQ ID NO: 2289)5′-AAGAGGUGUUAUUUGGAACCUUGUUUU-3′ (SEQ ID NO: 6726)3′-UUCUCCACAAUAAACCUUGGAACAAAA-5′ (SEQ ID NO: 1181) βc-3600 Target:5′-AAGAGGTGTTATTTGGAACCTTGTTTT-3′ (SEQ ID NO: 2290)5′-GUGUUAUUUGGAACCUUGUUUUGGACA-3′ (SEQ ID NO: 6727)3′-CACAAUAAACCUUGGAACAAAACCUGU-5′ (SEQ ID NO: 1182) βc-3605 Target:5′-GTGTTATTTGGAACCTTGTTTTGGACA-3′ (SEQ ID NO: 2291)5′-GAACCUUGUUUUGGACAGUUUACCAGU-3′ (SEQ ID NO: 6728)3′-CUUGGAACAAAACCUGUCAAAUGGUCA-5′ (SEQ ID NO: 1183) βc-3615 Target:5′-GAACCTTGTTTTGGACAGTTTACCAGT-3′ (SEQ ID NO: 2292)5′-GUGAUACGAUGCUUCAAGAGAAAAUGC-3′ (SEQ ID NO: 6729)3′-CACUAUGCUACGAAGUUCUCUUUUACG-5′ (SEQ ID NO: 1184) βc-3674 Target:5′-GTGATACGATGCTTCAAGAGAAAATGC-3′ (SEQ ID NO: 2293)5′-UUCAAGAGAAAAUGCGGUUAUAAAAAA-3′ (SEQ ID NO: 6730)3′-AAGUUCUCUUUUACGCCAAUAUUUUUU-5′ (SEQ ID NO: 1185) βc-3686 Target:5′-TTCAAGAGAAAATGCGGTTATAAAAAA-3′ (SEQ ID NO: 2294)5′-GAGAAAAUGCGGUUAUAAAAAAUGGUU-3′ (SEQ ID NO: 6731)3′-CUCUUUUACGCCAAUAUUUUUUACCAA-5′ (SEQ ID NO: 1186) βc-3691 Target:5′-GAGAAAATGCGGTTATAAAAAATGGTT-3′ (SEQ ID NO: 2295)5′-CGGUUAUAAAAAAUGGUUCAGAAUUAA-3′ (SEQ ID NO: 6732)3′-GCCAAUAUUUUUUACCAAGUCUUAAUU-5′ (SEQ ID NO: 1187) βc-3700 Target:5′-CGGTTATAAAAAATGGTTCAGAATTAA-3′ (SEQ ID NO: 2296)5′-AAAAAAUGGUUCAGAAUUAAACUUUUA-3′ (SEQ ID NO: 6733)3′-UUUUUUACCAAGUCUUAAUUUGAAAAU-5′ (SEQ ID NO: 1188) βc-3707 Target:5′-AAAAAATGGTTCAGAATTAAACTTTTA-3′ (SEQ ID NO: 2297)5′-CAGCGUGGACAAUGGCUACUCAAGCUG-3′ (SEQ ID NO: 6734)3′-GUCGCACCUGUUACCGAUGAGUUCGAC-5′ (SEQ ID NO: 1189) βc-284 Target:5′-CAGCGTGGACAATGGCTACTCAAGCTG-3′ (SEQ ID NO: 2298)5′-AGCGUGGACAAUGGCUACUCAAGCUGA-3′ (SEQ ID NO: 6735)3′-UCGCACCUGUUACCGAUGAGUUCGACU-5′ (SEQ ID NO: 1190) βc-285 Target:5′-AGCGTGGACAATGGCTACTCAAGCTGA-3′ (SEQ ID NO: 2299)5′-GCGUGGACAAUGGCUACUCAAGCUGAU-3′ (SEQ ID NO: 6736)3′-CGCACCUGUUACCGAUGAGUUCGACUA-5′ (SEQ ID NO: 1191) βc-286 Target:5′-GCGTGGACAATGGCTACTCAAGCTGAT-3′ (SEQ ID NO: 2300)5′-CGUGGACAAUGGCUACUCAAGCUGAUU-3′ (SEQ ID NO: 6737)3′-GCACCUGUUACCGAUGAGUUCGACUAA-5′ (SEQ ID NO: 1192) βc-287 Target:5′-CGTGGACAATGGCTACTCAAGCTGATT-3′ (SEQ ID NO: 2301)5′-GUGGACAAUGGCUACUCAAGCUGAUUU-3′ (SEQ ID NO: 6738)3′-CACCUGUUACCGAUGAGUUCGACUAAA-5′ (SEQ ID NO: 1193) βc-288 Target:5′-GTGGACAATGGCTACTCAAGCTGATTT-3′ (SEQ ID NO: 2302)5′-UGGACAAUGGCUACUCAAGCUGAUUUG-3′ (SEQ ID NO: 6739)3′-ACCUGUUACCGAUGAGUUCGACUAAAC-5′ (SEQ ID NO: 1194) βc-289 Target:5′-TGGACAATGGCTACTCAAGCTGATTTG-3′ (SEQ ID NO: 2303)5′-GGACAAUGGCUACUCAAGCUGAUUUGA-3′ (SEQ ID NO: 6740)3′-CCUGUUACCGAUGAGUUCGACUAAACU-5′ (SEQ ID NO: 1195) βc-290 Target:5′-GGACAATGGCTACTCAAGCTGATTTGA-3′ (SEQ ID NO: 2304)5′-GACAAUGGCUACUCAAGCUGAUUUGAU-3′ (SEQ ID NO: 6741)3′-CUGUUACCGAUGAGUUCGACUAAACUA-5′ (SEQ ID NO: 1196) βc-291 Target:5′-GACAATGGCTACTCAAGCTGATTTGAT-3′ (SEQ ID NO: 2305)5′-UUUGAUGGAGUUGGACAUGGCCAUGGA-3′ (SEQ ID NO: 6742)3′-AAACUACCUCAACCUGUACCGGUACCU-5′ (SEQ ID NO: 1197) βc-312 Target:5′-TTTGATGGAGTTGGACATGGCCATGGA-3′ (SEQ ID NO: 2306)5′-UUGAUGGAGUUGGACAUGGCCAUGGAA-3′ (SEQ ID NO: 6743)3′-AACUACCUCAACCUGUACCGGUACCUU-5′ (SEQ ID NO: 1198) βc-313 Target:5′-TTGATGGAGTTGGACATGGCCATGGAA-3′ (SEQ ID NO: 2307)5′-UGAUGGAGUUGGACAUGGCCAUGGAAC-3′ (SEQ ID NO: 6744)3′-ACUACCUCAACCUGUACCGGUACCUUG-5′ (SEQ ID NO: 1199) βc-314 Target:5′-TGATGGAGTTGGACATGGCCATGGAAC-3′ (SEQ ID NO: 2308)5′-GAUGGAGUUGGACAUGGCCAUGGAACC-3′ (SEQ ID NO: 6745)3′-CUACCUCAACCUGUACCGGUACCUUGG-5′ (SEQ ID NO: 1200) βc-315 Target:5′-GATGGAGTTGGACATGGCCATGGAACC-3′ (SEQ ID NO: 2309)5′-AUGGAGUUGGACAUGGCCAUGGAACCA-3′ (SEQ ID NO: 6746)3′-UACCUCAACCUGUACCGGUACCUUGGU-5′ (SEQ ID NO: 1201) βc-316 Target:5′-ATGGAGTTGGACATGGCCATGGAACCA-3′ (SEQ ID NO: 2310)5′-UGGAGUUGGACAUGGCCAUGGAACCAG-3′ (SEQ ID NO: 6747)3′-ACCUCAACCUGUACCGGUACCUUGGUC-5′ (SEQ ID NO: 1202) βc-317 Target:5′-TGGAGTTGGACATGGCCATGGAACCAG-3′ (SEQ ID NO: 2311)5′-GGAGUUGGACAUGGCCAUGGAACCAGA-3′ (SEQ ID NO: 6748)3′-CCUCAACCUGUACCGGUACCUUGGUCU-5′ (SEQ ID NO: 1203) βc-318 Target:5′-GGAGTTGGACATGGCCATGGAACCAGA-3′ (SEQ ID NO: 2312)5′-ACUCUGGAAUCCAUUCUGGUGCCACUA-3′ (SEQ ID NO: 6749)3′-UGAGACCUUAGGUAAGACCACGGUGAU-5′ (SEQ ID NO: 1204) βc-389 Target:5′-ACTCTGGAATCCATTCTGGTGCCACTA-3′ (SEQ ID NO: 2313)5′-CUCUGGAAUCCAUUCUGGUGCCACUAC-3′ (SEQ ID NO: 6750)3′-GAGACCUUAGGUAAGACCACGGUGAUG-5′ (SEQ ID NO: 1205) βc-390 Target:5′-CTCTGGAATCCATTCTGGTGCCACTAC-3′ (SEQ ID NO: 2314)5′-UCUGGAAUCCAUUCUGGUGCCACUACC-3′ (SEQ ID NO: 6751)3′-AGACCUUAGGUAAGACCACGGUGAUGG-5′ (SEQ ID NO: 1206) βc-391 Target:5′-TCTGGAATCCATTCTGGTGCCACTACC-3′ (SEQ ID NO: 2315)5′-CUGGAAUCCAUUCUGGUGCCACUACCA-3′ (SEQ ID NO: 6752)3′-GACCUUAGGUAAGACCACGGUGAUGGU-5′ (SEQ ID NO: 1207) βc-392 Target:5′-CTGGAATCCATTCTGGTGCCACTACCA-3′ (SEQ ID NO: 2316)5′-UGGAAUCCAUUCUGGUGCCACUACCAC-3′ (SEQ ID NO: 6753)3′-ACCUUAGGUAAGACCACGGUGAUGGUG-5′ (SEQ ID NO: 1208) βc-393 Target:5′-TGGAATCCATTCTGGTGCCACTACCAC-3′ (SEQ ID NO: 2317)5′-AUUAGAUGAGGGCAUGCAGAUCCCAUC-3′ (SEQ ID NO: 6754)3′-UAAUCUACUCCCGUACGUCUAGGGUAG-5′ (SEQ ID NO: 1209) βc-600 Target:5′-ATTAGATGAGGGCATGCAGATCCCATC-3′ (SEQ ID NO: 2318)5′-UUAGAUGAGGGCAUGCAGAUCCCAUCU-3′ (SEQ ID NO: 6755)3′-AAUCUACUCCCGUACGUCUAGGGUAGA-5′ (SEQ ID NO: 1210) βc-601 Target:5′-TTAGATGAGGGCATGCAGATCCCATCT-3′ (SEQ ID NO: 2319)5′-UAGAUGAGGGCAUGCAGAUCCCAUCUA-3′ (SEQ ID NO: 6756)3′-AUCUACUCCCGUACGUCUAGGGUAGAU-5′ (SEQ ID NO: 1211) βc-602 Target:5′-TAGATGAGGGCATGCAGATCCCATCTA-3′ (SEQ ID NO: 2320)5′-AGAUGAGGGCAUGCAGAUCCCAUCUAC-3′ (SEQ ID NO: 6757)3′-UCUACUCCCGUACGUCUAGGGUAGAUG-5′ (SEQ ID NO: 1212) βc-603 Target:5′-AGATGAGGGCATGCAGATCCCATCTAC-3′ (SEQ ID NO: 2321)5′-GAUGAGGGCAUGCAGAUCCCAUCUACA-3′ (SEQ ID NO: 6758)3′-CUACUCCCGUACGUCUAGGGUAGAUGU-5′ (SEQ ID NO: 1213) βc-604 Target:5′-GATGAGGGCATGCAGATCCCATCTACA-3′ (SEQ ID NO: 2322)5′-AUGAGGGCAUGCAGAUCCCAUCUACAC-3′ (SEQ ID NO: 6759)3′-UACUCCCGUACGUCUAGGGUAGAUGUG-5′ (SEQ ID NO: 1214) βc-605 Target:5′-ATGAGGGCATGCAGATCCCATCTACAC-3′ (SEQ ID NO: 2323)5′-AUGCUGCUCAUCCCACUAAUGUCCAGC-3′ (SEQ ID NO: 6760)3′-UACGACGAGUAGGGUGAUUACAGGUCG-5′ (SEQ ID NO: 1215) βc-638 Target:5′-ATGCTGCTCATCCCACTAATGTCCAGC-3′ (SEQ ID NO: 2324)5′-UGCUGCUCAUCCCACUAAUGUCCAGCG-3′ (SEQ ID NO: 6761)3′-ACGACGAGUAGGGUGAUUACAGGUCGC-5′ (SEQ ID NO: 1216) βc-639 Target:5′-TGCTGCTCATCCCACTAATGTCCAGCG-3′ (SEQ ID NO: 2325)5′-GCUGCUCAUCCCACUAAUGUCCAGCGU-3′ (SEQ ID NO: 6762)3′-CGACGAGUAGGGUGAUUACAGGUCGCA-5′ (SEQ ID NO: 1217) βc-640 Target:5′-GCTGCTCATCCCACTAATGTCCAGCGT-3′ (SEQ ID NO: 2326)5′-CUGCUCAUCCCACUAAUGUCCAGCGUU-3′ (SEQ ID NO: 6763)3′-GACGAGUAGGGUGAUUACAGGUCGCAA-5′ (SEQ ID NO: 1218) βc-641 Target:5′-CTGCTCATCCCACTAATGTCCAGCGTT-3′ (SEQ ID NO: 2327)5′-UGCUCAUCCCACUAAUGUCCAGCGUUU-3′ (SEQ ID NO: 6764)3′-ACGAGUAGGGUGAUUACAGGUCGCAAA-5′ (SEQ ID NO: 1219) βc-642 Target:5′-TGCTCATCCCACTAATGTCCAGCGTTT-3′ (SEQ ID NO: 2328)5′-GCUCAUCCCACUAAUGUCCAGCGUUUG-3′ (SEQ ID NO: 6765)3′-CGAGUAGGGUGAUUACAGGUCGCAAAC-5′ (SEQ ID NO: 1220) βc-643 Target:5′-GCTCATCCCACTAATGTCCAGCGTTTG-3′ (SEQ ID NO: 2329)5′-CUCAUCCCACUAAUGUCCAGCGUUUGG-3′ (SEQ ID NO: 6766)3′-GAGUAGGGUGAUUACAGGUCGCAAACC-5′ (SEQ ID NO: 1221) βc-644 Target:5′-CTCATCCCACTAATGTCCAGCGTTTGG-3′ (SEQ ID NO: 2330)5′-UCAUCCCACUAAUGUCCAGCGUUUGGC-3′ (SEQ ID NO: 6767)3′-AGUAGGGUGAUUACAGGUCGCAAACCG-5′ (SEQ ID NO: 1222) βc-645 Target:5′-TCATCCCACTAATGTCCAGCGTTTGGC-3′ (SEQ ID NO: 2331)5′-GUUUGGCUGAACCAUCACAGAUGCUGA-3′ (SEQ ID NO: 6768)3′-CAAACCGACUUGGUAGUGUCUACGACU-5′ (SEQ ID NO: 1223) βc-665 Target:5′-GTTTGGCTGAACCATCACAGATGCTGA-3′ (SEQ ID NO: 2332)5′-UUUGGCUGAACCAUCACAGAUGCUGAA-3′ (SEQ ID NO: 6769)3′-AAACCGACUUGGUAGUGUCUACGACUU-5′ (SEQ ID NO: 1224) βc-666 Target:5′-TTTGGCTGAACCATCACAGATGCTGAA-3′ (SEQ ID NO: 2333)5′-UUGGCUGAACCAUCACAGAUGCUGAAA-3′ (SEQ ID NO: 6770)3′-AACCGACUUGGUAGUGUCUACGACUUU-5′ (SEQ ID NO: 1225) βc-667 Target:5′-TTGGCTGAACCATCACAGATGCTGAAA-3′ (SEQ ID NO: 2334)5′-CAGAACUUGCCACACGUGCAAUCCCUG-3′ (SEQ ID NO: 6771)3′-GUCUUGAACGGUGUGCACGUUAGGGAC-5′ (SEQ ID NO: 1226) βc-731 Target:5′-CAGAACTTGCCACACGTGCAATCCCTG-3′ (SEQ ID NO: 2335)5′-AGAACUUGCCACACGUGCAAUCCCUGA-3′ (SEQ ID NO: 6772)3′-UCUUGAACGGUGUGCACGUUAGGGACU-5′ (SEQ ID NO: 1227) βc-732 Target:5′-AGAACTTGCCACACGTGCAATCCCTGA-3′ (SEQ ID NO: 2336)5′-CAGUUAUGGUCCAUCAGCUUUCUAAAA-3′ (SEQ ID NO: 6773)3′-GUCAAUACCAGGUAGUCGAAAGAUUUU-5′ (SEQ ID NO: 1228) βc-809 Target:5′-CAGTTATGGTCCATCAGCTTTCTAAAA-3′ (SEQ ID NO: 2337)5′-AGUUAUGGUCCAUCAGCUUUCUAAAAA-3′ (SEQ ID NO: 6774)3′-UCAAUACCAGGUAGUCGAAAGAUUUUU-5′ (SEQ ID NO: 1229) βc-810 Target:5′-AGTTATGGTCCATCAGCTTTCTAAAAA-3′ (SEQ ID NO: 2338)5′-CUAAAAAGGAAGCUUCCAGACACGCUA-3′ (SEQ ID NO: 6775)3′-GAUUUUUCCUUCGAAGGUCUGUGCGAU-5′ (SEQ ID NO: 1230) βc-830 Target:5′-CTAAAAAGGAAGCTTCCAGACACGCTA-3′ (SEQ ID NO: 2339)5′-UAAAAAGGAAGCUUCCAGACACGCUAU-3′ (SEQ ID NO: 6776)3′-AUUUUUCCUUCGAAGGUCUGUGCGAUA-5′ (SEQ ID NO: 1231) βc-831 Target:5′-TAAAAAGGAAGCTTCCAGACACGCTAT-3′ (SEQ ID NO: 2340)5′-GUACCAUGCAGAAUACAAAUGAUGUAG-3′ (SEQ ID NO: 6777)3′-CAUGGUACGUCUUAUGUUUACUACAUC-5′ (SEQ ID NO: 1232) βc-893 Target:5′-GTACCATGCAGAATACAAATGATGTAG-3′ (SEQ ID NO: 2341)5′-UACCAUGCAGAAUACAAAUGAUGUAGA-3′ (SEQ ID NO: 6778)3′-AUGGUACGUCUUAUGUUUACUACAUCU-5′ (SEQ ID NO: 1233) βc-894 Target:5′-TACCATGCAGAATACAAATGATGTAGA-3′ (SEQ ID NO: 2342)5′-ACCAUGCAGAAUACAAAUGAUGUAGAA-3′ (SEQ ID NO: 6779)3′-UGGUACGUCUUAUGUUUACUACAUCUU-5′ (SEQ ID NO: 1234) βc-895 Target:5′-ACCATGCAGAATACAAATGATGTAGAA-3′ (SEQ ID NO: 2343)5′-CCAUGCAGAAUACAAAUGAUGUAGAAA-3′ (SEQ ID NO: 6780)3′-GGUACGUCUUAUGUUUACUACAUCUUU-5′ (SEQ ID NO: 1235) βc-896 Target:5′-CCATGCAGAATACAAATGATGTAGAAA-3′ (SEQ ID NO: 2344)5′-CAUGCAGAAUACAAAUGAUGUAGAAAC-3′ (SEQ ID NO: 6781)3′-GUACGUCUUAUGUUUACUACAUCUUUG-5′ (SEQ ID NO: 1236) βc-897 Target:5′-CATGCAGAATACAAATGATGTAGAAAC-3′ (SEQ ID NO: 2345)5′-AUGCAGAAUACAAAUGAUGUAGAAACA-3′ (SEQ ID NO: 6782)3′-UACGUCUUAUGUUUACUACAUCUUUGU-5′ (SEQ ID NO: 1237) βc-898 Target:5′-ATGCAGAATACAAATGATGTAGAAACA-3′ (SEQ ID NO: 2346)5′-UGCAGAAUACAAAUGAUGUAGAAACAG-3′ (SEQ ID NO: 6783)3′-ACGUCUUAUGUUUACUACAUCUUUGUC-5′ (SEQ ID NO: 1238) βc-899 Target:5′-TGCAGAATACAAATGATGTAGAAACAG-3′ (SEQ ID NO: 2347)5′-GCAGAAUACAAAUGAUGUAGAAACAGC-3′ (SEQ ID NO: 6784)3′-CGUCUUAUGUUUACUACAUCUUUGUCG-5′ (SEQ ID NO: 1239) βc-900 Target:5′-GCAGAATACAAATGATGTAGAAACAGC-3′ (SEQ ID NO: 2348)5′-UACUGGCCAUCUUUAAGUCUGGAGGCA-3′ (SEQ ID NO: 6785)3′-AUGACCGGUAGAAAUUCAGACCUCCGU-5′ (SEQ ID NO: 1240) βc-977 Target:5′-TACTGGCCATCTTTAAGTCTGGAGGCA-3′ (SEQ ID NO: 2349)5′-ACUGGCCAUCUUUAAGUCUGGAGGCAU-3′ (SEQ ID NO: 6786)3′-UGACCGGUAGAAAUUCAGACCUCCGUA-5′ (SEQ ID NO: 1241) βc-978 Target:5′-ACTGGCCATCTTTAAGTCTGGAGGC-3′ (SEQ ID NO: 2350)5′-AAGAAGGAGCUAAAAUGGCAGUGCGUU-3′ (SEQ ID NO: 6787)3′-UUCUUCCUCGAUUUUACCGUCACGCAA-5′ (SEQ ID NO: 1242) βc-1091 Target:5′-AAGAAGGAGCTAAAATGGCAGTGCGTT-3′ (SEQ ID NO: 2351)5′-AGAAGGAGCUAAAAUGGCAGUGCGUUU-3′ (SEQ ID NO: 6788)3′-UCUUCCUCGAUUUUACCGUCACGCAAA-5′ (SEQ ID NO: 1243) βc-1092 Target:5′-AGAAGGAGCTAAAATGGCAGTGCGTTT-3′ (SEQ ID NO: 2352)5′-GAAGGAGCUAAAAUGGCAGUGCGUUUA-3′ (SEQ ID NO: 6789)3′-CUUCCUCGAUUUUACCGUCACGCAAAU-5′ (SEQ ID NO: 1244) βc-1093 Target:5′-GAAGGAGCTAAAATGGCAGTGCGTTTA-3′ (SEQ ID NO: 2353)5′-AAGGAGCUAAAAUGGCAGUGCGUUUAG-3′ (SEQ ID NO: 6790)3′-UUCCUCGAUUUUACCGUCACGCAAAUC-5′ (SEQ ID NO: 1245) βc-1094 Target:5′-AAGGAGCTAAAATGGCAGTGCGTTTAG-3′ (SEQ ID NO: 2354)5′-AGGAGCUAAAAUGGCAGUGCGUUUAGC-3′ (SEQ ID NO: 6791)3′-UCCUCGAUUUUACCGUCACGCAAAUCG-5′ (SEQ ID NO: 1246) βc-1095 Target:5′-AGGAGCTAAAATGGCAGTGCGTTTAGC-3′ (SEQ ID NO: 2355)5′-UACUGUGGACCACAAGCAGAGUGCUGA-3′ (SEQ ID NO: 6792)3′-AUGACACCUGGUGUUCGUCUCACGACU-5′ (SEQ ID NO: 1247) βc-1301 Target:5′-TACTGTGGACCACAAGCAGAGTGCTGA-3′ (SEQ ID NO: 2356)5′-ACUGUGGACCACAAGCAGAGUGCUGAA-3′ (SEQ ID NO: 6793)3′-UGACACCUGGUGUUCGUCUCACGACUU-5′ (SEQ ID NO: 1248) βc-1302 Target:5′-ACTGTGGACCACAAGCAGAGTGCTGAA-3′ (SEQ ID NO: 2357)5′-CUGUGGACCACAAGCAGAGUGCUGAAG-3′ (SEQ ID NO: 6794)3′-GACACCUGGUGUUCGUCUCACGACUUC-5′ (SEQ ID NO: 1249) βc-1303 Target:5′-CTGTGGACCACAAGCAGAGTGCTGAAG-3′ (SEQ ID NO: 2358)5′-UGUGGACCACAAGCAGAGUGCUGAAGG-3′ (SEQ ID NO: 6795)3′-ACACCUGGUGUUCGUCUCACGACUUCC-5′ (SEQ ID NO: 1250) βc-1304 Target:5′-TGTGGACCACAAGCAGAGTGCTGAAGG-3′ (SEQ ID NO: 2359)5′-GUGGACCACAAGCAGAGUGCUGAAGGU-3′ (SEQ ID NO: 6796)3′-CACCUGGUGUUCGUCUCACGACUUCCA-5′ (SEQ ID NO: 1251) βc-1305 Target:5′-GTGGACCACAAGCAGAGTGCTGAAGGT-3′ (SEQ ID NO: 2360)5′-UGGACCACAAGCAGAGUGCUGAAGGUG-3′ (SEQ ID NO: 6797)3′-ACCUGGUGUUCGUCUCACGACUUCCAC-5′ (SEQ ID NO: 1252) βc-1306 Target:5′-TGGACCACAAGCAGAGTGCTGAAGGTG-3′ (SEQ ID NO: 2361)5′-GGACCACAAGCAGAGUGCUGAAGGUGC-3′ (SEQ ID NO: 6798)3′-CCUGGUGUUCGUCUCACGACUUCCACG-5′ (SEQ ID NO: 1253) βc-1307 Target:5′-GGACCACAAGCAGAGTGCTGAAGGTGC-3′ (SEQ ID NO: 2362)5′-GACCACAAGCAGAGUGCUGAAGGUGCU-3′ (SEQ ID NO: 6799)3′-CUGGUGUUCGUCUCACGACUUCCACGA-5′ (SEQ ID NO: 1254) βc-1308 Target:5′-GACCACAAGCAGAGTGCTGAAGGTGCT-3′ (SEQ ID NO: 2363)5′-ACCACAAGCAGAGUGCUGAAGGUGCUA-3′ (SEQ ID NO: 6800)3′-UGGUGUUCGUCUCACGACUUCCACGAU-5′ (SEQ ID NO: 1255) βc-1309 Target:5′-ACCACAAGCAGAGTGCTGAAGGTGCTA-3′ (SEQ ID NO: 2364)5′-CCACAAGCAGAGUGCUGAAGGUGCUAU-3′ (SEQ ID NO: 6801)3′-GGUGUUCGUCUCACGACUUCCACGAUA-5′ (SEQ ID NO: 1256) βc-1310 Target:5′-CCACAAGCAGAGTGCTGAAGGTGCTAT-3′ (SEQ ID NO: 2365)5′-CACAAGCAGAGUGCUGAAGGUGCUAUC-3′ (SEQ ID NO: 6802)3′-GUGUUCGUCUCACGACUUCCACGAUAG-5′ (SEQ ID NO: 1257) βc-1311 Target:5′-CACAAGCAGAGTGCTGAAGGTGCTATC-3′ (SEQ ID NO: 2366)5′-ACAAGCAGAGUGCUGAAGGUGCUAUCU-3′ (SEQ ID NO: 6803)3′-UGUUCGUCUCACGACUUCCACGAUAGA-5′ (SEQ ID NO: 1258) βc-1312 Target:5′-ACAAGCAGAGTGCTGAAGGTGCTATCT-3′ (SEQ ID NO: 2367)5′-CAAGCAGAGUGCUGAAGGUGCUAUCUG-3′ (SEQ ID NO: 6804)3′-GUUCGUCUCACGACUUCCACGAUAGAC-5′ (SEQ ID NO: 1259) βc-1313 Target:5′-CAAGCAGAGTGCTGAAGGTGCTATCTG-3′ (SEQ ID NO: 2368)5′-AAGCAGAGUGCUGAAGGUGCUAUCUGU-3′ (SEQ ID NO: 6805)3′-UUCGUCUCACGACUUCCACGAUAGACA-5′ (SEQ ID NO: 1260) βc-1314 Target:5′-AAGCAGAGTGCTGAAGGTGCTATCTGT-3′ (SEQ ID NO: 2369)5′-AGAACUGUCUUUGGACUCUCAGGAAUC-3′ (SEQ ID NO: 6806)3′-UCUUGACAGAAACCUGAGAGUCCUUAG-5′ (SEQ ID NO: 1261) βc-1430 Target:5′-AGAACTGTCTTTGGACTCTCAGGAATC-3′ (SEQ ID NO: 2370)5′-GAACUGUCUUUGGACUCUCAGGAAUCU-3′ (SEQ ID NO: 6807)3′-CUUGACAGAAACCUGAGAGUCCUUAGA-5′ (SEQ ID NO: 1262) βc-1431 Target:5′-GAACTGTCTTTGGACTCTCAGGAATCT-3′ (SEQ ID NO: 2371)5′-CAGAUGAUAUAAAUGUGGUCACCUGUG-3′ (SEQ ID NO: 6808)3′-GUCUACUAUAUUUACACCAGUGGACAC-5′ (SEQ ID NO: 1263) βc-1526 Target:5′-CAGATGATATAAATGTGGTCACCTGTG-3′ (SEQ ID NO: 2372)5′-AGAUGAUAUAAAUGUGGUCACCUGUGC-3′ (SEQ ID NO: 6809)3′-UCUACUAUAUUUACACCAGUGGACACG-5′ (SEQ ID NO: 1264) βc-1527 Target:5′-AGATGATATAAATGTGGTCACCTGTGC-3′ (SEQ ID NO: 2373)5′-GAUGAUAUAAAUGUGGUCACCUGUGCA-3′ (SEQ ID NO: 6810)3′-CUACUAUAUUUACACCAGUGGACACGU-5′ (SEQ ID NO: 1265) βc-1528 Target:5′-GATGATATAAATGTGGTCACCTGTGCA-3′ (SEQ ID NO: 2374)5′-AUGAUAUAAAUGUGGUCACCUGUGCAG-3′ (SEQ ID NO: 6811)3′-UACUAUAUUUACACCAGUGGACACGUC-5′ (SEQ ID NO: 1266) βc-1529 Target:5′-ATGATATAAATGTGGTCACCTGTGCAG-3′ (SEQ ID NO: 2375)5′-UGAUAUAAAUGUGGUCACCUGUGCAGC-3′ (SEQ ID NO: 6812)3′-ACUAUAUUUACACCAGUGGACACGUCG-5′ (SEQ ID NO: 1267) βc-1530 Target:5′-TGATATAAATGTGGTCACCTGTGCAGC-3′ (SEQ ID NO: 2376)5′-GAUAUAAAUGUGGUCACCUGUGCAGCU-3′ (SEQ ID NO: 6813)3′-CUAUAUUUACACCAGUGGACACGUCGA-5′ (SEQ ID NO: 1268) βc-1531 Target:5′-GATATAAATGTGGTCACCTGTGCAGCT-3′ (SEQ ID NO: 2377)5′-AUAUAAAUGUGGUCACCUGUGCAGCUG-3′ (SEQ ID NO: 6814)3′-UAUAUUUACACCAGUGGACACGUCGAC-5′ (SEQ ID NO: 1269) βc-1532 Target:5′-ATATAAATGTGGTCACCTGTGCAGCTG-3′ (SEQ ID NO: 2378)5′-UAUAAAUGUGGUCACCUGUGCAGCUGG-3′ (SEQ ID NO: 6815)3′-AUAUUUACACCAGUGGACACGUCGACC-5′ (SEQ ID NO: 1270) βc-1533 Target:5′-TATAAATGTGGTCACCTGTGCAGCTGG-3′ (SEQ ID NO: 2379)5′-AUAAAUGUGGUCACCUGUGCAGCUGGA-3′ (SEQ ID NO: 6816)3′-UAUUUACACCAGUGGACACGUCGACCU-5′ (SEQ ID NO: 1271) βc-1534 Target:5′-ATAAATGTGGTCACCTGTGCAGCTGGA-3′ (SEQ ID NO: 2380)5′-UAAAUGUGGUCACCUGUGCAGCUGGAA-3′ (SEQ ID NO: 6817)3′-AUUUACACCAGUGGACACGUCGACCUU-5′ (SEQ ID NO: 1272) βc-1535 Target:5′-TAAATGTGGTCACCTGTGCAGCTGGAA-3′ (SEQ ID NO: 2381)5′-AAAUGUGGUCACCUGUGCAGCUGGAAU-3′ (SEQ ID NO: 6818)3′-UUUACACCAGUGGACACGUCGACCUUA-5′ (SEQ ID NO: 1273) βc-1536 Target:5′-AAATGTGGTCACCTGTGCAGCTGGAAT-3′ (SEQ ID NO: 2382)5′-AAUGUGGUCACCUGUGCAGCUGGAAUU-3′ (SEQ ID NO: 6819)3′-UUACACCAGUGGACACGUCGACCUUAA-5′ (SEQ ID NO: 1274) βc-1537 Target:5′-AATGTGGTCACCTGTGCAGCTGGAATT-3′ (SEQ ID NO: 2383)5′-AUGUGGUCACCUGUGCAGCUGGAAUUC-3′ (SEQ ID NO: 6820)3′-UACACCAGUGGACACGUCGACCUUAAG-5′ (SEQ ID NO: 1275) βc-1538 Target:5′-ATGTGGTCACCTGTGCAGCTGGAATTC-3′ (SEQ ID NO: 2384)5′-UGUGGUCACCUGUGCAGCUGGAAUUCU-3′ (SEQ ID NO: 6821)3′-ACACCAGUGGACACGUCGACCUUAAGA-5′ (SEQ ID NO: 1276) βc-1539 Target:5′-TGTGGTCACCTGTGCAGCTGGAATTCT-3′ (SEQ ID NO: 2385)5′-GUGGUCACCUGUGCAGCUGGAAUUCUU-3′ (SEQ ID NO: 6822)3′-CACCAGUGGACACGUCGACCUUAAGAA-5′ (SEQ ID NO: 1277) βc-1540 Target:5′-GTGGTCACCTGTGCAGCTGGAATTCTT-3′ (SEQ ID NO: 2386)5′-UGGUCACCUGUGCAGCUGGAAUUCUUU-3′ (SEQ ID NO: 6823)3′-ACCAGUGGACACGUCGACCUUAAGAAA-5′ (SEQ ID NO: 1278) βc-1541 Target:5′-TGGTCACCTGTGCAGCTGGAATTCTTT-3′ (SEQ ID NO: 2387)5′-GGUCACCUGUGCAGCUGGAAUUCUUUC-3′ (SEQ ID NO: 6824)3′-CCAGUGGACACGUCGACCUUAAGAAAG-5′ (SEQ ID NO: 1279) βc-1542 Target:5′-GGTCACCTGTGCAGCTGGAATTCTTTC-3′ (SEQ ID NO: 2388)5′-GUCACCUGUGCAGCUGGAAUUCUUUCU-3′ (SEQ ID NO: 6825)3′-CAGUGGACACGUCGACCUUAAGAAAGA-5′ (SEQ ID NO: 1280) βc-1543 Target:5′-GTCACCTGTGCAGCTGGAATTCTTTCT-3′ (SEQ ID NO: 2389)5′-UCACCUGUGCAGCUGGAAUUCUUUCUA-3′ (SEQ ID NO: 6826)3′-AGUGGACACGUCGACCUUAAGAAAGAU-5′ (SEQ ID NO: 1281) βc-1544 Target:5′-TCACCTGTGCAGCTGGAATTCTTTCTA-3′ (SEQ ID NO: 2390)5′-CACCUGUGCAGCUGGAAUUCUUUCUAA-3′ (SEQ ID NO: 6827)3′-GUGGACACGUCGACCUUAAGAAAGAUU-5′ (SEQ ID NO: 1282) βc-1545 Target:5′-CACCTGTGCAGCTGGAATTCTTTCTAA-3′ (SEQ ID NO: 2391)5′-UUUCUAACCUCACUUGCAAUAAUUAUA-3′ (SEQ ID NO: 6828)3′-AAAGAUUGGAGUGAACGUUAUUAAUAU-5′ (SEQ ID NO: 1283) βc-1565 Target:5′-TTTCTAACCTCACTTGCAATAATTATA-3′ (SEQ ID NO: 2392)5′-UUCUAACCUCACUUGCAAUAAUUAUAA-3′ (SEQ ID NO: 6829)3′-AAGAUUGGAGUGAACGUUAUUAAUAUU-5′ (SEQ ID NO: 1284) βc-1566 Target:5′-TTCTAACCTCACTTGCAATAATTATAA-3′ (SEQ ID NO: 2393)5′-UCUAACCUCACUUGCAAUAAUUAUAAG-3′ (SEQ ID NO: 6830)3′-AGAUUGGAGUGAACGUUAUUAAUAUUC-5′ (SEQ ID NO: 1285) βc-1567 Target:5′-TCTAACCTCACTTGCAATAATTATAAG-3′ (SEQ ID NO: 2394)5′-CUAACCUCACUUGCAAUAAUUAUAAGA-3′ (SEQ ID NO: 6831)3′-GAUUGGAGUGAACGUUAUUAAUAUUCU-5′ (SEQ ID NO: 1286) βc-1568 Target:5′-CTAACCTCACTTGCAATAATTATAAGA-3′ (SEQ ID NO: 2395)5′-UAACCUCACUUGCAAUAAUUAUAAGAA-3′ (SEQ ID NO: 6832)3′-AUUGGAGUGAACGUUAUUAAUAUUCUU-5′ (SEQ ID NO: 1287) βc-1569 Target:5′-TAACCTCACTTGCAATAATTATAAGAA-3′ (SEQ ID NO: 2396)5′-GGGCUGGUGACAGGGAAGACAUCACUG-3′ (SEQ ID NO: 6833)3′-CCCGACCACUGUCCCUUCUGUAGUGAC-5′ (SEQ ID NO: 1288) βc-1652 Target:5′-GGGCTGGTGACAGGGAAGACATCACTG-3′ (SEQ ID NO: 2397)5′-GGCUGGUGACAGGGAAGACAUCACUGA-3′ (SEQ ID NO: 6834)3′-CCGACCACUGUCCCUUCUGUAGUGACU-5′ (SEQ ID NO: 1289) βc-1653 Target:5′-GGCTGGTGACAGGGAAGACATCACTGA-3′ (SEQ ID NO: 2398)5′-GCUGGUGACAGGGAAGACAUCACUGAG-3′ (SEQ ID NO: 6835)3′-CGACCACUGUCCCUUCUGUAGUGACUC-5′ (SEQ ID NO: 1290) βc-1654 Target:5′-GCTGGTGACAGGGAAGACATCACTGAG-3′ (SEQ ID NO: 2399)5′-CUGGUGACAGGGAAGACAUCACUGAGC-3′ (SEQ ID NO: 6836)3′-GACCACUGUCCCUUCUGUAGUGACUCG-5′ (SEQ ID NO: 1291) βc-1655 Target:5′-CTGGTGACAGGGAAGACATCACTGAGC-3′ (SEQ ID NO: 2400)5′-UGGUGACAGGGAAGACAUCACUGAGCC-3′ (SEQ ID NO: 6837)3′-ACCACUGUCCCUUCUGUAGUGACUCGG-5′ (SEQ ID NO: 1292) βc-1656 Target:5′-TGGTGACAGGGAAGACATCACTGAGCC-3′ (SEQ ID NO: 2401)5′-GGUGACAGGGAAGACAUCACUGAGCCU-3′ (SEQ ID NO: 6838)3′-CCACUGUCCCUUCUGUAGUGACUCGGA-5′ (SEQ ID NO: 1293) βc-1657 Target:5′-GGTGACAGGGAAGACATCACTGAGCCT-3′ (SEQ ID NO: 2402)5′-GUGACAGGGAAGACAUCACUGAGCCUG-3′ (SEQ ID NO: 6839)3′-CACUGUCCCUUCUGUAGUGACUCGGAC-5′ (SEQ ID NO: 1294) βc-1658 Target:5′-GTGACAGGGAAGACATCACTGAGCCTG-3′ (SEQ ID NO: 2403)5′-UGACAGGGAAGACAUCACUGAGCCUGC-3′ (SEQ ID NO: 6840)3′-ACUGUCCCUUCUGUAGUGACUCGGACG-5′ (SEQ ID NO: 1295) βc-1659 Target:5′-TGACAGGGAAGACATCACTGAGCCTGC-3′ (SEQ ID NO: 2404)5′-GACAGGGAAGACAUCACUGAGCCUGCC-3′ (SEQ ID NO: 6841)3′-CUGUCCCUUCUGUAGUGACUCGGACGG-5′ (SEQ ID NO: 1296) βc-1660 Target:5′-GACAGGGAAGACATCACTGAGCCTGCC-3′ (SEQ ID NO: 2405)5′-ACAGGGAAGACAUCACUGAGCCUGCCA-3′ (SEQ ID NO: 6842)3′-UGUCCCUUCUGUAGUGACUCGGACGGU-5′ (SEQ ID NO: 1297) βc-1661 Target:5′-ACAGGGAAGACATCACTGAGCCTGCCA-3′ (SEQ ID NO: 2406)5′-CAGGGAAGACAUCACUGAGCCUGCCAU-3′ (SEQ ID NO: 6843)3′-GUCCCUUCUGUAGUGACUCGGACGGUA-5′ (SEQ ID NO: 1298) βc-1662 Target:5′-CAGGGAAGACATCACTGAGCCTGCC-3′ (SEQ ID NO: 2407)5′-AGGGAAGACAUCACUGAGCCUGCCAUC-3′ (SEQ ID NO: 6844)3′-UCCCUUCUGUAGUGACUCGGACGGUAG-5′ (SEQ ID NO: 1299) βc-1663 Target:5′-AGGGAAGACATCACTGAGCCTGCCATC-3′ (SEQ ID NO: 2408)5′-GGGAAGACAUCACUGAGCCUGCCAUCU-3′ (SEQ ID NO: 6845)3′-CCCUUCUGUAGUGACUCGGACGGUAGA-5′ (SEQ ID NO: 1300) βc-1664 Target:5′-GGGAAGACATCACTGAGCCTGCCATCT-3′ (SEQ ID NO: 2409)5′-GGAAGACAUCACUGAGCCUGCCAUCUG-3′ (SEQ ID NO: 6846)3′-CCUUCUGUAGUGACUCGGACGGUAGAC-5′ (SEQ ID NO: 1301) βc-1665 Target:5′-GGAAGACATCACTGAGCCTGCCATCTG-3′ (SEQ ID NO: 2410)5′-GAAGACAUCACUGAGCCUGCCAUCUGU-3′ (SEQ ID NO: 6847)3′-CUUCUGUAGUGACUCGGACGGUAGACA-5′ (SEQ ID NO: 1302) βc-1666 Target:5′-GAAGACATCACTGAGCCTGCCATCTGT-3′ (SEQ ID NO: 2411)5′-AAGACAUCACUGAGCCUGCCAUCUGUG-3′ (SEQ ID NO: 6848)3′-UUCUGUAGUGACUCGGACGGUAGACAC-5′ (SEQ ID NO: 1303) βc-1667 Target:5′-AAGACATCACTGAGCCTGCCATCTGTG-3′ (SEQ ID NO: 2412)5′-AGACAUCACUGAGCCUGCCAUCUGUGC-3′ (SEQ ID NO: 6849)3′-UCUGUAGUGACUCGGACGGUAGACACG-5′ (SEQ ID NO: 1304) βc-1668 Target:5′-AGACATCACTGAGCCTGCCATCTGTGC-3′ (SEQ ID NO: 2413)5′-GACAUCACUGAGCCUGCCAUCUGUGCU-3′ (SEQ ID NO: 6850)3′-CUGUAGUGACUCGGACGGUAGACACGA-5′ (SEQ ID NO: 1305) βc-1669 Target:5′-GACATCACTGAGCCTGCCATCTGTGCT-3′ (SEQ ID NO: 2414)5′-ACAUCACUGAGCCUGCCAUCUGUGCUC-3′ (SEQ ID NO: 6851)3′-UGUAGUGACUCGGACGGUAGACACGAG-5′ (SEQ ID NO: 1306) βc-1670 Target:5′-ACATCACTGAGCCTGCCATCTGTGCTC-3′ (SEQ ID NO: 2415)5′-CAUCACUGAGCCUGCCAUCUGUGCUCU-3′ (SEQ ID NO: 6852)3′-GUAGUGACUCGGACGGUAGACACGAGA-5′ (SEQ ID NO: 1307) βc-1671 Target:5′-CATCACTGAGCCTGCCATCTGTGCTCT-3′ (SEQ ID NO: 2416)5′-AUCACUGAGCCUGCCAUCUGUGCUCUU-3′ (SEQ ID NO: 6853)3′-UAGUGACUCGGACGGUAGACACGAGAA-5′ (SEQ ID NO: 1308) βc-1672 Target:5′-ATCACTGAGCCTGCCATCTGTGCTCTT-3′ (SEQ ID NO: 2417)5′-UCACUGAGCCUGCCAUCUGUGCUCUUC-3′ (SEQ ID NO: 6854)3′-AGUGACUCGGACGGUAGACACGAGAAG-5′ (SEQ ID NO: 1309) βc-1673 Target:5′-TCACTGAGCCTGCCATCTGTGCTCTTC-3′ (SEQ ID NO: 2418)5′-CACUGAGCCUGCCAUCUGUGCUCUUCG-3′ (SEQ ID NO: 6855)3′-GUGACUCGGACGGUAGACACGAGAAGC-5′ (SEQ ID NO: 1310) βc-1674 Target:5′-CACTGAGCCTGCCATCTGTGCTCTTCG-3′ (SEQ ID NO: 2419)5′-ACUGAGCCUGCCAUCUGUGCUCUUCGU-3′ (SEQ ID NO: 6856)3′-UGACUCGGACGGUAGACACGAGAAGCA-5′ (SEQ ID NO: 1311) βc-1675 Target:5′-ACTGAGCCTGCCATCTGTGCTCTTCGT-3′ (SEQ ID NO: 2420)5′-CUGAGCCUGCCAUCUGUGCUCUUCGUC-3′ (SEQ ID NO: 6857)3′-GACUCGGACGGUAGACACGAGAAGCAG-5′ (SEQ ID NO: 1312) βc-1676 Target:5′-CTGAGCCTGCCATCTGTGCTCTTCGTC-3′ (SEQ ID NO: 2421)5′-UGAGCCUGCCAUCUGUGCUCUUCGUCA-3′ (SEQ ID NO: 6858)3′-ACUCGGACGGUAGACACGAGAAGCAGU-5′ (SEQ ID NO: 1313) βc-1677 Target:5′-TGAGCCTGCCATCTGTGCTCTTCGTCA-3′ (SEQ ID NO: 2422)5′-GAGCCUGCCAUCUGUGCUCUUCGUCAU-3′ (SEQ ID NO: 6859)3′-CUCGGACGGUAGACACGAGAAGCAGUA-5′ (SEQ ID NO: 1314) βc-1678 Target:5′-GAGCCTGCCATCTGTGCTCTTCGTC-3′ (SEQ ID NO: 2423)5′-AGCCUGCCAUCUGUGCUCUUCGUCAUC-3′ (SEQ ID NO: 6860)3′-UCGGACGGUAGACACGAGAAGCAGUAG-5′ (SEQ ID NO: 1315) βc-1679 Target:5′-AGCCTGCCATCTGTGCTCTTCGTCATC-3′ (SEQ ID NO: 2424)5′-GCCUGCCAUCUGUGCUCUUCGUCAUCU-3′ (SEQ ID NO: 6861)3′-CGGACGGUAGACACGAGAAGCAGUAGA-5′ (SEQ ID NO: 1316) βc-1680 Target:5′-GCCTGCCATCTGTGCTCTTCGTCATCT-3′ (SEQ ID NO: 2425)5′-CCUGCCAUCUGUGCUCUUCGUCAUCUG-3′ (SEQ ID NO: 6862)3′-GGACGGUAGACACGAGAAGCAGUAGAC-5′ (SEQ ID NO: 1317) βc-1681 Target:5′-CCTGCCATCTGTGCTCTTCGTCATCTG-3′ (SEQ ID NO: 2426)5′-CUGCCAUCUGUGCUCUUCGUCAUCUGA-3′ (SEQ ID NO: 6863)3′-GACGGUAGACACGAGAAGCAGUAGACU-5′ (SEQ ID NO: 1318) βc-1682 Target:5′-CTGCCATCTGTGCTCTTCGTCATCTGA-3′ (SEQ ID NO: 2427)5′-UGCCAUCUGUGCUCUUCGUCAUCUGAC-3′ (SEQ ID NO: 6864)3′-ACGGUAGACACGAGAAGCAGUAGACUG-5′ (SEQ ID NO: 1319) βc-1683 Target:5′-TGCCATCTGTGCTCTTCGTCATCTGAC-3′ (SEQ ID NO: 2428)5′-GCCAUCUGUGCUCUUCGUCAUCUGACC-3′ (SEQ ID NO: 6865)3′-CGGUAGACACGAGAAGCAGUAGACUGG-5′ (SEQ ID NO: 1320) βc-1684 Target:5′-GCCATCTGTGCTCTTCGTCATCTGACC-3′ (SEQ ID NO: 2429)5′-CCAUCUGUGCUCUUCGUCAUCUGACCA-3′ (SEQ ID NO: 6866)3′-GGUAGACACGAGAAGCAGUAGACUGGU-5′ (SEQ ID NO: 1321) βc-1685 Target:5′-CCATCTGTGCTCTTCGTCATCTGACCA-3′ (SEQ ID NO: 2430)5′-CAUCUGUGCUCUUCGUCAUCUGACCAG-3′ (SEQ ID NO: 6867)3′-GUAGACACGAGAAGCAGUAGACUGGUC-5′ (SEQ ID NO: 1322) βc-1686 Target:5′-CATCTGTGCTCTTCGTCATCTGACCAG-3′ (SEQ ID NO: 2431)5′-AUCUGUGCUCUUCGUCAUCUGACCAGC-3′ (SEQ ID NO: 6868)3′-UAGACACGAGAAGCAGUAGACUGGUCG-5′ (SEQ ID NO: 1323) βc-1687 Target:5′-ATCTGTGCTCTTCGTCATCTGACCAGC-3′ (SEQ ID NO: 2432)5′-UCUGUGCUCUUCGUCAUCUGACCAGCC-3′ (SEQ ID NO: 6869)3′-AGACACGAGAAGCAGUAGACUGGUCGG-5′ (SEQ ID NO: 1324) βc-1688 Target:5′-TCTGTGCTCTTCGTCATCTGACCAGCC-3′ (SEQ ID NO: 2433)5′-CUGUGCUCUUCGUCAUCUGACCAGCCG-3′ (SEQ ID NO: 6870)3′-GACACGAGAAGCAGUAGACUGGUCGGC-5′ (SEQ ID NO: 1325) βc-1689 Target:5′-CTGTGCTCTTCGTCATCTGACCAGCCG-3′ (SEQ ID NO: 2434)5′-UGUGCUCUUCGUCAUCUGACCAGCCGA-3′ (SEQ ID NO: 6871)3′-ACACGAGAAGCAGUAGACUGGUCGGCU-5′ (SEQ ID NO: 1326) βc-1690 Target:5′-TGTGCTCTTCGTCATCTGACCAGCCGA-3′ (SEQ ID NO: 2435)5′-GUGCUCUUCGUCAUCUGACCAGCCGAC-3′ (SEQ ID NO: 6872)3′-CACGAGAAGCAGUAGACUGGUCGGCUG-5′ (SEQ ID NO: 1327) βc-1691 Target:5′-GTGCTCTTCGTCATCTGACCAGCCGAC-3′ (SEQ ID NO: 2436)5′-UGCUCUUCGUCAUCUGACCAGCCGACA-3′ (SEQ ID NO: 6873)3′-ACGAGAAGCAGUAGACUGGUCGGCUGU-5′ (SEQ ID NO: 1328) βc-1692 Target:5′-TGCTCTTCGTCATCTGACCAGCCGACA-3′ (SEQ ID NO: 2437)5′-GCUCUUCGUCAUCUGACCAGCCGACAC-3′ (SEQ ID NO: 6874)3′-CGAGAAGCAGUAGACUGGUCGGCUGUG-5′ (SEQ ID NO: 1329) βc-1693 Target:5′-GCTCTTCGTCATCTGACCAGCCGACAC-3′ (SEQ ID NO: 2438)5′-CUCUUCGUCAUCUGACCAGCCGACACC-3′ (SEQ ID NO: 6875)3′-GAGAAGCAGUAGACUGGUCGGCUGUGG-5′ (SEQ ID NO: 1330) βc-1694 Target:5′-CTCTTCGTCATCTGACCAGCCGACACC-3′ (SEQ ID NO: 2439)5′-UCUUCGUCAUCUGACCAGCCGACACCA-3′ (SEQ ID NO: 6876)3′-AGAAGCAGUAGACUGGUCGGCUGUGGU-5′ (SEQ ID NO: 1331) βc-1695 Target:5′-TCTTCGTCATCTGACCAGCCGACACCA-3′ (SEQ ID NO: 2440)5′-UACACCCACCAUCCCACUGGCCUCUGA-3′ (SEQ ID NO: 6877)3′-AUGUGGGUGGUAGGGUGACCGGAGACU-5′ (SEQ ID NO: 1332) βc-1787 Target:5′-TACACCCACCATCCCACTGGCCTCTGA-3′ (SEQ ID NO: 2441)5′-ACACCCACCAUCCCACUGGCCUCUGAU-3′ (SEQ ID NO: 6878)3′-UGUGGGUGGUAGGGUGACCGGAGACUA-5′ (SEQ ID NO: 1333) βc-1788 Target:5′-ACACCCACCATCCCACTGGCCTCTGAT-3′ (SEQ ID NO: 2442)5′-CACCCACCAUCCCACUGGCCUCUGAUA-3′ (SEQ ID NO: 6879)3′-GUGGGUGGUAGGGUGACCGGAGACUAU-5′ (SEQ ID NO: 1334) βc-1789 Target:5′-CACCCACCATCCCACTGGCCTCTGATA-3′ (SEQ ID NO: 2443)5′-ACCCACCAUCCCACUGGCCUCUGAUAA-3′ (SEQ ID NO: 6880)3′-UGGGUGGUAGGGUGACCGGAGACUAUU-5′ (SEQ ID NO: 1335) βc-1790 Target:5′-ACCCACCATCCCACTGGCCTCTGATAA-3′ (SEQ ID NO: 2444)5′-CCCACCAUCCCACUGGCCUCUGAUAAA-3′ (SEQ ID NO: 6881)3′-GGGUGGUAGGGUGACCGGAGACUAUUU-5′ (SEQ ID NO: 1336) βc-1791 Target:5′-CCCACCATCCCACTGGCCTCTGATAAA-3′ (SEQ ID NO: 2445)5′-CCACCAUCCCACUGGCCUCUGAUAAAG-3′ (SEQ ID NO: 6882)3′-GGUGGUAGGGUGACCGGAGACUAUUUC-5′ (SEQ ID NO: 1337) βc-1792 Target:5′-CCACCATCCCACTGGCCTCTGATAAAG-3′ (SEQ ID NO: 2446)5′-CACCAUCCCACUGGCCUCUGAUAAAGG-3′ (SEQ ID NO: 6883)3′-GUGGUAGGGUGACCGGAGACUAUUUCC-5′ (SEQ ID NO: 1338) βc-1793 Target:5′-CACCATCCCACTGGCCTCTGATAAAGG-3′ (SEQ ID NO: 2447)5′-ACCAUCCCACUGGCCUCUGAUAAAGGC-3′ (SEQ ID NO: 6884)3′-UGGUAGGGUGACCGGAGACUAUUUCCG-5′ (SEQ ID NO: 1339) βc-1794 Target:5′-ACCATCCCACTGGCCTCTGATAAAGGC-3′ (SEQ ID NO: 2448)5′-CCAUCCCACUGGCCUCUGAUAAAGGCU-3′ (SEQ ID NO: 6885)3′-GGUAGGGUGACCGGAGACUAUUUCCGA-5′ (SEQ ID NO: 1340) βc-1795 Target:5′-CCATCCCACTGGCCTCTGATAAAGGCT-3′ (SEQ ID NO: 2449)5′-CAUCCCACUGGCCUCUGAUAAAGGCUA-3′ (SEQ ID NO: 6886)3′-GUAGGGUGACCGGAGACUAUUUCCGAU-5′ (SEQ ID NO: 1341) βc-1796 Target:5′-CATCCCACTGGCCTCTGATAAAGGCTA-3′ (SEQ ID NO: 2450)5′-AUCCCACUGGCCUCUGAUAAAGGCUAC-3′ (SEQ ID NO: 6887)3′-UAGGGUGACCGGAGACUAUUUCCGAUG-5′ (SEQ ID NO: 1342) βc-1797 Target:5′-ATCCCACTGGCCTCTGATAAAGGCTAC-3′ (SEQ ID NO: 2451)5′-UCCCACUGGCCUCUGAUAAAGGCUACU-3′ (SEQ ID NO: 6888)3′-AGGGUGACCGGAGACUAUUUCCGAUGA-5′ (SEQ ID NO: 1343) βc-1798 Target:5′-TCCCACTGGCCTCTGATAAAGGCTACT-3′ (SEQ ID NO: 2452)5′-CCCACUGGCCUCUGAUAAAGGCUACUG-3′ (SEQ ID NO: 6889)3′-GGGUGACCGGAGACUAUUUCCGAUGAC-5′ (SEQ ID NO: 1344) βc-1799 Target:5′-CCCACTGGCCTCTGATAAAGGCTACTG-3′ (SEQ ID NO: 2453)5′-CCACUGGCCUCUGAUAAAGGCUACUGU-3′ (SEQ ID NO: 6890)3′-GGUGACCGGAGACUAUUUCCGAUGACA-5′ (SEQ ID NO: 1345) βc-1800 Target:5′-CCACTGGCCTCTGATAAAGGCTACTGT-3′ (SEQ ID NO: 2454)5′-CUACUGUUGGAUUGAUUCGAAAUCUUG-3′ (SEQ ID NO: 6891)3′-GAUGACAACCUAACUAAGCUUUAGAAC-5′ (SEQ ID NO: 1346) βc-1820 Target:5′-CTACTGTTGGATTGATTCGAAATCTTG-3′ (SEQ ID NO: 2455)5′-UACUGUUGGAUUGAUUCGAAAUCUUGC-3′ (SEQ ID NO: 6892)3′-AUGACAACCUAACUAAGCUUUAGAACG-5′ (SEQ ID NO: 1347) βc-1821 Target:5′-TACTGTTGGATTGATTCGAAATCTTGC-3′ (SEQ ID NO: 2456)5′-UAAAUACCAUUCCAUUGUUUGUGCAGC-3′ (SEQ ID NO: 6893)3′-AUUUAUGGUAAGGUAACAAACACGUCG-5′ (SEQ ID NO: 1348) βc-2072 Target:5′-TAAATACCATTCCATTGTTTGTGCAGC-3′ (SEQ ID NO: 2457)5′-AAAUACCAUUCCAUUGUUUGUGCAGCU-3′ (SEQ ID NO: 6894)3′-UUUAUGGUAAGGUAACAAACACGUCGA-5′ (SEQ ID NO: 1349) βc-2073 Target:5′-AAATACCATTCCATTGTTTGTGCAGCT-3′ (SEQ ID NO: 2458)5′-AAUACCAUUCCAUUGUUUGUGCAGCUG-3′ (SEQ ID NO: 6895)3′-UUAUGGUAAGGUAACAAACACGUCGAC-5′ (SEQ ID NO: 1350) βc-2074 Target:5′-AATACCATTCCATTGTTTGTGCAGCTG-3′ (SEQ ID NO: 2459)5′-AUACCAUUCCAUUGUUUGUGCAGCUGC-3′ (SEQ ID NO: 6896)3′-UAUGGUAAGGUAACAAACACGUCGACG-5′ (SEQ ID NO: 1351) βc-2075 Target:5′-ATACCATTCCATTGTTTGTGCAGCTGC-3′ (SEQ ID NO: 2460)5′-UACCAUUCCAUUGUUUGUGCAGCUGCU-3′ (SEQ ID NO: 6897)3′-AUGGUAAGGUAACAAACACGUCGACGA-5′ (SEQ ID NO: 1352) βc-2076 Target:5′-TACCATTCCATTGTTTGTGCAGCTGCT-3′ (SEQ ID NO: 2461)5′-ACCAUUCCAUUGUUUGUGCAGCUGCUU-3′ (SEQ ID NO: 6898)3′-UGGUAAGGUAACAAACACGUCGACGAA-5′ (SEQ ID NO: 1353) βc-2077 Target:5′-ACCATTCCATTGTTTGTGCAGCTGCTT-3′ (SEQ ID NO: 2462)5′-GCUGCUUUAUUCUCCCAUUGAAAACAU-3′ (SEQ ID NO: 6899)3′-CGACGAAAUAAGAGGGUAACUUUUGUA-5′ (SEQ ID NO: 1354) βc-2097 Target:5′-GCTGCTTTATTCTCCCATTGAAAAC-3′ (SEQ ID NO: 2463)5′-CUGCUUUAUUCUCCCAUUGAAAACAUC-3′ (SEQ ID NO: 6900)3′-GACGAAAUAAGAGGGUAACUUUUGUAG-5′ (SEQ ID NO: 1355) βc-2098 Target:5′-CTGCTTTATTCTCCCATTGAAAACATC-3′ (SEQ ID NO: 2464)5′-UGCUUUAUUCUCCCAUUGAAAACAUCC-3′ (SEQ ID NO: 6901)3′-ACGAAAUAAGAGGGUAACUUUUGUAGG-5′ (SEQ ID NO: 1356) βc-2099 Target:5′-TGCTTTATTCTCCCATTGAAAACATCC-3′ (SEQ ID NO: 2465)5′-GCUUUAUUCUCCCAUUGAAAACAUCCA-3′ (SEQ ID NO: 6902)3′-CGAAAUAAGAGGGUAACUUUUGUAGGU-5′ (SEQ ID NO: 1357) βc-2100 Target:5′-GCTTTATTCTCCCATTGAAAACATCCA-3′ (SEQ ID NO: 2466)5′-GGGUCCUCUGUGAACUUGCUCAGGACA-3′ (SEQ ID NO: 6903)3′-CCCAGGAGACACUUGAACGAGUCCUGU-5′ (SEQ ID NO: 1358) βc-2141 Target:5′-GGGTCCTCTGTGAACTTGCTCAGGACA-3′ (SEQ ID NO: 2467)5′-GGUCCUCUGUGAACUUGCUCAGGACAA-3′ (SEQ ID NO: 6904)3′-CCAGGAGACACUUGAACGAGUCCUGUU-5′ (SEQ ID NO: 1359) βc-2142 Target:5′-GGTCCTCTGTGAACTTGCTCAGGACAA-3′ (SEQ ID NO: 2468)5′-GUCCUCUGUGAACUUGCUCAGGACAAG-3′ (SEQ ID NO: 6905)3′-CAGGAGACACUUGAACGAGUCCUGUUC-5′ (SEQ ID NO: 1360) βc-2143 Target:5′-GTCCTCTGTGAACTTGCTCAGGACAAG-3′ (SEQ ID NO: 2469)5′-UCCUCUGUGAACUUGCUCAGGACAAGG-3′ (SEQ ID NO: 6906)3′-AGGAGACACUUGAACGAGUCCUGUUCC-5′ (SEQ ID NO: 1361) βc-2144 Target:5′-TCCTCTGTGAACTTGCTCAGGACAAGG-3′ (SEQ ID NO: 2470)5′-CCUCUGUGAACUUGCUCAGGACAAGGA-3′ (SEQ ID NO: 6907)3′-GGAGACACUUGAACGAGUCCUGUUCCU-5′ (SEQ ID NO: 1362) βc-2145 Target:5′-CCTCTGTGAACTTGCTCAGGACAAGGA-3′ (SEQ ID NO: 2471)5′-CUCUGUGAACUUGCUCAGGACAAGGAA-3′ (SEQ ID NO: 6908)3′-GAGACACUUGAACGAGUCCUGUUCCUU-5′ (SEQ ID NO: 1363) βc-2146 Target:5′-CTCTGTGAACTTGCTCAGGACAAGGAA-3′ (SEQ ID NO: 2472)5′-UCUGUGAACUUGCUCAGGACAAGGAAG-3′ (SEQ ID NO: 6909)3′-AGACACUUGAACGAGUCCUGUUCCUUC-5′ (SEQ ID NO: 1364) βc-2147 Target:5′-TCTGTGAACTTGCTCAGGACAAGGAAG-3′ (SEQ ID NO: 2473)5′-CUGUGAACUUGCUCAGGACAAGGAAGC-3′ (SEQ ID NO: 6910)3′-GACACUUGAACGAGUCCUGUUCCUUCG-5′ (SEQ ID NO: 1365) βc-2148 Target:5′-CTGTGAACTTGCTCAGGACAAGGAAGC-3′ (SEQ ID NO: 2474)5′-UGUGAACUUGCUCAGGACAAGGAAGCU-3′ (SEQ ID NO: 6911)3′-ACACUUGAACGAGUCCUGUUCCUUCGA-5′ (SEQ ID NO: 1366) βc-2149 Target:5′-TGTGAACTTGCTCAGGACAAGGAAGCT-3′ (SEQ ID NO: 2475)5′-GUGAACUUGCUCAGGACAAGGAAGCUG-3′ (SEQ ID NO: 6912)3′-CACUUGAACGAGUCCUGUUCCUUCGAC-5′ (SEQ ID NO: 1367) βc-2150 Target:5′-GTGAACTTGCTCAGGACAAGGAAGCTG-3′ (SEQ ID NO: 2476)5′-UGAACUUGCUCAGGACAAGGAAGCUGC-3′ (SEQ ID NO: 6913)3′-ACUUGAACGAGUCCUGUUCCUUCGACG-5′ (SEQ ID NO: 1368) βc-2151 Target:5′-TGAACTTGCTCAGGACAAGGAAGCTGC-3′ (SEQ ID NO: 2477)5′-CUAUUGAAGCUGAGGGAGCCACAGCUC-3′ (SEQ ID NO: 6914)3′-GAUAACUUCGACUCCCUCGGUGUCGAG-5′ (SEQ ID NO: 1369) βc-2183 Target:5′-CTATTGAAGCTGAGGGAGCCACAGCTC-3′ (SEQ ID NO: 2478)5′-UAUUGAAGCUGAGGGAGCCACAGCUCC-3′ (SEQ ID NO: 6915)3′-AUAACUUCGACUCCCUCGGUGUCGAGG-5′ (SEQ ID NO: 1370) βc-2184 Target:5′-TATTGAAGCTGAGGGAGCCACAGCTCC-3′ (SEQ ID NO: 2479)5′-AUUGAAGCUGAGGGAGCCACAGCUCCU-3′ (SEQ ID NO: 6916)3′-UAACUUCGACUCCCUCGGUGUCGAGGA-5′ (SEQ ID NO: 1371) βc-2185 Target:5′-ATTGAAGCTGAGGGAGCCACAGCTCCT-3′ (SEQ ID NO: 2480)5′-UGUUCCGAAUGUCUGAGGACAAGCCAC-3′ (SEQ ID NO: 6917)3′-ACAAGGCUUACAGACUCCUGUUCGGUG-5′ (SEQ ID NO: 1372) βc-2270 Target:5′-TGTTCCGAATGTCTGAGGACAAGCCAC-3′ (SEQ ID NO: 2481)5′-GUUCCGAAUGUCUGAGGACAAGCCACA-3′ (SEQ ID NO: 6918)3′-CAAGGCUUACAGACUCCUGUUCGGUGU-5′ (SEQ ID NO: 1373) βc-2271 Target:5′-GTTCCGAATGTCTGAGGACAAGCCACA-3′ (SEQ ID NO: 2482)5′-UUCCGAAUGUCUGAGGACAAGCCACAA-3′ (SEQ ID NO: 6919)3′-AAGGCUUACAGACUCCUGUUCGGUGUU-5′ (SEQ ID NO: 1374) βc-2272 Target:5′-TTCCGAATGTCTGAGGACAAGCCACAA-3′ (SEQ ID NO: 2483)5′-UCCGAAUGUCUGAGGACAAGCCACAAG-3′ (SEQ ID NO: 6920)3′-AGGCUUACAGACUCCUGUUCGGUGUUC-5′ (SEQ ID NO: 1375) βc-2273 Target:5′-TCCGAATGTCTGAGGACAAGCCACAAG-3′ (SEQ ID NO: 2484)5′-CCGAAUGUCUGAGGACAAGCCACAAGA-3′ (SEQ ID NO: 6921)3′-GGCUUACAGACUCCUGUUCGGUGUUCU-5′ (SEQ ID NO: 1376) βc-2274 Target:5′-CCGAATGTCTGAGGACAAGCCACAAGA-3′ (SEQ ID NO: 2485)5′-CGAAUGUCUGAGGACAAGCCACAAGAU-3′ (SEQ ID NO: 6922)3′-GCUUACAGACUCCUGUUCGGUGUUCUA-5′ (SEQ ID NO: 1377) βc-2275 Target:5′-CGAATGTCTGAGGACAAGCCACAAGAT-3′ (SEQ ID NO: 2486)5′-GAAUGUCUGAGGACAAGCCACAAGAUU-3′ (SEQ ID NO: 6923)3′-CUUACAGACUCCUGUUCGGUGUUCUAA-5′ (SEQ ID NO: 1378) βc-2276 Target:5′-GAATGTCTGAGGACAAGCCACAAGATT-3′ (SEQ ID NO: 2487)5′-AAUGUCUGAGGACAAGCCACAAGAUUA-3′ (SEQ ID NO: 6924)3′-UUACAGACUCCUGUUCGGUGUUCUAAU-5′ (SEQ ID NO: 1379) βc-2277 Target:5′-AATGTCTGAGGACAAGCCACAAGATTA-3′ (SEQ ID NO: 2488)5′-GAACAGAGCCAAUGGCUUGGAAUGAGA-3′ (SEQ ID NO: 6925)3′-CUUGUCUCGGUUACCGAACCUUACUCU-5′ (SEQ ID NO: 1380) βc-2345 Target:5′-GAACAGAGCCAATGGCTTGGAATGAGA-3′ (SEQ ID NO: 2489)5′-AACAGAGCCAAUGGCUUGGAAUGAGAC-3′ (SEQ ID NO: 6926)3′-UUGUCUCGGUUACCGAACCUUACUCUG-5′ (SEQ ID NO: 1381) βc-2346 Target:5′-AACAGAGCCAATGGCTTGGAATGAGAC-3′ (SEQ ID NO: 2490)5′-ACAGAGCCAAUGGCUUGGAAUGAGACU-3′ (SEQ ID NO: 6927)3′-UGUCUCGGUUACCGAACCUUACUCUGA-5′ (SEQ ID NO: 1382) βc-2347 Target:5′-ACAGAGCCAATGGCTTGGAATGAGACT-3′ (SEQ ID NO: 2491)5′-CAGAGCCAAUGGCUUGGAAUGAGACUG-3′ (SEQ ID NO: 6928)3′-GUCUCGGUUACCGAACCUUACUCUGAC-5′ (SEQ ID NO: 1383) βc-2348 Target:5′-CAGAGCCAATGGCTTGGAATGAGACTG-3′ (SEQ ID NO: 2492)5′-AGAGCCAAUGGCUUGGAAUGAGACUGC-3′ (SEQ ID NO: 6929)3′-UCUCGGUUACCGAACCUUACUCUGACG-5′ (SEQ ID NO: 1384) βc-2349 Target:5′-AGAGCCAATGGCTTGGAATGAGACTGC-3′ (SEQ ID NO: 2493)5′-GAGCCAAUGGCUUGGAAUGAGACUGCU-3′ (SEQ ID NO: 6930)3′-CUCGGUUACCGAACCUUACUCUGACGA-5′ (SEQ ID NO: 1385) βc-2350 Target:5′-GAGCCAATGGCTTGGAATGAGACTGCT-3′ (SEQ ID NO: 2494)5′-AGCCAAUGGCUUGGAAUGAGACUGCUG-3′ (SEQ ID NO: 6931)3′-UCGGUUACCGAACCUUACUCUGACGAC-5′ (SEQ ID NO: 1386) βc-2351 Target:5′-AGCCAATGGCTTGGAATGAGACTGCTG-3′ (SEQ ID NO: 2495)5′-GCCAAUGGCUUGGAAUGAGACUGCUGA-3′ (SEQ ID NO: 6932)3′-CGGUUACCGAACCUUACUCUGACGACU-5′ (SEQ ID NO: 1387) βc-2352 Target:5′-GCCAATGGCTTGGAATGAGACTGCTGA-3′ (SEQ ID NO: 2496)5′-CCAAUGGCUUGGAAUGAGACUGCUGAU-3′ (SEQ ID NO: 6933)3′-GGUUACCGAACCUUACUCUGACGACUA-5′ (SEQ ID NO: 1388) βc-2353 Target:5′-CCAATGGCTTGGAATGAGACTGCTGAT-3′ (SEQ ID NO: 2497)5′-CAAUGGCUUGGAAUGAGACUGCUGAUC-3′ (SEQ ID NO: 6934)3′-GUUACCGAACCUUACUCUGACGACUAG-5′ (SEQ ID NO: 1389) βc-2354 Target:5′-CAATGGCTTGGAATGAGACTGCTGATC-3′ (SEQ ID NO: 2498)5′-AAUGGCUUGGAAUGAGACUGCUGAUCU-3′ (SEQ ID NO: 6935)3′-UUACCGAACCUUACUCUGACGACUAGA-5′ (SEQ ID NO: 1390) βc-2355 Target:5′-AATGGCTTGGAATGAGACTGCTGATCT-3′ (SEQ ID NO: 2499)5′-CCCUUGGAUAUCGCCAGGAUGAUCCUA-3′ (SEQ ID NO: 6936)3′-GGGAACCUAUAGCGGUCCUACUAGGAU-5′ (SEQ ID NO: 1391) βc-2411 Target:5′-CCCTTGGATATCGCCAGGATGATCCTA-3′ (SEQ ID NO: 2500)5′-CCUUGGAUAUCGCCAGGAUGAUCCUAG-3′ (SEQ ID NO: 6937)3′-GGAACCUAUAGCGGUCCUACUAGGAUC-5′ (SEQ ID NO: 1392) βc-2412 Target:5′-CCTTGGATATCGCCAGGATGATCCTAG-3′ (SEQ ID NO: 2501)5′-CUUGGAUAUCGCCAGGAUGAUCCUAGC-3′ (SEQ ID NO: 6938)3′-GAACCUAUAGCGGUCCUACUAGGAUCG-5′ (SEQ ID NO: 1393) βc-2413 Target:5′-CTTGGATATCGCCAGGATGATCCTAGC-3′ (SEQ ID NO: 2502)5′-UUGGAUAUCGCCAGGAUGAUCCUAGCU-3′ (SEQ ID NO: 6939)3′-AACCUAUAGCGGUCCUACUAGGAUCGA-5′ (SEQ ID NO: 1394) βc-2414 Target:5′-TTGGATATCGCCAGGATGATCCTAGCT-3′ (SEQ ID NO: 2503)5′-UGGAUAUCGCCAGGAUGAUCCUAGCUA-3′ (SEQ ID NO: 6940)3′-ACCUAUAGCGGUCCUACUAGGAUCGAU-5′ (SEQ ID NO: 1395) βc-2415 Target:5′-TGGATATCGCCAGGATGATCCTAGCTA-3′ (SEQ ID NO: 2504)5′-AUCGUUCUUUUCACUCUGGUGGAUAUG-3′ (SEQ ID NO: 6941)3′-UAGCAAGAAAAGUGAGACCACCUAUAC-5′ (SEQ ID NO: 1396) βc-2441 Target:5′-ATCGTTCTTTTCACTCTGGTGGATATG-3′ (SEQ ID NO: 2505)5′-UCGUUCUUUUCACUCUGGUGGAUAUGG-3′ (SEQ ID NO: 6942)3′-AGCAAGAAAAGUGAGACCACCUAUACC-5′ (SEQ ID NO: 1397) βc-2442 Target:5′-TCGTTCTTTTCACTCTGGTGGATATGG-3′ (SEQ ID NO: 2506)5′-CGUUCUUUUCACUCUGGUGGAUAUGGC-3′ (SEQ ID NO: 6943)3′-GCAAGAAAAGUGAGACCACCUAUACCG-5′ (SEQ ID NO: 1398) βc-2443 Target:5′-CGTTCTTTTCACTCTGGTGGATATGGC-3′ (SEQ ID NO: 2507)5′-GUUCUUUUCACUCUGGUGGAUAUGGCC-3′ (SEQ ID NO: 6944)3′-CAAGAAAAGUGAGACCACCUAUACCGG-5′ (SEQ ID NO: 1399) βc-2444 Target:5′-GTTCTTTTCACTCTGGTGGATATGGCC-3′ (SEQ ID NO: 2508)5′-UUCUUUUCACUCUGGUGGAUAUGGCCA-3′ (SEQ ID NO: 6945)3′-AAGAAAAGUGAGACCACCUAUACCGGU-5′ (SEQ ID NO: 1400) βc-2445 Target:5′-TTCTTTTCACTCTGGTGGATATGGCCA-3′ (SEQ ID NO: 2509)5′-AACAUGAGAUGGGUGGCCACCACCCUG-3′ (SEQ ID NO: 6946)3′-UUGUACUCUACCCACCGGUGGUGGGAC-5′ (SEQ ID NO: 1401) βc-2501 Target:5′-AACATGAGATGGGTGGCCACCACCCTG-3′ (SEQ ID NO: 2510)5′-ACAUGAGAUGGGUGGCCACCACCCUGG-3′ (SEQ ID NO: 6947)3′-UGUACUCUACCCACCGGUGGUGGGACC-5′ (SEQ ID NO: 1402) βc-2502 Target:5′-ACATGAGATGGGTGGCCACCACCCTGG-3′ (SEQ ID NO: 2511)5′-CAUGAGAUGGGUGGCCACCACCCUGGU-3′ (SEQ ID NO: 6948)3′-GUACUCUACCCACCGGUGGUGGGACCA-5′ (SEQ ID NO: 1403) βc-2503 Target:5′-CATGAGATGGGTGGCCACCACCCTGGT-3′ (SEQ ID NO: 2512)5′-AUGAGAUGGGUGGCCACCACCCUGGUG-3′ (SEQ ID NO: 6949)3′-UACUCUACCCACCGGUGGUGGGACCAC-5′ (SEQ ID NO: 1404) βc-2504 Target:5′-ATGAGATGGGTGGCCACCACCCTGGTG-3′ (SEQ ID NO: 2513)5′-UGAGAUGGGUGGCCACCACCCUGGUGC-3′ (SEQ ID NO: 6950)3′-ACUCUACCCACCGGUGGUGGGACCACG-5′ (SEQ ID NO: 1405) βc-2505 Target:5′-TGAGATGGGTGGCCACCACCCTGGTGC-3′ (SEQ ID NO: 2514)5′-GAGAUGGGUGGCCACCACCCUGGUGCU-3′ (SEQ ID NO: 6951)3′-CUCUACCCACCGGUGGUGGGACCACGA-5′ (SEQ ID NO: 1406) βc-2506 Target:5′-GAGATGGGTGGCCACCACCCTGGTGCT-3′ (SEQ ID NO: 2515)5′-AGAUGGGUGGCCACCACCCUGGUGCUG-3′ (SEQ ID NO: 6952)3′-UCUACCCACCGGUGGUGGGACCACGAC-5′ (SEQ ID NO: 1407) βc-2507 Target:5′-AGATGGGTGGCCACCACCCTGGTGCTG-3′ (SEQ ID NO: 2516)5′-GAUGGGUGGCCACCACCCUGGUGCUGA-3′ (SEQ ID NO: 6953)3′-CUACCCACCGGUGGUGGGACCACGACU-5′ (SEQ ID NO: 1408) βc-2508 Target:5′-GATGGGTGGCCACCACCCTGGTGCTGA-3′ (SEQ ID NO: 2517)5′-AUGGGUGGCCACCACCCUGGUGCUGAC-3′ (SEQ ID NO: 6954)3′-UACCCACCGGUGGUGGGACCACGACUG-5′ (SEQ ID NO: 1409) βc-2509 Target:5′-ATGGGTGGCCACCACCCTGGTGCTGAC-3′ (SEQ ID NO: 2518)5′-UGGGUGGCCACCACCCUGGUGCUGACU-3′ (SEQ ID NO: 6955)3′-ACCCACCGGUGGUGGGACCACGACUGA-5′ (SEQ ID NO: 1410) βc-2510 Target:5′-TGGGTGGCCACCACCCTGGTGCTGACT-3′ (SEQ ID NO: 2519)5′-GGGUGGCCACCACCCUGGUGCUGACUA-3′ (SEQ ID NO: 6956)3′-CCCACCGGUGGUGGGACCACGACUGAU-5′ (SEQ ID NO: 1411) βc-2511 Target:5′-GGGTGGCCACCACCCTGGTGCTGACTA-3′ (SEQ ID NO: 2520)5′-GGUGGCCACCACCCUGGUGCUGACUAU-3′ (SEQ ID NO: 6957)3′-CCACCGGUGGUGGGACCACGACUGAUA-5′ (SEQ ID NO: 1412) βc-2512 Target:5′-GGTGGCCACCACCCTGGTGCTGACTAT-3′ (SEQ ID NO: 2521)5′-GUGGCCACCACCCUGGUGCUGACUAUC-3′ (SEQ ID NO: 6958)3′-CACCGGUGGUGGGACCACGACUGAUAG-5′ (SEQ ID NO: 1413) βc-2513 Target:5′-GTGGCCACCACCCTGGTGCTGACTATC-3′ (SEQ ID NO: 2522)5′-UGGCCACCACCCUGGUGCUGACUAUCC-3′ (SEQ ID NO: 6959)3′-ACCGGUGGUGGGACCACGACUGAUAGG-5′ (SEQ ID NO: 1414) βc-2514 Target:5′-TGGCCACCACCCTGGTGCTGACTATCC-3′ (SEQ ID NO: 2523)5′-GGCCACCACCCUGGUGCUGACUAUCCA-3′ (SEQ ID NO: 6960)3′-CCGGUGGUGGGACCACGACUGAUAGGU-5′ (SEQ ID NO: 1415) βc-2515 Target:5′-GGCCACCACCCTGGTGCTGACTATCCA-3′ (SEQ ID NO: 2524)5′-GCCACCACCCUGGUGCUGACUAUCCAG-3′ (SEQ ID NO: 6961)3′-CGGUGGUGGGACCACGACUGAUAGGUC-5′ (SEQ ID NO: 1416) βc-2516 Target:5′-GCCACCACCCTGGTGCTGACTATCCAG-3′ (SEQ ID NO: 2525)5′-CCACCACCCUGGUGCUGACUAUCCAGU-3′ (SEQ ID NO: 6962)3′-GGUGGUGGGACCACGACUGAUAGGUCA-5′ (SEQ ID NO: 1417) βc-2517 Target:5′-CCACCACCCTGGTGCTGACTATCCAGT-3′ (SEQ ID NO: 2526)5′-CACCACCCUGGUGCUGACUAUCCAGUU-3′ (SEQ ID NO: 6963)3′-GUGGUGGGACCACGACUGAUAGGUCAA-5′ (SEQ ID NO: 1418) βc-2518 Target:5′-CACCACCCTGGTGCTGACTATCCAGTT-3′ (SEQ ID NO: 2527)5′-ACCACCCUGGUGCUGACUAUCCAGUUG-3′ (SEQ ID NO: 6964)3′-UGGUGGGACCACGACUGAUAGGUCAAC-5′ (SEQ ID NO: 1419) βc-2519 Target:5′-ACCACCCTGGTGCTGACTATCCAGTTG-3′ (SEQ ID NO: 2528)5′-CCACCCUGGUGCUGACUAUCCAGUUGA-3′ (SEQ ID NO: 6965)3′-GGUGGGACCACGACUGAUAGGUCAACU-5′ (SEQ ID NO: 1420) βc-2520 Target:5′-CCACCCTGGTGCTGACTATCCAGTTGA-3′ (SEQ ID NO: 2529)5′-CACCCUGGUGCUGACUAUCCAGUUGAU-3′ (SEQ ID NO: 6966)3′-GUGGGACCACGACUGAUAGGUCAACUA-5′ (SEQ ID NO: 1421) βc-2521 Target:5′-CACCCTGGTGCTGACTATCCAGTTGAT-3′ (SEQ ID NO: 2530)5′-ACCCUGGUGCUGACUAUCCAGUUGAUG-3′ (SEQ ID NO: 6967)3′-UGGGACCACGACUGAUAGGUCAACUAC-5′ (SEQ ID NO: 1422) βc-2522 Target:5′-ACCCTGGTGCTGACTATCCAGTTGATG-3′ (SEQ ID NO: 2531)5′-CCCUGGUGCUGACUAUCCAGUUGAUGG-3′ (SEQ ID NO: 6968)3′-GGGACCACGACUGAUAGGUCAACUACC-5′ (SEQ ID NO: 1423) βc-2523 Target:5′-CCCTGGTGCTGACTATCCAGTTGATGG-3′ (SEQ ID NO: 2532)5′-CCUGGUGCUGACUAUCCAGUUGAUGGG-3′ (SEQ ID NO: 6969)3′-GGACCACGACUGAUAGGUCAACUACCC-5′ (SEQ ID NO: 1424) βc-2524 Target:5′-CCTGGTGCTGACTATCCAGTTGATGGG-3′ (SEQ ID NO: 2533)5′-CUGGUGCUGACUAUCCAGUUGAUGGGC-3′ (SEQ ID NO: 6970)3′-GACCACGACUGAUAGGUCAACUACCCG-5′ (SEQ ID NO: 1425) βc-2525 Target:5′-CTGGTGCTGACTATCCAGTTGATGGGC-3′ (SEQ ID NO: 2534)5′-UGGUGCUGACUAUCCAGUUGAUGGGCU-3′ (SEQ ID NO: 6971)3′-ACCACGACUGAUAGGUCAACUACCCGA-5′ (SEQ ID NO: 1426) βc-2526 Target:5′-TGGTGCTGACTATCCAGTTGATGGGCT-3′ (SEQ ID NO: 2535)5′-GGUGCUGACUAUCCAGUUGAUGGGCUG-3′ (SEQ ID NO: 6972)3′-CCACGACUGAUAGGUCAACUACCCGAC-5′ (SEQ ID NO: 1427) βc-2527 Target:5′-GGTGCTGACTATCCAGTTGATGGGCTG-3′ (SEQ ID NO: 2536)5′-GUGCUGACUAUCCAGUUGAUGGGCUGC-3′ (SEQ ID NO: 6973)3′-CACGACUGAUAGGUCAACUACCCGACG-5′ (SEQ ID NO: 1428) βc-2528 Target:5′-GTGCTGACTATCCAGTTGATGGGCTGC-3′ (SEQ ID NO: 2537)5′-UGCUGACUAUCCAGUUGAUGGGCUGCC-3′ (SEQ ID NO: 6974)3′-ACGACUGAUAGGUCAACUACCCGACGG-5′ (SEQ ID NO: 1429) βc-2529 Target:5′-TGCTGACTATCCAGTTGATGGGCTGCC-3′ (SEQ ID NO: 2538)5′-GCUGACUAUCCAGUUGAUGGGCUGCCA-3′ (SEQ ID NO: 6975)3′-CGACUGAUAGGUCAACUACCCGACGGU-5′ (SEQ ID NO: 1430) βc-2530 Target:5′-GCTGACTATCCAGTTGATGGGCTGCCA-3′ (SEQ ID NO: 2539)5′-CUGACUAUCCAGUUGAUGGGCUGCCAG-3′ (SEQ ID NO: 6976)3′-GACUGAUAGGUCAACUACCCGACGGUC-5′ (SEQ ID NO: 1431) βc-2531 Target:5′-CTGACTATCCAGTTGATGGGCTGCCAG-3′ (SEQ ID NO: 2540)5′-UGACUAUCCAGUUGAUGGGCUGCCAGA-3′ (SEQ ID NO: 6977)3′-ACUGAUAGGUCAACUACCCGACGGUCU-5′ (SEQ ID NO: 1432) βc-2532 Target:5′-TGACTATCCAGTTGATGGGCTGCCAGA-3′ (SEQ ID NO: 2541)5′-GACUAUCCAGUUGAUGGGCUGCCAGAU-3′ (SEQ ID NO: 6978)3′-CUGAUAGGUCAACUACCCGACGGUCUA-5′ (SEQ ID NO: 1433) βc-2533 Target:5′-GACTATCCAGTTGATGGGCTGCCAGAT-3′ (SEQ ID NO: 2542)5′-ACUAUCCAGUUGAUGGGCUGCCAGAUC-3′ (SEQ ID NO: 6979)3′-UGAUAGGUCAACUACCCGACGGUCUAG-5′ (SEQ ID NO: 1434) βc-2534 Target:5′-ACTATCCAGTTGATGGGCTGCCAGATC-3′ (SEQ ID NO: 2543)5′-CUAUCCAGUUGAUGGGCUGCCAGAUCU-3′ (SEQ ID NO: 6980)3′-GAUAGGUCAACUACCCGACGGUCUAGA-5′ (SEQ ID NO: 1435) βc-2535 Target:5′-CTATCCAGTTGATGGGCTGCCAGATCT-3′ (SEQ ID NO: 2544)5′-AUGCCCAGGACCUCAUGGAUGGGCUGC-3′ (SEQ ID NO: 6981)3′-UACGGGUCCUGGAGUACCUACCCGACG-5′ (SEQ ID NO: 1436) βc-2567 Target:5′-ATGCCCAGGACCTCATGGATGGGCTGC-3′ (SEQ ID NO: 2545)5′-UGCCCAGGACCUCAUGGAUGGGCUGCC-3′ (SEQ ID NO: 6982)3′-ACGGGUCCUGGAGUACCUACCCGACGG-5′ (SEQ ID NO: 1437) βc-2568 Target:5′-TGCCCAGGACCTCATGGATGGGCTGCC-3′ (SEQ ID NO: 2546)5′-GCCCAGGACCUCAUGGAUGGGCUGCCU-3′ (SEQ ID NO: 6983)3′-CGGGUCCUGGAGUACCUACCCGACGGA-5′ (SEQ ID NO: 1438) βc-2569 Target:5′-GCCCAGGACCTCATGGATGGGCTGCCT-3′ (SEQ ID NO: 2547)5′-ACAGCAAUCAGCUGGCCUGGUUUGAUA-3′ (SEQ ID NO: 6984)3′-UGUCGUUAGUCGACCGGACCAAACUAU-5′ (SEQ ID NO: 1439) βc-2603 Target:5′-ACAGCAATCAGCTGGCCTGGTTTGATA-3′ (SEQ ID NO: 2548)5′-CAGCAAUCAGCUGGCCUGGUUUGAUAC-3′ (SEQ ID NO: 6985)3′-GUCGUUAGUCGACCGGACCAAACUAUG-5′ (SEQ ID NO: 1440) βc-2604 Target:5′-CAGCAATCAGCTGGCCTGGTTTGATAC-3′ (SEQ ID NO: 2549)5′-AGCAAUCAGCUGGCCUGGUUUGAUACU-3′ (SEQ ID NO: 6986)3′-UCGUUAGUCGACCGGACCAAACUAUGA-5′ (SEQ ID NO: 1441) βc-2605 Target:5′-AGCAATCAGCTGGCCTGGTTTGATACT-3′ (SEQ ID NO: 2550)5′-GCAAUCAGCUGGCCUGGUUUGAUACUG-3′ (SEQ ID NO: 6987)3′-CGUUAGUCGACCGGACCAAACUAUGAC-5′ (SEQ ID NO: 1442) βc-2606 Target:5′-GCAATCAGCTGGCCTGGTTTGATACTG-3′ (SEQ ID NO: 2551)5′-CAAUCAGCUGGCCUGGUUUGAUACUGA-3′ (SEQ ID NO: 6988)3′-GUUAGUCGACCGGACCAAACUAUGACU-5′ (SEQ ID NO: 1443) βc-2607 Target:5′-CAATCAGCTGGCCTGGTTTGATACTGA-3′ (SEQ ID NO: 2552)5′-AAUCAGCUGGCCUGGUUUGAUACUGAC-3′ (SEQ ID NO: 6989)3′-UUAGUCGACCGGACCAAACUAUGACUG-5′ (SEQ ID NO: 1444) βc-2608 Target:5′-AATCAGCTGGCCTGGTTTGATACTGAC-3′ (SEQ ID NO: 2553)5′-AUCAGCUGGCCUGGUUUGAUACUGACC-3′ (SEQ ID NO: 6990)3′-UAGUCGACCGGACCAAACUAUGACUGG-5′ (SEQ ID NO: 1445) βc-2609 Target:5′-ATCAGCTGGCCTGGTTTGATACTGACC-3′ (SEQ ID NO: 2554)5′-UCAGCUGGCCUGGUUUGAUACUGACCU-3′ (SEQ ID NO: 6991)3′-AGUCGACCGGACCAAACUAUGACUGGA-5′ (SEQ ID NO: 1446) βc-2610 Target:5′-TCAGCTGGCCTGGTTTGATACTGACCT-3′ (SEQ ID NO: 2555)5′-CAGCUGGCCUGGUUUGAUACUGACCUG-3′ (SEQ ID NO: 6992)3′-GUCGACCGGACCAAACUAUGACUGGAC-5′ (SEQ ID NO: 1447) βc-2611 Target:5′-CAGCTGGCCTGGTTTGATACTGACCTG-3′ (SEQ ID NO: 2556)5′-AGCUGGCCUGGUUUGAUACUGACCUGU-3′ (SEQ ID NO: 6993)3′-UCGACCGGACCAAACUAUGACUGGACA-5′ (SEQ ID NO: 1448) βc-2612 Target:5′-AGCTGGCCTGGTTTGATACTGACCTGT-3′ (SEQ ID NO: 2557)5′-GCUGGCCUGGUUUGAUACUGACCUGUA-3′ (SEQ ID NO: 6994)3′-CGACCGGACCAAACUAUGACUGGACAU-5′ (SEQ ID NO: 1449) βc-2613 Target:5′-GCTGGCCTGGTTTGATACTGACCTGTA-3′ (SEQ ID NO: 2558)5′-CUGGCCUGGUUUGAUACUGACCUGUAA-3′ (SEQ ID NO: 6995)3′-GACCGGACCAAACUAUGACUGGACAUU-5′ (SEQ ID NO: 1450) βc-2614 Target:5′-CTGGCCTGGTTTGATACTGACCTGTAA-3′ (SEQ ID NO: 2559)5′-UGGCCUGGUUUGAUACUGACCUGUAAA-3′ (SEQ ID NO: 6996)3′-ACCGGACCAAACUAUGACUGGACAUUU-5′ (SEQ ID NO: 1451) βc-2615 Target:5′-TGGCCTGGTTTGATACTGACCTGTAAA-3′ (SEQ ID NO: 2560)5′-GGCCUGGUUUGAUACUGACCUGUAAAU-3′ (SEQ ID NO: 6997)3′-CCGGACCAAACUAUGACUGGACAUUUA-5′ (SEQ ID NO: 1452) βc-2616 Target:5′-GGCCTGGTTTGATACTGACCTGTAAAT-3′ (SEQ ID NO: 2561)5′-GCCUGGUUUGAUACUGACCUGUAAAUC-3′ (SEQ ID NO: 6998)3′-CGGACCAAACUAUGACUGGACAUUUAG-5′ (SEQ ID NO: 1453) βc-2617 Target:5′-GCCTGGTTTGATACTGACCTGTAAATC-3′ (SEQ ID NO: 2562)5′-CCUGGUUUGAUACUGACCUGUAAAUCA-3′ (SEQ ID NO: 6999)3′-GGACCAAACUAUGACUGGACAUUUAGU-5′ (SEQ ID NO: 1454) βc-2618 Target:5′-CCTGGTTTGATACTGACCTGTAAATCA-3′ (SEQ ID NO: 2563)5′-CUGGUUUGAUACUGACCUGUAAAUCAU-3′ (SEQ ID NO: 7000)3′-GACCAAACUAUGACUGGACAUUUAGUA-5′ (SEQ ID NO: 1455) βc-2619 Target:5′-CTGGTTTGATACTGACCTGTAAATC-3′ (SEQ ID NO: 2564)5′-UGGUUUGAUACUGACCUGUAAAUCAUC-3′ (SEQ ID NO: 7001)3′-ACCAAACUAUGACUGGACAUUUAGUAG-5′ (SEQ ID NO: 1456) βc-2620 Target:5′-TGGTTTGATACTGACCTGTAAATCATC-3′ (SEQ ID NO: 2565)5′-GGUUUGAUACUGACCUGUAAAUCAUCC-3′ (SEQ ID NO: 7002)3′-CCAAACUAUGACUGGACAUUUAGUAGG-5′ (SEQ ID NO: 1457) βc-2621 Target:5′-GGTTTGATACTGACCTGTAAATCATCC-3′ (SEQ ID NO: 2566)5′-GUUUGAUACUGACCUGUAAAUCAUCCU-3′ (SEQ ID NO: 7003)3′-CAAACUAUGACUGGACAUUUAGUAGGA-5′ (SEQ ID NO: 1458) βc-2622 Target:5′-GTTTGATACTGACCTGTAAATCATCCT-3′ (SEQ ID NO: 2567)5′-UUUGAUACUGACCUGUAAAUCAUCCUU-3′ (SEQ ID NO: 7004)3′-AAACUAUGACUGGACAUUUAGUAGGAA-5′ (SEQ ID NO: 1459) βc-2623 Target:5′-TTTGATACTGACCTGTAAATCATCCTT-3′ (SEQ ID NO: 2568)5′-UUUUUUGCCACAGCUUUUGCAACUUAA-3′ (SEQ ID NO: 7005)3′-AAAAAACGGUGUCGAAAACGUUGAAUU-5′ (SEQ ID NO: 1460) βc-2869 Target:5′-TTTTTTGCCACAGCTTTTGCAACTTAA-3′ (SEQ ID NO: 2569)5′-AAUGAGUAACAUUUGCUGUUUUAAACA-3′ (SEQ ID NO: 7006)3′-UUACUCAUUGUAAACGACAAAAUUUGU-5′ (SEQ ID NO: 1461) βc-2902 Target:5′-AATGAGTAACATTTGCTGTTTTAAACA-3′ (SEQ ID NO: 2570)5′-UAAACAUUAAUAGCAGCCUUUCUCUCU-3′ (SEQ ID NO: 7007)3′-AUUUGUAAUUAUCGUCGGAAAGAGAGA-5′ (SEQ ID NO: 1462) βc-2923 Target:5′-TAAACATTAATAGCAGCCTTTCTCTCT-3′ (SEQ ID NO: 2571)5′-AACAUUAAUAGCAGCCUUUCUCUCUUU-3′ (SEQ ID NO: 7008)3′-UUGUAAUUAUCGUCGGAAAGAGAGAAA-5′ (SEQ ID NO: 1463) βc-2925 Target:5′-AACATTAATAGCAGCCTTTCTCTCTTT-3′ (SEQ ID NO: 2572)5′-CAUUAAUAGCAGCCUUUCUCUCUUUAU-3′ (SEQ ID NO: 7009)3′-GUAAUUAUCGUCGGAAAGAGAGAAAUA-5′ (SEQ ID NO: 1464) βc-2927 Target:5′-CATTAATAGCAGCCTTTCTCTCTTTAT-3′ (SEQ ID NO: 2573)5′-UUAAUAGCAGCCUUUCUCUCUUUAUAC-3′ (SEQ ID NO: 7010)3′-AAUUAUCGUCGGAAAGAGAGAAAUAUG-5′ (SEQ ID NO: 1465) βc-2929 Target:5′-TTAATAGCAGCCTTTCTCTCTTTATAC-3′ (SEQ ID NO: 2574)5′-UUGCAUUGUGAUUGGCCUGUAGAGUUG-3′ (SEQ ID NO: 7011)3′-AACGUAACACUAACCGGACAUCUCAAC-5′ (SEQ ID NO: 1466) βc-2973 Target:5′-TTGCATTGTGATTGGCCTGTAGAGTTG-3′ (SEQ ID NO: 2575)5′-GCAUUGUGAUUGGCCUGUAGAGUUGCU-3′ (SEQ ID NO: 7012)3′-CGUAACACUAACCGGACAUCUCAACGA-5′ (SEQ ID NO: 1467) βc-2975 Target:5′-GCATTGTGATTGGCCTGTAGAGTTGCT-3′ (SEQ ID NO: 2576)5′-AUUGUGAUUGGCCUGUAGAGUUGCUGA-3′ (SEQ ID NO: 7013)3′-UAACACUAACCGGACAUCUCAACGACU-5′ (SEQ ID NO: 1468) βc-2977 Target:5′-ATTGTGATTGGCCTGTAGAGTTGCTGA-3′ (SEQ ID NO: 2577)5′-UGUGAUUGGCCUGUAGAGUUGCUGAGA-3′ (SEQ ID NO: 7014)3′-ACACUAACCGGACAUCUCAACGACUCU-5′ (SEQ ID NO: 1469) βc-2979 Target:5′-TGTGATTGGCCTGTAGAGTTGCTGAGA-3′ (SEQ ID NO: 2578)5′-UGAUUGGCCUGUAGAGUUGCUGAGAGG-3′ (SEQ ID NO: 7015)3′-ACUAACCGGACAUCUCAACGACUCUCC-5′ (SEQ ID NO: 1470) βc-2981 Target:5′-TGATTGGCCTGTAGAGTTGCTGAGAGG-3′ (SEQ ID NO: 2579)5′-AUUGGCCUGUAGAGUUGCUGAGAGGGC-3′ (SEQ ID NO: 7016)3′-UAACCGGACAUCUCAACGACUCUCCCG-5′ (SEQ ID NO: 1471) βc-2983 Target:5′-ATTGGCCTGTAGAGTTGCTGAGAGGGC-3′ (SEQ ID NO: 2580)5′-UGGCCUGUAGAGUUGCUGAGAGGGCUC-3′ (SEQ ID NO: 7017)3′-ACCGGACAUCUCAACGACUCUCCCGAG-5′ (SEQ ID NO: 1472) βc-2985 Target:5′-TGGCCTGTAGAGTTGCTGAGAGGGCTC-3′ (SEQ ID NO: 2581)5′-GCCUGUAGAGUUGCUGAGAGGGCUCGA-3′ (SEQ ID NO: 7018)3′-CGGACAUCUCAACGACUCUCCCGAGCU-5′ (SEQ ID NO: 1473) βc-2987 Target:5′-GCCTGTAGAGTTGCTGAGAGGGCTCGA-3′ (SEQ ID NO: 2582)5′-CUGUAGAGUUGCUGAGAGGGCUCGAGG-3′ (SEQ ID NO: 7019)3′-GACAUCUCAACGACUCUCCCGAGCUCC-5′ (SEQ ID NO: 1474) βc-2989 Target:5′-CTGTAGAGTTGCTGAGAGGGCTCGAGG-3′ (SEQ ID NO: 2583)5′-GGGUGGGCUGGUAUCUCAGAAAGUGCC-3′ (SEQ ID NO: 7020)3′-CCCACCCGACCAUAGAGUCUUUCACGG-5′ (SEQ ID NO: 1475) βc-3015 Target:5′-GGGTGGGCTGGTATCTCAGAAAGTGCC-3′ (SEQ ID NO: 2584)5′-GUGGGCUGGUAUCUCAGAAAGUGCCUG-3′ (SEQ ID NO: 7021)3′-CACCCGACCAUAGAGUCUUUCACGGAC-5′ (SEQ ID NO: 1476) βc-3017 Target:5′-GTGGGCTGGTATCTCAGAAAGTGCCTG-3′ (SEQ ID NO: 2585)5′-GGGCUGGUAUCUCAGAAAGUGCCUGAC-3′ (SEQ ID NO: 7022)3′-CCCGACCAUAGAGUCUUUCACGGACUG-5′ (SEQ ID NO: 1477) βc-3019 Target:5′-GGGCTGGTATCTCAGAAAGTGCCTGAC-3′ (SEQ ID NO: 2586)5′-GCUGGUAUCUCAGAAAGUGCCUGACAC-3′ (SEQ ID NO: 7023)3′-CGACCAUAGAGUCUUUCACGGACUGUG-5′ (SEQ ID NO: 1478) βc-3021 Target:5′-GCTGGTATCTCAGAAAGTGCCTGACAC-3′ (SEQ ID NO: 2587)5′-ACACUAACCAAGCUGAGUUUCCUAUGG-3′ (SEQ ID NO: 7024)3′-UGUGAUUGGUUCGACUCAAAGGAUACC-5′ (SEQ ID NO: 1479) βc-3046 Target:5′-ACACTAACCAAGCTGAGTTTCCTATGG-3′ (SEQ ID NO: 2588)5′-ACUAACCAAGCUGAGUUUCCUAUGGGA-3′ (SEQ ID NO: 7025)3′-UGAUUGGUUCGACUCAAAGGAUACCCU-5′ (SEQ ID NO: 1480) βc-3048 Target:5′-ACTAACCAAGCTGAGTTTCCTATGGGA-3′ (SEQ ID NO: 2589)5′-UAACCAAGCUGAGUUUCCUAUGGGAAC-3′ (SEQ ID NO: 7026)3′-AUUGGUUCGACUCAAAGGAUACCCUUG-5′ (SEQ ID NO: 1481) βc-3050 Target:5′-TAACCAAGCTGAGTTTCCTATGGGAAC-3′ (SEQ ID NO: 2590)5′-ACCAAGCUGAGUUUCCUAUGGGAACAA-3′ (SEQ ID NO: 7027)3′-UGGUUCGACUCAAAGGAUACCCUUGUU-5′ (SEQ ID NO: 1482) βc-3052 Target:5′-ACCAAGCTGAGTTTCCTATGGGAACAA-3′ (SEQ ID NO: 2591)5′-CAAGCUGAGUUUCCUAUGGGAACAAUU-3′ (SEQ ID NO: 7028)3′-GUUCGACUCAAAGGAUACCCUUGUUAA-5′ (SEQ ID NO: 1483) βc-3054 Target:5′-CAAGCTGAGTTTCCTATGGGAACAATT-3′ (SEQ ID NO: 2592)5′-AGCUGAGUUUCCUAUGGGAACAAUUGA-3′ (SEQ ID NO: 7029)3′-UCGACUCAAAGGAUACCCUUGUUAACU-5′ (SEQ ID NO: 1484) βc-3056 Target:5′-AGCTGAGTTTCCTATGGGAACAATTGA-3′ (SEQ ID NO: 2593)5′-AACUUUUUGUUCUGGUCCUUUUUGGUC-3′ (SEQ ID NO: 7030)3′-UUGAAAAACAAGACCAGGAAAAACCAG-5′ (SEQ ID NO: 1485) βc-3087 Target:5′-AACTTTTTGTTCTGGTCCTTTTTGGTC-3′ (SEQ ID NO: 2594)5′-CUUUUUGUUCUGGUCCUUUUUGGUCGA-3′ (SEQ ID NO: 7031)3′-GAAAAACAAGACCAGGAAAAACCAGCU-5′ (SEQ ID NO: 1486) βc-3089 Target:5′-CTTTTTGTTCTGGTCCTTTTTGGTCGA-3′ (SEQ ID NO: 2595)5′-UUUUGUUCUGGUCCUUUUUGGUCGAGG-3′ (SEQ ID NO: 7032)3′-AAAACAAGACCAGGAAAAACCAGCUCC-5′ (SEQ ID NO: 1487) βc-3091 Target:5′-TTTTGTTCTGGTCCTTTTTGGTCGAGG-3′ (SEQ ID NO: 2596)5′-UUGUUCUGGUCCUUUUUGGUCGAGGAG-3′ (SEQ ID NO: 7033)3′-AACAAGACCAGGAAAAACCAGCUCCUC-5′ (SEQ ID NO: 1488) βc-3093 Target:5′-TTGTTCTGGTCCTTTTTGGTCGAGGAG-3′ (SEQ ID NO: 2597)5′-GUUCUGGUCCUUUUUGGUCGAGGAGUA-3′ (SEQ ID NO: 7034)3′-CAAGACCAGGAAAAACCAGCUCCUCAU-5′ (SEQ ID NO: 1489) βc-3095 Target:5′-GTTCTGGTCCTTTTTGGTCGAGGAGTA-3′ (SEQ ID NO: 2598)5′-UCUGGUCCUUUUUGGUCGAGGAGUAAC-3′ (SEQ ID NO: 7035)3′-AGACCAGGAAAAACCAGCUCCUCAUUG-5′ (SEQ ID NO: 1490) βc-3097 Target:5′-TCTGGTCCTTTTTGGTCGAGGAGTAAC-3′ (SEQ ID NO: 2599)5′-UGGUCCUUUUUGGUCGAGGAGUAACAA-3′ (SEQ ID NO: 7036)3′-ACCAGGAAAAACCAGCUCCUCAUUGUU-5′ (SEQ ID NO: 1491) βc-3099 Target:5′-TGGTCCTTTTTGGTCGAGGAGTAACAA-3′ (SEQ ID NO: 2600)5′-GUCCUUUUUGGUCGAGGAGUAACAAUA-3′ (SEQ ID NO: 7037)3′-CAGGAAAAACCAGCUCCUCAUUGUUAU-5′ (SEQ ID NO: 1492) βc-3101 Target:5′-GTCCTTTTTGGTCGAGGAGTAACAATA-3′ (SEQ ID NO: 2601)5′-CCUUUUUGGUCGAGGAGUAACAAUACA-3′ (SEQ ID NO: 7038)3′-GGAAAAACCAGCUCCUCAUUGUUAUGU-5′ (SEQ ID NO: 1493) βc-3103 Target:5′-CCTTTTTGGTCGAGGAGTAACAATACA-3′ (SEQ ID NO: 2602)5′-UUUUUGGUCGAGGAGUAACAAUACAAA-3′ (SEQ ID NO: 7039)3′-AAAAACCAGCUCCUCAUUGUUAUGUUU-5′ (SEQ ID NO: 1494) βc-3105 Target:5′-TTTTTGGTCGAGGAGTAACAATACAAA-3′ (SEQ ID NO: 2603)5′-UUUGGUCGAGGAGUAACAAUACAAAUG-3′ (SEQ ID NO: 7040)3′-AAACCAGCUCCUCAUUGUUAUGUUUAC-5′ (SEQ ID NO: 1495) βc-3107 Target:5′-TTTGGTCGAGGAGTAACAATACAAATG-3′ (SEQ ID NO: 2604)5′-UGGUCGAGGAGUAACAAUACAAAUGGA-3′ (SEQ ID NO: 7041)3′-ACCAGCUCCUCAUUGUUAUGUUUACCU-5′ (SEQ ID NO: 1496) βc-3109 Target:5′-TGGTCGAGGAGTAACAATACAAATGGA-3′ (SEQ ID NO: 2605)5′-GUCGAGGAGUAACAAUACAAAUGGAUU-3′ (SEQ ID NO: 7042)3′-CAGCUCCUCAUUGUUAUGUUUACCUAA-5′ (SEQ ID NO: 1497) βc-3111 Target:5′-GTCGAGGAGTAACAATACAAATGGATT-3′ (SEQ ID NO: 2606)5′-CGAGGAGUAACAAUACAAAUGGAUUUU-3′ (SEQ ID NO: 7043)3′-GCUCCUCAUUGUUAUGUUUACCUAAAA-5′ (SEQ ID NO: 1498) βc-3113 Target:5′-CGAGGAGTAACAATACAAATGGATTTT-3′ (SEQ ID NO: 2607)5′-AGGAGUAACAAUACAAAUGGAUUUUGG-3′ (SEQ ID NO: 7044)3′-UCCUCAUUGUUAUGUUUACCUAAAACC-5′ (SEQ ID NO: 1499) βc-3115 Target:5′-AGGAGTAACAATACAAATGGATTTTGG-3′ (SEQ ID NO: 2608)5′-UUUAUCAAACCCUAGCCUUGCUUGUUA-3′ (SEQ ID NO: 7045)3′-AAAUAGUUUGGGAUCGGAACGAACAAU-5′ (SEQ ID NO: 1500) βc-3191 Target:5′-TTTATCAAACCCTAGCCTTGCTTGTTA-3′ (SEQ ID NO: 2609)5′-UAUCAAACCCUAGCCUUGCUUGUUAAA-3′ (SEQ ID NO: 7046)3′-AUAGUUUGGGAUCGGAACGAACAAUUU-5′ (SEQ ID NO: 1501) βc-3193 Target:5′-TATCAAACCCTAGCCTTGCTTGTTAAA-3′ (SEQ ID NO: 2610)5′-UCAAACCCUAGCCUUGCUUGUUAAAUU-3′ (SEQ ID NO: 7047)3′-AGUUUGGGAUCGGAACGAACAAUUUAA-5′ (SEQ ID NO: 1502) βc-3195 Target:5′-TCAAACCCTAGCCTTGCTTGTTAAATT-3′ (SEQ ID NO: 2611)5′-UUGAGUAAUGGUGUAGAACACUAAUUC-3′ (SEQ ID NO: 7048)3′-AACUCAUUACCACAUCUUGUGAUUAAG-5′ (SEQ ID NO: 1503) βc-3387 Target:5′-TTGAGTAATGGTGTAGAACACTAATTC-3′ (SEQ ID NO: 2612)5′-GAGUAAUGGUGUAGAACACUAAUUCAU-3′ (SEQ ID NO: 7049)3′-CUCAUUACCACAUCUUGUGAUUAAGUA-5′ (SEQ ID NO: 1504) βc-3389 Target:5′-GAGTAATGGTGTAGAACACTAATTC-3′ (SEQ ID NO: 2613)5′-GUAAUGGUGUAGAACACUAAUUCAUAA-3′ (SEQ ID NO: 7050)3′-CAUUACCACAUCUUGUGAUUAAGUAUU-5′ (SEQ ID NO: 1505) βc-3391 Target:5′-GTAATGGTGTAGAACACTAATTCATAA-3′ (SEQ ID NO: 2614)5′-AAUGGUGUAGAACACUAAUUCAUAAUC-3′ (SEQ ID NO: 7051)3′-UUACCACAUCUUGUGAUUAAGUAUUAG-5′ (SEQ ID NO: 1506) βc-3393 Target:5′-AATGGTGTAGAACACTAATTCATAATC-3′ (SEQ ID NO: 2615)5′-UGGUGUAGAACACUAAUUCAUAAUCAC-3′ (SEQ ID NO: 7052)3′-ACCACAUCUUGUGAUUAAGUAUUAGUG-5′ (SEQ ID NO: 1507) βc-3395 Target:5′-TGGTGTAGAACACTAATTCATAATCAC-3′ (SEQ ID NO: 2616)5′-GUGUAGAACACUAAUUCAUAAUCACUC-3′ (SEQ ID NO: 7053)3′-CACAUCUUGUGAUUAAGUAUUAGUGAG-5′ (SEQ ID NO: 1508) βc-3397 Target:5′-GTGTAGAACACTAATTCATAATCACTC-3′ (SEQ ID NO: 2617)5′-GUAGAACACUAAUUCAUAAUCACUCUA-3′ (SEQ ID NO: 7054)3′-CAUCUUGUGAUUAAGUAUUAGUGAGAU-5′ (SEQ ID NO: 1509) βc-3399 Target:5′-GTAGAACACTAATTCATAATCACTCTA-3′ (SEQ ID NO: 2618)5′-AGAACACUAAUUCAUAAUCACUCUAAU-3′ (SEQ ID NO: 7055)3′-UCUUGUGAUUAAGUAUUAGUGAGAUUA-5′ (SEQ ID NO: 1510) βc-3401 Target:5′-AGAACACTAATTCATAATCACTCTAAT-3′ (SEQ ID NO: 2619)5′-AAUUAGUUUCCUUUUUAAUAUGCUUAA-3′ (SEQ ID NO: 7056)3′-UUAAUCAAAGGAAAAAUUAUACGAAUU-5′ (SEQ ID NO: 1511) βc-3500 Target:5′-AATTAGTTTCCTTTTTAATATGCTTAA-3′ (SEQ ID NO: 2620)5′-UUAGUUUCCUUUUUAAUAUGCUUAAAA-3′ (SEQ ID NO: 7057)3′-AAUCAAAGGAAAAAUUAUACGAAUUUU-5′ (SEQ ID NO: 1512) βc-3502 Target:5′-TTAGTTTCCTTTTTAATATGCTTAAAA-3′ (SEQ ID NO: 2621)5′-AGUUUCCUUUUUAAUAUGCUUAAAAUA-3′ (SEQ ID NO: 7058)3′-UCAAAGGAAAAAUUAUACGAAUUUUAU-5′ (SEQ ID NO: 1513) βc-3504 Target:5′-AGTTTCCTTTTTAATATGCTTAAAATA-3′ (SEQ ID NO: 2622)5′-UUUCCUUUUUAAUAUGCUUAAAAUAAG-3′ (SEQ ID NO: 7059)3′-AAAGGAAAAAUUAUACGAAUUUUAUUC-5′ (SEQ ID NO: 1514) βc-3506 Target:5′-TTTCCTTTTTAATATGCTTAAAATAAG-3′ (SEQ ID NO: 2623)5′-UCCUUUUUAAUAUGCUUAAAAUAAGCA-3′ (SEQ ID NO: 7060)3′-AGGAAAAAUUAUACGAAUUUUAUUCGU-5′ (SEQ ID NO: 1515) βc-3508 Target:5′-TCCTTTTTAATATGCTTAAAATAAGCA-3′ (SEQ ID NO: 2624)5′-CCUUUUUAAUAUGCUUAAAAUAAGCAG-3′ (SEQ ID NO: 7061)3′-GGAAAAAUUAUACGAAUUUUAUUCGUC-5′ (SEQ ID NO: 1516) βc-3509 Target:5′-CCTTTTTAATATGCTTAAAATAAGCAG-3′ (SEQ ID NO: 2625)5′-CUUUUUAAUAUGCUUAAAAUAAGCAGG-3′ (SEQ ID NO: 7062)3′-GAAAAAUUAUACGAAUUUUAUUCGUCC-5′ (SEQ ID NO: 1517) βc-3510 Target:5′-CTTTTTAATATGCTTAAAATAAGCAGG-3′ (SEQ ID NO: 2626)5′-UUUUAAUAUGCUUAAAAUAAGCAGGUG-3′ (SEQ ID NO: 7063)3′-AAAAUUAUACGAAUUUUAUUCGUCCAC-5′ (SEQ ID NO: 1518) βc-3512 Target:5′-TTTTAATATGCTTAAAATAAGCAGGTG-3′ (SEQ ID NO: 2627)5′-UUAAUAUGCUUAAAAUAAGCAGGUGGA-3′ (SEQ ID NO: 7064)3′-AAUUAUACGAAUUUUAUUCGUCCACCU-5′ (SEQ ID NO: 1519) βc-3514 Target:5′-TTAATATGCTTAAAATAAGCAGGTGGA-3′ (SEQ ID NO: 2628)5′-AAUAUGCUUAAAAUAAGCAGGUGGAUC-3′ (SEQ ID NO: 7065)3′-UUAUACGAAUUUUAUUCGUCCACCUAG-5′ (SEQ ID NO: 1520) βc-3516 Target:5′-AATATGCTTAAAATAAGCAGGTGGATC-3′ (SEQ ID NO: 2629)5′-UAUGCUUAAAAUAAGCAGGUGGAUCUA-3′ (SEQ ID NO: 7066)3′-AUACGAAUUUUAUUCGUCCACCUAGAU-5′ (SEQ ID NO: 1521) βc-3518 Target:5′-TATGCTTAAAATAAGCAGGTGGATCTA-3′ (SEQ ID NO: 2630)5′-UGCUUAAAAUAAGCAGGUGGAUCUAUU-3′ (SEQ ID NO: 7067)3′-ACGAAUUUUAUUCGUCCACCUAGAUAA-5′ (SEQ ID NO: 1522) βc-3520 Target:5′-TGCTTAAAATAAGCAGGTGGATCTATT-3′ (SEQ ID NO: 2631)5′-CUUAAAAUAAGCAGGUGGAUCUAUUUC-3′ (SEQ ID NO: 7068)3′-GAAUUUUAUUCGUCCACCUAGAUAAAG-5′ (SEQ ID NO: 1523) βc-3522 Target:5′-CTTAAAATAAGCAGGTGGATCTATTTC-3′ (SEQ ID NO: 2632)5′-UAAAAUAAGCAGGUGGAUCUAUUUCAU-3′ (SEQ ID NO: 7069)3′-AUUUUAUUCGUCCACCUAGAUAAAGUA-5′ (SEQ ID NO: 1524) βc-3524 Target:5′-TAAAATAAGCAGGTGGATCTATTTC-3′ (SEQ ID NO: 2633)5′-AAAUAAGCAGGUGGAUCUAUUUCAUGU-3′ (SEQ ID NO: 7070)3′-UUUAUUCGUCCACCUAGAUAAAGUACA-5′ (SEQ ID NO: 1525) βc-3526 Target:5′-AAATAAGCAGGTGGATCTATTTCATGT-3′ (SEQ ID NO: 2634)5′-AUAAGCAGGUGGAUCUAUUUCAUGUUU-3′ (SEQ ID NO: 7071)3′-UAUUCGUCCACCUAGAUAAAGUACAAA-5′ (SEQ ID NO: 1526) βc-3528 Target:5′-ATAAGCAGGTGGATCTATTTCATGTTT-3′ (SEQ ID NO: 2635)5′-AAGCAGGUGGAUCUAUUUCAUGUUUUU-3′ (SEQ ID NO: 7072)3′-UUCGUCCACCUAGAUAAAGUACAAAAA-5′ (SEQ ID NO: 1527) βc-3530 Target:5′-AAGCAGGTGGATCTATTTCATGTTTTT-3′ (SEQ ID NO: 2636)5′-GCAGGUGGAUCUAUUUCAUGUUUUUGA-3′ (SEQ ID NO: 7073)3′-CGUCCACCUAGAUAAAGUACAAAAACU-5′ (SEQ ID NO: 1528) βc-3532 Target:5′-GCAGGTGGATCTATTTCATGTTTTTGA-3′ (SEQ ID NO: 2637)5′-AGGUGGAUCUAUUUCAUGUUUUUGAUC-3′ (SEQ ID NO: 7074)3′-UCCACCUAGAUAAAGUACAAAAACUAG-5′ (SEQ ID NO: 1529) βc-3534 Target:5′-AGGTGGATCTATTTCATGTTTTTGATC-3′ (SEQ ID NO: 2638)5′-GUGGAUCUAUUUCAUGUUUUUGAUCAA-3′ (SEQ ID NO: 7075)3′-CACCUAGAUAAAGUACAAAAACUAGUU-5′ (SEQ ID NO: 1530) βc-3536 Target:5′-GTGGATCTATTTCATGTTTTTGATCAA-3′ (SEQ ID NO: 2639)5′-GGAUCUAUUUCAUGUUUUUGAUCAAAA-3′ (SEQ ID NO: 7076)3′-CCUAGAUAAAGUACAAAAACUAGUUUU-5′ (SEQ ID NO: 1531) βc-3538 Target:5′-GGATCTATTTCATGTTTTTGATCAAAA-3′ (SEQ ID NO: 2640)5′-GGGUAGGGUAAAUCAGUAAGAGGUGUU-3′ (SEQ ID NO: 7077)3′-CCCAUCCCAUUUAGUCAUUCUCCACAA-5′ (SEQ ID NO: 1532) βc-3583 Target:5′-GGGTAGGGTAAATCAGTAAGAGGTGTT-3′ (SEQ ID NO: 2641)5′-GUAGGGUAAAUCAGUAAGAGGUGUUAU-3′ (SEQ ID NO: 7078)3′-CAUCCCAUUUAGUCAUUCUCCACAAUA-5′ (SEQ ID NO: 1533) βc-3585 Target:5′-GTAGGGTAAATCAGTAAGAGGTGTTAT-3′ (SEQ ID NO: 2642)5′-AGGGUAAAUCAGUAAGAGGUGUUAUUU-3′ (SEQ ID NO: 7079)3′-UCCCAUUUAGUCAUUCUCCACAAUAAA-5′ (SEQ ID NO: 1534) βc-3587 Target:5′-AGGGTAAATCAGTAAGAGGTGTTATTT-3′ (SEQ ID NO: 2643)5′-GGUAAAUCAGUAAGAGGUGUUAUUUGG-3′ (SEQ ID NO: 7080)3′-CCAUUUAGUCAUUCUCCACAAUAAACC-5′ (SEQ ID NO: 1535) βc-3589 Target:5′-GGTAAATCAGTAAGAGGTGTTATTTGG-3′ (SEQ ID NO: 2644)5′-UAAAUCAGUAAGAGGUGUUAUUUGGAA-3′ (SEQ ID NO: 7081)3′-AUUUAGUCAUUCUCCACAAUAAACCUU-5′ (SEQ ID NO: 1536) βc-3591 Target:5′-TAAATCAGTAAGAGGTGTTATTTGGAA-3′ (SEQ ID NO: 2645)5′-AAUCAGUAAGAGGUGUUAUUUGGAACC-3′ (SEQ ID NO: 7082)3′-UUAGUCAUUCUCCACAAUAAACCUUGG-5′ (SEQ ID NO: 1537) βc-3593 Target:5′-AATCAGTAAGAGGTGTTATTTGGAACC-3′ (SEQ ID NO: 2646)5′-UUUACCAGUUGCCUUUUAUCCCAAAGU-3′ (SEQ ID NO: 7083)3′-AAAUGGUCAACGGAAAAUAGGGUUUCA-5′ (SEQ ID NO: 1538) βc-3633 Target:5′-TTTACCAGTTGCCTTTTATCCCAAAGT-3′ (SEQ ID NO: 2647)5′-UACCAGUUGCCUUUUAUCCCAAAGUUG-3′ (SEQ ID NO: 7084)3′-AUGGUCAACGGAAAAUAGGGUUUCAAC-5′ (SEQ ID NO: 1539) βc-3635 Target:5′-TACCAGTTGCCTTTTATCCCAAAGTTG-3′ (SEQ ID NO: 2648)5′-CCAGUUGCCUUUUAUCCCAAAGUUGUU-3′ (SEQ ID NO: 7085)3′-GGUCAACGGAAAAUAGGGUUUCAACAA-5′ (SEQ ID NO: 1540) βc-3637 Target:5′-CCAGTTGCCTTTTATCCCAAAGTTGTT-3′ (SEQ ID NO: 2649)5′-AGUUGCCUUUUAUCCCAAAGUUGUUGU-3′ (SEQ ID NO: 7086)3′-UCAACGGAAAAUAGGGUUUCAACAACA-5′ (SEQ ID NO: 1541) βc-3639 Target:5′-AGTTGCCTTTTATCCCAAAGTTGTTGT-3′ (SEQ ID NO: 2650)5′-UUGCCUUUUAUCCCAAAGUUGUUGUAA-3′ (SEQ ID NO: 7087)3′-AACGGAAAAUAGGGUUUCAACAACAUU-5′ (SEQ ID NO: 1542) βc-3641 Target:5′-TTGCCTTTTATCCCAAAGTTGTTGTAA-3′ (SEQ ID NO: 2651)5′-GCCUUUUAUCCCAAAGUUGUUGUAACC-3′ (SEQ ID NO: 7088)3′-CGGAAAAUAGGGUUUCAACAACAUUGG-5′ (SEQ ID NO: 1543) βc-3643 Target:5′-GCCTTTTATCCCAAAGTTGTTGTAACC-3′ (SEQ ID NO: 2652)5′-CUUUUAUCCCAAAGUUGUUGUAACCUG-3′ (SEQ ID NO: 7089)3′-GAAAAUAGGGUUUCAACAACAUUGGAC-5′ (SEQ ID NO: 1544) βc-3645 Target:5′-CTTTTATCCCAAAGTTGTTGTAACCTG-3′ (SEQ ID NO: 2653)5′-UUUAUCCCAAAGUUGUUGUAACCUGCU-3′ (SEQ ID NO: 7090)3′-AAAUAGGGUUUCAACAACAUUGGACGA-5′ (SEQ ID NO: 1545) βc-3647 Target:5′-TTTATCCCAAAGTTGTTGTAACCTGCT-3′ (SEQ ID NO: 2654)5′-UAUCCCAAAGUUGUUGUAACCUGCUGU-3′ (SEQ ID NO: 7091)3′-AUAGGGUUUCAACAACAUUGGACGACA-5′ (SEQ ID NO: 1546) βc-3649 Target:5′-TATCCCAAAGTTGTTGTAACCTGCTGT-3′ (SEQ ID NO: 2655)5′-UCCCAAAGUUGUUGUAACCUGCUGUGA-3′ (SEQ ID NO: 7092)3′-AGGGUUUCAACAACAUUGGACGACACU-5′ (SEQ ID NO: 1547) βc-3651 Target:5′-TCCCAAAGTTGTTGTAACCTGCTGTGA-3′ (SEQ ID NO: 2656)5′-CCAAAGUUGUUGUAACCUGCUGUGAUA-3′ (SEQ ID NO: 7093)3′-GGUUUCAACAACAUUGGACGACACUAU-5′ (SEQ ID NO: 1548) βc-3653 Target:5′-CCAAAGTTGTTGTAACCTGCTGTGATA-3′ (SEQ ID NO: 2657)5′-AAAGUUGUUGUAACCUGCUGUGAUACG-3′ (SEQ ID NO: 7094)3′-UUUCAACAACAUUGGACGACACUAUGC-5′ (SEQ ID NO: 1549) βc-3655 Target:5′-AAAGTTGTTGTAACCTGCTGTGATACG-3′ (SEQ ID NO: 2658)5′-AGUUGUUGUAACCUGCUGUGAUACGAU-3′ (SEQ ID NO: 7095)3′-UCAACAACAUUGGACGACACUAUGCUA-5′ (SEQ ID NO: 1550) βc-3657 Target:5′-AGTTGTTGTAACCTGCTGTGATACGAT-3′ (SEQ ID NO: 2659)5′-UUGUUGUAACCUGCUGUGAUACGAUGC-3′ (SEQ ID NO: 7096)3′-AACAACAUUGGACGACACUAUGCUACG-5′ (SEQ ID NO: 1551) βc-3659 Target:5′-TTGTTGTAACCTGCTGTGATACGATGC-3′ (SEQ ID NO: 2660)5′-AAAAAUGGUUCAGAAUUAAACUUUUAA-3′ (SEQ ID NO: 7097)3′-UUUUUACCAAGUCUUAAUUUGAAAAUU-5′ (SEQ ID NO: 1552) βc-3708 Target:5′-AAAAATGGTTCAGAATTAAACTTTTAA-3′ (SEQ ID NO: 2661)5′-AAAUGGUUCAGAAUUAAACUUUUAAUU-3′ (SEQ ID NO: 7098)3′-UUUACCAAGUCUUAAUUUGAAAAUUAA-5′ (SEQ ID NO: 1553) βc-3710 Target:5′-AAATGGTTCAGAATTAAACTTTTAATT-3′ (SEQ ID NO: 2662)5′-AUGGUUCAGAAUUAAACUUUUAAUUCA-3′ (SEQ ID NO: 7099)3′-UACCAAGUCUUAAUUUGAAAAUUAAGU-5′ (SEQ ID NO: 1554) βc-3712 Target:5′-ATGGTTCAGAATTAAACTTTTAATTCA-3′ (SEQ ID NO: 2663)5′-GGUUCAGAAUUAAACUUUUAAUUCAUU-3′ (SEQ ID NO: 7100)3′-CCAAGUCUUAAUUUGAAAAUUAAGUAA-5′ (SEQ ID NO: 1555) βc-3714 Target:5′-GGTTCAGAATTAAACTTTTAATTCATT-3′ (SEQ ID NO: 2664)5′-UUCAGAAUUAAACUUUUAAUUCAUUCG-3′ (SEQ ID NO: 7101)3′-AAGUCUUAAUUUGAAAAUUAAGUAAGC-5′ (SEQ ID NO: 1556) βc-3716 Target:5′-TTCAGAATTAAACTTTTAATTCATTCG-3′ (SEQ ID NO: 2665)5′-CAGCAGCAGUCUUACUUGGAUUCUGGA-3′ (SEQ ID NO: 7102)3′-GUCGUCGUCAGAAUGAACCUAAGACCU-5′ (SEQ ID NO: 1557) βc-m314 Target:5′-CAGCAGCAGTCTTACTTGGATTCTGGA-3′ (SEQ ID NO: 2666)5′-UUACUUGGAUUCUGGAAUCCAUUCUGG-3′ (SEQ ID NO: 7103)3′-AAUGAACCUAAGACCUUAGGUAAGACC-5′ (SEQ ID NO: 1558) βc-m325 Target:5′-TTACTTGGATTCTGGAATCCATTCTGG-3′ (SEQ ID NO: 2667)5′-UUGACACCUCCCAAGUCCUUUAUGAAU-3′ (SEQ ID NO: 7104)3′-AACUGUGGAGGGUUCAGGAAAUACUUA-5′ (SEQ ID NO: 1559) βc-m408 Target:5′-TTGACACCTCCCAAGTCCTTTATGAAT-3′ (SEQ ID NO: 2668)5′-CACGCAAGAGCAAGUAGCUGAUAUUGA-3′ (SEQ ID NO: 7105)3′-GUGCGUUCUCGUUCAUCGACUAUAACU-5′ (SEQ ID NO: 1560) βc-m460 Target:5′-CACGCAAGAGCAAGTAGCTGATATTGA-3′ (SEQ ID NO: 2669)5′-UGCCAUGUUCCCUGAGACGCUAGAUGA-3′ (SEQ ID NO: 7106)3′-ACGGUACAAGGGACUCUGCGAUCUACU-5′ (SEQ ID NO: 1561) βc-m526 Target:5′-TGCCATGTTCCCTGAGACGCTAGATGA-3′ (SEQ ID NO: 2670)5′-GUUGAAACAUGCAGUUGUCAAUUUGAU-3′ (SEQ ID NO: 7107)3′-CAACUUUGUACGUCAACAGUUAAACUA-5′ (SEQ ID NO: 1562) βc-m631 Target:5′-GTTGAAACATGCAGTTGTCAATTTGAT-3′ (SEQ ID NO: 2671)5′-AACAUGCAGUUGUCAAUUUGAUUAACU-3′ (SEQ ID NO: 7108)3′-UUGUACGUCAACAGUUAAACUAAUUGA-5′ (SEQ ID NO: 1563) βc-m636 Target:5′-AACATGCAGTTGTCAATTTGATTAACT-3′ (SEQ ID NO: 2672)5′-CAGUUGUCAAUUUGAUUAACUAUCAGG-3′ (SEQ ID NO: 7109)3′-GUCAACAGUUAAACUAAUUGAUAGUCC-5′ (SEQ ID NO: 1564) βc-m642 Target:5′-CAGTTGTCAATTTGATTAACTATCAGG-3′ (SEQ ID NO: 2673)5′-AUGAGGACCAGGUGGUAGUUAAUAAAG-3′ (SEQ ID NO: 7110)3′-UACUCCUGGUCCACCAUCAAUUAUUUC-5′ (SEQ ID NO: 1565) βc-m723 Target:5′-ATGAGGACCAGGTGGTAGTTAATAAAG-3′ (SEQ ID NO: 2674)5′-UGGGUCACCAGUGGAUUCUGUACUGUU-3′ (SEQ ID NO: 7111)3′-ACCCAGUGGUCACCUAAGACAUGACAA-5′ (SEQ ID NO: 1566) βc-m970 Target:5′-TGGGTCACCAGTGGATTCTGTACTGTT-3′ (SEQ ID NO: 2675)5′-ACCAGUGGAUUCUGUACUGUUCUACGC-3′ (SEQ ID NO: 7112)3′-UGGUCACCUAAGACAUGACAAGAUGCG-5′ (SEQ ID NO: 1567) βc-m976 Target:5′-ACCAGTGGATTCTGTACTGTTCTACGC-3′ (SEQ ID NO: 2676)5′-UGGAUUCUGUACUGUUCUACGCCAUCA-3′ (SEQ ID NO: 7113)3′-ACCUAAGACAUGACAAGAUGCGGUAGU-5′ (SEQ ID NO: 1568) βc-m981 Target:5′-TGGATTCTGTACTGTTCTACGCCATCA-3′ (SEQ ID NO: 2677)5′-UGGUGGACUGCAGAAAAUGGUUGCUUU-3′ (SEQ ID NO: 7114)3′-ACCACCUGACGUCUUUUACCAACGAAA-5′ (SEQ ID NO: 1569) βc-m1066 Target:5′-TGGTGGACTGCAGAAAATGGTTGCTTT-3′ (SEQ ID NO: 2678)5′-AACGUGAAAUUCUUGGCUAUUACAACA-3′ (SEQ ID NO: 7115)3′-UUGCACUUUAAGAACCGAUAAUGUUGU-5′ (SEQ ID NO: 1570) βc-m1106 Target:5′-AACGTGAAATTCTTGGCTATTACAACA-3′ (SEQ ID NO: 2679)5′-CCCAAGUCAGCGACUUGUUCAAAACUG-3′ (SEQ ID NO: 7116)3′-GGGUUCAGUCGCUGAACAAGUUUUGAC-5′ (SEQ ID NO: 1571) βc-m1354 Target:5′-CCCAAGTCAGCGACTTGTTCAAAACTG-3′ (SEQ ID NO: 2680)5′-GCGACUUGUUCAAAACUGUCUUUGGAC-3′ (SEQ ID NO: 7117)3′-CGCUGAACAAGUUUUGACAGAAACCUG-5′ (SEQ ID NO: 1572) βc-m1363 Target:5′-GCGACTTGTTCAAAACTGTCTTTGGAC-3′ (SEQ ID NO: 2681)5′-CAAAACUGUCUUUGGACUCUCAGAAAC-3′ (SEQ ID NO: 7118)3′-GUUUUGACAGAAACCUGAGAGUCUUUG-5′ (SEQ ID NO: 1573) βc-m1373 Target:5′-CAAAACTGTCTTTGGACTCTCAGAAAC-3′ (SEQ ID NO: 2682)5′-CUCUCUAACCUCACUUGCAAUAAUUAC-3′ (SEQ ID NO: 7119)3′-GAGAGAUUGGAGUGAACGUUAUUAAUG-5′ (SEQ ID NO: 1574) βc-m1508 Target:5′-CTCTCTAACCTCACTTGCAATAATTAC-3′ (SEQ ID NO: 2683)5′-ACCUCACUUGCAAUAAUUACAAAAACA-3′ (SEQ ID NO: 7120)3′-UGGAGUGAACGUUAUUAAUGUUUUUGU-5′ (SEQ ID NO: 1575) βc-m1515 Target:5′-ACCTCACTTGCAATAATTACAAAAACA-3′ (SEQ ID NO: 2684)5′-CAGAAUGCCGUUCGCCUUCAUUAUGGA-3′ (SEQ ID NO: 7121)3′-GUCUUACGGCAAGCGGAAGUAAUACCU-5′ (SEQ ID NO: 1576) βc-m1682 Target:5′-CAGAATGCCGTTCGCCTTCATTATGGA-3′ (SEQ ID NO: 2685)5′-UCGCCUUCAUUAUGGACUGCCUGUUGU-3′ (SEQ ID NO: 7122)3′-AGCGGAAGUAAUACCUGACGGACAACA-5′ (SEQ ID NO: 1577) βc-m1693 Target:5′-TCGCCTTCATTATGGACTGCCTGTTGT-3′ (SEQ ID NO: 2686)5′-UUCAUUAUGGACUGCCUGUUGUGGUUA-3′ (SEQ ID NO: 7123)3′-AAGUAAUACCUGACGGACAACACCAAU-5′ (SEQ ID NO: 1578) βc-m1698 Target:5′-TTCATTATGGACTGCCTGTTGTGGTTA-3′ (SEQ ID NO: 2687)5′-UGGACUGCCUGUUGUGGUUAAACUCCU-3′ (SEQ ID NO: 7124)3′-ACCUGACGGACAACACCAAUUUGAGGA-5′ (SEQ ID NO: 1579) βc-m1705 Target:5′-TGGACTGCCTGTTGTGGTTAAACTCCT-3′ (SEQ ID NO: 2688)5′-GCAACUGUUGGAUUGAUUCGAAACCUU-3′ (SEQ ID NO: 7125)3′-CGUUGACAACCUAACUAAGCUUUGGAA-5′ (SEQ ID NO: 1580) βc-m1763 Target:5′-GCAACTGTTGGATTGATTCGAAACCTT-3′ (SEQ ID NO: 2689)5′-CCGAGGACUCAAUACCAUUCCAUUGUU-3′ (SEQ ID NO: 7126)3′-GGCUCCUGAGUUAUGGUAAGGUAACAA-5′ (SEQ ID NO: 1581) βc-m2008 Target:5′-CCGAGGACTCAATACCATTCCATTGTT-3′ (SEQ ID NO: 2690)5′-CUGAGGACAAGCCACAGGAUUACAAGA-3′ (SEQ ID NO: 7127)3′-GACUCCUGUUCGGUGUCCUAAUGUUCU-5′ (SEQ ID NO: 1582) βc-m2226 Target:5′-CTGAGGACAAGCCACAGGATTACAAGA-3′ (SEQ ID NO: 2691)5′-GGAUGGACCCUAUGAUGGAGCAUGAGA-3′ (SEQ ID NO: 7128)3′-CCUACCUGGGAUACUACCUCGUACUCU-5′ (SEQ ID NO: 1583) βc-m2427 Target:5′-GGATGGACCCTATGATGGAGCATGAGA-3′ (SEQ ID NO: 2692)5′-UUGAUACUGACCUGUAAAUCGUCCUUU-3′ (SEQ ID NO: 7129)3′-AACUAUGACUGGACAUUUAGCAGGAAA-5′ (SEQ ID NO: 1584) βc-m2568 Target:5′-TTGATACTGACCTGTAAATCGTCCTTT-3′ (SEQ ID NO: 2693)5′-AGCCAGUGUGGGUGAAUACUUUACUCU-3′ (SEQ ID NO: 7130)3′-UCGGUCACACCCACUUAUGAAAUGAGA-5′ (SEQ ID NO: 1585) βc-m2614 Target:5′-AGCCAGTGTGGGTGAATACTTTACTCT-3′ (SEQ ID NO: 2694)5′-UGCCACAGCUUUUGCAGCGUUAUACUC-3′ (SEQ ID NO: 7131)3′-ACGGUGUCGAAAACGUCGCAAUAUGAG-5′ (SEQ ID NO: 1586) βc-m2770 Target:5′-TGCCACAGCTTTTGCAGCGTTATACTC-3′ (SEQ ID NO: 2695)5′-GCUUUUGCAGCGUUAUACUCAGAUGAG-3′ (SEQ ID NO: 7132)3′-CGAAAACGUCGCAAUAUGAGUCUACUC-5′ (SEQ ID NO: 1587) βc-m2777 Target:5′-GCTTTTGCAGCGTTATACTCAGATGAG-3′ (SEQ ID NO: 2696)5′-CAGCGUUAUACUCAGAUGAGUAACAUU-3′ (SEQ ID NO: 7133)3′-GUCGCAAUAUGAGUCUACUCAUUGUAA-5′ (SEQ ID NO: 1588) βc-m2784 Target:5′-CAGCGTTATACTCAGATGAGTAACATT-3′ (SEQ ID NO: 2697)5′-ACAUUUGCUGUUUUCAACAUUAAUAGC-3′ (SEQ ID NO: 7134)3′-UGUAAACGACAAAAGUUGUAAUUAUCG-5′ (SEQ ID NO: 1589) βc-m2806 Target:5′-ACATTTGCTGTTTTCAACATTAATAGC-3′ (SEQ ID NO: 2698)5′-AGCUGUAGUGUCUGAACGUGCAUUGUG-3′ (SEQ ID NO: 7135)3′-UCGACAUCACAGACUUGCACGUAACAC-5′ (SEQ ID NO: 1590) βc-m2850 Target:5′-AGCTGTAGTGTCTGAACGTGCATTGTG-3′ (SEQ ID NO: 2699)5′-GGGAACAGUCGAAGUACGCUUUUUGUU-3′ (SEQ ID NO: 7136)3′-CCCUUGUCAGCUUCAUGCGAAAAACAA-5′ (SEQ ID NO: 1591) βc-m2965 Target:5′-GGGAACAGTCGAAGTACGCTTTTTGTT-3′ (SEQ ID NO: 2700)5′-CAGUCGAAGUACGCUUUUUGUUCUGGU-3′ (SEQ ID NO: 7137)3′-GUCAGCUUCAUGCGAAAAACAAGACCA-5′ (SEQ ID NO: 1592) βc-m2970 Target:5′-CAGTCGAAGTACGCTTTTTGTTCTGGT-3′ (SEQ ID NO: 2701)5′-AAGUACGCUUUUUGUUCUGGUCCUUUU-3′ (SEQ ID NO: 7138)3′-UUCAUGCGAAAAACAAGACCAGGAAAA-5′ (SEQ ID NO: 1593) βc-m2976 Target:5′-AAGTACGCTTTTTGTTCTGGTCCTTTT-3′ (SEQ ID NO: 2702)5′-ACCCUAGCCUUGCUUGUUCUUUGUUUU-3′ (SEQ ID NO: 7139)3′-UGGGAUCGGAACGAACAAGAAACAAAA-5′ (SEQ ID NO: 1594) βc-m3092 Target:5′-ACCCTAGCCTTGCTTGTTCTTTGTTTT-3′ (SEQ ID NO: 2703)5′-AGCCUUGCUUGUUCUUUGUUUUAAUAU-3′ (SEQ ID NO: 7140)3′-UCGGAACGAACAAGAAACAAAAUUAUA-5′ (SEQ ID NO: 1595) βc-m3097 Target:5′-AGCCTTGCTTGTTCTTTGTTTTAATAT-3′ (SEQ ID NO: 2704)5′-UGAACCUGCUACAGCAAUUUCUGAUUU-3′ (SEQ ID NO: 7141)3′-ACUUGGACGAUGUCGUUAAAGACUAAA-5′ (SEQ ID NO: 1596) βc-m3198 Target:5′-TGAACCTGCTACAGCAATTTCTGATTT-3′ (SEQ ID NO: 2705)5′-UACAGCAAUUUCUGAUUUCUAAGAACC-3′ (SEQ ID NO: 7142)3′-AUGUCGUUAAAGACUAAAGAUUCUUGG-5′ (SEQ ID NO: 1597) βc-m3207 Target:5′-TACAGCAATTTCTGATTTCTAAGAACC-3′ (SEQ ID NO: 2706)5′-CAGUAAGAGGUGUUAUUUGAGCCUUGU-3′ (SEQ ID NO: 7143)3′-GUCAUUCUCCACAAUAAACUCGGAACA-5′ (SEQ ID NO: 1598) βc-m3433 Target:5′-CAGTAAGAGGTGTTATTTGAGCCTTGT-3′ (SEQ ID NO: 2707)5′-GAGGUGUUAUUUGAGCCUUGUUUUGGA-3′ (SEQ ID NO: 7144)3′-CUCCACAAUAAACUCGGAACAAAACCU-5′ (SEQ ID NO: 1599) βc-m3439 Target:5′-GAGGTGTTATTTGAGCCTTGTTTTGGA-3′ (SEQ ID NO: 2708)5′-GUUAUUUGAGCCUUGUUUUGGACAGUA-3′ (SEQ ID NO: 7145)3′-CAAUAAACUCGGAACAAAACCUGUCAU-5′ (SEQ ID NO: 1600) βc-m3444 Target:5′-GTTATTTGAGCCTTGTTTTGGACAGTA-3′ (SEQ ID NO: 2709)5′-UUGAGCCUUGUUUUGGACAGUAUACCA-3′ (SEQ ID NO: 7146)3′-AACUCGGAACAAAACCUGUCAUAUGGU-5′ (SEQ ID NO: 1601) βc-m3449 Target:5′-TTGAGCCTTGTTTTGGACAGTATACCA-3′ (SEQ ID NO: 2710)5′-UUCAACAGAUGCGGUUAUAGAAAUGGU-3′ (SEQ ID NO: 7147)3′-AAGUUGUCUACGCCAAUAUCUUUACCA-5′ (SEQ ID NO: 1602) βc-m3522 Target:5′-TTCAACAGATGCGGTTATAGAAATGGT-3′ (SEQ ID NO: 2711)5′-CGGUUAUAGAAAUGGUUCAGAAUUAAA-3′ (SEQ ID NO: 7148)3′-GCCAAUAUCUUUACCAAGUCUUAAUUU-5′ (SEQ ID NO: 1603) βc-m3533 Target:5′-CGGTTATAGAAATGGTTCAGAATTAAA-3′ (SEQ ID NO: 2712)5′-AUAGAAAUGGUUCAGAAUUAAACUUUU-3′ (SEQ ID NO: 7149)3′-UAUCUUUACCAAGUCUUAAUUUGAAAA-5′ (SEQ ID NO: 1604) βc-m3538 Target:5′-ATAGAAATGGTTCAGAATTAAACTTTT-3′ (SEQ ID NO: 2713)

TABLE 9 Additional Selected Anti-β-catenin DsiRNAs, 25/27mer Duplexes5′-UGUAUGGUAUACUUCAAAUACCCtc-3′ (SEQ ID NO: 496)3′-CAACAUACCAUAUGAAGUUUAUGGGAG-5′ (SEQ ID NO: 1605) βc-244 Target:5′-GTTGTATGGTATACTTCAAATACCCTC-3′ (SEQ ID NO: 2714)5′-AAACAGUUGUAUGGUAUACUUCAaa-3′ (SEQ ID NO: 497)3′-GUUUUGUCAACAUACCAUAUGAAGUUU-5′ (SEQ ID NO: 1606) βc-251 Target:5′-CAAAACAGTTGTATGGTATACTTCAAA-3′ (SEQ ID NO: 2715)5′-AAAACAGUUGUAUGGUAUACUUCaa-3′ (SEQ ID NO: 498)3′-AGUUUUGUCAACAUACCAUAUGAAGUU-5′ (SEQ ID NO: 1607) βc-252 Target:5′-TCAAAACAGTTGTATGGTATACTTCAA-3′ (SEQ ID NO: 2716)5′-UCAAAACAGUUGUAUGGUAUACUtc-3′ (SEQ ID NO: 499)3′-AAAGUUUUGUCAACAUACCAUAUGAAG-5′ (SEQ ID NO: 1608) βc-254 Target:5′-TTTCAAAACAGTTGTATGGTATACTTC-3′ (SEQ ID NO: 2717)5′-UUCAAAACAGUUGUAUGGUAUACtt-3′ (SEQ ID NO: 500)3′-AAAAGUUUUGUCAACAUACCAUAUGAA-5′ (SEQ ID NO: 1609) βc-255 Target:5′-TTTTCAAAACAGTTGTATGGTATACTT-3′ (SEQ ID NO: 2718)5′-UUUCAAAACAGUUGUAUGGUAUAct-3′ (SEQ ID NO: 501)3′-UAAAAGUUUUGUCAACAUACCAUAUGA-5′ (SEQ ID NO: 1610) βc-256 Target:5′-ATTTTCAAAACAGTTGTATGGTATACT-3′ (SEQ ID NO: 2719)5′-GUCCACGCUGGAUUUUCAAAACAgt-3′ (SEQ ID NO: 502)3′-AACAGGUGCGACCUAAAAGUUUUGUCA-5′ (SEQ ID NO: 1611) βc-269 Target:5′-TTGTCCACGCTGGATTTTCAAAACAGT-3′ (SEQ ID NO: 2720)5′-UGUCCACGCUGGAUUUUCAAAACag-3′ (SEQ ID NO: 503)3′-UAACAGGUGCGACCUAAAAGUUUUGUC-5′ (SEQ ID NO: 1612) βc-270 Target:5′-ATTGTCCACGCTGGATTTTCAAAACAG-3′ (SEQ ID NO: 2721)5′-AUCAAAUCAGCUUGAGUAGCCAUtg-3′ (SEQ ID NO: 504)3′-GGUAGUUUAGUCGAACUCAUCGGUAAC-5′ (SEQ ID NO: 1613) βc-293 Target:5′-CCATCAAATCAGCTTGAGTAGCCATTG-3′ (SEQ ID NO: 2722)5′-UCCAACUCCAUCAAAUCAGCUUGag-3′ (SEQ ID NO: 505)3′-ACAGGUUGAGGUAGUUUAGUCGAACUC-5′ (SEQ ID NO: 1614) βc-302 Target:5′-TGTCCAACTCCATCAAATCAGCTTGAG-3′ (SEQ ID NO: 2723)5′-UCCUCAGGAUUGCCUUUACCACUca-3′ (SEQ ID NO: 506)3′-GAAGGAGUCCUAACGGAAAUGGUGAGU-5′ (SEQ ID NO: 1615) βc-431 Target:5′-CTTCCTCAGGATTGCCTTTACCACTCA-3′ (SEQ ID NO: 2724)5′-UUCCUCAGGAUUGCCUUUACCACtc-3′ (SEQ ID NO: 507)3′-AGAAGGAGUCCUAACGGAAAUGGUGAG-5′ (SEQ ID NO: 1616) βc-432 Target:5′-TCTTCCTCAGGATTGCCTTTACCACTC-3′ (SEQ ID NO: 2725)5′-UCAAUAUCAGCUACUUGUUCUUGag-3′ (SEQ ID NO: 508)3′-GUAGUUAUAGUCGAUGAACAAGAACUC-5′ (SEQ ID NO: 1617) βc-518 Target:5′-CATCAATATCAGCTACTTGTTCTTGAG-3′ (SEQ ID NO: 2726)5′-AUCAAUAUCAGCUACUUGUUCUUga-3′ (SEQ ID NO: 509)3′-GGUAGUUAUAGUCGAUGAACAAGAACU-5′ (SEQ ID NO: 1618) βc-519 Target:5′-CCATCAATATCAGCTACTTGTTCTTGA-3′ (SEQ ID NO: 2727)5′-UGUCCAUCAAUAUCAGCUACUUGtt-3′ (SEQ ID NO: 510)3′-UGACAGGUAGUUAUAGUCGAUGAACAA-5′ (SEQ ID NO: 1619) βc-524 Target:5′-ACTGTCCATCAATATCAGCTACTTGTT-3′ (SEQ ID NO: 2728)5′-UGCAUACUGUCCAUCAAUAUCAGct-3′ (SEQ ID NO: 511)3′-UAACGUAUGACAGGUAGUUAUAGUCGA-5′ (SEQ ID NO: 1620) βc-531 Target:5′-ATTGCATACTGTCCATCAATATCAGCT-3′ (SEQ ID NO: 2729)5′-AGUCAUUGCAUACUGUCCAUCAAta-3′ (SEQ ID NO: 512)3′-GCUCAGUAACGUAUGACAGGUAGUUAU-5′ (SEQ ID NO: 1621) βc-537 Target:5′-CGAGTCATTGCATACTGTCCATCAATA-3′ (SEQ ID NO: 2730)5′-UCAUCUAAUGUCUCAGGGAACAUag-3′ (SEQ ID NO: 513)3′-GGAGUAGAUUACAGAGUCCCUUGUAUC-5′ (SEQ ID NO: 1622) βc-584 Target:5′-CCTCATCTAATGTCTCAGGGAACATAG-3′ (SEQ ID NO: 2731)5′-ACAACUGCAUGUUUCAGCAUCUGtg-3′ (SEQ ID NO: 514)3′-AAUGUUGACGUACAAAGUCGUAGACAC-5′ (SEQ ID NO: 1623) βc-680 Target:5′-TTACAACTGCATGTTTCAGCATCTGTG-3′ (SEQ ID NO: 2732)5′-UUACAACUGCAUGUUUCAGCAUCtg-3′ (SEQ ID NO: 515)3′-CAAAUGUUGACGUACAAAGUCGUAGAC-5′ (SEQ ID NO: 1624) βc-682 Target:5′-GTTTACAACTGCATGTTTCAGCATCTG-3′ (SEQ ID NO: 2733)5′-UUAAUCAAGUUUACAACUGCAUGtt-3′ (SEQ ID NO: 516)3′-UCAAUUAGUUCAAAUGUUGACGUACAA-5′ (SEQ ID NO: 1625) βc-692 Target:5′-AGTTAATCAAGTTTACAACTGCATGTT-3′ (SEQ ID NO: 2734)5′-UGAUAGUUAAUCAAGUUUACAACtg-3′ (SEQ ID NO: 517)3′-GAACUAUCAAUUAGUUCAAAUGUUGAC-5′ (SEQ ID NO: 1626) βc-698 Target:5′-CTTGATAGTTAATCAAGTTTACAACTG-3′ (SEQ ID NO: 2735)5′-GCAUCAUCUUGAUAGUUAAUCAAgt-3′ (SEQ ID NO: 518)3′-GACGUAGUAGAACUAUCAAUUAGUUCA-5′ (SEQ ID NO: 1627) βc-707 Target:5′-CTGCATCATCTTGATAGTTAATCAAGT-3′ (SEQ ID NO: 2736)5′-UGCAUCAUCUUGAUAGUUAAUCAag-3′ (SEQ ID NO: 519)3′-AGACGUAGUAGAACUAUCAAUUAGUUC-5′ (SEQ ID NO: 1628) βc-708 Target:5′-TCTGCATCATCTTGATAGTTAATCAAG-3′ (SEQ ID NO: 2737)5′-GGUCCUCGUCAUUUAGCAGUUUUgt-3′ (SEQ ID NO: 520)3′-GACCAGGAGCAGUAAAUCGUCAAAACA-5′ (SEQ ID NO: 1629) βc-763 Target:5′-CTGGTCCTCGTCATTTAGCAGTTTTGT-3′ (SEQ ID NO: 2738)5′-UAACUGCAGCCUUAUUAACCACCac-3′ (SEQ ID NO: 521)3′-GUAUUGACGUCGGAAUAAUUGGUGGUG-5′ (SEQ ID NO: 1630) βc-790 Target:5′-CATAACTGCAGCCTTATTAACCACCAC-3′ (SEQ ID NO: 2739)5′-AUAACUGCAGCCUUAUUAACCACca-3′ (SEQ ID NO: 522)3′-GGUAUUGACGUCGGAAUAAUUGGUGGU-5′ (SEQ ID NO: 1631) βc-791 Target:5′-CCATAACTGCAGCCTTATTAACCACCA-3′ (SEQ ID NO: 2740)5′-ACCAUAACUGCAGCCUUAUUAACca-3′ (SEQ ID NO: 523)3′-CCUGGUAUUGACGUCGGAAUAAUUGGU-5′ (SEQ ID NO: 1632) βc-794 Target:5′-GGACCATAACTGCAGCCTTATTAACCA-3′ (SEQ ID NO: 2741)5′-UUUUUAGAAAGCUGAUGGACCAUaa-3′ (SEQ ID NO: 524)3′-GGAAAAAUCUUUCGACUACCUGGUAUU-5′ (SEQ ID NO: 1633) βc-812 Target:5′-CCTTTTTAGAAAGCTGATGGACCATAA-3′ (SEQ ID NO: 2742)5′-GGUACGUACAAUAGCAGACACCAtc-3′ (SEQ ID NO: 525)3′-UACCAUGCAUGUUAUCGUCUGUGGUAG-5′ (SEQ ID NO: 1634) βc-873 Target:5′-ATGGTACGTACAATAGCAGACACCATC-3′ (SEQ ID NO: 2743)5′-UCAUUUGUAUUCUGCAUGGUACGta-3′ (SEQ ID NO: 526)3′-GUAGUAAACAUAAGACGUACCAUGCAU-5′ (SEQ ID NO: 1635) βc-890 Target:5′-CATCATTTGTATTCTGCATGGTACGTA-3′ (SEQ ID NO: 2744)5′-GUUUCUACAUCAUUUGUAUUCUGca-3′ (SEQ ID NO: 527)3′-GACAAAGAUGUAGUAAACAUAAGACGU-5′ (SEQ ID NO: 1636) βc-899 Target:5′-CTGTTTCTACATCATTTGTATTCTGCA-3′ (SEQ ID NO: 2745)5′-UGUUUCUACAUCAUUUGUAUUCUgc-3′ (SEQ ID NO: 528)3′-CGACAAAGAUGUAGUAAACAUAAGACG-5′ (SEQ ID NO: 1637) βc-900 Target:5′-GCTGTTTCTACATCATTTGTATTCTGC-3′ (SEQ ID NO: 2746)5′-ACAACGAGCUGUUUCUACAUCAUtt-3′ (SEQ ID NO: 529)3′-CAUGUUGCUCGACAAAGAUGUAGUAAA-5′ (SEQ ID NO: 1638) βc-909 Target:5′-GTACAACGAGCTGTTTCTACATCATTT-3′ (SEQ ID NO: 2747)5′-GUACAACGAGCUGUUUCUACAUCat-3′ (SEQ ID NO: 530)3′-GCCAUGUUGCUCGACAAAGAUGUAGUA-5′ (SEQ ID NO: 1639) βc-911 Target:5′-CGGTACAACGAGCTGTTTCTACATC-3′ (SEQ ID NO: 2748)5′-GGUACAACGAGCUGUUUCUACAUca-3′ (SEQ ID NO: 531)3′-CGCCAUGUUGCUCGACAAAGAUGUAGU-5′ (SEQ ID NO: 1640) βc-912 Target:5′-GCGGTACAACGAGCTGTTTCTACATCA-3′ (SEQ ID NO: 2749)5′-AUAAAACAACACAGAAUCCACUGgt-3′ (SEQ ID NO: 532)3′-CGUAUUUUGUUGUGUCUUAGGUGACCA-5′ (SEQ ID NO: 1641) βc-1032 Target:5′-GCATAAAACAACACAGAATCCACTGGT-3′ (SEQ ID NO: 2750)5′-GCAUAAAACAACACAGAAUCCACtg-3′ (SEQ ID NO: 533)3′-ACCGUAUUUUGUUGUGUCUUAGGUGAC-5′ (SEQ ID NO: 1642) βc-1034 Target:5′-TGGCATAAAACAACACAGAATCCACTG-3′ (SEQ ID NO: 2751)5′-GGCAUAAAACAACACAGAAUCCAct-3′ (SEQ ID NO: 534)3′-UACCGUAUUUUGUUGUGUCUUAGGUGA-5′ (SEQ ID NO: 1643) βc-1035 Target:5′-ATGGCATAAAACAACACAGAATCCACT-3′ (SEQ ID NO: 2752)5′-GCUCCUUCUUGAUGUAAUAAAAGgt-3′ (SEQ ID NO: 535)3′-AUCGAGGAAGAACUACAUUAUUUUCCA-5′ (SEQ ID NO: 1644) βc-1076 Target:5′-TAGCTCCTTCTTGATGTAATAAAAGGT-3′ (SEQ ID NO: 2753)5′-AGCUCCUUCUUGAUGUAAUAAAAgg-3′ (SEQ ID NO: 536)3′-AAUCGAGGAAGAACUACAUUAUUUUCC-5′ (SEQ ID NO: 1645) βc-1077 Target:5′-TTAGCTCCTTCTTGATGTAATAAAAGG-3′ (SEQ ID NO: 2754)5′-UAACAUUUGUUUUGUUGAGCAAGgc-3′ (SEQ ID NO: 537)3′-AAAUUGUAAACAAAACAACUCGUUCCG-5′ (SEQ ID NO: 1646) βc-1144 Target:5′-TTTAACATTTGTTTTGTTGAGCAAGGC-3′ (SEQ ID NO: 2755)5′-GCCAAGAAUUUAACAUUUGUUUUgt-3′ (SEQ ID NO: 538)3′-AUCGGUUCUUAAAUUGUAAACAAAACA-5′ (SEQ ID NO: 1647) βc-1154 Target:5′-TAGCCAAGAATTTAACATTTGTTTTGT-3′ (SEQ ID NO: 2756)5′-UAAUAGCCAAGAAUUUAACAUUUgt-3′ (SEQ ID NO: 539)3′-GCAUUAUCGGUUCUUAAAUUGUAAACA-5′ (SEQ ID NO: 1648) βc-1159 Target:5′-CGTAATAGCCAAGAATTTAACATTTGT-3′ (SEQ ID NO: 2757)5′-GUAAUAGCCAAGAAUUUAACAUUtg-3′ (SEQ ID NO: 540)3′-AGCAUUAUCGGUUCUUAAAUUGUAAAC-5′ (SEQ ID NO: 1649) βc-1160 Target:5′-TCGTAATAGCCAAGAATTTAACATTTG-3′ (SEQ ID NO: 2758)5′-AGCUAAAAUUUGAAGGCAGUCUGtc-3′ (SEQ ID NO: 541)3′-AUUCGAUUUUAAACUUCCGUCAGACAG-5′ (SEQ ID NO: 1650) βc-1185 Target:5′-TAAGCTAAAATTTGAAGGCAGTCTGTC-3′ (SEQ ID NO: 2759)5′-GGUCCUCAUUAUAUUUACUAAAGct-3′ (SEQ ID NO: 542)3′-AUCCAGGAGUAAUAUAAAUGAUUUCGA-5′ (SEQ ID NO: 1651) βc-1260 Target:5′-TAGGTCCTCATTATATTTACTAAAGCT-3′ (SEQ ID NO: 2760)5′-GUAUAGGUCCUCAUUAUAUUUACta-3′ (SEQ ID NO: 543)3′-UUCAUAUCCAGGAGUAAUAUAAAUGAU-5′ (SEQ ID NO: 1652) βc-1265 Target:5′-AAGTATAGGTCCTCATTATATTTACTA-3′ (SEQ ID NO: 2761)5′-AGUAUAGGUCCUCAUUAUAUUUAct-3′ (SEQ ID NO: 544)3′-AUUCAUAUCCAGGAGUAAUAUAAAUGA-5′ (SEQ ID NO: 1653) βc-1266 Target:5′-TAAGTATAGGTCCTCATTATATTTACT-3′ (SEQ ID NO: 2762)5′-UUUUCGUAAGUAUAGGUCCUCAUta-3′ (SEQ ID NO: 545)3′-CAAAAAGCAUUCAUAUCCAGGAGUAAU-5′ (SEQ ID NO: 1654) βc-1274 Target:5′-GTTTTTCGTAAGTATAGGTCCTCATTA-3′ (SEQ ID NO: 2763)5′-UUUUUCGUAAGUAUAGGUCCUCAtt-3′ (SEQ ID NO: 546)3′-UCAAAAAGCAUUCAUAUCCAGGAGUAA-5′ (SEQ ID NO: 1655) βc-1275 Target:5′-AGTTTTTCGTAAGTATAGGTCCTCATT-3′ (SEQ ID NO: 2764)5′-GUUUUUCGUAAGUAUAGGUCCUCat-3′ (SEQ ID NO: 547)3′-AUCAAAAAGCAUUCAUAUCCAGGAGUA-5′ (SEQ ID NO: 1656) βc-1276 Target:5′-TAGTTTTTCGTAAGTATAGGTCCTC-3′ (SEQ ID NO: 2765)5′-AGUUUUUCGUAAGUAUAGGUCCUca-3′ (SEQ ID NO: 548)3′-CAUCAAAAAGCAUUCAUAUCCAGGAGU-5′ (SEQ ID NO: 1657) βc-1277 Target:5′-GTAGTTTTTCGTAAGTATAGGTCCTCA-3′ (SEQ ID NO: 2766)5′-GGUCCACAGUAGUUUUUCGUAAGta-3′ (SEQ ID NO: 549)3′-CACCAGGUGUCAUCAAAAAGCAUUCAU-5′ (SEQ ID NO: 1658) βc-1287 Target:5′-GTGGTCCACAGTAGTTTTTCGTAAGTA-3′ (SEQ ID NO: 2767)5′-UACAAUAGCCGGCUUAUUACUAGag-3′ (SEQ ID NO: 550)3′-AGAUGUUAUCGGCCGAAUAAUGAUCUC-5′ (SEQ ID NO: 1659) βc-1344 Target:5′-TCTACAATAGCCGGCTTATTACTAGAG-3′ (SEQ ID NO: 2768)5′-UCUACAAUAGCCGGCUUAUUACUag-3′ (SEQ ID NO: 551)3′-GAAGAUGUUAUCGGCCGAAUAAUGAUC-5′ (SEQ ID NO: 1660) βc-1346 Target:5′-CTTCTACAATAGCCGGCTTATTACTAG-3′ (SEQ ID NO: 2769)5′-UCCUAAAGCUUGCAUUCCACCAGct-3′ (SEQ ID NO: 552)3′-UCAGGAUUUCGAACGUAAGGUGGUCGA-5′ (SEQ ID NO: 1661) βc-1371 Target:5′-AGTCCTAAAGCTTGCATTCCACCAGCT-3′ (SEQ ID NO: 2770)5′-GUCCUAAAGCUUGCAUUCCACCAgc-3′ (SEQ ID NO: 553)3′-UUCAGGAUUUCGAACGUAAGGUGGUCG-5′ (SEQ ID NO: 1662) βc-1372 Target:5′-AAGTCCTAAAGCTTGCATTCCACCAGC-3′ (SEQ ID NO: 2771)5′-AGUCCUAAAGCUUGCAUUCCACCag-3′ (SEQ ID NO: 554)3′-CUUCAGGAUUUCGAACGUAAGGUGGUC-5′ (SEQ ID NO: 1663) βc-1373 Target:5′-GAAGTCCTAAAGCTTGCATTCCACCAG-3′ (SEQ ID NO: 2772)5′-GUUCUGAACAAGACGUUGACUUGga-3′ (SEQ ID NO: 555)3′-GUCAAGACUUGUUCUGCAACUGAACCU-5′ (SEQ ID NO: 1664) βc-1410 Target:5′-CAGTTCTGAACAAGACGTTGACTTGGA-3′ (SEQ ID NO: 2773)5′-AGUUCUGAACAAGACGUUGACUUgg-3′ (SEQ ID NO: 556)3′-UGUCAAGACUUGUUCUGCAACUGAACC-5′ (SEQ ID NO: 1665) βc-1411 Target:5′-ACAGTTCTGAACAAGACGTTGACTTGG-3′ (SEQ ID NO: 2774)5′-GUCCAAAGACAGUUCUGAACAAGac-3′ (SEQ ID NO: 557)3′-CUCAGGUUUCUGUCAAGACUUGUUCUG-5′ (SEQ ID NO: 1666) βc-1421 Target:5′-GAGTCCAAAGACAGTTCTGAACAAGAC-3′ (SEQ ID NO: 2775)5′-UUCCUGUUUAGUUGCAGCAUCUGaa-3′ (SEQ ID NO: 558)3′-GGAAGGACAAAUCAACGUCGUAGACUU-5′ (SEQ ID NO: 1667) βc-1458 Target:5′-CCTTCCTGTTTAGTTGCAGCATCTGAA-3′ (SEQ ID NO: 2776)5′-ACAUUUAUAUCAUCUGAACCCAGaa-3′ (SEQ ID NO: 559)3′-GGUGUAAAUAUAGUAGACUUGGGUCUU-5′ (SEQ ID NO: 1668) βc-1517 Target:5′-CCACATTTATATCATCTGAACCCAGAA-3′ (SEQ ID NO: 2777)5′-ACCACAUUUAUAUCAUCUGAACCca-3′ (SEQ ID NO: 560)3′-ACUGGUGUAAAUAUAGUAGACUUGGGU-5′ (SEQ ID NO: 1669) βc-1520 Target:5′-TGACCACATTTATATCATCTGAACCCA-3′ (SEQ ID NO: 2778)5′-GCACAGGUGACCACAUUUAUAUCat-3′ (SEQ ID NO: 561)3′-GACGUGUCCACUGGUGUAAAUAUAGUA-5′ (SEQ ID NO: 1670) βc-1529 Target:5′-CTGCACAGGTGACCACATTTATATC-3′ (SEQ ID NO: 2779)5′-UGCACAGGUGACCACAUUUAUAUca-3′ (SEQ ID NO: 562)3′-CGACGUGUCCACUGGUGUAAAUAUAGU-5′ (SEQ ID NO: 1671) βc-1530 Target:5′-GCTGCACAGGTGACCACATTTATATCA-3′ (SEQ ID NO: 2780)5′-UGCAAGUGAGGUUAGAAAGAAUUcc-3′ (SEQ ID NO: 563)3′-UAACGUUCACUCCAAUCUUUCUUAAGG-5′ (SEQ ID NO: 1672) βc-1558 Target:5′-ATTGCAAGTGAGGTTAGAAAGAATTCC-3′ (SEQ ID NO: 2781)5′-AUAAUUAUUGCAAGUGAGGUUAGaa-3′ (SEQ ID NO: 564)3′-AAUAUUAAUAACGUUCACUCCAAUCUU-5′ (SEQ ID NO: 1673) βc-1566 Target:5′-TTATAATTATTGCAAGTGAGGTTAGAA-3′ (SEQ ID NO: 2782)5′-UCAUCUUGUUCUUAUAAUUAUUGca-3′ (SEQ ID NO: 565)3′-GUAGUAGAACAAGAAUAUUAAUAACGU-5′ (SEQ ID NO: 1674) βc-1579 Target:5′-CATCATCTTGTTCTTATAATTATTGCA-3′ (SEQ ID NO: 2783)5′-AUCAUCUUGUUCUUAUAAUUAUUgc-3′ (SEQ ID NO: 566)3′-GGUAGUAGAACAAGAAUAUUAAUAACG-5′ (SEQ ID NO: 1675) βc-1580 Target:5′-CCATCATCTTGTTCTTATAATTATTGC-3′ (SEQ ID NO: 2784)5′-ACCAUCAUCUUGUUCUUAUAAUUat-3′ (SEQ ID NO: 567)3′-UCUGGUAGUAGAACAAGAAUAUUAAUA-5′ (SEQ ID NO: 1676) βc-1583 Target:5′-AGACCATCATCTTGTTCTTATAATTAT-3′ (SEQ ID NO: 2785)5′-AGACCAUCAUCUUGUUCUUAUAAtt-3′ (SEQ ID NO: 568)3′-CGUCUGGUAGUAGAACAAGAAUAUUAA-5′ (SEQ ID NO: 1677) βc-1585 Target:5′-GCAGACCATCATCTTGTTCTTATAATT-3′ (SEQ ID NO: 2786)5′-AAUCCAACAGUAGCCUUUAUCAGag-3′ (SEQ ID NO: 569)3′-AGUUAGGUUGUCAUCGGAAAUAGUCUC-5′ (SEQ ID NO: 1678) βc-1808 Target:5′-TCAATCCAACAGTAGCCTTTATCAGAG-3′ (SEQ ID NO: 2787)5′-GAAUCAAUCCAACAGUAGCCUUUat-3′ (SEQ ID NO: 570)3′-AGCUUAGUUAGGUUGUCAUCGGAAAUA-5′ (SEQ ID NO: 1679) βc-1813 Target:5′-TCGAATCAATCCAACAGTAGCCTTTAT-3′ (SEQ ID NO: 2788)5′-UCCACAAAUUGCUGCUGUGUCCCac-3′ (SEQ ID NO: 571)3′-GGAGGUGUUUAACGACGACACAGGGUG-5′ (SEQ ID NO: 1680) βc-1955 Target:5′-CCTCCACAAATTGCTGCTGTGTCCCAC-3′ (SEQ ID NO: 2789)5′-ACAACCUUCAACUAUUUCUUCCAtg-3′ (SEQ ID NO: 572)3′-CAUGUUGGAAGUUGAUAAAGAAGGUAC-5′ (SEQ ID NO: 1681) βc-1989 Target:5′-GTACAACCTTCAACTATTTCTTCCATG-3′ (SEQ ID NO: 2790)5′-UACAACCUUCAACUAUUUCUUCCat-3′ (SEQ ID NO: 573)3′-CCAUGUUGGAAGUUGAUAAAGAAGGUA-5′ (SEQ ID NO: 1682) βc-1990 Target:5′-GGTACAACCTTCAACTATTTCTTCC-3′ (SEQ ID NO: 2791)5′-GUACAACCUUCAACUAUUUCUUCca-3′ (SEQ ID NO: 574)3′-GCCAUGUUGGAAGUUGAUAAAGAAGGU-5′ (SEQ ID NO: 1683) βc-1991 Target:5′-CGGTACAACCTTCAACTATTTCTTCCA-3′ (SEQ ID NO: 2792)5′-GGUACAACCUUCAACUAUUUCUUcc-3′ (SEQ ID NO: 575)3′-GGCCAUGUUGGAAGUUGAUAAAGAAGG-5′ (SEQ ID NO: 1684) βc-1992 Target:5′-CCGGTACAACCTTCAACTATTTCTTCC-3′ (SEQ ID NO: 2793)5′-GCUCCGGUACAACCUUCAACUAUtt-3′ (SEQ ID NO: 576)3′-CCCGAGGCCAUGUUGGAAGUUGAUAAA-5′ (SEQ ID NO: 1685) βc-1997 Target:5′-GGGCTCCGGTACAACCTTCAACTATTT-3′ (SEQ ID NO: 2794)5′-ACAAUUCGGUUGUGAACAUCCCGag-3′ (SEQ ID NO: 577)3′-AUUGUUAAGCCAACACUUGUAGGGCUC-5′ (SEQ ID NO: 1686) βc-2036 Target:5′-TAACAATTCGGTTGTGAACATCCCGAG-3′ (SEQ ID NO: 2795)5′-AACAAUUCGGUUGUGAACAUCCCga-3′ (SEQ ID NO: 578)3′-UAUUGUUAAGCCAACACUUGUAGGGCU-5′ (SEQ ID NO: 1687) βc-2037 Target:5′-ATAACAATTCGGTTGTGAACATCCCGA-3′ (SEQ ID NO: 2796)5′-UAACAAUUCGGUUGUGAACAUCCcg-3′ (SEQ ID NO: 579)3′-CUAUUGUUAAGCCAACACUUGUAGGGC-5′ (SEQ ID NO: 1688) βc-2038 Target:5′-GATAACAATTCGGTTGTGAACATCCCG-3′ (SEQ ID NO: 2797)5′-AUAACAAUUCGGUUGUGAACAUCcc-3′ (SEQ ID NO: 580)3′-ACUAUUGUUAAGCCAACACUUGUAGGG-5′ (SEQ ID NO: 1689) βc-2039 Target:5′-TGATAACAATTCGGTTGTGAACATCCC-3′ (SEQ ID NO: 2798)5′-GAUAACAAUUCGGUUGUGAACAUcc-3′ (SEQ ID NO: 581)3′-GACUAUUGUUAAGCCAACACUUGUAGG-5′ (SEQ ID NO: 1690) βc-2040 Target:5′-CTGATAACAATTCGGTTGTGAACATCC-3′ (SEQ ID NO: 2799)5′-UGAUAACAAUUCGGUUGUGAACAtc-3′ (SEQ ID NO: 582)3′-AGACUAUUGUUAAGCCAACACUUGUAG-5′ (SEQ ID NO: 1691) βc-2041 Target:5′-TCTGATAACAATTCGGTTGTGAACATC-3′ (SEQ ID NO: 2800)5′-AUUUAGUCCUCUGAUAACAAUUCgg-3′ (SEQ ID NO: 583)3′-CAUAAAUCAGGAGACUAUUGUUAAGCC-5′ (SEQ ID NO: 1692) βc-2052 Target:5′-GTATTTAGTCCTCTGATAACAATTCGG-3′ (SEQ ID NO: 2801)5′-UAUUUAGUCCUCUGAUAACAAUUcg-3′ (SEQ ID NO: 584)3′-CCAUAAAUCAGGAGACUAUUGUUAAGC-5′ (SEQ ID NO: 1693) βc-2053 Target:5′-GGTATTTAGTCCTCTGATAACAATTCG-3′ (SEQ ID NO: 2802)5′-GUAUUUAGUCCUCUGAUAACAAUtc-3′ (SEQ ID NO: 585)3′-ACCAUAAAUCAGGAGACUAUUGUUAAG-5′ (SEQ ID NO: 1694) βc-2054 Target:5′-TGGTATTTAGTCCTCTGATAACAATTC-3′ (SEQ ID NO: 2803)5′-GGUAUUUAGUCCUCUGAUAACAAtt-3′ (SEQ ID NO: 586)3′-UACCAUAAAUCAGGAGACUAUUGUUAA-5′ (SEQ ID NO: 1695) βc-2055 Target:5′-ATGGTATTTAGTCCTCTGATAACAATT-3′ (SEQ ID NO: 2804)5′-ACAAUGGAAUGGUAUUUAGUCCUct-3′ (SEQ ID NO: 587)3′-UUUGUUACCUUACCAUAAAUCAGGAGA-5′ (SEQ ID NO: 1696) βc-2065 Target:5′-AAACAATGGAATGGTATTTAGTCCTCT-3′ (SEQ ID NO: 2805)5′-ACAAACAAUGGAAUGGUAUUUAGtc-3′ (SEQ ID NO: 588)3′-CGUGUUUGUUACCUUACCAUAAAUCAG-5′ (SEQ ID NO: 1697) βc-2069 Target:5′-GCACAAACAATGGAATGGTATTTAGTC-3′ (SEQ ID NO: 2806)5′-GCACAAACAAUGGAAUGGUAUUUag-3′ (SEQ ID NO: 589)3′-GACGUGUUUGUUACCUUACCAUAAAUC-5′ (SEQ ID NO: 1698) βc-2071 Target:5′-CTGCACAAACAATGGAATGGTATTTAG-3′ (SEQ ID NO: 2807)5′-UGCACAAACAAUGGAAUGGUAUUta-3′ (SEQ ID NO: 590)3′-CGACGUGUUUGUUACCUUACCAUAAAU-5′ (SEQ ID NO: 1699) βc-2072 Target:5′-GCTGCACAAACAATGGAATGGTATTTA-3′ (SEQ ID NO: 2808)5′-GCUACUCUUUGGAUGUUUUCAAUgg-3′ (SEQ ID NO: 591)3′-GUCGAUGAGAAACCUACAAAAGUUACC-5′ (SEQ ID NO: 1700) βc-2111 Target:5′-CAGCTACTCTTTGGATGTTTTCAATGG-3′ (SEQ ID NO: 2809)5′-AGCUACUCUUUGGAUGUUUUCAAtg-3′ (SEQ ID NO: 592)3′-CGUCGAUGAGAAACCUACAAAAGUUAC-5′ (SEQ ID NO: 1701) βc-2112 Target:5′-GCAGCTACTCTTTGGATGTTTTCAATG-3′ (SEQ ID NO: 2810)5′-GCUUCAAUAGCUUCUGCAGCUUCct-3′ (SEQ ID NO: 593)3′-GUCGAAGUUAUCGAAGACGUCGAAGGA-5′ (SEQ ID NO: 1702) βc-2168 Target:5′-CAGCTTCAATAGCTTCTGCAGCTTCCT-3′ (SEQ ID NO: 2811)5′-UCCCUCAGCUUCAAUAGCUUCUGca-3′ (SEQ ID NO: 594)3′-CGAGGGAGUCGAAGUUAUCGAAGACGU-5′ (SEQ ID NO: 1703) βc-2175 Target:5′-GCTCCCTCAGCTTCAATAGCTTCTGCA-3′ (SEQ ID NO: 2812)5′-GCUCCCUCAGCUUCAAUAGCUUCtg-3′ (SEQ ID NO: 595)3′-ACCGAGGGAGUCGAAGUUAUCGAAGAC-5′ (SEQ ID NO: 1704) βc-2177 Target:5′-TGGCTCCCTCAGCTTCAATAGCTTCTG-3′ (SEQ ID NO: 2813)5′-AUUCCUAGAGUGAAGUAACUCUGtc-3′ (SEQ ID NO: 596)3′-AGUAAGGAUCUCACUUCAUUGAGACAG-5′ (SEQ ID NO: 1705) βc-2214 Target:5′-TCATTCCTAGAGTGAAGTAACTCTGTC-3′ (SEQ ID NO: 2814)5′-UCAUUCCUAGAGUGAAGUAACUCtg-3′ (SEQ ID NO: 597)3′-GAAGUAAGGAUCUCACUUCAUUGAGAC-5′ (SEQ ID NO: 1706) βc-2216 Target:5′-CTTCATTCCTAGAGTGAAGTAACTCTG-3′ (SEQ ID NO: 2815)5′-UUCAUUCCUAGAGUGAAGUAACUct-3′ (SEQ ID NO: 598)3′-GGAAGUAAGGAUCUCACUUCAUUGAGA-5′ (SEQ ID NO: 1707) βc-2217 Target:5′-CCTTCATTCCTAGAGTGAAGTAACTCT-3′ (SEQ ID NO: 2816)5′-UCCUCAGACAUUCGGAACAAAACag-3′ (SEQ ID NO: 599)3′-ACAGGAGUCUGUAAGCCUUGUUUUGUC-5′ (SEQ ID NO: 1708) βc-2264 Target:5′-TGTCCTCAGACATTCGGAACAAAACAG-3′ (SEQ ID NO: 2817)5′-UGUCCUCAGACAUUCGGAACAAAac-3′ (SEQ ID NO: 600)3′-GAACAGGAGUCUGUAAGCCUUGUUUUG-5′ (SEQ ID NO: 1709) βc-2266 Target:5′-CTTGTCCTCAGACATTCGGAACAAAAC-3′ (SEQ ID NO: 2818)5′-GUUUCUUGUAAUCUUGUGGCUUGtc-3′ (SEQ ID NO: 601)3′-GGCAAAGAACAUUAGAACACCGAACAG-5′ (SEQ ID NO: 1710) βc-2287 Target:5′-CCGTTTCTTGTAATCTTGTGGCTTGTC-3′ (SEQ ID NO: 2819)5′-UGAAAGCCGUUUCUUGUAAUCUUgt-3′ (SEQ ID NO: 602)3′-UGACUUUCGGCAAAGAACAUUAGAACA-5′ (SEQ ID NO: 1711) βc-2295 Target:5′-ACTGAAAGCCGTTTCTTGTAATCTTGT-3′ (SEQ ID NO: 2820)5′-GCUCAACUGAAAGCCGUUUCUUGta-3′ (SEQ ID NO: 603)3′-GUCGAGUUGACUUUCGGCAAAGAACAU-5′ (SEQ ID NO: 1712) βc-2302 Target:5′-CAGCTCAACTGAAAGCCGTTTCTTGTA-3′ (SEQ ID NO: 2821)5′-AGUCCAAGAUCAGCAGUCUCAUUcc-3′ (SEQ ID NO: 604)3′-GUUCAGGUUCUAGUCGUCAGAGUAAGG-5′ (SEQ ID NO: 1713) βc-2363 Target:5′-CAAGTCCAAGATCAGCAGTCTCATTCC-3′ (SEQ ID NO: 2822)5′-ACCAAUAUCAAGUCCAAGAUCAGca-3′ (SEQ ID NO: 605)3′-CGUGGUUAUAGUUCAGGUUCUAGUCGU-5′ (SEQ ID NO: 1714) βc-2373 Target:5′-GCACCAATATCAAGTCCAAGATCAGCA-3′ (SEQ ID NO: 2823)5′-AGAACGAUAGCUAGGAUCAUCCUgg-3′ (SEQ ID NO: 606)3′-UUUCUUGCUAUCGAUCCUAGUAGGACC-5′ (SEQ ID NO: 1715) βc-2424 Target:5′-AAAGAACGATAGCTAGGATCATCCTGG-3′ (SEQ ID NO: 2824)5′-UAUCCACCAGAGUGAAAAGAACGat-3′ (SEQ ID NO: 607)3′-GUAUAGGUGGUCUCACUUUUCUUGCUA-5′ (SEQ ID NO: 1716) βc-2441 Target:5′-CATATCCACCAGAGTGAAAAGAACGAT-3′ (SEQ ID NO: 2825)5′-AUUUACAGGUCAGUAUCAAACCAgg-3′ (SEQ ID NO: 608)3′-ACUAAAUGUCCAGUCAUAGUUUGGUCC-5′ (SEQ ID NO: 1717) βc-2618 Target:5′-TGATTTACAGGTCAGTATCAAACCAGG-3′ (SEQ ID NO: 2826)5′-GAUUUACAGGUCAGUAUCAAACCag-3′ (SEQ ID NO: 609)3′-UACUAAAUGUCCAGUCAUAGUUUGGUC-5′ (SEQ ID NO: 1718) βc-2619 Target:5′-ATGATTTACAGGTCAGTATCAAACCAG-3′ (SEQ ID NO: 2827)5′-UGAUUUACAGGUCAGUAUCAAACca-3′ (SEQ ID NO: 610)3′-CUACUAAAUGUCCAGUCAUAGUUUGGU-5′ (SEQ ID NO: 1719) βc-2620 Target:5′-GATGATTTACAGGTCAGTATCAAACCA-3′ (SEQ ID NO: 2828)5′-UCUUACCUAAAGGAUGAUUUACAgg-3′ (SEQ ID NO: 611)3′-GAAGAAUGGAUUUCCUACUAAAUGUCC-5′ (SEQ ID NO: 1720) βc-2634 Target:5′-CTTCTTACCTAAAGGATGATTTACAGG-3′ (SEQ ID NO: 2829)5′-UUCUUACCUAAAGGAUGAUUUACag-3′ (SEQ ID NO: 612)3′-UGAAGAAUGGAUUUCCUACUAAAUGUC-5′ (SEQ ID NO: 1721) βc-2635 Target:5′-ACTTCTTACCTAAAGGATGATTTACAG-3′ (SEQ ID NO: 2830)5′-ACUUCUUACCUAAAGGAUGAUUUac-3′ (SEQ ID NO: 613)3′-UUUGAAGAAUGGAUUUCCUACUAAAUG-5′ (SEQ ID NO: 1722) βc-2637 Target:5′-AAACTTCTTACCTAAAGGATGATTTAC-3′ (SEQ ID NO: 2831)5′-UUUUUAAAACUUCUUACCUAAAGga-3′ (SEQ ID NO: 614)3′-CGAAAAAUUUUGAAGAAUGGAUUUCCU-5′ (SEQ ID NO: 1723) βc-2645 Target:5′-GCTTTTTAAAACTTCTTACCTAAAGGA-3′ (SEQ ID NO: 2832)5′-GCUUUUUAAAACUUCUUACCUAAag-3′ (SEQ ID NO: 615)3′-ACCGAAAAAUUUUGAAGAAUGGAUUUC-5′ (SEQ ID NO: 1724) βc-2647 Target:5′-TGGCTTTTTAAAACTTCTTACCTAAAG-3′ (SEQ ID NO: 2833)5′-AAACUGGCUUUUUAAAACUUCUUac-3′ (SEQ ID NO: 616)3′-GGUUUGACCGAAAAAUUUUGAAGAAUG-5′ (SEQ ID NO: 1725) βc-2653 Target:5′-CCAAACTGGCTTTTTAAAACTTCTTAC-3′ (SEQ ID NO: 2834)5′-ACCCAAACUGGCUUUUUAAAACUtc-3′ (SEQ ID NO: 617)3′-AAUGGGUUUGACCGAAAAAUUUUGAAG-5′ (SEQ ID NO: 1726) βc-2657 Target:5′-TTACCCAAACTGGCTTTTTAAAACTTC-3′ (SEQ ID NO: 2835)5′-UACCCAAACUGGCUUUUUAAAACtt-3′ (SEQ ID NO: 618)3′-AAAUGGGUUUGACCGAAAAAUUUUGAA-5′ (SEQ ID NO: 1727) βc-2658 Target:5′-TTTACCCAAACTGGCTTTTTAAAACTT-3′ (SEQ ID NO: 2836)5′-UUACCCAAACUGGCUUUUUAAAAct-3′ (SEQ ID NO: 619)3′-AAAAUGGGUUUGACCGAAAAAUUUUGA-5′ (SEQ ID NO: 1728) βc-2659 Target:5′-TTTTACCCAAACTGGCTTTTTAAAACT-3′ (SEQ ID NO: 2837)5′-UUUACCCAAACUGGCUUUUUAAAac-3′ (SEQ ID NO: 620)3′-UAAAAUGGGUUUGACCGAAAAAUUUUG-5′ (SEQ ID NO: 1729) βc-2660 Target:5′-ATTTTACCCAAACTGGCTTTTTAAAAC-3′ (SEQ ID NO: 2838)5′-AACCAAGUCUUUCUGAAGUUCUGta-3′ (SEQ ID NO: 621)3′-GGUUGGUUCAGAAAGACUUCAAGACAU-5′ (SEQ ID NO: 1730) βc-2701 Target:5′-CCAACCAAGTCTTTCTGAAGTTCTGTA-3′ (SEQ ID NO: 2839)5′-ACCCUACCAACCAAGUCUUUCUGaa-3′ (SEQ ID NO: 622)3′-GGUGGGAUGGUUGGUUCAGAAAGACUU-5′ (SEQ ID NO: 1731) βc-2709 Target:5′-CCACCCTACCAACCAAGTCTTTCTGAA-3′ (SEQ ID NO: 2840)5′-UUACAAAUAGCCUAAACCACUCCca-3′ (SEQ ID NO: 623)3′-UAAAUGUUUAUCGGAUUUGGUGAGGGU-5′ (SEQ ID NO: 1732) βc-2733 Target:5′-ATTTACAAATAGCCTAAACCACTCCCA-3′ (SEQ ID NO: 2841)5′-UUUACAAAUAGCCUAAACCACUCcc-3′ (SEQ ID NO: 624)3′-CUAAAUGUUUAUCGGAUUUGGUGAGGG-5′ (SEQ ID NO: 1733) βc-2734 Target:5′-GATTTACAAATAGCCTAAACCACTCCC-3′ (SEQ ID NO: 2842)5′-AUUUACAAAUAGCCUAAACCACUcc-3′ (SEQ ID NO: 625)3′-UCUAAAUGUUUAUCGGAUUUGGUGAGG-5′ (SEQ ID NO: 1734) βc-2735 Target:5′-AGATTTACAAATAGCCTAAACCACTCC-3′ (SEQ ID NO: 2843)5′-GAUUUACAAAUAGCCUAAACCACtc-3′ (SEQ ID NO: 626)3′-GUCUAAAUGUUUAUCGGAUUUGGUGAG-5′ (SEQ ID NO: 1735) βc-2736 Target:5′-CAGATTTACAAATAGCCTAAACCACTC-3′ (SEQ ID NO: 2844)5′-UUUUUGUGGCAGAUUUACAAAUAgc-3′ (SEQ ID NO: 627)3′-ACAAAAACACCGUCUAAAUGUUUAUCG-5′ (SEQ ID NO: 1736) βc-2747 Target:5′-TGTTTTTGTGGCAGATTTACAAATAGC-3′ (SEQ ID NO: 2845)5′-GUUUUUGUGGCAGAUUUACAAAUag-3′ (SEQ ID NO: 628)3′-GACAAAAACACCGUCUAAAUGUUUAUC-5′ (SEQ ID NO: 1737) βc-2748 Target:5′-CTGTTTTTGTGGCAGATTTACAAATAG-3′ (SEQ ID NO: 2846)5′-UGUUUUUGUGGCAGAUUUACAAAta-3′ (SEQ ID NO: 629)3′-GGACAAAAACACCGUCUAAAUGUUUAU-5′ (SEQ ID NO: 1738) βc-2749 Target:5′-CCTGTTTTTGTGGCAGATTTACAAATA-3′ (SEQ ID NO: 2847)5′-AUACCUGUUUUUGUGGCAGAUUUac-3′ (SEQ ID NO: 630)3′-UAUAUGGACAAAAACACCGUCUAAAUG-5′ (SEQ ID NO: 1739) βc-2754 Target:5′-ATATACCTGTTTTTGTGGCAGATTTAC-3′ (SEQ ID NO: 2848)5′-UUCAAAGUAUAUACCUGUUUUUGtg-3′ (SEQ ID NO: 631)3′-GAAAGUUUCAUAUAUGGACAAAAACAC-5′ (SEQ ID NO: 1740) βc-2764 Target:5′-CTTTCAAAGTATATACCTGTTTTTGTG-3′ (SEQ ID NO: 2849)5′-UCUCCUUUCAAAGUAUAUACCUGtt-3′ (SEQ ID NO: 632)3′-GUAGAGGAAAGUUUCAUAUAUGGACAA-5′ (SEQ ID NO: 1741) βc-2770 Target:5′-CATCTCCTTTCAAAGTATATACCTGTT-3′ (SEQ ID NO: 2850)5′-AUCUCCUUUCAAAGUAUAUACCUgt-3′ (SEQ ID NO: 633)3′-UGUAGAGGAAAGUUUCAUAUAUGGACA-5′ (SEQ ID NO: 1742) βc-2771 Target:5′-ACATCTCCTTTCAAAGTATATACCTGT-3′ (SEQ ID NO: 2851)5′-ACAUCUCCUUUCAAAGUAUAUACct-3′ (SEQ ID NO: 634)3′-UCUGUAGAGGAAAGUUUCAUAUAUGGA-5′ (SEQ ID NO: 1743) βc-2773 Target:5′-AGACATCTCCTTTCAAAGTATATACCT-3′ (SEQ ID NO: 2852)5′-GACAUCUCCUUUCAAAGUAUAUAcc-3′ (SEQ ID NO: 635)3′-UUCUGUAGAGGAAAGUUUCAUAUAUGG-5′ (SEQ ID NO: 1744) βc-2774 Target:5′-AAGACATCTCCTTTCAAAGTATATACC-3′ (SEQ ID NO: 2853)5′-AGACAUCUCCUUUCAAAGUAUAUac-3′ (SEQ ID NO: 636)3′-GUUCUGUAGAGGAAAGUUUCAUAUAUG-5′ (SEQ ID NO: 1745) βc-2775 Target:5′-CAAGACATCTCCTTTCAAAGTATATAC-3′ (SEQ ID NO: 2854)5′-UUCCAAGACAUCUCCUUUCAAAGta-3′ (SEQ ID NO: 637)3′-ACAAGGUUCUGUAGAGGAAAGUUUCAU-5′ (SEQ ID NO: 1746) βc-2780 Target:5′-TGTTCCAAGACATCTCCTTTCAAAGTA-3′ (SEQ ID NO: 2855)5′-UUCCAAUGUUCCAAGACAUCUCCtt-3′ (SEQ ID NO: 638)3′-GUAAGGUUACAAGGUUCUGUAGAGGAA-5′ (SEQ ID NO: 1747) βc-2788 Target:5′-CATTCCAATGTTCCAAGACATCTCCTT-3′ (SEQ ID NO: 2856)5′-AUUCCAAUGUUCCAAGACAUCUCct-3′ (SEQ ID NO: 639)3′-UGUAAGGUUACAAGGUUCUGUAGAGGA-5′ (SEQ ID NO: 1748) βc-2789 Target:5′-ACATTCCAATGTTCCAAGACATCTCCT-3′ (SEQ ID NO: 2857)5′-ACAUUCCAAUGUUCCAAGACAUCtc-3′ (SEQ ID NO: 640)3′-CUUGUAAGGUUACAAGGUUCUGUAGAG-5′ (SEQ ID NO: 1749) βc-2791 Target:5′-GAACATTCCAATGTTCCAAGACATCTC-3′ (SEQ ID NO: 2858)5′-AGAAAUCUGAGAACAUUCCAAUGtt-3′ (SEQ ID NO: 641)3′-GGUCUUUAGACUCUUGUAAGGUUACAA-5′ (SEQ ID NO: 1750) βc-2803 Target:5′-CCAGAAATCTGAGAACATTCCAATGTT-3′ (SEQ ID NO: 2859)5′-AACCAGAAAUCUGAGAACAUUCCaa-3′ (SEQ ID NO: 642)3′-UGUUGGUCUUUAGACUCUUGUAAGGUU-5′ (SEQ ID NO: 1751) βc-2807 Target:5′-ACAACCAGAAATCTGAGAACATTCCAA-3′ (SEQ ID NO: 2860)5′-ACAACCAGAAAUCUGAGAACAUUcc-3′ (SEQ ID NO: 643)3′-AUUGUUGGUCUUUAGACUCUUGUAAGG-5′ (SEQ ID NO: 1752) βc-2809 Target:5′-TAACAACCAGAAATCTGAGAACATTCC-3′ (SEQ ID NO: 2861)5′-AACAACCAGAAAUCUGAGAACAUtc-3′ (SEQ ID NO: 644)3′-UAUUGUUGGUCUUUAGACUCUUGUAAG-5′ (SEQ ID NO: 1753) βc-2810 Target:5′-ATAACAACCAGAAATCTGAGAACATTC-3′ (SEQ ID NO: 2862)5′-UAACAACCAGAAAUCUGAGAACAtt-3′ (SEQ ID NO: 645)3′-GUAUUGUUGGUCUUUAGACUCUUGUAA-5′ (SEQ ID NO: 1754) βc-2811 Target:5′-CATAACAACCAGAAATCTGAGAACATT-3′ (SEQ ID NO: 2863)5′-AUCACAUAACAACCAGAAAUCUGag-3′ (SEQ ID NO: 646)3′-ACUAGUGUAUUGUUGGUCUUUAGACUC-5′ (SEQ ID NO: 1755) βc-2817 Target:5′-TGATCACATAACAACCAGAAATCTGAG-3′ (SEQ ID NO: 2864)5′-GAUCACAUAACAACCAGAAAUCUga-3′ (SEQ ID NO: 647)3′-UACUAGUGUAUUGUUGGUCUUUAGACU-5′ (SEQ ID NO: 1756) βc-2818 Target:5′-ATGATCACATAACAACCAGAAATCTGA-3′ (SEQ ID NO: 2865)5′-ACACAUGAUCACAUAACAACCAGaa-3′ (SEQ ID NO: 648)3′-GGUGUGUACUAGUGUAUUGUUGGUCUU-5′ (SEQ ID NO: 1757) βc-2824 Target:5′-CCACACATGATCACATAACAACCAGAA-3′ (SEQ ID NO: 2866)5′-UCCACACAUGAUCACAUAACAACca-3′ (SEQ ID NO: 649)3′-GAAGGUGUGUACUAGUGUAUUGUUGGU-5′ (SEQ ID NO: 1758) βc-2827 Target:5′-CTTCCACACATGATCACATAACAACCA-3′ (SEQ ID NO: 2867)5′-UAACUUCCACACAUGAUCACAUAac-3′ (SEQ ID NO: 650)3′-UUAUUGAAGGUGUGUACUAGUGUAUUG-5′ (SEQ ID NO: 1759) βc-2832 Target:5′-AATAACTTCCACACATGATCACATAAC-3′ (SEQ ID NO: 2868)5′-AUAACUUCCACACAUGAUCACAUaa-3′ (SEQ ID NO: 651)3′-AUUAUUGAAGGUGUGUACUAGUGUAUU-5′ (SEQ ID NO: 1760) βc-2833 Target:5′-TAATAACTTCCACACATGATCACATAA-3′ (SEQ ID NO: 2869)5′-AAUAACUUCCACACAUGAUCACAta-3′ (SEQ ID NO: 652)3′-AAUUAUUGAAGGUGUGUACUAGUGUAU-5′ (SEQ ID NO: 1761) βc-2834 Target:5′-TTAATAACTTCCACACATGATCACATA-3′ (SEQ ID NO: 2870)5′-UAAUAACUUCCACACAUGAUCACat-3′ (SEQ ID NO: 653)3′-CAAUUAUUGAAGGUGUGUACUAGUGUA-5′ (SEQ ID NO: 1762) βc-2835 Target:5′-GTTAATAACTTCCACACATGATCAC-3′ (SEQ ID NO: 2871)5′-UUAAAGUUAAUAACUUCCACACAtg-3′ (SEQ ID NO: 654)3′-GUAAUUUCAAUUAUUGAAGGUGUGUAC-5′ (SEQ ID NO: 1763) βc-2842 Target:5′-CATTAAAGTTAATAACTTCCACACATG-3′ (SEQ ID NO: 2872)5′-AUUAAAGUUAAUAACUUCCACACat-3′ (SEQ ID NO: 655)3′-UGUAAUUUCAAUUAUUGAAGGUGUGUA-5′ (SEQ ID NO: 1764) βc-2843 Target:5′-ACATTAAAGTTAATAACTTCCACAC-3′ (SEQ ID NO: 2873)5′-ACAUUAAAGUUAAUAACUUCCACac-3′ (SEQ ID NO: 656)3′-UUUGUAAUUUCAAUUAUUGAAGGUGUG-5′ (SEQ ID NO: 1765) βc-2845 Target:5′-AAACATTAAAGTTAATAACTTCCACAC-3′ (SEQ ID NO: 2874)5′-AACAUUAAAGUUAAUAACUUCCAca-3′ (SEQ ID NO: 657)3′-UUUUGUAAUUUCAAUUAUUGAAGGUGU-5′ (SEQ ID NO: 1766) βc-2846 Target:5′-AAAACATTAAAGTTAATAACTTCCACA-3′ (SEQ ID NO: 2875)5′-AAACAUUAAAGUUAAUAACUUCCac-3′ (SEQ ID NO: 658)3′-UUUUUGUAAUUUCAAUUAUUGAAGGUG-5′ (SEQ ID NO: 1767) βc-2847 Target:5′-AAAAACATTAAAGTTAATAACTTCCAC-3′ (SEQ ID NO: 2876)5′-AAAACAUUAAAGUUAAUAACUUCca-3′ (SEQ ID NO: 659)3′-UUUUUUGUAAUUUCAAUUAUUGAAGGU-5′ (SEQ ID NO: 1768) βc-2848 Target:5′-AAAAAACATTAAAGTTAATAACTTCCA-3′ (SEQ ID NO: 2877)5′-AAAAACAUUAAAGUUAAUAACUUcc-3′ (SEQ ID NO: 660)3′-GUUUUUUGUAAUUUCAAUUAUUGAAGG-5′ (SEQ ID NO: 1769) βc-2849 Target:5′-CAAAAAACATTAAAGTTAATAACTTCC-3′ (SEQ ID NO: 2878)5′-AAAAAACAUUAAAGUUAAUAACUtc-3′ (SEQ ID NO: 661)3′-CGUUUUUUGUAAUUUCAAUUAUUGAAG-5′ (SEQ ID NO: 1770) βc-2850 Target:5′-GCAAAAAACATTAAAGTTAATAACTTC-3′ (SEQ ID NO: 2879)5′-GCAAAAAACAUUAAAGUUAAUAAct-3′ (SEQ ID NO: 662)3′-ACCGUUUUUUGUAAUUUCAAUUAUUGA-5′ (SEQ ID NO: 1771) βc-2852 Target:5′-TGGCAAAAAACATTAAAGTTAATAACT-3′ (SEQ ID NO: 2880)5′-GGCAAAAAACAUUAAAGUUAAUAac-3′ (SEQ ID NO: 663)3′-CACCGUUUUUUGUAAUUUCAAUUAUUG-5′ (SEQ ID NO: 1772) βc-2853 Target:5′-GTGGCAAAAAACATTAAAGTTAATAAC-3′ (SEQ ID NO: 2881)5′-GCAAAAGCUGUGGCAAAAAACAUta-3′ (SEQ ID NO: 664)3′-AACGUUUUCGACACCGUUUUUUGUAAU-5′ (SEQ ID NO: 1773) βc-2864 Target:5′-TTGCAAAAGCTGTGGCAAAAAACATTA-3′ (SEQ ID NO: 2882)5′-UGCAAAAGCUGUGGCAAAAAACAtt-3′ (SEQ ID NO: 665)3′-CAACGUUUUCGACACCGUUUUUUGUAA-5′ (SEQ ID NO: 1774) βc-2865 Target:5′-GTTGCAAAAGCTGTGGCAAAAAACATT-3′ (SEQ ID NO: 2883)5′-UCAUUUGAGUAUUAAGUUGCAAAag-3′ (SEQ ID NO: 666)3′-UGAGUAAACUCAUAAUUCAACGUUUUC-5′ (SEQ ID NO: 1775) βc-2882 Target:5′-ACTCATTTGAGTATTAAGTTGCAAAAG-3′ (SEQ ID NO: 2884)5′-AAAACAGCAAAUGUUACUCAUUUga-3′ (SEQ ID NO: 667)3′-AAUUUUGUCGUUUACAAUGAGUAAACU-5′ (SEQ ID NO: 1776) βc-2899 Target:5′-TTAAAACAGCAAATGTTACTCATTTGA-3′ (SEQ ID NO: 2885)5′-UAAAACAGCAAAUGUUACUCAUUtg-3′ (SEQ ID NO: 668)3′-AAAUUUUGUCGUUUACAAUGAGUAAAC-5′ (SEQ ID NO: 1777) βc-2900 Target:5′-TTTAAAACAGCAAATGTTACTCATTTG-3′ (SEQ ID NO: 2886)5′-UUAAAACAGCAAAUGUUACUCAUtt-3′ (SEQ ID NO: 669)3′-CAAAUUUUGUCGUUUACAAUGAGUAAA-5′ (SEQ ID NO: 1778) βc-2901 Target:5′-GTTTAAAACAGCAAATGTTACTCATTT-3′ (SEQ ID NO: 2887)5′-UUUAAAACAGCAAAUGUUACUCAtt-3′ (SEQ ID NO: 670)3′-ACAAAUUUUGUCGUUUACAAUGAGUAA-5′ (SEQ ID NO: 1779) βc-2902 Target:5′-TGTTTAAAACAGCAAATGTTACTCATT-3′ (SEQ ID NO: 2888)5′-GUUUAAAACAGCAAAUGUUACUCat-3′ (SEQ ID NO: 671)3′-UACAAAUUUUGUCGUUUACAAUGAGUA-5′ (SEQ ID NO: 1780) βc-2903 Target:5′-ATGTTTAAAACAGCAAATGTTACTC-3′ (SEQ ID NO: 2889)5′-UGUUUAAAACAGCAAAUGUUACUca-3′ (SEQ ID NO: 672)3′-UUACAAAUUUUGUCGUUUACAAUGAGU-5′ (SEQ ID NO: 1781) βc-2904 Target:5′-AATGTTTAAAACAGCAAATGTTACTCA-3′ (SEQ ID NO: 2890)5′-AUUAAUGUUUAAAACAGCAAAUGtt-3′ (SEQ ID NO: 673)3′-GAUAAUUACAAAUUUUGUCGUUUACAA-5′ (SEQ ID NO: 1782) βc-2909 Target:5′-CTATTAATGTTTAAAACAGCAAATGTT-3′ (SEQ ID NO: 2891)5′-AGAAAGGCUGCUAUUAAUGUUUAaa-3′ (SEQ ID NO: 674)3′-UCUCUUUCCGACGAUAAUUACAAAUUU-5′ (SEQ ID NO: 1783) βc-2921 Target:5′-AGAGAAAGGCTGCTATTAATGTTTAAA-3′ (SEQ ID NO: 2892)5′-AGUUCAGACAAUACAGCUGUAUAaa-3′ (SEQ ID NO: 675)3′-GUUCAAGUCUGUUAUGUCGACAUAUUU-5′ (SEQ ID NO: 1784) βc-2949 Target:5′-CAAGTTCAGACAATACAGCTGTATAAA-3′ (SEQ ID NO: 2893)5′-ACAAUGCAAGUUCAGACAAUACAgc-3′ (SEQ ID NO: 676)3′-AGUGUUACGUUCAAGUCUGUUAUGUCG-5′ (SEQ ID NO: 1785) βc-2957 Target:5′-TCACAATGCAAGTTCAGACAATACAGC-3′ (SEQ ID NO: 2894)5′-UCACAAUGCAAGUUCAGACAAUAca-3′ (SEQ ID NO: 677)3′-UUAGUGUUACGUUCAAGUCUGUUAUGU-5′ (SEQ ID NO: 1786) βc-2959 Target:5′-AATCACAATGCAAGTTCAGACAATACA-3′ (SEQ ID NO: 2895)5′-AAUCACAAUGCAAGUUCAGACAAta-3′ (SEQ ID NO: 678)3′-GGUUAGUGUUACGUUCAAGUCUGUUAU-5′ (SEQ ID NO: 1787) βc-2961 Target:5′-CCAATCACAATGCAAGTTCAGACAATA-3′ (SEQ ID NO: 2896)5′-GGCCAAUCACAAUGCAAGUUCAGac-3′ (SEQ ID NO: 679)3′-GUCCGGUUAGUGUUACGUUCAAGUCUG-5′ (SEQ ID NO: 1788) βc-2965 Target:5′-CAGGCCAATCACAATGCAAGTTCAGAC-3′ (SEQ ID NO: 2897)5′-GUUCCCAUAGGAAACUCAGCUUGgt-3′ (SEQ ID NO: 680)3′-AACAAGGGUAUCCUUUGAGUCGAACCA-5′ (SEQ ID NO: 1789) βc-3052 Target:5′-TTGTTCCCATAGGAAACTCAGCTTGGT-3′ (SEQ ID NO: 2898)5′-UCAAUUGUUCCCAUAGGAAACUCag-3′ (SEQ ID NO: 681)3′-GAAGUUAACAAGGGUAUCCUUUGAGUC-5′ (SEQ ID NO: 1790) βc-3058 Target:5′-CTTCAATTGTTCCCATAGGAAACTCAG-3′ (SEQ ID NO: 2899)5′-UUCAAUUGUUCCCAUAGGAAACUca-3′ (SEQ ID NO: 682)3′-UGAAGUUAACAAGGGUAUCCUUUGAGU-5′ (SEQ ID NO: 1791) βc-3059 Target:5′-ACTTCAATTGTTCCCATAGGAAACTCA-3′ (SEQ ID NO: 2900)5′-GUUUACUUCAAUUGUUCCCAUAGga-3′ (SEQ ID NO: 683)3′-UUCAAAUGAAGUUAACAAGGGUAUCCU-5′ (SEQ ID NO: 1792) βc-3065 Target:5′-AAGTTTACTTCAATTGTTCCCATAGGA-3′ (SEQ ID NO: 2901)5′-AGUUUACUUCAAUUGUUCCCAUAgg-3′ (SEQ ID NO: 684)3′-UUUCAAAUGAAGUUAACAAGGGUAUCC-5′ (SEQ ID NO: 1793) βc-3066 Target:5′-AAAGTTTACTTCAATTGTTCCCATAGG-3′ (SEQ ID NO: 2902)5′-AAAAAGUUUACUUCAAUUGUUCCca-3′ (SEQ ID NO: 685)3′-UGUUUUUCAAAUGAAGUUAACAAGGGU-5′ (SEQ ID NO: 1794) βc-3070 Target:5′-ACAAAAAGTTTACTTCAATTGTTCCCA-3′ (SEQ ID NO: 2903)5′-GAACAAAAAGUUUACUUCAAUUGtt-3′ (SEQ ID NO: 686)3′-GUCUUGUUUUUCAAAUGAAGUUAACAA-5′ (SEQ ID NO: 1795) βc-3074 Target:5′-CAGAACAAAAAGTTTACTTCAATTGTT-3′ (SEQ ID NO: 2904)5′-GACCAGAACAAAAAGUUUACUUCaa-3′ (SEQ ID NO: 687)3′-UCCUGGUCUUGUUUUUCAAAUGAAGUU-5′ (SEQ ID NO: 1796) βc-3079 Target:5′-AGGACCAGAACAAAAAGTTTACTTCAA-3′ (SEQ ID NO: 2905)5′-GGACCAGAACAAAAAGUUUACUUca-3′ (SEQ ID NO: 688)3′-UUCCUGGUCUUGUUUUUCAAAUGAAGU-5′ (SEQ ID NO: 1797) βc-3080 Target:5′-AAGGACCAGAACAAAAAGTTTACTTCA-3′ (SEQ ID NO: 2906)5′-ACCAAAAAGGACCAGAACAAAAAgt-3′ (SEQ ID NO: 689)3′-GCUGGUUUUUCCUGGUCUUGUUUUUCA-5′ (SEQ ID NO: 1798) βc-3088 Target:5′-CGACCAAAAAGGACCAGAACAAAAAGT-3′ (SEQ ID NO: 2907)5′-GACCAAAAAGGACCAGAACAAAAag-3′ (SEQ ID NO: 690)3′-AGCUGGUUUUUCCUGGUCUUGUUUUUC-5′ (SEQ ID NO: 1799) βc-3089 Target:5′-TCGACCAAAAAGGACCAGAACAAAAAG-3′ (SEQ ID NO: 2908)5′-ACUCCUCGACCAAAAAGGACCAGaa-3′ (SEQ ID NO: 691)3′-AAUGAGGAGCUGGUUUUUCCUGGUCUU-5′ (SEQ ID NO: 1800) βc-3096 Target:5′-TTACTCCTCGACCAAAAAGGACCAGAA-3′ (SEQ ID NO: 2909)5′-UCCAUUUGUAUUGUUACUCCUCGac-3′ (SEQ ID NO: 692)3′-UUAGGUAAACAUAACAAUGAGGAGCUG-5′ (SEQ ID NO: 1801) βc-3111 Target:5′-AATCCATTTGTATTGTTACTCCTCGAC-3′ (SEQ ID NO: 2910)5′-AUCCAUUUGUAUUGUUACUCCUCga-3′ (SEQ ID NO: 693)3′-UUUAGGUAAACAUAACAAUGAGGAGCU-5′ (SEQ ID NO: 1802) βc-3112 Target:5′-AAATCCATTTGTATTGTTACTCCTCGA-3′ (SEQ ID NO: 2911)5′-AAUCCAUUUGUAUUGUUACUCCUcg-3′ (SEQ ID NO: 694)3′-UUUUAGGUAAACAUAACAAUGAGGAGC-5′ (SEQ ID NO: 1803) βc-3113 Target:5′-AAAATCCATTTGTATTGTTACTCCTCG-3′ (SEQ ID NO: 2912)5′-AAAUCCAUUUGUAUUGUUACUCCtc-3′ (SEQ ID NO: 695)3′-GUUUUAGGUAAACAUAACAAUGAGGAG-5′ (SEQ ID NO: 1804) βc-3114 Target:5′-CAAAATCCATTTGTATTGTTACTCCTC-3′ (SEQ ID NO: 2913)5′-AAAAUCCAUUUGUAUUGUUACUCct-3′ (SEQ ID NO: 696)3′-GGUUUUAGGUAAACAUAACAAUGAGGA-5′ (SEQ ID NO: 1805) βc-3115 Target:5′-CCAAAATCCATTTGTATTGTTACTCCT-3′ (SEQ ID NO: 2914)5′-ACUCCCAAAAUCCAUUUGUAUUGtt-3′ (SEQ ID NO: 697)3′-AGUGAGGGUUUUAGGUAAACAUAACAA-5′ (SEQ ID NO: 1806) βc-3121 Target:5′-TCACTCCCAAAATCCATTTGTATTGTT-3′ (SEQ ID NO: 2915)5′-UUCACUUCUUGAGUCACUCCCAAaa-3′ (SEQ ID NO: 698)3′-AGAAGUGAAGAACUCAGUGAGGGUUUU-5′ (SEQ ID NO: 1807) βc-3136 Target:5′-TCTTCACTTCTTGAGTCACTCCCAAAA-3′ (SEQ ID NO: 2916)5′-UCUUCACUUCUUGAGUCACUCCCaa-3′ (SEQ ID NO: 699)3′-UAAGAAGUGAAGAACUCAGUGAGGGUU-5′ (SEQ ID NO: 1808) βc-3138 Target:5′-ATTCTTCACTTCTTGAGTCACTCCCAA-3′ (SEQ ID NO: 2917)5′-UUCUUCACUUCUUGAGUCACUCCca-3′ (SEQ ID NO: 700)3′-GUAAGAAGUGAAGAACUCAGUGAGGGU-5′ (SEQ ID NO: 1809) βc-3139 Target:5′-CATTCTTCACTTCTTGAGTCACTCCCA-3′ (SEQ ID NO: 2918)5′-AUUCUUCACUUCUUGAGUCACUCcc-3′ (SEQ ID NO: 701)3′-CGUAAGAAGUGAAGAACUCAGUGAGGG-5′ (SEQ ID NO: 1810) βc-3140 Target:5′-GCATTCTTCACTTCTTGAGTCACTCCC-3′ (SEQ ID NO: 2919)5′-GCAUUCUUCACUUCUUGAGUCACtc-3′ (SEQ ID NO: 702)3′-CACGUAAGAAGUGAAGAACUCAGUGAG-5′ (SEQ ID NO: 1811) βc-3142 Target:5′-GTGCATTCTTCACTTCTTGAGTCACTC-3′ (SEQ ID NO: 2920)5′-AUUCUUGUGCAUUCUUCACUUCUtg-3′ (SEQ ID NO: 703)3′-GGUAAGAACACGUAAGAAGUGAAGAAC-5′ (SEQ ID NO: 1812) βc-3150 Target:5′-CCATTCTTGTGCATTCTTCACTTCTTG-3′ (SEQ ID NO: 2921)5′-UCCAUUCUUGUGCAUUCUUCACUtc-3′ (SEQ ID NO: 704)3′-CUAGGUAAGAACACGUAAGAAGUGAAG-5′ (SEQ ID NO: 1813) βc-3153 Target:5′-GATCCATTCTTGTGCATTCTTCACTTC-3′ (SEQ ID NO: 2922)5′-AUCCAUUCUUGUGCAUUCUUCACtt-3′ (SEQ ID NO: 705)3′-ACUAGGUAAGAACACGUAAGAAGUGAA-5′ (SEQ ID NO: 1814) βc-3154 Target:5′-TGATCCATTCTTGTGCATTCTTCACTT-3′ (SEQ ID NO: 2923)5′-GAUCCAUUCUUGUGCAUUCUUCAct-3′ (SEQ ID NO: 706)3′-CACUAGGUAAGAACACGUAAGAAGUGA-5′ (SEQ ID NO: 1815) βc-3155 Target:5′-GTGATCCATTCTTGTGCATTCTTCACT-3′ (SEQ ID NO: 2924)5′-AAUUCCAUCUUGUGAUCCAUUCUtg-3′ (SEQ ID NO: 707)3′-AUUUAAGGUAGAACACUAGGUAAGAAC-5′ (SEQ ID NO: 1816) βc-3168 Target:5′-TAAATTCCATCTTGTGATCCATTCTTG-3′ (SEQ ID NO: 2925)5′-UAAAUUCCAUCUUGUGAUCCAUUct-3′ (SEQ ID NO: 708)3′-CUAUUUAAGGUAGAACACUAGGUAAGA-5′ (SEQ ID NO: 1817) βc-3170 Target:5′-GATAAATTCCATCTTGTGATCCATTCT-3′ (SEQ ID NO: 2926)5′-AUAAAUUCCAUCUUGUGAUCCAUtc-3′ (SEQ ID NO: 709)3′-ACUAUUUAAGGUAGAACACUAGGUAAG-5′ (SEQ ID NO: 1818) βc-3171 Target:5′-TGATAAATTCCATCTTGTGATCCATTC-3′ (SEQ ID NO: 2927)5′-GAUAAAUUCCAUCUUGUGAUCCAtt-3′ (SEQ ID NO: 710)3′-AACUAUUUAAGGUAGAACACUAGGUAA-5′ (SEQ ID NO: 1819) βc-3172 Target:5′-TTGATAAATTCCATCTTGTGATCCATT-3′ (SEQ ID NO: 2928)5′-UGAUAAAUUCCAUCUUGUGAUCCat-3′ (SEQ ID NO: 711)3′-AAACUAUUUAAGGUAGAACACUAGGUA-5′ (SEQ ID NO: 1820) βc-3173 Target:5′-TTTGATAAATTCCATCTTGTGATCC-3′ (SEQ ID NO: 2929)5′-GGCUAGGGUUUGAUAAAUUCCAUct-3′ (SEQ ID NO: 712)3′-UUCCGAUCCCAAACUAUUUAAGGUAGA-5′ (SEQ ID NO: 1821) βc-3183 Target:5′-AAGGCTAGGGTTTGATAAATTCCATCT-3′ (SEQ ID NO: 2930)5′-AAAAAUUUAACAAGCAAGGCUAGgg-3′ (SEQ ID NO: 713)3′-UUUUUUUAAAUUGUUCGUUCCGAUCCC-5′ (SEQ ID NO: 1822) βc-3200 Target:5′-AAAAAAATTTAACAAGCAAGGCTAGGG-3′ (SEQ ID NO: 2931)5′-AAAAAAAAAAAAAAUUUAACAAGca-3′ (SEQ ID NO: 714)3′-UUUUUUUUUUUUUUUUAAAUUGUUCGU-5′ (SEQ ID NO: 1823) βc-3209 Target:5′-AAAAAAAAAAAAAAAATTTAACAAGCA-3′ (SEQ ID NO: 2932)5′-AAAAAAAAAAAAAAAUUUAACAAgc-3′ (SEQ ID NO: 715)3′-UUUUUUUUUUUUUUUUUAAAUUGUUCG-5′ (SEQ ID NO: 1824) βc-3210 Target:5′-AAAAAAAAAAAAAAAAATTTAACAAGC-3′ (SEQ ID NO: 2933)5′-AAAAAAAAAAAAAAAAUUUAACAag-3′ (SEQ ID NO: 716)3′-UUUUUUUUUUUUUUUUUUAAAUUGUUC-5′ (SEQ ID NO: 1825) βc-3211 Target:5′-AAAAAAAAAAAAAAAAAATTTAACAAG-3′ (SEQ ID NO: 2934)5′-AAAAAAAAAAAAAAAAAUUUAACaa-3′ (SEQ ID NO: 717)3′-UUUUUUUUUUUUUUUUUUUAAAUUGUU-5′ (SEQ ID NO: 1826) βc-3212 Target:5′-AAAAAAAAAAAAAAAAAAATTTAACAA-3′ (SEQ ID NO: 2935)5′-AAAAAAAAAAAAAAAAAAUUUAAca-3′ (SEQ ID NO: 718)3′-AUUUUUUUUUUUUUUUUUUUAAAUUGU-5′ (SEQ ID NO: 1827) βc-3213 Target:5′-TAAAAAAAAAAAAAAAAAAATTTAACA-3′ (SEQ ID NO: 2936)5′-AAAAAAAAAAAAAAAAAAAUUUAac-3′ (SEQ ID NO: 719)3′-AAUUUUUUUUUUUUUUUUUUUAAAUUG-5′ (SEQ ID NO: 1828) βc-3214 Target:5′-TTAAAAAAAAAAAAAAAAAAATTTAAC-3′ (SEQ ID NO: 2937)5′-UAAAAAAAAAAAAAAAAAAAUUUaa-3′ (SEQ ID NO: 720)3′-GAAUUUUUUUUUUUUUUUUUUUAAAUU-5′ (SEQ ID NO: 1829) βc-3215 Target:5′-CTTAAAAAAAAAAAAAAAAAAATTTAA-3′ (SEQ ID NO: 2938)5′-UUAAAAAAAAAAAAAAAAAAAUUta-3′ (SEQ ID NO: 721)3′-AGAAUUUUUUUUUUUUUUUUUUUAAAU-5′ (SEQ ID NO: 1830) βc-3216 Target:5′-TCTTAAAAAAAAAAAAAAAAAAATTTA-3′ (SEQ ID NO: 2939)5′-UCUUAAAAAAAAAAAAAAAAAAAtt-3′ (SEQ ID NO: 722)3′-UAAGAAUUUUUUUUUUUUUUUUUUUAA-5′ (SEQ ID NO: 1831) βc-3218 Target:5′-ATTCTTAAAAAAAAAAAAAAAAAAATT-3′ (SEQ ID NO: 2940)5′-UUCUUAAAAAAAAAAAAAAAAAAat-3′ (SEQ ID NO: 723)3′-AUAAGAAUUUUUUUUUUUUUUUUUUUA-5′ (SEQ ID NO: 1832) βc-3219 Target:5′-TATTCTTAAAAAAAAAAAAAAAAAAAT-3′ (SEQ ID NO: 2941)5′-AUUCUUAAAAAAAAAAAAAAAAAaa-3′ (SEQ ID NO: 724)3′-UAUAAGAAUUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1833) βc-3220 Target:5′-ATATTCTTAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2942)5′-UAUUCUUAAAAAAAAAAAAAAAAaa-3′ (SEQ ID NO: 725)3′-CUAUAAGAAUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1834) βc-3221 Target:5′-GATATTCTTAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2943)5′-AUAUUCUUAAAAAAAAAAAAAAAaa-3′ (SEQ ID NO: 726)3′-UCUAUAAGAAUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1835) βc-3222 Target:5′-AGATATTCTTAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2944)5′-GAUAUUCUUAAAAAAAAAAAAAAaa-3′ (SEQ ID NO: 727)3′-GUCUAUAAGAAUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1836) βc-3223 Target:5′-CAGATATTCTTAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2945)5′-AGAUAUUCUUAAAAAAAAAAAAAaa-3′ (SEQ ID NO: 728)3′-UGUCUAUAAGAAUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1837) βc-3224 Target:5′-ACAGATATTCTTAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2946)5′-UUACAGAUAUUCUUAAAAAAAAAaa-3′ (SEQ ID NO: 729)3′-GUAAUGUCUAUAAGAAUUUUUUUUUUU-5′ (SEQ ID NO: 1838) βc-3228 Target:5′-CATTACAGATATTCTTAAAAAAAAAAA-3′ (SEQ ID NO: 2947)5′-AUUACAGAUAUUCUUAAAAAAAAaa-3′ (SEQ ID NO: 730)3′-GGUAAUGUCUAUAAGAAUUUUUUUUUU-5′ (SEQ ID NO: 1839) βc-3229 Target:5′-CCATTACAGATATTCTTAAAAAAAAAA-3′ (SEQ ID NO: 2948)5′-UACCAUUACAGAUAUUCUUAAAAaa-3′ (SEQ ID NO: 731)3′-UCAUGGUAAUGUCUAUAAGAAUUUUUU-5′ (SEQ ID NO: 1840) βc-3233 Target:5′-AGTACCATTACAGATATTCTTAAAAAA-3′ (SEQ ID NO: 2949)5′-GUACCAUUACAGAUAUUCUUAAAaa-3′ (SEQ ID NO: 732)3′-GUCAUGGUAAUGUCUAUAAGAAUUUUU-5′ (SEQ ID NO: 1841) βc-3234 Target:5′-CAGTACCATTACAGATATTCTTAAAAA-3′ (SEQ ID NO: 2950)5′-AGUACCAUUACAGAUAUUCUUAAaa-3′ (SEQ ID NO: 733)3′-AGUCAUGGUAAUGUCUAUAAGAAUUUU-5′ (SEQ ID NO: 1842) βc-3235 Target:5′-TCAGTACCATTACAGATATTCTTAAAA-3′ (SEQ ID NO: 2951)5′-AGUCAGUACCAUUACAGAUAUUCtt-3′ (SEQ ID NO: 734)3′-UUUCAGUCAUGGUAAUGUCUAUAAGAA-5′ (SEQ ID NO: 1843) βc-3239 Target:5′-AAAGTCAGTACCATTACAGATATTCTT-3′ (SEQ ID NO: 2952)5′-UACUUCAAAGCAAGCAAAGUCAGta-3′ (SEQ ID NO: 735)3′-CGAUGAAGUUUCGUUCGUUUCAGUCAU-5′ (SEQ ID NO: 1844) βc-3256 Target:5′-GCTACTTCAAAGCAAGCAAAGTCAGTA-3′ (SEQ ID NO: 2953)5′-AAAAAGAGCUACUUCAAAGCAAGca-3′ (SEQ ID NO: 736)3′-UUUUUUUCUCGAUGAAGUUUCGUUCGU-5′ (SEQ ID NO: 1845) βc-3265 Target:5′-AAAAAAAGAGCTACTTCAAAGCAAGCA-3′ (SEQ ID NO: 2954)5′-AAAAAAAAAAGAGCUACUUCAAAgc-3′ (SEQ ID NO: 737)3′-UUUUUUUUUUUUCUCGAUGAAGUUUCG-5′ (SEQ ID NO: 1846) βc-3270 Target:5′-AAAAAAAAAAAAGAGCTACTTCAAAGC-3′ (SEQ ID NO: 2955)5′-AAAAAAAAAAAGAGCUACUUCAAag-3′ (SEQ ID NO: 738)3′-UUUUUUUUUUUUUCUCGAUGAAGUUUC-5′ (SEQ ID NO: 1847) βc-3271 Target:5′-AAAAAAAAAAAAAGAGCTACTTCAAAG-3′ (SEQ ID NO: 2956)5′-AAAAAAAAAAAAAGAGCUACUUCaa-3′ (SEQ ID NO: 739)3′-UUUUUUUUUUUUUUUCUCGAUGAAGUU-5′ (SEQ ID NO: 1848) βc-3273 Target:5′-AAAAAAAAAAAAAAAGAGCTACTTCAA-3′ (SEQ ID NO: 2957)5′-AAAAAAAAAAAAAAGAGCUACUUca-3′ (SEQ ID NO: 740)3′-UUUUUUUUUUUUUUUUCUCGAUGAAGU-5′ (SEQ ID NO: 1849) βc-3274 Target:5′-AAAAAAAAAAAAAAAAGAGCTACTTCA-3′ (SEQ ID NO: 2958)5′-AAAAAAAAAAAAAAAGAGCUACUtc-3′ (SEQ ID NO: 741)3′-UUUUUUUUUUUUUUUUUCUCGAUGAAG-5′ (SEQ ID NO: 1850) βc-3275 Target:5′-AAAAAAAAAAAAAAAAAGAGCTACTTC-3′ (SEQ ID NO: 2959)5′-AAAAAAAAAAAAAAAAGAGCUACtt-3′ (SEQ ID NO: 742)3′-UUUUUUUUUUUUUUUUUUCUCGAUGAA-5′ (SEQ ID NO: 1851) βc-3276 Target:5′-AAAAAAAAAAAAAAAAAAGAGCTACTT-3′ (SEQ ID NO: 2960)5′-AAAAAAAAAAAAAAAAAAAAAAGag-3′ (SEQ ID NO: 743)3′-UUUUUUUUUUUUUUUUUUUUUUUUCUC-5′ (SEQ ID NO: 1852) βc-3282 Target:5′-AAAAAAAAAAAAAAAAAAAAAAAAGAG-3′ (SEQ ID NO: 2961)5′-AAAAAAAAAAAAAAAAAAAAAAAga-3′ (SEQ ID NO: 744)3′-UUUUUUUUUUUUUUUUUUUUUUUUUCU-5′ (SEQ ID NO: 1853) βc-3283 Target:5′-AAAAAAAAAAAAAAAAAAAAAAAAAGA-3′ (SEQ ID NO: 2962)5′-AAAAAAAAAAAAAAAAAAAAAAAag-3′ (SEQ ID NO: 745)3′-GUUUUUUUUUUUUUUUUUUUUUUUUUC-5′ (SEQ ID NO: 1854) βc-3284 Target:5′-CAAAAAAAAAAAAAAAAAAAAAAAAAG-3′ (SEQ ID NO: 2963)5′-AAAAAAAAAAAAAAAAAAAAAAAaa-3′ (SEQ ID NO: 746)3′-CGUUUUUUUUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1855) βc-3285 Target:5′-GCAAAAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2964)5′-GCAAAAAAAAAAAAAAAAAAAAAaa-3′ (SEQ ID NO: 747)3′-GACGUUUUUUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1856) βc-3287 Target:5′-CTGCAAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2965)5′-UGCAAAAAAAAAAAAAAAAAAAAaa-3′ (SEQ ID NO: 748)3′-UGACGUUUUUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1857) βc-3288 Target:5′-ACTGCAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2966)5′-UUACUGCAAAAAAAAAAAAAAAAaa-3′ (SEQ ID NO: 749)3′-UCAAUGACGUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1858) βc-3292 Target:5′-AGTTACTGCAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2967)5′-GUUACUGCAAAAAAAAAAAAAAAaa-3′ (SEQ ID NO: 750)3′-GUCAAUGACGUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1859) βc-3293 Target:5′-CAGTTACTGCAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2968)5′-AGUUACUGCAAAAAAAAAAAAAAaa-3′ (SEQ ID NO: 751)3′-UGUCAAUGACGUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1860) βc-3294 Target:5′-ACAGTTACTGCAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2969)5′-AAACAGUUACUGCAAAAAAAAAAaa-3′ (SEQ ID NO: 752)3′-UUUUUGUCAAUGACGUUUUUUUUUUUU-5′ (SEQ ID NO: 1861) βc-3298 Target:5′-AAAAACAGTTACTGCAAAAAAAAAAAA-3′ (SEQ ID NO: 2970)5′-AAAACAGUUACUGCAAAAAAAAAaa-3′ (SEQ ID NO: 753)3′-UUUUUUGUCAAUGACGUUUUUUUUUUU-5′ (SEQ ID NO: 1862) βc-3299 Target:5′-AAAAAACAGTTACTGCAAAAAAAAAAA-3′ (SEQ ID NO: 2971)5′-AAAAACAGUUACUGCAAAAAAAAaa-3′ (SEQ ID NO: 754)3′-AUUUUUUGUCAAUGACGUUUUUUUUUU-5′ (SEQ ID NO: 1863) βc-3300 Target:5′-TAAAAAACAGTTACTGCAAAAAAAAAA-3′ (SEQ ID NO: 2972)5′-UAAAAAACAGUUACUGCAAAAAAaa-3′ (SEQ ID NO: 755)3′-GAAUUUUUUGUCAAUGACGUUUUUUUU-5′ (SEQ ID NO: 1864) βc-3302 Target:5′-CTTAAAAAACAGTTACTGCAAAAAAAA-3′ (SEQ ID NO: 2973)5′-UUAAAAAACAGUUACUGCAAAAAaa-3′ (SEQ ID NO: 756)3′-UGAAUUUUUUGUCAAUGACGUUUUUUU-5′ (SEQ ID NO: 1865) βc-3303 Target:5′-ACTTAAAAAACAGTTACTGCAAAAAAA-3′ (SEQ ID NO: 2974)5′-ACUUAAAAAACAGUUACUGCAAAaa-3′ (SEQ ID NO: 757)3′-UCUGAAUUUUUUGUCAAUGACGUUUUU-5′ (SEQ ID NO: 1866) βc-3305 Target:5′-AGACTTAAAAAACAGTTACTGCAAAAA-3′ (SEQ ID NO: 2975)5′-ACUACGAGAGACUUAAAAAACAGtt-3′ (SEQ ID NO: 758)3′-UGUGAUGCUCUCUGAAUUUUUUGUCAA-5′ (SEQ ID NO: 1867) βc-3315 Target:5′-ACACTACGAGAGACTTAAAAAACAGTT-3′ (SEQ ID NO: 2976)5′-ACACUACGAGAGACUUAAAAAACag-3′ (SEQ ID NO: 759)3′-AUUGUGAUGCUCUCUGAAUUUUUUGUC-5′ (SEQ ID NO: 1868) βc-3317 Target:5′-TAACACTACGAGAGACTTAAAAAACAG-3′ (SEQ ID NO: 2977)5′-AACACUACGAGAGACUUAAAAAAca-3′ (SEQ ID NO: 760)3′-AAUUGUGAUGCUCUCUGAAUUUUUUGU-5′ (SEQ ID NO: 1869) βc-3318 Target:5′-TTAACACTACGAGAGACTTAAAAAACA-3′ (SEQ ID NO: 2978)5′-UUAACACUACGAGAGACUUAAAAaa-3′ (SEQ ID NO: 761)3′-UGAAUUGUGAUGCUCUCUGAAUUUUUU-5′ (SEQ ID NO: 1870) βc-3320 Target:5′-ACTTAACACTACGAGAGACTTAAAAAA-3′ (SEQ ID NO: 2979)5′-AACUUAACACUACGAGAGACUUAaa-3′ (SEQ ID NO: 762)3′-UAUUGAAUUGUGAUGCUCUCUGAAUUU-5′ (SEQ ID NO: 1871) βc-3323 Target:5′-ATAACTTAACACTACGAGAGACTTAAA-3′ (SEQ ID NO: 2980)5′-UAACUUAACACUACGAGAGACUUaa-3′ (SEQ ID NO: 763)3′-AUAUUGAAUUGUGAUGCUCUCUGAAUU-5′ (SEQ ID NO: 1872) βc-3324 Target:5′-TATAACTTAACACTACGAGAGACTTAA-3′ (SEQ ID NO: 2981)5′-AUUCACUAUAACUUAACACUACGag-3′ (SEQ ID NO: 764)3′-CAUAAGUGAUAUUGAAUUGUGAUGCUC-5′ (SEQ ID NO: 1873) βc-3332 Target:5′-GTATTCACTATAACTTAACACTACGAG-3′ (SEQ ID NO: 2982)5′-UAUUCACUAUAACUUAACACUACga-3′ (SEQ ID NO: 765)3′-UCAUAAGUGAUAUUGAAUUGUGAUGCU-5′ (SEQ ID NO: 1874) βc-3333 Target:5′-AGTATTCACTATAACTTAACACTACGA-3′ (SEQ ID NO: 2983)5′-GUAUUCACUAUAACUUAACACUAcg-3′ (SEQ ID NO: 766)3′-GUCAUAAGUGAUAUUGAAUUGUGAUGC-5′ (SEQ ID NO: 1875) βc-3334 Target:5′-CAGTATTCACTATAACTTAACACTACG-3′ (SEQ ID NO: 2984)5′-AGUAUUCACUAUAACUUAACACUac-3′ (SEQ ID NO: 767)3′-CGUCAUAAGUGAUAUUGAAUUGUGAUG-5′ (SEQ ID NO: 1876) βc-3335 Target:5′-GCAGTATTCACTATAACTTAACACTAC-3′ (SEQ ID NO: 2985)5′-AAAUUGCUGUAGCAGUAUUCACUat-3′ (SEQ ID NO: 768)3′-UCUUUAACGACAUCGUCAUAAGUGAUA-5′ (SEQ ID NO: 1877) βc-3348 Target:5′-AGAAATTGCTGTAGCAGTATTCACTAT-3′ (SEQ ID NO: 2986)5′-GAAAUUGCUGUAGCAGUAUUCACta-3′ (SEQ ID NO: 769)3′-AUCUUUAACGACAUCGUCAUAAGUGAU-5′ (SEQ ID NO: 1878) βc-3349 Target:5′-TAGAAATTGCTGTAGCAGTATTCACTA-3′ (SEQ ID NO: 2987)5′-AGAAAUUGCUGUAGCAGUAUUCAct-3′ (SEQ ID NO: 770)3′-AAUCUUUAACGACAUCGUCAUAAGUGA-5′ (SEQ ID NO: 1879) βc-3350 Target:5′-TTAGAAATTGCTGTAGCAGTATTCACT-3′ (SEQ ID NO: 2988)5′-UCAAUUCUUAAAAAUUAGAAAUUgc-3′ (SEQ ID NO: 771)3′-UGAGUUAAGAAUUUUUAAUCUUUAACG-5′ (SEQ ID NO: 1880) βc-3366 Target:5′-ACTCAATTCTTAAAAATTAGAAATTGC-3′ (SEQ ID NO: 2989)5′-AUUACUCAAUUCUUAAAAAUUAGaa-3′ (SEQ ID NO: 772)3′-GGUAAUGAGUUAAGAAUUUUUAAUCUU-5′ (SEQ ID NO: 1881) βc-3371 Target:5′-CCATTACTCAATTCTTAAAAATTAGAA-3′ (SEQ ID NO: 2990)5′-ACCAUUACUCAAUUCUUAAAAAUta-3′ (SEQ ID NO: 773)3′-UGUGGUAAUGAGUUAAGAAUUUUUAAU-5′ (SEQ ID NO: 1882) βc-3374 Target:5′-ACACCATTACTCAATTCTTAAAAATTA-3′ (SEQ ID NO: 2991)5′-ACACCAUUACUCAAUUCUUAAAAat-3′ (SEQ ID NO: 774)3′-GAUGUGGUAAUGAGUUAAGAAUUUUUA-5′ (SEQ ID NO: 1883) βc-3376 Target:5′-CTACACCATTACTCAATTCTTAAAAAT-3′ (SEQ ID NO: 2992)5′-UACACCAUUACUCAAUUCUUAAAaa-3′ (SEQ ID NO: 775)3′-AGAUGUGGUAAUGAGUUAAGAAUUUUU-5′ (SEQ ID NO: 1884) βc-3377 Target:5′-TCTACACCATTACTCAATTCTTAAAAA-3′ (SEQ ID NO: 2993)5′-UCUACACCAUUACUCAAUUCUUAaa-3′ (SEQ ID NO: 776)3′-CAAGAUGUGGUAAUGAGUUAAGAAUUU-5′ (SEQ ID NO: 1885) βc-3379 Target:5′-GTTCTACACCATTACTCAATTCTTAAA-3′ (SEQ ID NO: 2994)5′-GUUCUACACCAUUACUCAAUUCUta-3′ (SEQ ID NO: 777)3′-CACAAGAUGUGGUAAUGAGUUAAGAAU-5′ (SEQ ID NO: 1886) βc-3381 Target:5′-GTGTTCTACACCATTACTCAATTCTTA-3′ (SEQ ID NO: 2995)5′-GAAUUAGUGUUCUACACCAUUACtc-3′ (SEQ ID NO: 778)3′-UACUUAAUCACAAGAUGUGGUAAUGAG-5′ (SEQ ID NO: 1887) βc-3389 Target:5′-ATGAATTAGTGTTCTACACCATTACTC-3′ (SEQ ID NO: 2996)5′-AUUAUGAAUUAGUGUUCUACACCat-3′ (SEQ ID NO: 779)3′-ACUAAUACUUAAUCACAAGAUGUGGUA-5′ (SEQ ID NO: 1888) βc-3394 Target:5′-TGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 2997)5′-GAUUAUGAAUUAGUGUUCUACACca-3′ (SEQ ID NO: 780)3′-CACUAAUACUUAAUCACAAGAUGUGGU-5′ (SEQ ID NO: 1889) βc-3395 Target:5′-GTGATTATGAATTAGTGTTCTACACCA-3′ (SEQ ID NO: 2998)5′-UGAUUAUGAAUUAGUGUUCUACAcc-3′ (SEQ ID NO: 781)3′-UCACUAAUACUUAAUCACAAGAUGUGG-5′ (SEQ ID NO: 1890) βc-3396 Target:5′-AGTGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 2999)5′-UAAUUAGAGUGAUUAUGAAUUAGtg-3′ (SEQ ID NO: 782)3′-UAAUUAAUCUCACUAAUACUUAAUCAC-5′ (SEQ ID NO: 1891) βc-3405 Target:5′-ATTAATTAGAGTGATTATGAATTAGTG-3′ (SEQ ID NO: 3000)5′-UUAAUUAGAGUGAUUAUGAAUUAgt-3′ (SEQ ID NO: 783)3′-UUAAUUAAUCUCACUAAUACUUAAUCA-5′ (SEQ ID NO: 1892) βc-3406 Target:5′-AATTAATTAGAGTGATTATGAATTAGT-3′ (SEQ ID NO: 3001)5′-AUUAAUUAGAGUGAUUAUGAAUUag-3′ (SEQ ID NO: 784)3′-GUUAAUUAAUCUCACUAAUACUUAAUC-5′ (SEQ ID NO: 1893) βc-3407 Target:5′-CAATTAATTAGAGTGATTATGAATTAG-3′ (SEQ ID NO: 3002)5′-UACAAUUAAUUAGAGUGAUUAUGaa-3′ (SEQ ID NO: 785)3′-UAAUGUUAAUUAAUCUCACUAAUACUU-5′ (SEQ ID NO: 1894) βc-3411 Target:5′-ATTACAATTAATTAGAGTGATTATGAA-3′ (SEQ ID NO: 3003)5′-UUACAAUUAAUUAGAGUGAUUAUga-3′ (SEQ ID NO: 786)3′-CUAAUGUUAAUUAAUCUCACUAAUACU-5′ (SEQ ID NO: 1895) βc-3412 Target:5′-GATTACAATTAATTAGAGTGATTATGA-3′ (SEQ ID NO: 3004)5′-AUUACAAUUAAUUAGAGUGAUUAtg-3′ (SEQ ID NO: 787)3′-UCUAAUGUUAAUUAAUCUCACUAAUAC-5′ (SEQ ID NO: 1896) βc-3413 Target:5′-AGATTACAATTAATTAGAGTGATTATG-3′ (SEQ ID NO: 3005)5′-UUAUUCAGAUUACAAUUAAUUAGag-3′ (SEQ ID NO: 788)3′-GAAAUAAGUCUAAUGUUAAUUAAUCUC-5′ (SEQ ID NO: 1897) βc-3421 Target:5′-CTTTATTCAGATTACAATTAATTAGAG-3′ (SEQ ID NO: 3006)5′-UUUAUUCAGAUUACAAUUAAUUAga-3′ (SEQ ID NO: 789)3′-UGAAAUAAGUCUAAUGUUAAUUAAUCU-5′ (SEQ ID NO: 1898) βc-3422 Target:5′-ACTTTATTCAGATTACAATTAATTAGA-3′ (SEQ ID NO: 3007)5′-ACACUUUAUUCAGAUUACAAUUAat-3′ (SEQ ID NO: 790)3′-AAUGUGAAAUAAGUCUAAUGUUAAUUA-5′ (SEQ ID NO: 1899) βc-3426 Target:5′-TTACACTTTATTCAGATTACAATTAAT-3′ (SEQ ID NO: 3008)5′-UACACUUUAUUCAGAUUACAAUUaa-3′ (SEQ ID NO: 791)3′-CAAUGUGAAAUAAGUCUAAUGUUAAUU-5′ (SEQ ID NO: 1900) βc-3427 Target:5′-GTTACACTTTATTCAGATTACAATTAA-3′ (SEQ ID NO: 3009)5′-UUACACUUUAUUCAGAUUACAAUta-3′ (SEQ ID NO: 792)3′-ACAAUGUGAAAUAAGUCUAAUGUUAAU-5′ (SEQ ID NO: 1901) βc-3428 Target:5′-TGTTACACTTTATTCAGATTACAATTA-3′ (SEQ ID NO: 3010)5′-GUUACACUUUAUUCAGAUUACAAtt-3′ (SEQ ID NO: 793)3′-AACAAUGUGAAAUAAGUCUAAUGUUAA-5′ (SEQ ID NO: 1902) βc-3429 Target:5′-TTGTTACACTTTATTCAGATTACAATT-3′ (SEQ ID NO: 3011)5′-UGUUACACUUUAUUCAGAUUACAat-3′ (SEQ ID NO: 794)3′-UAACAAUGUGAAAUAAGUCUAAUGUUA-5′ (SEQ ID NO: 1903) βc-3430 Target:5′-ATTGTTACACTTTATTCAGATTACAAT-3′ (SEQ ID NO: 3012)5′-ACACAAUUGUUACACUUUAUUCAga-3′ (SEQ ID NO: 795)3′-GAUGUGUUAACAAUGUGAAAUAAGUCU-5′ (SEQ ID NO: 1904) βc-3437 Target:5′-CTACACAATTGTTACACTTTATTCAGA-3′ (SEQ ID NO: 3013)5′-GGCUACACAAUUGUUACACUUUAtt-3′ (SEQ ID NO: 796)3′-UUCCGAUGUGUUAACAAUGUGAAAUAA-5′ (SEQ ID NO: 1905) βc-3441 Target:5′-AAGGCTACACAATTGTTACACTTTATT-3′ (SEQ ID NO: 3014)5′-AAAAAGGCUACACAAUUGUUACAct-3′ (SEQ ID NO: 797)3′-UGUUUUUCCGAUGUGUUAACAAUGUGA-5′ (SEQ ID NO: 1906) βc-3446 Target:5′-ACAAAAAGGCTACACAATTGTTACACT-3′ (SEQ ID NO: 3015)5′-UUAUACAAAAAGGCUACACAAUUgt-3′ (SEQ ID NO: 798)3′-AAAAUAUGUUUUUCCGAUGUGUUAACA-5′ (SEQ ID NO: 1907) βc-3452 Target:5′-TTTTATACAAAAAGGCTACACAATTGT-3′ (SEQ ID NO: 3016)5′-UUUAUACAAAAAGGCUACACAAUtg-3′ (SEQ ID NO: 799)3′-UAAAAUAUGUUUUUCCGAUGUGUUAAC-5′ (SEQ ID NO: 1908) βc-3453 Target:5′-ATTTTATACAAAAAGGCTACACAATTG-3′ (SEQ ID NO: 3017)5′-AUUUUAUACAAAAAGGCUACACAat-3′ (SEQ ID NO: 800)3′-GAUAAAAUAUGUUUUUCCGAUGUGUUA-5′ (SEQ ID NO: 1909) βc-3455 Target:5′-CTATTTTATACAAAAAGGCTACACAAT-3′ (SEQ ID NO: 3018)5′-UAUUUUAUACAAAAAGGCUACACaa-3′ (SEQ ID NO: 801)3′-AGAUAAAAUAUGUUUUUCCGAUGUGUU-5′ (SEQ ID NO: 1910) βc-3456 Target:5′-TCTATTTTATACAAAAAGGCTACACAA-3′ (SEQ ID NO: 3019)5′-UCUAUUUUAUACAAAAAGGCUACac-3′ (SEQ ID NO: 802)3′-ACAGAUAAAAUAUGUUUUUCCGAUGUG-5′ (SEQ ID NO: 1911) βc-3458 Target:5′-TGTCTATTTTATACAAAAAGGCTACAC-3′ (SEQ ID NO: 3020)5′-UAUUUGUCUAUUUUAUACAAAAAgg-3′ (SEQ ID NO: 803)3′-AGAUAAACAGAUAAAAUAUGUUUUUCC-5′ (SEQ ID NO: 1912) βc-3464 Target:5′-TCTATTTGTCTATTTTATACAAAAAGG-3′ (SEQ ID NO: 3021)5′-UCUAUUUGUCUAUUUUAUACAAAaa-3′ (SEQ ID NO: 804)3′-AAAGAUAAACAGAUAAAAUAUGUUUUU-5′ (SEQ ID NO: 1913) βc-3466 Target:5′-TTTCTATTTGTCTATTTTATACAAAAA-3′ (SEQ ID NO: 3022)5′-UUCUAUUUGUCUAUUUUAUACAAaa-3′ (SEQ ID NO: 805)3′-AAAAGAUAAACAGAUAAAAUAUGUUUU-5′ (SEQ ID NO: 1914) βc-3467 Target:5′-TTTTCTATTTGTCTATTTTATACAAAA-3′ (SEQ ID NO: 3023)5′-UUUCUAUUUGUCUAUUUUAUACAaa-3′ (SEQ ID NO: 806)3′-UAAAAGAUAAACAGAUAAAAUAUGUUU-5′ (SEQ ID NO: 1915) βc-3468 Target:5′-ATTTTCTATTTGTCTATTTTATACAAA-3′ (SEQ ID NO: 3024)5′-UUUUCUAUUUGUCUAUUUUAUACaa-3′ (SEQ ID NO: 807)3′-GUAAAAGAUAAACAGAUAAAAUAUGUU-5′ (SEQ ID NO: 1916) βc-3469 Target:5′-CATTTTCTATTTGTCTATTTTATACAA-3′ (SEQ ID NO: 3025)5′-AUUUUCUAUUUGUCUAUUUUAUAca-3′ (SEQ ID NO: 808)3′-GGUAAAAGAUAAACAGAUAAAAUAUGU-5′ (SEQ ID NO: 1917) βc-3470 Target:5′-CCATTTTCTATTTGTCTATTTTATACA-3′ (SEQ ID NO: 3026)5′-ACCAUUUUCUAUUUGUCUAUUUUat-3′ (SEQ ID NO: 809)3′-CCUGGUAAAAGAUAAACAGAUAAAAUA-5′ (SEQ ID NO: 1918) βc-3473 Target:5′-GGACCATTTTCTATTTGTCTATTTTAT-3′ (SEQ ID NO: 3027)5′-GACCAUUUUCUAUUUGUCUAUUUta-3′ (SEQ ID NO: 810)3′-ACCUGGUAAAAGAUAAACAGAUAAAAU-5′ (SEQ ID NO: 1919) βc-3474 Target:5′-TGGACCATTTTCTATTTGTCTATTTTA-3′ (SEQ ID NO: 3028)5′-GGACCAUUUUCUAUUUGUCUAUUtt-3′ (SEQ ID NO: 811)3′-AACCUGGUAAAAGAUAAACAGAUAAAA-5′ (SEQ ID NO: 1920) βc-3475 Target:5′-TTGGACCATTTTCTATTTGTCTATTTT-3′ (SEQ ID NO: 3029)5′-ACUAAUUGGACCAUUUUCUAUUUgt-3′ (SEQ ID NO: 812)3′-UUUGAUUAACCUGGUAAAAGAUAAACA-5′ (SEQ ID NO: 1921) βc-3482 Target:5′-AAACTAATTGGACCATTTTCTATTTGT-3′ (SEQ ID NO: 3030)5′-AACUAAUUGGACCAUUUUCUAUUtg-3′ (SEQ ID NO: 813)3′-CUUUGAUUAACCUGGUAAAAGAUAAAC-5′ (SEQ ID NO: 1922) βc-3483 Target:5′-GAAACTAATTGGACCATTTTCTATTTG-3′ (SEQ ID NO: 3031)5′-AAACUAAUUGGACCAUUUUCUAUtt-3′ (SEQ ID NO: 814)3′-CCUUUGAUUAACCUGGUAAAAGAUAAA-5′ (SEQ ID NO: 1923) βc-3484 Target:5′-GGAAACTAATTGGACCATTTTCTATTT-3′ (SEQ ID NO: 3032)5′-GAAACUAAUUGGACCAUUUUCUAtt-3′ (SEQ ID NO: 815)3′-UCCUUUGAUUAACCUGGUAAAAGAUAA-5′ (SEQ ID NO: 1924) βc-3485 Target:5′-AGGAAACTAATTGGACCATTTTCTATT-3′ (SEQ ID NO: 3033)5′-AAAAAGGAAACUAAUUGGACCAUtt-3′ (SEQ ID NO: 816)3′-AAUUUUUCCUUUGAUUAACCUGGUAAA-5′ (SEQ ID NO: 1925) βc-3491 Target:5′-TTAAAAAGGAAACTAATTGGACCATTT-3′ (SEQ ID NO: 3034)5′-UAAAAAGGAAACUAAUUGGACCAtt-3′ (SEQ ID NO: 817)3′-UAAUUUUUCCUUUGAUUAACCUGGUAA-5′ (SEQ ID NO: 1926) βc-3492 Target:5′-ATTAAAAAGGAAACTAATTGGACCATT-3′ (SEQ ID NO: 3035)5′-GCAUAUUAAAAAGGAAACUAAUUgg-3′ (SEQ ID NO: 818)3′-UUCGUAUAAUUUUUCCUUUGAUUAACC-5′ (SEQ ID NO: 1927) βc-3498 Target:5′-AAGCATATTAAAAAGGAAACTAATTGG-3′ (SEQ ID NO: 3036)5′-AGCAUAUUAAAAAGGAAACUAAUtg-3′ (SEQ ID NO: 819)3′-AUUCGUAUAAUUUUUCCUUUGAUUAAC-5′ (SEQ ID NO: 1928) βc-3499 Target:5′-TAAGCATATTAAAAAGGAAACTAATTG-3′ (SEQ ID NO: 3037)5′-UUUAAGCAUAUUAAAAAGGAAACta-3′ (SEQ ID NO: 820)3′-UAAAAUUCGUAUAAUUUUUCCUUUGAU-5′ (SEQ ID NO: 1929) βc-3503 Target:5′-ATTTTAAGCATATTAAAAAGGAAACTA-3′ (SEQ ID NO: 3038)5′-GCUUAUUUUAAGCAUAUUAAAAAgg-3′ (SEQ ID NO: 821)3′-GACGAAUAAAAUUCGUAUAAUUUUUCC-5′ (SEQ ID NO: 1930) βc-3509 Target:5′-CTGCTTATTTTAAGCATATTAAAAAGG-3′ (SEQ ID NO: 3039)5′-UGCUUAUUUUAAGCAUAUUAAAAag-3′ (SEQ ID NO: 822)3′-GGACGAAUAAAAUUCGUAUAAUUUUUC-5′ (SEQ ID NO: 1931) βc-3510 Target:5′-CCTGCTTATTTTAAGCATATTAAAAAG-3′ (SEQ ID NO: 3040)5′-UCCACCUGCUUAUUUUAAGCAUAtt-3′ (SEQ ID NO: 823)3′-CUAGGUGGACGAAUAAAAUUCGUAUAA-5′ (SEQ ID NO: 1932) βc-3516 Target:5′-GATCCACCTGCTTATTTTAAGCATATT-3′ (SEQ ID NO: 3041)5′-AAAACAUGAAAUAGAUCCACCUGct-3′ (SEQ ID NO: 824)3′-GUUUUUGUACUUUAUCUAGGUGGACGA-5′ (SEQ ID NO: 1933) βc-3531 Target:5′-CAAAAACATGAAATAGATCCACCTGCT-3′ (SEQ ID NO: 3042)5′-AAAAACAUGAAAUAGAUCCACCUgc-3′ (SEQ ID NO: 825)3′-AGUUUUUGUACUUUAUCUAGGUGGACG-5′ (SEQ ID NO: 1934) βc-3532 Target:5′-TCAAAAACATGAAATAGATCCACCTGC-3′ (SEQ ID NO: 3043)5′-UCAAAAACAUGAAAUAGAUCCACct-3′ (SEQ ID NO: 826)3′-CUAGUUUUUGUACUUUAUCUAGGUGGA-5′ (SEQ ID NO: 1935) βc-3534 Target:5′-GATCAAAAACATGAAATAGATCCACCT-3′ (SEQ ID NO: 3044)5′-AUCAAAAACAUGAAAUAGAUCCAcc-3′ (SEQ ID NO: 827)3′-ACUAGUUUUUGUACUUUAUCUAGGUGG-5′ (SEQ ID NO: 1936) βc-3535 Target:5′-TGATCAAAAACATGAAATAGATCCACC-3′ (SEQ ID NO: 3045)5′-GAUCAAAAACAUGAAAUAGAUCCac-3′ (SEQ ID NO: 828)3′-AACUAGUUUUUGUACUUUAUCUAGGUG-5′ (SEQ ID NO: 1937) βc-3536 Target:5′-TTGATCAAAAACATGAAATAGATCCAC-3′ (SEQ ID NO: 3046)5′-UUUUUGAUCAAAAACAUGAAAUAga-3′ (SEQ ID NO: 829)3′-UCAAAAACUAGUUUUUGUACUUUAUCU-5′ (SEQ ID NO: 1938) βc-3541 Target:5′-AGTTTTTGATCAAAAACATGAAATAGA-3′ (SEQ ID NO: 3047)5′-AAAUAGUUUUUGAUCAAAAACAUga-3′ (SEQ ID NO: 830)3′-GGUUUAUCAAAAACUAGUUUUUGUACU-5′ (SEQ ID NO: 1939) βc-3547 Target:5′-CCAAATAGTTTTTGATCAAAAACATGA-3′ (SEQ ID NO: 3048)5′-UCCCAAAUAGUUUUUGAUCAAAAac-3′ (SEQ ID NO: 831)3′-AUAGGGUUUAUCAAAAACUAGUUUUUG-5′ (SEQ ID NO: 1940) βc-3551 Target:5′-TATCCCAAATAGTTTTTGATCAAAAAC-3′ (SEQ ID NO: 3049)5′-AUCCCAAAUAGUUUUUGAUCAAAaa-3′ (SEQ ID NO: 832)3′-UAUAGGGUUUAUCAAAAACUAGUUUUU-5′ (SEQ ID NO: 1941) βc-3552 Target:5′-ATATCCCAAATAGTTTTTGATCAAAAA-3′ (SEQ ID NO: 3050)5′-UAUCCCAAAUAGUUUUUGAUCAAaa-3′ (SEQ ID NO: 833)3′-GUAUAGGGUUUAUCAAAAACUAGUUUU-5′ (SEQ ID NO: 1942) βc-3553 Target:5′-CATATCCCAAATAGTTTTTGATCAAAA-3′ (SEQ ID NO: 3051)5′-AUAUCCCAAAUAGUUUUUGAUCAaa-3′ (SEQ ID NO: 834)3′-UGUAUAGGGUUUAUCAAAAACUAGUUU-5′ (SEQ ID NO: 1943) βc-3554 Target:5′-ACATATCCCAAATAGTTTTTGATCAAA-3′ (SEQ ID NO: 3052)5′-AUACAUAUCCCAAAUAGUUUUUGat-3′ (SEQ ID NO: 835)3′-GGUAUGUAUAGGGUUUAUCAAAAACUA-5′ (SEQ ID NO: 1944) βc-3558 Target:5′-CCATACATATCCCAAATAGTTTTTGAT-3′ (SEQ ID NO: 3053)5′-ACCCUACCCAUACAUAUCCCAAAta-3′ (SEQ ID NO: 836)3′-AAUGGGAUGGGUAUGUAUAGGGUUUAU-5′ (SEQ ID NO: 1945) βc-3567 Target:5′-TTACCCTACCCATACATATCCCAAATA-3′ (SEQ ID NO: 3054)5′-UACCCUACCCAUACAUAUCCCAAat-3′ (SEQ ID NO: 837)3′-AAAUGGGAUGGGUAUGUAUAGGGUUUA-5′ (SEQ ID NO: 1946) βc-3568 Target:5′-TTTACCCTACCCATACATATCCCAAAT-3′ (SEQ ID NO: 3055)5′-UUACCCUACCCAUACAUAUCCCAaa-3′ (SEQ ID NO: 838)3′-UAAAUGGGAUGGGUAUGUAUAGGGUUU-5′ (SEQ ID NO: 1947) βc-3569 Target:5′-ATTTACCCTACCCATACATATCCCAAA-3′ (SEQ ID NO: 3056)5′-ACCUCUUACUGAUUUACCCUACCca-3′ (SEQ ID NO: 839)3′-UGUGGAGAAUGACUAAAUGGGAUGGGU-5′ (SEQ ID NO: 1948) βc-3582 Target:5′-ACACCTCTTACTGATTTACCCTACCCA-3′ (SEQ ID NO: 3057)5′-ACACCUCUUACUGAUUUACCCUAcc-3′ (SEQ ID NO: 840)3′-AUUGUGGAGAAUGACUAAAUGGGAUGG-5′ (SEQ ID NO: 1949) βc-3584 Target:5′-TAACACCTCTTACTGATTTACCCTACC-3′ (SEQ ID NO: 3058)5′-AACACCUCUUACUGAUUUACCCUac-3′ (SEQ ID NO: 841)3′-UAUUGUGGAGAAUGACUAAAUGGGAUG-5′ (SEQ ID NO: 1950) βc-3585 Target:5′-ATAACACCTCTTACTGATTTACCCTAC-3′ (SEQ ID NO: 3059)5′-UAACACCUCUUACUGAUUUACCCta-3′ (SEQ ID NO: 842)3′-UUAUUGUGGAGAAUGACUAAAUGGGAU-5′ (SEQ ID NO: 1951) βc-3586 Target:5′-AATAACACCTCTTACTGATTTACCCTA-3′ (SEQ ID NO: 3060)5′-AUAACACCUCUUACUGAUUUACCct-3′ (SEQ ID NO: 843)3′-UUUAUUGUGGAGAAUGACUAAAUGGGA-5′ (SEQ ID NO: 1952) βc-3587 Target:5′-AAATAACACCTCTTACTGATTTACCCT-3′ (SEQ ID NO: 3061)5′-AAUAACACCUCUUACUGAUUUACcc-3′ (SEQ ID NO: 844)3′-GUUUAUUGUGGAGAAUGACUAAAUGGG-5′ (SEQ ID NO: 1953) βc-3588 Target:5′-CAAATAACACCTCTTACTGATTTACCC-3′ (SEQ ID NO: 3062)5′-GUUCCAAAUAACACCUCUUACUGat-3′ (SEQ ID NO: 845)3′-UCCAAGGUUUAUUGUGGAGAAUGACUA-5′ (SEQ ID NO: 1954) βc-3594 Target:5′-AGGTTCCAAATAACACCTCTTACTGAT-3′ (SEQ ID NO: 3063)5′-AACAAGGUUCCAAAUAACACCUCtt-3′ (SEQ ID NO: 846)3′-UUUUGUUCCAAGGUUUAUUGUGGAGAA-5′ (SEQ ID NO: 1955) βc-3600 Target:5′-AAAACAAGGTTCCAAATAACACCTCTT-3′ (SEQ ID NO: 3064)5′-AAACAAGGUUCCAAAUAACACCUct-3′ (SEQ ID NO: 847)3′-GUUUUGUUCCAAGGUUUAUUGUGGAGA-5′ (SEQ ID NO: 1956) βc-3601 Target:5′-CAAAACAAGGTTCCAAATAACACCTCT-3′ (SEQ ID NO: 3065)5′-AAAACAAGGUUCCAAAUAACACCtc-3′ (SEQ ID NO: 848)3′-GGUUUUGUUCCAAGGUUUAUUGUGGAG-5′ (SEQ ID NO: 1957) βc-3602 Target:5′-CCAAAACAAGGTTCCAAATAACACCTC-3′ (SEQ ID NO: 3066)5′-UGUCCAAAACAAGGUUCCAAAUAac-3′ (SEQ ID NO: 849)3′-UGACAGGUUUUGUUCCAAGGUUUAUUG-5′ (SEQ ID NO: 1958) βc-3607 Target:5′-ACTGTCCAAAACAAGGTTCCAAATAAC-3′ (SEQ ID NO: 3067)5′-AAACUGUCCAAAACAAGGUUCCAaa-3′ (SEQ ID NO: 850)3′-CAUUUGACAGGUUUUGUUCCAAGGUUU-5′ (SEQ ID NO: 1959) βc-3611 Target:5′-GTAAACTGTCCAAAACAAGGTTCCAAA-3′ (SEQ ID NO: 3068)5′-UAAACUGUCCAAAACAAGGUUCCaa-3′ (SEQ ID NO: 851)3′-CCAUUUGACAGGUUUUGUUCCAAGGUU-5′ (SEQ ID NO: 1960) βc-3612 Target:5′-GGTAAACTGTCCAAAACAAGGTTCCAA-3′ (SEQ ID NO: 3069)5′-GCAACUGGUAAACUGUCCAAAACaa-3′ (SEQ ID NO: 852)3′-UCCGUUGACCAUUUGACAGGUUUUGUU-5′ (SEQ ID NO: 1961) βc-3620 Target:5′-AGGCAACTGGTAAACTGTCCAAAACAA-3′ (SEQ ID NO: 3070)5′-GAUAAAAGGCAACUGGUAAACUGtc-3′ (SEQ ID NO: 853)3′-CCCUAUUUUCCGUUGACCAUUUGACAG-5′ (SEQ ID NO: 1962) βc-3628 Target:5′-GGGATAAAAGGCAACTGGTAAACTGTC-3′ (SEQ ID NO: 3071)5′-GGAUAAAAGGCAACUGGUAAACUgt-3′ (SEQ ID NO: 854)3′-ACCCUAUUUUCCGUUGACCAUUUGACA-5′ (SEQ ID NO: 1963) βc-3629 Target:5′-TGGGATAAAAGGCAACTGGTAAACTGT-3′ (SEQ ID NO: 3072)5′-AACUUUGGGAUAAAAGGCAACUGgt-3′ (SEQ ID NO: 855)3′-UGUUGAAACCCUAUUUUCCGUUGACCA-5′ (SEQ ID NO: 1964) βc-3636 Target:5′-ACAACTTTGGGATAAAAGGCAACTGGT-3′ (SEQ ID NO: 3073)5′-ACAACUUUGGGAUAAAAGGCAACtg-3′ (SEQ ID NO: 856)3′-GUUGUUGAAACCCUAUUUUCCGUUGAC-5′ (SEQ ID NO: 1965) βc-3638 Target:5′-CAACAACTTTGGGATAAAAGGCAACTG-3′ (SEQ ID NO: 3074)5′-UUACAACAACUUUGGGAUAAAAGgc-3′ (SEQ ID NO: 857)3′-CCAAUGUUGUUGAAACCCUAUUUUCCG-5′ (SEQ ID NO: 1966) βc-3643 Target:5′-GGTTACAACAACTTTGGGATAAAAGGC-3′ (SEQ ID NO: 3075)5′-GUUACAACAACUUUGGGAUAAAAgg-3′ (SEQ ID NO: 858)3′-UCCAAUGUUGUUGAAACCCUAUUUUCC-5′ (SEQ ID NO: 1967) βc-3644 Target:5′-AGGTTACAACAACTTTGGGATAAAAGG-3′ (SEQ ID NO: 3076)5′-GGUUACAACAACUUUGGGAUAAAag-3′ (SEQ ID NO: 859)3′-GUCCAAUGUUGUUGAAACCCUAUUUUC-5′ (SEQ ID NO: 1968) βc-3645 Target:5′-CAGGTTACAACAACTTTGGGATAAAAG-3′ (SEQ ID NO: 3077)5′-UCACAGCAGGUUACAACAACUUUgg-3′ (SEQ ID NO: 860)3′-AUAGUGUCGUCCAAUGUUGUUGAAACC-5′ (SEQ ID NO: 1969) βc-3653 Target:5′-TATCACAGCAGGTTACAACAACTTTGG-3′ (SEQ ID NO: 3078)5′-AUCACAGCAGGUUACAACAACUUtg-3′ (SEQ ID NO: 861)3′-CAUAGUGUCGUCCAAUGUUGUUGAAAC-5′ (SEQ ID NO: 1970) βc-3654 Target:5′-GTATCACAGCAGGTTACAACAACTTTG-3′ (SEQ ID NO: 3079)5′-GUAUCACAGCAGGUUACAACAACtt-3′ (SEQ ID NO: 862)3′-AGCAUAGUGUCGUCCAAUGUUGUUGAA-5′ (SEQ ID NO: 1971) βc-3656 Target:5′-TCGTATCACAGCAGGTTACAACAACTT-3′ (SEQ ID NO: 3080)5′-UCUCUUGAAGCAUCGUAUCACAGca-3′ (SEQ ID NO: 863)3′-AAAGAGAACUUCGUAGCAUAGUGUCGU-5′ (SEQ ID NO: 1972) βc-3670 Target:5′-TTTCTCTTGAAGCATCGTATCACAGCA-3′ (SEQ ID NO: 3081)5′-UUCUCUUGAAGCAUCGUAUCACAgc-3′ (SEQ ID NO: 864)3′-AAAAGAGAACUUCGUAGCAUAGUGUCG-5′ (SEQ ID NO: 1973) βc-3671 Target:5′-TTTTCTCTTGAAGCATCGTATCACAGC-3′ (SEQ ID NO: 3082)5′-UUUUCUCUUGAAGCAUCGUAUCAca-3′ (SEQ ID NO: 865)3′-GUAAAAGAGAACUUCGUAGCAUAGUGU-5′ (SEQ ID NO: 1974) βc-3673 Target:5′-CATTTTCTCTTGAAGCATCGTATCACA-3′ (SEQ ID NO: 3083)5′-UUUUAUAACCGCAUUUUCUCUUGaa-3′ (SEQ ID NO: 866)3′-AAAAAAUAUUGGCGUAAAAGAGAACUU-5′ (SEQ ID NO: 1975) βc-3686 Target:5′-TTTTTTATAACCGCATTTTCTCTTGAA-3′ (SEQ ID NO: 3084)5′-UUUUUAUAACCGCAUUUUCUCUUga-3′ (SEQ ID NO: 867)3′-UAAAAAAUAUUGGCGUAAAAGAGAACU-5′ (SEQ ID NO: 1976) βc-3687 Target:5′-ATTTTTTATAACCGCATTTTCTCTTGA-3′ (SEQ ID NO: 3085)5′-UUUUUUAUAACCGCAUUUUCUCUtg-3′ (SEQ ID NO: 868)3′-GUAAAAAAUAUUGGCGUAAAAGAGAAC-5′ (SEQ ID NO: 1977) βc-3688 Target:5′-CATTTTTTATAACCGCATTTTCTCTTG-3′ (SEQ ID NO: 3086)5′-AUUUUUUAUAACCGCAUUUUCUCtt-3′ (SEQ ID NO: 869)3′-GGUAAAAAAUAUUGGCGUAAAAGAGAA-5′ (SEQ ID NO: 1978) βc-3689 Target:5′-CCATTTTTTATAACCGCATTTTCTCTT-3′ (SEQ ID NO: 3087)5′-GAACCAUUUUUUAUAACCGCAUUtt-3′ (SEQ ID NO: 870)3′-GACUUGGUAAAAAAUAUUGGCGUAAAA-5′ (SEQ ID NO: 1979) βc-3694 Target:5′-CTGAACCATTTTTTATAACCGCATTTT-3′ (SEQ ID NO: 3088)5′-AUUCUGAACCAUUUUUUAUAACCgc-3′ (SEQ ID NO: 871)3′-AUUAAGACUUGGUAAAAAAUAUUGGCG-5′ (SEQ ID NO: 1980) βc-3699 Target:5′-TAATTCTGAACCATTTTTTATAACCGC-3′ (SEQ ID NO: 3089)5′-AAUUCUGAACCAUUUUUUAUAACcg-3′ (SEQ ID NO: 872)3′-AAUUAAGACUUGGUAAAAAAUAUUGGC-5′ (SEQ ID NO: 1981) βc-3700 Target:5′-TTAATTCTGAACCATTTTTTATAACCG-3′ (SEQ ID NO: 3090)5′-UAAUUCUGAACCAUUUUUUAUAAcc-3′ (SEQ ID NO: 873)3′-AAAUUAAGACUUGGUAAAAAAUAUUGG-5′ (SEQ ID NO: 1982) βc-3701 Target:5′-TTTAATTCTGAACCATTTTTTATAACC-3′ (SEQ ID NO: 3091)5′-UUAAUUCUGAACCAUUUUUUAUAac-3′ (SEQ ID NO: 874)3′-CAAAUUAAGACUUGGUAAAAAAUAUUG-5′ (SEQ ID NO: 1983) βc-3702 Target:5′-GTTTAATTCTGAACCATTTTTTATAAC-3′ (SEQ ID NO: 3092)5′-UUUAAUUCUGAACCAUUUUUUAUaa-3′ (SEQ ID NO: 875)3′-UCAAAUUAAGACUUGGUAAAAAAUAUU-5′ (SEQ ID NO: 1984) βc-3703 Target:5′-AGTTTAATTCTGAACCATTTTTTATAA-3′ (SEQ ID NO: 3093)5′-GUUUAAUUCUGAACCAUUUUUUAta-3′ (SEQ ID NO: 876)3′-UUCAAAUUAAGACUUGGUAAAAAAUAU-5′ (SEQ ID NO: 1985) βc-3704 Target:5′-AAGTTTAATTCTGAACCATTTTTTATA-3′ (SEQ ID NO: 3094)5′-UAAAAGUUUAAUUCUGAACCAUUtt-3′ (SEQ ID NO: 877)3′-UAAUUUUCAAAUUAAGACUUGGUAAAA-5′ (SEQ ID NO: 1986) βc-3709 Target:5′-ATTAAAAGTTTAATTCTGAACCATTTT-3′ (SEQ ID NO: 3095)5′-UUAAAAGUUUAAUUCUGAACCAUtt-3′ (SEQ ID NO: 878)3′-UUAAUUUUCAAAUUAAGACUUGGUAAA-5′ (SEQ ID NO: 1987) βc-3710 Target:5′-AATTAAAAGTTTAATTCTGAACCATTT-3′ (SEQ ID NO: 3096)5′-AAUUAAAAGUUUAAUUCUGAACCat-3′ (SEQ ID NO: 879)3′-ACUUAAUUUUCAAAUUAAGACUUGGUA-5′ (SEQ ID NO: 1988) βc-3712 Target:5′-TGAATTAAAAGTTTAATTCTGAACC-3′ (SEQ ID NO: 3097)5′-AUACAGCUAAAGGAUGAUUUACAgg-3′ (SEQ ID NO: 880)3′-GUUAUGUCGAUUUCCUACUAAAUGUCC-5′ (SEQ ID NO: 1989) βc-2634t2 Target:5′-CAATACAGCTAAAGGATGATTTACAGG-3′ (SEQ ID NO: 3098)5′-AAUACAGCUAAAGGAUGAUUUACag-3′ (SEQ ID NO: 881)3′-UGUUAUGUCGAUUUCCUACUAAAUGUC-5′ (SEQ ID NO: 1990) βc-2635t2 Target:5′-ACAATACAGCTAAAGGATGATTTACAG-3′ (SEQ ID NO: 3099)5′-ACAAUACAGCUAAAGGAUGAUUUac-3′ (SEQ ID NO: 882)3′-UCUGUUAUGUCGAUUUCCUACUAAAUG-5′ (SEQ ID NO: 1991) βc-2637t2 Target:5′-AGACAATACAGCTAAAGGATGATTTAC-3′ (SEQ ID NO: 3100)5′-UACUCCUAAAGGAUGAUUUACAGgt-3′ (SEQ ID NO: 883)3′-CAAUGAGGAUUUCCUACUAAAUGUCCA-5′ (SEQ ID NO: 1992) βc-2633t3 Target:5′-GTTACTCCTAAAGGATGATTTACAGGT-3′ (SEQ ID NO: 3101)5′-UUACUCCUAAAGGAUGAUUUACAgg-3′ (SEQ ID NO: 884)3′-ACAAUGAGGAUUUCCUACUAAAUGUCC-5′ (SEQ ID NO: 1993) βc-2634t3 Target:5′-TGTTACTCCTAAAGGATGATTTACAGG-3′ (SEQ ID NO: 3102)5′-GUUACUCCUAAAGGAUGAUUUACag-3′ (SEQ ID NO: 885)3′-AACAAUGAGGAUUUCCUACUAAAUGUC-5′ (SEQ ID NO: 1994) βc-2635t3 Target:5′-TTGTTACTCCTAAAGGATGATTTACAG-3′ (SEQ ID NO: 3103)5′-UGUUACUCCUAAAGGAUGAUUUAca-3′ (SEQ ID NO: 886)3′-UAACAAUGAGGAUUUCCUACUAAAUGU-5′ (SEQ ID NO: 1995) βc-2636t3 Target:5′-ATTGTTACTCCTAAAGGATGATTTACA-3′ (SEQ ID NO: 3104)5′-AUUCCAGAAUCCAAGUAAGACUGct-3′ (SEQ ID NO: 887)3′-CCUAAGGUCUUAGGUUCAUUCUGACGA-5′ (SEQ ID NO: 1996) βc-m318 Target:5′-GGATTCCAGAATCCAAGTAAGACTGCT-3′ (SEQ ID NO: 3105)5′-UGCUCCCAUUCAUAAAGGACUUGgg-3′ (SEQ ID NO: 888)3′-GAACGAGGGUAAGUAUUUCCUGAACCC-5′ (SEQ ID NO: 1997) βc-m417 Target:5′-CTTGCTCCCATTCATAAAGGACTTGGG-3′ (SEQ ID NO: 3106)5′-UCAAUAUCAGCUACUUGCUCUUGcg-3′ (SEQ ID NO: 889)3′-GCAGUUAUAGUCGAUGAACGAGAACGC-5′ (SEQ ID NO: 1998) βc-m462 Target:5′-CGTCAATATCAGCTACTTGCTCTTGCG-3′ (SEQ ID NO: 3107)5′-GUCAAUAUCAGCUACUUGCUCUUgc-3′ (SEQ ID NO: 890)3′-GGCAGUUAUAGUCGAUGAACGAGAACG-5′ (SEQ ID NO: 1999) βc-m463 Target:5′-CCGTCAATATCAGCTACTTGCTCTTGC-3′ (SEQ ID NO: 3108)5′-UGCCCGUCAAUAUCAGCUACUUGct-3′ (SEQ ID NO: 891)3′-UGACGGGCAGUUAUAGUCGAUGAACGA-5′ (SEQ ID NO: 2000) βc-m468 Target:5′-ACTGCCCGTCAATATCAGCTACTTGCT-3′ (SEQ ID NO: 3109)5′-UUUCAACAUCUGUGAUGGUUCAGcc-3′ (SEQ ID NO: 892)3′-ACAAAGUUGUAGACACUACCAAGUCGG-5′ (SEQ ID NO: 2001) βc-m613 Target:5′-TGTTTCAACATCTGTGATGGTTCAGCC-3′ (SEQ ID NO: 3110)5′-GUUUCAACAUCUGUGAUGGUUCAgc-3′ (SEQ ID NO: 893)3′-UACAAAGUUGUAGACACUACCAAGUCG-5′ (SEQ ID NO: 2002) βc-m614 Target:5′-ATGTTTCAACATCTGTGATGGTTCAGC-3′ (SEQ ID NO: 3111)5′-ACAACUGCAUGUUUCAACAUCUGtg-3′ (SEQ ID NO: 894)3′-ACUGUUGACGUACAAAGUUGUAGACAC-5′ (SEQ ID NO: 2003) βc-m624 Target:5′-TGACAACTGCATGTTTCAACATCTGTG-3′ (SEQ ID NO: 3112)5′-UGACAACUGCAUGUUUCAACAUCtg-3′ (SEQ ID NO: 895)3′-UAACUGUUGACGUACAAAGUUGUAGAC-5′ (SEQ ID NO: 2004) βc-m626 Target:5′-ATTGACAACTGCATGTTTCAACATCTG-3′ (SEQ ID NO: 3113)5′-AAAUUGACAACUGCAUGUUUCAAca-3′ (SEQ ID NO: 896)3′-AGUUUAACUGUUGACGUACAAAGUUGU-5′ (SEQ ID NO: 2005) βc-m630 Target:5′-TCAAATTGACAACTGCATGTTTCAACA-3′ (SEQ ID NO: 3114)5′-UUAAUCAAAUUGACAACUGCAUGtt-3′ (SEQ ID NO: 897)3′-UCAAUUAGUUUAACUGUUGACGUACAA-5′ (SEQ ID NO: 2006) βc-m636 Target:5′-AGTTAATCAAATTGACAACTGCATGTT-3′ (SEQ ID NO: 3115)5′-UGAUAGUUAAUCAAAUUGACAACtg-3′ (SEQ ID NO: 898)3′-GGACUAUCAAUUAGUUUAACUGUUGAC-5′ (SEQ ID NO: 2007) βc-m642 Target:5′-CCTGATAGTTAATCAAATTGACAACTG-3′ (SEQ ID NO: 3116)5′-UCAUCCUGAUAGUUAAUCAAAUUga-3′ (SEQ ID NO: 899)3′-GCAGUAGGACUAUCAAUUAGUUUAACU-5′ (SEQ ID NO: 2008) βc-m648 Target:5′-CGTCATCCTGATAGTTAATCAAATTGA-3′ (SEQ ID NO: 3117)5′-GUCAUCCUGAUAGUUAAUCAAAUtg-3′ (SEQ ID NO: 900)3′-CGCAGUAGGACUAUCAAUUAGUUUAAC-5′ (SEQ ID NO: 2009) βc-m649 Target:5′-GCGTCATCCTGATAGTTAATCAAATTG-3′ (SEQ ID NO: 3118)5′-UCAUCGUUUAGCAGUUUUGUCAGct-3′ (SEQ ID NO: 901)3′-GGAGUAGCAAAUCGUCAAAACAGUCGA-5′ (SEQ ID NO: 2010) βc-m702 Target:5′-CCTCATCGTTTAGCAGTTTTGTCAGCT-3′ (SEQ ID NO: 3119)5′-GGUCCUCAUCGUUUAGCAGUUUUgt-3′ (SEQ ID NO: 902)3′-GACCAGGAGUAGCAAAUCGUCAAAACA-5′ (SEQ ID NO: 2011) βc-m707 Target:5′-CTGGTCCTCATCGTTTAGCAGTTTTGT-3′ (SEQ ID NO: 3120)5′-UAACAGCAGCUUUAUUAACUACCac-3′ (SEQ ID NO: 903)3′-GUAUUGUCGUCGAAAUAAUUGAUGGUG-5′ (SEQ ID NO: 2012) βc-m734 Target:5′-CATAACAGCAGCTTTATTAACTACCAC-3′ (SEQ ID NO: 3121)5′-AUAACAGCAGCUUUAUUAACUACca-3′ (SEQ ID NO: 904)3′-GGUAUUGUCGUCGAAAUAAUUGAUGGU-5′ (SEQ ID NO: 2013) βc-m735 Target:5′-CCATAACAGCAGCTTTATTAACTACCA-3′ (SEQ ID NO: 3122)5′-ACCAUAACAGCAGCUUUAUUAACta-3′ (SEQ ID NO: 905)3′-CCUGGUAUUGUCGUCGAAAUAAUUGAU-5′ (SEQ ID NO: 2014) βc-m738 Target:5′-GGACCATAACAGCAGCTTTATTAACTA-3′ (SEQ ID NO: 3123)5′-GACCAUAACAGCAGCUUUAUUAAct-3′ (SEQ ID NO: 906)3′-ACCUGGUAUUGUCGUCGAAAUAAUUGA-5′ (SEQ ID NO: 2015) βc-m739 Target:5′-TGGACCATAACAGCAGCTTTATTAACT-3′ (SEQ ID NO: 3124)5′-GUCUCUACAUCAUUUGUAUUCUGca-3′ (SEQ ID NO: 907)3′-GACAGAGAUGUAGUAAACAUAAGACGU-5′ (SEQ ID NO: 2016) βc-m843 Target:5′-CTGTCTCTACATCATTTGTATTCTGCA-3′ (SEQ ID NO: 3125)5′-UGUCUCUACAUCAUUUGUAUUCUgc-3′ (SEQ ID NO: 908)3′-CGACAGAGAUGUAGUAAACAUAAGACG-5′ (SEQ ID NO: 2017) βc-m844 Target:5′-GCTGTCTCTACATCATTTGTATTCTGC-3′ (SEQ ID NO: 3126)5′-AACCAUUUUCUGCAGUCCACCAGct-3′ (SEQ ID NO: 909)3′-CGUUGGUAAAAGACGUCAGGUGGUCGA-5′ (SEQ ID NO: 2018) βc-m1063 Target:5′-GCAACCATTTTCTGCAGTCCACCAGCT-3′ (SEQ ID NO: 3127)5′-GCAACCAUUUUCUGCAGUCCACCag-3′ (SEQ ID NO: 910)3′-UUCGUUGGUAAAAGACGUCAGGUGGUC-5′ (SEQ ID NO: 2019) βc-m1065 Target:5′-AAGCAACCATTTTCTGCAGTCCACCAG-3′ (SEQ ID NO: 3128)5′-GUUUUGUUGAGCAAAGCAACCAUtt-3′ (SEQ ID NO: 911)3′-AACAAAACAACUCGUUUCGUUGGUAAA-5′ (SEQ ID NO: 2020) βc-m1080 Target:5′-TTGTTTTGTTGAGCAAAGCAACCATTT-3′ (SEQ ID NO: 3129)5′-UGUUUUGUUGAGCAAAGCAACCAtt-3′ (SEQ ID NO: 912)3′-AAACAAAACAACUCGUUUCGUUGGUAA-5′ (SEQ ID NO: 2021) βc-m1081 Target:5′-TTTGTTTTGTTGAGCAAAGCAACCATT-3′ (SEQ ID NO: 3130)5′-GCCAAGAAUUUCACGUUUGUUUUgt-3′ (SEQ ID NO: 913)3′-AUCGGUUCUUAAAGUGCAAACAAAACA-5′ (SEQ ID NO: 2022) βc-m1098 Target:5′-TAGCCAAGAATTTCACGTTTGTTTTGT-3′ (SEQ ID NO: 3131)5′-UGAUUGCCAUAAGCUAAGAUCUGaa-3′ (SEQ ID NO: 914)3′-GAACUAACGGUAUUCGAUUCUAGACUU-5′ (SEQ ID NO: 2023) βc-m1140 Target:5′-CTTGATTGCCATAAGCTAAGATCTGAA-3′ (SEQ ID NO: 3132)5′-UCUCUUGAUUGCCAUAAGCUAAGat-3′ (SEQ ID NO: 915)3′-CGAGAGAACUAACGGUAUUCGAUUCUA-5′ (SEQ ID NO: 2024) βc-m1145 Target:5′-GCTCTCTTGATTGCCATAAGCTAAGAT-3′ (SEQ ID NO: 3133)5′-UCUCAUAAGUGUAGGUCCUCAUUat-3′ (SEQ ID NO: 916)3′-GAAGAGUAUUCACAUCCAGGAGUAAUA-5′ (SEQ ID NO: 2025) βc-m1217 Target:5′-CTTCTCATAAGTGTAGGTCCTCATTAT-3′ (SEQ ID NO: 3134)5′-UUCUCAUAAGUGUAGGUCCUCAUta-3′ (SEQ ID NO: 917)3′-CGAAGAGUAUUCACAUCCAGGAGUAAU-5′ (SEQ ID NO: 2026) βc-m1218 Target:5′-GCTTCTCATAAGTGTAGGTCCTCATTA-3′ (SEQ ID NO: 3135)5′-GCUUCUCAUAAGUGUAGGUCCUCat-3′ (SEQ ID NO: 918)3′-UUCGAAGAGUAUUCACAUCCAGGAGUA-5′ (SEQ ID NO: 2027) βc-m1220 Target:5′-AAGCTTCTCATAAGTGTAGGTCCTC-3′ (SEQ ID NO: 3136)5′-AGCUUCUCAUAAGUGUAGGUCCUca-3′ (SEQ ID NO: 919)3′-CUUCGAAGAGUAUUCACAUCCAGGAGU-5′ (SEQ ID NO: 2028) βc-m1221 Target:5′-GAAGCTTCTCATAAGTGTAGGTCCTCA-3′ (SEQ ID NO: 3137)5′-GUCCAAAGACAGUUUUGAACAAGtc-3′ (SEQ ID NO: 920)3′-CUCAGGUUUCUGUCAAAACUUGUUCAG-5′ (SEQ ID NO: 2029) βc-m1365 Target:5′-GAGTCCAAAGACAGTTTTGAACAAGTC-3′ (SEQ ID NO: 3138)5′-AGUCCAAAGACAGUUUUGAACAAgt-3′ (SEQ ID NO: 921)3′-UCUCAGGUUUCUGUCAAAACUUGUUCA-5′ (SEQ ID NO: 2030) βc-m1366 Target:5′-AGAGTCCAAAGACAGTTTTGAACAAGT-3′ (SEQ ID NO: 3139)5′-ACAUUUAUAUCAUCGGAACCCAGaa-3′ (SEQ ID NO: 922)3′-GGUGUAAAUAUAGUAGCCUUGGGUCUU-5′ (SEQ ID NO: 2031) βc-m1461 Target:5′-CCACATTTATATCATCGGAACCCAGAA-3′ (SEQ ID NO: 3140)5′-ACCACAUUUAUAUCAUCGGAACCca-3′ (SEQ ID NO: 923)3′-ACUGGUGUAAAUAUAGUAGCCUUGGGU-5′ (SEQ ID NO: 2032) βc-m1464 Target:5′-TGACCACATTTATATCATCGGAACCCA-3′ (SEQ ID NO: 3141)5′-GCACAGGUGACCACAUUUAUAUCat-3′ (SEQ ID NO: 924)3′-GACGUGUCCACUGGUGUAAAUAUAGUA-5′ (SEQ ID NO: 2033) βc-m1473 Target:5′-CTGCACAGGTGACCACATTTATATC-3′ (SEQ ID NO: 3142)5′-UGCACAGGUGACCACAUUUAUAUca-3′ (SEQ ID NO: 925)3′-CGACGUGUCCACUGGUGUAAAUAUAGU-5′ (SEQ ID NO: 2034) βc-m1474 Target:5′-GCTGCACAGGTGACCACATTTATATCA-3′ (SEQ ID NO: 3143)5′-GUAAUUAUUGCAAGUGAGGUUAGag-3′ (SEQ ID NO: 926)3′-AACAUUAAUAACGUUCACUCCAAUCUC-5′ (SEQ ID NO: 2035) βc-m1510 Target:5′-TTGTAATTATTGCAAGTGAGGTTAGAG-3′ (SEQ ID NO: 3144)5′-UCAUCUUGUUUUUGUAAUUAUUGca-3′ (SEQ ID NO: 927)3′-GUAGUAGAACAAAAACAUUAAUAACGU-5′ (SEQ ID NO: 2036) βc-m1523 Target:5′-CATCATCTTGTTTTTGTAATTATTGCA-3′ (SEQ ID NO: 3145)5′-AUCAUCUUGUUUUUGUAAUUAUUgc-3′ (SEQ ID NO: 928)3′-GGUAGUAGAACAAAAACAUUAAUAACG-5′ (SEQ ID NO: 2037) βc-m1524 Target:5′-CCATCATCTTGTTTTTGTAATTATTGC-3′ (SEQ ID NO: 3146)5′-ACCAUCAUCUUGUUUUUGUAAUUat-3′ (SEQ ID NO: 929)3′-UGUGGUAGUAGAACAAAAACAUUAAUA-5′ (SEQ ID NO: 2038) βc-m1527 Target:5′-ACACCATCATCTTGTTTTTGTAATTAT-3′ (SEQ ID NO: 3147)5′-GGCACACCAUCAUCUUGUUUUUGta-3′ (SEQ ID NO: 930)3′-AACCGUGUGGUAGUAGAACAAAAACAU-5′ (SEQ ID NO: 2039) βc-m1532 Target:5′-TTGGCACACCATCATCTTGTTTTTGTA-3′ (SEQ ID NO: 3148)5′-AAUCCAACAGUUGCCUUUAUCAGag-3′ (SEQ ID NO: 931)3′-AGUUAGGUUGUCAACGGAAAUAGUCUC-5′ (SEQ ID NO: 2040) βc-m1752 Target:5′-TCAATCCAACAGTTGCCTTTATCAGAG-3′ (SEQ ID NO: 3149)5′-GAAUCAAUCCAACAGUUGCCUUUat-3′ (SEQ ID NO: 932)3′-AGCUUAGUUAGGUUGUCAACGGAAAUA-5′ (SEQ ID NO: 2041) βc-m1757 Target:5′-TCGAATCAATCCAACAGTTGCCTTTAT-3′ (SEQ ID NO: 3150)5′-UGAACUAGUCGUGGAAUAGCACCct-3′ (SEQ ID NO: 933)3′-CGACUUGAUCAGCACCUUAUCGUGGGA-5′ (SEQ ID NO: 2042) βc-m1827 Target:5′-GCTGAACTAGTCGTGGAATAGCACCCT-3′ (SEQ ID NO: 3151)5′-UACACCCUUCUACUAUCUCCUCCat-3′ (SEQ ID NO: 934)3′-UCAUGUGGGAAGAUGAUAGAGGAGGUA-5′ (SEQ ID NO: 2043) βc-m1934 Target:5′-AGTACACCCTTCTACTATCTCCTCC-3′ (SEQ ID NO: 3152)5′-GUACACCCUUCUACUAUCUCCUCca-3′ (SEQ ID NO: 935)3′-GUCAUGUGGGAAGAUGAUAGAGGAGGU-5′ (SEQ ID NO: 2044) βc-m1935 Target:5′-CAGTACACCCTTCTACTATCTCCTCCA-3′ (SEQ ID NO: 3153)5′-AGUACACCCUUCUACUAUCUCCUcc-3′ (SEQ ID NO: 936)3′-GGUCAUGUGGGAAGAUGAUAGAGGAGG-5′ (SEQ ID NO: 2045) βc-m1936 Target:5′-CCAGTACACCCTTCTACTATCTCCTCC-3′ (SEQ ID NO: 3154)5′-GCUCCAGUACACCCUUCUACUAUct-3′ (SEQ ID NO: 937)3′-CUCGAGGUCAUGUGGGAAGAUGAUAGA-5′ (SEQ ID NO: 2046) βc-m1941 Target:5′-GAGCTCCAGTACACCCTTCTACTATCT-3′ (SEQ ID NO: 3155)5′-ACAAUGGAAUGGUAUUGAGUCCUcg-3′ (SEQ ID NO: 938)3′-UUUGUUACCUUACCAUAACUCAGGAGC-5′ (SEQ ID NO: 2047) βc-m2009 Target:5′-AAACAATGGAATGGTATTGAGTCCTCG-3′ (SEQ ID NO: 3156)5′-GCACAAACAAUGGAAUGGUAUUGag-3′ (SEQ ID NO: 939)3′-GACGUGUUUGUUACCUUACCAUAACUC-5′ (SEQ ID NO: 2048) βc-m2015 Target:5′-CTGCACAAACAATGGAATGGTATTGAG-3′ (SEQ ID NO: 3157)5′-UGCACAAACAAUGGAAUGGUAUUga-3′ (SEQ ID NO: 940)3′-UGACGUGUUUGUUACCUUACCAUAACU-5′ (SEQ ID NO: 2049) βc-m2016 Target:5′-ACTGCACAAACAATGGAATGGTATTGA-3′ (SEQ ID NO: 3158)5′-GCAACUGCACAAACAAUGGAAUGgt-3′ (SEQ ID NO: 941)3′-UUCGUUGACGUGUUUGUUACCUUACCA-5′ (SEQ ID NO: 2050) βc-m2021 Target:5′-AAGCAACTGCACAAACAATGGAATGGT-3′ (SEQ ID NO: 3159)5′-GAAUAAAGCAACUGCACAAACAAtg-3′ (SEQ ID NO: 942)3′-CUCUUAUUUCGUUGACGUGUUUGUUAC-5′ (SEQ ID NO: 2051) βc-m2028 Target:5′-GAGAATAAAGCAACTGCACAAACAATG-3′ (SEQ ID NO: 3160)5′-UCAAUGGGAGAAUAAAGCAACUGca-3′ (SEQ ID NO: 943)3′-AAAGUUACCCUCUUAUUUCGUUGACGU-5′ (SEQ ID NO: 2052) βc-m2037 Target:5′-TTTCAATGGGAGAATAAAGCAACTGCA-3′ (SEQ ID NO: 3161)5′-UUCAAUGGGAGAAUAAAGCAACUgc-3′ (SEQ ID NO: 944)3′-AAAAGUUACCCUCUUAUUUCGUUGACG-5′ (SEQ ID NO: 2053) βc-m2038 Target:5′-TTTTCAATGGGAGAATAAAGCAACTGC-3′ (SEQ ID NO: 3162)5′-UUUCAAUGGGAGAAUAAAGCAACtg-3′ (SEQ ID NO: 945)3′-UAAAAGUUACCCUCUUAUUUCGUUGAC-5′ (SEQ ID NO: 2054) βc-m2039 Target:5′-ATTTTCAATGGGAGAATAAAGCAACTG-3′ (SEQ ID NO: 3163)5′-AUAUUUUCAAUGGGAGAAUAAAGca-3′ (SEQ ID NO: 946)3′-CCUAUAAAAGUUACCCUCUUAUUUCGU-5′ (SEQ ID NO: 2055) βc-m2043 Target:5′-GGATATTTTCAATGGGAGAATAAAGCA-3′ (SEQ ID NO: 3164)5′-GAUAUUUUCAAUGGGAGAAUAAAgc-3′ (SEQ ID NO: 947)3′-ACCUAUAAAAGUUACCCUCUUAUUUCG-5′ (SEQ ID NO: 2056) βc-m2044 Target:5′-TGGATATTTTCAATGGGAGAATAAAGC-3′ (SEQ ID NO: 3165)5′-GGAUAUUUUCAAUGGGAGAAUAAag-3′ (SEQ ID NO: 948)3′-AACCUAUAAAAGUUACCCUCUUAUUUC-5′ (SEQ ID NO: 2057) βc-m2045 Target:5′-TTGGATATTTTCAATGGGAGAATAAAG-3′ (SEQ ID NO: 3166)5′-GCUACUCUUUGGAUAUUUUCAAUgg-3′ (SEQ ID NO: 949)3′-GUCGAUGAGAAACCUAUAAAAGUUACC-5′ (SEQ ID NO: 2058) βc-m2055 Target:5′-CAGCTACTCTTTGGATATTTTCAATGG-3′ (SEQ ID NO: 3167)5′-AGCUACUCUUUGGAUAUUUUCAAtg-3′ (SEQ ID NO: 950)3′-CGUCGAUGAGAAACCUAUAAAAGUUAC-5′ (SEQ ID NO: 2059) βc-m2056 Target:5′-GCAGCTACTCTTTGGATATTTTCAATG-3′ (SEQ ID NO: 3168)5′-GCUUCUUGUAAUCCUGUGGCUUGtc-3′ (SEQ ID NO: 951)3′-GGCGAAGAACAUUAGGACACCGAACAG-5′ (SEQ ID NO: 2060) βc-m2231 Target:5′-CCGCTTCTTGTAATCCTGTGGCTTGTC-3′ (SEQ ID NO: 3169)5′-AGUCCAAGAUCUGCAGUCUCAUUcc-3′ (SEQ ID NO: 952)3′-GGUCAGGUUCUAGACGUCAGAGUAAGG-5′ (SEQ ID NO: 2061) βc-m2307 Target:5′-CCAGTCCAAGATCTGCAGTCTCATTCC-3′ (SEQ ID NO: 3170)5′-UAUCCACCAGAGUGAAAAGAACGgt-3′ (SEQ ID NO: 953)3′-GCAUAGGUGGUCUCACUUUUCUUGCCA-5′ (SEQ ID NO: 2062) βc-m2385 Target:5′-CGTATCCACCAGAGTGAAAAGAACGGT-3′ (SEQ ID NO: 3171)5′-GGCCAGCUGAUUGCUAUCACCUGgg-3′ (SEQ ID NO: 954)3′-GUCCGGUCGACUAACGAUAGUGGACCC-5′ (SEQ ID NO: 2063) βc-m2539 Target:5′-CAGGCCAGCTGATTGCTATCACCTGGG-3′ (SEQ ID NO: 3172)5′-AUUUACAGGUCAGUAUCAAACCAgg-3′ (SEQ ID NO: 955)3′-GCUAAAUGUCCAGUCAUAGUUUGGUCC-5′ (SEQ ID NO: 2064) βc-m2562 Target:5′-CGATTTACAGGTCAGTATCAAACCAGG-3′ (SEQ ID NO: 3173)5′-GAUUUACAGGUCAGUAUCAAACCag-3′ (SEQ ID NO: 956)3′-UGCUAAAUGUCCAGUCAUAGUUUGGUC-5′ (SEQ ID NO: 2065) βc-m2563 Target:5′-ACGATTTACAGGTCAGTATCAAACCAG-3′ (SEQ ID NO: 3174)5′-UCUUACCUAAAGGACGAUUUACAgg-3′ (SEQ ID NO: 957)3′-AAAGAAUGGAUUUCCUGCUAAAUGUCC-5′ (SEQ ID NO: 2066) βc-m2578 Target:5′-TTTCTTACCTAAAGGACGATTTACAGG-3′ (SEQ ID NO: 3175)5′-UUUCUUACCUAAAGGACGAUUUAca-3′ (SEQ ID NO: 958)3′-CGAAAGAAUGGAUUUCCUGCUAAAUGU-5′ (SEQ ID NO: 2067) βc-m2580 Target:5′-GCTTTCTTACCTAAAGGACGATTTACA-3′ (SEQ ID NO: 3176)5′-UUUAUAAGCUUUCUUACCUAAAGga-3′ (SEQ ID NO: 959)3′-GAAAAUAUUCGAAAGAAUGGAUUUCCU-5′ (SEQ ID NO: 2068) βc-m2589 Target:5′-CTTTTATAAGCTTTCTTACCTAAAGGA-3′ (SEQ ID NO: 3177)5′-UUUUAUAAGCUUUCUUACCUAAAgg-3′ (SEQ ID NO: 960)3′-CGAAAAUAUUCGAAAGAAUGGAUUUCC-5′ (SEQ ID NO: 2069) βc-m2590 Target:5′-GCTTTTATAAGCTTTCTTACCTAAAGG-3′ (SEQ ID NO: 3178)5′-GGCUUUUAUAAGCUUUCUUACCUaa-3′ (SEQ ID NO: 961)3′-GACCGAAAAUAUUCGAAAGAAUGGAUU-5′ (SEQ ID NO: 2070) βc-m2593 Target:5′-CTGGCTTTTATAAGCTTTCTTACCTAA-3′ (SEQ ID NO: 3179)5′-ACACUGGCUUUUAUAAGCUUUCUta-3′ (SEQ ID NO: 962)3′-GGUGUGACCGAAAAUAUUCGAAAGAAU-5′ (SEQ ID NO: 2071) βc-m2598 Target:5′-CCACACTGGCTTTTATAAGCTTTCTTA-3′ (SEQ ID NO: 3180)5′-UCACCCACACUGGCUUUUAUAAGct-3′ (SEQ ID NO: 963)3′-UAAGUGGGUGUGACCGAAAAUAUUCGA-5′ (SEQ ID NO: 2072) βc-m2604 Target:5′-ATTCACCCACACTGGCTTTTATAAGCT-3′ (SEQ ID NO: 3181)5′-UACCAAGUCUUUCUGGAGUUCUGca-3′ (SEQ ID NO: 964)3′-GGAUGGUUCAGAAAGACCUCAAGACGU-5′ (SEQ ID NO: 2073) βc-m2644 Target:5′-CCTACCAAGTCTTTCTGGAGTTCTGCA-3′ (SEQ ID NO: 3182)5′-UUACAAACAGGCCUAAAACCAUUcc-3′ (SEQ ID NO: 965)3′-UAAAUGUUUGUCCGGAUUUUGGUAAGG-5′ (SEQ ID NO: 2074) βc-m2674 Target:5′-ATTTACAAACAGGCCTAAAACCATTCC-3′ (SEQ ID NO: 3183)5′-UUUACAAACAGGCCUAAAACCAUtc-3′ (SEQ ID NO: 966)3′-CUAAAUGUUUGUCCGGAUUUUGGUAAG-5′ (SEQ ID NO: 2075) βc-m2675 Target:5′-GATTTACAAACAGGCCTAAAACCATTC-3′ (SEQ ID NO: 3184)5′-AUUUACAAACAGGCCUAAAACCAtt-3′ (SEQ ID NO: 967)3′-UCUAAAUGUUUGUCCGGAUUUUGGUAA-5′ (SEQ ID NO: 2076) βc-m2676 Target:5′-AGATTTACAAACAGGCCTAAAACCATT-3′ (SEQ ID NO: 3185)5′-UCUCCUUCCAAGGUAUGUAUCUGtt-3′ (SEQ ID NO: 968)3′-GUAGAGGAAGGUUCCAUACAUAGACAA-5′ (SEQ ID NO: 2077) βc-m2710 Target:5′-CATCTCCTTCCAAGGTATGTATCTGTT-3′ (SEQ ID NO: 3186)5′-AUCUCCUUCCAAGGUAUGUAUCUgt-3′ (SEQ ID NO: 969)3′-UGUAGAGGAAGGUUCCAUACAUAGACA-5′ (SEQ ID NO: 2078) βc-m2711 Target:5′-ACATCTCCTTCCAAGGTATGTATCTGT-3′ (SEQ ID NO: 3187)5′-UUCCACACAUGAACAUCUCCUUCca-3′ (SEQ ID NO: 970)3′-UGAAGGUGUGUACUUGUAGAGGAAGGU-5′ (SEQ ID NO: 2079) βc-m2725 Target:5′-ACTTCCACACATGAACATCTCCTTCCA-3′ (SEQ ID NO: 3188)5′-AACUUCCACACAUGAACAUCUCCtt-3′ (SEQ ID NO: 971)3′-CUUUGAAGGUGUGUACUUGUAGAGGAA-5′ (SEQ ID NO: 2080) βc-m2728 Target:5′-GAAACTTCCACACATGAACATCTCCTT-3′ (SEQ ID NO: 3189)5′-AAACUUCCACACAUGAACAUCUCct-3′ (SEQ ID NO: 972)3′-UCUUUGAAGGUGUGUACUUGUAGAGGA-5′ (SEQ ID NO: 2081) βc-m2729 Target:5′-AGAAACTTCCACACATGAACATCTCCT-3′ (SEQ ID NO: 3190)5′-GAAACUUCCACACAUGAACAUCUcc-3′ (SEQ ID NO: 973)3′-CUCUUUGAAGGUGUGUACUUGUAGAGG-5′ (SEQ ID NO: 2082) βc-m2730 Target:5′-GAGAAACTTCCACACATGAACATCTCC-3′ (SEQ ID NO: 3191)5′-AGAAACUUCCACACAUGAACAUCtc-3′ (SEQ ID NO: 974)3′-ACUCUUUGAAGGUGUGUACUUGUAGAG-5′ (SEQ ID NO: 2083) βc-m2731 Target:5′-TGAGAAACTTCCACACATGAACATCTC-3′ (SEQ ID NO: 3192)5′-UCAACGUGAGAAACUUCCACACAtg-3′ (SEQ ID NO: 975)3′-GUAGUUGCACUCUUUGAAGGUGUGUAC-5′ (SEQ ID NO: 2084) βc-m2739 Target:5′-CATCAACGTGAGAAACTTCCACACATG-3′ (SEQ ID NO: 3193)5′-ACAUCAACGUGAGAAACUUCCACac-3′ (SEQ ID NO: 976)3′-UUUGUAGUUGCACUCUUUGAAGGUGUG-5′ (SEQ ID NO: 2085) βc-m2742 Target:5′-AAACATCAACGTGAGAAACTTCCACAC-3′ (SEQ ID NO: 3194)5′-AACAUCAACGUGAGAAACUUCCAca-3′ (SEQ ID NO: 977)3′-UUUUGUAGUUGCACUCUUUGAAGGUGU-5′ (SEQ ID NO: 2086) βc-m2743 Target:5′-AAAACATCAACGTGAGAAACTTCCACA-3′ (SEQ ID NO: 3195)5′-AAACAUCAACGUGAGAAACUUCCac-3′ (SEQ ID NO: 978)3′-UUUUUGUAGUUGCACUCUUUGAAGGUG-5′ (SEQ ID NO: 2087) βc-m2744 Target:5′-AAAAACATCAACGTGAGAAACTTCCAC-3′ (SEQ ID NO: 3196)5′-AAAACAUCAACGUGAGAAACUUCca-3′ (SEQ ID NO: 979)3′-GUUUUUGUAGUUGCACUCUUUGAAGGU-5′ (SEQ ID NO: 2088) βc-m2745 Target:5′-CAAAAACATCAACGTGAGAAACTTCCA-3′ (SEQ ID NO: 3197)5′-AAAAACAUCAACGUGAGAAACUUcc-3′ (SEQ ID NO: 980)3′-CGUUUUUGUAGUUGCACUCUUUGAAGG-5′ (SEQ ID NO: 2089) βc-m2746 Target:5′-GCAAAAACATCAACGTGAGAAACTTCC-3′ (SEQ ID NO: 3198)5′-GCAAAAACAUCAACGUGAGAAACtt-3′ (SEQ ID NO: 981)3′-ACCGUUUUUGUAGUUGCACUCUUUGAA-5′ (SEQ ID NO: 2090) βc-m2748 Target:5′-TGGCAAAAACATCAACGTGAGAAACTT-3′ (SEQ ID NO: 3199)5′-GCAAAAGCUGUGGCAAAAACAUCaa-3′ (SEQ ID NO: 982)3′-GACGUUUUCGACACCGUUUUUGUAGUU-5′ (SEQ ID NO: 2091) βc-m2760 Target:5′-CTGCAAAAGCTGTGGCAAAAACATCAA-3′ (SEQ ID NO: 3200)5′-UGCAAAAGCUGUGGCAAAAACAUca-3′ (SEQ ID NO: 983)3′-CGACGUUUUCGACACCGUUUUUGUAGU-5′ (SEQ ID NO: 2092) βc-m2761 Target:5′-GCTGCAAAAGCTGTGGCAAAAACATCA-3′ (SEQ ID NO: 3201)5′-UCAUCUGAGUAUAACGCUGCAAAag-3′ (SEQ ID NO: 984)3′-UGAGUAGACUCAUAUUGCGACGUUUUC-5′ (SEQ ID NO: 2093) βc-m2778 Target:5′-ACTCATCTGAGTATAACGCTGCAAAAG-3′ (SEQ ID NO: 3202)5′-AAAACAGCAAAUGUUACUCAUCUga-3′ (SEQ ID NO: 985)3′-ACUUUUGUCGUUUACAAUGAGUAGACU-5′ (SEQ ID NO: 2094) βc-m2795 Target:5′-TGAAAACAGCAAATGTTACTCATCTGA-3′ (SEQ ID NO: 3203)5′-GAAAACAGCAAAUGUUACUCAUCtg-3′ (SEQ ID NO: 986)3′-AACUUUUGUCGUUUACAAUGAGUAGAC-5′ (SEQ ID NO: 2095) βc-m2796 Target:5′-TTGAAAACAGCAAATGTTACTCATCTG-3′ (SEQ ID NO: 3204)5′-UGAAAACAGCAAAUGUUACUCAUct-3′ (SEQ ID NO: 987)3′-CAACUUUUGUCGUUUACAAUGAGUAGA-5′ (SEQ ID NO: 2096) βc-m2797 Target:5′-GTTGAAAACAGCAAATGTTACTCATCT-3′ (SEQ ID NO: 3205)5′-AUUAAUGUUGAAAACAGCAAAUGtt-3′ (SEQ ID NO: 988)3′-GAUAAUUACAACUUUUGUCGUUUACAA-5′ (SEQ ID NO: 2097) βc-m2805 Target:5′-CTATTAATGTTGAAAACAGCAAATGTT-3′ (SEQ ID NO: 3206)5′-ACUACAGCUGUAUAGAGAGAAAGgc-3′ (SEQ ID NO: 989)3′-UGUGAUGUCGACAUAUCUCUCUUUCCG-5′ (SEQ ID NO: 2098) βc-m2834 Target:5′-ACACTACAGCTGTATAGAGAGAAAGGC-3′ (SEQ ID NO: 3207)5′-GGCCAAUCACAAUGCACGUUCAGac-3′ (SEQ ID NO: 990)3′-GUCCGGUUAGUGUUACGUGCAAGUCUG-5′ (SEQ ID NO: 2099) βc-m2859 Target:5′-CAGGCCAATCACAATGCACGTTCAGAC-3′ (SEQ ID NO: 3208)5′-GUUCCCAUAGGAAACUCAGCUUGgt-3′ (SEQ ID NO: 991)3′-GACAAGGGUAUCCUUUGAGUCGAACCA-5′ (SEQ ID NO: 2100) βc-m2946 Target:5′-CTGTTCCCATAGGAAACTCAGCTTGGT-3′ (SEQ ID NO: 3209)5′-GAACAAAAAGCGUACUUCGACUGtt-3′ (SEQ ID NO: 992)3′-GUCUUGUUUUUCGCAUGAAGCUGACAA-5′ (SEQ ID NO: 2101) βc-m2968 Target:5′-CAGAACAAAAAGCGTACTTCGACTGTT-3′ (SEQ ID NO: 3210)5′-GGACCAGAACAAAAAGCGUACUUcg-3′ (SEQ ID NO: 993)3′-UUCCUGGUCUUGUUUUUCGCAUGAAGC-5′ (SEQ ID NO: 2102) βc-m2974 Target:5′-AAGGACCAGAACAAAAAGCGTACTTCG-3′ (SEQ ID NO: 3211)5′-ACCAAAAAGGACCAGAACAAAAAgc-3′ (SEQ ID NO: 994)3′-GCUGGUUUUUCCUGGUCUUGUUUUUCG-5′ (SEQ ID NO: 2103) βc-m2982 Target:5′-CGACCAAAAAGGACCAGAACAAAAAGC-3′ (SEQ ID NO: 3212)5′-GACCAAAAAGGACCAGAACAAAAag-3′ (SEQ ID NO: 995)3′-AGCUGGUUUUUCCUGGUCUUGUUUUUC-5′ (SEQ ID NO: 2104) βc-m2983 Target:5′-TCGACCAAAAAGGACCAGAACAAAAAG-3′ (SEQ ID NO: 3213)5′-ACUCCUCGACCAAAAAGGACCAGaa-3′ (SEQ ID NO: 996)3′-AAUGAGGAGCUGGUUUUUCCUGGUCUU-5′ (SEQ ID NO: 2105) βc-m2990 Target:5′-TTACTCCTCGACCAAAAAGGACCAGAA-3′ (SEQ ID NO: 3214)5′-UCCAUUUGUAUUGUUACUCCUCGac-3′ (SEQ ID NO: 997)3′-UUAGGUAAACAUAACAAUGAGGAGCUG-5′ (SEQ ID NO: 2106) βc-m3005 Target:5′-AATCCATTTGTATTGTTACTCCTCGAC-3′ (SEQ ID NO: 3215)5′-AUCCAUUUGUAUUGUUACUCCUCga-3′ (SEQ ID NO: 998)3′-UUUAGGUAAACAUAACAAUGAGGAGCU-5′ (SEQ ID NO: 2107) βc-m3006 Target:5′-AAATCCATTTGTATTGTTACTCCTCGA-3′ (SEQ ID NO: 3216)5′-AAUCCAUUUGUAUUGUUACUCCUcg-3′ (SEQ ID NO: 999)3′-GUUUAGGUAAACAUAACAAUGAGGAGC-5′ (SEQ ID NO: 2108) βc-m3007 Target:5′-CAAATCCATTTGTATTGTTACTCCTCG-3′ (SEQ ID NO: 3217)5′-AAAUCCAUUUGUAUUGUUACUCCtc-3′ (SEQ ID NO: 1000)3′-GGUUUAGGUAAACAUAACAAUGAGGAG-5′ (SEQ ID NO: 2109) βc-m3008 Target:5′-CCAAATCCATTTGTATTGTTACTCCTC-3′ (SEQ ID NO: 3218)5′-ACUCCCCAAAUCCAUUUGUAUUGtt-3′ (SEQ ID NO: 1001)3′-AGUGAGGGGUUUAGGUAAACAUAACAA-5′ (SEQ ID NO: 2110) βc-m3015 Target:5′-TCACTCCCCAAATCCATTTGTATTGTT-3′ (SEQ ID NO: 3219)5′-UCCAUUCGUGUGCAUUCUUCACUgc-3′ (SEQ ID NO: 1002)3′-CUAGGUAAGCACACGUAAGAAGUGACG-5′ (SEQ ID NO: 2111) βc-m3047 Target:5′-GATCCATTCGTGTGCATTCTTCACTGC-3′ (SEQ ID NO: 3220)5′-AUCCAUUCGUGUGCAUUCUUCACtg-3′ (SEQ ID NO: 1003)3′-ACUAGGUAAGCACACGUAAGAAGUGAC-5′ (SEQ ID NO: 2112) βc-m3048 Target:5′-TGATCCATTCGTGTGCATTCTTCACTG-3′ (SEQ ID NO: 3221)5′-GAUCCAUUCGUGUGCAUUCUUCAct-3′ (SEQ ID NO: 1004)3′-CACUAGGUAAGCACACGUAAGAAGUGA-5′ (SEQ ID NO: 2113) βc-m3049 Target:5′-GTGATCCATTCGTGTGCATTCTTCACT-3′ (SEQ ID NO: 3222)5′-AAACAAAGAACAAGCAAGGCUAGgg-3′ (SEQ ID NO: 1005)3′-AUUUUGUUUCUUGUUCGUUCCGAUCCC-5′ (SEQ ID NO: 2114) βc-m3093 Target:5′-TAAAACAAAGAACAAGCAAGGCTAGGG-3′ (SEQ ID NO: 3223)5′-ACCACUACAGAUAUUAAAACAAAga-3′ (SEQ ID NO: 1006)3′-CGUGGUGAUGUCUAUAAUUUUGUUUCU-5′ (SEQ ID NO: 2115) βc-m3109 Target:5′-GCACCACTACAGATATTAAAACAAAGA-3′ (SEQ ID NO: 3224)5′-GCACCACUACAGAUAUUAAAACAaa-3′ (SEQ ID NO: 1007)3′-GUCGUGGUGAUGUCUAUAAUUUUGUUU-5′ (SEQ ID NO: 2116) βc-m3111 Target:5′-CAGCACCACTACAGATATTAAAACAAA-3′ (SEQ ID NO: 3225)5′-AGCACCACUACAGAUAUUAAAACaa-3′ (SEQ ID NO: 1008)3′-AGUCGUGGUGAUGUCUAUAAUUUUGUU-5′ (SEQ ID NO: 2117) βc-m3112 Target:5′-TCAGCACCACTACAGATATTAAAACAA-3′ (SEQ ID NO: 3226)5′-AAAAUAAAAGCAAGCAAAGUCAGca-3′ (SEQ ID NO: 1009)3′-UUUUUUAUUUUCGUUCGUUUCAGUCGU-5′ (SEQ ID NO: 2118) βc-m3133 Target:5′-AAAAAATAAAAGCAAGCAAAGTCAGCA-3′ (SEQ ID NO: 3227)5′-GCAAAAAAUAAAAGCAAGCAAAGtc-3′ (SEQ ID NO: 1010)3′-GACGUUUUUUAUUUUCGUUCGUUUCAG-5′ (SEQ ID NO: 2119) βc-m3137 Target:5′-CTGCAAAAAATAAAAGCAAGCAAAGTC-3′ (SEQ ID NO: 3228)5′-UUACUGCAAAAAAUAAAAGCAAGca-3′ (SEQ ID NO: 1011)3′-UCAAUGACGUUUUUUAUUUUCGUUCGU-5′ (SEQ ID NO: 2120) βc-m3142 Target:5′-AGTTACTGCAAAAAATAAAAGCAAGCA-3′ (SEQ ID NO: 3229)5′-UAACAGUUACUGCAAAAAAUAAAag-3′ (SEQ ID NO: 1012)3′-UGAUUGUCAAUGACGUUUUUUAUUUUC-5′ (SEQ ID NO: 2121) βc-m3148 Target:5′-ACTAACAGTTACTGCAAAAAATAAAAG-3′ (SEQ ID NO: 3230)5′-ACUAACAGUUACUGCAAAAAAUAaa-3′ (SEQ ID NO: 1013)3′-UUUGAUUGUCAAUGACGUUUUUUAUUU-5′ (SEQ ID NO: 2122) βc-m3150 Target:5′-AAACTAACAGTTACTGCAAAAAATAAA-3′ (SEQ ID NO: 3231)5′-AAACUAACAGUUACUGCAAAAAAta-3′ (SEQ ID NO: 1014)3′-UUUUUGAUUGUCAAUGACGUUUUUUAU-5′ (SEQ ID NO: 2123) βc-m3152 Target:5′-AAAAACTAACAGTTACTGCAAAAAATA-3′ (SEQ ID NO: 3232)5′-AAAACUAACAGUUACUGCAAAAAat-3′ (SEQ ID NO: 1015)3′-AUUUUUGAUUGUCAAUGACGUUUUUUA-5′ (SEQ ID NO: 2124) βc-m3153 Target:5′-TAAAAACTAACAGTTACTGCAAAAAAT-3′ (SEQ ID NO: 3233)5′-UAAAAACUAACAGUUACUGCAAAaa-3′ (SEQ ID NO: 1016)3′-GAAUUUUUGAUUGUCAAUGACGUUUUU-5′ (SEQ ID NO: 2125) βc-m3155 Target:5′-CTTAAAAACTAACAGTTACTGCAAAAA-3′ (SEQ ID NO: 3234)5′-UACUUAAAAACUAACAGUUACUGca-3′ (SEQ ID NO: 1017)3′-UGAUGAAUUUUUGAUUGUCAAUGACGU-5′ (SEQ ID NO: 2126) βc-m3159 Target:5′-ACTACTTAAAAACTAACAGTTACTGCA-3′ (SEQ ID NO: 3235)5′-ACUACUUAAAAACUAACAGUUACtg-3′ (SEQ ID NO: 1018)3′-UGUGAUGAAUUUUUGAUUGUCAAUGAC-5′ (SEQ ID NO: 2127) βc-m3161 Target:5′-ACACTACTTAAAAACTAACAGTTACTG-3′ (SEQ ID NO: 3236)5′-UAACACUACUUAAAAACUAACAGtt-3′ (SEQ ID NO: 1019)3′-GUAUUGUGAUGAAUUUUUGAUUGUCAA-5′ (SEQ ID NO: 2128) βc-m3165 Target:5′-CATAACACTACTTAAAAACTAACAGTT-3′ (SEQ ID NO: 3237)5′-AUAACACUACUUAAAAACUAACAgt-3′ (SEQ ID NO: 1020)3′-UGUAUUGUGAUGAAUUUUUGAUUGUCA-5′ (SEQ ID NO: 2129) βc-m3166 Target:5′-ACATAACACTACTTAAAAACTAACAGT-3′ (SEQ ID NO: 3238)5′-ACAUAACACUACUUAAAAACUAAca-3′ (SEQ ID NO: 1021)3′-CUUGUAUUGUGAUGAAUUUUUGAUUGU-5′ (SEQ ID NO: 2130) βc-m3168 Target:5′-GAACATAACACTACTTAAAAACTAACA-3′ (SEQ ID NO: 3239)5′-AACAUAACACUACUUAAAAACUAac-3′ (SEQ ID NO: 1022)3′-UCUUGUAUUGUGAUGAAUUUUUGAUUG-5′ (SEQ ID NO: 2131) βc-m3169 Target:5′-AGAACATAACACTACTTAAAAACTAAC-3′ (SEQ ID NO: 3240)5′-GAACAUAACACUACUUAAAAACUaa-3′ (SEQ ID NO: 1023)3′-AUCUUGUAUUGUGAUGAAUUUUUGAUU-5′ (SEQ ID NO: 2132) βc-m3170 Target:5′-TAGAACATAACACTACTTAAAAACTAA-3′ (SEQ ID NO: 3241)5′-AGAACAUAACACUACUUAAAAACta-3′ (SEQ ID NO: 1024)3′-GAUCUUGUAUUGUGAUGAAUUUUUGAU-5′ (SEQ ID NO: 2133) βc-m3171 Target:5′-CTAGAACATAACACTACTTAAAAACTA-3′ (SEQ ID NO: 3242)5′-UCACUAGAACAUAACACUACUUAaa-3′ (SEQ ID NO: 1025)3′-CAAGUGAUCUUGUAUUGUGAUGAAUUU-5′ (SEQ ID NO: 2134) βc-m3176 Target:5′-GTTCACTAGAACATAACACTACTTAAA-3′ (SEQ ID NO: 3243)5′-GUUCACUAGAACAUAACACUACUta-3′ (SEQ ID NO: 1026)3′-UCCAAGUGAUCUUGUAUUGUGAUGAAU-5′ (SEQ ID NO: 2135) βc-m3178 Target:5′-AGGTTCACTAGAACATAACACTACTTA-3′ (SEQ ID NO: 3244)5′-GGUUCACUAGAACAUAACACUACtt-3′ (SEQ ID NO: 1027)3′-GUCCAAGUGAUCUUGUAUUGUGAUGAA-5′ (SEQ ID NO: 2136) βc-m3179 Target:5′-CAGGTTCACTAGAACATAACACTACTT-3′ (SEQ ID NO: 3245)5′-AUUACUCGGUUCUUAGAAAUCAGaa-3′ (SEQ ID NO: 1028)3′-GGUAAUGAGCCAAGAAUCUUUAGUCUU-5′ (SEQ ID NO: 2137) βc-m3216 Target:5′-CCATTACTCGGTTCTTAGAAATCAGAA-3′ (SEQ ID NO: 3246)5′-ACCAUUACUCGGUUCUUAGAAAUca-3′ (SEQ ID NO: 1029)3′-UGUGGUAAUGAGCCAAGAAUCUUUAGU-5′ (SEQ ID NO: 2138) βc-m3219 Target:5′-ACACCATTACTCGGTTCTTAGAAATCA-3′ (SEQ ID NO: 3247)5′-UCUACACCAUUACUCGGUUCUUAga-3′ (SEQ ID NO: 1030)3′-CAAGAUGUGGUAAUGAGCCAAGAAUCU-5′ (SEQ ID NO: 2139) βc-m3224 Target:5′-GTTCTACACCATTACTCGGTTCTTAGA-3′ (SEQ ID NO: 3248)5′-GAAUUAGUGUUCUACACCAUUACtc-3′ (SEQ ID NO: 1031)3′-UACUUAAUCACAAGAUGUGGUAAUGAG-5′ (SEQ ID NO: 2140) βc-m3234 Target:5′-ATGAATTAGTGTTCTACACCATTACTC-3′ (SEQ ID NO: 3249)5′-AUUAUGAAUUAGUGUUCUACACCat-3′ (SEQ ID NO: 1032)3′-ACUAAUACUUAAUCACAAGAUGUGGUA-5′ (SEQ ID NO: 2141) βc-m3239 Target:5′-TGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 3250)5′-GAUUAUGAAUUAGUGUUCUACACca-3′ (SEQ ID NO: 1033)3′-CACUAAUACUUAAUCACAAGAUGUGGU-5′ (SEQ ID NO: 2142) βc-m3240 Target:5′-GTGATTATGAATTAGTGTTCTACACCA-3′ (SEQ ID NO: 3251)5′-UGAUUAUGAAUUAGUGUUCUACAcc-3′ (SEQ ID NO: 1034)3′-GCACUAAUACUUAAUCACAAGAUGUGG-5′ (SEQ ID NO: 2143) βc-m3241 Target:5′-CGTGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 3252)5′-ACAAUUAGCGUGAUUAUGAAUUAgt-3′ (SEQ ID NO: 1035)3′-AAUGUUAAUCGCACUAAUACUUAAUCA-5′ (SEQ ID NO: 2144) βc-m3251 Target:5′-TTACAATTAGCGTGATTATGAATTAGT-3′ (SEQ ID NO: 3253)5′-UACAAUUAGCGUGAUUAUGAAUUag-3′ (SEQ ID NO: 1036)3′-UAAUGUUAAUCGCACUAAUACUUAAUC-5′ (SEQ ID NO: 2145) βc-m3252 Target:5′-ATTACAATTAGCGTGATTATGAATTAG-3′ (SEQ ID NO: 3254)5′-AGAUUACAAUUAGCGUGAUUAUGaa-3′ (SEQ ID NO: 1037)3′-GGUCUAAUGUUAAUCGCACUAAUACUU-5′ (SEQ ID NO: 2146) βc-m3256 Target:5′-CCAGATTACAATTAGCGTGATTATGAA-3′ (SEQ ID NO: 3255)5′-UACACGUCUCCAGAUUACAAUUAgc-3′ (SEQ ID NO: 1038)3′-CAAUGUGCAGAGGUCUAAUGUUAAUCG-5′ (SEQ ID NO: 2147) βc-m3267 Target:5′-GTTACACGTCTCCAGATTACAATTAGC-3′ (SEQ ID NO: 3256)5′-GUUACACGUCUCCAGAUUACAAUta-3′ (SEQ ID NO: 1039)3′-UACAAUGUGCAGAGGUCUAAUGUUAAU-5′ (SEQ ID NO: 2148) βc-m3269 Target:5′-ATGTTACACGTCTCCAGATTACAATTA-3′ (SEQ ID NO: 3257)5′-UACACAAUGUUACACGUCUCCAGat-3′ (SEQ ID NO: 1040)3′-CGAUGUGUUACAAUGUGCAGAGGUCUA-5′ (SEQ ID NO: 2149) βc-m3277 Target:5′-GCTACACAATGTTACACGTCTCCAGAT-3′ (SEQ ID NO: 3258)5′-GCUACACAAUGUUACACGUCUCCag-3′ (SEQ ID NO: 1041)3′-UCCGAUGUGUUACAAUGUGCAGAGGUC-5′ (SEQ ID NO: 2150) βc-m3279 Target:5′-AGGCTACACAATGTTACACGTCTCCAG-3′ (SEQ ID NO: 3259)5′-ACAAAAGGCUACACAAUGUUACAcg-3′ (SEQ ID NO: 1042)3′-UAUGUUUUCCGAUGUGUUACAAUGUGC-5′ (SEQ ID NO: 2151) βc-m3286 Target:5′-ATACAAAAGGCTACACAATGTTACACG-3′ (SEQ ID NO: 3260)5′-UACAAAAGGCUACACAAUGUUACac-3′ (SEQ ID NO: 1043)3′-AUAUGUUUUCCGAUGUGUUACAAUGUG-5′ (SEQ ID NO: 2152) βc-m3287 Target:5′-TATACAAAAGGCTACACAATGTTACAC-3′ (SEQ ID NO: 3261)5′-UUUAUACAAAAGGCUACACAAUGtt-3′ (SEQ ID NO: 1044)3′-AUAAAUAUGUUUUCCGAUGUGUUACAA-5′ (SEQ ID NO: 2153) βc-m3291 Target:5′-TATTTATACAAAAGGCTACACAATGTT-3′ (SEQ ID NO: 3262)5′-AUUUAUACAAAAGGCUACACAAUgt-3′ (SEQ ID NO: 1045)3′-GAUAAAUAUGUUUUCCGAUGUGUUACA-5′ (SEQ ID NO: 2154) βc-m3292 Target:5′-CTATTTATACAAAAGGCTACACAATGT-3′ (SEQ ID NO: 3263)5′-UCUAUUUAUACAAAAGGCUACACaa-3′ (SEQ ID NO: 1046)3′-ACAGAUAAAUAUGUUUUCCGAUGUGUU-5′ (SEQ ID NO: 2155) βc-m3295 Target:5′-TGTCTATTTATACAAAAGGCTACACAA-3′ (SEQ ID NO: 3264)5′-GUCUAUUUAUACAAAAGGCUACAca-3′ (SEQ ID NO: 1047)3′-GACAGAUAAAUAUGUUUUCCGAUGUGU-5′ (SEQ ID NO: 2156) βc-m3296 Target:5′-CTGTCTATTTATACAAAAGGCTACACA-3′ (SEQ ID NO: 3265)5′-UGUCUAUUUAUACAAAAGGCUACac-3′ (SEQ ID NO: 1048)3′-AGACAGAUAAAUAUGUUUUCCGAUGUG-5′ (SEQ ID NO: 2157) βc-m3297 Target:5′-TCTGTCTATTTATACAAAAGGCTACAC-3′ (SEQ ID NO: 3266)5′-UCUAUCUGUCUAUUUAUACAAAAgg-3′ (SEQ ID NO: 1049)3′-AAAGAUAGACAGAUAAAUAUGUUUUCC-5′ (SEQ ID NO: 2158) βc-m3303 Target:5′-TTTCTATCTGTCTATTTATACAAAAGG-3′ (SEQ ID NO: 3267)5′-UUCUAUCUGUCUAUUUAUACAAAag-3′ (SEQ ID NO: 1050)3′-UAAAGAUAGACAGAUAAAUAUGUUUUC-5′ (SEQ ID NO: 2159) βc-m3304 Target:5′-ATTTCTATCTGTCTATTTATACAAAAG-3′ (SEQ ID NO: 3268)5′-UUUCUAUCUGUCUAUUUAUACAAaa-3′ (SEQ ID NO: 1051)3′-GUAAAGAUAGACAGAUAAAUAUGUUUU-5′ (SEQ ID NO: 2160) βc-m3305 Target:5′-CATTTCTATCTGTCTATTTATACAAAA-3′ (SEQ ID NO: 3269)5′-AUUUCUAUCUGUCUAUUUAUACAaa-3′ (SEQ ID NO: 1052)3′-GGUAAAGAUAGACAGAUAAAUAUGUUU-5′ (SEQ ID NO: 2161) βc-m3306 Target:5′-CCATTTCTATCTGTCTATTTATACAAA-3′ (SEQ ID NO: 3270)5′-GACCAUUUCUAUCUGUCUAUUUAta-3′ (SEQ ID NO: 1053)3′-GCCUGGUAAAGAUAGACAGAUAAAUAU-5′ (SEQ ID NO: 2162) βc-m3310 Target:5′-CGGACCATTTCTATCTGTCTATTTATA-3′ (SEQ ID NO: 3271)5′-GGACCAUUUCUAUCUGUCUAUUUat-3′ (SEQ ID NO: 1054)3′-AGCCUGGUAAAGAUAGACAGAUAAAUA-5′ (SEQ ID NO: 2163) βc-m3311 Target:5′-TCGGACCATTTCTATCTGTCTATTTAT-3′ (SEQ ID NO: 3272)5′-ACUAAUCGGACCAUUUCUAUCUGtc-3′ (SEQ ID NO: 1055)3′-UUUGAUUAGCCUGGUAAAGAUAGACAG-5′ (SEQ ID NO: 2164) βc-m3318 Target:5′-AAACTAATCGGACCATTTCTATCTGTC-3′ (SEQ ID NO: 3273)5′-AACUAAUCGGACCAUUUCUAUCUgt-3′ (SEQ ID NO: 1056)3′-CUUUGAUUAGCCUGGUAAAGAUAGACA-5′ (SEQ ID NO: 2165) βc-m3319 Target:5′-GAAACTAATCGGACCATTTCTATCTGT-3′ (SEQ ID NO: 3274)5′-AAACUAAUCGGACCAUUUCUAUCtg-3′ (SEQ ID NO: 1057)3′-CCUUUGAUUAGCCUGGUAAAGAUAGAC-5′ (SEQ ID NO: 2166) βc-m3320 Target:5′-GGAAACTAATCGGACCATTTCTATCTG-3′ (SEQ ID NO: 3275)5′-GAAACUAAUCGGACCAUUUCUAUct-3′ (SEQ ID NO: 1058)3′-UCCUUUGAUUAGCCUGGUAAAGAUAGA-5′ (SEQ ID NO: 2167) βc-m3321 Target:5′-AGGAAACTAATCGGACCATTTCTATCT-3′ (SEQ ID NO: 3276)5′-UAAAAAGGAAACUAAUCGGACCAtt-3′ (SEQ ID NO: 1059)3′-UAAUUUUUCCUUUGAUUAGCCUGGUAA-5′ (SEQ ID NO: 2168) βc-m3328 Target:5′-ATTAAAAAGGAAACTAATCGGACCATT-3′ (SEQ ID NO: 3277)5′-GCAUAUUAAAAAGGAAACUAAUCgg-3′ (SEQ ID NO: 1060)3′-UUCGUAUAAUUUUUCCUUUGAUUAGCC-5′ (SEQ ID NO: 2169) βc-m3334 Target:5′-AAGCATATTAAAAAGGAAACTAATCGG-3′ (SEQ ID NO: 3278)5′-AGCAUAUUAAAAAGGAAACUAAUcg-3′ (SEQ ID NO: 1061)3′-AUUCGUAUAAUUUUUCCUUUGAUUAGC-5′ (SEQ ID NO: 2170) βc-m3335 Target:5′-TAAGCATATTAAAAAGGAAACTAATCG-3′ (SEQ ID NO: 3279)5′-UUUAAGCAUAUUAAAAAGGAAACta-3′ (SEQ ID NO: 1062)3′-UAAAAUUCGUAUAAUUUUUCCUUUGAU-5′ (SEQ ID NO: 2171) βc-m3339 Target:5′-ATTTTAAGCATATTAAAAAGGAAACTA-3′ (SEQ ID NO: 3280)5′-GCUUAUUUUAAGCAUAUUAAAAAgg-3′ (SEQ ID NO: 1063)3′-GACGAAUAAAAUUCGUAUAAUUUUUCC-5′ (SEQ ID NO: 2172) βc-m3345 Target:5′-CTGCTTATTTTAAGCATATTAAAAAGG-3′ (SEQ ID NO: 3281)5′-UGCUUAUUUUAAGCAUAUUAAAAag-3′ (SEQ ID NO: 1064)3′-GGACGAAUAAAAUUCGUAUAAUUUUUC-5′ (SEQ ID NO: 2173) βc-m3346 Target:5′-CCTGCTTATTTTAAGCATATTAAAAAG-3′ (SEQ ID NO: 3282)5′-UCCACCUGCUUAUUUUAAGCAUAtt-3′ (SEQ ID NO: 1065)3′-CUAGGUGGACGAAUAAAAUUCGUAUAA-5′ (SEQ ID NO: 2174) βc-m3352 Target:5′-GATCCACCTGCTTATTTTAAGCATATT-3′ (SEQ ID NO: 3283)5′-AAAACAUGAAAUAGAUCCACCUGct-3′ (SEQ ID NO: 1066)3′-GUUUUUGUACUUUAUCUAGGUGGACGA-5′ (SEQ ID NO: 2175) βc-m3367 Target:5′-CAAAAACATGAAATAGATCCACCTGCT-3′ (SEQ ID NO: 3284)5′-AAAAACAUGAAAUAGAUCCACCUgc-3′ (SEQ ID NO: 1067)3′-AGUUUUUGUACUUUAUCUAGGUGGACG-5′ (SEQ ID NO: 2176) βc-m3368 Target:5′-TCAAAAACATGAAATAGATCCACCTGC-3′ (SEQ ID NO: 3285)5′-UCAAAAACAUGAAAUAGAUCCACct-3′ (SEQ ID NO: 1068)3′-CAAGUUUUUGUACUUUAUCUAGGUGGA-5′ (SEQ ID NO: 2177) βc-m3370 Target:5′-GTTCAAAAACATGAAATAGATCCACCT-3′ (SEQ ID NO: 3286)5′-UUCAAAAACAUGAAAUAGAUCCAcc-3′ (SEQ ID NO: 1069)3′-ACAAGUUUUUGUACUUUAUCUAGGUGG-5′ (SEQ ID NO: 2178) βc-m3371 Target:5′-TGTTCAAAAACATGAAATAGATCCACC-3′ (SEQ ID NO: 3287)5′-GUUCAAAAACAUGAAAUAGAUCCac-3′ (SEQ ID NO: 1070)3′-AACAAGUUUUUGUACUUUAUCUAGGUG-5′ (SEQ ID NO: 2179) βc-m3372 Target:5′-TTGTTCAAAAACATGAAATAGATCCAC-3′ (SEQ ID NO: 3288)5′-UUUUUGUUCAAAAACAUGAAAUAga-3′ (SEQ ID NO: 1071)3′-UCAAAAACAAGUUUUUGUACUUUAUCU-5′ (SEQ ID NO: 2180) βc-m3377 Target:5′-AGTTTTTGTTCAAAAACATGAAATAGA-3′ (SEQ ID NO: 3289)5′-AUAAAGUUUUUGUUCAAAAACAUga-3′ (SEQ ID NO: 1072)3′-GCUAUUUCAAAAACAAGUUUUUGUACU-5′ (SEQ ID NO: 2181) βc-m3383 Target:5′-CGATAAAGTTTTTGTTCAAAAACATGA-3′ (SEQ ID NO: 3290)5′-UCCCCGAUAAAGUUUUUGUUCAAaa-3′ (SEQ ID NO: 1073)3′-AUAGGGGCUAUUUCAAAAACAAGUUUU-5′ (SEQ ID NO: 2182) βc-m3389 Target:5′-TATCCCCGATAAAGTTTTTGTTCAAAA-3′ (SEQ ID NO: 3291)5′-AUCCCCGAUAAAGUUUUUGUUCAaa-3′ (SEQ ID NO: 1074)3′-CAUAGGGGCUAUUUCAAAAACAAGUUU-5′ (SEQ ID NO: 2183) βc-m3390 Target:5′-GTATCCCCGATAAAGTTTTTGTTCAAA-3′ (SEQ ID NO: 3292)5′-ACCUCUUACUGAUUUACCCUACCgc-3′ (SEQ ID NO: 1075)3′-UGUGGAGAAUGACUAAAUGGGAUGGCG-5′ (SEQ ID NO: 2184) βc-m3419 Target:5′-ACACCTCTTACTGATTTACCCTACCGC-3′ (SEQ ID NO: 3293)5′-ACACCUCUUACUGAUUUACCCUAcc-3′ (SEQ ID NO: 1076)3′-AUUGUGGAGAAUGACUAAAUGGGAUGG-5′ (SEQ ID NO: 2185) βc-m3421 Target:5′-TAACACCTCTTACTGATTTACCCTACC-3′ (SEQ ID NO: 3294)5′-AACACCUCUUACUGAUUUACCCUac-3′ (SEQ ID NO: 1077)3′-UAUUGUGGAGAAUGACUAAAUGGGAUG-5′ (SEQ ID NO: 2186) βc-m3422 Target:5′-ATAACACCTCTTACTGATTTACCCTAC-3′ (SEQ ID NO: 3295)5′-UAACACCUCUUACUGAUUUACCCta-3′ (SEQ ID NO: 1078)3′-UUAUUGUGGAGAAUGACUAAAUGGGAU-5′ (SEQ ID NO: 2187) βc-m3423 Target:5′-AATAACACCTCTTACTGATTTACCCTA-3′ (SEQ ID NO: 3296)5′-AUAACACCUCUUACUGAUUUACCct-3′ (SEQ ID NO: 1079)3′-UUUAUUGUGGAGAAUGACUAAAUGGGA-5′ (SEQ ID NO: 2188) βc-m3424 Target:5′-AAATAACACCTCTTACTGATTTACCCT-3′ (SEQ ID NO: 3297)5′-AAUAACACCUCUUACUGAUUUACcc-3′ (SEQ ID NO: 1080)3′-GUUUAUUGUGGAGAAUGACUAAAUGGG-5′ (SEQ ID NO: 2189) βc-m3425 Target:5′-CAAATAACACCTCTTACTGATTTACCC-3′ (SEQ ID NO: 3298)5′-GGCUCAAAUAACACCUCUUACUGat-3′ (SEQ ID NO: 1081)3′-UUCCGAGUUUAUUGUGGAGAAUGACUA-5′ (SEQ ID NO: 2190) βc-m3431 Target:5′-AAGGCTCAAATAACACCTCTTACTGAT-3′ (SEQ ID NO: 3299)5′-AACAAGGCUCAAAUAACACCUCUta-3′ (SEQ ID NO: 1082)3′-UUUUGUUCCGAGUUUAUUGUGGAGAAU-5′ (SEQ ID NO: 2191) βc-m3436 Target:5′-AAAACAAGGCTCAAATAACACCTCTTA-3′ (SEQ ID NO: 3300)5′-AAACAAGGCUCAAAUAACACCUCtt-3′ (SEQ ID NO: 1083)3′-GUUUUGUUCCGAGUUUAUUGUGGAGAA-5′ (SEQ ID NO: 2192) βc-m3437 Target:5′-CAAAACAAGGCTCAAATAACACCTCTT-3′ (SEQ ID NO: 3301)5′-AAAACAAGGCUCAAAUAACACCUct-3′ (SEQ ID NO: 1084)3′-GGUUUUGUUCCGAGUUUAUUGUGGAGA-5′ (SEQ ID NO: 2193) βc-m3438 Target:5′-CCAAAACAAGGCTCAAATAACACCTCT-3′ (SEQ ID NO: 3302)5′-UCCAAAACAAGGCUCAAAUAACAcc-3′ (SEQ ID NO: 1085)3′-ACAGGUUUUGUUCCGAGUUUAUUGUGG-5′ (SEQ ID NO: 2194) βc-m3441 Target:5′-TGTCCAAAACAAGGCTCAAATAACACC-3′ (SEQ ID NO: 3303)5′-UGUCCAAAACAAGGCUCAAAUAAca-3′ (SEQ ID NO: 1086)3′-UGACAGGUUUUGUUCCGAGUUUAUUGU-5′ (SEQ ID NO: 2195) βc-m3443 Target:5′-ACTGTCCAAAACAAGGCTCAAATAACA-3′ (SEQ ID NO: 3304)5′-UAUACUGUCCAAAACAAGGCUCAaa-3′ (SEQ ID NO: 1087)3′-CCAUAUGACAGGUUUUGUUCCGAGUUU-5′ (SEQ ID NO: 2196) βc-m3448 Target:5′-GGTATACTGTCCAAAACAAGGCTCAAA-3′ (SEQ ID NO: 3305)5′-GCAACUGGUAUACUGUCCAAAACaa-3′ (SEQ ID NO: 1088)3′-UCCGUUGACCAUAUGACAGGUUUUGUU-5′ (SEQ ID NO: 2197) βc-m3456 Target:5′-AGGCAACTGGTATACTGTCCAAAACAA-3′ (SEQ ID NO: 3306)5′-GAUAAAAGGCAACUGGUAUACUGtc-3′ (SEQ ID NO: 1089)3′-CCCUAUUUUCCGUUGACCAUAUGACAG-5′ (SEQ ID NO: 2198) βc-m3464 Target:5′-GGGATAAAAGGCAACTGGTATACTGTC-3′ (SEQ ID NO: 3307)5′-GGAUAAAAGGCAACUGGUAUACUgt-3′ (SEQ ID NO: 1090)3′-ACCCUAUUUUCCGUUGACCAUAUGACA-5′ (SEQ ID NO: 2199) βc-m3465 Target:5′-TGGGATAAAAGGCAACTGGTATACTGT-3′ (SEQ ID NO: 3308)5′-AACUUUGGGAUAAAAGGCAACUGgt-3′ (SEQ ID NO: 1091)3′-UGUUGAAACCCUAUUUUCCGUUGACCA-5′ (SEQ ID NO: 2200) βc-m3472 Target:5′-ACAACTTTGGGATAAAAGGCAACTGGT-3′ (SEQ ID NO: 3309)5′-ACAACUUUGGGAUAAAAGGCAACtg-3′ (SEQ ID NO: 1092)3′-GUUGUUGAAACCCUAUUUUCCGUUGAC-5′ (SEQ ID NO: 2201) βc-m3474 Target:5′-CAACAACTTTGGGATAAAAGGCAACTG-3′ (SEQ ID NO: 3310)5′-UUACAACAACUUUGGGAUAAAAGgc-3′ (SEQ ID NO: 1093)3′-CCAAUGUUGUUGAAACCCUAUUUUCCG-5′ (SEQ ID NO: 2202) βc-m3479 Target:5′-GGTTACAACAACTTTGGGATAAAAGGC-3′ (SEQ ID NO: 3311)5′-GUUACAACAACUUUGGGAUAAAAgg-3′ (SEQ ID NO: 1094)3′-UCCAAUGUUGUUGAAACCCUAUUUUCC-5′ (SEQ ID NO: 2203) βc-m3480 Target:5′-AGGTTACAACAACTTTGGGATAAAAGG-3′ (SEQ ID NO: 3312)5′-GGUUACAACAACUUUGGGAUAAAag-3′ (SEQ ID NO: 1095)3′-GUCCAAUGUUGUUGAAACCCUAUUUUC-5′ (SEQ ID NO: 2204) βc-m3481 Target:5′-CAGGTTACAACAACTTTGGGATAAAAG-3′ (SEQ ID NO: 3313)5′-UCACAGCAGGUUACAACAACUUUgg-3′ (SEQ ID NO: 1096)3′-AUAGUGUCGUCCAAUGUUGUUGAAACC-5′ (SEQ ID NO: 2205) βc-m3489 Target:5′-TATCACAGCAGGTTACAACAACTTTGG-3′ (SEQ ID NO: 3314)5′-AUCACAGCAGGUUACAACAACUUtg-3′ (SEQ ID NO: 1097)3′-CAUAGUGUCGUCCAAUGUUGUUGAAAC-5′ (SEQ ID NO: 2206) βc-m3490 Target:5′-GTATCACAGCAGGTTACAACAACTTTG-3′ (SEQ ID NO: 3315)5′-GUAUCACAGCAGGUUACAACAACtt-3′ (SEQ ID NO: 1098)3′-AACAUAGUGUCGUCCAAUGUUGUUGAA-5′ (SEQ ID NO: 2207) βc-m3492 Target:5′-TTGTATCACAGCAGGTTACAACAACTT-3′ (SEQ ID NO: 3316)5′-GCAUCUGUUGAAGCAUUGUAUCAca-3′ (SEQ ID NO: 1099)3′-GGCGUAGACAACUUCGUAACAUAGUGU-5′ (SEQ ID NO: 2208) βc-m3509 Target:5′-CCGCATCTGTTGAAGCATTGTATCACA-3′ (SEQ ID NO: 3317)5′-UGAACCAUUUCUAUAACCGCAUCtg-3′ (SEQ ID NO: 1100)3′-AGACUUGGUAAAGAUAUUGGCGUAGAC-5′ (SEQ ID NO: 2209) βc-m3527 Target:5′-TCTGAACCATTTCTATAACCGCATCTG-3′ (SEQ ID NO: 3318)5′-AUUCUGAACCAUUUCUAUAACCGca-3′ (SEQ ID NO: 1101)3′-AUUAAGACUUGGUAAAGAUAUUGGCGU-5′ (SEQ ID NO: 2210) βc-m3531 Target:5′-TAATTCTGAACCATTTCTATAACCGCA-3′ (SEQ ID NO: 3319)5′-UAAUUCUGAACCAUUUCUAUAACcg-3′ (SEQ ID NO: 1102)3′-AAAUUAAGACUUGGUAAAGAUAUUGGC-5′ (SEQ ID NO: 2211) βc-m3533 Target:5′-TTTAATTCTGAACCATTTCTATAACCG-3′ (SEQ ID NO: 3320)5′-UUAAUUCUGAACCAUUUCUAUAAcc-3′ (SEQ ID NO: 1103)3′-CAAAUUAAGACUUGGUAAAGAUAUUGG-5′ (SEQ ID NO: 2212) βc-m3534 Target:5′-GTTTAATTCTGAACCATTTCTATAACC-3′ (SEQ ID NO: 3321)5′-UUUAAUUCUGAACCAUUUCUAUAac-3′ (SEQ ID NO: 1104)3′-UCAAAUUAAGACUUGGUAAAGAUAUUG-5′ (SEQ ID NO: 2213) βc-m3535 Target:5′-AGTTTAATTCTGAACCATTTCTATAAC-3′ (SEQ ID NO: 3322)5′-GUUUAAUUCUGAACCAUUUCUAUaa-3′ (SEQ ID NO: 1105)3′-UUCAAAUUAAGACUUGGUAAAGAUAUU-5′ (SEQ ID NO: 2214) βc-m3536 Target:5′-AAGTTTAATTCTGAACCATTTCTATAA-3′ (SEQ ID NO: 3323)5′-UAAAAGUUUAAUUCUGAACCAUUtc-3′ (SEQ ID NO: 1106)3′-UAAUUUUCAAAUUAAGACUUGGUAAAG-5′ (SEQ ID NO: 2215) βc-m3541 Target:5′-ATTAAAAGTTTAATTCTGAACCATTTC-3′ (SEQ ID NO: 3324)5′-UUAAAAGUUUAAUUCUGAACCAUtt-3′ (SEQ ID NO: 1107)3′-UUAAUUUUCAAAUUAAGACUUGGUAAA-5′ (SEQ ID NO: 2216) βc-m3542 Target:5′-AATTAAAAGTTTAATTCTGAACCATTT-3′ (SEQ ID NO: 3325)5′-AAUUAAAAGUUUAAUUCUGAACCat-3′ (SEQ ID NO: 1108)3′-ACUUAAUUUUCAAAUUAAGACUUGGUA-5′ (SEQ ID NO: 2217) βc-m3544 Target:5′-TGAATTAAAAGTTTAATTCTGAACC-3′ (SEQ ID NO: 3326)5′-UGAAUGAAUUAAAAGUUUAAUUCtg-3′ (SEQ ID NO: 1109)3′-AAACUUACUUAAUUUUCAAAUUAAGAC-5′ (SEQ ID NO: 2218) βc-m3550 Target:5′-TTTGAATGAATTAAAAGTTTAATTCTG-3′ (SEQ ID NO: 3327)5′-UUUUUGAAUGAAUUAAAAGUUUAat-3′ (SEQ ID NO: 1110)3′-AAAAAAACUUACUUAAUUUUCAAAUUA-5′ (SEQ ID NO: 2219) βc-m3554 Target:5′-TTTTTTTGAATGAATTAAAAGTTTAAT-3′ (SEQ ID NO: 3328)5′-UUUUUUUUUGAAUGAAUUAAAAGtt-3′ (SEQ ID NO: 1111)3′-AAAAAAAAAAACUUACUUAAUUUUCAA-5′ (SEQ ID NO: 2220) βc-m3558 Target:5′-TTTTTTTTTTTGAATGAATTAAAAGTT-3′ (SEQ ID NO: 3329)5′-UUUUUUUUUUGAAUGAAUUAAAAgt-3′ (SEQ ID NO: 1112)3′-AAAAAAAAAAAACUUACUUAAUUUUCA-5′ (SEQ ID NO: 2221) βc-m3559 Target:5′-TTTTTTTTTTTTGAATGAATTAAAAGT-3′ (SEQ ID NO: 3330)5′-UUUUUUUUUUUGAAUGAAUUAAAag-3′ (SEQ ID NO: 1113)3′-AAAAAAAAAAAAACUUACUUAAUUUUC-5′ (SEQ ID NO: 2222) βc-m3560 Target:5′-TTTTTTTTTTTTTGAATGAATTAAAAG-3′ (SEQ ID NO: 3331)5′-UUUUUUUUUUUUGAAUGAAUUAAaa-3′ (SEQ ID NO: 1114)3′-AAAAAAAAAAAAAACUUACUUAAUUUU-5′ (SEQ ID NO: 2223) βc-m3561 Target:5′-TTTTTTTTTTTTTTGAATGAATTAAAA-3′ (SEQ ID NO: 3332)5′-UUUUUUUUUUUUUGAAUGAAUUAaa-3′ (SEQ ID NO: 1115)3′-AAAAAAAAAAAAAAACUUACUUAAUUU-5′ (SEQ ID NO: 2224) βc-m3562 Target:5′-TTTTTTTTTTTTTTTGAATGAATTAAA-3′ (SEQ ID NO: 3333)5′-UUUUUUUUUUUUUUGAAUGAAUUaa-3′ (SEQ ID NO: 1116)3′-AAAAAAAAAAAAAAAACUUACUUAAUU-5′ (SEQ ID NO: 2225) βc-m3563 Target:5′-TTTTTTTTTTTTTTTTGAATGAATTAA-3′ (SEQ ID NO: 3334)

Projected 21 nucleotide target sequences for each DsiRNA of Table 9above and of Tables 11-13 below are presented in Table 10.

TABLE 10 21 Nucleotide Target Sequences of Additional Selected DsiRNAsβc-244 21 nt Target: 5′-GTTGTATGGTATACTTCAAAT-3′ (SEQ ID NO: 4932)βc-251 21 nt Target: 5′-CAAAACAGTTGTATGGTATAC-3′ (SEQ ID NO: 4933)βc-252 21 nt Target: 5′-TCAAAACAGTTGTATGGTATA-3′ (SEQ ID NO: 4934)βc-254 21 nt Target: 5′-TTTCAAAACAGTTGTATGGTA-3′ (SEQ ID NO: 4935)βc-255 21 nt Target: 5′-TTTTCAAAACAGTTGTATGGT-3′ (SEQ ID NO: 4936)βc-256 21 nt Target: 5′-ATTTTCAAAACAGTTGTATGG-3′ (SEQ ID NO: 4937)βc-269 21 nt Target: 5′-TTGTCCACGCTGGATTTTCAA-3′ (SEQ ID NO: 4938)βc-270 21 nt Target: 5′-ATTGTCCACGCTGGATTTTCA-3′ (SEQ ID NO: 4939)βc-293 21 nt Target: 5′-CCATCAAATCAGCTTGAGTAG-3′ (SEQ ID NO: 4940)βc-302 21 nt Target: 5′-TGTCCAACTCCATCAAATCAG-3′ (SEQ ID NO: 4941)βc-431 21 nt Target: 5′-CTTCCTCAGGATTGCCTTTAC-3′ (SEQ ID NO: 4942)βc-432 21 nt Target: 5′-TCTTCCTCAGGATTGCCTTTA-3′ (SEQ ID NO: 4943)βc-518 21 nt Target: 5′-CATCAATATCAGCTACTTGTT-3′ (SEQ ID NO: 4944)βc-519 21 nt Target: 5′-CCATCAATATCAGCTACTTGT-3′ (SEQ ID NO: 4945)βc-524 21 nt Target: 5′-ACTGTCCATCAATATCAGCTA-3′ (SEQ ID NO: 4946)βc-531 21 nt Target: 5′-ATTGCATACTGTCCATCAATA-3′ (SEQ ID NO: 4947)βc-537 21 nt Target: 5′-CGAGTCATTGCATACTGTCCA-3′ (SEQ ID NO: 4948)βc-584 21 nt Target: 5′-CCTCATCTAATGTCTCAGGGA-3′ (SEQ ID NO: 4949)βc-680 21 nt Target: 5′-TTACAACTGCATGTTTCAGCA-3′ (SEQ ID NO: 4950)βc-682 21 nt Target: 5′-GTTTACAACTGCATGTTTCAG-3′ (SEQ ID NO: 4951)βc-692 21 nt Target: 5′-AGTTAATCAAGTTTACAACTG-3′ (SEQ ID NO: 4952)βc-698 21 nt Target: 5′-CTTGATAGTTAATCAAGTTTA-3′ (SEQ ID NO: 4953)βc-707 21 nt Target: 5′-CTGCATCATCTTGATAGTTAA-3′ (SEQ ID NO: 4954)βc-708 21 nt Target: 5′-TCTGCATCATCTTGATAGTTA-3′ (SEQ ID NO: 4955)βc-763 21 nt Target: 5′-CTGGTCCTCGTCATTTAGCAG-3′ (SEQ ID NO: 4956)βc-790 21 nt Target: 5′-CATAACTGCAGCCTTATTAAC-3′ (SEQ ID NO: 4957)βc-791 21 nt Target: 5′-CCATAACTGCAGCCTTATTAA-3′ (SEQ ID NO: 4958)βc-794 21 nt Target: 5′-GGACCATAACTGCAGCCTTAT-3′ (SEQ ID NO: 4959)βc-812 21 nt Target: 5′-CCTTTTTAGAAAGCTGATGGA-3′ (SEQ ID NO: 4960)βc-873 21 nt Target: 5′-ATGGTACGTACAATAGCAGAC-3′ (SEQ ID NO: 4961)βc-890 21 nt Target: 5′-CATCATTTGTATTCTGCATGG-3′ (SEQ ID NO: 4962)βc-899 21 nt Target: 5′-CTGTTTCTACATCATTTGTAT-3′ (SEQ ID NO: 4963)βc-900 21 nt Target: 5′-GCTGTTTCTACATCATTTGTA-3′ (SEQ ID NO: 4964)βc-909 21 nt Target: 5′-GTACAACGAGCTGTTTCTACA-3′ (SEQ ID NO: 4965)βc-911 21 nt Target: 5′-CGGTACAACGAGCTGTTTCTA-3′ (SEQ ID NO: 4966)βc-912 21 nt Target: 5′-GCGGTACAACGAGCTGTTTCT-3′ (SEQ ID NO: 4967)βc-1032 21 nt Target: 5′-GCATAAAACAACACAGAATCC-3′ (SEQ ID NO: 4968)βc-1034 21 nt Target: 5′-TGGCATAAAACAACACAGAAT-3′ (SEQ ID NO: 4969)βc-1035 21 nt Target: 5′-ATGGCATAAAACAACACAGAA-3′ (SEQ ID NO: 4970)βc-1076 21 nt Target: 5′-TAGCTCCTTCTTGATGTAATA-3′ (SEQ ID NO: 4971)βc-1077 21 nt Target: 5′-TTAGCTCCTTCTTGATGTAAT-3′ (SEQ ID NO: 4972)βc-1144 21 nt Target: 5′-TTTAACATTTGTTTTGTTGAG-3′ (SEQ ID NO: 4973)βc-1154 21 nt Target: 5′-TAGCCAAGAATTTAACATTTG-3′ (SEQ ID NO: 4974)βc-1159 21 nt Target: 5′-CGTAATAGCCAAGAATTTAAC-3′ (SEQ ID NO: 4975)βc-1160 21 nt Target: 5′-TCGTAATAGCCAAGAATTTAA-3′ (SEQ ID NO: 4976)βc-1185 21 nt Target: 5′-TAAGCTAAAATTTGAAGGCAG-3′ (SEQ ID NO: 4977)βc-1260 21 nt Target: 5′-TAGGTCCTCATTATATTTACT-3′ (SEQ ID NO: 4978)βc-1265 21 nt Target: 5′-AAGTATAGGTCCTCATTATAT-3′ (SEQ ID NO: 4979)βc-1266 21 nt Target: 5′-TAAGTATAGGTCCTCATTATA-3′ (SEQ ID NO: 4980)βc-1274 21 nt Target: 5′-GTTTTTCGTAAGTATAGGTCC-3′ (SEQ ID NO: 4981)βc-1275 21 nt Target: 5′-AGTTTTTCGTAAGTATAGGTC-3′ (SEQ ID NO: 4982)βc-1276 21 nt Target: 5′-TAGTTTTTCGTAAGTATAGGT-3′ (SEQ ID NO: 4983)βc-1277 21 nt Target: 5′-GTAGTTTTTCGTAAGTATAGG-3′ (SEQ ID NO: 4984)βc-1287 21 nt Target: 5′-GTGGTCCACAGTAGTTTTTCG-3′ (SEQ ID NO: 4985)βc-1344 21 nt Target: 5′-TCTACAATAGCCGGCTTATTA-3′ (SEQ ID NO: 4986)βc-1346 21 nt Target: 5′-CTTCTACAATAGCCGGCTTAT-3′ (SEQ ID NO: 4987)βc-1371 21 nt Target: 5′-AGTCCTAAAGCTTGCATTCCA-3′ (SEQ ID NO: 4988)βc-1372 21 nt Target: 5′-AAGTCCTAAAGCTTGCATTCC-3′ (SEQ ID NO: 4989)βc-1373 21 nt Target: 5′-GAAGTCCTAAAGCTTGCATTC-3′ (SEQ ID NO: 4990)βc-1410 21 nt Target: 5′-CAGTTCTGAACAAGACGTTGA-3′ (SEQ ID NO: 4991)βc-1411 21 nt Target: 5′-ACAGTTCTGAACAAGACGTTG-3′ (SEQ ID NO: 4992)βc-1421 21 nt Target: 5′-GAGTCCAAAGACAGTTCTGAA-3′ (SEQ ID NO: 4993)βc-1458 21 nt Target: 5′-CCTTCCTGTTTAGTTGCAGCA-3′ (SEQ ID NO: 4994)βc-1517 21 nt Target: 5′-CCACATTTATATCATCTGAAC-3′ (SEQ ID NO: 4995)βc-1520 21 nt Target: 5′-TGACCACATTTATATCATCTG-3′ (SEQ ID NO: 4996)βc-1529 21 nt Target: 5′-CTGCACAGGTGACCACATTTA-3′ (SEQ ID NO: 4997)βc-1530 21 nt Target: 5′-GCTGCACAGGTGACCACATTT-3′ (SEQ ID NO: 4998)βc-1558 21 nt Target: 5′-ATTGCAAGTGAGGTTAGAAAG-3′ (SEQ ID NO: 4999)βc-1566 21 nt Target: 5′-TTATAATTATTGCAAGTGAGG-3′ (SEQ ID NO: 5000)βc-1579 21 nt Target: 5′-CATCATCTTGTTCTTATAATT-3′ (SEQ ID NO: 5001)βc-1580 21 nt Target: 5′-CCATCATCTTGTTCTTATAAT-3′ (SEQ ID NO: 5002)βc-1583 21 nt Target: 5′-AGACCATCATCTTGTTCTTAT-3′ (SEQ ID NO: 5003)βc-1585 21 nt Target: 5′-GCAGACCATCATCTTGTTCTT-3′ (SEQ ID NO: 5004)βc-1808 21 nt Target: 5′-TCAATCCAACAGTAGCCTTTA-3′ (SEQ ID NO: 5005)βc-1813 21 nt Target: 5′-TCGAATCAATCCAACAGTAGC-3′ (SEQ ID NO: 5006)βc-1955 21 nt Target: 5′-CCTCCACAAATTGCTGCTGTG-3′ (SEQ ID NO: 5007)βc-1989 21 nt Target: 5′-GTACAACCTTCAACTATTTCT-3′ (SEQ ID NO: 5008)βc-1990 21 nt Target: 5′-GGTACAACCTTCAACTATTTC-3′ (SEQ ID NO: 5009)βc-1991 21 nt Target: 5′-CGGTACAACCTTCAACTATTT-3′ (SEQ ID NO: 5010)βc-1992 21 nt Target: 5′-CCGGTACAACCTTCAACTATT-3′ (SEQ ID NO: 5011)βc-1997 21 nt Target: 5′-GGGCTCCGGTACAACCTTCAA-3′ (SEQ ID NO: 5012)βc-2036 21 nt Target: 5′-TAACAATTCGGTTGTGAACAT-3′ (SEQ ID NO: 5013)βc-2037 21 nt Target: 5′-ATAACAATTCGGTTGTGAACA-3′ (SEQ ID NO: 5014)βc-2038 21 nt Target: 5′-GATAACAATTCGGTTGTGAAC-3′ (SEQ ID NO: 5015)βc-2039 21 nt Target: 5′-TGATAACAATTCGGTTGTGAA-3′ (SEQ ID NO: 5016)βc-2040 21 nt Target: 5′-CTGATAACAATTCGGTTGTGA-3′ (SEQ ID NO: 5017)βc-2041 21 nt Target: 5′-TCTGATAACAATTCGGTTGTG-3′ (SEQ ID NO: 5018)βc-2052 21 nt Target: 5′-GTATTTAGTCCTCTGATAACA-3′ (SEQ ID NO: 5019)βc-2053 21 nt Target: 5′-GGTATTTAGTCCTCTGATAAC-3′ (SEQ ID NO: 5020)βc-2054 21 nt Target: 5′-TGGTATTTAGTCCTCTGATAA-3′ (SEQ ID NO: 5021)βc-2055 21 nt Target: 5′-ATGGTATTTAGTCCTCTGATA-3′ (SEQ ID NO: 5022)βc-2065 21 nt Target: 5′-AAACAATGGAATGGTATTTAG-3′ (SEQ ID NO: 5023)βc-2069 21 nt Target: 5′-GCACAAACAATGGAATGGTAT-3′ (SEQ ID NO: 5024)βc-2071 21 nt Target: 5′-CTGCACAAACAATGGAATGGT-3′ (SEQ ID NO: 5025)βc-2072 21 nt Target: 5′-GCTGCACAAACAATGGAATGG-3′ (SEQ ID NO: 5026)βc-2111 21 nt Target: 5′-CAGCTACTCTTTGGATGTTTT-3′ (SEQ ID NO: 5027)βc-2112 21 nt Target: 5′-GCAGCTACTCTTTGGATGTTT-3′ (SEQ ID NO: 5028)βc-2168 21 nt Target: 5′-CAGCTTCAATAGCTTCTGCAG-3′ (SEQ ID NO: 5029)βc-2175 21 nt Target: 5′-GCTCCCTCAGCTTCAATAGCT-3′ (SEQ ID NO: 5030)βc-2177 21 nt Target: 5′-TGGCTCCCTCAGCTTCAATAG-3′ (SEQ ID NO: 5031)βc-2214 21 nt Target: 5′-TCATTCCTAGAGTGAAGTAAC-3′ (SEQ ID NO: 5032)βc-2216 21 nt Target: 5′-CTTCATTCCTAGAGTGAAGTA-3′ (SEQ ID NO: 5033)βc-2217 21 nt Target: 5′-CCTTCATTCCTAGAGTGAAGT-3′ (SEQ ID NO: 5034)βc-2264 21 nt Target: 5′-TGTCCTCAGACATTCGGAACA-3′ (SEQ ID NO: 5035)βc-2266 21 nt Target: 5′-CTTGTCCTCAGACATTCGGAA-3′ (SEQ ID NO: 5036)βc-2287 21 nt Target: 5′-CCGTTTCTTGTAATCTTGTGG-3′ (SEQ ID NO: 5037)βc-2295 21 nt Target: 5′-ACTGAAAGCCGTTTCTTGTAA-3′ (SEQ ID NO: 5038)βc-2302 21 nt Target: 5′-CAGCTCAACTGAAAGCCGTTT-3′ (SEQ ID NO: 5039)βc-2363 21 nt Target: 5′-CAAGTCCAAGATCAGCAGTCT-3′ (SEQ ID NO: 5040)βc-2373 21 nt Target: 5′-GCACCAATATCAAGTCCAAGA-3′ (SEQ ID NO: 5041)βc-2424 21 nt Target: 5′-AAAGAACGATAGCTAGGATCA-3′ (SEQ ID NO: 5042)βc-2441 21 nt Target: 5′-CATATCCACCAGAGTGAAAAG-3′ (SEQ ID NO: 5043)βc-2618 21 nt Target: 5′-TGATTTACAGGTCAGTATCAA-3′ (SEQ ID NO: 5044)βc-2619 21 nt Target: 5′-ATGATTTACAGGTCAGTATCA-3′ (SEQ ID NO: 5045)βc-2620 21 nt Target: 5′-GATGATTTACAGGTCAGTATC-3′ (SEQ ID NO: 5046)βc-2634 21 nt Target: 5′-CTTCTTACCTAAAGGATGATT-3′ (SEQ ID NO: 5047)βc-2635 21 nt Target: 5′-ACTTCTTACCTAAAGGATGAT-3′ (SEQ ID NO: 5048)βc-2637 21 nt Target: 5′-AAACTTCTTACCTAAAGGATG-3′ (SEQ ID NO: 5049)βc-2645 21 nt Target: 5′-GCTTTTTAAAACTTCTTACCT-3′ (SEQ ID NO: 5050)βc-2647 21 nt Target: 5′-TGGCTTTTTAAAACTTCTTAC-3′ (SEQ ID NO: 5051)βc-2653 21 nt Target: 5′-CCAAACTGGCTTTTTAAAACT-3′ (SEQ ID NO: 5052)βc-2657 21 nt Target: 5′-TTACCCAAACTGGCTTTTTAA-3′ (SEQ ID NO: 5053)βc-2658 21 nt Target: 5′-TTTACCCAAACTGGCTTTTTA-3′ (SEQ ID NO: 5054)βc-2659 21 nt Target: 5′-TTTTACCCAAACTGGCTTTTT-3′ (SEQ ID NO: 5055)βc-2660 21 nt Target: 5′-ATTTTACCCAAACTGGCTTTT-3′ (SEQ ID NO: 5056)βc-2701 21 nt Target: 5′-CCAACCAAGTCTTTCTGAAGT-3′ (SEQ ID NO: 5057)βc-2709 21 nt Target: 5′-CCACCCTACCAACCAAGTCTT-3′ (SEQ ID NO: 5058)βc-2733 21 nt Target: 5′-ATTTACAAATAGCCTAAACCA-3′ (SEQ ID NO: 5059)βc-2734 21 nt Target: 5′-GATTTACAAATAGCCTAAACC-3′ (SEQ ID NO: 5060)βc-2735 21 nt Target: 5′-AGATTTACAAATAGCCTAAAC-3′ (SEQ ID NO: 5061)βc-2736 21 nt Target: 5′-CAGATTTACAAATAGCCTAAA-3′ (SEQ ID NO: 5062)βc-2747 21 nt Target: 5′-TGTTTTTGTGGCAGATTTACA-3′ (SEQ ID NO: 5063)βc-2748 21 nt Target: 5′-CTGTTTTTGTGGCAGATTTAC-3′ (SEQ ID NO: 5064)βc-2749 21 nt Target: 5′-CCTGTTTTTGTGGCAGATTTA-3′ (SEQ ID NO: 5065)βc-2754 21 nt Target: 5′-ATATACCTGTTTTTGTGGCAG-3′ (SEQ ID NO: 5066)βc-2764 21 nt Target: 5′-CTTTCAAAGTATATACCTGTT-3′ (SEQ ID NO: 5067)βc-2770 21 nt Target: 5′-CATCTCCTTTCAAAGTATATA-3′ (SEQ ID NO: 5068)βc-2771 21 nt Target: 5′-ACATCTCCTTTCAAAGTATAT-3′ (SEQ ID NO: 5069)βc-2773 21 nt Target: 5′-AGACATCTCCTTTCAAAGTAT-3′ (SEQ ID NO: 5070)βc-2774 21 nt Target: 5′-AAGACATCTCCTTTCAAAGTA-3′ (SEQ ID NO: 5071)βc-2775 21 nt Target: 5′-CAAGACATCTCCTTTCAAAGT-3′ (SEQ ID NO: 5072)βc-2780 21 nt Target: 5′-TGTTCCAAGACATCTCCTTTC-3′ (SEQ ID NO: 5073)βc-2788 21 nt Target: 5′-CATTCCAATGTTCCAAGACAT-3′ (SEQ ID NO: 5074)βc-2789 21 nt Target: 5′-ACATTCCAATGTTCCAAGACA-3′ (SEQ ID NO: 5075)βc-2791 21 nt Target: 5′-GAACATTCCAATGTTCCAAGA-3′ (SEQ ID NO: 5076)βc-2803 21 nt Target: 5′-CCAGAAATCTGAGAACATTCC-3′ (SEQ ID NO: 5077)βc-2807 21 nt Target: 5′-ACAACCAGAAATCTGAGAACA-3′ (SEQ ID NO: 5078)βc-2809 21 nt Target: 5′-TAACAACCAGAAATCTGAGAA-3′ (SEQ ID NO: 5079)βc-2810 21 nt Target: 5′-ATAACAACCAGAAATCTGAGA-3′ (SEQ ID NO: 5080)βc-2811 21 nt Target: 5′-CATAACAACCAGAAATCTGAG-3′ (SEQ ID NO: 5081)βc-2817 21 nt Target: 5′-TGATCACATAACAACCAGAAA-3′ (SEQ ID NO: 5082)βc-2818 21 nt Target: 5′-ATGATCACATAACAACCAGAA-3′ (SEQ ID NO: 5083)βc-2824 21 nt Target: 5′-CCACACATGATCACATAACAA-3′ (SEQ ID NO: 5084)βc-2827 21 nt Target: 5′-CTTCCACACATGATCACATAA-3′ (SEQ ID NO: 5085)βc-2832 21 nt Target: 5′-AATAACTTCCACACATGATCA-3′ (SEQ ID NO: 5086)βc-2833 21 nt Target: 5′-TAATAACTTCCACACATGATC-3′ (SEQ ID NO: 5087)βc-2834 21 nt Target: 5′-TTAATAACTTCCACACATGAT-3′ (SEQ ID NO: 5088)βc-2835 21 nt Target: 5′-GTTAATAACTTCCACACATGA-3′ (SEQ ID NO: 5089)βc-2842 21 nt Target: 5′-CATTAAAGTTAATAACTTCCA-3′ (SEQ ID NO: 5090)βc-2843 21 nt Target: 5′-ACATTAAAGTTAATAACTTCC-3′ (SEQ ID NO: 5091)βc-2845 21 nt Target: 5′-AAACATTAAAGTTAATAACTT-3′ (SEQ ID NO: 5092)βc-2846 21 nt Target: 5′-AAAACATTAAAGTTAATAACT-3′ (SEQ ID NO: 5093)βc-2847 21 nt Target: 5′-AAAAACATTAAAGTTAATAAC-3′ (SEQ ID NO: 5094)βc-2848 21 nt Target: 5′-AAAAAACATTAAAGTTAATAA-3′ (SEQ ID NO: 5095)βc-2849 21 nt Target: 5′-CAAAAAACATTAAAGTTAATA-3′ (SEQ ID NO: 5096)βc-2850 21 nt Target: 5′-GCAAAAAACATTAAAGTTAAT-3′ (SEQ ID NO: 5097)βc-2852 21 nt Target: 5′-TGGCAAAAAACATTAAAGTTA-3′ (SEQ ID NO: 5098)βc-2853 21 nt Target: 5′-GTGGCAAAAAACATTAAAGTT-3′ (SEQ ID NO: 5099)βc-2864 21 nt Target: 5′-TTGCAAAAGCTGTGGCAAAAA-3′ (SEQ ID NO: 5100)βc-2865 21 nt Target: 5′-GTTGCAAAAGCTGTGGCAAAA-3′ (SEQ ID NO: 5101)βc-2882 21 nt Target: 5′-ACTCATTTGAGTATTAAGTTG-3′ (SEQ ID NO: 5102)βc-2899 21 nt Target: 5′-TTAAAACAGCAAATGTTACTC-3′ (SEQ ID NO: 5103)βc-2900 21 nt Target: 5′-TTTAAAACAGCAAATGTTACT-3′ (SEQ ID NO: 5104)βc-2901 21 nt Target: 5′-GTTTAAAACAGCAAATGTTAC-3′ (SEQ ID NO: 5105)βc-2902 21 nt Target: 5′-TGTTTAAAACAGCAAATGTTA-3′ (SEQ ID NO: 5106)βc-2903 21 nt Target: 5′-ATGTTTAAAACAGCAAATGTT-3′ (SEQ ID NO: 5107)βc-2904 21 nt Target: 5′-AATGTTTAAAACAGCAAATGT-3′ (SEQ ID NO: 5108)βc-2909 21 nt Target: 5′-CTATTAATGTTTAAAACAGCA-3′ (SEQ ID NO: 5109)βc-2921 21 nt Target: 5′-AGAGAAAGGCTGCTATTAATG-3′ (SEQ ID NO: 5110)βc-2949 21 nt Target: 5′-CAAGTTCAGACAATACAGCTG-3′ (SEQ ID NO: 5111)βc-2957 21 nt Target: 5′-TCACAATGCAAGTTCAGACAA-3′ (SEQ ID NO: 5112)βc-2959 21 nt Target: 5′-AATCACAATGCAAGTTCAGAC-3′ (SEQ ID NO: 5113)βc-2961 21 nt Target: 5′-CCAATCACAATGCAAGTTCAG-3′ (SEQ ID NO: 5114)βc-2965 21 nt Target: 5′-CAGGCCAATCACAATGCAAGT-3′ (SEQ ID NO: 5115)βc-3052 21 nt Target: 5′-TTGTTCCCATAGGAAACTCAG-3′ (SEQ ID NO: 5116)βc-3058 21 nt Target: 5′-CTTCAATTGTTCCCATAGGAA-3′ (SEQ ID NO: 5117)βc-3059 21 nt Target: 5′-ACTTCAATTGTTCCCATAGGA-3′ (SEQ ID NO: 5118)βc-3065 21 nt Target: 5′-AAGTTTACTTCAATTGTTCCC-3′ (SEQ ID NO: 5119)βc-3066 21 nt Target: 5′-AAAGTTTACTTCAATTGTTCC-3′ (SEQ ID NO: 5120)βc-3070 21 nt Target: 5′-ACAAAAAGTTTACTTCAATTG-3′ (SEQ ID NO: 5121)βc-3074 21 nt Target: 5′-CAGAACAAAAAGTTTACTTCA-3′ (SEQ ID NO: 5122)βc-3079 21 nt Target: 5′-AGGACCAGAACAAAAAGTTTA-3′ (SEQ ID NO: 5123)βc-3080 21 nt Target: 5′-AAGGACCAGAACAAAAAGTTT-3′ (SEQ ID NO: 5124)βc-3088 21 nt Target: 5′-CGACCAAAAAGGACCAGAACA-3′ (SEQ ID NO: 5125)βc-3089 21 nt Target: 5′-TCGACCAAAAAGGACCAGAAC-3′ (SEQ ID NO: 5126)βc-3096 21 nt Target: 5′-TTACTCCTCGACCAAAAAGGA-3′ (SEQ ID NO: 5127)βc-3111 21 nt Target: 5′-AATCCATTTGTATTGTTACTC-3′ (SEQ ID NO: 5128)βc-3112 21 nt Target: 5′-AAATCCATTTGTATTGTTACT-3′ (SEQ ID NO: 5129)βc-3113 21 nt Target: 5′-AAAATCCATTTGTATTGTTAC-3′ (SEQ ID NO: 5130)βc-3114 21 nt Target: 5′-CAAAATCCATTTGTATTGTTA-3′ (SEQ ID NO: 5131)βc-3115 21 nt Target: 5′-CCAAAATCCATTTGTATTGTT-3′ (SEQ ID NO: 5132)βc-3121 21 nt Target: 5′-TCACTCCCAAAATCCATTTGT-3′ (SEQ ID NO: 5133)βc-3136 21 nt Target: 5′-TCTTCACTTCTTGAGTCACTC-3′ (SEQ ID NO: 5134)βc-3138 21 nt Target: 5′-ATTCTTCACTTCTTGAGTCAC-3′ (SEQ ID NO: 5135)βc-3139 21 nt Target: 5′-CATTCTTCACTTCTTGAGTCA-3′ (SEQ ID NO: 5136)βc-3140 21 nt Target: 5′-GCATTCTTCACTTCTTGAGTC-3′ (SEQ ID NO: 5137)βc-3142 21 nt Target: 5′-GTGCATTCTTCACTTCTTGAG-3′ (SEQ ID NO: 5138)βc-3150 21 nt Target: 5′-CCATTCTTGTGCATTCTTCAC-3′ (SEQ ID NO: 5139)βc-3153 21 nt Target: 5′-GATCCATTCTTGTGCATTCTT-3′ (SEQ ID NO: 5140)βc-3154 21 nt Target: 5′-TGATCCATTCTTGTGCATTCT-3′ (SEQ ID NO: 5141)βc-3155 21 nt Target: 5′-GTGATCCATTCTTGTGCATTC-3′ (SEQ ID NO: 5142)βc-3168 21 nt Target: 5′-TAAATTCCATCTTGTGATCCA-3′ (SEQ ID NO: 5143)βc-3170 21 nt Target: 5′-GATAAATTCCATCTTGTGATC-3′ (SEQ ID NO: 5144)βc-3171 21 nt Target: 5′-TGATAAATTCCATCTTGTGAT-3′ (SEQ ID NO: 5145)βc-3172 21 nt Target: 5′-TTGATAAATTCCATCTTGTGA-3′ (SEQ ID NO: 5146)βc-3173 21 nt Target: 5′-TTTGATAAATTCCATCTTGTG-3′ (SEQ ID NO: 5147)βc-3183 21 nt Target: 5′-AAGGCTAGGGTTTGATAAATT-3′ (SEQ ID NO: 5148)βc-3200 21 nt Target: 5′-AAAAAAATTTAACAAGCAAGG-3′ (SEQ ID NO: 5149)βc-3209 21 nt Target: 5′-AAAAAAAAAAAAAAAATTTAA-3′ (SEQ ID NO: 5150)βc-3210 21 nt Target: 5′-AAAAAAAAAAAAAAAAATTTA-3′ (SEQ ID NO: 5151)βc-3211 21 nt Target: 5′-AAAAAAAAAAAAAAAAAATTT-3′ (SEQ ID NO: 5152)βc-3212 21 nt Target: 5′-AAAAAAAAAAAAAAAAAAATT-3′ (SEQ ID NO: 5153)βc-3213 21 nt Target: 5′-TAAAAAAAAAAAAAAAAAAAT-3′ (SEQ ID NO: 5154)βc-3214 21 nt Target: 5′-TTAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 5155)βc-3215 21 nt Target: 5′-CTTAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 5156)βc-3216 21 nt Target: 5′-TCTTAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 5157)βc-3218 21 nt Target: 5′-ATTCTTAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 5158)βc-3219 21 nt Target: 5′-TATTCTTAAAAAAAAAAAAAA-3′ (SEQ ID NO: 5159)βc-3220 21 nt Target: 5′-ATATTCTTAAAAAAAAAAAAA-3′ (SEQ ID NO: 5160)βc-3221 21 nt Target: 5′-GATATTCTTAAAAAAAAAAAA-3′ (SEQ ID NO: 5161)βc-3222 21 nt Target: 5′-AGATATTCTTAAAAAAAAAAA-3′ (SEQ ID NO: 5162)βc-3223 21 nt Target: 5′-CAGATATTCTTAAAAAAAAAA-3′ (SEQ ID NO: 5163)βc-3224 21 nt Target: 5′-ACAGATATTCTTAAAAAAAAA-3′ (SEQ ID NO: 5164)βc-3228 21 nt Target: 5′-CATTACAGATATTCTTAAAAA-3′ (SEQ ID NO: 5165)βc-3229 21 nt Target: 5′-CCATTACAGATATTCTTAAAA-3′ (SEQ ID NO: 5166)βc-3233 21 nt Target: 5′-AGTACCATTACAGATATTCTT-3′ (SEQ ID NO: 5167)βc-3234 21 nt Target: 5′-CAGTACCATTACAGATATTCT-3′ (SEQ ID NO: 5168)βc-3235 21 nt Target: 5′-TCAGTACCATTACAGATATTC-3′ (SEQ ID NO: 5169)βc-3239 21 nt Target: 5′-AAAGTCAGTACCATTACAGAT-3′ (SEQ ID NO: 5170)βc-3256 21 nt Target: 5′-GCTACTTCAAAGCAAGCAAAG-3′ (SEQ ID NO: 5171)βc-3265 21 nt Target: 5′-AAAAAAAGAGCTACTTCAAAG-3′ (SEQ ID NO: 5172)βc-3270 21 nt Target: 5′-AAAAAAAAAAAAGAGCTACTT-3′ (SEQ ID NO: 5173)βc-3271 21 nt Target: 5′-AAAAAAAAAAAAAGAGCTACT-3′ (SEQ ID NO: 5174)βc-3273 21 nt Target: 5′-AAAAAAAAAAAAAAAGAGCTA-3′ (SEQ ID NO: 5175)βc-3274 21 nt Target: 5′-AAAAAAAAAAAAAAAAGAGCT-3′ (SEQ ID NO: 5176)βc-3275 21 nt Target: 5′-AAAAAAAAAAAAAAAAAGAGC-3′ (SEQ ID NO: 5177)βc-3276 21 nt Target: 5′-AAAAAAAAAAAAAAAAAAGAG-3′ (SEQ ID NO: 5178)βc-3282 21 nt Target: 5′-AAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 5179)βc-3283 21 nt Target: 5′-AAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 5180)βc-3284 21 nt Target: 5′-CAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 5181)βc-3285 21 nt Target: 5′-GCAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 5182)βc-3287 21 nt Target: 5′-CTGCAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 5183)βc-3288 21 nt Target: 5′-ACTGCAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 5184)βc-3292 21 nt Target: 5′-AGTTACTGCAAAAAAAAAAAA-3′ (SEQ ID NO: 5185)βc-3293 21 nt Target: 5′-CAGTTACTGCAAAAAAAAAAA-3′ (SEQ ID NO: 5186)βc-3294 21 nt Target: 5′-ACAGTTACTGCAAAAAAAAAA-3′ (SEQ ID NO: 5187)βc-3298 21 nt Target: 5′-AAAAACAGTTACTGCAAAAAA-3′ (SEQ ID NO: 5188)βc-3299 21 nt Target: 5′-AAAAAACAGTTACTGCAAAAA-3′ (SEQ ID NO: 5189)βc-3300 21 nt Target: 5′-TAAAAAACAGTTACTGCAAAA-3′ (SEQ ID NO: 5190)βc-3302 21 nt Target: 5′-CTTAAAAAACAGTTACTGCAA-3′ (SEQ ID NO: 5191)βc-3303 21 nt Target: 5′-ACTTAAAAAACAGTTACTGCA-3′ (SEQ ID NO: 5192)βc-3305 21 nt Target: 5′-AGACTTAAAAAACAGTTACTG-3′ (SEQ ID NO: 5193)βc-3315 21 nt Target: 5′-ACACTACGAGAGACTTAAAAA-3′ (SEQ ID NO: 5194)βc-3317 21 nt Target: 5′-TAACACTACGAGAGACTTAAA-3′ (SEQ ID NO: 5195)βc-3318 21 nt Target: 5′-TTAACACTACGAGAGACTTAA-3′ (SEQ ID NO: 5196)βc-3320 21 nt Target: 5′-ACTTAACACTACGAGAGACTT-3′ (SEQ ID NO: 5197)βc-3323 21 nt Target: 5′-ATAACTTAACACTACGAGAGA-3′ (SEQ ID NO: 5198)βc-3324 21 nt Target: 5′-TATAACTTAACACTACGAGAG-3′ (SEQ ID NO: 5199)βc-3332 21 nt Target: 5′-GTATTCACTATAACTTAACAC-3′ (SEQ ID NO: 5200)βc-3333 21 nt Target: 5′-AGTATTCACTATAACTTAACA-3′ (SEQ ID NO: 5201)βc-3334 21 nt Target: 5′-CAGTATTCACTATAACTTAAC-3′ (SEQ ID NO: 5202)βc-3335 21 nt Target: 5′-GCAGTATTCACTATAACTTAA-3′ (SEQ ID NO: 5203)βc-3348 21 nt Target: 5′-AGAAATTGCTGTAGCAGTATT-3′ (SEQ ID NO: 5204)βc-3349 21 nt Target: 5′-TAGAAATTGCTGTAGCAGTAT-3′ (SEQ ID NO: 5205)βc-3350 21 nt Target: 5′-TTAGAAATTGCTGTAGCAGTA-3′ (SEQ ID NO: 5206)βc-3366 21 nt Target: 5′-ACTCAATTCTTAAAAATTAGA-3′ (SEQ ID NO: 5207)βc-3371 21 nt Target: 5′-CCATTACTCAATTCTTAAAAA-3′ (SEQ ID NO: 5208)βc-3374 21 nt Target: 5′-ACACCATTACTCAATTCTTAA-3′ (SEQ ID NO: 5209)βc-3376 21 nt Target: 5′-CTACACCATTACTCAATTCTT-3′ (SEQ ID NO: 5210)βc-3377 21 nt Target: 5′-TCTACACCATTACTCAATTCT-3′ (SEQ ID NO: 5211)βc-3379 21 nt Target: 5′-GTTCTACACCATTACTCAATT-3′ (SEQ ID NO: 5212)βc-3381 21 nt Target: 5′-GTGTTCTACACCATTACTCAA-3′ (SEQ ID NO: 5213)βc-3389 21 nt Target: 5′-ATGAATTAGTGTTCTACACCA-3′ (SEQ ID NO: 5214)βc-3394 21 nt Target: 5′-TGATTATGAATTAGTGTTCTA-3′ (SEQ ID NO: 5215)βc-3395 21 nt Target: 5′-GTGATTATGAATTAGTGTTCT-3′ (SEQ ID NO: 5216)βc-3396 21 nt Target: 5′-AGTGATTATGAATTAGTGTTC-3′ (SEQ ID NO: 5217)βc-3405 21 nt Target: 5′-ATTAATTAGAGTGATTATGAA-3′ (SEQ ID NO: 5218)βc-3406 21 nt Target: 5′-AATTAATTAGAGTGATTATGA-3′ (SEQ ID NO: 5219)βc-3407 21 nt Target: 5′-CAATTAATTAGAGTGATTATG-3′ (SEQ ID NO: 5220)βc-3411 21 nt Target: 5′-ATTACAATTAATTAGAGTGAT-3′ (SEQ ID NO: 5221)βc-3412 21 nt Target: 5′-GATTACAATTAATTAGAGTGA-3′ (SEQ ID NO: 5222)βc-3413 21 nt Target: 5′-AGATTACAATTAATTAGAGTG-3′ (SEQ ID NO: 5223)βc-3421 21 nt Target: 5′-CTTTATTCAGATTACAATTAA-3′ (SEQ ID NO: 5224)βc-3422 21 nt Target: 5′-ACTTTATTCAGATTACAATTA-3′ (SEQ ID NO: 5225)βc-3426 21 nt Target: 5′-TTACACTTTATTCAGATTACA-3′ (SEQ ID NO: 5226)βc-3427 21 nt Target: 5′-GTTACACTTTATTCAGATTAC-3′ (SEQ ID NO: 5227)βc-3428 21 nt Target: 5′-TGTTACACTTTATTCAGATTA-3′ (SEQ ID NO: 5228)βc-3429 21 nt Target: 5′-TTGTTACACTTTATTCAGATT-3′ (SEQ ID NO: 5229)βc-3430 21 nt Target: 5′-ATTGTTACACTTTATTCAGAT-3′ (SEQ ID NO: 5230)βc-3437 21 nt Target: 5′-CTACACAATTGTTACACTTTA-3′ (SEQ ID NO: 5231)βc-3441 21 nt Target: 5′-AAGGCTACACAATTGTTACAC-3′ (SEQ ID NO: 5232)βc-3446 21 nt Target: 5′-ACAAAAAGGCTACACAATTGT-3′ (SEQ ID NO: 5233)βc-3452 21 nt Target: 5′-TTTTATACAAAAAGGCTACAC-3′ (SEQ ID NO: 5234)βc-3453 21 nt Target: 5′-ATTTTATACAAAAAGGCTACA-3′ (SEQ ID NO: 5235)βc-3455 21 nt Target: 5′-CTATTTTATACAAAAAGGCTA-3′ (SEQ ID NO: 5236)βc-3456 21 nt Target: 5′-TCTATTTTATACAAAAAGGCT-3′ (SEQ ID NO: 5237)βc-3458 21 nt Target: 5′-TGTCTATTTTATACAAAAAGG-3′ (SEQ ID NO: 5238)βc-3464 21 nt Target: 5′-TCTATTTGTCTATTTTATACA-3′ (SEQ ID NO: 5239)βc-3466 21 nt Target: 5′-TTTCTATTTGTCTATTTTATA-3′ (SEQ ID NO: 5240)βc-3467 21 nt Target: 5′-TTTTCTATTTGTCTATTTTAT-3′ (SEQ ID NO: 5241)βc-3468 21 nt Target: 5′-ATTTTCTATTTGTCTATTTTA-3′ (SEQ ID NO: 5242)βc-3469 21 nt Target: 5′-CATTTTCTATTTGTCTATTTT-3′ (SEQ ID NO: 5243)βc-3470 21 nt Target: 5′-CCATTTTCTATTTGTCTATTT-3′ (SEQ ID NO: 5244)βc-3473 21 nt Target: 5′-GGACCATTTTCTATTTGTCTA-3′ (SEQ ID NO: 5245)βc-3474 21 nt Target: 5′-TGGACCATTTTCTATTTGTCT-3′ (SEQ ID NO: 5246)βc-3475 21 nt Target: 5′-TTGGACCATTTTCTATTTGTC-3′ (SEQ ID NO: 5247)βc-3482 21 nt Target: 5′-AAACTAATTGGACCATTTTCT-3′ (SEQ ID NO: 5248)βc-3483 21 nt Target: 5′-GAAACTAATTGGACCATTTTC-3′ (SEQ ID NO: 5249)βc-3484 21 nt Target: 5′-GGAAACTAATTGGACCATTTT-3′ (SEQ ID NO: 5250)βc-3485 21 nt Target: 5′-AGGAAACTAATTGGACCATTT-3′ (SEQ ID NO: 5251)βc-3491 21 nt Target: 5′-TTAAAAAGGAAACTAATTGGA-3′ (SEQ ID NO: 5252)βc-3492 21 nt Target: 5′-ATTAAAAAGGAAACTAATTGG-3′ (SEQ ID NO: 5253)βc-3498 21 nt Target: 5′-AAGCATATTAAAAAGGAAACT-3′ (SEQ ID NO: 5254)βc-3499 21 nt Target: 5′-TAAGCATATTAAAAAGGAAAC-3′ (SEQ ID NO: 5255)βc-3503 21 nt Target: 5′-ATTTTAAGCATATTAAAAAGG-3′ (SEQ ID NO: 5256)βc-3509 21 nt Target: 5′-CTGCTTATTTTAAGCATATTA-3′ (SEQ ID NO: 5257)βc-3510 21 nt Target: 5′-CCTGCTTATTTTAAGCATATT-3′ (SEQ ID NO: 5258)βc-3516 21 nt Target: 5′-GATCCACCTGCTTATTTTAAG-3′ (SEQ ID NO: 5259)βc-3531 21 nt Target: 5′-CAAAAACATGAAATAGATCCA-3′ (SEQ ID NO: 5260)βc-3532 21 nt Target: 5′-TCAAAAACATGAAATAGATCC-3′ (SEQ ID NO: 5261)βc-3534 21 nt Target: 5′-GATCAAAAACATGAAATAGAT-3′ (SEQ ID NO: 5262)βc-3535 21 nt Target: 5′-TGATCAAAAACATGAAATAGA-3′ (SEQ ID NO: 5263)βc-3536 21 nt Target: 5′-TTGATCAAAAACATGAAATAG-3′ (SEQ ID NO: 5264)βc-3541 21 nt Target: 5′-AGTTTTTGATCAAAAACATGA-3′ (SEQ ID NO: 5265)βc-3547 21 nt Target: 5′-CCAAATAGTTTTTGATCAAAA-3′ (SEQ ID NO: 5266)βc-3551 21 nt Target: 5′-TATCCCAAATAGTTTTTGATC-3′ (SEQ ID NO: 5267)βc-3552 21 nt Target: 5′-ATATCCCAAATAGTTTTTGAT-3′ (SEQ ID NO: 5268)βc-3553 21 nt Target: 5′-CATATCCCAAATAGTTTTTGA-3′ (SEQ ID NO: 5269)βc-3554 21 nt Target: 5′-ACATATCCCAAATAGTTTTTG-3′ (SEQ ID NO: 5270)βc-3558 21 nt Target: 5′-CCATACATATCCCAAATAGTT-3′ (SEQ ID NO: 5271)βc-3567 21 nt Target: 5′-TTACCCTACCCATACATATCC-3′ (SEQ ID NO: 5272)βc-3568 21 nt Target: 5′-TTTACCCTACCCATACATATC-3′ (SEQ ID NO: 5273)βc-3569 21 nt Target: 5′-ATTTACCCTACCCATACATAT-3′ (SEQ ID NO: 5274)βc-3582 21 nt Target: 5′-ACACCTCTTACTGATTTACCC-3′ (SEQ ID NO: 5275)βc-3584 21 nt Target: 5′-TAACACCTCTTACTGATTTAC-3′ (SEQ ID NO: 5276)βc-3585 21 nt Target: 5′-ATAACACCTCTTACTGATTTA-3′ (SEQ ID NO: 5277)βc-3586 21 nt Target: 5′-AATAACACCTCTTACTGATTT-3′ (SEQ ID NO: 5278)βc-3587 21 nt Target: 5′-AAATAACACCTCTTACTGATT-3′ (SEQ ID NO: 5279)βc-3588 21 nt Target: 5′-CAAATAACACCTCTTACTGAT-3′ (SEQ ID NO: 5280)βc-3594 21 nt Target: 5′-AGGTTCCAAATAACACCTCTT-3′ (SEQ ID NO: 5281)βc-3600 21 nt Target: 5′-AAAACAAGGTTCCAAATAACA-3′ (SEQ ID NO: 5282)βc-3601 21 nt Target: 5′-CAAAACAAGGTTCCAAATAAC-3′ (SEQ ID NO: 5283)βc-3602 21 nt Target: 5′-CCAAAACAAGGTTCCAAATAA-3′ (SEQ ID NO: 5284)βc-3607 21 nt Target: 5′-ACTGTCCAAAACAAGGTTCCA-3′ (SEQ ID NO: 5285)βc-3611 21 nt Target: 5′-GTAAACTGTCCAAAACAAGGT-3′ (SEQ ID NO: 5286)βc-3612 21 nt Target: 5′-GGTAAACTGTCCAAAACAAGG-3′ (SEQ ID NO: 5287)βc-3620 21 nt Target: 5′-AGGCAACTGGTAAACTGTCCA-3′ (SEQ ID NO: 5288)βc-3628 21 nt Target: 5′-GGGATAAAAGGCAACTGGTAA-3′ (SEQ ID NO: 5289)βc-3629 21 nt Target: 5′-TGGGATAAAAGGCAACTGGTA-3′ (SEQ ID NO: 5290)βc-3636 21 nt Target: 5′-ACAACTTTGGGATAAAAGGCA-3′ (SEQ ID NO: 5291)βc-3638 21 nt Target: 5′-CAACAACTTTGGGATAAAAGG-3′ (SEQ ID NO: 5292)βc-3643 21 nt Target: 5′-GGTTACAACAACTTTGGGATA-3′ (SEQ ID NO: 5293)βc-3644 21 nt Target: 5′-AGGTTACAACAACTTTGGGAT-3′ (SEQ ID NO: 5294)βc-3645 21 nt Target: 5′-CAGGTTACAACAACTTTGGGA-3′ (SEQ ID NO: 5295)βc-3653 21 nt Target: 5′-TATCACAGCAGGTTACAACAA-3′ (SEQ ID NO: 5296)βc-3654 21 nt Target: 5′-GTATCACAGCAGGTTACAACA-3′ (SEQ ID NO: 5297)βc-3656 21 nt Target: 5′-TCGTATCACAGCAGGTTACAA-3′ (SEQ ID NO: 5298)βc-3670 21 nt Target: 5′-TTTCTCTTGAAGCATCGTATC-3′ (SEQ ID NO: 5299)βc-3671 21 nt Target: 5′-TTTTCTCTTGAAGCATCGTAT-3′ (SEQ ID NO: 5300)βc-3673 21 nt Target: 5′-CATTTTCTCTTGAAGCATCGT-3′ (SEQ ID NO: 5301)βc-3686 21 nt Target: 5′-TTTTTTATAACCGCATTTTCT-3′ (SEQ ID NO: 5302)βc-3687 21 nt Target: 5′-ATTTTTTATAACCGCATTTTC-3′ (SEQ ID NO: 5303)βc-3688 21 nt Target: 5′-CATTTTTTATAACCGCATTTT-3′ (SEQ ID NO: 5304)βc-3689 21 nt Target: 5′-CCATTTTTTATAACCGCATTT-3′ (SEQ ID NO: 5305)βc-3694 21 nt Target: 5′-CTGAACCATTTTTTATAACCG-3′ (SEQ ID NO: 5306)βc-3699 21 nt Target: 5′-TAATTCTGAACCATTTTTTAT-3′ (SEQ ID NO: 5307)βc-3700 21 nt Target: 5′-TTAATTCTGAACCATTTTTTA-3′ (SEQ ID NO: 5308)βc-3701 21 nt Target: 5′-TTTAATTCTGAACCATTTTTT-3′ (SEQ ID NO: 5309)βc-3702 21 nt Target: 5′-GTTTAATTCTGAACCATTTTT-3′ (SEQ ID NO: 5310)βc-3703 21 nt Target: 5′-AGTTTAATTCTGAACCATTTT-3′ (SEQ ID NO: 5311)βc-3704 21 nt Target: 5′-AAGTTTAATTCTGAACCATTT-3′ (SEQ ID NO: 5312)βc-3709 21 nt Target: 5′-ATTAAAAGTTTAATTCTGAAC-3′ (SEQ ID NO: 5313)βc-3710 21 nt Target: 5′-AATTAAAAGTTTAATTCTGAA-3′ (SEQ ID NO: 5314)βc-3712 21 nt Target: 5′-TGAATTAAAAGTTTAATTCTG-3′ (SEQ ID NO: 5315)βc-2634t2 21 nt Target: 5′-CAATACAGCTAAAGGATGATT-3′ (SEQ ID NO: 5316)βc-2635t2 21 nt Target: 5′-ACAATACAGCTAAAGGATGAT-3′ (SEQ ID NO: 5317)βc-2637t2 21 nt Target: 5′-AGACAATACAGCTAAAGGATG-3′ (SEQ ID NO: 5318)βc-2633t3 21 nt Target: 5′-GTTACTCCTAAAGGATGATTT-3′ (SEQ ID NO: 5319)βc-2634t3 21 nt Target: 5′-TGTTACTCCTAAAGGATGATT-3′ (SEQ ID NO: 5320)βc-2635t3 21 nt Target: 5′-TTGTTACTCCTAAAGGATGAT-3′ (SEQ ID NO: 5321)βc-2636t3 21 nt Target: 5′-ATTGTTACTCCTAAAGGATGA-3′ (SEQ ID NO: 5322)βc-m318 21 nt Target: 5′-GGATTCCAGAATCCAAGTAAG-3′ (SEQ ID NO: 5323)βc-m417 21 nt Target: 5′-CTTGCTCCCATTCATAAAGGA-3′ (SEQ ID NO: 5324)βc-m462 21 nt Target: 5′-CGTCAATATCAGCTACTTGCT-3′ (SEQ ID NO: 5325)βc-m463 21 nt Target: 5′-CCGTCAATATCAGCTACTTGC-3′ (SEQ ID NO: 5326)βc-m468 21 nt Target: 5′-ACTGCCCGTCAATATCAGCTA-3′ (SEQ ID NO: 5327)βc-m613 21 nt Target: 5′-TGTTTCAACATCTGTGATGGT-3′ (SEQ ID NO: 5328)βc-m614 21 nt Target: 5′-ATGTTTCAACATCTGTGATGG-3′ (SEQ ID NO: 5329)βc-m624 21 nt Target: 5′-TGACAACTGCATGTTTCAACA-3′ (SEQ ID NO: 5330)βc-m626 21 nt Target: 5′-ATTGACAACTGCATGTTTCAA-3′ (SEQ ID NO: 5331)βc-m630 21 nt Target: 5′-TCAAATTGACAACTGCATGTT-3′ (SEQ ID NO: 5332)βc-m636 21 nt Target: 5′-AGTTAATCAAATTGACAACTG-3′ (SEQ ID NO: 5333)βc-m642 21 nt Target: 5′-CCTGATAGTTAATCAAATTGA-3′ (SEQ ID NO: 5334)βc-m648 21 nt Target: 5′-CGTCATCCTGATAGTTAATCA-3′ (SEQ ID NO: 5335)βc-m649 21 nt Target: 5′-GCGTCATCCTGATAGTTAATC-3′ (SEQ ID NO: 5336)βc-m702 21 nt Target: 5′-CCTCATCGTTTAGCAGTTTTG-3′ (SEQ ID NO: 5337)βc-m707 21 nt Target: 5′-CTGGTCCTCATCGTTTAGCAG-3′ (SEQ ID NO: 5338)βc-m734 21 nt Target: 5′-CATAACAGCAGCTTTATTAAC-3′ (SEQ ID NO: 5339)βc-m735 21 nt Target: 5′-CCATAACAGCAGCTTTATTAA-3′ (SEQ ID NO: 5340)βc-m738 21 nt Target: 5′-GGACCATAACAGCAGCTTTAT-3′ (SEQ ID NO: 5341)βc-m739 21 nt Target: 5′-TGGACCATAACAGCAGCTTTA-3′ (SEQ ID NO: 5342)βc-m843 21 nt Target: 5′-CTGTCTCTACATCATTTGTAT-3′ (SEQ ID NO: 5343)βc-m844 21 nt Target: 5′-GCTGTCTCTACATCATTTGTA-3′ (SEQ ID NO: 5344)βc-m1063 21 nt Target: 5′-GCAACCATTTTCTGCAGTCCA-3′ (SEQ ID NO: 5345)βc-m1065 21 nt Target: 5′-AAGCAACCATTTTCTGCAGTC-3′ (SEQ ID NO: 5346)βc-m1080 21 nt Target: 5′-TTGTTTTGTTGAGCAAAGCAA-3′ (SEQ ID NO: 5347)βc-m1081 21 nt Target: 5′-TTTGTTTTGTTGAGCAAAGCA-3′ (SEQ ID NO: 5348)βc-m1098 21 nt Target: 5′-TAGCCAAGAATTTCACGTTTG-3′ (SEQ ID NO: 5349)βc-m1140 21 nt Target: 5′-CTTGATTGCCATAAGCTAAGA-3′ (SEQ ID NO: 5350)βc-m1145 21 nt Target: 5′-GCTCTCTTGATTGCCATAAGC-3′ (SEQ ID NO: 5351)βc-m1217 21 nt Target: 5′-CTTCTCATAAGTGTAGGTCCT-3′ (SEQ ID NO: 5352)βc-m1218 21 nt Target: 5′-GCTTCTCATAAGTGTAGGTCC-3′ (SEQ ID NO: 5353)βc-m1220 21 nt Target: 5′-AAGCTTCTCATAAGTGTAGGT-3′ (SEQ ID NO: 5354)βc-m1221 21 nt Target: 5′-GAAGCTTCTCATAAGTGTAGG-3′ (SEQ ID NO: 5355)βc-m1365 21 nt Target: 5′-GAGTCCAAAGACAGTTTTGAA-3′ (SEQ ID NO: 5356)βc-m1366 21 nt Target: 5′-AGAGTCCAAAGACAGTTTTGA-3′ (SEQ ID NO: 5357)βc-m1461 21 nt Target: 5′-CCACATTTATATCATCGGAAC-3′ (SEQ ID NO: 5358)βc-m1464 21 nt Target: 5′-TGACCACATTTATATCATCGG-3′ (SEQ ID NO: 5359)βc-m1473 21 nt Target: 5′-CTGCACAGGTGACCACATTTA-3′ (SEQ ID NO: 5360)βc-m1474 21 nt Target: 5′-GCTGCACAGGTGACCACATTT-3′ (SEQ ID NO: 5361)βc-m1510 21 nt Target: 5′-TTGTAATTATTGCAAGTGAGG-3′ (SEQ ID NO: 5362)βc-m1523 21 nt Target: 5′-CATCATCTTGTTTTTGTAATT-3′ (SEQ ID NO: 5363)βc-m1524 21 nt Target: 5′-CCATCATCTTGTTTTTGTAAT-3′ (SEQ ID NO: 5364)βc-m1527 21 nt Target: 5′-ACACCATCATCTTGTTTTTGT-3′ (SEQ ID NO: 5365)βc-m1532 21 nt Target: 5′-TTGGCACACCATCATCTTGTT-3′ (SEQ ID NO: 5366)βc-m1752 21 nt Target: 5′-TCAATCCAACAGTTGCCTTTA-3′ (SEQ ID NO: 5367)βc-m1757 21 nt Target: 5′-TCGAATCAATCCAACAGTTGC-3′ (SEQ ID NO: 5368)βc-m1827 21 nt Target: 5′-GCTGAACTAGTCGTGGAATAG-3′ (SEQ ID NO: 5369)βc-m1934 21 nt Target: 5′-AGTACACCCTTCTACTATCTC-3′ (SEQ ID NO: 5370)βc-m1935 21 nt Target: 5′-CAGTACACCCTTCTACTATCT-3′ (SEQ ID NO: 5371)βc-m1936 21 nt Target: 5′-CCAGTACACCCTTCTACTATC-3′ (SEQ ID NO: 5372)βc-m1941 21 nt Target: 5′-GAGCTCCAGTACACCCTTCTA-3′ (SEQ ID NO: 5373)βc-m2009 21 nt Target: 5′-AAACAATGGAATGGTATTGAG-3′ (SEQ ID NO: 5374)βc-m2015 21 nt Target: 5′-CTGCACAAACAATGGAATGGT-3′ (SEQ ID NO: 5375)βc-m2016 21 nt Target: 5′-ACTGCACAAACAATGGAATGG-3′ (SEQ ID NO: 5376)βc-m2021 21 nt Target: 5′-AAGCAACTGCACAAACAATGG-3′ (SEQ ID NO: 5377)βc-m2028 21 nt Target: 5′-GAGAATAAAGCAACTGCACAA-3′ (SEQ ID NO: 5378)βc-m2037 21 nt Target: 5′-TTTCAATGGGAGAATAAAGCA-3′ (SEQ ID NO: 5379)βc-m2038 21 nt Target: 5′-TTTTCAATGGGAGAATAAAGC-3′ (SEQ ID NO: 5380)βc-m2039 21 nt Target: 5′-ATTTTCAATGGGAGAATAAAG-3′ (SEQ ID NO: 5381)βc-m2043 21 nt Target: 5′-GGATATTTTCAATGGGAGAAT-3′ (SEQ ID NO: 5382)βc-m2044 21 nt Target: 5′-TGGATATTTTCAATGGGAGAA-3′ (SEQ ID NO: 5383)βc-m2045 21 nt Target: 5′-TTGGATATTTTCAATGGGAGA-3′ (SEQ ID NO: 5384)βc-m2055 21 nt Target: 5′-CAGCTACTCTTTGGATATTTT-3′ (SEQ ID NO: 5385)βc-m2056 21 nt Target: 5′-GCAGCTACTCTTTGGATATTT-3′ (SEQ ID NO: 5386)βc-m2231 21 nt Target: 5′-CCGCTTCTTGTAATCCTGTGG-3′ (SEQ ID NO: 5387)βc-m2307 21 nt Target: 5′-CCAGTCCAAGATCTGCAGTCT-3′ (SEQ ID NO: 5388)βc-m2385 21 nt Target: 5′-CGTATCCACCAGAGTGAAAAG-3′ (SEQ ID NO: 5389)βc-m2539 21 nt Target: 5′-CAGGCCAGCTGATTGCTATCA-3′ (SEQ ID NO: 5390)βc-m2562 21 nt Target: 5′-CGATTTACAGGTCAGTATCAA-3′ (SEQ ID NO: 5391)βc-m2563 21 nt Target: 5′-ACGATTTACAGGTCAGTATCA-3′ (SEQ ID NO: 5392)βc-m2578 21 nt Target: 5′-TTTCTTACCTAAAGGACGATT-3′ (SEQ ID NO: 5393)βc-m2580 21 nt Target: 5′-GCTTTCTTACCTAAAGGACGA-3′ (SEQ ID NO: 5394)βc-m2589 21 nt Target: 5′-CTTTTATAAGCTTTCTTACCT-3′ (SEQ ID NO: 5395)βc-m2590 21 nt Target: 5′-GCTTTTATAAGCTTTCTTACC-3′ (SEQ ID NO: 5396)βc-m2593 21 nt Target: 5′-CTGGCTTTTATAAGCTTTCTT-3′ (SEQ ID NO: 5397)βc-m2598 21 nt Target: 5′-CCACACTGGCTTTTATAAGCT-3′ (SEQ ID NO: 5398)βc-m2604 21 nt Target: 5′-ATTCACCCACACTGGCTTTTA-3′ (SEQ ID NO: 5399)βc-m2644 21 nt Target: 5′-CCTACCAAGTCTTTCTGGAGT-3′ (SEQ ID NO: 5400)βc-m2674 21 nt Target: 5′-ATTTACAAACAGGCCTAAAAC-3′ (SEQ ID NO: 5401)βc-m2675 21 nt Target: 5′-GATTTACAAACAGGCCTAAAA-3′ (SEQ ID NO: 5402)βc-m2676 21 nt Target: 5′-AGATTTACAAACAGGCCTAAA-3′ (SEQ ID NO: 5403)βc-m2710 21 nt Target: 5′-CATCTCCTTCCAAGGTATGTA-3′ (SEQ ID NO: 5404)βc-m2711 21 nt Target: 5′-ACATCTCCTTCCAAGGTATGT-3′ (SEQ ID NO: 5405)βc-m2725 21 nt Target: 5′-ACTTCCACACATGAACATCTC-3′ (SEQ ID NO: 5406)βc-m2728 21 nt Target: 5′-GAAACTTCCACACATGAACAT-3′ (SEQ ID NO: 5407)βc-m2729 21 nt Target: 5′-AGAAACTTCCACACATGAACA-3′ (SEQ ID NO: 5408)βc-m2730 21 nt Target: 5′-GAGAAACTTCCACACATGAAC-3′ (SEQ ID NO: 5409)βc-m2731 21 nt Target: 5′-TGAGAAACTTCCACACATGAA-3′ (SEQ ID NO: 5410)βc-m2739 21 nt Target: 5′-CATCAACGTGAGAAACTTCCA-3′ (SEQ ID NO: 5411)βc-m2742 21 nt Target: 5′-AAACATCAACGTGAGAAACTT-3′ (SEQ ID NO: 5412)βc-m2743 21 nt Target: 5′-AAAACATCAACGTGAGAAACT-3′ (SEQ ID NO: 5413)βc-m2744 21 nt Target: 5′-AAAAACATCAACGTGAGAAAC-3′ (SEQ ID NO: 5414)βc-m2745 21 nt Target: 5′-CAAAAACATCAACGTGAGAAA-3′ (SEQ ID NO: 5415)βc-m2746 21 nt Target: 5′-GCAAAAACATCAACGTGAGAA-3′ (SEQ ID NO: 5416)βc-m2748 21 nt Target: 5′-TGGCAAAAACATCAACGTGAG-3′ (SEQ ID NO: 5417)βc-m2760 21 nt Target: 5′-CTGCAAAAGCTGTGGCAAAAA-3′ (SEQ ID NO: 5418)βc-m2761 21 nt Target: 5′-GCTGCAAAAGCTGTGGCAAAA-3′ (SEQ ID NO: 5419)βc-m2778 21 nt Target: 5′-ACTCATCTGAGTATAACGCTG-3′ (SEQ ID NO: 5420)βc-m2795 21 nt Target: 5′-TGAAAACAGCAAATGTTACTC-3′ (SEQ ID NO: 5421)βc-m2796 21 nt Target: 5′-TTGAAAACAGCAAATGTTACT-3′ (SEQ ID NO: 5422)βc-m2797 21 nt Target: 5′-GTTGAAAACAGCAAATGTTAC-3′ (SEQ ID NO: 5423)βc-m2805 21 nt Target: 5′-CTATTAATGTTGAAAACAGCA-3′ (SEQ ID NO: 5424)βc-m2834 21 nt Target: 5′-ACACTACAGCTGTATAGAGAG-3′ (SEQ ID NO: 5425)βc-m2859 21 nt Target: 5′-CAGGCCAATCACAATGCACGT-3′ (SEQ ID NO: 5426)βc-m2946 21 nt Target: 5′-CTGTTCCCATAGGAAACTCAG-3′ (SEQ ID NO: 5427)βc-m2968 21 nt Target: 5′-CAGAACAAAAAGCGTACTTCG-3′ (SEQ ID NO: 5428)βc-m2974 21 nt Target: 5′-AAGGACCAGAACAAAAAGCGT-3′ (SEQ ID NO: 5429)βc-m2982 21 nt Target: 5′-CGACCAAAAAGGACCAGAACA-3′ (SEQ ID NO: 5430)βc-m2983 21 nt Target: 5′-TCGACCAAAAAGGACCAGAAC-3′ (SEQ ID NO: 5431)βc-m2990 21 nt Target: 5′-TTACTCCTCGACCAAAAAGGA-3′ (SEQ ID NO: 5432)βc-m3005 21 nt Target: 5′-AATCCATTTGTATTGTTACTC-3′ (SEQ ID NO: 5433)βc-m3006 21 nt Target: 5′-AAATCCATTTGTATTGTTACT-3′ (SEQ ID NO: 5434)βc-m3007 21 nt Target: 5′-CAAATCCATTTGTATTGTTAC-3′ (SEQ ID NO: 5435)βc-m3008 21 nt Target: 5′-CCAAATCCATTTGTATTGTTA-3′ (SEQ ID NO: 5436)βc-m3015 21 nt Target: 5′-TCACTCCCCAAATCCATTTGT-3′ (SEQ ID NO: 5437)βc-m3047 21 nt Target: 5′-GATCCATTCGTGTGCATTCTT-3′ (SEQ ID NO: 5438)βc-m3048 21 nt Target: 5′-TGATCCATTCGTGTGCATTCT-3′ (SEQ ID NO: 5439)βc-m3049 21 nt Target: 5′-GTGATCCATTCGTGTGCATTC-3′ (SEQ ID NO: 5440)βc-m3093 21 nt Target: 5′-TAAAACAAAGAACAAGCAAGG-3′ (SEQ ID NO: 5441)βc-m3109 21 nt Target: 5′-GCACCACTACAGATATTAAAA-3′ (SEQ ID NO: 5442)βc-m3111 21 nt Target: 5′-CAGCACCACTACAGATATTAA-3′ (SEQ ID NO: 5443)βc-m3112 21 nt Target: 5′-TCAGCACCACTACAGATATTA-3′ (SEQ ID NO: 5444)βc-m3133 21 nt Target: 5′-AAAAAATAAAAGCAAGCAAAG-3′ (SEQ ID NO: 5445)βc-m3137 21 nt Target: 5′-CTGCAAAAAATAAAAGCAAGC-3′ (SEQ ID NO: 5446)βc-m3142 21 nt Target: 5′-AGTTACTGCAAAAAATAAAAG-3′ (SEQ ID NO: 5447)βc-m3148 21 nt Target: 5′-ACTAACAGTTACTGCAAAAAA-3′ (SEQ ID NO: 5448)βc-m3150 21 nt Target: 5′-AAACTAACAGTTACTGCAAAA-3′ (SEQ ID NO: 5449)βc-m3152 21 nt Target: 5′-AAAAACTAACAGTTACTGCAA-3′ (SEQ ID NO: 5450)βc-m3153 21 nt Target: 5′-TAAAAACTAACAGTTACTGCA-3′ (SEQ ID NO: 5451)βc-m3155 21 nt Target: 5′-CTTAAAAACTAACAGTTACTG-3′ (SEQ ID NO: 5452)βc-m3159 21 nt Target: 5′-ACTACTTAAAAACTAACAGTT-3′ (SEQ ID NO: 5453)βc-m3161 21 nt Target: 5′-ACACTACTTAAAAACTAACAG-3′ (SEQ ID NO: 5454)βc-m3165 21 nt Target: 5′-CATAACACTACTTAAAAACTA-3′ (SEQ ID NO: 5455)βc-m3166 21 nt Target: 5′-ACATAACACTACTTAAAAACT-3′ (SEQ ID NO: 5456)βc-m3168 21 nt Target: 5′-GAACATAACACTACTTAAAAA-3′ (SEQ ID NO: 5457)βc-m3169 21 nt Target: 5′-AGAACATAACACTACTTAAAA-3′ (SEQ ID NO: 5458)βc-m3170 21 nt Target: 5′-TAGAACATAACACTACTTAAA-3′ (SEQ ID NO: 5459)βc-m3171 21 nt Target: 5′-CTAGAACATAACACTACTTAA-3′ (SEQ ID NO: 5460)βc-m3176 21 nt Target: 5′-GTTCACTAGAACATAACACTA-3′ (SEQ ID NO: 5461)βc-m3178 21 nt Target: 5′-AGGTTCACTAGAACATAACAC-3′ (SEQ ID NO: 5462)βc-m3179 21 nt Target: 5′-CAGGTTCACTAGAACATAACA-3′ (SEQ ID NO: 5463)βc-m3216 21 nt Target: 5′-CCATTACTCGGTTCTTAGAAA-3′ (SEQ ID NO: 5464)βc-m3219 21 nt Target: 5′-ACACCATTACTCGGTTCTTAG-3′ (SEQ ID NO: 5465)βc-m3224 21 nt Target: 5′-GTTCTACACCATTACTCGGTT-3′ (SEQ ID NO: 5466)βc-m3234 21 nt Target: 5′-ATGAATTAGTGTTCTACACCA-3′ (SEQ ID NO: 5467)βc-m3239 21 nt Target: 5′-TGATTATGAATTAGTGTTCTA-3′ (SEQ ID NO: 5468)βc-m3240 21 nt Target: 5′-GTGATTATGAATTAGTGTTCT-3′ (SEQ ID NO: 5469)βc-m3241 21 nt Target: 5′-CGTGATTATGAATTAGTGTTC-3′ (SEQ ID NO: 5470)βc-m3251 21 nt Target: 5′-TTACAATTAGCGTGATTATGA-3′ (SEQ ID NO: 5471)βc-m3252 21 nt Target: 5′-ATTACAATTAGCGTGATTATG-3′ (SEQ ID NO: 5472)βc-m3256 21 nt Target: 5′-CCAGATTACAATTAGCGTGAT-3′ (SEQ ID NO: 5473)βc-m3267 21 nt Target: 5′-GTTACACGTCTCCAGATTACA-3′ (SEQ ID NO: 5474)βc-m3269 21 nt Target: 5′-ATGTTACACGTCTCCAGATTA-3′ (SEQ ID NO: 5475)βc-m3277 21 nt Target: 5′-GCTACACAATGTTACACGTCT-3′ (SEQ ID NO: 5476)βc-m3279 21 nt Target: 5′-AGGCTACACAATGTTACACGT-3′ (SEQ ID NO: 5477)βc-m3286 21 nt Target: 5′-ATACAAAAGGCTACACAATGT-3′ (SEQ ID NO: 5478)βc-m3287 21 nt Target: 5′-TATACAAAAGGCTACACAATG-3′ (SEQ ID NO: 5479)βc-m3291 21 nt Target: 5′-TATTTATACAAAAGGCTACAC-3′ (SEQ ID NO: 5480)βc-m3292 21 nt Target: 5′-CTATTTATACAAAAGGCTACA-3′ (SEQ ID NO: 5481)βc-m3295 21 nt Target: 5′-TGTCTATTTATACAAAAGGCT-3′ (SEQ ID NO: 5482)βc-m3296 21 nt Target: 5′-CTGTCTATTTATACAAAAGGC-3′ (SEQ ID NO: 5483)βc-m3297 21 nt Target: 5′-TCTGTCTATTTATACAAAAGG-3′ (SEQ ID NO: 5484)βc-m3303 21 nt Target: 5′-TTTCTATCTGTCTATTTATAC-3′ (SEQ ID NO: 5485)βc-m3304 21 nt Target: 5′-ATTTCTATCTGTCTATTTATA-3′ (SEQ ID NO: 5486)βc-m3305 21 nt Target: 5′-CATTTCTATCTGTCTATTTAT-3′ (SEQ ID NO: 5487)βc-m3306 21 nt Target: 5′-CCATTTCTATCTGTCTATTTA-3′ (SEQ ID NO: 5488)βc-m3310 21 nt Target: 5′-CGGACCATTTCTATCTGTCTA-3′ (SEQ ID NO: 5489)βc-m3311 21 nt Target: 5′-TCGGACCATTTCTATCTGTCT-3′ (SEQ ID NO: 5490)βc-m3318 21 nt Target: 5′-AAACTAATCGGACCATTTCTA-3′ (SEQ ID NO: 5491)βc-m3319 21 nt Target: 5′-GAAACTAATCGGACCATTTCT-3′ (SEQ ID NO: 5492)βc-m3320 21 nt Target: 5′-GGAAACTAATCGGACCATTTC-3′ (SEQ ID NO: 5493)βc-m3321 21 nt Target: 5′-AGGAAACTAATCGGACCATTT-3′ (SEQ ID NO: 5494)βc-m3328 21 nt Target: 5′-ATTAAAAAGGAAACTAATCGG-3′ (SEQ ID NO: 5495)βc-m3334 21 nt Target: 5′-AAGCATATTAAAAAGGAAACT-3′ (SEQ ID NO: 5496)βc-m3335 21 nt Target: 5′-TAAGCATATTAAAAAGGAAAC-3′ (SEQ ID NO: 5497)βc-m3339 21 nt Target: 5′-ATTTTAAGCATATTAAAAAGG-3′ (SEQ ID NO: 5498)βc-m3345 21 nt Target: 5′-CTGCTTATTTTAAGCATATTA-3′ (SEQ ID NO: 5499)βc-m3346 21 nt Target: 5′-CCTGCTTATTTTAAGCATATT-3′ (SEQ ID NO: 5500)βc-m3352 21 nt Target: 5′-GATCCACCTGCTTATTTTAAG-3′ (SEQ ID NO: 5501)βc-m3367 21 nt Target: 5′-CAAAAACATGAAATAGATCCA-3′ (SEQ ID NO: 5502)βc-m3368 21 nt Target: 5′-TCAAAAACATGAAATAGATCC-3′ (SEQ ID NO: 5503)βc-m3370 21 nt Target: 5′-GTTCAAAAACATGAAATAGAT-3′ (SEQ ID NO: 5504)βc-m3371 21 nt Target: 5′-TGTTCAAAAACATGAAATAGA-3′ (SEQ ID NO: 5505)βc-m3372 21 nt Target: 5′-TTGTTCAAAAACATGAAATAG-3′ (SEQ ID NO: 5506)βc-m3377 21 nt Target: 5′-AGTTTTTGTTCAAAAACATGA-3′ (SEQ ID NO: 5507)βc-m3383 21 nt Target: 5′-CGATAAAGTTTTTGTTCAAAA-3′ (SEQ ID NO: 5508)βc-m3389 21 nt Target: 5′-TATCCCCGATAAAGTTTTTGT-3′ (SEQ ID NO: 5509)βc-m3390 21 nt Target: 5′-GTATCCCCGATAAAGTTTTTG-3′ (SEQ ID NO: 5510)βc-m3419 21 nt Target: 5′-ACACCTCTTACTGATTTACCC-3′ (SEQ ID NO: 5511)βc-m3421 21 nt Target: 5′-TAACACCTCTTACTGATTTAC-3′ (SEQ ID NO: 5512)βc-m3422 21 nt Target: 5′-ATAACACCTCTTACTGATTTA-3′ (SEQ ID NO: 5513)βc-m3423 21 nt Target: 5′-AATAACACCTCTTACTGATTT-3′ (SEQ ID NO: 5514)βc-m3424 21 nt Target: 5′-AAATAACACCTCTTACTGATT-3′ (SEQ ID NO: 5515)βc-m3425 21 nt Target: 5′-CAAATAACACCTCTTACTGAT-3′ (SEQ ID NO: 5516)βc-m3431 21 nt Target: 5′-AAGGCTCAAATAACACCTCTT-3′ (SEQ ID NO: 5517)βc-m3436 21 nt Target: 5′-AAAACAAGGCTCAAATAACAC-3′ (SEQ ID NO: 5518)βc-m3437 21 nt Target: 5′-CAAAACAAGGCTCAAATAACA-3′ (SEQ ID NO: 5519)βc-m3438 21 nt Target: 5′-CCAAAACAAGGCTCAAATAAC-3′ (SEQ ID NO: 5520)βc-m3441 21 nt Target: 5′-TGTCCAAAACAAGGCTCAAAT-3′ (SEQ ID NO: 5521)βc-m3443 21 nt Target: 5′-ACTGTCCAAAACAAGGCTCAA-3′ (SEQ ID NO: 5522)βc-m3448 21 nt Target: 5′-GGTATACTGTCCAAAACAAGG-3′ (SEQ ID NO: 5523)βc-m3456 21 nt Target: 5′-AGGCAACTGGTATACTGTCCA-3′ (SEQ ID NO: 5524)βc-m3464 21 nt Target: 5′-GGGATAAAAGGCAACTGGTAT-3′ (SEQ ID NO: 5525)βc-m3465 21 nt Target: 5′-TGGGATAAAAGGCAACTGGTA-3′ (SEQ ID NO: 5526)βc-m3472 21 nt Target: 5′-ACAACTTTGGGATAAAAGGCA-3′ (SEQ ID NO: 5527)βc-m3474 21 nt Target: 5′-CAACAACTTTGGGATAAAAGG-3′ (SEQ ID NO: 5528)βc-m3479 21 nt Target: 5′-GGTTACAACAACTTTGGGATA-3′ (SEQ ID NO: 5529)βc-m3480 21 nt Target: 5′-AGGTTACAACAACTTTGGGAT-3′ (SEQ ID NO: 5530)βc-m3481 21 nt Target: 5′-CAGGTTACAACAACTTTGGGA-3′ (SEQ ID NO: 5531)βc-m3489 21 nt Target: 5′-TATCACAGCAGGTTACAACAA-3′ (SEQ ID NO: 5532)βc-m3490 21 nt Target: 5′-GTATCACAGCAGGTTACAACA-3′ (SEQ ID NO: 5533)βc-m3492 21 nt Target: 5′-TTGTATCACAGCAGGTTACAA-3′ (SEQ ID NO: 5534)βc-m3509 21 nt Target: 5′-CCGCATCTGTTGAAGCATTGT-3′ (SEQ ID NO: 5535)βc-m3527 21 nt Target: 5′-TCTGAACCATTTCTATAACCG-3′ (SEQ ID NO: 5536)βc-m3531 21 nt Target: 5′-TAATTCTGAACCATTTCTATA-3′ (SEQ ID NO: 5537)βc-m3533 21 nt Target: 5′-TTTAATTCTGAACCATTTCTA-3′ (SEQ ID NO: 5538)βc-m3534 21 nt Target: 5′-GTTTAATTCTGAACCATTTCT-3′ (SEQ ID NO: 5539)βc-m3535 21 nt Target: 5′-AGTTTAATTCTGAACCATTTC-3′ (SEQ ID NO: 5540)βc-m3536 21 nt Target: 5′-AAGTTTAATTCTGAACCATTT-3′ (SEQ ID NO: 5541)βc-m3541 21 nt Target: 5′-ATTAAAAGTTTAATTCTGAAC-3′ (SEQ ID NO: 5542)βc-m3542 21 nt Target: 5′-AATTAAAAGTTTAATTCTGAA-3′ (SEQ ID NO: 5543)βc-m3544 21 nt Target: 5′-TGAATTAAAAGTTTAATTCTG-3′ (SEQ ID NO: 5544)βc-m3550 21 nt Target: 5′-TTTGAATGAATTAAAAGTTTA-3′ (SEQ ID NO: 5545)βc-m3554 21 nt Target: 5′-TTTTTTTGAATGAATTAAAAG-3′ (SEQ ID NO: 5546)βc-m3558 21 nt Target: 5′-TTTTTTTTTTTGAATGAATTA-3′ (SEQ ID NO: 5547)βc-m3559 21 nt Target: 5′-TTTTTTTTTTTTGAATGAATT-3′ (SEQ ID NO: 5548)βc-m3560 21 nt Target: 5′-TTTTTTTTTTTTTGAATGAAT-3′ (SEQ ID NO: 5549)βc-m3561 21 nt Target: 5′-TTTTTTTTTTTTTTGAATGAA-3′ (SEQ ID NO: 5550)βc-m3562 21 nt Target: 5′-TTTTTTTTTTTTTTTGAATGA-3′ (SEQ ID NO: 5551)βc-m3563 21 nt Target: 5′-TTTTTTTTTTTTTTTTGAATG-3′ (SEQ ID NO: 5552)

TABLE 11 Additional Selected Anti-β-catenin DsiRNAs, 25/27mer Duplexes,Unmodified 5′-UGUAUGGUAUACUUCAAAUACCCUC-3′ (SEQ ID NO: 3823)3′-CAACAUACCAUAUGAAGUUUAUGGGAG-5′ (SEQ ID NO: 1605) βc-244 Target:5′-GTTGTATGGTATACTTCAAATACCCTC-3′ (SEQ ID NO: 2714)5′-AAACAGUUGUAUGGUAUACUUCAAA-3′ (SEQ ID NO: 3824)3′-GUUUUGUCAACAUACCAUAUGAAGUUU-5′ (SEQ ID NO: 1606) βc-251 Target:5′-CAAAACAGTTGTATGGTATACTTCAAA-3′ (SEQ ID NO: 2715)5′-AAAACAGUUGUAUGGUAUACUUCAA-3′ (SEQ ID NO: 3825)3′-AGUUUUGUCAACAUACCAUAUGAAGUU-5′ (SEQ ID NO: 1607) βc-252 Target:5′-TCAAAACAGTTGTATGGTATACTTCAA-3′ (SEQ ID NO: 2716)5′-UCAAAACAGUUGUAUGGUAUACUUC-3′ (SEQ ID NO: 3826)3′-AAAGUUUUGUCAACAUACCAUAUGAAG-5′ (SEQ ID NO: 1608) βc-254 Target:5′-TTTCAAAACAGTTGTATGGTATACTTC-3′ (SEQ ID NO: 2717)5′-UUCAAAACAGUUGUAUGGUAUACUU-3′ (SEQ ID NO: 3827)3′-AAAAGUUUUGUCAACAUACCAUAUGAA-5′ (SEQ ID NO: 1609) βc-255 Target:5′-TTTTCAAAACAGTTGTATGGTATACTT-3′ (SEQ ID NO: 2718)5′-UUUCAAAACAGUUGUAUGGUAUACU-3′ (SEQ ID NO: 3828)3′-UAAAAGUUUUGUCAACAUACCAUAUGA-5′ (SEQ ID NO: 1610) βc-256 Target:5′-ATTTTCAAAACAGTTGTATGGTATACT-3′ (SEQ ID NO: 2719)5′-GUCCACGCUGGAUUUUCAAAACAGU-3′ (SEQ ID NO: 3829)3′-AACAGGUGCGACCUAAAAGUUUUGUCA-5′ (SEQ ID NO: 1611) βc-269 Target:5′-TTGTCCACGCTGGATTTTCAAAACAGT-3′ (SEQ ID NO: 2720)5′-UGUCCACGCUGGAUUUUCAAAACAG-3′ (SEQ ID NO: 3830)3′-UAACAGGUGCGACCUAAAAGUUUUGUC-5′ (SEQ ID NO: 1612) βc-270 Target:5′-ATTGTCCACGCTGGATTTTCAAAACAG-3′ (SEQ ID NO: 2721)5′-AUCAAAUCAGCUUGAGUAGCCAUUG-3′ (SEQ ID NO: 3831)3′-GGUAGUUUAGUCGAACUCAUCGGUAAC-5′ (SEQ ID NO: 1613) βc-293 Target:5′-CCATCAAATCAGCTTGAGTAGCCATTG-3′ (SEQ ID NO: 2722)5′-UCCAACUCCAUCAAAUCAGCUUGAG-3′ (SEQ ID NO: 3832)3′-ACAGGUUGAGGUAGUUUAGUCGAACUC-5′ (SEQ ID NO: 1614) βc-302 Target:5′-TGTCCAACTCCATCAAATCAGCTTGAG-3′ (SEQ ID NO: 2723)5′-UCCUCAGGAUUGCCUUUACCACUCA-3′ (SEQ ID NO: 3833)3′-GAAGGAGUCCUAACGGAAAUGGUGAGU-5′ (SEQ ID NO: 1615) βc-431 Target:5′-CTTCCTCAGGATTGCCTTTACCACTCA-3′ (SEQ ID NO: 2724)5′-UUCCUCAGGAUUGCCUUUACCACUC-3′ (SEQ ID NO: 3834)3′-AGAAGGAGUCCUAACGGAAAUGGUGAG-5′ (SEQ ID NO: 1616) βc-432 Target:5′-TCTTCCTCAGGATTGCCTTTACCACTC-3′ (SEQ ID NO: 2725)5′-UCAAUAUCAGCUACUUGUUCUUGAG-3′ (SEQ ID NO: 3835)3′-GUAGUUAUAGUCGAUGAACAAGAACUC-5′ (SEQ ID NO: 1617) βc-518 Target:5′-CATCAATATCAGCTACTTGTTCTTGAG-3′ (SEQ ID NO: 2726)5′-AUCAAUAUCAGCUACUUGUUCUUGA-3′ (SEQ ID NO: 3836)3′-GGUAGUUAUAGUCGAUGAACAAGAACU-5′ (SEQ ID NO: 1618) βc-519 Target:5′-CCATCAATATCAGCTACTTGTTCTTGA-3′ (SEQ ID NO: 2727)5′-UGUCCAUCAAUAUCAGCUACUUGUU-3′ (SEQ ID NO: 3837)3′-UGACAGGUAGUUAUAGUCGAUGAACAA-5′ (SEQ ID NO: 1619) βc-524 Target:5′-ACTGTCCATCAATATCAGCTACTTGTT-3′ (SEQ ID NO: 2728)5′-UGCAUACUGUCCAUCAAUAUCAGCU-3′ (SEQ ID NO: 3838)3′-UAACGUAUGACAGGUAGUUAUAGUCGA-5′ (SEQ ID NO: 1620) βc-531 Target:5′-ATTGCATACTGTCCATCAATATCAGCT-3′ (SEQ ID NO: 2729)5′-AGUCAUUGCAUACUGUCCAUCAAUA-3′ (SEQ ID NO: 3839)3′-GCUCAGUAACGUAUGACAGGUAGUUAU-5′ (SEQ ID NO: 1621) βc-537 Target:5′-CGAGTCATTGCATACTGTCCATCAATA-3′ (SEQ ID NO: 2730)5′-UCAUCUAAUGUCUCAGGGAACAUAG-3′ (SEQ ID NO: 3840)3′-GGAGUAGAUUACAGAGUCCCUUGUAUC-5′ (SEQ ID NO: 1622) βc-584 Target:5′-CCTCATCTAATGTCTCAGGGAACATAG-3′ (SEQ ID NO: 2731)5′-ACAACUGCAUGUUUCAGCAUCUGUG-3′ (SEQ ID NO: 3841)3′-AAUGUUGACGUACAAAGUCGUAGACAC-5′ (SEQ ID NO: 1623) βc-680 Target:5′-TTACAACTGCATGTTTCAGCATCTGTG-3′ (SEQ ID NO: 2732)5′-UUACAACUGCAUGUUUCAGCAUCUG-3′ (SEQ ID NO: 3842)3′-CAAAUGUUGACGUACAAAGUCGUAGAC-5′ (SEQ ID NO: 1624) βc-682 Target:5′-GTTTACAACTGCATGTTTCAGCATCTG-3′ (SEQ ID NO: 2733)5′-UUAAUCAAGUUUACAACUGCAUGUU-3′ (SEQ ID NO: 3843)3′-UCAAUUAGUUCAAAUGUUGACGUACAA-5′ (SEQ ID NO: 1625) βc-692 Target:5′-AGTTAATCAAGTTTACAACTGCATGTT-3′ (SEQ ID NO: 2734)5′-UGAUAGUUAAUCAAGUUUACAACUG-3′ (SEQ ID NO: 3844)3′-GAACUAUCAAUUAGUUCAAAUGUUGAC-5′ (SEQ ID NO: 1626) βc-698 Target:5′-CTTGATAGTTAATCAAGTTTACAACTG-3′ (SEQ ID NO: 2735)5′-GCAUCAUCUUGAUAGUUAAUCAAGU-3′ (SEQ ID NO: 3845)3′-GACGUAGUAGAACUAUCAAUUAGUUCA-5′ (SEQ ID NO: 1627) βc-707 Target:5′-CTGCATCATCTTGATAGTTAATCAAGT-3′ (SEQ ID NO: 2736)5′-UGCAUCAUCUUGAUAGUUAAUCAAG-3′ (SEQ ID NO: 3846)3′-AGACGUAGUAGAACUAUCAAUUAGUUC-5′ (SEQ ID NO: 1628) βc-708 Target:5′-TCTGCATCATCTTGATAGTTAATCAAG-3′ (SEQ ID NO: 2737)5′-GGUCCUCGUCAUUUAGCAGUUUUGU-3′ (SEQ ID NO: 3847)3′-GACCAGGAGCAGUAAAUCGUCAAAACA-5′ (SEQ ID NO: 1629) βc-763 Target:5′-CTGGTCCTCGTCATTTAGCAGTTTTGT-3′ (SEQ ID NO: 2738)5′-UAACUGCAGCCUUAUUAACCACCAC-3′ (SEQ ID NO: 3848)3′-GUAUUGACGUCGGAAUAAUUGGUGGUG-5′ (SEQ ID NO: 1630) βc-790 Target:5′-CATAACTGCAGCCTTATTAACCACCAC-3′ (SEQ ID NO: 2739)5′-AUAACUGCAGCCUUAUUAACCACCA-3′ (SEQ ID NO: 3849)3′-GGUAUUGACGUCGGAAUAAUUGGUGGU-5′ (SEQ ID NO: 1631) βc-791 Target:5′-CCATAACTGCAGCCTTATTAACCACCA-3′ (SEQ ID NO: 2740)5′-ACCAUAACUGCAGCCUUAUUAACCA-3′ (SEQ ID NO: 3850)3′-CCUGGUAUUGACGUCGGAAUAAUUGGU-5′ (SEQ ID NO: 1632) βc-794 Target:5′-GGACCATAACTGCAGCCTTATTAACCA-3′ (SEQ ID NO: 2741)5′-UUUUUAGAAAGCUGAUGGACCAUAA-3′ (SEQ ID NO: 3851)3′-GGAAAAAUCUUUCGACUACCUGGUAUU-5′ (SEQ ID NO: 1633) βc-812 Target:5′-CCTTTTTAGAAAGCTGATGGACCATAA-3′ (SEQ ID NO: 2742)5′-GGUACGUACAAUAGCAGACACCAUC-3′ (SEQ ID NO: 3852)3′-UACCAUGCAUGUUAUCGUCUGUGGUAG-5′ (SEQ ID NO: 1634) βc-873 Target:5′-ATGGTACGTACAATAGCAGACACCATC-3′ (SEQ ID NO: 2743)5′-UCAUUUGUAUUCUGCAUGGUACGUA-3′ (SEQ ID NO: 3853)3′-GUAGUAAACAUAAGACGUACCAUGCAU-5′ (SEQ ID NO: 1635) βc-890 Target:5′-CATCATTTGTATTCTGCATGGTACGTA-3′ (SEQ ID NO: 2744)5′-GUUUCUACAUCAUUUGUAUUCUGCA-3′ (SEQ ID NO: 3854)3′-GACAAAGAUGUAGUAAACAUAAGACGU-5′ (SEQ ID NO: 1636) βc-899 Target:5′-CTGTTTCTACATCATTTGTATTCTGCA-3′ (SEQ ID NO: 2745)5′-UGUUUCUACAUCAUUUGUAUUCUGC-3′ (SEQ ID NO: 3855)3′-CGACAAAGAUGUAGUAAACAUAAGACG-5′ (SEQ ID NO: 1637) βc-900 Target:5′-GCTGTTTCTACATCATTTGTATTCTGC-3′ (SEQ ID NO: 2746)5′-ACAACGAGCUGUUUCUACAUCAUUU-3′ (SEQ ID NO: 3856)3′-CAUGUUGCUCGACAAAGAUGUAGUAAA-5′ (SEQ ID NO: 1638) βc-909 Target:5′-GTACAACGAGCTGTTTCTACATCATTT-3′ (SEQ ID NO: 2747)5′-GUACAACGAGCUGUUUCUACAUCAU-3′ (SEQ ID NO: 3857)3′-GCCAUGUUGCUCGACAAAGAUGUAGUA-5′ (SEQ ID NO: 1639) βc-911 Target:5′-CGGTACAACGAGCTGTTTCTACATC-3′ (SEQ ID NO: 2748)5′-GGUACAACGAGCUGUUUCUACAUCA-3′ (SEQ ID NO: 3858)3′-CGCCAUGUUGCUCGACAAAGAUGUAGU-5′ (SEQ ID NO: 1640) βc-912 Target:5′-GCGGTACAACGAGCTGTTTCTACATCA-3′ (SEQ ID NO: 2749)5′-AUAAAACAACACAGAAUCCACUGGU-3′ (SEQ ID NO: 3859)3′-CGUAUUUUGUUGUGUCUUAGGUGACCA-5′ (SEQ ID NO: 1641) βc-1032 Target:5′-GCATAAAACAACACAGAATCCACTGGT-3′ (SEQ ID NO: 2750)5′-GCAUAAAACAACACAGAAUCCACUG-3′ (SEQ ID NO: 3860)3′-ACCGUAUUUUGUUGUGUCUUAGGUGAC-5′ (SEQ ID NO: 1642) βc-1034 Target:5′-TGGCATAAAACAACACAGAATCCACTG-3′ (SEQ ID NO: 2751)5′-GGCAUAAAACAACACAGAAUCCACU-3′ (SEQ ID NO: 3861)3′-UACCGUAUUUUGUUGUGUCUUAGGUGA-5′ (SEQ ID NO: 1643) βc-1035 Target:5′-ATGGCATAAAACAACACAGAATCCACT-3′ (SEQ ID NO: 2752)5′-GCUCCUUCUUGAUGUAAUAAAAGGU-3′ (SEQ ID NO: 3862)3′-AUCGAGGAAGAACUACAUUAUUUUCCA-5′ (SEQ ID NO: 1644) βc-1076 Target:5′-TAGCTCCTTCTTGATGTAATAAAAGGT-3′ (SEQ ID NO: 2753)5′-AGCUCCUUCUUGAUGUAAUAAAAGG-3′ (SEQ ID NO: 3863)3′-AAUCGAGGAAGAACUACAUUAUUUUCC-5′ (SEQ ID NO: 1645) βc-1077 Target:5′-TTAGCTCCTTCTTGATGTAATAAAAGG-3′ (SEQ ID NO: 2754)5′-UAACAUUUGUUUUGUUGAGCAAGGC-3′ (SEQ ID NO: 3864)3′-AAAUUGUAAACAAAACAACUCGUUCCG-5′ (SEQ ID NO: 1646) βc-1144 Target:5′-TTTAACATTTGTTTTGTTGAGCAAGGC-3′ (SEQ ID NO: 2755)5′-GCCAAGAAUUUAACAUUUGUUUUGU-3′ (SEQ ID NO: 3865)3′-AUCGGUUCUUAAAUUGUAAACAAAACA-5′ (SEQ ID NO: 1647) βc-1154 Target:5′-TAGCCAAGAATTTAACATTTGTTTTGT-3′ (SEQ ID NO: 2756)5′-UAAUAGCCAAGAAUUUAACAUUUGU-3′ (SEQ ID NO: 3866)3′-GCAUUAUCGGUUCUUAAAUUGUAAACA-5′ (SEQ ID NO: 1648) βc-1159 Target:5′-CGTAATAGCCAAGAATTTAACATTTGT-3′ (SEQ ID NO: 2757)5′-GUAAUAGCCAAGAAUUUAACAUUUG-3′ (SEQ ID NO: 3867)3′-AGCAUUAUCGGUUCUUAAAUUGUAAAC-5′ (SEQ ID NO: 1649) βc-1160 Target:5′-TCGTAATAGCCAAGAATTTAACATTTG-3′ (SEQ ID NO: 2758)5′-AGCUAAAAUUUGAAGGCAGUCUGUC-3′ (SEQ ID NO: 3868)3′-AUUCGAUUUUAAACUUCCGUCAGACAG-5′ (SEQ ID NO: 1650) βc-1185 Target:5′-TAAGCTAAAATTTGAAGGCAGTCTGTC-3′ (SEQ ID NO: 2759)5′-GGUCCUCAUUAUAUUUACUAAAGCU-3′ (SEQ ID NO: 3869)3′-AUCCAGGAGUAAUAUAAAUGAUUUCGA-5′ (SEQ ID NO: 1651) βc-1260 Target:5′-TAGGTCCTCATTATATTTACTAAAGCT-3′ (SEQ ID NO: 2760)5′-GUAUAGGUCCUCAUUAUAUUUACUA-3′ (SEQ ID NO: 3870)3′-UUCAUAUCCAGGAGUAAUAUAAAUGAU-5′ (SEQ ID NO: 1652) βc-1265 Target:5′-AAGTATAGGTCCTCATTATATTTACTA-3′ (SEQ ID NO: 2761)5′-AGUAUAGGUCCUCAUUAUAUUUACU-3′ (SEQ ID NO: 3871)3′-AUUCAUAUCCAGGAGUAAUAUAAAUGA-5′ (SEQ ID NO: 1653) βc-1266 Target:5′-TAAGTATAGGTCCTCATTATATTTACT-3′ (SEQ ID NO: 2762)5′-UUUUCGUAAGUAUAGGUCCUCAUUA-3′ (SEQ ID NO: 3872)3′-CAAAAAGCAUUCAUAUCCAGGAGUAAU-5′ (SEQ ID NO: 1654) βc-1274 Target:5′-GTTTTTCGTAAGTATAGGTCCTCATTA-3′ (SEQ ID NO: 2763)5′-UUUUUCGUAAGUAUAGGUCCUCAUU-3′ (SEQ ID NO: 3873)3′-UCAAAAAGCAUUCAUAUCCAGGAGUAA-5′ (SEQ ID NO: 1655) βc-1275 Target:5′-AGTTTTTCGTAAGTATAGGTCCTCATT-3′ (SEQ ID NO: 2764)5′-GUUUUUCGUAAGUAUAGGUCCUCAU-3′ (SEQ ID NO: 3874)3′-AUCAAAAAGCAUUCAUAUCCAGGAGUA-5′ (SEQ ID NO: 1656) βc-1276 Target:5′-TAGTTTTTCGTAAGTATAGGTCCTC-3′ (SEQ ID NO: 2765)5′-AGUUUUUCGUAAGUAUAGGUCCUCA-3′ (SEQ ID NO: 3875)3′-CAUCAAAAAGCAUUCAUAUCCAGGAGU-5′ (SEQ ID NO: 1657) βc-1277 Target:5′-GTAGTTTTTCGTAAGTATAGGTCCTCA-3′ (SEQ ID NO: 2766)5′-GGUCCACAGUAGUUUUUCGUAAGUA-3′ (SEQ ID NO: 3876)3′-CACCAGGUGUCAUCAAAAAGCAUUCAU-5′ (SEQ ID NO: 1658) βc-1287 Target:5′-GTGGTCCACAGTAGTTTTTCGTAAGTA-3′ (SEQ ID NO: 2767)5′-UACAAUAGCCGGCUUAUUACUAGAG-3′ (SEQ ID NO: 3877)3′-AGAUGUUAUCGGCCGAAUAAUGAUCUC-5′ (SEQ ID NO: 1659) βc-1344 Target:5′-TCTACAATAGCCGGCTTATTACTAGAG-3′ (SEQ ID NO: 2768)5′-UCUACAAUAGCCGGCUUAUUACUAG-3′ (SEQ ID NO: 3878)3′-GAAGAUGUUAUCGGCCGAAUAAUGAUC-5′ (SEQ ID NO: 1660) βc-1346 Target:5′-CTTCTACAATAGCCGGCTTATTACTAG-3′ (SEQ ID NO: 2769)5′-UCCUAAAGCUUGCAUUCCACCAGCU-3′ (SEQ ID NO: 3879)3′-UCAGGAUUUCGAACGUAAGGUGGUCGA-5′ (SEQ ID NO: 1661) βc-1371 Target:5′-AGTCCTAAAGCTTGCATTCCACCAGCT-3′ (SEQ ID NO: 2770)5′-GUCCUAAAGCUUGCAUUCCACCAGC-3′ (SEQ ID NO: 3880)3′-UUCAGGAUUUCGAACGUAAGGUGGUCG-5′ (SEQ ID NO: 1662) βc-1372 Target:5′-AAGTCCTAAAGCTTGCATTCCACCAGC-3′ (SEQ ID NO: 2771)5′-AGUCCUAAAGCUUGCAUUCCACCAG-3′ (SEQ ID NO: 3881)3′-CUUCAGGAUUUCGAACGUAAGGUGGUC-5′ (SEQ ID NO: 1663) βc-1373 Target:5′-GAAGTCCTAAAGCTTGCATTCCACCAG-3′ (SEQ ID NO: 2772)5′-GUUCUGAACAAGACGUUGACUUGGA-3′ (SEQ ID NO: 3882)3′-GUCAAGACUUGUUCUGCAACUGAACCU-5′ (SEQ ID NO: 1664) βc-1410 Target:5′-CAGTTCTGAACAAGACGTTGACTTGGA-3′ (SEQ ID NO: 2773)5′-AGUUCUGAACAAGACGUUGACUUGG-3′ (SEQ ID NO: 3883)3′-UGUCAAGACUUGUUCUGCAACUGAACC-5′ (SEQ ID NO: 1665) βc-1411 Target:5′-ACAGTTCTGAACAAGACGTTGACTTGG-3′ (SEQ ID NO: 2774)5′-GUCCAAAGACAGUUCUGAACAAGAC-3′ (SEQ ID NO: 3884)3′-CUCAGGUUUCUGUCAAGACUUGUUCUG-5′ (SEQ ID NO: 1666) βc-1421 Target:5′-GAGTCCAAAGACAGTTCTGAACAAGAC-3′ (SEQ ID NO: 2775)5′-UUCCUGUUUAGUUGCAGCAUCUGAA-3′ (SEQ ID NO: 3885)3′-GGAAGGACAAAUCAACGUCGUAGACUU-5′ (SEQ ID NO: 1667) βc-1458 Target:5′-CCTTCCTGTTTAGTTGCAGCATCTGAA-3′ (SEQ ID NO: 2776)5′-ACAUUUAUAUCAUCUGAACCCAGAA-3′ (SEQ ID NO: 3886)3′-GGUGUAAAUAUAGUAGACUUGGGUCUU-5′ (SEQ ID NO: 1668) βc-1517 Target:5′-CCACATTTATATCATCTGAACCCAGAA-3′ (SEQ ID NO: 2777)5′-ACCACAUUUAUAUCAUCUGAACCCA-3′ (SEQ ID NO: 3887)3′-ACUGGUGUAAAUAUAGUAGACUUGGGU-5′ (SEQ ID NO: 1669) βc-1520 Target:5′-TGACCACATTTATATCATCTGAACCCA-3′ (SEQ ID NO: 2778)5′-GCACAGGUGACCACAUUUAUAUCAU-3′ (SEQ ID NO: 3888)3′-GACGUGUCCACUGGUGUAAAUAUAGUA-5′ (SEQ ID NO: 1670) βc-1529 Target:5′-CTGCACAGGTGACCACATTTATATC-3′ (SEQ ID NO: 2779)5′-UGCACAGGUGACCACAUUUAUAUCA-3′ (SEQ ID NO: 3889)3′-CGACGUGUCCACUGGUGUAAAUAUAGU-5′ (SEQ ID NO: 1671) βc-1530 Target:5′-GCTGCACAGGTGACCACATTTATATCA-3′ (SEQ ID NO: 2780)5′-UGCAAGUGAGGUUAGAAAGAAUUCC-3′ (SEQ ID NO: 3890)3′-UAACGUUCACUCCAAUCUUUCUUAAGG-5′ (SEQ ID NO: 1672) βc-1558 Target:5′-ATTGCAAGTGAGGTTAGAAAGAATTCC-3′ (SEQ ID NO: 2781)5′-AUAAUUAUUGCAAGUGAGGUUAGAA-3′ (SEQ ID NO: 3891)3′-AAUAUUAAUAACGUUCACUCCAAUCUU-5′ (SEQ ID NO: 1673) βc-1566 Target:5′-TTATAATTATTGCAAGTGAGGTTAGAA-3′ (SEQ ID NO: 2782)5′-UCAUCUUGUUCUUAUAAUUAUUGCA-3′ (SEQ ID NO: 3892)3′-GUAGUAGAACAAGAAUAUUAAUAACGU-5′ (SEQ ID NO: 1674) βc-1579 Target:5′-CATCATCTTGTTCTTATAATTATTGCA-3′ (SEQ ID NO: 2783)5′-AUCAUCUUGUUCUUAUAAUUAUUGC-3′ (SEQ ID NO: 3893)3′-GGUAGUAGAACAAGAAUAUUAAUAACG-5′ (SEQ ID NO: 1675) βc-1580 Target:5′-CCATCATCTTGTTCTTATAATTATTGC-3′ (SEQ ID NO: 2784)5′-ACCAUCAUCUUGUUCUUAUAAUUAU-3′ (SEQ ID NO: 3894)3′-UCUGGUAGUAGAACAAGAAUAUUAAUA-5′ (SEQ ID NO: 1676) βc-1583 Target:5′-AGACCATCATCTTGTTCTTATAATTAT-3′ (SEQ ID NO: 2785)5′-AGACCAUCAUCUUGUUCUUAUAAUU-3′ (SEQ ID NO: 3895)3′-CGUCUGGUAGUAGAACAAGAAUAUUAA-5′ (SEQ ID NO: 1677) βc-1585 Target:5′-GCAGACCATCATCTTGTTCTTATAATT-3′ (SEQ ID NO: 2786)5′-AAUCCAACAGUAGCCUUUAUCAGAG-3′ (SEQ ID NO: 3896)3′-AGUUAGGUUGUCAUCGGAAAUAGUCUC-5′ (SEQ ID NO: 1678) βc-1808 Target:5′-TCAATCCAACAGTAGCCTTTATCAGAG-3′ (SEQ ID NO: 2787)5′-GAAUCAAUCCAACAGUAGCCUUUAU-3′ (SEQ ID NO: 3897)3′-AGCUUAGUUAGGUUGUCAUCGGAAAUA-5′ (SEQ ID NO: 1679) βc-1813 Target:5′-TCGAATCAATCCAACAGTAGCCTTTAT-3′ (SEQ ID NO: 2788)5′-UCCACAAAUUGCUGCUGUGUCCCAC-3′ (SEQ ID NO: 3898)3′-GGAGGUGUUUAACGACGACACAGGGUG-5′ (SEQ ID NO: 1680) βc-1955 Target:5′-CCTCCACAAATTGCTGCTGTGTCCCAC-3′ (SEQ ID NO: 2789)5′-ACAACCUUCAACUAUUUCUUCCAUG-3′ (SEQ ID NO: 3899)3′-CAUGUUGGAAGUUGAUAAAGAAGGUAC-5′ (SEQ ID NO: 1681) βc-1989 Target:5′-GTACAACCTTCAACTATTTCTTCCATG-3′ (SEQ ID NO: 2790)5′-UACAACCUUCAACUAUUUCUUCCAU-3′ (SEQ ID NO: 3900)3′-CCAUGUUGGAAGUUGAUAAAGAAGGUA-5′ (SEQ ID NO: 1682) βc-1990 Target:5′-GGTACAACCTTCAACTATTTCTTCC-3′ (SEQ ID NO: 2791)5′-GUACAACCUUCAACUAUUUCUUCCA-3′ (SEQ ID NO: 3901)3′-GCCAUGUUGGAAGUUGAUAAAGAAGGU-5′ (SEQ ID NO: 1683) βc-1991 Target:5′-CGGTACAACCTTCAACTATTTCTTCCA-3′ (SEQ ID NO: 2792)5′-GGUACAACCUUCAACUAUUUCUUCC-3′ (SEQ ID NO: 3902)3′-GGCCAUGUUGGAAGUUGAUAAAGAAGG-5′ (SEQ ID NO: 1684) βc-1992 Target:5′-CCGGTACAACCTTCAACTATTTCTTCC-3′ (SEQ ID NO: 2793)5′-GCUCCGGUACAACCUUCAACUAUUU-3′ (SEQ ID NO: 3903)3′-CCCGAGGCCAUGUUGGAAGUUGAUAAA-5′ (SEQ ID NO: 1685) βc-1997 Target:5′-GGGCTCCGGTACAACCTTCAACTATTT-3′ (SEQ ID NO: 2794)5′-ACAAUUCGGUUGUGAACAUCCCGAG-3′ (SEQ ID NO: 3904)3′-AUUGUUAAGCCAACACUUGUAGGGCUC-5′ (SEQ ID NO: 1686) βc-2036 Target:5′-TAACAATTCGGTTGTGAACATCCCGAG-3′ (SEQ ID NO: 2795)5′-AACAAUUCGGUUGUGAACAUCCCGA-3′ (SEQ ID NO: 3905)3′-UAUUGUUAAGCCAACACUUGUAGGGCU-5′ (SEQ ID NO: 1687) βc-2037 Target:5′-ATAACAATTCGGTTGTGAACATCCCGA-3′ (SEQ ID NO: 2796)5′-UAACAAUUCGGUUGUGAACAUCCCG-3′ (SEQ ID NO: 3906)3′-CUAUUGUUAAGCCAACACUUGUAGGGC-5′ (SEQ ID NO: 1688) βc-2038 Target:5′-GATAACAATTCGGTTGTGAACATCCCG-3′ (SEQ ID NO: 2797)5′-AUAACAAUUCGGUUGUGAACAUCCC-3′ (SEQ ID NO: 3907)3′-ACUAUUGUUAAGCCAACACUUGUAGGG-5′ (SEQ ID NO: 1689) βc-2039 Target:5′-TGATAACAATTCGGTTGTGAACATCCC-3′ (SEQ ID NO: 2798)5′-GAUAACAAUUCGGUUGUGAACAUCC-3′ (SEQ ID NO: 3908)3′-GACUAUUGUUAAGCCAACACUUGUAGG-5′ (SEQ ID NO: 1690) βc-2040 Target:5′-CTGATAACAATTCGGTTGTGAACATCC-3′ (SEQ ID NO: 2799)5′-UGAUAACAAUUCGGUUGUGAACAUC-3′ (SEQ ID NO: 3909)3′-AGACUAUUGUUAAGCCAACACUUGUAG-5′ (SEQ ID NO: 1691) βc-2041 Target:5′-TCTGATAACAATTCGGTTGTGAACATC-3′ (SEQ ID NO: 2800)5′-AUUUAGUCCUCUGAUAACAAUUCGG-3′ (SEQ ID NO: 3910)3′-CAUAAAUCAGGAGACUAUUGUUAAGCC-5′ (SEQ ID NO: 1692) βc-2052 Target:5′-GTATTTAGTCCTCTGATAACAATTCGG-3′ (SEQ ID NO: 2801)5′-UAUUUAGUCCUCUGAUAACAAUUCG-3′ (SEQ ID NO: 3911)3′-CCAUAAAUCAGGAGACUAUUGUUAAGC-5′ (SEQ ID NO: 1693) βc-2053 Target:5′-GGTATTTAGTCCTCTGATAACAATTCG-3′ (SEQ ID NO: 2802)5′-GUAUUUAGUCCUCUGAUAACAAUUC-3′ (SEQ ID NO: 3912)3′-ACCAUAAAUCAGGAGACUAUUGUUAAG-5′ (SEQ ID NO: 1694) βc-2054 Target:5′-TGGTATTTAGTCCTCTGATAACAATTC-3′ (SEQ ID NO: 2803)5′-GGUAUUUAGUCCUCUGAUAACAAUU-3′ (SEQ ID NO: 3913)3′-UACCAUAAAUCAGGAGACUAUUGUUAA-5′ (SEQ ID NO: 1695) βc-2055 Target:5′-ATGGTATTTAGTCCTCTGATAACAATT-3′ (SEQ ID NO: 2804)5′-ACAAUGGAAUGGUAUUUAGUCCUCU-3′ (SEQ ID NO: 3914)3′-UUUGUUACCUUACCAUAAAUCAGGAGA-5′ (SEQ ID NO: 1696) βc-2065 Target:5′-AAACAATGGAATGGTATTTAGTCCTCT-3′ (SEQ ID NO: 2805)5′-ACAAACAAUGGAAUGGUAUUUAGUC-3′ (SEQ ID NO: 3915)3′-CGUGUUUGUUACCUUACCAUAAAUCAG-5′ (SEQ ID NO: 1697) βc-2069 Target:5′-GCACAAACAATGGAATGGTATTTAGTC-3′ (SEQ ID NO: 2806)5′-GCACAAACAAUGGAAUGGUAUUUAG-3′ (SEQ ID NO: 3916)3′-GACGUGUUUGUUACCUUACCAUAAAUC-5′ (SEQ ID NO: 1698) βc-2071 Target:5′-CTGCACAAACAATGGAATGGTATTTAG-3′ (SEQ ID NO: 2807)5′-UGCACAAACAAUGGAAUGGUAUUUA-3′ (SEQ ID NO: 3917)3′-CGACGUGUUUGUUACCUUACCAUAAAU-5′ (SEQ ID NO: 1699) βc-2072 Target:5′-GCTGCACAAACAATGGAATGGTATTTA-3′ (SEQ ID NO: 2808)5′-GCUACUCUUUGGAUGUUUUCAAUGG-3′ (SEQ ID NO: 3918)3′-GUCGAUGAGAAACCUACAAAAGUUACC-5′ (SEQ ID NO: 1700) βc-2111 Target:5′-CAGCTACTCTTTGGATGTTTTCAATGG-3′ (SEQ ID NO: 2809)5′-AGCUACUCUUUGGAUGUUUUCAAUG-3′ (SEQ ID NO: 3919)3′-CGUCGAUGAGAAACCUACAAAAGUUAC-5′ (SEQ ID NO: 1701) βc-2112 Target:5′-GCAGCTACTCTTTGGATGTTTTCAATG-3′ (SEQ ID NO: 2810)5′-GCUUCAAUAGCUUCUGCAGCUUCCU-3′ (SEQ ID NO: 3920)3′-GUCGAAGUUAUCGAAGACGUCGAAGGA-5′ (SEQ ID NO: 1702) βc-2168 Target:5′-CAGCTTCAATAGCTTCTGCAGCTTCCT-3′ (SEQ ID NO: 2811)5′-UCCCUCAGCUUCAAUAGCUUCUGCA-3′ (SEQ ID NO: 3921)3′-CGAGGGAGUCGAAGUUAUCGAAGACGU-5′ (SEQ ID NO: 1703) βc-2175 Target:5′-GCTCCCTCAGCTTCAATAGCTTCTGCA-3′ (SEQ ID NO: 2812)5′-GCUCCCUCAGCUUCAAUAGCUUCUG-3′ (SEQ ID NO: 3922)3′-ACCGAGGGAGUCGAAGUUAUCGAAGAC-5′ (SEQ ID NO: 1704) βc-2177 Target:5′-TGGCTCCCTCAGCTTCAATAGCTTCTG-3′ (SEQ ID NO: 2813)5′-AUUCCUAGAGUGAAGUAACUCUGUC-3′ (SEQ ID NO: 3923)3′-AGUAAGGAUCUCACUUCAUUGAGACAG-5′ (SEQ ID NO: 1705) βc-2214 Target:5′-TCATTCCTAGAGTGAAGTAACTCTGTC-3′ (SEQ ID NO: 2814)5′-UCAUUCCUAGAGUGAAGUAACUCUG-3′ (SEQ ID NO: 3924)3′-GAAGUAAGGAUCUCACUUCAUUGAGAC-5′ (SEQ ID NO: 1706) βc-2216 Target:5′-CTTCATTCCTAGAGTGAAGTAACTCTG-3′ (SEQ ID NO: 2815)5′-UUCAUUCCUAGAGUGAAGUAACUCU-3′ (SEQ ID NO: 3925)3′-GGAAGUAAGGAUCUCACUUCAUUGAGA-5′ (SEQ ID NO: 1707) βc-2217 Target:5′-CCTTCATTCCTAGAGTGAAGTAACTCT-3′ (SEQ ID NO: 2816)5′-UCCUCAGACAUUCGGAACAAAACAG-3′ (SEQ ID NO: 3926)3′-ACAGGAGUCUGUAAGCCUUGUUUUGUC-5′ (SEQ ID NO: 1708) βc-2264 Target:5′-TGTCCTCAGACATTCGGAACAAAACAG-3′ (SEQ ID NO: 2817)5′-UGUCCUCAGACAUUCGGAACAAAAC-3′ (SEQ ID NO: 3927)3′-GAACAGGAGUCUGUAAGCCUUGUUUUG-5′ (SEQ ID NO: 1709) βc-2266 Target:5′-CTTGTCCTCAGACATTCGGAACAAAAC-3′ (SEQ ID NO: 2818)5′-GUUUCUUGUAAUCUUGUGGCUUGUC-3′ (SEQ ID NO: 3928)3′-GGCAAAGAACAUUAGAACACCGAACAG-5′ (SEQ ID NO: 1710) βc-2287 Target:5′-CCGTTTCTTGTAATCTTGTGGCTTGTC-3′ (SEQ ID NO: 2819)5′-UGAAAGCCGUUUCUUGUAAUCUUGU-3′ (SEQ ID NO: 3929)3′-UGACUUUCGGCAAAGAACAUUAGAACA-5′ (SEQ ID NO: 1711) βc-2295 Target:5′-ACTGAAAGCCGTTTCTTGTAATCTTGT-3′ (SEQ ID NO: 2820)5′-GCUCAACUGAAAGCCGUUUCUUGUA-3′ (SEQ ID NO: 3930)3′-GUCGAGUUGACUUUCGGCAAAGAACAU-5′ (SEQ ID NO: 1712) βc-2302 Target:5′-CAGCTCAACTGAAAGCCGTTTCTTGTA-3′ (SEQ ID NO: 2821)5′-AGUCCAAGAUCAGCAGUCUCAUUCC-3′ (SEQ ID NO: 3931)3′-GUUCAGGUUCUAGUCGUCAGAGUAAGG-5′ (SEQ ID NO: 1713) βc-2363 Target:5′-CAAGTCCAAGATCAGCAGTCTCATTCC-3′ (SEQ ID NO: 2822)5′-ACCAAUAUCAAGUCCAAGAUCAGCA-3′ (SEQ ID NO: 3932)3′-CGUGGUUAUAGUUCAGGUUCUAGUCGU-5′ (SEQ ID NO: 1714) βc-2373 Target:5′-GCACCAATATCAAGTCCAAGATCAGCA-3′ (SEQ ID NO: 2823)5′-AGAACGAUAGCUAGGAUCAUCCUGG-3′ (SEQ ID NO: 3933)3′-UUUCUUGCUAUCGAUCCUAGUAGGACC-5′ (SEQ ID NO: 1715) βc-2424 Target:5′-AAAGAACGATAGCTAGGATCATCCTGG-3′ (SEQ ID NO: 2824)5′-UAUCCACCAGAGUGAAAAGAACGAU-3′ (SEQ ID NO: 3934)3′-GUAUAGGUGGUCUCACUUUUCUUGCUA-5′ (SEQ ID NO: 1716) βc-2441 Target:5′-CATATCCACCAGAGTGAAAAGAACGAT-3′ (SEQ ID NO: 2825)5′-AUUUACAGGUCAGUAUCAAACCAGG-3′ (SEQ ID NO: 3935)3′-ACUAAAUGUCCAGUCAUAGUUUGGUCC-5′ (SEQ ID NO: 1717) βc-2618 Target:5′-TGATTTACAGGTCAGTATCAAACCAGG-3′ (SEQ ID NO: 2826)5′-GAUUUACAGGUCAGUAUCAAACCAG-3′ (SEQ ID NO: 3936)3′-UACUAAAUGUCCAGUCAUAGUUUGGUC-5′ (SEQ ID NO: 1718) βc-2619 Target:5′-ATGATTTACAGGTCAGTATCAAACCAG-3′ (SEQ ID NO: 2827)5′-UGAUUUACAGGUCAGUAUCAAACCA-3′ (SEQ ID NO: 3937)3′-CUACUAAAUGUCCAGUCAUAGUUUGGU-5′ (SEQ ID NO: 1719) βc-2620 Target:5′-GATGATTTACAGGTCAGTATCAAACCA-3′ (SEQ ID NO: 2828)5′-UCUUACCUAAAGGAUGAUUUACAGG-3′ (SEQ ID NO: 3938)3′-GAAGAAUGGAUUUCCUACUAAAUGUCC-5′ (SEQ ID NO: 1720) βc-2634 Target:5′-CTTCTTACCTAAAGGATGATTTACAGG-3′ (SEQ ID NO: 2829)5′-UUCUUACCUAAAGGAUGAUUUACAG-3′ (SEQ ID NO: 3939)3′-UGAAGAAUGGAUUUCCUACUAAAUGUC-5′ (SEQ ID NO: 1721) βc-2635 Target:5′-ACTTCTTACCTAAAGGATGATTTACAG-3′ (SEQ ID NO: 2830)5′-ACUUCUUACCUAAAGGAUGAUUUAC-3′ (SEQ ID NO: 3940)3′-UUUGAAGAAUGGAUUUCCUACUAAAUG-5′ (SEQ ID NO: 1722) βc-2637 Target:5′-AAACTTCTTACCTAAAGGATGATTTAC-3′ (SEQ ID NO: 2831)5′-UUUUUAAAACUUCUUACCUAAAGGA-3′ (SEQ ID NO: 3941)3′-CGAAAAAUUUUGAAGAAUGGAUUUCCU-5′ (SEQ ID NO: 1723) βc-2645 Target:5′-GCTTTTTAAAACTTCTTACCTAAAGGA-3′ (SEQ ID NO: 2832)5′-GCUUUUUAAAACUUCUUACCUAAAG-3′ (SEQ ID NO: 3942)3′-ACCGAAAAAUUUUGAAGAAUGGAUUUC-5′ (SEQ ID NO: 1724) βc-2647 Target:5′-TGGCTTTTTAAAACTTCTTACCTAAAG-3′ (SEQ ID NO: 2833)5′-AAACUGGCUUUUUAAAACUUCUUAC-3′ (SEQ ID NO: 3943)3′-GGUUUGACCGAAAAAUUUUGAAGAAUG-5′ (SEQ ID NO: 1725) βc-2653 Target:5′-CCAAACTGGCTTTTTAAAACTTCTTAC-3′ (SEQ ID NO: 2834)5′-ACCCAAACUGGCUUUUUAAAACUUC-3′ (SEQ ID NO: 3944)3′-AAUGGGUUUGACCGAAAAAUUUUGAAG-5′ (SEQ ID NO: 1726) βc-2657 Target:5′-TTACCCAAACTGGCTTTTTAAAACTTC-3′ (SEQ ID NO: 2835)5′-UACCCAAACUGGCUUUUUAAAACUU-3′ (SEQ ID NO: 3945)3′-AAAUGGGUUUGACCGAAAAAUUUUGAA-5′ (SEQ ID NO: 1727) βc-2658 Target:5′-TTTACCCAAACTGGCTTTTTAAAACTT-3′ (SEQ ID NO: 2836)5′-UUACCCAAACUGGCUUUUUAAAACU-3′ (SEQ ID NO: 3946)3′-AAAAUGGGUUUGACCGAAAAAUUUUGA-5′ (SEQ ID NO: 1728) βc-2659 Target:5′-TTTTACCCAAACTGGCTTTTTAAAACT-3′ (SEQ ID NO: 2837)5′-UUUACCCAAACUGGCUUUUUAAAAC-3′ (SEQ ID NO: 3947)3′-UAAAAUGGGUUUGACCGAAAAAUUUUG-5′ (SEQ ID NO: 1729) βc-2660 Target:5′-ATTTTACCCAAACTGGCTTTTTAAAAC-3′ (SEQ ID NO: 2838)5′-AACCAAGUCUUUCUGAAGUUCUGUA-3′ (SEQ ID NO: 3948)3′-GGUUGGUUCAGAAAGACUUCAAGACAU-5′ (SEQ ID NO: 1730) βc-2701 Target:5′-CCAACCAAGTCTTTCTGAAGTTCTGTA-3′ (SEQ ID NO: 2839)5′-ACCCUACCAACCAAGUCUUUCUGAA-3′ (SEQ ID NO: 3949)3′-GGUGGGAUGGUUGGUUCAGAAAGACUU-5′ (SEQ ID NO: 1731) βc-2709 Target:5′-CCACCCTACCAACCAAGTCTTTCTGAA-3′ (SEQ ID NO: 2840)5′-UUACAAAUAGCCUAAACCACUCCCA-3′ (SEQ ID NO: 3950)3′-UAAAUGUUUAUCGGAUUUGGUGAGGGU-5′ (SEQ ID NO: 1732) βc-2733 Target:5′-ATTTACAAATAGCCTAAACCACTCCCA-3′ (SEQ ID NO: 2841)5′-UUUACAAAUAGCCUAAACCACUCCC-3′ (SEQ ID NO: 3951)3′-CUAAAUGUUUAUCGGAUUUGGUGAGGG-5′ (SEQ ID NO: 1733) βc-2734 Target:5′-GATTTACAAATAGCCTAAACCACTCCC-3′ (SEQ ID NO: 2842)5′-AUUUACAAAUAGCCUAAACCACUCC-3′ (SEQ ID NO: 3952)3′-UCUAAAUGUUUAUCGGAUUUGGUGAGG-5′ (SEQ ID NO: 1734) βc-2735 Target:5′-AGATTTACAAATAGCCTAAACCACTCC-3′ (SEQ ID NO: 2843)5′-GAUUUACAAAUAGCCUAAACCACUC-3′ (SEQ ID NO: 3953)3′-GUCUAAAUGUUUAUCGGAUUUGGUGAG-5′ (SEQ ID NO: 1735) βc-2736 Target:5′-CAGATTTACAAATAGCCTAAACCACTC-3′ (SEQ ID NO: 2844)5′-UUUUUGUGGCAGAUUUACAAAUAGC-3′ (SEQ ID NO: 3954)3′-ACAAAAACACCGUCUAAAUGUUUAUCG-5′ (SEQ ID NO: 1736) βc-2747 Target:5′-TGTTTTTGTGGCAGATTTACAAATAGC-3′ (SEQ ID NO: 2845)5′-GUUUUUGUGGCAGAUUUACAAAUAG-3′ (SEQ ID NO: 3955)3′-GACAAAAACACCGUCUAAAUGUUUAUC-5′ (SEQ ID NO: 1737) βc-2748 Target:5′-CTGTTTTTGTGGCAGATTTACAAATAG-3′ (SEQ ID NO: 2846)5′-UGUUUUUGUGGCAGAUUUACAAAUA-3′ (SEQ ID NO: 3956)3′-GGACAAAAACACCGUCUAAAUGUUUAU-5′ (SEQ ID NO: 1738) βc-2749 Target:5′-CCTGTTTTTGTGGCAGATTTACAAATA-3′ (SEQ ID NO: 2847)5′-AUACCUGUUUUUGUGGCAGAUUUAC-3′ (SEQ ID NO: 3957)3′-UAUAUGGACAAAAACACCGUCUAAAUG-5′ (SEQ ID NO: 1739) βc-2754 Target:5′-ATATACCTGTTTTTGTGGCAGATTTAC-3′ (SEQ ID NO: 2848)5′-UUCAAAGUAUAUACCUGUUUUUGUG-3′ (SEQ ID NO: 3958)3′-GAAAGUUUCAUAUAUGGACAAAAACAC-5′ (SEQ ID NO: 1740) βc-2764 Target:5′-CTTTCAAAGTATATACCTGTTTTTGTG-3′ (SEQ ID NO: 2849)5′-UCUCCUUUCAAAGUAUAUACCUGUU-3′ (SEQ ID NO: 3959)3′-GUAGAGGAAAGUUUCAUAUAUGGACAA-5′ (SEQ ID NO: 1741) βc-2770 Target:5′-CATCTCCTTTCAAAGTATATACCTGTT-3′ (SEQ ID NO: 2850)5′-AUCUCCUUUCAAAGUAUAUACCUGU-3′ (SEQ ID NO: 3960)3′-UGUAGAGGAAAGUUUCAUAUAUGGACA-5′ (SEQ ID NO: 1742) βc-2771 Target:5′-ACATCTCCTTTCAAAGTATATACCTGT-3′ (SEQ ID NO: 2851)5′-ACAUCUCCUUUCAAAGUAUAUACCU-3′ (SEQ ID NO: 3961)3′-UCUGUAGAGGAAAGUUUCAUAUAUGGA-5′ (SEQ ID NO: 1743) βc-2773 Target:5′-AGACATCTCCTTTCAAAGTATATACCT-3′ (SEQ ID NO: 2852)5′-GACAUCUCCUUUCAAAGUAUAUACC-3′ (SEQ ID NO: 3962)3′-UUCUGUAGAGGAAAGUUUCAUAUAUGG-5′ (SEQ ID NO: 1744) βc-2774 Target:5′-AAGACATCTCCTTTCAAAGTATATACC-3′ (SEQ ID NO: 2853)5′-AGACAUCUCCUUUCAAAGUAUAUAC-3′ (SEQ ID NO: 3963)3′-GUUCUGUAGAGGAAAGUUUCAUAUAUG-5′ (SEQ ID NO: 1745) βc-2775 Target:5′-CAAGACATCTCCTTTCAAAGTATATAC-3′ (SEQ ID NO: 2854)5′-UUCCAAGACAUCUCCUUUCAAAGUA-3′ (SEQ ID NO: 3964)3′-ACAAGGUUCUGUAGAGGAAAGUUUCAU-5′ (SEQ ID NO: 1746) βc-2780 Target:5′-TGTTCCAAGACATCTCCTTTCAAAGTA-3′ (SEQ ID NO: 2855)5′-UUCCAAUGUUCCAAGACAUCUCCUU-3′ (SEQ ID NO: 3965)3′-GUAAGGUUACAAGGUUCUGUAGAGGAA-5′ (SEQ ID NO: 1747) βc-2788 Target:5′-CATTCCAATGTTCCAAGACATCTCCTT-3′ (SEQ ID NO: 2856)5′-AUUCCAAUGUUCCAAGACAUCUCCU-3′ (SEQ ID NO: 3966)3′-UGUAAGGUUACAAGGUUCUGUAGAGGA-5′ (SEQ ID NO: 1748) βc-2789 Target:5′-ACATTCCAATGTTCCAAGACATCTCCT-3′ (SEQ ID NO: 2857)5′-ACAUUCCAAUGUUCCAAGACAUCUC-3′ (SEQ ID NO: 3967)3′-CUUGUAAGGUUACAAGGUUCUGUAGAG-5′ (SEQ ID NO: 1749) βc-2791 Target:5′-GAACATTCCAATGTTCCAAGACATCTC-3′ (SEQ ID NO: 2858)5′-AGAAAUCUGAGAACAUUCCAAUGUU-3′ (SEQ ID NO: 3968)3′-GGUCUUUAGACUCUUGUAAGGUUACAA-5′ (SEQ ID NO: 1750) βc-2803 Target:5′-CCAGAAATCTGAGAACATTCCAATGTT-3′ (SEQ ID NO: 2859)5′-AACCAGAAAUCUGAGAACAUUCCAA-3′ (SEQ ID NO: 3969)3′-UGUUGGUCUUUAGACUCUUGUAAGGUU-5′ (SEQ ID NO: 1751) βc-2807 Target:5′-ACAACCAGAAATCTGAGAACATTCCAA-3′ (SEQ ID NO: 2860)5′-ACAACCAGAAAUCUGAGAACAUUCC-3′ (SEQ ID NO: 3970)3′-AUUGUUGGUCUUUAGACUCUUGUAAGG-5′ (SEQ ID NO: 1752) βc-2809 Target:5′-TAACAACCAGAAATCTGAGAACATTCC-3′ (SEQ ID NO: 2861)5′-AACAACCAGAAAUCUGAGAACAUUC-3′ (SEQ ID NO: 3971)3′-UAUUGUUGGUCUUUAGACUCUUGUAAG-5′ (SEQ ID NO: 1753) βc-2810 Target:5′-ATAACAACCAGAAATCTGAGAACATTC-3′ (SEQ ID NO: 2862)5′-UAACAACCAGAAAUCUGAGAACAUU-3′ (SEQ ID NO: 3972)3′-GUAUUGUUGGUCUUUAGACUCUUGUAA-5′ (SEQ ID NO: 1754) βc-2811 Target:5′-CATAACAACCAGAAATCTGAGAACATT-3′ (SEQ ID NO: 2863)5′-AUCACAUAACAACCAGAAAUCUGAG-3′ (SEQ ID NO: 3973)3′-ACUAGUGUAUUGUUGGUCUUUAGACUC-5′ (SEQ ID NO: 1755) βc-2817 Target:5′-TGATCACATAACAACCAGAAATCTGAG-3′ (SEQ ID NO: 2864)5′-GAUCACAUAACAACCAGAAAUCUGA-3′ (SEQ ID NO: 3974)3′-UACUAGUGUAUUGUUGGUCUUUAGACU-5′ (SEQ ID NO: 1756) βc-2818 Target:5′-ATGATCACATAACAACCAGAAATCTGA-3′ (SEQ ID NO: 2865)5′-ACACAUGAUCACAUAACAACCAGAA-3′ (SEQ ID NO: 3975)3′-GGUGUGUACUAGUGUAUUGUUGGUCUU-5′ (SEQ ID NO: 1757) βc-2824 Target:5′-CCACACATGATCACATAACAACCAGAA-3′ (SEQ ID NO: 2866)5′-UCCACACAUGAUCACAUAACAACCA-3′ (SEQ ID NO: 3976)3′-GAAGGUGUGUACUAGUGUAUUGUUGGU-5′ (SEQ ID NO: 1758) βc-2827 Target:5′-CTTCCACACATGATCACATAACAACCA-3′ (SEQ ID NO: 2867)5′-UAACUUCCACACAUGAUCACAUAAC-3′ (SEQ ID NO: 3977)3′-UUAUUGAAGGUGUGUACUAGUGUAUUG-5′ (SEQ ID NO: 1759) βc-2832 Target:5′-AATAACTTCCACACATGATCACATAAC-3′ (SEQ ID NO: 2868)5′-AUAACUUCCACACAUGAUCACAUAA-3′ (SEQ ID NO: 3978)3′-AUUAUUGAAGGUGUGUACUAGUGUAUU-5′ (SEQ ID NO: 1760) βc-2833 Target:5′-TAATAACTTCCACACATGATCACATAA-3′ (SEQ ID NO: 2869)5′-AAUAACUUCCACACAUGAUCACAUA-3′ (SEQ ID NO: 3979)3′-AAUUAUUGAAGGUGUGUACUAGUGUAU-5′ (SEQ ID NO: 1761) βc-2834 Target:5′-TTAATAACTTCCACACATGATCACATA-3′ (SEQ ID NO: 2870)5′-UAAUAACUUCCACACAUGAUCACAU-3′ (SEQ ID NO: 3980)3′-CAAUUAUUGAAGGUGUGUACUAGUGUA-5′ (SEQ ID NO: 1762) βc-2835 Target:5′-GTTAATAACTTCCACACATGATCAC-3′ (SEQ ID NO: 2871)5′-UUAAAGUUAAUAACUUCCACACAUG-3′ (SEQ ID NO: 3981)3′-GUAAUUUCAAUUAUUGAAGGUGUGUAC-5′ (SEQ ID NO: 1763) βc-2842 Target:5′-CATTAAAGTTAATAACTTCCACACATG-3′ (SEQ ID NO: 2872)5′-AUUAAAGUUAAUAACUUCCACACAU-3′ (SEQ ID NO: 3982)3′-UGUAAUUUCAAUUAUUGAAGGUGUGUA-5′ (SEQ ID NO: 1764) βc-2843 Target:5′-ACATTAAAGTTAATAACTTCCACAC-3′ (SEQ ID NO: 2873)5′-ACAUUAAAGUUAAUAACUUCCACAC-3′ (SEQ ID NO: 3983)3′-UUUGUAAUUUCAAUUAUUGAAGGUGUG-5′ (SEQ ID NO: 1765) βc-2845 Target:5′-AAACATTAAAGTTAATAACTTCCACAC-3′ (SEQ ID NO: 2874)5′-AACAUUAAAGUUAAUAACUUCCACA-3′ (SEQ ID NO: 3984)3′-UUUUGUAAUUUCAAUUAUUGAAGGUGU-5′ (SEQ ID NO: 1766) βc-2846 Target:5′-AAAACATTAAAGTTAATAACTTCCACA-3′ (SEQ ID NO: 2875)5′-AAACAUUAAAGUUAAUAACUUCCAC-3′ (SEQ ID NO: 3985)3′-UUUUUGUAAUUUCAAUUAUUGAAGGUG-5′ (SEQ ID NO: 1767) βc-2847 Target:5′-AAAAACATTAAAGTTAATAACTTCCAC-3′ (SEQ ID NO: 2876)5′-AAAACAUUAAAGUUAAUAACUUCCA-3′ (SEQ ID NO: 3986)3′-UUUUUUGUAAUUUCAAUUAUUGAAGGU-5′ (SEQ ID NO: 1768) βc-2848 Target:5′-AAAAAACATTAAAGTTAATAACTTCCA-3′ (SEQ ID NO: 2877)5′-AAAAACAUUAAAGUUAAUAACUUCC-3′ (SEQ ID NO: 3987)3′-GUUUUUUGUAAUUUCAAUUAUUGAAGG-5′ (SEQ ID NO: 1769) βc-2849 Target:5′-CAAAAAACATTAAAGTTAATAACTTCC-3′ (SEQ ID NO: 2878)5′-AAAAAACAUUAAAGUUAAUAACUUC-3′ (SEQ ID NO: 3988)3′-CGUUUUUUGUAAUUUCAAUUAUUGAAG-5′ (SEQ ID NO: 1770) βc-2850 Target:5′-GCAAAAAACATTAAAGTTAATAACTTC-3′ (SEQ ID NO: 2879)5′-GCAAAAAACAUUAAAGUUAAUAACU-3′ (SEQ ID NO: 3989)3′-ACCGUUUUUUGUAAUUUCAAUUAUUGA-5′ (SEQ ID NO: 1771) βc-2852 Target:5′-TGGCAAAAAACATTAAAGTTAATAACT-3′ (SEQ ID NO: 2880)5′-GGCAAAAAACAUUAAAGUUAAUAAC-3′ (SEQ ID NO: 3990)3′-CACCGUUUUUUGUAAUUUCAAUUAUUG-5′ (SEQ ID NO: 1772) βc-2853 Target:5′-GTGGCAAAAAACATTAAAGTTAATAAC-3′ (SEQ ID NO: 2881)5′-GCAAAAGCUGUGGCAAAAAACAUUA-3′ (SEQ ID NO: 3991)3′-AACGUUUUCGACACCGUUUUUUGUAAU-5′ (SEQ ID NO: 1773) βc-2864 Target:5′-TTGCAAAAGCTGTGGCAAAAAACATTA-3′ (SEQ ID NO: 2882)5′-UGCAAAAGCUGUGGCAAAAAACAUU-3′ (SEQ ID NO: 3992)3′-CAACGUUUUCGACACCGUUUUUUGUAA-5′ (SEQ ID NO: 1774) βc-2865 Target:5′-GTTGCAAAAGCTGTGGCAAAAAACATT-3′ (SEQ ID NO: 2883)5′-UCAUUUGAGUAUUAAGUUGCAAAAG-3′ (SEQ ID NO: 3993)3′-UGAGUAAACUCAUAAUUCAACGUUUUC-5′ (SEQ ID NO: 1775) βc-2882 Target:5′-ACTCATTTGAGTATTAAGTTGCAAAAG-3′ (SEQ ID NO: 2884)5′-AAAACAGCAAAUGUUACUCAUUUGA-3′ (SEQ ID NO: 3994)3′-AAUUUUGUCGUUUACAAUGAGUAAACU-5′ (SEQ ID NO: 1776) βc-2899 Target:5′-TTAAAACAGCAAATGTTACTCATTTGA-3′ (SEQ ID NO: 2885)5′-UAAAACAGCAAAUGUUACUCAUUUG-3′ (SEQ ID NO: 3995)3′-AAAUUUUGUCGUUUACAAUGAGUAAAC-5′ (SEQ ID NO: 1777) βc-2900 Target:5′-TTTAAAACAGCAAATGTTACTCATTTG-3′ (SEQ ID NO: 2886)5′-UUAAAACAGCAAAUGUUACUCAUUU-3′ (SEQ ID NO: 3996)3′-CAAAUUUUGUCGUUUACAAUGAGUAAA-5′ (SEQ ID NO: 1778) βc-2901 Target:5′-GTTTAAAACAGCAAATGTTACTCATTT-3′ (SEQ ID NO: 2887)5′-UUUAAAACAGCAAAUGUUACUCAUU-3′ (SEQ ID NO: 3997)3′-ACAAAUUUUGUCGUUUACAAUGAGUAA-5′ (SEQ ID NO: 1779) βc-2902 Target:5′-TGTTTAAAACAGCAAATGTTACTCATT-3′ (SEQ ID NO: 2888)5′-GUUUAAAACAGCAAAUGUUACUCAU-3′ (SEQ ID NO: 3998)3′-UACAAAUUUUGUCGUUUACAAUGAGUA-5′ (SEQ ID NO: 1780) βc-2903 Target:5′-ATGTTTAAAACAGCAAATGTTACTC-3′ (SEQ ID NO: 2889)5′-UGUUUAAAACAGCAAAUGUUACUCA-3′ (SEQ ID NO: 3999)3′-UUACAAAUUUUGUCGUUUACAAUGAGU-5′ (SEQ ID NO: 1781) βc-2904 Target:5′-AATGTTTAAAACAGCAAATGTTACTCA-3′ (SEQ ID NO: 2890)5′-AUUAAUGUUUAAAACAGCAAAUGUU-3′ (SEQ ID NO: 4000)3′-GAUAAUUACAAAUUUUGUCGUUUACAA-5′ (SEQ ID NO: 1782) βc-2909 Target:5′-CTATTAATGTTTAAAACAGCAAATGTT-3′ (SEQ ID NO: 2891)5′-AGAAAGGCUGCUAUUAAUGUUUAAA-3′ (SEQ ID NO: 4001)3′-UCUCUUUCCGACGAUAAUUACAAAUUU-5′ (SEQ ID NO: 1783) βc-2921 Target:5′-AGAGAAAGGCTGCTATTAATGTTTAAA-3′ (SEQ ID NO: 2892)5′-AGUUCAGACAAUACAGCUGUAUAAA-3′ (SEQ ID NO: 4002)3′-GUUCAAGUCUGUUAUGUCGACAUAUUU-5′ (SEQ ID NO: 1784) βc-2949 Target:5′-CAAGTTCAGACAATACAGCTGTATAAA-3′ (SEQ ID NO: 2893)5′-ACAAUGCAAGUUCAGACAAUACAGC-3′ (SEQ ID NO: 4003)3′-AGUGUUACGUUCAAGUCUGUUAUGUCG-5′ (SEQ ID NO: 1785) βc-2957 Target:5′-TCACAATGCAAGTTCAGACAATACAGC-3′ (SEQ ID NO: 2894)5′-UCACAAUGCAAGUUCAGACAAUACA-3′ (SEQ ID NO: 4004)3′-UUAGUGUUACGUUCAAGUCUGUUAUGU-5′ (SEQ ID NO: 1786) βc-2959 Target:5′-AATCACAATGCAAGTTCAGACAATACA-3′ (SEQ ID NO: 2895)5′-AAUCACAAUGCAAGUUCAGACAAUA-3′ (SEQ ID NO: 4005)3′-GGUUAGUGUUACGUUCAAGUCUGUUAU-5′ (SEQ ID NO: 1787) βc-2961 Target:5′-CCAATCACAATGCAAGTTCAGACAATA-3′ (SEQ ID NO: 2896)5′-GGCCAAUCACAAUGCAAGUUCAGAC-3′ (SEQ ID NO: 4006)3′-GUCCGGUUAGUGUUACGUUCAAGUCUG-5′ (SEQ ID NO: 1788) βc-2965 Target:5′-CAGGCCAATCACAATGCAAGTTCAGAC-3′ (SEQ ID NO: 2897)5′-GUUCCCAUAGGAAACUCAGCUUGGU-3′ (SEQ ID NO: 4007)3′-AACAAGGGUAUCCUUUGAGUCGAACCA-5′ (SEQ ID NO: 1789) βc-3052 Target:5′-TTGTTCCCATAGGAAACTCAGCTTGGT-3′ (SEQ ID NO: 2898)5′-UCAAUUGUUCCCAUAGGAAACUCAG-3′ (SEQ ID NO: 4008)3′-GAAGUUAACAAGGGUAUCCUUUGAGUC-5′ (SEQ ID NO: 1790) βc-3058 Target:5′-CTTCAATTGTTCCCATAGGAAACTCAG-3′ (SEQ ID NO: 2899)5′-UUCAAUUGUUCCCAUAGGAAACUCA-3′ (SEQ ID NO: 4009)3′-UGAAGUUAACAAGGGUAUCCUUUGAGU-5′ (SEQ ID NO: 1791) βc-3059 Target:5′-ACTTCAATTGTTCCCATAGGAAACTCA-3′ (SEQ ID NO: 2900)5′-GUUUACUUCAAUUGUUCCCAUAGGA-3′ (SEQ ID NO: 4010)3′-UUCAAAUGAAGUUAACAAGGGUAUCCU-5′ (SEQ ID NO: 1792) βc-3065 Target:5′-AAGTTTACTTCAATTGTTCCCATAGGA-3′ (SEQ ID NO: 2901)5′-AGUUUACUUCAAUUGUUCCCAUAGG-3′ (SEQ ID NO: 4011)3′-UUUCAAAUGAAGUUAACAAGGGUAUCC-5′ (SEQ ID NO: 1793) βc-3066 Target:5′-AAAGTTTACTTCAATTGTTCCCATAGG-3′ (SEQ ID NO: 2902)5′-AAAAAGUUUACUUCAAUUGUUCCCA-3′ (SEQ ID NO: 4012)3′-UGUUUUUCAAAUGAAGUUAACAAGGGU-5′ (SEQ ID NO: 1794) βc-3070 Target:5′-ACAAAAAGTTTACTTCAATTGTTCCCA-3′ (SEQ ID NO: 2903)5′-GAACAAAAAGUUUACUUCAAUUGUU-3′ (SEQ ID NO: 4013)3′-GUCUUGUUUUUCAAAUGAAGUUAACAA-5′ (SEQ ID NO: 1795) βc-3074 Target:5′-CAGAACAAAAAGTTTACTTCAATTGTT-3′ (SEQ ID NO: 2904)5′-GACCAGAACAAAAAGUUUACUUCAA-3′ (SEQ ID NO: 4014)3′-UCCUGGUCUUGUUUUUCAAAUGAAGUU-5′ (SEQ ID NO: 1796) βc-3079 Target:5′-AGGACCAGAACAAAAAGTTTACTTCAA-3′ (SEQ ID NO: 2905)5′-GGACCAGAACAAAAAGUUUACUUCA-3′ (SEQ ID NO: 4015)3′-UUCCUGGUCUUGUUUUUCAAAUGAAGU-5′ (SEQ ID NO: 1797) βc-3080 Target:5′-AAGGACCAGAACAAAAAGTTTACTTCA-3′ (SEQ ID NO: 2906)5′-ACCAAAAAGGACCAGAACAAAAAGU-3′ (SEQ ID NO: 4016)3′-GCUGGUUUUUCCUGGUCUUGUUUUUCA-5′ (SEQ ID NO: 1798) βc-3088 Target:5′-CGACCAAAAAGGACCAGAACAAAAAGT-3′ (SEQ ID NO: 2907)5′-GACCAAAAAGGACCAGAACAAAAAG-3′ (SEQ ID NO: 4017)3′-AGCUGGUUUUUCCUGGUCUUGUUUUUC-5′ (SEQ ID NO: 1799) βc-3089 Target:5′-TCGACCAAAAAGGACCAGAACAAAAAG-3′ (SEQ ID NO: 2908)5′-ACUCCUCGACCAAAAAGGACCAGAA-3′ (SEQ ID NO: 4018)3′-AAUGAGGAGCUGGUUUUUCCUGGUCUU-5′ (SEQ ID NO: 1800) βc-3096 Target:5′-TTACTCCTCGACCAAAAAGGACCAGAA-3′ (SEQ ID NO: 2909)5′-UCCAUUUGUAUUGUUACUCCUCGAC-3′ (SEQ ID NO: 4019)3′-UUAGGUAAACAUAACAAUGAGGAGCUG-5′ (SEQ ID NO: 1801) βc-3111 Target:5′-AATCCATTTGTATTGTTACTCCTCGAC-3′ (SEQ ID NO: 2910)5′-AUCCAUUUGUAUUGUUACUCCUCGA-3′ (SEQ ID NO: 4020)3′-UUUAGGUAAACAUAACAAUGAGGAGCU-5′ (SEQ ID NO: 1802) βc-3112 Target:5′-AAATCCATTTGTATTGTTACTCCTCGA-3′ (SEQ ID NO: 2911)5′-AAUCCAUUUGUAUUGUUACUCCUCG-3′ (SEQ ID NO: 4021)3′-UUUUAGGUAAACAUAACAAUGAGGAGC-5′ (SEQ ID NO: 1803) βc-3113 Target:5′-AAAATCCATTTGTATTGTTACTCCTCG-3′ (SEQ ID NO: 2912)5′-AAAUCCAUUUGUAUUGUUACUCCUC-3′ (SEQ ID NO: 4022)3′-GUUUUAGGUAAACAUAACAAUGAGGAG-5′ (SEQ ID NO: 1804) βc-3114 Target:5′-CAAAATCCATTTGTATTGTTACTCCTC-3′ (SEQ ID NO: 2913)5′-AAAAUCCAUUUGUAUUGUUACUCCU-3′ (SEQ ID NO: 4023)3′-GGUUUUAGGUAAACAUAACAAUGAGGA-5′ (SEQ ID NO: 1805) βc-3115 Target:5′-CCAAAATCCATTTGTATTGTTACTCCT-3′ (SEQ ID NO: 2914)5′-ACUCCCAAAAUCCAUUUGUAUUGUU-3′ (SEQ ID NO: 4024)3′-AGUGAGGGUUUUAGGUAAACAUAACAA-5′ (SEQ ID NO: 1806) βc-3121 Target:5′-TCACTCCCAAAATCCATTTGTATTGTT-3′ (SEQ ID NO: 2915)5′-UUCACUUCUUGAGUCACUCCCAAAA-3′ (SEQ ID NO: 4025)3′-AGAAGUGAAGAACUCAGUGAGGGUUUU-5′ (SEQ ID NO: 1807) βc-3136 Target:5′-TCTTCACTTCTTGAGTCACTCCCAAAA-3′ (SEQ ID NO: 2916)5′-UCUUCACUUCUUGAGUCACUCCCAA-3′ (SEQ ID NO: 4026)3′-UAAGAAGUGAAGAACUCAGUGAGGGUU-5′ (SEQ ID NO: 1808) βc-3138 Target:5′-ATTCTTCACTTCTTGAGTCACTCCCAA-3′ (SEQ ID NO: 2917)5′-UUCUUCACUUCUUGAGUCACUCCCA-3′ (SEQ ID NO: 4027)3′-GUAAGAAGUGAAGAACUCAGUGAGGGU-5′ (SEQ ID NO: 1809) βc-3139 Target:5′-CATTCTTCACTTCTTGAGTCACTCCCA-3′ (SEQ ID NO: 2918)5′-AUUCUUCACUUCUUGAGUCACUCCC-3′ (SEQ ID NO: 4028)3′-CGUAAGAAGUGAAGAACUCAGUGAGGG-5′ (SEQ ID NO: 1810) βc-3140 Target:5′-GCATTCTTCACTTCTTGAGTCACTCCC-3′ (SEQ ID NO: 2919)5′-GCAUUCUUCACUUCUUGAGUCACUC-3′ (SEQ ID NO: 4029)3′-CACGUAAGAAGUGAAGAACUCAGUGAG-5′ (SEQ ID NO: 1811) βc-3142 Target:5′-GTGCATTCTTCACTTCTTGAGTCACTC-3′ (SEQ ID NO: 2920)5′-AUUCUUGUGCAUUCUUCACUUCUUG-3′ (SEQ ID NO: 4030)3′-GGUAAGAACACGUAAGAAGUGAAGAAC-5′ (SEQ ID NO: 1812) βc-3150 Target:5′-CCATTCTTGTGCATTCTTCACTTCTTG-3′ (SEQ ID NO: 2921)5′-UCCAUUCUUGUGCAUUCUUCACUUC-3′ (SEQ ID NO: 4031)3′-CUAGGUAAGAACACGUAAGAAGUGAAG-5′ (SEQ ID NO: 1813) βc-3153 Target:5′-GATCCATTCTTGTGCATTCTTCACTTC-3′ (SEQ ID NO: 2922)5′-AUCCAUUCUUGUGCAUUCUUCACUU-3′ (SEQ ID NO: 4032)3′-ACUAGGUAAGAACACGUAAGAAGUGAA-5′ (SEQ ID NO: 1814) βc-3154 Target:5′-TGATCCATTCTTGTGCATTCTTCACTT-3′ (SEQ ID NO: 2923)5′-GAUCCAUUCUUGUGCAUUCUUCACU-3′ (SEQ ID NO: 4033)3′-CACUAGGUAAGAACACGUAAGAAGUGA-5′ (SEQ ID NO: 1815) βc-3155 Target:5′-GTGATCCATTCTTGTGCATTCTTCACT-3′ (SEQ ID NO: 2924)5′-AAUUCCAUCUUGUGAUCCAUUCUUG-3′ (SEQ ID NO: 4034)3′-AUUUAAGGUAGAACACUAGGUAAGAAC-5′ (SEQ ID NO: 1816) βc-3168 Target:5′-TAAATTCCATCTTGTGATCCATTCTTG-3′ (SEQ ID NO: 2925)5′-UAAAUUCCAUCUUGUGAUCCAUUCU-3′ (SEQ ID NO: 4035)3′-CUAUUUAAGGUAGAACACUAGGUAAGA-5′ (SEQ ID NO: 1817) βc-3170 Target:5′-GATAAATTCCATCTTGTGATCCATTCT-3′ (SEQ ID NO: 2926)5′-AUAAAUUCCAUCUUGUGAUCCAUUC-3′ (SEQ ID NO: 4036)3′-ACUAUUUAAGGUAGAACACUAGGUAAG-5′ (SEQ ID NO: 1818) βc-3171 Target:5′-TGATAAATTCCATCTTGTGATCCATTC-3′ (SEQ ID NO: 2927)5′-GAUAAAUUCCAUCUUGUGAUCCAUU-3′ (SEQ ID NO: 4037)3′-AACUAUUUAAGGUAGAACACUAGGUAA-5′ (SEQ ID NO: 1819) βc-3172 Target:5′-TTGATAAATTCCATCTTGTGATCCATT-3′ (SEQ ID NO: 2928)5′-UGAUAAAUUCCAUCUUGUGAUCCAU-3′ (SEQ ID NO: 4038)3′-AAACUAUUUAAGGUAGAACACUAGGUA-5′ (SEQ ID NO: 1820) βc-3173 Target:5′-TTTGATAAATTCCATCTTGTGATCC-3′ (SEQ ID NO: 2929)5′-GGCUAGGGUUUGAUAAAUUCCAUCU-3′ (SEQ ID NO: 4039)3′-UUCCGAUCCCAAACUAUUUAAGGUAGA-5′ (SEQ ID NO: 1821) βc-3183 Target:5′-AAGGCTAGGGTTTGATAAATTCCATCT-3′ (SEQ ID NO: 2930)5′-AAAAAUUUAACAAGCAAGGCUAGGG-3′ (SEQ ID NO: 4040)3′-UUUUUUUAAAUUGUUCGUUCCGAUCCC-5′ (SEQ ID NO: 1822) βc-3200 Target:5′-AAAAAAATTTAACAAGCAAGGCTAGGG-3′ (SEQ ID NO: 2931)5′-AAAAAAAAAAAAAAUUUAACAAGCA-3′ (SEQ ID NO: 4041)3′-UUUUUUUUUUUUUUUUAAAUUGUUCGU-5′ (SEQ ID NO: 1823) βc-3209 Target:5′-AAAAAAAAAAAAAAAATTTAACAAGCA-3′ (SEQ ID NO: 2932)5′-AAAAAAAAAAAAAAAUUUAACAAGC-3′ (SEQ ID NO: 4042)3′-UUUUUUUUUUUUUUUUUAAAUUGUUCG-5′ (SEQ ID NO: 1824) βc-3210 Target:5′-AAAAAAAAAAAAAAAAATTTAACAAGC-3′ (SEQ ID NO: 2933)5′-AAAAAAAAAAAAAAAAUUUAACAAG-3′ (SEQ ID NO: 4043)3′-UUUUUUUUUUUUUUUUUUAAAUUGUUC-5′ (SEQ ID NO: 1825) βc-3211 Target:5′-AAAAAAAAAAAAAAAAAATTTAACAAG-3′ (SEQ ID NO: 2934)5′-AAAAAAAAAAAAAAAAAUUUAACAA-3′ (SEQ ID NO: 4044)3′-UUUUUUUUUUUUUUUUUUUAAAUUGUU-5′ (SEQ ID NO: 1826) βc-3212 Target:5′-AAAAAAAAAAAAAAAAAAATTTAACAA-3′ (SEQ ID NO: 2935)5′-AAAAAAAAAAAAAAAAAAUUUAACA-3′ (SEQ ID NO: 4045)3′-AUUUUUUUUUUUUUUUUUUUAAAUUGU-5′ (SEQ ID NO: 1827) βc-3213 Target:5′-TAAAAAAAAAAAAAAAAAAATTTAACA-3′ (SEQ ID NO: 2936)5′-AAAAAAAAAAAAAAAAAAAUUUAAC-3′ (SEQ ID NO: 4046)3′-AAUUUUUUUUUUUUUUUUUUUAAAUUG-5′ (SEQ ID NO: 1828) βc-3214 Target:5′-TTAAAAAAAAAAAAAAAAAAATTTAAC-3′ (SEQ ID NO: 2937)5′-UAAAAAAAAAAAAAAAAAAAUUUAA-3′ (SEQ ID NO: 4047)3′-GAAUUUUUUUUUUUUUUUUUUUAAAUU-5′ (SEQ ID NO: 1829) βc-3215 Target:5′-CTTAAAAAAAAAAAAAAAAAAATTTAA-3′ (SEQ ID NO: 2938)5′-UUAAAAAAAAAAAAAAAAAAAUUUA-3′ (SEQ ID NO: 4048)3′-AGAAUUUUUUUUUUUUUUUUUUUAAAU-5′ (SEQ ID NO: 1830) βc-3216 Target:5′-TCTTAAAAAAAAAAAAAAAAAAATTTA-3′ (SEQ ID NO: 2939)5′-UCUUAAAAAAAAAAAAAAAAAAAUU-3′ (SEQ ID NO: 4049)3′-UAAGAAUUUUUUUUUUUUUUUUUUUAA-5′ (SEQ ID NO: 1831) βc-3218 Target:5′-ATTCTTAAAAAAAAAAAAAAAAAAATT-3′ (SEQ ID NO: 2940)5′-UUCUUAAAAAAAAAAAAAAAAAAAU-3′ (SEQ ID NO: 4050)3′-AUAAGAAUUUUUUUUUUUUUUUUUUUA-5′ (SEQ ID NO: 1832) βc-3219 Target:5′-TATTCTTAAAAAAAAAAAAAAAAAAAT-3′ (SEQ ID NO: 2941)5′-AUUCUUAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 4051)3′-UAUAAGAAUUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1833) βc-3220 Target:5′-ATATTCTTAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2942)5′-UAUUCUUAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 4052)3′-CUAUAAGAAUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1834) βc-3221 Target:5′-GATATTCTTAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2943)5′-AUAUUCUUAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 4053)3′-UCUAUAAGAAUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1835) βc-3222 Target:5′-AGATATTCTTAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2944)5′-GAUAUUCUUAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 4054)3′-GUCUAUAAGAAUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1836) βc-3223 Target:5′-CAGATATTCTTAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2945)5′-AGAUAUUCUUAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 4055)3′-UGUCUAUAAGAAUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1837) βc-3224 Target:5′-ACAGATATTCTTAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2946)5′-UUACAGAUAUUCUUAAAAAAAAAAA-3′ (SEQ ID NO: 4056)3′-GUAAUGUCUAUAAGAAUUUUUUUUUUU-5′ (SEQ ID NO: 1838) βc-3228 Target:5′-CATTACAGATATTCTTAAAAAAAAAAA-3′ (SEQ ID NO: 2947)5′-AUUACAGAUAUUCUUAAAAAAAAAA-3′ (SEQ ID NO: 4057)3′-GGUAAUGUCUAUAAGAAUUUUUUUUUU-5′ (SEQ ID NO: 1839) βc-3229 Target:5′-CCATTACAGATATTCTTAAAAAAAAAA-3′ (SEQ ID NO: 2948)5′-UACCAUUACAGAUAUUCUUAAAAAA-3′ (SEQ ID NO: 4058)3′-UCAUGGUAAUGUCUAUAAGAAUUUUUU-5′ (SEQ ID NO: 1840) βc-3233 Target:5′-AGTACCATTACAGATATTCTTAAAAAA-3′ (SEQ ID NO: 2949)5′-GUACCAUUACAGAUAUUCUUAAAAA-3′ (SEQ ID NO: 4059)3′-GUCAUGGUAAUGUCUAUAAGAAUUUUU-5′ (SEQ ID NO: 1841) βc-3234 Target:5′-CAGTACCATTACAGATATTCTTAAAAA-3′ (SEQ ID NO: 2950)5′-AGUACCAUUACAGAUAUUCUUAAAA-3′ (SEQ ID NO: 4060)3′-AGUCAUGGUAAUGUCUAUAAGAAUUUU-5′ (SEQ ID NO: 1842) βc-3235 Target:5′-TCAGTACCATTACAGATATTCTTAAAA-3′ (SEQ ID NO: 2951)5′-AGUCAGUACCAUUACAGAUAUUCUU-3′ (SEQ ID NO: 4061)3′-UUUCAGUCAUGGUAAUGUCUAUAAGAA-5′ (SEQ ID NO: 1843) βc-3239 Target:5′-AAAGTCAGTACCATTACAGATATTCTT-3′ (SEQ ID NO: 2952)5′-UACUUCAAAGCAAGCAAAGUCAGUA-3′ (SEQ ID NO: 4062)3′-CGAUGAAGUUUCGUUCGUUUCAGUCAU-5′ (SEQ ID NO: 1844) βc-3256 Target:5′-GCTACTTCAAAGCAAGCAAAGTCAGTA-3′ (SEQ ID NO: 2953)5′-AAAAAGAGCUACUUCAAAGCAAGCA-3′ (SEQ ID NO: 4063)3′-UUUUUUUCUCGAUGAAGUUUCGUUCGU-5′ (SEQ ID NO: 1845) βc-3265 Target:5′-AAAAAAAGAGCTACTTCAAAGCAAGCA-3′ (SEQ ID NO: 2954)5′-AAAAAAAAAAGAGCUACUUCAAAGC-3′ (SEQ ID NO: 4064)3′-UUUUUUUUUUUUCUCGAUGAAGUUUCG-5′ (SEQ ID NO: 1846) βc-3270 Target:5′-AAAAAAAAAAAAGAGCTACTTCAAAGC-3′ (SEQ ID NO: 2955)5′-AAAAAAAAAAAGAGCUACUUCAAAG-3′ (SEQ ID NO: 4065)3′-UUUUUUUUUUUUUCUCGAUGAAGUUUC-5′ (SEQ ID NO: 1847) βc-3271 Target:5′-AAAAAAAAAAAAAGAGCTACTTCAAAG-3′ (SEQ ID NO: 2956)5′-AAAAAAAAAAAAAGAGCUACUUCAA-3′ (SEQ ID NO: 4066)3′-UUUUUUUUUUUUUUUCUCGAUGAAGUU-5′ (SEQ ID NO: 1848) βc-3273 Target:5′-AAAAAAAAAAAAAAAGAGCTACTTCAA-3′ (SEQ ID NO: 2957)5′-AAAAAAAAAAAAAAGAGCUACUUCA-3′ (SEQ ID NO: 4067)3′-UUUUUUUUUUUUUUUUCUCGAUGAAGU-5′ (SEQ ID NO: 1849) βc-3274 Target:5′-AAAAAAAAAAAAAAAAGAGCTACTTCA-3′ (SEQ ID NO: 2958)5′-AAAAAAAAAAAAAAAGAGCUACUUC-3′ (SEQ ID NO: 4068)3′-UUUUUUUUUUUUUUUUUCUCGAUGAAG-5′ (SEQ ID NO: 1850) βc-3275 Target:5′-AAAAAAAAAAAAAAAAAGAGCTACTTC-3′ (SEQ ID NO: 2959)5′-AAAAAAAAAAAAAAAAGAGCUACUU-3′ (SEQ ID NO: 4069)3′-UUUUUUUUUUUUUUUUUUCUCGAUGAA-5′ (SEQ ID NO: 1851) βc-3276 Target:5′-AAAAAAAAAAAAAAAAAAGAGCTACTT-3′ (SEQ ID NO: 2960)5′-AAAAAAAAAAAAAAAAAAAAAAGAG-3′ (SEQ ID NO: 4070)3′-UUUUUUUUUUUUUUUUUUUUUUUUCUC-5′ (SEQ ID NO: 1852) βc-3282 Target:5′-AAAAAAAAAAAAAAAAAAAAAAAAGAG-3′ (SEQ ID NO: 2961)5′-AAAAAAAAAAAAAAAAAAAAAAAGA-3′ (SEQ ID NO: 4071)3′-UUUUUUUUUUUUUUUUUUUUUUUUUCU-5′ (SEQ ID NO: 1853) βc-3283 Target:5′-AAAAAAAAAAAAAAAAAAAAAAAAAGA-3′ (SEQ ID NO: 2962)5′-AAAAAAAAAAAAAAAAAAAAAAAAG-3′ (SEQ ID NO: 4072)3′-GUUUUUUUUUUUUUUUUUUUUUUUUUC-5′ (SEQ ID NO: 1854) βc-3284 Target:5′-CAAAAAAAAAAAAAAAAAAAAAAAAAG-3′ (SEQ ID NO: 2963)5′-AAAAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 4073)3′-CGUUUUUUUUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1855) βc-3285 Target:5′-GCAAAAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2964)5′-GCAAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 4074)3′-GACGUUUUUUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1856) βc-3287 Target:5′-CTGCAAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2965)5′-UGCAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 4075)3′-UGACGUUUUUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1857) βc-3288 Target:5′-ACTGCAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2966)5′-UUACUGCAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 4076)3′-UCAAUGACGUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1858) βc-3292 Target:5′-AGTTACTGCAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2967)5′-GUUACUGCAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 4077)3′-GUCAAUGACGUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1859) βc-3293 Target:5′-CAGTTACTGCAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2968)5′-AGUUACUGCAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 4078)3′-UGUCAAUGACGUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1860) βc-3294 Target:5′-ACAGTTACTGCAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2969)5′-AAACAGUUACUGCAAAAAAAAAAAA-3′ (SEQ ID NO: 4079)3′-UUUUUGUCAAUGACGUUUUUUUUUUUU-5′ (SEQ ID NO: 1861) βc-3298 Target:5′-AAAAACAGTTACTGCAAAAAAAAAAAA-3′ (SEQ ID NO: 2970)5′-AAAACAGUUACUGCAAAAAAAAAAA-3′ (SEQ ID NO: 4080)3′-UUUUUUGUCAAUGACGUUUUUUUUUUU-5′ (SEQ ID NO: 1862) βc-3299 Target:5′-AAAAAACAGTTACTGCAAAAAAAAAAA-3′ (SEQ ID NO: 2971)5′-AAAAACAGUUACUGCAAAAAAAAAA-3′ (SEQ ID NO: 4081)3′-AUUUUUUGUCAAUGACGUUUUUUUUUU-5′ (SEQ ID NO: 1863) βc-3300 Target:5′-TAAAAAACAGTTACTGCAAAAAAAAAA-3′ (SEQ ID NO: 2972)5′-UAAAAAACAGUUACUGCAAAAAAAA-3′ (SEQ ID NO: 4082)3′-GAAUUUUUUGUCAAUGACGUUUUUUUU-5′ (SEQ ID NO: 1864) βc-3302 Target:5′-CTTAAAAAACAGTTACTGCAAAAAAAA-3′ (SEQ ID NO: 2973)5′-UUAAAAAACAGUUACUGCAAAAAAA-3′ (SEQ ID NO: 4083)3′-UGAAUUUUUUGUCAAUGACGUUUUUUU-5′ (SEQ ID NO: 1865) βc-3303 Target:5′-ACTTAAAAAACAGTTACTGCAAAAAAA-3′ (SEQ ID NO: 2974)5′-ACUUAAAAAACAGUUACUGCAAAAA-3′ (SEQ ID NO: 4084)3′-UCUGAAUUUUUUGUCAAUGACGUUUUU-5′ (SEQ ID NO: 1866) βc-3305 Target:5′-AGACTTAAAAAACAGTTACTGCAAAAA-3′ (SEQ ID NO: 2975)5′-ACUACGAGAGACUUAAAAAACAGUU-3′ (SEQ ID NO: 4085)3′-UGUGAUGCUCUCUGAAUUUUUUGUCAA-5′ (SEQ ID NO: 1867) βc-3315 Target:5′-ACACTACGAGAGACTTAAAAAACAGTT-3′ (SEQ ID NO: 2976)5′-ACACUACGAGAGACUUAAAAAACAG-3′ (SEQ ID NO: 4086)3′-AUUGUGAUGCUCUCUGAAUUUUUUGUC-5′ (SEQ ID NO: 1868) βc-3317 Target:5′-TAACACTACGAGAGACTTAAAAAACAG-3′ (SEQ ID NO: 2977)5′-AACACUACGAGAGACUUAAAAAACA-3′ (SEQ ID NO: 4087)3′-AAUUGUGAUGCUCUCUGAAUUUUUUGU-5′ (SEQ ID NO: 1869) βc-3318 Target:5′-TTAACACTACGAGAGACTTAAAAAACA-3′ (SEQ ID NO: 2978)5′-UUAACACUACGAGAGACUUAAAAAA-3′ (SEQ ID NO: 4088)3′-UGAAUUGUGAUGCUCUCUGAAUUUUUU-5′ (SEQ ID NO: 1870) βc-3320 Target:5′-ACTTAACACTACGAGAGACTTAAAAAA-3′ (SEQ ID NO: 2979)5′-AACUUAACACUACGAGAGACUUAAA-3′ (SEQ ID NO: 4089)3′-UAUUGAAUUGUGAUGCUCUCUGAAUUU-5′ (SEQ ID NO: 1871) βc-3323 Target:5′-ATAACTTAACACTACGAGAGACTTAAA-3′ (SEQ ID NO: 2980)5′-UAACUUAACACUACGAGAGACUUAA-3′ (SEQ ID NO: 4090)3′-AUAUUGAAUUGUGAUGCUCUCUGAAUU-5′ (SEQ ID NO: 1872) βc-3324 Target:5′-TATAACTTAACACTACGAGAGACTTAA-3′ (SEQ ID NO: 2981)5′-AUUCACUAUAACUUAACACUACGAG-3′ (SEQ ID NO: 4091)3′-CAUAAGUGAUAUUGAAUUGUGAUGCUC-5′ (SEQ ID NO: 1873) βc-3332 Target:5′-GTATTCACTATAACTTAACACTACGAG-3′ (SEQ ID NO: 2982)5′-UAUUCACUAUAACUUAACACUACGA-3′ (SEQ ID NO: 4092)3′-UCAUAAGUGAUAUUGAAUUGUGAUGCU-5′ (SEQ ID NO: 1874) βc-3333 Target:5′-AGTATTCACTATAACTTAACACTACGA-3′ (SEQ ID NO: 2983)5′-GUAUUCACUAUAACUUAACACUACG-3′ (SEQ ID NO: 4093)3′-GUCAUAAGUGAUAUUGAAUUGUGAUGC-5′ (SEQ ID NO: 1875) βc-3334 Target:5′-CAGTATTCACTATAACTTAACACTACG-3′ (SEQ ID NO: 2984)5′-AGUAUUCACUAUAACUUAACACUAC-3′ (SEQ ID NO: 4094)3′-CGUCAUAAGUGAUAUUGAAUUGUGAUG-5′ (SEQ ID NO: 1876) βc-3335 Target:5′-GCAGTATTCACTATAACTTAACACTAC-3′ (SEQ ID NO: 2985)5′-AAAUUGCUGUAGCAGUAUUCACUAU-3′ (SEQ ID NO: 4095)3′-UCUUUAACGACAUCGUCAUAAGUGAUA-5′ (SEQ ID NO: 1877) βc-3348 Target:5′-AGAAATTGCTGTAGCAGTATTCACTAT-3′ (SEQ ID NO: 2986)5′-GAAAUUGCUGUAGCAGUAUUCACUA-3′ (SEQ ID NO: 4096)3′-AUCUUUAACGACAUCGUCAUAAGUGAU-5′ (SEQ ID NO: 1878) βc-3349 Target:5′-TAGAAATTGCTGTAGCAGTATTCACTA-3′ (SEQ ID NO: 2987)5′-AGAAAUUGCUGUAGCAGUAUUCACU-3′ (SEQ ID NO: 4097)3′-AAUCUUUAACGACAUCGUCAUAAGUGA-5′ (SEQ ID NO: 1879) βc-3350 Target:5′-TTAGAAATTGCTGTAGCAGTATTCACT-3′ (SEQ ID NO: 2988)5′-UCAAUUCUUAAAAAUUAGAAAUUGC-3′ (SEQ ID NO: 4098)3′-UGAGUUAAGAAUUUUUAAUCUUUAACG-5′ (SEQ ID NO: 1880) βc-3366 Target:5′-ACTCAATTCTTAAAAATTAGAAATTGC-3′ (SEQ ID NO: 2989)5′-AUUACUCAAUUCUUAAAAAUUAGAA-3′ (SEQ ID NO: 4099)3′-GGUAAUGAGUUAAGAAUUUUUAAUCUU-5′ (SEQ ID NO: 1881) βc-3371 Target:5′-CCATTACTCAATTCTTAAAAATTAGAA-3′ (SEQ ID NO: 2990)5′-ACCAUUACUCAAUUCUUAAAAAUUA-3′ (SEQ ID NO: 4100)3′-UGUGGUAAUGAGUUAAGAAUUUUUAAU-5′ (SEQ ID NO: 1882) βc-3374 Target:5′-ACACCATTACTCAATTCTTAAAAATTA-3′ (SEQ ID NO: 2991)5′-ACACCAUUACUCAAUUCUUAAAAAU-3′ (SEQ ID NO: 4101)3′-GAUGUGGUAAUGAGUUAAGAAUUUUUA-5′ (SEQ ID NO: 1883) βc-3376 Target:5′-CTACACCATTACTCAATTCTTAAAAAT-3′ (SEQ ID NO: 2992)5′-UACACCAUUACUCAAUUCUUAAAAA-3′ (SEQ ID NO: 4102)3′-AGAUGUGGUAAUGAGUUAAGAAUUUUU-5′ (SEQ ID NO: 1884) βc-3377 Target:5′-TCTACACCATTACTCAATTCTTAAAAA-3′ (SEQ ID NO: 2993)5′-UCUACACCAUUACUCAAUUCUUAAA-3′ (SEQ ID NO: 4103)3′-CAAGAUGUGGUAAUGAGUUAAGAAUUU-5′ (SEQ ID NO: 1885) βc-3379 Target:5′-GTTCTACACCATTACTCAATTCTTAAA-3′ (SEQ ID NO: 2994)5′-GUUCUACACCAUUACUCAAUUCUUA-3′ (SEQ ID NO: 4104)3′-CACAAGAUGUGGUAAUGAGUUAAGAAU-5′ (SEQ ID NO: 1886) βc-3381 Target:5′-GTGTTCTACACCATTACTCAATTCTTA-3′ (SEQ ID NO: 2995)5′-GAAUUAGUGUUCUACACCAUUACUC-3′ (SEQ ID NO: 4105)3′-UACUUAAUCACAAGAUGUGGUAAUGAG-5′ (SEQ ID NO: 1887) βc-3389 Target:5′-ATGAATTAGTGTTCTACACCATTACTC-3′ (SEQ ID NO: 2996)5′-AUUAUGAAUUAGUGUUCUACACCAU-3′ (SEQ ID NO: 4106)3′-ACUAAUACUUAAUCACAAGAUGUGGUA-5′ (SEQ ID NO: 1888) βc-3394 Target:5′-TGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 2997)5′-GAUUAUGAAUUAGUGUUCUACACCA-3′ (SEQ ID NO: 4107)3′-CACUAAUACUUAAUCACAAGAUGUGGU-5′ (SEQ ID NO: 1889) βc-3395 Target:5′-GTGATTATGAATTAGTGTTCTACACCA-3′ (SEQ ID NO: 2998)5′-UGAUUAUGAAUUAGUGUUCUACACC-3′ (SEQ ID NO: 4108)3′-UCACUAAUACUUAAUCACAAGAUGUGG-5′ (SEQ ID NO: 1890) βc-3396 Target:5′-AGTGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 2999)5′-UAAUUAGAGUGAUUAUGAAUUAGUG-3′ (SEQ ID NO: 4109)3′-UAAUUAAUCUCACUAAUACUUAAUCAC-5′ (SEQ ID NO: 1891) βc-3405 Target:5′-ATTAATTAGAGTGATTATGAATTAGTG-3′ (SEQ ID NO: 3000)5′-UUAAUUAGAGUGAUUAUGAAUUAGU-3′ (SEQ ID NO: 4110)3′-UUAAUUAAUCUCACUAAUACUUAAUCA-5′ (SEQ ID NO: 1892) βc-3406 Target:5′-AATTAATTAGAGTGATTATGAATTAGT-3′ (SEQ ID NO: 3001)5′-AUUAAUUAGAGUGAUUAUGAAUUAG-3′ (SEQ ID NO: 4111)3′-GUUAAUUAAUCUCACUAAUACUUAAUC-5′ (SEQ ID NO: 1893) βc-3407 Target:5′-CAATTAATTAGAGTGATTATGAATTAG-3′ (SEQ ID NO: 3002)5′-UACAAUUAAUUAGAGUGAUUAUGAA-3′ (SEQ ID NO: 4112)3′-UAAUGUUAAUUAAUCUCACUAAUACUU-5′ (SEQ ID NO: 1894) βc-3411 Target:5′-ATTACAATTAATTAGAGTGATTATGAA-3′ (SEQ ID NO: 3003)5′-UUACAAUUAAUUAGAGUGAUUAUGA-3′ (SEQ ID NO: 4113)3′-CUAAUGUUAAUUAAUCUCACUAAUACU-5′ (SEQ ID NO: 1895) βc-3412 Target:5′-GATTACAATTAATTAGAGTGATTATGA-3′ (SEQ ID NO: 3004)5′-AUUACAAUUAAUUAGAGUGAUUAUG-3′ (SEQ ID NO: 4114)3′-UCUAAUGUUAAUUAAUCUCACUAAUAC-5′ (SEQ ID NO: 1896) βc-3413 Target:5′-AGATTACAATTAATTAGAGTGATTATG-3′ (SEQ ID NO: 3005)5′-UUAUUCAGAUUACAAUUAAUUAGAG-3′ (SEQ ID NO: 4115)3′-GAAAUAAGUCUAAUGUUAAUUAAUCUC-5′ (SEQ ID NO: 1897) βc-3421 Target:5′-CTTTATTCAGATTACAATTAATTAGAG-3′ (SEQ ID NO: 3006)5′-UUUAUUCAGAUUACAAUUAAUUAGA-3′ (SEQ ID NO: 4116)3′-UGAAAUAAGUCUAAUGUUAAUUAAUCU-5′ (SEQ ID NO: 1898) βc-3422 Target:5′-ACTTTATTCAGATTACAATTAATTAGA-3′ (SEQ ID NO: 3007)5′-ACACUUUAUUCAGAUUACAAUUAAU-3′ (SEQ ID NO: 4117)3′-AAUGUGAAAUAAGUCUAAUGUUAAUUA-5′ (SEQ ID NO: 1899) βc-3426 Target:5′-TTACACTTTATTCAGATTACAATTAAT-3′ (SEQ ID NO: 3008)5′-UACACUUUAUUCAGAUUACAAUUAA-3′ (SEQ ID NO: 4118)3′-CAAUGUGAAAUAAGUCUAAUGUUAAUU-5′ (SEQ ID NO: 1900) βc-3427 Target:5′-GTTACACTTTATTCAGATTACAATTAA-3′ (SEQ ID NO: 3009)5′-UUACACUUUAUUCAGAUUACAAUUA-3′ (SEQ ID NO: 4119)3′-ACAAUGUGAAAUAAGUCUAAUGUUAAU-5′ (SEQ ID NO: 1901) βc-3428 Target:5′-TGTTACACTTTATTCAGATTACAATTA-3′ (SEQ ID NO: 3010)5′-GUUACACUUUAUUCAGAUUACAAUU-3′ (SEQ ID NO: 4120)3′-AACAAUGUGAAAUAAGUCUAAUGUUAA-5′ (SEQ ID NO: 1902) βc-3429 Target:5′-TTGTTACACTTTATTCAGATTACAATT-3′ (SEQ ID NO: 3011)5′-UGUUACACUUUAUUCAGAUUACAAU-3′ (SEQ ID NO: 4121)3′-UAACAAUGUGAAAUAAGUCUAAUGUUA-5′ (SEQ ID NO: 1903) βc-3430 Target:5′-ATTGTTACACTTTATTCAGATTACAAT-3′ (SEQ ID NO: 3012)5′-ACACAAUUGUUACACUUUAUUCAGA-3′ (SEQ ID NO: 4122)3′-GAUGUGUUAACAAUGUGAAAUAAGUCU-5′ (SEQ ID NO: 1904) βc-3437 Target:5′-CTACACAATTGTTACACTTTATTCAGA-3′ (SEQ ID NO: 3013)5′-GGCUACACAAUUGUUACACUUUAUU-3′ (SEQ ID NO: 4123)3′-UUCCGAUGUGUUAACAAUGUGAAAUAA-5′ (SEQ ID NO: 1905) βc-3441 Target:5′-AAGGCTACACAATTGTTACACTTTATT-3′ (SEQ ID NO: 3014)5′-AAAAAGGCUACACAAUUGUUACACU-3′ (SEQ ID NO: 4124)3′-UGUUUUUCCGAUGUGUUAACAAUGUGA-5′ (SEQ ID NO: 1906) βc-3446 Target:5′-ACAAAAAGGCTACACAATTGTTACACT-3′ (SEQ ID NO: 3015)5′-UUAUACAAAAAGGCUACACAAUUGU-3′ (SEQ ID NO: 4125)3′-AAAAUAUGUUUUUCCGAUGUGUUAACA-5′ (SEQ ID NO: 1907) βc-3452 Target:5′-TTTTATACAAAAAGGCTACACAATTGT-3′ (SEQ ID NO: 3016)5′-UUUAUACAAAAAGGCUACACAAUUG-3′ (SEQ ID NO: 4126)3′-UAAAAUAUGUUUUUCCGAUGUGUUAAC-5′ (SEQ ID NO: 1908) βc-3453 Target:5′-ATTTTATACAAAAAGGCTACACAATTG-3′ (SEQ ID NO: 3017)5′-AUUUUAUACAAAAAGGCUACACAAU-3′ (SEQ ID NO: 4127)3′-GAUAAAAUAUGUUUUUCCGAUGUGUUA-5′ (SEQ ID NO: 1909) βc-3455 Target:5′-CTATTTTATACAAAAAGGCTACACAAT-3′ (SEQ ID NO: 3018)5′-UAUUUUAUACAAAAAGGCUACACAA-3′ (SEQ ID NO: 4128)3′-AGAUAAAAUAUGUUUUUCCGAUGUGUU-5′ (SEQ ID NO: 1910) βc-3456 Target:5′-TCTATTTTATACAAAAAGGCTACACAA-3′ (SEQ ID NO: 3019)5′-UCUAUUUUAUACAAAAAGGCUACAC-3′ (SEQ ID NO: 4129)3′-ACAGAUAAAAUAUGUUUUUCCGAUGUG-5′ (SEQ ID NO: 1911) βc-3458 Target:5′-TGTCTATTTTATACAAAAAGGCTACAC-3′ (SEQ ID NO: 3020)5′-UAUUUGUCUAUUUUAUACAAAAAGG-3′ (SEQ ID NO: 4130)3′-AGAUAAACAGAUAAAAUAUGUUUUUCC-5′ (SEQ ID NO: 1912) βc-3464 Target:5′-TCTATTTGTCTATTTTATACAAAAAGG-3′ (SEQ ID NO: 3021)5′-UCUAUUUGUCUAUUUUAUACAAAAA-3′ (SEQ ID NO: 4131)3′-AAAGAUAAACAGAUAAAAUAUGUUUUU-5′ (SEQ ID NO: 1913) βc-3466 Target:5′-TTTCTATTTGTCTATTTTATACAAAAA-3′ (SEQ ID NO: 3022)5′-UUCUAUUUGUCUAUUUUAUACAAAA-3′ (SEQ ID NO: 4132)3′-AAAAGAUAAACAGAUAAAAUAUGUUUU-5′ (SEQ ID NO: 1914) βc-3467 Target:5′-TTTTCTATTTGTCTATTTTATACAAAA-3′ (SEQ ID NO: 3023)5′-UUUCUAUUUGUCUAUUUUAUACAAA-3′ (SEQ ID NO: 4133)3′-UAAAAGAUAAACAGAUAAAAUAUGUUU-5′ (SEQ ID NO: 1915) βc-3468 Target:5′-ATTTTCTATTTGTCTATTTTATACAAA-3′ (SEQ ID NO: 3024)5′-UUUUCUAUUUGUCUAUUUUAUACAA-3′ (SEQ ID NO: 4134)3′-GUAAAAGAUAAACAGAUAAAAUAUGUU-5′ (SEQ ID NO: 1916) βc-3469 Target:5′-CATTTTCTATTTGTCTATTTTATACAA-3′ (SEQ ID NO: 3025)5′-AUUUUCUAUUUGUCUAUUUUAUACA-3′ (SEQ ID NO: 4135)3′-GGUAAAAGAUAAACAGAUAAAAUAUGU-5′ (SEQ ID NO: 1917) βc-3470 Target:5′-CCATTTTCTATTTGTCTATTTTATACA-3′ (SEQ ID NO: 3026)5′-ACCAUUUUCUAUUUGUCUAUUUUAU-3′ (SEQ ID NO: 4136)3′-CCUGGUAAAAGAUAAACAGAUAAAAUA-5′ (SEQ ID NO: 1918) βc-3473 Target:5′-GGACCATTTTCTATTTGTCTATTTTAT-3′ (SEQ ID NO: 3027)5′-GACCAUUUUCUAUUUGUCUAUUUUA-3′ (SEQ ID NO: 4137)3′-ACCUGGUAAAAGAUAAACAGAUAAAAU-5′ (SEQ ID NO: 1919) βc-3474 Target:5′-TGGACCATTTTCTATTTGTCTATTTTA-3′ (SEQ ID NO: 3028)5′-GGACCAUUUUCUAUUUGUCUAUUUU-3′ (SEQ ID NO: 4138)3′-AACCUGGUAAAAGAUAAACAGAUAAAA-5′ (SEQ ID NO: 1920) βc-3475 Target:5′-TTGGACCATTTTCTATTTGTCTATTTT-3′ (SEQ ID NO: 3029)5′-ACUAAUUGGACCAUUUUCUAUUUGU-3′ (SEQ ID NO: 4139)3′-UUUGAUUAACCUGGUAAAAGAUAAACA-5′ (SEQ ID NO: 1921) βc-3482 Target:5′-AAACTAATTGGACCATTTTCTATTTGT-3′ (SEQ ID NO: 3030)5′-AACUAAUUGGACCAUUUUCUAUUUG-3′ (SEQ ID NO: 4140)3′-CUUUGAUUAACCUGGUAAAAGAUAAAC-5′ (SEQ ID NO: 1922) βc-3483 Target:5′-GAAACTAATTGGACCATTTTCTATTTG-3′ (SEQ ID NO: 3031)5′-AAACUAAUUGGACCAUUUUCUAUUU-3′ (SEQ ID NO: 4141)3′-CCUUUGAUUAACCUGGUAAAAGAUAAA-5′ (SEQ ID NO: 1923) βc-3484 Target:5′-GGAAACTAATTGGACCATTTTCTATTT-3′ (SEQ ID NO: 3032)5′-GAAACUAAUUGGACCAUUUUCUAUU-3′ (SEQ ID NO: 4142)3′-UCCUUUGAUUAACCUGGUAAAAGAUAA-5′ (SEQ ID NO: 1924) βc-3485 Target:5′-AGGAAACTAATTGGACCATTTTCTATT-3′ (SEQ ID NO: 3033)5′-AAAAAGGAAACUAAUUGGACCAUUU-3′ (SEQ ID NO: 4143)3′-AAUUUUUCCUUUGAUUAACCUGGUAAA-5′ (SEQ ID NO: 1925) βc-3491 Target:5′-TTAAAAAGGAAACTAATTGGACCATTT-3′ (SEQ ID NO: 3034)5′-UAAAAAGGAAACUAAUUGGACCAUU-3′ (SEQ ID NO: 4144)3′-UAAUUUUUCCUUUGAUUAACCUGGUAA-5′ (SEQ ID NO: 1926) βc-3492 Target:5′-ATTAAAAAGGAAACTAATTGGACCATT-3′ (SEQ ID NO: 3035)5′-GCAUAUUAAAAAGGAAACUAAUUGG-3′ (SEQ ID NO: 4145)3′-UUCGUAUAAUUUUUCCUUUGAUUAACC-5′ (SEQ ID NO: 1927) βc-3498 Target:5′-AAGCATATTAAAAAGGAAACTAATTGG-3′ (SEQ ID NO: 3036)5′-AGCAUAUUAAAAAGGAAACUAAUUG-3′ (SEQ ID NO: 4146)3′-AUUCGUAUAAUUUUUCCUUUGAUUAAC-5′ (SEQ ID NO: 1928) βc-3499 Target:5′-TAAGCATATTAAAAAGGAAACTAATTG-3′ (SEQ ID NO: 3037)5′-UUUAAGCAUAUUAAAAAGGAAACUA-3′ (SEQ ID NO: 4147)3′-UAAAAUUCGUAUAAUUUUUCCUUUGAU-5′ (SEQ ID NO: 1929) βc-3503 Target:5′-ATTTTAAGCATATTAAAAAGGAAACTA-3′ (SEQ ID NO: 3038)5′-GCUUAUUUUAAGCAUAUUAAAAAGG-3′ (SEQ ID NO: 4148)3′-GACGAAUAAAAUUCGUAUAAUUUUUCC-5′ (SEQ ID NO: 1930) βc-3509 Target:5′-CTGCTTATTTTAAGCATATTAAAAAGG-3′ (SEQ ID NO: 3039)5′-UGCUUAUUUUAAGCAUAUUAAAAAG-3′ (SEQ ID NO: 4149)3′-GGACGAAUAAAAUUCGUAUAAUUUUUC-5′ (SEQ ID NO: 1931) βc-3510 Target:5′-CCTGCTTATTTTAAGCATATTAAAAAG-3′ (SEQ ID NO: 3040)5′-UCCACCUGCUUAUUUUAAGCAUAUU-3′ (SEQ ID NO: 4150)3′-CUAGGUGGACGAAUAAAAUUCGUAUAA-5′ (SEQ ID NO: 1932) βc-3516 Target:5′-GATCCACCTGCTTATTTTAAGCATATT-3′ (SEQ ID NO: 3041)5′-AAAACAUGAAAUAGAUCCACCUGCU-3′ (SEQ ID NO: 4151)3′-GUUUUUGUACUUUAUCUAGGUGGACGA-5′ (SEQ ID NO: 1933) βc-3531 Target:5′-CAAAAACATGAAATAGATCCACCTGCT-3′ (SEQ ID NO: 3042)5′-AAAAACAUGAAAUAGAUCCACCUGC-3′ (SEQ ID NO: 4152)3′-AGUUUUUGUACUUUAUCUAGGUGGACG-5′ (SEQ ID NO: 1934) βc-3532 Target:5′-TCAAAAACATGAAATAGATCCACCTGC-3′ (SEQ ID NO: 3043)5′-UCAAAAACAUGAAAUAGAUCCACCU-3′ (SEQ ID NO: 4153)3′-CUAGUUUUUGUACUUUAUCUAGGUGGA-5′ (SEQ ID NO: 1935) βc-3534 Target:5′-GATCAAAAACATGAAATAGATCCACCT-3′ (SEQ ID NO: 3044)5′-AUCAAAAACAUGAAAUAGAUCCACC-3′ (SEQ ID NO: 4154)3′-ACUAGUUUUUGUACUUUAUCUAGGUGG-5′ (SEQ ID NO: 1936) βc-3535 Target:5′-TGATCAAAAACATGAAATAGATCCACC-3′ (SEQ ID NO: 3045)5′-GAUCAAAAACAUGAAAUAGAUCCAC-3′ (SEQ ID NO: 4155)3′-AACUAGUUUUUGUACUUUAUCUAGGUG-5′ (SEQ ID NO: 1937) βc-3536 Target:5′-TTGATCAAAAACATGAAATAGATCCAC-3′ (SEQ ID NO: 3046)5′-UUUUUGAUCAAAAACAUGAAAUAGA-3′ (SEQ ID NO: 4156)3′-UCAAAAACUAGUUUUUGUACUUUAUCU-5′ (SEQ ID NO: 1938) βc-3541 Target:5′-AGTTTTTGATCAAAAACATGAAATAGA-3′ (SEQ ID NO: 3047)5′-AAAUAGUUUUUGAUCAAAAACAUGA-3′ (SEQ ID NO: 4157)3′-GGUUUAUCAAAAACUAGUUUUUGUACU-5′ (SEQ ID NO: 1939) βc-3547 Target:5′-CCAAATAGTTTTTGATCAAAAACATGA-3′ (SEQ ID NO: 3048)5′-UCCCAAAUAGUUUUUGAUCAAAAAC-3′ (SEQ ID NO: 4158)3′-AUAGGGUUUAUCAAAAACUAGUUUUUG-5′ (SEQ ID NO: 1940) βc-3551 Target:5′-TATCCCAAATAGTTTTTGATCAAAAAC-3′ (SEQ ID NO: 3049)5′-AUCCCAAAUAGUUUUUGAUCAAAAA-3′ (SEQ ID NO: 4159)3′-UAUAGGGUUUAUCAAAAACUAGUUUUU-5′ (SEQ ID NO: 1941) βc-3552 Target:5′-ATATCCCAAATAGTTTTTGATCAAAAA-3′ (SEQ ID NO: 3050)5′-UAUCCCAAAUAGUUUUUGAUCAAAA-3′ (SEQ ID NO: 4160)3′-GUAUAGGGUUUAUCAAAAACUAGUUUU-5′ (SEQ ID NO: 1942) βc-3553 Target:5′-CATATCCCAAATAGTTTTTGATCAAAA-3′ (SEQ ID NO: 3051)5′-AUAUCCCAAAUAGUUUUUGAUCAAA-3′ (SEQ ID NO: 4161)3′-UGUAUAGGGUUUAUCAAAAACUAGUUU-5′ (SEQ ID NO: 1943) βc-3554 Target:5′-ACATATCCCAAATAGTTTTTGATCAAA-3′ (SEQ ID NO: 3052)5′-AUACAUAUCCCAAAUAGUUUUUGAU-3′ (SEQ ID NO: 4162)3′-GGUAUGUAUAGGGUUUAUCAAAAACUA-5′ (SEQ ID NO: 1944) βc-3558 Target:5′-CCATACATATCCCAAATAGTTTTTGAT-3′ (SEQ ID NO: 3053)5′-ACCCUACCCAUACAUAUCCCAAAUA-3′ (SEQ ID NO: 4163)3′-AAUGGGAUGGGUAUGUAUAGGGUUUAU-5′ (SEQ ID NO: 1945) βc-3567 Target:5′-TTACCCTACCCATACATATCCCAAATA-3′ (SEQ ID NO: 3054)5′-UACCCUACCCAUACAUAUCCCAAAU-3′ (SEQ ID NO: 4164)3′-AAAUGGGAUGGGUAUGUAUAGGGUUUA-5′ (SEQ ID NO: 1946) βc-3568 Target:5′-TTTACCCTACCCATACATATCCCAAAT-3′ (SEQ ID NO: 3055)5′-UUACCCUACCCAUACAUAUCCCAAA-3′ (SEQ ID NO: 4165)3′-UAAAUGGGAUGGGUAUGUAUAGGGUUU-5′ (SEQ ID NO: 1947) βc-3569 Target:5′-ATTTACCCTACCCATACATATCCCAAA-3′ (SEQ ID NO: 3056)5′-ACCUCUUACUGAUUUACCCUACCCA-3′ (SEQ ID NO: 4166)3′-UGUGGAGAAUGACUAAAUGGGAUGGGU-5′ (SEQ ID NO: 1948) βc-3582 Target:5′-ACACCTCTTACTGATTTACCCTACCCA-3′ (SEQ ID NO: 3057)5′-ACACCUCUUACUGAUUUACCCUACC-3′ (SEQ ID NO: 4167)3′-AUUGUGGAGAAUGACUAAAUGGGAUGG-5′ (SEQ ID NO: 1949) βc-3584 Target:5′-TAACACCTCTTACTGATTTACCCTACC-3′ (SEQ ID NO: 3058)5′-AACACCUCUUACUGAUUUACCCUAC-3′ (SEQ ID NO: 4168)3′-UAUUGUGGAGAAUGACUAAAUGGGAUG-5′ (SEQ ID NO: 1950) βc-3585 Target:5′-ATAACACCTCTTACTGATTTACCCTAC-3′ (SEQ ID NO: 3059)5′-UAACACCUCUUACUGAUUUACCCUA-3′ (SEQ ID NO: 4169)3′-UUAUUGUGGAGAAUGACUAAAUGGGAU-5′ (SEQ ID NO: 1951) βc-3586 Target:5′-AATAACACCTCTTACTGATTTACCCTA-3′ (SEQ ID NO: 3060)5′-AUAACACCUCUUACUGAUUUACCCU-3′ (SEQ ID NO: 4170)3′-UUUAUUGUGGAGAAUGACUAAAUGGGA-5′ (SEQ ID NO: 1952) βc-3587 Target:5′-AAATAACACCTCTTACTGATTTACCCT-3′ (SEQ ID NO: 3061)5′-AAUAACACCUCUUACUGAUUUACCC-3′ (SEQ ID NO: 4171)3′-GUUUAUUGUGGAGAAUGACUAAAUGGG-5′ (SEQ ID NO: 1953) βc-3588 Target:5′-CAAATAACACCTCTTACTGATTTACCC-3′ (SEQ ID NO: 3062)5′-GUUCCAAAUAACACCUCUUACUGAU-3′ (SEQ ID NO: 4172)3′-UCCAAGGUUUAUUGUGGAGAAUGACUA-5′ (SEQ ID NO: 1954) βc-3594 Target:5′-AGGTTCCAAATAACACCTCTTACTGAT-3′ (SEQ ID NO: 3063)5′-AACAAGGUUCCAAAUAACACCUCUU-3′ (SEQ ID NO: 4173)3′-UUUUGUUCCAAGGUUUAUUGUGGAGAA-5′ (SEQ ID NO: 1955) βc-3600 Target:5′-AAAACAAGGTTCCAAATAACACCTCTT-3′ (SEQ ID NO: 3064)5′-AAACAAGGUUCCAAAUAACACCUCU-3′ (SEQ ID NO: 4174)3′-GUUUUGUUCCAAGGUUUAUUGUGGAGA-5′ (SEQ ID NO: 1956) βc-3601 Target:5′-CAAAACAAGGTTCCAAATAACACCTCT-3′ (SEQ ID NO: 3065)5′-AAAACAAGGUUCCAAAUAACACCUC-3′ (SEQ ID NO: 4175)3′-GGUUUUGUUCCAAGGUUUAUUGUGGAG-5′ (SEQ ID NO: 1957) βc-3602 Target:5′-CCAAAACAAGGTTCCAAATAACACCTC-3′ (SEQ ID NO: 3066)5′-UGUCCAAAACAAGGUUCCAAAUAAC-3′ (SEQ ID NO: 4176)3′-UGACAGGUUUUGUUCCAAGGUUUAUUG-5′ (SEQ ID NO: 1958) βc-3607 Target:5′-ACTGTCCAAAACAAGGTTCCAAATAAC-3′ (SEQ ID NO: 3067)5′-AAACUGUCCAAAACAAGGUUCCAAA-3′ (SEQ ID NO: 4177)3′-CAUUUGACAGGUUUUGUUCCAAGGUUU-5′ (SEQ ID NO: 1959) βc-3611 Target:5′-GTAAACTGTCCAAAACAAGGTTCCAAA-3′ (SEQ ID NO: 3068)5′-UAAACUGUCCAAAACAAGGUUCCAA-3′ (SEQ ID NO: 4178)3′-CCAUUUGACAGGUUUUGUUCCAAGGUU-5′ (SEQ ID NO: 1960) βc-3612 Target:5′-GGTAAACTGTCCAAAACAAGGTTCCAA-3′ (SEQ ID NO: 3069)5′-GCAACUGGUAAACUGUCCAAAACAA-3′ (SEQ ID NO: 4179)3′-UCCGUUGACCAUUUGACAGGUUUUGUU-5′ (SEQ ID NO: 1961) βc-3620 Target:5′-AGGCAACTGGTAAACTGTCCAAAACAA-3′ (SEQ ID NO: 3070)5′-GAUAAAAGGCAACUGGUAAACUGUC-3′ (SEQ ID NO: 4180)3′-CCCUAUUUUCCGUUGACCAUUUGACAG-5′ (SEQ ID NO: 1962) βc-3628 Target:5′-GGGATAAAAGGCAACTGGTAAACTGTC-3′ (SEQ ID NO: 3071)5′-GGAUAAAAGGCAACUGGUAAACUGU-3′ (SEQ ID NO: 4181)3′-ACCCUAUUUUCCGUUGACCAUUUGACA-5′ (SEQ ID NO: 1963) βc-3629 Target:5′-TGGGATAAAAGGCAACTGGTAAACTGT-3′ (SEQ ID NO: 3072)5′-AACUUUGGGAUAAAAGGCAACUGGU-3′ (SEQ ID NO: 4182)3′-UGUUGAAACCCUAUUUUCCGUUGACCA-5′ (SEQ ID NO: 1964) βc-3636 Target:5′-ACAACTTTGGGATAAAAGGCAACTGGT-3′ (SEQ ID NO: 3073)5′-ACAACUUUGGGAUAAAAGGCAACUG-3′ (SEQ ID NO: 4183)3′-GUUGUUGAAACCCUAUUUUCCGUUGAC-5′ (SEQ ID NO: 1965) βc-3638 Target:5′-CAACAACTTTGGGATAAAAGGCAACTG-3′ (SEQ ID NO: 3074)5′-UUACAACAACUUUGGGAUAAAAGGC-3′ (SEQ ID NO: 4184)3′-CCAAUGUUGUUGAAACCCUAUUUUCCG-5′ (SEQ ID NO: 1966) βc-3643 Target:5′-GGTTACAACAACTTTGGGATAAAAGGC-3′ (SEQ ID NO: 3075)5′-GUUACAACAACUUUGGGAUAAAAGG-3′ (SEQ ID NO: 4185)3′-UCCAAUGUUGUUGAAACCCUAUUUUCC-5′ (SEQ ID NO: 1967) βc-3644 Target:5′-AGGTTACAACAACTTTGGGATAAAAGG-3′ (SEQ ID NO: 3076)5′-GGUUACAACAACUUUGGGAUAAAAG-3′ (SEQ ID NO: 4186)3′-GUCCAAUGUUGUUGAAACCCUAUUUUC-5′ (SEQ ID NO: 1968) βc-3645 Target:5′-CAGGTTACAACAACTTTGGGATAAAAG-3′ (SEQ ID NO: 3077)5′-UCACAGCAGGUUACAACAACUUUGG-3′ (SEQ ID NO: 4187)3′-AUAGUGUCGUCCAAUGUUGUUGAAACC-5′ (SEQ ID NO: 1969) βc-3653 Target:5′-TATCACAGCAGGTTACAACAACTTTGG-3′ (SEQ ID NO: 3078)5′-AUCACAGCAGGUUACAACAACUUUG-3′ (SEQ ID NO: 4188)3′-CAUAGUGUCGUCCAAUGUUGUUGAAAC-5′ (SEQ ID NO: 1970) βc-3654 Target:5′-GTATCACAGCAGGTTACAACAACTTTG-3′ (SEQ ID NO: 3079)5′-GUAUCACAGCAGGUUACAACAACUU-3′ (SEQ ID NO: 4189)3′-AGCAUAGUGUCGUCCAAUGUUGUUGAA-5′ (SEQ ID NO: 1971) βc-3656 Target:5′-TCGTATCACAGCAGGTTACAACAACTT-3′ (SEQ ID NO: 3080)5′-UCUCUUGAAGCAUCGUAUCACAGCA-3′ (SEQ ID NO: 4190)3′-AAAGAGAACUUCGUAGCAUAGUGUCGU-5′ (SEQ ID NO: 1972) βc-3670 Target:5′-TTTCTCTTGAAGCATCGTATCACAGCA-3′ (SEQ ID NO: 3081)5′-UUCUCUUGAAGCAUCGUAUCACAGC-3′ (SEQ ID NO: 4191)3′-AAAAGAGAACUUCGUAGCAUAGUGUCG-5′ (SEQ ID NO: 1973) βc-3671 Target:5′-TTTTCTCTTGAAGCATCGTATCACAGC-3′ (SEQ ID NO: 3082)5′-UUUUCUCUUGAAGCAUCGUAUCACA-3′ (SEQ ID NO: 4192)3′-GUAAAAGAGAACUUCGUAGCAUAGUGU-5′ (SEQ ID NO: 1974) βc-3673 Target:5′-CATTTTCTCTTGAAGCATCGTATCACA-3′ (SEQ ID NO: 3083)5′-UUUUAUAACCGCAUUUUCUCUUGAA-3′ (SEQ ID NO: 4193)3′-AAAAAAUAUUGGCGUAAAAGAGAACUU-5′ (SEQ ID NO: 1975) βc-3686 Target:5′-TTTTTTATAACCGCATTTTCTCTTGAA-3′ (SEQ ID NO: 3084)5′-UUUUUAUAACCGCAUUUUCUCUUGA-3′ (SEQ ID NO: 4194)3′-UAAAAAAUAUUGGCGUAAAAGAGAACU-5′ (SEQ ID NO: 1976) βc-3687 Target:5′-ATTTTTTATAACCGCATTTTCTCTTGA-3′ (SEQ ID NO: 3085)5′-UUUUUUAUAACCGCAUUUUCUCUUG-3′ (SEQ ID NO: 4195)3′-GUAAAAAAUAUUGGCGUAAAAGAGAAC-5′ (SEQ ID NO: 1977) βc-3688 Target:5′-CATTTTTTATAACCGCATTTTCTCTTG-3′ (SEQ ID NO: 3086)5′-AUUUUUUAUAACCGCAUUUUCUCUU-3′ (SEQ ID NO: 4196)3′-GGUAAAAAAUAUUGGCGUAAAAGAGAA-5′ (SEQ ID NO: 1978) βc-3689 Target:5′-CCATTTTTTATAACCGCATTTTCTCTT-3′ (SEQ ID NO: 3087)5′-GAACCAUUUUUUAUAACCGCAUUUU-3′ (SEQ ID NO: 4197)3′-GACUUGGUAAAAAAUAUUGGCGUAAAA-5′ (SEQ ID NO: 1979) βc-3694 Target:5′-CTGAACCATTTTTTATAACCGCATTTT-3′ (SEQ ID NO: 3088)5′-AUUCUGAACCAUUUUUUAUAACCGC-3′ (SEQ ID NO: 4198)3′-AUUAAGACUUGGUAAAAAAUAUUGGCG-5′ (SEQ ID NO: 1980) βc-3699 Target:5′-TAATTCTGAACCATTTTTTATAACCGC-3′ (SEQ ID NO: 3089)5′-AAUUCUGAACCAUUUUUUAUAACCG-3′ (SEQ ID NO: 4199)3′-AAUUAAGACUUGGUAAAAAAUAUUGGC-5′ (SEQ ID NO: 1981) βc-3700 Target:5′-TTAATTCTGAACCATTTTTTATAACCG-3′ (SEQ ID NO: 3090)5′-UAAUUCUGAACCAUUUUUUAUAACC-3′ (SEQ ID NO: 4200)3′-AAAUUAAGACUUGGUAAAAAAUAUUGG-5′ (SEQ ID NO: 1982) βc-3701 Target:5′-TTTAATTCTGAACCATTTTTTATAACC-3′ (SEQ ID NO: 3091)5′-UUAAUUCUGAACCAUUUUUUAUAAC-3′ (SEQ ID NO: 4201)3′-CAAAUUAAGACUUGGUAAAAAAUAUUG-5′ (SEQ ID NO: 1983) βc-3702 Target:5′-GTTTAATTCTGAACCATTTTTTATAAC-3′ (SEQ ID NO: 3092)5′-UUUAAUUCUGAACCAUUUUUUAUAA-3′ (SEQ ID NO: 4202)3′-UCAAAUUAAGACUUGGUAAAAAAUAUU-5′ (SEQ ID NO: 1984) βc-3703 Target:5′-AGTTTAATTCTGAACCATTTTTTATAA-3′ (SEQ ID NO: 3093)5′-GUUUAAUUCUGAACCAUUUUUUAUA-3′ (SEQ ID NO: 4203)3′-UUCAAAUUAAGACUUGGUAAAAAAUAU-5′ (SEQ ID NO: 1985) βc-3704 Target:5′-AAGTTTAATTCTGAACCATTTTTTATA-3′ (SEQ ID NO: 3094)5′-UAAAAGUUUAAUUCUGAACCAUUUU-3′ (SEQ ID NO: 4204)3′-UAAUUUUCAAAUUAAGACUUGGUAAAA-5′ (SEQ ID NO: 1986) βc-3709 Target:5′-ATTAAAAGTTTAATTCTGAACCATTTT-3′ (SEQ ID NO: 3095)5′-UUAAAAGUUUAAUUCUGAACCAUUU-3′ (SEQ ID NO: 4205)3′-UUAAUUUUCAAAUUAAGACUUGGUAAA-5′ (SEQ ID NO: 1987) βc-3710 Target:5′-AATTAAAAGTTTAATTCTGAACCATTT-3′ (SEQ ID NO: 3096)5′-AAUUAAAAGUUUAAUUCUGAACCAU-3′ (SEQ ID NO: 4206)3′-ACUUAAUUUUCAAAUUAAGACUUGGUA-5′ (SEQ ID NO: 1988) βc-3712 Target:5′-TGAATTAAAAGTTTAATTCTGAACC-3′ (SEQ ID NO: 3097)5′-AUACAGCUAAAGGAUGAUUUACAGG-3′ (SEQ ID NO: 4207)3′-GUUAUGUCGAUUUCCUACUAAAUGUCC-5′ (SEQ ID NO: 1989) βc-2634t2 Target:5′-CAATACAGCTAAAGGATGATTTACAGG-3′ (SEQ ID NO: 3098)5′-AAUACAGCUAAAGGAUGAUUUACAG-3′ (SEQ ID NO: 4208)3′-UGUUAUGUCGAUUUCCUACUAAAUGUC-5′ (SEQ ID NO: 1990) βc-2635t2 Target:5′-ACAATACAGCTAAAGGATGATTTACAG-3′ (SEQ ID NO: 3099)5′-ACAAUACAGCUAAAGGAUGAUUUAC-3′ (SEQ ID NO: 4209)3′-UCUGUUAUGUCGAUUUCCUACUAAAUG-5′ (SEQ ID NO: 1991) βc-2637t2 Target:5′-AGACAATACAGCTAAAGGATGATTTAC-3′ (SEQ ID NO: 3100)5′-UACUCCUAAAGGAUGAUUUACAGGU-3′ (SEQ ID NO: 4210)3′-CAAUGAGGAUUUCCUACUAAAUGUCCA-5′ (SEQ ID NO: 1992) βc-2633t3 Target:5′-GTTACTCCTAAAGGATGATTTACAGGT-3′ (SEQ ID NO: 3101)5′-UUACUCCUAAAGGAUGAUUUACAGG-3′ (SEQ ID NO: 4211)3′-ACAAUGAGGAUUUCCUACUAAAUGUCC-5′ (SEQ ID NO: 1993) βc-2634t3 Target:5′-TGTTACTCCTAAAGGATGATTTACAGG-3′ (SEQ ID NO: 3102)5′-GUUACUCCUAAAGGAUGAUUUACAG-3′ (SEQ ID NO: 4212)3′-AACAAUGAGGAUUUCCUACUAAAUGUC-5′ (SEQ ID NO: 1994) βc-2635t3 Target:5′-TTGTTACTCCTAAAGGATGATTTACAG-3′ (SEQ ID NO: 3103)5′-UGUUACUCCUAAAGGAUGAUUUACA-3′ (SEQ ID NO: 4213)3′-UAACAAUGAGGAUUUCCUACUAAAUGU-5′ (SEQ ID NO: 1995) βc-2636t3 Target:5′-ATTGTTACTCCTAAAGGATGATTTACA-3′ (SEQ ID NO: 3104)5′-AUUCCAGAAUCCAAGUAAGACUGCU-3′ (SEQ ID NO: 4214)3′-CCUAAGGUCUUAGGUUCAUUCUGACGA-5′ (SEQ ID NO: 1996) βc-m318 Target:5′-GGATTCCAGAATCCAAGTAAGACTGCT-3′ (SEQ ID NO: 3105)5′-UGCUCCCAUUCAUAAAGGACUUGGG-3′ (SEQ ID NO: 4215)3′-GAACGAGGGUAAGUAUUUCCUGAACCC-5′ (SEQ ID NO: 1997) βc-m417 Target:5′-CTTGCTCCCATTCATAAAGGACTTGGG-3′ (SEQ ID NO: 3106)5′-UCAAUAUCAGCUACUUGCUCUUGCG-3′ (SEQ ID NO: 4216)3′-GCAGUUAUAGUCGAUGAACGAGAACGC-5′ (SEQ ID NO: 1998) βc-m462 Target:5′-CGTCAATATCAGCTACTTGCTCTTGCG-3′ (SEQ ID NO: 3107)5′-GUCAAUAUCAGCUACUUGCUCUUGC-3′ (SEQ ID NO: 4217)3′-GGCAGUUAUAGUCGAUGAACGAGAACG-5′ (SEQ ID NO: 1999) βc-m463 Target:5′-CCGTCAATATCAGCTACTTGCTCTTGC-3′ (SEQ ID NO: 3108)5′-UGCCCGUCAAUAUCAGCUACUUGCU-3′ (SEQ ID NO: 4218)3′-UGACGGGCAGUUAUAGUCGAUGAACGA-5′ (SEQ ID NO: 2000) βc-m468 Target:5′-ACTGCCCGTCAATATCAGCTACTTGCT-3′ (SEQ ID NO: 3109)5′-UUUCAACAUCUGUGAUGGUUCAGCC-3′ (SEQ ID NO: 4219)3′-ACAAAGUUGUAGACACUACCAAGUCGG-5′ (SEQ ID NO: 2001) βc-m613 Target:5′-TGTTTCAACATCTGTGATGGTTCAGCC-3′ (SEQ ID NO: 3110)5′-GUUUCAACAUCUGUGAUGGUUCAGC-3′ (SEQ ID NO: 4220)3′-UACAAAGUUGUAGACACUACCAAGUCG-5′ (SEQ ID NO: 2002) βc-m614 Target:5′-ATGTTTCAACATCTGTGATGGTTCAGC-3′ (SEQ ID NO: 3111)5′-ACAACUGCAUGUUUCAACAUCUGUG-3′ (SEQ ID NO: 4221)3′-ACUGUUGACGUACAAAGUUGUAGACAC-5′ (SEQ ID NO: 2003) βc-m624 Target:5′-TGACAACTGCATGTTTCAACATCTGTG-3′ (SEQ ID NO: 3112)5′-UGACAACUGCAUGUUUCAACAUCUG-3′ (SEQ ID NO: 4222)3′-UAACUGUUGACGUACAAAGUUGUAGAC-5′ (SEQ ID NO: 2004) βc-m626 Target:5′-ATTGACAACTGCATGTTTCAACATCTG-3′ (SEQ ID NO: 3113)5′-AAAUUGACAACUGCAUGUUUCAACA-3′ (SEQ ID NO: 4223)3′-AGUUUAACUGUUGACGUACAAAGUUGU-5′ (SEQ ID NO: 2005) βc-m630 Target:5′-TCAAATTGACAACTGCATGTTTCAACA-3′ (SEQ ID NO: 3114)5′-UUAAUCAAAUUGACAACUGCAUGUU-3′ (SEQ ID NO: 4224)3′-UCAAUUAGUUUAACUGUUGACGUACAA-5′ (SEQ ID NO: 2006) βc-m636 Target:5′-AGTTAATCAAATTGACAACTGCATGTT-3′ (SEQ ID NO: 3115)5′-UGAUAGUUAAUCAAAUUGACAACUG-3′ (SEQ ID NO: 4225)3′-GGACUAUCAAUUAGUUUAACUGUUGAC-5′ (SEQ ID NO: 2007) βc-m642 Target:5′-CCTGATAGTTAATCAAATTGACAACTG-3′ (SEQ ID NO: 3116)5′-UCAUCCUGAUAGUUAAUCAAAUUGA-3′ (SEQ ID NO: 4226)3′-GCAGUAGGACUAUCAAUUAGUUUAACU-5′ (SEQ ID NO: 2008) βc-m648 Target:5′-CGTCATCCTGATAGTTAATCAAATTGA-3′ (SEQ ID NO: 3117)5′-GUCAUCCUGAUAGUUAAUCAAAUUG-3′ (SEQ ID NO: 4227)3′-CGCAGUAGGACUAUCAAUUAGUUUAAC-5′ (SEQ ID NO: 2009) βc-m649 Target:5′-GCGTCATCCTGATAGTTAATCAAATTG-3′ (SEQ ID NO: 3118)5′-UCAUCGUUUAGCAGUUUUGUCAGCU-3′ (SEQ ID NO: 4228)3′-GGAGUAGCAAAUCGUCAAAACAGUCGA-5′ (SEQ ID NO: 2010) βc-m702 Target:5′-CCTCATCGTTTAGCAGTTTTGTCAGCT-3′ (SEQ ID NO: 3119)5′-GGUCCUCAUCGUUUAGCAGUUUUGU-3′ (SEQ ID NO: 4229)3′-GACCAGGAGUAGCAAAUCGUCAAAACA-5′ (SEQ ID NO: 2011) βc-m707 Target:5′-CTGGTCCTCATCGTTTAGCAGTTTTGT-3′ (SEQ ID NO: 3120)5′-UAACAGCAGCUUUAUUAACUACCAC-3′ (SEQ ID NO: 4230)3′-GUAUUGUCGUCGAAAUAAUUGAUGGUG-5′ (SEQ ID NO: 2012) βc-m734 Target:5′-CATAACAGCAGCTTTATTAACTACCAC-3′ (SEQ ID NO: 3121)5′-AUAACAGCAGCUUUAUUAACUACCA-3′ (SEQ ID NO: 4231)3′-GGUAUUGUCGUCGAAAUAAUUGAUGGU-5′ (SEQ ID NO: 2013) βc-m735 Target:5′-CCATAACAGCAGCTTTATTAACTACCA-3′ (SEQ ID NO: 3122)5′-ACCAUAACAGCAGCUUUAUUAACUA-3′ (SEQ ID NO: 4232)3′-CCUGGUAUUGUCGUCGAAAUAAUUGAU-5′ (SEQ ID NO: 2014) βc-m738 Target:5′-GGACCATAACAGCAGCTTTATTAACTA-3′ (SEQ ID NO: 3123)5′-GACCAUAACAGCAGCUUUAUUAACU-3′ (SEQ ID NO: 4233)3′-ACCUGGUAUUGUCGUCGAAAUAAUUGA-5′ (SEQ ID NO: 2015) βc-m739 Target:5′-TGGACCATAACAGCAGCTTTATTAACT-3′ (SEQ ID NO: 3124)5′-GUCUCUACAUCAUUUGUAUUCUGCA-3′ (SEQ ID NO: 4234)3′-GACAGAGAUGUAGUAAACAUAAGACGU-5′ (SEQ ID NO: 2016) βc-m843 Target:5′-CTGTCTCTACATCATTTGTATTCTGCA-3′ (SEQ ID NO: 3125)5′-UGUCUCUACAUCAUUUGUAUUCUGC-3′ (SEQ ID NO: 4235)3′-CGACAGAGAUGUAGUAAACAUAAGACG-5′ (SEQ ID NO: 2017) βc-m844 Target:5′-GCTGTCTCTACATCATTTGTATTCTGC-3′ (SEQ ID NO: 3126)5′-AACCAUUUUCUGCAGUCCACCAGCU-3′ (SEQ ID NO: 4236)3′-CGUUGGUAAAAGACGUCAGGUGGUCGA-5′ (SEQ ID NO: 2018) βc-m1063 Target:5′-GCAACCATTTTCTGCAGTCCACCAGCT-3′ (SEQ ID NO: 3127)5′-GCAACCAUUUUCUGCAGUCCACCAG-3′ (SEQ ID NO: 4237)3′-UUCGUUGGUAAAAGACGUCAGGUGGUC-5′ (SEQ ID NO: 2019) βc-m1065 Target:5′-AAGCAACCATTTTCTGCAGTCCACCAG-3′ (SEQ ID NO: 3128)5′-GUUUUGUUGAGCAAAGCAACCAUUU-3′ (SEQ ID NO: 4238)3′-AACAAAACAACUCGUUUCGUUGGUAAA-5′ (SEQ ID NO: 2020) βc-m1080 Target:5′-TTGTTTTGTTGAGCAAAGCAACCATTT-3′ (SEQ ID NO: 3129)5′-UGUUUUGUUGAGCAAAGCAACCAUU-3′ (SEQ ID NO: 4239)3′-AAACAAAACAACUCGUUUCGUUGGUAA-5′ (SEQ ID NO: 2021) βc-m1081 Target:5′-TTTGTTTTGTTGAGCAAAGCAACCATT-3′ (SEQ ID NO: 3130)5′-GCCAAGAAUUUCACGUUUGUUUUGU-3′ (SEQ ID NO: 4240)3′-AUCGGUUCUUAAAGUGCAAACAAAACA-5′ (SEQ ID NO: 2022) βc-m1098 Target:5′-TAGCCAAGAATTTCACGTTTGTTTTGT-3′ (SEQ ID NO: 3131)5′-UGAUUGCCAUAAGCUAAGAUCUGAA-3′ (SEQ ID NO: 4241)3′-GAACUAACGGUAUUCGAUUCUAGACUU-5′ (SEQ ID NO: 2023) βc-m1140 Target:5′-CTTGATTGCCATAAGCTAAGATCTGAA-3′ (SEQ ID NO: 3132)5′-UCUCUUGAUUGCCAUAAGCUAAGAU-3′ (SEQ ID NO: 4242)3′-CGAGAGAACUAACGGUAUUCGAUUCUA-5′ (SEQ ID NO: 2024) βc-m1145 Target:5′-GCTCTCTTGATTGCCATAAGCTAAGAT-3′ (SEQ ID NO: 3133)5′-UCUCAUAAGUGUAGGUCCUCAUUAU-3′ (SEQ ID NO: 4243)3′-GAAGAGUAUUCACAUCCAGGAGUAAUA-5′ (SEQ ID NO: 2025) βc-m1217 Target:5′-CTTCTCATAAGTGTAGGTCCTCATTAT-3′ (SEQ ID NO: 3134)5′-UUCUCAUAAGUGUAGGUCCUCAUUA-3′ (SEQ ID NO: 4244)3′-CGAAGAGUAUUCACAUCCAGGAGUAAU-5′ (SEQ ID NO: 2026) βc-m1218 Target:5′-GCTTCTCATAAGTGTAGGTCCTCATTA-3′ (SEQ ID NO: 3135)5′-GCUUCUCAUAAGUGUAGGUCCUCAU-3′ (SEQ ID NO: 4245)3′-UUCGAAGAGUAUUCACAUCCAGGAGUA-5′ (SEQ ID NO: 2027) βc-m1220 Target:5′-AAGCTTCTCATAAGTGTAGGTCCTC-3′ (SEQ ID NO: 3136)5′-AGCUUCUCAUAAGUGUAGGUCCUCA-3′ (SEQ ID NO: 4246)3′-CUUCGAAGAGUAUUCACAUCCAGGAGU-5′ (SEQ ID NO: 2028) βc-m1221 Target:5′-GAAGCTTCTCATAAGTGTAGGTCCTCA-3′ (SEQ ID NO: 3137)5′-GUCCAAAGACAGUUUUGAACAAGUC-3′ (SEQ ID NO: 4247)3′-CUCAGGUUUCUGUCAAAACUUGUUCAG-5′ (SEQ ID NO: 2029) βc-m1365 Target:5′-GAGTCCAAAGACAGTTTTGAACAAGTC-3′ (SEQ ID NO: 3138)5′-AGUCCAAAGACAGUUUUGAACAAGU-3′ (SEQ ID NO: 4248)3′-UCUCAGGUUUCUGUCAAAACUUGUUCA-5′ (SEQ ID NO: 2030) βc-m1366 Target:5′-AGAGTCCAAAGACAGTTTTGAACAAGT-3′ (SEQ ID NO: 3139)5′-ACAUUUAUAUCAUCGGAACCCAGAA-3′ (SEQ ID NO: 4249)3′-GGUGUAAAUAUAGUAGCCUUGGGUCUU-5′ (SEQ ID NO: 2031) βc-m1461 Target:5′-CCACATTTATATCATCGGAACCCAGAA-3′ (SEQ ID NO: 3140)5′-ACCACAUUUAUAUCAUCGGAACCCA-3′ (SEQ ID NO: 4250)3′-ACUGGUGUAAAUAUAGUAGCCUUGGGU-5′ (SEQ ID NO: 2032) βc-m1464 Target:5′-TGACCACATTTATATCATCGGAACCCA-3′ (SEQ ID NO: 3141)5′-GCACAGGUGACCACAUUUAUAUCAU-3′ (SEQ ID NO: 4251)3′-GACGUGUCCACUGGUGUAAAUAUAGUA-5′ (SEQ ID NO: 2033) βc-m1473 Target:5′-CTGCACAGGTGACCACATTTATATC-3′ (SEQ ID NO: 3142)5′-UGCACAGGUGACCACAUUUAUAUCA-3′ (SEQ ID NO: 4252)3′-CGACGUGUCCACUGGUGUAAAUAUAGU-5′ (SEQ ID NO: 2034) βc-m1474 Target:5′-GCTGCACAGGTGACCACATTTATATCA-3′ (SEQ ID NO: 3143)5′-GUAAUUAUUGCAAGUGAGGUUAGAG-3′ (SEQ ID NO: 4253)3′-AACAUUAAUAACGUUCACUCCAAUCUC-5′ (SEQ ID NO: 2035) βc-m1510 Target:5′-TTGTAATTATTGCAAGTGAGGTTAGAG-3′ (SEQ ID NO: 3144)5′-UCAUCUUGUUUUUGUAAUUAUUGCA-3′ (SEQ ID NO: 4254)3′-GUAGUAGAACAAAAACAUUAAUAACGU-5′ (SEQ ID NO: 2036) βc-m1523 Target:5′-CATCATCTTGTTTTTGTAATTATTGCA-3′ (SEQ ID NO: 3145)5′-AUCAUCUUGUUUUUGUAAUUAUUGC-3′ (SEQ ID NO: 4255)3′-GGUAGUAGAACAAAAACAUUAAUAACG-5′ (SEQ ID NO: 2037) βc-m1524 Target:5′-CCATCATCTTGTTTTTGTAATTATTGC-3′ (SEQ ID NO: 3146)5′-ACCAUCAUCUUGUUUUUGUAAUUAU-3′ (SEQ ID NO: 4256)3′-UGUGGUAGUAGAACAAAAACAUUAAUA-5′ (SEQ ID NO: 2038) βc-m1527 Target:5′-ACACCATCATCTTGTTTTTGTAATTAT-3′ (SEQ ID NO: 3147)5′-GGCACACCAUCAUCUUGUUUUUGUA-3′ (SEQ ID NO: 4257)3′-AACCGUGUGGUAGUAGAACAAAAACAU-5′ (SEQ ID NO: 2039) βc-m1532 Target:5′-TTGGCACACCATCATCTTGTTTTTGTA-3′ (SEQ ID NO: 3148)5′-AAUCCAACAGUUGCCUUUAUCAGAG-3′ (SEQ ID NO: 4258)3′-AGUUAGGUUGUCAACGGAAAUAGUCUC-5′ (SEQ ID NO: 2040) βc-m1752 Target:5′-TCAATCCAACAGTTGCCTTTATCAGAG-3′ (SEQ ID NO: 3149)5′-GAAUCAAUCCAACAGUUGCCUUUAU-3′ (SEQ ID NO: 4259)3′-AGCUUAGUUAGGUUGUCAACGGAAAUA-5′ (SEQ ID NO: 2041) βc-m1757 Target:5′-TCGAATCAATCCAACAGTTGCCTTTAT-3′ (SEQ ID NO: 3150)5′-UGAACUAGUCGUGGAAUAGCACCCU-3′ (SEQ ID NO: 4260)3′-CGACUUGAUCAGCACCUUAUCGUGGGA-5′ (SEQ ID NO: 2042) βc-m1827 Target:5′-GCTGAACTAGTCGTGGAATAGCACCCT-3′ (SEQ ID NO: 3151)5′-UACACCCUUCUACUAUCUCCUCCAU-3′ (SEQ ID NO: 4261)3′-UCAUGUGGGAAGAUGAUAGAGGAGGUA-5′ (SEQ ID NO: 2043) βc-m1934 Target:5′-AGTACACCCTTCTACTATCTCCTCC-3′ (SEQ ID NO: 3152)5′-GUACACCCUUCUACUAUCUCCUCCA-3′ (SEQ ID NO: 4262)3′-GUCAUGUGGGAAGAUGAUAGAGGAGGU-5′ (SEQ ID NO: 2044) βc-m1935 Target:5′-CAGTACACCCTTCTACTATCTCCTCCA-3′ (SEQ ID NO: 3153)5′-AGUACACCCUUCUACUAUCUCCUCC-3′ (SEQ ID NO: 4263)3′-GGUCAUGUGGGAAGAUGAUAGAGGAGG-5′ (SEQ ID NO: 2045) βc-m1936 Target:5′-CCAGTACACCCTTCTACTATCTCCTCC-3′ (SEQ ID NO: 3154)5′-GCUCCAGUACACCCUUCUACUAUCU-3′ (SEQ ID NO: 4264)3′-CUCGAGGUCAUGUGGGAAGAUGAUAGA-5′ (SEQ ID NO: 2046) βc-m1941 Target:5′-GAGCTCCAGTACACCCTTCTACTATCT-3′ (SEQ ID NO: 3155)5′-ACAAUGGAAUGGUAUUGAGUCCUCG-3′ (SEQ ID NO: 4265)3′-UUUGUUACCUUACCAUAACUCAGGAGC-5′ (SEQ ID NO: 2047) βc-m2009 Target:5′-AAACAATGGAATGGTATTGAGTCCTCG-3′ (SEQ ID NO: 3156)5′-GCACAAACAAUGGAAUGGUAUUGAG-3′ (SEQ ID NO: 4266)3′-GACGUGUUUGUUACCUUACCAUAACUC-5′ (SEQ ID NO: 2048) βc-m2015 Target:5′-CTGCACAAACAATGGAATGGTATTGAG-3′ (SEQ ID NO: 3157)5′-UGCACAAACAAUGGAAUGGUAUUGA-3′ (SEQ ID NO: 4267)3′-UGACGUGUUUGUUACCUUACCAUAACU-5′ (SEQ ID NO: 2049) βc-m2016 Target:5′-ACTGCACAAACAATGGAATGGTATTGA-3′ (SEQ ID NO: 3158)5′-GCAACUGCACAAACAAUGGAAUGGU-3′ (SEQ ID NO: 4268)3′-UUCGUUGACGUGUUUGUUACCUUACCA-5′ (SEQ ID NO: 2050) βc-m2021 Target:5′-AAGCAACTGCACAAACAATGGAATGGT-3′ (SEQ ID NO: 3159)5′-GAAUAAAGCAACUGCACAAACAAUG-3′ (SEQ ID NO: 4269)3′-CUCUUAUUUCGUUGACGUGUUUGUUAC-5′ (SEQ ID NO: 2051) βc-m2028 Target:5′-GAGAATAAAGCAACTGCACAAACAATG-3′ (SEQ ID NO: 3160)5′-UCAAUGGGAGAAUAAAGCAACUGCA-3′ (SEQ ID NO: 4270)3′-AAAGUUACCCUCUUAUUUCGUUGACGU-5′ (SEQ ID NO: 2052) βc-m2037 Target:5′-TTTCAATGGGAGAATAAAGCAACTGCA-3′ (SEQ ID NO: 3161)5′-UUCAAUGGGAGAAUAAAGCAACUGC-3′ (SEQ ID NO: 4271)3′-AAAAGUUACCCUCUUAUUUCGUUGACG-5′ (SEQ ID NO: 2053) βc-m2038 Target:5′-TTTTCAATGGGAGAATAAAGCAACTGC-3′ (SEQ ID NO: 3162)5′-UUUCAAUGGGAGAAUAAAGCAACUG-3′ (SEQ ID NO: 4272)3′-UAAAAGUUACCCUCUUAUUUCGUUGAC-5′ (SEQ ID NO: 2054) βc-m2039 Target:5′-ATTTTCAATGGGAGAATAAAGCAACTG-3′ (SEQ ID NO: 3163)5′-AUAUUUUCAAUGGGAGAAUAAAGCA-3′ (SEQ ID NO: 4273)3′-CCUAUAAAAGUUACCCUCUUAUUUCGU-5′ (SEQ ID NO: 2055) βc-m2043 Target:5′-GGATATTTTCAATGGGAGAATAAAGCA-3′ (SEQ ID NO: 3164)5′-GAUAUUUUCAAUGGGAGAAUAAAGC-3′ (SEQ ID NO: 4274)3′-ACCUAUAAAAGUUACCCUCUUAUUUCG-5′ (SEQ ID NO: 2056) βc-m2044 Target:5′-TGGATATTTTCAATGGGAGAATAAAGC-3′ (SEQ ID NO: 3165)5′-GGAUAUUUUCAAUGGGAGAAUAAAG-3′ (SEQ ID NO: 4275)3′-AACCUAUAAAAGUUACCCUCUUAUUUC-5′ (SEQ ID NO: 2057) βc-m2045 Target:5′-TTGGATATTTTCAATGGGAGAATAAAG-3′ (SEQ ID NO: 3166)5′-GCUACUCUUUGGAUAUUUUCAAUGG-3′ (SEQ ID NO: 4276)3′-GUCGAUGAGAAACCUAUAAAAGUUACC-5′ (SEQ ID NO: 2058) βc-m2055 Target:5′-CAGCTACTCTTTGGATATTTTCAATGG-3′ (SEQ ID NO: 3167)5′-AGCUACUCUUUGGAUAUUUUCAAUG-3′ (SEQ ID NO: 4277)3′-CGUCGAUGAGAAACCUAUAAAAGUUAC-5′ (SEQ ID NO: 2059) βc-m2056 Target:5′-GCAGCTACTCTTTGGATATTTTCAATG-3′ (SEQ ID NO: 3168)5′-GCUUCUUGUAAUCCUGUGGCUUGUC-3′ (SEQ ID NO: 4278)3′-GGCGAAGAACAUUAGGACACCGAACAG-5′ (SEQ ID NO: 2060) βc-m2231 Target:5′-CCGCTTCTTGTAATCCTGTGGCTTGTC-3′ (SEQ ID NO: 3169)5′-AGUCCAAGAUCUGCAGUCUCAUUCC-3′ (SEQ ID NO: 4279)3′-GGUCAGGUUCUAGACGUCAGAGUAAGG-5′ (SEQ ID NO: 2061) βc-m2307 Target:5′-CCAGTCCAAGATCTGCAGTCTCATTCC-3′ (SEQ ID NO: 3170)5′-UAUCCACCAGAGUGAAAAGAACGGU-3′ (SEQ ID NO: 4280)3′-GCAUAGGUGGUCUCACUUUUCUUGCCA-5′ (SEQ ID NO: 2062) βc-m2385 Target:5′-CGTATCCACCAGAGTGAAAAGAACGGT-3′ (SEQ ID NO: 3171)5′-GGCCAGCUGAUUGCUAUCACCUGGG-3′ (SEQ ID NO: 4281)3′-GUCCGGUCGACUAACGAUAGUGGACCC-5′ (SEQ ID NO: 2063) βc-m2539 Target:5′-CAGGCCAGCTGATTGCTATCACCTGGG-3′ (SEQ ID NO: 3172)5′-AUUUACAGGUCAGUAUCAAACCAGG-3′ (SEQ ID NO: 4282)3′-GCUAAAUGUCCAGUCAUAGUUUGGUCC-5′ (SEQ ID NO: 2064) βc-m2562 Target:5′-CGATTTACAGGTCAGTATCAAACCAGG-3′ (SEQ ID NO: 3173)5′-GAUUUACAGGUCAGUAUCAAACCAG-3′ (SEQ ID NO: 4283)3′-UGCUAAAUGUCCAGUCAUAGUUUGGUC-5′ (SEQ ID NO: 2065) βc-m2563 Target:5′-ACGATTTACAGGTCAGTATCAAACCAG-3′ (SEQ ID NO: 3174)5′-UCUUACCUAAAGGACGAUUUACAGG-3′ (SEQ ID NO: 4284)3′-AAAGAAUGGAUUUCCUGCUAAAUGUCC-5′ (SEQ ID NO: 2066) βc-m2578 Target:5′-TTTCTTACCTAAAGGACGATTTACAGG-3′ (SEQ ID NO: 3175)5′-UUUCUUACCUAAAGGACGAUUUACA-3′ (SEQ ID NO: 4285)3′-CGAAAGAAUGGAUUUCCUGCUAAAUGU-5′ (SEQ ID NO: 2067) βc-m2580 Target:5′-GCTTTCTTACCTAAAGGACGATTTACA-3′ (SEQ ID NO: 3176)5′-UUUAUAAGCUUUCUUACCUAAAGGA-3′ (SEQ ID NO: 4286)3′-GAAAAUAUUCGAAAGAAUGGAUUUCCU-5′ (SEQ ID NO: 2068) βc-m2589 Target:5′-CTTTTATAAGCTTTCTTACCTAAAGGA-3′ (SEQ ID NO: 3177)5′-UUUUAUAAGCUUUCUUACCUAAAGG-3′ (SEQ ID NO: 4287)3′-CGAAAAUAUUCGAAAGAAUGGAUUUCC-5′ (SEQ ID NO: 2069) βc-m2590 Target:5′-GCTTTTATAAGCTTTCTTACCTAAAGG-3′ (SEQ ID NO: 3178)5′-GGCUUUUAUAAGCUUUCUUACCUAA-3′ (SEQ ID NO: 4288)3′-GACCGAAAAUAUUCGAAAGAAUGGAUU-5′ (SEQ ID NO: 2070) βc-m2593 Target:5′-CTGGCTTTTATAAGCTTTCTTACCTAA-3′ (SEQ ID NO: 3179)5′-ACACUGGCUUUUAUAAGCUUUCUUA-3′ (SEQ ID NO: 4289)3′-GGUGUGACCGAAAAUAUUCGAAAGAAU-5′ (SEQ ID NO: 2071) βc-m2598 Target:5′-CCACACTGGCTTTTATAAGCTTTCTTA-3′ (SEQ ID NO: 3180)5′-UCACCCACACUGGCUUUUAUAAGCU-3′ (SEQ ID NO: 4290)3′-UAAGUGGGUGUGACCGAAAAUAUUCGA-5′ (SEQ ID NO: 2072) βc-m2604 Target:5′-ATTCACCCACACTGGCTTTTATAAGCT-3′ (SEQ ID NO: 3181)5′-UACCAAGUCUUUCUGGAGUUCUGCA-3′ (SEQ ID NO: 4291)3′-GGAUGGUUCAGAAAGACCUCAAGACGU-5′ (SEQ ID NO: 2073) βc-m2644 Target:5′-CCTACCAAGTCTTTCTGGAGTTCTGCA-3′ (SEQ ID NO: 3182)5′-UUACAAACAGGCCUAAAACCAUUCC-3′ (SEQ ID NO: 4292)3′-UAAAUGUUUGUCCGGAUUUUGGUAAGG-5′ (SEQ ID NO: 2074) βc-m2674 Target:5′-ATTTACAAACAGGCCTAAAACCATTCC-3′ (SEQ ID NO: 3183)5′-UUUACAAACAGGCCUAAAACCAUUC-3′ (SEQ ID NO: 4293)3′-CUAAAUGUUUGUCCGGAUUUUGGUAAG-5′ (SEQ ID NO: 2075) βc-m2675 Target:5′-GATTTACAAACAGGCCTAAAACCATTC-3′ (SEQ ID NO: 3184)5′-AUUUACAAACAGGCCUAAAACCAUU-3′ (SEQ ID NO: 4294)3′-UCUAAAUGUUUGUCCGGAUUUUGGUAA-5′ (SEQ ID NO: 2076) βc-m2676 Target:5′-AGATTTACAAACAGGCCTAAAACCATT-3′ (SEQ ID NO: 3185)5′-UCUCCUUCCAAGGUAUGUAUCUGUU-3′ (SEQ ID NO: 4295)3′-GUAGAGGAAGGUUCCAUACAUAGACAA-5′ (SEQ ID NO: 2077) βc-m2710 Target:5′-CATCTCCTTCCAAGGTATGTATCTGTT-3′ (SEQ ID NO: 3186)5′-AUCUCCUUCCAAGGUAUGUAUCUGU-3′ (SEQ ID NO: 4296)3′-UGUAGAGGAAGGUUCCAUACAUAGACA-5′ (SEQ ID NO: 2078) βc-m2711 Target:5′-ACATCTCCTTCCAAGGTATGTATCTGT-3′ (SEQ ID NO: 3187)5′-UUCCACACAUGAACAUCUCCUUCCA-3′ (SEQ ID NO: 4297)3′-UGAAGGUGUGUACUUGUAGAGGAAGGU-5′ (SEQ ID NO: 2079) βc-m2725 Target:5′-ACTTCCACACATGAACATCTCCTTCCA-3′ (SEQ ID NO: 3188)5′-AACUUCCACACAUGAACAUCUCCUU-3′ (SEQ ID NO: 4298)3′-CUUUGAAGGUGUGUACUUGUAGAGGAA-5′ (SEQ ID NO: 2080) βc-m2728 Target:5′-GAAACTTCCACACATGAACATCTCCTT-3′ (SEQ ID NO: 3189)5′-AAACUUCCACACAUGAACAUCUCCU-3′ (SEQ ID NO: 4299)3′-UCUUUGAAGGUGUGUACUUGUAGAGGA-5′ (SEQ ID NO: 2081) βc-m2729 Target:5′-AGAAACTTCCACACATGAACATCTCCT-3′ (SEQ ID NO: 3190)5′-GAAACUUCCACACAUGAACAUCUCC-3′ (SEQ ID NO: 4300)3′-CUCUUUGAAGGUGUGUACUUGUAGAGG-5′ (SEQ ID NO: 2082) βc-m2730 Target:5′-GAGAAACTTCCACACATGAACATCTCC-3′ (SEQ ID NO: 3191)5′-AGAAACUUCCACACAUGAACAUCUC-3′ (SEQ ID NO: 4301)3′-ACUCUUUGAAGGUGUGUACUUGUAGAG-5′ (SEQ ID NO: 2083) βc-m2731 Target:5′-TGAGAAACTTCCACACATGAACATCTC-3′ (SEQ ID NO: 3192)5′-UCAACGUGAGAAACUUCCACACAUG-3′ (SEQ ID NO: 4302)3′-GUAGUUGCACUCUUUGAAGGUGUGUAC-5′ (SEQ ID NO: 2084) βc-m2739 Target:5′-CATCAACGTGAGAAACTTCCACACATG-3′ (SEQ ID NO: 3193)5′-ACAUCAACGUGAGAAACUUCCACAC-3′ (SEQ ID NO: 4303)3′-UUUGUAGUUGCACUCUUUGAAGGUGUG-5′ (SEQ ID NO: 2085) βc-m2742 Target:5′-AAACATCAACGTGAGAAACTTCCACAC-3′ (SEQ ID NO: 3194)5′-AACAUCAACGUGAGAAACUUCCACA-3′ (SEQ ID NO: 4304)3′-UUUUGUAGUUGCACUCUUUGAAGGUGU-5′ (SEQ ID NO: 2086) βc-m2743 Target:5′-AAAACATCAACGTGAGAAACTTCCACA-3′ (SEQ ID NO: 3195)5′-AAACAUCAACGUGAGAAACUUCCAC-3′ (SEQ ID NO: 4305)3′-UUUUUGUAGUUGCACUCUUUGAAGGUG-5′ (SEQ ID NO: 2087) βc-m2744 Target:5′-AAAAACATCAACGTGAGAAACTTCCAC-3′ (SEQ ID NO: 3196)5′-AAAACAUCAACGUGAGAAACUUCCA-3′ (SEQ ID NO: 4306)3′-GUUUUUGUAGUUGCACUCUUUGAAGGU-5′ (SEQ ID NO: 2088) βc-m2745 Target:5′-CAAAAACATCAACGTGAGAAACTTCCA-3′ (SEQ ID NO: 3197)5′-AAAAACAUCAACGUGAGAAACUUCC-3′ (SEQ ID NO: 4307)3′-CGUUUUUGUAGUUGCACUCUUUGAAGG-5′ (SEQ ID NO: 2089) βc-m2746 Target:5′-GCAAAAACATCAACGTGAGAAACTTCC-3′ (SEQ ID NO: 3198)5′-GCAAAAACAUCAACGUGAGAAACUU-3′ (SEQ ID NO: 4308)3′-ACCGUUUUUGUAGUUGCACUCUUUGAA-5′ (SEQ ID NO: 2090) βc-m2748 Target:5′-TGGCAAAAACATCAACGTGAGAAACTT-3′ (SEQ ID NO: 3199)5′-GCAAAAGCUGUGGCAAAAACAUCAA-3′ (SEQ ID NO: 4309)3′-GACGUUUUCGACACCGUUUUUGUAGUU-5′ (SEQ ID NO: 2091) βc-m2760 Target:5′-CTGCAAAAGCTGTGGCAAAAACATCAA-3′ (SEQ ID NO: 3200)5′-UGCAAAAGCUGUGGCAAAAACAUCA-3′ (SEQ ID NO: 4310)3′-CGACGUUUUCGACACCGUUUUUGUAGU-5′ (SEQ ID NO: 2092) βc-m2761 Target:5′-GCTGCAAAAGCTGTGGCAAAAACATCA-3′ (SEQ ID NO: 3201)5′-UCAUCUGAGUAUAACGCUGCAAAAG-3′ (SEQ ID NO: 4311)3′-UGAGUAGACUCAUAUUGCGACGUUUUC-5′ (SEQ ID NO: 2093) βc-m2778 Target:5′-ACTCATCTGAGTATAACGCTGCAAAAG-3′ (SEQ ID NO: 3202)5′-AAAACAGCAAAUGUUACUCAUCUGA-3′ (SEQ ID NO: 4312)3′-ACUUUUGUCGUUUACAAUGAGUAGACU-5′ (SEQ ID NO: 2094) βc-m2795 Target:5′-TGAAAACAGCAAATGTTACTCATCTGA-3′ (SEQ ID NO: 3203)5′-GAAAACAGCAAAUGUUACUCAUCUG-3′ (SEQ ID NO: 4313)3′-AACUUUUGUCGUUUACAAUGAGUAGAC-5′ (SEQ ID NO: 2095) βc-m2796 Target:5′-TTGAAAACAGCAAATGTTACTCATCTG-3′ (SEQ ID NO: 3204)5′-UGAAAACAGCAAAUGUUACUCAUCU-3′ (SEQ ID NO: 4314)3′-CAACUUUUGUCGUUUACAAUGAGUAGA-5′ (SEQ ID NO: 2096) βc-m2797 Target:5′-GTTGAAAACAGCAAATGTTACTCATCT-3′ (SEQ ID NO: 3205)5′-AUUAAUGUUGAAAACAGCAAAUGUU-3′ (SEQ ID NO: 4315)3′-GAUAAUUACAACUUUUGUCGUUUACAA-5′ (SEQ ID NO: 2097) βc-m2805 Target:5′-CTATTAATGTTGAAAACAGCAAATGTT-3′ (SEQ ID NO: 3206)5′-ACUACAGCUGUAUAGAGAGAAAGGC-3′ (SEQ ID NO: 4316)3′-UGUGAUGUCGACAUAUCUCUCUUUCCG-5′ (SEQ ID NO: 2098) βc-m2834 Target:5′-ACACTACAGCTGTATAGAGAGAAAGGC-3′ (SEQ ID NO: 3207)5′-GGCCAAUCACAAUGCACGUUCAGAC-3′ (SEQ ID NO: 4317)3′-GUCCGGUUAGUGUUACGUGCAAGUCUG-5′ (SEQ ID NO: 2099) βc-m2859 Target:5′-CAGGCCAATCACAATGCACGTTCAGAC-3′ (SEQ ID NO: 3208)5′-GUUCCCAUAGGAAACUCAGCUUGGU-3′ (SEQ ID NO: 4318)3′-GACAAGGGUAUCCUUUGAGUCGAACCA-5′ (SEQ ID NO: 2100) βc-m2946 Target:5′-CTGTTCCCATAGGAAACTCAGCTTGGT-3′ (SEQ ID NO: 3209)5′-GAACAAAAAGCGUACUUCGACUGUU-3′ (SEQ ID NO: 4319)3′-GUCUUGUUUUUCGCAUGAAGCUGACAA-5′ (SEQ ID NO: 2101) βc-m2968 Target:5′-CAGAACAAAAAGCGTACTTCGACTGTT-3′ (SEQ ID NO: 3210)5′-GGACCAGAACAAAAAGCGUACUUCG-3′ (SEQ ID NO: 4320)3′-UUCCUGGUCUUGUUUUUCGCAUGAAGC-5′ (SEQ ID NO: 2102) βc-m2974 Target:5′-AAGGACCAGAACAAAAAGCGTACTTCG-3′ (SEQ ID NO: 3211)5′-ACCAAAAAGGACCAGAACAAAAAGC-3′ (SEQ ID NO: 4321)3′-GCUGGUUUUUCCUGGUCUUGUUUUUCG-5′ (SEQ ID NO: 2103) βc-m2982 Target:5′-CGACCAAAAAGGACCAGAACAAAAAGC-3′ (SEQ ID NO: 3212)5′-GACCAAAAAGGACCAGAACAAAAAG-3′ (SEQ ID NO: 4322)3′-AGCUGGUUUUUCCUGGUCUUGUUUUUC-5′ (SEQ ID NO: 2104) βc-m2983 Target:5′-TCGACCAAAAAGGACCAGAACAAAAAG-3′ (SEQ ID NO: 3213)5′-ACUCCUCGACCAAAAAGGACCAGAA-3′ (SEQ ID NO: 4323)3′-AAUGAGGAGCUGGUUUUUCCUGGUCUU-5′ (SEQ ID NO: 2105) βc-m2990 Target:5′-TTACTCCTCGACCAAAAAGGACCAGAA-3′ (SEQ ID NO: 3214)5′-UCCAUUUGUAUUGUUACUCCUCGAC-3′ (SEQ ID NO: 4324)3′-UUAGGUAAACAUAACAAUGAGGAGCUG-5′ (SEQ ID NO: 2106) βc-m3005 Target:5′-AATCCATTTGTATTGTTACTCCTCGAC-3′ (SEQ ID NO: 3215)5′-AUCCAUUUGUAUUGUUACUCCUCGA-3′ (SEQ ID NO: 4325)3′-UUUAGGUAAACAUAACAAUGAGGAGCU-5′ (SEQ ID NO: 2107) βc-m3006 Target:5′-AAATCCATTTGTATTGTTACTCCTCGA-3′ (SEQ ID NO: 3216)5′-AAUCCAUUUGUAUUGUUACUCCUCG-3′ (SEQ ID NO: 4326)3′-GUUUAGGUAAACAUAACAAUGAGGAGC-5′ (SEQ ID NO: 2108) βc-m3007 Target:5′-CAAATCCATTTGTATTGTTACTCCTCG-3′ (SEQ ID NO: 3217)5′-AAAUCCAUUUGUAUUGUUACUCCUC-3′ (SEQ ID NO: 4327)3′-GGUUUAGGUAAACAUAACAAUGAGGAG-5′ (SEQ ID NO: 2109) βc-m3008 Target:5′-CCAAATCCATTTGTATTGTTACTCCTC-3′ (SEQ ID NO: 3218)5′-ACUCCCCAAAUCCAUUUGUAUUGUU-3′ (SEQ ID NO: 4328)3′-AGUGAGGGGUUUAGGUAAACAUAACAA-5′ (SEQ ID NO: 2110) βc-m3015 Target:5′-TCACTCCCCAAATCCATTTGTATTGTT-3′ (SEQ ID NO: 3219)5′-UCCAUUCGUGUGCAUUCUUCACUGC-3′ (SEQ ID NO: 4329)3′-CUAGGUAAGCACACGUAAGAAGUGACG-5′ (SEQ ID NO: 2111) βc-m3047 Target:5′-GATCCATTCGTGTGCATTCTTCACTGC-3′ (SEQ ID NO: 3220)5′-AUCCAUUCGUGUGCAUUCUUCACUG-3′ (SEQ ID NO: 4330)3′-ACUAGGUAAGCACACGUAAGAAGUGAC-5′ (SEQ ID NO: 2112) βc-m3048 Target:5′-TGATCCATTCGTGTGCATTCTTCACTG-3′ (SEQ ID NO: 3221)5′-GAUCCAUUCGUGUGCAUUCUUCACU-3′ (SEQ ID NO: 4331)3′-CACUAGGUAAGCACACGUAAGAAGUGA-5′ (SEQ ID NO: 2113) βc-m3049 Target:5′-GTGATCCATTCGTGTGCATTCTTCACT-3′ (SEQ ID NO: 3222)5′-AAACAAAGAACAAGCAAGGCUAGGG-3′ (SEQ ID NO: 4332)3′-AUUUUGUUUCUUGUUCGUUCCGAUCCC-5′ (SEQ ID NO: 2114) βc-m3093 Target:5′-TAAAACAAAGAACAAGCAAGGCTAGGG-3′ (SEQ ID NO: 3223)5′-ACCACUACAGAUAUUAAAACAAAGA-3′ (SEQ ID NO: 4333)3′-CGUGGUGAUGUCUAUAAUUUUGUUUCU-5′ (SEQ ID NO: 2115) βc-m3109 Target:5′-GCACCACTACAGATATTAAAACAAAGA-3′ (SEQ ID NO: 3224)5′-GCACCACUACAGAUAUUAAAACAAA-3′ (SEQ ID NO: 4334)3′-GUCGUGGUGAUGUCUAUAAUUUUGUUU-5′ (SEQ ID NO: 2116) βc-m3111 Target:5′-CAGCACCACTACAGATATTAAAACAAA-3′ (SEQ ID NO: 3225)5′-AGCACCACUACAGAUAUUAAAACAA-3′ (SEQ ID NO: 4335)3′-AGUCGUGGUGAUGUCUAUAAUUUUGUU-5′ (SEQ ID NO: 2117) βc-m3112 Target:5′-TCAGCACCACTACAGATATTAAAACAA-3′ (SEQ ID NO: 3226)5′-AAAAUAAAAGCAAGCAAAGUCAGCA-3′ (SEQ ID NO: 4336)3′-UUUUUUAUUUUCGUUCGUUUCAGUCGU-5′ (SEQ ID NO: 2118) βc-m3133 Target:5′-AAAAAATAAAAGCAAGCAAAGTCAGCA-3′ (SEQ ID NO: 3227)5′-GCAAAAAAUAAAAGCAAGCAAAGUC-3′ (SEQ ID NO: 4337)3′-GACGUUUUUUAUUUUCGUUCGUUUCAG-5′ (SEQ ID NO: 2119) βc-m3137 Target:5′-CTGCAAAAAATAAAAGCAAGCAAAGTC-3′ (SEQ ID NO: 3228)5′-UUACUGCAAAAAAUAAAAGCAAGCA-3′ (SEQ ID NO: 4338)3′-UCAAUGACGUUUUUUAUUUUCGUUCGU-5′ (SEQ ID NO: 2120) βc-m3142 Target:5′-AGTTACTGCAAAAAATAAAAGCAAGCA-3′ (SEQ ID NO: 3229)5′-UAACAGUUACUGCAAAAAAUAAAAG-3′ (SEQ ID NO: 4339)3′-UGAUUGUCAAUGACGUUUUUUAUUUUC-5′ (SEQ ID NO: 2121) βc-m3148 Target:5′-ACTAACAGTTACTGCAAAAAATAAAAG-3′ (SEQ ID NO: 3230)5′-ACUAACAGUUACUGCAAAAAAUAAA-3′ (SEQ ID NO: 4340)3′-UUUGAUUGUCAAUGACGUUUUUUAUUU-5′ (SEQ ID NO: 2122) βc-m3150 Target:5′-AAACTAACAGTTACTGCAAAAAATAAA-3′ (SEQ ID NO: 3231)5′-AAACUAACAGUUACUGCAAAAAAUA-3′ (SEQ ID NO: 4341)3′-UUUUUGAUUGUCAAUGACGUUUUUUAU-5′ (SEQ ID NO: 2123) βc-m3152 Target:5′-AAAAACTAACAGTTACTGCAAAAAATA-3′ (SEQ ID NO: 3232)5′-AAAACUAACAGUUACUGCAAAAAAU-3′ (SEQ ID NO: 4342)3′-AUUUUUGAUUGUCAAUGACGUUUUUUA-5′ (SEQ ID NO: 2124) βc-m3153 Target:5′-TAAAAACTAACAGTTACTGCAAAAAAT-3′ (SEQ ID NO: 3233)5′-UAAAAACUAACAGUUACUGCAAAAA-3′ (SEQ ID NO: 4343)3′-GAAUUUUUGAUUGUCAAUGACGUUUUU-5′ (SEQ ID NO: 2125) βc-m3155 Target:5′-CTTAAAAACTAACAGTTACTGCAAAAA-3′ (SEQ ID NO: 3234)5′-UACUUAAAAACUAACAGUUACUGCA-3′ (SEQ ID NO: 4344)3′-UGAUGAAUUUUUGAUUGUCAAUGACGU-5′ (SEQ ID NO: 2126) βc-m3159 Target:5′-ACTACTTAAAAACTAACAGTTACTGCA-3′ (SEQ ID NO: 3235)5′-ACUACUUAAAAACUAACAGUUACUG-3′ (SEQ ID NO: 4345)3′-UGUGAUGAAUUUUUGAUUGUCAAUGAC-5′ (SEQ ID NO: 2127) βc-m3161 Target:5′-ACACTACTTAAAAACTAACAGTTACTG-3′ (SEQ ID NO: 3236)5′-UAACACUACUUAAAAACUAACAGUU-3′ (SEQ ID NO: 4346)3′-GUAUUGUGAUGAAUUUUUGAUUGUCAA-5′ (SEQ ID NO: 2128) βc-m3165 Target:5′-CATAACACTACTTAAAAACTAACAGTT-3′ (SEQ ID NO: 3237)5′-AUAACACUACUUAAAAACUAACAGU-3′ (SEQ ID NO: 4347)3′-UGUAUUGUGAUGAAUUUUUGAUUGUCA-5′ (SEQ ID NO: 2129) βc-m3166 Target:5′-ACATAACACTACTTAAAAACTAACAGT-3′ (SEQ ID NO: 3238)5′-ACAUAACACUACUUAAAAACUAACA-3′ (SEQ ID NO: 4348)3′-CUUGUAUUGUGAUGAAUUUUUGAUUGU-5′ (SEQ ID NO: 2130) βc-m3168 Target:5′-GAACATAACACTACTTAAAAACTAACA-3′ (SEQ ID NO: 3239)5′-AACAUAACACUACUUAAAAACUAAC-3′ (SEQ ID NO: 4349)3′-UCUUGUAUUGUGAUGAAUUUUUGAUUG-5′ (SEQ ID NO: 2131) βc-m3169 Target:5′-AGAACATAACACTACTTAAAAACTAAC-3′ (SEQ ID NO: 3240)5′-GAACAUAACACUACUUAAAAACUAA-3′ (SEQ ID NO: 4350)3′-AUCUUGUAUUGUGAUGAAUUUUUGAUU-5′ (SEQ ID NO: 2132) βc-m3170 Target:5′-TAGAACATAACACTACTTAAAAACTAA-3′ (SEQ ID NO: 3241)5′-AGAACAUAACACUACUUAAAAACUA-3′ (SEQ ID NO: 4351)3′-GAUCUUGUAUUGUGAUGAAUUUUUGAU-5′ (SEQ ID NO: 2133) βc-m3171 Target:5′-CTAGAACATAACACTACTTAAAAACTA-3′ (SEQ ID NO: 3242)5′-UCACUAGAACAUAACACUACUUAAA-3′ (SEQ ID NO: 4352)3′-CAAGUGAUCUUGUAUUGUGAUGAAUUU-5′ (SEQ ID NO: 2134) βc-m3176 Target:5′-GTTCACTAGAACATAACACTACTTAAA-3′ (SEQ ID NO: 3243)5′-GUUCACUAGAACAUAACACUACUUA-3′ (SEQ ID NO: 4353)3′-UCCAAGUGAUCUUGUAUUGUGAUGAAU-5′ (SEQ ID NO: 2135) βc-m3178 Target:5′-AGGTTCACTAGAACATAACACTACTTA-3′ (SEQ ID NO: 3244)5′-GGUUCACUAGAACAUAACACUACUU-3′ (SEQ ID NO: 4354)3′-GUCCAAGUGAUCUUGUAUUGUGAUGAA-5′ (SEQ ID NO: 2136) βc-m3179 Target:5′-CAGGTTCACTAGAACATAACACTACTT-3′ (SEQ ID NO: 3245)5′-AUUACUCGGUUCUUAGAAAUCAGAA-3′ (SEQ ID NO: 4355)3′-GGUAAUGAGCCAAGAAUCUUUAGUCUU-5′ (SEQ ID NO: 2137) βc-m3216 Target:5′-CCATTACTCGGTTCTTAGAAATCAGAA-3′ (SEQ ID NO: 3246)5′-ACCAUUACUCGGUUCUUAGAAAUCA-3′ (SEQ ID NO: 4356)3′-UGUGGUAAUGAGCCAAGAAUCUUUAGU-5′ (SEQ ID NO: 2138) βc-m3219 Target:5′-ACACCATTACTCGGTTCTTAGAAATCA-3′ (SEQ ID NO: 3247)5′-UCUACACCAUUACUCGGUUCUUAGA-3′ (SEQ ID NO: 4357)3′-CAAGAUGUGGUAAUGAGCCAAGAAUCU-5′ (SEQ ID NO: 2139) βc-m3224 Target:5′-GTTCTACACCATTACTCGGTTCTTAGA-3′ (SEQ ID NO: 3248)5′-GAAUUAGUGUUCUACACCAUUACUC-3′ (SEQ ID NO: 4358)3′-UACUUAAUCACAAGAUGUGGUAAUGAG-5′ (SEQ ID NO: 2140) βc-m3234 Target:5′-ATGAATTAGTGTTCTACACCATTACTC-3′ (SEQ ID NO: 3249)5′-AUUAUGAAUUAGUGUUCUACACCAU-3′ (SEQ ID NO: 4359)3′-ACUAAUACUUAAUCACAAGAUGUGGUA-5′ (SEQ ID NO: 2141) βc-m3239 Target:5′-TGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 3250)5′-GAUUAUGAAUUAGUGUUCUACACCA-3′ (SEQ ID NO: 4360)3′-CACUAAUACUUAAUCACAAGAUGUGGU-5′ (SEQ ID NO: 2142) βc-m3240 Target:5′-GTGATTATGAATTAGTGTTCTACACCA-3′ (SEQ ID NO: 3251)5′-UGAUUAUGAAUUAGUGUUCUACACC-3′ (SEQ ID NO: 4361)3′-GCACUAAUACUUAAUCACAAGAUGUGG-5′ (SEQ ID NO: 2143) βc-m3241 Target:5′-CGTGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 3252)5′-ACAAUUAGCGUGAUUAUGAAUUAGU-3′ (SEQ ID NO: 4362)3′-AAUGUUAAUCGCACUAAUACUUAAUCA-5′ (SEQ ID NO: 2144) βc-m3251 Target:5′-TTACAATTAGCGTGATTATGAATTAGT-3′ (SEQ ID NO: 3253)5′-UACAAUUAGCGUGAUUAUGAAUUAG-3′ (SEQ ID NO: 4363)3′-UAAUGUUAAUCGCACUAAUACUUAAUC-5′ (SEQ ID NO: 2145) βc-m3252 Target:5′-ATTACAATTAGCGTGATTATGAATTAG-3′ (SEQ ID NO: 3254)5′-AGAUUACAAUUAGCGUGAUUAUGAA-3′ (SEQ ID NO: 4364)3′-GGUCUAAUGUUAAUCGCACUAAUACUU-5′ (SEQ ID NO: 2146) βc-m3256 Target:5′-CCAGATTACAATTAGCGTGATTATGAA-3′ (SEQ ID NO: 3255)5′-UACACGUCUCCAGAUUACAAUUAGC-3′ (SEQ ID NO: 4365)3′-CAAUGUGCAGAGGUCUAAUGUUAAUCG-5′ (SEQ ID NO: 2147) βc-m3267 Target:5′-GTTACACGTCTCCAGATTACAATTAGC-3′ (SEQ ID NO: 3256)5′-GUUACACGUCUCCAGAUUACAAUUA-3′ (SEQ ID NO: 4366)3′-UACAAUGUGCAGAGGUCUAAUGUUAAU-5′ (SEQ ID NO: 2148) βc-m3269 Target:5′-ATGTTACACGTCTCCAGATTACAATTA-3′ (SEQ ID NO: 3257)5′-UACACAAUGUUACACGUCUCCAGAU-3′ (SEQ ID NO: 4367)3′-CGAUGUGUUACAAUGUGCAGAGGUCUA-5′ (SEQ ID NO: 2149) βc-m3277 Target:5′-GCTACACAATGTTACACGTCTCCAGAT-3′ (SEQ ID NO: 3258)5′-GCUACACAAUGUUACACGUCUCCAG-3′ (SEQ ID NO: 4368)3′-UCCGAUGUGUUACAAUGUGCAGAGGUC-5′ (SEQ ID NO: 2150) βc-m3279 Target:5′-AGGCTACACAATGTTACACGTCTCCAG-3′ (SEQ ID NO: 3259)5′-ACAAAAGGCUACACAAUGUUACACG-3′ (SEQ ID NO: 4369)3′-UAUGUUUUCCGAUGUGUUACAAUGUGC-5′ (SEQ ID NO: 2151) βc-m3286 Target:5′-ATACAAAAGGCTACACAATGTTACACG-3′ (SEQ ID NO: 3260)5′-UACAAAAGGCUACACAAUGUUACAC-3′ (SEQ ID NO: 4370)3′-AUAUGUUUUCCGAUGUGUUACAAUGUG-5′ (SEQ ID NO: 2152) βc-m3287 Target:5′-TATACAAAAGGCTACACAATGTTACAC-3′ (SEQ ID NO: 3261)5′-UUUAUACAAAAGGCUACACAAUGUU-3′ (SEQ ID NO: 4371)3′-AUAAAUAUGUUUUCCGAUGUGUUACAA-5′ (SEQ ID NO: 2153) βc-m3291 Target:5′-TATTTATACAAAAGGCTACACAATGTT-3′ (SEQ ID NO: 3262)5′-AUUUAUACAAAAGGCUACACAAUGU-3′ (SEQ ID NO: 4372)3′-GAUAAAUAUGUUUUCCGAUGUGUUACA-5′ (SEQ ID NO: 2154) βc-m3292 Target:5′-CTATTTATACAAAAGGCTACACAATGT-3′ (SEQ ID NO: 3263)5′-UCUAUUUAUACAAAAGGCUACACAA-3′ (SEQ ID NO: 4373)3′-ACAGAUAAAUAUGUUUUCCGAUGUGUU-5′ (SEQ ID NO: 2155) βc-m3295 Target:5′-TGTCTATTTATACAAAAGGCTACACAA-3′ (SEQ ID NO: 3264)5′-GUCUAUUUAUACAAAAGGCUACACA-3′ (SEQ ID NO: 4374)3′-GACAGAUAAAUAUGUUUUCCGAUGUGU-5′ (SEQ ID NO: 2156) βc-m3296 Target:5′-CTGTCTATTTATACAAAAGGCTACACA-3′ (SEQ ID NO: 3265)5′-UGUCUAUUUAUACAAAAGGCUACAC-3′ (SEQ ID NO: 4375)3′-AGACAGAUAAAUAUGUUUUCCGAUGUG-5′ (SEQ ID NO: 2157) βc-m3297 Target:5′-TCTGTCTATTTATACAAAAGGCTACAC-3′ (SEQ ID NO: 3266)5′-UCUAUCUGUCUAUUUAUACAAAAGG-3′ (SEQ ID NO: 4376)3′-AAAGAUAGACAGAUAAAUAUGUUUUCC-5′ (SEQ ID NO: 2158) βc-m3303 Target:5′-TTTCTATCTGTCTATTTATACAAAAGG-3′ (SEQ ID NO: 3267)5′-UUCUAUCUGUCUAUUUAUACAAAAG-3′ (SEQ ID NO: 4377)3′-UAAAGAUAGACAGAUAAAUAUGUUUUC-5′ (SEQ ID NO: 2159) βc-m3304 Target:5′-ATTTCTATCTGTCTATTTATACAAAAG-3′ (SEQ ID NO: 3268)5′-UUUCUAUCUGUCUAUUUAUACAAAA-3′ (SEQ ID NO: 4378)3′-GUAAAGAUAGACAGAUAAAUAUGUUUU-5′ (SEQ ID NO: 2160) βc-m3305 Target:5′-CATTTCTATCTGTCTATTTATACAAAA-3′ (SEQ ID NO: 3269)5′-AUUUCUAUCUGUCUAUUUAUACAAA-3′ (SEQ ID NO: 4379)3′-GGUAAAGAUAGACAGAUAAAUAUGUUU-5′ (SEQ ID NO: 2161) βc-m3306 Target:5′-CCATTTCTATCTGTCTATTTATACAAA-3′ (SEQ ID NO: 3270)5′-GACCAUUUCUAUCUGUCUAUUUAUA-3′ (SEQ ID NO: 4380)3′-GCCUGGUAAAGAUAGACAGAUAAAUAU-5′ (SEQ ID NO: 2162) βc-m3310 Target:5′-CGGACCATTTCTATCTGTCTATTTATA-3′ (SEQ ID NO: 3271)5′-GGACCAUUUCUAUCUGUCUAUUUAU-3′ (SEQ ID NO: 4381)3′-AGCCUGGUAAAGAUAGACAGAUAAAUA-5′ (SEQ ID NO: 2163) βc-m3311 Target:5′-TCGGACCATTTCTATCTGTCTATTTAT-3′ (SEQ ID NO: 3272)5′-ACUAAUCGGACCAUUUCUAUCUGUC-3′ (SEQ ID NO: 4382)3′-UUUGAUUAGCCUGGUAAAGAUAGACAG-5′ (SEQ ID NO: 2164) βc-m3318 Target:5′-AAACTAATCGGACCATTTCTATCTGTC-3′ (SEQ ID NO: 3273)5′-AACUAAUCGGACCAUUUCUAUCUGU-3′ (SEQ ID NO: 4383)3′-CUUUGAUUAGCCUGGUAAAGAUAGACA-5′ (SEQ ID NO: 2165) βc-m3319 Target:5′-GAAACTAATCGGACCATTTCTATCTGT-3′ (SEQ ID NO: 3274)5′-AAACUAAUCGGACCAUUUCUAUCUG-3′ (SEQ ID NO: 4384)3′-CCUUUGAUUAGCCUGGUAAAGAUAGAC-5′ (SEQ ID NO: 2166) βc-m3320 Target:5′-GGAAACTAATCGGACCATTTCTATCTG-3′ (SEQ ID NO: 3275)5′-GAAACUAAUCGGACCAUUUCUAUCU-3′ (SEQ ID NO: 4385)3′-UCCUUUGAUUAGCCUGGUAAAGAUAGA-5′ (SEQ ID NO: 2167) βc-m3321 Target:5′-AGGAAACTAATCGGACCATTTCTATCT-3′ (SEQ ID NO: 3276)5′-UAAAAAGGAAACUAAUCGGACCAUU-3′ (SEQ ID NO: 4386)3′-UAAUUUUUCCUUUGAUUAGCCUGGUAA-5′ (SEQ ID NO: 2168) βc-m3328 Target:5′-ATTAAAAAGGAAACTAATCGGACCATT-3′ (SEQ ID NO: 3277)5′-GCAUAUUAAAAAGGAAACUAAUCGG-3′ (SEQ ID NO: 4387)3′-UUCGUAUAAUUUUUCCUUUGAUUAGCC-5′ (SEQ ID NO: 2169) βc-m3334 Target:5′-AAGCATATTAAAAAGGAAACTAATCGG-3′ (SEQ ID NO: 3278)5′-AGCAUAUUAAAAAGGAAACUAAUCG-3′ (SEQ ID NO: 4388)3′-AUUCGUAUAAUUUUUCCUUUGAUUAGC-5′ (SEQ ID NO: 2170) βc-m3335 Target:5′-TAAGCATATTAAAAAGGAAACTAATCG-3′ (SEQ ID NO: 3279)5′-UUUAAGCAUAUUAAAAAGGAAACUA-3′ (SEQ ID NO: 4389)3′-UAAAAUUCGUAUAAUUUUUCCUUUGAU-5′ (SEQ ID NO: 2171) βc-m3339 Target:5′-ATTTTAAGCATATTAAAAAGGAAACTA-3′ (SEQ ID NO: 3280)5′-GCUUAUUUUAAGCAUAUUAAAAAGG-3′ (SEQ ID NO: 4390)3′-GACGAAUAAAAUUCGUAUAAUUUUUCC-5′ (SEQ ID NO: 2172) βc-m3345 Target:5′-CTGCTTATTTTAAGCATATTAAAAAGG-3′ (SEQ ID NO: 3281)5′-UGCUUAUUUUAAGCAUAUUAAAAAG-3′ (SEQ ID NO: 4391)3′-GGACGAAUAAAAUUCGUAUAAUUUUUC-5′ (SEQ ID NO: 2173) βc-m3346 Target:5′-CCTGCTTATTTTAAGCATATTAAAAAG-3′ (SEQ ID NO: 3282)5′-UCCACCUGCUUAUUUUAAGCAUAUU-3′ (SEQ ID NO: 4392)3′-CUAGGUGGACGAAUAAAAUUCGUAUAA-5′ (SEQ ID NO: 2174) βc-m3352 Target:5′-GATCCACCTGCTTATTTTAAGCATATT-3′ (SEQ ID NO: 3283)5′-AAAACAUGAAAUAGAUCCACCUGCU-3′ (SEQ ID NO: 4393)3′-GUUUUUGUACUUUAUCUAGGUGGACGA-5′ (SEQ ID NO: 2175) βc-m3367 Target:5′-CAAAAACATGAAATAGATCCACCTGCT-3′ (SEQ ID NO: 3284)5′-AAAAACAUGAAAUAGAUCCACCUGC-3′ (SEQ ID NO: 4394)3′-AGUUUUUGUACUUUAUCUAGGUGGACG-5′ (SEQ ID NO: 2176) βc-m3368 Target:5′-TCAAAAACATGAAATAGATCCACCTGC-3′ (SEQ ID NO: 3285)5′-UCAAAAACAUGAAAUAGAUCCACCU-3′ (SEQ ID NO: 4395)3′-CAAGUUUUUGUACUUUAUCUAGGUGGA-5′ (SEQ ID NO: 2177) βc-m3370 Target:5′-GTTCAAAAACATGAAATAGATCCACCT-3′ (SEQ ID NO: 3286)5′-UUCAAAAACAUGAAAUAGAUCCACC-3′ (SEQ ID NO: 4396)3′-ACAAGUUUUUGUACUUUAUCUAGGUGG-5′ (SEQ ID NO: 2178) βc-m3371 Target:5′-TGTTCAAAAACATGAAATAGATCCACC-3′ (SEQ ID NO: 3287)5′-GUUCAAAAACAUGAAAUAGAUCCAC-3′ (SEQ ID NO: 4397)3′-AACAAGUUUUUGUACUUUAUCUAGGUG-5′ (SEQ ID NO: 2179) βc-m3372 Target:5′-TTGTTCAAAAACATGAAATAGATCCAC-3′ (SEQ ID NO: 3288)5′-UUUUUGUUCAAAAACAUGAAAUAGA-3′ (SEQ ID NO: 4398)3′-UCAAAAACAAGUUUUUGUACUUUAUCU-5′ (SEQ ID NO: 2180) βc-m3377 Target:5′-AGTTTTTGTTCAAAAACATGAAATAGA-3′ (SEQ ID NO: 3289)5′-AUAAAGUUUUUGUUCAAAAACAUGA-3′ (SEQ ID NO: 4399)3′-GCUAUUUCAAAAACAAGUUUUUGUACU-5′ (SEQ ID NO: 2181) βc-m3383 Target:5′-CGATAAAGTTTTTGTTCAAAAACATGA-3′ (SEQ ID NO: 3290)5′-UCCCCGAUAAAGUUUUUGUUCAAAA-3′ (SEQ ID NO: 4400)3′-AUAGGGGCUAUUUCAAAAACAAGUUUU-5′ (SEQ ID NO: 2182) βc-m3389 Target:5′-TATCCCCGATAAAGTTTTTGTTCAAAA-3′ (SEQ ID NO: 3291)5′-AUCCCCGAUAAAGUUUUUGUUCAAA-3′ (SEQ ID NO: 4401)3′-CAUAGGGGCUAUUUCAAAAACAAGUUU-5′ (SEQ ID NO: 2183) βc-m3390 Target:5′-GTATCCCCGATAAAGTTTTTGTTCAAA-3′ (SEQ ID NO: 3292)5′-ACCUCUUACUGAUUUACCCUACCGC-3′ (SEQ ID NO: 4402)3′-UGUGGAGAAUGACUAAAUGGGAUGGCG-5′ (SEQ ID NO: 2184) βc-m3419 Target:5′-ACACCTCTTACTGATTTACCCTACCGC-3′ (SEQ ID NO: 3293)5′-ACACCUCUUACUGAUUUACCCUACC-3′ (SEQ ID NO: 4403)3′-AUUGUGGAGAAUGACUAAAUGGGAUGG-5′ (SEQ ID NO: 2185) βc-m3421 Target:5′-TAACACCTCTTACTGATTTACCCTACC-3′ (SEQ ID NO: 3294)5′-AACACCUCUUACUGAUUUACCCUAC-3′ (SEQ ID NO: 4404)3′-UAUUGUGGAGAAUGACUAAAUGGGAUG-5′ (SEQ ID NO: 2186) βc-m3422 Target:5′-ATAACACCTCTTACTGATTTACCCTAC-3′ (SEQ ID NO: 3295)5′-UAACACCUCUUACUGAUUUACCCUA-3′ (SEQ ID NO: 4405)3′-UUAUUGUGGAGAAUGACUAAAUGGGAU-5′ (SEQ ID NO: 2187) βc-m3423 Target:5′-AATAACACCTCTTACTGATTTACCCTA-3′ (SEQ ID NO: 3296)5′-AUAACACCUCUUACUGAUUUACCCU-3′ (SEQ ID NO: 4406)3′-UUUAUUGUGGAGAAUGACUAAAUGGGA-5′ (SEQ ID NO: 2188) βc-m3424 Target:5′-AAATAACACCTCTTACTGATTTACCCT-3′ (SEQ ID NO: 3297)5′-AAUAACACCUCUUACUGAUUUACCC-3′ (SEQ ID NO: 4407)3′-GUUUAUUGUGGAGAAUGACUAAAUGGG-5′ (SEQ ID NO: 2189) βc-m3425 Target:5′-CAAATAACACCTCTTACTGATTTACCC-3′ (SEQ ID NO: 3298)5′-GGCUCAAAUAACACCUCUUACUGAU-3′ (SEQ ID NO: 4408)3′-UUCCGAGUUUAUUGUGGAGAAUGACUA-5′ (SEQ ID NO: 2190) βc-m3431 Target:5′-AAGGCTCAAATAACACCTCTTACTGAT-3′ (SEQ ID NO: 3299)5′-AACAAGGCUCAAAUAACACCUCUUA-3′ (SEQ ID NO: 4409)3′-UUUUGUUCCGAGUUUAUUGUGGAGAAU-5′ (SEQ ID NO: 2191) βc-m3436 Target:5′-AAAACAAGGCTCAAATAACACCTCTTA-3′ (SEQ ID NO: 3300)5′-AAACAAGGCUCAAAUAACACCUCUU-3′ (SEQ ID NO: 4410)3′-GUUUUGUUCCGAGUUUAUUGUGGAGAA-5′ (SEQ ID NO: 2192) βc-m3437 Target:5′-CAAAACAAGGCTCAAATAACACCTCTT-3′ (SEQ ID NO: 3301)5′-AAAACAAGGCUCAAAUAACACCUCU-3′ (SEQ ID NO: 4411)3′-GGUUUUGUUCCGAGUUUAUUGUGGAGA-5′ (SEQ ID NO: 2193) βc-m3438 Target:5′-CCAAAACAAGGCTCAAATAACACCTCT-3′ (SEQ ID NO: 3302)5′-UCCAAAACAAGGCUCAAAUAACACC-3′ (SEQ ID NO: 4412)3′-ACAGGUUUUGUUCCGAGUUUAUUGUGG-5′ (SEQ ID NO: 2194) βc-m3441 Target:5′-TGTCCAAAACAAGGCTCAAATAACACC-3′ (SEQ ID NO: 3303)5′-UGUCCAAAACAAGGCUCAAAUAACA-3′ (SEQ ID NO: 4413)3′-UGACAGGUUUUGUUCCGAGUUUAUUGU-5′ (SEQ ID NO: 2195) βc-m3443 Target:5′-ACTGTCCAAAACAAGGCTCAAATAACA-3′ (SEQ ID NO: 3304)5′-UAUACUGUCCAAAACAAGGCUCAAA-3′ (SEQ ID NO: 4414)3′-CCAUAUGACAGGUUUUGUUCCGAGUUU-5′ (SEQ ID NO: 2196) βc-m3448 Target:5′-GGTATACTGTCCAAAACAAGGCTCAAA-3′ (SEQ ID NO: 3305)5′-GCAACUGGUAUACUGUCCAAAACAA-3′ (SEQ ID NO: 4415)3′-UCCGUUGACCAUAUGACAGGUUUUGUU-5′ (SEQ ID NO: 2197) βc-m3456 Target:5′-AGGCAACTGGTATACTGTCCAAAACAA-3′ (SEQ ID NO: 3306)5′-GAUAAAAGGCAACUGGUAUACUGUC-3′ (SEQ ID NO: 4416)3′-CCCUAUUUUCCGUUGACCAUAUGACAG-5′ (SEQ ID NO: 2198) βc-m3464 Target:5′-GGGATAAAAGGCAACTGGTATACTGTC-3′ (SEQ ID NO: 3307)5′-GGAUAAAAGGCAACUGGUAUACUGU-3′ (SEQ ID NO: 4417)3′-ACCCUAUUUUCCGUUGACCAUAUGACA-5′ (SEQ ID NO: 2199) βc-m3465 Target:5′-TGGGATAAAAGGCAACTGGTATACTGT-3′ (SEQ ID NO: 3308)5′-AACUUUGGGAUAAAAGGCAACUGGU-3′ (SEQ ID NO: 4418)3′-UGUUGAAACCCUAUUUUCCGUUGACCA-5′ (SEQ ID NO: 2200) βc-m3472 Target:5′-ACAACTTTGGGATAAAAGGCAACTGGT-3′ (SEQ ID NO: 3309)5′-ACAACUUUGGGAUAAAAGGCAACUG-3′ (SEQ ID NO: 4419)3′-GUUGUUGAAACCCUAUUUUCCGUUGAC-5′ (SEQ ID NO: 2201) βc-m3474 Target:5′-CAACAACTTTGGGATAAAAGGCAACTG-3′ (SEQ ID NO: 3310)5′-UUACAACAACUUUGGGAUAAAAGGC-3′ (SEQ ID NO: 4420)3′-CCAAUGUUGUUGAAACCCUAUUUUCCG-5′ (SEQ ID NO: 2202) βc-m3479 Target:5′-GGTTACAACAACTTTGGGATAAAAGGC-3′ (SEQ ID NO: 3311)5′-GUUACAACAACUUUGGGAUAAAAGG-3′ (SEQ ID NO: 4421)3′-UCCAAUGUUGUUGAAACCCUAUUUUCC-5′ (SEQ ID NO: 2203) βc-m3480 Target:5′-AGGTTACAACAACTTTGGGATAAAAGG-3′ (SEQ ID NO: 3312)5′-GGUUACAACAACUUUGGGAUAAAAG-3′ (SEQ ID NO: 4422)3′-GUCCAAUGUUGUUGAAACCCUAUUUUC-5′ (SEQ ID NO: 2204) βc-m3481 Target:5′-CAGGTTACAACAACTTTGGGATAAAAG-3′ (SEQ ID NO: 3313)5′-UCACAGCAGGUUACAACAACUUUGG-3′ (SEQ ID NO: 4423)3′-AUAGUGUCGUCCAAUGUUGUUGAAACC-5′ (SEQ ID NO: 2205) βc-m3489 Target:5′-TATCACAGCAGGTTACAACAACTTTGG-3′ (SEQ ID NO: 3314)5′-AUCACAGCAGGUUACAACAACUUUG-3′ (SEQ ID NO: 4424)3′-CAUAGUGUCGUCCAAUGUUGUUGAAAC-5′ (SEQ ID NO: 2206) βc-m3490 Target:5′-GTATCACAGCAGGTTACAACAACTTTG-3′ (SEQ ID NO: 3315)5′-GUAUCACAGCAGGUUACAACAACUU-3′ (SEQ ID NO: 4425)3′-AACAUAGUGUCGUCCAAUGUUGUUGAA-5′ (SEQ ID NO: 2207) βc-m3492 Target:5′-TTGTATCACAGCAGGTTACAACAACTT-3′ (SEQ ID NO: 3316)5′-GCAUCUGUUGAAGCAUUGUAUCACA-3′ (SEQ ID NO: 4426)3′-GGCGUAGACAACUUCGUAACAUAGUGU-5′ (SEQ ID NO: 2208) βc-m3509 Target:5′-CCGCATCTGTTGAAGCATTGTATCACA-3′ (SEQ ID NO: 3317)5′-UGAACCAUUUCUAUAACCGCAUCUG-3′ (SEQ ID NO: 4427)3′-AGACUUGGUAAAGAUAUUGGCGUAGAC-5′ (SEQ ID NO: 2209) βc-m3527 Target:5′-TCTGAACCATTTCTATAACCGCATCTG-3′ (SEQ ID NO: 3318)5′-AUUCUGAACCAUUUCUAUAACCGCA-3′ (SEQ ID NO: 4428)3′-AUUAAGACUUGGUAAAGAUAUUGGCGU-5′ (SEQ ID NO: 2210) βc-m3531 Target:5′-TAATTCTGAACCATTTCTATAACCGCA-3′ (SEQ ID NO: 3319)5′-UAAUUCUGAACCAUUUCUAUAACCG-3′ (SEQ ID NO: 4429)3′-AAAUUAAGACUUGGUAAAGAUAUUGGC-5′ (SEQ ID NO: 2211) βc-m3533 Target:5′-TTTAATTCTGAACCATTTCTATAACCG-3′ (SEQ ID NO: 3320)5′-UUAAUUCUGAACCAUUUCUAUAACC-3′ (SEQ ID NO: 4430)3′-CAAAUUAAGACUUGGUAAAGAUAUUGG-5′ (SEQ ID NO: 2212) βc-m3534 Target:5′-GTTTAATTCTGAACCATTTCTATAACC-3′ (SEQ ID NO: 3321)5′-UUUAAUUCUGAACCAUUUCUAUAAC-3′ (SEQ ID NO: 4431)3′-UCAAAUUAAGACUUGGUAAAGAUAUUG-5′ (SEQ ID NO: 2213) βc-m3535 Target:5′-AGTTTAATTCTGAACCATTTCTATAAC-3′ (SEQ ID NO: 3322)5′-GUUUAAUUCUGAACCAUUUCUAUAA-3′ (SEQ ID NO: 4432)3′-UUCAAAUUAAGACUUGGUAAAGAUAUU-5′ (SEQ ID NO: 2214) βc-m3536 Target:5′-AAGTTTAATTCTGAACCATTTCTATAA-3′ (SEQ ID NO: 3323)5′-UAAAAGUUUAAUUCUGAACCAUUUC-3′ (SEQ ID NO: 4433)3′-UAAUUUUCAAAUUAAGACUUGGUAAAG-5′ (SEQ ID NO: 2215) βc-m3541 Target:5′-ATTAAAAGTTTAATTCTGAACCATTTC-3′ (SEQ ID NO: 3324)5′-UUAAAAGUUUAAUUCUGAACCAUUU-3′ (SEQ ID NO: 4434)3′-UUAAUUUUCAAAUUAAGACUUGGUAAA-5′ (SEQ ID NO: 2216) βc-m3542 Target:5′-AATTAAAAGTTTAATTCTGAACCATTT-3′ (SEQ ID NO: 3325)5′-AAUUAAAAGUUUAAUUCUGAACCAU-3′ (SEQ ID NO: 4435)3′-ACUUAAUUUUCAAAUUAAGACUUGGUA-5′ (SEQ ID NO: 2217) βc-m3544 Target:5′-TGAATTAAAAGTTTAATTCTGAACC-3′ (SEQ ID NO: 3326)5′-UGAAUGAAUUAAAAGUUUAAUUCUG-3′ (SEQ ID NO: 4436)3′-AAACUUACUUAAUUUUCAAAUUAAGAC-5′ (SEQ ID NO: 2218) βc-m3550 Target:5′-TTTGAATGAATTAAAAGTTTAATTCTG-3′ (SEQ ID NO: 3327)5′-UUUUUGAAUGAAUUAAAAGUUUAAU-3′ (SEQ ID NO: 4437)3′-AAAAAAACUUACUUAAUUUUCAAAUUA-5′ (SEQ ID NO: 2219) βc-m3554 Target:5′-TTTTTTTGAATGAATTAAAAGTTTAAT-3′ (SEQ ID NO: 3328)5′-UUUUUUUUUGAAUGAAUUAAAAGUU-3′ (SEQ ID NO: 4438)3′-AAAAAAAAAAACUUACUUAAUUUUCAA-5′ (SEQ ID NO: 2220) βc-m3558 Target:5′-TTTTTTTTTTTGAATGAATTAAAAGTT-3′ (SEQ ID NO: 3329)5′-UUUUUUUUUUGAAUGAAUUAAAAGU-3′ (SEQ ID NO: 4439)3′-AAAAAAAAAAAACUUACUUAAUUUUCA-5′ (SEQ ID NO: 2221) βc-m3559 Target:5′-TTTTTTTTTTTTGAATGAATTAAAAGT-3′ (SEQ ID NO: 3330)5′-UUUUUUUUUUUGAAUGAAUUAAAAG-3′ (SEQ ID NO: 4440)3′-AAAAAAAAAAAAACUUACUUAAUUUUC-5′ (SEQ ID NO: 2222) βc-m3560 Target:5′-TTTTTTTTTTTTTGAATGAATTAAAAG-3′ (SEQ ID NO: 3331)5′-UUUUUUUUUUUUGAAUGAAUUAAAA-3′ (SEQ ID NO: 4441)3′-AAAAAAAAAAAAAACUUACUUAAUUUU-5′ (SEQ ID NO: 2223) βc-m3561 Target:5′-TTTTTTTTTTTTTTGAATGAATTAAAA-3′ (SEQ ID NO: 3332)5′-UUUUUUUUUUUUUGAAUGAAUUAAA-3′ (SEQ ID NO: 4442)3′-AAAAAAAAAAAAAAACUUACUUAAUUU-5′ (SEQ ID NO: 2224) βc-m3562 Target:5′-TTTTTTTTTTTTTTTGAATGAATTAAA-3′ (SEQ ID NO: 3333)5′-UUUUUUUUUUUUUUGAAUGAAUUAA-3′ (SEQ ID NO: 4443)3′-AAAAAAAAAAAAAAAACUUACUUAAUU-5′ (SEQ ID NO: 2225) βc-m3563 Target:5′-TTTTTTTTTTTTTTTTGAATGAATTAA-3′ (SEQ ID NO: 3334)

TABLE 12Additional Selected Anti-β-catenin DsiRNAs, Blunt/Frayed Duplexes

βc-244 Target: 5′-GTTGTATGGTATACTTCAAATACCCTC-3′ (SEQ ID NO: 2714)

βc-251 Target: 5′-CAAAACAGTTGTATGGTATACTTCAAA-3′ (SEQ ID NO: 2715)

βc-252 Target: 5′-TCAAAACAGTTGTATGGTATACTTCAA-3′ (SEQ ID NO: 2716)

βc-254 Target: 5′-TTTCAAAACAGTTGTATGGTATACTTC-3′ (SEQ ID NO: 2717)

βc-255 Target: 5′-TTTTCAAAACAGTTGTATGGTATACTT-3′ (SEQ ID NO: 2718)

βc-256 Target: 5′-ATTTTCAAAACAGTTGTATGGTATACT-3′ (SEQ ID NO: 2719)

βc-269 Target: 5′-TTGTCCACGCTGGATTTTCAAAACAGT-3′ (SEQ ID NO: 2720)

βc-270 Target: 5′-ATTGTCCACGCTGGATTTTCAAAACAG-3′ (SEQ ID NO: 2721)

βc-293 Target: 5′-CCATCAAATCAGCTTGAGTAGCCATTG-3′ (SEQ ID NO: 2722)

βc-302 Target: 5′-TGTCCAACTCCATCAAATCAGCTTGAG-3′ (SEQ ID NO: 2723)

βc-431 Target: 5′-CTTCCTCAGGATTGCCTTTACCACTCA-3′ (SEQ ID NO: 2724)

βc-432 Target: 5′-TCTTCCTCAGGATTGCCTTTACCACTC-3′ (SEQ ID NO: 2725)

βc-518 Target: 5′-CATCAATATCAGCTACTTGTTCTTGAG-3′ (SEQ ID NO: 2726)

βc-519 Target: 5′-CCATCAATATCAGCTACTTGTTCTTGA-3′ (SEQ ID NO: 2727)

βc-524 Target: 5′-ACTGTCCATCAATATCAGCTACTTGTT-3′ (SEQ ID NO: 2728)

βc-531 Target: 5′-ATTGCATACTGTCCATCAATATCAGCT-3′ (SEQ ID NO: 2729)

βc-537 Target: 5′-CGAGTCATTGCATACTGTCCATCAATA-3′ (SEQ ID NO: 2730)

βc-584 Target: 5′-CCTCATCTAATGTCTCAGGGAACATAG-3′ (SEQ ID NO: 2731)

βc-680 Target: 5′-TTACAACTGCATGTTTCAGCATCTGTG-3′ (SEQ ID NO: 2732)

βc-682 Target: 5′-GTTTACAACTGCATGTTTCAGCATCTG-3′ (SEQ ID NO: 2733)

βc-692 Target: 5′-AGTTAATCAAGTTTACAACTGCATGTT-3′ (SEQ ID NO: 2734)

βc-698 Target: 5′-CTTGATAGTTAATCAAGTTTACAACTG-3′ (SEQ ID NO: 2735)

βc-707 Target: 5′-CTGCATCATCTTGATAGTTAATCAAGT-3′ (SEQ ID NO: 2736)

βc-708 Target: 5′-TCTGCATCATCTTGATAGTTAATCAAG-3′ (SEQ ID NO: 2737)

βc-763 Target: 5′-CTGGTCCTCGTCATTTAGCAGTTTTGT-3′ (SEQ ID NO: 2738)

βc-790 Target: 5′-CATAACTGCAGCCTTATTAACCACCAC-3′ (SEQ ID NO: 2739)

βc-791 Target: 5′-CCATAACTGCAGCCTTATTAACCACCA-3′ (SEQ ID NO: 2740)

βc-794 Target: 5′-GGACCATAACTGCAGCCTTATTAACCA-3′ (SEQ ID NO: 2741)

βc-812 Target: 5′-CCTTTTTAGAAAGCTGATGGACCATAA-3′ (SEQ ID NO: 2742)

βc-873 Target: 5′-ATGGTACGTACAATAGCAGACACCATC-3′ (SEQ ID NO: 2743)

βc-890 Target: 5′-CATCATTTGTATTCTGCATGGTACGTA-3′ (SEQ ID NO: 2744)

βc-899 Target: 5′-CTGTTTCTACATCATTTGTATTCTGCA-3′ (SEQ ID NO: 2745)

βc-900 Target: 5′-GCTGTTTCTACATCATTTGTATTCTGC-3′ (SEQ ID NO: 2746)

βc-909 Target: 5′-GTACAACGAGCTGTTTCTACATCATTT-3′ (SEQ ID NO: 2747)

βc-911 Target: 5′-CGGTACAACGAGCTGTTTCTACATC-3′ (SEQ ID NO: 2748)

βc-912 Target: 5′-GCGGTACAACGAGCTGTTTCTACATCA-3′ (SEQ ID NO: 2749)

βc-1032 Target: 5′-GCATAAAACAACACAGAATCCACTGGT-3′ (SEQ ID NO: 2750)

βc-1034 Target: 5′-TGGCATAAAACAACACAGAATCCACTG-3′ (SEQ ID NO: 2751)

βc-1035 Target: 5′-ATGGCATAAAACAACACAGAATCCACT-3′ (SEQ ID NO: 2752)

βc-1076 Target: 5′-TAGCTCCTTCTTGATGTAATAAAAGGT-3′ (SEQ ID NO: 2753)

βc-1077 Target: 5′-TTAGCTCCTTCTTGATGTAATAAAAGG-3′ (SEQ ID NO: 2754)

βc-1144 Target: 5′-TTTAACATTTGTTTTGTTGAGCAAGGC-3′ (SEQ ID NO: 2755)

βc-1154 Target: 5′-TAGCCAAGAATTTAACATTTGTTTTGT-3′ (SEQ ID NO: 2756)

βc-1159 Target: 5′-CGTAATAGCCAAGAATTTAACATTTGT-3′ (SEQ ID NO: 2757)

βc-1160 Target: 5′-TCGTAATAGCCAAGAATTTAACATTTG-3′ (SEQ ID NO: 2758)

βc-1185 Target: 5′-TAAGCTAAAATTTGAAGGCAGTCTGTC-3′ (SEQ ID NO: 2759)

βc-1260 Target: 5′-TAGGTCCTCATTATATTTACTAAAGCT-3′ (SEQ ID NO: 2760)

βc-1265 Target: 5′-AAGTATAGGTCCTCATTATATTTACTA-3′ (SEQ ID NO: 2761)

βc-1266 Target: 5′-TAAGTATAGGTCCTCATTATATTTACT-3′ (SEQ ID NO: 2762)

βc-1274 Target: 5′-GTTTTTCGTAAGTATAGGTCCTCATTA-3′ (SEQ ID NO: 2763)

βc-1275 Target: 5′-AGTTTTTCGTAAGTATAGGTCCTCATT-3′ (SEQ ID NO: 2764)

βc-1276 Target: 5′-TAGTTTTTCGTAAGTATAGGTCCTC-3′ (SEQ ID NO: 2765)

βc-1277 Target: 5′-GTAGTTTTTCGTAAGTATAGGTCCTCA-3′ (SEQ ID NO: 2766)

βc-1287 Target: 5′-GTGGTCCACAGTAGTTTTTCGTAAGTA-3′ (SEQ ID NO: 2767)

βc-1344 Target: 5′-TCTACAATAGCCGGCTTATTACTAGAG-3′ (SEQ ID NO: 2768)

βc-1346 Target: 5′-CTTCTACAATAGCCGGCTTATTACTAG-3′ (SEQ ID NO: 2769)

βc-1371 Target: 5′-AGTCCTAAAGCTTGCATTCCACCAGCT-3′ (SEQ ID NO: 2770)

βc-1372 Target: 5′-AAGTCCTAAAGCTTGCATTCCACCAGC-3′ (SEQ ID NO: 2771)

βc-1373 Target: 5′-GAAGTCCTAAAGCTTGCATTCCACCAG-3′ (SEQ ID NO: 2772)

βc-1410 Target: 5′-CAGTTCTGAACAAGACGTTGACTTGGA-3′ (SEQ ID NO: 2773)

βc-1411 Target: 5′-ACAGTTCTGAACAAGACGTTGACTTGG-3′ (SEQ ID NO: 2774)

βc-1421 Target: 5′-GAGTCCAAAGACAGTTCTGAACAAGAC-3′ (SEQ ID NO: 2775)

βc-1458 Target: 5′-CCTTCCTGTTTAGTTGCAGCATCTGAA-3′ (SEQ ID NO: 2776)

βc-1517 Target: 5′-CCACATTTATATCATCTGAACCCAGAA-3′ (SEQ ID NO: 2777)

βc-1520 Target: 5′-TGACCACATTTATATCATCTGAACCCA-3′ (SEQ ID NO: 2778)

βc-1529 Target: 5′-CTGCACAGGTGACCACATTTATATC-3′ (SEQ ID NO: 2779)

βc-1530 Target: 5′-GCTGCACAGGTGACCACATTTATATCA-3′ (SEQ ID NO: 2780)

βc-1558 Target: 5′-ATTGCAAGTGAGGTTAGAAAGAATTCC-3′ (SEQ ID NO: 2781)

βc-1566 Target: 5′-TTATAATTATTGCAAGTGAGGTTAGAA-3′ (SEQ ID NO: 2782)

βc-1579 Target: 5′-CATCATCTTGTTCTTATAATTATTGCA-3′ (SEQ ID NO: 2783)

βc-1580 Target: 5′-CCATCATCTTGTTCTTATAATTATTGC-3′ (SEQ ID NO: 2784)

βc-1583 Target: 5′-AGACCATCATCTTGTTCTTATAATTAT-3′ (SEQ ID NO: 2785)

βc-1585 Target: 5′-GCAGACCATCATCTTGTTCTTATAATT-3′ (SEQ ID NO: 2786)

βc-1808 Target: 5′-TCAATCCAACAGTAGCCTTTATCAGAG-3′ (SEQ ID NO: 2787)

βc-1813 Target: 5′-TCGAATCAATCCAACAGTAGCCTTTAT-3′ (SEQ ID NO: 2788)

βc-1955 Target: 5′-CCTCCACAAATTGCTGCTGTGTCCCAC-3′ (SEQ ID NO: 2789)

βc-1989 Target: 5′-GTACAACCTTCAACTATTTCTTCCATG-3′ (SEQ ID NO: 2790)

βc-1990 Target: 5′-GGTACAACCTTCAACTATTTCTTCC-3′ (SEQ ID NO: 2791)

βc-1991 Target: 5′-CGGTACAACCTTCAACTATTTCTTCCA-3′ (SEQ ID NO: 2792)

βc-1992 Target: 5′-CCGGTACAACCTTCAACTATTTCTTCC-3′ (SEQ ID NO: 2793)

βc-1997 Target: 5′-GGGCTCCGGTACAACCTTCAACTATTT-3′ (SEQ ID NO: 2794)

βc-2036 Target: 5′-TAACAATTCGGTTGTGAACATCCCGAG-3′ (SEQ ID NO: 2795)

βc-2037 Target: 5′-ATAACAATTCGGTTGTGAACATCCCGA-3′ (SEQ ID NO: 2796)

βc-2038 Target: 5′-GATAACAATTCGGTTGTGAACATCCCG-3′ (SEQ ID NO: 2797)

βc-2039 Target: 5′-TGATAACAATTCGGTTGTGAACATCCC-3′ (SEQ ID NO: 2798)

βc-2040 Target: 5′-CTGATAACAATTCGGTTGTGAACATCC-3′ (SEQ ID NO: 2799)

βc-2041 Target: 5′-TCTGATAACAATTCGGTTGTGAACATC-3′ (SEQ ID NO: 2800)

βc-2052 Target: 5′-GTATTTAGTCCTCTGATAACAATTCGG-3′ (SEQ ID NO: 2801)

βc-2053 Target: 5′-GGTATTTAGTCCTCTGATAACAATTCG-3′ (SEQ ID NO: 2802)

βc-2054 Target: 5′-TGGTATTTAGTCCTCTGATAACAATTC-3′ (SEQ ID NO: 2803)

βc-2055 Target: 5′-ATGGTATTTAGTCCTCTGATAACAATT-3′ (SEQ ID NO: 2804)

βc-2065 Target: 5′-AAACAATGGAATGGTATTTAGTCCTCT-3′ (SEQ ID NO: 2805)

βc-2069 Target: 5′-GCACAAACAATGGAATGGTATTTAGTC-3′ (SEQ ID NO: 2806)

βc-2071 Target: 5′-CTGCACAAACAATGGAATGGTATTTAG-3′ (SEQ ID NO: 2807)

βc-2072 Target: 5′-GCTGCACAAACAATGGAATGGTATTTA-3′ (SEQ ID NO: 2808)

βc-2111 Target: 5′-CAGCTACTCTTTGGATGTTTTCAATGG-3′ (SEQ ID NO: 2809)

βc-2112 Target: 5′-GCAGCTACTCTTTGGATGTTTTCAATG-3′ (SEQ ID NO: 2810)

βc-2168 Target: 5′-CAGCTTCAATAGCTTCTGCAGCTTCCT-3′ (SEQ ID NO: 2811)

βc-2175 Target: 5′-GCTCCCTCAGCTTCAATAGCTTCTGCA-3′ (SEQ ID NO: 2812)

βc-2177 Target: 5′-TGGCTCCCTCAGCTTCAATAGCTTCTG-3′ (SEQ ID NO: 2813)

βc-2214 Target: 5′-TCATTCCTAGAGTGAAGTAACTCTGTC-3′ (SEQ ID NO: 2814)

βc-2216 Target: 5′-CTTCATTCCTAGAGTGAAGTAACTCTG-3′ (SEQ ID NO: 2815)

βc-2217 Target: 5′-CCTTCATTCCTAGAGTGAAGTAACTCT-3′ (SEQ ID NO: 2816)

βc-2264 Target: 5′-TGTCCTCAGACATTCGGAACAAAACAG-3′ (SEQ ID NO: 2817)

βc-2266 Target: 5′-CTTGTCCTCAGACATTCGGAACAAAAC-3′ (SEQ ID NO: 2818)

βc-2287 Target: 5′-CCGTTTCTTGTAATCTTGTGGCTTGTC-3′ (SEQ ID NO: 2819)

βc-2295 Target: 5′-ACTGAAAGCCGTTTCTTGTAATCTTGT-3′ (SEQ ID NO: 2820)

βc-2302 Target: 5′-CAGCTCAACTGAAAGCCGTTTCTTGTA-3′ (SEQ ID NO: 2821)

βc-2363 Target: 5′-CAAGTCCAAGATCAGCAGTCTCATTCC-3′ (SEQ ID NO: 2822)

βc-2373 Target: 5′-GCACCAATATCAAGTCCAAGATCAGCA-3′ (SEQ ID NO: 2823)

βc-2424 Target: 5′-AAAGAACGATAGCTAGGATCATCCTGG-3′ (SEQ ID NO: 2824)

βc-2441 Target: 5′-CATATCCACCAGAGTGAAAAGAACGAT-3′ (SEQ ID NO: 2825)

βc-2618 Target: 5′-TGATTTACAGGTCAGTATCAAACCAGG-3′ (SEQ ID NO: 2826)

βc-2619 Target: 5′-ATGATTTACAGGTCAGTATCAAACCAG-3′ (SEQ ID NO: 2827)

βc-2620 Target: 5′-GATGATTTACAGGTCAGTATCAAACCA-3′ (SEQ ID NO: 2828)

βc-2634 Target: 5′-CTTCTTACCTAAAGGATGATTTACAGG-3′ (SEQ ID NO: 2829)

βc-2635 Target: 5′-ACTTCTTACCTAAAGGATGATTTACAG-3′ (SEQ ID NO: 2830)

βc-2637 Target: 5′-AAACTTCTTACCTAAAGGATGATTTAC-3′ (SEQ ID NO: 2831)

βc-2645 Target: 5′-GCTTTTTAAAACTTCTTACCTAAAGGA-3′ (SEQ ID NO: 2832)

βc-2647 Target: 5′-TGGCTTTTTAAAACTTCTTACCTAAAG-3′ (SEQ ID NO: 2833)

βc-2653 Target: 5′-CCAAACTGGCTTTTTAAAACTTCTTAC-3′ (SEQ ID NO: 2834)

βc-2657 Target: 5′-TTACCCAAACTGGCTTTTTAAAACTTC-3′ (SEQ ID NO: 2835)

βc-2658 Target: 5′-TTTACCCAAACTGGCTTTTTAAAACTT-3′ (SEQ ID NO: 2836)

βc-2659 Target: 5′-TTTTACCCAAACTGGCTTTTTAAAACT-3′ (SEQ ID NO: 2837)

βc-2660 Target: 5′-ATTTTACCCAAACTGGCTTTTTAAAAC-3′ (SEQ ID NO: 2838)

βc-2701 Target: 5′-CCAACCAAGTCTTTCTGAAGTTCTGTA-3′ (SEQ ID NO: 2839)

βc-2709 Target: 5′-CCACCCTACCAACCAAGTCTTTCTGAA-3′ (SEQ ID NO: 2840)

βc-2733 Target: 5′-ATTTACAAATAGCCTAAACCACTCCCA-3′ (SEQ ID NO: 2841)

βc-2734 Target: 5′-GATTTACAAATAGCCTAAACCACTCCC-3′ (SEQ ID NO: 2842)

βc-2735 Target: 5′-AGATTTACAAATAGCCTAAACCACTCC-3′ (SEQ ID NO: 2843)

βc-2736 Target: 5′-CAGATTTACAAATAGCCTAAACCACTC-3′ (SEQ ID NO: 2844)

βc-2747 Target: 5′-TGTTTTTGTGGCAGATTTACAAATAGC-3′ (SEQ ID NO: 2845)

βc-2748 Target: 5′-CTGTTTTTGTGGCAGATTTACAAATAG-3′ (SEQ ID NO: 2846)

βc-2749 Target: 5′-CCTGTTTTTGTGGCAGATTTACAAATA-3′ (SEQ ID NO: 2847)

βc-2754 Target: 5′-ATATACCTGTTTTTGTGGCAGATTTAC-3′ (SEQ ID NO: 2848)

βc-2764 Target: 5′-CTTTCAAAGTATATACCTGTTTTTGTG-3′ (SEQ ID NO: 2849)

βc-2770 Target: 5′-CATCTCCTTTCAAAGTATATACCTGTT-3′ (SEQ ID NO: 2850)

βc-2771 Target: 5′-ACATCTCCTTTCAAAGTATATACCTGT-3′ (SEQ ID NO: 2851)

βc-2773 Target: 5′-AGACATCTCCTTTCAAAGTATATACCT-3′ (SEQ ID NO: 2852)

βc-2774 Target: 5′-AAGACATCTCCTTTCAAAGTATATACC-3′ (SEQ ID NO: 2853)

βc-2775 Target: 5′-CAAGACATCTCCTTTCAAAGTATATAC-3′ (SEQ ID NO: 2854)

βc-2780 Target: 5′-TGTTCCAAGACATCTCCTTTCAAAGTA-3′ (SEQ ID NO: 2855)

βc-2788 Target: 5′-CATTCCAATGTTCCAAGACATCTCCTT-3′ (SEQ ID NO: 2856)

βc-2789 Target: 5′-ACATTCCAATGTTCCAAGACATCTCCT-3′ (SEQ ID NO: 2857)

βc-2791 Target: 5′-GAACATTCCAATGTTCCAAGACATCTC-3′ (SEQ ID NO: 2858)

βc-2803 Target: 5′-CCAGAAATCTGAGAACATTCCAATGTT-3′ (SEQ ID NO: 2859)

βc-2807 Target: 5′-ACAACCAGAAATCTGAGAACATTCCAA-3′ (SEQ ID NO: 2860)

βc-2809 Target: 5′-TAACAACCAGAAATCTGAGAACATTCC-3′ (SEQ ID NO: 2861)

βc-2810 Target: 5′-ATAACAACCAGAAATCTGAGAACATTC-3′ (SEQ ID NO: 2862)

βc-2811 Target: 5′-CATAACAACCAGAAATCTGAGAACATT-3′ (SEQ ID NO: 2863)

βc-2817 Target: 5′-TGATCACATAACAACCAGAAATCTGAG-3′ (SEQ ID NO: 2864)

βc-2818 Target: 5′-ATGATCACATAACAACCAGAAATCTGA-3′ (SEQ ID NO: 2865)

βc-2824 Target: 5′-CCACACATGATCACATAACAACCAGAA-3′ (SEQ ID NO: 2866)

βc-2827 Target: 5′-CTTCCACACATGATCACATAACAACCA-3′ (SEQ ID NO: 2867)

βc-2832 Target: 5′-AATAACTTCCACACATGATCACATAAC-3′ (SEQ ID NO: 2868)

βc-2833 Target: 5′-TAATAACTTCCACACATGATCACATAA-3′ (SEQ ID NO: 2869)

βc-2834 Target: 5′-TTAATAACTTCCACACATGATCACATA-3′ (SEQ ID NO: 2870)

βc-2835 Target: 5′-GTTAATAACTTCCACACATGATCAC-3′ (SEQ ID NO: 2871)

βc-2842 Target: 5′-CATTAAAGTTAATAACTTCCACACATG-3′ (SEQ ID NO: 2872)

βc-2843 Target: 5′-ACATTAAAGTTAATAACTTCCACAC-3′ (SEQ ID NO: 2873)

βc-2845 Target: 5′-AAACATTAAAGTTAATAACTTCCACAC-3′ (SEQ ID NO: 2874)

βc-2846 Target: 5′-AAAACATTAAAGTTAATAACTTCCACA-3′ (SEQ ID NO: 2875)

βc-2847 Target: 5′-AAAAACATTAAAGTTAATAACTTCCAC-3′ (SEQ ID NO: 2876)

βc-2848 Target: 5′-AAAAAACATTAAAGTTAATAACTTCCA-3′ (SEQ ID NO: 2877)

βc-2849 Target: 5′-CAAAAAACATTAAAGTTAATAACTTCC-3′ (SEQ ID NO: 2878)

βc-2850 Target: 5′-GCAAAAAACATTAAAGTTAATAACTTC-3′ (SEQ ID NO: 2879)

βc-2852 Target: 5′-TGGCAAAAAACATTAAAGTTAATAACT-3′ (SEQ ID NO: 2880)

βc-2853 Target: 5′-GTGGCAAAAAACATTAAAGTTAATAAC-3′ (SEQ ID NO: 2881)

βc-2864 Target: 5′-TTGCAAAAGCTGTGGCAAAAAACATTA-3′ (SEQ ID NO: 2882)

βc-2865 Target: 5′-GTTGCAAAAGCTGTGGCAAAAAACATT-3′ (SEQ ID NO: 2883)

βc-2882 Target: 5′-ACTCATTTGAGTATTAAGTTGCAAAAG-3′ (SEQ ID NO: 2884)

βc-2899 Target: 5′-TTAAAACAGCAAATGTTACTCATTTGA-3′ (SEQ ID NO: 2885)

βc-2900 Target: 5′-TTTAAAACAGCAAATGTTACTCATTTG-3′ (SEQ ID NO: 2886)

βc-2901 Target: 5′-GTTTAAAACAGCAAATGTTACTCATTT-3′ (SEQ ID NO: 2887)

βc-2902 Target: 5′-TGTTTAAAACAGCAAATGTTACTCATT-3′ (SEQ ID NO: 2888)

βc-2903 Target: 5′-ATGTTTAAAACAGCAAATGTTACTC-3′ (SEQ ID NO: 2889)

βc-2904 Target: 5′-AATGTTTAAAACAGCAAATGTTACTCA-3′ (SEQ ID NO: 2890)

βc-2909 Target: 5′-CTATTAATGTTTAAAACAGCAAATGTT-3′ (SEQ ID NO: 2891)

βc-2921 Target: 5′-AGAGAAAGGCTGCTATTAATGTTTAAA-3′ (SEQ ID NO: 2892)

βc-2949 Target: 5′-CAAGTTCAGACAATACAGCTGTATAAA-3′ (SEQ ID NO: 2893)

βc-2957 Target: 5′-TCACAATGCAAGTTCAGACAATACAGC-3′ (SEQ ID NO: 2894)

βc-2959 Target: 5′-AATCACAATGCAAGTTCAGACAATACA-3′ (SEQ ID NO: 2895)

βc-2961 Target: 5′-CCAATCACAATGCAAGTTCAGACAATA-3′ (SEQ ID NO: 2896)

βc-2965 Target: 5′-CAGGCCAATCACAATGCAAGTTCAGAC-3′ (SEQ ID NO: 2897)

βc-3052 Target: 5′-TTGTTCCCATAGGAAACTCAGCTTGGT-3′ (SEQ ID NO: 2898)

βc-3058 Target: 5′-CTTCAATTGTTCCCATAGGAAACTCAG-3′ (SEQ ID NO: 2899)

βc-3059 Target: 5′-ACTTCAATTGTTCCCATAGGAAACTCA-3′ (SEQ ID NO: 2900)

βc-3065 Target: 5′-AAGTTTACTTCAATTGTTCCCATAGGA-3′ (SEQ ID NO: 2901)

βc-3066 Target: 5′-AAAGTTTACTTCAATTGTTCCCATAGG-3′ (SEQ ID NO: 2902)

βc-3070 Target: 5′-ACAAAAAGTTTACTTCAATTGTTCCCA-3′ (SEQ ID NO: 2903)

βc-3074 Target: 5′-CAGAACAAAAAGTTTACTTCAATTGTT-3′ (SEQ ID NO: 2904)

βc-3079 Target: 5′-AGGACCAGAACAAAAAGTTTACTTCAA-3′ (SEQ ID NO: 2905)

βc-3080 Target: 5′-AAGGACCAGAACAAAAAGTTTACTTCA-3′ (SEQ ID NO: 2906)

βc-3088 Target: 5′-CGACCAAAAAGGACCAGAACAAAAAGT-3′ (SEQ ID NO: 2907)

βc-3089 Target: 5′-TCGACCAAAAAGGACCAGAACAAAAAG-3′ (SEQ ID NO: 2908)

βc-3096 Target: 5′-TTACTCCTCGACCAAAAAGGACCAGAA-3′ (SEQ ID NO: 2909)

βc-3111 Target: 5′-AATCCATTTGTATTGTTACTCCTCGAC-3′ (SEQ ID NO: 2910)

βc-3112 Target: 5′-AAATCCATTTGTATTGTTACTCCTCGA-3′ (SEQ ID NO: 2911)

βc-3113 Target: 5′-AAAATCCATTTGTATTGTTACTCCTCG-3′ (SEQ ID NO: 2912)

βc-3114 Target: 5′-CAAAATCCATTTGTATTGTTACTCCTC-3′ (SEQ ID NO: 2913)

βc-3115 Target: 5′-CCAAAATCCATTTGTATTGTTACTCCT-3′ (SEQ ID NO: 2914)

βc-3121 Target: 5′-TCACTCCCAAAATCCATTTGTATTGTT-3′ (SEQ ID NO: 2915)

βc-3136 Target: 5′-TCTTCACTTCTTGAGTCACTCCCAAAA-3′ (SEQ ID NO: 2916)

βc-3138 Target: 5′-ATTCTTCACTTCTTGAGTCACTCCCAA-3′ (SEQ ID NO: 2917)

βc-3139 Target: 5′-CATTCTTCACTTCTTGAGTCACTCCCA-3′ (SEQ ID NO: 2918)

βc-3140 Target: 5′-GCATTCTTCACTTCTTGAGTCACTCCC-3′ (SEQ ID NO: 2919)

βc-3142 Target: 5′-GTGCATTCTTCACTTCTTGAGTCACTC-3′ (SEQ ID NO: 2920)

βc-3150 Target: 5′-CCATTCTTGTGCATTCTTCACTTCTTG-3′ (SEQ ID NO: 2921)

βc-3153 Target: 5′-GATCCATTCTTGTGCATTCTTCACTTC-3′ (SEQ ID NO: 2922)

βc-3154 Target: 5′-TGATCCATTCTTGTGCATTCTTCACTT-3′ (SEQ ID NO: 2923)

βc-3155 Target: 5′-GTGATCCATTCTTGTGCATTCTTCACT-3′ (SEQ ID NO: 2924)

βc-3168 Target: 5′-TAAATTCCATCTTGTGATCCATTCTTG-3′ (SEQ ID NO: 2925)

βc-3170 Target: 5′-GATAAATTCCATCTTGTGATCCATTCT-3′ (SEQ ID NO: 2926)

βc-3171 Target: 5′-TGATAAATTCCATCTTGTGATCCATTC-3′ (SEQ ID NO: 2927)

βc-3172 Target: 5′-TTGATAAATTCCATCTTGTGATCCATT-3′ (SEQ ID NO: 2928)

βc-3173 Target: 5′-TTTGATAAATTCCATCTTGTGATCC-3′ (SEQ ID NO: 2929)

βc-3183 Target: 5′-AAGGCTAGGGTTTGATAAATTCCATCT-3′ (SEQ ID NO: 2930)

βc-3200 Target: 5′-AAAAAAATTTAACAAGCAAGGCTAGGG-3′ (SEQ ID NO: 2931)

βc-3209 Target: 5′-AAAAAAAAAAAAAAAATTTAACAAGCA-3′ (SEQ ID NO: 2932)

βc-3210 Target: 5′-AAAAAAAAAAAAAAAAATTTAACAAGC-3′ (SEQ ID NO: 2933)

βc-3211 Target: 5′-AAAAAAAAAAAAAAAAAATTTAACAAG-3′ (SEQ ID NO: 2934)

βc-3212 Target: 5′-AAAAAAAAAAAAAAAAAAATTTAACAA-3′ (SEQ ID NO: 2935)

βc-3213 Target: 5′-TAAAAAAAAAAAAAAAAAAATTTAACA-3′ (SEQ ID NO: 2936)

βc-3214 Target: 5′-TTAAAAAAAAAAAAAAAAAAATTTAAC-3′ (SEQ ID NO: 2937)

βc-3215 Target: 5′-CTTAAAAAAAAAAAAAAAAAAATTTAA-3′ (SEQ ID NO: 2938)

βc-3216 Target: 5′-TCTTAAAAAAAAAAAAAAAAAAATTTA-3′ (SEQ ID NO: 2939)

βc-3218 Target: 5′-ATTCTTAAAAAAAAAAAAAAAAAAATT-3′ (SEQ ID NO: 2940)

βc-3219 Target: 5′-TATTCTTAAAAAAAAAAAAAAAAAAAT-3′ (SEQ ID NO: 2941)

βc-3220 Target: 5′-ATATTCTTAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2942)

βc-3221 Target: 5′-GATATTCTTAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2943)

βc-3222 Target: 5′-AGATATTCTTAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2944)

βc-3223 Target: 5′-CAGATATTCTTAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2945)

βc-3224 Target: 5′-ACAGATATTCTTAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2946)

βc-3228 Target: 5′-CATTACAGATATTCTTAAAAAAAAAAA-3′ (SEQ ID NO: 2947)

βc-3229 Target: 5′-CCATTACAGATATTCTTAAAAAAAAAA-3′ (SEQ ID NO: 2948)

βc-3233 Target: 5′-AGTACCATTACAGATATTCTTAAAAAA-3′ (SEQ ID NO: 2949)

βc-3234 Target: 5′-CAGTACCATTACAGATATTCTTAAAAA-3′ (SEQ ID NO: 2950)

βc-3235 Target: 5′-TCAGTACCATTACAGATATTCTTAAAA-3′ (SEQ ID NO: 2951)

βc-3239 Target: 5′-AAAGTCAGTACCATTACAGATATTCTT-3′ (SEQ ID NO: 2952)

βc-3256 Target: 5′-GCTACTTCAAAGCAAGCAAAGTCAGTA-3′ (SEQ ID NO: 2953)

βc-3265 Target: 5′-AAAAAAAGAGCTACTTCAAAGCAAGCA-3′ (SEQ ID NO: 2954)

βc-3270 Target: 5′-AAAAAAAAAAAAGAGCTACTTCAAAGC-3′ (SEQ ID NO: 2955)

βc-3271 Target: 5′-AAAAAAAAAAAAAGAGCTACTTCAAAG-3′ (SEQ ID NO: 2956)

βc-3273 Target: 5′-AAAAAAAAAAAAAAAGAGCTACTTCAA-3′ (SEQ ID NO: 2957)

βc-3274 Target: 5′-AAAAAAAAAAAAAAAAGAGCTACTTCA-3′ (SEQ ID NO: 2958)

βc-3275 Target: 5′-AAAAAAAAAAAAAAAAAGAGCTACTTC-3′ (SEQ ID NO: 2959)

βc-3276 Target: 5′-AAAAAAAAAAAAAAAAAAGAGCTACTT-3′ (SEQ ID NO: 2960)

βc-3282 Target: 5′-AAAAAAAAAAAAAAAAAAAAAAAAGAG-3′ (SEQ ID NO: 2961)

βc-3283 Target: 5′-AAAAAAAAAAAAAAAAAAAAAAAAAGA-3′ (SEQ ID NO: 2962)

βc-3284 Target: 5′-CAAAAAAAAAAAAAAAAAAAAAAAAAG-3′ (SEQ ID NO: 2963)

βc-3285 Target: 5′-GCAAAAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2964)

βc-3287 Target: 5′-CTGCAAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2965)

βc-3288 Target: 5′-ACTGCAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2966)

βc-3292 Target: 5′-AGTTACTGCAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2967)

βc-3293 Target: 5′-CAGTTACTGCAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2968)

βc-3294 Target: 5′-ACAGTTACTGCAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2969)

βc-3298 Target: 5′-AAAAACAGTTACTGCAAAAAAAAAAAA-3′ (SEQ ID NO: 2970)

βc-3299 Target: 5′-AAAAAACAGTTACTGCAAAAAAAAAAA-3′ (SEQ ID NO: 2971)

βc-3300 Target: 5′-TAAAAAACAGTTACTGCAAAAAAAAAA-3′ (SEQ ID NO: 2972)

βc-3302 Target: 5′-CTTAAAAAACAGTTACTGCAAAAAAAA-3′ (SEQ ID NO: 2973)

βc-3303 Target: 5′-ACTTAAAAAACAGTTACTGCAAAAAAA-3′ (SEQ ID NO: 2974)

βc-3305 Target: 5′-AGACTTAAAAAACAGTTACTGCAAAAA-3′ (SEQ ID NO: 2975)

βc-3315 Target: 5′-ACACTACGAGAGACTTAAAAAACAGTT-3′ (SEQ ID NO: 2976)

βc-3317 Target: 5′-TAACACTACGAGAGACTTAAAAAACAG-3′ (SEQ ID NO: 2977)

βc-3318 Target: 5′-TTAACACTACGAGAGACTTAAAAAACA-3′ (SEQ ID NO: 2978)

βc-3320 Target: 5′-ACTTAACACTACGAGAGACTTAAAAAA-3′ (SEQ ID NO: 2979)

βc-3323 Target: 5′-ATAACTTAACACTACGAGAGACTTAAA-3′ (SEQ ID NO: 2980)

βc-3324 Target: 5′-TATAACTTAACACTACGAGAGACTTAA-3′ (SEQ ID NO: 2981)

βc-3332 Target: 5′-GTATTCACTATAACTTAACACTACGAG-3′ (SEQ ID NO: 2982)

βc-3333 Target: 5′-AGTATTCACTATAACTTAACACTACGA-3′ (SEQ ID NO: 2983)

βc-3334 Target: 5′-CAGTATTCACTATAACTTAACACTACG-3′ (SEQ ID NO: 2984)

βc-3335 Target: 5′-GCAGTATTCACTATAACTTAACACTAC-3′ (SEQ ID NO: 2985)

βc-3348 Target: 5′-AGAAATTGCTGTAGCAGTATTCACTAT-3′ (SEQ ID NO: 2986)

βc-3349 Target: 5′-TAGAAATTGCTGTAGCAGTATTCACTA-3′ (SEQ ID NO: 2987)

βc-3350 Target: 5′-TTAGAAATTGCTGTAGCAGTATTCACT-3′ (SEQ ID NO: 2988)

βc-3366 Target: 5′-ACTCAATTCTTAAAAATTAGAAATTGC-3′ (SEQ ID NO: 2989)

βc-3371 Target: 5′-CCATTACTCAATTCTTAAAAATTAGAA-3′ (SEQ ID NO: 2990)

βc-3374 Target: 5′-ACACCATTACTCAATTCTTAAAAATTA-3′ (SEQ ID NO: 2991)

βc-3376 Target: 5′-CTACACCATTACTCAATTCTTAAAAAT-3′ (SEQ ID NO: 2992)

βc-3377 Target: 5′-TCTACACCATTACTCAATTCTTAAAAA-3′ (SEQ ID NO: 2993)

βc-3379 Target: 5′-GTTCTACACCATTACTCAATTCTTAAA-3′ (SEQ ID NO: 2994)

βc-3381 Target: 5′-GTGTTCTACACCATTACTCAATTCTTA-3′ (SEQ ID NO: 2995)

βc-3389 Target: 5′-ATGAATTAGTGTTCTACACCATTACTC-3′ (SEQ ID NO: 2996)

βc-3394 Target: 5′-TGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 2997)

βc-3395 Target: 5′-GTGATTATGAATTAGTGTTCTACACCA-3′ (SEQ ID NO: 2998)

βc-3396 Target: 5′-AGTGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 2999)

βc-3405 Target: 5′-ATTAATTAGAGTGATTATGAATTAGTG-3′ (SEQ ID NO: 3000)

βc-3406 Target: 5′-AATTAATTAGAGTGATTATGAATTAGT-3′ (SEQ ID NO: 3001)

βc-3407 Target: 5′-CAATTAATTAGAGTGATTATGAATTAG-3′ (SEQ ID NO: 3002)

βc-3411 Target: 5′-ATTACAATTAATTAGAGTGATTATGAA-3′ (SEQ ID NO: 3003)

βc-3412 Target: 5′-GATTACAATTAATTAGAGTGATTATGA-3′ (SEQ ID NO: 3004)

βc-3413 Target: 5′-AGATTACAATTAATTAGAGTGATTATG-3′ (SEQ ID NO: 3005)

βc-3421 Target: 5′-CTTTATTCAGATTACAATTAATTAGAG-3′ (SEQ ID NO: 3006)

βc-3422 Target: 5′-ACTTTATTCAGATTACAATTAATTAGA-3′ (SEQ ID NO: 3007)

βc-3426 Target: 5′-TTACACTTTATTCAGATTACAATTAAT-3′ (SEQ ID NO: 3008)

βc-3427 Target: 5′-GTTACACTTTATTCAGATTACAATTAA-3′ (SEQ ID NO: 3009)

βc-3428 Target: 5′-TGTTACACTTTATTCAGATTACAATTA-3′ (SEQ ID NO: 3010)

βc-3429 Target: 5′-TTGTTACACTTTATTCAGATTACAATT-3′ (SEQ ID NO: 3011)

βc-3430 Target: 5′-ATTGTTACACTTTATTCAGATTACAAT-3′ (SEQ ID NO: 3012)

βc-3437 Target: 5′-CTACACAATTGTTACACTTTATTCAGA-3′ (SEQ ID NO: 3013)

βc-3441 Target: 5′-AAGGCTACACAATTGTTACACTTTATT-3′ (SEQ ID NO: 3014)

βc-3446 Target: 5′-ACAAAAAGGCTACACAATTGTTACACT-3′ (SEQ ID NO: 3015)

βc-3452 Target: 5′-TTTTATACAAAAAGGCTACACAATTGT-3′ (SEQ ID NO: 3016)

βc-3453 Target: 5′-ATTTTATACAAAAAGGCTACACAATTG-3′ (SEQ ID NO: 3017)

βc-3455 Target: 5′-CTATTTTATACAAAAAGGCTACACAAT-3′ (SEQ ID NO: 3018)

βc-3456 Target: 5′-TCTATTTTATACAAAAAGGCTACACAA-3′ (SEQ ID NO: 3019)

βc-3458 Target: 5′-TGTCTATTTTATACAAAAAGGCTACAC-3′ (SEQ ID NO: 3020)

βc-3464 Target: 5′-TCTATTTGTCTATTTTATACAAAAAGG-3′ (SEQ ID NO: 3021)

βc-3466 Target: 5′-TTTCTATTTGTCTATTTTATACAAAAA-3′ (SEQ ID NO: 3022)

βc-3467 Target: 5′-TTTTCTATTTGTCTATTTTATACAAAA-3′ (SEQ ID NO: 3023)

βc-3468 Target: 5′-ATTTTCTATTTGTCTATTTTATACAAA-3′ (SEQ ID NO: 3024)

βc-3469 Target: 5′-CATTTTCTATTTGTCTATTTTATACAA-3′ (SEQ ID NO: 3025)

βc-3470 Target: 5′-CCATTTTCTATTTGTCTATTTTATACA-3′ (SEQ ID NO: 3026)

βc-3473 Target: 5′-GGACCATTTTCTATTTGTCTATTTTAT-3′ (SEQ ID NO: 3027)

βc-3474 Target: 5′-TGGACCATTTTCTATTTGTCTATTTTA-3′ (SEQ ID NO: 3028)

βc-3475 Target: 5′-TTGGACCATTTTCTATTTGTCTATTTT-3′ (SEQ ID NO: 3029)

βc-3482 Target: 5′-AAACTAATTGGACCATTTTCTATTTGT-3′ (SEQ ID NO: 3030)

βc-3483 Target: 5′-GAAACTAATTGGACCATTTTCTATTTG-3′ (SEQ ID NO: 3031)

βc-3484 Target: 5′-GGAAACTAATTGGACCATTTTCTATTT-3′ (SEQ ID NO: 3032)

βc-3485 Target: 5′-AGGAAACTAATTGGACCATTTTCTATT-3′ (SEQ ID NO: 3033)

βc-3491 Target: 5′-TTAAAAAGGAAACTAATTGGACCATTT-3′ (SEQ ID NO: 3034)

βc-3492 Target: 5′-ATTAAAAAGGAAACTAATTGGACCATT-3′ (SEQ ID NO: 3035)

βc-3498 Target: 5′-AAGCATATTAAAAAGGAAACTAATTGG-3′ (SEQ ID NO: 3036)

βc-3499 Target: 5′-TAAGCATATTAAAAAGGAAACTAATTG-3′ (SEQ ID NO: 3037)

βc-3503 Target: 5′-ATTTTAAGCATATTAAAAAGGAAACTA-3′ (SEQ ID NO: 3038)

βc-3509 Target: 5′-CTGCTTATTTTAAGCATATTAAAAAGG-3′ (SEQ ID NO: 3039)

βc-3510 Target: 5′-CCTGCTTATTTTAAGCATATTAAAAAG-3′ (SEQ ID NO: 3040)

βc-3516 Target: 5′-GATCCACCTGCTTATTTTAAGCATATT-3′ (SEQ ID NO: 3041)

βc-3531 Target: 5′-CAAAAACATGAAATAGATCCACCTGCT-3′ (SEQ ID NO: 3042)

βc-3532 Target: 5′-TCAAAAACATGAAATAGATCCACCTGC-3′ (SEQ ID NO: 3043)

βc-3534 Target: 5′-GATCAAAAACATGAAATAGATCCACCT-3′ (SEQ ID NO: 3044)

βc-3535 Target: 5′-TGATCAAAAACATGAAATAGATCCACC-3′ (SEQ ID NO: 3045)

βc-3536 Target: 5′-TTGATCAAAAACATGAAATAGATCCAC-3′ (SEQ ID NO: 3046)

βc-3541 Target: 5′-AGTTTTTGATCAAAAACATGAAATAGA-3′ (SEQ ID NO: 3047)

βc-3547 Target: 5′-CCAAATAGTTTTTGATCAAAAACATGA-3′ (SEQ ID NO: 3048)

βc-3551 Target: 5′-TATCCCAAATAGTTTTTGATCAAAAAC-3′ (SEQ ID NO: 3049)

βc-3552 Target: 5′-ATATCCCAAATAGTTTTTGATCAAAAA-3′ (SEQ ID NO: 3050)

βc-3553 Target: 5′-CATATCCCAAATAGTTTTTGATCAAAA-3′ (SEQ ID NO: 3051)

βc-3554 Target: 5′-ACATATCCCAAATAGTTTTTGATCAAA-3′ (SEQ ID NO: 3052)

βc-3558 Target: 5′-CCATACATATCCCAAATAGTTTTTGAT-3′ (SEQ ID NO: 3053)

βc-3567 Target: 5′-TTACCCTACCCATACATATCCCAAATA-3′ (SEQ ID NO: 3054)

βc-3568 Target: 5′-TTTACCCTACCCATACATATCCCAAAT-3′ (SEQ ID NO: 3055)

βc-3569 Target: 5′-ATTTACCCTACCCATACATATCCCAAA-3′ (SEQ ID NO: 3056)

βc-3582 Target: 5′-ACACCTCTTACTGATTTACCCTACCCA-3′ (SEQ ID NO: 3057)

βc-3584 Target: 5′-TAACACCTCTTACTGATTTACCCTACC-3′ (SEQ ID NO: 3058)

βc-3585 Target: 5′-ATAACACCTCTTACTGATTTACCCTAC-3′ (SEQ ID NO: 3059)

βc-3586 Target: 5′-AATAACACCTCTTACTGATTTACCCTA-3′ (SEQ ID NO: 3060)

βc-3587 Target: 5′-AAATAACACCTCTTACTGATTTACCCT-3′ (SEQ ID NO: 3061)

βc-3588 Target: 5′-CAAATAACACCTCTTACTGATTTACCC-3′ (SEQ ID NO: 3062)

βc-3594 Target: 5′-AGGTTCCAAATAACACCTCTTACTGAT-3′ (SEQ ID NO: 3063)

βc-3600 Target: 5′-AAAACAAGGTTCCAAATAACACCTCTT-3′ (SEQ ID NO: 3064)

βc-3601 Target: 5′-CAAAACAAGGTTCCAAATAACACCTCT-3′ (SEQ ID NO: 3065)

βc-3602 Target: 5′-CCAAAACAAGGTTCCAAATAACACCTC-3′ (SEQ ID NO: 3066)

βc-3607 Target: 5′-ACTGTCCAAAACAAGGTTCCAAATAAC-3′ (SEQ ID NO: 3067)

βc-3611 Target: 5′-GTAAACTGTCCAAAACAAGGTTCCAAA-3′ (SEQ ID NO: 3068)

βc-3612 Target: 5′-GGTAAACTGTCCAAAACAAGGTTCCAA-3′ (SEQ ID NO: 3069)

βc-3620 Target: 5′-AGGCAACTGGTAAACTGTCCAAAACAA-3′ (SEQ ID NO: 3070)

βc-3628 Target: 5′-GGGATAAAAGGCAACTGGTAAACTGTC-3′ (SEQ ID NO: 3071)

βc-3629 Target: 5′-TGGGATAAAAGGCAACTGGTAAACTGT-3′ (SEQ ID NO: 3072)

βc-3636 Target: 5′-ACAACTTTGGGATAAAAGGCAACTGGT-3′ (SEQ ID NO: 3073)

βc-3638 Target: 5′-CAACAACTTTGGGATAAAAGGCAACTG-3′ (SEQ ID NO: 3074)

βc-3643 Target: 5′-GGTTACAACAACTTTGGGATAAAAGGC-3′ (SEQ ID NO: 3075)

βc-3644 Target: 5′-AGGTTACAACAACTTTGGGATAAAAGG-3′ (SEQ ID NO: 3076)

βc-3645 Target: 5′-CAGGTTACAACAACTTTGGGATAAAAG-3′ (SEQ ID NO: 3077)

βc-3653 Target: 5′-TATCACAGCAGGTTACAACAACTTTGG-3′ (SEQ ID NO: 3078)

βc-3654 Target: 5′-GTATCACAGCAGGTTACAACAACTTTG-3′ (SEQ ID NO: 3079)

βc-3656 Target: 5′-TCGTATCACAGCAGGTTACAACAACTT-3′ (SEQ ID NO: 3080)

βc-3670 Target: 5′-TTTCTCTTGAAGCATCGTATCACAGCA-3′ (SEQ ID NO: 3081)

βc-3671 Target: 5′-TTTTCTCTTGAAGCATCGTATCACAGC-3′ (SEQ ID NO: 3082)

βc-3673 Target: 5′-CATTTTCTCTTGAAGCATCGTATCACA-3′ (SEQ ID NO: 3083)

βc-3686 Target: 5′-TTTTTTATAACCGCATTTTCTCTTGAA-3′ (SEQ ID NO: 3084)

βc-3687 Target: 5′-ATTTTTTATAACCGCATTTTCTCTTGA-3′ (SEQ ID NO: 3085)

βc-3688 Target: 5′-CATTTTTTATAACCGCATTTTCTCTTG-3′ (SEQ ID NO: 3086)

βc-3689 Target: 5′-CCATTTTTTATAACCGCATTTTCTCTT-3′ (SEQ ID NO: 3087)

βc-3694 Target: 5′-CTGAACCATTTTTTATAACCGCATTTT-3′ (SEQ ID NO: 3088)

βc-3699 Target: 5′-TAATTCTGAACCATTTTTTATAACCGC-3′ (SEQ ID NO: 3089)

βc-3700 Target: 5′-TTAATTCTGAACCATTTTTTATAACCG-3′ (SEQ ID NO: 3090)

βc-3701 Target: 5′-TTTAATTCTGAACCATTTTTTATAACC-3′ (SEQ ID NO: 3091)

βc-3702 Target: 5′-GTTTAATTCTGAACCATTTTTTATAAC-3′ (SEQ ID NO: 3092)

βc-3703 Target: 5′-AGTTTAATTCTGAACCATTTTTTATAA-3′ (SEQ ID NO: 3093)

βc-3704 Target: 5′-AAGTTTAATTCTGAACCATTTTTTATA-3′ (SEQ ID NO: 3094)

βc-3709 Target: 5′-ATTAAAAGTTTAATTCTGAACCATTTT-3′ (SEQ ID NO: 3095)

βc-3710 Target: 5′-AATTAAAAGTTTAATTCTGAACCATTT-3′ (SEQ ID NO: 3096)

βc-3712 Target: 5′-TGAATTAAAAGTTTAATTCTGAACC-3′ (SEQ ID NO: 3097)

βc-2634t2 Target: 5′-CAATACAGCTAAAGGATGATTTACAGG-3′ (SEQ ID NO: 3098)

βc-2635t2 Target: 5′-ACAATACAGCTAAAGGATGATTTACAG-3′ (SEQ ID NO: 3099)

βc-2637t2 Target: 5′-AGACAATACAGCTAAAGGATGATTTAC-3′ (SEQ ID NO: 3100)

βc-2633t3 Target: 5′-GTTACTCCTAAAGGATGATTTACAGGT-3′ (SEQ ID NO: 3101)

βc-2634t3 Target: 5′-TGTTACTCCTAAAGGATGATTTACAGG-3′ (SEQ ID NO: 3102)

βc-2635t3 Target: 5′-TTGTTACTCCTAAAGGATGATTTACAG-3′ (SEQ ID NO: 3103)

βc-2636t3 Target: 5′-ATTGTTACTCCTAAAGGATGATTTACA-3′ (SEQ ID NO: 3104)

βc-m318 Target: 5′-GGATTCCAGAATCCAAGTAAGACTGCT-3′ (SEQ ID NO: 3105)

βc-m417 Target: 5′-CTTGCTCCCATTCATAAAGGACTTGGG-3′ (SEQ ID NO: 3106)

βc-m462 Target: 5′-CGTCAATATCAGCTACTTGCTCTTGCG-3′ (SEQ ID NO: 3107)

βc-m463 Target: 5′-CCGTCAATATCAGCTACTTGCTCTTGC-3′ (SEQ ID NO: 3108)

βc-m468 Target: 5′-ACTGCCCGTCAATATCAGCTACTTGCT-3′ (SEQ ID NO: 3109)

βc-m613 Target: 5′-TGTTTCAACATCTGTGATGGTTCAGCC-3′ (SEQ ID NO: 3110)

βc-m614 Target: 5′-ATGTTTCAACATCTGTGATGGTTCAGC-3′ (SEQ ID NO: 3111)

βc-m624 Target: 5′-TGACAACTGCATGTTTCAACATCTGTG-3′ (SEQ ID NO: 3112)

βc-m626 Target: 5′-ATTGACAACTGCATGTTTCAACATCTG-3′ (SEQ ID NO: 3113)

βc-m630 Target: 5′-TCAAATTGACAACTGCATGTTTCAACA-3′ (SEQ ID NO: 3114)

βc-m636 Target: 5′-AGTTAATCAAATTGACAACTGCATGTT-3′ (SEQ ID NO: 3115)

βc-m642 Target: 5′-CCTGATAGTTAATCAAATTGACAACTG-3′ (SEQ ID NO: 3116)

βc-m648 Target: 5′-CGTCATCCTGATAGTTAATCAAATTGA-3′ (SEQ ID NO: 3117)

βc-m649 Target: 5′-GCGTCATCCTGATAGTTAATCAAATTG-3′ (SEQ ID NO: 3118)

βc-m702 Target: 5′-CCTCATCGTTTAGCAGTTTTGTCAGCT-3′ (SEQ ID NO: 3119)

βc-m707 Target: 5′-CTGGTCCTCATCGTTTAGCAGTTTTGT-3′ (SEQ ID NO: 3120)

βc-m734 Target: 5′-CATAACAGCAGCTTTATTAACTACCAC-3′ (SEQ ID NO: 3121)

βc-m735 Target: 5′-CCATAACAGCAGCTTTATTAACTACCA-3′ (SEQ ID NO: 3122)

βc-m738 Target: 5′-GGACCATAACAGCAGCTTTATTAACTA-3′ (SEQ ID NO: 3123)

βc-m739 Target: 5′-TGGACCATAACAGCAGCTTTATTAACT-3′ (SEQ ID NO: 3124)

βc-m843 Target: 5′-CTGTCTCTACATCATTTGTATTCTGCA-3′ (SEQ ID NO: 3125)

βc-m844 Target: 5′-GCTGTCTCTACATCATTTGTATTCTGC-3′ (SEQ ID NO: 3126)

βc-m1063 Target: 5′-GCAACCATTTTCTGCAGTCCACCAGCT-3′ (SEQ ID NO: 3127)

βc-m1065 Target: 5′-AAGCAACCATTTTCTGCAGTCCACCAG-3′ (SEQ ID NO: 3128)

βc-m1080 Target: 5′-TTGTTTTGTTGAGCAAAGCAACCATTT-3′ (SEQ ID NO: 3129)

βc-m1081 Target: 5′-TTTGTTTTGTTGAGCAAAGCAACCATT-3′ (SEQ ID NO: 3130)

βc-m1098 Target: 5′-TAGCCAAGAATTTCACGTTTGTTTTGT-3′ (SEQ ID NO: 3131)

βc-m1140 Target: 5′-CTTGATTGCCATAAGCTAAGATCTGAA-3′ (SEQ ID NO: 3132)

βc-m1145 Target: 5′-GCTCTCTTGATTGCCATAAGCTAAGAT-3′ (SEQ ID NO: 3133)

βc-m1217 Target: 5′-CTTCTCATAAGTGTAGGTCCTCATTAT-3′ (SEQ ID NO: 3134)

βc-m1218 Target: 5′-GCTTCTCATAAGTGTAGGTCCTCATTA-3′ (SEQ ID NO: 3135)

βc-m1220 Target: 5′-AAGCTTCTCATAAGTGTAGGTCCTC-3′ (SEQ ID NO: 3136)

βc-m1221 Target: 5′-GAAGCTTCTCATAAGTGTAGGTCCTCA-3′ (SEQ ID NO: 3137)

βc-m1365 Target: 5′-GAGTCCAAAGACAGTTTTGAACAAGTC-3′ (SEQ ID NO: 3138)

βc-m1366 Target: 5′-AGAGTCCAAAGACAGTTTTGAACAAGT-3′ (SEQ ID NO: 3139)

βc-m1461 Target: 5′-CCACATTTATATCATCGGAACCCAGAA-3′ (SEQ ID NO: 3140)

βc-m1464 Target: 5′-TGACCACATTTATATCATCGGAACCCA-3′ (SEQ ID NO: 3141)

βc-m1473 Target: 5′-CTGCACAGGTGACCACATTTATATC-3′ (SEQ ID NO: 3142)

βc-m1474 Target: 5′-GCTGCACAGGTGACCACATTTATATCA-3′ (SEQ ID NO: 3143)

βc-m1510 Target: 5′-TTGTAATTATTGCAAGTGAGGTTAGAG-3′ (SEQ ID NO: 3144)

βc-m1523 Target: 5′-CATCATCTTGTTTTTGTAATTATTGCA-3′ (SEQ ID NO: 3145)

βc-m1524 Target: 5′-CCATCATCTTGTTTTTGTAATTATTGC-3′ (SEQ ID NO: 3146)

βc-m1527 Target: 5′-ACACCATCATCTTGTTTTTGTAATTAT-3′ (SEQ ID NO: 3147)

βc-m1532 Target: 5′-TTGGCACACCATCATCTTGTTTTTGTA-3′ (SEQ ID NO: 3148)

βc-m1752 Target: 5′-TCAATCCAACAGTTGCCTTTATCAGAG-3′ (SEQ ID NO: 3149)

βc-m1757 Target: 5′-TCGAATCAATCCAACAGTTGCCTTTAT-3′ (SEQ ID NO: 3150)

βc-m1827 Target: 5′-GCTGAACTAGTCGTGGAATAGCACCCT-3′ (SEQ ID NO: 3151)

βc-m1934 Target: 5′-AGTACACCCTTCTACTATCTCCTCC-3′ (SEQ ID NO: 3152)

βc-m1935 Target: 5′-CAGTACACCCTTCTACTATCTCCTCCA-3′ (SEQ ID NO: 3153)

βc-m1936 Target: 5′-CCAGTACACCCTTCTACTATCTCCTCC-3′ (SEQ ID NO: 3154)

βc-m1941 Target: 5′-GAGCTCCAGTACACCCTTCTACTATCT-3′ (SEQ ID NO: 3155)

βc-m2009 Target: 5′-AAACAATGGAATGGTATTGAGTCCTCG-3′ (SEQ ID NO: 3156)

βc-m2015 Target: 5′-CTGCACAAACAATGGAATGGTATTGAG-3′ (SEQ ID NO: 3157)

βc-m2016 Target: 5′-ACTGCACAAACAATGGAATGGTATTGA-3′ (SEQ ID NO: 3158)

βc-m2021 Target: 5′-AAGCAACTGCACAAACAATGGAATGGT-3′ (SEQ ID NO: 3159)

βc-m2028 Target: 5′-GAGAATAAAGCAACTGCACAAACAATG-3′ (SEQ ID NO: 3160)

βc-m2037 Target: 5′-TTTCAATGGGAGAATAAAGCAACTGCA-3′ (SEQ ID NO: 3161)

βc-m2038 Target: 5′-TTTTCAATGGGAGAATAAAGCAACTGC-3′ (SEQ ID NO: 3162)

βc-m2039 Target: 5′-ATTTTCAATGGGAGAATAAAGCAACTG-3′ (SEQ ID NO: 3163)

βc-m2043 Target: 5′-GGATATTTTCAATGGGAGAATAAAGCA-3′ (SEQ ID NO: 3164)

βc-m2044 Target: 5′-TGGATATTTTCAATGGGAGAATAAAGC-3′ (SEQ ID NO: 3165)

βc-m2045 Target: 5′-TTGGATATTTTCAATGGGAGAATAAAG-3′ (SEQ ID NO: 3166)

βc-m2055 Target: 5′-CAGCTACTCTTTGGATATTTTCAATGG-3′ (SEQ ID NO: 3167)

βc-m2056 Target: 5′-GCAGCTACTCTTTGGATATTTTCAATG-3′ (SEQ ID NO: 3168)

βc-m2231 Target: 5′-CCGCTTCTTGTAATCCTGTGGCTTGTC-3′ (SEQ ID NO: 3169)

βc-m2307 Target: 5′-CCAGTCCAAGATCTGCAGTCTCATTCC-3′ (SEQ ID NO: 3170)

βc-m2385 Target: 5′-CGTATCCACCAGAGTGAAAAGAACGGT-3′ (SEQ ID NO: 3171)

βc-m2539 Target: 5′-CAGGCCAGCTGATTGCTATCACCTGGG-3′ (SEQ ID NO: 3172)

βc-m2562 Target: 5′-CGATTTACAGGTCAGTATCAAACCAGG-3′ (SEQ ID NO: 3173)

βc-m2563 Target: 5′-ACGATTTACAGGTCAGTATCAAACCAG-3′ (SEQ ID NO: 3174)

βc-m2578 Target: 5′-TTTCTTACCTAAAGGACGATTTACAGG-3′ (SEQ ID NO: 3175)

βc-m2580 Target: 5′-GCTTTCTTACCTAAAGGACGATTTACA-3′ (SEQ ID NO: 3176)

βc-m2589 Target: 5′-CTTTTATAAGCTTTCTTACCTAAAGGA-3′ (SEQ ID NO: 3177)

βc-m2590 Target: 5′-GCTTTTATAAGCTTTCTTACCTAAAGG-3′ (SEQ ID NO: 3178)

βc-m2593 Target: 5′-CTGGCTTTTATAAGCTTTCTTACCTAA-3′ (SEQ ID NO: 3179)

βc-m2598 Target: 5′-CCACACTGGCTTTTATAAGCTTTCTTA-3′ (SEQ ID NO: 3180)

βc-m2604 Target: 5′-ATTCACCCACACTGGCTTTTATAAGCT-3′ (SEQ ID NO: 3181)

βc-m2644 Target: 5′-CCTACCAAGTCTTTCTGGAGTTCTGCA-3′ (SEQ ID NO: 3182)

βc-m2674 Target: 5′-ATTTACAAACAGGCCTAAAACCATTCC-3′ (SEQ ID NO: 3183)

βc-m2675 Target: 5′-GATTTACAAACAGGCCTAAAACCATTC-3′ (SEQ ID NO: 3184)

βc-m2676 Target: 5′-AGATTTACAAACAGGCCTAAAACCATT-3′ (SEQ ID NO: 3185)

  βc-m2710 Target: 5′-CATCTCCTTCCAAGGTATGTATCTGTT-3′ (SEQ ID NO: 3186)

βc-m2711 Target: 5′-ACATCTCCTTCCAAGGTATGTATCTGT-3′ (SEQ ID NO: 3187)

βc-m2725 Target: 5′-ACTTCCACACATGAACATCTCCTTCCA-3′ (SEQ ID NO: 3188)

βc-m2728 Target: 5′-GAAACTTCCACACATGAACATCTCCTT-3′ (SEQ ID NO: 3189)

βc-m2729 Target: 5′-AGAAACTTCCACACATGAACATCTCCT-3′ (SEQ ID NO: 3190)

βc-m2730 Target: 5′-GAGAAACTTCCACACATGAACATCTCC-3′ (SEQ ID NO: 3191)

βc-m2731 Target: 5′-TGAGAAACTTCCACACATGAACATCTC-3′ (SEQ ID NO: 3192)

βc-m2739 Target: 5′-CATCAACGTGAGAAACTTCCACACATG-3′ (SEQ ID NO: 3193)

βc-m2742 Target: 5′-AAACATCAACGTGAGAAACTTCCACAC-3′ (SEQ ID NO: 3194)

βc-m2743 Target: 5′-AAAACATCAACGTGAGAAACTTCCACA-3′ (SEQ ID NO: 3195)

βc-m2744 Target: 5′-AAAAACATCAACGTGAGAAACTTCCAC-3′ (SEQ ID NO: 3196)

βc-m2745 Target: 5′-CAAAAACATCAACGTGAGAAACTTCCA-3′ (SEQ ID NO: 3197)

βc-m2746 Target: 5′-GCAAAAACATCAACGTGAGAAACTTCC-3′ (SEQ ID NO: 3198)

βc-m2748 Target: 5′-TGGCAAAAACATCAACGTGAGAAACTT-3′ (SEQ ID NO: 3199)

βc-m2760 Target: 5′-CTGCAAAAGCTGTGGCAAAAACATCAA-3′ (SEQ ID NO: 3200)

βc-m2761 Target: 5′-GCTGCAAAAGCTGTGGCAAAAACATCA-3′ (SEQ ID NO: 3201)

βc-m2778 Target: 5′-ACTCATCTGAGTATAACGCTGCAAAAG-3′ (SEQ ID NO: 3202)

βc-m2795 Target: 5′-TGAAAACAGCAAATGTTACTCATCTGA-3′ (SEQ ID NO: 3203)

βc-m2796 Target: 5′-TTGAAAACAGCAAATGTTACTCATCTG-3′ (SEQ ID NO: 3204)

βc-m2797 Target: 5′-GTTGAAAACAGCAAATGTTACTCATCT-3′ (SEQ ID NO: 3205)

βc-m2805 Target: 5′-CTATTAATGTTGAAAACAGCAAATGTT-3′ (SEQ ID NO: 3206)

βc-m2834 Target: 5′-ACACTACAGCTGTATAGAGAGAAAGGC-3′ (SEQ ID NO: 3207)

βc-m2859 Target: 5′-CAGGCCAATCACAATGCACGTTCAGAC-3′ (SEQ ID NO: 3208)

βc-m2946 Target: 5′-CTGTTCCCATAGGAAACTCAGCTTGGT-3′ (SEQ ID NO: 3209)

βc-m2968 Target: 5′-CAGAACAAAAAGCGTACTTCGACTGTT-3′ (SEQ ID NO: 3210)

βc-m2974 Target: 5′-AAGGACCAGAACAAAAAGCGTACTTCG-3′ (SEQ ID NO: 3211)

βc-m2982 Target: 5′-CGACCAAAAAGGACCAGAACAAAAAGC-3′ (SEQ ID NO: 3212)

βc-m2983 Target: 5′-TCGACCAAAAAGGACCAGAACAAAAAG-3′ (SEQ ID NO: 3213)

βc-m2990 Target: 5′-TTACTCCTCGACCAAAAAGGACCAGAA-3′ (SEQ ID NO: 3214)

βc-m3005 Target: 5′-AATCCATTTGTATTGTTACTCCTCGAC-3′ (SEQ ID NO: 3215)

βc-m3006 Target: 5′-AAATCCATTTGTATTGTTACTCCTCGA-3′ (SEQ ID NO: 3216)

βc-m3007 Target: 5′-CAAATCCATTTGTATTGTTACTCCTCG-3′ (SEQ ID NO: 3217)

βc-m3008 Target: 5′-CCAAATCCATTTGTATTGTTACTCCTC-3′ (SEQ ID NO: 3218)

βc-m3015 Target: 5′-TCACTCCCCAAATCCATTTGTATTGTT-3′ (SEQ ID NO: 3219)

βc-m3047 Target: 5′-GATCCATTCGTGTGCATTCTTCACTGC-3′ (SEQ ID NO: 3220)

βc-m3048 Target: 5′-TGATCCATTCGTGTGCATTCTTCACTG-3′ (SEQ ID NO: 3221)

βc-m3049 Target: 5′-GTGATCCATTCGTGTGCATTCTTCACT-3′ (SEQ ID NO: 3222)

βc-m3093 Target: 5′-TAAAACAAAGAACAAGCAAGGCTAGGG-3′ (SEQ ID NO: 3223)

βc-m3109 Target: 5′-GCACCACTACAGATATTAAAACAAAGA-3′ (SEQ ID NO: 3224)

βc-m3111 Target: 5′-CAGCACCACTACAGATATTAAAACAAA-3′ (SEQ ID NO: 3225)

βc-m3112 Target: 5′-TCAGCACCACTACAGATATTAAAACAA-3′ (SEQ ID NO: 3226)

βc-m3133 Target: 5′-AAAAAATAAAAGCAAGCAAAGTCAGCA-3′ (SEQ ID NO: 3227)

βc-m3137 Target: 5′-CTGCAAAAAATAAAAGCAAGCAAAGTC-3′ (SEQ ID NO: 3228)

βc-m3142 Target: 5′-AGTTACTGCAAAAAATAAAAGCAAGCA-3′ (SEQ ID NO: 3229)

βc-m3148 Target: 5′-ACTAACAGTTACTGCAAAAAATAAAAG-3′ (SEQ ID NO: 3230)

βc-m3150 Target: 5′-AAACTAACAGTTACTGCAAAAAATAAA-3′ (SEQ ID NO: 3231)

βc-m3152 Target: 5′-AAAAACTAACAGTTACTGCAAAAAATA-3′ (SEQ ID NO: 3232)

βc-m3153 Target: 5′-TAAAAACTAACAGTTACTGCAAAAAAT-3′ (SEQ ID NO: 3233)

βc-m3155 Target: 5′-CTTAAAAACTAACAGTTACTGCAAAAA-3′ (SEQ ID NO: 3234)

βc-m3159 Target: 5′-ACTACTTAAAAACTAACAGTTACTGCA-3′ (SEQ ID NO: 3235)

βc-m3161 Target: 5′-ACACTACTTAAAAACTAACAGTTACTG-3′ (SEQ ID NO: 3236)

βc-m3165 Target: 5′-CATAACACTACTTAAAAACTAACAGTT-3′ (SEQ ID NO: 3237)

βc-m3166 Target: 5′-ACATAACACTACTTAAAAACTAACAGT-3′ (SEQ ID NO: 3238)

βc-m3168 Target: 5′-GAACATAACACTACTTAAAAACTAACA-3′ (SEQ ID NO: 3239)

βc-m3169 Target: 5′-AGAACATAACACTACTTAAAAACTAAC-3′ (SEQ ID NO: 3240)

βc-m3170 Target: 5′-TAGAACATAACACTACTTAAAAACTAA-3′ (SEQ ID NO: 3241)

βc-m3171 Target: 5′-CTAGAACATAACACTACTTAAAAACTA-3′ (SEQ ID NO: 3242)

βc-m3176 Target: 5′-GTTCACTAGAACATAACACTACTTAAA-3′ (SEQ ID NO: 3243)

βc-m3178 Target: 5′-AGGTTCACTAGAACATAACACTACTTA-3′ (SEQ ID NO: 3244)

βc-m3179 Target: 5′-CAGGTTCACTAGAACATAACACTACTT-3′ (SEQ ID NO: 3245)

βc-m3216 Target: 5′-CCATTACTCGGTTCTTAGAAATCAGAA-3′ (SEQ ID NO: 3246)

βc-m3219 Target: 5′-ACACCATTACTCGGTTCTTAGAAATCA-3′ (SEQ ID NO: 3247)

βc-m3224 Target: 5′-GTTCTACACCATTACTCGGTTCTTAGA-3′ (SEQ ID NO: 3248)

βc-m3234 Target: 5′-ATGAATTAGTGTTCTACACCATTACTC-3′ (SEQ ID NO: 3249)

βc-m3239 Target: 5′-TGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 3250)

βc-m3240 Target: 5′-GTGATTATGAATTAGTGTTCTACACCA-3′ (SEQ ID NO: 3251)

βc-m3241 Target: 5′-CGTGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 3252)

βc-m3251 Target: 5′-TTACAATTAGCGTGATTATGAATTAGT-3′ (SEQ ID NO: 3253)

βc-m3252 Target: 5′-ATTACAATTAGCGTGATTATGAATTAG-3′ (SEQ ID NO: 3254)

βc-m3256 Target: 5′-CCAGATTACAATTAGCGTGATTATGAA-3′ (SEQ ID NO: 3255)

βc-m3267 Target: 5′-GTTACACGTCTCCAGATTACAATTAGC-3′ (SEQ ID NO: 3256)

βc-m3269 Target: 5′-ATGTTACACGTCTCCAGATTACAATTA-3′ (SEQ ID NO: 3257)

βc-m3277 Target: 5′-GCTACACAATGTTACACGTCTCCAGAT-3′ (SEQ ID NO: 3258)

βc-m3279 Target: 5′-AGGCTACACAATGTTACACGTCTCCAG-3′ (SEQ ID NO: 3259)

βc-m3286 Target: 5′-ATACAAAAGGCTACACAATGTTACACG-3′ (SEQ ID NO: 3260)

βc-m3287 Target: 5′-TATACAAAAGGCTACACAATGTTACAC-3′ (SEQ ID NO: 3261)

βc-m3291 Target: 5′-TATTTATACAAAAGGCTACACAATGTT-3′ (SEQ ID NO: 3262)

βc-m3292 Target: 5′-CTATTTATACAAAAGGCTACACAATGT-3′ (SEQ ID NO: 3263)

βc-m3295 Target: 5′-TGTCTATTTATACAAAAGGCTACACAA-3′ (SEQ ID NO: 3264)

βc-m3296 Target: 5′-CTGTCTATTTATACAAAAGGCTACACA-3′ (SEQ ID NO: 3265)

βc-m3297 Target: 5′-TCTGTCTATTTATACAAAAGGCTACAC-3′ (SEQ ID NO: 3266)

βc-m3303 Target: 5′-TTTCTATCTGTCTATTTATACAAAAGG-3′ (SEQ ID NO: 3267)

βc-m3304 Target: 5′-ATTTCTATCTGTCTATTTATACAAAAG-3′ (SEQ ID NO: 3268)

βc-m3305 Target: 5′-CATTTCTATCTGTCTATTTATACAAAA-3′ (SEQ ID NO: 3269)

βc-m3306 Target: 5′-CCATTTCTATCTGTCTATTTATACAAA-3′ (SEQ ID NO: 3270)

βc-m3310 Target: 5′-CGGACCATTTCTATCTGTCTATTTATA-3′ (SEQ ID NO: 3271)

βc-m3311 Target: 5′-TCGGACCATTTCTATCTGTCTATTTAT-3′ (SEQ ID NO: 3272)

βc-m3318 Target: 5′-AAACTAATCGGACCATTTCTATCTGTC-3′ (SEQ ID NO: 3273)

βc-m3319 Target: 5′-GAAACTAATCGGACCATTTCTATCTGT-3′ (SEQ ID NO: 3274)

βc-m3320 Target: 5′-GGAAACTAATCGGACCATTTCTATCTG-3′ (SEQ ID NO: 3275)

βc-m3321 Target: 5′-AGGAAACTAATCGGACCATTTCTATCT-3′ (SEQ ID NO: 3276)

βc-m3328 Target: 5′-ATTAAAAAGGAAACTAATCGGACCATT-3′ (SEQ ID NO: 3277)

βc-m3334 Target: 5′-AAGCATATTAAAAAGGAAACTAATCGG-3′ (SEQ ID NO: 3278)

βc-m3335 Target: 5′-TAAGCATATTAAAAAGGAAACTAATCG-3′ (SEQ ID NO: 3279)

βc-m3339 Target: 5′-ATTTTAAGCATATTAAAAAGGAAACTA-3′ (SEQ ID NO: 3280)

βc-m3345 Target: 5′-CTGCTTATTTTAAGCATATTAAAAAGG-3′ (SEQ ID NO: 3281)

βc-m3346 Target: 5′-CCTGCTTATTTTAAGCATATTAAAAAG-3′ (SEQ ID NO: 3282)

βc-m3352 Target: 5′-GATCCACCTGCTTATTTTAAGCATATT-3′ (SEQ ID NO: 3283)

βc-m3367 Target: 5′-CAAAAACATGAAATAGATCCACCTGCT-3′ (SEQ ID NO: 3284)

βc-m3368 Target: 5′-TCAAAAACATGAAATAGATCCACCTGC-3′ (SEQ ID NO: 3285)

βc-m3370 Target: 5′-GTTCAAAAACATGAAATAGATCCACCT-3′ (SEQ ID NO: 3286)

βc-m3371 Target: 5′-TGTTCAAAAACATGAAATAGATCCACC-3′ (SEQ ID NO: 3287)

βc-m3372 Target: 5′-TTGTTCAAAAACATGAAATAGATCCAC-3′ (SEQ ID NO: 3288)

βc-m3377 Target: 5′-AGTTTTTGTTCAAAAACATGAAATAGA-3′ (SEQ ID NO: 3289)

βc-m3383 Target: 5′-CGATAAAGTTTTTGTTCAAAAACATGA-3′ (SEQ ID NO: 3290)

βc-m3389 Target: 5′-TATCCCCGATAAAGTTTTTGTTCAAAA-3′ (SEQ ID NO: 3291)

βc-m3390 Target: 5′-GTATCCCCGATAAAGTTTTTGTTCAAA-3′ (SEQ ID NO: 3292)

βc-m3419 Target: 5′-ACACCTCTTACTGATTTACCCTACCGC-3′ (SEQ ID NO: 3293)

βc-m3421 Target: 5′-TAACACCTCTTACTGATTTACCCTACC-3′ (SEQ ID NO: 3294)

βc-m3422 Target: 5′-ATAACACCTCTTACTGATTTACCCTAC-3′ (SEQ ID NO: 3295)

βc-m3423 Target: 5′-AATAACACCTCTTACTGATTTACCCTA-3′ (SEQ ID NO: 3296)

βc-m3424 Target: 5′-AAATAACACCTCTTACTGATTTACCCT-3′ (SEQ ID NO: 3297)

βc-m3425 Target: 5′-CAAATAACACCTCTTACTGATTTACCC-3′ (SEQ ID NO: 3298)

βc-m3431 Target: 5′-AAGGCTCAAATAACACCTCTTACTGAT-3′ (SEQ ID NO: 3299)

βc-m3436 Target: 5′-AAAACAAGGCTCAAATAACACCTCTTA-3′ (SEQ ID NO: 3300)

βc-m3437 Target: 5′-CAAAACAAGGCTCAAATAACACCTCTT-3′ (SEQ ID NO: 3301)

βc-m3438 Target: 5′-CCAAAACAAGGCTCAAATAACACCTCT-3′ (SEQ ID NO: 3302)

βc-m3441 Target: 5′-TGTCCAAAACAAGGCTCAAATAACACC-3′ (SEQ ID NO: 3303)

βc-m3443 Target: 5′-ACTGTCCAAAACAAGGCTCAAATAACA-3′ (SEQ ID NO: 3304)

βc-m3448 Target: 5′-GGTATACTGTCCAAAACAAGGCTCAAA-3′ (SEQ ID NO: 3305)

βc-m3456 Target: 5′-AGGCAACTGGTATACTGTCCAAAACAA-3′ (SEQ ID NO: 3306)

βc-m3464 Target: 5′-GGGATAAAAGGCAACTGGTATACTGTC-3′ (SEQ ID NO: 3307)

βc-m3465 Target: 5′-TGGGATAAAAGGCAACTGGTATACTGT-3′ (SEQ ID NO: 3308)

βc-m3472 Target: 5′-ACAACTTTGGGATAAAAGGCAACTGGT-3′ (SEQ ID NO: 3309)

βc-m3474 Target: 5′-CAACAACTTTGGGATAAAAGGCAACTG-3′ (SEQ ID NO: 3310)

βc-m3479 Target: 5′-GGTTACAACAACTTTGGGATAAAAGGC-3′ (SEQ ID NO: 3311)

βc-m3480 Target: 5′-AGGTTACAACAACTTTGGGATAAAAGG-3′ (SEQ ID NO: 3312)

βc-m3481 Target: 5′-CAGGTTACAACAACTTTGGGATAAAAG-3′ (SEQ ID NO: 3313)

βc-m3489 Target: 5′-TATCACAGCAGGTTACAACAACTTTGG-3′ (SEQ ID NO: 3314)

βc-m3490 Target: 5′-GTATCACAGCAGGTTACAACAACTTTG-3′ (SEQ ID NO: 3315)

βc-m3492 Target: 5′-TTGTATCACAGCAGGTTACAACAACTT-3′ (SEQ ID NO: 3316)

βc-m3509 Target: 5′-CCGCATCTGTTGAAGCATTGTATCACA-3′ (SEQ ID NO: 3317)

βc-m3527 Target: 5′-TCTGAACCATTTCTATAACCGCATCTG-3′ (SEQ ID NO: 3318)

βc-m3531 Target: 5′-TAATTCTGAACCATTTCTATAACCGCA-3′ (SEQ ID NO: 3319)

βc-m3533 Target: 5′-TTTAATTCTGAACCATTTCTATAACCG-3′ (SEQ ID NO: 3320)

βc-m3534 Target: 5′-GTTTAATTCTGAACCATTTCTATAACC-3′ (SEQ ID NO: 3321)

βc-m3535 Target: 5′-AGTTTAATTCTGAACCATTTCTATAAC-3′ (SEQ ID NO: 3322)

βc-m3536 Target: 5′-AAGTTTAATTCTGAACCATTTCTATAA-3′ (SEQ ID NO: 3323)

βc-m3541 Target: 5′-ATTAAAAGTTTAATTCTGAACCATTTC-3′ (SEQ ID NO: 3324)

βc-m3542 Target: 5′-AATTAAAAGTTTAATTCTGAACCATTT-3′ (SEQ ID NO: 3325)

βc-m3544 Target: 5′-TGAATTAAAAGTTTAATTCTGAACC-3′ (SEQ ID NO: 3326)

βc-m3550 Target: 5′-TTTGAATGAATTAAAAGTTTAATTCTG-3′ (SEQ ID NO: 3327)

βc-m3554 Target: 5′-TTTTTTTGAATGAATTAAAAGTTTAAT-3′ (SEQ ID NO: 3328)

βc-m3558 Target: 5′-TTTTTTTTTTTGAATGAATTAAAAGTT-3′ (SEQ ID NO: 3329)

βc-m3559 Target: 5′-TTTTTTTTTTTTGAATGAATTAAAAGT-3′ (SEQ ID NO: 3330)

βc-m3560 Target: 5′-TTTTTTTTTTTTTGAATGAATTAAAAG-3′ (SEQ ID NO: 3331)

βc-m3561 Target: 5′-TTTTTTTTTTTTTTGAATGAATTAAAA-3′ (SEQ ID NO: 3332)

βc-m3562 Target: 5′-TTTTTTTTTTTTTTTGAATGAATTAAA-3′ (SEQ ID NO: 3333)

βc-m3563 Target: 5′-TTTTTTTTTTTTTTTTGAATGAATTAA-3′ (SEQ ID NO: 3334)

TABLE 13 Additional Selected Anti-β-catenin DsiRNAs, Blunt, UnfrayedDuplexes 5′-GUUGUAUGGUAUACUUCAAAUACCCUC-3′ (SEQ ID NO: 7150)3′-CAACAUACCAUAUGAAGUUUAUGGGAG-5′ (SEQ ID NO: 1605) βc-244 Target:5′-GTTGTATGGTATACTTCAAATACCCTC-3′ (SEQ ID NO: 2714)5′-CAAAACAGUUGUAUGGUAUACUUCAAA-3′ (SEQ ID NO: 7151)3′-GUUUUGUCAACAUACCAUAUGAAGUUU-5′ (SEQ ID NO: 1606) βc-251 Target:5′-CAAAACAGTTGTATGGTATACTTCAAA-3′ (SEQ ID NO: 2715)5′-UCAAAACAGUUGUAUGGUAUACUUCAA-3′ (SEQ ID NO: 7152)3′-AGUUUUGUCAACAUACCAUAUGAAGUU-5′ (SEQ ID NO: 1607) βc-252 Target:5′-TCAAAACAGTTGTATGGTATACTTCAA-3′ (SEQ ID NO: 2716)5′-UUUCAAAACAGUUGUAUGGUAUACUUC-3′ (SEQ ID NO: 7153)3′-AAAGUUUUGUCAACAUACCAUAUGAAG-5′ (SEQ ID NO: 1608) βc-254 Target:5′-TTTCAAAACAGTTGTATGGTATACTTC-3′ (SEQ ID NO: 2717)5′-UUUUCAAAACAGUUGUAUGGUAUACUU-3′ (SEQ ID NO: 7154)3′-AAAAGUUUUGUCAACAUACCAUAUGAA-5′ (SEQ ID NO: 1609) βc-255 Target:5′-TTTTCAAAACAGTTGTATGGTATACTT-3′ (SEQ ID NO: 2718)5′-AUUUUCAAAACAGUUGUAUGGUAUACU-3′ (SEQ ID NO: 7155)3′-UAAAAGUUUUGUCAACAUACCAUAUGA-5′ (SEQ ID NO: 1610) βc-256 Target:5′-ATTTTCAAAACAGTTGTATGGTATACT-3′ (SEQ ID NO: 2719)5′-UUGUCCACGCUGGAUUUUCAAAACAGU-3′ (SEQ ID NO: 7156)3′-AACAGGUGCGACCUAAAAGUUUUGUCA-5′ (SEQ ID NO: 1611) βc-269 Target:5′-TTGTCCACGCTGGATTTTCAAAACAGT-3′ (SEQ ID NO: 2720)5′-AUUGUCCACGCUGGAUUUUCAAAACAG-3′ (SEQ ID NO: 7157)3′-UAACAGGUGCGACCUAAAAGUUUUGUC-5′ (SEQ ID NO: 1612) βc-270 Target:5′-ATTGTCCACGCTGGATTTTCAAAACAG-3′ (SEQ ID NO: 2721)5′-CCAUCAAAUCAGCUUGAGUAGCCAUUG-3′ (SEQ ID NO: 7158)3′-GGUAGUUUAGUCGAACUCAUCGGUAAC-5′ (SEQ ID NO: 1613) βc-293 Target:5′-CCATCAAATCAGCTTGAGTAGCCATTG-3′ (SEQ ID NO: 2722)5′-UGUCCAACUCCAUCAAAUCAGCUUGAG-3′ (SEQ ID NO: 7159)3′-ACAGGUUGAGGUAGUUUAGUCGAACUC-5′ (SEQ ID NO: 1614) βc-302 Target:5′-TGTCCAACTCCATCAAATCAGCTTGAG-3′ (SEQ ID NO: 2723)5′-CUUCCUCAGGAUUGCCUUUACCACUCA-3′ (SEQ ID NO: 7160)3′-GAAGGAGUCCUAACGGAAAUGGUGAGU-5′ (SEQ ID NO: 1615) βc-431 Target:5′-CTTCCTCAGGATTGCCTTTACCACTCA-3′ (SEQ ID NO: 2724)5′-UCUUCCUCAGGAUUGCCUUUACCACUC-3′ (SEQ ID NO: 7161)3′-AGAAGGAGUCCUAACGGAAAUGGUGAG-5′ (SEQ ID NO: 1616) βc-432 Target:5′-TCTTCCTCAGGATTGCCTTTACCACTC-3′ (SEQ ID NO: 2725)5′-CAUCAAUAUCAGCUACUUGUUCUUGAG-3′ (SEQ ID NO: 7162)3′-GUAGUUAUAGUCGAUGAACAAGAACUC-5′ (SEQ ID NO: 1617) βc-518 Target:5′-CATCAATATCAGCTACTTGTTCTTGAG-3′ (SEQ ID NO: 2726)5′-CCAUCAAUAUCAGCUACUUGUUCUUGA-3′ (SEQ ID NO: 7163)3′-GGUAGUUAUAGUCGAUGAACAAGAACU-5′ (SEQ ID NO: 1618) βc-519 Target:5′-CCATCAATATCAGCTACTTGTTCTTGA-3′ (SEQ ID NO: 2727)5′-ACUGUCCAUCAAUAUCAGCUACUUGUU-3′ (SEQ ID NO: 7164)3′-UGACAGGUAGUUAUAGUCGAUGAACAA-5′ (SEQ ID NO: 1619) βc-524 Target:5′-ACTGTCCATCAATATCAGCTACTTGTT-3′ (SEQ ID NO: 2728)5′-AUUGCAUACUGUCCAUCAAUAUCAGCU-3′ (SEQ ID NO: 7165)3′-UAACGUAUGACAGGUAGUUAUAGUCGA-5′ (SEQ ID NO: 1620) βc-531 Target:5′-ATTGCATACTGTCCATCAATATCAGCT-3′ (SEQ ID NO: 2729)5′-CGAGUCAUUGCAUACUGUCCAUCAAUA-3′ (SEQ ID NO: 7166)3′-GCUCAGUAACGUAUGACAGGUAGUUAU-5′ (SEQ ID NO: 1621) βc-537 Target:5′-CGAGTCATTGCATACTGTCCATCAATA-3′ (SEQ ID NO: 2730)5′-CCUCAUCUAAUGUCUCAGGGAACAUAG-3′ (SEQ ID NO: 7167)3′-GGAGUAGAUUACAGAGUCCCUUGUAUC-5′ (SEQ ID NO: 1622) βc-584 Target:5′-CCTCATCTAATGTCTCAGGGAACATAG-3′ (SEQ ID NO: 2731)5′-UUACAACUGCAUGUUUCAGCAUCUGUG-3′ (SEQ ID NO: 7168)3′-AAUGUUGACGUACAAAGUCGUAGACAC-5′ (SEQ ID NO: 1623) βc-680 Target:5′-TTACAACTGCATGTTTCAGCATCTGTG-3′ (SEQ ID NO: 2732)5′-GUUUACAACUGCAUGUUUCAGCAUCUG-3′ (SEQ ID NO: 7169)3′-CAAAUGUUGACGUACAAAGUCGUAGAC-5′ (SEQ ID NO: 1624) βc-682 Target:5′-GTTTACAACTGCATGTTTCAGCATCTG-3′ (SEQ ID NO: 2733)5′-AGUUAAUCAAGUUUACAACUGCAUGUU-3′ (SEQ ID NO: 7170)3′-UCAAUUAGUUCAAAUGUUGACGUACAA-5′ (SEQ ID NO: 1625) βc-692 Target:5′-AGTTAATCAAGTTTACAACTGCATGTT-3′ (SEQ ID NO: 2734)5′-CUUGAUAGUUAAUCAAGUUUACAACUG-3′ (SEQ ID NO: 7171)3′-GAACUAUCAAUUAGUUCAAAUGUUGAC-5′ (SEQ ID NO: 1626) βc-698 Target:5′-CTTGATAGTTAATCAAGTTTACAACTG-3′ (SEQ ID NO: 2735)5′-CUGCAUCAUCUUGAUAGUUAAUCAAGU-3′ (SEQ ID NO: 7172)3′-GACGUAGUAGAACUAUCAAUUAGUUCA-5′ (SEQ ID NO: 1627) βc-707 Target:5′-CTGCATCATCTTGATAGTTAATCAAGT-3′ (SEQ ID NO: 2736)5′-UCUGCAUCAUCUUGAUAGUUAAUCAAG-3′ (SEQ ID NO: 7173)3′-AGACGUAGUAGAACUAUCAAUUAGUUC-5′ (SEQ ID NO: 1628) βc-708 Target:5′-TCTGCATCATCTTGATAGTTAATCAAG-3′ (SEQ ID NO: 2737)5′-CUGGUCCUCGUCAUUUAGCAGUUUUGU-3′ (SEQ ID NO: 7174)3′-GACCAGGAGCAGUAAAUCGUCAAAACA-5′ (SEQ ID NO: 1629) βc-763 Target:5′-CTGGTCCTCGTCATTTAGCAGTTTTGT-3′ (SEQ ID NO: 2738)5′-CAUAACUGCAGCCUUAUUAACCACCAC-3′ (SEQ ID NO: 7175)3′-GUAUUGACGUCGGAAUAAUUGGUGGUG-5′ (SEQ ID NO: 1630) βc-790 Target:5′-CATAACTGCAGCCTTATTAACCACCAC-3′ (SEQ ID NO: 2739)5′-CCAUAACUGCAGCCUUAUUAACCACCA-3′ (SEQ ID NO: 7176)3′-GGUAUUGACGUCGGAAUAAUUGGUGGU-5′ (SEQ ID NO: 1631) βc-791 Target:5′-CCATAACTGCAGCCTTATTAACCACCA-3′ (SEQ ID NO: 2740)5′-GGACCAUAACUGCAGCCUUAUUAACCA-3′ (SEQ ID NO: 7177)3′-CCUGGUAUUGACGUCGGAAUAAUUGGU-5′ (SEQ ID NO: 1632) βc-794 Target:5′-GGACCATAACTGCAGCCTTATTAACCA-3′ (SEQ ID NO: 2741)5′-CCUUUUUAGAAAGCUGAUGGACCAUAA-3′ (SEQ ID NO: 7178)3′-GGAAAAAUCUUUCGACUACCUGGUAUU-5′ (SEQ ID NO: 1633) βc-812 Target:5′-CCTTTTTAGAAAGCTGATGGACCATAA-3′ (SEQ ID NO: 2742)5′-AUGGUACGUACAAUAGCAGACACCAUC-3′ (SEQ ID NO: 7179)3′-UACCAUGCAUGUUAUCGUCUGUGGUAG-5′ (SEQ ID NO: 1634) βc-873 Target:5′-ATGGTACGTACAATAGCAGACACCATC-3′ (SEQ ID NO: 2743)5′-CAUCAUUUGUAUUCUGCAUGGUACGUA-3′ (SEQ ID NO: 7180)3′-GUAGUAAACAUAAGACGUACCAUGCAU-5′ (SEQ ID NO: 1635) βc-890 Target:5′-CATCATTTGTATTCTGCATGGTACGTA-3′ (SEQ ID NO: 2744)5′-CUGUUUCUACAUCAUUUGUAUUCUGCA-3′ (SEQ ID NO: 7181)3′-GACAAAGAUGUAGUAAACAUAAGACGU-5′ (SEQ ID NO: 1636) βc-899 Target:5′-CTGTTTCTACATCATTTGTATTCTGCA-3′ (SEQ ID NO: 2745)5′-GCUGUUUCUACAUCAUUUGUAUUCUGC-3′ (SEQ ID NO: 7182)3′-CGACAAAGAUGUAGUAAACAUAAGACG-5′ (SEQ ID NO: 1637) βc-900 Target:5′-GCTGTTTCTACATCATTTGTATTCTGC-3′ (SEQ ID NO: 2746)5′-GUACAACGAGCUGUUUCUACAUCAUUU-3′ (SEQ ID NO: 7183)3′-CAUGUUGCUCGACAAAGAUGUAGUAAA-5′ (SEQ ID NO: 1638) βc-909 Target:5′-GTACAACGAGCTGTTTCTACATCATTT-3′ (SEQ ID NO: 2747)5′-CGGUACAACGAGCUGUUUCUACAUCAU-3′ (SEQ ID NO: 7184)3′-GCCAUGUUGCUCGACAAAGAUGUAGUA-5′ (SEQ ID NO: 1639) βc-911 Target:5′-CGGTACAACGAGCTGTTTCTACATC-3′ (SEQ ID NO: 2748)5′-GCGGUACAACGAGCUGUUUCUACAUCA-3′ (SEQ ID NO: 7185)3′-CGCCAUGUUGCUCGACAAAGAUGUAGU-5′ (SEQ ID NO: 1640) βc-912 Target:5′-GCGGTACAACGAGCTGTTTCTACATCA-3′ (SEQ ID NO: 2749)5′-GCAUAAAACAACACAGAAUCCACUGGU-3′ (SEQ ID NO: 7186)3′-CGUAUUUUGUUGUGUCUUAGGUGACCA-5′ (SEQ ID NO: 1641) βc-1032 Target:5′-GCATAAAACAACACAGAATCCACTGGT-3′ (SEQ ID NO: 2750)5′-UGGCAUAAAACAACACAGAAUCCACUG-3′ (SEQ ID NO: 7187)3′-ACCGUAUUUUGUUGUGUCUUAGGUGAC-5′ (SEQ ID NO: 1642) βc-1034 Target:5′-TGGCATAAAACAACACAGAATCCACTG-3′ (SEQ ID NO: 2751)5′-AUGGCAUAAAACAACACAGAAUCCACU-3′ (SEQ ID NO: 7188)3′-UACCGUAUUUUGUUGUGUCUUAGGUGA-5′ (SEQ ID NO: 1643) βc-1035 Target:5′-ATGGCATAAAACAACACAGAATCCACT-3′ (SEQ ID NO: 2752)5′-UAGCUCCUUCUUGAUGUAAUAAAAGGU-3′ (SEQ ID NO: 7189)3′-AUCGAGGAAGAACUACAUUAUUUUCCA-5′ (SEQ ID NO: 1644) βc-1076 Target:5′-TAGCTCCTTCTTGATGTAATAAAAGGT-3′ (SEQ ID NO: 2753)5′-UUAGCUCCUUCUUGAUGUAAUAAAAGG-3′ (SEQ ID NO: 7190)3′-AAUCGAGGAAGAACUACAUUAUUUUCC-5′ (SEQ ID NO: 1645) βc-1077 Target:5′-TTAGCTCCTTCTTGATGTAATAAAAGG-3′ (SEQ ID NO: 2754)5′-UUUAACAUUUGUUUUGUUGAGCAAGGC-3′ (SEQ ID NO: 7191)3′-AAAUUGUAAACAAAACAACUCGUUCCG-5′ (SEQ ID NO: 1646) βc-1144 Target:5′-TTTAACATTTGTTTTGTTGAGCAAGGC-3′ (SEQ ID NO: 2755)5′-UAGCCAAGAAUUUAACAUUUGUUUUGU-3′ (SEQ ID NO: 7192)3′-AUCGGUUCUUAAAUUGUAAACAAAACA-5′ (SEQ ID NO: 1647) βc-1154 Target:5′-TAGCCAAGAATTTAACATTTGTTTTGT-3′ (SEQ ID NO: 2756)5′-CGUAAUAGCCAAGAAUUUAACAUUUGU-3′ (SEQ ID NO: 7193)3′-GCAUUAUCGGUUCUUAAAUUGUAAACA-5′ (SEQ ID NO: 1648) βc-1159 Target:5′-CGTAATAGCCAAGAATTTAACATTTGT-3′ (SEQ ID NO: 2757)5′-UCGUAAUAGCCAAGAAUUUAACAUUUG-3′ (SEQ ID NO: 7194)3′-AGCAUUAUCGGUUCUUAAAUUGUAAAC-5′ (SEQ ID NO: 1649) βc-1160 Target:5′-TCGTAATAGCCAAGAATTTAACATTTG-3′ (SEQ ID NO: 2758)5′-UAAGCUAAAAUUUGAAGGCAGUCUGUC-3′ (SEQ ID NO: 7195)3′-AUUCGAUUUUAAACUUCCGUCAGACAG-5′ (SEQ ID NO: 1650) βc-1185 Target:5′-TAAGCTAAAATTTGAAGGCAGTCTGTC-3′ (SEQ ID NO: 2759)5′-UAGGUCCUCAUUAUAUUUACUAAAGCU-3′ (SEQ ID NO: 7196)3′-AUCCAGGAGUAAUAUAAAUGAUUUCGA-5′ (SEQ ID NO: 1651) βc-1260 Target:5′-TAGGTCCTCATTATATTTACTAAAGCT-3′ (SEQ ID NO: 2760)5′-AAGUAUAGGUCCUCAUUAUAUUUACUA-3′ (SEQ ID NO: 7197)3′-UUCAUAUCCAGGAGUAAUAUAAAUGAU-5′ (SEQ ID NO: 1652) βc-1265 Target:5′-AAGTATAGGTCCTCATTATATTTACTA-3′ (SEQ ID NO: 2761)5′-UAAGUAUAGGUCCUCAUUAUAUUUACU-3′ (SEQ ID NO: 7198)3′-AUUCAUAUCCAGGAGUAAUAUAAAUGA-5′ (SEQ ID NO: 1653) βc-1266 Target:5′-TAAGTATAGGTCCTCATTATATTTACT-3′ (SEQ ID NO: 2762)5′-GUUUUUCGUAAGUAUAGGUCCUCAUUA-3′ (SEQ ID NO: 7199)3′-CAAAAAGCAUUCAUAUCCAGGAGUAAU-5′ (SEQ ID NO: 1654) βc-1274 Target:5′-GTTTTTCGTAAGTATAGGTCCTCATTA-3′ (SEQ ID NO: 2763)5′-AGUUUUUCGUAAGUAUAGGUCCUCAUU-3′ (SEQ ID NO: 7200)3′-UCAAAAAGCAUUCAUAUCCAGGAGUAA-5′ (SEQ ID NO: 1655) βc-1275 Target:5′-AGTTTTTCGTAAGTATAGGTCCTCATT-3′ (SEQ ID NO: 2764)5′-UAGUUUUUCGUAAGUAUAGGUCCUCAU-3′ (SEQ ID NO: 7201)3′-AUCAAAAAGCAUUCAUAUCCAGGAGUA-5′ (SEQ ID NO: 1656) βc-1276 Target:5′-TAGTTTTTCGTAAGTATAGGTCCTC-3′ (SEQ ID NO: 2765)5′-GUAGUUUUUCGUAAGUAUAGGUCCUCA-3′ (SEQ ID NO: 7202)3′-CAUCAAAAAGCAUUCAUAUCCAGGAGU-5′ (SEQ ID NO: 1657) βc-1277 Target:5′-GTAGTTTTTCGTAAGTATAGGTCCTCA-3′ (SEQ ID NO: 2766)5′-GUGGUCCACAGUAGUUUUUCGUAAGUA-3′ (SEQ ID NO: 7203)3′-CACCAGGUGUCAUCAAAAAGCAUUCAU-5′ (SEQ ID NO: 1658) βc-1287 Target:5′-GTGGTCCACAGTAGTTTTTCGTAAGTA-3′ (SEQ ID NO: 2767)5′-UCUACAAUAGCCGGCUUAUUACUAGAG-3′ (SEQ ID NO: 7204)3′-AGAUGUUAUCGGCCGAAUAAUGAUCUC-5′ (SEQ ID NO: 1659) βc-1344 Target:5′-TCTACAATAGCCGGCTTATTACTAGAG-3′ (SEQ ID NO: 2768)5′-CUUCUACAAUAGCCGGCUUAUUACUAG-3′ (SEQ ID NO: 7205)3′-GAAGAUGUUAUCGGCCGAAUAAUGAUC-5′ (SEQ ID NO: 1660) βc-1346 Target:5′-CTTCTACAATAGCCGGCTTATTACTAG-3′ (SEQ ID NO: 2769)5′-AGUCCUAAAGCUUGCAUUCCACCAGCU-3′ (SEQ ID NO: 7206)3′-UCAGGAUUUCGAACGUAAGGUGGUCGA-5′ (SEQ ID NO: 1661) βc-1371 Target:5′-AGTCCTAAAGCTTGCATTCCACCAGCT-3′ (SEQ ID NO: 2770)5′-AAGUCCUAAAGCUUGCAUUCCACCAGC-3′ (SEQ ID NO: 7207)3′-UUCAGGAUUUCGAACGUAAGGUGGUCG-5′ (SEQ ID NO: 1662) βc-1372 Target:5′-AAGTCCTAAAGCTTGCATTCCACCAGC-3′ (SEQ ID NO: 2771)5′-GAAGUCCUAAAGCUUGCAUUCCACCAG-3′ (SEQ ID NO: 7208)3′-CUUCAGGAUUUCGAACGUAAGGUGGUC-5′ (SEQ ID NO: 1663) βc-1373 Target:5′-GAAGTCCTAAAGCTTGCATTCCACCAG-3′ (SEQ ID NO: 2772)5′-CAGUUCUGAACAAGACGUUGACUUGGA-3′ (SEQ ID NO: 7209)3′-GUCAAGACUUGUUCUGCAACUGAACCU-5′ (SEQ ID NO: 1664) βc-1410 Target:5′-CAGTTCTGAACAAGACGTTGACTTGGA-3′ (SEQ ID NO: 2773)5′-ACAGUUCUGAACAAGACGUUGACUUGG-3′ (SEQ ID NO: 7210)3′-UGUCAAGACUUGUUCUGCAACUGAACC-5′ (SEQ ID NO: 1665) βc-1411 Target:5′-ACAGTTCTGAACAAGACGTTGACTTGG-3′ (SEQ ID NO: 2774)5′-GAGUCCAAAGACAGUUCUGAACAAGAC-3′ (SEQ ID NO: 7211)3′-CUCAGGUUUCUGUCAAGACUUGUUCUG-5′ (SEQ ID NO: 1666) βc-1421 Target:5′-GAGTCCAAAGACAGTTCTGAACAAGAC-3′ (SEQ ID NO: 2775)5′-CCUUCCUGUUUAGUUGCAGCAUCUGAA-3′ (SEQ ID NO: 7212)3′-GGAAGGACAAAUCAACGUCGUAGACUU-5′ (SEQ ID NO: 1667) βc-1458 Target:5′-CCTTCCTGTTTAGTTGCAGCATCTGAA-3′ (SEQ ID NO: 2776)5′-CCACAUUUAUAUCAUCUGAACCCAGAA-3′ (SEQ ID NO: 7213)3′-GGUGUAAAUAUAGUAGACUUGGGUCUU-5′ (SEQ ID NO: 1668) βc-1517 Target:5′-CCACATTTATATCATCTGAACCCAGAA-3′ (SEQ ID NO: 2777)5′-UGACCACAUUUAUAUCAUCUGAACCCA-3′ (SEQ ID NO: 7214)3′-ACUGGUGUAAAUAUAGUAGACUUGGGU-5′ (SEQ ID NO: 1669) βc-1520 Target:5′-TGACCACATTTATATCATCTGAACCCA-3′ (SEQ ID NO: 2778)5′-CUGCACAGGUGACCACAUUUAUAUCAU-3′ (SEQ ID NO: 7215)3′-GACGUGUCCACUGGUGUAAAUAUAGUA-5′ (SEQ ID NO: 1670) βc-1529 Target:5′-CTGCACAGGTGACCACATTTATATC-3′ (SEQ ID NO: 2779)5′-GCUGCACAGGUGACCACAUUUAUAUCA-3′ (SEQ ID NO: 7216)3′-CGACGUGUCCACUGGUGUAAAUAUAGU-5′ (SEQ ID NO: 1671) βc-1530 Target:5′-GCTGCACAGGTGACCACATTTATATCA-3′ (SEQ ID NO: 2780)5′-AUUGCAAGUGAGGUUAGAAAGAAUUCC-3′ (SEQ ID NO: 7217)3′-UAACGUUCACUCCAAUCUUUCUUAAGG-5′ (SEQ ID NO: 1672) βc-1558 Target:5′-ATTGCAAGTGAGGTTAGAAAGAATTCC-3′ (SEQ ID NO: 2781)5′-UUAUAAUUAUUGCAAGUGAGGUUAGAA-3′ (SEQ ID NO: 7218)3′-AAUAUUAAUAACGUUCACUCCAAUCUU-5′ (SEQ ID NO: 1673) βc-1566 Target:5′-TTATAATTATTGCAAGTGAGGTTAGAA-3′ (SEQ ID NO: 2782)5′-CAUCAUCUUGUUCUUAUAAUUAUUGCA-3′ (SEQ ID NO: 7219)3′-GUAGUAGAACAAGAAUAUUAAUAACGU-5′ (SEQ ID NO: 1674) βc-1579 Target:5′-CATCATCTTGTTCTTATAATTATTGCA-3′ (SEQ ID NO: 2783)5′-CCAUCAUCUUGUUCUUAUAAUUAUUGC-3′ (SEQ ID NO: 7220)3′-GGUAGUAGAACAAGAAUAUUAAUAACG-5′ (SEQ ID NO: 1675) βc-1580 Target:5′-CCATCATCTTGTTCTTATAATTATTGC-3′ (SEQ ID NO: 2784)5′-AGACCAUCAUCUUGUUCUUAUAAUUAU-3′ (SEQ ID NO: 7221)3′-UCUGGUAGUAGAACAAGAAUAUUAAUA-5′ (SEQ ID NO: 1676) βc-1583 Target:5′-AGACCATCATCTTGTTCTTATAATTAT-3′ (SEQ ID NO: 2785)5′-GCAGACCAUCAUCUUGUUCUUAUAAUU-3′ (SEQ ID NO: 7222)3′-CGUCUGGUAGUAGAACAAGAAUAUUAA-5′ (SEQ ID NO: 1677) βc-1585 Target:5′-GCAGACCATCATCTTGTTCTTATAATT-3′ (SEQ ID NO: 2786)5′-UCAAUCCAACAGUAGCCUUUAUCAGAG-3′ (SEQ ID NO: 7223)3′-AGUUAGGUUGUCAUCGGAAAUAGUCUC-5′ (SEQ ID NO: 1678) βc-1808 Target:5′-TCAATCCAACAGTAGCCTTTATCAGAG-3′ (SEQ ID NO: 2787)5′-UCGAAUCAAUCCAACAGUAGCCUUUAU-3′ (SEQ ID NO: 7224)3′-AGCUUAGUUAGGUUGUCAUCGGAAAUA-5′ (SEQ ID NO: 1679) βc-1813 Target:5′-TCGAATCAATCCAACAGTAGCCTTTAT-3′ (SEQ ID NO: 2788)5′-CCUCCACAAAUUGCUGCUGUGUCCCAC-3′ (SEQ ID NO: 7225)3′-GGAGGUGUUUAACGACGACACAGGGUG-5′ (SEQ ID NO: 1680) βc-1955 Target:5′-CCTCCACAAATTGCTGCTGTGTCCCAC-3′ (SEQ ID NO: 2789)5′-GUACAACCUUCAACUAUUUCUUCCAUG-3′ (SEQ ID NO: 7226)3′-CAUGUUGGAAGUUGAUAAAGAAGGUAC-5′ (SEQ ID NO: 1681) βc-1989 Target:5′-GTACAACCTTCAACTATTTCTTCCATG-3′ (SEQ ID NO: 2790)5′-GGUACAACCUUCAACUAUUUCUUCCAU-3′ (SEQ ID NO: 7227)3′-CCAUGUUGGAAGUUGAUAAAGAAGGUA-5′ (SEQ ID NO: 1682) βc-1990 Target:5′-GGTACAACCTTCAACTATTTCTTCC-3′ (SEQ ID NO: 2791)5′-CGGUACAACCUUCAACUAUUUCUUCCA-3′ (SEQ ID NO: 7228)3′-GCCAUGUUGGAAGUUGAUAAAGAAGGU-5′ (SEQ ID NO: 1683) βc-1991 Target:5′-CGGTACAACCTTCAACTATTTCTTCCA-3′ (SEQ ID NO: 2792)5′-CCGGUACAACCUUCAACUAUUUCUUCC-3′ (SEQ ID NO: 7229)3′-GGCCAUGUUGGAAGUUGAUAAAGAAGG-5′ (SEQ ID NO: 1684) βc-1992 Target:5′-CCGGTACAACCTTCAACTATTTCTTCC-3′ (SEQ ID NO: 2793)5′-GGGCUCCGGUACAACCUUCAACUAUUU-3′ (SEQ ID NO: 7230)3′-CCCGAGGCCAUGUUGGAAGUUGAUAAA-5′ (SEQ ID NO: 1685) βc-1997 Target:5′-GGGCTCCGGTACAACCTTCAACTATTT-3′ (SEQ ID NO: 2794)5′-UAACAAUUCGGUUGUGAACAUCCCGAG-3′ (SEQ ID NO: 7231)3′-AUUGUUAAGCCAACACUUGUAGGGCUC-5′ (SEQ ID NO: 1686) βc-2036 Target:5′-TAACAATTCGGTTGTGAACATCCCGAG-3′ (SEQ ID NO: 2795)5′-AUAACAAUUCGGUUGUGAACAUCCCGA-3′ (SEQ ID NO: 7232)3′-UAUUGUUAAGCCAACACUUGUAGGGCU-5′ (SEQ ID NO: 1687) βc-2037 Target:5′-ATAACAATTCGGTTGTGAACATCCCGA-3′ (SEQ ID NO: 2796)5′-GAUAACAAUUCGGUUGUGAACAUCCCG-3′ (SEQ ID NO: 7233)3′-CUAUUGUUAAGCCAACACUUGUAGGGC-5′ (SEQ ID NO: 1688) βc-2038 Target:5′-GATAACAATTCGGTTGTGAACATCCCG-3′ (SEQ ID NO: 2797)5′-UGAUAACAAUUCGGUUGUGAACAUCCC-3′ (SEQ ID NO: 7234)3′-ACUAUUGUUAAGCCAACACUUGUAGGG-5′ (SEQ ID NO: 1689) βc-2039 Target:5′-TGATAACAATTCGGTTGTGAACATCCC-3′ (SEQ ID NO: 2798)5′-CUGAUAACAAUUCGGUUGUGAACAUCC-3′ (SEQ ID NO: 7235)3′-GACUAUUGUUAAGCCAACACUUGUAGG-5′ (SEQ ID NO: 1690) βc-2040 Target:5′-CTGATAACAATTCGGTTGTGAACATCC-3′ (SEQ ID NO: 2799)5′-UCUGAUAACAAUUCGGUUGUGAACAUC-3′ (SEQ ID NO: 7236)3′-AGACUAUUGUUAAGCCAACACUUGUAG-5′ (SEQ ID NO: 1691) βc-2041 Target:5′-TCTGATAACAATTCGGTTGTGAACATC-3′ (SEQ ID NO: 2800)5′-GUAUUUAGUCCUCUGAUAACAAUUCGG-3′ (SEQ ID NO: 7237)3′-CAUAAAUCAGGAGACUAUUGUUAAGCC-5′ (SEQ ID NO: 1692) βc-2052 Target:5′-GTATTTAGTCCTCTGATAACAATTCGG-3′ (SEQ ID NO: 2801)5′-GGUAUUUAGUCCUCUGAUAACAAUUCG-3′ (SEQ ID NO: 7238)3′-CCAUAAAUCAGGAGACUAUUGUUAAGC-5′ (SEQ ID NO: 1693) βc-2053 Target:5′-GGTATTTAGTCCTCTGATAACAATTCG-3′ (SEQ ID NO: 2802)5′-UGGUAUUUAGUCCUCUGAUAACAAUUC-3′ (SEQ ID NO: 7239)3′-ACCAUAAAUCAGGAGACUAUUGUUAAG-5′ (SEQ ID NO: 1694) βc-2054 Target:5′-TGGTATTTAGTCCTCTGATAACAATTC-3′ (SEQ ID NO: 2803)5′-AUGGUAUUUAGUCCUCUGAUAACAAUU-3′ (SEQ ID NO: 7240)3′-UACCAUAAAUCAGGAGACUAUUGUUAA-5′ (SEQ ID NO: 1695) βc-2055 Target:5′-ATGGTATTTAGTCCTCTGATAACAATT-3′ (SEQ ID NO: 2804)5′-AAACAAUGGAAUGGUAUUUAGUCCUCU-3′ (SEQ ID NO: 7241)3′-UUUGUUACCUUACCAUAAAUCAGGAGA-5′ (SEQ ID NO: 1696) βc-2065 Target:5′-AAACAATGGAATGGTATTTAGTCCTCT-3′ (SEQ ID NO: 2805)5′-GCACAAACAAUGGAAUGGUAUUUAGUC-3′ (SEQ ID NO: 7242)3′-CGUGUUUGUUACCUUACCAUAAAUCAG-5′ (SEQ ID NO: 1697) βc-2069 Target:5′-GCACAAACAATGGAATGGTATTTAGTC-3′ (SEQ ID NO: 2806)5′-CUGCACAAACAAUGGAAUGGUAUUUAG-3′ (SEQ ID NO: 7243)3′-GACGUGUUUGUUACCUUACCAUAAAUC-5′ (SEQ ID NO: 1698) βc-2071 Target:5′-CTGCACAAACAATGGAATGGTATTTAG-3′ (SEQ ID NO: 2807)5′-GCUGCACAAACAAUGGAAUGGUAUUUA-3′ (SEQ ID NO: 7244)3′-CGACGUGUUUGUUACCUUACCAUAAAU-5′ (SEQ ID NO: 1699) βc-2072 Target:5′-GCTGCACAAACAATGGAATGGTATTTA-3′ (SEQ ID NO: 2808)5′-CAGCUACUCUUUGGAUGUUUUCAAUGG-3′ (SEQ ID NO: 7245)3′-GUCGAUGAGAAACCUACAAAAGUUACC-5′ (SEQ ID NO: 1700) βc-2111 Target:5′-CAGCTACTCTTTGGATGTTTTCAATGG-3′ (SEQ ID NO: 2809)5′-GCAGCUACUCUUUGGAUGUUUUCAAUG-3′ (SEQ ID NO: 7246)3′-CGUCGAUGAGAAACCUACAAAAGUUAC-5′ (SEQ ID NO: 1701) βc-2112 Target:5′-GCAGCTACTCTTTGGATGTTTTCAATG-3′ (SEQ ID NO: 2810)5′-CAGCUUCAAUAGCUUCUGCAGCUUCCU-3′ (SEQ ID NO: 7247)3′-GUCGAAGUUAUCGAAGACGUCGAAGGA-5′ (SEQ ID NO: 1702) βc-2168 Target:5′-CAGCTTCAATAGCTTCTGCAGCTTCCT-3′ (SEQ ID NO: 2811)5′-GCUCCCUCAGCUUCAAUAGCUUCUGCA-3′ (SEQ ID NO: 7248)3′-CGAGGGAGUCGAAGUUAUCGAAGACGU-5′ (SEQ ID NO: 1703) βc-2175 Target:5′-GCTCCCTCAGCTTCAATAGCTTCTGCA-3′ (SEQ ID NO: 2812)5′-UGGCUCCCUCAGCUUCAAUAGCUUCUG-3′ (SEQ ID NO: 7249)3′-ACCGAGGGAGUCGAAGUUAUCGAAGAC-5′ (SEQ ID NO: 1704) βc-2177 Target:5′-TGGCTCCCTCAGCTTCAATAGCTTCTG-3′ (SEQ ID NO: 2813)5′-UCAUUCCUAGAGUGAAGUAACUCUGUC-3′ (SEQ ID NO: 7250)3′-AGUAAGGAUCUCACUUCAUUGAGACAG-5′ (SEQ ID NO: 1705) βc-2214 Target:5′-TCATTCCTAGAGTGAAGTAACTCTGTC-3′ (SEQ ID NO: 2814)5′-CUUCAUUCCUAGAGUGAAGUAACUCUG-3′ (SEQ ID NO: 7251)3′-GAAGUAAGGAUCUCACUUCAUUGAGAC-5′ (SEQ ID NO: 1706) βc-2216 Target:5′-CTTCATTCCTAGAGTGAAGTAACTCTG-3′ (SEQ ID NO: 2815)5′-CCUUCAUUCCUAGAGUGAAGUAACUCU-3′ (SEQ ID NO: 7252)3′-GGAAGUAAGGAUCUCACUUCAUUGAGA-5′ (SEQ ID NO: 1707) βc-2217 Target:5′-CCTTCATTCCTAGAGTGAAGTAACTCT-3′ (SEQ ID NO: 2816)5′-UGUCCUCAGACAUUCGGAACAAAACAG-3′ (SEQ ID NO: 7253)3′-ACAGGAGUCUGUAAGCCUUGUUUUGUC-5′ (SEQ ID NO: 1708) βc-2264 Target:5′-TGTCCTCAGACATTCGGAACAAAACAG-3′ (SEQ ID NO: 2817)5′-CUUGUCCUCAGACAUUCGGAACAAAAC-3′ (SEQ ID NO: 7254)3′-GAACAGGAGUCUGUAAGCCUUGUUUUG-5′ (SEQ ID NO: 1709) βc-2266 Target:5′-CTTGTCCTCAGACATTCGGAACAAAAC-3′ (SEQ ID NO: 2818)5′-CCGUUUCUUGUAAUCUUGUGGCUUGUC-3′ (SEQ ID NO: 7255)3′-GGCAAAGAACAUUAGAACACCGAACAG-5′ (SEQ ID NO: 1710) βc-2287 Target:5′-CCGTTTCTTGTAATCTTGTGGCTTGTC-3′ (SEQ ID NO: 2819)5′-ACUGAAAGCCGUUUCUUGUAAUCUUGU-3′ (SEQ ID NO: 7256)3′-UGACUUUCGGCAAAGAACAUUAGAACA-5′ (SEQ ID NO: 1711) βc-2295 Target:5′-ACTGAAAGCCGTTTCTTGTAATCTTGT-3′ (SEQ ID NO: 2820)5′-CAGCUCAACUGAAAGCCGUUUCUUGUA-3′ (SEQ ID NO: 7257)3′-GUCGAGUUGACUUUCGGCAAAGAACAU-5′ (SEQ ID NO: 1712) βc-2302 Target:5′-CAGCTCAACTGAAAGCCGTTTCTTGTA-3′ (SEQ ID NO: 2821)5′-CAAGUCCAAGAUCAGCAGUCUCAUUCC-3′ (SEQ ID NO: 7258)3′-GUUCAGGUUCUAGUCGUCAGAGUAAGG-5′ (SEQ ID NO: 1713) βc-2363 Target:5′-CAAGTCCAAGATCAGCAGTCTCATTCC-3′ (SEQ ID NO: 2822)5′-GCACCAAUAUCAAGUCCAAGAUCAGCA-3′ (SEQ ID NO: 7259)3′-CGUGGUUAUAGUUCAGGUUCUAGUCGU-5′ (SEQ ID NO: 1714) βc-2373 Target:5′-GCACCAATATCAAGTCCAAGATCAGCA-3′ (SEQ ID NO: 2823)5′-AAAGAACGAUAGCUAGGAUCAUCCUGG-3′ (SEQ ID NO: 7260)3′-UUUCUUGCUAUCGAUCCUAGUAGGACC-5′ (SEQ ID NO: 1715) βc-2424 Target:5′-AAAGAACGATAGCTAGGATCATCCTGG-3′ (SEQ ID NO: 2824)5′-CAUAUCCACCAGAGUGAAAAGAACGAU-3′ (SEQ ID NO: 7261)3′-GUAUAGGUGGUCUCACUUUUCUUGCUA-5′ (SEQ ID NO: 1716) βc-2441 Target:5′-CATATCCACCAGAGTGAAAAGAACGAT-3′ (SEQ ID NO: 2825)5′-UGAUUUACAGGUCAGUAUCAAACCAGG-3′ (SEQ ID NO: 7262)3′-ACUAAAUGUCCAGUCAUAGUUUGGUCC-5′ (SEQ ID NO: 1717) βc-2618 Target:5′-TGATTTACAGGTCAGTATCAAACCAGG-3′ (SEQ ID NO: 2826)5′-AUGAUUUACAGGUCAGUAUCAAACCAG-3′ (SEQ ID NO: 7263)3′-UACUAAAUGUCCAGUCAUAGUUUGGUC-5′ (SEQ ID NO: 1718) βc-2619 Target:5′-ATGATTTACAGGTCAGTATCAAACCAG-3′ (SEQ ID NO: 2827)5′-GAUGAUUUACAGGUCAGUAUCAAACCA-3′ (SEQ ID NO: 7264)3′-CUACUAAAUGUCCAGUCAUAGUUUGGU-5′ (SEQ ID NO: 1719) βc-2620 Target:5′-GATGATTTACAGGTCAGTATCAAACCA-3′ (SEQ ID NO: 2828)5′-CUUCUUACCUAAAGGAUGAUUUACAGG-3′ (SEQ ID NO: 7265)3′-GAAGAAUGGAUUUCCUACUAAAUGUCC-5′ (SEQ ID NO: 1720) βc-2634 Target:5′-CTTCTTACCTAAAGGATGATTTACAGG-3′ (SEQ ID NO: 2829)5′-ACUUCUUACCUAAAGGAUGAUUUACAG-3′ (SEQ ID NO: 7266)3′-UGAAGAAUGGAUUUCCUACUAAAUGUC-5′ (SEQ ID NO: 1721) βc-2635 Target:5′-ACTTCTTACCTAAAGGATGATTTACAG-3′ (SEQ ID NO: 2830)5′-AAACUUCUUACCUAAAGGAUGAUUUAC-3′ (SEQ ID NO: 7267)3′-UUUGAAGAAUGGAUUUCCUACUAAAUG-5′ (SEQ ID NO: 1722) βc-2637 Target:5′-AAACTTCTTACCTAAAGGATGATTTAC-3′ (SEQ ID NO: 2831)5′-GCUUUUUAAAACUUCUUACCUAAAGGA-3′ (SEQ ID NO: 7268)3′-CGAAAAAUUUUGAAGAAUGGAUUUCCU-5′ (SEQ ID NO: 1723) βc-2645 Target:5′-GCTTTTTAAAACTTCTTACCTAAAGGA-3′ (SEQ ID NO: 2832)5′-UGGCUUUUUAAAACUUCUUACCUAAAG-3′ (SEQ ID NO: 7269)3′-ACCGAAAAAUUUUGAAGAAUGGAUUUC-5′ (SEQ ID NO: 1724) βc-2647 Target:5′-TGGCTTTTTAAAACTTCTTACCTAAAG-3′ (SEQ ID NO: 2833)5′-CCAAACUGGCUUUUUAAAACUUCUUAC-3′ (SEQ ID NO: 7270)3′-GGUUUGACCGAAAAAUUUUGAAGAAUG-5′ (SEQ ID NO: 1725) βc-2653 Target:5′-CCAAACTGGCTTTTTAAAACTTCTTAC-3′ (SEQ ID NO: 2834)5′-UUACCCAAACUGGCUUUUUAAAACUUC-3′ (SEQ ID NO: 7271)3′-AAUGGGUUUGACCGAAAAAUUUUGAAG-5′ (SEQ ID NO: 1726) βc-2657 Target:5′-TTACCCAAACTGGCTTTTTAAAACTTC-3′ (SEQ ID NO: 2835)5′-UUUACCCAAACUGGCUUUUUAAAACUU-3′ (SEQ ID NO: 7272)3′-AAAUGGGUUUGACCGAAAAAUUUUGAA-5′ (SEQ ID NO: 1727) βc-2658 Target:5′-TTTACCCAAACTGGCTTTTTAAAACTT-3′ (SEQ ID NO: 2836)5′-UUUUACCCAAACUGGCUUUUUAAAACU-3′ (SEQ ID NO: 7273)3′-AAAAUGGGUUUGACCGAAAAAUUUUGA-5′ (SEQ ID NO: 1728) βc-2659 Target:5′-TTTTACCCAAACTGGCTTTTTAAAACT-3′ (SEQ ID NO: 2837)5′-AUUUUACCCAAACUGGCUUUUUAAAAC-3′ (SEQ ID NO: 7274)3′-UAAAAUGGGUUUGACCGAAAAAUUUUG-5′ (SEQ ID NO: 1729) βc-2660 Target:5′-ATTTTACCCAAACTGGCTTTTTAAAAC-3′ (SEQ ID NO: 2838)5′-CCAACCAAGUCUUUCUGAAGUUCUGUA-3′ (SEQ ID NO: 7275)3′-GGUUGGUUCAGAAAGACUUCAAGACAU-5′ (SEQ ID NO: 1730) βc-2701 Target:5′-CCAACCAAGTCTTTCTGAAGTTCTGTA-3′ (SEQ ID NO: 2839)5′-CCACCCUACCAACCAAGUCUUUCUGAA-3′ (SEQ ID NO: 7276)3′-GGUGGGAUGGUUGGUUCAGAAAGACUU-5′ (SEQ ID NO: 1731) βc-2709 Target:5′-CCACCCTACCAACCAAGTCTTTCTGAA-3′ (SEQ ID NO: 2840)5′-AUUUACAAAUAGCCUAAACCACUCCCA-3′ (SEQ ID NO: 7277)3′-UAAAUGUUUAUCGGAUUUGGUGAGGGU-5′ (SEQ ID NO: 1732) βc-2733 Target:5′-ATTTACAAATAGCCTAAACCACTCCCA-3′ (SEQ ID NO: 2841)5′-GAUUUACAAAUAGCCUAAACCACUCCC-3′ (SEQ ID NO: 7278)3′-CUAAAUGUUUAUCGGAUUUGGUGAGGG-5′ (SEQ ID NO: 1733) βc-2734 Target:5′-GATTTACAAATAGCCTAAACCACTCCC-3′ (SEQ ID NO: 2842)5′-AGAUUUACAAAUAGCCUAAACCACUCC-3′ (SEQ ID NO: 7279)3′-UCUAAAUGUUUAUCGGAUUUGGUGAGG-5′ (SEQ ID NO: 1734) βc-2735 Target:5′-AGATTTACAAATAGCCTAAACCACTCC-3′ (SEQ ID NO: 2843)5′-CAGAUUUACAAAUAGCCUAAACCACUC-3′ (SEQ ID NO: 7280)3′-GUCUAAAUGUUUAUCGGAUUUGGUGAG-5′ (SEQ ID NO: 1735) βc-2736 Target:5′-CAGATTTACAAATAGCCTAAACCACTC-3′ (SEQ ID NO: 2844)5′-UGUUUUUGUGGCAGAUUUACAAAUAGC-3′ (SEQ ID NO: 7281)3′-ACAAAAACACCGUCUAAAUGUUUAUCG-5′ (SEQ ID NO: 1736) βc-2747 Target:5′-TGTTTTTGTGGCAGATTTACAAATAGC-3′ (SEQ ID NO: 2845)5′-CUGUUUUUGUGGCAGAUUUACAAAUAG-3′ (SEQ ID NO: 7282)3′-GACAAAAACACCGUCUAAAUGUUUAUC-5′ (SEQ ID NO: 1737) βc-2748 Target:5′-CTGTTTTTGTGGCAGATTTACAAATAG-3′ (SEQ ID NO: 2846)5′-CCUGUUUUUGUGGCAGAUUUACAAAUA-3′ (SEQ ID NO: 7283)3′-GGACAAAAACACCGUCUAAAUGUUUAU-5′ (SEQ ID NO: 1738) βc-2749 Target:5′-CCTGTTTTTGTGGCAGATTTACAAATA-3′ (SEQ ID NO: 2847)5′-AUAUACCUGUUUUUGUGGCAGAUUUAC-3′ (SEQ ID NO: 7284)3′-UAUAUGGACAAAAACACCGUCUAAAUG-5′ (SEQ ID NO: 1739) βc-2754 Target:5′-ATATACCTGTTTTTGTGGCAGATTTAC-3′ (SEQ ID NO: 2848)5′-CUUUCAAAGUAUAUACCUGUUUUUGUG-3′ (SEQ ID NO: 7285)3′-GAAAGUUUCAUAUAUGGACAAAAACAC-5′ (SEQ ID NO: 1740) βc-2764 Target:5′-CTTTCAAAGTATATACCTGTTTTTGTG-3′ (SEQ ID NO: 2849)5′-CAUCUCCUUUCAAAGUAUAUACCUGUU-3′ (SEQ ID NO: 7286)3′-GUAGAGGAAAGUUUCAUAUAUGGACAA-5′ (SEQ ID NO: 1741) βc-2770 Target:5′-CATCTCCTTTCAAAGTATATACCTGTT-3′ (SEQ ID NO: 2850)5′-ACAUCUCCUUUCAAAGUAUAUACCUGU-3′ (SEQ ID NO: 7287)3′-UGUAGAGGAAAGUUUCAUAUAUGGACA-5′ (SEQ ID NO: 1742) βc-2771 Target:5′-ACATCTCCTTTCAAAGTATATACCTGT-3′ (SEQ ID NO: 2851)5′-AGACAUCUCCUUUCAAAGUAUAUACCU-3′ (SEQ ID NO: 7288)3′-UCUGUAGAGGAAAGUUUCAUAUAUGGA-5′ (SEQ ID NO: 1743) βc-2773 Target:5′-AGACATCTCCTTTCAAAGTATATACCT-3′ (SEQ ID NO: 2852)5′-AAGACAUCUCCUUUCAAAGUAUAUACC-3′ (SEQ ID NO: 7289)3′-UUCUGUAGAGGAAAGUUUCAUAUAUGG-5′ (SEQ ID NO: 1744) βc-2774 Target:5′-AAGACATCTCCTTTCAAAGTATATACC-3′ (SEQ ID NO: 2853)5′-CAAGACAUCUCCUUUCAAAGUAUAUAC-3′ (SEQ ID NO: 7290)3′-GUUCUGUAGAGGAAAGUUUCAUAUAUG-5′ (SEQ ID NO: 1745) βc-2775 Target:5′-CAAGACATCTCCTTTCAAAGTATATAC-3′ (SEQ ID NO: 2854)5′-UGUUCCAAGACAUCUCCUUUCAAAGUA-3′ (SEQ ID NO: 7291)3′-ACAAGGUUCUGUAGAGGAAAGUUUCAU-5′ (SEQ ID NO: 1746) βc-2780 Target:5′-TGTTCCAAGACATCTCCTTTCAAAGTA-3′ (SEQ ID NO: 2855)5′-CAUUCCAAUGUUCCAAGACAUCUCCUU-3′ (SEQ ID NO: 7292)3′-GUAAGGUUACAAGGUUCUGUAGAGGAA-5′ (SEQ ID NO: 1747) βc-2788 Target:5′-CATTCCAATGTTCCAAGACATCTCCTT-3′ (SEQ ID NO: 2856)5′-ACAUUCCAAUGUUCCAAGACAUCUCCU-3′ (SEQ ID NO: 7293)3′-UGUAAGGUUACAAGGUUCUGUAGAGGA-5′ (SEQ ID NO: 1748) βc-2789 Target:5′-ACATTCCAATGTTCCAAGACATCTCCT-3′ (SEQ ID NO: 2857)5′-GAACAUUCCAAUGUUCCAAGACAUCUC-3′ (SEQ ID NO: 7294)3′-CUUGUAAGGUUACAAGGUUCUGUAGAG-5′ (SEQ ID NO: 1749) βc-2791 Target:5′-GAACATTCCAATGTTCCAAGACATCTC-3′ (SEQ ID NO: 2858)5′-CCAGAAAUCUGAGAACAUUCCAAUGUU-3′ (SEQ ID NO: 7295)3′-GGUCUUUAGACUCUUGUAAGGUUACAA-5′ (SEQ ID NO: 1750) βc-2803 Target:5′-CCAGAAATCTGAGAACATTCCAATGTT-3′ (SEQ ID NO: 2859)5′-ACAACCAGAAAUCUGAGAACAUUCCAA-3′ (SEQ ID NO: 7296)3′-UGUUGGUCUUUAGACUCUUGUAAGGUU-5′ (SEQ ID NO: 1751) βc-2807 Target:5′-ACAACCAGAAATCTGAGAACATTCCAA-3′ (SEQ ID NO: 2860)5′-UAACAACCAGAAAUCUGAGAACAUUCC-3′ (SEQ ID NO: 7297)3′-AUUGUUGGUCUUUAGACUCUUGUAAGG-5′ (SEQ ID NO: 1752) βc-2809 Target:5′-TAACAACCAGAAATCTGAGAACATTCC-3′ (SEQ ID NO: 2861)5′-AUAACAACCAGAAAUCUGAGAACAUUC-3′ (SEQ ID NO: 7298)3′-UAUUGUUGGUCUUUAGACUCUUGUAAG-5′ (SEQ ID NO: 1753) βc-2810 Target:5′-ATAACAACCAGAAATCTGAGAACATTC-3′ (SEQ ID NO: 2862)5′-CAUAACAACCAGAAAUCUGAGAACAUU-3′ (SEQ ID NO: 7299)3′-GUAUUGUUGGUCUUUAGACUCUUGUAA-5′ (SEQ ID NO: 1754) βc-2811 Target:5′-CATAACAACCAGAAATCTGAGAACATT-3′ (SEQ ID NO: 2863)5′-UGAUCACAUAACAACCAGAAAUCUGAG-3′ (SEQ ID NO: 7300)3′-ACUAGUGUAUUGUUGGUCUUUAGACUC-5′ (SEQ ID NO: 1755) βc-2817 Target:5′-TGATCACATAACAACCAGAAATCTGAG-3′ (SEQ ID NO: 2864)5′-AUGAUCACAUAACAACCAGAAAUCUGA-3′ (SEQ ID NO: 7301)3′-UACUAGUGUAUUGUUGGUCUUUAGACU-5′ (SEQ ID NO: 1756) βc-2818 Target:5′-ATGATCACATAACAACCAGAAATCTGA-3′ (SEQ ID NO: 2865)5′-CCACACAUGAUCACAUAACAACCAGAA-3′ (SEQ ID NO: 7302)3′-GGUGUGUACUAGUGUAUUGUUGGUCUU-5′ (SEQ ID NO: 1757) βc-2824 Target:5′-CCACACATGATCACATAACAACCAGAA-3′ (SEQ ID NO: 2866)5′-CUUCCACACAUGAUCACAUAACAACCA-3′ (SEQ ID NO: 7303)3′-GAAGGUGUGUACUAGUGUAUUGUUGGU-5′ (SEQ ID NO: 1758) βc-2827 Target:5′-CTTCCACACATGATCACATAACAACCA-3′ (SEQ ID NO: 2867)5′-AAUAACUUCCACACAUGAUCACAUAAC-3′ (SEQ ID NO: 7304)3′-UUAUUGAAGGUGUGUACUAGUGUAUUG-5′ (SEQ ID NO: 1759) βc-2832 Target:5′-AATAACTTCCACACATGATCACATAAC-3′ (SEQ ID NO: 2868)5′-UAAUAACUUCCACACAUGAUCACAUAA-3′ (SEQ ID NO: 7305)3′-AUUAUUGAAGGUGUGUACUAGUGUAUU-5′ (SEQ ID NO: 1760) βc-2833 Target:5′-TAATAACTTCCACACATGATCACATAA-3′ (SEQ ID NO: 2869)5′-UUAAUAACUUCCACACAUGAUCACAUA-3′ (SEQ ID NO: 7306)3′-AAUUAUUGAAGGUGUGUACUAGUGUAU-5′ (SEQ ID NO: 1761) βc-2834 Target:5′-TTAATAACTTCCACACATGATCACATA-3′ (SEQ ID NO: 2870)5′-GUUAAUAACUUCCACACAUGAUCACAU-3′ (SEQ ID NO: 7307)3′-CAAUUAUUGAAGGUGUGUACUAGUGUA-5′ (SEQ ID NO: 1762) βc-2835 Target:5′-GTTAATAACTTCCACACATGATCAC-3′ (SEQ ID NO: 2871)5′-CAUUAAAGUUAAUAACUUCCACACAUG-3′ (SEQ ID NO: 7308)3′-GUAAUUUCAAUUAUUGAAGGUGUGUAC-5′ (SEQ ID NO: 1763) βc-2842 Target:5′-CATTAAAGTTAATAACTTCCACACATG-3′ (SEQ ID NO: 2872)5′-ACAUUAAAGUUAAUAACUUCCACACAU-3′ (SEQ ID NO: 7309)3′-UGUAAUUUCAAUUAUUGAAGGUGUGUA-5′ (SEQ ID NO: 1764) βc-2843 Target:5′-ACATTAAAGTTAATAACTTCCACAC-3′ (SEQ ID NO: 2873)5′-AAACAUUAAAGUUAAUAACUUCCACAC-3′ (SEQ ID NO: 7310)3′-UUUGUAAUUUCAAUUAUUGAAGGUGUG-5′ (SEQ ID NO: 1765) βc-2845 Target:5′-AAACATTAAAGTTAATAACTTCCACAC-3′ (SEQ ID NO: 2874)5′-AAAACAUUAAAGUUAAUAACUUCCACA-3′ (SEQ ID NO: 7311)3′-UUUUGUAAUUUCAAUUAUUGAAGGUGU-5′ (SEQ ID NO: 1766) βc-2846 Target:5′-AAAACATTAAAGTTAATAACTTCCACA-3′ (SEQ ID NO: 2875)5′-AAAAACAUUAAAGUUAAUAACUUCCAC-3′ (SEQ ID NO: 7312)3′-UUUUUGUAAUUUCAAUUAUUGAAGGUG-5′ (SEQ ID NO: 1767) βc-2847 Target:5′-AAAAACATTAAAGTTAATAACTTCCAC-3′ (SEQ ID NO: 2876)5′-AAAAAACAUUAAAGUUAAUAACUUCCA-3′ (SEQ ID NO: 7313)3′-UUUUUUGUAAUUUCAAUUAUUGAAGGU-5′ (SEQ ID NO: 1768) βc-2848 Target:5′-AAAAAACATTAAAGTTAATAACTTCCA-3′ (SEQ ID NO: 2877)5′-CAAAAAACAUUAAAGUUAAUAACUUCC-3′ (SEQ ID NO: 7314)3′-GUUUUUUGUAAUUUCAAUUAUUGAAGG-5′ (SEQ ID NO: 1769) βc-2849 Target:5′-CAAAAAACATTAAAGTTAATAACTTCC-3′ (SEQ ID NO: 2878)5′-GCAAAAAACAUUAAAGUUAAUAACUUC-3′ (SEQ ID NO: 7315)3′-CGUUUUUUGUAAUUUCAAUUAUUGAAG-5′ (SEQ ID NO: 1770) βc-2850 Target:5′-GCAAAAAACATTAAAGTTAATAACTTC-3′ (SEQ ID NO: 2879)5′-UGGCAAAAAACAUUAAAGUUAAUAACU-3′ (SEQ ID NO: 7316)3′-ACCGUUUUUUGUAAUUUCAAUUAUUGA-5′ (SEQ ID NO: 1771) βc-2852 Target:5′-TGGCAAAAAACATTAAAGTTAATAACT-3′ (SEQ ID NO: 2880)5′-GUGGCAAAAAACAUUAAAGUUAAUAAC-3′ (SEQ ID NO: 7317)3′-CACCGUUUUUUGUAAUUUCAAUUAUUG-5′ (SEQ ID NO: 1772) βc-2853 Target:5′-GTGGCAAAAAACATTAAAGTTAATAAC-3′ (SEQ ID NO: 2881)5′-UUGCAAAAGCUGUGGCAAAAAACAUUA-3′ (SEQ ID NO: 7318)3′-AACGUUUUCGACACCGUUUUUUGUAAU-5′ (SEQ ID NO: 1773) βc-2864 Target:5′-TTGCAAAAGCTGTGGCAAAAAACATTA-3′ (SEQ ID NO: 2882)5′-GUUGCAAAAGCUGUGGCAAAAAACAUU-3′ (SEQ ID NO: 7319)3′-CAACGUUUUCGACACCGUUUUUUGUAA-5′ (SEQ ID NO: 1774) βc-2865 Target:5′-GTTGCAAAAGCTGTGGCAAAAAACATT-3′ (SEQ ID NO: 2883)5′-ACUCAUUUGAGUAUUAAGUUGCAAAAG-3′ (SEQ ID NO: 7320)3′-UGAGUAAACUCAUAAUUCAACGUUUUC-5′ (SEQ ID NO: 1775) βc-2882 Target:5′-ACTCATTTGAGTATTAAGTTGCAAAAG-3′ (SEQ ID NO: 2884)5′-UUAAAACAGCAAAUGUUACUCAUUUGA-3′ (SEQ ID NO: 7321)3′-AAUUUUGUCGUUUACAAUGAGUAAACU-5′ (SEQ ID NO: 1776) βc-2899 Target:5′-TTAAAACAGCAAATGTTACTCATTTGA-3′ (SEQ ID NO: 2885)5′-UUUAAAACAGCAAAUGUUACUCAUUUG-3′ (SEQ ID NO: 7322)3′-AAAUUUUGUCGUUUACAAUGAGUAAAC-5′ (SEQ ID NO: 1777) βc-2900 Target:5′-TTTAAAACAGCAAATGTTACTCATTTG-3′ (SEQ ID NO: 2886)5′-GUUUAAAACAGCAAAUGUUACUCAUUU-3′ (SEQ ID NO: 7323)3′-CAAAUUUUGUCGUUUACAAUGAGUAAA-5′ (SEQ ID NO: 1778) βc-2901 Target:5′-GTTTAAAACAGCAAATGTTACTCATTT-3′ (SEQ ID NO: 2887)5′-UGUUUAAAACAGCAAAUGUUACUCAUU-3′ (SEQ ID NO: 7324)3′-ACAAAUUUUGUCGUUUACAAUGAGUAA-5′ (SEQ ID NO: 1779) βc-2902 Target:5′-TGTTTAAAACAGCAAATGTTACTCATT-3′ (SEQ ID NO: 2888)5′-AUGUUUAAAACAGCAAAUGUUACUCAU-3′ (SEQ ID NO: 7325)3′-UACAAAUUUUGUCGUUUACAAUGAGUA-5′ (SEQ ID NO: 1780) βc-2903 Target:5′-ATGTTTAAAACAGCAAATGTTACTC-3′ (SEQ ID NO: 2889)5′-AAUGUUUAAAACAGCAAAUGUUACUCA-3′ (SEQ ID NO: 7326)3′-UUACAAAUUUUGUCGUUUACAAUGAGU-5′ (SEQ ID NO: 1781) βc-2904 Target:5′-AATGTTTAAAACAGCAAATGTTACTCA-3′ (SEQ ID NO: 2890)5′-CUAUUAAUGUUUAAAACAGCAAAUGUU-3′ (SEQ ID NO: 7327)3′-GAUAAUUACAAAUUUUGUCGUUUACAA-5′ (SEQ ID NO: 1782) βc-2909 Target:5′-CTATTAATGTTTAAAACAGCAAATGTT-3′ (SEQ ID NO: 2891)5′-AGAGAAAGGCUGCUAUUAAUGUUUAAA-3′ (SEQ ID NO: 7328)3′-UCUCUUUCCGACGAUAAUUACAAAUUU-5′ (SEQ ID NO: 1783) βc-2921 Target:5′-AGAGAAAGGCTGCTATTAATGTTTAAA-3′ (SEQ ID NO: 2892)5′-CAAGUUCAGACAAUACAGCUGUAUAAA-3′ (SEQ ID NO: 7329)3′-GUUCAAGUCUGUUAUGUCGACAUAUUU-5′ (SEQ ID NO: 1784) βc-2949 Target:5′-CAAGTTCAGACAATACAGCTGTATAAA-3′ (SEQ ID NO: 2893)5′-UCACAAUGCAAGUUCAGACAAUACAGC-3′ (SEQ ID NO: 7330)3′-AGUGUUACGUUCAAGUCUGUUAUGUCG-5′ (SEQ ID NO: 1785) βc-2957 Target:5′-TCACAATGCAAGTTCAGACAATACAGC-3′ (SEQ ID NO: 2894)5′-AAUCACAAUGCAAGUUCAGACAAUACA-3′ (SEQ ID NO: 7331)3′-UUAGUGUUACGUUCAAGUCUGUUAUGU-5′ (SEQ ID NO: 1786) βc-2959 Target:5′-AATCACAATGCAAGTTCAGACAATACA-3′ (SEQ ID NO: 2895)5′-CCAAUCACAAUGCAAGUUCAGACAAUA-3′ (SEQ ID NO: 7332)3′-GGUUAGUGUUACGUUCAAGUCUGUUAU-5′ (SEQ ID NO: 1787) βc-2961 Target:5′-CCAATCACAATGCAAGTTCAGACAATA-3′ (SEQ ID NO: 2896)5′-CAGGCCAAUCACAAUGCAAGUUCAGAC-3′ (SEQ ID NO: 7333)3′-GUCCGGUUAGUGUUACGUUCAAGUCUG-5′ (SEQ ID NO: 1788) βc-2965 Target:5′-CAGGCCAATCACAATGCAAGTTCAGAC-3′ (SEQ ID NO: 2897)5′-UUGUUCCCAUAGGAAACUCAGCUUGGU-3′ (SEQ ID NO: 7334)3′-AACAAGGGUAUCCUUUGAGUCGAACCA-5′ (SEQ ID NO: 1789) βc-3052 Target:5′-TTGTTCCCATAGGAAACTCAGCTTGGT-3′ (SEQ ID NO: 2898)5′-CUUCAAUUGUUCCCAUAGGAAACUCAG-3′ (SEQ ID NO: 7335)3′-GAAGUUAACAAGGGUAUCCUUUGAGUC-5′ (SEQ ID NO: 1790) βc-3058 Target:5′-CTTCAATTGTTCCCATAGGAAACTCAG-3′ (SEQ ID NO: 2899)5′-ACUUCAAUUGUUCCCAUAGGAAACUCA-3′ (SEQ ID NO: 7336)3′-UGAAGUUAACAAGGGUAUCCUUUGAGU-5′ (SEQ ID NO: 1791) βc-3059 Target:5′-ACTTCAATTGTTCCCATAGGAAACTCA-3′ (SEQ ID NO: 2900)5′-AAGUUUACUUCAAUUGUUCCCAUAGGA-3′ (SEQ ID NO: 7337)3′-UUCAAAUGAAGUUAACAAGGGUAUCCU-5′ (SEQ ID NO: 1792) βc-3065 Target:5′-AAGTTTACTTCAATTGTTCCCATAGGA-3′ (SEQ ID NO: 2901)5′-AAAGUUUACUUCAAUUGUUCCCAUAGG-3′ (SEQ ID NO: 7338)3′-UUUCAAAUGAAGUUAACAAGGGUAUCC-5′ (SEQ ID NO: 1793) βc-3066 Target:5′-AAAGTTTACTTCAATTGTTCCCATAGG-3′ (SEQ ID NO: 2902)5′-ACAAAAAGUUUACUUCAAUUGUUCCCA-3′ (SEQ ID NO: 7339)3′-UGUUUUUCAAAUGAAGUUAACAAGGGU-5′ (SEQ ID NO: 1794) βc-3070 Target:5′-ACAAAAAGTTTACTTCAATTGTTCCCA-3′ (SEQ ID NO: 2903)5′-CAGAACAAAAAGUUUACUUCAAUUGUU-3′ (SEQ ID NO: 7340)3′-GUCUUGUUUUUCAAAUGAAGUUAACAA-5′ (SEQ ID NO: 1795) βc-3074 Target:5′-CAGAACAAAAAGTTTACTTCAATTGTT-3′ (SEQ ID NO: 2904)5′-AGGACCAGAACAAAAAGUUUACUUCAA-3′ (SEQ ID NO: 7341)3′-UCCUGGUCUUGUUUUUCAAAUGAAGUU-5′ (SEQ ID NO: 1796) βc-3079 Target:5′-AGGACCAGAACAAAAAGTTTACTTCAA-3′ (SEQ ID NO: 2905)5′-AAGGACCAGAACAAAAAGUUUACUUCA-3′ (SEQ ID NO: 7342)3′-UUCCUGGUCUUGUUUUUCAAAUGAAGU-5′ (SEQ ID NO: 1797) βc-3080 Target:5′-AAGGACCAGAACAAAAAGTTTACTTCA-3′ (SEQ ID NO: 2906)5′-CGACCAAAAAGGACCAGAACAAAAAGU-3′ (SEQ ID NO: 7343)3′-GCUGGUUUUUCCUGGUCUUGUUUUUCA-5′ (SEQ ID NO: 1798) βc-3088 Target:5′-CGACCAAAAAGGACCAGAACAAAAAGT-3′ (SEQ ID NO: 2907)5′-UCGACCAAAAAGGACCAGAACAAAAAG-3′ (SEQ ID NO: 7344)3′-AGCUGGUUUUUCCUGGUCUUGUUUUUC-5′ (SEQ ID NO: 1799) βc-3089 Target:5′-TCGACCAAAAAGGACCAGAACAAAAAG-3′ (SEQ ID NO: 2908)5′-UUACUCCUCGACCAAAAAGGACCAGAA-3′ (SEQ ID NO: 7345)3′-AAUGAGGAGCUGGUUUUUCCUGGUCUU-5′ (SEQ ID NO: 1800) βc-3096 Target:5′-TTACTCCTCGACCAAAAAGGACCAGAA-3′ (SEQ ID NO: 2909)5′-AAUCCAUUUGUAUUGUUACUCCUCGAC-3′ (SEQ ID NO: 7346)3′-UUAGGUAAACAUAACAAUGAGGAGCUG-5′ (SEQ ID NO: 1801) βc-3111 Target:5′-AATCCATTTGTATTGTTACTCCTCGAC-3′ (SEQ ID NO: 2910)5′-AAAUCCAUUUGUAUUGUUACUCCUCGA-3′ (SEQ ID NO: 7347)3′-UUUAGGUAAACAUAACAAUGAGGAGCU-5′ (SEQ ID NO: 1802) βc-3112 Target:5′-AAATCCATTTGTATTGTTACTCCTCGA-3′ (SEQ ID NO: 2911)5′-AAAAUCCAUUUGUAUUGUUACUCCUCG-3′ (SEQ ID NO: 7348)3′-UUUUAGGUAAACAUAACAAUGAGGAGC-5′ (SEQ ID NO: 1803) βc-3113 Target:5′-AAAATCCATTTGTATTGTTACTCCTCG-3′ (SEQ ID NO: 2912)5′-CAAAAUCCAUUUGUAUUGUUACUCCUC-3′ (SEQ ID NO: 7349)3′-GUUUUAGGUAAACAUAACAAUGAGGAG-5′ (SEQ ID NO: 1804) βc-3114 Target:5′-CAAAATCCATTTGTATTGTTACTCCTC-3′ (SEQ ID NO: 2913)5′-CCAAAAUCCAUUUGUAUUGUUACUCCU-3′ (SEQ ID NO: 7350)3′-GGUUUUAGGUAAACAUAACAAUGAGGA-5′ (SEQ ID NO: 1805) βc-3115 Target:5′-CCAAAATCCATTTGTATTGTTACTCCT-3′ (SEQ ID NO: 2914)5′-UCACUCCCAAAAUCCAUUUGUAUUGUU-3′ (SEQ ID NO: 7351)3′-AGUGAGGGUUUUAGGUAAACAUAACAA-5′ (SEQ ID NO: 1806) βc-3121 Target:5′-TCACTCCCAAAATCCATTTGTATTGTT-3′ (SEQ ID NO: 2915)5′-UCUUCACUUCUUGAGUCACUCCCAAAA-3′ (SEQ ID NO: 7352)3′-AGAAGUGAAGAACUCAGUGAGGGUUUU-5′ (SEQ ID NO: 1807) βc-3136 Target:5′-TCTTCACTTCTTGAGTCACTCCCAAAA-3′ (SEQ ID NO: 2916)5′-AUUCUUCACUUCUUGAGUCACUCCCAA-3′ (SEQ ID NO: 7353)3′-UAAGAAGUGAAGAACUCAGUGAGGGUU-5′ (SEQ ID NO: 1808) βc-3138 Target:5′-ATTCTTCACTTCTTGAGTCACTCCCAA-3′ (SEQ ID NO: 2917)5′-CAUUCUUCACUUCUUGAGUCACUCCCA-3′ (SEQ ID NO: 7354)3′-GUAAGAAGUGAAGAACUCAGUGAGGGU-5′ (SEQ ID NO: 1809) βc-3139 Target:5′-CATTCTTCACTTCTTGAGTCACTCCCA-3′ (SEQ ID NO: 2918)5′-GCAUUCUUCACUUCUUGAGUCACUCCC-3′ (SEQ ID NO: 7355)3′-CGUAAGAAGUGAAGAACUCAGUGAGGG-5′ (SEQ ID NO: 1810) βc-3140 Target:5′-GCATTCTTCACTTCTTGAGTCACTCCC-3′ (SEQ ID NO: 2919)5′-GUGCAUUCUUCACUUCUUGAGUCACUC-3′ (SEQ ID NO: 7356)3′-CACGUAAGAAGUGAAGAACUCAGUGAG-5′ (SEQ ID NO: 1811) βc-3142 Target:5′-GTGCATTCTTCACTTCTTGAGTCACTC-3′ (SEQ ID NO: 2920)5′-CCAUUCUUGUGCAUUCUUCACUUCUUG-3′ (SEQ ID NO: 7357)3′-GGUAAGAACACGUAAGAAGUGAAGAAC-5′ (SEQ ID NO: 1812) βc-3150 Target:5′-CCATTCTTGTGCATTCTTCACTTCTTG-3′ (SEQ ID NO: 2921)5′-GAUCCAUUCUUGUGCAUUCUUCACUUC-3′ (SEQ ID NO: 7358)3′-CUAGGUAAGAACACGUAAGAAGUGAAG-5′ (SEQ ID NO: 1813) βc-3153 Target:5′-GATCCATTCTTGTGCATTCTTCACTTC-3′ (SEQ ID NO: 2922)5′-UGAUCCAUUCUUGUGCAUUCUUCACUU-3′ (SEQ ID NO: 7359)3′-ACUAGGUAAGAACACGUAAGAAGUGAA-5′ (SEQ ID NO: 1814) βc-3154 Target:5′-TGATCCATTCTTGTGCATTCTTCACTT-3′ (SEQ ID NO: 2923)5′-GUGAUCCAUUCUUGUGCAUUCUUCACU-3′ (SEQ ID NO: 7360)3′-CACUAGGUAAGAACACGUAAGAAGUGA-5′ (SEQ ID NO: 1815) βc-3155 Target:5′-GTGATCCATTCTTGTGCATTCTTCACT-3′ (SEQ ID NO: 2924)5′-UAAAUUCCAUCUUGUGAUCCAUUCUUG-3′ (SEQ ID NO: 7361)3′-AUUUAAGGUAGAACACUAGGUAAGAAC-5′ (SEQ ID NO: 1816) βc-3168 Target:5′-TAAATTCCATCTTGTGATCCATTCTTG-3′ (SEQ ID NO: 2925)5′-GAUAAAUUCCAUCUUGUGAUCCAUUCU-3′ (SEQ ID NO: 7362)3′-CUAUUUAAGGUAGAACACUAGGUAAGA-5′ (SEQ ID NO: 1817) βc-3170 Target:5′-GATAAATTCCATCTTGTGATCCATTCT-3′ (SEQ ID NO: 2926)5′-UGAUAAAUUCCAUCUUGUGAUCCAUUC-3′ (SEQ ID NO: 7363)3′-ACUAUUUAAGGUAGAACACUAGGUAAG-5′ (SEQ ID NO: 1818) βc-3171 Target:5′-TGATAAATTCCATCTTGTGATCCATTC-3′ (SEQ ID NO: 2927)5′-UUGAUAAAUUCCAUCUUGUGAUCCAUU-3′ (SEQ ID NO: 7364)3′-AACUAUUUAAGGUAGAACACUAGGUAA-5′ (SEQ ID NO: 1819) βc-3172 Target:5′-TTGATAAATTCCATCTTGTGATCCATT-3′ (SEQ ID NO: 2928)5′-UUUGAUAAAUUCCAUCUUGUGAUCCAU-3′ (SEQ ID NO: 7365)3′-AAACUAUUUAAGGUAGAACACUAGGUA-5′ (SEQ ID NO: 1820) βc-3173 Target:5′-TTTGATAAATTCCATCTTGTGATCC-3′ (SEQ ID NO: 2929)5′-AAGGCUAGGGUUUGAUAAAUUCCAUCU-3′ (SEQ ID NO: 7366)3′-UUCCGAUCCCAAACUAUUUAAGGUAGA-5′ (SEQ ID NO: 1821) βc-3183 Target:5′-AAGGCTAGGGTTTGATAAATTCCATCT-3′ (SEQ ID NO: 2930)5′-AAAAAAAUUUAACAAGCAAGGCUAGGG-3′ (SEQ ID NO: 7367)3′-UUUUUUUAAAUUGUUCGUUCCGAUCCC-5′ (SEQ ID NO: 1822) βc-3200 Target:5′-AAAAAAATTTAACAAGCAAGGCTAGGG-3′ (SEQ ID NO: 2931)5′-AAAAAAAAAAAAAAAAUUUAACAAGCA-3′ (SEQ ID NO: 7368)3′-UUUUUUUUUUUUUUUUAAAUUGUUCGU-5′ (SEQ ID NO: 1823) βc-3209 Target:5′-AAAAAAAAAAAAAAAATTTAACAAGCA-3′ (SEQ ID NO: 2932)5′-AAAAAAAAAAAAAAAAAUUUAACAAGC-3′ (SEQ ID NO: 7369)3′-UUUUUUUUUUUUUUUUUAAAUUGUUCG-5′ (SEQ ID NO: 1824) βc-3210 Target:5′-AAAAAAAAAAAAAAAAATTTAACAAGC-3′ (SEQ ID NO: 2933)5′-AAAAAAAAAAAAAAAAAAUUUAACAAG-3′ (SEQ ID NO: 7370)3′-UUUUUUUUUUUUUUUUUUAAAUUGUUC-5′ (SEQ ID NO: 1825) βc-3211 Target:5′-AAAAAAAAAAAAAAAAAATTTAACAAG-3′ (SEQ ID NO: 2934)5′-AAAAAAAAAAAAAAAAAAAUUUAACAA-3′ (SEQ ID NO: 7371)3′-UUUUUUUUUUUUUUUUUUUAAAUUGUU-5′ (SEQ ID NO: 1826) βc-3212 Target:5′-AAAAAAAAAAAAAAAAAAATTTAACAA-3′ (SEQ ID NO: 2935)5′-UAAAAAAAAAAAAAAAAAAAUUUAACA-3′ (SEQ ID NO: 7372)3′-AUUUUUUUUUUUUUUUUUUUAAAUUGU-5′ (SEQ ID NO: 1827) βc-3213 Target:5′-TAAAAAAAAAAAAAAAAAAATTTAACA-3′ (SEQ ID NO: 2936)5′-UUAAAAAAAAAAAAAAAAAAAUUUAAC-3′ (SEQ ID NO: 7373)3′-AAUUUUUUUUUUUUUUUUUUUAAAUUG-5′ (SEQ ID NO: 1828) βc-3214 Target:5′-TTAAAAAAAAAAAAAAAAAAATTTAAC-3′ (SEQ ID NO: 2937)5′-CUUAAAAAAAAAAAAAAAAAAAUUUAA-3′ (SEQ ID NO: 7374)3′-GAAUUUUUUUUUUUUUUUUUUUAAAUU-5′ (SEQ ID NO: 1829) βc-3215 Target:5′-CTTAAAAAAAAAAAAAAAAAAATTTAA-3′ (SEQ ID NO: 2938)5′-UCUUAAAAAAAAAAAAAAAAAAAUUUA-3′ (SEQ ID NO: 7375)3′-AGAAUUUUUUUUUUUUUUUUUUUAAAU-5′ (SEQ ID NO: 1830) βc-3216 Target:5′-TCTTAAAAAAAAAAAAAAAAAAATTTA-3′ (SEQ ID NO: 2939)5′-AUUCUUAAAAAAAAAAAAAAAAAAAUU-3′ (SEQ ID NO: 7376)3′-UAAGAAUUUUUUUUUUUUUUUUUUUAA-5′ (SEQ ID NO: 1831) βc-3218 Target:5′-ATTCTTAAAAAAAAAAAAAAAAAAATT-3′ (SEQ ID NO: 2940)5′-UAUUCUUAAAAAAAAAAAAAAAAAAAU-3′ (SEQ ID NO: 7377)3′-AUAAGAAUUUUUUUUUUUUUUUUUUUA-5′ (SEQ ID NO: 1832) βc-3219 Target:5′-TATTCTTAAAAAAAAAAAAAAAAAAAT-3′ (SEQ ID NO: 2941)5′-AUAUUCUUAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 7378)3′-UAUAAGAAUUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1833) βc-3220 Target:5′-ATATTCTTAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2942)5′-GAUAUUCUUAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 7379)3′-CUAUAAGAAUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1834) βc-3221 Target:5′-GATATTCTTAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2943)5′-AGAUAUUCUUAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 7380)3′-UCUAUAAGAAUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1835) βc-3222 Target:5′-AGATATTCTTAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2944)5′-CAGAUAUUCUUAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 7381)3′-GUCUAUAAGAAUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1836) βc-3223 Target:5′-CAGATATTCTTAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2945)5′-ACAGAUAUUCUUAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 7382)3′-UGUCUAUAAGAAUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1837) βc-3224 Target:5′-ACAGATATTCTTAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2946)5′-CAUUACAGAUAUUCUUAAAAAAAAAAA-3′ (SEQ ID NO: 7383)3′-GUAAUGUCUAUAAGAAUUUUUUUUUUU-5′ (SEQ ID NO: 1838) βc-3228 Target:5′-CATTACAGATATTCTTAAAAAAAAAAA-3′ (SEQ ID NO: 2947)5′-CCAUUACAGAUAUUCUUAAAAAAAAAA-3′ (SEQ ID NO: 7384)3′-GGUAAUGUCUAUAAGAAUUUUUUUUUU-5′ (SEQ ID NO: 1839) βc-3229 Target:5′-CCATTACAGATATTCTTAAAAAAAAAA-3′ (SEQ ID NO: 2948)5′-AGUACCAUUACAGAUAUUCUUAAAAAA-3′ (SEQ ID NO: 7385)3′-UCAUGGUAAUGUCUAUAAGAAUUUUUU-5′ (SEQ ID NO: 1840) βc-3233 Target:5′-AGTACCATTACAGATATTCTTAAAAAA-3′ (SEQ ID NO: 2949)5′-CAGUACCAUUACAGAUAUUCUUAAAAA-3′ (SEQ ID NO: 7386)3′-GUCAUGGUAAUGUCUAUAAGAAUUUUU-5′ (SEQ ID NO: 1841) βc-3234 Target:5′-CAGTACCATTACAGATATTCTTAAAAA-3′ (SEQ ID NO: 2950)5′-UCAGUACCAUUACAGAUAUUCUUAAAA-3′ (SEQ ID NO: 7387)3′-AGUCAUGGUAAUGUCUAUAAGAAUUUU-5′ (SEQ ID NO: 1842) βc-3235 Target:5′-TCAGTACCATTACAGATATTCTTAAAA-3′ (SEQ ID NO: 2951)5′-AAAGUCAGUACCAUUACAGAUAUUCUU-3′ (SEQ ID NO: 7388)3′-UUUCAGUCAUGGUAAUGUCUAUAAGAA-5′ (SEQ ID NO: 1843) βc-3239 Target:5′-AAAGTCAGTACCATTACAGATATTCTT-3′ (SEQ ID NO: 2952)5′-GCUACUUCAAAGCAAGCAAAGUCAGUA-3′ (SEQ ID NO: 7389)3′-CGAUGAAGUUUCGUUCGUUUCAGUCAU-5′ (SEQ ID NO: 1844) βc-3256 Target:5′-GCTACTTCAAAGCAAGCAAAGTCAGTA-3′ (SEQ ID NO: 2953)5′-AAAAAAAGAGCUACUUCAAAGCAAGCA-3′ (SEQ ID NO: 7390)3′-UUUUUUUCUCGAUGAAGUUUCGUUCGU-5′ (SEQ ID NO: 1845) βc-3265 Target:5′-AAAAAAAGAGCTACTTCAAAGCAAGCA-3′ (SEQ ID NO: 2954)5′-AAAAAAAAAAAAGAGCUACUUCAAAGC-3′ (SEQ ID NO: 7391)3′-UUUUUUUUUUUUCUCGAUGAAGUUUCG-5′ (SEQ ID NO: 1846) βc-3270 Target:5′-AAAAAAAAAAAAGAGCTACTTCAAAGC-3′ (SEQ ID NO: 2955)5′-AAAAAAAAAAAAAGAGCUACUUCAAAG-3′ (SEQ ID NO: 7392)3′-UUUUUUUUUUUUUCUCGAUGAAGUUUC-5′ (SEQ ID NO: 1847) βc-3271 Target:5′-AAAAAAAAAAAAAGAGCTACTTCAAAG-3′ (SEQ ID NO: 2956)5′-AAAAAAAAAAAAAAAGAGCUACUUCAA-3′ (SEQ ID NO: 7393)3′-UUUUUUUUUUUUUUUCUCGAUGAAGUU-5′ (SEQ ID NO: 1848) βc-3273 Target:5′-AAAAAAAAAAAAAAAGAGCTACTTCAA-3′ (SEQ ID NO: 2957)5′-AAAAAAAAAAAAAAAAGAGCUACUUCA-3′ (SEQ ID NO: 7394)3′-UUUUUUUUUUUUUUUUCUCGAUGAAGU-5′ (SEQ ID NO: 1849) βc-3274 Target:5′-AAAAAAAAAAAAAAAAGAGCTACTTCA-3′ (SEQ ID NO: 2958)5′-AAAAAAAAAAAAAAAAAGAGCUACUUC-3′ (SEQ ID NO: 7395)3′-UUUUUUUUUUUUUUUUUCUCGAUGAAG-5′ (SEQ ID NO: 1850) βc-3275 Target:5′-AAAAAAAAAAAAAAAAAGAGCTACTTC-3′ (SEQ ID NO: 2959)5′-AAAAAAAAAAAAAAAAAAGAGCUACUU-3′ (SEQ ID NO: 7396)3′-UUUUUUUUUUUUUUUUUUCUCGAUGAA-5′ (SEQ ID NO: 1851) βc-3276 Target:5′-AAAAAAAAAAAAAAAAAAGAGCTACTT-3′ (SEQ ID NO: 2960)5′-AAAAAAAAAAAAAAAAAAAAAAAAGAG-3′ (SEQ ID NO: 7397)3′-UUUUUUUUUUUUUUUUUUUUUUUUCUC-5′ (SEQ ID NO: 1852) βc-3282 Target:5′-AAAAAAAAAAAAAAAAAAAAAAAAGAG-3′ (SEQ ID NO: 2961)5′-AAAAAAAAAAAAAAAAAAAAAAAAAGA-3′ (SEQ ID NO: 7398)3′-UUUUUUUUUUUUUUUUUUUUUUUUUCU-5′ (SEQ ID NO: 1853) βc-3283 Target:5′-AAAAAAAAAAAAAAAAAAAAAAAAAGA-3′ (SEQ ID NO: 2962)5′-CAAAAAAAAAAAAAAAAAAAAAAAAAG-3′ (SEQ ID NO: 7399)3′-GUUUUUUUUUUUUUUUUUUUUUUUUUC-5′ (SEQ ID NO: 1854) βc-3284 Target:5′-CAAAAAAAAAAAAAAAAAAAAAAAAAG-3′ (SEQ ID NO: 2963)5′-GCAAAAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 7400)3′-CGUUUUUUUUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1855) βc-3285 Target:5′-GCAAAAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2964)5′-CUGCAAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 7401)3′-GACGUUUUUUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1856) βc-3287 Target:5′-CTGCAAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2965)5′-ACUGCAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 7402)3′-UGACGUUUUUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1857) βc-3288 Target:5′-ACTGCAAAAAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2966)5′-AGUUACUGCAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 7403)3′-UCAAUGACGUUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1858) βc-3292 Target:5′-AGTTACTGCAAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2967)5′-CAGUUACUGCAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 7404)3′-GUCAAUGACGUUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1859) βc-3293 Target:5′-CAGTTACTGCAAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2968)5′-ACAGUUACUGCAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 7405)3′-UGUCAAUGACGUUUUUUUUUUUUUUUU-5′ (SEQ ID NO: 1860) βc-3294 Target:5′-ACAGTTACTGCAAAAAAAAAAAAAAAA-3′ (SEQ ID NO: 2969)5′-AAAAACAGUUACUGCAAAAAAAAAAAA-3′ (SEQ ID NO: 7406)3′-UUUUUGUCAAUGACGUUUUUUUUUUUU-5′ (SEQ ID NO: 1861) βc-3298 Target:5′-AAAAACAGTTACTGCAAAAAAAAAAAA-3′ (SEQ ID NO: 2970)5′-AAAAAACAGUUACUGCAAAAAAAAAAA-3′ (SEQ ID NO: 7407)3′-UUUUUUGUCAAUGACGUUUUUUUUUUU-5′ (SEQ ID NO: 1862) βc-3299 Target:5′-AAAAAACAGTTACTGCAAAAAAAAAAA-3′ (SEQ ID NO: 2971)5′-UAAAAAACAGUUACUGCAAAAAAAAAA-3′ (SEQ ID NO: 7408)3′-AUUUUUUGUCAAUGACGUUUUUUUUUU-5′ (SEQ ID NO: 1863) βc-3300 Target:5′-TAAAAAACAGTTACTGCAAAAAAAAAA-3′ (SEQ ID NO: 2972)5′-CUUAAAAAACAGUUACUGCAAAAAAAA-3′ (SEQ ID NO: 7409)3′-GAAUUUUUUGUCAAUGACGUUUUUUUU-5′ (SEQ ID NO: 1864) βc-3302 Target:5′-CTTAAAAAACAGTTACTGCAAAAAAAA-3′ (SEQ ID NO: 2973)5′-ACUUAAAAAACAGUUACUGCAAAAAAA-3′ (SEQ ID NO: 7410)3′-UGAAUUUUUUGUCAAUGACGUUUUUUU-5′ (SEQ ID NO: 1865) βc-3303 Target:5′-ACTTAAAAAACAGTTACTGCAAAAAAA-3′ (SEQ ID NO: 2974)5′-AGACUUAAAAAACAGUUACUGCAAAAA-3′ (SEQ ID NO: 7411)3′-UCUGAAUUUUUUGUCAAUGACGUUUUU-5′ (SEQ ID NO: 1866) βc-3305 Target:5′-AGACTTAAAAAACAGTTACTGCAAAAA-3′ (SEQ ID NO: 2975)5′-ACACUACGAGAGACUUAAAAAACAGUU-3′ (SEQ ID NO: 7412)3′-UGUGAUGCUCUCUGAAUUUUUUGUCAA-5′ (SEQ ID NO: 1867) βc-3315 Target:5′-ACACTACGAGAGACTTAAAAAACAGTT-3′ (SEQ ID NO: 2976)5′-UAACACUACGAGAGACUUAAAAAACAG-3′ (SEQ ID NO: 7413)3′-AUUGUGAUGCUCUCUGAAUUUUUUGUC-5′ (SEQ ID NO: 1868) βc-3317 Target:5′-TAACACTACGAGAGACTTAAAAAACAG-3′ (SEQ ID NO: 2977)5′-UUAACACUACGAGAGACUUAAAAAACA-3′ (SEQ ID NO: 7414)3′-AAUUGUGAUGCUCUCUGAAUUUUUUGU-5′ (SEQ ID NO: 1869) βc-3318 Target:5′-TTAACACTACGAGAGACTTAAAAAACA-3′ (SEQ ID NO: 2978)5′-ACUUAACACUACGAGAGACUUAAAAAA-3′ (SEQ ID NO: 7415)3′-UGAAUUGUGAUGCUCUCUGAAUUUUUU-5′ (SEQ ID NO: 1870) βc-3320 Target:5′-ACTTAACACTACGAGAGACTTAAAAAA-3′ (SEQ ID NO: 2979)5′-AUAACUUAACACUACGAGAGACUUAAA-3′ (SEQ ID NO: 7416)3′-UAUUGAAUUGUGAUGCUCUCUGAAUUU-5′ (SEQ ID NO: 1871) βc-3323 Target:5′-ATAACTTAACACTACGAGAGACTTAAA-3′ (SEQ ID NO: 2980)5′-UAUAACUUAACACUACGAGAGACUUAA-3′ (SEQ ID NO: 7417)3′-AUAUUGAAUUGUGAUGCUCUCUGAAUU-5′ (SEQ ID NO: 1872) βc-3324 Target:5′-TATAACTTAACACTACGAGAGACTTAA-3′ (SEQ ID NO: 2981)5′-GUAUUCACUAUAACUUAACACUACGAG-3′ (SEQ ID NO: 7418)3′-CAUAAGUGAUAUUGAAUUGUGAUGCUC-5′ (SEQ ID NO: 1873) βc-3332 Target:5′-GTATTCACTATAACTTAACACTACGAG-3′ (SEQ ID NO: 2982)5′-AGUAUUCACUAUAACUUAACACUACGA-3′ (SEQ ID NO: 7419)3′-UCAUAAGUGAUAUUGAAUUGUGAUGCU-5′ (SEQ ID NO: 1874) βc-3333 Target:5′-AGTATTCACTATAACTTAACACTACGA-3′ (SEQ ID NO: 2983)5′-CAGUAUUCACUAUAACUUAACACUACG-3′ (SEQ ID NO: 7420)3′-GUCAUAAGUGAUAUUGAAUUGUGAUGC-5′ (SEQ ID NO: 1875) βc-3334 Target:5′-CAGTATTCACTATAACTTAACACTACG-3′ (SEQ ID NO: 2984)5′-GCAGUAUUCACUAUAACUUAACACUAC-3′ (SEQ ID NO: 7421)3′-CGUCAUAAGUGAUAUUGAAUUGUGAUG-5′ (SEQ ID NO: 1876) βc-3335 Target:5′-GCAGTATTCACTATAACTTAACACTAC-3′ (SEQ ID NO: 2985)5′-AGAAAUUGCUGUAGCAGUAUUCACUAU-3′ (SEQ ID NO: 7422)3′-UCUUUAACGACAUCGUCAUAAGUGAUA-5′ (SEQ ID NO: 1877) βc-3348 Target:5′-AGAAATTGCTGTAGCAGTATTCACTAT-3′ (SEQ ID NO: 2986)5′-UAGAAAUUGCUGUAGCAGUAUUCACUA-3′ (SEQ ID NO: 7423)3′-AUCUUUAACGACAUCGUCAUAAGUGAU-5′ (SEQ ID NO: 1878) βc-3349 Target:5′-TAGAAATTGCTGTAGCAGTATTCACTA-3′ (SEQ ID NO: 2987)5′-UUAGAAAUUGCUGUAGCAGUAUUCACU-3′ (SEQ ID NO: 7424)3′-AAUCUUUAACGACAUCGUCAUAAGUGA-5′ (SEQ ID NO: 1879) βc-3350 Target:5′-TTAGAAATTGCTGTAGCAGTATTCACT-3′ (SEQ ID NO: 2988)5′-ACUCAAUUCUUAAAAAUUAGAAAUUGC-3′ (SEQ ID NO: 7425)3′-UGAGUUAAGAAUUUUUAAUCUUUAACG-5′ (SEQ ID NO: 1880) βc-3366 Target:5′-ACTCAATTCTTAAAAATTAGAAATTGC-3′ (SEQ ID NO: 2989)5′-CCAUUACUCAAUUCUUAAAAAUUAGAA-3′ (SEQ ID NO: 7426)3′-GGUAAUGAGUUAAGAAUUUUUAAUCUU-5′ (SEQ ID NO: 1881) βc-3371 Target:5′-CCATTACTCAATTCTTAAAAATTAGAA-3′ (SEQ ID NO: 2990)5′-ACACCAUUACUCAAUUCUUAAAAAUUA-3′ (SEQ ID NO: 7427)3′-UGUGGUAAUGAGUUAAGAAUUUUUAAU-5′ (SEQ ID NO: 1882) βc-3374 Target:5′-ACACCATTACTCAATTCTTAAAAATTA-3′ (SEQ ID NO: 2991)5′-CUACACCAUUACUCAAUUCUUAAAAAU-3′ (SEQ ID NO: 7428)3′-GAUGUGGUAAUGAGUUAAGAAUUUUUA-5′ (SEQ ID NO: 1883) βc-3376 Target:5′-CTACACCATTACTCAATTCTTAAAAAT-3′ (SEQ ID NO: 2992)5′-UCUACACCAUUACUCAAUUCUUAAAAA-3′ (SEQ ID NO: 7429)3′-AGAUGUGGUAAUGAGUUAAGAAUUUUU-5′ (SEQ ID NO: 1884) βc-3377 Target:5′-TCTACACCATTACTCAATTCTTAAAAA-3′ (SEQ ID NO: 2993)5′-GUUCUACACCAUUACUCAAUUCUUAAA-3′ (SEQ ID NO: 7430)3′-CAAGAUGUGGUAAUGAGUUAAGAAUUU-5′ (SEQ ID NO: 1885) βc-3379 Target:5′-GTTCTACACCATTACTCAATTCTTAAA-3′ (SEQ ID NO: 2994)5′-GUGUUCUACACCAUUACUCAAUUCUUA-3′ (SEQ ID NO: 7431)3′-CACAAGAUGUGGUAAUGAGUUAAGAAU-5′ (SEQ ID NO: 1886) βc-3381 Target:5′-GTGTTCTACACCATTACTCAATTCTTA-3′ (SEQ ID NO: 2995)5′-AUGAAUUAGUGUUCUACACCAUUACUC-3′ (SEQ ID NO: 7432)3′-UACUUAAUCACAAGAUGUGGUAAUGAG-5′ (SEQ ID NO: 1887) βc-3389 Target:5′-ATGAATTAGTGTTCTACACCATTACTC-3′ (SEQ ID NO: 2996)5′-UGAUUAUGAAUUAGUGUUCUACACCAU-3′ (SEQ ID NO: 7433)3′-ACUAAUACUUAAUCACAAGAUGUGGUA-5′ (SEQ ID NO: 1888) βc-3394 Target:5′-TGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 2997)5′-GUGAUUAUGAAUUAGUGUUCUACACCA-3′ (SEQ ID NO: 7434)3′-CACUAAUACUUAAUCACAAGAUGUGGU-5′ (SEQ ID NO: 1889) βc-3395 Target:5′-GTGATTATGAATTAGTGTTCTACACCA-3′ (SEQ ID NO: 2998)5′-AGUGAUUAUGAAUUAGUGUUCUACACC-3′ (SEQ ID NO: 7435)3′-UCACUAAUACUUAAUCACAAGAUGUGG-5′ (SEQ ID NO: 1890) βc-3396 Target:5′-AGTGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 2999)5′-AUUAAUUAGAGUGAUUAUGAAUUAGUG-3′ (SEQ ID NO: 7436)3′-UAAUUAAUCUCACUAAUACUUAAUCAC-5′ (SEQ ID NO: 1891) βc-3405 Target:5′-ATTAATTAGAGTGATTATGAATTAGTG-3′ (SEQ ID NO: 3000)5′-AAUUAAUUAGAGUGAUUAUGAAUUAGU-3′ (SEQ ID NO: 7437)3′-UUAAUUAAUCUCACUAAUACUUAAUCA-5′ (SEQ ID NO: 1892) βc-3406 Target:5′-AATTAATTAGAGTGATTATGAATTAGT-3′ (SEQ ID NO: 3001)5′-CAAUUAAUUAGAGUGAUUAUGAAUUAG-3′ (SEQ ID NO: 7438)3′-GUUAAUUAAUCUCACUAAUACUUAAUC-5′ (SEQ ID NO: 1893) βc-3407 Target:5′-CAATTAATTAGAGTGATTATGAATTAG-3′ (SEQ ID NO: 3002)5′-AUUACAAUUAAUUAGAGUGAUUAUGAA-3′ (SEQ ID NO: 7439)3′-UAAUGUUAAUUAAUCUCACUAAUACUU-5′ (SEQ ID NO: 1894) βc-3411 Target:5′-ATTACAATTAATTAGAGTGATTATGAA-3′ (SEQ ID NO: 3003)5′-GAUUACAAUUAAUUAGAGUGAUUAUGA-3′ (SEQ ID NO: 7440)3′-CUAAUGUUAAUUAAUCUCACUAAUACU-5′ (SEQ ID NO: 1895) βc-3412 Target:5′-GATTACAATTAATTAGAGTGATTATGA-3′ (SEQ ID NO: 3004)5′-AGAUUACAAUUAAUUAGAGUGAUUAUG-3′ (SEQ ID NO: 7441)3′-UCUAAUGUUAAUUAAUCUCACUAAUAC-5′ (SEQ ID NO: 1896) βc-3413 Target:5′-AGATTACAATTAATTAGAGTGATTATG-3′ (SEQ ID NO: 3005)5′-CUUUAUUCAGAUUACAAUUAAUUAGAG-3′ (SEQ ID NO: 7442)3′-GAAAUAAGUCUAAUGUUAAUUAAUCUC-5′ (SEQ ID NO: 1897) βc-3421 Target:5′-CTTTATTCAGATTACAATTAATTAGAG-3′ (SEQ ID NO: 3006)5′-ACUUUAUUCAGAUUACAAUUAAUUAGA-3′ (SEQ ID NO: 7443)3′-UGAAAUAAGUCUAAUGUUAAUUAAUCU-5′ (SEQ ID NO: 1898) βc-3422 Target:5′-ACTTTATTCAGATTACAATTAATTAGA-3′ (SEQ ID NO: 3007)5′-UUACACUUUAUUCAGAUUACAAUUAAU-3′ (SEQ ID NO: 7444)3′-AAUGUGAAAUAAGUCUAAUGUUAAUUA-5′ (SEQ ID NO: 1899) βc-3426 Target:5′-TTACACTTTATTCAGATTACAATTAAT-3′ (SEQ ID NO: 3008)5′-GUUACACUUUAUUCAGAUUACAAUUAA-3′ (SEQ ID NO: 7445)3′-CAAUGUGAAAUAAGUCUAAUGUUAAUU-5′ (SEQ ID NO: 1900) βc-3427 Target:5′-GTTACACTTTATTCAGATTACAATTAA-3′ (SEQ ID NO: 3009)5′-UGUUACACUUUAUUCAGAUUACAAUUA-3′ (SEQ ID NO: 7446)3′-ACAAUGUGAAAUAAGUCUAAUGUUAAU-5′ (SEQ ID NO: 1901) βc-3428 Target:5′-TGTTACACTTTATTCAGATTACAATTA-3′ (SEQ ID NO: 3010)5′-UUGUUACACUUUAUUCAGAUUACAAUU-3′ (SEQ ID NO: 7447)3′-AACAAUGUGAAAUAAGUCUAAUGUUAA-5′ (SEQ ID NO: 1902) βc-3429 Target:5′-TTGTTACACTTTATTCAGATTACAATT-3′ (SEQ ID NO: 3011)5′-AUUGUUACACUUUAUUCAGAUUACAAU-3′ (SEQ ID NO: 7448)3′-UAACAAUGUGAAAUAAGUCUAAUGUUA-5′ (SEQ ID NO: 1903) βc-3430 Target:5′-ATTGTTACACTTTATTCAGATTACAAT-3′ (SEQ ID NO: 3012)5′-CUACACAAUUGUUACACUUUAUUCAGA-3′ (SEQ ID NO: 7449)3′-GAUGUGUUAACAAUGUGAAAUAAGUCU-5′ (SEQ ID NO: 1904) βc-3437 Target:5′-CTACACAATTGTTACACTTTATTCAGA-3′ (SEQ ID NO: 3013)5′-AAGGCUACACAAUUGUUACACUUUAUU-3′ (SEQ ID NO: 7450)3′-UUCCGAUGUGUUAACAAUGUGAAAUAA-5′ (SEQ ID NO: 1905) βc-3441 Target:5′-AAGGCTACACAATTGTTACACTTTATT-3′ (SEQ ID NO: 3014)5′-ACAAAAAGGCUACACAAUUGUUACACU-3′ (SEQ ID NO: 7451)3′-UGUUUUUCCGAUGUGUUAACAAUGUGA-5′ (SEQ ID NO: 1906) βc-3446 Target:5′-ACAAAAAGGCTACACAATTGTTACACT-3′ (SEQ ID NO: 3015)5′-UUUUAUACAAAAAGGCUACACAAUUGU-3′ (SEQ ID NO: 7452)3′-AAAAUAUGUUUUUCCGAUGUGUUAACA-5′ (SEQ ID NO: 1907) βc-3452 Target:5′-TTTTATACAAAAAGGCTACACAATTGT-3′ (SEQ ID NO: 3016)5′-AUUUUAUACAAAAAGGCUACACAAUUG-3′ (SEQ ID NO: 7453)3′-UAAAAUAUGUUUUUCCGAUGUGUUAAC-5′ (SEQ ID NO: 1908) βc-3453 Target:5′-ATTTTATACAAAAAGGCTACACAATTG-3′ (SEQ ID NO: 3017)5′-CUAUUUUAUACAAAAAGGCUACACAAU-3′ (SEQ ID NO: 7454)3′-GAUAAAAUAUGUUUUUCCGAUGUGUUA-5′ (SEQ ID NO: 1909) βc-3455 Target:5′-CTATTTTATACAAAAAGGCTACACAAT-3′ (SEQ ID NO: 3018)5′-UCUAUUUUAUACAAAAAGGCUACACAA-3′ (SEQ ID NO: 7455)3′-AGAUAAAAUAUGUUUUUCCGAUGUGUU-5′ (SEQ ID NO: 1910) βc-3456 Target:5′-TCTATTTTATACAAAAAGGCTACACAA-3′ (SEQ ID NO: 3019)5′-UGUCUAUUUUAUACAAAAAGGCUACAC-3′ (SEQ ID NO: 7456)3′-ACAGAUAAAAUAUGUUUUUCCGAUGUG-5′ (SEQ ID NO: 1911) βc-3458 Target:5′-TGTCTATTTTATACAAAAAGGCTACAC-3′ (SEQ ID NO: 3020)5′-UCUAUUUGUCUAUUUUAUACAAAAAGG-3′ (SEQ ID NO: 7457)3′-AGAUAAACAGAUAAAAUAUGUUUUUCC-5′ (SEQ ID NO: 1912) βc-3464 Target:5′-TCTATTTGTCTATTTTATACAAAAAGG-3′ (SEQ ID NO: 3021)5′-UUUCUAUUUGUCUAUUUUAUACAAAAA-3′ (SEQ ID NO: 7458)3′-AAAGAUAAACAGAUAAAAUAUGUUUUU-5′ (SEQ ID NO: 1913) βc-3466 Target:5′-TTTCTATTTGTCTATTTTATACAAAAA-3′ (SEQ ID NO: 3022)5′-UUUUCUAUUUGUCUAUUUUAUACAAAA-3′ (SEQ ID NO: 7459)3′-AAAAGAUAAACAGAUAAAAUAUGUUUU-5′ (SEQ ID NO: 1914) βc-3467 Target:5′-TTTTCTATTTGTCTATTTTATACAAAA-3′ (SEQ ID NO: 3023)5′-AUUUUCUAUUUGUCUAUUUUAUACAAA-3′ (SEQ ID NO: 7460)3′-UAAAAGAUAAACAGAUAAAAUAUGUUU-5′ (SEQ ID NO: 1915) βc-3468 Target:5′-ATTTTCTATTTGTCTATTTTATACAAA-3′ (SEQ ID NO: 3024)5′-CAUUUUCUAUUUGUCUAUUUUAUACAA-3′ (SEQ ID NO: 7461)3′-GUAAAAGAUAAACAGAUAAAAUAUGUU-5′ (SEQ ID NO: 1916) βc-3469 Target:5′-CATTTTCTATTTGTCTATTTTATACAA-3′ (SEQ ID NO: 3025)5′-CCAUUUUCUAUUUGUCUAUUUUAUACA-3′ (SEQ ID NO: 7462)3′-GGUAAAAGAUAAACAGAUAAAAUAUGU-5′ (SEQ ID NO: 1917) βc-3470 Target:5′-CCATTTTCTATTTGTCTATTTTATACA-3′ (SEQ ID NO: 3026)5′-GGACCAUUUUCUAUUUGUCUAUUUUAU-3′ (SEQ ID NO: 7463)3′-CCUGGUAAAAGAUAAACAGAUAAAAUA-5′ (SEQ ID NO: 1918) βc-3473 Target:5′-GGACCATTTTCTATTTGTCTATTTTAT-3′ (SEQ ID NO: 3027)5′-UGGACCAUUUUCUAUUUGUCUAUUUUA-3′ (SEQ ID NO: 7464)3′-ACCUGGUAAAAGAUAAACAGAUAAAAU-5′ (SEQ ID NO: 1919) βc-3474 Target:5′-TGGACCATTTTCTATTTGTCTATTTTA-3′ (SEQ ID NO: 3028)5′-UUGGACCAUUUUCUAUUUGUCUAUUUU-3′ (SEQ ID NO: 7465)3′-AACCUGGUAAAAGAUAAACAGAUAAAA-5′ (SEQ ID NO: 1920) βc-3475 Target:5′-TTGGACCATTTTCTATTTGTCTATTTT-3′ (SEQ ID NO: 3029)5′-AAACUAAUUGGACCAUUUUCUAUUUGU-3′ (SEQ ID NO: 7466)3′-UUUGAUUAACCUGGUAAAAGAUAAACA-5′ (SEQ ID NO: 1921) βc-3482 Target:5′-AAACTAATTGGACCATTTTCTATTTGT-3′ (SEQ ID NO: 3030)5′-GAAACUAAUUGGACCAUUUUCUAUUUG-3′ (SEQ ID NO: 7467)3′-CUUUGAUUAACCUGGUAAAAGAUAAAC-5′ (SEQ ID NO: 1922) βc-3483 Target:5′-GAAACTAATTGGACCATTTTCTATTTG-3′ (SEQ ID NO: 3031)5′-GGAAACUAAUUGGACCAUUUUCUAUUU-3′ (SEQ ID NO: 7468)3′-CCUUUGAUUAACCUGGUAAAAGAUAAA-5′ (SEQ ID NO: 1923) βc-3484 Target:5′-GGAAACTAATTGGACCATTTTCTATTT-3′ (SEQ ID NO: 3032)5′-AGGAAACUAAUUGGACCAUUUUCUAUU-3′ (SEQ ID NO: 7469)3′-UCCUUUGAUUAACCUGGUAAAAGAUAA-5′ (SEQ ID NO: 1924) βc-3485 Target:5′-AGGAAACTAATTGGACCATTTTCTATT-3′ (SEQ ID NO: 3033)5′-UUAAAAAGGAAACUAAUUGGACCAUUU-3′ (SEQ ID NO: 7470)3′-AAUUUUUCCUUUGAUUAACCUGGUAAA-5′ (SEQ ID NO: 1925) βc-3491 Target:5′-TTAAAAAGGAAACTAATTGGACCATTT-3′ (SEQ ID NO: 3034)5′-AUUAAAAAGGAAACUAAUUGGACCAUU-3′ (SEQ ID NO: 7471)3′-UAAUUUUUCCUUUGAUUAACCUGGUAA-5′ (SEQ ID NO: 1926) βc-3492 Target:5′-ATTAAAAAGGAAACTAATTGGACCATT-3′ (SEQ ID NO: 3035)5′-AAGCAUAUUAAAAAGGAAACUAAUUGG-3′ (SEQ ID NO: 7472)3′-UUCGUAUAAUUUUUCCUUUGAUUAACC-5′ (SEQ ID NO: 1927) βc-3498 Target:5′-AAGCATATTAAAAAGGAAACTAATTGG-3′ (SEQ ID NO: 3036)5′-UAAGCAUAUUAAAAAGGAAACUAAUUG-3′ (SEQ ID NO: 7473)3′-AUUCGUAUAAUUUUUCCUUUGAUUAAC-5′ (SEQ ID NO: 1928) βc-3499 Target:5′-TAAGCATATTAAAAAGGAAACTAATTG-3′ (SEQ ID NO: 3037)5′-AUUUUAAGCAUAUUAAAAAGGAAACUA-3′ (SEQ ID NO: 7474)3′-UAAAAUUCGUAUAAUUUUUCCUUUGAU-5′ (SEQ ID NO: 1929) βc-3503 Target:5′-ATTTTAAGCATATTAAAAAGGAAACTA-3′ (SEQ ID NO: 3038)5′-CUGCUUAUUUUAAGCAUAUUAAAAAGG-3′ (SEQ ID NO: 7475)3′-GACGAAUAAAAUUCGUAUAAUUUUUCC-5′ (SEQ ID NO: 1930) βc-3509 Target:5′-CTGCTTATTTTAAGCATATTAAAAAGG-3′ (SEQ ID NO: 3039)5′-CCUGCUUAUUUUAAGCAUAUUAAAAAG-3′ (SEQ ID NO: 7476)3′-GGACGAAUAAAAUUCGUAUAAUUUUUC-5′ (SEQ ID NO: 1931) βc-3510 Target:5′-CCTGCTTATTTTAAGCATATTAAAAAG-3′ (SEQ ID NO: 3040)5′-GAUCCACCUGCUUAUUUUAAGCAUAUU-3′ (SEQ ID NO: 7477)3′-CUAGGUGGACGAAUAAAAUUCGUAUAA-5′ (SEQ ID NO: 1932) βc-3516 Target:5′-GATCCACCTGCTTATTTTAAGCATATT-3′ (SEQ ID NO: 3041)5′-CAAAAACAUGAAAUAGAUCCACCUGCU-3′ (SEQ ID NO: 7478)3′-GUUUUUGUACUUUAUCUAGGUGGACGA-5′ (SEQ ID NO: 1933) βc-3531 Target:5′-CAAAAACATGAAATAGATCCACCTGCT-3′ (SEQ ID NO: 3042)5′-UCAAAAACAUGAAAUAGAUCCACCUGC-3′ (SEQ ID NO: 7479)3′-AGUUUUUGUACUUUAUCUAGGUGGACG-5′ (SEQ ID NO: 1934) βc-3532 Target:5′-TCAAAAACATGAAATAGATCCACCTGC-3′ (SEQ ID NO: 3043)5′-GAUCAAAAACAUGAAAUAGAUCCACCU-3′ (SEQ ID NO: 7480)3′-CUAGUUUUUGUACUUUAUCUAGGUGGA-5′ (SEQ ID NO: 1935) βc-3534 Target:5′-GATCAAAAACATGAAATAGATCCACCT-3′ (SEQ ID NO: 3044)5′-UGAUCAAAAACAUGAAAUAGAUCCACC-3′ (SEQ ID NO: 7481)3′-ACUAGUUUUUGUACUUUAUCUAGGUGG-5′ (SEQ ID NO: 1936) βc-3535 Target:5′-TGATCAAAAACATGAAATAGATCCACC-3′ (SEQ ID NO: 3045)5′-UUGAUCAAAAACAUGAAAUAGAUCCAC-3′ (SEQ ID NO: 7482)3′-AACUAGUUUUUGUACUUUAUCUAGGUG-5′ (SEQ ID NO: 1937) βc-3536 Target:5′-TTGATCAAAAACATGAAATAGATCCAC-3′ (SEQ ID NO: 3046)5′-AGUUUUUGAUCAAAAACAUGAAAUAGA-3′ (SEQ ID NO: 7483)3′-UCAAAAACUAGUUUUUGUACUUUAUCU-5′ (SEQ ID NO: 1938) βc-3541 Target:5′-AGTTTTTGATCAAAAACATGAAATAGA-3′ (SEQ ID NO: 3047)5′-CCAAAUAGUUUUUGAUCAAAAACAUGA-3′ (SEQ ID NO: 7484)3′-GGUUUAUCAAAAACUAGUUUUUGUACU-5′ (SEQ ID NO: 1939) βc-3547 Target:5′-CCAAATAGTTTTTGATCAAAAACATGA-3′ (SEQ ID NO: 3048)5′-UAUCCCAAAUAGUUUUUGAUCAAAAAC-3′ (SEQ ID NO: 7485)3′-AUAGGGUUUAUCAAAAACUAGUUUUUG-5′ (SEQ ID NO: 1940) βc-3551 Target:5′-TATCCCAAATAGTTTTTGATCAAAAAC-3′ (SEQ ID NO: 3049)5′-AUAUCCCAAAUAGUUUUUGAUCAAAAA-3′ (SEQ ID NO: 7486)3′-UAUAGGGUUUAUCAAAAACUAGUUUUU-5′ (SEQ ID NO: 1941) βc-3552 Target:5′-ATATCCCAAATAGTTTTTGATCAAAAA-3′ (SEQ ID NO: 3050)5′-CAUAUCCCAAAUAGUUUUUGAUCAAAA-3′ (SEQ ID NO: 7487)3′-GUAUAGGGUUUAUCAAAAACUAGUUUU-5′ (SEQ ID NO: 1942) βc-3553 Target:5′-CATATCCCAAATAGTTTTTGATCAAAA-3′ (SEQ ID NO: 3051)5′-ACAUAUCCCAAAUAGUUUUUGAUCAAA-3′ (SEQ ID NO: 7488)3′-UGUAUAGGGUUUAUCAAAAACUAGUUU-5′ (SEQ ID NO: 1943) βc-3554 Target:5′-ACATATCCCAAATAGTTTTTGATCAAA-3′ (SEQ ID NO: 3052)5′-CCAUACAUAUCCCAAAUAGUUUUUGAU-3′ (SEQ ID NO: 7489)3′-GGUAUGUAUAGGGUUUAUCAAAAACUA-5′ (SEQ ID NO: 1944) βc-3558 Target:5′-CCATACATATCCCAAATAGTTTTTGAT-3′ (SEQ ID NO: 3053)5′-UUACCCUACCCAUACAUAUCCCAAAUA-3′ (SEQ ID NO: 7490)3′-AAUGGGAUGGGUAUGUAUAGGGUUUAU-5′ (SEQ ID NO: 1945) βc-3567 Target:5′-TTACCCTACCCATACATATCCCAAATA-3′ (SEQ ID NO: 3054)5′-UUUACCCUACCCAUACAUAUCCCAAAU-3′ (SEQ ID NO: 7491)3′-AAAUGGGAUGGGUAUGUAUAGGGUUUA-5′ (SEQ ID NO: 1946) βc-3568 Target:5′-TTTACCCTACCCATACATATCCCAAAT-3′ (SEQ ID NO: 3055)5′-AUUUACCCUACCCAUACAUAUCCCAAA-3′ (SEQ ID NO: 7492)3′-UAAAUGGGAUGGGUAUGUAUAGGGUUU-5′ (SEQ ID NO: 1947) βc-3569 Target:5′-ATTTACCCTACCCATACATATCCCAAA-3′ (SEQ ID NO: 3056)5′-ACACCUCUUACUGAUUUACCCUACCCA-3′ (SEQ ID NO: 7493)3′-UGUGGAGAAUGACUAAAUGGGAUGGGU-5′ (SEQ ID NO: 1948) βc-3582 Target:5′-ACACCTCTTACTGATTTACCCTACCCA-3′ (SEQ ID NO: 3057)5′-UAACACCUCUUACUGAUUUACCCUACC-3′ (SEQ ID NO: 7494)3′-AUUGUGGAGAAUGACUAAAUGGGAUGG-5′ (SEQ ID NO: 1949) βc-3584 Target:5′-TAACACCTCTTACTGATTTACCCTACC-3′ (SEQ ID NO: 3058)5′-AUAACACCUCUUACUGAUUUACCCUAC-3′ (SEQ ID NO: 7495)3′-UAUUGUGGAGAAUGACUAAAUGGGAUG-5′ (SEQ ID NO: 1950) βc-3585 Target:5′-ATAACACCTCTTACTGATTTACCCTAC-3′ (SEQ ID NO: 3059)5′-AAUAACACCUCUUACUGAUUUACCCUA-3′ (SEQ ID NO: 7496)3′-UUAUUGUGGAGAAUGACUAAAUGGGAU-5′ (SEQ ID NO: 1951) βc-3586 Target:5′-AATAACACCTCTTACTGATTTACCCTA-3′ (SEQ ID NO: 3060)5′-AAAUAACACCUCUUACUGAUUUACCCU-3′ (SEQ ID NO: 7497)3′-UUUAUUGUGGAGAAUGACUAAAUGGGA-5′ (SEQ ID NO: 1952) βc-3587 Target:5′-AAATAACACCTCTTACTGATTTACCCT-3′ (SEQ ID NO: 3061)5′-CAAAUAACACCUCUUACUGAUUUACCC-3′ (SEQ ID NO: 7498)3′-GUUUAUUGUGGAGAAUGACUAAAUGGG-5′ (SEQ ID NO: 1953) βc-3588 Target:5′-CAAATAACACCTCTTACTGATTTACCC-3′ (SEQ ID NO: 3062)5′-AGGUUCCAAAUAACACCUCUUACUGAU-3′ (SEQ ID NO: 7499)3′-UCCAAGGUUUAUUGUGGAGAAUGACUA-5′ (SEQ ID NO: 1954) βc-3594 Target:5′-AGGTTCCAAATAACACCTCTTACTGAT-3′ (SEQ ID NO: 3063)5′-AAAACAAGGUUCCAAAUAACACCUCUU-3′ (SEQ ID NO: 7500)3′-UUUUGUUCCAAGGUUUAUUGUGGAGAA-5′ (SEQ ID NO: 1955) βc-3600 Target:5′-AAAACAAGGTTCCAAATAACACCTCTT-3′ (SEQ ID NO: 3064)5′-CAAAACAAGGUUCCAAAUAACACCUCU-3′ (SEQ ID NO: 7501)3′-GUUUUGUUCCAAGGUUUAUUGUGGAGA-5′ (SEQ ID NO: 1956) βc-3601 Target:5′-CAAAACAAGGTTCCAAATAACACCTCT-3′ (SEQ ID NO: 3065)5′-CCAAAACAAGGUUCCAAAUAACACCUC-3′ (SEQ ID NO: 7502)3′-GGUUUUGUUCCAAGGUUUAUUGUGGAG-5′ (SEQ ID NO: 1957) βc-3602 Target:5′-CCAAAACAAGGTTCCAAATAACACCTC-3′ (SEQ ID NO: 3066)5′-ACUGUCCAAAACAAGGUUCCAAAUAAC-3′ (SEQ ID NO: 7503)3′-UGACAGGUUUUGUUCCAAGGUUUAUUG-5′ (SEQ ID NO: 1958) βc-3607 Target:5′-ACTGTCCAAAACAAGGTTCCAAATAAC-3′ (SEQ ID NO: 3067)5′-GUAAACUGUCCAAAACAAGGUUCCAAA-3′ (SEQ ID NO: 7504)3′-CAUUUGACAGGUUUUGUUCCAAGGUUU-5′ (SEQ ID NO: 1959) βc-3611 Target:5′-GTAAACTGTCCAAAACAAGGTTCCAAA-3′ (SEQ ID NO: 3068)5′-GGUAAACUGUCCAAAACAAGGUUCCAA-3′ (SEQ ID NO: 7505)3′-CCAUUUGACAGGUUUUGUUCCAAGGUU-5′ (SEQ ID NO: 1960) βc-3612 Target:5′-GGTAAACTGTCCAAAACAAGGTTCCAA-3′ (SEQ ID NO: 3069)5′-AGGCAACUGGUAAACUGUCCAAAACAA-3′ (SEQ ID NO: 7506)3′-UCCGUUGACCAUUUGACAGGUUUUGUU-5′ (SEQ ID NO: 1961) βc-3620 Target:5′-AGGCAACTGGTAAACTGTCCAAAACAA-3′ (SEQ ID NO: 3070)5′-GGGAUAAAAGGCAACUGGUAAACUGUC-3′ (SEQ ID NO: 7507)3′-CCCUAUUUUCCGUUGACCAUUUGACAG-5′ (SEQ ID NO: 1962) βc-3628 Target:5′-GGGATAAAAGGCAACTGGTAAACTGTC-3′ (SEQ ID NO: 3071)5′-UGGGAUAAAAGGCAACUGGUAAACUGU-3′ (SEQ ID NO: 7508)3′-ACCCUAUUUUCCGUUGACCAUUUGACA-5′ (SEQ ID NO: 1963) βc-3629 Target:5′-TGGGATAAAAGGCAACTGGTAAACTGT-3′ (SEQ ID NO: 3072)5′-ACAACUUUGGGAUAAAAGGCAACUGGU-3′ (SEQ ID NO: 7509)3′-UGUUGAAACCCUAUUUUCCGUUGACCA-5′ (SEQ ID NO: 1964) βc-3636 Target:5′-ACAACTTTGGGATAAAAGGCAACTGGT-3′ (SEQ ID NO: 3073)5′-CAACAACUUUGGGAUAAAAGGCAACUG-3′ (SEQ ID NO: 7510)3′-GUUGUUGAAACCCUAUUUUCCGUUGAC-5′ (SEQ ID NO: 1965) βc-3638 Target:5′-CAACAACTTTGGGATAAAAGGCAACTG-3′ (SEQ ID NO: 3074)5′-GGUUACAACAACUUUGGGAUAAAAGGC-3′ (SEQ ID NO: 7511)3′-CCAAUGUUGUUGAAACCCUAUUUUCCG-5′ (SEQ ID NO: 1966) βc-3643 Target:5′-GGTTACAACAACTTTGGGATAAAAGGC-3′ (SEQ ID NO: 3075)5′-AGGUUACAACAACUUUGGGAUAAAAGG-3′ (SEQ ID NO: 7512)3′-UCCAAUGUUGUUGAAACCCUAUUUUCC-5′ (SEQ ID NO: 1967) βc-3644 Target:5′-AGGTTACAACAACTTTGGGATAAAAGG-3′ (SEQ ID NO: 3076)5′-CAGGUUACAACAACUUUGGGAUAAAAG-3′ (SEQ ID NO: 7513)3′-GUCCAAUGUUGUUGAAACCCUAUUUUC-5′ (SEQ ID NO: 1968) βc-3645 Target:5′-CAGGTTACAACAACTTTGGGATAAAAG-3′ (SEQ ID NO: 3077)5′-UAUCACAGCAGGUUACAACAACUUUGG-3′ (SEQ ID NO: 7514)3′-AUAGUGUCGUCCAAUGUUGUUGAAACC-5′ (SEQ ID NO: 1969) βc-3653 Target:5′-TATCACAGCAGGTTACAACAACTTTGG-3′ (SEQ ID NO: 3078)5′-GUAUCACAGCAGGUUACAACAACUUUG-3′ (SEQ ID NO: 7515)3′-CAUAGUGUCGUCCAAUGUUGUUGAAAC-5′ (SEQ ID NO: 1970) βc-3654 Target:5′-GTATCACAGCAGGTTACAACAACTTTG-3′ (SEQ ID NO: 3079)5′-UCGUAUCACAGCAGGUUACAACAACUU-3′ (SEQ ID NO: 7516)3′-AGCAUAGUGUCGUCCAAUGUUGUUGAA-5′ (SEQ ID NO: 1971) βc-3656 Target:5′-TCGTATCACAGCAGGTTACAACAACTT-3′ (SEQ ID NO: 3080)5′-UUUCUCUUGAAGCAUCGUAUCACAGCA-3′ (SEQ ID NO: 7517)3′-AAAGAGAACUUCGUAGCAUAGUGUCGU-5′ (SEQ ID NO: 1972) βc-3670 Target:5′-TTTCTCTTGAAGCATCGTATCACAGCA-3′ (SEQ ID NO: 3081)5′-UUUUCUCUUGAAGCAUCGUAUCACAGC-3′ (SEQ ID NO: 7518)3′-AAAAGAGAACUUCGUAGCAUAGUGUCG-5′ (SEQ ID NO: 1973) βc-3671 Target:5′-TTTTCTCTTGAAGCATCGTATCACAGC-3′ (SEQ ID NO: 3082)5′-CAUUUUCUCUUGAAGCAUCGUAUCACA-3′ (SEQ ID NO: 7519)3′-GUAAAAGAGAACUUCGUAGCAUAGUGU-5′ (SEQ ID NO: 1974) βc-3673 Target:5′-CATTTTCTCTTGAAGCATCGTATCACA-3′ (SEQ ID NO: 3083)5′-UUUUUUAUAACCGCAUUUUCUCUUGAA-3′ (SEQ ID NO: 7520)3′-AAAAAAUAUUGGCGUAAAAGAGAACUU-5′ (SEQ ID NO: 1975) βc-3686 Target:5′-TTTTTTATAACCGCATTTTCTCTTGAA-3′ (SEQ ID NO: 3084)5′-AUUUUUUAUAACCGCAUUUUCUCUUGA-3′ (SEQ ID NO: 7521)3′-UAAAAAAUAUUGGCGUAAAAGAGAACU-5′ (SEQ ID NO: 1976) βc-3687 Target:5′-ATTTTTTATAACCGCATTTTCTCTTGA-3′ (SEQ ID NO: 3085)5′-CAUUUUUUAUAACCGCAUUUUCUCUUG-3′ (SEQ ID NO: 7522)3′-GUAAAAAAUAUUGGCGUAAAAGAGAAC-5′ (SEQ ID NO: 1977) βc-3688 Target:5′-CATTTTTTATAACCGCATTTTCTCTTG-3′ (SEQ ID NO: 3086)5′-CCAUUUUUUAUAACCGCAUUUUCUCUU-3′ (SEQ ID NO: 7523)3′-GGUAAAAAAUAUUGGCGUAAAAGAGAA-5′ (SEQ ID NO: 1978) βc-3689 Target:5′-CCATTTTTTATAACCGCATTTTCTCTT-3′ (SEQ ID NO: 3087)5′-CUGAACCAUUUUUUAUAACCGCAUUUU-3′ (SEQ ID NO: 7524)3′-GACUUGGUAAAAAAUAUUGGCGUAAAA-5′ (SEQ ID NO: 1979) βc-3694 Target:5′-CTGAACCATTTTTTATAACCGCATTTT-3′ (SEQ ID NO: 3088)5′-UAAUUCUGAACCAUUUUUUAUAACCGC-3′ (SEQ ID NO: 7525)3′-AUUAAGACUUGGUAAAAAAUAUUGGCG-5′ (SEQ ID NO: 1980) βc-3699 Target:5′-TAATTCTGAACCATTTTTTATAACCGC-3′ (SEQ ID NO: 3089)5′-UUAAUUCUGAACCAUUUUUUAUAACCG-3′ (SEQ ID NO: 7526)3′-AAUUAAGACUUGGUAAAAAAUAUUGGC-5′ (SEQ ID NO: 1981) βc-3700 Target:5′-TTAATTCTGAACCATTTTTTATAACCG-3′ (SEQ ID NO: 3090)5′-UUUAAUUCUGAACCAUUUUUUAUAACC-3′ (SEQ ID NO: 7527)3′-AAAUUAAGACUUGGUAAAAAAUAUUGG-5′ (SEQ ID NO: 1982) βc-3701 Target:5′-TTTAATTCTGAACCATTTTTTATAACC-3′ (SEQ ID NO: 3091)5′-GUUUAAUUCUGAACCAUUUUUUAUAAC-3′ (SEQ ID NO: 7528)3′-CAAAUUAAGACUUGGUAAAAAAUAUUG-5′ (SEQ ID NO: 1983) βc-3702 Target:5′-GTTTAATTCTGAACCATTTTTTATAAC-3′ (SEQ ID NO: 3092)5′-AGUUUAAUUCUGAACCAUUUUUUAUAA-3′ (SEQ ID NO: 7529)3′-UCAAAUUAAGACUUGGUAAAAAAUAUU-5′ (SEQ ID NO: 1984) βc-3703 Target:5′-AGTTTAATTCTGAACCATTTTTTATAA-3′ (SEQ ID NO: 3093)5′-AAGUUUAAUUCUGAACCAUUUUUUAUA-3′ (SEQ ID NO: 7530)3′-UUCAAAUUAAGACUUGGUAAAAAAUAU-5′ (SEQ ID NO: 1985) βc-3704 Target:5′-AAGTTTAATTCTGAACCATTTTTTATA-3′ (SEQ ID NO: 3094)5′-AUUAAAAGUUUAAUUCUGAACCAUUUU-3′ (SEQ ID NO: 7531)3′-UAAUUUUCAAAUUAAGACUUGGUAAAA-5′ (SEQ ID NO: 1986) βc-3709 Target:5′-ATTAAAAGTTTAATTCTGAACCATTTT-3′ (SEQ ID NO: 3095)5′-AAUUAAAAGUUUAAUUCUGAACCAUUU-3′ (SEQ ID NO: 7532)3′-UUAAUUUUCAAAUUAAGACUUGGUAAA-5′ (SEQ ID NO: 1987) βc-3710 Target:5′-AATTAAAAGTTTAATTCTGAACCATTT-3′ (SEQ ID NO: 3096)5′-UGAAUUAAAAGUUUAAUUCUGAACCAU-3′ (SEQ ID NO: 7533)3′-ACUUAAUUUUCAAAUUAAGACUUGGUA-5′ (SEQ ID NO: 1988) βc-3712 Target:5′-TGAATTAAAAGTTTAATTCTGAACC-3′ (SEQ ID NO: 3097)5′-CAAUACAGCUAAAGGAUGAUUUACAGG-3′ (SEQ ID NO: 7534)3′-GUUAUGUCGAUUUCCUACUAAAUGUCC-5′ (SEQ ID NO: 1989) βc-2634t2 Target:5′-CAATACAGCTAAAGGATGATTTACAGG-3′ (SEQ ID NO: 3098)5′-ACAAUACAGCUAAAGGAUGAUUUACAG-3′ (SEQ ID NO: 7535)3′-UGUUAUGUCGAUUUCCUACUAAAUGUC-5′ (SEQ ID NO: 1990) βc-2635t2 Target:5′-ACAATACAGCTAAAGGATGATTTACAG-3′ (SEQ ID NO: 3099)5′-AGACAAUACAGCUAAAGGAUGAUUUAC-3′ (SEQ ID NO: 7536)3′-UCUGUUAUGUCGAUUUCCUACUAAAUG-5′ (SEQ ID NO: 1991) βc-2637t2 Target:5′-AGACAATACAGCTAAAGGATGATTTAC-3′ (SEQ ID NO: 3100)5′-GUUACUCCUAAAGGAUGAUUUACAGGU-3′ (SEQ ID NO: 7537)3′-CAAUGAGGAUUUCCUACUAAAUGUCCA-5′ (SEQ ID NO: 1992) βc-2633t3 Target:5′-GTTACTCCTAAAGGATGATTTACAGGT-3′ (SEQ ID NO: 3101)5′-UGUUACUCCUAAAGGAUGAUUUACAGG-3′ (SEQ ID NO: 7538)3′-ACAAUGAGGAUUUCCUACUAAAUGUCC-5′ (SEQ ID NO: 1993) βc-2634t3 Target:5′-TGTTACTCCTAAAGGATGATTTACAGG-3′ (SEQ ID NO: 3102)5′-UUGUUACUCCUAAAGGAUGAUUUACAG-3′ (SEQ ID NO: 7539)3′-AACAAUGAGGAUUUCCUACUAAAUGUC-5′ (SEQ ID NO: 1994) βc-2635t3 Target:5′-TTGTTACTCCTAAAGGATGATTTACAG-3′ (SEQ ID NO: 3103)5′-AUUGUUACUCCUAAAGGAUGAUUUACA-3′ (SEQ ID NO: 7540)3′-UAACAAUGAGGAUUUCCUACUAAAUGU-5′ (SEQ ID NO: 1995) βc-2636t3 Target:5′-ATTGTTACTCCTAAAGGATGATTTACA-3′ (SEQ ID NO: 3104)5′-GGAUUCCAGAAUCCAAGUAAGACUGCU-3′ (SEQ ID NO: 7541)3′-CCUAAGGUCUUAGGUUCAUUCUGACGA-5′ (SEQ ID NO: 1996) βc-m318 Target:5′-GGATTCCAGAATCCAAGTAAGACTGCT-3′ (SEQ ID NO: 3105)5′-CUUGCUCCCAUUCAUAAAGGACUUGGG-3′ (SEQ ID NO: 7542)3′-GAACGAGGGUAAGUAUUUCCUGAACCC-5′ (SEQ ID NO: 1997) βc-m417 Target:5′-CTTGCTCCCATTCATAAAGGACTTGGG-3′ (SEQ ID NO: 3106)5′-CGUCAAUAUCAGCUACUUGCUCUUGCG-3′ (SEQ ID NO: 7543)3′-GCAGUUAUAGUCGAUGAACGAGAACGC-5′ (SEQ ID NO: 1998) βc-m462 Target:5′-CGTCAATATCAGCTACTTGCTCTTGCG-3′ (SEQ ID NO: 3107)5′-CCGUCAAUAUCAGCUACUUGCUCUUGC-3′ (SEQ ID NO: 7544)3′-GGCAGUUAUAGUCGAUGAACGAGAACG-5′ (SEQ ID NO: 1999) βc-m463 Target:5′-CCGTCAATATCAGCTACTTGCTCTTGC-3′ (SEQ ID NO: 3108)5′-ACUGCCCGUCAAUAUCAGCUACUUGCU-3′ (SEQ ID NO: 7545)3′-UGACGGGCAGUUAUAGUCGAUGAACGA-5′ (SEQ ID NO: 2000) βc-m468 Target:5′-ACTGCCCGTCAATATCAGCTACTTGCT-3′ (SEQ ID NO: 3109)5′-UGUUUCAACAUCUGUGAUGGUUCAGCC-3′ (SEQ ID NO: 7546)3′-ACAAAGUUGUAGACACUACCAAGUCGG-5′ (SEQ ID NO: 2001) βc-m613 Target:5′-TGTTTCAACATCTGTGATGGTTCAGCC-3′ (SEQ ID NO: 3110)5′-AUGUUUCAACAUCUGUGAUGGUUCAGC-3′ (SEQ ID NO: 7547)3′-UACAAAGUUGUAGACACUACCAAGUCG-5′ (SEQ ID NO: 2002) βc-m614 Target:5′-ATGTTTCAACATCTGTGATGGTTCAGC-3′ (SEQ ID NO: 3111)5′-UGACAACUGCAUGUUUCAACAUCUGUG-3′ (SEQ ID NO: 7548)3′-ACUGUUGACGUACAAAGUUGUAGACAC-5′ (SEQ ID NO: 2003) βc-m624 Target:5′-TGACAACTGCATGTTTCAACATCTGTG-3′ (SEQ ID NO: 3112)5′-AUUGACAACUGCAUGUUUCAACAUCUG-3′ (SEQ ID NO: 7549)3′-UAACUGUUGACGUACAAAGUUGUAGAC-5′ (SEQ ID NO: 2004) βc-m626 Target:5′-ATTGACAACTGCATGTTTCAACATCTG-3′ (SEQ ID NO: 3113)5′-UCAAAUUGACAACUGCAUGUUUCAACA-3′ (SEQ ID NO: 7550)3′-AGUUUAACUGUUGACGUACAAAGUUGU-5′ (SEQ ID NO: 2005) βc-m630 Target:5′-TCAAATTGACAACTGCATGTTTCAACA-3′ (SEQ ID NO: 3114)5′-AGUUAAUCAAAUUGACAACUGCAUGUU-3′ (SEQ ID NO: 7551)3′-UCAAUUAGUUUAACUGUUGACGUACAA-5′ (SEQ ID NO: 2006) βc-m636 Target:5′-AGTTAATCAAATTGACAACTGCATGTT-3′ (SEQ ID NO: 3115)5′-CCUGAUAGUUAAUCAAAUUGACAACUG-3′ (SEQ ID NO: 7552)3′-GGACUAUCAAUUAGUUUAACUGUUGAC-5′ (SEQ ID NO: 2007) βc-m642 Target:5′-CCTGATAGTTAATCAAATTGACAACTG-3′ (SEQ ID NO: 3116)5′-CGUCAUCCUGAUAGUUAAUCAAAUUGA-3′ (SEQ ID NO: 7553)3′-GCAGUAGGACUAUCAAUUAGUUUAACU-5′ (SEQ ID NO: 2008) βc-m648 Target:5′-CGTCATCCTGATAGTTAATCAAATTGA-3′ (SEQ ID NO: 3117)5′-GCGUCAUCCUGAUAGUUAAUCAAAUUG-3′ (SEQ ID NO: 7554)3′-CGCAGUAGGACUAUCAAUUAGUUUAAC-5′ (SEQ ID NO: 2009) βc-m649 Target:5′-GCGTCATCCTGATAGTTAATCAAATTG-3′ (SEQ ID NO: 3118)5′-CCUCAUCGUUUAGCAGUUUUGUCAGCU-3′ (SEQ ID NO: 7555)3′-GGAGUAGCAAAUCGUCAAAACAGUCGA-5′ (SEQ ID NO: 2010) βc-m702 Target:5′-CCTCATCGTTTAGCAGTTTTGTCAGCT-3′ (SEQ ID NO: 3119)5′-CUGGUCCUCAUCGUUUAGCAGUUUUGU-3′ (SEQ ID NO: 7556)3′-GACCAGGAGUAGCAAAUCGUCAAAACA-5′ (SEQ ID NO: 2011) βc-m707 Target:5′-CTGGTCCTCATCGTTTAGCAGTTTTGT-3′ (SEQ ID NO: 3120)5′-CAUAACAGCAGCUUUAUUAACUACCAC-3′ (SEQ ID NO: 7557)3′-GUAUUGUCGUCGAAAUAAUUGAUGGUG-5′ (SEQ ID NO: 2012) βc-m734 Target:5′-CATAACAGCAGCTTTATTAACTACCAC-3′ (SEQ ID NO: 3121)5′-CCAUAACAGCAGCUUUAUUAACUACCA-3′ (SEQ ID NO: 7558)3′-GGUAUUGUCGUCGAAAUAAUUGAUGGU-5′ (SEQ ID NO: 2013) βc-m735 Target:5′-CCATAACAGCAGCTTTATTAACTACCA-3′ (SEQ ID NO: 3122)5′-GGACCAUAACAGCAGCUUUAUUAACUA-3′ (SEQ ID NO: 7559)3′-CCUGGUAUUGUCGUCGAAAUAAUUGAU-5′ (SEQ ID NO: 2014) βc-m738 Target:5′-GGACCATAACAGCAGCTTTATTAACTA-3′ (SEQ ID NO: 3123)5′-UGGACCAUAACAGCAGCUUUAUUAACU-3′ (SEQ ID NO: 7560)3′-ACCUGGUAUUGUCGUCGAAAUAAUUGA-5′ (SEQ ID NO: 2015) βc-m739 Target:5′-TGGACCATAACAGCAGCTTTATTAACT-3′ (SEQ ID NO: 3124)5′-CUGUCUCUACAUCAUUUGUAUUCUGCA-3′ (SEQ ID NO: 7561)3′-GACAGAGAUGUAGUAAACAUAAGACGU-5′ (SEQ ID NO: 2016) βc-m843 Target:5′-CTGTCTCTACATCATTTGTATTCTGCA-3′ (SEQ ID NO: 3125)5′-GCUGUCUCUACAUCAUUUGUAUUCUGC-3′ (SEQ ID NO: 7562)3′-CGACAGAGAUGUAGUAAACAUAAGACG-5′ (SEQ ID NO: 2017) βc-m844 Target:5′-GCTGTCTCTACATCATTTGTATTCTGC-3′ (SEQ ID NO: 3126)5′-GCAACCAUUUUCUGCAGUCCACCAGCU-3′ (SEQ ID NO: 7563)3′-CGUUGGUAAAAGACGUCAGGUGGUCGA-5′ (SEQ ID NO: 2018) βc-m1063 Target:5′-GCAACCATTTTCTGCAGTCCACCAGCT-3′ (SEQ ID NO: 3127)5′-AAGCAACCAUUUUCUGCAGUCCACCAG-3′ (SEQ ID NO: 7564)3′-UUCGUUGGUAAAAGACGUCAGGUGGUC-5′ (SEQ ID NO: 2019) βc-m1065 Target:5′-AAGCAACCATTTTCTGCAGTCCACCAG-3′ (SEQ ID NO: 3128)5′-UUGUUUUGUUGAGCAAAGCAACCAUUU-3′ (SEQ ID NO: 7565)3′-AACAAAACAACUCGUUUCGUUGGUAAA-5′ (SEQ ID NO: 2020) βc-m1080 Target:5′-TTGTTTTGTTGAGCAAAGCAACCATTT-3′ (SEQ ID NO: 3129)5′-UUUGUUUUGUUGAGCAAAGCAACCAUU-3′ (SEQ ID NO: 7566)3′-AAACAAAACAACUCGUUUCGUUGGUAA-5′ (SEQ ID NO: 2021) βc-m1081 Target:5′-TTTGTTTTGTTGAGCAAAGCAACCATT-3′ (SEQ ID NO: 3130)5′-UAGCCAAGAAUUUCACGUUUGUUUUGU-3′ (SEQ ID NO: 7567)3′-AUCGGUUCUUAAAGUGCAAACAAAACA-5′ (SEQ ID NO: 2022) βc-m1098 Target:5′-TAGCCAAGAATTTCACGTTTGTTTTGT-3′ (SEQ ID NO: 3131)5′-CUUGAUUGCCAUAAGCUAAGAUCUGAA-3′ (SEQ ID NO: 7568)3′-GAACUAACGGUAUUCGAUUCUAGACUU-5′ (SEQ ID NO: 2023) βc-m1140 Target:5′-CTTGATTGCCATAAGCTAAGATCTGAA-3′ (SEQ ID NO: 3132)5′-GCUCUCUUGAUUGCCAUAAGCUAAGAU-3′ (SEQ ID NO: 7569)3′-CGAGAGAACUAACGGUAUUCGAUUCUA-5′ (SEQ ID NO: 2024) βc-m1145 Target:5′-GCTCTCTTGATTGCCATAAGCTAAGAT-3′ (SEQ ID NO: 3133)5′-CUUCUCAUAAGUGUAGGUCCUCAUUAU-3′ (SEQ ID NO: 7570)3′-GAAGAGUAUUCACAUCCAGGAGUAAUA-5′ (SEQ ID NO: 2025) βc-m1217 Target:5′-CTTCTCATAAGTGTAGGTCCTCATTAT-3′ (SEQ ID NO: 3134)5′-GCUUCUCAUAAGUGUAGGUCCUCAUUA-3′ (SEQ ID NO: 7571)3′-CGAAGAGUAUUCACAUCCAGGAGUAAU-5′ (SEQ ID NO: 2026) βc-m1218 Target:5′-GCTTCTCATAAGTGTAGGTCCTCATTA-3′ (SEQ ID NO: 3135)5′-AAGCUUCUCAUAAGUGUAGGUCCUCAU-3′ (SEQ ID NO: 7572)3′-UUCGAAGAGUAUUCACAUCCAGGAGUA-5′ (SEQ ID NO: 2027) βc-m1220 Target:5′-AAGCTTCTCATAAGTGTAGGTCCTC-3′ (SEQ ID NO: 3136)5′-GAAGCUUCUCAUAAGUGUAGGUCCUCA-3′ (SEQ ID NO: 7573)3′-CUUCGAAGAGUAUUCACAUCCAGGAGU-5′ (SEQ ID NO: 2028) βc-m1221 Target:5′-GAAGCTTCTCATAAGTGTAGGTCCTCA-3′ (SEQ ID NO: 3137)5′-GAGUCCAAAGACAGUUUUGAACAAGUC-3′ (SEQ ID NO: 7574)3′-CUCAGGUUUCUGUCAAAACUUGUUCAG-5′ (SEQ ID NO: 2029) βc-m1365 Target:5′-GAGTCCAAAGACAGTTTTGAACAAGTC-3′ (SEQ ID NO: 3138)5′-AGAGUCCAAAGACAGUUUUGAACAAGU-3′ (SEQ ID NO: 7575)3′-UCUCAGGUUUCUGUCAAAACUUGUUCA-5′ (SEQ ID NO: 2030) βc-m1366 Target:5′-AGAGTCCAAAGACAGTTTTGAACAAGT-3′ (SEQ ID NO: 3139)5′-CCACAUUUAUAUCAUCGGAACCCAGAA-3′ (SEQ ID NO: 7576)3′-GGUGUAAAUAUAGUAGCCUUGGGUCUU-5′ (SEQ ID NO: 2031) βc-m1461 Target:5′-CCACATTTATATCATCGGAACCCAGAA-3′ (SEQ ID NO: 3140)5′-UGACCACAUUUAUAUCAUCGGAACCCA-3′ (SEQ ID NO: 7577)3′-ACUGGUGUAAAUAUAGUAGCCUUGGGU-5′ (SEQ ID NO: 2032) βc-m1464 Target:5′-TGACCACATTTATATCATCGGAACCCA-3′ (SEQ ID NO: 3141)5′-CUGCACAGGUGACCACAUUUAUAUCAU-3′ (SEQ ID NO: 7578)3′-GACGUGUCCACUGGUGUAAAUAUAGUA-5′ (SEQ ID NO: 2033) βc-m1473 Target:5′-CTGCACAGGTGACCACATTTATATC-3′ (SEQ ID NO: 3142)5′-GCUGCACAGGUGACCACAUUUAUAUCA-3′ (SEQ ID NO: 7579)3′-CGACGUGUCCACUGGUGUAAAUAUAGU-5′ (SEQ ID NO: 2034) βc-m1474 Target:5′-GCTGCACAGGTGACCACATTTATATCA-3′ (SEQ ID NO: 3143)5′-UUGUAAUUAUUGCAAGUGAGGUUAGAG-3′ (SEQ ID NO: 7580)3′-AACAUUAAUAACGUUCACUCCAAUCUC-5′ (SEQ ID NO: 2035) βc-m1510 Target:5′-TTGTAATTATTGCAAGTGAGGTTAGAG-3′ (SEQ ID NO: 3144)5′-CAUCAUCUUGUUUUUGUAAUUAUUGCA-3′ (SEQ ID NO: 7581)3′-GUAGUAGAACAAAAACAUUAAUAACGU-5′ (SEQ ID NO: 2036) βc-m1523 Target:5′-CATCATCTTGTTTTTGTAATTATTGCA-3′ (SEQ ID NO: 3145)5′-CCAUCAUCUUGUUUUUGUAAUUAUUGC-3′ (SEQ ID NO: 7582)3′-GGUAGUAGAACAAAAACAUUAAUAACG-5′ (SEQ ID NO: 2037) βc-m1524 Target:5′-CCATCATCTTGTTTTTGTAATTATTGC-3′ (SEQ ID NO: 3146)5′-ACACCAUCAUCUUGUUUUUGUAAUUAU-3′ (SEQ ID NO: 7583)3′-UGUGGUAGUAGAACAAAAACAUUAAUA-5′ (SEQ ID NO: 2038) βc-m1527 Target:5′-ACACCATCATCTTGTTTTTGTAATTAT-3′ (SEQ ID NO: 3147)5′-UUGGCACACCAUCAUCUUGUUUUUGUA-3′ (SEQ ID NO: 7584)3′-AACCGUGUGGUAGUAGAACAAAAACAU-5′ (SEQ ID NO: 2039) βc-m1532 Target:5′-TTGGCACACCATCATCTTGTTTTTGTA-3′ (SEQ ID NO: 3148)5′-UCAAUCCAACAGUUGCCUUUAUCAGAG-3′ (SEQ ID NO: 7585)3′-AGUUAGGUUGUCAACGGAAAUAGUCUC-5′ (SEQ ID NO: 2040) βc-m1752 Target:5′-TCAATCCAACAGTTGCCTTTATCAGAG-3′ (SEQ ID NO: 3149)5′-UCGAAUCAAUCCAACAGUUGCCUUUAU-3′ (SEQ ID NO: 7586)3′-AGCUUAGUUAGGUUGUCAACGGAAAUA-5′ (SEQ ID NO: 2041) βc-m1757 Target:5′-TCGAATCAATCCAACAGTTGCCTTTAT-3′ (SEQ ID NO: 3150)5′-GCUGAACUAGUCGUGGAAUAGCACCCU-3′ (SEQ ID NO: 7587)3′-CGACUUGAUCAGCACCUUAUCGUGGGA-5′ (SEQ ID NO: 2042) βc-m1827 Target:5′-GCTGAACTAGTCGTGGAATAGCACCCT-3′ (SEQ ID NO: 3151)5′-AGUACACCCUUCUACUAUCUCCUCCAU-3′ (SEQ ID NO: 7588)3′-UCAUGUGGGAAGAUGAUAGAGGAGGUA-5′ (SEQ ID NO: 2043) βc-m1934 Target:5′-AGTACACCCTTCTACTATCTCCTCC-3′ (SEQ ID NO: 3152)5′-CAGUACACCCUUCUACUAUCUCCUCCA-3′ (SEQ ID NO: 7589)3′-GUCAUGUGGGAAGAUGAUAGAGGAGGU-5′ (SEQ ID NO: 2044) βc-m1935 Target:5′-CAGTACACCCTTCTACTATCTCCTCCA-3′ (SEQ ID NO: 3153)5′-CCAGUACACCCUUCUACUAUCUCCUCC-3′ (SEQ ID NO: 7590)3′-GGUCAUGUGGGAAGAUGAUAGAGGAGG-5′ (SEQ ID NO: 2045) βc-m1936 Target:5′-CCAGTACACCCTTCTACTATCTCCTCC-3′ (SEQ ID NO: 3154)5′-GAGCUCCAGUACACCCUUCUACUAUCU-3′ (SEQ ID NO: 7591)3′-CUCGAGGUCAUGUGGGAAGAUGAUAGA-5′ (SEQ ID NO: 2046) βc-m1941 Target:5′-GAGCTCCAGTACACCCTTCTACTATCT-3′ (SEQ ID NO: 3155)5′-AAACAAUGGAAUGGUAUUGAGUCCUCG-3′ (SEQ ID NO: 7592)3′-UUUGUUACCUUACCAUAACUCAGGAGC-5′ (SEQ ID NO: 2047) βc-m2009 Target:5′-AAACAATGGAATGGTATTGAGTCCTCG-3′ (SEQ ID NO: 3156)5′-CUGCACAAACAAUGGAAUGGUAUUGAG-3′ (SEQ ID NO: 7593)3′-GACGUGUUUGUUACCUUACCAUAACUC-5′ (SEQ ID NO: 2048) βc-m2015 Target:5′-CTGCACAAACAATGGAATGGTATTGAG-3′ (SEQ ID NO: 3157)5′-ACUGCACAAACAAUGGAAUGGUAUUGA-3′ (SEQ ID NO: 7594)3′-UGACGUGUUUGUUACCUUACCAUAACU-5′ (SEQ ID NO: 2049) βc-m2016 Target:5′-ACTGCACAAACAATGGAATGGTATTGA-3′ (SEQ ID NO: 3158)5′-AAGCAACUGCACAAACAAUGGAAUGGU-3′ (SEQ ID NO: 7595)3′-UUCGUUGACGUGUUUGUUACCUUACCA-5′ (SEQ ID NO: 2050) βc-m2021 Target:5′-AAGCAACTGCACAAACAATGGAATGGT-3′ (SEQ ID NO: 3159)5′-GAGAAUAAAGCAACUGCACAAACAAUG-3′ (SEQ ID NO: 7596)3′-CUCUUAUUUCGUUGACGUGUUUGUUAC-5′ (SEQ ID NO: 2051) βc-m2028 Target:5′-GAGAATAAAGCAACTGCACAAACAATG-3′ (SEQ ID NO: 3160)5′-UUUCAAUGGGAGAAUAAAGCAACUGCA-3′ (SEQ ID NO: 7597)3′-AAAGUUACCCUCUUAUUUCGUUGACGU-5′ (SEQ ID NO: 2052) βc-m2037 Target:5′-TTTCAATGGGAGAATAAAGCAACTGCA-3′ (SEQ ID NO: 3161)5′-UUUUCAAUGGGAGAAUAAAGCAACUGC-3′ (SEQ ID NO: 7598)3′-AAAAGUUACCCUCUUAUUUCGUUGACG-5′ (SEQ ID NO: 2053) βc-m2038 Target:5′-TTTTCAATGGGAGAATAAAGCAACTGC-3′ (SEQ ID NO: 3162)5′-AUUUUCAAUGGGAGAAUAAAGCAACUG-3′ (SEQ ID NO: 7599)3′-UAAAAGUUACCCUCUUAUUUCGUUGAC-5′ (SEQ ID NO: 2054) βc-m2039 Target:5′-ATTTTCAATGGGAGAATAAAGCAACTG-3′ (SEQ ID NO: 3163)5′-GGAUAUUUUCAAUGGGAGAAUAAAGCA-3′ (SEQ ID NO: 7600)3′-CCUAUAAAAGUUACCCUCUUAUUUCGU-5′ (SEQ ID NO: 2055) βc-m2043 Target:5′-GGATATTTTCAATGGGAGAATAAAGCA-3′ (SEQ ID NO: 3164)5′-UGGAUAUUUUCAAUGGGAGAAUAAAGC-3′ (SEQ ID NO: 7601)3′-ACCUAUAAAAGUUACCCUCUUAUUUCG-5′ (SEQ ID NO: 2056) βc-m2044 Target:5′-TGGATATTTTCAATGGGAGAATAAAGC-3′ (SEQ ID NO: 3165)5′-UUGGAUAUUUUCAAUGGGAGAAUAAAG-3′ (SEQ ID NO: 7602)3′-AACCUAUAAAAGUUACCCUCUUAUUUC-5′ (SEQ ID NO: 2057) βc-m2045 Target:5′-TTGGATATTTTCAATGGGAGAATAAAG-3′ (SEQ ID NO: 3166)5′-CAGCUACUCUUUGGAUAUUUUCAAUGG-3′ (SEQ ID NO: 7603)3′-GUCGAUGAGAAACCUAUAAAAGUUACC-5′ (SEQ ID NO: 2058) βc-m2055 Target:5′-CAGCTACTCTTTGGATATTTTCAATGG-3′ (SEQ ID NO: 3167)5′-GCAGCUACUCUUUGGAUAUUUUCAAUG-3′ (SEQ ID NO: 7604)3′-CGUCGAUGAGAAACCUAUAAAAGUUAC-5′ (SEQ ID NO: 2059) βc-m2056 Target:5′-GCAGCTACTCTTTGGATATTTTCAATG-3′ (SEQ ID NO: 3168)5′-CCGCUUCUUGUAAUCCUGUGGCUUGUC-3′ (SEQ ID NO: 7605)3′-GGCGAAGAACAUUAGGACACCGAACAG-5′ (SEQ ID NO: 2060) βc-m2231 Target:5′-CCGCTTCTTGTAATCCTGTGGCTTGTC-3′ (SEQ ID NO: 3169)5′-CCAGUCCAAGAUCUGCAGUCUCAUUCC-3′ (SEQ ID NO: 7606)3′-GGUCAGGUUCUAGACGUCAGAGUAAGG-5′ (SEQ ID NO: 2061) βc-m2307 Target:5′-CCAGTCCAAGATCTGCAGTCTCATTCC-3′ (SEQ ID NO: 3170)5′-CGUAUCCACCAGAGUGAAAAGAACGGU-3′ (SEQ ID NO: 7607)3′-GCAUAGGUGGUCUCACUUUUCUUGCCA-5′ (SEQ ID NO: 2062) βc-m2385 Target:5′-CGTATCCACCAGAGTGAAAAGAACGGT-3′ (SEQ ID NO: 3171)5′-CAGGCCAGCUGAUUGCUAUCACCUGGG-3′ (SEQ ID NO: 7608)3′-GUCCGGUCGACUAACGAUAGUGGACCC-5′ (SEQ ID NO: 2063) βc-m2539 Target:5′-CAGGCCAGCTGATTGCTATCACCTGGG-3′ (SEQ ID NO: 3172)5′-CGAUUUACAGGUCAGUAUCAAACCAGG-3′ (SEQ ID NO: 7609)3′-GCUAAAUGUCCAGUCAUAGUUUGGUCC-5′ (SEQ ID NO: 2064) βc-m2562 Target:5′-CGATTTACAGGTCAGTATCAAACCAGG-3′ (SEQ ID NO: 3173)5′-ACGAUUUACAGGUCAGUAUCAAACCAG-3′ (SEQ ID NO: 7610)3′-UGCUAAAUGUCCAGUCAUAGUUUGGUC-5′ (SEQ ID NO: 2065) βc-m2563 Target:5′-ACGATTTACAGGTCAGTATCAAACCAG-3′ (SEQ ID NO: 3174)5′-UUUCUUACCUAAAGGACGAUUUACAGG-3′ (SEQ ID NO: 7611)3′-AAAGAAUGGAUUUCCUGCUAAAUGUCC-5′ (SEQ ID NO: 2066) βc-m2578 Target:5′-TTTCTTACCTAAAGGACGATTTACAGG-3′ (SEQ ID NO: 3175)5′-GCUUUCUUACCUAAAGGACGAUUUACA-3′ (SEQ ID NO: 7612)3′-CGAAAGAAUGGAUUUCCUGCUAAAUGU-5′ (SEQ ID NO: 2067) βc-m2580 Target:5′-GCTTTCTTACCTAAAGGACGATTTACA-3′ (SEQ ID NO: 3176)5′-CUUUUAUAAGCUUUCUUACCUAAAGGA-3′ (SEQ ID NO: 7613)3′-GAAAAUAUUCGAAAGAAUGGAUUUCCU-5′ (SEQ ID NO: 2068) βc-m2589 Target:5′-CTTTTATAAGCTTTCTTACCTAAAGGA-3′ (SEQ ID NO: 3177)5′-GCUUUUAUAAGCUUUCUUACCUAAAGG-3′ (SEQ ID NO: 7614)3′-CGAAAAUAUUCGAAAGAAUGGAUUUCC-5′ (SEQ ID NO: 2069) βc-m2590 Target:5′-GCTTTTATAAGCTTTCTTACCTAAAGG-3′ (SEQ ID NO: 3178)5′-CUGGCUUUUAUAAGCUUUCUUACCUAA-3′ (SEQ ID NO: 7615)3′-GACCGAAAAUAUUCGAAAGAAUGGAUU-5′ (SEQ ID NO: 2070) βc-m2593 Target:5′-CTGGCTTTTATAAGCTTTCTTACCTAA-3′ (SEQ ID NO: 3179)5′-CCACACUGGCUUUUAUAAGCUUUCUUA-3′ (SEQ ID NO: 7616)3′-GGUGUGACCGAAAAUAUUCGAAAGAAU-5′ (SEQ ID NO: 2071) βc-m2598 Target:5′-CCACACTGGCTTTTATAAGCTTTCTTA-3′ (SEQ ID NO: 3180)5′-AUUCACCCACACUGGCUUUUAUAAGCU-3′ (SEQ ID NO: 7617)3′-UAAGUGGGUGUGACCGAAAAUAUUCGA-5′ (SEQ ID NO: 2072) βc-m2604 Target:5′-ATTCACCCACACTGGCTTTTATAAGCT-3′ (SEQ ID NO: 3181)5′-CCUACCAAGUCUUUCUGGAGUUCUGCA-3′ (SEQ ID NO: 7618)3′-GGAUGGUUCAGAAAGACCUCAAGACGU-5′ (SEQ ID NO: 2073) βc-m2644 Target:5′-CCTACCAAGTCTTTCTGGAGTTCTGCA-3′ (SEQ ID NO: 3182)5′-AUUUACAAACAGGCCUAAAACCAUUCC-3′ (SEQ ID NO: 7619)3′-UAAAUGUUUGUCCGGAUUUUGGUAAGG-5′ (SEQ ID NO: 2074) βc-m2674 Target:5′-ATTTACAAACAGGCCTAAAACCATTCC-3′ (SEQ ID NO: 3183)5′-GAUUUACAAACAGGCCUAAAACCAUUC-3′ (SEQ ID NO: 7620)3′-CUAAAUGUUUGUCCGGAUUUUGGUAAG-5′ (SEQ ID NO: 2075) βc-m2675 Target:5′-GATTTACAAACAGGCCTAAAACCATTC-3′ (SEQ ID NO: 3184)5′-AGAUUUACAAACAGGCCUAAAACCAUU-3′ (SEQ ID NO: 7621)3′-UCUAAAUGUUUGUCCGGAUUUUGGUAA-5′ (SEQ ID NO: 2076) βc-m2676 Target:5′-AGATTTACAAACAGGCCTAAAACCATT-3′ (SEQ ID NO: 3185)5′-CAUCUCCUUCCAAGGUAUGUAUCUGUU-3′ (SEQ ID NO: 7622)3′-GUAGAGGAAGGUUCCAUACAUAGACAA-5′ (SEQ ID NO: 2077) βc-m2710 Target:5′-CATCTCCTTCCAAGGTATGTATCTGTT-3′ (SEQ ID NO: 3186)5′-ACAUCUCCUUCCAAGGUAUGUAUCUGU-3′ (SEQ ID NO: 7623)3′-UGUAGAGGAAGGUUCCAUACAUAGACA-5′ (SEQ ID NO: 2078) βc-m2711 Target:5′-ACATCTCCTTCCAAGGTATGTATCTGT-3′ (SEQ ID NO: 3187)5′-ACUUCCACACAUGAACAUCUCCUUCCA-3′ (SEQ ID NO: 7624)3′-UGAAGGUGUGUACUUGUAGAGGAAGGU-5′ (SEQ ID NO: 2079) βc-m2725 Target:5′-ACTTCCACACATGAACATCTCCTTCCA-3′ (SEQ ID NO: 3188)5′-GAAACUUCCACACAUGAACAUCUCCUU-3′ (SEQ ID NO: 7625)3′-CUUUGAAGGUGUGUACUUGUAGAGGAA-5′ (SEQ ID NO: 2080) βc-m2728 Target:5′-GAAACTTCCACACATGAACATCTCCTT-3′ (SEQ ID NO: 3189)5′-AGAAACUUCCACACAUGAACAUCUCCU-3′ (SEQ ID NO: 7626)3′-UCUUUGAAGGUGUGUACUUGUAGAGGA-5′ (SEQ ID NO: 2081) βc-m2729 Target:5′-AGAAACTTCCACACATGAACATCTCCT-3′ (SEQ ID NO: 3190)5′-GAGAAACUUCCACACAUGAACAUCUCC-3′ (SEQ ID NO: 7627)3′-CUCUUUGAAGGUGUGUACUUGUAGAGG-5′ (SEQ ID NO: 2082) βc-m2730 Target:5′-GAGAAACTTCCACACATGAACATCTCC-3′ (SEQ ID NO: 3191)5′-UGAGAAACUUCCACACAUGAACAUCUC-3′ (SEQ ID NO: 7628)3′-ACUCUUUGAAGGUGUGUACUUGUAGAG-5′ (SEQ ID NO: 2083) βc-m2731 Target:5′-TGAGAAACTTCCACACATGAACATCTC-3′ (SEQ ID NO: 3192)5′-CAUCAACGUGAGAAACUUCCACACAUG-3′ (SEQ ID NO: 7629)3′-GUAGUUGCACUCUUUGAAGGUGUGUAC-5′ (SEQ ID NO: 2084) βc-m2739 Target:5′-CATCAACGTGAGAAACTTCCACACATG-3′ (SEQ ID NO: 3193)5′-AAACAUCAACGUGAGAAACUUCCACAC-3′ (SEQ ID NO: 7630)3′-UUUGUAGUUGCACUCUUUGAAGGUGUG-5′ (SEQ ID NO: 2085) βc-m2742 Target:5′-AAACATCAACGTGAGAAACTTCCACAC-3′ (SEQ ID NO: 3194)5′-AAAACAUCAACGUGAGAAACUUCCACA-3′ (SEQ ID NO: 7631)3′-UUUUGUAGUUGCACUCUUUGAAGGUGU-5′ (SEQ ID NO: 2086) βc-m2743 Target:5′-AAAACATCAACGTGAGAAACTTCCACA-3′ (SEQ ID NO: 3195)5′-AAAAACAUCAACGUGAGAAACUUCCAC-3′ (SEQ ID NO: 7632)3′-UUUUUGUAGUUGCACUCUUUGAAGGUG-5′ (SEQ ID NO: 2087) βc-m2744 Target:5′-AAAAACATCAACGTGAGAAACTTCCAC-3′ (SEQ ID NO: 3196)5′-CAAAAACAUCAACGUGAGAAACUUCCA-3′ (SEQ ID NO: 7633)3′-GUUUUUGUAGUUGCACUCUUUGAAGGU-5′ (SEQ ID NO: 2088) βc-m2745 Target:5′-CAAAAACATCAACGTGAGAAACTTCCA-3′ (SEQ ID NO: 3197)5′-GCAAAAACAUCAACGUGAGAAACUUCC-3′ (SEQ ID NO: 7634)3′-CGUUUUUGUAGUUGCACUCUUUGAAGG-5′ (SEQ ID NO: 2089) βc-m2746 Target:5′-GCAAAAACATCAACGTGAGAAACTTCC-3′ (SEQ ID NO: 3198)5′-UGGCAAAAACAUCAACGUGAGAAACUU-3′ (SEQ ID NO: 7635)3′-ACCGUUUUUGUAGUUGCACUCUUUGAA-5′ (SEQ ID NO: 2090) βc-m2748 Target:5′-TGGCAAAAACATCAACGTGAGAAACTT-3′ (SEQ ID NO: 3199)5′-CUGCAAAAGCUGUGGCAAAAACAUCAA-3′ (SEQ ID NO: 7636)3′-GACGUUUUCGACACCGUUUUUGUAGUU-5′ (SEQ ID NO: 2091) βc-m2760 Target:5′-CTGCAAAAGCTGTGGCAAAAACATCAA-3′ (SEQ ID NO: 3200)5′-GCUGCAAAAGCUGUGGCAAAAACAUCA-3′ (SEQ ID NO: 7637)3′-CGACGUUUUCGACACCGUUUUUGUAGU-5′ (SEQ ID NO: 2092) βc-m2761 Target:5′-GCTGCAAAAGCTGTGGCAAAAACATCA-3′ (SEQ ID NO: 3201)5′-ACUCAUCUGAGUAUAACGCUGCAAAAG-3′ (SEQ ID NO: 7638)3′-UGAGUAGACUCAUAUUGCGACGUUUUC-5′ (SEQ ID NO: 2093) βc-m2778 Target:5′-ACTCATCTGAGTATAACGCTGCAAAAG-3′ (SEQ ID NO: 3202)5′-UGAAAACAGCAAAUGUUACUCAUCUGA-3′ (SEQ ID NO: 7639)3′-ACUUUUGUCGUUUACAAUGAGUAGACU-5′ (SEQ ID NO: 2094) βc-m2795 Target:5′-TGAAAACAGCAAATGTTACTCATCTGA-3′ (SEQ ID NO: 3203)5′-UUGAAAACAGCAAAUGUUACUCAUCUG-3′ (SEQ ID NO: 7640)3′-AACUUUUGUCGUUUACAAUGAGUAGAC-5′ (SEQ ID NO: 2095) βc-m2796 Target:5′-TTGAAAACAGCAAATGTTACTCATCTG-3′ (SEQ ID NO: 3204)5′-GUUGAAAACAGCAAAUGUUACUCAUCU-3′ (SEQ ID NO: 7641)3′-CAACUUUUGUCGUUUACAAUGAGUAGA-5′ (SEQ ID NO: 2096) βc-m2797 Target:5′-GTTGAAAACAGCAAATGTTACTCATCT-3′ (SEQ ID NO: 3205)5′-CUAUUAAUGUUGAAAACAGCAAAUGUU-3′ (SEQ ID NO: 7642)3′-GAUAAUUACAACUUUUGUCGUUUACAA-5′ (SEQ ID NO: 2097) βc-m2805 Target:5′-CTATTAATGTTGAAAACAGCAAATGTT-3′ (SEQ ID NO: 3206)5′-ACACUACAGCUGUAUAGAGAGAAAGGC-3′ (SEQ ID NO: 7643)3′-UGUGAUGUCGACAUAUCUCUCUUUCCG-5′ (SEQ ID NO: 2098) βc-m2834 Target:5′-ACACTACAGCTGTATAGAGAGAAAGGC-3′ (SEQ ID NO: 3207)5′-CAGGCCAAUCACAAUGCACGUUCAGAC-3′ (SEQ ID NO: 7644)3′-GUCCGGUUAGUGUUACGUGCAAGUCUG-5′ (SEQ ID NO: 2099) βc-m2859 Target:5′-CAGGCCAATCACAATGCACGTTCAGAC-3′ (SEQ ID NO: 3208)5′-CUGUUCCCAUAGGAAACUCAGCUUGGU-3′ (SEQ ID NO: 7645)3′-GACAAGGGUAUCCUUUGAGUCGAACCA-5′ (SEQ ID NO: 2100) βc-m2946 Target:5′-CTGTTCCCATAGGAAACTCAGCTTGGT-3′ (SEQ ID NO: 3209)5′-CAGAACAAAAAGCGUACUUCGACUGUU-3′ (SEQ ID NO: 7646)3′-GUCUUGUUUUUCGCAUGAAGCUGACAA-5′ (SEQ ID NO: 2101) βc-m2968 Target:5′-CAGAACAAAAAGCGTACTTCGACTGTT-3′ (SEQ ID NO: 3210)5′-AAGGACCAGAACAAAAAGCGUACUUCG-3′ (SEQ ID NO: 7647)3′-UUCCUGGUCUUGUUUUUCGCAUGAAGC-5′ (SEQ ID NO: 2102) βc-m2974 Target:5′-AAGGACCAGAACAAAAAGCGTACTTCG-3′ (SEQ ID NO: 3211)5′-CGACCAAAAAGGACCAGAACAAAAAGC-3′ (SEQ ID NO: 7648)3′-GCUGGUUUUUCCUGGUCUUGUUUUUCG-5′ (SEQ ID NO: 2103) βc-m2982 Target:5′-CGACCAAAAAGGACCAGAACAAAAAGC-3′ (SEQ ID NO: 3212)5′-UCGACCAAAAAGGACCAGAACAAAAAG-3′ (SEQ ID NO: 7649)3′-AGCUGGUUUUUCCUGGUCUUGUUUUUC-5′ (SEQ ID NO: 2104) βc-m2983 Target:5′-TCGACCAAAAAGGACCAGAACAAAAAG-3′ (SEQ ID NO: 3213)5′-UUACUCCUCGACCAAAAAGGACCAGAA-3′ (SEQ ID NO: 7650)3′-AAUGAGGAGCUGGUUUUUCCUGGUCUU-5′ (SEQ ID NO: 2105) βc-m2990 Target:5′-TTACTCCTCGACCAAAAAGGACCAGAA-3′ (SEQ ID NO: 3214)5′-AAUCCAUUUGUAUUGUUACUCCUCGAC-3′ (SEQ ID NO: 7651)3′-UUAGGUAAACAUAACAAUGAGGAGCUG-5′ (SEQ ID NO: 2106) βc-m3005 Target:5′-AATCCATTTGTATTGTTACTCCTCGAC-3′ (SEQ ID NO: 3215)5′-AAAUCCAUUUGUAUUGUUACUCCUCGA-3′ (SEQ ID NO: 7652)3′-UUUAGGUAAACAUAACAAUGAGGAGCU-5′ (SEQ ID NO: 2107) βc-m3006 Target:5′-AAATCCATTTGTATTGTTACTCCTCGA-3′ (SEQ ID NO: 3216)5′-CAAAUCCAUUUGUAUUGUUACUCCUCG-3′ (SEQ ID NO: 7653)3′-GUUUAGGUAAACAUAACAAUGAGGAGC-5′ (SEQ ID NO: 2108) βc-m3007 Target:5′-CAAATCCATTTGTATTGTTACTCCTCG-3′ (SEQ ID NO: 3217)5′-CCAAAUCCAUUUGUAUUGUUACUCCUC-3′ (SEQ ID NO: 7654)3′-GGUUUAGGUAAACAUAACAAUGAGGAG-5′ (SEQ ID NO: 2109) βc-m3008 Target:5′-CCAAATCCATTTGTATTGTTACTCCTC-3′ (SEQ ID NO: 3218)5′-UCACUCCCCAAAUCCAUUUGUAUUGUU-3′ (SEQ ID NO: 7655)3′-AGUGAGGGGUUUAGGUAAACAUAACAA-5′ (SEQ ID NO: 2110) βc-m3015 Target:5′-TCACTCCCCAAATCCATTTGTATTGTT-3′ (SEQ ID NO: 3219)5′-GAUCCAUUCGUGUGCAUUCUUCACUGC-3′ (SEQ ID NO: 7656)3′-CUAGGUAAGCACACGUAAGAAGUGACG-5′ (SEQ ID NO: 2111) βc-m3047 Target:5′-GATCCATTCGTGTGCATTCTTCACTGC-3′ (SEQ ID NO: 3220)5′-UGAUCCAUUCGUGUGCAUUCUUCACUG-3′ (SEQ ID NO: 7657)3′-ACUAGGUAAGCACACGUAAGAAGUGAC-5′ (SEQ ID NO: 2112) βc-m3048 Target:5′-TGATCCATTCGTGTGCATTCTTCACTG-3′ (SEQ ID NO: 3221)5′-GUGAUCCAUUCGUGUGCAUUCUUCACU-3′ (SEQ ID NO: 7658)3′-CACUAGGUAAGCACACGUAAGAAGUGA-5′ (SEQ ID NO: 2113) βc-m3049 Target:5′-GTGATCCATTCGTGTGCATTCTTCACT-3′ (SEQ ID NO: 3222)5′-UAAAACAAAGAACAAGCAAGGCUAGGG-3′ (SEQ ID NO: 7659)3′-AUUUUGUUUCUUGUUCGUUCCGAUCCC-5′ (SEQ ID NO: 2114) βc-m3093 Target:5′-TAAAACAAAGAACAAGCAAGGCTAGGG-3′ (SEQ ID NO: 3223)5′-GCACCACUACAGAUAUUAAAACAAAGA-3′ (SEQ ID NO: 7660)3′-CGUGGUGAUGUCUAUAAUUUUGUUUCU-5′ (SEQ ID NO: 2115) βc-m3109 Target:5′-GCACCACTACAGATATTAAAACAAAGA-3′ (SEQ ID NO: 3224)5′-CAGCACCACUACAGAUAUUAAAACAAA-3′ (SEQ ID NO: 7661)3′-GUCGUGGUGAUGUCUAUAAUUUUGUUU-5′ (SEQ ID NO: 2116) βc-m3111 Target:5′-CAGCACCACTACAGATATTAAAACAAA-3′ (SEQ ID NO: 3225)5′-UCAGCACCACUACAGAUAUUAAAACAA-3′ (SEQ ID NO: 7662)3′-AGUCGUGGUGAUGUCUAUAAUUUUGUU-5′ (SEQ ID NO: 2117) βc-m3112 Target:5′-TCAGCACCACTACAGATATTAAAACAA-3′ (SEQ ID NO: 3226)5′-AAAAAAUAAAAGCAAGCAAAGUCAGCA-3′ (SEQ ID NO: 7663)3′-UUUUUUAUUUUCGUUCGUUUCAGUCGU-5′ (SEQ ID NO: 2118) βc-m3133 Target:5′-AAAAAATAAAAGCAAGCAAAGTCAGCA-3′ (SEQ ID NO: 3227)5′-CUGCAAAAAAUAAAAGCAAGCAAAGUC-3′ (SEQ ID NO: 7664)3′-GACGUUUUUUAUUUUCGUUCGUUUCAG-5′ (SEQ ID NO: 2119) βc-m3137 Target:5′-CTGCAAAAAATAAAAGCAAGCAAAGTC-3′ (SEQ ID NO: 3228)5′-AGUUACUGCAAAAAAUAAAAGCAAGCA-3′ (SEQ ID NO: 7665)3′-UCAAUGACGUUUUUUAUUUUCGUUCGU-5′ (SEQ ID NO: 2120) βc-m3142 Target:5′-AGTTACTGCAAAAAATAAAAGCAAGCA-3′ (SEQ ID NO: 3229)5′-ACUAACAGUUACUGCAAAAAAUAAAAG-3′ (SEQ ID NO: 7666)3′-UGAUUGUCAAUGACGUUUUUUAUUUUC-5′ (SEQ ID NO: 2121) βc-m3148 Target:5′-ACTAACAGTTACTGCAAAAAATAAAAG-3′ (SEQ ID NO: 3230)5′-AAACUAACAGUUACUGCAAAAAAUAAA-3′ (SEQ ID NO: 7667)3′-UUUGAUUGUCAAUGACGUUUUUUAUUU-5′ (SEQ ID NO: 2122) βc-m3150 Target:5′-AAACTAACAGTTACTGCAAAAAATAAA-3′ (SEQ ID NO: 3231)5′-AAAAACUAACAGUUACUGCAAAAAAUA-3′ (SEQ ID NO: 7668)3′-UUUUUGAUUGUCAAUGACGUUUUUUAU-5′ (SEQ ID NO: 2123) βc-m3152 Target:5′-AAAAACTAACAGTTACTGCAAAAAATA-3′ (SEQ ID NO: 3232)5′-UAAAAACUAACAGUUACUGCAAAAAAU-3′ (SEQ ID NO: 7669)3′-AUUUUUGAUUGUCAAUGACGUUUUUUA-5′ (SEQ ID NO: 2124) βc-m3153 Target:5′-TAAAAACTAACAGTTACTGCAAAAAAT-3′ (SEQ ID NO: 3233)5′-CUUAAAAACUAACAGUUACUGCAAAAA-3′ (SEQ ID NO: 7670)3′-GAAUUUUUGAUUGUCAAUGACGUUUUU-5′ (SEQ ID NO: 2125) βc-m3155 Target:5′-CTTAAAAACTAACAGTTACTGCAAAAA-3′ (SEQ ID NO: 3234)5′-ACUACUUAAAAACUAACAGUUACUGCA-3′ (SEQ ID NO: 7671)3′-UGAUGAAUUUUUGAUUGUCAAUGACGU-5′ (SEQ ID NO: 2126) βc-m3159 Target:5′-ACTACTTAAAAACTAACAGTTACTGCA-3′ (SEQ ID NO: 3235)5′-ACACUACUUAAAAACUAACAGUUACUG-3′ (SEQ ID NO: 7672)3′-UGUGAUGAAUUUUUGAUUGUCAAUGAC-5′ (SEQ ID NO: 2127) βc-m3161 Target:5′-ACACTACTTAAAAACTAACAGTTACTG-3′ (SEQ ID NO: 3236)5′-CAUAACACUACUUAAAAACUAACAGUU-3′ (SEQ ID NO: 7673)3′-GUAUUGUGAUGAAUUUUUGAUUGUCAA-5′ (SEQ ID NO: 2128) βc-m3165 Target:5′-CATAACACTACTTAAAAACTAACAGTT-3′ (SEQ ID NO: 3237)5′-ACAUAACACUACUUAAAAACUAACAGU-3′ (SEQ ID NO: 7674)3′-UGUAUUGUGAUGAAUUUUUGAUUGUCA-5′ (SEQ ID NO: 2129) βc-m3166 Target:5′-ACATAACACTACTTAAAAACTAACAGT-3′ (SEQ ID NO: 3238)5′-GAACAUAACACUACUUAAAAACUAACA-3′ (SEQ ID NO: 7675)3′-CUUGUAUUGUGAUGAAUUUUUGAUUGU-5′ (SEQ ID NO: 2130) βc-m3168 Target:5′-GAACATAACACTACTTAAAAACTAACA-3′ (SEQ ID NO: 3239)5′-AGAACAUAACACUACUUAAAAACUAAC-3′ (SEQ ID NO: 7676)3′-UCUUGUAUUGUGAUGAAUUUUUGAUUG-5′ (SEQ ID NO: 2131) βc-m3169 Target:5′-AGAACATAACACTACTTAAAAACTAAC-3′ (SEQ ID NO: 3240)5′-UAGAACAUAACACUACUUAAAAACUAA-3′ (SEQ ID NO: 7677)3′-AUCUUGUAUUGUGAUGAAUUUUUGAUU-5′ (SEQ ID NO: 2132) βc-m3170 Target:5′-TAGAACATAACACTACTTAAAAACTAA-3′ (SEQ ID NO: 3241)5′-CUAGAACAUAACACUACUUAAAAACUA-3′ (SEQ ID NO: 7678)3′-GAUCUUGUAUUGUGAUGAAUUUUUGAU-5′ (SEQ ID NO: 2133) βc-m3171 Target:5′-CTAGAACATAACACTACTTAAAAACTA-3′ (SEQ ID NO: 3242)5′-GUUCACUAGAACAUAACACUACUUAAA-3′ (SEQ ID NO: 7679)3′-CAAGUGAUCUUGUAUUGUGAUGAAUUU-5′ (SEQ ID NO: 2134) βc-m3176 Target:5′-GTTCACTAGAACATAACACTACTTAAA-3′ (SEQ ID NO: 3243)5′-AGGUUCACUAGAACAUAACACUACUUA-3′ (SEQ ID NO: 7680)3′-UCCAAGUGAUCUUGUAUUGUGAUGAAU-5′ (SEQ ID NO: 2135) βc-m3178 Target:5′-AGGTTCACTAGAACATAACACTACTTA-3′ (SEQ ID NO: 3244)5′-CAGGUUCACUAGAACAUAACACUACUU-3′ (SEQ ID NO: 7681)3′-GUCCAAGUGAUCUUGUAUUGUGAUGAA-5′ (SEQ ID NO: 2136) βc-m3179 Target:5′-CAGGTTCACTAGAACATAACACTACTT-3′ (SEQ ID NO: 3245)5′-CCAUUACUCGGUUCUUAGAAAUCAGAA-3′ (SEQ ID NO: 7682)3′-GGUAAUGAGCCAAGAAUCUUUAGUCUU-5′ (SEQ ID NO: 2137) βc-m3216 Target:5′-CCATTACTCGGTTCTTAGAAATCAGAA-3′ (SEQ ID NO: 3246)5′-ACACCAUUACUCGGUUCUUAGAAAUCA-3′ (SEQ ID NO: 7683)3′-UGUGGUAAUGAGCCAAGAAUCUUUAGU-5′ (SEQ ID NO: 2138) βc-m3219 Target:5′-ACACCATTACTCGGTTCTTAGAAATCA-3′ (SEQ ID NO: 3247)5′-GUUCUACACCAUUACUCGGUUCUUAGA-3′ (SEQ ID NO: 7684)3′-CAAGAUGUGGUAAUGAGCCAAGAAUCU-5′ (SEQ ID NO: 2139) βc-m3224 Target:5′-GTTCTACACCATTACTCGGTTCTTAGA-3′ (SEQ ID NO: 3248)5′-AUGAAUUAGUGUUCUACACCAUUACUC-3′ (SEQ ID NO: 7685)3′-UACUUAAUCACAAGAUGUGGUAAUGAG-5′ (SEQ ID NO: 2140) βc-m3234 Target:5′-ATGAATTAGTGTTCTACACCATTACTC-3′ (SEQ ID NO: 3249)5′-UGAUUAUGAAUUAGUGUUCUACACCAU-3′ (SEQ ID NO: 7686)3′-ACUAAUACUUAAUCACAAGAUGUGGUA-5′ (SEQ ID NO: 2141) βc-m3239 Target:5′-TGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 3250)5′-GUGAUUAUGAAUUAGUGUUCUACACCA-3′ (SEQ ID NO: 7687)3′-CACUAAUACUUAAUCACAAGAUGUGGU-5′ (SEQ ID NO: 2142) βc-m3240 Target:5′-GTGATTATGAATTAGTGTTCTACACCA-3′ (SEQ ID NO: 3251)5′-CGUGAUUAUGAAUUAGUGUUCUACACC-3′ (SEQ ID NO: 7688)3′-GCACUAAUACUUAAUCACAAGAUGUGG-5′ (SEQ ID NO: 2143) βc-m3241 Target:5′-CGTGATTATGAATTAGTGTTCTACACC-3′ (SEQ ID NO: 3252)5′-UUACAAUUAGCGUGAUUAUGAAUUAGU-3′ (SEQ ID NO: 7689)3′-AAUGUUAAUCGCACUAAUACUUAAUCA-5′ (SEQ ID NO: 2144) βc-m3251 Target:5′-TTACAATTAGCGTGATTATGAATTAGT-3′ (SEQ ID NO: 3253)5′-AUUACAAUUAGCGUGAUUAUGAAUUAG-3′ (SEQ ID NO: 7690)3′-UAAUGUUAAUCGCACUAAUACUUAAUC-5′ (SEQ ID NO: 2145) βc-m3252 Target:5′-ATTACAATTAGCGTGATTATGAATTAG-3′ (SEQ ID NO: 3254)5′-CCAGAUUACAAUUAGCGUGAUUAUGAA-3′ (SEQ ID NO: 7691)3′-GGUCUAAUGUUAAUCGCACUAAUACUU-5′ (SEQ ID NO: 2146) βc-m3256 Target:5′-CCAGATTACAATTAGCGTGATTATGAA-3′ (SEQ ID NO: 3255)5′-GUUACACGUCUCCAGAUUACAAUUAGC-3′ (SEQ ID NO: 7692)3′-CAAUGUGCAGAGGUCUAAUGUUAAUCG-5′ (SEQ ID NO: 2147) βc-m3267 Target:5′-GTTACACGTCTCCAGATTACAATTAGC-3′ (SEQ ID NO: 3256)5′-AUGUUACACGUCUCCAGAUUACAAUUA-3′ (SEQ ID NO: 7693)3′-UACAAUGUGCAGAGGUCUAAUGUUAAU-5′ (SEQ ID NO: 2148) βc-m3269 Target:5′-ATGTTACACGTCTCCAGATTACAATTA-3′ (SEQ ID NO: 3257)5′-GCUACACAAUGUUACACGUCUCCAGAU-3′ (SEQ ID NO: 7694)3′-CGAUGUGUUACAAUGUGCAGAGGUCUA-5′ (SEQ ID NO: 2149) βc-m3277 Target:5′-GCTACACAATGTTACACGTCTCCAGAT-3′ (SEQ ID NO: 3258)5′-AGGCUACACAAUGUUACACGUCUCCAG-3′ (SEQ ID NO: 7695)3′-UCCGAUGUGUUACAAUGUGCAGAGGUC-5′ (SEQ ID NO: 2150) βc-m3279 Target:5′-AGGCTACACAATGTTACACGTCTCCAG-3′ (SEQ ID NO: 3259)5′-AUACAAAAGGCUACACAAUGUUACACG-3′ (SEQ ID NO: 7696)3′-UAUGUUUUCCGAUGUGUUACAAUGUGC-5′ (SEQ ID NO: 2151) βc-m3286 Target:5′-ATACAAAAGGCTACACAATGTTACACG-3′ (SEQ ID NO: 3260)5′-UAUACAAAAGGCUACACAAUGUUACAC-3′ (SEQ ID NO: 7697)3′-AUAUGUUUUCCGAUGUGUUACAAUGUG-5′ (SEQ ID NO: 2152) βc-m3287 Target:5′-TATACAAAAGGCTACACAATGTTACAC-3′ (SEQ ID NO: 3261)5′-UAUUUAUACAAAAGGCUACACAAUGUU-3′ (SEQ ID NO: 7698)3′-AUAAAUAUGUUUUCCGAUGUGUUACAA-5′ (SEQ ID NO: 2153) βc-m3291 Target:5′-TATTTATACAAAAGGCTACACAATGTT-3′ (SEQ ID NO: 3262)5′-CUAUUUAUACAAAAGGCUACACAAUGU-3′ (SEQ ID NO: 7699)3′-GAUAAAUAUGUUUUCCGAUGUGUUACA-5′ (SEQ ID NO: 2154) βc-m3292 Target:5′-CTATTTATACAAAAGGCTACACAATGT-3′ (SEQ ID NO: 3263)5′-UGUCUAUUUAUACAAAAGGCUACACAA-3′ (SEQ ID NO: 7700)3′-ACAGAUAAAUAUGUUUUCCGAUGUGUU-5′ (SEQ ID NO: 2155) βc-m3295 Target:5′-TGTCTATTTATACAAAAGGCTACACAA-3′ (SEQ ID NO: 3264)5′-CUGUCUAUUUAUACAAAAGGCUACACA-3′ (SEQ ID NO: 7701)3′-GACAGAUAAAUAUGUUUUCCGAUGUGU-5′ (SEQ ID NO: 2156) βc-m3296 Target:5′-CTGTCTATTTATACAAAAGGCTACACA-3′ (SEQ ID NO: 3265)5′-UCUGUCUAUUUAUACAAAAGGCUACAC-3′ (SEQ ID NO: 7702)3′-AGACAGAUAAAUAUGUUUUCCGAUGUG-5′ (SEQ ID NO: 2157) βc-m3297 Target:5′-TCTGTCTATTTATACAAAAGGCTACAC-3′ (SEQ ID NO: 3266)5′-UUUCUAUCUGUCUAUUUAUACAAAAGG-3′ (SEQ ID NO: 7703)3′-AAAGAUAGACAGAUAAAUAUGUUUUCC-5′ (SEQ ID NO: 2158) βc-m3303 Target:5′-TTTCTATCTGTCTATTTATACAAAAGG-3′ (SEQ ID NO: 3267)5′-AUUUCUAUCUGUCUAUUUAUACAAAAG-3′ (SEQ ID NO: 7704)3′-UAAAGAUAGACAGAUAAAUAUGUUUUC-5′ (SEQ ID NO: 2159) βc-m3304 Target:5′-ATTTCTATCTGTCTATTTATACAAAAG-3′ (SEQ ID NO: 3268)5′-CAUUUCUAUCUGUCUAUUUAUACAAAA-3′ (SEQ ID NO: 7705)3′-GUAAAGAUAGACAGAUAAAUAUGUUUU-5′ (SEQ ID NO: 2160) βc-m3305 Target:5′-CATTTCTATCTGTCTATTTATACAAAA-3′ (SEQ ID NO: 3269)5′-CCAUUUCUAUCUGUCUAUUUAUACAAA-3′ (SEQ ID NO: 7706)3′-GGUAAAGAUAGACAGAUAAAUAUGUUU-5′ (SEQ ID NO: 2161) βc-m3306 Target:5′-CCATTTCTATCTGTCTATTTATACAAA-3′ (SEQ ID NO: 3270)5′-CGGACCAUUUCUAUCUGUCUAUUUAUA-3′ (SEQ ID NO: 7707)3′-GCCUGGUAAAGAUAGACAGAUAAAUAU-5′ (SEQ ID NO: 2162) βc-m3310 Target:5′-CGGACCATTTCTATCTGTCTATTTATA-3′ (SEQ ID NO: 3271)5′-UCGGACCAUUUCUAUCUGUCUAUUUAU-3′ (SEQ ID NO: 7708)3′-AGCCUGGUAAAGAUAGACAGAUAAAUA-5′ (SEQ ID NO: 2163) βc-m3311 Target:5′-TCGGACCATTTCTATCTGTCTATTTAT-3′ (SEQ ID NO: 3272)5′-AAACUAAUCGGACCAUUUCUAUCUGUC-3′ (SEQ ID NO: 7709)3′-UUUGAUUAGCCUGGUAAAGAUAGACAG-5′ (SEQ ID NO: 2164) βc-m3318 Target:5′-AAACTAATCGGACCATTTCTATCTGTC-3′ (SEQ ID NO: 3273)5′-GAAACUAAUCGGACCAUUUCUAUCUGU-3′ (SEQ ID NO: 7710)3′-CUUUGAUUAGCCUGGUAAAGAUAGACA-5′ (SEQ ID NO: 2165) βc-m3319 Target:5′-GAAACTAATCGGACCATTTCTATCTGT-3′ (SEQ ID NO: 3274)5′-GGAAACUAAUCGGACCAUUUCUAUCUG-3′ (SEQ ID NO: 7711)3′-CCUUUGAUUAGCCUGGUAAAGAUAGAC-5′ (SEQ ID NO: 2166) βc-m3320 Target:5′-GGAAACTAATCGGACCATTTCTATCTG-3′ (SEQ ID NO: 3275)5′-AGGAAACUAAUCGGACCAUUUCUAUCU-3′ (SEQ ID NO: 7712)3′-UCCUUUGAUUAGCCUGGUAAAGAUAGA-5′ (SEQ ID NO: 2167) βc-m3321 Target:5′-AGGAAACTAATCGGACCATTTCTATCT-3′ (SEQ ID NO: 3276)5′-AUUAAAAAGGAAACUAAUCGGACCAUU-3′ (SEQ ID NO: 7713)3′-UAAUUUUUCCUUUGAUUAGCCUGGUAA-5′ (SEQ ID NO: 2168) βc-m3328 Target:5′-ATTAAAAAGGAAACTAATCGGACCATT-3′ (SEQ ID NO: 3277)5′-AAGCAUAUUAAAAAGGAAACUAAUCGG-3′ (SEQ ID NO: 7714)3′-UUCGUAUAAUUUUUCCUUUGAUUAGCC-5′ (SEQ ID NO: 2169) βc-m3334 Target:5′-AAGCATATTAAAAAGGAAACTAATCGG-3′ (SEQ ID NO: 3278)5′-UAAGCAUAUUAAAAAGGAAACUAAUCG-3′ (SEQ ID NO: 7715)3′-AUUCGUAUAAUUUUUCCUUUGAUUAGC-5′ (SEQ ID NO: 2170) βc-m3335 Target:5′-TAAGCATATTAAAAAGGAAACTAATCG-3′ (SEQ ID NO: 3279)5′-AUUUUAAGCAUAUUAAAAAGGAAACUA-3′ (SEQ ID NO: 7716)3′-UAAAAUUCGUAUAAUUUUUCCUUUGAU-5′ (SEQ ID NO: 2171) βc-m3339 Target:5′-ATTTTAAGCATATTAAAAAGGAAACTA-3′ (SEQ ID NO: 3280)5′-CUGCUUAUUUUAAGCAUAUUAAAAAGG-3′ (SEQ ID NO: 7717)3′-GACGAAUAAAAUUCGUAUAAUUUUUCC-5′ (SEQ ID NO: 2172) βc-m3345 Target:5′-CTGCTTATTTTAAGCATATTAAAAAGG-3′ (SEQ ID NO: 3281)5′-CCUGCUUAUUUUAAGCAUAUUAAAAAG-3′ (SEQ ID NO: 7718)3′-GGACGAAUAAAAUUCGUAUAAUUUUUC-5′ (SEQ ID NO: 2173) βc-m3346 Target:5′-CCTGCTTATTTTAAGCATATTAAAAAG-3′ (SEQ ID NO: 3282)5′-GAUCCACCUGCUUAUUUUAAGCAUAUU-3′ (SEQ ID NO: 7719)3′-CUAGGUGGACGAAUAAAAUUCGUAUAA-5′ (SEQ ID NO: 2174) βc-m3352 Target:5′-GATCCACCTGCTTATTTTAAGCATATT-3′ (SEQ ID NO: 3283)5′-CAAAAACAUGAAAUAGAUCCACCUGCU-3′ (SEQ ID NO: 7720)3′-GUUUUUGUACUUUAUCUAGGUGGACGA-5′ (SEQ ID NO: 2175) βc-m3367 Target:5′-CAAAAACATGAAATAGATCCACCTGCT-3′ (SEQ ID NO: 3284)5′-UCAAAAACAUGAAAUAGAUCCACCUGC-3′ (SEQ ID NO: 7721)3′-AGUUUUUGUACUUUAUCUAGGUGGACG-5′ (SEQ ID NO: 2176) βc-m3368 Target:5′-TCAAAAACATGAAATAGATCCACCTGC-3′ (SEQ ID NO: 3285)5′-GUUCAAAAACAUGAAAUAGAUCCACCU-3′ (SEQ ID NO: 7722)3′-CAAGUUUUUGUACUUUAUCUAGGUGGA-5′ (SEQ ID NO: 2177) βc-m3370 Target:5′-GTTCAAAAACATGAAATAGATCCACCT-3′ (SEQ ID NO: 3286)5′-UGUUCAAAAACAUGAAAUAGAUCCACC-3′ (SEQ ID NO: 7723)3′-ACAAGUUUUUGUACUUUAUCUAGGUGG-5′ (SEQ ID NO: 2178) βc-m3371 Target:5′-TGTTCAAAAACATGAAATAGATCCACC-3′ (SEQ ID NO: 3287)5′-UUGUUCAAAAACAUGAAAUAGAUCCAC-3′ (SEQ ID NO: 7724)3′-AACAAGUUUUUGUACUUUAUCUAGGUG-5′ (SEQ ID NO: 2179) βc-m3372 Target:5′-TTGTTCAAAAACATGAAATAGATCCAC-3′ (SEQ ID NO: 3288)5′-AGUUUUUGUUCAAAAACAUGAAAUAGA-3′ (SEQ ID NO: 7725)3′-UCAAAAACAAGUUUUUGUACUUUAUCU-5′ (SEQ ID NO: 2180) βc-m3377 Target:5′-AGTTTTTGTTCAAAAACATGAAATAGA-3′ (SEQ ID NO: 3289)5′-CGAUAAAGUUUUUGUUCAAAAACAUGA-3′ (SEQ ID NO: 7726)3′-GCUAUUUCAAAAACAAGUUUUUGUACU-5′ (SEQ ID NO: 2181) βc-m3383 Target:5′-CGATAAAGTTTTTGTTCAAAAACATGA-3′ (SEQ ID NO: 3290)5′-UAUCCCCGAUAAAGUUUUUGUUCAAAA-3′ (SEQ ID NO: 7727)3′-AUAGGGGCUAUUUCAAAAACAAGUUUU-5′ (SEQ ID NO: 2182) βc-m3389 Target:5′-TATCCCCGATAAAGTTTTTGTTCAAAA-3′ (SEQ ID NO: 3291)5′-GUAUCCCCGAUAAAGUUUUUGUUCAAA-3′ (SEQ ID NO: 7728)3′-CAUAGGGGCUAUUUCAAAAACAAGUUU-5′ (SEQ ID NO: 2183) βc-m3390 Target:5′-GTATCCCCGATAAAGTTTTTGTTCAAA-3′ (SEQ ID NO: 3292)5′-ACACCUCUUACUGAUUUACCCUACCGC-3′ (SEQ ID NO: 7729)3′-UGUGGAGAAUGACUAAAUGGGAUGGCG-5′ (SEQ ID NO: 2184) βc-m3419 Target:5′-ACACCTCTTACTGATTTACCCTACCGC-3′ (SEQ ID NO: 3293)5′-UAACACCUCUUACUGAUUUACCCUACC-3′ (SEQ ID NO: 7730)3′-AUUGUGGAGAAUGACUAAAUGGGAUGG-5′ (SEQ ID NO: 2185) βc-m3421 Target:5′-TAACACCTCTTACTGATTTACCCTACC-3′ (SEQ ID NO: 3294)5′-AUAACACCUCUUACUGAUUUACCCUAC-3′ (SEQ ID NO: 7731)3′-UAUUGUGGAGAAUGACUAAAUGGGAUG-5′ (SEQ ID NO: 2186) βc-m3422 Target:5′-ATAACACCTCTTACTGATTTACCCTAC-3′ (SEQ ID NO: 3295)5′-AAUAACACCUCUUACUGAUUUACCCUA-3′ (SEQ ID NO: 7732)3′-UUAUUGUGGAGAAUGACUAAAUGGGAU-5′ (SEQ ID NO: 2187) βc-m3423 Target:5′-AATAACACCTCTTACTGATTTACCCTA-3′ (SEQ ID NO: 3296)5′-AAAUAACACCUCUUACUGAUUUACCCU-3′ (SEQ ID NO: 7733)3′-UUUAUUGUGGAGAAUGACUAAAUGGGA-5′ (SEQ ID NO: 2188) βc-m3424 Target:5′-AAATAACACCTCTTACTGATTTACCCT-3′ (SEQ ID NO: 3297)5′-CAAAUAACACCUCUUACUGAUUUACCC-3′ (SEQ ID NO: 7734)3′-GUUUAUUGUGGAGAAUGACUAAAUGGG-5′ (SEQ ID NO: 2189) βc-m3425 Target:5′-CAAATAACACCTCTTACTGATTTACCC-3′ (SEQ ID NO: 3298)5′-AAGGCUCAAAUAACACCUCUUACUGAU-3′ (SEQ ID NO: 7735)3′-UUCCGAGUUUAUUGUGGAGAAUGACUA-5′ (SEQ ID NO: 2190) βc-m3431 Target:5′-AAGGCTCAAATAACACCTCTTACTGAT-3′ (SEQ ID NO: 3299)5′-AAAACAAGGCUCAAAUAACACCUCUUA-3′ (SEQ ID NO: 7736)3′-UUUUGUUCCGAGUUUAUUGUGGAGAAU-5′ (SEQ ID NO: 2191) βc-m3436 Target:5′-AAAACAAGGCTCAAATAACACCTCTTA-3′ (SEQ ID NO: 3300)5′-CAAAACAAGGCUCAAAUAACACCUCUU-3′ (SEQ ID NO: 7737)3′-GUUUUGUUCCGAGUUUAUUGUGGAGAA-5′ (SEQ ID NO: 2192) βc-m3437 Target:5′-CAAAACAAGGCTCAAATAACACCTCTT-3′ (SEQ ID NO: 3301)5′-CCAAAACAAGGCUCAAAUAACACCUCU-3′ (SEQ ID NO: 7738)3′-GGUUUUGUUCCGAGUUUAUUGUGGAGA-5′ (SEQ ID NO: 2193) βc-m3438 Target:5′-CCAAAACAAGGCTCAAATAACACCTCT-3′ (SEQ ID NO: 3302)5′-UGUCCAAAACAAGGCUCAAAUAACACC-3′ (SEQ ID NO: 7739)3′-ACAGGUUUUGUUCCGAGUUUAUUGUGG-5′ (SEQ ID NO: 2194) βc-m3441 Target:5′-TGTCCAAAACAAGGCTCAAATAACACC-3′ (SEQ ID NO: 3303)5′-ACUGUCCAAAACAAGGCUCAAAUAACA-3′ (SEQ ID NO: 7740)3′-UGACAGGUUUUGUUCCGAGUUUAUUGU-5′ (SEQ ID NO: 2195) βc-m3443 Target:5′-ACTGTCCAAAACAAGGCTCAAATAACA-3′ (SEQ ID NO: 3304)5′-GGUAUACUGUCCAAAACAAGGCUCAAA-3′ (SEQ ID NO: 7741)3′-CCAUAUGACAGGUUUUGUUCCGAGUUU-5′ (SEQ ID NO: 2196) βc-m3448 Target:5′-GGTATACTGTCCAAAACAAGGCTCAAA-3′ (SEQ ID NO: 3305)5′-AGGCAACUGGUAUACUGUCCAAAACAA-3′ (SEQ ID NO: 7742)3′-UCCGUUGACCAUAUGACAGGUUUUGUU-5′ (SEQ ID NO: 2197) βc-m3456 Target:5′-AGGCAACTGGTATACTGTCCAAAACAA-3′ (SEQ ID NO: 3306)5′-GGGAUAAAAGGCAACUGGUAUACUGUC-3′ (SEQ ID NO: 7743)3′-CCCUAUUUUCCGUUGACCAUAUGACAG-5′ (SEQ ID NO: 2198) βc-m3464 Target:5′-GGGATAAAAGGCAACTGGTATACTGTC-3′ (SEQ ID NO: 3307)5′-UGGGAUAAAAGGCAACUGGUAUACUGU-3′ (SEQ ID NO: 7744)3′-ACCCUAUUUUCCGUUGACCAUAUGACA-5′ (SEQ ID NO: 2199) βc-m3465 Target:5′-TGGGATAAAAGGCAACTGGTATACTGT-3′ (SEQ ID NO: 3308)5′-ACAACUUUGGGAUAAAAGGCAACUGGU-3′ (SEQ ID NO: 7745)3′-UGUUGAAACCCUAUUUUCCGUUGACCA-5′ (SEQ ID NO: 2200) βc-m3472 Target:5′-ACAACTTTGGGATAAAAGGCAACTGGT-3′ (SEQ ID NO: 3309)5′-CAACAACUUUGGGAUAAAAGGCAACUG-3′ (SEQ ID NO: 7746)3′-GUUGUUGAAACCCUAUUUUCCGUUGAC-5′ (SEQ ID NO: 2201) βc-m3474 Target:5′-CAACAACTTTGGGATAAAAGGCAACTG-3′ (SEQ ID NO: 3310)5′-GGUUACAACAACUUUGGGAUAAAAGGC-3′ (SEQ ID NO: 7747)3′-CCAAUGUUGUUGAAACCCUAUUUUCCG-5′ (SEQ ID NO: 2202) βc-m3479 Target:5′-GGTTACAACAACTTTGGGATAAAAGGC-3′ (SEQ ID NO: 3311)5′-AGGUUACAACAACUUUGGGAUAAAAGG-3′ (SEQ ID NO: 7748)3′-UCCAAUGUUGUUGAAACCCUAUUUUCC-5′ (SEQ ID NO: 2203) βc-m3480 Target:5′-AGGTTACAACAACTTTGGGATAAAAGG-3′ (SEQ ID NO: 3312)5′-CAGGUUACAACAACUUUGGGAUAAAAG-3′ (SEQ ID NO: 7749)3′-GUCCAAUGUUGUUGAAACCCUAUUUUC-5′ (SEQ ID NO: 2204) βc-m3481 Target:5′-CAGGTTACAACAACTTTGGGATAAAAG-3′ (SEQ ID NO: 3313)5′-UAUCACAGCAGGUUACAACAACUUUGG-3′ (SEQ ID NO: 7750)3′-AUAGUGUCGUCCAAUGUUGUUGAAACC-5′ (SEQ ID NO: 2205) βc-m3489 Target:5′-TATCACAGCAGGTTACAACAACTTTGG-3′ (SEQ ID NO: 3314)5′-GUAUCACAGCAGGUUACAACAACUUUG-3′ (SEQ ID NO: 7751)3′-CAUAGUGUCGUCCAAUGUUGUUGAAAC-5′ (SEQ ID NO: 2206) βc-m3490 Target:5′-GTATCACAGCAGGTTACAACAACTTTG-3′ (SEQ ID NO: 3315)5′-UUGUAUCACAGCAGGUUACAACAACUU-3′ (SEQ ID NO: 7752)3′-AACAUAGUGUCGUCCAAUGUUGUUGAA-5′ (SEQ ID NO: 2207) βc-m3492 Target:5′-TTGTATCACAGCAGGTTACAACAACTT-3′ (SEQ ID NO: 3316)5′-CCGCAUCUGUUGAAGCAUUGUAUCACA-3′ (SEQ ID NO: 7753)3′-GGCGUAGACAACUUCGUAACAUAGUGU-5′ (SEQ ID NO: 2208) βc-m3509 Target:5′-CCGCATCTGTTGAAGCATTGTATCACA-3′ (SEQ ID NO: 3317)5′-UCUGAACCAUUUCUAUAACCGCAUCUG-3′ (SEQ ID NO: 7754)3′-AGACUUGGUAAAGAUAUUGGCGUAGAC-5′ (SEQ ID NO: 2209) βc-m3527 Target:5′-TCTGAACCATTTCTATAACCGCATCTG-3′ (SEQ ID NO: 3318)5′-UAAUUCUGAACCAUUUCUAUAACCGCA-3′ (SEQ ID NO: 7755)3′-AUUAAGACUUGGUAAAGAUAUUGGCGU-5′ (SEQ ID NO: 2210) βc-m3531 Target:5′-TAATTCTGAACCATTTCTATAACCGCA-3′ (SEQ ID NO: 3319)5′-UUUAAUUCUGAACCAUUUCUAUAACCG-3′ (SEQ ID NO: 7756)3′-AAAUUAAGACUUGGUAAAGAUAUUGGC-5′ (SEQ ID NO: 2211) βc-m3533 Target:5′-TTTAATTCTGAACCATTTCTATAACCG-3′ (SEQ ID NO: 3320)5′-GUUUAAUUCUGAACCAUUUCUAUAACC-3′ (SEQ ID NO: 7757)3′-CAAAUUAAGACUUGGUAAAGAUAUUGG-5′ (SEQ ID NO: 2212) βc-m3534 Target:5′-GTTTAATTCTGAACCATTTCTATAACC-3′ (SEQ ID NO: 3321)5′-AGUUUAAUUCUGAACCAUUUCUAUAAC-3′ (SEQ ID NO: 7758)3′-UCAAAUUAAGACUUGGUAAAGAUAUUG-5′ (SEQ ID NO: 2213) βc-m3535 Target:5′-AGTTTAATTCTGAACCATTTCTATAAC-3′ (SEQ ID NO: 3322)5′-AAGUUUAAUUCUGAACCAUUUCUAUAA-3′ (SEQ ID NO: 7759)3′-UUCAAAUUAAGACUUGGUAAAGAUAUU-5′ (SEQ ID NO: 2214) βc-m3536 Target:5′-AAGTTTAATTCTGAACCATTTCTATAA-3′ (SEQ ID NO: 3323)5′-AUUAAAAGUUUAAUUCUGAACCAUUUC-3′ (SEQ ID NO: 7760)3′-UAAUUUUCAAAUUAAGACUUGGUAAAG-5′ (SEQ ID NO: 2215) βc-m3541 Target:5′-ATTAAAAGTTTAATTCTGAACCATTTC-3′ (SEQ ID NO: 3324)5′-AAUUAAAAGUUUAAUUCUGAACCAUUU-3′ (SEQ ID NO: 7761)3′-UUAAUUUUCAAAUUAAGACUUGGUAAA-5′ (SEQ ID NO: 2216) βc-m3542 Target:5′-AATTAAAAGTTTAATTCTGAACCATTT-3′ (SEQ ID NO: 3325)5′-UGAAUUAAAAGUUUAAUUCUGAACCAU-3′ (SEQ ID NO: 7762)3′-ACUUAAUUUUCAAAUUAAGACUUGGUA-5′ (SEQ ID NO: 2217) βc-m3544 Target:5′-TGAATTAAAAGTTTAATTCTGAACC-3′ (SEQ ID NO: 3326)5′-UUUGAAUGAAUUAAAAGUUUAAUUCUG-3′ (SEQ ID NO: 7763)3′-AAACUUACUUAAUUUUCAAAUUAAGAC-5′ (SEQ ID NO: 2218) βc-m3550 Target:5′-TTTGAATGAATTAAAAGTTTAATTCTG-3′ (SEQ ID NO: 3327)5′-UUUUUUUGAAUGAAUUAAAAGUUUAAU-3′ (SEQ ID NO: 7764)3′-AAAAAAACUUACUUAAUUUUCAAAUUA-5′ (SEQ ID NO: 2219) βc-m3554 Target:5′-TTTTTTTGAATGAATTAAAAGTTTAAT-3′ (SEQ ID NO: 3328)5′-UUUUUUUUUUUGAAUGAAUUAAAAGUU-3′ (SEQ ID NO: 7765)3′-AAAAAAAAAAACUUACUUAAUUUUCAA-5′ (SEQ ID NO: 2220) βc-m3558 Target:5′-TTTTTTTTTTTGAATGAATTAAAAGTT-3′ (SEQ ID NO: 3329)5′-UUUUUUUUUUUUGAAUGAAUUAAAAGU-3′ (SEQ ID NO: 7766)3′-AAAAAAAAAAAACUUACUUAAUUUUCA-5′ (SEQ ID NO: 2221) βc-m3559 Target:5′-TTTTTTTTTTTTGAATGAATTAAAAGT-3′ (SEQ ID NO: 3330)5′-UUUUUUUUUUUUUGAAUGAAUUAAAAG-3′ (SEQ ID NO: 7767)3′-AAAAAAAAAAAAACUUACUUAAUUUUC-5′ (SEQ ID NO: 2222) βc-m3560 Target:5′-TTTTTTTTTTTTTGAATGAATTAAAAG-3′ (SEQ ID NO: 3331)5′-UUUUUUUUUUUUUUGAAUGAAUUAAAA-3′ (SEQ ID NO: 7768)3′-AAAAAAAAAAAAAACUUACUUAAUUUU-5′ (SEQ ID NO: 2223) βc-m3561 Target:5′-TTTTTTTTTTTTTTGAATGAATTAAAA-3′ (SEQ ID NO: 3332)5′-UUUUUUUUUUUUUUUGAAUGAAUUAAA-3′ (SEQ ID NO: 7769)3′-AAAAAAAAAAAAAAACUUACUUAAUUU-5′ (SEQ ID NO: 2224) βc-m3562 Target:5′-TTTTTTTTTTTTTTTGAATGAATTAAA-3′ (SEQ ID NO: 3333)5′-UUUUUUUUUUUUUUUUGAAUGAAUUAA-3′ (SEQ ID NO: 7770)3′-AAAAAAAAAAAAAAAACUUACUUAAUU-5′ (SEQ ID NO: 2225) βc-m3563 Target:5′-TTTTTTTTTTTTTTTTGAATGAATTAA-3′ (SEQ ID NO: 3334)

Within Tables 2-4 and 9 above, underlined residues indicate 2′-O-methylresidues. In Tables 2-4, 6-9 and 11-13 above, UPPER CASE indicatesribonucleotides, and lower case denotes deoxyribonucleotides. The DsiRNAagents of Tables 2-4 and 9 above are 25/27mer agents possessing a bluntend. The structures and/or modification patterning of the agents ofTables 2-4, 6, 9 and 11 above can be readily adapted to the abovegeneric sequence structures, e.g., the 3′ overhang of the second strandcan be extended or contracted, 2′-O-methylation of the second strand canbe expanded towards the 5′ end of the second strand, optionally atalternating sites, etc. Such further modifications are optional, as25/27mer DsiRNAs with such modifications can also be readily designedfrom the above DsiRNA agents and are also expected to be functionalinhibitors of β-catenin expression. Similarly, the 27mer “blunt/fray”and “blunt/blunt” DsiRNA structures and/or modification patterns of theagents of Tables 7-8 and 12-13 above can also be readily adapted to theabove generic sequence structures, e.g., for application of modificationpatterning of the antisense strand to such structures and/or adaptationof such sequences to the above generic structures.

In certain embodiments, 27mer DsiRNAs possessing independent strandlengths each of 27 nucleotides are designed and synthesized fortargeting of the same sites within the β-catenin transcript as theasymmetric “25/27” structures shown in Tables 2-4, 6, 9 and 11 herein.Exemplary “27/27” DsiRNAs are optionally designed with a “blunt/fray”structure as shown for the DsiRNAs of Tables 7 and 12 above, or with a“blunt/blunt” structure as shown for the DsiRNAs of Tables 8 and 13above.

In certain embodiments, the DsiRNA agents of the invention require,e.g., at least 19, at least 20, at least 21, at least 22, at least 23,at least 24, at least 25 or at least 26 residues of the first strand tobe complementary to corresponding residues of the second strand. Incertain related embodiments, these first strand residues complementaryto corresponding residues of the second strand are optionallyconsecutive residues.

As used herein “DsiRNAmm” refers to a DisRNA having a “mismatch tolerantregion” containing one, two, three or four mismatched base pairs of theduplex formed by the sense and antisense strands of the DsiRNA, wheresuch mismatches are positioned within the DsiRNA at a location(s) lyingbetween (and thus not including) the two terminal base pairs of eitherend of the DsiRNA. The mismatched base pairs are located within a“mismatch-tolerant region” which is defined herein with respect to thelocation of the projected Ago2 cut site of the corresponding targetnucleic acid. The mismatch tolerant region is located “upstream of” theprojected Ago2 cut site of the target strand. “Upstream” in this contextwill be understood as the 5′-most portion of the DsiRNAmm duplex, where5′ refers to the orientation of the sense strand of the DsiRNA duplex.Therefore, the mismatch tolerant region is upstream of the base on thesense (passenger) strand that corresponds to the projected Ago2 cut siteof the target nucleic acid (see FIG. 1); alternatively, when referringto the antisense (guide) strand of the DsiRNAmm, the mismatch tolerantregion can also be described as positioned downstream of the base thatis complementary to the projected Ago2 cut site of the target nucleicacid, that is, the 3′-most portion of the antisense strand of theDsiRNAmm (where position 1 of the antisense strand is the 5′ terminalnucleotide of the antisense strand, see FIG. 1).

In one embodiment, for example with numbering as depicted in FIG. 1, themismatch tolerant region is positioned between and including base pairs3-9 when numbered from the nucleotide starting at the 5′ end of thesense strand of the duplex. Therefore, a DsiRNAmm of the inventionpossesses a single mismatched base pair at any one of positions 3, 4, 5,6, 7, 8 or 9 of the sense strand of a right-hand extended DsiRNA (whereposition 1 is the 5′ terminal nucleotide of the sense strand andposition 9 is the nucleotide residue of the sense strand that isimmediately 5′ of the projected Ago2 cut site of the target β-cateninRNA sequence corresponding to the sense strand sequence). In certainembodiments, for a DsiRNAmm that possesses a mismatched base pairnucleotide at any of positions 3, 4, 5, 6, 7, 8 or 9 of the sensestrand, the corresponding mismatched base pair nucleotide of theantisense strand not only forms a mismatched base pair with the DsiRNAmmsense strand sequence, but also forms a mismatched base pair with aDsiRNAmm target β-catenin RNA sequence (thus, complementarity betweenthe antisense strand sequence and the sense strand sequence is disruptedat the mismatched base pair within the DsiRNAmm, and complementarity issimilarly disrupted between the antisense strand sequence of theDsiRNAmm and the target β-catenin RNA sequence). In alternativeembodiments, the mismatch base pair nucleotide of the antisense strandof a DsiRNAmm only form a mismatched base pair with a correspondingnucleotide of the sense strand sequence of the DsiRNAmm, yet base pairswith its corresponding target β-catenin RNA sequence nucleotide (thus,complementarity between the antisense strand sequence and the sensestrand sequence is disrupted at the mismatched base pair within theDsiRNAmm, yet complementarity is maintained between the antisense strandsequence of the DsiRNAmm and the target β-catenin RNA sequence).

A DsiRNAmm of the invention that possesses a single mismatched base pairwithin the mismatch-tolerant region (mismatch region) as described above(e.g., a DsiRNAmm harboring a mismatched nucleotide residue at any oneof positions 3, 4, 5, 6, 7, 8 or 9 of the sense strand) can furtherinclude one, two or even three additional mismatched base pairs. Inpreferred embodiments, these one, two or three additional mismatchedbase pairs of the DsiRNAmm occur at position(s) 3, 4, 5, 6, 7, 8 and/or9 of the sense strand (and at corresponding residues of the antisensestrand). In one embodiment where one additional mismatched base pair ispresent within a DsiRNAmm, the two mismatched base pairs of the sensestrand can occur, e.g., at nucleotides of both position 4 and position 6of the sense strand (with mismatch also occurring at correspondingnucleotide residues of the antisense strand).

In DsiRNAmm agents possessing two mismatched base pairs, mismatches canoccur consecutively (e.g., at consecutive positions along the sensestrand nucleotide sequence). Alternatively, nucleotides of the sensestrand that form mismatched base pairs with the antisense strandsequence can be interspersed by nucleotides that base pair with theantisense strand sequence (e.g., for a DsiRNAmm possessing mismatchednucleotides at positions 3 and 6, but not at positions 4 and 5, themismatched residues of sense strand positions 3 and 6 are interspersedby two nucleotides that form matched base pairs with correspondingresidues of the antisense strand). For example, two residues of thesense strand (located within the mismatch-tolerant region of the sensestrand) that form mismatched base pairs with the corresponding antisensestrand sequence can occur with zero, one, two, three, four or fivematched base pairs located between these mismatched base pairs.

For certain DsiRNAmm agents possessing three mismatched base pairs,mismatches can occur consecutively (e.g., in a triplet along the sensestrand nucleotide sequence). Alternatively, nucleotides of the sensestrand that form mismatched base pairs with the antisense strandsequence can be interspersed by nucleotides that form matched base pairswith the antisense strand sequence (e.g., for a DsiRNAmm possessingmismatched nucleotides at positions 3, 4 and 8, but not at positions 5,6 and 7, the mismatched residues of sense strand positions 3 and 4 areadjacent to one another, while the mismatched residues of sense strandpositions 4 and 8 are interspersed by three nucleotides that formmatched base pairs with corresponding residues of the antisense strand).For example, three residues of the sense strand (located within themismatch-tolerant region of the sense strand) that form mismatched basepairs with the corresponding antisense strand sequence can occur withzero, one, two, three or four matched base pairs located between any twoof these mismatched base pairs.

For certain DsiRNAmm agents possessing four mismatched base pairs,mismatches can occur consecutively (e.g., in a quadruplet along thesense strand nucleotide sequence). Alternatively, nucleotides of thesense strand that form mismatched base pairs with the antisense strandsequence can be interspersed by nucleotides that form matched base pairswith the antisense strand sequence (e.g., for a DsiRNAmm possessingmismatched nucleotides at positions 3, 5, 7 and 8, but not at positions4 and 6, the mismatched residues of sense strand positions 7 and 8 areadjacent to one another, while the mismatched residues of sense strandpositions 3 and 5 are interspersed by one nucleotide that forms amatched base pair with the corresponding residue of the antisensestrand—similarly, the mismatched residues of sense strand positions 5and 7 are also interspersed by one nucleotide that forms a matched basepair with the corresponding residue of the antisense strand). Forexample, four residues of the sense strand (located within themismatch-tolerant region of the sense strand) that form mismatched basepairs with the corresponding antisense strand sequence can occur withzero, one, two or three matched base pairs located between any two ofthese mismatched base pairs.

In another embodiment, for example with numbering also as depicted inFIG. 1, a DsiRNAmm of the invention comprises a mismatch tolerant regionwhich possesses a single mismatched base pair nucleotide at any one ofpositions 17, 18, 19, 20, 21, 22 or 23 of the antisense strand of theDsiRNA (where position 1 is the 5′ terminal nucleotide of the antisensestrand and position 17 is the nucleotide residue of the antisense strandthat is immediately 3′ (downstream) in the antisense strand of theprojected Ago2 cut site of the target β-catenin RNA sequencesufficiently complementary to the antisense strand sequence). In certainembodiments, for a DsiRNAmm that possesses a mismatched base pairnucleotide at any of positions 17, 18, 19, 20, 21, 22 or 23 of theantisense strand with respect to the sense strand of the DsiRNAmm, themismatched base pair nucleotide of the antisense strand not only forms amismatched base pair with the DsiRNAmm sense strand sequence, but alsoforms a mismatched base pair with a DsiRNAmm target β-catenin RNAsequence (thus, complementarity between the antisense strand sequenceand the sense strand sequence is disrupted at the mismatched base pairwithin the DsiRNAmm, and complementarity is similarly disrupted betweenthe antisense strand sequence of the DsiRNAmm and the target β-cateninRNA sequence). In alternative embodiments, the mismatch base pairnucleotide of the antisense strand of a DsiRNAmm only forms a mismatchedbase pair with a corresponding nucleotide of the sense strand sequenceof the DsiRNAmm, yet base pairs with its corresponding target β-cateninRNA sequence nucleotide (thus, complementarity between the antisensestrand sequence and the sense strand sequence is disrupted at themismatched base pair within the DsiRNAmm, yet complementarity ismaintained between the antisense strand sequence of the DsiRNAmm and thetarget β-catenin RNA sequence).

A DsiRNAmm of the invention that possesses a single mismatched base pairwithin the mismatch-tolerant region as described above (e.g., a DsiRNAmmharboring a mismatched nucleotide residue at positions 17, 18, 19, 20,21, 22 or 23 of the antisense strand) can further include one, two oreven three additional mismatched base pairs. In preferred embodiments,these one, two or three additional mismatched base pairs of the DsiRNAmmoccur at position(s) 17, 18, 19, 20, 21, 22 and/or 23 of the antisensestrand (and at corresponding residues of the sense strand). In oneembodiment where one additional mismatched base pair is present within aDsiRNAmm, the two mismatched base pairs of the antisense strand canoccur, e.g., at nucleotides of both position 18 and position 20 of theantisense strand (with mismatch also occurring at correspondingnucleotide residues of the sense strand).

In DsiRNAmm agents possessing two mismatched base pairs, mismatches canoccur consecutively (e.g., at consecutive positions along the antisensestrand nucleotide sequence). Alternatively, nucleotides of the antisensestrand that form mismatched base pairs with the sense strand sequencecan be interspersed by nucleotides that base pair with the sense strandsequence (e.g., for a DsiRNAmm possessing mismatched nucleotides atpositions 17 and 20, but not at positions 18 and 19, the mismatchedresidues of antisense strand positions 17 and 20 are interspersed by twonucleotides that form matched base pairs with corresponding residues ofthe sense strand). For example, two residues of the antisense strand(located within the mismatch-tolerant region of the sense strand) thatform mismatched base pairs with the corresponding sense strand sequencecan occur with zero, one, two, three, four, five, six or seven matchedbase pairs located between these mismatched base pairs.

For certain DsiRNAmm agents possessing three mismatched base pairs,mismatches can occur consecutively (e.g., in a triplet along theantisense strand nucleotide sequence). Alternatively, nucleotides of theantisense strand that form mismatched base pairs with the sense strandsequence can be interspersed by nucleotides that form matched base pairswith the sense strand sequence (e.g., for a DsiRNAmm possessingmismatched nucleotides at positions 17, 18 and 22, but not at positions19, 20 and 21, the mismatched residues of antisense strand positions 17and 18 are adjacent to one another, while the mismatched residues ofantisense strand positions 18 and 122 are interspersed by threenucleotides that form matched base pairs with corresponding residues ofthe sense strand). For example, three residues of the antisense strand(located within the mismatch-tolerant region of the antisense strand)that form mismatched base pairs with the corresponding sense strandsequence can occur with zero, one, two, three, four, five or six matchedbase pairs located between any two of these mismatched base pairs.

For certain DsiRNAmm agents possessing four mismatched base pairs,mismatches can occur consecutively (e.g., in a quadruplet along theantisense strand nucleotide sequence). Alternatively, nucleotides of theantisense strand that form mismatched base pairs with the sense strandsequence can be interspersed by nucleotides that form matched base pairswith the sense strand sequence (e.g., for a DsiRNAmm possessingmismatched nucleotides at positions 18, 20, 22 and 23, but not atpositions 19 and 21, the mismatched residues of antisense strandpositions 22 and 23 are adjacent to one another, while the mismatchedresidues of antisense strand positions 18 and 20 are interspersed by onenucleotide that forms a matched base pair with the corresponding residueof the sense strand—similarly, the mismatched residues of antisensestrand positions 20 and 22 are also interspersed by one nucleotide thatforms a matched base pair with the corresponding residue of the sensestrand). For example, four residues of the antisense strand (locatedwithin the mismatch-tolerant region of the antisense strand) that formmismatched base pairs with the corresponding sense strand sequence canoccur with zero, one, two, three, four or five matched base pairslocated between any two of these mismatched base pairs.

For reasons of clarity, the location(s) of mismatched nucleotideresidues within the above DsiRNAmm agents are numbered in reference tothe 5′ terminal residue of either sense or antisense strands of theDsiRNAmm. The numbering of positions located within themismatch-tolerant region (mismatch region) of the antisense strand canshift with variations in the proximity of the 5′ terminus of the senseor antisense strand to the projected Ago2 cleavage site. Thus, thelocation(s) of preferred mismatch sites within either antisense strandor sense strand can also be identified as the permissible proximity ofsuch mismatches to the projected Ago2 cut site. Accordingly, in onepreferred embodiment, the position of a mismatch nucleotide of the sensestrand of a DsiRNAmm is the nucleotide residue of the sense strand thatis located immediately 5′ (upstream) of the projected Ago2 cleavage siteof the corresponding target β-catenin RNA sequence. In other preferredembodiments, a mismatch nucleotide of the sense strand of a DsiRNAmm ispositioned at the nucleotide residue of the sense strand that is locatedtwo nucleotides 5′ (upstream) of the projected Ago2 cleavage site, threenucleotides 5′ (upstream) of the projected Ago2 cleavage site, fournucleotides 5′ (upstream) of the projected Ago2 cleavage site, fivenucleotides 5′ (upstream) of the projected Ago2 cleavage site, sixnucleotides 5′ (upstream) of the projected Ago2 cleavage site, sevennucleotides 5′ (upstream) of the projected Ago2 cleavage site, eightnucleotides 5′ (upstream) of the projected Ago2 cleavage site, or ninenucleotides 5′ (upstream) of the projected Ago2 cleavage site.

Exemplary single mismatch-containing 25/27mer DsiRNAs (DsiRNAmm) includethe following structures (such mismatch-containing structures may alsobe incorporated into other exemplary DsiRNA structures shown herein).

wherein “X”=RNA, “D”=DNA and “M”=Nucleic acid residues (RNA, DNA ornon-natural or modified nucleic acids) that do not base pair (hydrogenbond) with corresponding “M” residues of otherwise complementary strandwhen strands are annealed. Any of the residues of such agents canoptionally be 2′-O-methyl RNA monomers—alternating positioning of2′-O-methyl RNA monomers that commences from the 3′-terminal residue ofthe bottom (second) strand, as shown above, can also be used in theabove DsiRNAmm agents. For the above mismatch structures, the top strandis the sense strand, and the bottom strand is the antisense strand.

In certain embodiments, a DsiRNA of the invention can contain mismatchesthat exist in reference to the target β-catenin RNA sequence yet do notnecessarily exist as mismatched base pairs within the two strands of theDsiRNA—thus, a DsiRNA can possess perfect complementarity between firstand second strands of a DsiRNA, yet still possess mismatched residues inreference to a target β-catenin RNA (which, in certain embodiments, maybe advantageous in promoting efficacy and/or potency and/or duration ofeffect). In certain embodiments, where mismatches occur betweenantisense strand and target β-catenin RNA sequence, the position of amismatch is located within the antisense strand at a position(s) thatcorresponds to a sequence of the sense strand located 5′ of theprojected Ago2 cut site of the target region—e.g., antisense strandresidue(s) positioned within the antisense strand to the 3′ of theantisense residue which is complementary to the projected Ago2 cut siteof the target sequence.

Exemplary 25/27mer DsiRNAs that harbor a single mismatched residue inreference to target sequences include the following structures.

Target RNA Sequence: 5′-...AXXXXXXXXXXXXXXXXXXXX...-3′ DsiRNAmm SenseStrand: 5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand:3′-EXXXXXXXXXXXXXXXXXXXXXXXXXX-5′ Target RNA Sequence:5′-...XAXXXXXXXXXXXXXXXXXXX...-3′ DsiRNAmm Sense Strand:5′-XXXXXXXXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand:3′-XEXXXXXXXXXXXXXXXXXXXXXXXXX-5′ Target RNA Sequence:5′-...AXXXXXXXXXXXXXXXXXX...-3′ DsiRNAmm Sense Strand:5′-BXXXXXXXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand:3′-XXEXXXXXXXXXXXXXXXXXXXXXXXX-5′ Target RNA Sequence:5′-...XAXXXXXXXXXXXXXXXXX...-3′ DsiRNAmm Sense Strand:5′-XBXXXXXXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand:3′-XXXEXXXXXXXXXXXXXXXXXXXXXXX-5′ Target RNA Sequence:5′-...XXAXXXXXXXXXXXXXXXX...-3′ DsiRNAmm Sense Strand:5′-XXBXXXXXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand:3′-XXXXEXXXXXXXXXXXXXXXXXXXXXX-5′ Target RNA Sequence:5′-...XXXAXXXXXXXXXXXXXXX...-3′ DsiRNAmm Sense Strand:5′-XXXBXXXXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand:3′-XXXXXEXXXXXXXXXXXXXXXXXXXXX-5′ Target RNA Sequence:5′-...XXXXAXXXXXXXXXXXXXX...-3′ DsiRNAmm Sense Strand:5′-XXXXBXXXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand:3′-XXXXXXEXXXXXXXXXXXXXXXXXXXX-5′ Target RNA Sequence:5′-...XXXXXAXXXXXXXXXXXXX...-3′ DsiRNAmm Sense Strand:5′-XXXXXBXXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand:3′-XXXXXXXEXXXXXXXXXXXXXXXXXXX-5′ Target RNA Sequence:5′-...XXXXXXAXXXXXXXXXXXX...-3′ DsiRNAmm Sense Strand:5′-XXXXXXBXXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand:3′-XXXXXXXXEXXXXXXXXXXXXXXXXXX-5′ Target RNA Sequence:5′-...XXXXXXXAXXXXXXXXXXX...-3′ DsiRNAmm Sense Strand:5′-XXXXXXXBXXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand:3′-XXXXXXXXXEXXXXXXXXXXXXXXXXX-5′ Target RNA Sequence:5′-...XXXXXXXXAXXXXXXXXXX...-3′ DsiRNAmm Sense Strand:5′-XXXXXXXXBXXXXXXXXXXXXXXDD-3′ DsiRNAmm Antisense Strand:3′-XXXXXXXXXXEXXXXXXXXXXXXXXXX-5′wherein “X”=RNA, “D”=DNA and “E”=Nucleic acid residues (RNA, DNA ornon-natural or modified nucleic acids) that do not base pair (hydrogenbond) with corresponding “A” RNA residues of otherwise complementary(target) strand when strands are annealed, yet optionally do base pairwith corresponding “B” residues (“B” residues are also RNA, DNA ornon-natural or modified nucleic acids). Any of the residues of suchagents can optionally be 2′-O-methyl RNA monomers—alternatingpositioning of 2′-O-methyl RNA monomers that commences from the3′-terminal residue of the bottom (second) strand, as shown above, canalso be used in the above DsiRNA agents.

In addition to the above-exemplified structures, DsiRNAs of theinvention can also possess one, two or three additional residues thatform further mismatches with the target β-catenin RNA sequence. Suchmismatches can be consecutive, or can be interspersed by nucleotidesthat form matched base pairs with the target β-catenin RNA sequence.Where interspersed by nucleotides that form matched base pairs,mismatched residues can be spaced apart from each other within a singlestrand at an interval of one, two, three, four, five, six, seven or eveneight base paired nucleotides between such mismatch-forming residues.

As for the above-described DsiRNAmm agents, a preferred location withinDsiRNAs for antisense strand nucleotides that form mismatched base pairswith target β-catenin RNA sequence (yet may or may not form mismatcheswith corresponding sense strand nucleotides) is within the antisensestrand region that is located 3′ (downstream) of the antisense strandsequence which is complementary to the projected Ago2 cut site of theDsiRNA (e.g., in FIG. 1, the region of the antisense strand which is 3′of the projected Ago2 cut site is preferred for mismatch-formingresidues and happens to be located at positions 17-23 of the antisensestrand for the 25/27mer agent shown in FIG. 1). Thus, in one embodiment,the position of a mismatch nucleotide (in relation to the targetβ-catenin RNA sequence) of the antisense strand of a DsiRNAmm is thenucleotide residue of the antisense strand that is located immediately3′ (downstream) within the antisense strand sequence of the projectedAgo2 cleavage site of the corresponding target β-catenin RNA sequence.In other preferred embodiments, a mismatch nucleotide of the antisensestrand of a DsiRNAmm (in relation to the target β-catenin RNA sequence)is positioned at the nucleotide residue of the antisense strand that islocated two nucleotides 3′ (downstream) of the corresponding projectedAgo2 cleavage site, three nucleotides 3′ (downstream) of thecorresponding projected Ago2 cleavage site, four nucleotides 3′(downstream) of the corresponding projected Ago2 cleavage site, fivenucleotides 3′ (downstream) of the corresponding projected Ago2 cleavagesite, six nucleotides 3′ (downstream) of the projected Ago2 cleavagesite, seven nucleotides 3′ (downstream) of the projected Ago2 cleavagesite, eight nucleotides 3′ (downstream) of the projected Ago2 cleavagesite, or nine nucleotides 3′ (downstream) of the projected Ago2 cleavagesite.

In DsiRNA agents possessing two mismatch-forming nucleotides of theantisense strand (where mismatch-forming nucleotides are mismatchforming in relation to target β-catenin RNA sequence), mismatches canoccur consecutively (e.g., at consecutive positions along the antisensestrand nucleotide sequence). Alternatively, nucleotides of the antisensestrand that form mismatched base pairs with the target β-catenin RNAsequence can be interspersed by nucleotides that base pair with thetarget β-catenin RNA sequence (e.g., for a DsiRNA possessingmismatch-forming nucleotides at positions 17 and 20 (starting from the5′ terminus (position 1) of the antisense strand of the 25/27mer agentshown in FIG. 1), but not at positions 18 and 19, the mismatchedresidues of sense strand positions 17 and 20 are interspersed by twonucleotides that form matched base pairs with corresponding residues ofthe target β-catenin RNA sequence). For example, two residues of theantisense strand (located within the mismatch-tolerant region of theantisense strand) that form mismatched base pairs with the correspondingtarget β-catenin RNA sequence can occur with zero, one, two, three, fouror five matched base pairs (with respect to target β-catenin RNAsequence) located between these mismatch-forming base pairs.

For certain DsiRNAs possessing three mismatch-forming base pairs(mismatch-forming with respect to target β-catenin RNA sequence),mismatch-forming nucleotides can occur consecutively (e.g., in a tripletalong the antisense strand nucleotide sequence). Alternatively,nucleotides of the antisense strand that form mismatched base pairs withthe target β-catenin RNA sequence can be interspersed by nucleotidesthat form matched base pairs with the target β-catenin RNA sequence(e.g., for a DsiRNA possessing mismatched nucleotides at positions 17,18 and 22, but not at positions 19, 20 and 21, the mismatch-formingresidues of antisense strand positions 17 and 18 are adjacent to oneanother, while the mismatch-forming residues of antisense strandpositions 18 and 22 are interspersed by three nucleotides that formmatched base pairs with corresponding residues of the target β-cateninRNA). For example, three residues of the antisense strand (locatedwithin the mismatch-tolerant region of the antisense strand) that formmismatched base pairs with the corresponding target β-catenin RNAsequence can occur with zero, one, two, three or four matched base pairslocated between any two of these mismatch-forming base pairs.

For certain DsiRNAs possessing four mismatch-forming base pairs(mismatch-forming with respect to target β-catenin RNA sequence),mismatch-forming nucleotides can occur consecutively (e.g., in aquadruplet along the sense strand nucleotide sequence). Alternatively,nucleotides of the antisense strand that form mismatched base pairs withthe target β-catenin RNA sequence can be interspersed by nucleotidesthat form matched base pairs with the target β-catenin RNA sequence(e.g., for a DsiRNA possessing mismatch-forming nucleotides at positions17, 19, 21 and 22, but not at positions 18 and 20, the mismatch-formingresidues of antisense strand positions 21 and 22 are adjacent to oneanother, while the mismatch-forming residues of antisense strandpositions 17 and 19 are interspersed by one nucleotide that forms amatched base pair with the corresponding residue of the target β-cateninRNA sequence—similarly, the mismatch-forming residues of antisensestrand positions 19 and 21 are also interspersed by one nucleotide thatforms a matched base pair with the corresponding residue of the targetβ-catenin RNA sequence). For example, four residues of the antisensestrand (located within the mismatch-tolerant region of the antisensestrand) that form mismatched base pairs with the corresponding targetβ-catenin RNA sequence can occur with zero, one, two or three matchedbase pairs located between any two of these mismatch-forming base pairs.

The above DsiRNAmm and other DsiRNA structures are described in order toexemplify certain structures of DsiRNAmm and DsiRNA agents. Design ofthe above DsiRNAmm and DsiRNA structures can be adapted to generate,e.g., DsiRNAmm forms of other DsiRNA structures shown infra. Asexemplified above, DsiRNAs can also be designed that possess singlemismatches (or two, three or four mismatches) between the antisensestrand of the DsiRNA and a target sequence, yet optionally can retainperfect complementarity between sense and antisense strand sequences ofa DsiRNA.

It is further noted that the DsiRNA agents exemplified infra can alsopossess insertion/deletion (in/del) structures within theirdouble-stranded and/or target β-catenin RNA-aligned structures.Accordingly, the DsiRNAs of the invention can be designed to possessin/del variations in, e.g., antisense strand sequence as compared totarget β-catenin RNA sequence and/or antisense strand sequence ascompared to sense strand sequence, with preferred location(s) forplacement of such in/del nucleotides corresponding to those locationsdescribed above for positioning of mismatched and/or mismatch-formingbase pairs.

It is also noted that the DsiRNAs of the instant invention can toleratemismatches within the 3′-terminal region of the sense strand/5′-terminalregion of the antisense strand, as this region is modeled to beprocessed by Dicer and liberated from the guide strand sequence thatloads into RISC. Exemplary DsiRNA structures of the invention thatharbor such mismatches include the following:

Target RNA Sequence: 5′-...XXXXXXXXXXXXXXXXXXXXXHXXX...-3′ DsiRNA SenseStrand: 5′-XXXXXXXXXXXXXXXXXXXXXIXDD-3′ DsiRNA Antisense Strand:3′-XXXXXXXXXXXXXXXXXXXXXXXJXXX-5′ Target RNA Sequence:5′-...XXXXXXXXXXXXXXXXXXXXXXHXX...-3′ DsiRNA Sense Strand:5′-XXXXXXXXXXXXXXXXXXXXXXIDD-3′ DsiRNA Antisense Strand:3′-XXXXXXXXXXXXXXXXXXXXXXXXJXX-5′ Target RNA Sequence:5′-...XXXXXXXXXXXXXXXXXXXXXXXHX...-3′ DsiRNA Sense Strand:5′-XXXXXXXXXXXXXXXXXXXXXXXID-3′ DsiRNA Antisense Strand:3′-XXXXXXXXXXXXXXXXXXXXXXXXXJX-5′ Target RNA Sequence:5′-...XXXXXXXXXXXXXXXXXXXXXXXXH...-3′ DsiRNA Sense Strand:5′-XXXXXXXXXXXXXXXXXXXXXXXDI-3′ DsiRNA Antisense Strand:3′-XXXXXXXXXXXXXXXXXXXXXXXXXXJ-5′wherein “X”=RNA, “D”=DNA and “I” and “J”=Nucleic acid residues (RNA, DNAor non-natural or modified nucleic acids) that do not base pair(hydrogen bond) with one another, yet optionally “J” is complementary totarget RNA sequence nucleotide “H”. Any of the residues of such agentscan optionally be 2′-O-methyl RNA monomers—alternating positioning of2′-O-methyl RNA monomers that commences from the 3′-terminal residue ofthe bottom (second) strand, as shown above—or any of the above-describedmethylation patterns—can also be used in the above DsiRNA agents. Theabove mismatches can also be combined within the DsiRNAs of the instantinvention.

In the below structures, such mismatches are introduced within theasymmetric βc-1569 DsiRNA (newly-introduced mismatch residues areitalicized):

βc-1569 25/27mer DsiRNA, mismatch position=22 of sense strand (from5′-terminus)

Optionally, the mismatched “C” residue of position 22 of the sensestrand is alternatively “U” or “G”.βc-1569 25/27mer DsiRNA, mismatch position=23 of sense strand

Optionally, the mismatched “U” residue of position 23 of the sensestrand is alternatively “A” or “C”.βc-1569 25/27mer DsiRNA, mismatch position=24 of sense strand

Optionally, the mismatched “c” residue of position 24 of the sensestrand is alternatively “t” or “g”.βc-1569 25/27mer DsiRNA, mismatch position=25 of sense strand

Optionally, the mismatched “c” residue of position 25 of the sensestrand is alternatively “t” or “g”.βc-1569 25/27mer DsiRNA, mismatch position=1 of antisense strand

Optionally, the mismatched “G” residue of position 1 of the antisensestrand is alternatively “A” or “C”.βc-1569 25/27mer DsiRNA, mismatch position=2 of antisense strand

Optionally, the mismatched “G” residue of position 2 of the antisensestrand is alternatively “A” or “C”.βc-1569 25/27mer DsiRNA, mismatch position=3 of antisense strand

Optionally, the mismatched “A” residue of position 3 of the antisensestrand is alternatively “U” or “G”.βc-1569 25/27mer DsiRNA, mismatch position=4 of antisense strand

Optionally, the mismatched “G” residue of position 4 of the antisensestrand is alternatively “A” or “C”.

As an additional example, such mismatches are introduced within theasymmetric βc-3393 DsiRNA (newly-introduced mismatch residues areitalicized):

βc-3393 25/27mer DsiRNA, mismatch position=22 of sense strand (from5′-terminus)

Optionally, the mismatched “C” residue of position 22 of the sensestrand is alternatively “U” or “G”.βc-3393 25/27mer DsiRNA, mismatch position=23 of sense strand

Optionally, the mismatched “C” residue of position 23 of the sensestrand is alternatively “G” or “U”.βc-3393 25/27mer DsiRNA, mismatch position=24 of sense strand

Optionally, the mismatched “c” residue of position 24 of the sensestrand is alternatively “a” or “g”.βc-3393 25/27mer DsiRNA, mismatch position=25 of sense strand

Optionally, the mismatched “a” residue of position 25 of the sensestrand is alternatively “t” or “g”.βc-3393 25/27mer DsiRNA, mismatch position=1 of antisense strand

Optionally, the mismatched “A” residue of position 1 of the antisensestrand is alternatively “U” or “C”.βc-3393 25/27mer DsiRNA, mismatch position=2 of antisense strand

Optionally, the mismatched “C” residue of position 2 of the antisensestrand is alternatively “G” or “U”.βc-3393 25/27mer DsiRNA, mismatch position=3 of antisense strand

Optionally, the mismatched “C” residue of position 3 of the antisensestrand is alternatively “U” or “A”.βc-3393 25/27mer DsiRNA, mismatch position=4 of antisense strand

Optionally, the mismatched “C” residue of position 4 of the antisensestrand is alternatively “U” or “A”.

As noted above, introduction of such mismatches can be performed uponany of the DsiRNAs described herein.

The mismatches of such DsiRNA structures can be combined to produce aDsiRNA possessing, e.g., two, three or even four mismatches within the3′-terminal four nucleotides of the sense strand/5′-terminal fournucleotides of the antisense strand.

Indeed, in view of the flexibility of sequences which can beincorporated into DsiRNAs at the 3′-terminal residues of the sensestrand/5′-terminal residues of the antisense strand, in certainembodiments, the sequence requirements of an asymmetric DsiRNA of theinstant invention can be represented as the following (minimalist)structure (shown for an exemplary βc-1569 DsiRNA sequence):

(SEQ ID NO: 7783) 5′-ACCUCACUUGCAAUAAUUAUAXXX[X]_(n)-3′ (SEQ ID NO:7784) 3′-AUUGGAGUGAACGUUAUUAAUXXXXX[X]_(n)-5′where n=1 to 5, 1 to 10, 1 to 20, 1 to 30, 1 to 50, or 1 to 80 or more.

βc-1569 Target: (SEQ ID NO: 7785) 5′-TAACCTCACTTGCAATAATTAXXXXXX-3′

The β-catenin target site may also be a site which is targeted by one ormore of several oligonucleotides whose complementary target sitesoverlap with a stated target site. For example, for an exemplary βc-288DsiRNA, it is noted that certain DsiRNAs targeting overlapping and onlyslightly offset β-catenin sequences can exhibit activity levels similarto that of βc-288 (specifically, see βc-284, (βc-285, βc-286, βc-287,βc-289, βc-290 and βc-291 DsiRNAs of Table 14 below). Thus, in certainembodiments, a designated target sequence region can be effectivelytargeted by a series of DsiRNAs possessing largely overlappingsequences. (E.g., if considering DsiRNAs surrounding the βc-288 site, amore encompassing β-catenin target sequence might be recited as, e.g.,5′-CAGCGTGGACAATGGCTACTCAAGCTGATTTGAT-3′ (SEQ ID NO: 7786), wherein anygiven DsiRNA (e.g., a DsiRNA selected from βc-284, (βc-285, βc-286,βc-287, (βc-288, (βc-289, βc-290 and βc-291) only targets a sub-sequencewithin such a sequence region, yet the entire sequence can be considereda viable target for such a series of DsiRNAs).

Additionally and/or alternatively, mismatches within the 3′-terminalfour nucleotides of the sense strand/5′-terminal four nucleotides of theantisense strand can be combined with mismatches positioned at othermismatch-tolerant positions, as described above.

In view of the present identification of the above-described Dicersubstrate agents (DsiRNAs) as inhibitors of β-catenin levels viatargeting of specific β-catenin sequences, it is also recognized thatDsiRNAs having structures similar to those described herein can also besynthesized which target other sequences within the β-catenin sequenceof SEQ ID NOs: 1-3 or SEQ ID NOs: 5-6, or within variants thereof (e.g.,target sequences possessing 80% identity, 90% identity, 95% identity,96% identity, 97% identity, 98% identity, 99% or more identity to asequence of SEQ ID NOs: 1-3 or SEQ ID NOs: 5-6).

Anti-β-Catenin DsiRNA Design/Synthesis

It has been found empirically that longer dsRNA species of from 25 to 35nucleotides (DsiRNAs) and especially from 25 to 30 nucleotides giveunexpectedly effective results in terms of potency and duration ofaction, as compared to 19-23mer siRNA agents. Without wishing to bebound by the underlying theory of the dsRNA processing mechanism, it isthought that the longer dsRNA species serve as a substrate for the Dicerenzyme in the cytoplasm of a cell. In addition to cleaving the dsRNA ofthe invention into shorter segments, Dicer is thought to facilitate theincorporation of a single-stranded cleavage product derived from thecleaved dsRNA into the RISC complex that is responsible for thedestruction of the cytoplasmic RNA (e.g., β-catenin RNA) of or derivedfrom the target gene, β-catenin (or other gene associated with aβ-catenin-associated disease or disorder). Prior studies (Rossi et al.,U.S. Patent Application No. 2007/0265220) have shown that thecleavability of a dsRNA species (specifically, a DsiRNA agent) by Dicercorresponds with increased potency and duration of action of the dsRNAspecies.

Certain preferred anti-β-catenin DsiRNA agents were selected from apre-screened population. Design of DsiRNAs can optionally involve use ofpredictive scoring algorithms that perform in silico assessments of theprojected activity/efficacy of a number of possible DsiRNA agentsspanning a region of sequence. Information regarding the design of suchscoring algorithms can be found, e.g., in Gong et al. (BMCBioinformatics 2006, 7:516), though a more recent “v3” algorithmrepresents a theoretically improved algorithm relative to siRNA scoringalgorithms previously available in the art. (E.g., the “v3” and “v4”scoring algorithms are machine learning algorithms that are not reliantupon any biases in human sequence. In addition, the “v3” and “v4”algorithms derive from data sets that are many-fold larger than thatfrom which an older “v2” algorithm such as that described in Gong et al.derives.)

The first and second oligonucleotides of the DsiRNA agents of theinstant invention are not required to be completely complementary. Infact, in one embodiment, the 3′-terminus of the sense strand containsone or more mismatches. In one aspect, two mismatches are incorporatedat the 3′ terminus of the sense strand. In another embodiment, theDsiRNA of the invention is a double stranded RNA molecule containing twoRNA oligonucleotides each of which is 27 nucleotides in length and, whenannealed to each other, have blunt ends and a two nucleotide mismatch onthe 3′-terminus of the sense strand (the 5′-terminus of the antisensestrand). The use of mismatches or decreased thermodynamic stability(specifically at the 3′-sense/5′-antisense position) has been proposedto facilitate or favor entry of the antisense strand into RISC (Schwarzet al., 2003, Cell 115: 199-208; Khvorova et al., 2003, Cell 115:209-216), presumably by affecting some rate-limiting unwinding stepsthat occur with entry of the siRNA into RISC. Thus, terminal basecomposition has been included in design algorithms for selecting active21mer siRNA duplexes (Ui-Tei et al., 2004, Nucleic Acids Res 32:936-948; Reynolds et al., 2004, Nat Biotechnol 22: 326-330). With Dicercleavage of the dsRNA of this embodiment, the small end-terminalsequence which contains the mismatches will either be left unpaired withthe antisense strand (become part of a 3′-overhang) or be cleavedentirely off the final 21-mer siRNA. These “mismatches”, therefore, donot persist as mismatches in the final RNA component of RISC. Thefinding that base mismatches or destabilization of segments at the3′-end of the sense strand of Dicer substrate improved the potency ofsynthetic duplexes in RNAi, presumably by facilitating processing byDicer, was a surprising finding of past works describing the design anduse of 25-30mer dsRNAs (also termed “DsiRNAs” herein; Rossi et al., U.S.Patent Application Nos. 2005/0277610, 2005/0244858 and 2007/0265220).

Modification of Anti-β-Catenin DsiRNAs

One major factor that inhibits the effect of double stranded RNAs(“dsRNAs”) is the degradation of dsRNAs (e.g., siRNAs and DsiRNAs) bynucleases. A 3′-exonuclease is the primary nuclease activity present inserum and modification of the 3′-ends of antisense DNA oligonucleotidesis crucial to prevent degradation (Eder et al., 1991, Antisense Res Dev,1: 141-151). An RNase-T family nuclease has been identified called ERI-1which has 3′ to 5′ exonuclease activity that is involved in regulationand degradation of siRNAs (Kennedy et al., 2004, Nature 427: 645-649;Hong et al., 2005, Biochem J, 390: 675-679). This gene is also known asThex1 (NM_02067) in mice or THEX1 (NM_153332) in humans and is involvedin degradation of histone mRNA; it also mediates degradation of3′-overhangs in siRNAs, but does not degrade duplex RNA (Yang et al.,2006, J Biol Chem, 281: 30447-30454). It is therefore reasonable toexpect that 3′-end-stabilization of dsRNAs, including the DsiRNAs of theinstant invention, will improve stability.

XRN1 (NM_019001) is a 5′ to 3′ exonuclease that resides in P-bodies andhas been implicated in degradation of mRNA targeted by miRNA (Rehwinkelet al., 2005, RNA 11: 1640-1647) and may also be responsible forcompleting degradation initiated by internal cleavage as directed by asiRNA. XRN2 (NM_012255) is a distinct 5′ to 3′ exonuclease that isinvolved in nuclear RNA processing.

RNase A is a major endonuclease activity in mammals that degrades RNAs.It is specific for ssRNA and cleaves at the 3′-end of pyrimidine bases.SiRNA degradation products consistent with RNase A cleavage can bedetected by mass spectrometry after incubation in serum (Turner et al.,2007, Mol Biosyst 3: 43-50). The 3′-overhangs enhance the susceptibilityof siRNAs to RNase degradation. Depletion of RNase A from serum reducesdegradation of siRNAs; this degradation does show some sequencepreference and is worse for sequences having poly A/U sequence on theends (Haupenthal et al., 2006 Biochem Pharmacol 71: 702-710). Thissuggests the possibility that lower stability regions of the duplex may“breathe” and offer transient single-stranded species available fordegradation by RNase A. RNase A inhibitors can be added to serum andimprove siRNA longevity and potency (Haupenthal et al., 2007, Int J.Cancer 121: 206-210).

In 21mers, phosphorothioate or boranophosphate modifications directlystabilize the internucleoside phosphate linkage. Boranophosphatemodified RNAs are highly nuclease resistant, potent as silencing agents,and are relatively non-toxic. Boranophosphate modified RNAs cannot bemanufactured using standard chemical synthesis methods and instead aremade by in vitro transcription (IVT) (Hall et al., 2004, Nucleic AcidsRes 32: 5991-6000; Hall et al., 2006, Nucleic Acids Res 34: 2773-2781).Phosphorothioate (PS) modifications can be easily placed in the RNAduplex at any desired position and can be made using standard chemicalsynthesis methods. The PS modification shows dose-dependent toxicity, somost investigators have recommended limited incorporation in siRNAs,favoring the 3′-ends where protection from nucleases is most important(Harborth et al., 2003, Antisense Nucleic Acid Drug Dev 13: 83-105; Chiuand Rana, 2003, Mol Cell 10: 549-561; Braasch et al., 2003, Biochemistry42: 7967-7975; Amarzguioui et al., 2003, Nucleic Acids Research 31:589-595). More extensive PS modification can be compatible with potentRNAi activity; however, use of sugar modifications (such as 2′-O-methylRNA) may be superior (Choung et al., 2006, Biochem Biophys Res Commun342: 919-927).

A variety of substitutions can be placed at the 2′-position of theribose which generally increases duplex stability (T_(m)) and cangreatly improve nuclease resistance. 2′-O-methyl RNA is a naturallyoccurring modification found in mammalian ribosomal RNAs and transferRNAs. 2′-O-methyl modification in siRNAs is known, but the preciseposition of modified bases within the duplex is important to retainpotency and complete substitution of 2′-O-methyl RNA for RNA willinactivate the siRNA. For example, a pattern that employs alternating2′-O-methyl bases can have potency equivalent to unmodified RNA and isquite stable in serum (Choung et al., 2006, Biochem Biophys Res Commun342: 919-927; Czauderna et al., 2003, Nucleic Acids Research 31:2705-2716).

The 2′-fluoro (2′-F) modification is also compatible with dsRNA (e.g.,siRNA and DsiRNA) function; it is most commonly placed at pyrimidinesites (due to reagent cost and availability) and can be combined with2′-O-methyl modification at purine positions; 2′-F purines are availableand can also be used. Heavily modified duplexes of this kind can bepotent triggers of RNAi in vitro (Allerson et al., 2005, J Med Chem 48:901-904; Prakash et al., 2005, J Med Chem 48: 4247-4253; Kraynack andBaker, 2006, RNA 12: 163-176) and can improve performance and extendduration of action when used in vivo (Morrissey et al., 2005, Hepatology41: 1349-1356; Morrissey et al., 2005, Nat Biotechnol 23: 1002-1007). Ahighly potent, nuclease stable, blunt 19mer duplex containingalternative 2′-F and 2′-O-Me bases is taught by Allerson. In thisdesign, alternating 2′-O-Me residues are positioned in an identicalpattern to that employed by Czauderna, however the remaining RNAresidues are converted to 2′-F modified bases. A highly potent, nucleaseresistant siRNA employed by Morrissey employed a highly potent, nucleaseresistant siRNA in vivo. In addition to 2′-O-Me RNA and 2′-F RNA, thisduplex includes DNA, RNA, inverted abasic residues, and a 3′-terminal PSinternucleoside linkage. While extensive modification has certainbenefits, more limited modification of the duplex can also improve invivo performance and is both simpler and less costly to manufacture.Soutschek et al. (2004, Nature 432: 173-178) employed a duplex in vivoand was mostly RNA with two 2′-O-Me RNA bases and limited 3′-terminal PSinternucleoside linkages.

Locked nucleic acids (LNAs) are a different class of 2′-modificationthat can be used to stabilize dsRNA (e.g., siRNA and DsiRNA). Patternsof LNA incorporation that retain potency are more restricted than2′-O-methyl or 2′-F bases, so limited modification is preferred (Braaschet al., 2003, Biochemistry 42: 7967-7975; Grunweller et al., 2003,Nucleic Acids Res 31: 3185-3193; Elmen et al., 2005, Nucleic Acids Res33: 439-447). Even with limited incorporation, the use of LNAmodifications can improve dsRNA performance in vivo and may also alteror improve off target effect profiles (Mook et al., 2007, Mol CancerTher 6: 833-843).

Synthetic nucleic acids introduced into cells or live animals can berecognized as “foreign” and trigger an immune response. Immunestimulation constitutes a major class of off-target effects which candramatically change experimental results and even lead to cell death.The innate immune system includes a collection of receptor moleculesthat specifically interact with DNA and RNA that mediate theseresponses, some of which are located in the cytoplasm and some of whichreside in endosomes (Marques and Williams, 2005, Nat Biotechnol 23:1399-1405; Schlee et al., 2006, Mol Ther 14: 463-470). Delivery ofsiRNAs by cationic lipids or liposomes exposes the siRNA to bothcytoplasmic and endosomal compartments, maximizing the risk fortriggering a type 1 interferon (IFN) response both in vitro and in vivo(Morrissey et al., 2005, Nat Biotechnol 23: 1002-1007; Sioud andSorensen, 2003, Biochem Biophys Res Commun 312: 1220-1225; Sioud, 2005,J Mol Biol 348: 1079-1090; Ma et al., 2005, Biochem Biophys Res Commun330: 755-759). RNAs transcribed within the cell are less immunogenic(Robbins et al., 2006, Nat Biotechnol 24: 566-571) and synthetic RNAsthat are immunogenic when delivered using lipid-based methods can evadeimmune stimulation when introduced unto cells by mechanical means, evenin vivo (Heidel et al., 2004, Nat Biotechnol 22: 1579-1582). However,lipid based delivery methods are convenient, effective, and widely used.Some general strategy to prevent immune responses is needed, especiallyfor in vivo application where all cell types are present and the risk ofgenerating an immune response is highest. Use of chemically modifiedRNAs may solve most or even all of these problems.

In certain embodiments, modifications can be included in theanti-β-catenin DsiRNA agents of the present invention so long as themodification does not prevent the DsiRNA agent from possessing β-catenininhibitory activity. In one embodiment, one or more modifications aremade that enhance Dicer processing of the DsiRNA agent (an assay fordetermining Dicer processing of a DsiRNA is described supra). In asecond embodiment, one or more modifications are made that result inmore effective β-catenin inhibition (as described herein, β-catenininhibition/β-catenin inhibitory activity of a DsiRNA can be assayed viaart-recognized methods for determining RNA levels, or for determiningβ-catenin polypeptide levels, should such levels be assessed in lieu ofor in addition to assessment of, e.g., β-catenin mRNA levels). In athird embodiment, one or more modifications are made that supportgreater β-catenin inhibitory activity (means of determining β-catenininhibitory activity are described supra). In a fourth embodiment, one ormore modifications are made that result in greater potency of β-catenininhibitory activity per each DsiRNA agent molecule to be delivered tothe cell (potency of β-catenin inhibitory activity is described supra).Modifications can be incorporated in the 3′-terminal region, the5′-terminal region, in both the 3′-terminal and 5′-terminal region or insome instances in various positions within the sequence. With therestrictions noted above in mind, numbers and combinations ofmodifications can be incorporated into the DsiRNA agent. Where multiplemodifications are present, they may be the same or different.Modifications to bases, sugar moieties, the phosphate backbone, andtheir combinations are contemplated. Either 5′-terminus can bephosphorylated.

Examples of modifications contemplated for the phosphate backboneinclude phosphonates, including methylphosphonate, phosphorothioate, andphosphotriester modifications such as alkylphosphotriesters, and thelike. Examples of modifications contemplated for the sugar moietyinclude 2′-alkyl pyrimidine, such as 2′-O-methyl, 2′-fluoro, amino, anddeoxy modifications and the like (see, e.g., Amarzguioui et al., 2003,Nucleic Acids Research 31: 589-595). Examples of modificationscontemplated for the base groups include abasic sugars, 2-O-alkylmodified pyrimidines, 4-thiouracil, 5-bromouracil, 5-iodouracil, and5-(3-aminoallyl)-uracil and the like. Locked nucleic acids, or LNA's,could also be incorporated. Many other modifications are known and canbe used so long as the above criteria are satisfied. Examples ofmodifications are also disclosed in U.S. Pat. Nos. 5,684,143, 5,858,988and 6,291,438 and in U.S. published patent application No. 2004/0203145A1. Other modifications are disclosed in Herdewijn (2000, AntisenseNucleic Acid Drug Dev 10: 297-310), Eckstein (2000, Antisense NucleicAcid Drug Dev 10: 117-21), Rusckowski et al. (2000, Antisense NucleicAcid Drug Dev 10: 333-345), Stein et al. (2001, Antisense Nucleic AcidDrug Dev 11: 317-25); Vorobjev et al. (2001, Antisense Nucleic Acid DrugDev 11: 77-85).

One or more modifications contemplated can be incorporated into eitherstrand. The placement of the modifications in the DsiRNA agent cangreatly affect the characteristics of the DsiRNA agent, includingconferring greater potency and stability, reducing toxicity, enhanceDicer processing, and minimizing an immune response. In one embodiment,the antisense strand or the sense strand or both strands have one ormore 2′-O-methyl modified nucleotides. In another embodiment, theantisense strand contains 2′-O-methyl modified nucleotides. In anotherembodiment, the antisense stand contains a 3′ overhang that is comprisedof 2′-O-methyl modified nucleotides. The antisense strand could alsoinclude additional 2′-O-methyl modified nucleotides.

In certain embodiments of the present invention, the anti-β-cateninDsiRNA agent has one or more of the following properties: (i) the DsiRNAagent is asymmetric, e.g., has a 3′ overhang on the antisense strand and(ii) the DsiRNA agent has a modified 3′ end on the sense strand todirect orientation of Dicer binding and processing of the dsRNA to anactive siRNA. According to this embodiment, the longest strand in thedsRNA comprises 25-35 nucleotides (e.g., 25, 26, 27, 28, 29, 30, 31, 32,33, 34 or 35 nucleotides). In certain such embodiments, the DsiRNA agentis asymmetric such that the sense strand comprises 25-34 nucleotides andthe 3′ end of the sense strand forms a blunt end with the 5′ end of theantisense strand while the antisense strand comprises 26-35 nucleotidesand forms an overhang on the 3′ end of the antisense strand. In oneembodiment, the DsiRNA agent is asymmetric such that the sense strandcomprises 25-28 nucleotides and the antisense strand comprises 25-30nucleotides. Thus, the resulting dsRNA has an overhang on the 3′ end ofthe antisense strand. The overhang is 1-4 nucleotides, for example 2nucleotides. The sense strand may also have a 5′ phosphate.

In other embodiments, the sense strand of the DsiRNA agent is modifiedfor Dicer processing by suitable modifiers located at the 3′ end of thesense strand, i.e., the DsiRNA agent is designed to direct orientationof Dicer binding and processing. Suitable modifiers include nucleotidessuch as deoxyribonucleotides, dideoxyribonucleotides, acyclonucleotidesand the like and sterically hindered molecules, such as fluorescentmolecules and the like. Acyclonucleotides substitute a2-hydroxyethoxymethyl group for the 2′-deoxyribofuranosyl sugar normallypresent in dNMPs. Other nucleotides modifiers could include3′-deoxyadenosine (cordycepin), 3′-azido-3′-deoxythymidine (AZT),2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxy-3′-thiacytidine (3TC),2′,3′-didehydro-2′,3′-dideoxythymidine (d4T) and the monophosphatenucleotides of 3′-azido-3′-deoxythymidine (AZT),2′,3′-dideoxy-3′-thiacytidine (3TC) and2′,3′-didehydro-2′,3′-dideoxythymidine (d4T). In one embodiment,deoxynucleotides are used as the modifiers. When nucleotide modifiersare utilized, 1-3 nucleotide modifiers, or 2 nucleotide modifiers aresubstituted for the ribonucleotides on the 3′ end of the sense strand.When sterically hindered molecules are utilized, they are attached tothe ribonucleotide at the 3′ end of the antisense strand. Thus, thelength of the strand does not change with the incorporation of themodifiers. In another embodiment, the invention contemplatessubstituting two DNA bases in the DsiRNA agent to direct the orientationof Dicer processing of the antisense strand. In a further embodiment ofthe present invention, two terminal DNA bases are substituted for tworibonucleotides on the 3′-end of the sense strand forming a blunt end ofthe duplex on the 3′ end of the sense strand and the 5′ end of theantisense strand, and a two-nucleotide RNA overhang is located on the3′-end of the antisense strand. This is an asymmetric composition withDNA on the blunt end and RNA bases on the overhanging end.

The sense and antisense strands of a DsiRNA agent of the instantinvention anneal under biological conditions, such as the conditionsfound in the cytoplasm of a cell. In addition, a region of one of thesequences, particularly of the antisense strand, of the DsiRNA agent hasa sequence length of at least 15 (in certain embodiments, 19)nucleotides, wherein these nucleotides are adjacent to the 3′ end ofantisense strand (e.g., in the 21-nucleotide region adjacent to the 3′end of the antisense strand) and are sufficiently complementary to anucleotide sequence of the target β-catenin RNA.

Additionally, the DsiRNA agent structure can be optimized to ensure thatthe oligonucleotide segment generated from Dicer's cleavage will be theportion of the oligonucleotide that is most effective in inhibiting geneexpression. For example, in one embodiment of the invention, a 27-bpoligonucleotide of the DsiRNA agent structure is synthesized wherein theanticipated 21 to 22-bp segment that will inhibit gene expression islocated on the 3′-end of the antisense strand. The remaining baseslocated on the 5′-end of the antisense strand will be cleaved by Dicerand will be discarded. This cleaved portion can be homologous (i.e.,based on the sequence of the target sequence) or non-homologous andadded to extend the nucleic acid strand.

The DsiRNA agent can also have one or more of the following additionalproperties: (a) the antisense strand has a right shift from the typical21mer (e.g., the DsiRNA comprises a length of antisense strandnucleotides that extends to the 5′ of a projected Dicer cleavage sitewithin the DsiRNA, with such antisense strand nucleotides base pairedwith corresponding nucleotides of the sense strand extending 3′ of aprojected Dicer cleavage site in the sense strand), (b) the strands maynot be completely complementary, i.e., the strands may contain simplemismatched base pairs (in certain embodiments, the DsiRNAs of theinvention possess 1, 2, 3, 4 or even 5 or more mismatched base pairs,provided that β-catenin inhibitory activity of the DsiRNA possessingmismatched base pairs is retained at sufficient levels (e.g., retains atleast 50% β-catenin inhibitory activity or more, at least 60% β-catenininhibitory activity or more, at least 70% β-catenin inhibitory activityor more, at least 80% β-catenin inhibitory activity or more, at least90% β-catenin inhibitory activity or more or at least 95% β-catenininhibitory activity or more as compared to a corresponding DsiRNA notpossessing mismatched base pairs. In certain embodiments, mismatchedbase pairs exist between the antisense and sense strands of a DsiRNA. Insome embodiments, mismatched base pairs exist (or are predicted toexist) between the antisense strand and the target RNA. In certainembodiments, the presence of a mismatched base pair(s) between anantisense strand residue and a corresponding residue within the targetRNA that is located 3′ in the target RNA sequence of a projected Ago2cleavage site retains and may even enhance β-catenin inhibitory activityof a DsiRNA of the invention) and (c) base modifications such as lockednucleic acid(s) may be included in the 5′ end of the sense strand. A“typical” 21mer siRNA is designed using conventional techniques. In onetechnique, a variety of sites are commonly tested in parallel or poolscontaining several distinct siRNA duplexes specific to the same targetwith the hope that one of the reagents will be effective (Ji et al.,2003, FEBS Lett 552: 247-252). Other techniques use design rules andalgorithms to increase the likelihood of obtaining active RNAi effectormolecules (Schwarz et al., 2003, Cell 115: 199-208; Khvorova et al.,2003, Cell 115: 209-216; Ui-Tei et al., 2004, Nucleic Acids Res 32:936-948; Reynolds et al., 2004, Nat Biotechnol 22: 326-330; Krol et al.,2004, J Biol Chem 279: 42230-42239; Yuan et al., 2004, Nucl Acids Res32(Webserver issue):W130-134; Boese et al., 2005, Methods Enzymol 392:73-96). High throughput selection of siRNA has also been developed (U.S.published patent application No. 2005/0042641 A1). Potential targetsites can also be analyzed by secondary structure predictions (Heale etal., 2005, Nucleic Acids Res 33(3): e30). This 21mer is then used todesign a right shift to include 3-9 additional nucleotides on the 5′ endof the 21mer. The sequence of these additional nucleotides is notrestricted. In one embodiment, the added ribonucleotides are based onthe sequence of the target gene. Even in this embodiment, fullcomplementarity between the target sequence and the antisense siRNA isnot required.

The first and second oligonucleotides of a DsiRNA agent of the instantinvention are not required to be completely complementary. They onlyneed to be sufficiently complementary to anneal under biologicalconditions and to provide a substrate for Dicer that produces a siRNAsufficiently complementary to the target sequence. Locked nucleic acids,or LNA's, are well known to a skilled artisan (Elmen et al., 2005,Nucleic Acids Res 33: 439-447; Kurreck et al., 2002, Nucleic Acids Res30: 1911-1918; Crinelli et al., 2002, Nucleic Acids Res 30: 2435-2443;Braasch and Corey, 2001, Chem Biol 8: 1-7; Bondensgaard et al., 2000,Chemistry 6: 2687-2695; Wahlestedt et al., 2000, Proc Natl Acad Sci USA97: 5633-5638). In one embodiment, an LNA is incorporated at the 5′terminus of the sense strand. In another embodiment, an LNA isincorporated at the 5′ terminus of the sense strand in duplexes designedto include a 3′ overhang on the antisense strand.

In certain embodiments, the DsiRNA agent of the instant invention has anasymmetric structure, with the sense strand having a 25-base pairlength, and the antisense strand having a 27-base pair length with a 2base 3′-overhang. In other embodiments, this DsiRNA agent having anasymmetric structure further contains 2 deoxynucleotides at the 3′ endof the sense strand in place of two of the ribonucleotides.

Certain DsiRNA agent compositions containing two separateoligonucleotides can be linked by a third structure. The third structurewill not block Dicer activity on the DsiRNA agent and will not interferewith the directed destruction of the RNA transcribed from the targetgene. In one embodiment, the third structure may be a chemical linkinggroup. Many suitable chemical linking groups are known in the art andcan be used. Alternatively, the third structure may be anoligonucleotide that links the two oligonucleotides of the DsiRNA agentin a manner such that a hairpin structure is produced upon annealing ofthe two oligonucleotides making up the dsRNA composition. The hairpinstructure will not block Dicer activity on the DsiRNA agent and will notinterfere with the directed destruction of the β-catenin RNA.

In certain embodiments, the anti-β-catenin DsiRNA agent of the inventionhas several properties which enhance its processing by Dicer. Accordingto such embodiments, the DsiRNA agent has a length sufficient such thatit is processed by Dicer to produce an siRNA and at least one of thefollowing properties: (i) the DsiRNA agent is asymmetric, e.g., has a 3′overhang on the sense strand and (ii) the DsiRNA agent has a modified 3′end on the antisense strand to direct orientation of Dicer binding andprocessing of the dsRNA to an active siRNA. According to theseembodiments, the longest strand in the DsiRNA agent comprises 25-30nucleotides. In one embodiment, the sense strand comprises 25-30nucleotides and the antisense strand comprises 25-28 nucleotides. Thus,the resulting dsRNA has an overhang on the 3′ end of the sense strand.The overhang is 1-4 nucleotides, such as 2 nucleotides. The antisensestrand may also have a 5′ phosphate.

In certain embodiments, the sense strand of a DsiRNA agent is modifiedfor Dicer processing by suitable modifiers located at the 3′ end of thesense strand, i.e., the DsiRNA agent is designed to direct orientationof Dicer binding and processing. Suitable modifiers include nucleotidessuch as deoxyribonucleotides, dideoxyribonucleotides, acyclonucleotidesand the like and sterically hindered molecules, such as fluorescentmolecules and the like. Acyclonucleotides substitute a2-hydroxyethoxymethyl group for the 2′-deoxyribofuranosyl sugar normallypresent in dNMPs. Other nucleotide modifiers could include3′-deoxyadenosine (cordycepin), 3′-azido-3′-deoxythymidine (AZT),2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxy-3′-thiacytidine (3TC),2′,3′-didehydro-2′,3′-dideoxythymidine (d4T) and the monophosphatenucleotides of 3′-azido-3′-deoxythymidine (AZT),2′,3′-dideoxy-3′-thiacytidine (3TC) and2′,3′-didehydro-2′,3′-dideoxythymidine (d4T). In one embodiment,deoxynucleotides are used as the modifiers. When nucleotide modifiersare utilized, 1-3 nucleotide modifiers, or 2 nucleotide modifiers aresubstituted for the ribonucleotides on the 3′ end of the sense strand.When sterically hindered molecules are utilized, they are attached tothe ribonucleotide at the 3′ end of the antisense strand. Thus, thelength of the strand does not change with the incorporation of themodifiers. In another embodiment, the invention contemplatessubstituting two DNA bases in the dsRNA to direct the orientation ofDicer processing. In a further invention, two terminal DNA bases arelocated on the 3′ end of the sense strand in place of tworibonucleotides forming a blunt end of the duplex on the 5′ end of theantisense strand and the 3′ end of the sense strand, and atwo-nucleotide RNA overhang is located on the 3′-end of the antisensestrand. This is an asymmetric composition with DNA on the blunt end andRNA bases on the overhanging end.

In certain other embodiments, the antisense strand of a DsiRNA agent ismodified for Dicer processing by suitable modifiers located at the 3′end of the antisense strand, i.e., the DsiRNA agent is designed todirect orientation of Dicer binding and processing. Suitable modifiersinclude nucleotides such as deoxyribonucleotides,dideoxyribonucleotides, acyclonucleotides and the like and stericallyhindered molecules, such as fluorescent molecules and the like.Acyclonucleotides substitute a 2-hydroxyethoxymethyl group for the2′-deoxyribofuranosyl sugar normally present in dNMPs. Other nucleotidemodifiers could include 3′-deoxyadenosine (cordycepin),3′-azido-3′-deoxythymidine (AZT), 2′,3′-dideoxyinosine (ddI),2′,3′-dideoxy-3′-thiacytidine (3TC),2′,3′-didehydro-2′,3′-dideoxythymidine (d4T) and the monophosphatenucleotides of 3′-azido-3′-deoxythymidine (AZT),2′,3′-dideoxy-3′-thiacytidine (3TC) and2′,3′-didehydro-2′,3′-dideoxythymidine (d4T). In one embodiment,deoxynucleotides are used as the modifiers. When nucleotide modifiersare utilized, 1-3 nucleotide modifiers, or 2 nucleotide modifiers aresubstituted for the ribonucleotides on the 3′ end of the antisensestrand. When sterically hindered molecules are utilized, they areattached to the ribonucleotide at the 3′ end of the antisense strand.Thus, the length of the strand does not change with the incorporation ofthe modifiers. In another embodiment, the invention contemplatessubstituting two DNA bases in the dsRNA to direct the orientation ofDicer processing. In a further invention, two terminal DNA bases arelocated on the 3′ end of the antisense strand in place of tworibonucleotides forming a blunt end of the duplex on the 5′ end of thesense strand and the 3′ end of the antisense strand, and atwo-nucleotide RNA overhang is located on the 3′-end of the sensestrand. This is also an asymmetric composition with DNA on the blunt endand RNA bases on the overhanging end.

The sense and antisense strands anneal under biological conditions, suchas the conditions found in the cytoplasm of a cell. In addition, aregion of one of the sequences, particularly of the antisense strand, ofthe dsRNA has a sequence length of at least 19 nucleotides, whereinthese nucleotides are adjacent to the 3′ end of antisense strand and aresufficiently complementary to a nucleotide sequence of the targetβ-catenin RNA.

Additionally, the DsiRNA agent structure contains two portions based onDicer cleavage, a first portion which survives the Dicer-cleavageprocess and proceeds to actively engage the target RNA as part of theRISC complex and a second portion which is not active in RISC. The firstportion will contain the sequence known to be most effective at RNAinterference at the target RNA/RISC level, whereas the second portionmay or may not be complementary to the target sequence. For example, inone embodiment of the invention, a 27-bp oligonucleotide of the DsiRNAagent structure is synthesized wherein the anticipated 21 to 22-bpsegment that forms a hybrid with the target nucleic acid and therebyinhibits gene expression is located on the 3′-end of the antisensestrand. The remaining bases located on the 5′-end of the antisensestrand will be cleaved by Dicer and thus will not be a contiguous partof the Dicer-cleaved RNAi molecule. This second portion can behomologous (i.e., based on the sequence of the target sequence) ornon-homologous and added to extend the nucleic acid strand.

US 2007/0265220 discloses that 27mer DsiRNAs show improved stability inserum over comparable 21mer siRNA compositions, even absent chemicalmodification. Modifications of DsiRNA agents, such as inclusion of2′-O-methyl RNA in the antisense strand, in patterns such as detailedabove, when coupled with addition of a 5′ Phosphate, can improvestability of DsiRNA agents. Addition of 5′-phosphate to all strands insynthetic RNA duplexes may be an inexpensive and physiological method toconfer some limited degree of nuclease stability.

The chemical modification patterns of the dsRNA agents of the instantinvention are designed to enhance the efficacy of such agents.Accordingly, such modifications are designed to avoid reducing potencyof dsRNA agents; to avoid interfering with Dicer processing of DsiRNAagents; to improve stability in biological fluids (reduce nucleasesensitivity) of dsRNA agents; or to block or evade detection by theinnate immune system. Such modifications are also designed to avoidbeing toxic and to avoid increasing the cost or impact the ease ofmanufacturing the instant dsRNA agents of the invention.

β-Catenin Biology and Biochemistry

Known human and mouse β-catenin cDNA and polypeptide sequences includethe following:

Human Wild-Type β-Catenin (Cadherin-Associated Protein) Sequence,Transcript Variant 1 (SEQ ID NO: 1; Homo sapiens CTNNB1, TranscriptVariant 1; GenBank Accession No. NM_001904.3):

AGGATACAGCGGCTTCTGCGCGACTTATAAGAGCTCCTTGTGCGGCGCCATTTTAAGCCTCTCGGTCTGTGGCAGCAGCGTTGGCCCGGCCCCGGGAGCGGAGAGCGAGGGGAGGCGGAGACGGAGGAAGGTCTGAGGAGCAGCTTCAGTCCCCGCCGAGCCGCCACCGCAGGTCGAGGACGGTCGGACTCCCGCGGCGGGAGGAGCCTGTTCCCCTGAGGGTATTTGAAGTATACCATACAACTGTTTTGAAAATCCAGCGTGGACAATGGCTACTCAAGCTGATTTGATGGAGTTGGACATGGCCATGGAACCAGACAGAAAAGCGGCTGTTAGTCACTGGCAGCAACAGTCTTACCTGGACTCTGGAATCCATTCTGGTGCCACTACCACAGCTCCTTCTCTGAGTGGTAAAGGCAATCCTGAGGAAGAGGATGTGGATACCTCCCAAGTCCTGTATGAGTGGGAACAGGGATTTTCTCAGTCCTTCACTCAAGAACAAGTAGCTGATATTGATGGACAGTATGCAATGACTCGAGCTCAGAGGGTACGAGCTGCTATGTTCCCTGAGACATTAGATGAGGGCATGCAGATCCCATCTACACAGTTTGATGCTGCTCATCCCACTAATGTCCAGCGTTTGGCTGAACCATCACAGATGCTGAAACATGCAGTTGTAAACTTGATTAACTATCAAGATGATGCAGAACTTGCCACACGTGCAATCCCTGAACTGACAAAACTGCTAAATGACGAGGACCAGGTGGTGGTTAATAAGGCTGCAGTTATGGTCCATCAGCTTTCTAAAAAGGAAGCTTCCAGACACGCTATCATGCGTTCTCCTCAGATGGTGTCTGCTATTGTACGTACCATGCAGAATACAAATGATGTAGAAACAGCTCGTTGTACCGCTGGGACCTTGCATAACCTTTCCCATCATCGTGAGGGCTTACTGGCCATCTTTAAGTCTGGAGGCATTCCTGCCCTGGTGAAAATGCTTGGTTCACCAGTGGATTCTGTGTTGTTTTATGCCATTACAACTCTCCACAACCTTTTATTACATCAAGAAGGAGCTAAAATGGCAGTGCGTTTAGCTGGTGGGCTGCAGAAAATGGTTGCCTTGCTCAACAAAACAAATGTTAAATTCTTGGCTATTACGACAGACTGCCTTCAAATTTTAGCTTATGGCAACCAAGAAAGCAAGCTCATCATACTGGCTAGTGGTGGACCCCAAGCTTTAGTAAATATAATGAGGACCTATACTTACGAAAAACTACTGTGGACCACAAGCAGAGTGCTGAAGGTGCTATCTGTCTGCTCTAGTAATAAGCCGGCTATTGTAGAAGCTGGTGGAATGCAAGCTTTAGGACTTCACCTGACAGATCCAAGTCAACGTCTTGTTCAGAACTGTCTTTGGACTCTCAGGAATCTTTCAGATGCTGCAACTAAACAGGAAGGGATGGAAGGTCTCCTTGGGACTCTTGTTCAGCTTCTGGGTTCAGATGATATAAATGTGGTCACCTGTGCAGCTGGAATTCTTTCTAACCTCACTTGCAATAATTATAAGAACAAGATGATGGTCTGCCAAGTGGGTGGTATAGAGGCTCTTGTGCGTACTGTCCTTCGGGCTGGTGACAGGGAAGACATCACTGAGCCTGCCATCTGTGCTCTTCGTCATCTGACCAGCCGACACCAAGAAGCAGAGATGGCCCAGAATGCAGTTCGCCTTCACTATGGACTACCAGTTGTGGTTAAGCTCTTACACCCACCATCCCACTGGCCTCTGATAAAGGCTACTGTTGGATTGATTCGAAATCTTGCCCTTTGTCCCGCAAATCATGCACCTTTGCGTGAGCAGGGTGCCATTCCACGACTAGTTCAGTTGCTTGTTCGTGCACATCAGGATACCCAGCGCCGTACGTCCATGGGTGGGACACAGCAGCAATTTGTGGAGGGGGTCCGCATGGAAGAAATAGTTGAAGGTTGTACCGGAGCCCTTCACATCCTAGCTCGGGATGTTCACAACCGAATTGTTATCAGAGGACTAAATACCATTCCATTGTTTGTGCAGCTGCTTTATTCTCCCATTGAAAACATCCAAAGAGTAGCTGCAGGGGTCCTCTGTGAACTTGCTCAGGACAAGGAAGCTGCAGAAGCTATTGAAGCTGAGGGAGCCACAGCTCCTCTGACAGAGTTACTTCACTCTAGGAATGAAGGTGTGGCGACATATGCAGCTGCTGTTTTGTTCCGAATGTCTGAGGACAAGCCACAAGATTACAAGAAACGGCTTTCAGTTGAGCTGACCAGCTCTCTCTTCAGAACAGAGCCAATGGCTTGGAATGAGACTGCTGATCTTGGACTTGATATTGGTGCCCAGGGAGAACCCCTTGGATATCGCCAGGATGATCCTAGCTATCGTTCTTTTCACTCTGGTGGATATGGCCAGGATGCCTTGGGTATGGACCCCATGATGGAACATGAGATGGGTGGCCACCACCCTGGTGCTGACTATCCAGTTGATGGGCTGCCAGATCTGGGGCATGCCCAGGACCTCATGGATGGGCTGCCTCCAGGTGACAGCAATCAGCTGGCCTGGTTTGATACTGACCTGTAAATCATCCTTTAGGTAAGAAGTTTTAAAAAGCCAGTTTGGGTAAAATACTTTTACTCTGCCTACAGAACTTCAGAAAGACTTGGTTGGTAGGGTGGGAGTGGTTTAGGCTATTTGTAAATCTGCCACAAAAACAGGTATATACTTTGAAAGGAGATGTCTTGGAACATTGGAATGTTCTCAGATTTCTGGTTGTTATGTGATCATGTGTGGAAGTTATTAACTTTAATGTTTTTTGCCACAGCTTTTGCAACTTAATACTCAAATGAGTAACATTTGCTGTTTTAAACATTAATAGCAGCCTTTCTCTCTTTATACAGCTGTATTGTCTGAACTTGCATTGTGATTGGCCTGTAGAGTTGCTGAGAGGGCTCGAGGGGTGGGCTGGTATCTCAGAAAGTGCCTGACACACTAACCAAGCTGAGTTTCCTATGGGAACAATTGAAGTAAACTTTTTGTTCTGGTCCTTTTTGGTCGAGGAGTAACAATACAAATGGATTTTGGGAGTGACTCAAGAAGTGAAGAATGCACAAGAATGGATCACAAGATGGAATTTATCAAACCCTAGCCTTGCTTGTTAAATTTTTTTTTTTTTTTTTTTAAGAATATCTGTAATGGTACTGACTTTGCTTGCTTTGAAGTAGCTCTTTTTTTTTTTTTTTTTTTTTTTTTGCAGTAACTGTTTTTTAAGTCTCTCGTAGTGTTAAGTTATAGTGAATACTGCTACAGCAATTTCTAATTTTTAAGAATTGAGTAATGGTGTAGAACACTAATTCATAATCACTCTAATTAATTGTAATCTGAATAAAGTGTAACAATTGTGTAGCCTTTTTGTATAAAATAGACAAATAGAAAATGGTCCAATTAGTTTCCTTTTTAATATGCTTAAAATAAGCAGGTGGATCTATTTCATGTTTTTGATCAAAAACTATTTGGGATATGTATGGGTAGGGTAAATCAGTAAGAGGTGTTATTTGGAACCTTGTTTTGGACAGTTTACCAGTTGCCTTTTATCCCAAAGTTGTTGTAACCTGCTGTGATACGATGCTTCAAGAGAAAATGCGGTTATAAAAAATGGTTCAGAATTAA ACTTTTAATTCATTCGATTGHuman Wild-Type β-Catenin (Cadherin-Associated Protein) Sequence,Transcript Variant 2 (SEQ ID NO: 2; Homo sapiens CTNNB1, TranscriptVariant 2; GenBank Accession No. NM_001098209.1):

AGGATACAGCGGCTTCTGCGCGACTTATAAGAGCTCCTTGTGCGGCGCCATTTTAAGCCTCTCGGTCTGTGGCAGCAGCGTTGGCCCGGCCCCGGGAGCGGAGAGCGAGGGGAGGCGGAGACGGAGGAAGGTCTGAGGAGCAGCTTCAGTCCCCGCCGAGCCGCCACCGCAGGTCGAGGACGGTCGGACTCCCGCGGCGGGAGGAGCCTGTTCCCCTGAGGGTATTTGAAGTATACCATACAACTGTTTTGAAAATCCAGCGTGGACAATGGCTACTCAAGCTGATTTGATGGAGTTGGACATGGCCATGGAACCAGACAGAAAAGCGGCTGTTAGTCACTGGCAGCAACAGTCTTACCTGGACTCTGGAATCCATTCTGGTGCCACTACCACAGCTCCTTCTCTGAGTGGTAAAGGCAATCCTGAGGAAGAGGATGTGGATACCTCCCAAGTCCTGTATGAGTGGGAACAGGGATTTTCTCAGTCCTTCACTCAAGAACAAGTAGCTGATATTGATGGACAGTATGCAATGACTCGAGCTCAGAGGGTACGAGCTGCTATGTTCCCTGAGACATTAGATGAGGGCATGCAGATCCCATCTACACAGTTTGATGCTGCTCATCCCACTAATGTCCAGCGTTTGGCTGAACCATCACAGATGCTGAAACATGCAGTTGTAAACTTGATTAACTATCAAGATGATGCAGAACTTGCCACACGTGCAATCCCTGAACTGACAAAACTGCTAAATGACGAGGACCAGGTGGTGGTTAATAAGGCTGCAGTTATGGTCCATCAGCTTTCTAAAAAGGAAGCTTCCAGACACGCTATCATGCGTTCTCCTCAGATGGTGTCTGCTATTGTACGTACCATGCAGAATACAAATGATGTAGAAACAGCTCGTTGTACCGCTGGGACCTTGCATAACCTTTCCCATCATCGTGAGGGCTTACTGGCCATCTTTAAGTCTGGAGGCATTCCTGCCCTGGTGAAAATGCTTGGTTCACCAGTGGATTCTGTGTTGTTTTATGCCATTACAACTCTCCACAACCTTTTATTACATCAAGAAGGAGCTAAAATGGCAGTGCGTTTAGCTGGTGGGCTGCAGAAAATGGTTGCCTTGCTCAACAAAACAAATGTTAAATTCTTGGCTATTACGACAGACTGCCTTCAAATTTTAGCTTATGGCAACCAAGAAAGCAAGCTCATCATACTGGCTAGTGGTGGACCCCAAGCTTTAGTAAATATAATGAGGACCTATACTTACGAAAAACTACTGTGGACCACAAGCAGAGTGCTGAAGGTGCTATCTGTCTGCTCTAGTAATAAGCCGGCTATTGTAGAAGCTGGTGGAATGCAAGCTTTAGGACTTCACCTGACAGATCCAAGTCAACGTCTTGTTCAGAACTGTCTTTGGACTCTCAGGAATCTTTCAGATGCTGCAACTAAACAGGAAGGGATGGAAGGTCTCCTTGGGACTCTTGTTCAGCTTCTGGGTTCAGATGATATAAATGTGGTCACCTGTGCAGCTGGAATTCTTTCTAACCTCACTTGCAATAATTATAAGAACAAGATGATGGTCTGCCAAGTGGGTGGTATAGAGGCTCTTGTGCGTACTGTCCTTCGGGCTGGTGACAGGGAAGACATCACTGAGCCTGCCATCTGTGCTCTTCGTCATCTGACCAGCCGACACCAAGAAGCAGAGATGGCCCAGAATGCAGTTCGCCTTCACTATGGACTACCAGTTGTGGTTAAGCTCTTACACCCACCATCCCACTGGCCTCTGATAAAGGCTACTGTTGGATTGATTCGAAATCTTGCCCTTTGTCCCGCAAATCATGCACCTTTGCGTGAGCAGGGTGCCATTCCACGACTAGTTCAGTTGCTTGTTCGTGCACATCAGGATACCCAGCGCCGTACGTCCATGGGTGGGACACAGCAGCAATTTGTGGAGGGGGTCCGCATGGAAGAAATAGTTGAAGGTTGTACCGGAGCCCTTCACATCCTAGCTCGGGATGTTCACAACCGAATTGTTATCAGAGGACTAAATACCATTCCATTGTTTGTGCAGCTGCTTTATTCTCCCATTGAAAACATCCAAAGAGTAGCTGCAGGGGTCCTCTGTGAACTTGCTCAGGACAAGGAAGCTGCAGAAGCTATTGAAGCTGAGGGAGCCACAGCTCCTCTGACAGAGTTACTTCACTCTAGGAATGAAGGTGTGGCGACATATGCAGCTGCTGTTTTGTTCCGAATGTCTGAGGACAAGCCACAAGATTACAAGAAACGGCTTTCAGTTGAGCTGACCAGCTCTCTCTTCAGAACAGAGCCAATGGCTTGGAATGAGACTGCTGATCTTGGACTTGATATTGGTGCCCAGGGAGAACCCCTTGGATATCGCCAGGATGATCCTAGCTATCGTTCTTTTCACTCTGGTGGATATGGCCAGGATGCCTTGGGTATGGACCCCATGATGGAACATGAGATGGGTGGCCACCACCCTGGTGCTGACTATCCAGTTGATGGGCTGCCAGATCTGGGGCATGCCCAGGACCTCATGGATGGGCTGCCTCCAGGTGACAGCAATCAGCTGGCCTGGTTTGATACTGACCTGTAAATCATCCTTTAGCTGTATTGTCTGAACTTGCATTGTGATTGGCCTGTAGAGTTGCTGAGAGGGCTCGAGGGGTGGGCTGGTATCTCAGAAAGTGCCTGACACACTAACCAAGCTGAGTTTCCTATGGGAACAATTGAAGTAAACTTTTTGTTCTGGTCCTTTTTGGTCGAGGAGTAACAATACAAATGGATTTTGGGAGTGACTCAAGAAGTGAAGAATGCACAAGAATGGATCACAAGATGGAATTTATCAAACCCTAGCCTTGCTTGTTAAATTTTTTTTTTTTTTTTTTTAAGAATATCTGTAATGGTACTGACTTTGCTTGCTTTGAAGTAGCTCTTTTTTTTTTTTTTTTTTTTTTTTTGCAGTAACTGTTTTTTAAGTCTCTCGTAGTGTTAAGTTATAGTGAATACTGCTACAGCAATTTCTAATTTTTAAGAATTGAGTAATGGTGTAGAACACTAATTCATAATCACTCTAATTAATTGTAATCTGAATAAAGTGTAACAATTGTGTAGCCTTTTTGTATAAAATAGACAAATAGAAAATGGTCCAATTAGTTTCCTTTTTAATATGCTTAAAATAAGCAGGTGGATCTATTTCATGTTTTTGATCAAAAACTATTTGGGATATGTATGGGTAGGGTAAATCAGTAAGAGGTGTTATTTGGAACCTTGTTTTGGACAGTTTACCAGTTGCCTTTTATCCCAAAGTTGTTGTAACCTGCTGTGATACGATGCTTCAAGAGAAAATGCGGTTATAAAAAATGGTTCAGAATTAAACTTT TAATTCATTCGATTGHuman Wild-Type β-Catenin (Cadherin-Associated Protein) Sequence,Transcript Variant 3 (SEQ ID NO: 3; Homo sapiens CTNNB1, TranscriptVariant 3; GenBank Accession No. NM_001098210.1):

AGGATACAGCGGCTTCTGCGCGACTTATAAGAGCTCCTTGTGCGGCGCCATTTTAAGCCTCTCGGTCTGTGGCAGCAGCGTTGGCCCGGCCCCGGGAGCGGAGAGCGAGGGGAGGCGGAGACGGAGGAAGGTCTGAGGAGCAGCTTCAGTCCCCGCCGAGCCGCCACCGCAGGTCGAGGACGGTCGGACTCCCGCGGCGGGAGGAGCCTGTTCCCCTGAGGGTATTTGAAGTATACCATACAACTGTTTTGAAAATCCAGCGTGGACAATGGCTACTCAAGCTGATTTGATGGAGTTGGACATGGCCATGGAACCAGACAGAAAAGCGGCTGTTAGTCACTGGCAGCAACAGTCTTACCTGGACTCTGGAATCCATTCTGGTGCCACTACCACAGCTCCTTCTCTGAGTGGTAAAGGCAATCCTGAGGAAGAGGATGTGGATACCTCCCAAGTCCTGTATGAGTGGGAACAGGGATTTTCTCAGTCCTTCACTCAAGAACAAGTAGCTGATATTGATGGACAGTATGCAATGACTCGAGCTCAGAGGGTACGAGCTGCTATGTTCCCTGAGACATTAGATGAGGGCATGCAGATCCCATCTACACAGTTTGATGCTGCTCATCCCACTAATGTCCAGCGTTTGGCTGAACCATCACAGATGCTGAAACATGCAGTTGTAAACTTGATTAACTATCAAGATGATGCAGAACTTGCCACACGTGCAATCCCTGAACTGACAAAACTGCTAAATGACGAGGACCAGGTGGTGGTTAATAAGGCTGCAGTTATGGTCCATCAGCTTTCTAAAAAGGAAGCTTCCAGACACGCTATCATGCGTTCTCCTCAGATGGTGTCTGCTATTGTACGTACCATGCAGAATACAAATGATGTAGAAACAGCTCGTTGTACCGCTGGGACCTTGCATAACCTTTCCCATCATCGTGAGGGCTTACTGGCCATCTTTAAGTCTGGAGGCATTCCTGCCCTGGTGAAAATGCTTGGTTCACCAGTGGATTCTGTGTTGTTTTATGCCATTACAACTCTCCACAACCTTTTATTACATCAAGAAGGAGCTAAAATGGCAGTGCGTTTAGCTGGTGGGCTGCAGAAAATGGTTGCCTTGCTCAACAAAACAAATGTTAAATTCTTGGCTATTACGACAGACTGCCTTCAAATTTTAGCTTATGGCAACCAAGAAAGCAAGCTCATCATACTGGCTAGTGGTGGACCCCAAGCTTTAGTAAATATAATGAGGACCTATACTTACGAAAAACTACTGTGGACCACAAGCAGAGTGCTGAAGGTGCTATCTGTCTGCTCTAGTAATAAGCCGGCTATTGTAGAAGCTGGTGGAATGCAAGCTTTAGGACTTCACCTGACAGATCCAAGTCAACGTCTTGTTCAGAACTGTCTTTGGACTCTCAGGAATCTTTCAGATGCTGCAACTAAACAGGAAGGGATGGAAGGTCTCCTTGGGACTCTTGTTCAGCTTCTGGGTTCAGATGATATAAATGTGGTCACCTGTGCAGCTGGAATTCTTTCTAACCTCACTTGCAATAATTATAAGAACAAGATGATGGTCTGCCAAGTGGGTGGTATAGAGGCTCTTGTGCGTACTGTCCTTCGGGCTGGTGACAGGGAAGACATCACTGAGCCTGCCATCTGTGCTCTTCGTCATCTGACCAGCCGACACCAAGAAGCAGAGATGGCCCAGAATGCAGTTCGCCTTCACTATGGACTACCAGTTGTGGTTAAGCTCTTACACCCACCATCCCACTGGCCTCTGATAAAGGCTACTGTTGGATTGATTCGAAATCTTGCCCTTTGTCCCGCAAATCATGCACCTTTGCGTGAGCAGGGTGCCATTCCACGACTAGTTCAGTTGCTTGTTCGTGCACATCAGGATACCCAGCGCCGTACGTCCATGGGTGGGACACAGCAGCAATTTGTGGAGGGGGTCCGCATGGAAGAAATAGTTGAAGGTTGTACCGGAGCCCTTCACATCCTAGCTCGGGATGTTCACAACCGAATTGTTATCAGAGGACTAAATACCATTCCATTGTTTGTGCAGCTGCTTTATTCTCCCATTGAAAACATCCAAAGAGTAGCTGCAGGGGTCCTCTGTGAACTTGCTCAGGACAAGGAAGCTGCAGAAGCTATTGAAGCTGAGGGAGCCACAGCTCCTCTGACAGAGTTACTTCACTCTAGGAATGAAGGTGTGGCGACATATGCAGCTGCTGTTTTGTTCCGAATGTCTGAGGACAAGCCACAAGATTACAAGAAACGGCTTTCAGTTGAGCTGACCAGCTCTCTCTTCAGAACAGAGCCAATGGCTTGGAATGAGACTGCTGATCTTGGACTTGATATTGGTGCCCAGGGAGAACCCCTTGGATATCGCCAGGATGATCCTAGCTATCGTTCTTTTCACTCTGGTGGATATGGCCAGGATGCCTTGGGTATGGACCCCATGATGGAACATGAGATGGGTGGCCACCACCCTGGTGCTGACTATCCAGTTGATGGGCTGCCAGATCTGGGGCATGCCCAGGACCTCATGGATGGGCTGCCTCCAGGTGACAGCAATCAGCTGGCCTGGTTTGATACTGACCTGTAAATCATCCTTTAGGAGTAACAATACAAATGGATTTTGGGAGTGACTCAAGAAGTGAAGAATGCACAAGAATGGATCACAAGATGGAATTTATCAAACCCTAGCCTTGCTTGTTAAATTTTTTTTTTTTTTTTTTTAAGAATATCTGTAATGGTACTGACTTTGCTTGCTTTGAAGTAGCTCTTTTTTTTTTTTTTTTTTTTTTTTTGCAGTAACTGTTTTTTAAGTCTCTCGTAGTGTTAAGTTATAGTGAATACTGCTACAGCAATTTCTAATTTTTAAGAATTGAGTAATGGTGTAGAACACTAATTCATAATCACTCTAATTAATTGTAATCTGAATAAAGTGTAACAATTGTGTAGCCTTTTTGTATAAAATAGACAAATAGAAAATGGTCCAATTAGTTTCCTTTTTAATATGCTTAAAATAAGCAGGTGGATCTATTTCATGTTTTTGATCAAAAACTATTTGGGATATGTATGGGTAGGGTAAATCAGTAAGAGGTGTTATTTGGAACCTTGTTTTGGACAGTTTACCAGTTGCCTTTTATCCCAAAGTTGTTGTAACCTGCTGTGATACGATGCTTCAAGAGAAAATGCGGTTATAAAAAATGGTTCAGAATTAAACTTTTAATTCATT CGATTGHuman Wild-Type β-Catenin Sequence, Amino Acid Sequence NP_001895.1 (SEQID NO: 4; Translation of NM_001904.3, NM_001098209.1 or NM_001098210.1):

MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDLMouse Wild-Type β-Catenin Sequence (SEQ ID NO: 5; Mus musculus Catenin(Cadherin Associated Protein), Beta 1 (Ctnnb1), Transcript Variant 1 inC57BL/6; GenBank Accession No. NM_007614.3; Note: Mouse DsiRNA TargetSequence Positions Correspond to NM_007614.2 Below):

GCGCGGCGGAACGCTCCGCGCGGAGCGGCAGCGGCAGGATACACGGTGCCGCGCCGCTTATAAATCGCTCCTTGTGCGGCGCCATCTTAAGCCCTCGCTCGGTGGCGGCCGCGTCAGCTCGTGTCCTGTGAAGCCCGCGGCCCGGGGAGGCGGAGACGGAGCACGGTGGGCGCCGAGCCGTCAGTGCAGGAGGCCGAGGCCGAGCGGGCGGCCGCGAGTGAGCAGCGCGCGGGCCTGAGGGTACCTGAAGCTCAGCGCACAGCTGCTGTGACACCGCTGCGTGGACAATGGCTACTCAAGCTGACCTGATGGAGTTGGACATGGCCATGGAGCCGGACAGAAAAGCTGCTGTCAGCCACTGGCAGCAGCAGTCTTACTTGGATTCTGGAATCCATTCTGGTGCCACCACCACAGCTCCTTCCCTGAGTGGCAAGGGCAACCCTGAGGAAGAAGATGTTGACACCTCCCAAGTCCTTTATGAATGGGAGCAAGGCTTTTCCCAGTCCTTCACGCAAGAGCAAGTAGCTGATATTGACGGGCAGTATGCAATGACTAGGGCTCAGAGGGTCCGAGCTGCCATGTTCCCTGAGACGCTAGATGAGGGCATGCAGATCCCATCCACGCAGTTTGACGCTGCTCATCCCACTAATGTCCAGCGCTTGGCTGAACCATCACAGATGTTGAAACATGCAGTTGTCAATTTGATTAACTATCAGGATGACGCGGAACTTGCCACACGTGCAATTCCTGAGCTGACAAAACTGCTAAACGATGAGGACCAGGTGGTAGTTAATAAAGCTGCTGTTATGGTCCATCAGCTTTCCAAAAAGGAAGCTTCCAGACATGCCATCATGCGCTCCCCTCAGATGGTGTCTGCCATTGTACGCACCATGCAGAATACAAATGATGTAGAGACAGCTCGTTGTACTGCTGGGACTCTGCACAACCTTTCTCACCACCGCGAGGGCTTGCTGGCCATCTTTAAGTCTGGTGGCATCCCAGCGCTGGTGAAAATGCTTGGGTCACCAGTGGATTCTGTACTGTTCTACGCCATCACGACACTGCATAATCTCCTGCTCCATCAGGAAGGAGCTAAAATGGCAGTGCGCCTAGCTGGTGGACTGCAGAAAATGGTTGCTTTGCTCAACAAAACAAACGTGAAATTCTTGGCTATTACAACAGACTGCCTTCAGATCTTAGCTTATGGCAATCAAGAGAGCAAGCTCATCATTCTGGCCAGTGGTGGACCCCAAGCCTTAGTAAACATAATGAGGACCTACACTTATGAGAAGCTTCTGTGGACCACAAGCAGAGTGCTGAAGGTGCTGTCTGTCTGCTCTAGCAACAAGCCGGCCATTGTAGAAGCTGGTGGGATGCAGGCACTGGGGCTTCATCTGACAGACCCAAGTCAGCGACTTGTTCAAAACTGTCTTTGGACTCTCAGAAACCTTTCAGATGCAGCGACTAAGCAGGAAGGGATGGAAGGCCTCCTTGGGACTCTAGTGCAGCTTCTGGGTTCCGATGATATAAATGTGGTCACCTGTGCAGCTGGAATTCTCTCTAACCTCACTTGCAATAATTACAAAAACAAGATGATGGTGTGCCAAGTGGGTGGCATAGAGGCTCTTGTACGCACCGTCCTTCGTGCTGGTGACAGGGAAGACATCACTGAGCCTGCCATCTGTGCTCTTCGTCATCTGACCAGCCGGCATCAGGAAGCCGAGATGGCCCAGAATGCCGTTCGCCTTCATTATGGACTGCCTGTTGTGGTTAAACTCCTGCACCCACCATCCCACTGGCCTCTGATAAAGGCAACTGTTGGATTGATTCGAAACCTTGCCCTTTGCCCAGCAAATCATGCGCCTTTGCGGGAACAGGGTGCTATTCCACGACTAGTTCAGCTGCTTGTACGAGCACATCAGGACACCCAACGGCGCACCTCCATGGGTGGAACGCAGCAGCAGTTTGTGGAGGGCGTGCGCATGGAGGAGATAGTAGAAGGGTGTACTGGAGCTCTCCACATCCTTGCTCGGGACGTTCACAACCGGATTGTAATCCGAGGACTCAATACCATTCCATTGTTTGTGCAGTTGCTTTATTCTCCCATTGAAAATATCCAAAGAGTAGCTGCAGGGGTCCTCTGTGAACTTGCTCAGGACAAGGAGGCTGCAGAGGCCATTGAAGCTGAGGGAGCCACAGCTCCCCTGACAGAGTTACTCCACTCCAGGAATGAAGGCGTGGCAACATACGCAGCTGCTGTCCTATTCCGAATGTCTGAGGACAAGCCACAGGATTACAAGAAGCGGCTTTCAGTCGAGCTGACCAGTTCCCTCTTCAGGACAGAGCCAATGGCTTGGAATGAGACTGCAGATCTTGGACTGGACATTGGTGCCCAGGGAGAAGCCCTTGGATATCGCCAGGATGATCCCAGCTACCGTTCTTTTCACTCTGGTGGATACGGCCAGGATGCCTTGGGGATGGACCCTATGATGGAGCATGAGATGGGTGGCCACCACCCTGGTGCTGACTATCCAGTTGATGGGCTGCCTGATCTGGGACACGCCCAGGACCTCATGGATGGGCTGCCCCCAGGTGATAGCAATCAGCTGGCCTGGTTTGATACTGACCTGTAAATCGTCCTTTAGGTAAGAAAGCTTATAAAAGCCAGTGTGGGTGAATACTTTACTCTGCCTGCAGAACTCCAGAAAGACTTGGTAGGGTGGGAATGGTTTTAGGCCTGTTTGTAAATCTGCCACCAAACAGATACATACCTTGGAAGGAGATGTTCATGTGTGGAAGTTTCTCACGTTGATGTTTTTGCCACAGCTTTTGCAGCGTTATACTCAGATGAGTAACATTTGCTGTTTTCAACATTAATAGCAGCCTTTCTCTCTATACAGCTGTAGTGTCTGAACGTGCATTGTGATTGGCCTGTAGAGTTGCTGAGAGGGCTCGAGGGGTGGGCTGGTATCTCAGAAAGTGCCTGACACACTAACCAAGCTGAGTTTCCTATGGGAACAGTCGAAGTACGCTTTTTGTTCTGGTCCTTTTTGGTCGAGGAGTAACAATACAAATGGATTTGGGGAGTGACTCACGCAGTGAAGAATGCACACGAATGGATCACAAGATGGCGTTATCAAACCCTAGCCTTGCTTGTTCTTTGTTTTAATATCTGTAGTGGTGCTGACTTTGCTTGCTTTTATTTTTTGCAGTAACTGTTAGTTTTTAAGTAGTGTTATGTTCTAGTGAACCTGCTACAGCAATTTCTGATTTCTAAGAACCGAGTAATGGTGTAGAACACTAATTCATAATCACGCTAATTGTAATCTGGAGACGTGTAACATTGTGTAGCCTTTTGTATAAATAGACAGATAGAAATGGTCCGATTAGTTTCCTTTTTAATATGCTTAAAATAAGCAGGTGGATCTATTTCATGTTTTTGAACAAAAACTTTATCGGGGATACGTGCGGTAGGGTAAATCAGTAAGAGGTGTTATTTGAGCCTTGTTTTGGACAGTATACCAGTTGCCTTTTATCCCAAAGTTGTTGTAACCTGCTGTGATACAATGCTTCAACAGATGCGGTTATAGAAATGGTTCAGAATTAAACTTTTAATTCATTCAAAAAAAAAAAAAAAAAAMouse Wild-Type β-Catenin Sequence (SEQ ID NO: 6; Mus musculus Catenin(Cadherin Associated Protein), Beta 1 (Ctnnb1) in C57BL/6; GenBankAccession No. NM_007614.2; Mouse DsiRNA Target Sequence PositionsCorrespond to NM_007614.2):

GCGGCGCCATCTTAAGCCCTCGCTCGGTGGCGGCCGCGTCAGCTCGTGTCCTGTGAAGCCCGCGGCCCGGGGAGGCGGAGACGGAGCACGGTGGGCGCCGAGCCGTCAGTGCAGGAGGCCGAGGCCGAGCGGGCGGCCGCGAGTGAGCAGCGCGCGGGCCTGAGGGTACCTGAAGCTCAGCGCACAGCTGCTGTGACACCGCTGCGTGGACAATGGCTACTCAAGCTGACCTGATGGAGTTGGACATGGCCATGGAGCCGGACAGAAAAGCTGCTGTCAGCCACTGGCAGCAGCAGTCTTACTTGGATTCTGGAATCCATTCTGGTGCCACCACCACAGCTCCTTCCCTGAGTGGCAAGGGCAACCCTGAGGAAGAAGATGTTGACACCTCCCAAGTCCTTTATGAATGGGAGCAAGGCTTTTCCCAGTCCTTCACGCAAGAGCAAGTAGCTGATATTGACGGGCAGTATGCAATGACTAGGGCTCAGAGGGTCCGAGCTGCCATGTTCCCTGAGACGCTAGATGAGGGCATGCAGATCCCATCCACGCAGTTTGACGCTGCTCATCCCACTAATGTCCAGCGCTTGGCTGAACCATCACAGATGTTGAAACATGCAGTTGTCAATTTGATTAACTATCAGGATGACGCGGAACTTGCCACACGTGCAATTCCTGAGCTGACAAAACTGCTAAACGATGAGGACCAGGTGGTAGTTAATAAAGCTGCTGTTATGGTCCATCAGCTTTCCAAAAAGGAAGCTTCCAGACATGCCATCATGCGCTCCCCTCAGATGGTGTCTGCCATTGTACGCACCATGCAGAATACAAATGATGTAGAGACAGCTCGTTGTACTGCTGGGACTCTGCACAACCTTTCTCACCACCGCGAGGGCTTGCTGGCCATCTTTAAGTCTGGTGGCATCCCAGCGCTGGTGAAAATGCTTGGGTCACCAGTGGATTCTGTACTGTTCTACGCCATCACGACACTGCATAATCTCCTGCTCCATCAGGAAGGAGCTAAAATGGCAGTGCGCCTAGCTGGTGGACTGCAGAAAATGGTTGCTTTGCTCAACAAAACAAACGTGAAATTCTTGGCTATTACAACAGACTGCCTTCAGATCTTAGCTTATGGCAATCAAGAGAGCAAGCTCATCATTCTGGCCAGTGGTGGACCCCAAGCCTTAGTAAACATAATGAGGACCTACACTTATGAGAAGCTTCTGTGGACCACAAGCAGAGTGCTGAAGGTGCTGTCTGTCTGCTCTAGCAACAAGCCGGCCATTGTAGAAGCTGGTGGGATGCAGGCACTGGGGCTTCATCTGACAGACCCAAGTCAGCGACTTGTTCAAAACTGTCTTTGGACTCTCAGAAACCTTTCAGATGCAGCGACTAAGCAGGAAGGGATGGAAGGCCTCCTTGGGACTCTAGTGCAGCTTCTGGGTTCCGATGATATAAATGTGGTCACCTGTGCAGCTGGAATTCTCTCTAACCTCACTTGCAATAATTACAAAAACAAGATGATGGTGTGCCAAGTGGGTGGCATAGAGGCTCTTGTACGCACCGTCCTTCGTGCTGGTGACAGGGAAGACATCACTGAGCCTGCCATCTGTGCTCTTCGTCATCTGACCAGCCGGCATCAGGAAGCCGAGATGGCCCAGAATGCCGTTCGCCTTCATTATGGACTGCCTGTTGTGGTTAAACTCCTGCACCCACCATCCCACTGGCCTCTGATAAAGGCAACTGTTGGATTGATTCGAAACCTTGCCCTTTGCCCAGCAAATCATGCGCCTTTGCGGGAACAGGGTGCTATTCCACGACTAGTTCAGCTGCTTGTACGAGCACATCAGGACACCCAACGGCGCACCTCCATGGGTGGAACGCAGCAGCAGTTTGTGGAGGGCGTGCGCATGGAGGAGATAGTAGAAGGGTGTACTGGAGCTCTCCACATCCTTGCTCGGGACGTTCACAACCGGATTGTAATCCGAGGACTCAATACCATTCCATTGTTTGTGCAGTTGCTTTATTCTCCCATTGAAAATATCCAAAGAGTAGCTGCAGGGGTCCTCTGTGAACTTGCTCAGGACAAGGAGGCTGCAGAGGCCATTGAAGCTGAGGGAGCCACAGCTCCCCTGACAGAGTTACTCCACTCCAGGAATGAAGGCGTGGCAACATACGCAGCTGCTGTCCTATTCCGAATGTCTGAGGACAAGCCACAGGATTACAAGAAGCGGCTTTCAGTCGAGCTGACCAGTTCCCTCTTCAGGACAGAGCCAATGGCTTGGAATGAGACTGCAGATCTTGGACTGGACATTGGTGCCCAGGGAGAAGCCCTTGGATATCGCCAGGATGATCCCAGCTACCGTTCTTTTCACTCTGGTGGATACGGCCAGGATGCCTTGGGGATGGACCCTATGATGGAGCATGAGATGGGTGGCCACCACCCTGGTGCTGACTATCCAGTTGATGGGCTGCCTGATCTGGGACACGCCCAGGACCTCATGGATGGGCTGCCCCCAGGTGATAGCAATCAGCTGGCCTGGTTTGATACTGACCTGTAAATCGTCCTTTAGGTAAGAAAGCTTATAAAAGCCAGTGTGGGTGAATACTTTACTCTGCCTGCAGAACTCCAGAAAGACTTGGTAGGGTGGGAATGGTTTTAGGCCTGTTTGTAAATCTGCCACCAAACAGATACATACCTTGGAAGGAGATGTTCATGTGTGGAAGTTTCTCACGTTGATGTTTTTGCCACAGCTTTTGCAGCGTTATACTCAGATGAGTAACATTTGCTGTTTTCAACATTAATAGCAGCCTTTCTCTCTATACAGCTGTAGTGTCTGAACGTGCATTGTGATTGGCCTGTAGAGTTGCTGAGAGGGCTCGAGGGGTGGGCTGGTATCTCAGAAAGTGCCTGACACACTAACCAAGCTGAGTTTCCTATGGGAACAGTCGAAGTACGCTTTTTGTTCTGGTCCTTTTTGGTCGAGGAGTAACAATACAAATGGATTTGGGGAGTGACTCACGCAGTGAAGAATGCACACGAATGGATCACAAGATGGCGTTATCAAACCCTAGCCTTGCTTGTTCTTTGTTTTAATATCTGTAGTGGTGCTGACTTTGCTTGCTTTTATTTTTTGCAGTAACTGTTAGTTTTTAAGTAGTGTTATGTTCTAGTGAACCTGCTACAGCAATTTCTGATTTCTAAGAACCGAGTAATGGTGTAGAACACTAATTCATAATCACGCTAATTGTAATCTGGAGACGTGTAACATTGTGTAGCCTTTTGTATAAATAGACAGATAGAAATGGTCCGATTAGTTTCCTTTTTAATATGCTTAAAATAAGCAGGTGGATCTATTTCATGTTTTTGAACAAAAACTTTATCGGGGATACGTGCGGTAGGGTAAATCAGTAAGAGGTGTTATTTGAGCCTTGTTTTGGACAGTATACCAGTTGCCTTTTATCCCAAAGTTGTTGTAACCTGCTGTGATACAATGCTTCAACAGATGCGGTTATAGAAATGGTTCAGAATTAAACTTTTAATTCATTCAAA AAAAAAAAAAAAAAAMouse Wild-Type β-Catenin Amino Acid Sequence NP_031640.1 (SEQ ID NO: 7;Translation of NM_007614.2 or NM_007614.3):

MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEALGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL

β-catenin is a protein that in humans is encoded by the CTNNB1 gene(Kraus et al. Genomics 23: 272-4)—accordingly, reference herein to thehuman “β-catenin gene” specifically refers to the CTNNB1 gene. β-cateninis a subunit of the cadherin protein complex and has been demonstratedto be an integral component in the Wnt signaling pathway. Drosophilaarmadillo is a β-catenin homolog, rendering β-catenin a member of thearmadillo family.

As a member of the armadillo family, the β-catenin protein containsmultiple copies of the so-called armadillo repeat domain, which is adomain specialized for protein-protein binding. When β-catenin is notassociated with cadherins and alpha-catenin, it can interact with otherproteins such as ICAT and APC.

Functionally, cadherin complexes constitute adherens junctions (Ajs),which are required for creation and maintenance of epithelial celllayers via regulation of cell growth and adhesion between neighboringcells. β-catenin also anchors the actin cytoskeleton and is modeled tobe responsible for transmitting contact inhibition signals that causecells to stop dividing once an epithelial sheet is complete (EntrezGene:catenin). β-catenin has been shown to play a significant role in liverbiology, e.g., liver development (both embryonic and postnatal), liverregeneration following partial hepatectomy, HGF-induced hepatomegaly,liver zonation, and pathogenesis of liver cancer (Thompson and Monga.Hepatology 45: 1298-1305).

Without being bound by theory, β-catenin is modeled to function in theWnt signaling pathway in the following manner. When Wnt is not present,GSK-3 (a kinase) constitutively phosphorylates the β-catenin protein.β-catenin is associated with axin (scaffolding protein) complexed withGSK3 and APC (adenomatosis polyposis coli). The creation of this complexacts to substantially increase the phosphorylation of β-catenin byfacilitating the action of GSK3. When β-catenin is phosphorylated, it isdegraded and, thus, β-catenin does not build up in the cell to asignificant level. When Wnt binds to frizzled (Fz), its receptor,disheveled (Dsh), is recruited to the membrane. GSK3 is inhibited by theactivation of Dsh by Fz. Because of this, β-catenin is permitted tobuild up in the cytosol and can be subsequently translocated into thenucleus, where it performs a variety of functions. β-catenin can act inconjunction with TCF and LEF to activate specific target genes involvedin different processes.

β-catenin is an oncogene. An increase in β-catenin production has beennoted in subjects with basal cell carcinoma, and such increase leads tothe increase in proliferation of related tumors (Saldanha et al. Br. JDermatol. 151: 157-64). Mutations in β-catenin are a cause of colorectalcancer (CRC), pilomatrixoma (PTR), medulloblastoma (MDB), and ovariancancer. β-catenin also binds to the product of the APC gene, which ismutated in adenomatous polyposis of the colon.

The ability of β-catenin to bind to other proteins is regulated bytyrosine kinases (Lilien and Balsamo Curr. Opin. Cell Biol. 17: 459-65)and serine kinases such as GSK-3 (Castellone et al. Science 310:1504-10). When β-catenin is not assembled in complexes with cadherins,it can form a complex with axin. While bound to axin, β-catenin can bephosphorylated by GSK-3, which creates a signal for the rapidubiquitin-dependent degradation of β-catenin by proteosomes. Varioussignals such as the Wnt signalling pathway can inhibit GSK-3-mediatedphosphorylation of β-catenin (Liu et al. Curr. Biol. 15: 1989-97),allowing β-catenin to go to the cell nucleus, interact withtranscription factors, and regulate gene transcription.

β-catenin can be phosphorylated by other kinases such as protein kinaseA (PKA). Phosphorylation of β-catenin by PKA has been associated withreduced degradation of β-catenin, increased levels of β-catenin in thenucleus and interaction of β-catenin with TCF family transcriptionfactors to regulate gene expression (Hino et al. Mol. Cell. Biol. 25:9063-72).

β-catenin has also been shown to interact with the following proteins:Androgen receptor, APC, AXIN1, CBY1, CDH1, CDH2, CDH3, CDK5R1, CHUK,CTNNA1, CTNND1, EGFR, FHL2, GSK3B, HER2/neu, HNF4A, IKK2, LEF1, MAGI1,MUC1, NR5A1, PCAF, PHF17, Plakoglobin, PTPN14, PTPRF, PRPRK, PSEN1,RuvB-like 1, SMAD7, SLC9A3R1, SMARCA4, USP9X and VE-cadherin(http://en.wikipedia.org/wiki/Beta-catenin).

In Vitro Assay to Assess DsiRNA β-Catenin Inhibitory Activity

An in vitro assay that recapitulates RNAi in a cell-free system can beused to evaluate DsiRNA constructs targeting β-catenin RNA sequence(s),and thus to assess β-catenin-specific gene inhibitory activity (alsoreferred to herein as β-catenin inhibitory activity) of a DsiRNA. Theassay comprises the system described by Tuschl et al., 1999, Genes andDevelopment, 13, 3191-3197 and Zamore et al., 2000, Cell, 101, 25-33adapted for use with DsiRNA agents directed against β-catenin RNA. ADrosophila extract derived from syncytial blastoderm is used toreconstitute RNAi activity in vitro. Target RNA is generated via invitro transcription from a selected 1-catenin expressing plasmid usingT7 RNA polymerase or via chemical synthesis. Sense and antisense DsiRNAstrands (for example 20 uM each) are annealed by incubation in buffer(such as 100 mM potassium acetate, 30 mM HEPES-KOH, pH 7.4, 2 mMmagnesium acetate) for 1 minute at 90° C. followed by 1 hour at 37° C.,then diluted in lysis buffer (for example 100 mM potassium acetate, 30mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate). Annealing can bemonitored by gel electrophoresis on an agarose gel in TBE buffer andstained with ethidium bromide. The Drosophila lysate is prepared usingzero to two-hour-old embryos from Oregon R flies collected on yeastedmolasses agar that are dechorionated and lysed. The lysate iscentrifuged and the supernatant isolated. The assay comprises a reactionmixture containing 50% lysate [vol/vol], RNA (10-50 pM finalconcentration), and 10% [vol/vol] lysis buffer containing DsiRNA (10 nMfinal concentration). The reaction mixture also contains 10 mM creatinephosphate, 10 ug/ml creatine phosphokinase, 100 um GTP, 100 uM UTP, 100uM CTP, 500 uM ATP, 5 mM DTT, 0.1 U/uL RNasin (Promega), and 100 uM ofeach amino acid. The final concentration of potassium acetate isadjusted to 100 mM. The reactions are pre-assembled on ice andpreincubated at 25° C. for 10 minutes before adding RNA, then incubatedat 25° C. for an additional 60 minutes. Reactions are quenched with 4volumes of 1.25× Passive Lysis Buffer (Promega). Target RNA cleavage isassayed by RT-PCR analysis or other methods known in the art and arecompared to control reactions in which DsiRNA is omitted from thereaction.

Alternately, internally-labeled target RNA for the assay is prepared byin vitro transcription in the presence of [alpha-³²P] CTP, passed over aG50 Sephadex column by spin chromatography and used as target RNAwithout further purification. Optionally, target RNA is 5′-³²P-endlabeled using T4 polynucleotide kinase enzyme. Assays are performed asdescribed above and target RNA and the specific RNA cleavage productsgenerated by RNAi are visualized on an autoradiograph of a gel. Thepercentage of cleavage is determined by PHOSPHOR IMAGER®(autoradiography) quantitation of bands representing intact control RNAor RNA from control reactions without DsiRNA and the cleavage productsgenerated by the assay.

In one embodiment, this assay is used to determine target sites in theβ-catenin RNA target for DsiRNA mediated RNAi cleavage, wherein aplurality of DsiRNA constructs are screened for RNAi mediated cleavageof the β-catenin RNA target, for example, by analyzing the assayreaction by electrophoresis of labeled target RNA, or by northernblotting, as well as by other methodology well known in the art.

In certain embodiments, a DsiRNA of the invention is deemed to possessβ-catenin inhibitory activity if, e.g., a 50% reduction in β-catenin RNAlevels is observed in a system, cell, tissue or organism, relative to asuitable control. Additional metes and bounds for determination ofβ-catenin inhibitory activity of a DsiRNA of the invention are describedsupra.

Conjugation and Delivery of Anti-β-Catenin DsiRNA Agents

In certain embodiments the present invention relates to a method fortreating a subject having a β-catenin-associated disease or disorder, orat risk of developing a β-catenin-associated disease or disorder. Insuch embodiments, the DsiRNA can act as novel therapeutic agents forcontrolling the β-catenin-associated disease or disorder. The methodcomprises administering a pharmaceutical composition of the invention tothe patient (e.g., human), such that the expression, level and/oractivity of a β-catenin RNA is reduced. The expression, level and/oractivity of a polypeptide encoded by a β-catenin RNA might also bereduced by a DsiRNA of the instant invention, even where said DsiRNA isdirected against a non-coding region of the β-catenin transcript (e.g.,a targeted 5′ UTR or 3′ UTR sequence). Because of their highspecificity, the DsiRNAs of the present invention can specificallytarget β-catenin sequences of cells and tissues, optionally in anallele-specific manner where polymorphic alleles exist within anindividual and/or population.

In the treatment of a β-catenin-associated disease or disorder, theDsiRNA can be brought into contact with the cells or tissue of asubject, e.g., the cells or tissue of a subject exhibiting disregulationof β-catenin and/or otherwise targeted for reduction of β-cateninlevels. For example, DsiRNA substantially identical to all or part of aβ-catenin RNA sequence, may be brought into contact with or introducedinto such a cell, either in vivo or in vitro. Similarly, DsiRNAsubstantially identical to all or part of a β-catenin RNA sequence mayadministered directly to a subject having or at risk of developing aβ-catenin-associated disease or disorder.

Therapeutic use of the DsiRNA agents of the instant invention caninvolve use of formulations of DsiRNA agents comprising multipledifferent DsiRNA agent sequences. For example, two or more, three ormore, four or more, five or more, etc. of the presently described agentscan be combined to produce a formulation that, e.g., targets multipledifferent regions of the β-catenin RNA, or that not only targetβ-catenin RNA but also target, e.g., cellular target genes associatedwith a β-catenin-associated disease or disorder. A DsiRNA agent of theinstant invention may also be constructed such that either strand of theDsiRNA agent independently targets two or more regions of β-catenin RNA,or such that one of the strands of the DsiRNA agent targets a cellulartarget gene of β-catenin known in the art.

Use of multifunctional DsiRNA molecules that target more then one regionof a target nucleic acid molecule can also provide potent inhibition ofβ-catenin RNA levels and expression. For example, a singlemultifunctional DsiRNA construct of the invention can target both theβc-1569 and βc-1683 sites simultaneously; additionally and/oralternatively, single or multifunctional agents of the invention can bedesigned to selectively target one splice variant of β-catenin overanother.

Thus, the DsiRNA agents of the instant invention, individually, or incombination or in conjunction with other drugs, can be used to treat,inhibit, reduce, or prevent a β-catenin-associated disease or disorder.For example, the DsiRNA molecules can be administered to a subject orcan be administered to other appropriate cells evident to those skilledin the art, individually or in combination with one or more drugs underconditions suitable for the treatment.

The DsiRNA molecules also can be used in combination with other knowntreatments to treat, inhibit, reduce, or prevent a β-catenin-associateddisease or disorder in a subject or organism. For example, the describedmolecules could be used in combination with one or more known compounds,treatments, or procedures to treat, inhibit, reduce, or prevent aβ-catenin-associated disease or disorder in a subject or organism as areknown in the art.

A DsiRNA agent of the invention can be conjugated (e.g., at its 5′ or 3′terminus of its sense or antisense strand) or unconjugated to anothermoiety (e.g. a non-nucleic acid moiety such as a peptide), an organiccompound (e.g., a dye, cholesterol, or the like). Modifying DsiRNAagents in this way may improve cellular uptake or enhance cellulartargeting activities of the resulting DsiRNA agent derivative ascompared to the corresponding unconjugated DsiRNA agent, are useful fortracing the DsiRNA agent derivative in the cell, or improve thestability of the DsiRNA agent derivative compared to the correspondingunconjugated DsiRNA agent.

Methods of Introducing Nucleic Acids, Vectors, and Host Cells

DsiRNA agents of the invention may be directly introduced into a cell(i.e., intracellularly); or introduced extracellularly into a cavity,interstitial space, into the circulation of an organism, introducedorally, or may be introduced by bathing a cell or organism in a solutioncontaining the nucleic acid. Vascular or extravascular circulation, theblood or lymph system, and the cerebrospinal fluid are sites where thenucleic acid may be introduced.

The DsiRNA agents of the invention can be introduced using nucleic aciddelivery methods known in art including injection of a solutioncontaining the nucleic acid, bombardment by particles covered by thenucleic acid, soaking the cell or organism in a solution of the nucleicacid, or electroporation of cell membranes in the presence of thenucleic acid. Other methods known in the art for introducing nucleicacids to cells may be used, such as lipid-mediated carrier transport,chemical-mediated transport, and cationic liposome transfection such ascalcium phosphate, and the like. The nucleic acid may be introducedalong with other components that perform one or more of the followingactivities: enhance nucleic acid uptake by the cell or other-wiseincrease inhibition of the target β-catenin RNA.

A cell having a target β-catenin RNA may be from the germ line orsomatic, totipotent or pluripotent, dividing or non-dividing, parenchymaor epithelium, immortalized or transformed, or the like. The cell may bea stem cell or a differentiated cell. Cell types that are differentiatedinclude adipocytes, fibroblasts, myocytes, cardiomyocytes, endothelium,neurons, glia, blood cells, megakaryocytes, lymphocytes, macrophages,neutrophils, eosinophils, basophils, mast cells, leukocytes,granulocytes, keratinocytes, chondrocytes, osteoblasts, osteoclasts,hepatocytes, and cells of the endocrine or exocrine glands.

Depending on the particular target β-catenin RNA sequence and the doseof DsiRNA agent material delivered, this process may provide partial orcomplete loss of function for the β-catenin RNA. A reduction or loss ofRNA levels or expression (either β-catenin RNA expression or encodedpolypeptide expression) in at least 50%, 60%, 70%, 80%, 90%, 95% or 99%or more of targeted cells is exemplary. Inhibition of β-catenin RNAlevels or expression refers to the absence (or observable decrease) inthe level of β-catenin RNA or β-catenin RNA-encoded protein. Specificityrefers to the ability to inhibit the β-catenin RNA without manifesteffects on other genes of the cell. The consequences of inhibition canbe confirmed by examination of the outward properties of the cell ororganism or by biochemical techniques such as RNA solutionhybridization, nuclease protection, Northern hybridization, reversetranscription, gene expression monitoring with a microarray, antibodybinding, enzyme linked immunosorbent assay (ELISA), Western blotting,radioimmunoassay (RIA), other immunoassays, and fluorescence activatedcell analysis (FACS). Inhibition of target β-catenin RNA sequence(s) bythe DsiRNA agents of the invention also can be measured based upon theeffect of administration of such DsiRNA agents upondevelopment/progression of a β-catenin-associated disease or disorder,e.g., tumor formation, growth, metastasis, etc., either in vivo or invitro.

Treatment and/or reductions in tumor or cancer cell levels can includehalting or reduction of growth of tumor or cancer cell levels orreductions of, e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or99% or more, and can also be measured in logarithmic terms, e.g.,10-fold, 100-fold, 1000-fold, 10⁵-fold, 10⁶-fold, 10⁷-fold reduction incancer cell levels could be achieved via administration of the DsiRNAagents of the invention to cells, a tissue, or a subject.

For RNA-mediated inhibition in a cell line or whole organism, expressiona reporter or drug resistance gene whose protein product is easilyassayed can be measured. Such reporter genes include acetohydroxyacidsynthase (AHAS), alkaline phosphatase (AP), β galactosidase (LacZ), βglucoronidase (GUS), chloramphenicol acetyltransferase (CAT), greenfluorescent protein (GFP), horseradish peroxidase (HRP), luciferase(Luc), nopaline synthase (NOS), octopine synthase (OCS), and derivativesthereof. Multiple selectable markers are available that conferresistance to ampicillin, bleomycin, chloramphenicol, gentarnycin,hygromycin, kanamycin, lincomycin, methotrexate, phosphinothricin,puromycin, and tetracyclin. Depending on the assay, quantitation of theamount of gene expression allows one to determine a degree of inhibitionwhich is greater than 10%, 33%, 50%, 90%, 95% or 99% as compared to acell not treated according to the present invention.

Lower doses of injected material and longer times after administrationof RNA silencing agent may result in inhibition in a smaller fraction ofcells (e.g., at least 10%, 20%, 50%, 75%, 90%, or 95% of targetedcells). Quantitation of gene expression in a cell may show similaramounts of inhibition at the level of accumulation of target β-cateninRNA or translation of target protein. As an example, the efficiency ofinhibition may be determined by assessing the amount of gene product inthe cell; RNA may be detected with a hybridization probe having anucleotide sequence outside the region used for the inhibitory DsiRNA,or translated polypeptide may be detected with an antibody raisedagainst the polypeptide sequence of that region.

The DsiRNA agent may be introduced in an amount which allows delivery ofat least one copy per cell. Higher doses (e.g., at least 5, 10, 100, 500or 1000 copies per cell) of material may yield more effectiveinhibition; lower doses may also be useful for specific applications.

Pharmaceutical Compositions

In certain embodiments, the present invention provides for apharmaceutical composition comprising the DsiRNA agent of the presentinvention. The DsiRNA agent sample can be suitably formulated andintroduced into the environment of the cell by any means that allows fora sufficient portion of the sample to enter the cell to induce genesilencing, if it is to occur. Many formulations for dsRNA are known inthe art and can be used so long as the dsRNA gains entry to the targetcells so that it can act. See, e.g., U.S. published patent applicationNos. 2004/0203145 A1 and 2005/0054598 A1. For example, the DsiRNA agentof the instant invention can be formulated in buffer solutions such asphosphate buffered saline solutions, liposomes, micellar structures, andcapsids. Formulations of DsiRNA agent with cationic lipids can be usedto facilitate transfection of the DsiRNA agent into cells. For example,cationic lipids, such as lipofectin (U.S. Pat. No. 5,705,188), cationicglycerol derivatives, and polycationic molecules, such as polylysine(published PCT International Application WO 97/30731), can be used.Suitable lipids include Oligofectamine, Lipofectamine (LifeTechnologies), NC388 (Ribozyme Pharmaceuticals, Inc., Boulder, Colo.),or FuGene 6 (Roche) all of which can be used according to themanufacturer's instructions.

Such compositions typically include the nucleic acid molecule and apharmaceutically acceptable carrier. As used herein the language“pharmaceutically acceptable carrier” includes saline, solvents,dispersion media, coatings, antibacterial and antifungal agents,isotonic and absorption delaying agents, and the like, compatible withpharmaceutical administration. Supplementary active compounds can alsobe incorporated into the compositions.

A pharmaceutical composition is formulated to be compatible with itsintended route of administration. Examples of routes of administrationinclude parenteral, e.g., intravenous, intradermal, subcutaneous, oral(e.g., inhalation), transdermal (topical), transmucosal, and rectaladministration. Solutions or suspensions used for parenteral,intradermal, or subcutaneous application can include the followingcomponents: a sterile diluent such as water for injection, salinesolution, fixed oils, polyethylene glycols, glycerine, propylene glycolor other synthetic solvents; antibacterial agents such as benzyl alcoholor methyl parabens; antioxidants such as ascorbic acid or sodiumbisulfite; cHeLating agents such as ethylenediaminetetraacetic acid;buffers such as acetates, citrates or phosphates and agents for theadjustment of tonicity such as sodium chloride or dextrose. pH can beadjusted with acids or bases, such as hydrochloric acid or sodiumhydroxide. The parenteral preparation can be enclosed in ampoules,disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterileaqueous solutions (where water soluble) or dispersions and sterilepowders for the extemporaneous preparation of sterile injectablesolutions or dispersion. For intravenous administration, suitablecarriers include physiological saline, bacteriostatic water, CremophorEL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In allcases, the composition must be sterile and should be fluid to the extentthat easy syringability exists. It should be stable under the conditionsof manufacture and storage and must be preserved against thecontaminating action of microorganisms such as bacteria and fungi. Thecarrier can be a solvent or dispersion medium containing, for example,water, ethanol, polyol (for example, glycerol, propylene glycol, andliquid polyetheylene glycol, and the like), and suitable mixturesthereof. The proper fluidity can be maintained, for example, by the useof a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersion and by the use of surfactants.Prevention of the action of microorganisms can be achieved by variousantibacterial and antifungal agents, for example, parabens,chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In manycases, it will be preferable to include isotonic agents, for example,sugars, polyalcohols such as manitol, sorbitol, sodium chloride in thecomposition. Prolonged absorption of the injectable compositions can bebrought about by including in the composition an agent which delaysabsorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the activecompound in the required amount in a selected solvent with one or acombination of ingredients enumerated above, as required, followed byfiltered sterilization. Generally, dispersions are prepared byincorporating the active compound into a sterile vehicle, which containsa basic dispersion medium and the required other ingredients from thoseenumerated above. In the case of sterile powders for the preparation ofsterile injectable solutions, the preferred methods of preparation arevacuum drying and freeze-drying which yields a powder of the activeingredient plus any additional desired ingredient from a previouslysterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an ediblecarrier. For the purpose of oral therapeutic administration, the activecompound can be incorporated with excipients and used in the form oftablets, troches, or capsules, e.g., gelatin capsules. Oral compositionscan also be prepared using a fluid carrier for use as a mouthwash.Pharmaceutically compatible binding agents, and/or adjuvant materialscan be included as part of the composition. The tablets, pills,capsules, troches and the like can contain any of the followingingredients, or compounds of a similar nature: a binder such asmicrocrystalline cellulose, gum tragacanth or gelatin; an excipient suchas starch or lactose, a disintegrating agent such as alginic acid,Primogel, or corn starch; a lubricant such as magnesium stearate orSterotes; a glidant such as colloidal silicon dioxide; a sweeteningagent such as sucrose or saccharin; or a flavoring agent such aspeppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in theform of an aerosol spray from pressured container or dispenser whichcontains a suitable propellant, e.g., a gas such as carbon dioxide, or anebulizer. Such methods include those described in U.S. Pat. No.6,468,798.

Systemic administration can also be by transmucosal or transdermalmeans. For transmucosal or transdermal administration, penetrantsappropriate to the barrier to be permeated are used in the formulation.Such penetrants are generally known in the art, and include, forexample, for transmucosal administration, detergents, bile salts, andfusidic acid derivatives. Transmucosal administration can beaccomplished through the use of nasal sprays or suppositories. Fortransdermal administration, the active compounds are formulated intoointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g.,with conventional suppository bases such as cocoa butter and otherglycerides) or retention enemas for rectal delivery.

The compounds can also be administered by transfection or infectionusing methods known in the art, including but not limited to the methodsdescribed in McCaffrey et al. (2002), Nature, 418(6893), 38-9(hydrodynamic transfection); Xia et al. (2002), Nature Biotechnol.,20(10), 1006-10 (viral-mediated delivery); or Putnam (1996), Am. J.Health Syst. Pharm. 53(2), 151-160, erratum at Am. J. Health Syst.Pharm. 53(3), 325 (1996).

The compounds can also be administered by a method suitable foradministration of nucleic acid agents, such as a DNA vaccine. Thesemethods include gene guns, bio injectors, and skin patches as well asneedle-free methods such as the micro-particle DNA vaccine technologydisclosed in U.S. Pat. No. 6,194,389, and the mammalian transdermalneedle-free vaccination with powder-form vaccine as disclosed in U.S.Pat. No. 6,168,587. Additionally, intranasal delivery is possible, asdescribed in, inter alia, Hamajima et al. (1998), Clin. Immunol.Immunopathol., 88(2), 205-10. Liposomes (e.g., as described in U.S. Pat.No. 6,472,375) and microencapsulation can also be used. Biodegradabletargetable microparticle delivery systems can also be used (e.g., asdescribed in U.S. Pat. No. 6,471,996).

In one embodiment, the active compounds are prepared with carriers thatwill protect the compound against rapid elimination from the body, suchas a controlled release formulation, including implants andmicroencapsulated delivery systems. Biodegradable, biocompatiblepolymers can be used, such as ethylene vinyl acetate, polyanhydrides,polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Suchformulations can be prepared using standard techniques. The materialscan also be obtained commercially from Alza Corporation and NovaPharmaceuticals, Inc. Liposomal suspensions (including liposomestargeted to infected cells with monoclonal antibodies to viral antigens)can also be used as pharmaceutically acceptable carriers. These can beprepared according to methods known to those skilled in the art, forexample, as described in U.S. Pat. No. 4,522,811.

Toxicity and therapeutic efficacy of such compounds can be determined bystandard pharmaceutical procedures in cell cultures or experimentalanimals, e.g., for determining the LD₅₀ (the dose lethal to 50% of thepopulation) and the ED₅₀ (the dose therapeutically effective in 50% ofthe population). The dose ratio between toxic and therapeutic effects isthe therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀.Compounds which exhibit high therapeutic indices are preferred. Whilecompounds that exhibit toxic side effects may be used, care should betaken to design a delivery system that targets such compounds to thesite of affected tissue in order to minimize potential damage touninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can beused in formulating a range of dosage for use in humans. The dosage ofsuch compounds lies preferably within a range of circulatingconcentrations that include the ED₅₀ with little or no toxicity. Thedosage may vary within this range depending upon the dosage formemployed and the route of administration utilized. For a compound usedin the method of the invention, the therapeutically effective dose canbe estimated initially from cell culture assays. A dose may beformulated in animal models to achieve a circulating plasmaconcentration range that includes the IC₅₀ (i.e., the concentration ofthe test compound which achieves a half-maximal inhibition of symptoms)as determined in cell culture. Such information can be used to moreaccurately determine useful doses in humans. Levels in plasma may bemeasured, for example, by high performance liquid chromatography.

As defined herein, a therapeutically effective amount of a nucleic acidmolecule (i.e., an effective dosage) depends on the nucleic acidselected. For instance, if a plasmid encoding a DsiRNA agent isselected, single dose amounts in the range of approximately 1 pg to 1000mg may be administered; in some embodiments, 10, 30, 100, or 1000 pg, or10, 30, 100, or 1000 ng, or 10, 30, 100, or 1000 μg, or 10, 30, 100, or1000 mg may be administered. In some embodiments, 1-5 g of thecompositions can be administered. The compositions can be administeredone from one or more times per day to one or more times per week;including once every other day. The skilled artisan will appreciate thatcertain factors may influence the dosage and timing required toeffectively treat a subject, including but not limited to the severityof the disease or disorder, previous treatments, the general healthand/or age of the subject, and other diseases present. Moreover,treatment of a subject with a therapeutically effective amount of aprotein, polypeptide, or antibody can include a single treatment or,preferably, can include a series of treatments.

The nucleic acid molecules of the invention can be inserted intoexpression constructs, e.g., viral vectors, retroviral vectors,expression cassettes, or plasmid viral vectors, e.g., using methodsknown in the art, including but not limited to those described in Xia etal., (2002), supra. Expression constructs can be delivered to a subjectby, for example, inhalation, orally, intravenous injection, localadministration (see U.S. Pat. No. 5,328,470) or by stereotacticinjection (see e.g., Chen et al. (1994), Proc. Natl. Acad. Sci. USA, 91,3054-3057). The pharmaceutical preparation of the delivery vector caninclude the vector in an acceptable diluent, or can comprise a slowrelease matrix in which the delivery vehicle is imbedded. Alternatively,where the complete delivery vector can be produced intact fromrecombinant cells, e.g., retroviral vectors, the pharmaceuticalpreparation can include one or more cells which produce the genedelivery system.

The expression constructs may be constructs suitable for use in theappropriate expression system and include, but are not limited toretroviral vectors, linear expression cassettes, plasmids and viral orvirally-derived vectors, as known in the art. Such expression constructsmay include one or more inducible promoters, RNA Pol III promotersystems such as U6 snRNA promoters or H1 RNA polymerase III promoters,or other promoters known in the art. The constructs can include one orboth strands of the siRNA. Expression constructs expressing both strandscan also include loop structures linking both strands, or each strandcan be separately transcribed from separate promoters within the sameconstruct. Each strand can also be transcribed from a separateexpression construct, e.g., Tuschl (2002, Nature Biotechnol 20:500-505).

It can be appreciated that the method of introducing DsiRNA agents intothe environment of the cell will depend on the type of cell and the makeup of its environment. For example, when the cells are found within aliquid, one preferable formulation is with a lipid formulation such asin lipofectamine and the DsiRNA agents can be added directly to theliquid environment of the cells. Lipid formulations can also beadministered to animals such as by intravenous, intramuscular, orintraperitoneal injection, or orally or by inhalation or other methodsas are known in the art. When the formulation is suitable foradministration into animals such as mammals and more specificallyhumans, the formulation is also pharmaceutically acceptable.Pharmaceutically acceptable formulations for administeringoligonucleotides are known and can be used. In some instances, it may bepreferable to formulate DsiRNA agents in a buffer or saline solution anddirectly inject the formulated DsiRNA agents into cells, as in studieswith oocytes. The direct injection of DsiRNA agents duplexes may also bedone. For suitable methods of introducing dsRNA (e.g., DsiRNA agents),see U.S. published patent application No. 2004/0203145 A1.

Suitable amounts of a DsiRNA agent must be introduced and these amountscan be empirically determined using standard methods. Typically,effective concentrations of individual DsiRNA agent species in theenvironment of a cell will be 50 nanomolar or less, 10 nanomolar orless, or compositions in which concentrations of 1 nanomolar or less canbe used. In another embodiment, methods utilizing a concentration of 200picomolar or less, 100 picomolar or less, 50 picomolar or less, 20picomolar or less, and even a concentration of 10 picomolar or less, 5picomolar or less, 2 picomolar or less or 1 picomolar or less can beused in many circumstances.

The method can be carried out by addition of the DsiRNA agentcompositions to an extracellular matrix in which cells can live providedthat the DsiRNA agent composition is formulated so that a sufficientamount of the DsiRNA agent can enter the cell to exert its effect. Forexample, the method is amenable for use with cells present in a liquidsuch as a liquid culture or cell growth media, in tissue explants, or inwhole organisms, including animals, such as mammals and especiallyhumans.

The level or activity of a β-catenin RNA can be determined by a suitablemethod now known in the art or that is later developed. It can beappreciated that the method used to measure a target RNA and/or the“expression” of a target gene can depend upon the nature of the targetgene and its encoded RNA. For example, where the target β-catenin RNAsequence encodes a protein, the term “expression” can refer to a proteinor the β-catenin RNA/transcript derived from the β-catenin gene (eithergenomic or of exogenous origin). In such instances the expression of thetarget β-catenin RNA can be determined by measuring the amount ofβ-catenin RNA/transcript directly or by measuring the amount ofβ-catenin protein. Protein can be measured in protein assays such as bystaining or immunoblotting or, if the protein catalyzes a reaction thatcan be measured, by measuring reaction rates. All such methods are knownin the art and can be used. Where target β-catenin RNA levels are to bemeasured, art-recognized methods for detecting RNA levels can be used(e.g., RT-PCR, Northern Blotting, etc.). In targeting β-catenin RNAswith the DsiRNA agents of the instant invention, it is also anticipatedthat measurement of the efficacy of a DsiRNA agent in reducing levels ofβ-catenin RNA or protein in a subject, tissue, in cells, either in vitroor in vivo, or in cell extracts can also be used to determine the extentof reduction of β-catenin-associated phenotypes (e.g., disease ordisorders, e.g., cancer or tumor formation, growth, metastasis, spread,etc.). The above measurements can be made on cells, cell extracts,tissues, tissue extracts or other suitable source material.

The determination of whether the expression of a β-catenin RNA has been“reduced” can be by a suitable method that can reliably detect changesin RNA levels. Typically, the determination is made by introducing intothe environment of a cell undigested DsiRNA such that at least a portionof that DsiRNA agent enters the cytoplasm, and then measuring the levelof the target RNA. The same measurement is made on identical untreatedcells and the results obtained from each measurement are compared.

The DsiRNA agent can be formulated as a pharmaceutical composition whichcomprises a pharmacologically effective amount of a DsiRNA agent andpharmaceutically acceptable carrier. A pharmacologically ortherapeutically effective amount refers to that amount of a DsiRNA agenteffective to produce the intended pharmacological, therapeutic orpreventive result. The phrases “pharmacologically effective amount” and“therapeutically effective amount” or simply “effective amount” refer tothat amount of an RNA effective to produce the intended pharmacological,therapeutic or preventive result. For example, if a given clinicaltreatment is considered effective when there is at least a 20% reductionin a measurable parameter associated with a disease or disorder, atherapeutically effective amount of a drug for the treatment of thatdisease or disorder is the amount necessary to effect at least a 20%reduction in that parameter.

Suitably formulated pharmaceutical compositions of this invention can beadministered by means known in the art such as by parenteral routes,including intravenous, intramuscular, intraperitoneal, subcutaneous,transdermal, airway (aerosol), rectal, vaginal and topical (includingbuccal and sublingual) administration. In some embodiments, thepharmaceutical compositions are administered by intravenous orintraparenteral infusion or injection.

In general, a suitable dosage unit of dsRNA will be in the range of0.001 to 0.25 milligrams per kilogram body weight of the recipient perday, or in the range of 0.01 to 20 micrograms per kilogram body weightper day, or in the range of 0.01 to 10 micrograms per kilogram bodyweight per day, or in the range of 0.10 to 5 micrograms per kilogrambody weight per day, or in the range of 0.1 to 2.5 micrograms perkilogram body weight per day. Pharmaceutical composition comprising thedsRNA can be administered once daily. However, the therapeutic agent mayalso be dosed in dosage units containing two, three, four, five, six ormore sub-doses administered at appropriate intervals throughout the day.In that case, the dsRNA contained in each sub-dose must becorrespondingly smaller in order to achieve the total daily dosage unit.The dosage unit can also be compounded for a single dose over severaldays, e.g., using a conventional sustained release formulation whichprovides sustained and consistent release of the dsRNA over a severalday period. Sustained release formulations are well known in the art. Inthis embodiment, the dosage unit contains a corresponding multiple ofthe daily dose. Regardless of the formulation, the pharmaceuticalcomposition must contain dsRNA in a quantity sufficient to inhibitexpression of the target gene in the animal or human being treated. Thecomposition can be compounded in such a way that the sum of the multipleunits of dsRNA together contain a sufficient dose.

Data can be obtained from cell culture assays and animal studies toformulate a suitable dosage range for humans. The dosage of compositionsof the invention lies within a range of circulating concentrations thatinclude the ED₅₀ (as determined by known methods) with little or notoxicity. The dosage may vary within this range depending upon thedosage form employed and the route of administration utilized.

For a compound used in the method of the invention, the therapeuticallyeffective dose can be estimated initially from cell culture assays. Adose may be formulated in animal models to achieve a circulating plasmaconcentration range of the compound that includes the IC₅₀ (i.e., theconcentration of the test compound which achieves a half-maximalinhibition of symptoms) as determined in cell culture. Such informationcan be used to more accurately determine useful doses in humans. Levelsof dsRNA in plasma may be measured by standard methods, for example, byhigh performance liquid chromatography.

The pharmaceutical compositions can be included in a kit, container,pack, or dispenser together with instructions for administration.

Methods of Treatment

The present invention provides for both prophylactic and therapeuticmethods of treating a subject at risk of (or susceptible to) a diseaseor disorder caused, in whole or in part, by β-catenin (e.g.,misregulation and/or elevation of β-catenin transcript and/or β-cateninprotein levels), or treatable via selective targeting of β-catenin.

“Treatment”, or “treating” as used herein, is defined as the applicationor administration of a therapeutic agent (e.g., a DsiRNA agent or vectoror transgene encoding same) to a patient, or application oradministration of a therapeutic agent to an isolated tissue or cell linefrom a patient, who has the disease or disorder, a symptom of disease ordisorder or a predisposition toward a disease or disorder, with thepurpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate,improve or affect the disease or disorder, the symptoms of the diseaseor disorder, or the predisposition toward disease.

In one aspect, the invention provides a method for preventing in asubject, a disease or disorder as described above (including, e.g.,prevention of the commencement of transforming events within a subjectvia inhibition of β-catenin expression), by administering to the subjecta therapeutic agent (e.g., a DsiRNA agent or vector or transgeneencoding same). Subjects at risk for the disease can be identified by,for example, one or a combination of diagnostic or prognostic assays asdescribed herein. Administration of a prophylactic agent can occur priorto the detection of, e.g., cancer in a subject, or the manifestation ofsymptoms characteristic of the disease or disorder, such that thedisease or disorder is prevented or, alternatively, delayed in itsprogression.

Another aspect of the invention pertains to methods of treating subjectstherapeutically, i.e., altering the onset of symptoms of the disease ordisorder. These methods can be performed in vitro (e.g., by culturingthe cell with the DsiRNA agent) or, alternatively, in vivo (e.g., byadministering the DsiRNA agent to a subject).

With regards to both prophylactic and therapeutic methods of treatment,such treatments may be specifically tailored or modified, based onknowledge obtained from the field of pharmacogenomics.“Pharmacogenomics”, as used herein, refers to the application ofgenomics technologies such as gene sequencing, statistical genetics, andgene expression analysis to drugs in clinical development and on themarket. More specifically, the term refers the study of how a patient'sgenes determine his or her response to a drug (e.g., a patient's “drugresponse phenotype”, or “drug response genotype”). Thus, another aspectof the invention provides methods for tailoring an individual'sprophylactic or therapeutic treatment with either the target β-cateninRNA molecules of the present invention or target β-catenin RNAmodulators according to that individual's drug response genotype.Pharmacogenomics allows a clinician or physician to target prophylacticor therapeutic treatments to patients who will most benefit from thetreatment and to avoid treatment of patients who will experience toxicdrug-related side effects.

Therapeutic agents can be tested in a selected animal model. Forexample, a DsiRNA agent (or expression vector or transgene encodingsame) as described herein can be used in an animal model to determinethe efficacy, toxicity, or side effects of treatment with said agent.Alternatively, an agent (e.g., a therapeutic agent) can be used in ananimal model to determine the mechanism of action of such an agent.

Models Useful to Evaluate the Down-Regulation of β-Catenin mRNA Levelsand Expression

Cell Culture

The DsiRNA agents of the invention can be tested for cleavage activityin vivo, for example, using the following procedure. The nucleotidesequences within the β-catenin cDNA targeted by the DsiRNA agents of theinvention are shown in the above β-catenin sequences.

The DsiRNA reagents of the invention can be tested in cell culture usingHeLa or other mammalian cells to determine the extent of β-catenin RNAand β-catenin protein inhibition. DsiRNA reagents (e.g., see FIG. 1, andabove-recited structures) are selected against the β-catenin target asdescribed herein. β-catenin RNA inhibition is measured after delivery ofthese reagents by a suitable transfection agent to, for example,cultured HeLa cells or other transformed or non-transformed mammaliancells in culture. Relative amounts of target β-catenin RNA are measuredversus actin or other appropriate control using real-time PCR monitoringof amplification (e.g., ABI 7700 TAQMAN®). A comparison is made to amixture of oligonucleotide sequences made to unrelated targets or to arandomized DsiRNA control with the same overall length and chemistry,but randomly substituted at each position, or simply to appropriatevehicle-treated or untreated controls. Primary and secondary leadreagents are chosen for the target and optimization performed. After anoptimal transfection agent concentration is chosen, a RNA time-course ofinhibition is performed with the lead DsiRNA molecule.

TAQMAN® (Real-Time PCR Monitoring of Amplification) and LightcyclerQuantification of mRNA

Total RNA is prepared from cells following DsiRNA delivery, for example,using Ambion Rnaqueous 4-PCR purification kit for large scaleextractions, or Promega SV96 for 96-well assays. For Taqman analysis,dual-labeled probes are synthesized with, for example, the reporter dyesFAM or VIC covalently linked at the 5′-end and the quencher dye TAMARAconjugated to the 3′-end. PCR amplifications are performed on, forexample, an ABI PRISM 7700 Sequence detector using 50 uL reactionsconsisting of 10 uL total RNA, 100 nM forward primer, 100 mM reverseprimer, 100 nM probe, 1× TaqMan PCR reaction buffer (PE-AppliedBiosystems), 5.5 mM MgCl2, 100 uM each dATP, dCTP, dGTP and dTTP, 0.2 URNase Inhibitor (Promega), 0.025 U AmpliTaq Gold (PE-Applied Biosystems)and 0.2 U M-MLV Reverse Transcriptase (Promega). The thermal cyclingconditions can consist of 30 minutes at 48° C., 10 minutes at 95° C.,followed by 40 cycles of 15 seconds at 95° C. and 1 minute at 60° C.Quantitation of target β-catenin mRNA level is determined relative tostandards generated from serially diluted total cellular RNA (300, 100,30, 10 ng/r×n) and normalizing to, for example, 36B4 mRNA in eitherparallel or same tube TaqMan reactions.

Western Blotting

Cellular protein extracts can be prepared using a standard micropreparation technique (for example using RIPA buffer). Cellular proteinextracts are run on 4-12% Tris-Glycine polyacrylamide gel andtransferred onto membranes. Non-specific binding can be blocked byincubation, for example, with 5% non-fat milk for 1 hour followed byprimary antibody for 16 hours at 4° C. Following washes, the secondaryantibody is applied, for example (1:10,000 dilution) for 1 hour at roomtemperature and the signal detected on a VersaDoc imaging system

In several cell culture systems, cationic lipids have been shown toenhance the bioavailability of oligonucleotides to cells in culture(Bennet, et al., 1992, Mol. Pharmacology, 41, 1023-1033). In oneembodiment, DsiRNA molecules of the invention are complexed withcationic lipids for cell culture experiments. DsiRNA and cationic lipidmixtures are prepared in serum-free OptimMEM (InVitrogen) immediatelyprior to addition to the cells. OptiMEM is warmed to room temperature(about 20-25° C.) and cationic lipid is added to the final desiredconcentration. DsiRNA molecules are added to OptiMEM to the desiredconcentration and the solution is added to the diluted DsiRNA andincubated for 15 minutes at room temperature. In dose responseexperiments, the RNA complex is serially diluted into OptiMEM prior toaddition of the cationic lipid.

Animal Models

Evaluating the efficacy of anti-β-catenin DsiRNA agents in animal modelsis performed as follows. Animal models of cancer and/or proliferativediseases, conditions, or disorders as are known in the art can be usedfor evaluation of the efficacy, potency, toxicity, etc. ofanti-β-catenin DsiRNAs. Suitable animal models of proliferative diseaseinclude, e.g., transgenic rodents (e.g., mice, rats) bearing gain offunction proto-oncogenes (e.g., Myc, Src) and/or loss of function oftumour suppressor proteins (e.g., p53, Rb) or rodents that have beenexposed to radiation or chemical mutagens that induce DNA changes thatfacilitate neoplastic transformation. Many such animal models arecommercially available, for example, from The Jackson Laboratory, BarHarbor, Me., USA. These animal models may be used as a source cells ortissue for assays of the compositions of the invention. Such models canalso be used or adapted for use for pre-clinical evaluation of theefficacy of DsiRNA compositions of the invention in modulating β-cateningene expression toward therapeutic use.

As in cell culture models, the most β-catenin relevant mouse tumorxenografts are those derived from cancer cells that express β-cateninproteins, such as SW480 or HCT116 colon cancer cells. Xenograft modelsof colon cancer relevant to study of the anti-tumor effect of modulatingβ-catenin have been described by various groups. A xenograft animalmodel useful according to the invention is described in Verma et al.2003, Clinical Cancer Research 9: 1291-1300. Use of these models hasdemonstrated that inhibition of β-catenin expression by anti-β-cateninagents causes inhibition of tumor growth in animals.

Such models can be used in evaluating the efficacy of DsiRNA moleculesof the invention to inhibit β-catenin levels, expression, tumor/cancerformation, growth, spread, development of other β-catenin-associatedphenotypes, diseases or disorders, etc. These models and others cansimilarly be used to evaluate the safety/toxicity and efficacy of DsiRNAmolecules of the invention in a pre-clinical setting.

Examples of animal model systems useful for evaluation of theβ-catenin-targeting DsiRNAs of the invention include wild-type mice, andorthotopic or subcutaneous SW480 or HCT116 xenograft tumor model mice.In an exemplary in vivo experiment, DsiRNAs of the invention are tailvein injected into such mouse models at doses ranging from 1 to 10 mg/kgor, alternatively, repeated doses are administered at single-dose IC₅₀levels, and organs (e.g., prostate, liver, kidney, lung, pancreas,colon, skin, spleen, bone marrow, lymph nodes, mammary fat pad, etc.)are harvested 24 hours after administration of the final dose. Suchorgans are then evaluated for mouse and/or human β-catenin levels,depending upon the model used. Duration of action can also be examinedat, e.g., 1, 4, 7, 14, 21 or more days after final DsiRNAadministration.

The practice of the present invention employs, unless otherwiseindicated, conventional techniques of chemistry, molecular biology,microbiology, recombinant DNA, genetics, immunology, cell biology, cellculture and transgenic biology, which are within the skill of the art.See, e.g., Maniatis et al., 1982, Molecular Cloning (Cold Spring HarborLaboratory Press, Cold Spring Harbor, N.Y.); Sambrook et al., 1989,Molecular Cloning, 2nd Ed. (Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y.); Sambrook and Russell, 2001, Molecular Cloning, 3rdEd. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.);Ausubel et al., 1992), Current Protocols in Molecular Biology (JohnWiley & Sons, including periodic updates); Glover, 1985, DNA Cloning(IRL Press, Oxford); Anand, 1992; Guthrie and Fink, 1991; Harlow andLane, 1988, Antibodies, (Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y.); Jakoby and Pastan, 1979; Nucleic AcidHybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription AndTranslation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of AnimalCells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells AndEnzymes (IRL Press, 1986); B. Perbal, A Practical Guide To MolecularCloning (1984); the treatise, Methods In Enzymology (Academic Press,Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller andM. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods InEnzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical MethodsIn Cell And Molecular Biology (Mayer and Walker, eds., Academic Press,London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M.Weir and C. C. Blackwell, eds., 1986); Riott, Essential Immunology, 6thEdition, Blackwell Scientific Publications, Oxford, 1988; Hogan et al.,Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press,Cold Spring Harbor, N. Y., 1986); Westerfield, M., The zebrafish book. Aguide for the laboratory use of zebrafish (Danio rerio), (4th Ed., Univ.of Oregon Press, Eugene, 2000).

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the present invention, suitable methods andmaterials are described below. All publications, patent applications,patents, and other references mentioned herein are incorporated byreference in their entirety. In case of conflict, the presentspecification, including definitions, will control. In addition, thematerials, methods, and examples are illustrative only and not intendedto be limiting.

EXAMPLES

The present invention is described by reference to the followingExamples, which are offered by way of illustration and are not intendedto limit the invention in any manner. Standard techniques well known inthe art or the techniques specifically described below were utilized.

Anti-β-Catenin DsiRNAs

Anti-β-catenin DsiRNA agents were provided as follows.

Example 1 Preparation and Assessment of Double-Stranded RNAOligonucleotides

Oligonucleotide Synthesis and Purification

DsiRNA molecules according to the invention target sites on humanβ-catenin sequences or mouse β-catenin sequences (such DsiRNAs aretermed “common” DsiRNAs). The sequence of one strand of each DsiRNAmolecule was complementary to the target β-catenin site sequencesdescribed above. The DsiRNA molecules were chemically synthesized usingmethods described herein. Generally, DsiRNA constructs were synthesizedusing solid phase oligonucleotide synthesis methods as described for19-23mer siRNAs (see for example Usman et al., U.S. Pat. Nos. 5,804,683;5,831,071; 5,998,203; 6,117,657; 6,353,098; 6,362,323; 6,437,117;6,469,158; Scaringe et al., U.S. Pat. Nos. 6,111,086; 6,008,400;6,111,086).

Individual RNA strands were synthesized and HPLC purified according tostandard methods (Integrated DNA Technologies, Coralville, Iowa). Forexample, RNA oligonucleotides were synthesized using solid phasephosphoramidite chemistry, deprotected and desalted on NAP-5 columns(Amersham Pharmacia Biotech, Piscataway, N.J.) using standard techniques(Damha and Olgivie, 1993, Methods Mol Biol 20: 81-114; Wincott et al.,1995, Nucleic Acids Res 23: 2677-84). The oligomers were purified usingion-exchange high performance liquid chromatography (IE-HPLC) on anAmersham Source 15Q column (1.0 cm×25 cm; Amersham Pharmacia Biotech,Piscataway, N.J.) using a 15 min step-linear gradient. The gradientvaries from 90:10 Buffers A:B to 52:48 Buffers A:B, where Buffer A is100 mM Tris pH 8.5 and Buffer B is 100 mM Tris pH 8.5, 1 M NaCl. Sampleswere monitored at 260 nm and peaks corresponding to the full-lengtholigonucleotide species are collected, pooled, desalted on NAP-5columns, and lyophilized.

The purity of each oligomer was determined by capillary electrophoresis(CE) on a Beckman PACE 5000 (Beckman Coulter, Inc., Fullerton, Calif.).The CE capillaries had a 100 μm inner diameter and contains ssDNA 100RGel (Beckman-Coulter). Typically, about 0.6 nmole of oligonucleotide wasinjected into a capillary, run in an electric field of 444 V/cm anddetected by UV absorbance at 260 nm. Denaturing Tris-Borate-7 M-urearunning buffer was purchased from Beckman-Coulter. Oligoribonucleotideswere obtained that are at least 90% pure as assessed by CE for use inexperiments described below. Compound identity was verified bymatrix-assisted laser desorption ionization time-of-flight (MALDI-TOF)mass spectroscopy on a Voyager DE™ Biospectometry Work Station (AppliedBiosystems, Foster City, Calif.) following the manufacturer'srecommended protocol. Relative molecular masses of all oligomers wereobtained, often within 0.2% of expected molecular mass.

Preparation of Duplexes

Single-stranded RNA (ssRNA) oligomers were resuspended, e.g., at 100 μMconcentration in duplex buffer consisting of 100 mM potassium acetate,30 mM HEPES, pH 7.5. Complementary sense and antisense strands weremixed in equal molar amounts to yield a final solution of, e.g., 50 μMduplex. Samples were heated to 100° C. for 5′ in RNA buffer (IDT) andallowed to cool to room temperature before use. Double-stranded RNA(dsRNA) oligomers were stored at −20° C. Single-stranded RNA oligomerswere stored lyophilized or in nuclease-free water at −80° C.

Nomenclature

For consistency, the following nomenclature has been employed in theinstant specification. Names given to duplexes indicate the length ofthe oligomers and the presence or absence of overhangs. A “25/27” is anasymmetric duplex having a 25 base sense strand and a 27 base antisensestrand with a 2-base 3′-overhang. A “27/25” is an asymmetric duplexhaving a 27 base sense strand and a 25 base antisense strand.

Cell Culture and RNA Transfection

HeLa cells were obtained from ATCC and maintained in DMEM (HyClone)supplemented with 10% fetal bovine serum (HyClone) at 37° C. under 5%CO₂. Hepa 1-6 cells were obtained from ATCC and maintained in DMEM(HyClone) supplemented with 10% fetal bovine serum (HyClone) at 37° C.under 5% CO₂. For RNA transfections, cells were transfected with DsiRNAsas indicated at a final concentration of 1 nM or 0.1 nM usingLipofectamine™ RNAiMAX (Invitrogen) and following manufacturer'sinstructions. Briefly, an aliquot of stock solution of each DsiRNA wasmixed with Opti-MEM I (Invitrogen) to reach a volume of 87.5 uL;Lipofectamine™ RNAiMAX was diluted in OptiMEM to 87.5 uL. The resulting150 μL mix was added at 50 uL per well into triplicate individual wellsof 96 well plates and incubated for 20 min at RT to allowDsiRNA:Lipofectamine™ RNAiMAX complexes to form. Meanwhile, HeLa cellswere trypsinized and resuspended in medium. Finally, 100 uL of the cellsuspension were added to each well (final volume 150 uL) and plates wereplaced into the incubator for 24 hours.

Assessment of β-Catenin Inhibition

β-catenin target gene knockdown was determined by qRT-PCR, with valuesnormalized to HPRT and SFRS9 housekeeping genes, and to transfectionswith control DsiRNAs.

RNA Isolation and Analysis

Media was aspirated, and total RNA was extracted using the SV96 kit(Promega). Approximately 100 ng of total RNA was reverse-transcribedusing SuperscriptII, Oligo dT, and random hexamers followingmanufacturer's instructions. Typically, one-sixth of the resulting cDNAwas analyzed by qPCR using primers and probes specific for both theβ-catenin gene and for the human genes HPRT-1 and SFRS9. An ABI 7700 wasused for the amplification reactions. Each sample was tested intriplicate. Relative β-catenin RNA levels were normalized to HPRT1 andSFRS9 RNA levels and compared with RNA levels obtained in controlsamples treated with the control DsiRNAs.

Example 2 DsiRNA Inhibition of β-Catenin—Primary Screen

DsiRNA molecules targeting β-catenin were designed and synthesized asdescribed above and tested in HeLa cells for inhibition. Fortransfection, annealed DsiRNAs were mixed with the transfection reagent(Lipofectamine™ RNAiMAX, Invitrogen) in a volume of 50 μl/well andincubated for 20 minutes at room temperature. The HeLa (human) or Hepa1-6 (mouse) cells were trypsinized, resuspended in media, and added towells (100 uL per well) to give a final DsiRNA concentration of 1 nM ina volume of 150 μl. Each DsiRNA transfection mixture was added to 3wells for triplicate DsiRNA treatments. Cells were incubated at 37° C.for 24 hours in the continued presence of the DsiRNA transfectionmixture. At 24 hours, RNA was prepared from each well of treated cells.The supernatants with the transfection mixtures were first removed anddiscarded, then the cells were lysed and RNA prepared from each well.Target β-catenin RNA levels following treatment were evaluated byqRT-PCR for the β-catenin target gene, with values normalized to thoseobtained for controls. Triplicate data was averaged and the % errordetermined for each treatment. Normalized data were graphed and thereduction of target mRNA by active DsiRNAs in comparison to controls wasdetermined.

β-catenin targeting DsiRNAs of Tables 2-4 above were examined forβ-catenin inhibitory efficacy.

488 asymmetric DsiRNAs (tested DsiRNAs possessed a 25/27mer structure)were prepared and tested for β-catenin inhibitory efficacy in human HeLaand mouse Hepa 1-6 cells incubated in the presence of such DsiRNAs at aconcentration of 1 nM. Sequences and structures of all 488 testedasymmetric DsiRNAs are shown above in Tables 2-4, with underlinednucleotide residues indicating 2′-O-methyl modified residues;ribonucleotide residues are shown as UPPER CASE, whiledeoxyribonucleotide residues are shown as lower case.

Assay of these 488 β-catenin targeting DsiRNAs in human HeLa and mouseHepa 1-6 cells at 1 nM revealed the following β-catenin inhibitoryefficacies, presented in Tables 14-17. β-catenin levels were determinedusing qPCR assays positioned at locations within the β-catenintranscript (for human HeLa cell experiments, paired qPCR assays wereperformed for the human β-catenin 1297-1397 amplicon (Yakima Yellow) andthe human β-catenin 3506-3659 amplicon (FAM); for mouse Hepa 1-6 cellexperiments, paired qPCR assays were performed for the mouse β-catenin1232-1394 amplicon (FAM) and mouse β-catenin 2848-2930 amplicon (MAX);values presented in Tables 14-17 below are averaged values of thesepaired qPCR assays).

TABLE 14 β-Catenin Inhibitory Efficacy of DsiRNAs Assayed at 1 nM inHuman HeLa Cells Tested DsiRNA (Target Mouse β-catenin % Remaining β-Location in human β-catenin Target Location catenin mRNA ± transcriptvariant 1) (in NM_007614.2) % Error βc-240    5 ± 21.1 βc-244  3.8 ± 2.8βc-253  5.5 ± 1.7 βc-259   3.6 ± 11.3 βc-264  4.1 ± 9.5 βc-496  3.9 ±5.3 βc-516  4.4 ± 6.5 βc-522   8.6 ± 11.7 βc-524   6.7 ± 10.9 βc-540 5.3 ± 4.7 βc-582  3.8 ± 6.8 βc-686  2.1 ± 2.8 βc-692  2.2 ± 4.9 βc-697 3.9 ± 4.4 βc-707  4.3 ± 6.9 βc-753  5.2 ± 6.1 βc-870   3 ± 7.7 βc-889 2.9 ± 4.9 βc-1060  4 ± 3.6 βc-1065 7.7 ± 4.6 βc-1070 4.6 ± 2.1 βc-10767.1 ± 5.1 βc-1154  3.2 ± 10.7 βc-1180 4.8 ± 4  βc-1185 7.6 ± 9  βc-12608.7 ± 5.5 βc-1294 16.7 ± 6.2  βc-1412  6.4 ± 12.1 βc-1418  6.1 ± 10.4βc-1423 153.2 ± 5.2  βc-1520  8.5 ± 10.4 βc-1561 7.5 ± 5.8 βc-1571  5 ±3.4 βc-1579 5.9 ± 4.4 βc-1620 3.7 ± 4.1 βc-1816 4.9 ± 3.4 βc-1987 8.2 ±3.1 βc-1989 10.6 ± 4.9  βc-2111 12.1 ± 2.2  βc-2282 6.2 ± 5.6 βc-2624 12 ± 46.4 βc-2647 103.1 ± 4.4  βc-2770 121.5 ± 5.1  βc-2848 107.6 ±4.3  βc-2874 44.2 ± 3.3  βc-2909 100.8 ± 4.9  βc-3074 81.1 ± 5.5 βc-3197  8.4 ± 11.8 βc-3203 5.1 ± 8.3 βc-3273 67.6 ± 5.1  βc-3333 5.5 ±8.4 βc-3349 6.5 ± 9.7 βc-3354  5.6 ± 11.1 βc-3371 15.5 ± 16.8 βc-337621.5 ± 9.1  βc-3411 8.7 ± 7.5 βc-3426  5.9 ± N/A βc-3431 3.4 ± 7 βc-3437 6.5 ± 5  βc-3458 9.2 ± 2.3 βc-3468 7.1 ± 4.5 βc-3488 7.5 ± 4.3βc-3496 9.2 ± 5.1 βc-3552 25.9 ± 4   βc-3600 8.2 ± 7.4 βc-3605 6.2 ± 5.8βc-3615 5.4 ± 3.9 βc-3674 5.8 ± 4.1 βc-3686 6.4 ± 4  βc-3691 4.6 ± 3 βc-3700 8.7 ± 4  βc-3707 7.2 ± 4.6 βc-284  228  4.9 ± 14.1 βc-285  2296.7 ± 3.2 βc-286  230 6.7 ± 6.3 βc-287  231 7.8 ± 7.4 βc-288  232 5.3 ±4  βc-289  233  5.9 ± 13.9 βc-290  234 6.7 ± 3.2 βc-291  235 6.1 ± 6.2βc-312  256 13.1 ± 3.1  βc-313  257  14 ± 5.3 βc-314  258 17.7 ± 8.9 βc-315  259 40.2 ± 5   βc-316  260 23.2 ± 3.6  βc-317  261 12.4 ± 2.7 βc-318  262  18 ± 4.7 βc-389  333 51.5 ± 3.8  βc-390  334 10.9 ± 4.8 βc-391  335 7.6 ± 9.4 βc-392  336 15.7 ± 3.9  βc-393  337 7.8 ± 2.5βc-600  544 63.1 ± 4.6  βc-601  545 59.2 ± 3.7  βc-602  546 31.8 ± 2.5 βc-603  547 14.9 ± 9   βc-604  548 21.9 ± 4   βc-605  549 10.1 ± 1.4 βc-638  582 9.9 ± 2.7 βc-639  583 4.6 ± 7.8 βc-640  584 100.3 ± 11.7 βc-641  585 10.4 ± 2.3  βc-642  586 13.5 ± 4.2  βc-643  587 41.8 ± 5.2 βc-644  588 32.5 ± N/A βc-645  589 10.5 ± 2.5  βc-665  609 8.8 ± 5.6βc-666  610 6.7 ± 2  βc-667  611 8.9 ± 3.2 βc-731  675 7.3 ± 6.9 βc-732 676 53.9 ± 6.1  βc-809  753 8.6 ± 1.7 βc-810  754 12.2 ± 8.3  βc-830 774 5.8 ± 3  βc-831  775 10.5 ± 2.6  βc-893  837 3.6 ± 6.2 βc-894  8383.5 ± 2  βc-895  839 3.6 ± 2.1 βc-896  840  4.3 ± 10.3 βc-897  841 4.9 ±8.8 βc-898  842 7.9 ± 9.3 βc-899  843 6.8 ± 6.3 βc-900  844 3.9 ± 2.8βc-977  921 10.4 ± 5   βc-978  922 28.1 ± 2.4  βc-1091 1035 8.8 ± 7.7βc-1092 1036 25.4 ± 3.2  βc-1093 1037 11.9 ± 1.6  βc-1094 1038 10.1 ±3.4  βc-1095 1039 7.9 ± 4.5 βc-1301 1245 12.4 ± 5.2  βc-1302 1246 14.2 ±5.8  βc-1303 1247  10 ± 4.8 βc-1304 1248 8.4 ± 3.8 βc-1305 1249 6.8 ± 8 βc-1306 1250 6.1 ± 9.5 βc-1307 1251 5.7 ± 3.6 βc-1308 1252 5.7 ± 5.1βc-1309 1253 6.9 ± 3.7 βc-1310 1254 4.5 ± 3.2 βc-1311 1255 5.3 ± 4.5βc-1312 1256 9.8 ± 1.2 βc-1313 1257 5.7 ± 6.3 βc-1314 1258 5.2 ± 5.9βc-1430 1374 20.6 ± 7.8  βc-1431 1375 17.5 ± 4   βc-1526 1470 35.8 ±4.5  βc-1527 1471 40.7 ± 10.2 βc-1528 1472 22.8 ± 4.2  βc-1529 1473 21.8± 7.6  βc-1530 1474 17.3 ± 11.4 βc-1531 1475 62.1 ± 8.3  βc-1532 147637.8 ± 19.1 βc-1533 1477 16.3 ± 6.2  βc-1534 1478 80.7 ± 17  βc-15351479 27.1 ± 6.7  βc-1536 1480 13.3 ± 4.3  βc-1537 1481 12.9 ± 4.1 βc-1538 1482 11.9 ± 3   βc-1539 1483 10.9 ± 8.9  βc-1540 1484  5 ± 6.1βc-1541 1485 4.2 ± 9.8 βc-1542 1486 9.8 ± 2.1 βc-1543 1487 5.7 ± 6.4βc-1544 1488 4.8 ± 5.8 βc-1545 1489  4 ± 5.5 βc-1565 1509 6.5 ± 8.5βc-1566 1510 3.6 ± 6.6 βc-1567 1511  3.5 ± 17.3 βc-1568 1512 3.2 ± 8.4βc-1569 1513 2.7 ± 13  βc-1652 1596  5.1 ± 14.3 βc-1653 1597  5.8 ± 13.2βc-1654 1598 26.4 ± 2.6  βc-1655 1599 17.8 ± 3.9  βc-1656 1600 18.7 ±7.4  βc-1657 1601 35.4 ± 7.7  βc-1658 1602  10 ± 4.4 βc-1659 1603 10.2 ±10.5 βc-1660 1604 31.5 ± 2.4  βc-1661 1605 14.3 ± 5   βc-1662 1606  5 ±4.4 βc-1663 1607 21.7 ± 4.7  βc-1664 1608  67 ± 8.6 βc-1665 1609 16.6 ±14.3 βc-1666 1610 11.3 ± 6.3  βc-1667 1611  6.2 ± 19.5 βc-1668 1612 33.5± 6.3  βc-1669 1613 26.1 ± 3   βc-1670 1614 27.7 ± 3.8  βc-1671 1615 9.3± 2.2 βc-1672 1616 23.4 ± 5.4  βc-1673 1617 21.7 ± 9.1  βc-1674 161815.1 ± 4   βc-1675 1619  31 ± 5.9 βc-1676 1620 12.1 ± 10.6 βc-1677 162123.2 ± 15.4 βc-1678 1622  6.9 ± 10.8 βc-1679 1623  13 ± 9.6 βc-1680 1624  5 ± 10.6 βc-1681 1625  4 ± 6.5 βc-1682 1626 2.8 ± 6.2 βc-1683 1627 2.8± 5.7 βc-1684 1628 7.4 ± 2.7 βc-1685 1629 11.3 ± 6.3  βc-1686 1630 15.6± 4.3  βc-1687 1631 7.6 ± 4.4 βc-1688 1632 17.8 ± 5   βc-1689 1633 23.7± 7.5  βc-1690 1634 8.1 ± 3  βc-1691 1635 8.5 ± 4.6 βc-1692 1636 33.9 ±28.1 βc-1693 1637 45.6 ± 4.8  βc-1694 1638 12.7 ± 3.4  βc-1695 1639 9.4± 5.6 βc-1787 1731 46.4 ± 6.2  βc-1788 1732  28 ± 3.8 βc-1789 1733 28.6± 6.5  βc-1790 1734 65.2 ± 5.1  βc-1791 1735 13.6 ± 4   βc-1792 173610.2 ± 16.3 βc-1793 1737 18.7 ± 7.7  βc-1794 1738 36.7 ± 5   βc-17951739 31.2 ± 9.1  βc-1796 1740 8.5 ± 5  βc-1797 1741 23.8 ± 4.1  βc-17981742 49.2 ± 3.1  βc-1799 1743 58 ± 3  βc-1800 1744 26.3 ± 5.7  βc-18201764 3.8 ± 7.8 βc-1821 1765  4.8 ± 13.4 βc-2072 2016 7.6 ± 14  βc-20732017 12.4 ± 8.5  βc-2074 2018 10.8 ± 6.2  βc-2075 2019 7.6 ± 1.9 βc-20762020 13.5 ± 6.5  βc-2077 2021 12.1 ± 7   βc-2097 2041 3.9 ± 2.7 βc-20982042 6.2 ± 3.6 βc-2099 2043  6 ± 3.8 βc-2100 2044 11.4 ± 8.6  βc-21412085 8.3 ± 8.7 βc-2142 2086 17.9 ± 2.4  βc-2143 2087  6.2 ± 11.2 βc-21442088  4.4 ± 16.1 βc-2145 2089  8.8 ± 12.2 βc-2146 2090 9.4 ± 9.6 βc-21472091 10.5 ± 12.2 βc-2148 2092 6.5 ± 2.7 βc-2149 2093 16.3 ± 5.8  βc-21502094 10.7 ± 5.2  βc-2151 2095 5.7 ± 3.2 βc-2183 2127 38.1 ± 2.9  βc-21842128 41.5 ± 4.3  βc-2185 2129 83.7 ± 2.3  βc-2270 2214 23.8 ± 12.6βc-2271 2215 18.8 ± 9.6  βc-2272 2216 6.7 ± 3.5 βc-2273 2217 8.4 ± 5.5βc-2274 2218 6.2 ± 4.4 βc-2275 2219 7.2 ± 5.8 βc-2276 2220 7.1 ± 2.4βc-2277 2221 4.8 ± 2.8 βc-2345 2289 8.5 ± 2.5 βc-2346 2290  7 ± 4.5βc-2347 2291 6.8 ± 5.9 βc-2348 2292 12.3 ± 14.8 βc-2349 2293  6.2 ± 12.8βc-2350 2294  4.1 ± 11.7 βc-2351 2295 6.9 ± 9.1 βc-2352 2296 11.5 ± 13 βc-2353 2297 19.1 ± 4.7  βc-2354 2298 17.1 ± 3.6  βc-2355 2299 8.1 ± 6.5βc-2411 2355 6.6 ± 2.1 βc-2412 2356 8.1 ± 3.9 βc-2413 2357 10.1 ± 3.5 βc-2414 2358 9.8 ± 1  βc-2415 2359 10.9 ± 4.3  βc-2441 2385 9.5 ± 3 βc-2442 2386 5.2 ± 5  βc-2443 2387  8.8 ± 11.9 βc-2444 2388 10.2 ± 4  βc-2445 2389 5.3 ± 6.4 βc-2501 2445 74.5 ± 3.1  βc-2502 2446 95.4 ± 4.2 βc-2503 2447 116.5 ± 5    βc-2504 2448 108.9 ± 5.3  βc-2505 2449 98.7 ±5   βc-2506 2450 43.5 ± 2.7  βc-2507 2451 89.5 ± 1.9  βc-2508 2452 54.6± 7   βc-2509 2453 19.4 ± 10.5 βc-2510 2454 47.1 ± 3.5  βc-2511 245560.7 ± 4.9  βc-2512 2456 53.7 ± 9.7  βc-2513 2457  18 ± N/A βc-2514 24586.5 ± 4.9 βc-2515 2459 13.5 ± 3.7  βc-2516 2460 11.3 ± 3   βc-2517 24616.2 ± 3.5 βc-2518 2462 6.9 ± 4.8 βc-2519 2463 9.1 ± 2.8 βc-2520 2464 6.6± 4  βc-2521 2465 6.4 ± 3.9 βc-2522 2466 7.6 ± 5.6 βc-2523 2467 6.1 ±7.6 βc-2524 2468 5.5 ± 3  βc-2525 2469 3.6 ± 1.3 βc-2526 2470 4.9 ± 2.8βc-2527 2471  58 ± 9.2 βc-2528 2472 22.5 ± 5.3  βc-2529 2473 24.5 ± 9.5 βc-2530 2474 53.5 ± 1.3  βc-2531 2475 19.3 ± 9.1  βc-2532 2476 17.2 ±11.5 βc-2533 2477 21.5 ± 9.8  βc-2534 2478 77.4 ± 2.4  βc-2535 2479 55.4± 4.3  βc-2567 2511 77.9 ± 4.1  βc-2568 2512 51.2 ± 9.2  βc-2569 251338.2 ± 2.8  βc-2603 2547  11 ± 7.7 βc-2604 2548 9.7 ± 5.6 βc-2605 254929.1 ± 4.2  βc-2606 2550 23.4 ± 4.4  βc-2607 2551 10.6 ± 2.6  βc-26082552  16 ± 6.4 βc-2609 2553 23.3 ± 15.2 βc-2610 2554 16.2 ± 5.1  βc-26112555 3.8 ± 1.4 βc-2612 2556 2.2 ± 4.6 βc-2613 2557 8.4 ± 2.3 βc-26142558 4.9 ± 3.4 βc-2615 2559 6.7 ± 6.4 βc-2616 2560 8.4 ± 7.7 βc-26172561 6.2 ± 6.3 βc-2618 2562 6.6 ± 6.2 βc-2619 2563  6 ± 4.1 βc-2620 2564 5.9 ± 11.4 βc-2621 2565  9.5 ± 13.2 βc-2622 2566 7.3 ± 10  βc-2623 25677.2 ± 9.8 βc-2869 2765 86.5 ± 9.1  βc-2902 2798 67.7 ± 3.1  βc-2923 281976.5 ± 3.1  βc-2925 2821 88.6 ± 5.6  βc-2927 2823 79.9 ± 6.5  βc-29292825 71.1 ± 1.2  βc-2973 2867 49.8 ± 6.9  βc-2975 2869 46.3 ± 5.6 βc-2977 2871 43.2 ± 1.4  βc-2979 2873 59.3 ± 4.3  βc-2981 2875  47 ± 5.2βc-2983 2877 59.8 ± 1.9  βc-2985 2879 50.9 ± 3.1  βc-2987 2881 54.5 ±2.8  βc-2989 2883 50.7 ± 2.4  βc-3015 2909 72.2 ± 2.5  βc-3017 2911 56.9± 3.9  βc-3019 2913 62.5 ± 4.1  βc-3021 2915 59.5 ± 3.2  βc-3046 294077.4 ± 19.4 βc-3048 2942 45.3 ± 15.3 βc-3050 2944 60.2 ± 10.5 βc-30522946 58.5 ± 5.3  βc-3054 2948 84.7 ± 5.1  βc-3056 2950 64.8 ± 7.4 βc-3087 2981 58.7 ± 6.6  βc-3089 2983 47.4 ± 6   βc-3091 2985 52.6 ± 6  βc-3093 2987 45.7 ± 14.5 βc-3095 2989 49.7 ± 3.8  βc-3097 2991 72.3 ±13.4 βc-3099 2993 39.7 ± 3.4  βc-3101 2995 31.4 ± 13.3 βc-3103 2997 35.6± 9   βc-3105 2999  16 ± 7.7 βc-3107 3001 41.3 ± 33.6 βc-3109 3003  5.3± 35.8 βc-3111 3005 4.5 ± 7.6 βc-3113 3007 7.5 ± 9.8 βc-3115 3009  5.1 ±15.4 βc-3191 3084 10.2 ± 9.9  βc-3193 3086 9.3 ± 5.5 βc-3195 3088 4.4 ±3.1 βc-3387 3232 4.8 ± 7.8 βc-3389 3234 3.6 ± 6  βc-3391 3236 4.7 ± 7.2βc-3393 3238 2.7 ± 7.1 βc-3395 3240 4.9 ± 3.7 βc-3397 3242 4.8 ± 3.1βc-3399 3244 3.9 ± 9.3 βc-3401 3246 4.8 ± 9.8 βc-3500 3336 5.7 ± 3.4βc-3502 3338 8.3 ± 3.9 βc-3504 3340  7 ± 6.2 βc-3506 3342 9.7 ± 2.3βc-3508 3344 9.2 ± 2.9 βc-3509 3345 13.8 ± 4.2  βc-3510 3346 56.3 ± 5  βc-3512 3348 20.8 ± 4.6  βc-3514 3350 9.7 ± 3.3 βc-3516 3352 12.7 ± 7.4 βc-3518 3354 7.5 ± 5.7 βc-3520 3356 6.6 ± 2.6 βc-3522 3358 7.5 ± 7.1βc-3524 3360 10.5 ± 4.4  βc-3526 3362  9.4 ± N/A βc-3528 3364 8.2 ± 8.9βc-3530 3366 8.2 ± 9  βc-3532 3368 7.5 ± 5.4 βc-3534 3370  5.6 ± 11.9βc-3536 3372 5.7 ± 2.8 βc-3538 3374 7.5 ± 2.8 βc-3583 3420  10 ± 5.2βc-3585 3422 9.4 ± 7.8 βc-3587 3424 7 ± 5 βc-3589 3426 6.5 ± 5.6 βc-35913428 5.4 ± 6.6 βc-3593 3430 11.5 ± 5.7  βc-3633 3469 14.6 ± 3.9  βc-36353471 9.5 ± 3.6 βc-3637 3473 11.6 ± 5   βc-3639 3475 18.9 ± 10.1 βc-36413477 8.4 ± 5.4 βc-3643 3479 10.8 ± 5.6  βc-3645 3481 12.6 ± 3.2  βc-36473483 15.1 ± 2.7  βc-3649 3485 14.4 ± 3.1  βc-3651 3487  7.2 ± 11.1βc-3653 3489 6.3 ± 5.7 βc-3655 3491 10.9 ± 7.7  βc-3657 3493  7 ± 3.5βc-3659 3495 5.4 ± 8.4 βc-3708 3540  6.3 ± 11.3 βc-3710 3542  5.5 ± 11.8βc-3712 3544 4.8 ± 8.1 βc-3714 3546 7.4 ± 3.6 βc-3716 3548 20.2 ± 11.6The data shown in above Table 14 were also plotted graphically (seeFIGS. 2 and 3).

TABLE 15 100 Human β-Catenin-Targeting DsiRNAs (Rank Ordered byInhibition) Tested DsiRNA (Target Mouse β-catenin % Remaining β-Location in human β-catenin Target Location catenin mRNA ± transcriptvariant 1) (in NM_007614.2) % Error βc-686  2.1 ± 2.8 βc-692  2.2 ± 4.9βc-2612 2556 2.2 ± 4.6 βc-1569 1513 2.7 ± 13  βc-3393 3238 2.7 ± 7.1βc-1682 1626 2.8 ± 6.2 βc-1683 1627 2.8 ± 5.7 βc-889  2.9 ± 4.9 βc-870  3 ± 7.7 βc-1154  3.2 ± 10.7 βc-1568 1512 3.2 ± 8.4 βc-3431 3.4 ± 7 βc-894  838 3.5 ± 2  βc-1567 1511  3.5 ± 17.3 βc-259   3.6 ± 11.3βc-893  837 3.6 ± 6.2 βc-895  839 3.6 ± 2.1 βc-1566 1510 3.6 ± 6.6βc-2525 2469 3.6 ± 1.3 βc-3389 3234 3.6 ± 6  βc-1620 3.7 ± 4.1 βc-244 3.8 ± 2.8 βc-582  3.8 ± 6.8 βc-1820 1764 3.8 ± 7.8 βc-2611 2555 3.8 ±1.4 βc-496  3.9 ± 5.3 βc-697  3.9 ± 4.4 βc-900  844 3.9 ± 2.8 βc-20972041 3.9 ± 2.7 βc-3399 3244 3.9 ± 9.3 βc-1060  4 ± 3.6 βc-1545 1489  4 ±5.5 βc-1681 1625  4 ± 6.5 βc-264  4.1 ± 9.5 βc-2350 2294  4.1 ± 11.7βc-1541 1485 4.2 ± 9.8 βc-707  4.3 ± 6.9 βc-896  840  4.3 ± 10.3 βc-516 4.4 ± 6.5 βc-2144 2088  4.4 ± 16.1 βc-3195 3088 4.4 ± 3.1 βc-1310 12544.5 ± 3.2 βc-3111 3005 4.5 ± 7.6 βc-1070 4.6 ± 2.1 βc-3691 4.6 ± 3 βc-639  583 4.6 ± 7.8 βc-3391 3236 4.7 ± 7.2 βc-1180 4.8 ± 4  βc-15441488 4.8 ± 5.8 βc-1821 1765  4.8 ± 13.4 βc-2277 2221 4.8 ± 2.8 βc-33873232 4.8 ± 7.8 βc-3397 3242 4.8 ± 3.1 βc-3401 3246 4.8 ± 9.8 βc-37123544 4.8 ± 8.1 βc-1816 4.9 ± 3.4 βc-284  228  4.9 ± 14.1 βc-897  841 4.9± 8.8 βc-2526 2470 4.9 ± 2.8 βc-2614 2558 4.9 ± 3.4 βc-3395 3240 4.9 ±3.7 βc-240    5 ± 21.1 βc-1571  5 ± 3.4 βc-1540 1484  5 ± 6.1 βc-16621606  5 ± 4.4 βc-1680 1624   5 ± 10.6 βc-3203 5.1 ± 8.3 βc-1652 1596 5.1 ± 14.3 βc-3115 3009  5.1 ± 15.4 βc-753  5.2 ± 6.1 βc-1314 1258 5.2± 5.9 βc-2442 2386 5.2 ± 5  βc-540  5.3 ± 4.7 βc-288  232 5.3 ± 4 βc-1311 1255 5.3 ± 4.5 βc-2445 2389 5.3 ± 6.4 βc-3109 3003  5.3 ± 35.8βc-3615 5.4 ± 3.9 βc-3591 3428 5.4 ± 6.6 βc-3659 3495 5.4 ± 8.4 βc-253 5.5 ± 1.7 βc-3333 5.5 ± 8.4 βc-2524 2468 5.5 ± 3  βc-3710 3542  5.5 ±11.8 βc-3354  5.6 ± 11.1 βc-3534 3370  5.6 ± 11.9 βc-1307 1251 5.7 ± 3.6βc-1308 1252 5.7 ± 5.1 βc-1313 1257 5.7 ± 6.3 βc-1543 1487 5.7 ± 6.4βc-2151 2095 5.7 ± 3.2 βc-3500 3336 5.7 ± 3.4 βc-3536 3372 5.7 ± 2.8βc-3674 5.8 ± 4.1 βc-830  774 5.8 ± 3  βc-1653 1597  5.8 ± 13.2 βc-15795.9 ± 4.4 βc-3426  5.9 ± N/A βc-289  233  5.9 ± 13.9 βc-2620 2564  5.9 ±11.4

TABLE 16 β-Catenin Inhibitory Efficacy of DsiRNAs at 1 nM in Mouse Hepa1-6 Cells Tested DsiRNA/Mouse β- Tested DsiRNA/Human % Remaining cateninTarget Location β-catenin transcript β-catenin (in NM_007614.2) variant1 Target Location mRNA ± % Error 228 βc-284   32 ± 23 229 βc-285   27.2± 10.7 230 βc-286   24.5 ± 14.5 231 βc-287   35.9 ± 19.7 232 βc-288 43.1 ± 12  233 βc-289  34.8 ± 7  234 βc-290   41.6 ± 15.9 235 βc-291  48.4 ± 25.1 256 βc-312  109.7 ± N/A 257 βc-313  68.5 ± 6.7 258 βc-314 93.4 ± 8.6 259 βc-315  69.4 ± 3.4 260 βc-316   101 ± 3.4 261 βc-317  67.6 ± 10.5 262 βc-318   88 ± 11 333 βc-389  107.4 ± 6.7  334 βc-390  99.2 ± 14.4 335 βc-391  68.5 ± 7.4 336 βc-392  77.4 ± 5.5 337 βc-393 53.8 ± 6.8 544 βc-600  65.9 ± 7.7 545 βc-601  54.1 ± 6.3 546 βc-602  44.1 ± 12.9 547 βc-603  37.3 ± 7.3 548 βc-604    83 ± 14.5 549 βc-605 44.6 ± 9.2 582 βc-638  22.6 ± 5.9 583 βc-639   12.2 ± 15.4 584 βc-640 102.1 ± 8.4  585 βc-641  24.4 ± 9  586 βc-642   32.3 ± 29.7 587 βc-643  62.1 ± 10.6 588 βc-644  56.1 ± 6.8 589 βc-645  18.4 ± 6.2 609 βc-665 23.7 ± 7  610 βc-666  23.3 ± 7.2 611 βc-667  18.5 ± 6.1 675 βc-731  34.4 ± 13.7 676 βc-732  127.2 ± 3.4  753 βc-809   56 ± 7.6 754 βc-810 82.4 ± 5.4 774 βc-830  26.5 ± 6.2 775 βc-831  16.1 ± 7.3 837 βc-893  9.2 ± 9.5 838 βc-894  10.5 ± 9.4 839 βc-895   12.5 ± 16.7 840 βc-896  14.1 ± 19.2 841 βc-897  25.7 ± 10  842 βc-898   20.1 ± 19.7 843 βc-899  21.5 ± 13.6 844 βc-900  13.8 ± 9.7 921 βc-977  44.1 ± 12  922 βc-978 58.4 ± 43  1035 βc-1091  97.2 ± 10.9 1036 βc-1092 111.4 ± 10.5 1037βc-1093  122 ± 13.4 1038 βc-1094 54.1 ± 3.6 1039 βc-1095 53.2 ± 6.9 1245βc-1301 25.5 ± 3.9 1246 βc-1302 28.7 ± 5.2 1247 βc-1303 33.5 ± 3.2 1248βc-1304  31.2 ± 11.2 1249 βc-1305  22.1 ± 17.3 1250 βc-1306  23.5 ± 15.81251 βc-1307  15.7 ± 13.3 1252 βc-1308  16.4 ± 13.6 1253 βc-1309 13.5 ±4.8 1254 βc-1310 14.9 ± 8.1 1255 βc-1311  17.6 ± 12.9 1256 βc-1312 33.4± 6.4 1257 βc-1313  16.8 ± 11.1 1258 βc-1314 18.4 ± 4.8 1374 βc-143057.1 ± 4.4 1375 βc-1431 42.3 ± 7.5 1470 βc-1526 64.7 ± 8.8 1471 βc-1527 36.8 ± 12.4 1472 βc-1528  31.6 ± 18.8 1473 βc-1529  25.7 ± 13.3 1474βc-1530  30.3 ± 13.7 1475 βc-1531 56.3 ± 2.2 1476 βc-1532 31.5 ± 5  1477βc-1533 21.2 ± 2.6 1478 βc-1534 77.6 ± 5.7 1479 βc-1535 34.3 ± 8.3 1480βc-1536 14.7 ± 3.6 1481 βc-1537 14.1 ± 9  1482 βc-1538 21.1 ± 4  1483βc-1539 19.5 ± 8.4 1484 βc-1540  11.7 ± N/A 1485 βc-1541  7.3 ± 7.1 1486βc-1542 14.7 ± 7.8 1487 βc-1543 11.7 ± 5.9 1488 βc-1544  8.2 ± 8.2 1489βc-1545  7.4 ± 10.1 1509 βc-1565 21.2 ± 9.1 1510 βc-1566    9 ± 18.11511 βc-1567  10.7 ± 16.4 1512 βc-1568  8.3 ± 14.9 1513 βc-1569    7 ±12.8 1596 βc-1652  10.1 ± 13.9 1597 βc-1653  23.4 ± 32.9 1598 βc-1654 67.3 ± 27.6 1599 βc-1655  38.5 ± 12.3 1600 βc-1656  26.3 ± 14.2 1601βc-1657  38 ± 8.9 1602 βc-1658 12.7 ± 6.8 1603 βc-1659 25.9 ± 7.6 1604βc-1660  56.5 ± 12.8 1605 βc-1661  27.3 ± 13.4 1606 βc-1662  12.3 ± 18.11607 βc-1663  46.1 ± 27.2 1608 βc-1664  71.2 ± 17.1 1609 βc-1665  25.8 ±11.4 1610 βc-1666 15.7 ± 4.7 1611 βc-1667 20.8 ± 4  1612 βc-1668   61 ±29.3 1613 βc-1669  46.7 ± 11.4 1614 βc-1670 44.9 ± 1.6 1615 βc-1671 30.7 ± 20.8 1616 βc-1672  52.8 ± 12.9 1617 βc-1673  56.7 ± 11.2 1618βc-1674 28 ± 7 1619 βc-1675  37.5 ± 11.1 1620 βc-1676  16 ± 7.2 1621βc-1677 40.8 ± 3.1 1622 βc-1678  14.1 ± 10.8 1623 βc-1679  26.7 ± 14.41624 βc-1680 14.8 ± 7.4 1625 βc-1681 10.7 ± 5  1626 βc-1682  10.9 ± 21.31627 βc-1683  7.3 ± 11 1628 βc-1684 11.1 ± 3.3 1629 βc-1685 21.5 ± 18 1630 βc-1686 23.4 ± 4.7 1631 βc-1687  15.2 ± 16.6 1632 βc-1688 21.6 ±4.9 1633 βc-1689  33.6 ± 34.5 1634 βc-1690  24.1 ± 10.9 1635 βc-1691 33.7 ± 10.9 1636 βc-1692 42.5 ± 3.9 1637 βc-1693 83.4 ± 14  1638βc-1694 19.8 ± 2.6 1639 βc-1695  15.9 ± 10.9 1731 βc-1787 65.2 ± 8.71732 βc-1788  33.4 ± 25.5 1733 βc-1789  35.4 ± 16.3 1734 βc-1790  46.6 ±16.4 1735 βc-1791  15 ± 9.5 1736 βc-1792 12.8 ± 4.4 1737 βc-1793 15.8 ±8.3 1738 βc-1794 28.4 ± 7.1 1739 βc-1795  23.5 ± 17.2 1740 βc-1796    9± 14.1 1741 βc-1797 26.1 ± 6.6 1742 βc-1798  50.2 ± 10.2 1743 βc-179955.9 ± 2.7 1744 βc-1800 36.3 ± 6.5 1764 βc-1820  7.3 ± 37.9 1765 βc-1821 5.6 ± 13.9 2016 βc-2072 12.3 ± 15  2017 βc-2073  12.4 ± 10.3 2018βc-2074  16.3 ± 14.8 2019 βc-2075  8.2 ± 15.3 2020 βc-2076  9.8 ± 7.12021 βc-2077 16.9 ± 42  2041 βc-2097  5.6 ± 10.2 2042 βc-2098 7.4 ± 6 2043 βc-2099  12.6 ± 21.8 2044 βc-2100 28.7 ± 7.6 2085 βc-2141  29.7 ±14.1 2086 βc-2142 46.2 ± 4.4 2087 βc-2143   16 ± 10.8 2088 βc-2144  13.8± 18.6 2089 βc-2145  29.6 ± 10.3 2090 βc-2146 40.5 ± 5.3 2091 βc-2147 27.9 ± 11.4 2092 βc-2148 21.8 ± 2.2 2093 βc-2149 60.3 ± 4.4 2094βc-2150 42.8 ± 3.9 2095 βc-2151  29 ± 2.4 2127 βc-2183  75 ± 4.7 2128βc-2184 76.5 ± 4.7 2129 βc-2185 129.6 ± 16.4 2214 βc-2270 65.8 ± 4.72215 βc-2271  40.8 ± N/A 2216 βc-2272 13.5 ± 8.5 2217 βc-2273 21.5 ± 3 2218 βc-2274 17.6 ± 6.2 2219 βc-2275 28.9 ± 6.2 2220 βc-2276 21.2 ± 5.42221 βc-2277 26.9 ± 2.8 2289 βc-2345 20.8 ± 8.7 2290 βc-2346 13.6 ± 7.22291 βc-2347   17 ± 12.8 2292 βc-2348 19.2 ± 3.3 2293 βc-2349  9.6 ± 6.42294 βc-2350  10.4 ± 12.8 2295 βc-2351  17 ± 8.9 2296 βc-2352  31.2 ±13.1 2297 βc-2353  37.1 ± N/A 2298 βc-2354 32.4 ± 6  2299 βc-2355 21.5 ±5.3 2355 βc-2411 16.6 ± 6.3 2356 βc-2412 12.8 ± 8  2357 βc-2413 18.6 ±5.8 2358 βc-2414  16.3 ± 12.4 2359 βc-2415  27.2 ± 11.4 2385 βc-2441 20.1 ± 18.9 2386 βc-2442 9.2 ± 4  2387 βc-2443 14.4 ± 8.1 2388 βc-244414.2 ± 3.4 2389 βc-2445  9.8 ± 7.6 2445 βc-2501 67.3 ± 5.1 2446 βc-250272.4 ± 6.2 2447 βc-2503 96.8 ± 6.3 2448 βc-2504 112.6 ± 7.5  2449βc-2505 68.5 ± 9.4 2450 βc-2506 128.8 ± 10.4 2451 βc-2507 144.3 ± 12.92452 βc-2508 99.5 ± 8.8 2453 βc-2509 80.5 ± 8.4 2454 βc-2510  88.6 ±10.6 2455 βc-2511 105.9 ± 8.8  2456 βc-2512 126.3 ± 18.2 2457 βc-2513 30.4 ± 13.7 2458 βc-2514 22.6 ± 2.4 2459 βc-2515  45.2 ± 30.1 2460βc-2516 27.6 ± 7.2 2461 βc-2517  19.7 ± N/A 2462 βc-2518  21.9 ± 10.52463 βc-2519  29.9 ± 14.6 2464 βc-2520 27.2 ± 6.1 2465 βc-2521  11.5 ±N/A 2466 βc-2522 17.9 ± 8.4 2467 βc-2523 18.5 ± 4.5 2468 βc-2524 16.8 ±6.6 2469 βc-2525  19.4 ± 14.4 2470 βc-2526 10.7 ± 6.8 2471 βc-2527 62.5± 8.1 2472 βc-2528  64.5 ± 14.2 2473 βc-2529  41.4 ± 12.6 2474 βc-253073.5 ± 7.1 2475 βc-2531  32.2 ± 10.4 2476 βc-2532  23.9 ± 18.7 2477βc-2533  40 ± 10 2478 βc-2534  60.4 ± N/A 2479 βc-2535 81.3 ± 4.9 2511βc-2567 104.5 ± 12.9 2512 βc-2568 53 ± 9 2513 βc-2569 67.1 ± 3.6 2547βc-2603 18.1 ± 7.9 2548 βc-2604 14.2 ± 2.5 2549 βc-2605 28.9 ± 5.9 2550βc-2606 23.7 ± 6.8 2551 βc-2607  17.1 ± 16.7 2552 βc-2608 18.1 ± 3.62553 βc-2609  23.8 ± N/A 2554 βc-2610  22.6 ± 21.5 2555 βc-2611  9.4 ±7.6 2556 βc-2612  5.1 ± 4.1 2557 βc-2613 16.3 ± 7.8 2558 βc-2614  11 ±8.5 2559 βc-2615 11.6 ± 4  2560 βc-2616 14.8 ± 4.1 2561 βc-2617  9.8 ±8.1 2562 βc-2618  12 ± 8.8 2563 βc-2619  10.7 ± 13.7 2564 βc-2620  9.2 ±18.9 2565 βc-2621 16.9 ± 9.6 2566 βc-2622 15.5 ± 7.2 2567 βc-2623  15 ±6.1 2765 βc-2869  24.5 ± 26.4 2798 βc-2902 10.1 ± 9.5 2819 βc-2923 16.9± 2  2821 βc-2925 11.2 ± 6.3 2823 βc-2927 15.4 ± 9.6 2825 βc-2929  9.8 ±10 2867 βc-2973 16.6 ± 5.2 2869 βc-2975  28.7 ± 12.7 2871 βc-2977  17 ±9.7 2873 βc-2979  20 ± 13 2875 βc-2981   20 ± 17.9 2877 βc-2983  29 ±5.7 2879 βc-2985 12.1 ± 13  2881 βc-2987 18.3 ± 7.6 2883 βc-2989 12.4 ±6.9 2909 βc-3015  12 ± 9.6 2911 βc-3017  18.6 ± 21.3 2913 βc-3019  15.8± 16.6 2915 βc-3021  24 ± 5.9 2940 βc-3046 24.3 ± 5.1 2942 βc-3048  10.8± 18.4 2944 βc-3050 15.9 ± 7.1 2946 βc-3052   16 ± 15.8 2948 βc-305413.4 ± 8.2 2950 βc-3056  35.2 ± 11.8 2981 βc-3087  8.9 ± 27.7 2983βc-3089 11.3 ± 3.5 2985 βc-3091 26.6 ± 4.1 2987 βc-3093  7.3 ± 6.4 2989βc-3095 16.1 ± 7  2991 βc-3097  6.7 ± 4.3 2993 βc-3099 12.5 ± 5.7 2995βc-3101 11.4 ± 3.3 2997 βc-3103  7.4 ± 9.7 2999 βc-3105 7.4 ± 3  3001βc-3107  8.6 ± 5.1 3003 βc-3109  6.3 ± 9.2 3005 βc-3111  5.8 ± 6.9 3007βc-3113   8 ± 3.6 3009 βc-3115  7.9 ± 8.8 3084 βc-3191 15.9 ± 4.2 3086βc-3193 22.1 ± 8.4 3088 βc-3195  11.1 ± 14.2 3232 βc-3387  8.3 ± 12.43234 βc-3389  6.1 ± 16.4 3236 βc-3391  7.5 ± 12.1 3238 βc-3393  5.9 ±14.7 3240 βc-3395  9.6 ± 8.1 3242 βc-3397 12.7 ± 2.5 3244 βc-3399  5.4 ±9.6 3246 βc-3401  9.4 ± 10.7 3336 βc-3500 10.2 ± 1.6 3338 βc-3502   8 ±6.6 3340 βc-3504  9 ± 3 3342 βc-3506 17.7 ± 3.3 3344 βc-3508 23.8 ± 4 3345 βc-3509 25.3 ± 3.6 3346 βc-3510  63.9 ± 10.6 3348 βc-3512 25.2 ±6.4 3350 βc-3514 10.1 ± 2  3352 βc-3516 17.9 ± 1.9 3354 βc-3518 11.1 ±5.4 3356 βc-3520  8.5 ± 2.6 3358 βc-3522 12.5 ± 8.6 3360 βc-3524 15.4 ±7.4 3362 βc-3526   7 ± 7.7 3364 βc-3528  10.5 ± 10.7 3366 βc-3530  12.9± 11.6 3368 βc-3532  7.2 ± 15.4 3370 βc-3534  7.7 ± 13.4 3372 βc-3536 9.7 ± 15.8 3374 βc-3538 12.6 ± 8.8 3420 βc-3583 19.8 ± 4  3422 βc-358510.6 ± 2.4 3424 βc-3587  8.7 ± 2.9 3426 βc-3589  9.7 ± 1.7 3428 βc-3591 7.5 ± 4.2 3430 βc-3593  22 ± 1.7 3469 βc-3633 14.2 ± 5.1 3471 βc-363512.1 ± 7.6 3473 βc-3637 17.3 ± 5.6 3475 βc-3639  9.8 ± 5.4 3477 βc-3641 9.7 ± 6.5 3479 βc-3643  11 ± 5.2 3481 βc-3645  6.9 ± 8.9 3483 βc-364717.5 ± 5  3485 βc-3649 16.7 ± 1.8 3487 βc-3651 12.2 ± 4.3 3489 βc-365316.5 ± 3.3 3491 βc-3655  11.4 ± 14.1 3493 βc-3657   10 ± 10.2 3495βc-3659 8.7 ± 5  3540 βc-3708 7.4 ± 7  3542 βc-3710  8.7 ± 3.2 3544βc-3712   6 ± 9.4 3546 βc-3714 11.9 ± 2.9 3548 βc-3716  27 ± 7.1βc-m314   77.1 ± 15.6 βc-m325   99.1 ± 19.3 βc-m408   50.4 ± 23.7βc-m460   58.7 ± 16.5 βc-m526  12.9 ± 4.5 βc-m631   13.7 ± 11.2 βc-m636  16.5 ± 19.9 βc-m642  10.8 ± 8.5 βc-m723   13.7 ± 12.1 βc-m970   12.3 ±10.9 βc-m976   12 ± 9.5 βc-m981  15.3 ± 4.1 βc-m1066 11.3 ± 8.6 βc-m110610.6 ± 7.8 βc-m1354  9.7 ± 6.1 βc-m1363 11.1 ± 3.3 βc-m1373  11.8 ± N/Aβc-m1508 11.5 ± 7.1 βc-m1515  9.4 ± 6.9 βc-m1682  11.8 ± 11.4 βc-m1693 16 ± 14 βc-m1698 13.5 ± 6  βc-m1705 10.7 ± 5.3 βc-m1763  7.7 ± 14.2βc-m2008 18.3 ± 3.5 βc-m2226 11.7 ± 10  βc-m2427 30.8 ± 2.4 βc-m2568 9.7 ± 3.9 βc-m2614 13.3 ± 4.1 βc-m2770 17.5 ± 4.9 βc-m2777  29.8 ± 17.2βc-m2784   16 ± 15.1 βc-m2806 8.6 ± 8  βc-m2850 13.4 ± 3.1 βc-m2965 12.5 ± 10.3 βc-m2970 11.6 ± 7.6 βc-m2976 12.8 ± 4.3 βc-m3092  7.5 ±29.8 βc-m3097 11.6 ± 2.7 βc-m3198 14.7 ± 9.3 βc-m3207  7.9 ± N/Aβc-m3433 15.4 ± 6.4 βc-m3439 14.3 ± 4.4 βc-m3444  9.7 ± 8.4 βc-m3449 9.9 ± 15.8 βc-m3522 10.3 ± 5.5 βc-m3533  10 ± 5.2 βc-m3538 10.1 ± 4.5The data shown in above Table 16 were also plotted graphically (seeFIGS. 4 and 5).

TABLE 17 100 Mouse β-Catenin-Targeting DsiRNAs (Rank Ordered byInhibition) Tested DsiRNA/Mouse β- Tested DsiRNA/Human % Remainingcatenin Target Location β-catenin transcript β-catenin (in NM_007614.2)variant 1 Target Location mRNA ± % Error 2556 βc-2612 5.1 ± 4.1 3244βc-3399 5.4 ± 9.6 1765 βc-1821  5.6 ± 13.9 2041 βc-2097  5.6 ± 10.2 3005βc-3111 5.8 ± 6.9 3238 βc-3393  5.9 ± 14.7 3544 βc-3712  6 ± 9.4 3234βc-3389  6.1 ± 16.4 3003 βc-3109 6.3 ± 9.2 2991 βc-3097 6.7 ± 4.3 3481βc-3645 6.9 ± 8.9 1513 βc-1569   7 ± 12.8 3362 βc-3526  7 ± 7.7 3368βc-3532  7.2 ± 15.4 1485 βc-1541 7.3 ± 7.1 1627 βc-1683 7.3 ± 11  1764βc-1820  7.3 ± 37.9 2987 βc-3093 7.3 ± 6.4 1489 βc-1545  7.4 ± 10.1 2042βc-2098 7.4 ± 6  2997 βc-3103 7.4 ± 9.7 2999 βc-3105 7.4 ± 3  3540βc-3708 7.4 ± 7  3236 βc-3391  7.5 ± 12.1 3428 βc-3591 7.5 ± 4.2βc-m3092  7.5 ± 29.8 3370 βc-3534  7.7 ± 13.4 βc-m1763  7.7 ± 14.2 3009βc-3115 7.9 ± 8.8 βc-m3207  7.9 ± N/A 3007 βc-3113  8 ± 3.6 3338 βc-3502 8 ± 6.6 1488 βc-1544 8.2 ± 8.2 2019 βc-2075  8.2 ± 15.3 1512 βc-1568 8.3 ± 14.9 3232 βc-3387  8.3 ± 12.4 3356 βc-3520 8.5 ± 2.6 3001 βc-31078.6 ± 5.1 βc-m2806 8.6 ± 8  3424 βc-3587 8.7 ± 2.9 3495 βc-3659 8.7 ± 5 3542 βc-3710 8.7 ± 3.2 2981 βc-3087  8.9 ± 27.7 1510 βc-1566   9 ± 18.11740 βc-1796   9 ± 14.1 3340 βc-3504 9 ± 3  837 βc-893  9.2 ± 9.5 2386βc-2442 9.2 ± 4  2564 βc-2620  9.2 ± 18.9 2555 βc-2611 9.4 ± 7.6 3246βc-3401  9.4 ± 10.7 βc-m1515 9.4 ± 6.9 2293 βc-2349 9.6 ± 6.4 3240βc-3395 9.6 ± 8.1 3372 βc-3536  9.7 ± 15.8 3426 βc-3589 9.7 ± 1.7 3477βc-3641 9.7 ± 6.5 βc-m1354 9.7 ± 6.1 βc-m2568 9.7 ± 3.9 βc-m3444 9.7 ±8.4 2020 βc-2076 9.8 ± 7.1 2389 βc-2445 9.8 ± 7.6 2561 βc-2617 9.8 ± 8.12825 βc-2929 9.8 ± 10  3475 βc-3639 9.8 ± 5.4 βc-m3449  9.9 ± 15.8 3493βc-3657  10 ± 10.2 βc-m3533  10 ± 5.2 1596 βc-1652 10.1 ± 13.9 2798βc-2902 10.1 ± 9.5  3350 βc-3514 10.1 ± 2   βc-m3538 10.1 ± 4.5  3336βc-3500 10.2 ± 1.6  βc-m3522 10.3 ± 5.5  2294 βc-2350 10.4 ± 12.8  838βc-894  10.5 ± 9.4  3364 βc-3528 10.5 ± 10.7 3422 βc-3585 10.6 ± 2.4 βc-m1106 10.6 ± 7.8  1511 βc-1567 10.7 ± 16.4 1625 βc-1681 10.7 ± 5  2470 βc-2526 10.7 ± 6.8  2563 βc-2619 10.7 ± 13.7 βc-m1705 10.7 ± 5.3 2942 βc-3048 10.8 ± 18.4 βc-m642  10.8 ± 8.5  1626 βc-1682 10.9 ± 21.32558 βc-2614  11 ± 8.5 3479 βc-3643  11 ± 5.2 1628 βc-1684 11.1 ± 3.3 3088 βc-3195 11.1 ± 14.2 3354 βc-3518 11.1 ± 5.4  βc-m1363 11.1 ± 3.3 2821 βc-2925 11.2 ± 6.3  2983 βc-3089 11.3 ± 3.5  βc-m1066 11.3 ± 8.6 2995 βc-3101 11.4 ± 3.3  3491 βc-3655 11.4 ± 14.1 2465 βc-2521 11.5 ±N/A βc-m1508 11.5 ± 7.1 

As shown in above Table 14, 348 of 440 asymmetric DsiRNAs examined inhuman HeLa cells showed greater than 70% reduction of human β-cateninlevels in HeLa cells at 1 nM. Of these 348 DsiRNAs, 317 exhibited 80% orgreater reduction of human β-catenin levels in HeLa cells at 1 nM, and229 exhibited 90% or greater reduction of human β-catenin levels in HeLacells at 1 nM. A number of these DsiRNAs uniquely targeted humanβ-catenin.

As shown in above Table 16, 295 of 416 asymmetric DsiRNAs examined inmouse Hepa 1-6 cells showed greater than 70% reduction of mouseβ-catenin levels in Hepa 1-6 cells at 1 nM. Of these 295 DsiRNAs, 225exhibited 80% or greater reduction of mouse β-catenin levels in Hepa 1-6cells at 1 nM, and 68 exhibited 90% or greater reduction of mouseβ-catenin levels in Hepa 1-6 cells at 1 nM. A number of these DsiRNAsuniquely targeted mouse β-catenin.

Example 3 β-Catenin Targeting DsiRNAs Effectively Reduced β-Catenin RNALevels in Tumor Cells and Inhibited Tumor Cell Growth

Cell Culture, RNA Transfection and Analysis

HCT116 cells were maintained in McCoy's 5a Medium with 10% Fetal BovineSerum (FBS); HepG2 cells were maintained in MEM with 10% FBS (both mediacontained penicillin and streptomycin). For transfection, cells wereseeded into 24-well plates at 40,000 cells per well the day beforetransfection, in antibiotic-free medium. To transfect, DsiRNAs werecomplexed with the lipid transfection reagent RNAiMAX, in OptiMem mediumand then added to the cells in medium to yield the indicated finalDsiRNA concentrations. Controls included Untransfected cells, Mock cellstreated with RNAiMAX without DsiRNA, and Control DsiRNA #114 (withnon-specific sequence). After six hours of exposure, the cell culturemedium was removed, cells were washed, and fresh medium was added.

For RNA expression analysis, RNA was isolated one day aftertransfection, using the Promega SV96 RNA isolation kit. RNA wasreverse-transcribed, and then Taqman quantitative PCR was performed on aBioRad CFX96, in multiplex using primer and probe sets specific forCTNNB1/B-catenin and the housekeeping gene HPRT1 for normalization.

Cell growth was assayed three days after transfection, using the PromegaCell Titer Blue (CTB) reagent. Briefly, culture medium was replaced withfresh medium containing CTB reagent; after one hour, fluorescence at theappropriate wavelength was measured one a plate reader. Cell numbervalues were graphed relative to Mock treatments.

To examine whether human β-catenin targeting DsiRNAs identified aseffective at reducing β-catenin transcript levels in HeLa cells werealso effective inhibitors of β-catenin in colon cancer cells, fourDsiRNAs (βc-1569, βc-1683, βc-2612 and βc-3393) were transfected intocolon carcinoma cell line HCT116. As shown in FIG. 6, βc-1569, βc-1683,βc-2612 and βc-3393 DsiRNAs dramatically (>80%) reduced human β-catenintranscript levels in colon carcinoma cell line HCT116 cells at both 3 nMand 10 nM concentrations in the environment of these cells.

The effects of β-catenin targeting DsiRNAs βc-1569, βc-1683, βc-2612 andβc-3393 were also examined in hepatocarcinoma cell line HepG2, with theeffect of DsiRNA treatment upon growth of the hepatocarcinoma cell lineassessed. As shown in FIG. 7, following three days of incubation at 3 nMconcentration in the environment of HepG2 cells, all four assayedβ-catenin targeting DsiRNAs showed significant reduction in tumor cellnumber (relative to mock-treated and control DsiRNA-treated cells,approximately 30% to 60% or greater cell growth inhibition was observedat day 3 post-transfection). Notably, the β-catenin targeting βc-1569DsiRNA exhibited approximately 70% reduction in tumor cell numbers,demonstrating the remarkable efficacy of this β-catenin targeting DsiRNAupon a phenotype of therapeutic significance.

Example 4 DsiRNA Inhibition of β-Catenin—Secondary Screen

96 asymmetric DsiRNAs of the above experiment are examined in asecondary assay (“Phase 2”). Specifically, 96 asymmetric DsiRNAs (e.g.,βc-284, βc-288, βc-639, βc-830, βc-893, βc-894, βc-895, βc-900, βc-1306,βc-1310, βc-1314, βc-1541, βc-1545, βc-1566, βc-1567, βc-1568, βc-1569,βc-1652, βc-1662, βc-1667, βc-1681, βc-1682, βc-1683, βc-1820, βc-2097,βc-2144, βc-2151, βc-2277, βc-2350, βc-2442, βc-2445, βc-2517, βc-2521,βc-2525, βc-2611, βc-2612, βc-2620, βc-3111, βc-3195, βc-3389, βc-3393,βc-3399, βc-3500, βc-3534, βc-3589, βc-3591, βc-3653, βc-3659, βc-3708,βc-3712, βc-240, βc-244, βc-253, βc-259, βc-264, βc-496, βc-516, βc-540,βc-582, βc-686, βc-692, βc-697, βc-707, βc-753, βc-870, βc-889, βc-1060,βc-1070, βc-1154, βc-1180, βc-1412, βc-1418, βc-1579, βc-1620, βc-1816,βc-2282, βc-3203, βc-3333, βc-3354, βc-3426, βc-3431, βc-3605, βc-3615,βc-3674, βc-3686, βc-3691, βc-m1354, βc-m1515, βc-m1763, βc-m2568,βc-m2806, βc-m3092, βc-m3207, βc-m3444, βc-m3449 and βc-m3533) wereassessed for inhibition of human β-catenin at 1 nM, 0.3 nM and 0.1 nM inthe environment of human HeLa cells. These 96 asymmetric DsiRNAs arealso assessed for inhibition of mouse β-catenin at 1 nM, 0.3 nM and 0.1nM in the environment of mouse Hepa 1-6 cells. As shown in FIGS. 8-11, aremarkable number of asymmetric DsiRNAs reproducibly exhibited robusthuman β-catenin inhibitory efficacies at sub-nanomolar concentrationswhen assayed in the environment of HeLa cells. In addition, as shown inFIGS. 12-15, a number of these asymmetric DsiRNAs also showed robustmouse HIF-1α inhibitory efficacies at 1 nM, 300 pM and 100 pM whenassayed in the environment of mouse Hepa 1-6 cells. (Meanwhile, bothhuman β-catenin-specific and mouse β-catenin-specific inhibitoryasymmetric DsiRNAs were also identified.)

While IC₅₀ values were not formally calculated during secondaryscreening, it is clear from FIGS. 8-11 that sub-nanomolar (and, indeed,sub-100 pM) IC₅₀ values were observed for the vast majority of DsiRNAs.Thus, β-catenin-targeting DsiRNAs were demonstrated to be remarkablypotent and effective inhibitors of β-catenin expression.

Example 5 Modified Forms of β-Catenin-Targeting DsiRNAs Reduce β-CateninLevels In Vitro

32 β-catenin-targeting DsiRNAs (βc-1545, βc-1683, βc-2097, βc-2277,βc-2612, βc-3111, βc-3195, βc-3389, βc-3393, βc-3399, βc-3534, βc-3653,βc-3659, βc-3708, βc-3712, (βc-253, βc-259, βc-686, βc-692, (βc-697,βc-870, βc-889, βc-1154, βc-1180, βc-1412, βc-2282, (βc-3203, βc-3431,βc-m1763, βc-m2806, βc-m3207 and βc-m3533) were prepared with2′-O-methyl modification patterns as shown in schematic of FIG. 16. Foreach of the 32 DsiRNA sequences, DsiRNAs possessing each of the sixantisense (guide) strand modification patterns were assayed forβ-catenin inhibition in human HeLa cells at 0.1 nM (in parallel assays)and 1.0 nM concentrations in the environment of the HeLa cells. Resultsof these experiments are presented as histograms in FIGS. 17 to 24. Ingeneral, the 32 DsiRNA sequences exhibited a trend towards somewhatreduced efficacy of β-catenin inhibition as the extent of 2′-O-methylmodification of the guide strand increased. However, for almost allDsiRNA sequences examined, a modification pattern could be identifiedthat allowed the DsiRNA to retain significant β-catenin inhibitoryefficacy in vitro. It was also notable that many DsiRNAs (e.g., βc-1545,βc-1683, βc-3195, βc-3389, βc-3393, βc-3399, βc-3534, βc-3659, βc-3712,βc-253 and βc-3203) exhibited robust β-catenin inhibitory efficacy ineven the most highly modified states examined. These data confirm thatit is possible to identify highly effective β-catenin inhibitory DsiRNAsthat are robustly tolerant to modification, such that levels ofmodification sufficient to stabilize such DsiRNAs and/or reduceimmunogenicity of such DsiRNAs when therapeutically administered to asubject in vivo can be applied to these DsiRNAs.

In certain embodiments, the invention provides a DsiRNA selected fromamong one or more of the following:

TABLE 18 Select β-Catenin-Targeting DsiRNAs DsiRNA Name 27 nt TargetSequence 21 nt Target Sequence βc-496  SEQ ID NO: 2231 SEQ ID NO: 4449βc-540  SEQ ID NO: 2235 SEQ ID NO: 4453 βc-639  SEQ ID NO: 2325 SEQ IDNO: 4543 βc-900  SEQ ID NO: 2348 SEQ ID NO: 4566 βc-1545 SEQ ID NO: 2391SEQ ID NO: 4609 βc-2151 SEQ ID NO: 2477 SEQ ID NO: 4695 βc-3203 SEQ IDNO: 2274 SEQ ID NO: 4492 βc-3399 SEQ ID NO: 2618 SEQ ID NO: 4836 βc-3591SEQ ID NO: 2645 SEQ ID NO: 4863 βc-3708 SEQ ID NO: 2661 SEQ ID NO: 4879Among the DsiRNAs of Table 18 that were tested in the above-describedmodified DsiRNA assays, (βc-1545, βc-3203 and βc-3399 were shown to berobustly effective DsiRNA sequences even when modified (and βc-1545 andβc-3399 were observed to be highly effective inhibitors of β-cateninunder all modification conditions examined).

Example 6 β-Catenin-Targeting DsiRNAs Reduced Axin-2 Levels In Vitro

The impact of β-catenin-targeting DsiRNAs upon Axin-2, a knowndownstream target of β-catenin was examined in both HCT116 (coloncarcinoma) and HepG2 (hepatocellular carcinoma) cell lines. As shown inFIG. 26, βcat-h1569, βcat-h1683, βcat-h2612 and βcat-h3393 were allrobust inhibitors of Axin-2, with approximately 80%-90% knockdownobserved for each of these DsiRNAs in both cell lines. Cells wereassayed at two days post-transfection at indicated concentrations (3 nMand 10 nM) with designated DsiRNAs. Thus, the effect of β-cateninknockdown was also observed in the mRNA levels of the downstream targetof β-catenin, Axin-2.

Example 7 β-Catenin Targeting DsiRNAs Inhibited Tumor Cell Growth inColorectal and Hepatocellular Carcinoma Cell Lines

As described above, FIG. 7 shows the growth inhibitory impact ofβ-catenin-targeting DsiRNAs upon HepG2 hepatocellular carcinoma cells.To identify whether such cell growth inhibitory effects could also beobserved in other cancer cell lines, the impact of j-catenin-targetingDsiRNAs upon growth of both HCT116 (colorectal carcinoma) and HuH7(hepatocellular carcinoma) cell lines was also examined. As shown inFIG. 26, transfection of human colorectal cancer cell line HCT116 cellswith certain DsiRNAs targeting human β-catenin (βc-1683, βc-2612 andβc-3393) inhibited the growth of such cells at five dayspost-transfection, as compared to cells administered a control DsiRNA.Cell growth inhibition was assayed using a CellTiter-Blue® CellViability Assay (Promega) at five days post-transfection.

More robust inhibition of cancer cell line growth was observed followingadministration of βc-3393 DsiRNA to human hepatocellular carcinoma cellline HuH7 cells (FIG. 27). At five days post-transfection, approximately40% inhibition of HuH7 cell growth was observed, as compared to cellsadministered a control DsiRNA. Cell growth inhibition was assayed usinga CellTiter-Blue® Cell Viability Assay (Promega) at five dayspost-transfection. Thus, the cancer cell line growth inhibitory effectof β-catenin-targeting DsiRNAs was observed to be generalizable acrossat least three distinct cell lines (and was surprisingly robust in thetwo distinct hepatocellular carcinoma cell lines examined, HepG2 andHuH7).

As shown in FIG. 28, transfection of human hepatocellular carcinoma cellline HuH7 cells with a DsiRNA targeting human β-catenin (specifically, aβc-3393 25/27mer possessing an “M11” modified antisense (guide) strandconsisting of 2′-O-methyl modifications at the following positionsstarting from the 5′-terminus (position 1) of the antisense strand: 1,2, 3, 4, 11, 13, 25 and 27) produced knockdown of β-catenin mRNA levelsof approximately 80% at two days post-transfection, when administeredwith a control DsiRNA, as compared to cells administered only thecontrol DsiRNA. Thus, β-catenin-targeting DsiRNAs were potent inhibitorsof both β-catenin expression levels and of cell growth in hepatocellularcarcinoma cell lines HepG2 and HuH7.

The expression of β-Catenin in human HeLa, HepG2 and HCT116 carcinomacell lines was confirmed in vitro, with subcellular distribution ofexpressed β-Catenin protein also examined. Nuclear and cytoplasmiclevels of β-catenin were identified for each cell line via Western blot(FIG. 29), with β-actin levels assayed as an internal control. Cellextracts were obtained from confluent six well plates, using a NE-PERNuclear and Cytoplasmic Extraction Reagents Kit (Thermo FisherScientific Inc). 75 ug of protein was loaded from each cell line. HeLa(cervical cancer), HepG2 (hepatocellular liver carcinoma) and HCT116(colorectal carcinoma) cell lines each expressed β-Catenin protein atrobust levels, with β-Catenin protein primarily found in the cytoplasmof each cell type (though significant nuclear fractions were alsoobserved for each cell type). Notably, a known truncation mutant form ofβ-catenin protein was observed in HepG2 cells.

Example 8 β-Catenin-Targeting DsiRNAs Reduced β-Catenin mRNA and ProteinLevels In Vivo

The impact of β-Catenin-targeting DsiRNAs upon β-Catenin expressionlevels was examined in vivo. Specifically, human β-catenin-targetingDsiRNAs βc-1683, βc-1820 and βc-3393 (previously noted as also beingactive inhibitors of mouse β-Catenin) were demonstrated to be remarkablyeffective inhibitors of mouse β-catenin expression in vivo in normalmouse liver, inhibiting both β-catenin mRNA (FIG. 30, top panel) andprotein (FIG. 30, bottom panel) levels significantly (e.g., for theseDsiRNAs, approximately 70-90% knockdown was observed) when administeredas a single dose intravenously to normal mice (n=5 mice per group) at 10mg/kg and formulated in Invivofectamine® 2.0 (Invitrogen™, Carlsbad,Calif.). In such experiments, liver tissue was harvested at 72 hourspost-administration. All DsiRNAs targeting β-catenin possessed “M11”modified antisense (guide) strands. Notably, βc-1563 also exhibitedrobust inhibition of β-catenin mRNA levels in vivo; however,corresponding β-catenin protein levels were not assessed for thisDsiRNA. Meanwhile, βc-2612 was also observed to inhibit β-catenin mRNAlevels, even if not to the extent observed for βc-1563, βc-1683, βc-1820and βc-3393, or to the extent observed for certain modified forms ofβc-2612 in additional experiments described below.

The above in vivo results were confirmed and expanded upon underdiffering conditions in subsequent experiments that also employedmodified forms of certain DsiRNAs. As shown in FIG. 31, DsiRNAstargeting β-catenin were shown to be active in vivo inhibitors of bothβ-catenin and Axin-2 in normal mouse liver, inhibiting both β-cateninmRNA (top panel) and Axin-2 mRNA (bottom panel) levels significantly(e.g., in many instances, approximately 70-90% knockdown was observed)when administered as a single dose intravenously to normal mice (n=5mice per group) at 10 mg/kg and formulated in Invivofectamine® 2.0(Invitrogen™ Carlsbad, Calif.). For such experiments, liver tissue washarvested at 72 hours post-administration. In these experiments, βc-3393and βc-2612 DsiRNAs possessed varying modification patterns as indicatedin FIG. 31, with, e.g., an “M0/M11” pattern corresponding to a 25/27merDsiRNA possessing an unmodified sense (passenger) strand and a modifiedantisense (guide) strand having the “M11” pattern of 2′-O-methlyation.(Meanwhile, the “M14” modification pattern of the sense strand employedfor βc-3393-M14/M12 corresponds to modification of the sense strand atthe following positions, starting from the 5′-terminus (position 1) ofthe sense strand: 2, 4, 6, 8, 12, 14, 16 and 18. All three assayedDsiRNAs (βc-2612-M0/M11 and parallel differentially modified forms ofβc-3393) showed greater than 80% inhibition of β-catenin levels in vivoin normal mouse liver, and at least 60% knockdown of Axin-2.

Modified forms of βc-3393 and βc-2612 DsiRNAs were also observed to beactive inhibitors of β-catenin and Axin-2 expression at a 48 hourtimepoint in vivo in normal mouse liver. Specifically, as shown in FIG.32, βc-3393-M0/M11 (MS), βc-3393-M0/M11 (LS), βc-3393-M14/M12 andβc-2612-M0/M11 DsiRNAs all robustly inhibited both β-catenin mRNA (toppanel) and Axin-2 mRNA (bottom panel) levels significantly (e.g., in allinstances, approximately 70-90% knockdown was observed) whenadministered as a single dose intravenously to normal mice (n=5 mice pergroup) at 10 mg/kg and formulated in Invivofectamine® 2.0 (Invitrogen™,Carlsbad, Calif.). In these experiments, liver tissue was harvested at48 hours post-administration. DsiRNAs targeting β-catenin possessedvarying modification patterns as indicated in FIG. 32 and as describedabove. Control DsiRNAs possessed similar patterns of modification ofsense and antisense strands.

Thus, β-catenin DsiRNAs were observed to be surprisingly potent andeffective inhibitors of β-catenin expression in vivo.

Example 9 Inhibition of β-Catenin by Additional Preferred DsiRNAs

The remaining DsiRNA molecules shown in Table 9, possessing sense andantisense strand sequences as shown and targeting β-catenin wild-typesequences (and variant sequences where applicable) are designed andsynthesized as described above and tested in HeLa cells (and,optionally, in mouse Hepa 1-6 cells) for inhibitory efficacy asdescribed in Examples 3 and 4 above. The ability of these DsiRNA agentsto inhibit β-catenin expression is optionally assessed in comparison tocorresponding β-catenin target sequence-directed 21mer siRNAs (21nucleotide target sequences of β-catenin dsRNA agents described hereinare presented in Tables 5 and 10 above). These additional DsiRNAs andthe DsiRNAs tested herein are also examined for the ability tooutperform cognate siRNAs, as determined via measurement of efficacy indecreasing levels of β-catenin target relative to a cognate 21mer siRNAagent. The duration of such inhibitory effects is also examined at both24 hours and 48 hours post-administration, with concentrations of 0.1nM, 0.3 nM, 1 nM and 5 nM tested. DsiRNAs of the instant invention areexamined for the ability to outperform their cognate 21mer siRNA, asdetermined via measurement of potency and/or duration of effect.

Optionally, the DsiRNA molecules shown in Tables 6-8 and 11-13 above arealso similarly synthesized and tested.

Example 10 Indications

As described herein, the nucleic acid molecules of the present inventionare used in assays to diagnose disease state related to β-cateninlevels. In addition, the nucleic acid molecules can be used to treatdisease state related to β-catenin misregulation, levels, etc.

Particular disorders and disease states that can be associated withβ-catenin expression modulation include, but are not limited to cancerand/or proliferative diseases, conditions, or disorders and otherdiseases, conditions or disorders that are related to or will respond tothe levels of β-catenin in a cell or tissue, alone or in combinationwith other therapies. Particular degenerative and disease states thatare associated with β-catenin expression modulation include but are notlimited to, for example prostate cancer, lung cancer, colorectal cancer,bladder cancer, pancreatic cancer, and breast cancer.

In certain therapeutic embodiments, the disease or disorder to betreated is selected from the group consisting of a hyperproliferativedisorder, such as cancer, such as a cancer selected from the groupconsisting of colorectal cancer, hepatocellular cancer, endometrialcancer, malignant melanoma, ovarian cancer, pancreatic cancer, pituitarycancer, oesophageal cancer, lung cancer, breast cancer, kidney cancer,haematopoetic system cancer, cervical cancer, CNS cancer, bone cancer,biliary tract cancer and adrenal gland cancer. Optionally, the diseaseor disorder is a cancer selected from the group consisting of colorectalcancer, hepatocellular cancer, endometrial cancer, and malignantmelanoma. In certain embodiments, the disorder is a cancer selected fromthe group consisting of liver cancer and kidney cancer. In certainembodiments, the disease or disorder is associated with a mutation inthe β-catenin gene or a gene whose protein product is associated with orinteracts with β-catenin, such as the APC gene. Therefore, in variousembodiments, the target mRNA is a mutated form of the β-cateninsequence, for example it may comprise one or more single pointmutations, such as SNPs associated with cancer.

Examples of such diseases where mutations in the β-catenin or APC genelead to abnormal levels of β-catenin activity are: (1) Colorectalcancer, APC and β-catenin are mutually mutated in more than 70% of allcases (Powell et al., Nature, 1992; Morin et al., Science, 1997; Sparkset al., Cancer Res, 1998); (2) Hepatocellular cancer, β-catenin aremutated in more than 25% of cases (de La Coste A, PNAS, 1998); (3)Endometrial cancer, β-catenin are mutated >10%; and (4) Malignantmelanoma, β-catenin are mutated >10% (Rubinfeld et al., Science, 1997).

Further examples of such diseases are cancer of the ovary, pancreas,pituitary, oesophagus, lung, breast, kidney, haematopoetic system,cervix, CNS, bone, biliary tract and adrenal gland. It has been shownthat mutations in the β-catenin or APC gene are associated with thesediseases (Catalogue of Somatic Mutations in Cancer available from theSanger Institute (United Kingdom) homepage http://www.sanger.ac.uk/).

In certain embodiments, the disease or disorder is associated withabnormal levels of a mutated form of β-catenin. In certain embodiments,the disease or disorder is associated with abnormal levels of awild-type form of β-catenin. One aspect of the invention is directed toa method of treating a mammal suffering from or susceptible toconditions associated with abnormal levels of β-catenin, comprisingadministering to the mammal a therapeutically effective amount of aDsiRNA of the invention targeted to β-catenin or various compositions orconjugates thereof.

Gemcytabine and cyclophosphamide are non-limiting examples ofchemotherapeutic agents that can be combined with or used in conjunctionwith the nucleic acid molecules (e.g. DsiRNA molecules) of the instantinvention. Those skilled in the art will recognize that other drugs suchas anti-cancer compounds and therapies can be similarly be readilycombined with the nucleic acid molecules of the instant invention (e.g.DsiRNA molecules) and are hence within the scope of the instantinvention. Such compounds and therapies are well known in the art (seefor example Cancer: Principles and Practice of Oncology, Volumes 1 and2, eds Devita, V. T., Hellman, S., and Rosenberg, S. A., J.B. LippincottCompany, Philadelphia, USA) and include, without limitations,antifolates; fluoropyrimidines; cytarabine; purine analogs; adenosineanalogs; amsacrine; topoisomerase I inhibitors; anthrapyrazoles;retinoids; antibiotics such as bleomycin, anthacyclins, mitomycin C,dactinomycin, and mithramycin; hexamethylmelamine; dacarbazine;1-asperginase; platinum analogs; alkylating agents such as nitrogenmustard, melphalan, chlorambucil, busulfan, ifosfamide,4-hydroperoxycyclophosphamide, nitrosoureas, thiotepa; plant derivedcompounds such as vinca alkaloids, epipodophyllotoxins, taxol;Tamoxifen; radiation therapy; surgery; nutritional supplements; genetherapy; radiotherapy such as 3D-CRT; immunotoxin therapy such as ricin,monoclonal antibodies Herceptin; and the like. For combination therapy,the nucleic acids of the invention are prepared in one of two ways.First, the agents are physically combined in a preparation of nucleicacid and chemotherapeutic agent, such as a mixture of a nucleic acid ofthe invention encapsulated in liposomes and ifosfamide in a solution forintravenous administration, wherein both agents are present in atherapeutically effective concentration (e.g., ifosfamide in solution todeliver 1000-1250 mg/m2/day and liposome-associated nucleic acid of theinvention in the same solution to deliver 0.1-100 mg/kg/day).Alternatively, the agents are administered separately but simultaneouslyin their respective effective doses (e.g., 1000-1250 mg/m2/d ifosfamideand 0.1 to 100 mg/kg/day nucleic acid of the invention).

Those skilled in the art will recognize that other compounds andtherapies used to treat the diseases and conditions described herein cansimilarly be combined with the nucleic acid molecules of the instantinvention (e.g. siNA molecules) and are hence within the scope of theinstant invention.

Example 11 Serum Stability of DsiRNAs

Serum stability of DsiRNA agents is assessed via incubation of DsiRNAagents in 50% fetal bovine serum for various periods of time (up to 24h) at 37° C. Serum is extracted and the nucleic acids are separated on a20% non-denaturing PAGE and can be visualized with Gelstar stain.Relative levels of protection from nuclease degradation are assessed forDsiRNAs (with and without modifications).

Example 12 Use of Additional Cell Culture Models to Evaluate theDown-Regulation of β-Catenin Gene Expression

A variety of endpoints have been used in cell culture models to look atβ-catenin-mediated effects after treatment with anti-β-catenin agents.Phenotypic endpoints include inhibition of cell proliferation, RNAexpression, and reduction of β-catenin protein expression. Becauseβ-catenin mutations are directly associated with increased proliferationof certain tumor cells, a proliferation endpoint for cell culture assayscan be used as a screen, e.g., as documented in the above examples.There are several methods by which this endpoint can be measured.Following treatment of cells with DsiRNA, cells are allowed to grow(typically 5 days), after which the cell viability, the incorporation ofbromodeoxyuridine (BrdU) into cellular DNA and/or the cell density aremeasured. The assay of cell density can be done in a 96-well format,e.g. by using commercially available fluorescent nucleic acid stains(such as Syto® 13 or CyQuant®). As a secondary, confirmatory endpoint, aDsiRNA-mediated decrease in the level of β-catenin protein expressioncan be evaluated using a β-catenin-specific ELISA.

Example 13 Evaluation of Anti-β-Catenin DsiRNA Efficacy in a Mouse Modelof β-Catenin Misregulation

Anti-β-catenin DsiRNA chosen from in vitro assays can be further testedin mouse models, including, e.g., xenograft and other animal models asrecited above. In one example, mice possessing misregulated (e.g.,elevated) β-catenin levels are administered a DsiRNA agent of thepresent invention via hydrodynamic tail vein injection. 3-4 mice pergroup (divided based upon specific DsiRNA agent tested) are injectedwith 50 μg or 200 μg of DsiRNA. Levels of β-catenin RNA are evaluatedusing RT-qPCR. Additionally or alternatively, levels of β-catenin (e.g.,β-catenin protein levels and/or cancer cell/tumor formation, growth orspread) can be evaluated using an art-recognized method, or phenotypesassociated with misregulation of β-catenin (e.g., tumor formation,growth, metastasis, etc.) are monitored (optionally as a proxy formeasurement of β-catenin transcript or β-catenin protein levels). ActiveDsiRNA in such animal models can also be subsequently tested incombination with standard chemotherapies.

Example 14 Diagnostic Uses

The DsiRNA molecules of the invention can be used in a variety ofdiagnostic applications, such as in the identification of moleculartargets (e.g., RNA) in a variety of applications, for example, inclinical, industrial, environmental, agricultural and/or researchsettings. Such diagnostic use of DsiRNA molecules involves utilizingreconstituted RNAi systems, for example, using cellular lysates orpartially purified cellular lysates. DsiRNA molecules of this inventioncan be used as diagnostic tools to examine genetic drift and mutationswithin diseased cells. The close relationship between DsiRNA activityand the structure of the target β-catenin RNA allows the detection ofmutations in a region of the β-catenin molecule, which alters thebase-pairing and three-dimensional structure of the target β-cateninRNA. By using multiple DsiRNA molecules described in this invention, onecan map nucleotide changes, which are important to RNA structure andfunction in vitro, as well as in cells and tissues. Cleavage of targetβ-catenin RNAs with DsiRNA molecules can be used to inhibit geneexpression and define the role of specified gene products in theprogression of a β-catenin-associated disease or disorder. In thismanner, other genetic targets can be defined as important mediators ofthe disease. These experiments will lead to better treatment of thedisease progression by affording the possibility of combinationtherapies (e.g., multiple DsiRNA molecules targeted to different genes,DsiRNA molecules coupled with known small molecule inhibitors, orintermittent treatment with combinations of DsiRNA molecules and/orother chemical or biological molecules). Other in vitro uses of DsiRNAmolecules of this invention are well known in the art, and includedetection of the presence of RNAs associated with a disease or relatedcondition. Such RNA is detected by determining the presence of acleavage product after treatment with a DsiRNA using standardmethodologies, for example, fluorescence resonance emission transfer(FRET).

In a specific example, DsiRNA molecules that cleave only wild-type ormutant or polymorphic forms of the target β-catenin RNA are used for theassay. The first DsiRNA molecules (i.e., those that cleave onlywild-type forms of target β-catenin RNA) are used to identify wild-typeβ-catenin RNA present in the sample and the second DsiRNA molecules(i.e., those that cleave only mutant or polymorphic forms of target RNA)are used to identify mutant or polymorphic β-catenin RNA in the sample.As reaction controls, synthetic substrates of both wild-type and mutantor polymorphic β-catenin RNA are cleaved by both DsiRNA molecules todemonstrate the relative DsiRNA efficiencies in the reactions and theabsence of cleavage of the “non-targeted” β-catenin RNA species. Thecleavage products from the synthetic substrates also serve to generatesize markers for the analysis of wild-type and mutant β-catenin RNAs inthe sample population. Thus, each analysis requires two DsiRNAmolecules, two substrates and one unknown sample, which is combined intosix reactions. The presence of cleavage products is determined using anRNase protection assay so that full-length and cleavage fragments ofeach β-catenin RNA can be analyzed in one lane of a polyacrylamide gel.It is not absolutely required to quantify the results to gain insightinto the expression of mutant or polymorphic β-catenin RNAs and putativerisk of j-catenin-associated phenotypic changes in target cells. Theexpression of β-catenin mRNA whose protein product is implicated in thedevelopment of the phenotype (i.e., disease related/associated) isadequate to establish risk. If probes of comparable specific activityare used for both transcripts, then a qualitative comparison ofβ-catenin RNA levels is adequate and decreases the cost of the initialdiagnosis. Higher mutant or polymorphic form to wild-type ratios arecorrelated with higher risk whether β-catenin RNA levels are comparedqualitatively or quantitatively.

All patents and publications mentioned in the specification areindicative of the levels of skill of those skilled in the art to whichthe invention pertains. All references cited in this disclosure areincorporated by reference to the same extent as if each reference hadbeen incorporated by reference in its entirety individually.

One skilled in the art would readily appreciate that the presentinvention is well adapted to carry out the objects and obtain the endsand advantages mentioned, as well as those inherent therein. The methodsand compositions described herein as presently representative ofpreferred embodiments are exemplary and are not intended as limitationson the scope of the invention. Changes therein and other uses will occurto those skilled in the art, which are encompassed within the spirit ofthe invention, are defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varyingsubstitutions and modifications can be made to the invention disclosedherein without departing from the scope and spirit of the invention.Thus, such additional embodiments are within the scope of the presentinvention and the following claims. The present invention teaches oneskilled in the art to test various combinations and/or substitutions ofchemical modifications described herein toward generating nucleic acidconstructs with improved activity for mediating RNAi activity. Suchimproved activity can comprise improved stability, improvedbioavailability, and/or improved activation of cellular responsesmediating RNAi. Therefore, the specific embodiments described herein arenot limiting and one skilled in the art can readily appreciate thatspecific combinations of the modifications described herein can betested without undue experimentation toward identifying DsiRNA moleculeswith improved RNAi activity.

The invention illustratively described herein suitably can be practicedin the absence of any element or elements, limitation or limitationsthat are not specifically disclosed herein. Thus, for example, in eachinstance herein any of the terms “comprising”, “consisting essentiallyof”, and “consisting of” may be replaced with either of the other twoterms. The terms and expressions which have been employed are used asterms of description and not of limitation, and there is no intentionthat in the use of such terms and expressions of excluding anyequivalents of the features shown and described or portions thereof, butit is recognized that various modifications are possible within thescope of the invention claimed. Thus, it should be understood thatalthough the present invention has been specifically disclosed bypreferred embodiments, optional features, modification and variation ofthe concepts herein disclosed may be resorted to by those skilled in theart, and that such modifications and variations are considered to bewithin the scope of this invention as defined by the description and theappended claims.

In addition, where features or aspects of the invention are described interms of Markush groups or other grouping of alternatives, those skilledin the art will recognize that the invention is also thereby describedin terms of any individual member or subgroup of members of the Markushgroup or other group.

The use of the terms “a” and “an” and “the” and similar referents in thecontext of describing the invention (especially in the context of thefollowing claims) are to be construed to cover both the singular and theplural, unless otherwise indicated herein or clearly contradicted bycontext. The terms “comprising,” “having,” “including,” and “containing”are to be construed as open-ended terms (i.e., meaning “including, butnot limited to,”) unless otherwise noted. Recitation of ranges of valuesherein are merely intended to serve as a shorthand method of referringindividually to each separate value falling within the range, unlessotherwise indicated herein, and each separate value is incorporated intothe specification as if it were individually recited herein. All methodsdescribed herein can be performed in any suitable order unless otherwiseindicated herein or otherwise clearly contradicted by context. The useof any and all examples, or exemplary language (e.g., “such as”)provided herein, is intended merely to better illuminate the inventionand does not pose a limitation on the scope of the invention unlessotherwise claimed. No language in the specification should be construedas indicating any non-claimed element as essential to the practice ofthe invention.

Embodiments of this invention are described herein, including the bestmode known to the inventors for carrying out the invention. Variationsof those embodiments may become apparent to those of ordinary skill inthe art upon reading the foregoing description.

The inventors expect skilled artisans to employ such variations asappropriate, and the inventors intend for the invention to be practicedotherwise than as specifically described herein. Accordingly, thisinvention includes all modifications and equivalents of the subjectmatter recited in the claims appended hereto as permitted by applicablelaw. Moreover, any combination of the above-described elements in allpossible variations thereof is encompassed by the invention unlessotherwise indicated herein or otherwise clearly contradicted by context.Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments of the invention described herein. Such equivalents areintended to be encompassed by the following claims.

We claim:
 1. A double-stranded nucleic acid (dsNA) comprising first andsecond nucleic acid strands and a duplex region of at least 19 basepairs, wherein said second strand is sufficiently complementary to atarget β-catenin cDNA sequence selected from the group consisting of SEQID NOs: 2226-3334 along at least 15 nucleotides of said secondoligonucleotide strand length to reduce β-catenin target gene expressionwhen said double stranded nucleic acid is introduced into a mammaliancell.
 2. The dsNA of claim 1, wherein said dsNA possesses a modifiednucleotide or backbone modification.
 3. The dsNA of claim 2, wherein thedsRNA possesses one or more modifications selected from the groupconsisting of a 2′-O-methyl nucleotide, a 2′-methoxyethoxy nucleotide, a2′-fluoro nucleotide, a 2′-allyl nucleotide, a2′-O-[2-(methylamino)-2-oxoethyl]nucleotide, a 4′-thio nucleotide, a4′-CH2-O-2′-bridge, a 4′-(CH2)2-O-2′-bridge, a locked nucleic acid(LNA), a 2′-amino, a 2′-O—(N-methlycarbamate), a 2′-O-alkylribonucleotide, a deoxyribonucleotide, a dideoxyribonucleotide, anacyclonucleotide, a 3′-deoxyadenosine (cordycepin), a3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxyinosine (ddI), a2′,3′-dideoxy-3′-thiacytidine (3TC), a2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a monophosphate nucleotideof 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxy-3′-thiacytidine(3TC) and a monophosphate nucleotide of2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a 4-thiouracil, a5-bromouracil, a 5-iodouracil, a 5-(3-aminoallyl)-uracil, a phosphonatebackbone modification, a phosphorothioate backbone modification and aphosphotriesterphosphate backbone modification.
 4. The dsNA of claim 1,wherein starting from the first nucleotide (position 1) at the 3′terminus of the first strand, position 1, 2 and/or 3 is substituted withone or more modified nucleotides.
 5. The dsNA of claim 4, wherein saidmodified nucleotide is a deoxyribonucletide.
 6. The dsNA of claim 2,wherein starting from the first nucleotide (position 1) at the 3′terminus of the first strand, positions 1 and 2 are substituted with adeoxyribonucleotide.
 7. The dsNA of claim 2, wherein starting from thefirst nucleotide (position 1) at the 3′ terminus of the second strand,positions 1, 2 and 3 are substituted with a 2′-O-methyl ribonucleotide.8. The dsNA of claim 1, wherein said first strand comprises a sequenceselected from the group consisting of SEQ ID NOs: SEQ ID NOs: 8-1116,3335-3822 and 3823-4443.
 9. The dsNA of claim 1, wherein said firststrand consists of a sequence selected from the group consisting of SEQID NOs: SEQ ID NOs: 8-1116, 3335-3822 and 3823-4443.
 10. The dsNA ofclaim 1, wherein said second strand comprises a sequence selected fromthe group consisting of SEQ ID NOs: 1117-2225.
 11. The isolated dsRNA ofclaim 1, wherein said dsNA is cleaved endogenously in said cell byDicer.
 12. The dsNA of claim 1, wherein the first and second strands arejoined by a chemical linker.
 13. The dsNA of claim 1, wherein saidsecond strand comprises 1-5 single-stranded nucleotides at its 3′terminus.
 14. The dsNA of claim 1, wherein said first strand is 25nucleotides in length.
 15. The dsNA of claim 1, wherein said secondstrand is up to 50 nucleotides in length.
 16. The dsNA of claim 1,wherein said second strand is complementary to GenBank Accession No.NM_001904.3 at 27 or fewer consecutive nucleotides of said second strandlength.
 17. A method for reducing expression of a target β-catenin genein a mammal comprising administering an isolated dsRNA of claim 1 to amammal in an amount sufficient to reduce expression of a targetβ-catenin gene in the mammal.
 18. A mammalian cell containing theisolated dsRNA of claim
 1. 19. A pharmaceutical composition comprisingthe isolated dsRNA of claim 1 and a pharmaceutically acceptable carrier.20. A kit comprising the isolated dsRNA of claim 1 and instructions forits use.